GUIDELINES

For

GENERAL PRACTITIONERS

2024

Press record

First Edition

Printed by SARANA PRESS (Dr. Aung Kyaw Min)

249, Theinbyu Road, Mingalartaungnyunt Township, Yangon, Myanmar

2018

Cover Designer (Tun Zaw)

Inner Designer (Tun Zaw)

Second Edition

Digital Copy Printing (TMO)

249, Theinbyu Road, Mingalartaungnyunt Township, Yangon, Myanmar.

2024 April

Cover Designer (Tun Zaw & Win Zaw)

Inner Designer (TMO)

FOREWORD

It is a great honor for me to write a foreword to Guidelines for General Practitioners by General Practitioners' society, Myanmar Medical Association (Central).

General practitioners are the primary health providers in the community looking after the majority of the people of our country. They are being trusted and depend upon by every families in the surrounding area where they practice. The first and foremost care by the General Practitioners are the most important for all the people.

Guidelines based on a critical appraisal of scientific evidence (evidence-based guidelines) clarify which interventions are of proved benefit and document the quality of the supporting data. They alert clinicians to interventions unsupported by good science, reinforce the importance and methods of critical appraisal, and call attention to ineffective, dangerous, and wasteful practices.

Clinical guidelines can improve the quality of clinical decisions. They offer explicit recommendations for clinicians who are uncertain about how to proceed, overturn the beliefs of doctors accustomed to outdated practices, improve the consistency of care, and provide authoritative recommendations that reassure practitioners about the appropriateness of their treatment policies.

The Myanmar Medical Association together with the GP society has been helping out with the CME and CPD program for the Member doctors both inhouse sessions and online courses. This guideline is one of the essential parts of this CPD for the GPs.

I would like to congratulate the GP society for their effort for producing this guideline and also, I would like to encourage them to review and updated regularly.

Professor Aye Aung
President
Myanmar Medical Association

April, 2024

PREFACE

We are writing this letter to express our sincerest gratitude and appreciation for the successful completion of the **second edition** of the **General Practitioners' Guidelines**. This accomplishment is the result of an exceptional collaborative effort, and we would like to extend our thanks to all those involved.

The General Practitioners' Guidelines has been an invaluable resource since its inception with the launch of the first edition in November 2017. As per the initial plan, the guidelines were intended to be updated every three years to ensure the most up-to-date information reaches Myanmar General Practitioners, enhancing their knowledge in primary healthcare and family health.

However, the unforeseen outbreak of the Covid-19 pandemic disrupted our plans and posed numerous challenges for the team. In-person meetings became impossible due to safety concerns, making it necessary for us to find alternative means of communication and collaboration. Despite the adversity faced, the team members demonstrated remarkable resilience and adaptability by utilizing online platforms and technology to continue the update process.

We would like to extend our deepest gratitude to the dedicated team members who persevered and worked tirelessly during these trying times. Their commitment, professionalism, and unwavering dedication to the project enabled us to overcome the obstacles posed by the pandemic and successfully complete the second edition of the guideline.

Furthermore, we would like to express our sincere appreciation to the specialist societies that actively contributed to the development of the guidelines. Their expertise and invaluable insights have ensured that the content remains current, accurate, and relevant, enabling our General Practitioners to provide the highest quality of care to their patients.

We would also like to extend our heartfelt thanks to the esteemed President of the Myanmar Medical Association, for their continuous support and guidance throughout this endeavor. Their leadership and unwavering commitment to advancing medical knowledge in Myanmar have been instrumental in the success of this Guidelines.

Moreover, the decision to distribute the guideline as electronic copies reflects our commitment to ensuring easy access for all Myanmar General Practitioners. By making it available in this format, we aim to facilitate the dissemination of updated knowledge, thus empowering our healthcare professionals to deliver the best possible care to the community.

In conclusion, we would like to express our deepest gratitude to all those who contributed to the development and distribution of the General Practitioners' Guidelines Second Edition. The unwavering supports and collective efforts have made a significant impact on enhancing primary healthcare and family health care in Myanmar.

Once again, thank you for your outstanding dedication, resilience, and invaluable contributions. We look forward to our continued collaboration in advancing medical knowledge and improving healthcare outcomes for all.

Dr Khine Soe Win and Dr Win Zaw April, 2024
General Practitioners' Society (Central)
Myanmar Medical Association

EDITORIAL

It is my privilege to inform you that our updated and revised edition of "**Guidelines for General Practitioners**" will be published very soon and it is my great pleasure to be the editor-in-chief of this guideline book. There are various reasons for revising and updating the previous edition.

This is the fact that some important topics, for example, malaria and family violence are missing in the first edition and some clinical practice guidelines like Diabetes Management have been changed during the interim period. Of course, this opportunity arises due to the emergence of COVID-19 in the world. As all you know, Medicine is an ever-changing science; we need to consider updating our guidelines at least five- yearly. Hence the time is up now!

Education is achieved by assimilating information from many resources and readers of this book can enhance their learning experience in terms of reflecting in their daily Family/General Practice. We all take immerse pride in contributing good educational resource dedicated to Myanmar General Practitioners. The editors and authors anticipate that the readers will both enjoy and profit from their work in preparing this volume.

Happy studying and learning,

Dr Win Lwin Thein
Editor-in chief
Vice President (GP Society)
April, 2024

ACKNOWLEDGEMENT

We would like to thank all our talented and hard-working colleagues who have contributed to the ongoing development of the **Guidelines for General Practitioners**.

Especially, we would like to highlight the significance of the second edition which appears when the family medicine development process in Myanmar is being idle. Many factors are impeding the developing process lately, which has been accelerated previously by the commitment of the MOHS, the medical universities, and the General Practitioners' Society before the COVID-19 pandemic started.

No one can deny that the Myanmar health care system is lacking a strong and effective primary care task force. The best solution to mend this defect is retraining the thousands of general practitioners who are working individually across the country. Here comes the role of family medicine to train these GPs and primary care doctors to be able to use its principles effectively and, in turn, strengthen primary care.

Many GPs are using some family medicine principles consciously or unconsciously in varying degree of competency. Person-centered care, continuity of care, and family-oriented care became the culture of most practices for a long time. But only a few GPs can enjoy the most effective coordinated care and seamless continuity of care with secondary and tertiary care providers. The reasons behind this would be the absence of standardization in general practitioners' service quality and unawareness of the value of family medicine practitioners by other specialties and the public.

To resolve this ambiguity, primary care doctors should be involved in the retraining programs and thereafter CME/CPD and other life-long-learning programs which prescribe family medicine curricula.

We also acknowledge the effort of the contributors to make this new edition more family medicine-oriented, in addition to the Family Medicine chapter at the beginning of the book. We genuinely believe that the new edition will be a better reference for the GP/FP who wants to practice quality primary care and for future family medicine programs in Myanmar.

Finally, we would like to thank all academic writers who contributed to the General Practice Guidelines-first edition. Without their kind support, this second edition could never have happened.

Regards,

Dr. Tin Aye and Dr. Kyaw Thu

General Practitioners' Society (Central), MMA **April, 2024**

LIST OF CONTRIBUTORS

1. *Aung Cho Myint, Prof*
2. *Aung Maw, Dr*
3. *Aye Aung, Prof*
4. *Aye Aye Than, Dr*
5. *Aye Aye Thein, Dr*
6. *Chit Soe, Prof*
7. *Hla Myat Nwe, Prof*
8. *Hla Myint Tun, Dr*
9. *Hlaing Mya Win, Prof*
10. *Hlaing Myint, Dr*
11. *Htay Win, Dr*
12. *Htin Aung Saw, Prof*
13. *Htun Lwin Nyein, Prof*
14. *Khin Hla Hla, Prof*
15. *Khin Hta Yi, Prof*
16. *Khin Mi Mi, Dr*
17. *Khin Ohnmar Khine, Prof*
18. *Khin Saw Than, Prof*
19. *Khine Khine Zaw, Prof*
20. *Khine Soe Win, Dr*
21. *Ko Ko, Prof*
22. *Kyaw Myint Naing, Prof*
23. *Kyaw Thu, Dr*
24. *Kyaw Zin Wai, Prof*
25. *Kyi Kyi Nyunt, Prof*
26. *Kyi Kyi Thinn, Prof*
27. *Kyin Htwe, Dr*
28. *Lin Htet, Dr*
29. *Lwin May Oo, Dr*
30. *Mar Mar Kyi, Prof*
31. *Maung Maung Sein, Prof*
32. *May Thandar Oo, Dr*
33. *Min Han, Prof*
34. *Min Yazar, Dr*
35. *Min Zaw Oo, Prof*
36. *Moe Naing, Dr*
37. *Moe Wint Aung, Prof*
38. *Mya Thae Han, Dr*
39. *Mya Win Hnit, Dr*
40. *Myint Thaung, Prof*
41. *Myo Khine, Dr*
42. *Myo Lwin Nyein, Prof*
43. *Myo Nyunt Aung, Dr*
44. *Myo Oo, Prof*
45. *Naing Oo, Prof*
46. *Nang Phyu Phyu Aung, Prof*
47. *Nwe Mar Tun, Prof*
48. *Nwe Nwe Aung, Dr*
49. *Nyein Moe Thaw, Dr*
50. *Phyu Phyu Khaing, Dr*
51. *Rai Mra, Prof*
52. *Samuel Kyaw Hla, Prof*
53. *Saw Win, Prof*
54. *Sein Way Lwin, Dr*
55. *Than Htike, Dr*
56. *Than Than Aung, A Prof*
57. *Than Than Aye, Prof*
58. *Thar Thar Oo, Dr*
59. *Thein Aung, Prof*
60. *Thein Myint, Prof*
61. *Thet Naing Maung, Dr*
62. *Thin Thin Nwe, Dr*
63. *Tin Aye, Dr*
64. *Tin Nyunt, Dr*
65. *Tin Tin Aye, Dr*
66. *Tin Tin Hla, Dr*
67. *Tint Tint Kyi, Prof*
68. *Vijay Kumar, Dr*
69. *Win Lwin Thein, Dr*
70. *Win Zaw, Dr*
71. *Yin Yin Soe, Prof*
72. *Yin Yin Zaw, Prof*
73. *Yu Yu Lwin, Dr*
74. *Zaw Lynn Aung, Prof*

SYMBOLS AND ABBREVIATIONS

AAA abdominal aortic aneurysm
ABC airway, breathing, circulation
ABCD airway, breathing, circulation, dextrose
ABO A, B and O blood groups
ACE angiotensin-converting enzyme
ACEI angiotensin-converting enzyme inhibitor
ACTH adrenocorticotrophic hormone
ADHD attention deficit hyperactivity disorder
ADT adult diphtheria vaccine
AFP alpha-fetoprotein
AI aortic incompetence
AIDS acquired immunodeficiency syndrome
AIIRA angiotensin II (2) reuptake antagonist
AKF acute kidney failure
ALE average life expectancy
ALL acute lymphocytic leukaemia
ALP alkaline phosphatase
ALT alanine aminotransferase
AMI acute myocardial infarction
AML acute myeloid leukaemia
ANA antinuclear antibody
ANF antinuclear factor
AP anterior–posterior
APH ante-partum haemorrhage
ASD atrial septal defect
ASIS anterior superior iliac spine
ASOT antistreptolysin O titre
AST aspartate aminotransferase
AV atrioventricular
AZT azidothymidine
BCC basal cell carcinoma
BCG bacille Calmette-Guérin
BMD bone mass density
BMI body mass index
BP blood pressure
BPH benign prostatic hyperplasia
Ca carcinoma
CABG coronary artery bypass grafting
CAD coronary artery disease
CAP community acquired pneumonia
CBT cognitive behaviour therapy
CCF congestive cardiac failure
CCU coronary care unit
CD4 T helper cell
CD8 T suppressor cell
CDT combined diphtheria/tetanus vaccine
CEA carcinoembryonic antigen
CFS chronic fatigue syndrome
CHD coronary heart disease
CHF chronic heart failure
CIN cervical intraepithelial neoplasia
CK creatinine kinase
CKD chronic kidney disease
CKF chronic kidney failure
CML chronic myeloid leukaemia
CMV cytomegalovirus
CNS central nervous system
COAD chronic obstructive airways disease
COC combined oral contraceptive
COCP combined oral contraceptive pill
COPD chronic obstructive pulmonary disease
COX cyclooxygenase
CPA cardiopulmonary arrest
CPAP continuous positive airways pressure
CPK creatine phosphokinase
CPR cardiopulmonary resuscitation
CR controlled release
CREST calcinosis cutis; Raynaud's phenomenon; oesophageal involvement; sclerodactyly; telangiectasia
CRF chronic renal failure
CR(K)F chronic renal (kidney) failure
CRP C-reactive protein
CSF cerebrospinal fluid
CT computerised tomography
CTS carpal tunnel syndrome
CVA cerebrovascular accident
CVS cardiovascular system
CXR chest X-ray
DBP diastolic blood pressure
DC direct current
DHA docosahexaenoic acid
DI diabetes insipidus
DIC disseminated intravascular coagulation
dL decilitre
DMARDs disease modifying antirheumatic drugs
DNA deoxyribose-nucleic acid
DRABC defibrillation, resuscitation, airway, breathing, circulation
drug dosage bd—twice daily, tid/tds -three times daily, qid/qds -four times daily
ds double strand
DS double strength
DSM diagnostic and statistical manual (of mental disorders)
DU duodenal ulcer
DUB dysfunctional uterine bleeding
DVT deep venous thrombosis
EBM Epstein-Barr mononucleosis (glandular fever)
EBV Epstein-Barr virus
ECG electrocardiogram
ECT electroconvulsive therapy
EDD expected due date
EEG electroencephalogram
ELISA enzyme linked immunosorbent assay
ESRF end-stage renal failure
ESR(K)F end stage renal (kidney) failure
ERCP endoscopic retrograde cholangiopancreatography
esp. especially
ESR erythrocyte sedimentation rate
FB foreign body
FBE full blood count

FEV1 forced expiratory volume in 1 second
fL femtolitre = (1e–15) litre
FSH follicle stimulating hormone
FUO fever of undetermined origin
FVC forced vital capacity
g gram
GA general anaesthetic
GABHS group A beta-haemolytic streptococcus
GBS Guillain-Barré syndrome
GFR glomerular filtration rate
GI glycaemic index
GIT gastrointestinal tract
GLP glucagon-like peptide
GnRH gonadotrophin-releasing hormone
GO gastro-oesophageal
GORD gastro-oesophageal refl ux
GP general practitioner
G-6-PD glucose-6-phosphate
GU gastric ulcer
HAV hepatitis A virus
anti-HAV hepatitis A antibody
Hb haemoglobin
HbA haemoglobin A
anti-HBc hepatitis B core antibody
HBeAg hepatitis B e antigen
anti-HBs hepatitis B surface antibody
HBsAg hepatitis B surface antigen
HBV hepatitis B virus
HCG human chorionic gonadotropin
HCV hepatitis C virus
anti-HCV hepatitis C virus antibody
HDL high-density lipoprotein
HEV hepatitis E virus
HFM hand, foot and mouth
HFV hepatitis F virus
HGV hepatitis G virus
HIV human immunodeficiency virus
HNPCC hereditary nonpolyposis colorectal cancer
HPV human papilloma virus
HRT hormone replacement therapy
HSV herpes simplex viral infection
IBS irritable bowel syndrome
ICE ice, compression, elevation
ICS inhaled corticosteroid
ICS intercondylar separation
ICT immunochromatographic test
IDDM insulin dependent diabetes mellitus
IDU injecting drug user
IgE immunoglobulin E
IgG immunoglobulin G
IgM immunoglobulin M
IHD ischaemic heart disease
IM, IMI intramuscular injection
inc. including
IPPV intermittent positive pressure variation
IR internal rotation
ITP idiopathic (or immune) thrombocytopenia purpura
IUCD intrauterine contraceptive device
IUGR intrauterine growth retardation
IV intravenous
IVI intravenous injection
IVP intravenous pyelogram
IVU intravenous urogram
JCA juvenile chronic arthritis
JVP jugular venous pulse
KA keratoacanthoma
kg kilogram
KOH potassium hydroxide
LA local anaesthetic
LABA long acting beta agonist
LBBB left branch bundle block
LBO large bowel obstruction
LBP low back pain
LDH/LH lactic dehydrogenase
LDL low-density lipoprotein
LFTs liver function tests
LH luteinising hormone
LHRH luteinising hormone releasing hormone
LIF left iliac fossa
LMN lower motor neurone
LNG levonorgestrel
LRTI lower respiratory tract infection
LSD lysergic acid
LUQ left upper quadrant
LUTS lower urinary tract symptoms
LV left ventricular
LVH left ventricular hypertrophy
mane in morning
MAOI monoamine oxidase inhibitor
mcg microgram (also µg)
MCV mean corpuscular volume
MDI metered dose inhaler
MDR multi-drug resistant TB
MI myocardial infarction
MRCP magnetic resonance cholangiography
MRI magnetic resonance imaging
MS multiple sclerosis
MSM men who have sex with men
MSU midstream urine
N normal
NAD no abnormality detected
NGU non-gonococcal urethritis
NHL non-Hodgkin's lymphoma
NIDDM non-insulin dependent diabetes mellitus
nocte at night
NSAIDs non-steroidal anti-inflammatory drugs
NSU non-specific urethritis
(o) taken orally
OA osteoarthritis
OCP oral contraceptive pill
OGTT oral glucose tolerance test
OSA obstructive sleep apnoea
OTC over the counter
PA posterior–anterior
PAN polyarteritis nodosa
Pap Papanicolaou
pc after meals
PCA percutaneous continuous analgesia
PCB post coital bleeding

PCL posterior cruciate ligament
PCOS polycystic ovarian syndrome
PCP pneumocystis carinii pneumonia
PCR polymerase chain reaction
PCV packed cell volume
PDA patent ductus arteriosus
PEF peak expiratory flow
PEFR peak expiratory flow rate
PET pre-eclamptic toxaemia
PFT pulmonary function test
PH past history
PID pelvic inflammatory disease
PLISSIT permission: limited information: specific suggestion: intensive therapy
PMS premenstrual syndrome
PMT premenstrual tension
POP plaster of Paris
POP progestogen-only pill
PPI proton-pump inhibitor
PPROM preterm premature rupture of membranes
PR per rectum
prn as and when needed
PROM premature rupture of membranes
PSA prostate specific antigen
PSIS posterior superior iliac spine
PSVT paroxysmal supraventricular tachycardia
PT prothrombin time
PTC percutaneous transhepatic cholangiography
PU peptic ulcer
PUO pyrexia of undetermined origin
pv per vagina
qds, qid four times daily
RA rheumatoid arthritis
RBBB right branch bundle block
RBC red blood cell
RCT randomised controlled trial
RF rheumatic fever
Rh rhesus
RIB rest in bed
RICE rest, ice, compression, elevation
RIF right iliac fossa
RPR rapid plasma reagin
RR relative risk
RSV respiratory syncytial virus
RT reverse transcriptase
rtPA recombinant tissue plasminogen activator
SAH subarachnoid haemorrhage
SARS severe acute respiratory distress syndrome
SBE subacute bacterial endocarditis
SBO small bowel obstruction
SBP systolic blood pressure
SC/SCI subcutaneous/subcutaneous injection
SCC squamous cell carcinoma
SCG sodium cromoglycate
SIADH syndrome of secretion of inappropriate antidiuretic hormone
SIDS sudden infant death syndrome
SIJ sacroiliac joint
SL sublingual
SLE systemic lupus erythematosus
SLR straight leg raising
SND sensorineural deafness
SNHL sensorineural hearing loss
SNRI serotonin noradrenaline reuptake inhibitor
SOB shortness of breath
sp species
SR sustained release
SSRI selective serotonin reuptake inhibitor
SSS sick sinus syndrome
stat at once
STI sexually transmitted infection
SVC superior vena cava
SVT supraventricular tachycardia
T3 tri-iodothyronine
T4 thyroxine
TB tuberculosis
tds, tid three times daily
TENS transcutaneous electrical nerve stimulation
TFTs thyroid function tests
TG triglyceride
TIA transient ischaemic attack
TIBC total iron binding capacity
TM tympanic membrane
TMJ temporomandibular joint
TNF tissue necrosis factor
TOF tracheo-oesophageal fistula
TORCH toxoplasmosis, rubella, cytomegalovirus, herpes virus
TPHA Treponema pallidum haemoglutination test
TSE testicular self-examination
TSH thyroid-stimulating hormone
TT thrombin time
TV tidal volume
U units
UC ulcerative colitis
U & E urea and electrolytes
µg microgram
UMN upper motor neurone
URTI upper respiratory tract infection
US ultrasound
UTI urinary tract infection
U ultraviolet
VC vital capacity
VDRL Venereal Disease Reference Laboratory
VF ventricular fibrillation
VMA vanillyl mandelic acid
VSD ventricular septal defect
VT ventricular tachycardia
VUR vesico-ureteric reflux
VWD von Willebrand's disease
WBC white blood cells
WCC white cell count
WHO World Health Organization
WPW Wolff-Parkinson-White
XL sex linked

Chapter (1)

Family Medicine

- Family Medicine
- Diagnostic Process in Family Medicine
- Family Oriented Primary Care (FOPC)
- Community-Oriented Primary Care (COPC)
- The Sick Role, Illness Behaviour and Problem Behavior
- Setting Up a Practice
- Medical Records and Referral
- Emergency Care and The GP's House Call
- Continuing Medical Education for General Practitioners
- Continuing Professional Development
- Evidence- Based Decision Making in Family Practice
- Terminal/Palliative Care and Care of Cancer Patients in General Practice
- Family Violence

MODULE 1:

DEFINITION OF FAMILY MEDICINE

A specialty of medicine which is concerned with providing comprehensive care to individuals and families and integrating biomedical, behavioral and social sciences; an academic medicine discipline that includes comprehensive healthcare services, education and research; known as general practice in some countries.



Source : https://www.vecteezy.com/vector-art/2165375-family-medicine-word-concepts-banner

DEFINITION OF FAMILY DOCTOR OR FAMILY PHYSICIAN

A medical practitioner who is a specialist trained to provide healthcare services to all individuals regardless of age, sex, or type of health problem; provides primary and continuing care for entire families within their communities; addresses physical, psychological and social problems; coordinates comprehensive healthcare services with other specialists as needed; may also be known as a family physician.

DEFINITION OF FAMILY PRACTICE OR GENERAL PRACTICE

Healthcare services provided by family doctors; characterized by comprehensive, continuous, coordinated, collaborative, personal, family and community-oriented services, comprehensive medical care with a particular emphasis on the family units.

DEVELOPMENT OF FAMILY MEDICINE

Family practice is a relatively new area of specialization. The concept of this discipline evolved in 1960s in the UK and USA. In USA, family medicine evolved from general practice as a felt need in personal health care. American Board of Family Medicine (ABFM) conducts certified board examination and accreditate the quality of Family Physician. In UK, the same trend has been noticed in the introduction of a general practice as a specialty of the Royal College of General Practitioners with systematic training programmes or par with other Royal Colleges of the UK.

PRINCIPLES OF FAMILY MEDICINE OR THE ATTRIBUTES OF FAMILY DOCTORS

PRIMARY CARE

It is often used interchangeably with first level of care. The part of a health services system that assures person focused care overtime to a defined population, accessibility to facilitate receipt of care when it is first needed. Quality features of primary care include effectiveness, safety, people-centeredness, comprehensiveness, continuity and integration. When needed, patients and populations know the family doctor is the first point of access to Health Care System.

PERSONAL CARE (PEOPLE-CENTERED CARE)

Care that is focused and organized around the health needs and expectations of people and communities rather than on diseases. Person-centered care extends the concept of patient-centered care to individuals, families, communities and society. The family doctor provides personal health services targeted at the individual, including health promotion, timely disease prevention, diagnosis and treatment, rehabilitation, palliative care and acute-care and long-term care services.

PREVENTIVE CARE

The family physician views his or her practice as a "population at risk" and sees every contact with patients as an opportunity for disease prevention and health promotion. Prevention is central to Family Medicine and its key mission is preserving and promoting health and maximizing functions of patients throughout their lives. Most commitment preventive activity of a family physician is empowering patients in making healthy lifestyle changes.

CONTINUITY OF CARE

A term used to indicate one or more of the following attributes of care (i) the provision of services that are coordinated across levels of care-primary care and referral facilities, across settings and providers; (ii) the provision of care throughout the life cycle (iii) care that continues uninterrupted until the resolution of an episode of disease or risk (iv) the degree to which series of discrete health care events are experienced by people as coherent and interconnected overtime, and are consistent with their health needs and preferences.

COMPREHENSIVE CARE

The extent to which the spectrum of care and range of resources made available responds to the full range of health problems in a given community. Comprehensive care encompasses holistic care, multidisciplinary care, multifaceted care, multipurpose care, pro-active and reactive care, acute care and chronic care. It deals with the interface between illness and disease, and integrates the humanistic and ethical aspects of the doctor-patient relationship with clinical decision making.

COORDINATED CARE

As medicine becomes more and more specialized and sophisticated, the family physician's role as the integrator of health services becomes increasingly significant, by facilitating the patient's access to the whole health care system and interprets the activities of this system to the patient, explaining the nature of the illness, the implications of the treatment, the effects of both on the patient's way of life. (Role of conductor of an orchestra)

THE FAMILY AS A UNIT OF CARE (FAMILY ORIENTED PRIMARY CARE/FOPC)

The family physician recognizes the universal importance of the family and the influence of the family on health and disease. This is the reason why he or she focuses on family oriented primary care. Family Practice addresses the health problems of individuals in the context of their families.

COMMUNITY ORIENTED PRIMARY CARE (COPC)

Family medicine basically integrates individual healthcare and community healthcare virtue of practicing utilization of epidemiological data, screening, environmental health, population health through collected social actions, often provided by state or local health authorities. The family physician sees himself or herself as a part of community wide network of supportive and healthcare agencies. So, family physicians can be much more effective if they can deploy all the resources of the community for the benefit of their patients.

EVIDENCE- BASED PRACTICE

The rapid growth of clinical research over the past 30 years has necessitated the development of a new and different approach to the practice of Family Medicine. The evidence-based approach requires us to make conscientious, explicit and judicious use of the current best research evidence when making clinical decision for our patients. It also requires the integration of the best evidence with our clinical expertise and our patient's unique values and circumstances. (David Sackett)
The family physician has to practice Evidence based medicine (EBM) both in diagnostic reasoning of Hypothetico – deductive approach and management. Basically, there are seven steps of evidence-based practice: Cultivate, Ask, Search, Appraise, Integrate, Evaluate, Disseminate (pneumonic: CASAIED).

PATIENT EMPOWERMENT

Patient empowerment is not only one of the key elements of patient-centered care but also a major principle of Family Medicine. It is basically defined as a process that helps people gain control over their own lives and increases their capacity to act on issues that they themselves define as important. According to the WHO, it is a process through which people gain greater control over decisions and actions affecting their health. Patient Empowerment is processed through four main phases:

(1) patient enablement
(2) patient activation
(3) patient engagement
(4) patient involvement

Working from a similar conceptual framework, the College of Canada has defined four principles that underlie family medicine :-

1. The patient-doctor relationship (PDR) is central to family medicine.
2. The family doctor is an effective clinician.
3. Family medicine is community based.
4. The family doctor is a resource to a defined practice population.

ESTABLISHMENT OF WONCA

As the WHO was articulating a vision of health for all in the 1970, a significant evolution in the training of generalist physicians was occurring in countries around the world. Instead of being educated in an undifferentiated manner as in the past, generalist physicians, termed family doctors, were provided with postgraduate training specifically designed to prepare them to diagnose and treat the majority of the people's health problems within the context of the people's families and communities. These efforts received substantial reinforcement at the 5th world conference on General/Family Practice in Melbourne, Australia in 1972, when representatives of 23 countries established the World Organization of National Colleges, Academies and Academic Association of General Practitioners/Family Physicians (WONCA). Today, WONCA has over 100 member organizations including Myanmar representing family doctors from over 130 countries in all regions of the world. WONCA has expanded rapidly in recent years and now represents more than 300,000 family doctors worldwide.

SCOPE OF PRACTICE OF FAMILY DOCTORS

- Care for patients of all ages, from "womb to tomb"
- Ensure access to comprehensive primary and secondary services
- Manage infectious and chronic diseases
- Provide emergency, acute and long-term care
- Serve as clinicians, teachers, advocates and leaders
- Coordinate individual clinical, community and public health services

Further reading:

1. *The contribution of family Medicine to improving Health Systems (2nd Edition) Edited by Michal Kidd, WONCA, Radcliffe publishing (2013)*
2. *Text book of Family Medicine (9thEdition) Robert, E.Rakle et.al, Elsevier (2016)*

MODULE 2:

DIAGNOSTIC PROCESS IN FAMILY MEDICINE

- Traditional medical training teaches students to elicit an entire (thorough) history and then examine all the systems of the body before considering the provisional diagnosis (Inductive method of problem solving or diagnostic reasoning).
- From the moment the patient enters the room the family doctor starts to formulate hypotheses (Neighbour, 1987). First, allow the patient to tell his/her problem. Family doctors do not collect all the information from a thorough history, full examination and side room tests and then sit down to decide on a diagnosis. Rather it is a continuous process of hypotheses being formulated and tested from the start of the consultation. During one consultation, a number of working hypotheses may be created, tested and discarded. It is quite different from long exhausting lists of differential diagnosis.
- Diagnosis in family medicine (*Consultation skills, by Dr. Ekran A Jalali)*
    - Pattern recognition
    - Hypothetical deductive reasoning method
    - using Clinical epidemiology
    - Living with uncertainty
    - No diagnosis

(HYPOTHETICO-DEDUCTIVE METHOD OF PROBLEM SOLVING OR DIAGNOSTIC REASONING).

Example: -

The information	The Hypothesis
The patient complains of **shortness of breath**	***Asthma****?* The family doctor asks about history of asthma, wheeze/ cough and so on
The patient's answers are not consistent with asthma, but she does seem nervous	Hyperventilation due to ***anxiety?*** The family doctor asks about stress and feelings of anxiety.
The patient has not experienced more stress than usual lately and her anxiety is related to her fear of hearing a bad diagnosis	***Cardiac failure?*** The family doctor asks about change in effort tolerance/ orthopnoea/nocturnal dyspnoea and swollen ankles.
The patient confirms these cardiac failure symptoms.	The family doctor looks for signs and causes of cardiac failure

Initial Hypotheses should relate to the most probable cause in terms of high prevalence to family practice. And also serious hypothesis (high pay off) should be considered (Red Flag consultation).
(e.g. ***Red flags for low back pain*** *(Royal College of General Practitioners, 1997).*

1. *Presentations under 20 yrs of age or over 55 years*
2. *Thoracic pain*
3. *A past history of cancer, steroid use, or HIV*
4. *A feeling of being unwell, weight loss and night sweats*
5. *Neurological signs or symptoms*
6. *Structural deformity*
7. *Sphincter disturbance, gait disturbance and saddle anaesthesia.*

Hypotheses may be reformulated and tested between consultations.

PATTERN RECOGNITION

Combination of Hypothetico-deductive method (HDM) and pattern recognition (PR) is vital to the diagnosis in Family Practice.
Some conditions in family practice are common and you can easily recognize them at a glance, e.g. Shingles, Impetigo, Down Syndrome
Another example is a patient with alcohol problem who frequently asks for a sick certificate and presents with sexually transmitted infections (pattern-recognition).

REFERENCES:

1. Handbook of Family Medicine edited by Bob Mash, second edition, oxford university press.
2. Clinical Method edited by Robin C. Fraser, third edition, Butter worth/Heinemann Press (2008).

STUDY QUESTIONS (FOR HYPOTHETICO-DEDUCTIVE DIAGNOSTIC METHOD)

SCENARIO 1

Hla Hla is a university student, aged 21 years. She attends infrequently for minor illness and holiday immunizations. Today she enters looking well, but appears worried. She tells you she has had lower abdominal pain 'off and on' for some months, and that it 'has got a lot worse' over the last month. It is now present 'almost all the time'.

Q 1

What is your initial diagnostic hypothesis? Explain how you arrived at these.

Q 2

What questions would you want to ask to test your respective hypothesis? Explain how the questions might help you.

Sample Answer for Q 1

Pre diagnostic interpretations

Although the problem is chronic and getting worse, serious pathology is unlikely because she is well despite several months of abdominal pain. However, she is an infrequent attendee and today looks concerned, suggesting she is either worried by her symptoms or is finding they are beginning to interfere with her life. Her age would suggest she is in her final year at University approaching examinations. Accordingly, the most likely cause of her chronic lower abdominal pain could be either physical (GI cause or Gynecological cause) or psychological/social cause. (Bio-psychosocial approach of family medicine)

Hypotheses

Most likely	Less likely
Irritable bowel syndrome (IBS)	Pelvic inflammation disease (PID)
Anxiety state	

IBS is common in young females, is non-serious and you would expect the patient to look well. The pain would be of a recurrent chronic nature, and could be aggravated by the stress of examinations. There may be other worries in her life, e.g. boyfriend difficulties, which would induce anxiety and may present as abdominal pain. Her abdominal pain may itself have induced concern of serious underlying disease that may then have exacerbated it. PID is possible in a young sexually active female, but you as yet unaware of her sexual history and any associated infection.

Sample Answer for Q2

First, clarify the presenting symptom of abdominal pain. This will determine whether it is the same pain throughout, despite becoming worse. If not, you may be required to develop now hypotheses.

1. Site ± radiation. Generalized (lower) abdominal pain would support IBS and anxiety. Pelvic pain would be more supported of PID. Radiation is unlikely to be a feature of either.
2. Quality. A colicky pain would support IBS, a more constant pain would support anxiety and a dragging, constant pain would support PID.
3. Severity. This is likely to be very variable in both IBS and anxiety. The pain of IBS would tend to be either mild or moderate, whilst that of anxiety would tend to be either mild or moderate, whilst that of anxiety would be proportionate to the severity of the anxiety. PID is usually of mild to moderate severity, although it can, rarely, mimic an acute abdomen.
4. Periodicity. You already know the duration and progression of symptoms. You now need to look for alterations within the day or week. Association with food/mealtimes support IBS, times of increased stress would exacerbate the pain of anxiety, whilst increased pain related to her menses would support PID.
5. Precipitating, exacerbating or relieving factors. Is the patient aware of any change that has coincided with the onset or increases of the pain? Stress would aggravate or precipitate the pain of IBS and anxiety, whilst defecation might ease the pain in IBS. Sexual intercourse would aggravate PID pain (deep dyspareunia), whilst the coincidence of pain onset with a new partner might suggest the start of an infection.
6. Associated features. A variable bowel habit alternating between constipation and diarrhoea with abdominal distension, bloating, flatus or mucous per rectum supports IBS. Other symptoms of anxiety include disturbed sleep, palpitations and reduced appetite. Generalized systemic upset would suggest PID, which would further supported by a fever, change in menstrual cycle or vaginal discharge.
7. Confirm the patient's concerns and reason for attendance today. She might be finding the pain unbearable as it is now continuous. However, there may be underlying concerns about what the pain might signify, e.g. "Cervical cancer, that you would be unlikely to address unless mentioned by the patient." Ask and open question, e.g. "You look concerned about the pain, is there anything in particular worrying you?"

It would then be appropriate to search for specific associated feature relating to be search for specific associated feature relating to each hypothesis still being considered. In doing so, you would need to indicate to the patient the reasons for your particular line of enquiry (signaling), thereby giving implied consent to continue. IBS is recognized to have strong psychological component. You therefore need to explore psychological issues and their effects with appropriate sensitivity. Areas of enquiry would include her studies (remember she is probably nearing her final examinations), relatives and partner(s).

This would also help identify underlying cause of anxiety. If these are not forthcoming, you need to ask specifically about particular symptoms of anxiety.

To diagnose PID you would need to take a sexual history, including previous and present partners who may have put her at potential risk. Establishing her method of contraception is important, as only barrier methods offer protection against PID.

HYPOTHETICO-DEDUCTIVE METHOD OF PROBLEM SOLVING

(SOURCE: ELSTEIN ET.AS., 1978)



MODULE 3:

FAMILY ORIENTED PRIMARY CARE (FOPC)

The family physician provides family oriented primary care (FPOC) by mobilizing the patient's natural support system to enhance health and well-being.

BASIC PREMISES OF FAMILY-CENTERED MEDICAL CARE:

1. Family-oriented healthcare is based on a biopsychosocial systems approach.
2. The primary focus of healthcare is the patient in the context of the family.
3. The patient, family and family physician are partners in the form of triad.



The therapeutic triangle in Family Medicine

4. The family-oriented clinician reflects on how he or she is part of the treatment system.



I. LEARNING TO THINK FAMILY

Five helpful questions when 'thinking family' (adapted from Cole-Kelly, 2005)

1. Has anyone else in the family had a similar problem? ***(EXPERIENCE)***
2. What do family members believe caused the problem and how do they think it should be treated? ***(BELIEF AND IDEA)***
3. Who in the family is most concerned about the problem? ***(CONCERN)***
4. Have there been any other recent changes or stresses in your life? ***(TRAUMA)***
5. How can your family or friends help you in dealing with this problem? ***(SUPPORT)***

II. THE IMPORTANCE OF THE GENOGRAM

- The genogram is an essential tool in the practice of family-oriented primary care (FOPC).
- **Drawing a genogram** and identifying the value of a genogram is essential skills for a family physician.

Figure 4.2 Genogram conventions



NOTE: Enter the date of the genogram and family name clearly

III. The family within a larger system _ use of an ecomap

The ecomap is one way of diagrammatically assessing the larger system within which a family operates.

ECOMAP CONVENTIONS

Name.....
Date.....



Fill in connections where they exist. Draw different kinds of lines:
———— for strong, --------- tenuous, and - - - - - - for stressful.

IV. CHRONIC ILLNESS AND DISABILITY _ SUPPORTING FAMILY CAREGIVERS

- formulate a three stage assessment of the problems.

A framework for three stage assessment and managements (adapted from Fehrsen & Henbest 1993)

	Assessment	Management plan
Clinical		
Individual		
Contextual		

THE CLINICAL COMPONENT

This is the medical part of the assessment, based on the symptoms, signs and investigations, relating to the patient's disease. This is recorded at the highest level of certainty.

THE INDIVIDUAL COMPONENT

This is the assessment of how the patient is experiencing the illness. It is his/her perception of the problem. It includes the patient's key ideas, fears, expectations, loss of functions and any other important emotions or reactions.

THE CONTEXTUAL COMPONENT

This is the assessment of the patient's environment and how it affects the patient, as well as how the illness impacts on the environment. It includes the person's family, life stage, work, community, environment, and so on.

V. WORKING WITH FAMILY MEMBERS _ THE FAMILY CONFERENCE



Each level beyond level 1 requires additional knowledge, personal development, and skills
SOURCE: Adapted from Doherty and Baird (1986)

VI. IDENTIFYING THE FAMILY AT RISK

Family physicians play an important health promotion role. Attending to personal and family health needs shifts the focus from illness and disease to maintaining and promoting health.
Six Questions to assess family health and identify the family at risk (McWilliam, 1993)

1. What does health mean to this family?
2. What does this family need to maintain or restore its health?
3. Are there any physical, psycho-emotional, or socioeconomic threats to the health of this family? How can I help this family to overcome them.
4. What capacity does this family have to make healthy choices?
5. What does this family need from society to optimize its health?
6. How can I promote a balance between the family needs and expectations and the constraints of the healthcare system.

To consider the key aspects of family functioning, the family physician should use the acronym:
PRACTICE (Christie-Seely 1984)

P – **P**resenting problem
R – **R**oles
A – **A**ffect

C – **C**ommunication patterns
T – **T**ime in life cycle
I – **I**llness history
C – **C**oping with stress
E – **E**cology and culture

FAMILY ASSESSMENT

- Being a family physician, family assessment begins with the first visit and is a continuous process.
- It is important to interview all family members at the same time to observe communication and decision- making patterns.

COMPONENTS OF FAMILY ASSESSMENT

(1) ASSESS EACH FAMILY MEMBER'S HEALTH

(2) ASSESS FAMILY'S HEALTH HISTORY

- Complete a genogram (Family anatomy)

- Include at least two generations back

- Include ages at death and cause of death

- Note patterns of illness distribution across generations (for example: cancer)

(3) ASSESS FAMILY STRUCTURE

- Single, nuclear, nuclear dyad, extended and/or Multigenerational, Single parent, Step family, same gender

(4) ASSESS FAMILY ROLES (FRIEDMAN, 1992)

Format:

- Breadwinner(s)
- Homemaker(s)
- Childrearer(s)
- Financial Manager(s)
- Chauffeur(s)
- Cook(s)
- House repair

Informal roles (Selected)

- Encourager (praises defers)
- Harmonizer (mediator)
- Blocker (opposer)
- Compromiser (yielder / comes halfway)
- Blamer (Faultfinder)
- Scapegoat (recipients of family hostilities)
- Caregiver (nurturer)

Identify the (Alliance and Coalition)

(5) Assess family health

- Concepts of health and illness
- Perceived level of health
- Family health promotion Strategies
- Family Stressors
- Family Strengths
- Support Systems
- Family diet, mealtime practices, who prepares meals
- Family activities
- Time taken for sharing
- Spirituality
- Participation in the Community

- Is has a place for respite, for nurturing?

- Health-seeking behaviours:

- Physical examinations, dental care, family physician, emergency department use, immunization status

- Source of insurance, adequacy of coverage

(6) Assess Family income

- Source (s)
- Adequacy

(7) Assess Family power (Friedman, 1992)

1. Assess who makes decisions about

Household management
Discipline of children
Financial matters
Health care
Family leisure time activities

2. Assess who makes the decision and/or wins when major decisions are made

3. Assess type and sources of power used by family

4. Legitimate: One person is the authority / and this authority is believed by all family members to be appropriate.

5. Helpless and/or powerless: The victims (disabled family members or the children, for instance) gain.

- Referent Power: power gained From Family member's positive identification (parental power)
- Resource and/or expert power: Power is based on who has the most resources (attributes, possessions, expertise). For example, Family member who controls the finances may control decision making in general
- Reward power: When one family member has the power to reward other members
- Coercive power: When power is gained through the use of violence, threats. or coercion
- Informational power: power gained by persuasion
- Affective power: When power is gained by controlling the allocation of affection or sex
- Torsion management power: When power is gained through the use of teas, disagreements or pouting

(8) Assess power or decision- making process

- consensus: mutual agreement
- accommodation: concessions made
- De facto: no decision made

(9) Assess family communication patterns (Clark, 1999)

* Dysfunctional patterns:

- **The Wheel**: one person directs all Communication
- **The Chain:** Communication goes down the ling without opportuning for interaction
- **The isolate:** One person excluded

* Functional pattern of communication:

- The switchboard fair (Communication between all members in all directions)

(10) Assess Family developmental Stage

(Stanhope and Lancaster, 1996)

- Beginning Family: Establish marriage
- Early child bearing family: Stabilize family, facilitate developmental needs of family members
- Family with preschool children: maintain marriage, nurture and socialize children
- Family with school-age children: maintain marriage/ socialize children and promote their school achievement
- Family with teenagers: maintain marriage, maintain parent-child communication, build foundation for future family stages, balance teen freedom/responsibility
- Launching family: readjust marriage/ Launch children as young adults, assist aging parents
- Middle-age family: Strengthen marriage, maintain relationship with children/parents, provide healthy environment, cultivate leisure activities

- **Aging Family**: Adjust to retirement, reduced income, health problems, death of spouse: maintain satisfactory living assessment.

- Parenting practices:

- Hopes and plans for children
- Uses parenting styles learned from own parents
- Disciplines children
- Empowers children
- Develops positive attitudes in children toward education, religion, athletics, extra-curricular activities
- Role models for children and teaches altruism, respect for alters.
- Draw ECOMAP depicting family in the center circle with spokes drawn to interacting systems.

Depict direction of emergency exchange and presence of stressful of tenuous relationships.



(11) FAMILY CAREGIVER ASSESSMENT

When are family member is ill or disabled another family member often takes over the role of family caregivers. In home health setting, that role often makes the difference as to wider the family member can remain at home. The family medicine physician in those settings will need do conduct either a complete family assessment or at least the following/mole focused family caregiver assessment especially chronic debilitating illness like STROKE.

Overview

- Age
- Relationship to care recipient
- Number of months since onset of care giving
- Number of hours per day spent in care giving
- Feelings toward care giving: Both negative and positive, advantages and disadvantages.
- Knowledge of care recipient's care needs (physical and emotional)
- Knowledge of care recipient's Medications
- Knowledge of what is involved in the care
- Evaluation of welter care recipient can be left alone
- Evaluation of what care recipient can do for himself or herself.
- Evaluation of whether the care recipient's dependency has increased in the last month
- Personal medical problems
- Personal medications
- Personal illness patterns
- Personal sleep patterns: Length, pattern of interrupted or uninterrupted sleep, place for caregiver to sleep
- Personal nutrition
- Personal exercise
- Personal stress reduction activities
- Frequency of leaving the home, purpose, duration
- Availability and use of respite services: hospital, nursing facility, family, friends, church
- Number of times in last year care recipient has been hospitalized
- Number of times in last year care recipient was hospitalized to provide caregiver with needed rest
- Assistance caregiver identifies as being needed

Family Medicine is one of academic disciplines.

UNDERSTANDING THE FAMILY

The importance of the family-to-family physician is inherent in the paradigm of Family Medicine. Family Medicine does not separate disease from person or person from environment.

THE INFLUENCE OF THE FAMILY ON HEALTH AND DISEASE

The family has six main effects on the health of its members.

1. Genetic influences
2. The family is crucial in child development
3. Some families are more vulnerable to illness than others
4. Infectious diseases spread in families
5. Family factors affect morbidity and mortality in adults
6. The family is important in recovery from illness

The Family Life Cycle (David Duvall, 1977) (or) Stages of family life cycle



1. Married couples (without children)
2. Childbearing families (oldest child, birth – 30months)
3. Families with preschool children (oldest child 30months – 6years)
4. Families with schoolchildren (oldest child 6 – 13years)
5. Families with teenagers (oldest child 13 – 20years)
6. Family launching young adults (first child gone to last child leaving home)
7. Middle-aged parents (empty nest to retirement)
8. Aging family members (retirement to deaths of both spouses)

An understanding of the family life cycle, together with an understanding of individual development, can help a family physician form good hypotheses about problems patients are experiencing. American Sociologist David Duvall (1977) has developed an eight-stage schema of the family life cycle. In this cycle, the family goes through a number of predictable transitions: marriage, childbirth, school years and adolescence, school graduation and starting work or further education, children leaving home, involution, retirement, widowhood. Families also experience unexpected crises that demand adaptive responses: illnesses, accidents, divorce, loss of job, death of a family member.

Developmental Tasks:

Stages of the Family Life Cycle	Positions in the Family	Stage-Critical Family Development Tasks
1. Married Couple	• Wife • Husband	• Established a mutual satisfying marriage • Adjusting to pregnancy and promise of parenthood • Fitting into the kin network
2. Childbearing	• Wife→ Mother • Husband→ Father • Infant: daughter or son or both	• Having, adjusting to, and encouraging the development of infants • Establishing a satisfying home for both parents and infants
3. Preschool age	• Wife – Mother • Husband - Father • Daughter - Sister • Son - Brother	• Adapting to the critical needs and interests if preschool children in stimulating, growth-promoting ways • Coping with energy depletion and lack of privacy as parents
4. School age	• Wife – Mother • Husband - Father • Daughter - Sister • Son - Brother	• Fitting into the community of school-age families in constructive ways • Encouraging children's educational achievement
5. Teenage	• Wife – Mother • Husband - Father • Daughter - Sister • Son - Brother	• Balancing freedom with responsibility as teenagers mature and emancipate themselves • Establishing post-parental interests and careers as growing parents
6. Launching centre	• Wife-mother-grandmother • Husband-father-grandfather • Daughter-sister-aunt • Son-brother-uncle	• **Releasing young adults into work**, military service, marriage, etc., with **appropriate rituals and assistance**
7. Middle-aged parent	• Wife-mother-grandmother • Husband-father-grandfather	• **Rebuilding the marriage relationship** • Maintaining kin ties with older and younger generations
8. Aging family members	• Widow-Widower • Wife-mother-grandmother • Husband-father-grandfather	• Coping with **bereavement and living alone** • Closing the **family home or adapting it to aging** • Adjusting to retirement

FAMILY ORIENTED PREGNANCY CARE: THE BIRTH OF A FAMILY

Pre-pregnancy

- Encourage the couple to discuss their ideas and plans regarding pregnancy and children.
- Evaluate the extended family and their attitudes about pregnancy.
- Briefly assess where the couple is in the family life cycle and how they have negotiated the tasks of previous stages.
- Review biological and psychological risk factors.
- Support health habits.

First Trimester

- Explore whether pregnancy was desired or planned, and whether there are any thoughts of terminating pregnancy.
- Find out about social supports (e.g., father of child, parents, siblings, friends), and how these people feel about the pregnancy.
- Invite the father of the baby to all prenatal visits.
- Involve the father early on in the pregnancy.
- Be positive and direct about your need for the father to participate in prenatal care.
- Emphasize the importance of the father in the care of the pregnancy; stress the benefits of the partner's involvement to the patient and the pregnancy.
- Offer to call the partner yourself if needed.
- Request that the father come in for one prenatal visit, just to listen, without asking him to participate.

- Meet with the couple.
- Establish rapport with the father at the very beginning of the visit. Ask about his work, hobbies, or other interests.
- Acknowledge the father's importance throughout the pregnancy and after delivery. Use him as a consultant and ask him how he thinks the pregnancy is going.
- Encourage the father to attend prenatal visits whenever possible, and to listen to the fetal heartbeat.
- Suggest that the father also attend to his health.
- When there are signs of marital conflict, acknowledge the stress of pregnancy on a marriage.

Second Trimester

- Elicit the couple's concerns and fears about the pregnancy, especially regarding possible complications of labor or delivery, pain during labor, and birth defects.
- Have the couple go together for any necessary tests, especially ultrasound.
- Invite important family members and friends to prenatal visits. Consider having the woman's mother come for a visit.
- Discuss sexual issues of pregnancy with the couple, including the safety of intercourse throughout pregnancy and the use of different positions.
- Begin the discussion of breastfeeding early on, and provide information about its benefits to the baby and the family.
- Encourage the couple to take a minivacation or "second honeymoon" alone together during the second trimester; suggest that the father schedule one or two weeks of paternity leave for the time of delivery.
- Find out what the couple has told or plans to tell the other child(ren) about the pregnancy.
- Discuss with the couple how they want their children involved in the labor and delivery.
- Help parents anticipate sibling rivalry and regressions in development of siblings of a new baby (e.g., bedwetting, thumbsucking) and offer some suggestions.

Third Trimester

- Provide anticipatory education about mother's and father's roles during labor and delivery.
- Discuss ways for the father to be supportive to the mother during labor and delivery.
- Make preliminary decisions about: where to labor and deliver pain medication breast feeding circumcision

Labor and Delivery

- Encourage families to use family birthing centers, when available.
- Avoid interventions such as enemas, fetal monitoring, IVs, and medication, unless clearly indicated. Encourage the father to take an active role in assisting during labor.
- Recommend continuous support throughout labor.
- If the delivery is uncomplicated, encourage the father to assist as much as he likes (e.g., helping to deliver the baby's head or to cut the umbilical cord); encourage nursing as soon as it is desired.
- Clearly explain to the couple what is happening, especially if complications arise. Allow the father to be present for a Cesarian section if it is required.
- Examine the baby at the bedside and explain normal findings to both parents; when birth anomalies are present, inform parents immediately, but stress the overall health of the baby.

Postpartum

- Encourage feeding on demand and rooming-in, and avoid supplementing breastfeeding; if the mother is having difficulty with breastfeeding, observe a feeding to see what the problems are.
- Encourage siblings to visit when the mother and infant are in the hospital.
- Conduct the newborn's discharge physical at the mother's bedside, and have the couple participate in the examination.
- At 2 weeks, make a home visit to assess how the infant feeding is going and the new family is coping.

Infertility

- Provide education.
- Encourage communication.
- Keep it in perspective.
- Acknowledge the stress.
- Acknowledge the grief.
- Mobilize resources.
- Develop a loving story.

Adoption

- Review motivation for adoption and address any unresolved grief over failure of infertility treatment (if applicable).
- Educate about options for adoption and use knowledge of the family to facilitate appropriate referral.
- Be proactive about addressing risks of adoption and making expectations realistic.
- Acknowledge both emotional and financial stresses.
- Encourage parents to tell their adopted child that they are adopted in an age-appropriate way.
- Provide anticipatory guidance and attend to special cross cultural/ethnic issues; encourage parents to adopt a dual-culture identity.

FURTHER READING

1. *Text book of Family Medicine, 9th Edition, Robert.E.Rakel et.al, Elsevier.2016*
2. *Behavioral Medicine: A Guide for Clinical Practice 3rd Edition, Mitchell D. Feldman, Mc,Graw Hill,2008.*
3. *Family Oriented Primary Care, 2nd Edition,Susan H,Mc.Daniel et.al, Springer, 2005*
4. *Essential Family Medicine: Fundamentals and case studies, 3rd Edition, Robert.E.Rakel et.al, Elsevier,2009.*
5. *Handbook of Family Medicine, Edited by Bob Mash, Oxford University Press, SA, 2007.*
6. *Practical Guide to Health Assessment, through the life span (3rd Edition)*
7. *Mildred O. Hogstel, Linda Cox Curry, (2001.F.A Davis Company)*

MODULE 4:

COMMUNITY-ORIENTED PRIMARY CARE (COPC)

A continuous process by which primary health care is provided to a defined community on the basis of its assed health needs, by the planned integration of primary care practice and public health.(Abramson,1988)
A systemic approach to improving primary health care service through integrating clinical medicine with public health at community level. (Abramson, Nutting, Kark), view
The family physician seeks to understand the context of the illness, view his/her practice as a population at risk, is part of community-wide network of supportive and health care agencies, and is a manager of resources. (Mc Whinney, 1981)

COMPONENTS OF COPC

1. Defining a community by geographical, demographic or other characteristics (defining practice population)
2. Determine the health needs of the community in a systematic manner.
3. Identifying and prioritizing health problems
4. Developing programs to address priorities within the context of primary health care.
5. Assessing outcome.

COPC is a combination of primary care and community care.

Domain	Primary Care	Community Care
Focus of care	Patients seen as individuals Focus an active users	Member of a population Active and inactive users
Assessment Method	Patient-oriented clinical skills	Epidemiological skills
Planning bias	Utilization by active users	Health needs of community
Personnel	Family physicians, Specialists, and ancillary staffs	Community groups and family physicians
Interventions	Individualized patient education and treatment	Community outreach prevention programmes
Evaluation	Health of the individual patient	Health status of an identified population

A STEP-WISE APPROACH TO COPC

Step 1 Practice profile	Work out (ten) commonest clinical problems presenting to a practice, clinic, ward, or hospital
Step 2 Individual assessment	Find a patient (or patients) with that problem, and understand the individual(s) in detail
Step 3 Home visit	Visit that patient's home, then describe the family and the context in which the illness developed
Step 4 Community assessment	Define/describe the community e.g: denominator data, resources, structures and functioning.
Step 5 Priorities	Identify and prioritize health problems in the community

Step 6 Team formation	Convene a team appropriate to the priority issue in consultation with the district management team or interest groups
Step 7 Plan for action	Plan and complement activities that address the most important problems
Step 8 Evaluation	Evaluate what has happened in terms of the experiences of individuals patients

COPC integrates individual and population-based care, blending the clinical skills of the family physician with epidemiology, preventive medicine and health promotion. The sequence is a dynamic process that may not be linear. The main point is that this process is designed to improve the health of a population through systemic application of principles that have been shown to have health benefit for communities.



FURTHER READING

1. *The contribution of Family Medicine to improving health systems, edited by Michael Kidd. WONCA Paddiffle publishing.2013 WONCA*
2. *Handbook of Family Medicine, Edited by Bob Mash,2nd Ed, Oxford University press, South Africa, 2007*
3. *Family Medicine Module of DFM by family Medicine core faculty,2004*

MODULE 5:

THE SICK ROLE, ILLNESS BEHAVIOUR AND PROBLEM BEHAVIOUR

These three concepts are helpful in analyzing the decision to consult a physician.

1.The concept of the sick role (Sigerist 1960 and Talcott Parsons 1951).

When a person has consulted a physician and been defined as sick, he or she occupies a special role in society. Entering the sick role has certain obligations and privileges. The individual is exempted from normal social obligations and is not held responsible for his or her incapacity. On the other hand, the sick person is expected to seek professional help and to make every effort toward recovery. Whether or not a person decides to enter the sick role when he or she becomes ill is dependent on many individual and group factors that are independent of the severity of the illness.

2. The concept of illness behavior (Mechanic 1962).

The ways in which given symptoms may be differentially perceived, evaluated, and acted (or not acted) upon by different kinds of persons. The illness behaviour exhibited by an individual determines whether or not he or she will enter the sick role and consult a physician. An understanding of illness behaviour can change the physician's perspective "why did the patient come?"

3.The problem behavior (Lamberts 1984).

The action of a patient with a problem of living as distinct from an illness is regarded as the problem behaviour.

Variation in illness behaviour:

a) Under-reporting of serious symptoms and consultation for minor symptoms:-

In the Glasgow survey, failure to consult for serious symptoms was associated with unemployment due to illness, passive religious allegiance, lower social class, living alone, and higher neuroticism scores.

b) Self care and other alternatives to medical care

1. High rates of self-medication (between 50-80% of adults reported taking an OTC medication in a 2-4 weeks period. (Freer 1978).
   In Myanmar, the so-called pharmacists (Combo-pack sellers) are often resources of advice to community. The reason of utilization is easy accessibility, low cost and other multifactorial factors. (The most common of these were URTI, stomach and bowel complaints, pain and enquires about vitamins.)
2. Although most attention has been focused on medication, a large number of other remedial actions may be taken. In a study using the health diary method, a large number of nonmedical actions were reported. Some of these were social actions, like talking to friends or relatives, attending a club, or going out for meal.
3. There may be lay referral, or consultation with family members, friends, neighbors, and other nonprofessional people whose advice may be sought. Certain individuals in a neighborhood may have a reputation for being knowledgeable in health matters.
4. Folk healers and practitioners of alternative medicine are widely available in most societies. They may be used as the initial source of care, or as an additional resource when the health care system has not met the patient's expectations.

THE BIOPSYCHOSOCIAL MODEL OF ILLNESS (ENGEL, 1980)

Let's see a following example of a young woman of nineteen injured her knee while playing and admitted to hospital for surgery.

SYSTEMS HIERARCHY

PATIENT'S LIFE IN SYSTEMS TERMS BEFORE KNEE INJURY



Resolution of problems in system terms (After Engel, 1980)

Establishment of therapeutic relationship

Community	Mobilization of rehabilitation resources
Family	Reduced anxiety, increase understanding
Doctor-patient	Communication, therapeutic relationship
Person	Development of insight, adjustment of life goals, restoration of self respect
Nervous system	Return to normal weight and heart rate, recovered function in knee
Organ (organ system)	Return to normal weight and heart rate, recovered function in knee
Tissue	Muscle strength restored, surgical repair of knee joint
Cell	Healing of knee joint
Molecule	

A Health Belief Model (1950, USA Social Psychologists)



DECISION TO CONSULT

STRESS, LIFE EVENTS AND COPING



THE DEVELOPMENT OF THE PATIENT-DOCTOR RELATIONSHIP

1. Forming the relationship
   - The consultation has always been central to medicine as the main point of interaction with patients. The patient-doctor relationship has moved towards a true *partnership* from traditional *paternalistic* approach.
   - In working towards a partnership family physicians try to develop an open relationship with patients, making sure that they are well informed and involved in any decisions about their treatment.
   - Concordance or adherence used to be unwittingly called compliance and it means that the doctor and patient have discussed, negotiated and mutually agreed on a plan of action rather than the patient 'submitting' to the doctor's ideas.
2. Achieving rapport
3. Addressing patients, respect and titles
4. Patient Enablement or Empowerment
5. Developing partnerships through meeting a patient's ideas, concerns and expectations (ICE)
6. Shared Decision making and the mutual management plan

EMPATHY

Empathy is the ability to put yourself in the patient's place and act accordingly. It is more than just an intellectual appreciation of the patient's situation. It is a blend of understanding and caring, which is evident to the patient in your actions and words.

Empathy supports the therapeutic relationship between patient and doctor. It is the cognitive and behavioural aspect of compassion and care. Empathy can be enhanced by training. It is a key component of a patient-centre approach.

PATIENT SATISFACTION (PS) (ATTRIBUTES CONSIDERED MOST IMPORTANT FOR PS)

What patients want in a physician (Stock Keister et.al., 2004)

- Does not judge
- Understand and supports me
- Is always honest and direct
- Acts as a partner in maintaining my health
- Treats serious and non-serious conditions
- Attends to my emotional as well as physical health
- Truly listens to me
- Encourage me to lead a healthier lifestyle
- Tries to get to know me
- Can help with any problem
- Is someone I can stay with as I grow older

MODULE 6:

SETTING UP A PRACTICE

INTRODUCTION

General Practitioners (GPs) provide primary care, in a personalized manner, on continuing basic with a comprehensive approach to all patients regardless of their age, sex or type of illness and extend the care to their family members taking into account the total environment of the patient.

CHARACTERISTICS OF GENERAL PRACTICE (GP) FAMILY MEDICINE (FM) ARE;

(1) The GP/Family doctor is an effective clinician.
(2) The doctor - patient relationship is central to GP/FM.
(3) GP/FM is person - centered, family - oriented, and community - based.
(4) GP/FD is a resource to a defined practice population.

ART AND SCIENCE OF GENERAL PRACTICE

Considering the above principles and attributes of GP/FM, the quality as well as success in clinical practice not only depend on technical competency (knowledge and skills) but the same weight and age bear on good - doctor patient relationship. General practice is science as well as art. Both qualities are indispensable. Many a times, personality and tact help more than academic ability. Long - term relationship, mutual trust, sympathy, friendship and confidence encourage the doctor and the patient (family) to pull together through many serious illnesses.

SETTING UP A PRACTICE

1. LOCALITY AND LOCATION

A good locality should be chosen considering the population background and catchments area. The location of clinic should be easily approached from various parts of that locality.

2. THE PREMISES

Building is an important criterion. The patient must have a good impression as soon as he enters. The clinic should be in general, tidy, neat and modern. The basic requirements are:

(a) Waiting room
(b) Reception room
(c) Consultation room
(d) Treatment room
(e) Toilet

(a) Waiting room

Generally, the entrance, the waiting room and the reception should be arranged for easier interface. It should be decorated in light colours and look welcoming. It should be adequately ventilated and lighted. The size can vary from (100 - 600 sqft) where (10 - 20) persons can be accommodated.
Ornament (pictures, flowers) and printed information (newspapers, magazines, brochures) will help to make the waiting timeless tedious for persons who are ill or depressed. Opportunity

should be taken to display health education materials - books, pamphlets etc. and also others like posters and models can be displayed. Comfortable seats should be placed.

(b) Reception room

It could be used as a reception for incoming patients, for keeping patient's records, storage of drugs, cash desk, dispensing and stationeries. It needs to be sited so that the receptionist cum nurse is in control of patient entering the waiting room, can contact doctor (carrying the records) and also be available to patient leaving the consultation room to dispense the medicines etc. It should be spacious and need large desk area for stationeries, telephone etc.
In a bigger clinic or at a Group Practice Clinic it is desirable to have a Pharmacy or Dispensary point separately.

(c) Consultation room

The size of consultation room could be (100 sq-ft = 10 ft x 10 ft) or larger where a screened couch can be put. The room can be divided into (3) function zones. Zone (1) is doctor area which needs the best day light and where all his equipment and needs are grouped to be within reach of his chair. It will include desk, swivel chair, worktop, stationeries, and examination instruments. Zone (2) is the patient seating area with sufficient space for an additional accompanying person. Zone (3) is the examination area with couch including drawers, shelves, table or trolley for instruments, injection syringes, place for emergency kit, basin, dust bin, etc. There must be sufficient space for examination from the side.

(d) Treatment room

It could be attached to consultation room or better a separate room (if possible) where could be provide;

(i) Emergency tray
(ii) Minor surgery - dressing, I& D, suturing, etc.
(iii) Minor procedures - catherization, PR exam, SE, VE, Pap smear taking, N/G suction etc..
(iv) Essential laboratory facilities - urine test kit (sugar, albumin, UCG) etc.
(v) Provisional facility for wastage from clinic.

(e) Toilet

It should be conveniently situated with hand washing facility and always kept clean.

3. EQUIPMENT AND INSTRUMENTS

At least minimum facilities should be kept; more can be added depending on growth of practice and interest of GP.

(a) Furniture - for waiting room, reception, consultation room has been described. The chairs, cupboards, desks, the wall and the floor should be kept always clean.
(b) Equipment - Stethoscope, BP apparatus, thermometer, torch, hammer, tongue depressor, inch tape, weighing machine, high stand, etc.
(c) Instruments- Forceps (artery, tooth/ non - tooth) , knives, scissors (straight, curve), suture mate rails (needles, needle - holder), proctoscope, Vaginal speculum, urinary catheters, enema set, kidney trays, bowls, breast pump, stomach wash tube, Ryle's tube, Foreign body removal set (probes, forceps, ear syringes), dressing materials (bandage, sterilized gauze), drip stand sterilizer etc. Instruments needed may vary according to the interest and capability of individual GP.

4. STAFF OF THE PRACTICE

(1) Medical officer/doctor - one in solo, more in group practice.
(2) Practice nurse/dispensary nurse.

(3) Receptionist/Secretary.
(4) Workers - cleaner, watchman etc. Note 1) + 2) must be qualified and fully licensed.

5. SERVICES AVAILABLE

- General Consultation and treatment, Consultation - visiting
- Counseling on STDs, HIV/AIDS, Birth spacing etc..
- Office (minor) surgery.
- Special clinics - well - woman, well - baby, youth friendly clinics, asthma, hypertension diabetes and immunization etc.
- Referral services.

6. LEGAL REQUIREMENT FOR CLINIC REGISTRATION

MODULE 7:

MEDICAL RECORDS

"As a medical student when I entered hospital, I was advised to keep records of all the patients whom I encountered. I was taught that clinical records are a greater educational value than textbooks. Since then, I have kept detailed records of patients who have come under my care."

"PROFESSOR HODGKIN"

1. INTRODUCTORY COMMENTS:

- An effective record keeping system contributes to the standard of care. In fact, this is vital in our daily practice of a family physician. To improve the quality of medical care, GP/family physicians should be able to maintain a good record keeping system,
- Medical records are more than an aide me moiré or a documentation of clinical details just in case medico-legal circumstances arise. Properly kept and used, they allow us to see the problem-solving process from which we can deliver better care.

2. AIM:

To develop a good record keeping system in family practice leading to quality of care.

3. LEARNING OBJECTIVES:

At the end of this learning session, the candidates should be able to

3.1 describe the utility of records and pitfalls

3.2 achieve knowledge on different types of records – the source oriented medical records (SOMR) and problem oriented medical records (POMR) including their components

3.3 initiate in implementation of a problem oriented medical record keeping systems

4. WHAT IS A MEDICAL RECORD?

Record is the statement of facts / written document or stored information. Medical record is the scientific, administrative and legal document in respect of the patient care relating to sequence of events, observations, investigations, diagnosis, treatment planned and carried out.

There are 2 types of records –

1. Records on work of practice (*e.g., patient register; daily prescription book, accounting records*)
2. Medical Records which contain a summary of the patient's clinical condition to enable the attending doctor and nurses to make out at a glance the essentials of an illness and the treatment given

4.1. UTILITY OF RECORDS AND PITFALLS.

UTILITY

(1) The main objective of maintaining medical record is to improve the quality of patient care, avoid omissions, unnecessary repetition of diagnostic tests, procedures and other treatment measures

(2) It helps to maintain the continuity of medical care (Continuing Care)

(3) It also forms the basis to issue necessary medical certificates for the purpose of leave, insurance, employment etc…

(4) It helps to evaluate, self-evaluation, CME, CPD and medical audit.

(5) Record information forms the basics of observation, analysis, inference, proving or disproving the hypothesis (sheet anchor of medical research leading to evidence based GP)
(6) Medical Records further help to determine the morbidity and mortality patterns, public health measures for prevention and control, monitoring of health programmes, their evaluation and planning of the alternate strategies etc…
(7) It acts as a communication tool between one physician and another.

MEDICAL RECORD (PITFALLS)

1. Traditionally GP has been family physician to this patient and has grown with the families under his care and most of the events pertaining to the families under his care having a bearing on health have been stored in his brain. There is reluctance on his part to adopt a change.
2. There is lack of motivation, training, knowledge and skill on part of physician to maintain effective records.
3. For the fear of losing confidentiality of the information and thus
4. For the fear of recorded information being used as evidence against the physician for alleged malpractice.
5. For the fear of records forming the basis of assessment of income and other taxes.
6. For the fear of being blamed by the family/patient for not organizing scientific treatment, investigations, referral and planning of the treatment

PRINCIPLES OF GOOD RECORD KEEPING

1. Data Gathering
2. Recording
3. Retrieval
4. Storage

Data gathering

Not possible for comprehensive information at first visit
Selective information
After DPR – more personal & sensitive information

Help by consistent

- filing
- Indexing
- Logical grouping
- Summary

Recording

- Must be legible and clearly recorded
- Information should be accurate and concise

Retrieval

Storage

- Confidentiality
- Easily retrievable

4.2 SOMR Vs POMR

4.2.1. SOMR (Source Oriented medical Record)

- In this system, the information is recorded chronologically and sequentially as they are available irrespective of the type of data or clinical context.
- The SOMR is still the main format used in in-patient care (Hospital practice) where detailed clinical records from many sources are accumulated as they become available.
- In family practice SOMR is still used but POMR is increasingly implemented.

4.2.2. POMR (Problem oriented Medical Record)

This was first described by Weed LL in 1969 as an attempt to address the deficiencies of SOMR. It consists of 4 elements viz. The master record, the progress notes, the flow charts and the source documents.

POMR has 3 strengths;

- Every item of information has a defined place in clinical contexts,
- Rapid retrieval of information is possible as one knows where exactly the information is recorded.
- Problems stand out whether they are active or inactive; unsolved problems can be seen in context of the whole history

Here we should learn the POMR record system of Singapore which was documented by Prof: Cheong PY, Goh LG and Yeo H (1988). It has 4 elements;

THE MASTER RECORD

- Bio-data
- Problem List
- Report Summaries
- Graphic Space

BIO-DATA – BACKGROUND INFORMATION OF PATIENT AND FAMILY

- Fixed: SEX, DOB, previous illnesses, immunization, family history.
- Changing: Marital status, occupation, address, screening tests.

PROBLEM LIST

- It has 3 columns viz. Active date, the problem and inactive date.

REPORT SUMMARIES

There are table for immunization records and also events. Events are summary information such as referrals, hospitalization etc…

GRAPHIC SPACE

This is meant for the family genogram or significant physical signs which are best drawn

PROGRESS NOTES AND SOURCE DOCUMENTS

FOUR-COLUMN VERSION

First 2 columns - date and problem number indexed to the problem list
3rd column - SOA (Subjective, Objective, Assessment or Analysis

4th column - plans (P) which are prefixed with D, T or for diagnostic, treatment or therapeutic or Instruction

FLOW CHARTS

Very useful for continuing care for chronic problems (e.g., Hypertension, Diabetes and Bronchial Asthma) or structured consultation such as medical check-ups.



Report Summaries

Date	Event	Result

Genogram

Subjective (S)	Objective (O)	Assessment (A)	Plan (s) (P)

PRACTICE MANAGEMENT (POMR)

Scenario

U Sein Win, 55 years old man presents to your clinic with 2 day history of shortness of breath, frequency of urine and feeling thirsty. He has family history of Diabetes and IHD in his father. He denies any history of smoking and alcohol drinking. He has history of Diabetes for 5 years and Hypertension for 10 years.

Regarding the past history, he gives history of calculus cholecystitis and cholecystectomy done in 1995.And also history of right sided inguinal hernia and operation done in 1990.

On Examination
Height – 1.63 cm , weight – 69 kg
BMI – 26 , Waist / Hip 0.9
No edema , JVP not increased
BP 160/100mmHg, HR 90 / min(sinus rhythm)
VBS all over the lung fields
Abdomen – no significant finding

On investigation

RBS - 350 mg%
Urine RE - sugar present, No pus cell
ECG - within normal limits
CXR - Normal film

Diagnosis- Uncontrolled Diabetes with Hypertension
Treatment given

Gliclazide MR60 - 1 OD
Metformin - 1 BD
Perindopril - 4 mg OD

The next day, he returned your clinic for follow up, He is feeling better.
BP 130/80 mmHg
HR 80 / min(Sinus rhythm)
RBS (2 hour PP) -180 mg%

You are happy with the results, but you have to do further investigations such as lipid profile. You would like to provide Education on Diet and Exercise.

TASK

Please record your findings in a SOAP format of problem oriented medical record.

PROBLEM LISTS

Active	Problems	Inactive
2002	Diabetes	
1997	Hypertension	
	Calcus cholecystitis Cholecystectotomy	1995
	RIH & Operation	1990

Subjective (S)	Objective (O)	Assessment (A)	Plan (P)
Date 1			
SOB	*Ht - 1.63 m*	*DM uncontrolled*	*To control DM, HT*
Frequency of urine	*Wt - 69 kg*	*Hypertension*	
Thirsty	*BMI - 26*	*No IHD*	*GliclazideMR60 1 OD*
Smoking (-)	*WHP - 0.9*	*No Heart failure*	*Metformin 1 BD*
Alcohol (-)	*Oedema (-)*	*No Lung problems*	*Perindopril 4 mg OD*
DM & IHD in father	*JVP - normal*		*To Review tomorrow*
	BP – 160 / 100 mmHg		
	HR – 90 / min, SR		
	VBS – all over		
	Abdomen - soft		
	Move with respiration		
	BS (+)		
	RBS 350 mg %		
	Urine RE , Sugar +		
	Sugar +, Pus cell (-)		
	ECG - NAD		
	CXR - NAD		
Date 2			
Feeling better	*BP - 130 / 80 mmHg*	*DM & HT controlled*	*Same treatment*
Symptoms - decreased	*HR - 80 / min*		*Diet & HE*
	RBS(2 hr PP)180mg%		*Review tomorrow*
			& to continue

OVERVIEW OF PATIENT CONFIDENTIALITY

The doctor-patient relationship (DPR) is based and built on trust and confidentiality of information provided is a cornerstone of this relationship.

FOUR ETHICAL PRINCIPLES (4 'CS')

This applied to 4 conditions in which the family doctor should breach the confidentiality of the patient.

- In the Course of care of the patient
- With the patient's Consent
- Under statutory Compulsion
- In situations with strongly countervailing public interest

IN THE COURSE OF CARE OF THE PATIENT:

- Health Care Provider providing direct care to the patient

- Confidentiality should be based on a need-to know-basis

WITH THE PATIENT'S CONSENT

Consent of the patient can be implied or explicit.

UNDER STATUTORY COMPULSION

Laws in most countries enacted in public interest to compel disclosure and notification of certain diseases.

In situations with strongly countervailing public interest

- The preventing harm to others and preventing crime could exceptionally outweigh both the private and public interest.
- There must be a real and serious risk of some other person or persons suffering harm if the confidence is not broken e.g. SARS, AVIAN FLU, H1N1 Flu

MODULE 8:

EMERGENCY CARE AND THE GP'S HOUSE CALL

INTRODUCTION

Emergency care and house call services are part and parcel of our daily practice and every GP should be prepared to provide these services whenever he or she is called upon emergency care outside the hospital represents one of the most interesting and rewarding areas of medical practice.

AIM

- To improve the candidate's awareness on components and importance of emergency care and house calls under the umbrella of primary care

OBJECTIVES

At the completion of this module the candidates should be:

1. Familiar with the underlying principles of dealing with common emergencies encountered in general practice
2. Able to plan safe and effective emergency care and house called services
3. Able to prepare the house call bag using available resources - the choice of drugs and equipments and their uses.
4. Able to respond effectively to a call for home visit

EMERGENCY CARE, THE GP'S HOUSE CALL AND THE DOCTOR'S BAG

Almost everyone who goes to bed counts upon a full night's rest: like a picket at the outputs, the doctor must be ever on call. (Karl F. Max (1796-1877)

DEFINITION

An event demanding immediate medical attention.
The demand is determined by patients, relatives, neighbors, nurses, police and others, but is sometimes modified by the doctor or his or her staff.
In dealing with a specific emergency, the doctor adopts a different approach instead of taking a history and performing an examination in the usual way, he or she replaces this with a technique of rapid assessment and immediate management. In fact, the diagnosis may be possible on the information available over the telephone.

GENERAL PRINCIPLES CONCERNING THE EMERGENCY CARE AND THE HOUSE CALL SERVICES.

I. BE A GOOD GP

A good GP = a sound basic knowledge + common sense

1. Common things occur commonly
2. The race may not always be to the swift nor the battle to the strong, but it's a good idea to bet that way.
3. When you hear hoof beats think of horse: not zebra.
4. Place your own capabilities and limitations.

II. REALIZE YOUR OWN CAPABILITIES AND LIMITATIONS

1. If what you're doing is working, keep doing it.

2. If what you're doing is not working, stop doing it.
3. If you don't know what to do, don't do anything.

III. QUESTIONS YOU SHOULD ASK YOURSELF BEFORE TREATING ANY PATIENT

Q: Can I treat patient?
A1: Yes - go ahead
A2: No - refer
A3: No sure - call for help
Q: Should I be treating this patient?

- Patient is much safer in more experienced hands if you lack enough practical experience, although you have theoretical knowledge.

IV. HAVE AN ACCESS TO SPECIALIST NETWORK AND HOSPITALS.

- Establish effective communication between the GP and the specialist.

V. TAKE EXTRA CARE WHEN DEALING WITH EXTREME OF AGES, THE VERY YOUNG AND THE VERY OLD.

- Sign and symptoms are very vague & misleading in this age group. And don't be overconfident.

VI. BE PREPARED FOR THE UNEXPECTED

- Sometimes you may be called upon for an apparently trivial c/o like giddiness or fainting but the underlying cause can turn out to be something serious. e.g, silent myocardial infarction.

VII. BEWARE OF MEDICO-LEGAL ISSUES

- Suicide
- Homicide
- RTA
- Death certification

VIII. WHEN TO GET UP AND GO

- It is important to get up and go when the call signals danger.
- The following signs and symptoms make attendance at emergency mandatory
    - Unconsciousness
    - Convulsions
    - Chest pain in an adult especially associated with pallor and sweating.
    - Pallor and sweating in any patient with pain, collapse or injury
    - Collapse especially at toilet
    - Significant haemorrhage
    - Breathlessness including bronchial asthma
    - The agitated patient threatening homicide or suicide (take a policemen or company)
    - Serious accidents

IX. TWELVE GOLDEN RULES

1. Acute chest pain represents myocardial infarction until proved otherwise.
2. Always consider the possibility of hypoglycaemia and opioid over-dosage in the unconscious patient.
3. Always consider the possibility of acute anaphylaxis in patient with past history of allergies.
4. Beware of the asthmatics who cyanosed with a silent chest and tachycardia.
5. Consider ventricular fibrillation or other arrhythmias foremost in as adult with sudden collapse or dizziness.

6. The sudden onset of severe headache adds up to subarachnoid haemorrhage
7. If a patient is found cyanosed always consider upper airway obstruction first.
8. Exclude acute epiglottitis in a child with a sudden onset of respiratory distress and pallor.
9. Consider the possibility of a ruptured intra-abdominal viscus in any person especially a child with persistent post traumatic abdominal pain.
10. Consider intra abdominal bleeding first and foremost in a patient with abdominal pain who collapses at toilet.
11. Always consider the possibility of depression in a post partum woman, presenting with undifferentiated illness or problems in coping with the baby.
12. Always consider ectopic pregnancy in any woman of child bearing age presenting with acute abdominal pain.

SCOPE OF EMERGENCY CARE SEEN IN GENERAL PRACTICE:

Paediatric emergencies	*e.g. Persistent crying, abdominal pain, fits.*
Cardiovascular emergencies	*e.g. chest pain, acute left ventricular failure.*
Respiratory emergencies	*Asthma, pneumothorax*
Gastrointestinal emergencies	*Abdominal pain, haemetemesis, melena.*
Urogenital emergencies	*Acute urinary retention, renal colic,*
Obstetric and gynaecological emergencies	*Antepartum haemorrhage, ectopic pregnancy, twisted ovarian cyst*
Neuromuscular emergencies	*e.g. stroke, transient ischaemic attack, loss of consciousness.*
ENT and eye emergencies	*Foreign bodies, glaucoma, ear ache, epistaxis*
Endocrine emergencies	*Not common, e.g. diabetic ketoacidosis and hypoglycaemic coma*
Bites and stings, burns and scalds	
Forensic emergencies	*e.g. assault or rape*
Psychological or psychiatric emergencies	*e.g. acutely confused, suicidal, extremely anxious, aggressive or violent, acutely psychotic*

DELIVERY OF EMERGENCY CARE

APPROPRIATE PREPARATION

- Equipment and Clinic Organisation
  - Basic equipment and essential drugs. House call bag.
  - Clinic staff trained to recognize emergency situations.
  - Priority treatment for such patients

MANAGEMENT PROTOCOLS

Work out in advance management protocols for the emergencies likely to be encountered. Clinic staff should be familiar with their roles in these protocols.

Acute paediatric problems

- Many are trivial from a purely medical point of view, but parental anxiety can be tremendous, take the parents seriously, assess each case according to severity and treat, reassure or refer as necessary.

Chest pain

- The task of the general practitioner is to identify those that are medical emergencies (e.g. acute myocardial infarction), refer these for further management, and treat the others as appropriate.

Loss of consciousness

- May be potentially life threatening or trivial
- Immediate treatment required e.g. hypoglycaemic coma
- Urgent hospital referral required e.g. head injuries, poisoning
- Non-life threatening causes e.g. vasovagal attack ('faint') and hysterical conversion. Management depends on the particular circumstances. Referral may or may not be necessary.

Acute respiratory distress

- Quick history and clinical assessment.
- Urgent stabilization before referral e.g. acute laryngeal oedema
- Urgent referral required without intervention e.g. acute epiglottitis in children.
- Non-urgent conditions, e.g. hyperventilation.

Severe abdominal pain

- It is worthwhile spending time on a careful history and keeping a high index of suspicion for the unusual.
- Difficult to decide whether to make a visit, or to give advice over the telephone. E.g. renal, biliary or abdominal colic, can be managed as outpatient initially followed by referral if indicated.

Gynaecological emergencies

- Such as ectopic pregnancy and twisted ovarian cyst must be referred immediately following initial stabilization.

Bleeding in pregnancy –

- If ectopic pregnancy is suspected, do not do a pelvic examination and arrange for urgent hospital admission.

Injuries

- Mild to severe. The doctor's task is to quickly assess the severity, amount of bleeding, decide whether to institute first aid measures and refer to the hospital straight away, or whether the patient can be treated in the clinic.

Allergic reactions

- The task of the general practitioner is to treat those conditions that are life threatening e.g. subcutaneous adrenaline in angioedema, arrange for hospital referral those that are potentially severe e.g. early Steven-Johnson syndrome

The disturbed patient/forensic problems

- The family physician often has to decide how to alleviate the crisis over the next 24 hours, rather than trying to find a definitive solution to a long term problem. Cases of alleged rape need to be referred. In the case of sudden death, a post mortem is always prudent.

Patient Education

- It is important that patients are educated as to which situation constitutes an emergency and which doesn't.

SCOPE OF HOUSE CALLS AS SEEN IN GENERAL PRACTICE

ASSESSMENT AND/OR MANAGEMENT OF ACUTE ILLNESSES

- Assessment for home management vs. hospitalization: Home conditions and availability of family support important factors to consider.

ASSESSMENT AND MANAGEMENT OF PATIENTS DISCHARGED FROM HOSPITAL

- e.g. post-surgery or recovering from myocardial infarction and stroke.

MANAGEMENT OF PATIENTS WITH CHRONIC ILLNESS –

- e.g. patients with stroke.

MANAGEMENT OF PATIENTS WITH TERMINAL ILLNESS

- Assessment of home conditions and family function
- Opportunity for the doctor to meet family members, observe interactions among them, provide family counseling.
- To allay patient or caller anxiety
- To allay anxiety alone is sometimes a good enough reason to make a home visit.

DOING A HOUSE CALL

PREPARATION

Personal preparation: The doctor's readiness.

- The doctor must be prepared personally to do house calls.
- Should be contactable.
- Appropriate vocational training.
- Ensure the doctor's safety as far as is possible.

Clinic organization: *Staff readiness.*

- Clinic staff trained to recognize an urgent call.
- Good to document details of all requests for house calls, any advice given, and whether or not a visit was made.

THE HOUSE CALL BAG

- A matter of personal choice, also depend upon the type of practice. The doctor's bag needs to be stocked and ready at all times, contents should be checked and updated regularly.

HANDLING A REQUEST FOR HOUSE CALL

- Establish identity of the caller, contact telephone number, name of the patient, and location.
- Collect only enough information to decide whether a visit is necessary and if necessary, how quickly; whether any extra equipment needed; and whether to call for an ambulance at the same time.

THE DOCTOR'S BAG

Essential requirements for the bag

- sturdiness: disposable single use items
- lockable: light, port able equipment
- uncluttered

- regular checks to ensure non-expired drugs
- ready interior access - storage in cool place (not boot of car)

Recommended Contents & Stationery

- Drugs
- Equipment
- Stationery
- Miscellaneous items

Drugs

Oral

- Analgesics
- Antihistamines
- Antibiotics
- Sedatives
- Antidiarrhoeal agents
- Glyceryl trinitrate
- Antiemetics
- Soluble aspirin (for myocardial infarction)

Sprays

- Salbutamol aerosol
- Glyceryl trinitrate

Suppositories

- Paracetamol
- Diclofenac

Equipment

- Arenoid sphygmomanometer
- Stethoscope
- Diagnostic set (auriscope + ophthalmoscope)
- Tongue depressors
- Tourniquet
- Scissors
- Syringes 2, 5, 10, 20 ml
- Needles 19, 21, 23, 25 G
- Scalp vein (butterfly) needles
- Examination glove
- IV cannulae 16, 18, 20 G
- Alcohol swabs
- Micropore tape
- Thermometer
- Artery forceps
- Torch
- Patellar hammer
- Oral airway
- Scalpel

Stationery

- Practice letterhead & envelops
- Prescription pads
- X-ray, pathology referral forms
- Dangerous drugs record books, Pens

Miscellaneous items

- The doctor's bag check list
- Dosage details of drugs all age groups
- Important telephone numbers
- Handbook of emergency medicine

Drug	Presentation	Indication
1. Adrenaline	1 mg/ml	Hypersensitivity reactions & anaphylactic shock, VF (to assist CPR)
2. Atropine sulphate	0.6 mg/ml	Bradycardia, ureteric colic, worm colic, organophosphate poisoning
3. Benzyl penicillin	600 mg with 2ml water	Meningococcaemia, pneumonia (adults), Leptospirosis
4. Chlorpheniramine maleate	Burmeton 10 mg	Allergy, anaphylaxis
5. Dexamethasone	4 mg/ml	Acute severe asthma, increased ICP
6. Diazepam	10 mg/2ml	Status epilepticus and any convulsion such as eclampsia, sedation in acute anxiety & severe tension headache, psychiatric emergency
7. Ergometrine maleate	0.25 mg/ml	Uterine bleeding, abortion or PPH
8. Frusemide	Lasix 20mg/2ml	LVF, acute pulmonary oedema
9. Glucose, 50%, 25%	5g/10ml	Hypoglycaemia
10. Haloperidol	Serenace 2mg/ml	Psychiatric emergencies usch as severe agitation, psychosis
11. Hydrocortisone sodium succinate	Solucortef, 100mg/2ml, 250mg/2ml	Analphylactic shock, acute severe asthma, Addisonina crisis, thyroid crisis, acute allergies
12. Hyoscine butylbromide	Buscopan 20mg/ml	*Ureteric and biliary colics, acute pancreatitis
13. Lignocaine	Xylocard 100mg/5ml	Ventricular arrhythmias especially VT and VF
14. Metoclopramide or Prochlorperazine	Maxolon 10mg/ml Stemetil 12.5mg/ml	Severe vomiting (e.g. Meniere's disease, gastritis), acute labyrinthitis, migraine
15. Morphine sulphate	15mg/ml	Acute pulmonary oedema, relief of severe pain (not due to muscular spasm) such as MI
16. Pethidine	100mg/2ml	Severe pain such as ureteric and biliary colic
17. Naloxone	Narcan 0.4mg/ml	Opiate overdose
18. Vitamin K	10mg/ml	Anticoagulant overdose with haemorrhage, haemorrhagic disease or newborn
19. Salbutamol	Ventolin 0.5mg/ml	Bronchial asthma, other bronchospasm
20. Water for injection	5 ml	Diluent

*May be useful as an alternative drug

Picture: Doctor's bag (call bag)

HOSPITAL AT HOME CARE

Hospital-at-home care is an alternative type of care, most probably suitable for terminally ill elders

- Patients allocated to hospital-at-home care had a significantly reduced risk of death at six months.
- They conclude that admission-avoidance hospital-at-home can provide an effective alternative for certain older patients.
- The degree of patient selection may reflect the high levels of satisfaction, with those taking part preferring to be treated at home.

Note: Permission already obtained from this patient and his family

MODULE 9:

CONTINUING MEDICAL EDUCATION FOR GENERAL PRACTITIONERS

"Education is a life-long process"

"Socrates"

"All doctors in whatever branch of medicine (including GP) must have the opportunity and the time for continuing education in order to keep up to date in their own field and to remain reasonably well acquainted with developments in others"

"Scottish Council for P/G Medical Education (1973-74)

OBJECTIVE

- To help doctors to provide optimal care by changing their behaviour to reflect advances in knowledge base and practice of medicine.

This is accomplished both by imparting new information and by reaffirming that the existing information used by the physician is the most appropriate at that time.

DEFINITION

Continuing medical education (CME) is a process of gaining professional experiences from the time of initial graduation throughout the course of life-long career.

The prime purpose of CME activities is thus to enhance the competence and performance of general practitioner (GP), by providing clinically useful information, skills and attitude which could be translated into better patient care thus improving the health of population.

CME programme includes lectures, seminars, symposia, workshops, panel discussions, clinical meetings, conferences, on various topic - clinical, administrative and medico-legal issues by family physician and or for by eminent specialists.

WHY CME IN GENERAL PRACTICE?

Medical science as a whole and general practice in particular is growing, changing, expanding broader and deeper and ever pervading into social life. The GP must exercise continuous learning in theoretical, therapeutic and management skills and to meet the changing demands of the society.

Community expects on GP to be knowledgeable, skillful, understanding and readily available. The qualities of physician which actually make him a GP/ family physician (FP) like courtesy, compassion, communication, organization of collected information, identification of patient's problems, a good listener and counsellor etc. are not taught during his undergraduate years. To be able to do GP/FP sincerely, GP needs to be turned in the following spectrums:

- multidisplinary (internal medicine, surgery, O&G, child health, psychiatry, etc.)
- multidimentional approach (preventive, promotive, curative, rehabilitative)
- multifaceted subject (socio-economic, cultural, psychosomatic, knowledge, skill, attitude, value)

General practitioner sticks neither on one particular disease nor organ entity but it rather focused on the sick person as a whole. GP attends all ages (from to tomb) and both sexes. For its breath life-long continuing self-directed learning is essential in general practice. Through long term and close contact with the patient and his family, GP becomes a friend, a guide, advisor and coordinator in managing patient's sufferings.

No practitioner should be engaged in clinical practice unless he has had training appropriate to his responsibilities and unless he maintains and enhance his skills, through regular assessment and CME.

General family practice is the point of first contact for majority of patients. GP has often to deal with problem complexes or undifferentiated cases. He has also to response to house calls, accident and emergency cases in the clinic, on the road or in the hospital. He must be able to make a total assessment

of the patient's condition without subjecting unnecessary investigations, procedures and treatment or referral.

One shall also notice the fact that, in five years' time, the average medical graduate would have forgotten half the amount of the facts he had so laboriously swatted up during his final exams from the remaining half, 50% could be out of date and of no relevance to contemporary medical thinking. If he is lucky enough he is still left with 25% medical knowledge he can use.

General medical practitioners (public or private) accounting nearly 75% of the total medical force, form the back-bone of the profession.

It is mandatory to improve the quality of GPs by proper CME. With proper CME GPs will be more acceptable, accessible and affordable for quality and cost- effective care to the vast majority of the people irrespective of their age, sex and nature of disease.

THE NEED OF CME

1. To maintain standard of care and improve quality of care
2. To be able to apply new knowledge's
3. For adapting to change health needs
4. To correct the weakness/ inadequacy in initial training
5. To use resources more economically
6. To fulfill the need of health workers own desire to learn.

PRINCIPLES OF CME

1. Should respond to needs of health system/needs of people
2. Should also answer the needs of the health workers
3. Should form a bridge between training and practice
4. Should be accessible to all. (Universality)
5. Should be consistent at all levels, fully determined in content, duration and frequency, not sporadically (consistency).
6. Should be a permanent progressive learning process, learners participate on a regular sequential basis (sequentially)
7. Should be monitored and supervised with reviews and guidance.
8. Should be participants offered with accreditation certificates.

There are four concepts to be considered regarding the need of continuing medical education (CME) for general practitioners (GPs)

1. Every individual GP needs CME to improve his competency for better performance in his day to day practice.
2. Provision of CME is the most important role of medical colleges (Institutions) and professional organizations in order to maintain standard, raise quality and keep uniformity in medical practice.
3. Community demands quality and cost effectiveness in health care service and for that CME is a necessity.
4. Governments also support CME programmes for health care providers especially at primary care level to achieve optimal health care delivery.

STANDARD AND QUALITY IN MEDICAL PRACTICE

The process of standard and quality assurance in medical care and medical practice is intended to ensure that medical practitioners attain adequate level of education and professional training.

Medical colleges and professional organizations are responsible to organize, orientate and educate medical practitioners in line of community need and demands. It clearly shows that, to maintain standard, quality and uniformity among medical practitioners, CME is a must.

Both CME and research together with educational (training) programme and field of practice will identify general practice as a distinct discipline.

STRATEGIC CONSIDERATIONS

1. CME programs should be centrally developed (to mind standard, uniformity and quality but decentralized in implementation.)
2. The training should be conducted in such a way that their (GPs) daily practice sessions are not disturbed (Part-time, distance learning)
3. CME programs should be equitable access to all GPs throughout the country.
4. The course content should be based on learner's need, GP-oriented, GP friendly.
5. Make use of cooperation of all partners and resources within and without profession.

REFERENCES:

1. *Miller, G.E (1967) Continuing Education for what? J.Med Ed (42)*
2. *Collected reports of the Scottish Council for P/G Med Education 1973-1984 (33).*
3. *Departments of family medicine in medical colleges is a necessity. IMA CGP publication 1989 (12)*
4. *Dr. H.S Wong, Singapore family physicina 1988, vol XIV, NOH*
5. *Dr. Rajakumar (Past president of WONCA, Chairman of CGP Malaysia) (Family medicine education workshop Manila 1993).*
6. *Making medical practice and education more relevant to people's needs WHO-WONCA 1994 Conference, in Ontario, Canada, page (7)*
7. *Improving the performance of health centers in district health system WHO-Geneva 1997, Page (1)*
8. *Abbatt & Mejia, continuing education for health workers WHO, Geneva 1988.*
9. *Dr. Tin Aye, Continuing Medical Education for General Practitioners.*
    a. *MMJ: Volume 42, Number 3,4, December, 1998.*
    b. *MMJ: Volume 43, Number 1,2, June, 1999.*
    c. *MMJ: Volume 43, Number 3,4, December 1999.*
10. *Continuing the education of health workers - F R Abbatt, A Mejia WHO 1988.*

MODULE 10:

CONTINUING PROFESSIONAL DEVELOPMENT

DEFINITION

"The aim of continuing professional development (CPD) is to sustain the professional development of general practitioners and help them to provide high quality patient care throughout their careers."

(Oxford handbook of General Practice, Page 62, 2002)

General practitioner, to be able to accept the new, wider and changing roles and functions to master new jobs and skills, should be always thinking how to improve himself in all relevant fields as a professional and also as a working citizen. Thus, CPD may include a mixture of various educational activities e.g.

1. Further training in related specialties - psychiatry, pediatrics, acute and emergency medicine, behavioural Science, management of STDs and HIV/AIDS, reproductive health research etc.
2. English (and other) Language proficiency, art of presentation and public speaking, etc.
3. Philosophy- Psychology, Counselling Skills, etc.
4. Business, administration and management
5. Technical, computer use in general practice, minor surgery, etc.
6. Training in teaching, research, writing papers, etc.
7. As organizers in professional organizations, etc.

Unlike CME which is more or less limited to continuing medical educational activities, CPD on the other hand, encompasses any subject which may be useful in the professional life of a general practitioner allowing to develop to his maximal potential.

These activities may be formal (leading to certificate/ degree) or informal (trainings, scientific, meetings, seminars, workshops etc..). In many parts of the world, where GP/FM is recognized as a special discipline and where colleges of general practitioners/ departments of family medicine are well established in medical education the different kinds of CPD programs are provided for GPs. If a GP has time, interest and money, apart from his vocational training, he can attend and obtain many other related certificates (DCH, Diploma in Obstetrics & Gynaecology, geriatrics) Diploma in Reproductive Health, Diploma in Dermatology etc..

In CPD, required knowledge and skill is based upon the need of the learner, grounded in practice and thus has a personal value for the learner. As such the newly acquired knowledge and skill is more meaningful and is readily absorbed into practice. CPD comprises purposeful, systematic activity by individuals and their organizations to maintain and develop the knowledge, skills and attributes which are needed for effective professional practice. In fact, it is a process life-long learning and professional development.

In conclusion, a saying of Greek Argonauts is worthy to be mentioned here "the essential thing is not to live, the essential thing is to navigate (sail)."

A PROFESSIONAL

A professional is a person who possesses a body of knowledge and skill for a particular task. He is also a member of the professional society and has to uphold ethics. He has privilege to practice his own professional occupation. At the same time, he has the obligation to serve the society and should be accountable for him professional conduct and performance. A professional always updates his knowledge and improves his skill and excels in his performance. A true professional, unlike an amateur produces a good quality work. A professional always self-audit and self-correct his short comings. He keeps his patients and the people's health needs above his own interest.

In short “a profession is an occupation requiring specialized knowledge and skills with which a person earns his living.”

Three Pillars of Profession

Expertise
Ethics
Service





MODULE 11:

TOWARDS EVIDENCE- BASED DECISION MAKING IN FAMILY PRACTICE

DEFINITION OF EVIDENCE-BASED MEDICINE (EBM):

The integration of best research evidence with clinical expertise and patient value
Evidence-based practice is a systematic process primarily aimed at improving the care of patients.



THE BEST RESEARCH EVIDENCE

Clinically relevant
Patient-centered research about:

- Diagnostic tests
- Prognostic markers
- Therapeutic / preventive regimens
- Clinical Guidelines

CLINICAL EXPERTISE

- Ability to use our clinical skills & past experience to rapidly identify:
  - Each patient's unique health state.
  - Their individual risks and benefits of potential interventions.
  - Their personal values and expectations.
  - Availability of resources in the community

PATIENT VALUES

- The unique preferences, concerns, and expectations each patient brings to a clinical encounter.
- These must be integrated into clinical decisions if they are to serve the patient.

LIMITATIONS OF CURRENT CLINICAL PRACTICE

- **Variation in current practice**
  - ***Practice patterns of local "opinion leaders"***

- ***Advertising***
- ***Pharmaceutical representatives***
- ***Specialists who may see a different spectrum of patients***

UPDATING KNOWLEDGE

The following chart shows knowledge of hypertension management typically decrease after 20 years of practice.





Father of EBM

FIVE STEPS OF EBM (5 AS)

1. **Framing a focused question (ASK)**
2. **Searching thoroughly for research-derived evidence (ACQUIRE)**
3. **Appraising the evidence for its validity and relevance (APPRAISE)**
4. **Seeking and incorporating the user's values and preferences (APPLY)**
5. **Evaluating effectiveness through planned review against agreed success criteria (ASSESS)**

Step 1: ASK—formulating clinical questions: in order to practice evidence-based medicine, the initial step involves converting a clinical encounter into a clinical question.
A useful approach to formatting a clinical question is using PICO framework.
1. **P**---patient/population: which patients or population group of patients are you interested in?
2. **I**—intervention: which intervention/treatment is being evaluated?
3. **C**---comparison/control: what is/are the main alternative/s compared to the intervention
4. **O**—outcome: what is the most important outcome for the patient?

Evidence-based medicine is relevant for three other key domains: Etiology, Diagnosis, and Prognosis

Clinical Encounter:

UHM, 40 yr-old patient with chronic dyspepsia, who has no other sinister features that suggest malignancy, prefers to have non-invasive investigations to establish the diagnosis. His chronic dyspepsia has responded well to H2antagonists in the past. You think that his condition may be associated with H: pylori, but he refuses to have invasive procedures done to confirm the diagnosis.

PICO question

In a 40 yr-old patient with chronic dyspepsia (PATIENT), what are the sensitivity, specificity and predictive value of a non-invasive test (INTERVENTION) compared to that of a gold standard endoscopic biopsy (COMPARISON) in terms of diagnosing H.pylori (OUTCOME)?

Step 2: ACQUIRE----identifying relevance evidence from EBM resources:

- ✓ www.ovid.com MEDLINE/MEDLINE in process
- ✓ www.cochrane.org CDSR,DARE,CENTRAL
- ✓ www.acpjc.org
- ✓ www.clinicalevidence.com
- ✓ www.nim.nih.gov
- ✓ EMBASE
- ✓ PUBMED

Evidence should be identified using systematic, transparent and reproducible database searches. While a number of medical databases exist; the particular source used to identify evidence of clinical effectiveness will depend on clinical question.

You can use the following criteria to search the MEDLINE database:

- A keyword or phrase from your focused question(for example, H.pylori)
- The MeSH term (medical subject heading), which are the terms used to index the articles
- The title (the search will look for words in the title of the paper)
- The author (the last name and initial)
- The name of the journal (for example, Myanmar Medical journal)
- The type of publication (for example, randomized controlled trial)



CLASSIFICATION OF EVIDENCE

- Grade 1: meta-analysis/systematic review of multiple well designed RCTs
- Grade 2: at least one RCT with definitive results
- Grade 3: published well designed trials without randomization, cohort or matched case controlled study
- Grade 4: well-designed non-experimental studies from more than one center or research groups including cross sectional surveys and case reports
- Grade 5: expert opinion, reports of consensus

Table 1. Levels of evidence and grades of recommendation

Grade of recommendation	Level of evidence	Therapy/prevention, aetiology/harm	Prognosis	Diagnosis	Economic alanysis
A	1a	SR (with homogeneity) of RCTs	SR (with homogeneity) of inception cohort studies; or a CPG validated on a test set	SR (with homogeneity) of level 1 diagnostic studies; or a CPG validated on a test set	SR (with homogeneity) of level 1 economic studies
	1b	Individual RCT (with narrow confidence interval)	Individual inception cohort study with ≥ 80% follow-up	Independent blind comparison of an appropriate spectrum of consecutive patients, all of whom have undergone both the diagnostic test and the reference standard	Analysis comparing all (critically validated) alternative outcomes against appropriate cost measurement, and including a sensitivity analysis incorporating clinically sensible variations in important variables
	1c	All or none	All or none case series	Absolute SpPins and SnNouts	Clearly as good or better, but cheaper. Clearly as bad or worse but more expensive. Clearly better or worse at the same cost.
B	2a	SR (with homogeneity) of cohort studies	SR (with homogeneity) of either retrospective cohort studies or untreated control groups in RCTs	SR (with homogeneity) of level ≥2 economic studies	
	2b	Individual cohort study (including low-quality RCT; e.g. <80% B follow-up	Retrospective cohort study or follow-up of untreated control patients, in an RCT, or CPG not validated in a test set	Independent blind comparison but either in non-consecutive patients or confined to a narrow spectrum of study individuals (or both), all of whom have undergone both the diagnostic test and the reference standard; or a diagnostic CPG not validated in a test set	Analysis comparing a limited number of alternative outcomes against appropriate cost measurement, and including a sensitivity analysis incorporating clinically sensible variations in important variables
	2c	"Outcomes" research	"Outcomes" research		
	3a	SR (with homogeneity) of case-control studies			
	3b	Individual case-control study		Independent blind comparison of an appropriate spectrum, but the reference standard was not applied to all study patients	Analysis without accurate cost measurement, but including a sensitivity analysis incorporating clinically sensible variations in important variables
C	4	Case series (and poor-quality cohort and case-control studies)	Case series (and poor-quality prognostic cohort studies)	Reference standard was not applied independently or not applied blindly	Analysis with no sensitivity analysis
D	5	Expert opinion without explicit critical appraisal or based on physiology, bench research or "first principles"	Expert opinion without explicit critical appraisal, or based on physiology, bench research or "first principle"	Expert opinion without explicit critical appraisal, or based on physiology, bench research or "first principles"	Expert opinion without explicit critical appraisal, or based on economic theory

STRENGTH OF RECOMMENDATION (SOR)

A. Consistent, good quality patient orient evidence
B. Inconsistent or limited-quality patient oriented evidence
C. Consensus, disease-oriented evidence, usual practice, expert opinion, or case series

Step 3: APPRAISE: it is the process of systematically examining the available evidence to judge its validity and relevance in a particular context. The appraiser should make and objective assessment of the study quality and potential for bias.

- **Accessibility**: Can I easily obtain or retrieve the study?
- **Internal validity**: Is it close to the truth? Is it accurate? Can I believe it? Any bias, chances, confounding, causality?
- **External validity**: Can the results be generalized to my practice population?
- **Applicability**: Are the results applicable to and acceptable to my specific patient?
- **Statistical Significance**: are the results of the study valid?
- **Clinical significance**: what were the results?
- **Personal significance:** will the results help me in caring for my patients?

Step 4: APPLY having already critically appraised the evidence, extracted the most useful results and determined whether they are important, you must decide whether this evidence can be applied to your individual patient or population. There are important points to determine whether
Your patient has similar characteristics to those subjects enrolled in the studies from which the evidence was obtained.

- The outcomes considered in the evidence are clinically important to your patient.
- The study results are applicable to your patent.
- The evidence regarding risks is available.
- An economic analysis has been performed.

This process requires a partnership between the doctor and the patient. If at the end of the process the decision is made not to apply the available evidence, that decision should be a shared and conscious one.

Step 5: ASSESS
Evaluate the effectiveness and efficiency of the process

- Are you asking any questions at all?
- What is your success rate in asking answerable questions?
- How is your searching going?
- Are you critically appraising your search results?
- Are you applying your evidence in clinical practice?

DOE DISEASE-ORIENTED EVIDENCE (INTERMEDIATE OUTCOMES)

- A test result/A physiological number

POEM PATIENT-ORIENTED EVIDENCE (FINAL OUTCOMES)

- that Matters to the Patient

Will I die? Will I suffer? My quality of life?

Disease/con.	DOE evidence	POEM evidence
Doxazosin use for hypertension	Decrease BP	Increase mortality in African Americans
Anti-arrhythmic after MI	Suppress arrhythmias	Increase mortality
Sleeping infants on their stomach	Anatomy and physiology decrease aspiration	Increase SIDS
Vitamin E prevention of heart disease	Reduce levels of free radicals	No change in mortality
PPI and H2 receptor blocker for NUD	Significantly reduce gastric pH levels	Little or no improvement in symptoms
HRT to prevent heart disease	Reduce LDL, increase HDL	Increase CV events
Beta blockers in heart failure	Reduce cardiac output	Reduce mortality in moderate to severe heart failure

EVIDENCE BASED DIAGNOSIS

- Sensitivity (true positive rate)-TP/(TP+FN) --- Snout
- Specificity (false negative rate)-FN/(TP+FN) ---- Spin
- Positive Predictive value (PPV)
- Negative Predictive value (NPV)
- Likely hood Ratio (LR)

Ways of expressing summary results

- The risk decreases from 10% to 8% (AR)
- Risk reduction is 20% (RRR)
- Risk decreases by 2% (ARR)
- One heart attack or stroke is prevented among 50 patients (NNT)
- Every 50 patients,49 will not receive benefit (NNT, negative spin)

Table: The accuracy of right lower quadrant tenderness in the diagnosis of appendicitis

	Primary care settings Appendicitis		Tertiary care settings Appendicitis	
	Yes (%)	No (%)	Yes (%)	No (%)
Right lower quadrant tenderness				
Present	84	11	81	84
Absent	16	89	19	16
Total	100	100	100	100
Frequency of appendicitis	14%		63%	
Frequency of positive sign	21%		82%	
Sensitivity	84%		81%	
Specificity	89%		16%	
LR+	7.6		1	
LR-	0.2		1	

- Pre-test probability----Probability of disease before test is performed. May use prevalence of disease.
- Post-test probability----predictive value of the test

Table: Examples of pre-test probabilities

Symptoms or clinical problems	Source	Work-up	Disease probabilities
Anaemia of chronic disease	90 adults admitted to a general medical ward of a county hospital of North America[a]	Clinical examination blood testing selected other testing	Infection 36% Malignant 19% Inflammation 6% Other 24%

Dizziness >2 weeks	100 adult patients seen in primary care sites in one North American city[b]	Clinical examination neurological Ophthalmologic and psychological testing selected other testing	Vertigo 54& Psychiatric 16% Multicausal 12% Other 19% Unknown 8%
Dyspnoea >4 weeks unexplained by exam9in. radiograph and spirometry	72 adults referred to outpatient pulmonary clinic in North America[c]	Standardized examination, testing and treatment	Respiratory 36% Cardiac 14% Hyperventilation 19% Other 12% Unexplained 19%
Epilepsy, new onset in adults	333 adults presenting to a major urban emergency department in North America (excluded alcohol, head trauma, hypoglycemia)[d]	Standardized examination, testing (including head CT), and treatment	Unknown 44% Stroke 11% Tumour 7% Infection 17% Metabolic 5% Other 16%
Palpitations	190 patients from acute care sites in on North American city[e]	Clinical examination, cardiac and psychological testing, selected other tests	Cardiac 43% Psychiatric 31% Miscellaneous 10% Unknown 16%
Raynaud's phenomenon	Literature review of published reports of secondary diseases in 639 patients with Raynaud's from various settings[f]	Variable. usually clinical examination, selected serology and follow-up	Only 12.6% had or developed "secondary disorders" (e.g. systemic sclerosis, MCTD, SLE, etc.)
[a]Am J Med 1969, 87: 638-44 [c]Chest 1991; 100: 1293-9 [e]Am J Med 1996; 100: 138-48		[b]Ann Intern Med 1992; 117: 898-904 [d]Ann Emerg Med 1994; 24: 1108-14 [f]Arch Intern Med 1998; 158: 595-600	

Case Study 1 (low pre-test probability)

- *A 31 –yr-old woman presents with a 3-week h/o intermittent chest pain unrelated to activity, unrelieved by rest and is non-radiating. The onset of pain is usually associated with food intake. No CVD risk factors.*
- *Pre-tp of CAD-10%*
- *With a low prevalence and relatively high specificity, NPV is high. Therefore, NPV of 96%, if test (-)—true negative—exclude CAD.*

Case study 2 (moderate pre-test probability)

- *A 41-yr-old female who has a background H/O h/T and smoking presents with a 2-week H/O central, stabbing chest pain. It is sometimes precipitated by moderate exertion and there is costochondral tenderness.*
- *Her Pre-tp of CAD-50%*
- *With a moderate prevalence of 50% and relatively high sensitivity and specificity, both PPV and NPV are high.*
- *It is likely that patient need an Angiogram if exercise stress test-EST(+)*
- *It is unlikely that patient would need angiogram if EST (-).But 29% probability (100-NPV%)-angiogram may be warranted if resources are available. And enough clinical suspicion.*

Case study 3 (high pretest probability)

- *A 65-yr-old male with background h/o hypertension presents with a 6 week-H/O intermittent central crushing chest pain that radiates to his jaw. It is usually precipitated by mild exertion and relieved by GTN or rest.*
- *His pre-tp of CAD—90%*

- *With a high prevalence and high PPV (96%), only 4% who test + will not have CAD.*
- *NPV is only 21%, who test- will actually have CAD.*
- *If pre-tp is high, EST doesn't help with clinical decision making.*
- *If very high pre-tp of 90%, perform angiogram*

From pretest probability to post-test probability: Bayes' theorem

- *Post test odds = pretest odds times likely hood ratio*
- *X = O x LR*
  - *X = post test odds, O = pretest odds, LR = likely hood ratio*
- *Post test probability = pretest probability* x *test sensitivity/pretest probability* x *test sensitivity + (1-pre tp)* x *test false positive rate*

Estimation of post-test probability from pre-test probability and likelihood ratio goes as follows:[2]

- Pretest odds = (Pretest probability / (1 - Pretest probability)
- Posttest odds = Pretest odds * Likelihood ratio

In equation above, *positive post-test probability* is calculated using the *likelihood ratio positive*, and the *negative post-test probability* is calculated using the *likelihood ratio negative*.

- Posttest probability = Posttest odds / (Posttest odds + 1)
- Posttest probability = $\frac{Posttest\ odds}{Posttest\ odds+1} = \frac{Pretest\ odds \times likelihood\ ratio}{(Pretest\ odds \times likelihood\ ratio)+1}$

Figure 3.1 A likelihood ratio nomogram.



- *LR >1 indicates that the test result is associated with the presence of the disease.*
- *LR <0.1 indicates that the test result is associated with the absence of disease.*

EVIDENCE_BASED CLINICAL DECISION MAKING

Please study this following scenario:

U Hla (42) presents to you with classical clinical features of acute maxillary sinusitis: nasal obstruction, purulent discharge and pain and tenderness over his maxillary sinuses. X Rays of his sinuses reveal

mucosal thickening consistent with maxillary sinusitis. This is his first episode, which you ascribe to a recent viral respiratory tract infection.

Example of evidence-based decision making in patient with maxillary sinusitis:

1.Evidence What is the diagnostic accuracy and predictive value of clinical signs, nasopharyngeal swabs and x-rays? What are the efficacy, effectiveness and safety of the following advice and medication? • Nasal douches and steam inhalation • Decongestants • Analgesics • Antibiotics(e.g. Amoxicillin 7-10 days) if symptom persists **Evidence is needed ideally from relevant, high-quality systematic reviews; EBM guidelines or RCTs**
2. Resources-cost effectiveness What are the costs of medication or other treatments? Do the potential benefits of the treatment outweigh the harms and cost?
3. Patient preferences What are the possible side-effects of the medication? What is important to the patient? What other options is the patient interested in?

The family physician has a duty of beneficence towards patients, which involves making sure patients understand information and assisting them in making appropriate health choices based on sound research evidence. Evidence therefore is but one component of the decision making process and is necessary, but not sufficient for delivering high quality patient care.

Further reading:

1. *Evidence-Based Medicine: Reading and writing Medical Papers by Kaura, Mosby Elsevier,2013*
2. *Handbook of Family Medicine,2nd Ed, edited by Bob Mash, Oxford university Press SA, 2006*
3. *Evidence-Based of clinical diagnosis, edited by Knottnerus, BMJ publishing group, 2002.*
4. *Making right decision in Family medicine, CME lecture notes, by Dr Win Lwin Thein, 2018*

MODULE 12:

TERMINAL CARE, PALLIATIVE CARE AND CARE OF CANCER PATIENTS IN GENERAL PRACTICE

TERMINAL CARE

DEFINITION

Terminal Care refers to the management of the patient in whom the advent of death is felt to be certain and not too far off and for whom medical effort has turned from active therapy to concentrate on the relief of symptoms, support of both patient and family.
Terminal Care applies not only to malignant disease but it should also apply to terminal phase of chronic disease. (e.g. HIV/AIDS, end stage of renal failure)

CONCEPTS OF DEATH AND DEFINITIONS

Death is still a fearful and frightening, event and the fear of death is universal. What has changed his own way of coping and dealing with death and dying and without dying patients.
Our duty is composed 2 parts

- Part (1) Dealing with dying patient and family
- Part (2) to confirm the diagnosis of death and give bereavement counselling to his/her family

MEDICAL DEFINITION

It is usually based on cessation of respiratory (or) circulatory function. The most acceptable criterion of genuine and complete death occurs when the categories of cardiac arrest, respiratory cessation, brain death and complete loss of vital sign are satisfied and this condition remain permanently through rigor mortis and physical decay.

DEATH AND THE PATIENT

The thought in the mind of a dying patient usually passes through different stages and at each stages the patient and his relatives have to adjust to the changing circumstances.
There are five stages through which a patient may progress before achieving acceptance of death.

Stage 1. **Denial (No! not me!):** Feeling of denial accompanied by self –pity, irritability and isolation from others

Stage 2. **Anger (Why me?):** Anger about what is appending and grief for what is being lost. Anger displaced and projected to environment.

Stage 3 **Bargaining (Yes, it is me, but...):** negotiating with hospital staff or secretly with God to postpone death

Stage 4. **Depression ('It is me'):** feeling of depression, fear of being dead, of process of dying of pain, of leaving loved ones and happy associations

Stage 5. **Acceptance:** last stage, reached when patients find peace

- Not in all patients
- Help us to identify needs of dying patients and respond appropriately to them, contributing towards acceptance.

DEATH WITH DIGNITY

- It implies that highest possible quality of life will be maintained.
- dying person's rights and wishes be respected by caregivers.
- Give the chance to maintain his self-esteem and sense of integrity. e.g. Dying at home as familiar surroundings help the patient maintain a sense identity.
- The dying person is permitted to retain some control
- Has the freedom to choose his her style of dying
- To discuss death openly
- Allowed to prepare for dying in his/her own way
- Dying patient's care focuses on maintaining quality of life
- Intervention when the prognosis is hopeless, is inappropriate if it violates the patient's wishes
- Ethical Considerations
- Principle of truth-telling, beneficence, autonomy, proportionately and distributive justice.
- Help patients make difficult decisions about care including withdrawal of support
- Others: patient have right to stop unwanted medical treatment including artificial nutrition and hydration

FOUR CARDINAL PRINCIPLE OF TERMINAL CARE

- Patient autonomy (respect for the patient as a person)
- Beneficence (do good)
- Non-maleficence (Minimize harm)
- Justice (fair use of available resource)

The four cardinal principle need to be applied against a background of respect for life and acceptance of ultimate inevitability of death

In practice, there comprise three dichotomies which need to be applied in a balanced manner. Three dichotomies are

- the potential benefits of treatment must be balanced against the potential burden
- striving to preserve life but when biologically futile, providing comfort on dying
- individual need are balanced against those of society

WHEN SHOULD BE THE END-OF-LIFE DISCUSSION BE INITIATED?

1. **Urgent indications**
   - Imminent death –talk about wanting to die
   - Inquiries about hospice or palliative care
   - Recently hospitalised for severe progressive illness
   - Severe suffering and poor prognosis
2. **Routine indications**.
   - Discussing prognosis
   - Discussing treatment with low probability of success
   - Discussing hopes and fear
   - Physician would not be surprised if patient died in 6.12 months

EUTHANASIA

Literal meaning-Death without suffering

1. Active Euthanasia - refers to physician talking an active role in the death of patient. (e.g. giving a lethal dose)
2. Passive euthanasia- means taking no further measures (or therapy) that the patient does not desire. (e.g. giving solucortef)

DNAR ORDERS

Initially DNR (Do Not Resuscitate)
Now DNAR (Do Not Attempt Resuscitations)
CPR can restore people to vigorous health.

DUTY OF PHYSICIAN

- Inform about possible consequences of surviving CPR attempt like fracture ribs, lacerated internal organ and likelihood of requiring aggressive interventions such ICU care.
- Encourage patients and families to make proactive decision about what is wanted in end of life care.
- physician should write DNAR orders and reasons for them in medical record.

Factors to consider

- Nature of Emergency
- General condition of patient
- Disease state and prognosis
- Concomitant pathologies
- Symptomatology
- Effectiveness and toxicity of available t/m
- Patients' and carers, wishes

CARE OF DYING PATIENT

Aim

- to make the person as comfortable as possible
- to pursue cure of potentially reversible disease provide comfort and help the patient prepare for death.

TREATMENT PLANNING FOR A TERMINAL ILLNESS

Discussing Terminal Treatment Guidelines in the Ambulatory Setting

1. While taking a routine genogram, ask, "who in your family do you turn to for support?" Follow up by asking, "Should you become seriously ill or injured, would that be the person you would like me to consult regarding treatment decisions?"
2. Ask about the patient's values, and then his or her wishes for treatment.
3. Be as specific as possible.
4. Encourage the patient to discuss his or her wishes with family members.
5. Introduce the idea of a "living will," which should:
    a. Consider specific possibilities, such as respiratory support, nutritional support, antibiotics, and resuscitation.
    b. Name a healthcare proxy who can have final authority, in consultation with other family members, to make unforeseen treatment decisions.
    c. Contain the signatures of two witnesses.
    d. Be updated yearly and/or prior to any hospitalization.
    e. Be copied and given to family members, with a copy in the chart

Guidelines for Terminal Treatment Planning with the Patient

1. Set attainable goals
2. Help the patient:
    a. Reminisce about life; emphasize accomplishments and positive memories.
    b. Identify valued personal characteristics.
    c. Let go of unfinished business.

    d. Participate in decision making about treatment; let go of the need to control what cannot be controlled.
    e. Forgive oneself, and ask for forgiveness.
    f. Express love directly to loved ones.
    g. Discuss beliefs about spirituality, the meaning of his or her life, in particular, any afterlife.
3. Encourage the use of meaningful religious rites and rituals.
4. Assess for clinical depression (vs grieving), and suicidality; consider antidepressants if warranted

Guidelines for Terminal Treatment Planning at a Family Conference

1. Ask the patient or family if they want their priest, minister, or rabbi to attend the meeting.
2. Begin the conference by asking about less-difficult issues, then move on to more highly charged issues.
3. What are the treatment options?
    - What does the treatment offer the patient?
    - What are the probabilities of success and failure?
    - Will the treatment cause additional illness?
4. Solicit questions to help decide how much and what kind of medical information the patient and family want. Be as straightforward as possible and acknowledge any personal biases. Be careful not to medicalize what are actually ethical issues.
5. Describe and encourage the use of hospice care.
6. Help the patient and/or family weigh potentially good outcomes against potentially undesirable ones.
7. Help both patient and family stay focused on the patient's personal goals as primary.
8. Be as no anxious as possible.
9. Use clear, jargon-free language. Be a supportive, active listener. Track others' communications and clarify confusing statements made by any participant.
10. Model an ability to tolerate the ambiguity and uncertainty that accompanies. Address such relevant medical issues as: all these decisions.
11. Communicate a willingness to sustain contact with the patient and the family regardless of their treatment decisions.

Principles for Terminal Treatment Planning at a Family Conference in Which a Patient Is Unable to Participate

1. Keep the care, comfort, and concern for the patient primary.
2. Include all available family in the conference.
3. Hold the conference at the patient's bedside.
4. Remind the family that their job is to decide what the patient would wish to have done, rather than what they themselves would want.
5. Recognize the family's pain, and acknowledge the difficulty of the process.

Notifying the Family About a Death

1. Encourage the family to be present at the time of death, if at all possible.
2. When the family is expecting the death of one of its members, ask how they would prefer to be notified if they are not present.
3. Notify the family immediately at the time of death:
    a. With an expected death, call on the family as previously agreed.
    b. With an unexpected death, ask the family as a whole to come to the hospital and discuss the events leading up to the death.
4. Think about what you want to say before making the call: Many people remember the exact words spoken by whoever told them of the death.

5. While being sympathetic and sensitive, avoid euphemisms: Use the words “death, dying, and dead.”
6. Say, “You have my sympathy,” rather than, “I am sorry,” which could be construed as an apology.
7. Give the family the opportunity to view the body and say their goodbyes.
    a. Arrange for the viewing to occur in a private room.
    b. Make sure the body has been cleaned and prepared.
    c. Offer to have a member of the healthcare team stay with the family.
    d. Allow them to remain with the deceased as long as they wish.
8. Meet with the family.
    a. Before or after the viewing to show concern and facilitate a healthy early grieving process.
    b. Provide information about the cause of death: Solicit and answer any questions.
    c. Answer any questions about autopsy or organ donations.
    d. Use active listening skills: Expect expressions of intense emotions.
    e. Make yourself available as a support for the family: Offer to have follow-up meetings, either to discuss autopsy results or questions about the deceased that will likely arise in the future.
    f. Remind the family to call their funeral director.
    g. Encourage the family to include children, especially those older than
2. 5 years, in the funeral and other family gatherings.
9. With an unanticipated or traumatic death, consider making a home visit soon thereafter: With an anticipated death, send a sympathy card to the family and/or attend the calling hours or funeral.
10. With an anticipated death, telephone the family 1–2 weeks after the death to inquire about them, answer any questions, and encourage any necessary follow up.

Primary Care Grief Counselling

1. With a traumatic death, schedule an office visit soon after the funeral, and consider rapid referral to a family therapist: With an anticipated death, schedule an office visit at within 1 month with interested family members to review the death and the autopsy results.
2. Encourage family members to talk about the circumstances surrounding the death, recall memories, and openly discuss feelings of sadness, anger, and guilt.
3. Inquire about any significant changes in financial status.
4. Normalize signs of grieving during the first year (e.g., crying spells, lack of energy, and preoccupation with the deceased).
5. Avoid the use of such psychotropic medication as sedatives or hypnotics, except when previously prescribed or when a family has a serious sleep disturbance.
6. Monitor the medical status of the recently bereaved: Encourage family members to come in for a health evaluation at 6 months to evaluate any increased risk for illness or delayed difficulties with grieving.
7. Refer interested family members to community-based self-help support groups.
8. Monitor family members for signs of unresolved grief reaction; refer if necessary.

THE NEED OF DYING PATIENT AND CARE

Psychological Care

- Give explanation about the symptom and the disease
- Counselling of patient have to provide psychosocial and spiritual support

Physical Care

- Symptomatic treatment for comfort
- Symptom control
- Pain control

Social Care

- Religion and culture of patient can and do influence and determine the expectation and ability to cope with terminal illness and death

Care of family

- Timely, frequent and consistent communication
- Focusing on patients' wishes
- Being aware of family conflict
- Accommodating family's grief
- Refocusing hope
- Encouraging planning
- Remaining available
- Following up with family after death
- Role of family physicians
- 1st to know the terminal illness
- Final one to take care of the patient
- Prepared to give empathic care and medical expertise
- Don't forget the family
- Provide emotional support
- Listen to family's concerns
- Encourage family members to stay with patient
- Refer family to community resources, e.g. Hospice
- Reassure family that everything reasonable was done before death
- Reassure family that you will do all possible to provide comfort
- Facilitate the issuing of the death certificate and instruct the family the procedure of reporting death
- Visiting the family just before and immediately after death of the patient may be great confidence booster to the family
- It is the family physician's responsibility to provide coherent management by offering treatment, guidance, and safe conduct throughout the course of disease

Bereavement

- The family doctor is the best person to provide skilled and compassionate bereavement support.

Specialist/Hospitals

- The need for specialist is usually early, to make confirm the diagnosis, to give all management possible to cure (or) to alleviate disease.

Hospice care

- Is an approach to provide a caring environment for meeting the physical and emotional needs of the terminally ill.
- Focus on the patient and family rather than disease.
- Provide comfort and pain relief rather than treating illness e.g. treat patient with morphine and antipyretics rather than antibiotics, for the dying
- Individualised attention, human contact, interdisciplinary team approach
- Advise increase patient's satisfaction, ease the family's anxiety, reduce the costs.

Home care

- Is provision of care and support service by formal and informal caregiver in home, in order to promote restore and maintain a person's maximal level of comfort, function and health including care toward a dignified death.

- Specialist home care nurse licence with primary health care and offer advice on treatment and care. They provide support for the whole family, more patients are able to remain at home until death.

Task after death

The pronouncement and death certificate

- Confirm and verify death
- Note finding and time of death in patient's chart
- Provide words of sympathy and reassurance, time for questions and initial grief and quite private room for family
- Reporting
- Death certificate should contain:
    - Major cause of death
    - Contributory cause
    - Associated conditions

Autopsy and organ donation

- Law specify that physician who declares a patient dead must not be involved with a patient who is waiting for a donor organ
- Patients and family have their right to limit autopsy or organ donation

Follow up and grieving

- Following up family and reassure the nature of normal grief and identify complicated grief or depression
- Recommend support groups and counselling
- for physicians ,grieving the loss of patient is normal
- attending the funeral of the patient is satisfying personal experience that is almost universally appreciated by families and that may be the final element in caring well for people at the end- of- life.

PALLIATIVE CARE

DEFINITION

Palliative Care is an approach that improves the quality of life of patients and their families facing the problems associated with life-threatening illness, through the prevention and relief of suffering by means of early identification and impeccable assessment and treatment of pain and other problems, physical, psychological and spiritual.

PRINCIPLES OF PALLIATIVE CARE



WHAT IS PALLIATIVE CARE?

- Palliative care is the active, holistic care of patients with advanced, progressive illness
- Palliative care is all about looking after people with illnesses that cannot be cured, relieving their suffering and supporting them through difficult times
- Management of pain and other symptoms and provision of psychological, social and spiritual support is paramount.
- The goal of palliative care is achievement of the best quality of life for patients and their families.

WHY DO WE NEED PALLIATIVE CARE?

To help people suffering from:

- Cancer
- HIV
- Progressive neurological illnesses
- Severe kidney or heart failure
- End-stage lung disease
- Other life-limiting illnesses

WHAT IS DIFFERENT ABOUT PALLIATIVE CARE?

The holistic approach to problems

- Physical
- Psychological

- Social
- Spiritual

DIFFERENT MODELS OF PALLIATIVE CARE DELIVERY INCLUDE

- Palliative care within home base care
- Palliative care clinic
- Day care support
- Hospital palliative care team
- Inpatient unit

THE MANAGEMENT OF PAIN

DEFINITION OF PAIN

Pain is an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage**.**

ASSESSMENT OF PAIN

A. Key components of a pain assessment

- Description of the onset and duration of the pain
- Description of the pain e.g. location, quality, pattern, character
- Rating of pain intensity
- Description of aggravating and relieving factors
- Description of associated symptoms and signs
- Description of the effects of pain on functioning and quality of life
- Description of current pain management regimen and assessment of effectiveness
- Summary of the past history of pain management
- Identification of the patient's goals of treatment
- Physical examination
- Diagnostic testing, where appropriate

S *Site of pain* Where? Any radiation? Numbness where pain felt? Pattern of involvement?

O *Onset* When did it start? How did it start? What started it? Change over time?

C *Character of pain* Type of pain — burning, shooting, stabbing, dull etc.; pattern of pain, e.g. colicky, constant, etc.

R *Radiation* Does the pain go anywhere else?

A *Associated features* Are there any skin or joint changes, e.g. bruising, redness, or swelling?

T *Timing/pattern* Is it worse at any time of day? Is it associated with any particular activities, e.g. movement, urination, eating, passing stool, coughing?

E *Exacerbating and relieving factors*

S *Severity* Record, especially if the pain is chronic and you want to measure change over time. Consider a patient diary.

Ask about:

Pain intensity, e.g. none-mild-moderate-severe; rank on a 1–10 scale.

• Record interference with sleep or usual activities.

• Pain relief e.g. none-slight-moderate-good-complete
Onset When did it start? How did it start? What started it? Change over time?

PAIN ASSESSMENT TOOLS

- **Visual analogue scales (VAS)**
  No pain_____ Worst pain
- **Categorical verbal rating scales (VRS)**
  None Mild Moderate Severe
- **Categorical numerical rating scales (NRS)**
  0___1____2___3__4___5__6_____7___8____9_____10
  No pain Worst pain

PAIN CLASSIFICATION

1. Nociceptive pain

may result from injury to somatic structures (somatic pain) or injury to visceral structures (visceral pain) Pain which is transmitted by an undamaged nervous system and is usually opioid-responsive.

2. Neuropathic pain

is caused by injury to the peripheral and/ or CNS. Pain which is transmitted by a damaged nervous system and which is usually opioid-sensitive.

PRINCIPLES OF PAIN MANAGEMENT

- WHO three –step analgesic ladder.
- The WHO method can be summarized in five phrases:
  - by the mouth
  - by the clock
  - by the ladder
  - for the individual
  - attention to detail

WHO ANALGESIC LADDER



Classification of analgesics

- ❑ **Non-opioids**
  aspirin, paracetamol, and NSAIDs
- ❑ **Opioids**
  opioids for mild to moderate pain
  opioids for moderate to severe pain
- ❑ **Adjuvant analgesics**

Adjuvant analgesic	Use
Antidepressant	Neuropathic pain
Anticonvulsant	Neuropathic pain
Antispasmodic	Pain due to colic
Bisphosphonate	Pain due to bone metastases
Corticosteroid	Pain due to oedema or nerve compression
Muscle relaxant	Pain due to muscle spasm or cramp
NMDA- receptor blocker	Neuropathic pain

Step 1:Non-opioid ±adjuvants

- Patients with mild pain
  For example –patient with mild neuropathic pain – paracetamol 500 mg-1 g q 6-8 hr regularly (maximum daily dose 4g) in combination with amitriptyline 25-75 mg o.d

Step 2: Opioid for mild –moderate pain + non-opioid ± adjuvants

For example –a patient with moderate neuropathic pain

codeine 30-60 mg q 6 hr in combination with paracetamol 1 g q 6 hr and amitriptyline 25-75 mg o.d

Step 3: strong opioid+ non-opioid ± adjuvants

Oral morphine, in either immediate-release (i/r) or modified-release (m/r) form is the opioid of choice for treating moderate or severe cancer pain.

Step 1 analgesics

- Aspirin, paracetamol and NSAIDs
- Non-specific COX inhibitors, such as aspirin, ibuprofen and diclofenac, inhibit both coenzymes
- Newer NSAIDs inhibit COX-2 only are associated with reduced GI effects.

Step 2 Analgesics:

- **Codeine phosphate**
  is available in tablet and syrup formulations.
  dose of 30-60 mg po. 4-hour maximum dose of 240 mg in 24 hours.
- **Tramadol**
  Tramadol displays weak opioid activity and it is also a noradrenaline and selective serotonin-reuptake inhibitor (SSRI)
  Adverse effects include nausea, vomiting, dizziness and drowsiness.
  Preparations: caps:50mg, injection 100mg/2ml
  Starting dose: 50 mg qds. po. or 100 mg bd. po (12 h m/r)

Step 3 Analgesics:

Starting morphine

- Opioids are safe, effective and appropriate drugs for the management of cancer pain.
- Use immediate-release morphine (oramorph or sevredol) to titrate the dose needed for pain relief.
- If moving from step 2 give 5-10 mg 4 hourly and PRN
- If step 2 has not been used (opioid naïve), in the elderly or those with renal impairment, use smaller doses (2.5 – 5 mg) with closer monitoring.
- Reassess pain control regularly
- If pain not controlled, titrate the dose by 30-50% every 2-3 days (or sooner if necessary) to achieve pain relief
- Increase the PRN dose in line with the increase in the background analgesia
- If pain is not responding consider an alternative strong opioid or seek specialist help

Symptoms and signs of opioid toxicity

- Drowsiness
- Hallucinations(most commonly visual)
- Confusion
- Vomiting
- Myoclonus
- Pinpoint pupils

- Respiratory depression

Alternative opioids

- Diamorphine
- Fentanyl
- Buprenorphine
- Methadone
- Oxycodone
- Hydromorphone

NEUROPATHIC PAIN

- The medical treatment of neuropathic pain is unsatisfactory and pain can prove difficult to control.

➢ **Drugs for painful polyneuropathy**

- Amitriptyline, clomipramine, imipramine (tricyclic antidepressant)
- Venlafaxine
- Duloxetine
- Oxcarbazepine
- Lamotrigine
- Gabapentin
- Oxycodone
- Tramadol

MANAGEMENT OF SPECIFIC PROBLEMS

- **Malignant bone pain**
    1. Radiotherapy
    2. Bisphosphonates

TREATMENT OF OTHER CAUSES OF POORLY CONTROLLED PAIN

pain	Possible co-analgesics
Headache due to cerebral oedema	Dexamethasone
Painful wound	Metronidazole
Intestinal colic	Hyoscine butylbromide or hydrobromide
Gastric mucosa	Lansoprazole
Gastric distension	Asilone+domperidone
Skeletal muscle spasm	Baclofen/diazepam
Cardiac pain	Nitrates/nifedipine
Oesphageal spasm	Nitrates /nifedipine

COMPLEMENTARY THERAPIES AND OTHER NON-PHARMACOLOGICAL PAIN INTERVENTIONS

Complementary therapies	Other non-pharmacological interventions
Acupuncture Reflexology Aromatherapy Art therapy Music therapy Touch therapy	Positioning Catheterization Reassurance Good communication Diversional therapy TENS Splinting of a fracture limb Psychological support

- **Alternative medical therapy** –Acupuncture, Homeotherapy
- **Mind-body therapies** –Relaxation therapy, Hypnotherapy, Guided imagery and visualisation, Meditation, spiritual healing
- **Creative therapies** –Art and Music therapies
- **Biologically-based practices** –Herbal medicine, Aromatherapy
- **Manipulative and body-based therapies** –Massage, Reflexology

COMMON SYMPTOMS CONTROL

GASTROINTESTINAL SYMPTOMS

- Oral problems –Coated tongue/dirty mouth (e.g. Fluconazole 50 mg od x 7 days)
  -Dirty mouth, sore mouth and difficulty swallowing
  -painful mouth and stomatitis (e.g. benzydamine mouth wash)
  -Ulceration of oral mucosa (e.g. genelog)
  -Drooling (e.g. hyocine)
- Nausea and vomiting (e.g. domperidone 10 mg tds pre-meal)
- Constipation (e.g. laxative, enema)
- Diarrhoea (e.g. loparamide)
- Intestinal obstruction (e.g. refer for surgery if appropriate)
- Hiccup (mexilon, dexamethasone)
- Anorexia/cahexia/asthenia (dexamethasone 2-4 mg od)
- Dyspepsia
- Gastrointestinal bleeding
- Bowel stoma care

RESPIRATORY SYMPTOMS

- **Breathlessness**
- **Cough**
- **Breathlessness**

  Principle of management

  –general measure
  -treatment of reversible causes
  -Disease-specific treatment
  -Symptomatic management-including pharmacological and non-pharmacological measure
  Management of treatable causes e.g.
  lung tumour → radiotherapy or chemotherapy
  bronchospasm → bronchodilators, corticosteroids
  anaemia → blood transfusion, iron, erythropoietin
  Cough → pharyngeal irritation → simple linctus
  → bronchial irritation → nebulized bupivacaine

SKIN PROBLEMS IN PALLIATIVE CARE

Wound care =bacterial ,fungal skin infections, abscesses
Pruritus(itch)

ANXIETY AND SLEEPLESSNESS

GENITOURINARY SYSTEM

= urinary retention, bladder spasms

PSYCHOSOCIAL SUPPORT AND SPIRITUAL SUPPORT

The spiritual aspects of an illness concern the human experiences of sickness(dis-ease) and search for meaning within it.

- Emotional and spiritual support
- Counselling
- Assist by hospice organization, social workers, chaplain, volunteers
- Important issues by consultation of breaking bad news
- Revealing of diagnosis, &prognosis
- Reaction to and copying with knowledge of diagnosis and prognosis
- Refusal or concern about treatment.
- Fears of dying-separation anxiety
- Placement issues-hospice, home
- Bereavement issues

SPIRITUAL ASSESSMENT/ SUPPORT

- ❑ **H**ope
- ❑ **O**rganised religion
- ❑ **P**ersonal issues
- ❑ **E**ffect on our care

- What sources of **H**ope, strength, comfort, meaning, peace, love and connection does the patient have?
- What role does **O**rganized religion play in the patient's life?
- What is the patient **P**ersonal spirituality and practice?
- What will be the **E**ffects of these factors on the patient's medical care and end-of-life decisions?

SUPPORTIVE CARE OF CANCER PATIENTS AT HOME AND AT HOSPICE



At home

- monitoring of symptoms
- dealing with emergencies
- daily self-care needs
- when death is near-what they need to do
- after death-what to do, whom to call, how to obtain death certificate

Hospices services

- Inpatient hospices, nursing homes
- Have a social workers, chaplain, volunteers
- Can assist with preparation of a legacy, financial issues& support for bereaved family members

At hospital

- To protect the patient from end-of-life suffering.
- Admitted for terminal care.
- To control refractory symptoms.

REFERENCE

1. *Diploma in Family Medicine module*
2. *Oxford handbook of General Practice, 4th Edition*

CARE OF CANCER PATIENTS IN GENERAL PRACTICE

DEFINITION

It is the approach that improves the quality of life of patients and their families facing the problems associated with life threatening illnesses, through prevention, relief of suffering by means of early identification assessment treatment of pain, other problems (physical, psychological, spiritual)

ROLE OF GENERAL PRACTITIONER

1. Primary Prevention

   Health education to public for cancer awareness.
   Screening procedures

2. Early Diagnosis

   Awareness of cancer warning signs
   Diagnostic procedure

3. Support for the patients and their families during the process of diagnosis and treatments
4. Continuing care after treatment when patients need surveillance, support and all possible relief from any residual disabilities
5. Diagnosis of recurrence
6. Care and guidance of patients in the palliative and terminal phase including bereavement counseling
7. Treatment of cancer Surgery, Radiotherapy, Hormonal therapy, Immunotherapy, Molecular targeted therapy, Gene therapy are used.
8. GP should know early recognition and timely referral of common oncologic emergencies e.g. superior vena cava obstruction, Pericardia effusion, spinal cord compression, hypercalcemia, and hyponatremia.

COMMON PROBLEMS IN PATIENTS WITH CANCER AND HOME CARE OF TERMINALLY ILL PATIENTS:

- Pain management
- Lymphoedema
- Skin care
- Fungating malignant ulcers
- Stoma care
- Bleeding
- Mucositis
- Nutrition and cancer treatment

PAIN MANAGEMENT

CANCER PAIN

Cancer pain is mediated by inflammatory signalling mechanism related to tissue injury by cancer.
Chronic cancer pain is commonly mediated by prolonged firing of nociceptive C fibres.

Assessment of pain

Position, quality, radiation, severity, timing, understanding and values.

Severity

Numerical rating scale is used to quantify the severity of pain, rating scale is 0-10
None =0. Mild =1-3.Moderate =4-6.Severe =7-10

Categories of pain

- Visceral pain, arise from internal organs, peritoneum or pleural cavity
- Somatic pain, arise from skin, muscle, bone, joint or ligaments
- Neuropathic pain, signal is generated by damaged nervous system

WHO analgesic ladder

Step 1 = Non opioid + or - adjuvant
Step 2 = weak opioid + or - non opioid + or - adjuvant
Step 3 = strong opioid + or - non opioid + or - adjuvant

Non-opioid analgesics

Acetaminophan and non-steroidal antinflammatory drugs (NSAID)

- Effective for mild to moderate somatic or visceral pain
- Side effect of acetaminophen is potential hepatotoxicity.
- NSAID must be used with caution in renal impairment, peptic ulcer disease and elderly.

OPIOID ANALGESICS

Classification

1. Weak opioids (Codeine, tramadol)

   Used for mild to moderate episodic or constant pain, Involve in pain management of WHO analgesic ladder step 2

2. Strong opioids (Morphine, Hydromorphine, Oxycodone, Fentanyl, Methadone)

   Used for Moderate to severe pain, involve in pain management of WHO analgesic ladder step 3

Weak Opioids

Codeine
Naturally occurring opium alkaloid. Oral or parenteral formulations, combination with acetaminophen or caffeine.
Dose is 15mg, 30mg, 60mg. (Major side effects: Constipation)
Tramadol
Dual mechanism of action, through opioid receptor, Inhibition of serotonin & norepinephrine reuptake.
Oral or parentral form, 50 mg, 100 mg. Maximum dose 300 mg/day

Strong Opioids

Morphine Injection Morphine
Hydromorphine

- Semi-synthetic morphine derivative, (5 times potent than morphine, Oral, rectal, injection form**)**

Oxycodone

- Semi-synthetic morphine congener
- Fixed combination with acetaminophen (available only as oral)

Fentanyl

- Synthetic opioid and 100 times potent than morphine, rapid onset & short half life (buccal, sublingual, parenteral)
- Used in Palliative care as transdermal skin patch (TD). TD patch provide analgesics for 72 hrs
- Choice for patients with renal insufficiency
- Less constipation than opioids

Transdermal Fentanyl (TD)

- Indicated in following situations

Compromised oral route, Head & Neck Cancer, Oesophageal, gastric and bowel obstruction, variable level of consciousness, Poor compliance with oral form and other opioid have adverse effects

Methadone

Synthetic opioid

Oral opioid

Regular dosing

- Appropriate dose is the lowest dose that achieve desired effect with few side-effects
- To provide the patients with serum drug levels that is in the therapeutic range, but below sedation threshold.

Immediate release form

- Oral morphine, hydromorphone, oxycodone
- Onset of action within 45-60 min, half-life is 4-6 hrs
- Dosing interval of 4 hrs is good starting point
- Opioid-naïve patient, good starting dose might be as follows

Morphine 5-10 mg by mouth every 4 hrs, Hydromorphone 1 mg by mouth every 4 hrs, Oxycodone 2.5 mg by mouth every 4 hrs.

Slow release long-acting preparation

- Usually start after dose titration
- Onset of action peak is 3-4 hrs.
- These medications are administered every 12hrs.
- Initially use same total daily dose of mediation when switch from immediate-release to slow-release opioid preparation, for example: Oramorph: 30, 60, 100mg tab

Break though dosing

- Break through pain and break through dosing.
- Break through dose is half of regularly scheduled 4-hrly dose or 10% of total daily opioid dose.
- Breakthrough medication is immediate release formulation.
- Number of breaks through doses should be monitored.
- Re-evaluation of regular opioid dose should be undertaken when there have three breakthroughs dose a day.

Common side-effects of opioids

Some side effects are idiosyncratic. Develop when initiating an opioid or when there is escalation in dose

GI side effects

Nausea, vomiting and constipation. Prokinetic agent such as metoclopramide or domperidone can be used in opioid involved nausea.

CNS side effects

Sedation, confusion, respiratory depression

Other side effects

Non-cardiogenic pulmonary oedema, Xerostomia, Urinary retention, SIADH, Endocrine, Hypothyroidism, hypercalcaemia, pruritus

OPIOID ROTATION
(Switching opioids)

- Opioid rotation may be undertaken for following reasons
- Patient may require change of route of administration, pain is escalating or under suboptimal control and Dose of current opioid is causing unacceptable side effects

Opioids in renal failure

Both Fentanyl and Methadone are considered opioid for patients with renal impairment or who are on dialysis.

Other routes of opioid administration

Regular subcutaneous delivery of opioid (every 4hrs), continuously administered with pump, Intravenous route, TD Fentanyl

MANAGEMENT OF BONE PAIN

- NSAID, COX2 inhibitor, corticosteroid, bisphosphonate and calcitonin are used according to severity.
- External beam radiotherapy is considered when there is no adequate pain control with analgesic.
- Orthopaedic intervention is considered in situation when pain is difficult to control with other measures.

MANAGEMENT OF NEUROPATHIC PAIN

Tricyclic antidepressant (TCAs), serotonin-norepinephrine reuptake inhibitors (SNRIs), Anticonvulsants, Topical lidocaine, conventional opioid analgesics, methadone, corticosteroid and NMDA antagonists

SUPERIOR VENA CAVA OBSTRUCTION (SVC OBSTRUCTION)

Definition

SVC obstruction restrict the venous return from upper body resulting in oedema of arm and face, distention of neck and arm vein, headache and dusky blue skin discoloration over the upper chest, arms and face.

Aetiology

Malignant aetiology

a. Lung Cancer
   Account for 75% of malignancy causing SVC Obstruction.

b. Non-Hodgkin Lymphoma
Account for 10-15% of cases of Malignant SVC obstruction.

c. Other Malignant aetiology
Those include thymoma, mediastinal germ cell neoplasm and solid tumor with mediastinal lymph node metastases.

Benign aetiology

a. Mediastinal fibrosis and chronic infections
Those include fibrosing mediastinitis such as TB, Aspergillosis, lymphatic filariasis, idiopathic fibrosing mediastinitis and RT to mediastinum.

b. Thrombosis of Vena cava such as central line, polycythemia, Bachet syndrome & Idiopathic.
c. Benign mediastinal tumor such as thymoma, goitre, sarcoidosis and aortic aneurysm.

Diagnosis

1. Symptoms
Shortness of breath (50% of patients), neck and facial swelling (40%), Sensation of choking, fullness in head, headache and rarely convulsion

2. Signs
Thoracic vein distension (65%), neck vein distension & oedema of face (55%), tachypnoea (40%), plethora of face and cyanosis (15%), oedema of upper extremities (10%), paralysis of vocal cord or Horner Syndrome.

3. Radiographs
a. Chest radiograph
Demonstration a mass in 90% of patients, usually located in right superior mediastinum in 75% of cases.

b. Chest CT
Contrast enhanced CT can detect area of obstruction, degree of occlusion and presence of collateral veins.

c. Superior Venogram
Bilateral upper extremities venogram and MR venography are used for identification of SVC obstruction and extent of thrombus formation.

4. Histological diagnosis
a. Cytology of sputum positive in 60% of patients with SVC obstruction due to lung cancer.
b. Lymph node Biopsy of palpable lymph node can be helpful
c. Transthoracic fine needle aspiration can be used for peripheral lesion.
d. Video assisted thoracoscopic surgery usually results in definite histological diagnosis.
e. Mediastinoscopy is performed in helping selected group of patients.

Management

1. Endovascular Stents
- Percutaneous placement of stent give symptomatic relieve in 90% to 100% patient.
- This stent is placed via subclavian or femoral vein under local anaesthesia.
- Two indications are SVC obstruction with previously undiagnosed non-small cell carcinoma, that was followed by RT and recurrent SVC obstruction previously treated with RT.
- Short term anticoagulant with warfarin or dual antiplatelet for 3months after stent replacement.

2. Radiotherapy (RT)

- RT is indicated for SVC obstruction caused by NSCLC and combine with chemo in SVC obstruction caused by SCLC and lymphoma.
- Total dose varies between 3000& 5000 CGy. RT is associated with complete relief of symptoms within two weeks in 70% of patient.
- Median Survival is 10 month for SCLC and 3-5 months for NSCLC.

3. Chemotherapy

- Chemotherapies indicated in patient with NHL, SCLC, germ cell tumor, Breast cancer with SVC obstruction.

4. Supportive treatment

- Oxygen administered for hypoxia. Head should be raised to reduce hydrostatic pressure. Corticosteroid is indicated to reduce Brain oedema. Diuretic may be helpful.

5. Anticoagulants and antifibrolytic

- These agents may be helpful in SVC thrombosis.

6. Surgical decompression

- By passing SVC obstruction by using saphenous venous graft or sapheno-axillary vein bypass, which can be done under local anaesthesia.

GASTROINTESTINAL SYSTEM

NAUSEA/VOMITING

Causes

1. Higher center stimulation
2. Direct vomiting center stimulation
3. Vagal and sympathetic stimulation
4. Vestibular nerve stimulation

Management

1. Due to higher center stimulation (counseling, explanation, listening)
2. Direct vomiting center stimulation due to radiotherapy, raised intracranial pressure (Cyclizine, Dexamethasone)
3. Vagal, Sympathetic (Cough, constipation, bronchial secretion) Due to gastric stasis domperidone, metoclopramide, erythromycin
4. Chemoreceptor trigger zone (Haloperidol, Levomepromazine)
5. Vestibular stimulation (Cyclizine, Hyoscine patch)
6. Others (Acupuncture, Ginger)

MOUTH ULCERS AND MOUTH CARE

Mouth problems are common occurring in 90% of patients
Appropriate and effective oral assessment should be carried out

- Is the mouth dry or painful or infected
- Nutritional status of patient
- Tongue condition, Type of saliva and lip,

- Mental state of the patients, ability and willingness to participate in their care
- Uses of medications opioids may cause dry mouth
- (Steroids may cause oral candidiasis)
- Management and prevention (Health Education)
- Regular tooth and denture brushing twice daily
- Regular use of antibacterial antifungal mouth wash
- Check of fit of dentures
- Regular dental check

SKIN PROBLEMS

- Bed sores: Due to pressure necrosis of skin. Immobile patients are high risk especially in shoulder blades, elbow, buttock, knees, ankles and heels.
- To prevent bed sores, carer should use protective mattresses, cushions, incontinence advice on positioning and movement.
- Treat any sores that develop aggressively and admit if not resolving.

MANAGEMENT

- Use aids to movement where appropriate
- Discuss management with patient and home care.
- Turn the patient every 2, 3 hours
- In incontinent patients protect vulnerable skin with zinc and castor oil cream and consider catheterization
- If nutritional state is poor, advice on nutritious diet.

MONONEUROPATHY

DEFINITION

Mononeuropathy means lesions of individual peripheral (including cranial) nerves which may be due to trauma, Diabetes, Leprosy, cancer, and sarcoidosis.

MANAGEMENT PLAN

History taking

When we do history taking, we should discuss the severity of pain, underlying cause of pain, why a particular pharmacological treatment is being offered, the importance of dosage titration, other physical, psychological therapies and surgery.
To consider referring the person to specialist clinic if their pain is severe, their pain limits their lifestyle, daily activities. Regular clinical reviews need to assess and monitor the effectiveness of treatment, to assess pain control, physical well-being.

Clinical examination.

Sensory lost, numbness, tingling, burning sensation on extremities and certain areas, e.g. Median nerve C5-T1 sensory lost on lateral 3 fingers and palm, wasting of thenar muscles. Ulnar C7-T1 weakness, wasting of hypothenar eminence.
Sciatic L4-S2 Weakness of hamstrings and all muscles below knee,
Loss of sensation below knee laterally.

Common mononeuropathies are…..

1. Bell's palsy.
2. Autonomic neuropathy
3. Herpes zoster oticus (Ramsay hunt Syndrome)

Causes of mononeuropathy

- 30% idiopathic,
- Diabetes, B2 Folic vitamin deficiency,
- Drugs chemotherapy, HIV medicines.
- Poisons, Insecticides.
- Chronic kidney, Liver disease
- Injuries, Connective tissue diseases.
- Cancers, Alcohol.

Treatment

- Treat underlying cause
- Advise patients to stand slowly, raise the head of the bed at night, Eat little or often
- Reduce alcohol, Nonsteroids, noninflammatory drugs, Anticonvulsant, antidepressant drugs
- Treatment of underlying disease: Diabetes

ALTERNATIVE TO PAIN MANAGEMENT

Electrical stimulation
Physical therapy
Acupuncture
Massage therapy
Relaxation therapy

OTHER PERIPHERAL NEUROPATHY

Mononeuropathy: Carpel tunnel syndrome, Ulnar nerve palsy, Radial nerve

REFERENCE

- Oxford Handbook General Practice, 4th Edition
- John Murtagh's General Practice, 10th Edition

MODULE 13:

FAMILY VIOLENCE

- Family violence includes child abuse, intimate partner violence, and elder mistreatment.
- Estimating the true prevalence of family violence is challenging, because it occurs in the privacy of the home and not all cases come to medical or professional attention, but it appears to be a common under-reporting problem in Myanmar.
- All forms of family violence can have serious physical and mental health consequences. It is important that the family physician be alert to signs that might suggest family violence and understand approaches to managing the problem.

CHILD MALTREATMENT

- Child maltreatment includes physical abuse, sexual abuse, psychological abuse, and neglect.
- Child maltreatment often presents with symptoms of inattention, school failure, disruptive symptoms, anxiety, depression, failure to thrive, and a broad range of somatic symptoms (ranging from the physical pain of a broken bone to psychogenic symptoms such as recurrent abdominal pain).

Sexual Abuse

- Sexual abuse includes all forms of sexual contact (oral-genital, genital, anal) involving a child in which there is age or developmental discordance between the child and the perpetrator. It also includes noncontact abuse such as exhibitionism, voyeurism, and use of a child to produce pornography.
- Child sexual abuse usually presents with child disclosure. However, presentations may vary and include acute sexual trauma, sexually transmitted diseases, pregnancy, extremes of sexualized behavior, and somatic symptoms such as dysuria and enuresis.
- Interviewing children for evidence of sexual abuse requires special skill and training. That does not preclude the family physician from taking a thorough medical history of a child, including open-ended and nonleading questions about various types of trauma and the etiology of specific findings. In this nonthreatening and familiar setting, a child may disclose abuse. These disclosures are admissible in court.
- When possible, medical history documentation of a disclosure should include direct quotations of questions asked by the provider and responses of the victim.

Neglect

- Neglect alone accounts for more than one third of the annual child maltreatment fatalities. Neglect can be thought of as failing to meet the basic needs of a child.
- These needs include adequate supervision, food, clothing, shelter, medical care, education, and love. Neglect, unlike physical and sexual abuse, often manifests as a pattern of chronic unmet needs, sometimes along one domain, but often along multiple domains. Situations due to poverty are excluded from reporting laws in some states. However, the family physician should avoid this judgment if he or she recognizes inadequate care that may jeopardize the health or development of a child.
- The cause of neglect may not be malevolent, but the risk to the child remains the same. For example, a poor single father may leave his 2-year-old child home alone sleeping at night to work a second-shift job.

- Even though his circumstances drove him to this omission of care, the child is still at risk of significant harm.

Psychological Abuse

- Psychological abuse of children is common; however, it is the least often substantiated type of abuse because of social norms and the challenges of proving both intent of the parent and harm to the child.

The followings are the examples:

- Threatening to leave or abandon a child,
- Threatening to kick a child out of the home
- Locking a child out of the house
- Calling a name like stupid, ugly, or useless
- It is difficult to determine when such behavior is abusive, as it is common, often chronic, and harm is difficult to measure or prove.

Assessment

PHYSICAL ABUSE

- In considering an injury for suspicion of abuse, many physicians use the practical 24-hour rule. That is, if a mark lasts 24 hours, it is considered a significant injury.
- Red marks from spanking (with open hand, paddle, or switch) that resolve in_24 hours do not rise to the level of concern for injury by protective services in most jurisdictions.
- In evaluating any injury to a child, a detailed history should be obtained and carefully documented. In the case of suspicious injuries, detailed drawings or photographs can be helpful.
- The injury should be carefully matched to the reported mechanism. Does the skin mark resemble a known pattern of injury? Loops, teeth marks, and linear welts (from belts or switches) are common patterns in abusive injuries.
- Studies have shown that pre-mobile children rarely bruise: fewer than 1% of children no yet cruising have bruises thought to be due to unintentional injury.
- Certain skeletal injuries are highly suggestive of abuse. Children younger than age 2 years with rib fractures (in the absence of a high impact trauma history or metabolic bone disease) are nearly always the result of abuse.
- Likewise, metaphyseal corner fractures of the long bones are usually from abuse in children younger than age 2. Inflicted head injury is the most common cause of death from child physical abuse.
- Children younger than age 2 with other significant abusive injuries should be evaluated with brain imaging (computed tomography or magnetic resonance imaging) to identify occult brain injury and a skeletal survey to evaluate for bony injuries.
- The most important factor in identifying physical abuse is a high index of suspicion. Clinicians with special training or experience in child abuse can be helpful in clarifying mechanisms in ambiguous injuries.
- These clinicians will also help search for alternative explanations for disease and injury patterns (e.g., coagulopathy, metabolic bone disease).

- Detailed documentation of history and physical exam is essential for protective service and legal investigation. Table 46.1 lists injuries that are suspicious for abuse and deserve careful history taking and documentation.

Table: Suspicious Injuries for Child Abuse
Bruises in non-weight-bearing child
Numerous bruises
Bruises over fleshy body parts (i.e., buttocks, thighs, cheeks)
Scalds (especially symmetric, perineal, clear margins)
Rib fractures
Metaphyseal fractures in children younger than age 2 years
Brain injuries (especially subdural haemorrhage)
Pattern skin injuries (i.e., iron, stove eye, loop, cigarette burn)
Oral injuries (especially labial frenulum laceration in non-weight bearing child)

SEXUAL ABUSE

- The physical examination for child sexual abuse should include visual inspection of the genitals and anus in supine frog-leg and knee-chest positions.
- This exam may be aided by the use of specialized instruments such as lighting devices and a colposcope for magnification.
- Instruments such as probes or specula should never be inserted into a prepubertal vagina without anesthesia or conscious sedation.
- Photodocumentation can be helpful for legal reference, but accurate pen and paper diagrams can be used when photocolposcopy is unavailable.
- Routine cultures for sexually transmitted diseases are not necessary in the absence of symptoms.
- Clinicians unskilled in the physical exam for sexual abuse should seek expert consultation. In the case of uncertain findings, photodocumentation or expert consultation can clarify equivocal findings.
- In the overwhelming majority of cases of chronic or past sexual abuse, physical exam findings will be either normal or nonspecific, making the history critical in determining sexual abuse victimization.

NEGLECT

- Neglect may come to the family physician’s attention in the form of medical nonadherence, failure or delay in seeking medical care, failure to thrive, unmanaged obesity, behaviour problems, school failure, poor hygiene, or homelessness.
- In identifying a child suspected of being neglected, asking nonjudgmental questions about resources can help identify sources of problems and potential solutions.
- Because neglect often manifests as a chronic pattern, the physician must have a way to follow children over time.
- If a child failing to thrive does not return as scheduled, the physician should have a system in place to call the patient, reschedule the appointment, and identify barriers to follow through.
- When a pattern of omissions in care (or a single egregious episode) rises to the level of harm or significant risk of harm, the physician is obligated to report the case to protective services.

PSYCHOLOGICAL ABUSE

- The diagnosis of psychological abuse is often made only through long-term observation of parent–child interaction. This can be facilitated by querying other adults involved in the life of the child (e.g., teachers, coaches).
- Symptoms of psychological abuse include: aggressiveness, impulsivity, depression, hyperactivity, school failure, inattention, disturbances of conduct, anxiety, eating disorders, and somatic symptoms.
- In the evaluation of children with disorders of behavior and development, parents may be witnessed belittling children in cruel ways ("he's stupid just like his daddy" or "she drives me crazy").
- Discussing destructive behaviour and role modelling positive behaviour can help ameliorate a difficult visit and begin to help a parent identify problem parenting. However, in the setting of this type of abusive behavior, a child struggling at home or school will be very difficult to treat with any measure of success.
- When such behavior is observed over time or seems to be correlated with behavioural symptoms, the treating physician should consider a referral for family therapy or to protective services.

Management

- It is important for the parent involved to understand that the report is not placing blame or making judgment, but carrying out a legal responsibility. This helps to absolve some of the guilt that a physician may feel in making a report to child protective services.
- It is not required by law that a person reporting must inform the parent of the report to be made; however, this can set the stage for an open dialog and continued support of a family. How this is framed will depend on the nature of the suspected maltreatment and the suspected perpetrator. Attention to careful documentation of history (both questions asked and responses in quotes) and careful documentation of injuries with drawings or photo documentation is critical.
- In many cases, a physician caring for a child suspected to be a victim of abuse or neglect may need to make a safety plan in conjunction with social services while the child is in the clinic, emergency room, or hospital.
- Ongoing evaluation will often include ancillary studies (i.e., skeletal survey, head computed tomography, coagulation studies). In many communities, the family physician will have access to a provider with special skill and training in the evaluation of children suspected to be maltreatment victims.

INTIMATE PARTNER VIOLENCE (formerly called Domestic Violence)

- Intimate partner violence (IPV), which includes physical, emotional and sexual harm by a current or former partner or spouse, is a common problem with serious physical and mental health consequences for victims and their children.
- Although women are most commonly affected, IPV affects both men and women and occurs in married and unmarried couples, affecting both heterosexual and same-sex couples.
- The Centers for Disease Control and Prevention defines IPV according to the following categories:
- **Physical violence** is the intentional use of physical force with the potential for causing death, disability, injury, or harm. Physical violence includes, but is not limited to, scratching;

pushing; shoving; throwing; grabbing; biting; choking; shaking; slapping; punching; burning; use of a weapon; and use of restraints or one's body, size, or strength against another person.

- **Sexual violence** is divided into three categories:
  - (i) use of physical force to compel a person to engage in a sexual act against his or her will, whether or not the act is completed;
  - (ii) attempted or completed sex act involving a person who is unable to understand the nature or condition of the act, to decline participation, or to communicate unwillingness to engage in the sexual act (e.g., because of illness, disability, or the influence of alcohol or other drugs, or because of intimidation or pressure); and
  - (iii) abusive sexual contact.
- **Psychological/emotional violence** involves trauma to the victim caused by acts, threats of acts, or coercive tactics. Psychological/emotional abuse can include, but is not limited to, humiliating the victim, controlling what the victim can and cannot do, withholding information from the victim, deliberately doing something to make the victim feel diminished or embarrassed, isolating the victim from friends and family, and denying the victim access to money or other basic resources.
- Although IPV affects all ages, races, ethnicities, and socioeconomic strata, young women and individuals with low incomes are at greatest risk.
- A prior history of IPV, child abuse victimization, or sexual assault is all associated with increased risk of IPV, as is a history of alcohol or other drug use and separated or divorced marital status.
- In addition to the toll that IPV takes on individuals and their families, the cost of IPV to society is large. Because victims of IPV tend to have high rates of physical and mental health morbidity, they are frequent users of the health care system.
- For this reason, rates of IPV seen in primary care practices and emergency departments are even higher than those seen in the general population. One study of women enrolled in health maintenance organizations demonstrated that 44% of adult female patients reported IPV in their lifetimes and 8% had experienced IPV in the past year. Intimate partner violence is thus a condition that family physicians can expect to encounter frequently over the course of their careers.

Common Presentations

- IPV influences multiple aspects of physical and mental health, affecting victims' health for many years, even after abuse. Negative health effects occur whether abuse is physical, sexual, or emotional.

INJURIES

- The most direct health effect of IPV is injury. Certain patterns of injury, such as injuries to the head, neck, breast, or abdomen, should raise suspicion of intentional injury. Facial trauma, for example an orbital fracture or dental injury, is particularly suggestive.
- Fractures, sprains, or dislocations of the extremities account for about one quarter of IPV-related injuries. Victims of IPV also suffer long-term sequelae of injury, such as symptoms of traumatic brain injury or problems with swallowing and speech.
- The most serious direct consequence of IPV is mortality: more than 1,000 women are killed by intimate partners in the United States annually. Myanmar data is not known.

OTHER PHYSICAL HEALTH EFFECTS

- Many of the health effects of IPV are not directly attributable to trauma. Concerns related to sexual health, such as sexually transmitted infections, cervical dysplasia, and unplanned pregnancy, are more common in victims of IPV.
- In addition, victims of IPV are at increased risk for cardiovascular disease and stroke. Functional gastrointestinal disorders such as irritable bowel syndrome and a variety of chronic pain complaints, such as arthritis, migraine, fibromyalgia, chronic fatigue syndrome, and temporomandibular joint syndrome are all more common in victims of IPV.
- Patients with IPV may present with multiple somatic complaints, such as stomach pain, back pain, menstrual problems, headaches, chest pain, dizziness, fainting spells, palpitations, shortness of breath, constipation, generalized fatigue, and insomnia.
- The reason that IPV increases risk for such a wide range of conditions is unknown but may be related to the direct consequences of trauma, the long-term accumulated effects of chronic stress, and high prevalence of risky health behaviours.
- Interestingly these complex symptoms are commonly brought to GP/FP's daily practice. That is why we should consider IPV in case of undifferentiated symptoms. (See Chapter 2)

IPV AND PREGNANCY

- IPV often continues throughout pregnancy, increasing risk for complications such as spontaneous abortion, hypertensive disorders of pregnancy, vaginal bleeding, placental abruption, severe nausea and vomiting, dehydration, diabetes, urinary tract infection, and premature rupture of membranes.
- Victims of IPV are often delayed in seeking prenatal care, and the possibility of IPV should be considered in women who receive late or no prenatal care. IPV-related homicide is the leading cause of maternal mortality, accounting for 13% to 24% of all deaths in pregnancy.
- Infants of mothers who experience IPV during pregnancy also are at risk for medical complications, including low birth weight, prematurity, and perinatal death.

MENTAL HEALTH

- IPV, whether it is physical, sexual, or emotional, also has mental health consequences. Victims of IPV commonly experience depression, suicidal thoughts and attempts, and posttraumatic stress disorder.
- Tobacco, alcohol, and illicit drug abuse are common , and victims of IPV are more likely to engage in risky sexual behaviours.
- Women who are abused are more likely to engage in disordered eating patterns. Adverse mental health consequences, such as depression, oppositional defiant disorder, developmental delay, school failure, or future violent behavior, are also seen in children who witness IPV.

Assessment

- Assessing for IPV in the clinical setting can fall into one of two categories: clinicians may inquire about IPV in all patients at risk regardless of clinical suspicion **(a universal screening approach),** or they may confine inquiries to situations in which there is some suspicion that violence is occurring or in which knowledge of violence would be relevant to the presenting complaint.

- Although routine screening for IPV is recommended by some organizations, the United States Preventive Services Task Force (USPSTF) states that there is insufficient evidence to recommend for or against routinely screening women for IPV.
- This recommendation was based on the lack of evidence regarding accuracy of IPV screening questionnaires, and more importantly, the lack evidence that primary care based interventions are helpful in preventing the negative consequences of IPV.
- Recent systematic reviews have confirmed that there is not yet strong evidence of effectiveness of any intervention, although some strategies show promise in mitigating the effects of IPV.
- After the USPSTF recommendation was published, a randomized controlled trial of screening for IPV in health care settings did not support a significant benefit from screening.
- The USPSTF does state, however, that "all clinicians examining children and adults should be alert to physical and behavioral signs and symptoms associated with abuse or neglect. Patients in whom abuse is suspected should receive proper following points
  1.documentation of the incident and physical findings
  2. treatment for physical injuries
  3. arrangement for skilled counselling by a mental health professional
  4. the telephone number of local crisis centers, shelters, and protective service agencies"
- . In other words, although there may be weak evidence for *screening* for IPV, clinicians should still maintain an index of suspicion for IPV, remaining alert to situations suggestive IPV and providing appropriate treatment resources for patients in whom IPV is detected.
- When patients present with issues consistent with IPV
- (Table 46.2), clinicians should consider inquiring about IPV, not only because intervention may be beneficial but also because knowledge of IPV could influence the treatment plan and help the clinician understand barriers to treatment adherence.

Table: Situations that should raise suspicion for Intimate Partner Violence

Injuries to the face or trunk
Pattern of injury not consistent with explanation given
Frequent somatic complaints
Chronic pain syndromes
Recurrent sexual health concerns
Late entry into prenatal care
Frequent late or missed appointments
Substance abuse
Frequent mental health complaints

- Women with a history of IPV often have frequent primary care and emergency room visits and may be perceived to overuse the health care system. They often report strained relationships with their physicians.
- However, what physicians perceive as poor adherence to medical recommendations and lack of motivation may in fact be related to the abuse a patient is experiencing. Interference with receipt of health care may be part of the control that abusers exert in their partners' lives.
- Primary care physicians who diagnose IPV, and therefore begin to understand the barriers that their abused patients face, may be able to form more effective therapeutic relationships.
- Identifying IPV also provides an important opportunity for providing the patient with empathic support and reassurance that the violence is not her fault; educating her regarding the dynamics

of IPV and the future risks it poses to her and her children; and opening the door to future conversations.

- Several questionnaires for assessing for IPV have been validated in a variety of populations and patient care settings and are practical for use in the primary care setting (Table 46.3).

Table: Tools to Assess for Intimate Partner Violence

Test	Sensitivity (%)	Specificity (%)
Abuse Assessment Screen	93	55
1. Have you ever been emotionally or physically abused by your partner or someone important to you?		
2. Within the last year, have you been hit, slapped, kicked, or otherwise physically hurt by someone?		
3. Since you've been pregnant, have you been slapped, kicked, or otherwise physically hurt by someone? If YES, who?		
4. Within the last year, has anyone forced you to have sexual activities? If YES, who?		
5. Are you afraid of your partner or anyone you listed above?		
Any YES answer considered positive for abuse		
HITS	86-96	91-99
1. How often does your partner physically HURT you?		
2. How often does your partner INSULT or talk down to you?		
3. How often does your partner THREATEN you with physical harm?		
4. How often does your partner SCREAM or curse at you?		
Each question is answered on a 5 point scale: 1=never, 2=rarely, 3=sometimes, 4=fairly often, 5=frequently Score ≥10 considered positive for abuse		
Partner Violence Screen	65-71	80-84
1. Have you been hit, kicked, punched, or otherwise hurt by someone within the past year? If so, by whom?		
2. Do you feel safe in your current relationship?		
3. Is there a partner from a previous relationship who is making you feel unsafe now?		
Yes answer to question 1 if perpetrator is current or former partner, no answer to question 2 or yes answer to question 3 considered a positive test		
WAST short	92	100
1. In general, how would you describe your relationship?		
• A lot of tension		
• Some tension		
• No tension		
1. Do you and your partner work out arguments with:		
• Great difficulty?		
• Some difficulty?		
• No difficulty?		
"A lot of tension" on question 1 or "great difficulty" on question 2 considered a positive test		

Table: Intimate Partner Violence Red Flags indicating Increased Risk for Serious Injury or Homicide

Increasing frequency or severity of violence
Recent use of or threats with a weapon
Homicide or suicide threat
Hostage taking or stalking
Alcohol or drug use
Recent separation from or threats to leave partner

- It must be kept in mind with each of these questionnaires, however, that what is considered a "positive" test depends on how IPV is defined, and sensitivity and specificity of the test depend on what criterion standard is used to define a true positive or negative test.
- Because it is difficult to objectively confirm the presence of IPV, determining accuracy of specific questions can be problematic.

- Regardless of whether a clinician uses a structured instrument or simply asks questions informally in the context of a patient interview, several principles are important to follow. Physicians should ensure a private setting, without friends or family members (other than children under age three) present.
- They should assure patients of confidentiality, but notify them if any reporting requirements apply. Language should be direct and nonjudgmental. It is often helpful to preface questions about IPV with statements that normalize the inquiry; for example, "Because violence is a common problem, I routinely ask my patients about it," or "Many people with [condition] have worse symptoms if they have been physically, emotionally, or sexually abused in the past."
- If any language barriers are present, physicians should use the assistance of an interpreter, ideally one who has been trained to ask about IPV.

Management

- When IPV is detected in the clinical setting, it is important that clinicians respond in a way that builds trust and sets the stage for an ongoing therapeutic relationship.
- Key components of an initial interaction should include validation of the patient's concerns, education regarding the dynamics and consequences of IPV, safety assessment, and referral to local resources.
- It is important to realize that IPV is usually a chronic problem that will not be solved in the one or two visits, but rather can be worked on over time. Because intervening on IPV is a complex and slow process, with outcomes that are often difficult to measure objectively, the evidence base for most health care–based interventions IPV is weak.
- Recommendations for management of intimate partner violence in the clinical setting are therefore largely based on expert opinion. An initial response to a disclosure of IPV should include listening to the patient empathically and non-judgmentally, expressing a concern for her health and safety, and affirming a commitment to help her address the problem.
- Women who have long been subjected to abuse may have very low self-esteem and may believe that the abuse is their fault. Physicians can help counter this belief, reassuring patients that although partner violence is a common problem, it is unacceptable and not the fault of the victim.
- It is also important to convey to victims of IPV a respect for their choices regarding how to respond to the violence. Taking control and attempting to steer a patient toward a specific course of action, for example leaving an abusive partner, can actually replicate a pattern of abuse, disempowering a patient who already has very little control over the circumstances of her life.
- Victims of IPV may have a clearer understanding than clinicians about the dynamics of their relationships and what courses of action may result in increased danger. If patients need to move slowly, scheduling frequent office visits can be helpful, providing ongoing support and addressing medical problems.
- It is, however, important that clinicians provide patients with education on the dynamics of partner violence and potential effects on victims and their children.
- Patients should be helped to understand that once violent dynamics are established in a relationship, the violence generally continues and escalates over time.
- In a nonjudgmental way, physicians can convey concern to patients regarding the negative physical and mental effects that IPV may have on patients and their children.

- Although addressing IPV is usually a long-term, ongoing process, physicians should be alert to potential crisis situations that could indicate imminent danger to patients' health or safety (Table 46.4).
- Even if none of these risk factors is currently present, assessing for them can help educate patients regarding what situations to be alert for that could indicate increased risk. It can be useful to offer patients a handout or brochure on safety planning and go over it with them.
- Finally, physicians should provide victims of IPV with referral to local resources that can provide advocacy and support.
- Family physicians should be familiar with the organizations in their communities that can provide assistance to victims of IPV, including organizations' capacity to accommodate specific populations such as immigrants; specific ethnic or cultural groups; teens; lesbian, gay, bisexual, or transgender clients; or people with disabilities.
- Resources might include community-based advocacy groups, shelters, law enforcement agencies, social workers, or support systems within the healthcare setting.
- If immediate concerns for safety exist, the physician can offer for the patient to contact these resources from the office. A follow-up visit should be scheduled, and IPV should be readdressed at future visits.

ELDER MISTREATMENT

- Elder abuse is a less well-understood phenomenon than child abuse and IPV, but a growing body of research suggests that it is a common problem with potential for serious morbidity and mortality.
- A recent panel convened by the National Academy of Sciences to outline a research agenda in the field defined elder mistreatment as "(a) intentional actions that cause harm or create a serious risk of harm (whether or not harm is intended) to a vulnerable elder by a caregiver or other person who stands in a trust relationship to the elder or (b) failure by a caregiver to satisfy the elder's basic needs or to protect the elder from harm".
- Elder mistreatment includes physical abuse, psychological abuse, sexual abuse, financial exploitation, and neglect. Elder self-neglect, or the failure of an elderly person to meet his or her own basic needs or protect his or her health and safety, is also sometimes considered to be a type of elder mistreatment. Recent population-based studies suggest that between 2% and 11% of older adults report having been subject to some form of abuse in the past year.
- Neglect is most commonly reported, followed by emotional mistreatment, physical mistreatment, and sexual mistreatment. A minority of these events are ever brought to the attention of physicians or adult protective services agencies.
- Elder mistreatment, however, is difficult to measure, so the accuracy of prevalence estimates is unclear.
- Population-based research has generally relied on self-report of abuse from cognitively intact, community dwelling individuals and is therefore unable to accurately estimate the prevalence of mistreatment in vulnerable elders who suffer from dementia or live in long-term care facilities.
- Family caregivers and long-term care staff report even higher levels of abuse than do the elders themselves. In surveys of long-term care staff, 10% admit to physical abuse of residents, 40% admit to psychological abuse, and, impressively, 80% report having witnessed abuse.
- By any of these measures elder mistreatment is a common enough problem that any family physician who cares for elderly patients in outpatient, inpatient, or long-term care settings will encounter elder abuse frequently in clinical practice.

- Although the causes of elder mistreatment are not well understood, several patient, caregiver, social, and environmental factors are markers of increased risk.
- Elders who live with their caregivers are more likely to be victims of mistreatment; probably simply from tensions that arise when there are greater opportunities for contact. Social isolation of both elders and their caregivers also appears to increase risk for mistreatment.
- Patients with dementia, in particular patients who have disruptive behavior or aggression, are at increased risk. Research on the role of physical frailty and dependence play in risk of abuse has been inconsistent.
- Caregiver factors that increase risk of mistreatment include mental illness, especially depression and alcohol abuse, and financial dependency on the elder.
- Factors that increase risk of abuse in long-term care facilities include inadequate staffing and staff training, staff burnout, and aggressive behavior by residents. Elder mistreatment has been linked to adverse health outcomes, including increased depression, hospitalizations, nursing home placement, and mortality.

Assessment

- As with child maltreatment and intimate partner violence, the USPSTF states that there is insufficient evidence to recommend for or against routine screening for elder abuse, because of the lack of clear evidence that we can accurately identify and effectively intervene upon elder abuse in the clinical setting.
- The lack of evidence for universal screening, however, does not obviate the need for remaining alert to signs of elder mistreatment and appropriately treating when elder mistreatment is identified.
- Unlike some of the patterns of injury that are clearly suggestive of child maltreatment—for example, the retinal hemorrhages and metaphyseal corner fractures of shaken baby syndrome—there is no clear constellation of symptoms that is suggestive of elder mistreatment.
- Falls and fractures are common in the frail elderly, and skin may be fragile and bruise easily. Weight loss may be a symptom of late stages of many illnesses seen in the elderly, but could also be a sign of neglect.
- Identification of elder mistreatment is also complicated by the fact that elderly individuals with cognitive impairment, who are particularly vulnerable, may not be able to give accurate accounts of abuse or neglect.
- Mistrust of caregivers can be part of the dementia process itself; it may be difficult to distinguish between financial exploitation and appropriate efforts by caregivers to take control of finances for an elder who is no longer able to manage independently.
- Although there is no pattern of presenting symptoms that is specific to abuse, providers should remain alert to bruises or burns in unusual locations or injuries that are not consistent with the explanation offered. Injuries to wrists or ankles could be an indication of use of restraints.
- Genital or breast injuries should raise suspicion of sexual abuse. Findings that should raise suspicion for neglect include dehydration or malnutrition, pressure ulcers, poor hygiene, or medical non-adherence.
- Several instruments have been developed to assess for elder mistreatment, but none have been well validated across different clinical settings and with different patient populations.
- In the absence of clear evidence for specific approaches to identifying elder mistreatment, several principles may guide clinicians who are attempting to determine whether abuse and/or neglect are occurring.

- If mistreatment is suspected, the patient should be questioned and examined in private, away from caregivers. General questions about home environment and safety can be followed with more direct questions about whether the patient has been hurt or threatened, food or medicines have been denied, the patient has been made to feel guilty about asking for help, personal belongings have been taken away, or unwanted touch has occurred.
- Any affirmative answers should be followed up with questions about details about the circumstances and frequency of potential abuse. Answers and physical findings should be documented carefully.
- For patients who have cognitive impairment, assessment of decision-making capacity is important, because it will guide an approach to intervention.
- Caregivers may also be questioned directly about abuse or neglect, but physicians must be careful to avoid alienating caregivers, who could in turn restrict access to the elderly patient.
- It may be helpful to precede direct inquiries with permissive statements, such as “Caring for your father must be stressful. How do you manage?” If a caregiver does disclose abuse or neglect, the physician should be careful to refrain from passing judgment.

Management

- There is a paucity of evidence to support any specific approach to intervening on elder mistreatment.
- Research on effective interventions is difficult for a number of reasons: elder mistreatment encompasses a heterogeneous group of problems with diverse causes; interventions for elder abuse are generally multifactorial and multidisciplinary and are difficult to standardize in the context of a controlled trial; elderly patients often have several serious comorbidities, including cognitive impairment, that make comparing outcomes across individual patients difficult; and access to patients may be limited by their caregivers.
- The most appropriate strategy for intervention will be determined by the nature of the abuse or neglect and the circumstances of the individual patient.
- Strategies for managing elder mistreatment should be tailored to the specific situation. Lack of social support appears to be a risk factor for most types of abuse, so connecting elders with resources that can provide social support is likely to be beneficial in most situations.
- If abuse is thought primarily due to caregiver burden or mental health concerns, interventions can be targeted toward caregivers. These interventions might include caregiver education regarding what constitutes abuse, referral to respite care resources, connection with social support, and psychotherapy or pharmacotherapy to address mental health concerns.
- If abuse is a response to or is perpetrated by an aggressive patient with dementia, interventions to address behavior in the patient with dementia are indicated. If the abuse is a continuation of longstanding intimate partner violence, referral local IPV support organizations may be helpful.
- For patients who lack capacity for decision-making, pursuing guardianship may be necessary. Ideally, physicians should enlist the assistance of a multidisciplinary team (which might include physicians, nurses, government agencies, social workers, legal professionals, and law enforcement personnel) with expertise in various aspects of elder mistreatment.

Reference

Essentials of Family Medicine ,6th edition: Phillip D Sloane et al, Lippincott Williams & Walkins,2012

Chapter 2

Common Symptoms in General Practice

1. Fatigue
2. Weight Loss
3. Fever
4. Dyspepsia
5. Breathlessness
6. Cough
7. Sore Throat
8. Chest Pain
9. Diarrhoea
10. Constipation
11. Vomiting
12. Abdominal Pain
13. Skin Rash
14. Backpain
15. Joint Pain
16. Dizziness
17. Headache
18. Insomnia
19. Multiple Unexplained Physical Symptoms (MUPS)
20. Red Eye

COMMON SYMPTOMS IN GENERAL PRACTICE

1. FATIGUE

A Common and Practical Definition

- Defined as a sensation of exhaustion during or after usual activities, or a feeling of inadequate energy to begin these activities.
- Fatigue may be defined as excessive tiredness of body or mind. Patients may use different words to express it: weariness, loss of energy, listlessness and exhaustion.

Relevance to General Practice

- Primary-care-based surveys have shown that between 11% and 33% of patients report significant fatigue, resulting in approximately 7 million office visits per year in the US. Fatigue is also a common complaint in the general population, with prevalence between 4.3% and 13.4%.
- Everyone is occasionally tired. For some, the tiredness may be severe enough to prompt a visit to the primary care physician.
- Most patients bothered by being tired all the time come to the doctor looking for an organic cause. Although most studies of chronic fatigue syndrome (CFS) find the vast majority to have a psychological cause, few patients initially report psychological symptoms as secondary to a medical illness. Attempts by the doctor to address psychological issues may be misinterpreted by the patient as not being taken seriously.
- The task of the primary care physician is to pick up the patient which an organic cause for definitive treatment and to provide advice and reassurance to the rest.
- **Anaemia** is the commonest physical cause of fatigue. Other physical causes include hypothyroidism, cardiovascular disease, diabetes, carcinoma and post infectious mononucleosis infection. A full blood count is therefore the single most useful test if investigation is considered necessary.

- Remember to review the patient's medication as a possible contributing factor.

Classification

Fatigue can be classified as;

- **Physiological** (i.e., fatigue which can normally be expected in a mentally and physically healthy individual when an imbalance in exercises, rest or diet exists.
- **Acute** (not explainable by physiological fatigue, present for fewer than six months and not resolving with bed rest), and
- **Chronic** (present for six or more months).

Common Case Scenario In Myanmar:

- A 25-year-old MTZ comes to your GP Clinic with a 9-month history of "unbearable fatigue". Before the fatigue began 9 months ago, she worked as a high school chemistry teacher. Since the fatigue began, she has been unable to work at all. She tells you that "I'm feeling tired all the time, so could you give me an IV?"

Filtering:

- In this case, first question you should ask is "How long have you been suffering from this sort of feeling –tiredness all the time?"
- Duration >2 weeks-depression ¼, physical disease 1/4, no cause ¼, CFS and other possibilities ¼
- Duration > 6 months-depression ½, somatisation disorder and other psychiatric ¼, CFS 10%, prolonged fatigue NOS (not other specified) and chronic physical in the remainder

Causes

- It is helpful to start by drawing up a shortlist of possible causes so that realistic diagnostic probabilities can be considered. In those patients in whom a positive diagnosis can be made, being tired all the time (TATT) is much more likely to arise from psychological or social causes than physical ones.
- About 75% of cases may have psychological or social causes. 10% have physical causes and the remaining 15% have unexplained fatigue. (See Table 1)

Table 1. Causes of feeling tired all the time

PSYCHOLOGICAL AND SOCIAL

- Anxiety, depression or mixed

PHYSICAL

- Uncommon (less than 10%)
- anaemia
- diabetes
- hypothyroidism
- side-effects of medication
- cardiovascular disease
- malignancy (rare-less than 1%)
- postviral fatigue syndrome

UNEXPLAINED

- Relatively uncommon (15%)

Source Ridsdale I, Evans A, Jerrei Wet al. Patients with fatigue in general practice: a prospective study BMJ 1993:307:103-

Table 2: Prevalence of the disease in GP:

- Depression-17-40% (it is the commonest cause of chronic fatigue>6 months)
- Others psychiatric(anxiety)-25%
- Boredom, overwork, other types of unhappiness-
- Alcohol misuse-16%
- Insomnia
- Obstructive sleep apnoea (OSA)-2.4%
- Chronic fatigue syndrome (CFS)-0.2-2.6%
- Fibromyalgia 2.4%
- Others physical-anaemia-4%hypothyroid-1.5%, diabetes-0.5%,
- Drugs-1 in 57 patients treated a year

Psychological

- Anxiety or depression, or a combination of the two, are overwhelmingly responsible for most cases of feeling tired all the time. Such anxiety or depression is often linked to psychological stress and usually has a clear underlying cause.

Anaemia

- For anaemia to be a cause, it has to be seven, that is, 7G /100ml. Lassitude prevails, at times in association with exertional dyspnoea or with postural hypotension when blood loss is acute.

Endocrine

- Diabetes mellitus is the most common endocrine cause for fatigue. Less common, but should be looked out for, are hypothyroidism and apathetic hyperthyroidism in the elderly.

Pharmacologic

- Drugs commonly causing tiredness include antihistamines, antihypertensives and psychotropics.

Cardiopulmonary and other vital organ dysfunction

- Failure of any of the vital organs can present as fatigue, e.g. congestive cardiac failure, chronic renal failure, hepatocellular failure and chronic obstructive lung disease. In the diabetic patient and in the elderly, acute myocardial infarction may present as tiredness.
- Chronic fatigue from disturbed step due to sleep apnoca is an often-overlooked aetiology. Daytime sleepiness, excessive snoring, irregular breeding, disturbed sleep, and haemoglobin desaturation are characteristics of this condition.

Malignancy

- Occult malignancy is a much-feared etiology. Fatigue and lassitude accompany most cancers, but pancreatic carcinoma is the typical example of a tumour that may present initially as marked fatigue with few localizing symptoms.
- Also, severe weight loss, depression and apathy may also dominate clinical picture before other manifestations of the malignancy become evident. Malignancies causing hypercalcemia (e.g. breast cancer, mycloma) may present with fatigue, although the hypercalcemia is usually a late development.

Infections

- Occult infections like tuberculosis or endocarditis, prodromal phase of hepatitis, and acute infections can all cause fatigue.
- Post viral fatigue syndromes are relatively uncommon. Fatigue due to infectious mononucleosis is well documented.

Physiological tiredness

- Tiredness following any form of exertion, be it mental of physical, is normal. It is unusual for patients to complain of this form of tiredness to the doctor, unless it is used as a “ticket of entry” for another problem.

Workup

History

- It is important to ensure that the patient and the doctor are talking about the same thing. Patients should be questioned about what they mean by “tiredness”. Local muscle aches or shortness of breath may be described as “tiredness”.
- A brief perusal of the patient’s records should disclose past and present medical history, including current drug therapy, and may give a clue to the present complaint.
- The initial part of the consultation should concentrate on open questions, allowing the patient to elaborate on his on her complaints, before focusing on specific questions designed to confirm or refute the diagnostic hypotheses forming in the doctor’s mind.
- If a psychological disorder seems unlikely, then systematic questioning is needed to elucidate the problems.

General questions

Duration of complaint is important.

- days – prodromal phase of infections, recent infarct
- weeks – underlying malignancy, chronic infections
- months, or life-long duration – psychological cause.

Periodicity

- constant – organic problem
- fluctuating – functional aetiology

Worst time of the day

- In the morning, especially after a good night's sleep – functional cause more likely
- worsens as the day progresses – physical cause more likely

Significant preceding event

- acute – e.g. bereavement
- sometime past – e.g. dental extraction resulting in sub-acute bacterial endocarditis (infective endocarditis).

System review

- If a psychological disorder seems unlikely then systematic questioning, for example about change in weight, cough, dyspnoea, polydipsia, polyuria, or a recent history of viral illness, should help to confirm or refute possible physical causes.

Exploration of possible psychological factors

- A psychological cause, as for example, over-burdened life situations, may cause fatigue. A grandparent who suddenly has to look after a grandchild may well be tired out by the responsibility.

History

- **Depression**-two screening questions: in the last month have you often been bothered by feeling down, depressed or hopeless? -----by little interest or pleasure in doing things? If yes, test is positive.
  Sensitivity 96%, specificity-57%.PPV 33%, NPV 98%
- **Anxiety-** Do you find yourself worrying a lot or on edge? HADS score>8 is positive LR =4
- **Dissatisfaction-** Do you usually get out of bed in the morning looking forward to the day ahead?
- **Sleep-** snoring, diurnal somnolence, morning dry mouth and headache, Epworth sleepiness scale: total score>11 supports the diagnosis of OSA
- Limb discomfort at rest, involuntary limb movement, restlessness of legs, disturbed sleep, depressed mood could indicate Restless Leg syndrome (RLS)
- **Alcohol** how often do you have an alcohol drink?
- **Prolonged fatigue syndromes-SOFA scale**
- **Infectious mononucleosis** sore throat, fever, swollen glands
- **Drugs**
- **Concomitant illnesses**

Red flags

- Suicidal ideation and marked social withdrawal (MDD and high suicide risk)
- History of substance abuse (withdrawal syndrome and HIV)
- Fever, chills, hypotension (life threatening infection)
- Recent onset of severe or worsening fatigue (severe anemia)
- Gradual onset of fatigue with HIV risk (AIDS)
- Orthopnoea, edema, cardiomegaly, basal crackles (CCF)
- Polyuria and polydipsia (Diabetes)

Physical Examination

- The **general condition** of the patient is important. If the patient looks obviously well, then a functional cause is more likely, though this does not preclude a thorough physical examination.
- If the patient looks unwell, then one should look very hard for physical signs that may be pointers to the underlying problem.
- Pallor-conjunctiva (LR+2.2) multiple sites (LR+ 4.5)
- Hypotension

- Hypothyroid-hand, pulse, voice, coarse skin (LR+5.6), speech (LR+5.4), bradycardia <70 (LR+4.1), wrist puffiness (LR+2.9), periorbital puffiness (LR+2.8), goiter (LR+2.8) In the absence (LR-0.01)
- Hyperthyroid-lid retraction (LR+31.5) lid lag (LR+17.6), fine tremor (LR+11.4) moist warm skin (LR+6.7) tachycardia >90 (LR+4.4) absence of any signs LR-0.01
- Lympadenopathy and hepatosplenomegaly of chronic infection and malignancy

Investigation:

- FBC-if anaemia (+)
- ESR
- RBS
- TSH to exclude Hypothyroid
- Endomysial antibody for coeliac disease
- RCGP recommend LFT, U&E, CK if fatigue more than 6 months

Management

Specific Problems

If there is a specific problem, management is directed forwards the underlying cause.

Functional Problems

- It is important to separate clearly patients who suffer from depression or anxiety from patients who are basically normal but are not coping with excessive stress.
- Patient education and explanation as to why the patient is feeling fatigued helps in the latter group. Showing him or her normal investigation results also help to reinforce the message of normality.
- Anxiolytics can be used in conjunction with advice and counseling. Improvement can be expected in 6 weeks.
- Work situation and social considerations may need modification.
- Family support is important. Explanation and call for supportive attitude on the part of the family members helps.

CHRONIC FATIGUE SYNDROME

- A proportion of individuals with fatigue remain unexplained. Over the past 20 years, there has been considerable worldwide consensus on the criteria for diagnosing this condition.
- The Centres for Disease Control (CDC) in the US has defined the 2 criteria for its diagnosis.
  1. Type of fatigue-chronic fatigue lasting more than 6 months which is:
- Clinically evaluated and unexplained
- Persistent or relapsing
- With a definite onset
- Not the result of ongoing exertion
- Not substantially alleviated by rest
- Results in a substantial reduction in previous levels of occupational, educational, social or personal activities.
  2. Symptoms-Four or more of the following should be present:
- Substantial impairment in short-term memory or concentration
- Sore throat
- Tender lymph nodes
- Muscle pain and tenderness
- Headaches of a new type, pattern or severity
- Unrefreshing sleep and
- Post-exertional malaise lasting more than 24 hours

Symptoms must have persisted or recurred during six or more consecutive months of illness and must not have predated the fatigue.

Minimal Clinical and laboratory evaluation of CFS

- Full clinical examination
- Urinalysis
- FBC, ESR/CRP, autoantibodies
- Thyroid function rests
- Fasting morning cortisol
- Epstein-Barr virology including nuclear antibody

Management

Once organic causes are excluded, management is symptomatic and supportive.

Treatment of Chronic Fatigue syndrome:

1. Multidisplinary rehabilitation treatment is more effective at reducing long-term fatigue severity than CBT in patients with chronic fatigue.
2. Cognitive behavioral therapy (CBT) is a psychotherapeutic intervention aimed at modifying thoughts, feelings, and behaviors. CBT and graduated exercise therapy are cost effective treatment especially associated with co morbid depression.
3. Because the prevalence of clinical depression and/or anxiety in patients with CFS is about 40%, the treatment of depression/anxiety is indicated for CFS.
4. As studies of migraine associated with CFS suggested that around2/3 of patients with CFS have migraine, treatment of migraine is beneficial in case of CFS.
5. Symptom specific treatments are useful e.g., anticholinergic drugs for rhinorrhea.

References

1. Murtagh J. Fatigue – a general diagnostic approach. Aust Fam Physician Nov 2003, 32:11:873-876.
2. Goroll AH. Evaluation of chronic fatigue. In: Goroll et al. Primary Care Medicine, 3rd ed. Philadelphia: Lippincott, 1995:32-37.
3. Maire-Loise Dick & osie Sundin. Psychological and psychiatric cause of fatigue. Aust Fam Physician. Nov. 2003, 32:11:877-881.
4. Ridadale L. Evans A. Jerret W et. Al.Patients with fatigue in general practice: a prospective study BMJ 1993, 307:103-6.
5. J Campheli Murdoch. Chronic fatigue syndrome. Aust Fam Physician Nov. 2003: 32:11 : 883-887
6. Diploma in Family Medicine Notes by Dr Win Lwin Thein, Nov.2017

2. WEIGHT LOSS

Definition

- As involuntary weight loss of greater than 5% within 6 months or greater or equal to 10% within a year should trigger concern. The significance of weight loss should not be underestimated: in about one third of patients, there is no specific cause, but in the rest, serious underlying pathology is found.
- The minorities of these are psychiatric; 90% have organic illness. Thorough assessment from the start is the rule.

Relevance to general practice

- An organic cause need to looked for, although a substantial fraction of patients eventually turns out to be free of any organic disease.
- The task of the primary care physician is to determine at the time of initial presentation who requires extensive medical evaluation and who can be followed up expectantly.

Causes

- The differential diagnosis of involuntary weight loss is extensive, but case studies indicate cancer, depression, and disorders of the gastrointestinal tract to be the most common causes.
- In approximately 25% of cases, no cause of weight loss is found despite extensive evaluation and prolonged follow-up. The main causes are shown in Table 1.

Medical causes

Cancer

- Malignancy is probably the most common cause of weight loss, especially when major signs and symptoms are absent. Although any cancer may present with weight loss, the gastrointestinal tract, including the pancreas and liver, is the most frequent site for occult tumours to be found.
- Lymphoma and leukemia as well as cancer of the lung, ovaries or prostate should be searched for in such patients.

Endocrine and metabolic causes

- Hyperthyroidism, hypothyroidism and diabetes mellitus need to be considered. Weight loss has been described as the most common presenting symptom of hyperthyroidism in the elderly.
- Although hypothyroidism is often thought to cause weight gain, it may also result in anorexia and apathy resulting in weight loss, especially in the elderly.

Infection

- Hidden infection should be searched for in many patients with unexplained weight loss. Tuberculosis, fungal disease, amoebic abscess and subacute bacterial endocarditis should be considered.

Table 1, Some Important Causes of Involuntary Weight Loss

Medical causes
• Cancer
• Endocrine and metabolic causes
• Infection
• Gastrointestinal disease
• Cardiac disorders
• Respiratory disorders
• Renal disease
• Connective tissue diseases

- Oral disorders
- Age-related factors

Neurologic causes

- Dementia
- Parkinson’s disease
- Stroke

Social causes

- isolation
- Economic hardship

Psychiatric and behavioural causes

- Depression
- Anxiety
- Bereavement
- Alcoholism
- Sociopathy

Source: Relfe. Med. Clin N Am 1995 March, 78:2:299-312

Gastrointestinal disease

- Patients with prior abdominal surgery may have partial intestinal obstruction with discomfort, vomiting, and weight loss. Patients who have had a partial gastronomy for ulcer discuss may have malabsorption and loss of weight.

Cardiac, respiratory and renal discuss

- End-stage cardiac, respiratory and renal diseases have varying degrees of loss of appetite which result in weight loss.

Oral disorders, age-related factors

- Absence of teeth, ill-fitting dentures and pain with eating may be a cause of involuntary weight loss in the older patient. A number of functional disabilities may make it increasingly difficult for elderly patients to shop or prepare food; these factors include arthritis, stroke, visual impairment, cardiac disease and dementia. **Neurologic causes**

Dementia

- Such patients may lose the ability to eat independently. The time required to feed these patients may overwhelm family resources or institutional staffing, and patients may not be adequately fed.

Parkinson’s disease

- Such patients with late-stage disease may develop swallowing difficulties.

Stroke

- A stroke may result in dysphagia, weakness and depression, all of which may cause patients to decrease food intake.

Social causes

Isolation

- People tend to eat more in social situation, and social isolation from any reason may result in decreased food intake.

Economic hardship

- Economic hardship as the result of the events may result in difficult financial choices and healthy food may not always be affordable.

Psychiatric and behavioural causes

Depression

- Depression is an important disorder in later life. It may lead to apathy, anorexia and weight loss.

Anxiety

- Patients may be preoccupied and forget to eat. They may not have appetite.

Bereavement

- Loss of a loved one may cause bereavement over an extended period of time with loss of interest in eating entirely.

Alcoholism

- The diagnosis of alcoholism can be difficult to make, and vague complaints such as anorexia or weight loss may be the only signs of an underlying problem.

Sociopathy

- As a patients age, they may lose a sense of control Food refusal may be used as a way to gain back some degree of control and increase interaction with others.

Ready reckoner

	Normal stress	depression	Eating disorders	hyperthyroidism	Malignancy
Mild anxiety	Yes	Possible	No	No	No
Loss of appetite	Possible	Yes	No	No	Yes
Distorted body image	No	No	Yes	No	No
Recurrent problem	Yes	Possible	Possible	Possible	No
Severe malaise	No	Yes	No	Possible	Yes

WORKUP

A thorough history and physical examination, in most cases, reveal possible causes of weight loss and yield a plan to begin an evaluation.

History

Documentation of weight loss

- Assess the extent of weight loss from previous weight records and change in clothing size
- Check that the patient is not dieting
- Determine the time course of weight loss

Identification of mechanisms for weight loss

- Ascertain whether the appetite is good, normal or decreased.
- Weight loss in the presence of increased appetite is seen in thyrotoxicosis, diabetes mellitus and malabsorption.
- Weight loss in the presence of normal or decreased appetite is seen in malignancy, infection, inflammatory disease, malabsorption and depression.

Ask for symptoms accompanying the weight loss

Examples are symptoms of diabetes mellitus; bulky stools in malabsorption; symptoms of thyrotoxicosis, cough in tuberculosis.

Past history of relevance

Examples are: gastrointestinal surgery, cancer surgery.

Family history of chronic discuss

Ask for diabetes mellitus, thyroid disease and malignancy.

Psychiatric history

Ask for symptoms suggestive of depression or anxiety.

Social history

Changes in socio-economic status or life events may be the underlying cause.

Physical Examination

Assessment of degree of weight loss

- Clinical signs to confirm weight loss e.g. loose clothing, loose skin folds.
- Accurate weight determination.

Systems check for signs of diseases

- fever, tachycardia, pallor, ecchymoses, jaundice, signs of hyperthyroidism, hepatocellular failure
- head and neck for glossitis, stomatitis, poor dentition, goiter, lymphadenopathy
- lungs and heart for crepitations, consolidation, effusion, cardiomegaly and murmurs
- abdomen for distention, tenderness, masses and ascites
- return for masses, tenderness and appearance of the stool
- neurological examination

Examination of mental state

- for depression and dementia

Laboratory Investigations

Laboratory investigations should be selective, based on clues obtained from history and physical examination.

Basic investigation

- complete blood count and PBF
- ESR
- selected blood chemistry (calcium, albumin, protein, transaminases and blood urea)
- urinalysis and culture if indicated
- chest X-ray
- This may show a pertinent abnormally like a mass, infiltrate, heart failure or lymphadenopathy in up to 41% in one study.

Further investigations were indicated

- Stools for inspection and test for malabsorption.
- blood sugar
- thyroid function tests.

Search for occult carcinoma

- One of the most difficult diagnostic issues encountered in the workup of weight loss concern the possibility of result malignancy.

- Investigations for occult malignancy may need to be very extensive, and should be considered in the light of the likelihood of finding a cause and the chance that it will be treatable.
- Unfortunately, by the time that weight loss has occurred, most gastro-intestinal malignancies are rather advanced. When weight loss is the only symptom, pancreatic carcinoma may still be resectable it no other symptoms have appeared.
- If an initial assessment does not identify a course; careful follow-up rather than undirected diagnostic tests is the optimum management of the patient.

Management

- A patient with weight loss should be accessed clinically.
- Patients with no significant history and found to be normal on physical examination can be watched and followed up. The risk of serious disease is small.

Indications for referral

- Severe unexplained weight loss where an organic cause is suspected, such as malignancy.
- Referral to a gastroenterologist for those with symptoms of malabsorption such as bulky and foul stools.
- Referral to a psychiatrist for those suspected to have anorexia nervosa.
- Continued unexplained weight loss.

References

1. Reife CM. Involuntary weight loss. Med Clin N Am 1995 March 79.2.299-312
2. Goroll AH. Evaluation of weight loss in: Goroll et al (ed). Primary Care Medicine, 3rd ed. Philadelphia: Lippincott, 1995 March, 95;4:143-150
3. K.Hopcroft. Symptom Sorter,3rd Ed., Radcliffe publishing,2007

3. FEVER

Definition

- The average normal oral body temperature is 36.7ºC (range 36-37.4C), or 98ºF (range 96.8º-99.3ºF). The normal rectal or vaginal temperature is 0.5ºC (1ºF) higher than the oral temperature, and the normal auxiliary temperature is correspondingly lower.
- Rectal temperature is more reliable then and temperature in patients who are mouth breathers or who are tachypnoeic.

Relevance to general practice

- Fever is a symptom that is most readily recognized as a sign of illness and brings the patient quickly to the doctor.
- In the febrile patient with a short history and who is otherwise well, symptomatic treatment based on a presumed viral etiology is usual. The doctor uses time as a diagnostic tool. It the fever persists, or if the condition of the patient deteriorates, the anxiety of both patient and doctor is then quickly aroused to further action.

Causes

- Many infectious, inflammatory, neoplastic and hypersensitivity reactions may produce fever.
- Fever can be broadly divided into short lived fever and prolonged fever.

Short lived fever (<1week)

- Most acute fevers encountered in the ambulatory care setting are of obvious cause and due to upper respiratory or urinary traction infection.
- Viral illness, drug allergy (especially to antibiotics), and connective tissue disease are other important causes, Symposiums accompanying the fever, if present, help in the diagnosis.
- In such cases, the fever would have settled within a few days. Especially in the rainy season, Dengue fever/DHF should bear in mind.

Prolonged fever (>1week)

- For most patients with a fever lasting one or two weeks, the underlying cause is soon discovered or the patient recovers spontaneously. In the latter case, a protracted viral illness is usually presumed to be the source of fever.
- In a small group of patients, physical examination and the basic tests do not reveal the cause of the protracted fever.
- Such a patient is considered to have a fever of unknown origin (PUO) if there has been a daily elevation in oral temperature to 38ºC or higher for three weeks without an identified cause.
- From studies utilizing this definition, the various causes and incidence of longstanding fevers can be assessed. These are shown in Table 1.

Table 1. Causes of Fever of Unknown Origin

Infection (40%)

- Tuberculosis
- Enteric fever
- UTI
- Endocarditis
- Abscess
- Zoonoses (Q fever, brucellosis, leptospirosis)
- Epstein-Barr virus, cytomegalovirus

Neoplasia (20%)

- Hodgkin's disease
- Other lymphomas
- Hypernephroma
- Leukemia
- Hepatoma

Immune-mediated (20%)

- Systemic lupus erythromatosus
- Polymyalgia nodosa
- Stills disease
- Idiopathic vasculitis

Miscellaneous (20%)

- No diagnosis
- Drug fever (gold, phenytoin, penicillin)
- Granulomatous disease (sarcoid, Crohn's)

Source: Whithy M. The febrile patient Aust Fam Physician 1993 Oct, 22:10:1753-1761) modified into local causes

- The following conditions are particularly important causes of fever in general practice, either because they are relatively common, or because they are easily treated or because they have particularly unfortunate consequences if the diagnosis is missed or delayed. In all those conditions the essential step in the diagnosis is to have thought of the possibility.

Infections

Meningitis

- This has to be considered in acute fevers if there is neck stiffness photophobic or vomiting. Lumbar puncture is necessary for confirmation. The prognosis is made worse if bacterial meningitis is not promptly diagnosed.

Urinary tract infection

- At any age this is a common and easily missed cause of fever. Perhaps it is particularly in young children that this condition commonly presents as a PLO, often with vomiting and irritability, but without any obvious urinary symptoms. The microscopic examination of the urine is an essential diagnostic procedure in the investigation of a PUO and the earlier it is done the better. The presence of pus cells in a fresh spun specimen establishes the diagnosis which can be confirmed by culture. Its diagnosis is often made more difficult by antibiotic therapy given in the absence of a diagnosis.

Hidden pus

- This is often a cause of PUO. The three most likely sites are under the diaphragm, in the pelvis, or round the kidney.

Subacute bacterial endocarditis

- This is another cause of PUO. It may not be a common disease but must be thought of. Increasingly it tends to occur in an older age group, to attack valves damaged by arteriosclerotic degeneration as well as rheumatic fever, and to be a complication of abdominal or pelvic surgery or instrumentation of the urinary tract, as well as dental work.

Septicaemia

- This is a possibility that should always be in the doctor's mind. If it is suspected, a blood culture is obligatory.

Pneumonia

- Segmental pneumonia can cause fever with few symptoms or clear diagnosis signs. In the elderly, particularly when they are all and are lying in bed, pneumonia may be hard to diagnosed and physical signs in the chest difficult to interpret.

Enteric fever (typhoid and paratyphoid)

- In the easily stages of the disease, there is a fever without localizing signs or symptoms. The diagnosis is best made on a blood culture.

Gall-bladder Infection

- Cholecystitis, empyema of the gall-bladder and ascending cholangitis can present as fever without any convincing local symptoms or signs. The patient may be very ill. Blood culture may be positive.

Diverticulitis

- This is common in the elderly and may cause fever without any clear localizing signs. Abscesses, either paracolic or pelvic, may occur.

Infectious diseases associated with travel

- The case of modern travel has made certain diseases a real diagnosis possibility in any case of PUO. Specific enquiry must be made about recent travel and to name the countries travelled to. One has to be aware of conditions endemic to specific countries.

Malaria

- The most dangerous condition to leave untreated in a traveler is malaria and every doctor should be prepared to take a thick blood film for examination by the laboratory in patients presenting with high fever in which malaria is a possibility. Enteric fevers and hepatitis have also to be considered.

Tuberculosis

- Pulmonary and extra-pulmonary TB should be considered in case of PUO. It is more likely in persons with Diabetes and HIV.

Viral diseases

- There is a group of viral diseases, or diseases of possible viral etiology which may present as obscure fever.

Infective hepatitis:

- This can present with a fever which may last for four or five days before jaundice becomes clinically evident. Anorexia and nausea are likely to the prominent symptoms. Enlargement of the liver may be noticed before the jaundice appears. Urobilinogen in the urine precedes the appearance of jaundice and of bile in the urine.

Infectious mononucleosis (glandular fever):

- This can present with prolonged fever.

Non-infectious diseases

- Fever does not, of course, always mean infection and there are some relatively common causes of fever from non-infectious diseases that should be in the doctor's mind. As a general principle, the longer the fever persists, the less likely a diagnosis of infection becomes. The more common causes of such fever are:

Malignant disease, including leukemia and Hodgkin's disease

- These can present as fever of unknown origin for several weeks.

Auto-Immune disorders

- Auto-immune disorders such as systemic lupus erythematosus are rare but possible causes of prolonged fever. Rheumatoid arthritis causes fever but the local joint signs are likely to make the diagnosis clear.

Miscellaneous causes

Dehydration

- Dehydration can cause fever. It is particularly important to think of this possibility in the elderly and in the infant.

Drugs

- Drugs must always be suspected as a possible cause of fever. Even drugs taken for long periods without any ill-effect can still cause fever unexpectedly. Self-prescribed drugs as well as those given by doctors may be the causes of fever. Careful enquiry must be made should all forms of medication.

Venous thrombosis

- Venous thrombosis may cause fever without any dramatic local symptoms. Examination of the calves should be a routine in the physical examination of patients with fever, but it should be remembered that thrombosis may affect veins not accessible to external physical examination.

WORKUP

- The **acutely febrile patient** presents common but demanding problems in differential diagnosis. In most cases, a careful history and physical examination will reveal the diagnosis clues, so that laboratory studies can be used selectively.
- The evaluation of **persistent fever** can be more demanding. The initial office evaluation should help determine the proper pace of diagnostic testing and the need for therapeutic intervention.
- If the patient is a compromised host, or if he is acutely ill and toxic, several immediate diagnosis studies are needed such as blood counts and blood cultures to confirm an infective cause and treatment may even be required such as antibiotics given empirically before all the results are available. Hospitalization is usually necessary in such cases.
- If the patient is **not toxic and clinically stable**, the workup can be less rushed. The diagnostic use of time is an essential problem-solving method for the general practitioner. Certain safeguards, however, are required.
- The patient must understand that the doctor needs to above if the illness changes in a significant way or if his general condition deteriorates unexpectedly. Patients do sometimes conclude that because no treatment has been given the doctor considers the illness insignificant.
- Developments of importance **either for diagnosis or management** may then not be communicated to the doctor. The patient should understand what is happening, when the doctor is going to see him again, and under what circumstances he should seek advice before that time.
- The doctors must be available so that it is possible for his patient to find him in case of unexpected or worrying developments, or, if this is impossible, the patient must have clear instructions about whom to contact.
- In the modern organization of general practice it often happens that the patient who calls unexpectedly has to be seen by another doctor. This make it important that the clinical record should make clear the diagnostic and management plans of the original doctor so that any other person who has to take over responsibility for the patient can understand them, and integrate his own sections in line with them.
- For instance, if the **presence of fever and a heart murmur in an elderly** patient makes the original doctors think that he should exclude the possibility of bacterial endocarditis, the should be clearly stated in the notes. If not, a second doctor called in unexpectedly is quite likely to prescribe an antibiotic without perhaps considering that a blood culture might be required.

History

- Duration and progression of fever, accompanying symptoms, chills and rigors if any, recent travel, similar cases at home, drugs taken so far, and the number of other doctors consulted should be asked.

Physical examination

- Where the site of infection is obvious e.g. a URTI or UTI, a selective examination may suffice.
- In suspected Dengue case, Hess Test (tourniquet test) should be done.
- For the rest, a more extensive examination of the chest, abdomen, CNS and neck stiffness will be needed noting in particular, if any skin rash is present.

Investigations

If the history and physical examination provide among indications of an infectious process, laboratory studies can be used selectively to condition or refute the clinical diagnosis.

- Initial investigations may not be necessary if the cause is obvious e.g., a URTI. However, if pneumonia is a possibility, then a chest X-ray and complete blood count would be necessary.
- In suspected Dengue, NS1 antigen (positive on first 2 days) and IgG/IgM antibody (positive on day5 onwards), CP auto (leucopenia, thrombocytopenia, rising haematocrit) should be investigated.
- Urine FEME, blood film for malaria parasite may be indicated based on the history.
- Sputum for AFB for suspected pulmonary TB or patchy opacities in CXR
- In other patients, more extensive tests are needed to establish the diagnosis when the cause of fever remains unknown. Although such studies must be individualized, the approach to diagnostic would include the following.
- complete blood count, differential total white and sedimentation rate.
- urinalysis, Isolated hematuria may be a clue to underlying glomerular disease or urinary tract malignancy.
- chest X-ray may detect infiltrates, effusions or masses even in the absence of abnormalities on physical examination; a KUB and upright abdominal films can disclose air-fluid levels in the bowel, ultrasound or CAT study may be needed if there is a suspicion of a mass lesion, such as an abscess or a turmour.
- blood cultures: if the patient has a heart murmur or a prosthetic heart valve or appears seriously ill.
- serological tests: Widal and Well Felix tests may help to confirm typhoid fever.

Management

Initial routine management

- symptomatic relief of fever
- antibiotics of bacterial infection is thought likely
- advice on fluid intake
- advice further action to report back if fever does not settle in a day or two or there are new development e.g., rash, patient becomes more ill.
- ill patients are referred for admission.

Prevention of complications

- The complications of fever likely to be seen in general practice are dehydration and seen in general practice are dehydration and febrile convulsions in childhood, and confusional states in the elderly. Old people also become easily dehydrated when febrile and ill.
- Dehydration in children occurs more quickly than in adults and children may fall to drink when ill. Their parents need clear instructions about maintaining an adequate fluid intake.
- In the elderly, fever, dehydration and confusion are interrelated problems. Confusion results in failure to drink and dehydration increases the confusion. It is just not enough to leave a jug of water beside the bed. At least 1½ litres of urine should be passed daily and this requires a fluid intake of 2 to 3 litres.
- If doubt exists a regular routine fluid intake should be organized and the intake recorded.
- Febrile convulsions deserved a special world. They occur chiefly between the age of 1 and 3 years.
- There is often a family history. The most important principle in the management of febrile convulsions is control of the temperature. The parents must be taught to do this with confidence.

- For the patient having the first febrile fit, admission for observation and investigation will be needed. In a patient with a patient with a known history of febrile fits, a single febrile convulsion is not a reason for admission to hospital but, if the fits continue or recur, or if there is any clinical suspicion of meningitis, the child must be in hospital, since a lumbar puncture is the only certain way to exclude meningitis.

Subsequent management

- The initial wait-and-see diagnostic period where the presumptive diagnostic is a viral infection commonly lasts from two to five days. During that time, it is useful to have in mind the expected times for the appearance of the rashes of specific fevers.
- **Chickenpox** appears on the first day, rubella on the second or third, and measles on the fourth.
- If by the end of the fifth day no rash has appeared, measles can usually be excluded. Most viral illnesses will have run their course by that time.
- Beyond this period, both doctors and patients begin to feel that something more must be done.
- It is often not until then that the doctor feels obliged to treat the situation more seriously and the diagnostic label tends to change from a presumed viral illness to provide of uncertain origin. This is not in fact a common situation in general practice but it is a worrying one for the general practitioner, and an important one for the patient.

Indications for referral

- The ill patient
- Dengue fever/DHF with clinical and lab warning signs (see DHF module)
- Clinically diagnosed serious conditions: meningitis, pneumonia, cholecystitis, to name a few.
- The patient whose fever persists beyond a week and the cause is still uncertain.

References

1. Whitby M. The febrile patient. Aust Fam Physician 1993 Oct. 22:10: 1753-1764.
2. Simon HB. Evaluation of fever in Goroll et.al. Primary Care Medicine. 3rd ed. Philadeipha: Lippincott. 1995; 48-53.
3. Kamal Amin & Carol A. Kauffman. Fever of unknown origin. Postgraduate Medicine Sep. 2003; 114.3:69-75
4. Pediatric Management Guidelines, MPS, 3rd edition, 2018

4. DYSPEPSIA

Definition

Dyspepsia is defined as upper abdominal discomfort which could have various combinations of nausea, vomiting, heartburn, epigastric fullness, belching, nausea and bloating.

Relevance to general practice

- Dyspepsia is a common presenting complaint in general practice
- The majority of patients who complain of dyspepsia do not have serious disease and will respond to symptomatic treatment
- Vigilance is needed to pick out the alarm features of serious disease in the minority of patients
- Dyspepsia presenting for the first time in those 45 years and older is an alarm feature and the cause need to be investigated

Causes

The causes of Dyspepsia are shown in Table 1.

Table 1. Causes of Dyspepsia

Common causes	
	Simple dietary indiscretion
	Non-ulcer dyspepsia (NUD)
	Gastric erosion due to drugs
Less common causes	
	chronic peptic ulceration
	gastro-oesophageal reflux oesophagitis
Important not to miss	
	Carcinoma of stomach
	Ischaemic heart disease

Simple dietary indiscretion

- These are acute episodes of epigastric distress due to excessive dietary or alcohol intake. They respond to symptomatic treatment.

Non-ulcer Dyspepsia (NUD) or Functional Dyspepsia (FD)

- NUD is diagnosed by excluding a focal lesion on endoscopy. It is divided into four groups based on the predominant symptoms.
- Ulcer-like dyspepsia – well-localised epigastric pain, nocturnal in nature and relieved by antacids.
- Gastro-oesophageal reflux-like dyspepsia – heartburn, burning epigastric pain or regurgitation.
- Dysmotility-like dyspepsia – this overlap with irritable bowel syndrome (IBS) and is associated with flatulence, bloatedness, distension, nausea, early satiety.
- Nonspecific dyspepsia – no specific features. Anxiety neurosis with increase or decrease acid secretions resulting in anorexia and fullness of abdomen or sensation of “bloated feeling”.
- There is overlap between the four different groups of NUD and with irritable bowel syndrome (IBS).

Gastric erosions due to drugs

- NSAIDs cause acute gastric and duodenal damage in 30% users. It should be remembered as a possible.

Chronic peptic ulceration

- Approximately 20% of patients with dyspepsia presenting in general practice have a chronic peptic ulcer. The three major causes are Helicobacter pylori gastritis, NSAIDs and the rare Zollinger-Ellison syndrome.

Gastro-oesophageal reflux

- Reflux of gastric contents into the oesophagus is very common in the general population. A diagnosis can be made on the basis of typical symptoms of heartburn.

Gastric cancer

- Advanced cancer, which is not curable by resection, caused dyspepsia as well as anorexia and weight loss. Early gastric cancer may cause vague abdominal symptoms. Gastric cancer should be considered in any patient over the age of 45 years who presents with a history of dyspepsia for the first time.

Ischaemic heart disease

- Ischaemic heart disease can masquerade as a dyspepsia. A high index of suspicion in an elderly patient is required.

WORKUP

History

Ask for:

- dietary cause
- standard alarm features: VBAD: vomiting, bleeding or anaemia, abdominal mass or unintended weight loss, dysphagia
- number of recurrences and the past treatment given – may support diagnosis of peptic ulcer disease
- drug history especially NSAIDs for arthritic complaints

Physical examination

This should be done systematically looking for signs of physical disease

- General: anaemia or recent weight loss
- Abdominal examination: mass, supraclavicular node
- other systems: cardiovascular disease, lung disease

Investigations

Most cases of dyspeptic symptoms without red flags are relieved by symptomatic treatment. A specific history helps to determine if immediate testing is warranted.

- Baseline investigations – This depends on the diagnosis, e.g. an ECG is needed if one suspects the dyspepsia to be of cardiac origin. A chest X-ray is also useful to provide baseline information.
- Barium studies (including swallow and meal) or endoscopy – either can be used to exclude a gastric cancer. The advantage of the latter is the ability for a biopsy to be taken.

Should all dyspeptic patients be investigated?

Definitely necessary (“high risk”)

- >45 yrs with recent onset of dyspeptic complaints, history of gastro-intestinal bleed
- anorexia
- weight loss
- non-responders to treatment in younger patients:
- no resolution of symptoms after 4-6 weeks of H_2 blocker therapy
- frequent relapses i.e. more than 3 attacks in a year
- obviously unwell
- anaemia

Unnecessary to investigate at first consultation ("low risk")

- young <45 yrs
- supporting history of overeating, alcoholic intake
- presence of family/social problems
- previous negative investigation
- long history with preservation of good health

Helicobacter pylori infection can be confirmed by noninvasive testing or by endoscopic gastric biopsy

- Either serology antibody test or fecal antigen test is recommended as the most cost-effective initial test but because a positive test is indicative of active infection, the fecal antigen assay may be the preferred non-invasive screening test for Helicobacter pylori.
- Urea breath test also has excellent sensitivity and specificity (90%), and a positive test is indicative of active infection; the higher cost may make it less attractive compared to either the serology antibody test or fecal antigen test in most clinical settings.
- Endoscopy is not indicated to diagnose Helicobacter pylori infection in most circumstances. However, when it is performed for another reason, gastric biopsy specimens can be obtained for detection of Helicobacter pylori and tested for active infection by urease production. This simple inexpensive test has excellent sensitivity and specificity (90%)

Management

Low risk group/first presentation

The initial treatment is symptomatic if no serious disease is found or suspected:

- Antacids for pain, metoclopramide for dysmotility – like symptoms and mild tranquilisers if stress is a factor.
- Dietary advice – bland food, avoidance of alcohol and cigarettes
- Counselling and advice on life's stresses and family problems where indicated
- Stop/reduce dose of ulcerogenic drugs e.g., NSAIDs

High-risk group/recurrent episodes (>3 times a year)

- If patient has never investigated before:
- refer for investigations (endoscopy or barium meal)
- meanwhile give antacid only, do not give H_2 blockers
- If a patient has been previously investigated fully and a diagnosis made (e.g. functional dyspepsia, oesophagitis), then the patient should be considered to have a relapse of the condition and treated appropriately.

Chronic peptic ulceration

- If Helicobacter pylori testing shows the presence of active infection, a two weeks' course of treatment is warranted. Only triple and quadruple therapies should be used. One such triple therapy regime is Omeprazole 20mg bd (or Lansoprazole 30 mg bd), Amoxicillin 1g bd (or Metronidazole 500 mg bd) plus Clarithromycin 500 mg bd.
- Follow-up of H pylori treated ulcers is not routine to confirm cure of the infection, unless the ulcer has previously bled or perforated.
- Follow-up of infection status requires either endoscopic biopsy or the non-invasive urea breath test rather than serology. The Urea Breath Test is probably the best way to assess eradication. It is important to wait at least 4 weeks after completion of eradication therapies as there may be transient decrease in bacteria numbers without full clearance.

NSAID ulcers

- Ulceration due to NSAIDs should be treated with an anti-ulcer drugs e.g. cimetidine or ranitidine and if at all possible, the NSAIFs should be stopped and the therapy given for 8-12 weeks.
- Ulcers that are associated with both NSAIDs and H pylori should be treated as for H pylori ulcers, and the NSAIDs should be stopped.

Non-ulcer dyspepsia

- Non-ulcer dyspepsia is diagnosed by excluding other causes of dyspepsia.
- The "gold standard" is endoscopy. However, testing for Helicobacter pylori and treating the patient if found decrease the number of endoscopic performed for dyspepsia by one third3.
- Note that treating a patient with endoscopically confirmed NUD without evidence of active Helicobacter pylori infection; on the other hand, with eradication therapy does not improve the symptoms of NUD.
- Management of NUD is multifactorial and includes making a diagnosis early and explaining the situation to the patient.
- It is important for the physician neither to investigate excessively nor to investigate the presenting symptoms alone.
- New investigation in a patient who has been previously diagnosed with NUD should be done whenever alarm symptoms present (weight loss, vomiting, or blood in the stool) or if there is a new objective symptom. It is important for the physician to determine why the patient with chronic symptoms presented at this particular time.
- Psychological factors can exacerbate symptoms, so it is important for physicians to address these issues and offer counseling.
- A mainstay of management is post-evaluation reassurance of the patient concerning the diagnosis and the absence of alarm symptoms.
- Patients should avoid any food or substance that tends to exacerbate symptoms (NSAIDs, alcohol, or tobacco).
- If symptoms of bloating or postprandial fullness are present, the patient should ear six small meals a day, which may help ameliorate symptoms.
- Management of the predominant symptom with the appropriate medications may be considered. Not all patients however, may want or need to take medications routinely.

Drug therapy in dyspepsia

Antacids

- Useful in both ulcer and non0ulcer dyspepsia
- Give 10-30 ml, four or more times per day, between meals and at bedtime.
- Liquids more effective than solid preparations.
- Compound proprietary preparations have no clear advantage over simpler preparations.
- Antacids should not be taken at same time as other drugs because the absorption of the latter may be impaired.
- Avoid high sodium preparations e.g. sodium bicarbonate mixtures or mist. magnesium trisilicate in salt-restricted patients.

Prokinetic agents

- Examples of prokinetic agents are metoclopramide, domperidone and cisapride.
- The place of prokinetic agents for NUD has dwindled in importance because of drug safety reasons.
- Cisapride has been taken off the market because of cardiac arrhythmias and sudden deaths.
- Short term use of metoclopramide in non-ulcer dyspepsia has been helpful. Unfortunately, ling term use is associated with tardive dyskinesia.

H_2 blockers

- Has a place in ulcer therapy

- Impaired metabolism caused by cimetidine and ranitidine of warfarin, theophylline, phenytoin, carbamazepine, propranolol, nifedipine, imipramine, metronidazole will result in raised serum levels of these drugs.
- Cimetidine and ranitidine decrease the absorption of ketoconazole due to elevation of gastric pH.
- Magnesium, and aluminium, hydroxide antacids reduce by 30-4- percent the bioavailability of cimetidine and ranitidine. Thus, if an antacid is used concurrently with and H_2 blocker, the antacid should ideally be given at least two hours either before or after the H_2 blockers.

Indications for maintenance H2 blocker therapy

- This is indicated under the following circumstances
- peptic ulcer
- history of complication e.g. bleeding, perforation, outlet obstruction
- rapid relapse after previous treatment
- frequent relapses (3 or more times a year)
- difficult to heal
- elderly (>65 years)
- intercurrent illness (where risk of bleed can jeopardize life)
- continued NSAID use
- Zollinger-Ellison syndrome

Hydrogen-potassium-ATPase inhibitor

- Omeprazole is capable of almost completely eliminating gastric acid secretion. It would be useful for treatment of refractory peptic ulcer disease at a dose of 20mg/day

Indications for referral

- Initially, if organic disease is present or suspected:
    - carcinoma stomach (based on age, anaemia, weight loss and anorexia)
    - chronic peptic ulcer
- Patient requiring confirmation of non-ulcer dyspepsia by endoscopy
- Patient's request

Reference:

1. Dickerson LM & King DE. Evaluation and management of nonulcer dyspepsia. Am Fam Physician 2004 Jul 1; 70(1): 107-14
2. Neurer LN & Bower DJ. Management of Helicobacter pylori Infection. Am Fm Physician 2002;65:1327-36,1339.
3. Barter C & Dunne L. Nonulcer dyspepsia. In: Jeanette E South-Paul et al, Current diagnosis and Treatment in Family Medicine. New York: McGraw-Hill, 2004:355-356.
4. McQuaid K. Helicobacter pylori gastritis. In: Tierney LM et al. Current Medical Diagnosis & Treatment. New York: McGraw-Hill, 2003-569.

5. BREATHLESSNESS

Definition

- Breathlessness (dyspnoea) or shortness of breath may be defined as the sensation of being out of breath. It implies difficult or uncomfortable breathing.

Relevance to general practice

- Shortness of breath may be physiological or pathological. Accurate diagnosis depends on a carefully taken history and clinical examination.
- Acute shortness of breath requires prompt assessment and appropriate emergency treatment.
- Management of chronic breathlessness focuses on management of the underlying cause.

Causes

An approach to the causes of breathlessness is to classify them based on the mode of onset (Table 1)

Table 1 Causes of Breathlessness

Sudden onset: patient previously not short of breath

- Cardiovascular
  - Acute heart failure e.g. AMI
- Severe respiratory infection
  - Pneumonia
  - acute epiglottitis (children)
  - acute bronchiolitis (children)
- Respiratory disorders
  - inhaled foreign bodies
  - upper airways obstruction
  - pneumothorax
  - atelectasis
- hyperventilatory syndrome

Sudden onset; patient had similar attacks

- acute left ventricular failure
- bronchial asthma

Insidious onset; within few days or weeks

- cardiac cause
- respiratory cause
- severe chronic anaemia
- psychological

Sudden onset; patient previously not short of breath

- Acute and severe shortness of breath is a medical emergency and, although treatment directed to its relief must be given with the least possible delay.
- It is still all-important to attempt to reach a diagnosis of its cause.

Sudden onset; patient had similar attacks

- The only two conditions which commonly give rise to recurrent attacks of sudden shortness of breath are left ventricular failure and bronchial asthma.

Insidious onset; within few days or weeks

Cardiac causes

The causes under this group are congestive cardiac failure and other cardiac causes of pulmonary venous congestion (mitral stenosis and mitral regurgitation)

Respiratory causes

Respiratory causes of chronic dyspnoea are: chronic obstructive pulmonary disease, pulmonary parenchymal disease, pulmonary hypertension, severe kyphoscoliosis, large pleural effusion and chronic asthma.

Severe chronic anaemia

This causes breathlessness from tissue anoxia.

Psychological

The cue may be the way patients describe their shortness of breath. Often there is an admitted fear of lung disease which may have originated from knowledge of a close acquaintance in whom a serious lung disease has recently diagnosed or has caused death.

Ready reckoner

Important symptoms/signs	Asthma	Pneumonia	LVF	AE COPD	Hyperventilation
Purulent phlegm	Possible	Yes	No	Yes	No
Coarse crackles	No	Yes	No	Yes	No
Bilateral wheeze	Yes	No	Possible	Yes	No
Bilateral fine crackles	No	No	Yes	Possible	No
Focal reduced air entry	No	Yes	No	No	No

WORKUP

History

- The most difficult task in the evaluation of acute dyspnoea is differentiating dyspnoea due to cardiac disease from that resulting from pulmonary pathology. Both aetiologies share a number of clinical features. In general, a past history dominated by chronic cough, sputum production, recurrent respiratory functions, occupational exposure, or heaving smoking points more to the lung rather than to a cardiac disease.
- Dyspnoea that is a manifestation of a chronic anxiety state may superficially mimic cardiopulmonary disease and cause some confusion. Onsets at rest in conjunction with a sense of chest tightness, suffocation, or inability to take in air are characteristic feature of the history.
- It is helpful to define as precisely as possible the degree of activity that precipitates the sensation of dispense, in order to estimate the severity of disease, determine the extent of disability, and detect changes over time. One means of achieving these objectives is to relate symptoms to the patient's daily activities and interpret the degree of restriction in terms of the expected endurance of a patient of similar age.
- The occupational history is particularly important, as the relationships between exposure and lung disease are becoming evident.

Physical examination

- General examination – fever, anaemia, tachypnoea, tachycardia, respiratory efforts, pedal oedema and phlebitis.
- Respiratory system – air flow obstruction, percussion note, and breath sounds.

- Cardiac examination – raised JVP, third heart sound, cardiac murmurs, and carotid pulse abnormalities. It should be recognized that many of the signs of right sided failure may be a consequence of longstanding pulmonary disease and therefore are not specific for a cardiac pathology.
- Abdomen – Ascites and hepatojugular reflux.

Management

Acute Breathlessness

This should be managed as an emergency.

- **Foreign body** – acute onset with stridor should immediately suggest its site and cause. A history of having swallowed a foreign body is likely to be elicited. An attempt should be made to dislodge it by the finger or by tipping the patient upside down and vigorously thumping his back. If these measures fail, a tracheostomy must be undertaken as a life-saving emergency.
- **Acute left ventricular failure and/or acute severe asthma** - if the differential diagnosis is in doubt, nebulised salbutamol and a diuretic such as frusemide, are safe to give in either condition. The patient should be admitted after emergency treatment.
- **Croup** – in a young child, the presence of cyanosis, restlessness or exhaustion requires urgent hospitalization.
- **Acute asthma** – nebulizer treatment with salbutamol has replaced the need for subcutaneous adrenaline. Re-examination for improvement is done after such treatment. If relieved, bronchodilator therapy, and antibiotics with adequate explanation of the need for continuing treatment and follow-up follows.

Chromic breathlessness

- Treatment depends on the underlying cause which may be establish after a careful history, examination and appropriate investigations, including chest X-rays and lung function tests.

Anxiety induced breathlessness

- The neurotic patient with anxiety-induced dyspnoea often benefits from having a chest film and simple pulmonary function tests; the conformation of a well-functioning respiratory system may provide some reassurance and lessen concern over bodily symptoms.
- At times, a walk with the patient up and down a few flights of stairs is just as convincing for both the physician and patient.
- One must however, remember that the patient with Guillian Barre syndrome with respiratory muscle paralysis may be misdiagnosed as anxiety induced breathlessness.

Indication for referral

- Bronchial asthma – cyanosis, patient exhaustion, a quiet chest, marked tachycardia, pulsus paradoxus, obvious use of accessory muscles of respiration, failure to respond to full non-steroidal therapy, and subjective report of severe difficulty in breathing.
- Referral for further workup in the patient with insidious onset of breathlessness may be needed.

References

1. Goroll AH. Evaluation of Chronic Dyspnoea. in: Goroll et al. Primary Care Medicine, 3rd ed., Philadelphia: Lippincott, 1995:227-231.
2. Murtagh J. Accident and emergency medicine unit 6. Acute dyspnoea. Aust Fam Physician 1995 April; 24;4:663-669.
3. K.Hopcroft. Symptom Sorter,3rd Ed., Radcliffe publishing,2007

6. COUGH

Relevance to general practice

- Cough is the commonest single symptoms presented to the general practitioner.
- Cough in general practice can mean a problem that is acute and serious, non-acute but serious, acute and self-limiting or a persistent or recurring disease. It could also be a ticket of entry for another problem.
- Cough can be grouped into acute or chronic. Just like the acute cough, the chronic cough can have aetiologies that range from trivial conditions to life-threatening illnesses.

Causes

- Cough is a reflex act occurring in response to irritation of the lining of the respiratory tract. There are several ways that causes of cough can be classified.
- The traditional approach to classification by pathological process used in the hospital setting is also useful in ambulatory setting.

Infection

- Infections underlie most of the cough and cold seen in general practice. The majority of these are viral. Most viruses are associated with short-lived illnesses but a number are associated with bacterial superinfection, especially in patients with asthma or chronic bronchitis, and this must not be overlooked in prolonged or recurrent episodes of cough.
- The respiratory syncytial virus (RSV) is a common cause of more severe respiratory illness in children as is influenza A virus in adults, and persisting cough during epidemics of these infections requires careful reassessment.
- Occasionally, the causal agent may be mycoplasma or fungal. Coliform and staphylococcal infections are normally found in debilitated patients or in patients with bronchiectasis or recent hospital infection.

Physical and chemical

- The effect of cold and of smoke (especially from tobacco) in aggravating, prolonging, or causing cough is well known.

Cardiac failure

- Particularly in the elderly, a persistent drug cough may be found in the early stages of heart failure. Although confirmatory physical signs may be absent, the response to diuretics. The prompt relief from a short course of diuretics confirms the diagnosis.

Allergic

- Cough, in particular night cough, may occur in patients with an allergic tendency with or without asthma.

Medications

- Several medications can cause an acute, disruptive cough. The angiotensin-converting enzyme (ACE) inhibitors cause a dry, hacking cough in more than 15% of patients taking these medications, possibly by stimulating C fibres in the airways and activating the cough reflex arc.
- After discontinuation of the causative drug, the cough usually resolves within 1 to 14 days. Beta blockers can cause cough as a result of drug induced bronchospasm. Inhaled medications, such as beta agonists, disodium cromoglycate and corticosteroids have also been found to sometimes cause a dry hacking cough, apparently by local irritation.

Psychological

- Psychological or social problems may present as a habit cough as a form of nervous tic.

Neoplastic

- Low in the order of frequency but high in the list of fatal causes of cough is bronchial carcinoma.

Other causes

- Inhaled foreign body should also be thought of.

WORKUP

History

- The first priority is to determine the seriousness and time scale of the illness. The possibility that the presentation of the symptom is an excuse to discuss a psychological issue exists (ticket of entry) but will not be developed in detail here.
- There is widespread agreement that a brief history and carrying out a chest examination is normally sufficient. The taking of an extensive history and the carrying out of a more complete respiratory or other general examination are usually restricted to patients who are very young, are looking ill, or are failing to make the normal progress to recovery which would be expected.
- Clearly patients with coexisting symptoms suggesting greater probability of serious disease (e.g., haemoptysis or weight loss) will also be handled in a manner different from the normal, including the use of specialized investigations.

Acute serious disease

- The history may indicate a specific diagnosis. In acute cough with associated symptoms such as fever, hoarseness of voice and nasal catarrh, the diagnosis is not difficult.
- Cough associated with generalized wheezing may be produced by bronchospasm. Illnesses in this group are usually associated with restlessness and distress – physical and emotional – and signs of fatigue.

Non-acute serious disease

- Non-acute serious illness is suggested by the continuation of cough beyond the normal natural history of acute treated bacterial or viral illness in the absence of a history suggesting obstructive or allergic respiratory disease.

Acute self-limiting disease

- Acute self-limiting illness is characterized by a history compatible with an acute infective process (coryza, influenza) and the absence of the general signs of serious illness. The patient may have the headache, myalgia and malaise of the acute underlying process or may have passed from that early stage to one in which cough is the only significant complaint.
- Here the history taking normally aims to identify any tendency to chest trouble (asthma and chronic bronchitis in particular) and the nature and colour of any sputum being produced.
- Chest examination will allow exclusion of signs of localized infection but the management decision is usually established on the basis of the history along. Mothers expect their children's chests to be examined and, if for no other reason, this is a wise policy. The elderly – often barricaded in by layers of clothing – may seem happier not to be examined but the frequency with which basal crepitations are recognized justifies overruling this wish.

Persisting or relapsing illness

- Among these, particular mention should be made of three common 'coughing syndrome', again usually a childhood complaint; the 'smoker's cough' with its inescapable and often unnoticed progress to chronic bronchitis.
- The child with persistent or recurrent episodes of cough, worse at night, is a common cause of anxiety, especially to young parents. The child is often at the sage of attending school or play-group for the first time and may have a past history of croup or eczema. A family history of allergic respiratory illness may coexist.

- The common pattern is one of recurrent bouts of acute wheezy respiratory infections interspersed by periods of comparative health often, however, including nights interrupted b y persisting dry cough. The tendency for the child to be well and free of abnormal signs when seen by the doctor may create the unfair impression of fussing parents. Careful history taking will identify the syndrome, and the possible additional precipitating causes of animal or plant allergy may be identified on specific questioning or a home visit.

Physical examination

- A selective examination of the upper respiratory tract, cervical lymph nodes and the lungs, (not forgetting to note down the temperature and the pulse), is usually sufficient in cases of upper respiratory tract infection causing cough.
- In cases where the history indicates that the cause may be more complex, a more thorough examination is warranted. Acute serious illness is normally suggested by breathlessness, complaint of chest pain or the general condition of the patient.
- The presence of cyanosis or ashen pallor is more worrying than the flushing caused by fever. The absence of rhonchi with decreased air entry in a breathless patient indicates a more severe form of airway obstruction than when rhonchi are heard.
- Carious teeth, infected gums, tonsillar disease or sinusitis are often associated with bronchiectasis and lung abscess. An inspiratory stridor may be due to upper airway obstruction from various causes. One should look out for scars of previous surgery e.g., tracheostomy, thoracotomy.
- Localised inspiratory and expiratory wheeze may indicate a major airway obstructive lesion. Localised areas of dullness on percussion of the chest may indicate consolidation, pleural effusion or atelectasis. Finally, non-acute serious disease may not have much definitive physical signs.

Investigations

- Investigations are not indicated in cases of self-limiting acute cough, unless one wants to determine the aetiology for management purposes, e.g. in streptococcal infections.
- Chronic cough should be thoroughly investigated. Some of the investigations can be initiated by the general practitioner.

Sputum examination

- Sputum examination in cases of productive cough may yield much information as to the aetiological cause. Culture may be necessary.

Radiology

- The chest X-ray is essential in the WORKUP of any patient with chronic cough. Two views may be necessary to give a better anatomical assessment. Oblique views, tomograms and bronchography may occasionally be needed.

Pulmonary function tests

- Pulmonary function tests may be useful in diagnosing early or mild bronchial asthma in patients, who present with chronic cough as the sole symptom.

Bronchoscopy

- Bronchoscopy should be considered in any patient in whom the cause of a chronic cough is not clear.

Management

- Symptomatic treatment with or without antibiotics as the case may be is usually sufficient in patients with acute cough.
- Patient education and explanation are necessary in patients with recurrent cough due to bronchial asthma.
- Management of chronic cough will depend on the cause.

Indication for referral

- In acute severe cough associated with symptoms such as dyspnoea and cyanosis, in-patient management may be necessary.
- Referral may be needed to investigate a prolonged cough.

References

1. Howie JGR. The Patient Complaining of Cough, in: Practice – a Handbook of Primary Medical Care. London; Kluwer, 1984.
2. Braunwald E et al, Harrison's Principles of Internal Medicine, 11th Edition, New York: McGraw-Hill, 1987.
3. Zervnos NJ. Acute disruptive cough, Postgraduate Medicine 1994 March; 95:4:153-168.

7. SORE THROAT

Relevance to general practice

- One of the most common presenting symptoms in general practice
- 70% of sore throat are viral in origin
- The task of the primary care physician is to exclude serious causes of sore throat, have a rational approach to the use of antibiotics and provide symptomatic expectant management for those not initially requiring antibiotics.

Causes

- Is has been estimated that about a third of the sore throats are caused by bacterial infections, a third by viral and other microorganisms and the remaining one third by non-infective causes.

Bacterial infection

Group A beta haemolytic streptococcus (GABHS)

- This is isolated in 10-15% of throat culture done in adults. It is important to recognize, treat early and adequately such infections with penicillin or erythromycin because this prevents the occurrence of acute rheumatic fever, a non-suppurative complication.
- Unfortunately, only some 15% present with the triad of fever, pharyngeal exudates and tender anterior cervical adenopathy, so diagnosis may not be so easy in the remaining 85% of cases.

Non-group A streptococcus

- Rarely produces non-suppurative complications.

Haemophilus influenza

- Haemophilus influenza causes a painful sore throat and it may be complicated by acute otitis media.

Corynaebacterium diphtheria

- Almost never seen today because of early immunization. It must however be thought of in a patient not immunized against diphtheria for some reason. The white adherent membrane over the tonsil is diagnostic.

Gonococci

- This is uncommon in the local setting.

Viral causes

- A viral aetiology is found in 17-25% of adults and children over 2 years of age. The most common viral causes are the:

"Respiratory" viruses

- Namely rhinovirus, influenza virus, parainfluenza virus, adenovirus, and others. Symptoms may include rhinitis, cough, fever, body aches and malaise.

Coxsackie and herpes simplex

- May cause painful ulcers in the oral mucosa and oropharynx.

Epstein-Barr virus

- Causes the infectious mononucleosis syndrome. The sore throat may be prolonged and constitutional upset prominent.

Other microorganisms

- Chlamydia trachomatis and Mycoplasma pneumoniae are found to be quite common, contrary to what is previously known.

Candida

- Especially in immunocompromised individuals, and may be an early sign of acquired immunodeficiency syndrome (AIDS).

Non-infectious causes

- There are a number of such causes: referred pain; drying of pharyngeal epithelium from mouth breathing; chemical irritation from smoking or other toxic inhalation; and cancer of pharynx or tongue which may present as persistent sore throat but this is uncommon.

WORKUP

History

- The presence of accompanying running nose suggests a viral cause. Knowledge of family members being similarly affected and presence of an epidermic helps in the diagnosis. Use of medicals should be asked e.g. carbimazole.

Physical examination

- A general examination, examination of the oro-pharyngitis, anterior cervical nodes and selectively other systems is required.

General examination

- This includes the temperature, presence of jaundice (jaundice is present in 5-10% of patients with infectious mononucleosis).

Examination of the oro-pharynx

- Posterior mouth ulcers are typically caused by Coxsackie virus whilst herpes simplex ulcers are found only in the anterior parts of the mouth and lips. Candidiasis is characterized by white, curdy exudates.
- Acute epiglottitis should be suspected in patient with high fever, hoarseness of voice and stridor in a child or adult. The enlarged and inflamed epiglottis may be visible on inspection.
- Do not attempt to examine in detail lest a spasm of the oro-pharynx is provoked. Though rare, it is important to pick up this condition as it is potentially life-threatening. The patient should be admitted as an emergency.
- Enlarged tonsils may be streptococcal or viral in origin. Drooling and pain on opening mouth should lead the doctor suspect the presence of peritonsillar or retropharyngeal abscess; unilateral erythema of the soft palate accompanied by deviation of the uvula confirms the diagnosis.
- Palatine petechiae are sometimes found in patient with infectious mononucleosis.
- Exudates are seen in streptococcal sore throat, infectious mononucleosis and diphtheria. The latter is suspected if the tonsils and pharyngeal wall are covered by a gray membranous exudate that bleeds easily on removal.

Systemic Examination

- Anterior cervical lymph nodes are usually found in patients with streptococcal sore throat.
- Posterior cervical lymph nodes are enlarged in 90% of patients with infectious mononucleosis in the first week.
- Generalised lymphadenopathy, hepatic tenderness and splenomegaly further indicate infectious mononucleosis. Most children (up to 80%) with glandular fever will have splenomegaly at some time during the illness, but this is found less commonly in adults.

Laboratory investigations

Throat culture

- This is not needed in every case. Patients with no clinical evidence of streptococcal infections, and with typical signs and symptoms of viral upper respiratory tract infection, do not warrant a throat culture.
- Culture is indicated in patients with special risk factor for streptococcal disease.

Sore Throat Score (CENTOR SCORE)

Approach to diagnosis and management of GABHS infection:

POINTS

- Cough absent? 1
- H/O fever >38? 1
- Tonsillar Exudate? 1
- Swollen tender anterior nodes? 1
- Age 3-4 year? 1
- Age 15-44 year? 0
- Age ≥ 45? -1

Score	0	1	2	3	4
Change that patient has strept throat	2-3%	3-7%	8-16%	19-34%	41-61%
Suggested action	No culture or antibiotic		Culture all treat only positive		Culture all treated with antibiotics on clinical ground

- Clinical ground includes high fever or other indicators that the patient is clinically unwell and is presenting early in the course of the illness.

Limitations:

- This score is not applicable to patients <3 year of age. If an outbreak of illness caused by GAS, the score is invalid and should not be used.

Useful investigations

- T&DC. Atypical lymphocytes, if consisting >20% of total white cells, indicate infectious mononucleosis.

Specific investigations

- Anti-streptolysin O titre. Lack of a four-fold rise of convalescing serum indicates carrier status, estimated to comprise 20-30% of positive throat culture.
- Rapid office diagnosis. Latex agglutination and ELISA techniques.
- Tests to confirm EBV Paul Bunnel or Monospot test.
- Investigations to identify specific causation agents are done only if the illness is prolonged.

Management

Symptomatic Treatment

- This is sufficient when a viral cause is suspected. Antipyretics, antihistamines, decongestants and lozenges are prescribed where indicated.
- Rest and sufficient fluid intake should be stressed. Symptomatic treatment is also indicated in infectious mononucleosis, as no definite antiviral therapy is as yet available.

Use of antibiotics:

antibiotic prescription can probably be avoided in most patients.

- Benefits: antibiotics give a modest benefit in symptom relief (8 hour less symptom) and may confer slight protection against some complications (e.g. quinsy, otitis media). There is no evidence antibiotics protect against rheumatic fever and AGN.
- Risks: possibility of side effect with antibiotic use. Increased in antibiotic resistance, increased faith in antibiotics.

Reasons to give antibiotics immediately

1. Acute sore throat where >3 Centor criteria are present.
2. Patient is systematically unwell.
3. Symptoms and signs of serious illness and/or complications.
4. High risk of serious complications because of pre-existing comorbidity

Streptococcal pharyngitis

Recommended treatment regimens are as follows:

- Penicillin G, benzathine penicillin 1.2 million units i/m in one single dose, or
- Penicillin V 250 mg qid for 10 days, or
- Erythromycin 250 mg qid for 10 days, in patients sensitive to penicillin.

Other infections

- A trial of 10-day course of erythromycin or tetracycline 250 mg qid is probably justified in prolonged sore throat, to eradicate any mycoplasma present. Treat other rater form of pharyngitis according to the specific treatment regimens for the particular organism.

Indications for referral

- suppurative e.g. peritonsillar or retropharyngeal abscess
- Life-threatening conditions e.g. acute epiglottitis.

References

1. Kiselica D Group A beta Haemolytic Streptococcal Pharyngitis: Current Clinical Concepts. Am Fam Physician, 1994 April; 1147-1154
2. England JA. The many faces of Epstein-Barr virus. Postgrad Med 1988;83:167-78
3. Goroll AH et al, Approach to the patient with pharyngitis. in: Primary Care Medicine, 2nd ed. 1987; 885-880 Oxford hand book of general practice, 4th Ed, Oxford university press,2014

8. CHEST PAIN

Relevance to general practice

- Chest pain is taken seriously by the patient.
- In general practice, it is common to find that chest pain is of muscular origin or psychogenic origin.
- The important tasks of the primary care physician are first to distinguish between cardiac and non-cardiac pain, and then to decide whether this is serious or not serious, whether urgent or not urgent.

Causes

- Chest pain may be classified according to anatomical structures, e.g. chest wall pain, visceral pain and referred pain.
- It is more useful in practice to classify the causes into acute and chronic or intermittent chest pain and within each of these categories, serious and non-serious causes of chest pain.

Acute chest pain

- Serious causes of acute chest pain arise from (1) the heart, (2) the lungs and (3) the aorta. As these are potentially life-threatening, it is important that the diagnosis be made early.
- Once these causes are excluded, there is less urgency in diagnosis and management. Four important life-threatening causes of acute chest pain are:
  1. Acute coronary syndrome/AMI
  2. Tension pneumothorax
  3. Dissecting aortic aneurysm
  4. Pulmonary Embolism

Serious causes

Common

Ischaemic cardiac pain

There is increased likelihood of ischaemic cardiac pain in the presence of cardiovascular risk factors. This must be excluded if the patient:

- is male
- is aged ≥ 40 years
- is of Indian ethnic group
- has a history of ischaemic heart disease, diabetes mellitus

Severity of ischaemia ranges from angina to infarction.

Pain of infarction

- is more severe
- usually occurs at rest
- lasts longer than 20 minutes
- is typically associated with sweating and vomiting
- is not relieved by glyceryl trinitrate tablets.

Gall stones and peptic ulcer

- Gall stones and peptic ulcer may present with chest pain and be mistaken for myocardial infarction. Hypotension, tachycardia and extrasystoles may also occur if there is bleeding from the gastrointestinal tract. Melaena or haemetesis if present differentiates the diagnosis.

Less common

Pericardial pain

Common causes of pericardial pain

- Viral – young person, presence of systemic symptoms of viral illness

- Myocardial infarction – within a few hours, or after 1-2 weeks (Dressler's syndrome)
- This should be suspected when pain is worse on lying down, and patient prefers to sit up and lean forward. Pericardial rub is diagnostic.

Pneumothorax

- Most cases of pneumothorax are idiopathic. Known causes of pneumothorax are asthma, bullous emphysema and interstitial lung disease.

Pleural pain

- Pleural pain can be a feature of bacterial pneumonias, viral infections and connective tissue diseases. There may be associated with cough, haemoptysis and dyspnoea. If a pleural rub is present, this will be diagnostic.

Uncommon

- Rare causes include pulmonary embolism and dissecting aortic aneurysm. Patient is usually ill and needs immediate referral.

Non-serious causes

Common

Reflux oesophagitis

- This is commonly described as 'indigestion'. It is related to eating, exacerbated by bending down, relieved by antacids. Nocturnal pain may be experienced.
- As its prevalence is 30-40% of the population, it may coexist with other causes of chest pain. It may also be relieved by nitroglycerin, further confusing it with angina.

Musculoskeletal pain

- Musculoskeletal pain is common. It can be result of strain involving muscles of the neck, shoulder, thorax; rib and sterna pain of various causes. Such chest wall pain is usually superficial, localized and can be reproduced or aggravated by pressure applied to the affected area, or with movement.
- Viral illnesses can cause intercostals myalgia. Tietze's syndrome – an idiopathic costochondritis is diagnosed by tenderness at the particular costochondral junction.

Psychogenic chest pain

- Psychogenic causes may be due to anxiety, depression, or the means to 'secondary gain', e.g. malingering, financial compensation, sympathy. Nature of pain variable. Usually described as sharp, stabbing and intermittent.
- In hyperventilation syndrome, the patient is usually a young female presenting with diaphoresis and acute respiratory distress. Carpopedal spasm helps to confirm the diagnosis.

Less common

Oesophageal spasm

- A motility disorder that is sometimes seen in diabetes mellitus. Patient complains of severe chest pain on swallowing a large bolus of food or cold drinks.
- This may be relieved by nitroglycerin, and may hence be further confused with angina. Diagnosis by fluoroscopy during barium meal.

Neurovascular

- Herpes zoster infection can cause chest wall pain (a radiculitis) before the onset of the rash, which is diagnostic. Post-herpetic neuralgia may persist for weeks after the acute episode.
- Degenerative changes in the spine, metastatic tumours to the spine, can impinge on the dorsal nerve root and cause chest pain.

Chronic or intermittent chest pain

- Chronic or intermittent chest pain may be due to repeated attacks of acute pain, e.g. angina, reflux oesophagitis, musculoskeletal problems.
- The term 'nonspecific chest pain' is used to describe chest pain when ischaemic heart disease is unlikely and no other cause can be found.
- A middle-aged man may also have non-specific chest pain. Distinguishing features are listed in table 1.

Table 1. Diagnosis of chest pain

Anginal pain	Non-specific pain
Described as a 'discomfort' or 'ache'	Patient complains of pain, rather than discomfort, stabbing in nature, lasting a few seconds.
Occurs in the centre of chest. Radiation to jaw and neck diagnostic. Commonly also radiate to the arms. L>R, and to the back.	Pain radiates down left arm, but not to neck or jaw.
Pain induced by exercise, and after a meal. Pain induced by sexual intercourse.	Apparent relationship with exercise, but pain usually comes on at the end of a busy day and not after exercise.
Pain improves with rest.	Pain not relieved by rest.
Relieved by sublingual nitrates within seconds or within 2 minutes.	Patient often claims that nitrates are helpful, but only after 20-30 minutes.

Adapted from Hampton J, The patient with chest pain and breathlessness. Medicine International 1989, 3:2723

WORKUP

History

- History taking should be directed towards confirming or disproving the serious causes of chest pain.
- Cardiac pain is located in the front of the chest, mid or upper sternum radiating to the left arm or both arms, round the chest or into the jaw. The duration is rarely of more than 30 minutes, unless a coronary thrombosis has occurred. The words used to describe it are: "tight, heavy, constricting, crushing, numbing or burning".
- Pneumothorax is a condition seen off and on in general practice. Pulmonary embolism is uncommon. Pleurisy, mediastinitis and pneumomediastinum are rare but serious causes of chest pain. The pain of pneumothorax is described as stabbing, sudden in onset, localized; associated with dyspnoea, sometimes giddiness and fainting. Pulmonary embolism is also associated with sudden onset chest pain and dyspnoea.
- Dissecting aortic aneurysm usually causes excruciating pain radiating down the back. The patient may be in shock or hemiplegic.
- Past history, family history, a history of social habits, life style and current medications need to be asked for.

Physical Examination

- The physical examination further helps distinguish the serious from the not serious causes of chest pain. It should be approached systematically.

General

- Is the patient distressed, pale, sweating, dyspnoeic or tachypnoeic? Check the vital signs. Abnormalities in any suggest an unstable, urgent condition. Palpate the pulses. Unequal pulses may mean aortic dissection.

Examination of the heart and lungs

- Murmurs, abnormal heart sounds, rhythm abnormalities especially bradycardia, crepitations in the lungs and poor air entry all indicate a pathological cause of the chest pain.
- Raised jugular venous pressure, the presence of 3rd or 4th heart sounds, pericardial rub are other abnormal sings. Pneumothorax result in increased percussion resonance and diminished breath sounds on the affected side.

Examination of the other systems

- Examination of the musculoskeletal system may point to the anatomical site of musculoskeletal chest pain.
- One should remember to examine the breast and the abdomen. Examination of the patient's mental state is also important if serious causes of chest pain are not suspected.

Investigation

- The extent of initial investigations is guided by the urgency of the presenting problem. If the patient is very ill, minimal investigations necessary are done in the physician's office before urgent referral.
- If the patient's general condition is well and especially if the cause is still unclear after history and physical examination, then further investigations should be done.

Electrocardiogram

- In establishing a diagnosis of ischaemic cardiac pain, a resting ECG should be done to detect presence of ischaemic changes.
- If ECG shows evidence of ischaemic heart disease/old infarction, the patient requires referral for further evaluation of the ischaemic heart disease.
- If ECG is normal, then a treadmill test is required.
- The ECG is useful to diagnose the type of arrhythmia if one is suspected clinically.
- An exercise ECG may be considered. A normal stress ECG reduces considerably the chance that ischaemic heart disease is a cause of chest pain.
- In pericarditis, the ECG is not very helpful unless ST segments are present.

Radiology/Echocardiography

- A chest X-ray is a useful adjunct in the diagnosis of cardiac and pulmonary causes. It may show a widened cardiac silhouette in pericardial effusion but this may not be obvious. Chest X-ray may be normal, or show pleural thickening or effusion. Chest X-rays are diagnostic in pneumothorax.
- Radionuclide angiocardiography, coronary arteriography, lung scans, echocardiography may be helpful in pulmonary embolism. Echocardiography is helpful in diagnosis of pericardial effusion.
- Barium studies, X-ray cervical spine may need to be done if the suspected cause of chest pain is outside the chest.

Laboratory investigations

- Biochemical cardiac markers are now available for early diagnosis of ischaemic heart disease causing chest pain.
- Troponins, CK-MB, and myoglobin elevation will be confirmatory. The patient should be referred if there is a likelihood if ischaemic chest pain.

Management

- A decision is made on the likelihood of an acute, life-threatening condition. If this is not likely, symptomatic and expectant management is given; there are patients who diagnosis of musculoskeletal chest pain is clear from history, examination with or without simple investigations.
- Where a psychogenic cause is clear, the physician should delve further into the family and social background and enlist help from these quarters in the management of the patient if necessary.

Indications for referral

- In acute, life-threatening conditions, referral for hospital management should be made urgently, after having stabilised the patient in whatever emergency measure available, e.g. setting up an intravenous infusion.
- Where diagnosis is in doubt, or where the investigative procedures required are sophisticated, the patient should be referred to the appropriate specialists for further management. The threshold for referral is reduced in a patient with multiple cardiac risk factors.
- Where the chest pain does not improve with symptomatic and expectant treatment, or becomes more frequent, a review and possibly referral should be made.

Recurrent chest pain

- Repeated ECG evaluation may be worthwhile.
- If chest pain is stress-related, exploring cause/s of stress may be helpful.

References

1. Rakel RE, Textbook of Family Practice, 4th Edition, Philadelphia: WB Saunders, 1990;874-882.
2. Hampton J. The patient with chest pain and breathlessness. Medicine International 1989;3:2720-5.

9. DIARRHOEA

DIARRHOEA IN ADULTS

Relevance to general practice

- Diarrhoea is an affliction familiar to everyone. Most episodes are brief, self-limited and well-tolerated without need for medical attention.
- Diarrhoea being a self-limiting complaint, it is useful to find out why for this episode, the patient needs to see the doctor.
- Symptomatic treatment is often all that is necessary for acute diarrhea. However, one should be alert for the occasional serious cause.

WORKUP

History

- **Onset:** It is important to establish whether the diarrhoea is an acute problem of a few days duration or a chronic one spanning some time.
- **Timing:** One should ask when the diarrhea usually occurs. Diarrhoea occurring at night is always pathological.
- **Nature of stools:** Watery stools constitute diarrhea whereas loosely formed stools do not and may indicate a different pathology like irritable bowel syndrome. It is also important to ask whether the stools are mucoid, blood stained or foul smelling and floating.
- **Travel:** Recent travel overseas may be aetiologically important.
- **Food taken:** Although it is often difficult to establish the source of the diarrhea, a history of the types of food taken within the last 24 hours may be helpful.
- Milk and dairy products can cause loose stools in the susceptible adult.
- If an epidemic of food poisoning occurs, information on the type of food eaten and the place where it was served will help the Ministry of Environment (Health) in its investigations.
- **Associated symptoms:** Vomiting, nausea, dizziness, colicky abdominal pain, fever, thirst indicates that a bacterial infective cause for the diarrhea is likely.

Physical Examination

Assessing dehydration

- One should look at the tongue and mucous membranes as well as the turgor of the patient's skin. A dry tongue and mucous membrane with or without a rapid pulse rate indicate that dehydration needs to be corrected.

Abdomen

- An examination of the abdomen for tenderness and bowel sound is warranted to reassure the patient, that there is nothing more serious. A rectal examination is indicated if bloody diarrhea is present.

Other system

- If a systemic cause for the diarrhea is suspected, a full examination should be done.

Investigations

- There are not necessary for the majority of mild acute diarrhea. Chronic cases will require a workup or hospital referral.
- Stool culture and smear for cysts and organisms are useful if giardiasis or amoebiasis is suspected.
- Endoscopy, barium enema or barium meal may be needed for the evaluation of a chronic diarrhea.
- Other investigations: Thyroid function tests, glucose tolerance tests and other endocrine tests may be necessary.

Management

The adult patient

Most acute cases need only symptomatic treatment.
These are:

- Bed rest if diarrhea is severe or frequent
- Adequate fluid and electrolyte replacement
- Drugs like kaolin, charcoal which have some absorptive properties may be prescribed.
- Anti-cholinergics like loparamide or opiates like codeine phosphate may help to relieve the symptoms if diarrhea is severe
- Antibiotics and metronidazole are rarely indicated unless the responsible organism is identified as being bacterial or amoebic respectively.
- Anti-emetics may be useful if vomiting is severe.

Indications for referral

Referral may be indicated for the following:

- Severe cases which may be infectious or warranting IV fluid replacement
- Chronic cases for diagnosis and treatment
- Cases where the diagnosis is not clear.

Diarrhoea in infants and children

Relevance to general practice

- Diarrhoea in a child had to be attended to promptly as the patient is more prone to suffer from dehydration and its consequences.
- Parents may have their incorrect views of diarrhea in their child; thus teething does not cause diarrhea, contrary to what is often believed by mothers.
- Fully breast-fed babies may have loose stools. Their stools are explosive, contain cured and may be bright green in colour. These babies should not be treated for diarrhea.
- Starvation stools should not be confused with diarrhea.

Common causes

Mild formula and improper feeding

- Infants vary widely in tolerance to quantity and quality of food. The contents of protein, fat and carbohydrate affect the volume of stools.
- Volume of water in stool varies directly with fat and sugar content of formula, e.g. babies on formula high in polyunsaturated fats have looser stools than those on formula containing greater percentage of saturated fats.
- Also, if sugar content in formula is greater than 7.2% weight per volume, stools tend to be soft and watery. With age the gut matures and tolerance to food content improves.

Breastfed babies may have frequent loose stools. This is normal.

Infections

- Infection, as a cause of diarrhea, is common. It may be enteral or parental. Rotavirus is the commonest cause. If blood is associated with diarrhea, Shigella or Salmonella should be suspected.
- Cholera produces profuse rice water stools. Stool culture should be done if a bacterial cause is suspected, such as dysentery, typhoid or cholera.

Management

Management begins with assessment of the severity of the diarrhea and degree of dehydration (see table)

Table 1. How severe is the dehydration?

		Mild	Moderate	Severe
1. Ask	Diarrhoea	less than 4 liquid stools/day	4-10 liquid stools/day	More than 10 liquid stools/day, with or without blood and/or mucus
	Vomiting	Normal	Some	Very frequent
	Thirst	Normal	More than normal	Unable to drink
	Urine	Normal	Small amount, dark coloured	No urine for 6 hours
2. Look	Condition	Well, alert	Unwell, drowsy or irritable	Very sleepy, floppy, unconscious, having fits or seizure
	Eyes	Normal	Sunken	Very dry and sunken
	Mouth and Tongue	Wet	Dry	Very dry
	Breathing	Normal	Faster than normal	Very fast and deep
3. Feel	Skin	Pinch, goes back quickly	Pinch, goes back slowly	Pinch, goes back very slowly
	Pulse	Normal	Faster than normal	Very fast, weak, or cannot be felt
	Fontanelle (in infant)	Normal	Sunken	Very sunken
4. Weigh		No weight loss	Weight loss of 25-100g for each kg of weight	Weight loss of >100g for each kg of weight
5. Take temperature				Fever >39ºC (102ºF)
6. Decide		Treat	Treat	Refer patient to hospital speedily

Children above age of one year
Mild diarrhea (<4 stools/day)

- Continue breastfeeding if child is breastfed.
- Establish cause of diarrhea, e.g. overfeeding, dietary indiscretion, viral upper respiratory tract infection, systemic infection and food allergy
- Treat the underlying cause. If mild dehydration and child is able to retain fluids – treat as outpatient.

Moderate diarrhea (4-10 stools/day)

- Off solid diet
- Half-strength milk
- Oral rehydration fluid, e.g. rice-water or dextrose saline solution. Oral rehydration by commercially available solutions. Give 50-100ml after each stool.

Severe diarrhea (>10 stools/day)

- Off solid and off milk. Only Oral Rehydration Solution (ORS).
- Continue ORS till at least 3 consecutive stools of normal frequency and consistency. When reverting back to milk formula, advice graduated increase in strength of milk.
- If diarrhea recurs on restarting milk gradually, suspect lactose intolerance (usually temporary).
- May need to continue on soy formula for a longer duration before attempting to switch back to milk. May consider lactose free cow's milk.
- Refer to hospital if no improvement and symptoms deteriorate.

Infants

- **Mild diarrhea:** not more than 1 stool every 2 hours, give 10-15 ml/kg/hr ORS until diarrhea stops (approximately 1 dissolved ORS tablet for each liquid stool). If breastfed, continue breastfeeding.
- **Moderate diarrhea:** >1 liquid stool every 2 hours. Give 10-15 ml/kg/hr ORS until diarrhea becomes mild (approximately 1 dissolved ORS tablet every hour or as much as patient will accept). If breastfed, continue breastfeeding. Solution should be given slowly, in sips at short intervals to reduce vomiting and improve absorption.
- **Severe diarrhea:** refer to the hospital.

References

1. Richter JM. Evaluation and management of diarrhea. in: Goroll et al. Primary Care Medicine, 3rd ed. Philadelphia: Lippincott, 1995: 357-368.
2. Goepp JG, Katz SA. Oral rehydration therapy. American Family Physician 1993;47:4: 843-848.
3. Haffezee IE. Nutritional management during acute infantile diarrhea. Maternal and Child Health. June 1992:175-179
4. WHO. Treatment and prevention of dehydration in diarrhoeal diseases – a guide at primary care level. WHO: Geneva, 1976.
5. Biloo AG. Infantile diarrhea: management with oral rehydration. Medical Progress Feb 1986: 15-24
6. Bames G. The Child with diarrhea. In: Robinson MJ, ed. Practical Paediatrics. Churchill Livingstone, 1990:505-513

10. CONSTIPATION

Definition

- There is no uniform definition of constipation. To some it means movements that are too infrequent or stools that are too hard. Others complain of incomplete or difficult evacuation.
- Among normal people, bowel habits vary widely, and there are diverse perceptions of what is normal. Population studies show that most normal people have more than three bowel movements per weeks.

CONSTIPATION IN ADULT

Relevance to general practice

- Constipation is a common symptom in general practice. It is among the most frequent reasons for self-medication and is particularly troublesome in the elderly.
- There is a need to clarify what the patient means by constipation and what is the normal bowel habit for that patient.
- The primary care doctor must be able to uncover any underlying pathology and to provide symptomatic relief to those without a structural lesion.

Causes

The common causes of constipation in the adult are shown in table 1.

Table 1. Causes of constipation

General

Poor fluid intake
Inadequate dietary fibre
Inconvenience toilet access
Inactivity

Specific pathology

Depression
Hypothyroidism
Abdominal tumour – large bowel cancer, external compression
Spinal cord compression

Drugs

Opiates
Anticholinergics
Tricyclic antidepressants
Phenothiazines, haloperidol
Antacids containing calcium or aluminium
Iron

WORKUP

History

The presence of associated symptoms is sought to define any underlying cause, which may be serious.

- Abdominal pain, recurring and colicky – suggests mechanical obstruction
- Perianal pain – suggests anal fissure or abscess
- Alternating diarrhea and constipation, with or without blood in stools – suggest colonic carcinoma
- Low mood, negative feeling and fatigue – there are symptoms of depression
- Observation of family members that the patient shows a slowing of physical and mental activities, weight gain and cold intolerance – there are symptoms of hypothyroidism.

Physical examination

A selective physical examination includes:

- observation of the general health of the patient and mental state
- abdominal examination for faecal masses and other masses, abdominal distension and tenderness
- rectal examination is useful to detect perianal conditions, faecal impaction, and also to obtain a sample of stools for inspection and occult blood testing.
- the hypothyroid patient has characteristic facies and delayed relaxation of deep tendon reflexes.

Investigations

- Investigations are unnecessary where a cause of constipation can be found.
- A barium enema may be considered if a large bowel carcinoma is suspected.

Management

- The management of constipation extends well beyond the use of laxatives. Attention to other issues – diet, fluid intake, mobility, physical activity, and barriers to physical activity including pain – contributes to an effective outcome.

SIMPLE CONSTIPATION

- Attend to patients' concerns about constipation
- Advice to increase
    - fluid intake
    - fibre intake e.g. at least 1-2 servings of vegetables for lunch and dinner; include fruits in the diet if not already done.
- Advice to increase physical activity
- Laxatives or suppositories as a temporary measure (table 2)

Faecal impaction in the bedridden elderly

- Manual evacuation followed by regular enemas and laxatives may be necessary
- Advice to increase fibre and fluid intake but bearing in mind the problems of eating in the elderly
- Fruits like bananas, papaya are suitable and the making purees of vegetables will be necessary.

Table 2. Laxative Effects and Side Effects

Type of laxative	Mechanism of action	Onset of action	Potential adverse effects
Bulk laxative • Psyllium seed • Bran • Calcium polycarbophil	Increase faecal bulk as well as the fluid retained in the bowel lumen	12-24 hrs or more	Increased gas; bloating; bowel obstruction if strictures present; chocking if powder forms are not taken with enough liquid
Emollients and stool softeners • Dioctyl sodium • Calcium sulfosuccinate (docusate sodium)	Lubricates and softens faecal mass	24-48 hrs	Minor effects such as better taste and nausea
Stimulants and irritants • Bisacodyl	Alters intestinal mucosal permeability	10 minutes (Sodium bicarbonate+	Dermatitis; electrolyte imbalance; melanosis coli

• Senna • Cascara • Sodium bicarbonate+ potassium bitartrate	Stimulates muscle activity and fluid secretion	potassium bitartrate suppository) 2-12 hrs	
Osmotic laxative • Ricinoleic acid • Lactulose • Magnesium salts • Sodium salts • Sorbitol	Salts lead to retained fluid in the bowel lumen, with a net increase of fluid secretions in the small intestines	2-48 hrs	Electrolyte imbalance; excessive gas; hypermagnesemia, hypocalcemia, and hyperphosphatemia in patient with renal failure; dehydration
Enema • Tap water • Saline • Sodium phosphate • oil	causes reflex evacuation	within 30 minutes	Dehydration; hypocalcemia and hyperphosphatemia in patients with chronic renal failure

Schaffer & Cheksin, 1998

Indications for referral

- Further assessment is indicated where a colonic carcinoma is suspected.

CONSTIPATION IN THE CHILD

Relevance to general practice

- Breastfed infants tend to have frequent loose stool, whereas bottle-fed infects tend to have less frequent hard stools
- Some older children may normally have a bowel movement as seldom as once or twice a week
- Parents often worry about whether their child's bowel movements are normal.

Causes

- The diet is the commonest cause: inadequate fluid and fibre intake; and excessively concentrated formula milk in the younger child.
- The child fearful of defecation or crying after defecation, and blood in stools point to the presence of a perianal fissure.
- Serious causes are rare:
- Hypothyroidism in a child may present as persistent constipation in the neonate
- Acute intestinal obstruction would present with associated abdominal pain or a persistently crying baby
- Stubborn constipation (obstipation) with failure to thrive is present in Hirschsprung's disease (very rare)

WORKUP

History

- A detailed history is important. It should cover age of onset; precipitating events such as diet changes, toilet-training problems, pain and bleeding with defaecation; abdominal pain; bowel routine; behavioural problems; previous treatment including punitive measures; and medications for other reasons.

Physical examination

- An observation is made of the child's well-being and general health, growth and development. Children with the rate serious causes like Hirschsprung's disease and hypothyroidism frequently fail to thrive.
- Abdominal palpation often reveals faecal masses. Perianal inspection may reveal a fissure.

Management

For simple constipation

- Allay parental anxiety and concern about constipation and advice on bowel training where necessary.
- Advice about bottle feeding, increasing fluid and fibre intake e.g. water and fruit juices for the older infant.
- A laxative may be prescribed liquid paraffin or (sodium citrate and sodium lauryl sulfoacetate).

Indications for referral

- Referral is indicated for intestinal obstruction and anal fissure.

References

1. Goroll AH. Approach to the patient with constipation in: Goroll et al. Primary Care Medicine, 3rd ed. Philadelphia: Lippincott, 1995:369-372
2. Ebelt VJ Constipation in childhood, Can Fam Physician 1992 September 38:2167-2174
3. Schaffer DC & Cheskin LJ. Constipation in the Elderly. Am Fam Physician 1998; 58(4): 907-14

11. VOMITING

Relevance to general practice

- Vomiting is a relatively common presenting symptom in general practice and is twice as common in children as in adults.
- It is a non-specific symptom covering a wide range of possible causes which will be identified only by piecing together other clinical features of the illness presented.

Causes

- There are many possible causes of nausea and vomiting and it requires time, observation, clinical experience and awareness to decide on the cause of the problem and the correct management. Nausea and vomiting may result from local, central or general causes.

Local causes

- 'Acute gastritis' (a useful label for the syndrome of vomiting abdominal pain and malaise).
- This may be caused by an infective agent (e.g. viral) or some other ingested gastric irritant (in particular, excessive alcohol consumption).

Central causes

- Acute vertigo associated with nausea and vomiting (as in Meniere's syndrome or acute labyrinthitis), motion sickness, migraine and rarer conditions like vestibular neuronitis and tumour.

General causes

- Reactions to drugs (e.g. digoxin and aspirin), uraemia, diabetes ketoacidosis, and rarities like Addison's disease.

WORKUP

History

- The history will give guidance to a likely diagnosis. Systematic enquiry should be made on how the symptoms began and how long they have been present. Any nausea and/or vomiting that go on longer than three to four days, in the absence of pregnancy, must raise possibilities of an underlying cause.
- The timing of the vomiting may be noteworthy. Vomiting of relatively unaltered food soon after a meal suggests and oesophageal obstruction. Pyloric stenosis is associated with large offensive vomitus but with no evidence of bile. A gastro-colic fistula characteristically produces faeculent vomit.
- The possibility of nausea and vomiting being part of a psychiatric disturbance is unlikely. They are not features of an anxiety state or depression. In anorexia nervosa, although refusal of and abstention from eating are the main symptoms, there may also be induced vomiting.

Examination

- The many possible causes of vomiting make it necessary to carry out a full physical examination of patients presenting with this symptom. Associated symptoms, however, may direct particular attention to certain areas.

The child patient

- The pyrexial infant or child who presents with vomiting will lead the practitioner to look particularly for neck stiffness, signs of inflammation in the ears and throat, and abdominal tenderness. In the presence of respiratory distress or cough he will try to elicit signs of pulmonary infection. In the absence of any abnormalities in these systems he will examine a mid-stream specimen of urine bacteriologically.

- Very often vomiting in infancy is caused by mold gastroenteritis, when the practitioner's main concern will be with eliciting signs of dehydration, in the absence of which rapid recovery may be expected.
- A question about the frequency with which the infant is wetting his nappies is a useful guide to impending dehydration.
- In the apyrexial infant in the first few weeks of life pyloric stenosis may be suspected by the presence of projectile vomiting and the doctor will then examine the infant during a feed in order to identify a pyloric tumour.

The adult patient

- The apyrexial adult presenting with vomiting associated with colicky abdominal pain and possibly diarrhea is almost certainly suffering from an acute dietary indiscretion or gastrointestinal infection. In these cases it is always wise to examine the abdomen for localized tenderness to exclude appendicitis.
- Nausea and vomiting associated with vertigo or headache should lead to a careful neurological examination with particular examination of the optic fundi for signs of raised intracranial pressure, eye movements for nystagmus, and for signs of ataxia in the limbs. The ears should also be examined.
- Nausea and vomiting of gradual onset will draw special attention to the gastrointestinal tract. The practitioner should look for signs of weight loss, abdominal masses, visible peristalsis and abdominal distension and should carry out a rectal examination.
- In the young adult infective hepatitis often presents with nausea and jaundice and liver tenderness should be looked for.
- In a young woman pregnancy is a common cause of nausea. This may be confirmed by a urine pregnancy test.

Investigations

- This will depend on the history and examination. In the vast majority of patients presenting in general practice with vomiting they will add nothing to the diagnosis.
- In the second half of life, patients presenting with nausea and vomiting of gradual onset will require a full investigation to exclude organic bowel disease.

Management

- In selecting the treatment for patients presenting with nausea and vomiting, the first priority is to make a correct diagnosis.

The child patient

- In the infant and child most cases will be due to feeding problems, gastrointestinal infections or infections of the upper respiratory tract. Feeding problems are most commonly due to faulty technique rather than faults in the content of the feed. They require time for diagnosis and not only must a careful history be taken, the mother must be observed feeding her infant.
- In treating acute gastro-intestinal infections in the child, (and adult), the most important step is to stop all solid food and to ensure an adequate intake of simple fluids, of which water is the most appropriate. In the infant, dehydration may occur rapidly.
- The mother should be instructed to give 30-120 ml of water every two hours, the amount depending on the size of the infant. In most cases this will maintain hydration and vomiting will cease.
- Probably more harm than good comes from administering electrolyte solution to infants in general practice. As vomiting ceases, the child should be slowly weaned back on to a normal diet. Should electrolyte replacement become necessary the child should be admitted to hospital.
- Acute infections in childhood other than gastro-intestinal should be treated with an appropriate antibiotic. In the vomiting child this should normally be administered by intramuscular injection. Parents in this situation should be particularly warned not to use aspirin which may exacerbate the gastro-intestinal upset.

The adult patient

- In the adult patient the most common cause of vomiting is a dietary indiscretion or gastro-intestinal infection. Treatment consists of bed rest, withdrawal of all solid food and adequate simple fluids.

- Very commonly diarrhea follows the gastric symptoms and may be relieved by a kaolin mixture or codeine phosphate, 30 mg four hourly, loparamide 2 tabs tds or Imodium 2 tabs tds.
- Some of the specific causes of nausea and vomiting may be treated with more specific remedies. Thus, vestibular disorders, including motion sickness, vestibular neuronitis and Meniere's disease, may be helped by the use of hyoscine hydrobromide 0.1-0.5 mg or one of the anti-emetic antihistamines, e.g. diphenhydramine 50mg or prochlorperazine maleate 5mg.
- Transdermal scopolamine is also effective for prevention of motion sickness. The major side-effects are dry mouth and lightheadedness. A single patch lasts up to 72 hours.
- Vomiting in pregnancy will usually resolve without specific treatment but with reassurance and advice about taking something by mouth before rising in the morning, and small frequent snacks, rather than large meals, during the day. The more resistant case may be helped by use of meclozine hydrochloride, 25mg, or diphenhydramine 50mg which has stood the test of the time and for which there is no evidence of teratogenicity.
- Vomiting may be a troublesome symptom in migraine. It may be prevented by the administration of ergotamine tartrate, 2mg, early in an attack and in some proprietary preparations this drug is combined with an anti-emetic antihistamine. In the established attack, suppositories of prochlorperazine maleate may be useful.
- In terminal illness, particularly that due to gastro-intestinal neoplasm, vomiting may be troublesome. The use of morphine for pain relief may exacerbate this symptom. In such cases diamorphine should be preferred and this may be combined with chlorpromazine or prochlorperazine.

Indications for referral

- The child with more than mild dehydration
- The patient with serious organic gastrointestinal disease. Referral for surgical treatment may be required urgently.
- The patient with hyperemesis gravidarum. Give nothing by mouth for 48 hours, and maintain hydration and electrolyte balance by giving appropriate parenteral fluids and vitamin supplements as indicated.

References

1. Fry J. The patient complaining of nausea and vomiting. in: Cormack J, Marinker M and Morrell D, Practice: A handbook of primary medical care. London:Kluwer, 1982;436-441.
2. Goroll AH. Evaluation of Nausea and Vomiting. in: Goroll AH, May LA and Mulley AG. Primary Care Medicine, 2nd ed. Philadelphia:Lippincott, 1987;270-274.

12. ABDOMINAL PAIN

Relevance to general practice

- The causes of abdominal pain in general practice cover a wide clinical spectrum. Although most cases may not be dramatic, the GP must be vigilant for the occasional patient with serious physical pathology.
- A careful history followed by appropriate examination helps to clarify the cause.
- The probability of various diseases depends on the age group. A practical classification of abdominal pain in general practice is according to the mode of onset.
- The patient with acute abdominal pain requires a careful early assessment. Non-acute abdominal pain allows the doctor more time to think and act but a systematic approach is essential in the history, examination and investigation.

Causes

Abdominal pain may be divided chronologically into acute and less acute pain.

Acute abdominal pain

A useful classification of acute onset of abdominal pain is summarised in Table1.

- Group A causes are life-threatening which require surgical intervention except for acute pancreatitis
- Group B causes are managed medically initially
- Group C causes are the commonest causes which may upset the patient or family tremendously, but are not life-threatening.

Other causes to keep in mind are:

- Acute myocardial infarction
- pneumonia
- diabetic ketoacidosis
- herpes zoster (pre-rash stage)
- ruptured aortic aneurysm (rare)
- Munchausen syndrome

Less-acute abdominal pain

- Organic – any intra-abdominal organic disease can present as a less acute or even have an insidious onset of abdominal pain, e.g. appendicitis
- Functional – irritable bowel syndrome and periodic syndrome are common conditions in young adults and children respectively.

Table 1. Causes of Acute Abdominal Pain

Group A: Life-threatening conditions which must be excluded

Appendicitis
Acute obstruction
Perforated peptic ulcer
Liver abscess
Acute pancreatitis
Ectopic pregnancy
Twisted ovarian cyst
Obstructed hernia

Group B: Less urgent but important conditions

Acute cholecystitis
Biliary colic
Hepatitis
Renal colic
Pelvic inflammatory

Group C: Common causes

Gastritis/Dyspepsia
Mesenteric adenitis
Dietary indiscretion
Gastro-enteritis
Alcohol abuse
Migraine
Constipation

The likely diagnosis varies with age:
Age related conditions are:

In infancy: Intussusception
In children: periodic syndrome, any febrile illness
Young adults: gastritis, peptic ulcer, hepatitis, irritable bowel syndrome, dysmenorrhoea
Middle age: peptic ulcer, gall bladder disease, irritable bowel syndrome, carcinoma of stomach, colon, pancreas or liver
Elderly: gastric ulcers, gall bladder disease, neoplasms, obstructed hernia

Acute appendicitis and acute intestinal obstruction are important causes to exclude in all age groups (although acute appendicitis is most common in young children and young adults).
Acute gastroenteritis is a common cause in all age group.

WORKUP

Three questions to answer
The questions facing the general practitioner presented with a patient with abdominal pain are:

- Is there a surgical or medical cause of pain?
    - If not surgical, should the patient be admitted or managed at home?
- Is this an acute abdomen?
    - If not clearly, an **acute abdomen** should the patient be admitted for observation?
- If managed at home, what should be done?

ACUTE ABDOMINAL PAIN

History

A good history may reveal as much, if not more (about the likely cause), than the physical examination.

- It is helpful to assess and manage the patient and family in the context of past knowledge of their demeanour, attitudes and beliefs. Nevertheless, it is wise to remember that even the most neurotic, anxious and depressed patients may suffer from serious abdominal disease at times.
- Any relevant history of previous abdominal diseases and operations should be noted, A family history for major diseases e.g. carcinoma of colon, should also be recorded.
- Clarity the features of the abdominal pain:
    - duration
    - site and radiation
    - character: colicky or dull ache
    - onset and progression: constant, intermittent, increasingly severe, recurrent
    - severity: dull ache or agonizing pain
    - aggravating and relieving factors
- Look for associated features:
    - nausea and vomiting
    - loss of appetite
    - change in bowel habits
    - delayed or current menstruation
    - frequency, dysuria or haematuria

Examination

General

- the patient's general demeanour
- appearance, pallor or jaundice
- temperature
- pulse
- character of respiration
- tongue and
- skin turgor

Abdomen

- **Observe** any obvious distension, movement with respiration, and any obvious skin signs e.g. an occasional case of herpes zoster
- **Palpate** all quadrants of the abdomen carefully; note any masses and tenderness (any deep tenderness in area of pain?). Search specifically for right iliac fossa pain of appendicitis, Murphy's sing of cholecystitis and renal angle tenderness of pyelonephritis.
- **Percuss** for: air, fluid, or mass abnormalities
- **Auscultate** for: a silent or a very noisy abdomen which may be high significant in the context of suspected ileus or intestinal obstruction.

Other examination

If the diagnosis is in doubt, the examination may be extended to include the chest, back and central nervous system. Frequently a rectal and/or vaginal examination will be necessary to clarify the diagnosis or exclude disease in the pelvis.
Cardinal features of some major causes of an acute abdomen are shown in Table 2.

Table 2. Cardinal Features of Major Causes of Acute Abdomen

Cause	Features
Colic	Arise from viscera – exaggerated peristalsis (pain typically waxes and wanes)
Renal colic	Site of pain: loin Radiation: loin to groin Associated features: vomiting, dysuria and haematuria
Biliary colic	Site of pain: right hypochondrium or epigastric region Tenderness in right hypochondrium
Appendicitis	Site of pain: early states periumbilical region and later right iliac fossa pain Pain worse on coughing Vomiting Guarding if perforated Mild fever, non in early stages Constipation or diarrhea may be a presentation Tenderness in right iliac fossa Rectal tenderness
Peritonitis	Site of pain: generalized Rebound tenderness and board-like rigidity Associated with perforated peptic ulcer, ruptured appendix, or ruptured ectopic pregnancy
Peptic ulcer	Site of pain: epigastrium History of drug intake – NSAIDs, steroid Relation to meals – night pains in duodenal ulcer and postpreandial pain in gastric ulcer
Pancreatitis	Site of pain: epigastrium and radiating to the back Severity out of proportion to clinical findings May be in hypovolaemic shock Serum amylase is markedly elevated

Investigations

- No investigations will be required in the majority of patients with abdominal pain, who suffer from relatively minor conditions of short duration.

Non-acute abdominal pain

- In such cases, there is more time to think and act, but a systematic approach is essential in the history, examination and investigation.
- A relatively small number of causes of non-acute recurrent of persistent abdominal pain account for most of the symptoms. These causes include peptic ulcer, hiatus hernia, gall bladder disease, the irritable bowel and new growths of the large bowel or stomach.
- Relevant useful investigations available in the clinic and its support facilities include:
    - urine tests for infection
    - stool examination for occult blood, ova or cysts
    - haemoglobin, total white, serum amylase and liver function tests
    - ultrasound of liver, gall bladder, pancreas, kidneys and pelvis
    - plain X-rays, contrast radiography and CAT scan
    - endoscopic procedures

Special aspect of chronic abdominal pain

Irritable Bowel Syndrome (IBS)

- **Ask about alarm symptoms (RED FLAGS)**
  Rectal bleeding, anaemia, weight loss, persistent diarrhoea, severe constipation, fever, a family H/O CRC, age>50
- Ask about other non-GI symptoms

  Lethargy, insomnia, muscle pains, urinary frequency, anxiety, depression, somatization
- Check for other related conditions:

  Fibromyalgia (32% Vs 2%) CFS (14% Vs 0.4%) chronic pelvic pain (35% Vs 14%) TMJ disorder (16% Vs 5%)
- Ask about family H/O functional abdominal pain (double likely IBS)
- Examine for organic pathology: look for abdominal or rectal mass
- Check for CP, ESR
- If there are no alarm S/S, check Rome criteria

  The Rome 2 criteria

- Abdominal discomfort or pain for 12 weeks or more in the last year, with at least two of the following features:

1. Relieved with defecation
2. Onset associated with a change in the frequency of the stool
3. Onset associated with a change in the form of the stool

- Symptoms supporting the Dx of IBS
- a. abnormal stool frequency (>3 a day or <3 a week)
- b. abnormal stool form (lumpy/hard or loose/watery stool)
- c. abnormal passage of stool (straining, urgency or feeling of incomplete defecation)
- d. Passage of mucous
- e. Bloating or feeling of abdominal distension
    - Criteria met—LR (4.7) probability (86%)
    - Criteria not met-LR (0.3) probability (30%)
    - Note

1. 17% of those with organic disease met Rome criteria
2. 30% of those who did not meet Rome criteria still had a functional bowel disorder
3. The GP should realize that these LR may not apply to primary care

ABCDE diagnosis of IBS

A. Abdominal pain
B. Bloating
C. Change in bowel habit
D. Defecation –relieved with defecation
E. Evacuation-incomplete

Management

Acute abdomen pain

- Where the cause is clear and minor, symptomatic and definitive treatment may be all that is necessary.
- Where the decision is to observe the patient, as for example, when the diagnosis of the mesenteric adenitis is made, the patient should be pain increase over the next six hours.
- This asked to report back or to go to hospital should be emphasized to the patient. Hospital admission is necessary for the obvious acute abdomen or when an acute abdomen cannot be excluded.
- It is better to err on the side of caution than to take the risk of leaving a patient at home with a possible progressing abdominal emergency.

Non-acute abdominal pain

- The management of the patient with a non-acute abdominal pain depends on the underlying pathology. Psychological causes should be liked for if organic causes have been excluded.
- Attention to reasons for encounter may provide useful cues, where no organic cause is found, the patient should be reassured and followed-up.

Reference

1. Goroll AH, Evaluation of chronic fatigue. in: Goroll et al. Primary Care Medicine, 3rd ed. Philadelphia: Lippincott, 1995. 325-333.
2. Scott BR. Recurrent abdominal pain during childhood. Can Family Physician Mar 1994;40:539-547
3. Diploma in Family Medicine Module by Dr Win Lwin Thein, 2017

13. SKIN RASHES

Relevance to general practice

- A rash account for 5% of all new symptoms presented in general practice
- Extent of involvement and the presence or absence of accompaniments of itch or constitutional upset is helpful in differential diagnosis.

Definitions

It is important to define the terms commonly used to describe skin rashes.

Macule - A flat spot which differs in colour from the surrounding skin
Papule - A raised spot on the surface of the skin
Nodule - A lump deeply set in the skin
Scale - A flake of horny cells loosened from the skin surface
Crust - Dried serum adherent to the skin
Vesicle - A skin bleb filled with clear fluid
Bulla - A blister filled with clear or blood-stained fluid
Pustule - A skin bleb filled with pus
Urticaria - An irregular white or pink pruritic weal

Causes

An approach to skin rashes is to group them into the following:

Generalised rash of acute onset

- accompanied by malaise and fever
- accompanied by acute pruritis as a prominent feature
- accompanied by minimal constitutional upset or pruritis

Localised rash (at times can be widespread)

Generalised rash of acute onset
Accompanied by malaise and fever

Most are due to specific infectious diseases:

- **Measles:** This is commonly associated with cough, running nose and conjunctivitis. The child is usually miserable. Koplik spots may be found on the oral mucosa before the onset of the rash. The rash itself consists of dusky red macules which coalesce to form irregular blotches. The rash remains as a brownish staining for 2-3 weeks after the fever has subsided.
- **Rubella:** The constitutional upset is mild compared to measles. The rash consists of pale pink macules, and first appears on the face. It spreads rapidly over the trunk and limbs and fades in 2-4 days. Generalised lymphadenopathy is an accompanying feature. **Enlargement of the suboccipital lymph nodes are typical.**
- **Chicken pox:** The rash appears as macules which rapidly progress to umbilicated papules and vesicles. It appears in crops and is commonly found to be in different stages of development on the same patient. It first appears on the trunk and has a centripetal distribution.
- **Non-specific viral infections:** These are usually accompanied by catarrhal symptoms. The rash is commonly macular or erythematous, clinically similar to rubella, and fades in 24-48 hours without leaving any serious sequelae.
- **Infectious mononucleosis:** The rash, which occurs in 10% of patients, consists of an erythematous eruption occurring on the trunk, buttocks and extensor surfaces of the limbs. Accompanying features include membranous tonsillitis, lymphadenopathy, and splenomegaly. **Patients given ampicillin will develop a widespread, maculopapular erythematous eruption.**

Accompanied by acute pruritis as a prominent feature

- The causes may be drugs, insect bites or allergens. The morphology of the rash ranges from erythematous papules and macules to urticaria and purpura. Mucous membrane lesions are sometimes present. The reaction may be mild, lasting several days, or may be severe and life-threatening.

Accompanied by minimal constitutional upset or pruritis

These are not so common. Two conditions which are sometimes seen in general practice are:-

- **Erythema multiforme:** The rash consists of slightly raised macules up to 1 cm in diameter which may coalesce and show target lesions. Steven-Johnson Syndrome is a more severe form, with mucous membrane involvement.
- **Pityriasis rosea:** seen mainly in young adults. The rash consists of symmetrical oval-shaped macules, spreading over the trunk and proximal parts of the limbs. This may be preceded by a **herald patch** several days earlier.

Localised rash

- These are usually not associated with any constitutional symptoms, and may have typical sites of occurrence. The cause may be endogenous or exogenous. Exogenous causes may be infective or non-infective.

Atopic eczema

This is part of the eczema-asthma-hay fever syndrome, Onset is usually in the second year of the life. The rash is typically located in the flexures of the elbows and knees. It can also be found on the face, neck, wrists and buttocks. In the infantile form, it may be generalized, but it usually persists as a recurrent flexural eczema in older children.

Irritant dermatitis

These are produced by substances that chemically damage the skin. Some are very powerful, and produce eczematous skin changes even with very short contact. Examples are alkalis and certain solvents. Other irritants are low grade, and cause changes on prolonged repeated contact. Detergents and soaps can be classified under this category. The skin changes are varied, but are usually localized to the site of contact.

Allergic dermatitis

This occurs when the skin is in contact with a substance to which the patient is allergic. The reaction may be localized, or may spread to other areas not in contact with the allergen. Examples are allergy to nickel and cement.

Other eczemas

These include ***seborrhoeic dermatitis***, which is of exudative nature, and can be found on the hair margins, face, axillae, chest and groin; ***pompholyx***, which is a blistering condition occurring on the palms and soles; ***lichen planus*** and others of uncertain aetiology classified under morphology and distribution.

Psoriasis

This presents most commonly in early adult life. The characteristic lesion is a raised red plaque with a well-defined margin, covered with silvery scales. The lesions occur mainly on the extensor aspects of the knees and elbows, the sacrum and the scalp. Psoriasis may also present as ***guttate psoriasis*** which appears as small lesions 0.5-1 cm in diameter scattered over the skin surface, sometimes after a streptococcal infection. Other forms of psoriasis include ***pustular*** and ***erythrodermic*** form, which are potentially serious. Nail involvement is common, Arthritis occurs in about 10% of patients.

Skin infections

These may be bacterial or fungal.

- Bacterial infections include **impetigo**, which is mainly localized, and had characteristically golden yellow crusts; **folliculitis**, involving the hair follicles; **boils** and **carbuncles**.
- Fungal infections run a more chronic course, and are spread over a wider area. Those caused by dermatophytes are classified according to the distribution, e.g. tinea capitis, tinea cruris. The lesions are typically annual, with the outer edge as the most active area, and central clearing. Scales may be present. Tinea versicolor is caused by a yeast.
- The lesions may be hypo- or hyperpigmented. There is no characteristic distribution. Candida albicans is an opportunistic yeast. The skin lesions are found mainly in the warm, moist parts of the body, and consist of inflammatory reaction with satellite lesions. Mucous membrane involvement consists of white exudative plaque.

Parasitic infestations/insect bites

Scabies is caused by the mite *Sarcoptes scabiei*. The characteristic lesion is a burrow, at the end of which the mite can sometimes be found. The distribution is typically in the skin fold areas, between the fingers and toes, and in the groin.

Papular urticaria represents an urticarial and vesicular response to a variety of insect bites, including fleas, bedbugs, motes, and mosquitoes. The lesions are seen mainly on the exposed parts of the body.

WORKUP

History

- One should establish the duration of illness, the site and distribution of the rash.
- In patients presenting with skin rash of short duration, the presence of associated symptoms should be asked for, namely, constitutional disturbance, and itch.
- A history of prior unaccustomed food and drugs ingestion, immunization, allergy should be obtained. A working diagnosis can often be reached even before the patient is examined.
- In patients presenting with a more chronic rash, it is important to establish the site of onset and mode of spread of the rash, any aggravating or relieving factors, or allergy. Past, family, social, and occupational histories are also important, as for example, in atopic eczema, in contact dermatitis.

Physical Examination

- Examination of the skin should include examination of the mucous membranes and the nails. Some conditions can be diagnosed by morphology and distribution e.g. pompholyx.
- Some acute conditions have characteristic non-cutaneous physical signs, e.g. presence of suboccipital lymph nodes in rubella, which help in narrowing down the differentials.
- Look out also for signs confirming certain symptoms, e.g. excoriation marks in patients complaining of pruritis, lichenification in long-standing rash. A magnifying glass is a useful aid in studying the morphology of the rash.

The distribution of rashes provides a useful guide as to the differential diagnoses in rashes of insidious onset.

- Rashes affecting
    - **the hands** – irritant eczema, pompholyx, scabies
    - the flexor aspects of the arms and leg – atopic eczema most common
    - **the feet** – tinea pedis most common, contact dermatitis due to leather, or dye from shoes also common
    - **the extensor surfaces of the limbs** – characteristic in psoriasis, uncommonly dermatitis herpetiformis
    - **the groin area** – tinea cruris, seborrhoeic dermatitis
    - **the axilla** – contact eczema e.g. due to deodorants, less commonly seborrhoeic dermatitis, tinea capitis, psoriasis, impetigo

    - **the trunk** – seborrhoeic dermatitis, guttate psoriasis, tinea corporis, tinea versicolor, pityriasis rosea, rarely secondary syphilis
    - **the buttocks** – scabies, psoriasis, napkin rash, and atopic dermatitis in infants
- **Mucous membrane lesions** – moniliasis, less commonly Steven-Johnson syndrome, syphilis, lichen planus, etc.

Laboratory investigations

- Laboratory investigations are limited in the office setting. One useful procedure is skin scrapping for the diagnosis of fungal infections using potassium hydroxide.
- Other more involved investigative methods e.g. biopsy, and patch testing can be done if facilities are available.

Management

- Management depends on the diagnosis. Acute infections of viral origin need only symptomatic treatment. Patient education and reassurance are important.
- Allergic and contact eczema are managed by identification and avoidance of the offending agent, antihistamines, topical applications and steroids for severe cases.
- Psoriasis and skin infections are treated according to specific protocols.
- General guidelines regarding the vehicle for therapeutic agents of all rashes are as follows: -
- Lotions to be used for moist or weeping lesions
- Creams for oedematous but not exudative lesions
- Ointment for dry lichenified fissured lesion.

Indications for referral

- For consultation where diagnosis is in doubt
- For specialized investigative procedures e.g. patch testing, or management e.g. ultraviolet light treatment in psoriasis
- In acute life-threatening conditions e.g. erythrodermic psoriasis, exfoliative dermatitis, severe allergic reactions.

References

1. Morell D, The patient complaining of a rash. in: Cormack et al. Practice: A handbook of primary health care. London:Kluwer. 1982.

14. BACK PAIN

Relevance to general practice

- Backpain is a common accompaniment of common conditions like viral fever, urinary tract infections and multiple psychosomatic complaints.
- In over three-quarters of cases of acute backache, symptoms disappear within 4 weeks with simple general measures and analgesia.
- The remaining likely serious causes should be identified as early as possible.

Causes

Table 1. shows the main causes of back pain.

Table 1. Causes of Backache

Spondylogenic

- Injury
  - musculo-ligmentous strain
  - disc prolapsed
  - bony injuries
- Structural defect
  - scoliosis
  - spondylosis
  - spondylolisthesis
  - spinal stenosis
- Infection
  - tuberculosis
  - pyogenic
- Inflammatory arthritis
  - ankylosing spondylitis
  - rheumatoid arthritis
- Tumour
  - malignancies – myeloma, secondaries
  - vascular malformations
- Others
  - osteomalacia

Viscerogenic

- Pyelonephritis
- Pancreatitis
- Dysmenorrhoea

Psychogenic

- Functional overlay
- Tension
- Hysterical conversion
- Depression

Important Causes of Low Back Pain

Mechanical (97%)	Nonmechanical Spinal Condition (1%)	Visceral Disease (2%)
Lumbar strain or sprain (70%)	Neoplasia (0.7%)	Aortic aneurysm
Degenerative disk or facet disease (10%)	Metastatic carcinoma	Renal disease
Herniated disk (4%)	Multiple myeloma	Pelvic disease
Osteoporotic compression fracture (3%)	Spinal cord tumor	Abdominal disease
Spondylolisthesis (2%)	Lymphoma, leukemia	
Trauma (<1%)	Infection (0.01%)	
Diskogenic disease	Osteomyelitis	
	Epidural abscess	
	Septic diskitis	

Inflammatory disease (0.3%)
Ankylosing spondylitis
Psoriatic arthritis
Reiter's syndrome
Inflammatory bowel disease

Adapted from Deyo RA, Weinstein JN. Low back pain. N Engl J Med 2001;344:363, with permission

WORKUP

- The cornerstone of the assessment of the patient with acute low back pain is a careful medical history and physical examination, which is critical in determining the presence of more serious conditions.

History

- General
- **Age:** This could indicate the likely diagnosis as many causes of back pain are age related, for example, degenerative diseases, Paget's disease and malignancy. In young and middle aged, PID is considered and Spinal stenosis in aged>50 years.
- **Occupation:** This should be asked as it may reveal the main reason for consultation, i.e. compensation, medical certification and therefore aid in the patient's management.
- Symptoms
- **Duration:** One should ask the duration and onset of the back pain and whether it has been recurrent.

Association: RED FLAGS

  - Age: < 20 > 55yrs
  - **Cancer:** History of cancer, unexplained weight loss, night pain/rest pain
  - **Infection:** fever, immunocompromised state (steroid, diabetes), rest pain, IVDU
  - **Cauda equine syndrome:** saddle anaethesia, urinary retention, fecal incontinence, bilateral lower extremity weakness/numbness or progressive neurological deficit
  - **Fracture:** use of steroids, recent significant trauma, age more than 70 years or history of osteoporosis
  - **Significant herniated nucleus pulposus:** major muscle weakness, pain worse if lying down
  - **Acute abdominal aneurysm:** rest/night pain, age more than 60 years, other atherosclerotic vascular disease

Psychogenic back pain (YELLOW FLAGS):

- Low back pain can also be psychogenic or a symptom of depression; however, other diagnosis must be excluded beforehand.
- Yellow flags-psycho-social features associated with progression to chronic problems or disability
- Is the patient reluctant to do anything that brings on the pain as they think that this is harmful?
- Does he fear the pain and is this fear making him increasingly inactive?
- Is he more inclined to think that passive –as opposed to active- treatment will help?
- How is his mood? Is he anxious, stressed or socially withdrawn?
- Is there a history problem at work?
- Are his families overprotective?
- An exaggerated response to examination can also be a yellow flag.

Indicators for nerve root problems:

- Unilateral leg pain other than low back pain
- Radiates to foot or toes
- Numbness and paraesthesia
- SLR test induces more leg pain especially below knee
- Localized neurology (limited to one nerve root)

Past history: A history of recurrent pain and what had been done for the patient in the past, e.g. surgery, traction, etc. would be helpful

Physical examination

- Observation of the back

  Acute disc prolapse: there may be a forward tilt obliterating lumbar lordosis and a lateral tilt (sciatic scoliosis)

- Palpation of the back

  Local tenderness common in apophyseal joint, ligmentous injury and often in acute disc prolapsed. Note that acutely tender areas due to strains may be helped by local injection.

- Movement (flexion, extension, rotation, lateral flexion, also test the sacroiliac joints)

  In ligmentous injuries the movements are likely to be full. In apophyseal joint dysfunction there may be locally reduced mobility. In disc prolapsed movements are restricted by pain but one or two movements (often flexion) restricted more than others.

- Straight leg raising (SLR) and Cross SLR

  Reduced in prolapsed intervertebral disc with sciatic nerve irritation. Cross SLR is more specific than SLR.

- Femoral stretch test (knee flexion when prone)

  Positive if upper lumbar root involvement.

- Power

  In particular movements of foot and big toe.

- Sensation

  Especially the saddle area, as saddle area anaesthesia may be a feature of central protrusion.

Table 2. Nerve Roots and Associated Neurological Signs

Nerve root	Changes in power	Reflexes
L2	Hip flexion	No changes
L3	Weakness of the quadriceps (knee extension)	Reduced or absent knee jerk
L4	Weakness of knee extension and dorsiflexion of the foot (foot drop)	Reduced or absent knee jerk
L5	Weakness of dorsiflexion of the foot and toes (foot drop)	No changes
S1	Weakness of planter flexion (unable to stand on tip-toe)	Absent ankle jerk
Cauda equina lesion	Any or all of the above with bladder and rectum paralysis	Ankle jerk lost, and reflexes lost

Investigations

- Laboratory testing should be reserved for patients who have red flags.
- Diagnostic imaging is rarely indicated in the acute setting of low back pain. Plain films remain the most widely available modality for imaging the lumbar spine. Plain X-rays are rarely useful in evaluating or guiding treatment of adults with acute low back pain in the absence of red flags.
- The primary objective if X-ray us to identify any bony and/or structural abnormality associated with back pain. Plain lumbar X-rays are helpful in detecting spinal fractures and in evaluating tumour and/or infection.
- In most instances, the routine ordering of plain lumbosacral spine films in patients presenting with back pain is low in yield and neither cost-effective nor useful for decision making
- Further investigations on imaging will be in the domain of the referred specialist.

NOTE:

- MRI and CT should be limited to patients who are either sufficiently symptomatic that surgical intervention must be considered or are suspected of having serious systemic disease.
- The high sensitivity of these tests for disk disease can produce misleading results unless the patient and clinician are aware that disk bulges and protrusions are extremely common (50% MRI is the test of choice in suspected cauda equina syndrome, epidural abscess, or cancer-related epidural spinal cord compression by virtue of its superiority in detecting soft-tissue pathology and 30%, respectively) in asymptomatic people.

Management

- Acute nonspecific back pain (no evidence of neurologic compromise or other serious pathology) is best managed conservatively because prognosis is generally very favorable.
- Such nonspecific acute low back resolves in about one third of patients by 1 week and in two thirds by 7 weeks. Even in those with disk herniation, the figures are similarly favorable, with only about 10% needing consideration of surgery at week 6; moreover, disk herniation tends to regress over time.
- **Analgesia:** Consider muscle relaxants, physiotherapy.

General back care:

- Staying active rather than bed rest
- Avoid lifting heavy weight
- Avoid bending the back: when lifting objects, bend at the knees keeping back straight.
- Posture: when sitting, do not hunch; a small cushion as lumbar support is useful; try to get a well-designed chair.
- Attend to psychogenic factors. (Yellow flags)

Follow up:

- When conservative treatment fails –
- review compliance
- reassess home/work environment
- reassess clinically, as thoroughly as on the initial examination
- refer to specialist assessment

Indications for referral

For diagnosis

- Suspected serious disease i.e. neoplasia, TB, referred pain
- Treatment i.e. traction, surgery
- Failure of conservative therapy. This means failure of therapy after at least three weeks bed rest and analgesia faithfully complied with.
- Emergency referral for surgery i.e. cauda equina lesion. Symptoms are: saddle area anaesthesia, retention of urine/urinary symptoms, atomic anal sphincter, severe weakness of legs peripherally.

References

1. Boyd RJ: Evaluation of Back Pain in Primary Care Medicine. Ed. Goroll, May & Mulley, 2nd ed. 651-659
2. Quinet RJ and Serebro LH: Management of Regional Low Back Pain in Practical Care of the Ambulatory Patient by Stults & Dere, WB Saunders 1989, 479-489
3. Diploma in family Medicine Module by Dr Win Lwin Thein et al.,2017

15. JOINT PAIN AND MUCULO-SKELETAL PAIN

Relevance to general practice

- Patients with diffuse, chronic musculoskeletal pain but no evidence of arthritis account for a large number of office visits.
- Although the cause of the syndrome is unknown, it appears to be common and is estimated to have prevalence as high as 5% among adult women, who account for 80% to 90% of cases.
- Although osteoarthritis accounts for many of the more obvious cases of joint pain (particularly in the elderly), the differential diagnosis can encompass a bewildering array of conditions, both articular and non-articular, inflammatory and non-inflammatory.
- Many patients with joint pains self-medicate and seek advice from friends and alternative medicine practitioners before they consult a doctor.
- Careful attention to the history and physical examination helps chart a logical course to minimize diagnostic error and cost and maximize patient benefit.

Causes

- There are many ways that joint pains can be classified, One way is to classify aetiologically as table 1.

Table 1. Causes of Joint Pains seen in General Practice

ACQUIRED CAUSES

- Inflammatory
  - infective
  - non-infective
    - rheumatoid arthritis
    - ankylosing spondylitis
    - psoriatic arthritis
    - SLE, inflammatory bowel disease
  - metabolic
    - gout
    - pyrophosphate arthropathy
- Degenerative
  - Osteoarthritis, spondylosis, intervertebral disc prolapsed
- Trauma/overuse
  - Shoulder capsulitis, tendonitis, tenosynovitis, bursitis, carpel tunnel syndrome, ligment/muscle tear, chondromalacia patella, trigger finger, metatarsalgia, and planter fasciitis
- Miscellaneous
  - Psychogenic rheumatism, neoplasm

HEREDITARY (Uncommon)

- Marfan's syndrome, Ehlers-Danlos, Osteogenesis imperfect

Source: Grahame R. The Practitioner, 1986:316

WORKUP

History

The history should address the following questions:

- Is the problem articular or non-articular?
- Is it inflammatory or non-inflammatory?
- Is the involvement polyarticular (≥5) or pauci-articular?
- Are there any extra-articular manifestations?

- The site of maximal tenderness establishes whether the problem is within the joint or outside. Bursitis and tendonitis are conditions that are extra-articular.
- The features that differentiate between inflammatory and non-inflammatory joint pain are shown in Table 2.

Table 2. Inflammatory and Non-inflammatory Joint Disorders

Symptoms & Signs	Inflammatory	Non-inflammatory
Morning stiffness	>1 hr	<1 hr
Fatigue	Marked	Occasional
With activity	Better	Worse
With rest	Worse	Better
Soft tissue swelling	Yes	Uncommon
Bony swelling	Uncommon	Yes

Source: Catherine Alderice. Can Fam Physician 1990;36:553

- If the involvement is mono-articular, consider trauma, septic arthritis and monoarticular stage of a polyarthritis. Of these, septic arthritis is the most important condition to be sorted out.
- If the involvement is polyarthritis, the distribution of joints helps to define the underlying disorder. In rheumatoid arthritis, typically, the joints involved are the feet, metacarpophalangeal joints, proximal interphalangeal joints and wrists.
- In osteoarthritis, when the hands are involved, these joints are usually not involved.
- The presence of extra-articular manifestations helps to clinch the diagnosis. (Table 3)

Table 3. Extra-articular Manifestation in Joint Disorders

Inflammatory arthropathy	Extra-articular manifestations
Polyarthropathy	
Rheumatoid arthritis	Extra-articular manifestations tend to occur later in the course of disease. Subcutaneous nodules, sicca symptoms (dry eye and dry mouth); hand deformities – volar subluxation, swan neck, boutonniere deformity, ulnar deformity of metacarpophalangeal joints are common.
Systemic lupus erythematosus	Extra-articular manifestations are usually prominent, often preceding joint complaints: alopecia, mouth ulcers, Raynaud's phenomenon, butterfly rash, photosensitivity and serositis
Psoriatic arthritis	In 15% of patients with psoriatic arthritis, the arthritis appears first and the typical skin rash develops months to years later. Typically the skin lesions and nail changes clinch the diagnosis.
Chronic tophaceous gout	Tophaceous deposits found under the skin
Oligoarthropathy	
Ankylosing spondylitis	Iritis, aortic incompetence
Reuter's syndrome	Conjunctivitis, keratoderma blenorrhaghica, balanitis in males
Psoriatic arthritis	skin rash, nail changes reveal the diagnosis
Inflammatory bowel arthropathy	Ulcerative colitis and regional ileitis
Early rheumatoid arthritis	subcutaneous nodules

Physical examination

- Examination may be normal or there may be redness and swelling of affected joints, deformities and extra-articular manifestations.
- Every painful joint should be examined with regard to the following:
  - joint swelling and tenderness
  - synovial and capsular thickening

- deformity
- range of movement
- instability
- gait
- muscle power
- Next consider the pattern of affliction and symmetry of the disease:

- peripheral joints
  - symmetrical pattern in RA
  - asymmetrical pattern in gout (usually single joint affected)
- axial joints (sacroiliac, spine, lower limbs)
  - AS, Reiter's syndrome
- For polyarticular disease other systems need to be examined and these should include:
  - the eye e.g. conjunctiva, sclera, iris, and retina
  - skin – pattern of rash, ulcers, ischaemia and infarction, nodules, nails, and hair
  - mucous membranes – ulcers
  - abdomen and genitor-urinary system
  - cardiac murmurs
  - muscle wasting (disuse atrophy), dermatomyositis in SLE

Investigations

- Not all joint pains require further investigations. A negative result does not necessarily exclude the presence of the disease process.
- In inflammatory polyarthropathy, initial investigations need only to be confined to the following:

Erythrocyte sedimentation rate

The erythrocyte sedimentation rate (ESR) is a very useful test of inflammatory activity, particularly in patient with rheumatoid arthritis or polymyalgia rheumatic. In RA it is raised and very high in the acute stage. In the elderly with polymyalgia rheumatic (PMR) a markedly raised ESR is usually present.

Complete blood count

- Hb – moderate anaemia is the most common systemic manifestation of inflammatory joint disease. Its severity reflects the activity of the disease.
- TW – Total white is raised in infection, and in gout
- Platelets – can be raised or low.

Rheumatoid factor

Rheumatoid factor is an important test in confirming the diagnosis, but only if the positive results, correspond to the patient's symptoms and current knowledge of rheumatoid arthritis. Early in the disease, it may be negative in rheumatoid arthritis but will normally turn positive within one year. Rheumatoid factor is used mainly to confirm a diagnosis. It should never be used to monitor disease activity.

Anti-nuclear antibodies (ANA)

Anti-nuclear antibodies (ANA) should be approached in the same way as a positive test for rheumatoid factor. Only if the patient's symptoms strongly suggest SLE should a positive test for ANA be taken as confirmation of the diagnosis. Like rheumatoid factor, ANA tests are not useful to monitor disease activity.

Synovial fluid analysis

- In oligoarthropathy and monoarthropathy, synovial fluid analysis is helpful. It is almost diagnostic in septic arthritis and in gouty or pseudogout arthritis. By contrast, such analysis does not help to differentiate the aetiology of polyarthropathy.

Radiological investigations

- X-rays of joints are useful as a baseline examination and for monitoring progress. The following should be looked for:
    - soft tissue changes
    - juxta-articular osteoporosis
    - uniform narrowing of joint spaces
    - erosions at joint margins

Table 4. X-ray Features in Joint Disorders

Rheumatoid arthritis
: Periarticular osteoporosis, and periosteal reaction

Ankylosing spondylitis
: Typical diagnostic features: blurring of margins of sacro-iliac joints, erosions and squaring of lumbar vertebrae; "bamboo spine"

Gouty arthritis
: In late stages of disease, punched out juxta-articular erosions and degenerative joint changes

Osteoarthritis
: Narrowed joint space, irregular joint space, sclerosis of subchondral bone, subchondral cyst, osteophytes

Fibromyalgia Syndrome (FMS)

- **ACR criteria**

1. A history of widespread pain for at least 3 months involving left and right sides and areas above and below the waist, and involving the axial skeleton (cervical spine ,or thoracic spine, or anterior chest or lower back)
2. Where pressure on 11 out of 18 trigger points causes pain
3. Other features-fatigue, non-restorative sleep, mood alterations, non-neurological paresthesia, headaches, stiffness, irritable bowel syndrome, restless leg syndrome.

Management

This depends on the cause and stage of the joint disease and is based on a combination of:

- physiotherapy
- local injections
- drug therapy – a wide range of drugs is available from the simplest analgesics, NSAIDs, gold to cytotoxics,
- surgery - to joint and deformities
- aids for walking and ADL
- patient education and counseling
- social and community support/self-help groups

For the standpoint of management, patients can be divided into 3 groups:

- Inflammatory arthropathy and physical examination is positive
    - Patients whose history indicates inflammatory polyarthropathy and who have objective evidence of joint involvement are usually fairly easy to manage. If gouty arthritis or septic arthritis is present, the treatment is specific. In inflammatory polyarthritis, the initial management is symptomatic. Self-limiting conditions, particularly a viral illness (which can mimic rheumatoid arthritis), will resolve within six weeks.
    - If symptoms persist beyond six weeks, one must establish the most likely diagnosis and then treat the symptoms as they occur; the need for second line drugs may need to be sought.
- Inflammatory arthropathy but physical examination is normal

    - These patients probably have early arthritis like rheumatoid arthritis but may not have yet developed recognizable features. The patient may develop new symptoms over time or will have a complete resolution of their symptoms. Treatment at this time is with NSAIFs and they should be followed up more closely than the other two groups.
- Non-inflammatory arthropathy
    - These are patients who have no inflammatory features on physical examination of affected joints. Advice on judicious exercise, weight reduction of the overweight is needed.
    - Consider the Diagnosis of Rheumatic fever using Modified Jone's criteria.

References

1. Alderdice C, Approach to the patient with polyarthritis, Can Fam Physician 1990;36:549-551, 553-554.
2. Goroll AH, May LA and Mully, Management of rheumatoid arthritis. in:Primary Care Medicine, 3rd ed. Philadelphia: Lippincott, 1995:790-794.
3. Dorbrand I. et al. Chapter on Muscular Skeletal problems, In: Manual of clinical problems in adult ambulatory care, 1992. Toronto: Little Brown: 283-339.
4. Stuart RA & Macedo TF, Antirheumatic drugs. Medical Progress. August 1993:11-17.
5. Soll AH, Weinstein WM, Durara J & McCatrthy D, Non-steroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med 1991;114:307-19.
6. Diploma in family Medicine Module by Dr Win Lwin Thein et al.,2017

16. DIZZINESS

Relevance to general practice

- Dizziness is a common symptom and its interpretation can be difficult, made worse by its very subjective nature and the many disorders that can cause it, few doctors will not feel a sense of despair when confronted with a patient whose main complaint is that of dizziness.
- A careful history including drug intake will help determine whether the Dizziness is a true vertigo or pseudovertigo and pinpoint the diagnosis.
- Important serious causes to keep in mind are cerebral tumours and cardiac dysrhythmias.

Meaning of dizziness

- It is a term that includes many symptoms and presentations, none of which can be objectively measured.
- Dizziness is a sense of abnormal balance, and results from disturbance of one or more of the organs maintaining balance.
- When a patient complains of "dizziness", he or she can be using this term to describe many different phenomena, and hence a careful history is required to unravel the problem

Scenario

- A 30-year-old male comes to your office for assessment of dizziness. The dizziness occurs when he rolls over from lying position to either the left side or the right side. It also occurs when he is looking up. He describes a sensation of "the world spinning around "him. The episodes usually last 10 to 15 seconds. They have been occurring for the past 6 months and occur on average one to two times per day.
- It is useful to try and categorize the patient's symptoms into one of the following categories in Figure 1.

Figure 1. Classification of Dizziness



- **Vertigo** – a sense of rotation, that is either the patient or his surroundings are spinning around. In its severest form, it may be accompanied by nausea, vomiting, pallor and sweating.
- **Unsteadiness** – characterized by a tendency to fall; disequilibrium
- **Lightheadedness** – presyncopal feeling. May be relieved by assuming a supine position.
- **Giddiness** (hing-hing) – nonspecific; cannot be easily put into any recognizable pattern. In the elderly, consider a problem of multisensory deficits. These sufferers may have cataracts, neuropathy, limited neck movements and aging of the vestibular system.
- Differentiation into these categories must be attempted despite the obvious difficulty in doing so, because this helps in identifying the problem.

Causes

The causes of dizziness are show in Table 1.

Table 1. Causes of Dizziness

Peripheral disorders	
Labyrinth	Labyrinthitis Meniere's disease Benign paroxysmal positional vertigo Labyrinthine window fistula
Eighth nerve	Vestibular neuronitis Acoustic neuroma
Central causes	
Brain stem Cerebellum	Vertebro-basilar insufficiency Infarction Degeneration Tumour
Others	Hypotentive drugs, alcohol, tranquilisers, anticonvulsants, Cardiac dysrhythmias, Anaemia

Table 2. Red flags for patients with dizziness suggesting that the patient may have a serious, possibly urgent underlying disease

Red flag	**Suggested diagnoses**	**Suggested interventions**
Cardiovascular symptoms (e.g. chest pain, dyspnoea, palpitations)	Acute ischaemic heart disease or AMI, acute heart failure, arrhythmia, valvulopathy	ECG, Holter monitor, echocardiogram, cardiac markers (e.g. troponin level) Consult cardiologist
Central nervous system symptoms, such as cranial nerve palsies, visual symptoms or vision loss, unilateral weakness	Brainstem or cerebellar stroke, TIA, tumour, posttraumatic symptoms, multiple sclerosis	MRI of bran, cardiovascular risk evaluation Consult neurologist
Gradula hearing loss and tinnitus	Acoustic neuroma	MRI, audiogram, BAER Consult otolaryngologist
Severe otalgia and vesicular eruption, usually of the external canal and pinna	Herpes zoster oticus/Ramsay-Hunt syndrome	Neurologic examination, especially of cranial nerves Consult otolaryngologist
Propensity to pass out and/or severe lightheadedness on standing	Hypovolaemia, orthostatic hypotension, peripheral neuropathy, overmedication, multiple deficits (common in older people)	Medical assessment for volume depletion, anaemia, new or multiple medications, deconditioning, gait or balance disturbance Consult geriatrician
Vomiting blood, black stools, or gradual increase in weakness with postural presyncope, especially in patients with risk factors for GI bleed (e.g. anticoagulation, prior bleed, or NSAID use)	Upper or lower GI bleed	Complete blood count, stool for occult blood, additional testing for underlying cause Consult gastroenterologist

AMI=Acute myocardial infarction; BAER=Brainstem auditory evoked response; CHF=Congestive heart failure; ECG=Electrocardiogram; GI=Gastrointestinal; MRI=Magnetic resonance imaging; NSAID=Nonsteroidal anti-inflammatory drugs; TIA Transient ischaemic attack.

From the standpoint of diagnosis, it is useful to classify dizziness as with or without vertigo. **A. Dizziness without vertigo suggests one of the following:**

- **Acute infection usually viral in origin**. This may be associated with other symptoms such as gastric or bowel disturbance and aches and pains in the limbs or body.

Postural hypotension.

- This is seen most often in young women who are otherwise fit. This may be due to the earlier stages of pregnancy. Postural hypotension in the known hypertensive on treatment and the diabetic with autonomic neuropathy may also be a cause of dizziness. Postural hypotension
- Check the BP sitting then standing and again after standing for 3 minutes.
- Condition exists if there is fall in Systolic >20, or in Diastolic> 10 on changing from supine to standing. Or a fall in mean pressure of at least 20.
- Even then, significant fall does not mean this is a cause of the patient's symptoms and negative test does not rule it out.

Hyperventilation

- One of the important causes of dizziness especially when the patient complaints of lightheadedness is HVS (Hyperventilatory Syndrome)

Dx: the Nijmegen Questionnaire

- Do you have any of the following, and if so, how often? Feeling tense, chest pain, blurred vision, dizzy spells, feeling confused or out of touch, tight feelings in the chest, bloated feeling in stomach, faster/deeper breathing, short of breath, tingling in fingers, unable to breathe deeply, stiff fingers and arms, tight feelings around mouth, cold hands/feet, heart racing, feelings of anxiety
- 91% sensitivity (LR-0.05) 95% specificity (LR+18)
- Hyperventilation Test-ask the patient to breathe deeply and rapidly for 3 minutes(100% sensitivity, 79% specificity)
- Do not diagnose as a Dx of exclusion

Hyperventilation provocation test

- Ask the patient to breathe deeply and rapidly for 3 minutes.
- 100% sensitive,79% specific (Utah Study)

Dizziness of psychological origin

- A vague and imprecise history such as sensation of motion that does not suggest vertigo.
- Brief attacks that can occur several times/day.
- Normal or inconsistent clinical examination and investigations.
- Multiple other complaints that raise the suspicion of a somatisation disorder
- Do not diagnose dizziness of psychological origin as a diagnosis of exclusion.
- Anxiety and depression may be the causes of dizziness as the primary cause or secondary effects.

Dizziness as a geriatric syndrome

- Anxiety trait
- Depression
- Impaired balance
- Past MI
- Postural hypotension
- Five or more medications(polypharmacy)
- Impaired hearing

- Romberg's Test can distinguish organic from psychological ones.

Dizziness in older patients in the community (Edinburgh study)

- Cerebrovascular disease 70%
- Cervical spondylosis 66%
- Anxiety or hyperventilation 32%
- Poor vision 15%
- Postural hypotension 9%
- BPV 4%
- Other 26%
- No diagnosis made 4%

Total comes to >100% because some patients had more than one condition.

- **Hypoglycaemia**. This is associated with sweating and hunger, in a known diabetic or a one who omits his regular meals for whatever reason.
- **Drugs**. Drugs should not be forgotten as a cause of dizziness without vertigo. Examples are hypotensive drugs, tranquilisers and anticonvulsants.
- **Other causes**. Anaemia (often implicated but not substantiated) and cardiac disease (e.g. aortic stenosis and regurgitation; dysrhythmia) are other causes of dizziness without vertigo.

Dizziness with vertigo may be caused by:

Benign positional vertigo (BPV)

BPV is the most common cause of vertigo in General Practice setting.

- **Adults presenting with vertigo in primary care(Irish Study)**

1. BPV 42%
2. Vestibular neuronitis 41%
3. Vascular 3%
4. Neurological 1.5%
5. Psychological 1.5%
6. Unable to specify 1.5%

Diagnostic test: Dix-Hallpike maneuver –sensitivity 56%, specificity 90 % (LR+ 3.0, LR- 0.5)
With the patient in sitting position, turn the patient's head 30 degrees to one side. Move the patient quickly to the supine position, keeping the head turned, until the patient's head is hanging 30 degrees off the table.
This position places the lower ear's posterior semi-circular canal- that most commonly involved in BPV-in a plane relative to gravity, thereby causing the endolymph to spin and symptoms to be provoked.

Meniere's disease.

- The attacks of vertigo may last for hours. Malaise or instability may persist for a day or two, and there is always associated with deafness, which may be unilateral.
- Long periods of freedom between attacks are common.

Diagnostic triad

- At least two attacks of vertigo lasting at least 20 minutes each
- Hearing loss
- Tinnitus or fullness in the ear

Vestibular neuronitis. This is characterized by the acute onset of rotator vertigo with systemic disturbance. The vertigo may subside spontaneously after a day or few hours, and may recur on sudden head movement or on postural change during the following few weeks. This condition is usually self-limiting. A viral infection of labyrinth has been postulated, though there is little direct evidence for this.

Diagnostic triad of Vestibular Neuronitis

1. Vertigo that is usually sudden onset, although the patient may report several days of increasing problems
2. Absence of cochlear symptoms (deafness and tinnitus)
3. No central neurological symptoms and signs
   It affects the young and middle-aged. It is a single episode lasting 1-5 days. The most intense of all causes of vertigo:

- Often a single episode of persistent vertigo lasting days
- Can be exacerbated by any positional change, unlike the specific head movements that induce BPV attacks.
- May be preceded by a nonspecific viral infection.
- Little or no nystagmus or vertigo during Dix-Hallpike testing

Balance system screening evaluation

- Test for balance: vision, vestibular system, propioception
- If there is sway with eyes open---cerebellar problem
- If sway with eyes closed---Romberg Test (+)
- Vertigo+ R (+) -----vestibular problem
- Vertigo (-) R (+) -----propioceptive problem like Neuropathies

Diagnostic test of VN- Head impulse test

- Sensitivity 35-93%
- Specificity 61-97%
- Hold the patient's head with both hands.
- Ask the patient to fix his gaze on a distant object (examiner's nose)
- In a quick movement, rotate the patient's head about 15 degrees, watching his eyes.
- In vestibular disease, the patient loses fixation momentarily and the eyes then flick back to fix on the object again. The test is positive now.
- **Vertebro-basilar insufficiency**. This may be the result of, either arteriosclerotic narrowing of the blood vessels or narrowing of the intervertebral foramina secondary to osteoarthrosis. As expected, it is seen most commonly seen in the elderly.

Central vertigo

E.g. Brainstem stroke, lateral medullary Syndrome, cerebellar stroke

- Persistent and worsening vertigo
- Atypical vertigo(vertical)
- Severe headache
- Altered consciousness
- Eye symptoms (diplopia, visual disturbance)
- Cranial nerve and long tract signs
- Vertical nystagmus

Other causes. Temporal lobe epilepsy and an acoustic neuroma, also cause dizziness with vertigo.
Acoustic Neuroma

- Vertigo (50%)
- Postural instability (50%)
- Hearing loss (95%)
- Tinnitus (83%)

WORKUP

History

- When the patient present with 'light-headedness', not associated with rotation, the history and examination will be directed towards identifying a non-vestibular complaint.
- Does the patient experience the symptom after rising rapidly from the sitting position? Is the patient receiving treatment for hypertension or diabetes mellitus? Does the patient sweat or feel hungry during an attack, and is it relieved by eating food?
- In evaluating a patient with vertigo, there may be associated symptoms of tinnitus and impaired hearing. A patient complaining of vertigo should be asked if he has suffered any head injury in the recent past, or about ingestion of drugs with known toxic effects on the inner ear (such as salicylates, quinine and streptomycin).
- The addition of headache to these symptoms suggests the possibility of acoustic neuroma causing raised intracranial pressure.

Physical Examination

- The patient who suffers from 'light-headedness' unaccompanied by rotation is not suffering from any disease of the labyrinth. In such a patient, the clinical examination will be directed towards identifying a non-vestibular cause. It will include recording of the pulse, temperature and blood pressure on lying and standing.
- If an infective cause for the symptom is suggested by raised pulse and fever, then a general examination of throat, sinuses, ears, chest and abdomen will be conducted to identify the site of the infection.
- Signs of early pregnancy should be looked out for in the young woman complaining of dizziness, especially if her period is delayed.
- True vertigo requires detailed examination of the ears and function of the labyrinth. Conductive deafness (bone conduction better than air conduction in Rinne's test) will suggest a local middle ear cause for vertiginous symptoms, Perceptive deafness (air conduction greater than bone conduction) will suggest the possibilities of disease of eight nerve or cochlear end organ.
- Nystagmus should be looked out for, as it may be caused by disease of labyrinth or its central connections (though bearing in mind that it may occur in normal subjects on extreme lateral gaze, or if the test object is held too close).
- Benign positional vertigo is confirmed by a positive Dix-Hallpike maneuver. This is done with the patient sitting on the couch and suddenly lowering the patient to a position below horizontal and with the head turned 45º to the side. The patient is left in this position for about 30 seconds before returning to the sitting position with the head looking at the same direction for another 30 seconds.
- The test is then repeated with the head turned to the other side. Severe vertigo and nystagmus occurring some seconds (that is, with latency) after lowering the patient indicates a vertigo of peripheral origin. If fatigable (disappears after repeated testing) it is virtually diagnostic of benign positional vertigo. If there is no latency and there is no fatigability, a posterior fossa tumour has to be excluded,

Investigations

- A simple blood count, chest X-ray and electrocardiogram may be needed to further evaluate suspected anaemia or cardiac disease.
- The known diabetic requires measurement of his blood sugar level to identify hypoglycaemia as a cause of his symptoms.
- In a patient with associated deafness, audiometry will determine whether the deafness is caused by a lesion of the cochlear end organ (e.g. Meniere's disease). This will show the characteristic known as loudness recruitment: as the sound intensity is increased, the subjective loudness in the affected ear progressively approximates that of the good ear.
- More sophisticated tests for example computerized tomograms, cerebral arteriograms are required only when a posterior fossa tumour is suspected.

Management

- **Manage accordingly on diagnosis.**

Management of BPV

- The Epley maneuver—75% success rate at one week, majority being cured after one office visit
- Medication is not usually indicated except in severe or persistent cases in which vestibular sedative like Cinnarazine.
- Fig A-modified Epley maneuver, Fig B-Semont maneuver



- If the dizziness is due to a self-limiting viral infection, symptomatic treatment and fluids are all that are needed. If the site of the infection is identified and the organism amenable to antibiotics then appropriate antibiotics may also be required.
- Vestibular neuronitis is also treated with symptomatic remedies, such cinnarizine or prochlorperazine.

Treatment of Vestibular neuronitis

- Without treatment, the vertigo typically improves on a daily basis, such that within 7-10 days.
- During the acute phase, methyl prednisolone 100mg daily for 3 days then tapering to
- 10 mg daily for 3 weeks
- Metoclopramide 10 mg oral or IM
- Magnesium sulphate twice daily IV
- Gabapentin 300 mg BD or TDS
- TENS
- The hypertensive patient with postural hypotension will require readjustment of the dose or schedule of hypotensive agents. The hypoglycaemic attacks occurring in the known diabetic require similar reassessment of his regime of treatment.
- The elderly patient with dizzy attacks may benefit from the wearing of a cervical collar which will restrain the movement of the cervical spine.
- The advice to rise slowly from the sitting position and to avoid movements which will provoke the attack is also of help. Prochlorperazine tablets, 5 mg twice daily, will often reduce the intensity of the attacks.
- The medical treatment of Meniere's Disease is at present symptomatic. Low-salt diet and diuretics may be employed with variable degrees of success. Betahistine has had some success in a dose of 8 mg thrice daily. Vestibular sedatives are helpful and of these cinnarizine has been recommended.
- Vertigo in the presence of middle ear infection requires an urgent opinion from an ear specialist.
- If dizziness is caused by psychiatric illness, this may require appropriate management by psychotherapeutic means, tranquilisers or antidepressants.

Indications for referral

- **Central vertigo** – characterized by presence of neurological features. Vertebro-basilar stroke is an emergency.
- **Suspected serious disease** e.g. aortic stenosis, psychosis, for expert management.
- When the diagnosis is not clear.

References

1. Murtagh J. Dizziness (vertigo). Aust Fam Physician 1991 Oct; 20_20:1483-1489
2. Chong PN. Office evaluation of the dizzy patient, Sing Fam Physician 1990;16-2:72-75
3. Morrell DC. Gage, HG and Robinson, NA (1971) Symptoms in General Practice, Journal of the Royal College of General Practitioners, 21-32.
4. Hodgkin, K., Towards Earlier Diagnosis. 3rd ed. Edinburgh: Churchill Livingstone, 1987.
5. D.Sloane, Essentials of Family Medicine. 3rd Edition,Linpincott William & Wilkins,2015

17. HEADACHE

Relevance to general practice

- Headaches are a very common experience and about 90% of the population will have had this symptom within one year. Commonly, it is an accompaniment of acute febrile illness where the cause is clear. At other times, the causes are usually benign.
- The primary care physician's most immediate task is to identify on clinical grounds the occasional patient who requires aggressive work up. The ever-present possibility of a serious organic cause in the minority makes it incumbent for the doctor to take a careful history and conduct an appropriate examination in a patient with headache.
- The nature of the headache is of some value in diagnosis. An occipital headache is more likely than a frontal one to be due to an organic lesion. A headache of recent onset, changing character, increasing frequency or severity, persistent, or accompanied by vomiting or behavior change suggests an organic cause.

Causes

- Headache may be broadly classified as primary or secondary. Primary headaches are those without underlying structural pathology. Secondary headaches are caused by underlying disease. See Table 1.
- A diagnosis of primary headache requires the prior exclusion of a secondary headache. A previously diagnosed primary headache does not preclude a secondary headache developing.

Table 1. Causes of Headaches (2004)

PRIMARY HEADACUES – STRUCTURAL LESION ABSENT

- Migraine
- common
- classical (with aura)
- migraine variants
- Tension-type headache (TTH)
- Cluster headache and other trigeminal autonomic cephalalgias
- Other primary headaches e.g. cough headache

SECONDARY HEADACHES – UNDERLYING LESION PRESENT

- Headache attributed to:
- Head and/or neck trauma
- Cranial or cervical vascular disorder
- Non-vascular intracranial disorder
- Substance or its withdrawal
- Infection
- Disorder of homeostasis
- Disorder of cranium, neck, eyes, ears, nose, sinuses, teeth, mouth, or other cranial structures
- Psychiatric disorder
- Cranial neuralgias and central causes of facial pain
- Other headache, cranial neuralgia, central or primary facial pain not elsewhere classified

Source: International Headache Society Headache Classification & Diagnostic Criteria (2004), 2nd edition

WORKUP
ACUTE HEADACHE

History

- This should include inquiry into onset, severity, location, associated symptoms especially neurological deficits and fever. A previous history of headaches and head trauma should also be noted.

- Headache of extraordinary severity ("my worse headache ever") suggests a serious intracranial cause, namely, subarachnoid haemorrhage, raised intracranial pressure and meningitis.
- Diffuse headache in conjunction with a stiff neck and fever suggest acute meningitis.
- Subarachnoid haemorrhage typically produces a sudden severe headache – the ("thunder clap") headache.
- When acute headache and stiff neck occur in conjunction with ataxia of gait and profuse nausea and vomiting, a midline cerebellar haemorrhage is uncommon, but early recognition is important because prompt treatment can be life-saving.
- Acute fever with fronto-orbital headache is suggestive of acute sinusitis
- Eye pain and blurred vision raise the possibility of acute glaucoma.
- New onset of headache in an elderly patient requires consideration of temporal arteritis.
- Acute throbbing headaches are mostly vascular in aetiology: the patient needs to be asked about, fever, vasodilator use, drug withdrawal, and hypoglycaemia.
- Migraine (common migraine and classic migraine) produce a recurrent acute headache.
    - Common migraine (migraine without aura) – occurs in 80% of patients with migraine, the headache is bilateral or shifts sides, nausea, photophobia and related symptoms usually accompany the headache.
    - Classic migraine (migraine with aura) accounts for 10-15% of cases. It is characterized by prodrome of transient visual, motor or sensory disturbance followed by onset of a hemicranial throbbing headache, nausea, photophobia and sensitivity to noise.
- Hypertensive encephalopathy may be heralded by diffuse headache, nausea, vomiting and altered mental status.

Physical examination

- In a patient where headache is an accompaniment of fever or an acute respiratory infection, confirmation of the fever and selective examination of the affected part will be all that is necessary.

Where the cause is not immediately clear, physical examination to rule out a serious cause is necessary.

- The blood pressure and temperature should be checked for any elevations.
- Examination of the scalp for cranial artery tenderness; the sinuses for tenderness to percussion.
- Examination of eye: pupils are noted for loss of reactivity and the cornea for haziness due acute glaucoma; the disc margins for blurring from raised intracranial pressure.
- Examination of neck: neck rigidity on anterior flexion suggests meningitis or a vascular leak from an AV malformation or an aneurysm.
- Neurological examination for ataxia in patient with severe, profuse vomiting suggesting cerebellar haemorrhage; early recognition is important because prompt treatment can be life-saving.

Investigations

- If the causes are obvious and benign, investigations are not needed.
- Where organic neurologic cause is suspected patient should be referred to hospital for further investigation s such lumbar puncture, CT scan etc.

CHRONIC AND RECURRENT HEADACHES

History

It is important to keep in mind that more than one kind of headache may be present; a full description of each type of head pain must be elicited.

- A dull, steady, recurrent, unilateral headache that occurs in the same area each time and progressively worsens in frequency and severity is suggestive of an intracranial lesion (tumour, brain abscess).

- Recent head trauma and a symptom-interval between injury and onset of headache are characteristic of subdural haematomas; patients may show only subtle personality changes and be mistakenly thought to have a psychogenic problem.
- Most throbbing, recurrent headaches are of vascular origin; migraine accounts for the vast majority.
- Headache that are variable in quality and location, or constant over weeks to months but not relentlessly progressive in severity are likely to have a muscle contraction or psychogenic aetiology.

Physical Examination

- A complete examination is necessary. The finding of a fixed focal deficit is important evidence of intracranial pathology, especially in a patient with a headache that is progressively worsening.

Laboratory studies

- The patient with a chronic or recurrent headache that is getting worse with time deserves consideration for CT scan.

Management

- The effect taken to perform a careful history and physical examination are well worth the time, for these methods remain the best means available for the accurate diagnosis of headache.
- For benign causes, symptomatic management like analgesics should be given. Treatment of specific causes e.g. sinusitis, upper respiratory tract infections and migraine.
- For the patient in whom headache is a manifestation of a deep-seated conflict, psychotherapy is often necessary.

Recurrent headaches in children

- Headache in childhood that is not typical of migraine and not due to structural intracranial pathology is common. In some cases there is strong clinical evidence that acute or chronic psychological stress is important in the genesis of the headache and in a small number of children frank psychiatric illness such depression is present. However, in a not insignificant number of cases, the basis of the headache remains uncertain.
- It is of vital importance to remember that a stressful family or school situation does not protect the child from having significant intracranial pathology as the basis of headaches. Headaches due to psychological stress and psychiatric illness occur in several different situations with quite different implications for management.

Indications for referral

Urgent situations

- Any patient with evidence suggesting meningeal irritation, increased intracranial pressure, an AV malformation or malignant hypertension obviously requires prompt hospital admission.
- Presence of symptoms suggestive of an intracranial mass lesion requires hospital admission.
- The ophthalmologist needs to be consulted at once if acute glaucoma is felt to be the cause of an acute orbital headache.

Non-urgent situation

- Referral to neurologist for the rate case of migraine refractory to treatment, the patient with muscle contraction or psychogenic headache that requires reassurance.
- Dental consultation is indicated if temporo-mandibular joint problems appear refractory to conservative therapy.
- Referral for a vision check and assessment of the need for refraction.

Recurrent headache

- May require referral for a more thorough assessment to exclude space occupying lesion.

References

1. Lane RJM. Is it migraine? The differential diagnosis. Update 1991 Nov; 760-72
2. Pruitt AA. Approach to the patient with headache. In: Primary Care Medicine, 3rd ed. Philadelphia. Lippincott, 1995:821-829.
3. ISH. Classification of Headache & Diagnostic Criteria (2004), Second edition.

18. INSOMNIA

Definition

- Insomnia is defined as the complaint of long-standing (more than 2 weeks) trouble falling or staying asleep that is associated with compromised daytime functioning. In this framework insomnia is the end point of disorders in the initiation and maintenance of sleep (DIMS).

Working definition of Insomnia

- The World Health Organization defines insomnia as a problem initiating and/or maintaining sleep or the complaint of non-restorative sleep that occurs on at least three nights a week and is associated with daytime distress or impairment

Normal sleep

- By using the polysomnogram (a continuous, all-night recording of a patient's respirations, eye movements, electroencephalogram (EEG), muscle tone, blood oxygen saturation and electrocardiogram), normal sleep can be divided into two basic phases: REM, or rapid eye movement sleep, and nonREM (NREM).
- REM is a state of mental and physical activation. Pulse and respiration are increased but muscle tone is diminished, so little body movement occurs. The brain is active, and the EEG shows a pattern similar to that seen during waking. Most dreaming occurs during REM.
- In contrast, NREM is a time of deep rest. Pulse, respiration, and EEG all slow, and the patient goes from light sleep, called stages 1 and 2, to deep of delta sleep, called stages 3 and 4. REM and NREM normally cycle in a reciprocal pattern, giving a typical "architecture" to the polysomnogram. The entire cycle lasts about 90 minutes, and is repeated smoothly four or five times during the night.
- There is no polysomnographic pattern pathognomonic of insomnia. Some insomniacs have slightly shorter than normal sleep time. Some have less stages 3 and 4 sleep, but most have normal-appearing polysomnograms.
- Recent data suggest that slight disruptions of the normal smooth cycling caused by frequent brief arousals may be related to subjectively unsatisfying sleep. Other data indicate that psychological variable strongly influence and insomniac's perceptions of the time spent in bed and its influence on satisfaction during the day.

Relevance to general practice

- Insomnia is the most common sleep disorder in general practice with the incidence up to 30%.
- Impact of illness: they contribute greatly to decreased quality of life and increased morbidity. Improving sleep can be an invaluable way to improve overall health and quality of life of the patients and their families.
- The complaint of disordered sleep is common and it is estimated that as much as a quarter of adult population has sleep problems.
- The elderly and those with psychiatric problems are more likely to complain of sleep problems.
- The primary care doctor needs to be skilled in the assessment and therapy of insomnia, not because the problem is extremely common and a cause of considerable misery but also because it is an important precipitant of excessive drug use and habituation.

Classification of insomnia

- Primary insomnia-insomnia not caused by another disorder, underlying psychiatric or medical condition
- Secondary insomnia-insomnia due to underlying psychiatric or medical disorder

NIH consensus classification

- Transient insomnia< 1 wk

- Short term insomnia-1-3 wks
- Chronic insomnia-> 3wks

Causes

These are shown in Table 1.

Table 1. Disorders in Initiation and Maintenance of Sleep (DIMS)

Psychiatric Disorders – 50%

- Affective disorders: major depression, dysthymic disorder, manic depression disorder
- Character disorders: Anxiety, obsessive-compulsive, borderline, narcissistic character disorders
- Psychosis: schizophrenia

Drug and Alcohol Abuse – 10-15%

- Sedatives: alcohol, benzodiazepines, barbiturates, narcotics
- Stimulants: caffeine and stimulant xanthenes in coffee, tea, cola and chocolate
- Anti-asthmatics, decongestants: terbutaline, aminophylline, phenylpropanolamine
- Cigarettes

Medical/Surgical Problems – 10%

- Cardiovascular: nocturnal angina, arthopnoea, PND
- Respiratory: COPD
- Renal: UTI, urinary frequency
- Endocrine: hyperthyroidism, and hypothyroidism
- Delirium: dementia, infection, metabolic derangement, medication toxicity (e.g. anticholinergic delirium secondary to OTC sleep aids)

Primary Sleep Disorder – 10-20%

- Sleep apnoea
- Nocturnal myoclonus
- Phase shift (night shift, jet lag)

Other – 10%

- Idiopathic insomnia
- Psychophysiological, or conditioned insomnia
- Persistent complaint without objective evidence
- Unusual polysomnographical patterns: alpha-delta sleep

Source: Weilburg JB in Goroll et al Primary Care Medicine 3rd ed. Philadelphia Lippincott 1995: 1063

Causes of insomnia based on Primary and secondary causes

Primary sleep disorders	Secondary causes
stless leg $ Narcolepsy Primary insomnia	Anxiety Asthma CCF COPD Depression Fibromyalgia GORD Hyperthyroidism Menopause Pain Pruritus Urinary incontinence, Nocturia Drugs: Alcohol, Antidepressants, β blockers, Caffeine, Chemotherapy, Cimetidine, Diuretics, Herbal remedies, Nicotine, Phenytoin, Pseudoephedrine, Steroids, Stimulant laxatives, Theophylline

Initial Diagnostic work up

Find out more about the insomnia—

- Difficulty getting to sleep? (61%)
- Difficulty staying asleep, including early morning waking? (73%) more common in old age and excess alcohol use
- Poor sleep quality (48%)
- Check what effect the insomnia is having and has a vicious circle?

Look for a cause---

  - Ask about practical issues "Is there anything keeping you awake?"
  - Ask about the patient's sleep habits (daytime naps, eating or exercise immediately before trying to sleep)
  - Ask about the patient's mental state especially anxiety and depression
- Ask about drugs and excess caffeine use
- Ask about alcohol: When was the last time you had more than 5 drinks in a day (4 drinks for women)? Answer is within the last 3 months; the test is positive. sensitivity (85%) specificity (70%)
- Ask about physical illnesses-pain, breathlessness, nocturia, itchiness (to exclude CCF, COPD/asthma)
- Ask about specific sleep disorders- two screening questions for OSA: Do you habitually snore when asleep? Do you sometimes stop breathing when asleep?
- Ask about (Restless-leg-syndrome) screening question for RLS: are you kept awake by an uncontrolled urge to move their legs?
- Ask about practical issues: a snoring partner, noisy sounds
- Be reluctant to make a diagnosis of primary insomnia

PROPER WORKUP

History

- A careful clinical history, which systematically addresses the host of possible aetiologies of DIMS, is the key to the workup of insomnia.
- Close attention must be given to medication, drug, and food intake, current mental and physical status, past and family medical and psychiatric history, as well as occupational and travel patterns.
- Whenever possible, interviewing the spouse, bed partner, or family member is of great value.
- The use of a sleep log, or diary, which includes time in bed, estimate of time asleep, any awakenings, time of morning arousal, estimate of sleep quality, and comments on unusual events, recorded by the patient directly upon getting up each morning, should be standard procedure in every insomnia workup.
- Those who have a brief, time-limited disturbance or sleep related to stressful events in their lives also do not have "insomnia". The same pertains to the normal elderly patients who experience the decline in total sleep time, depth, and continuity which are a natural part or the aging process.
- **Psychiatric disorders** are believed by most experts to be the underlying cause of DIMS in about half of all insomnia cases.
  - Among the psychiatric aetiologies, the affective disorders – major depression and dysthymic disorder (mild depression, or the old "neurotic" depression) – account for approximately 50% of the cases. Patients suffering from dysthymic disorder typically complain of tired. They often feel irritable, have difficulty falling asleep and report that they cannot get enough sleep to feel rested. Sometimes they deny feeling or depressed and focus only on their physical complaints. Indeed, insomnia may be the major presenting complaint in many of these patients. Patients with major depression complain of either difficulty falling asleep or of waking in the early morning and being unable to return to sleep. /diurnal variation of mood is often noted.
  - Character disorders make up about 40$ of the other psychiatrically based DIMS. Patients with anxiety and obsessive disorders frequently have great difficulty falling asleep because they lie in

bed and ruminate. They have difficulty falling asleep because they focus on their lack of sleep as the source of all their troubles. They lie in bed, furiously trying to make themselves sleep. Such patients may use their insomnia as a justification for their inability to function or to improve their lives.

- Active psychosis of any type e.g. schizophrenia produces disturbed sleep and accounts for the other 10% of psychiatric insomnia. The other signs and symptoms of psychotic illness appear along with the insomnia, facilitating recognition of this problem.

- The remaining 50% of DIMS are non-psychiatrically based. Drug and alcohol abuse are responsible for about 10-15% of this group. Alcohol induces sedation, but the resulting sleep is often shallow, fragmented, and not restorative. Alcoholics can have prematurely "aged" sleep (i.e. shallow and short) during and for months after cessation of drinking. Sedatives, such as most benzodiazepines and especially barbiturates, and rebound anxiety prompt reuse, and tolerance a vicious cycle.
- Sedatives and alcohol depress respiratory function, which can lead to very poor-quality sleep in patients with sleep apnoea. Stimulant drugs such as amphetamine or methylphenidate, activating antidepressants such as phenelzine or protriptyline and the phenylpropanolamine found in many over-the-counter decongestants, cold and diet remedies can induce significant difficulty falling asleep. Terbutaline, aminophylline, and other anti-asthmatics can produce insomnia. The caffeine and stimulant xanthenes found in team coffee, cola drinks, and chocolate may produce difficulty falling asleep in most people if used in large enough quantities, and if used at all in some who are sensitive. Finally, the nicotine and other substances found in cigarette smoke have been shown to disrupt sleep induction and continuity.
- Medical problems of all types can cause insomnia and make up approximately 10% of all DIMS. Pain, of whatever source, is a frequent cause of insomnia in the elderly. Delirium is another frequent cause of insomnia in the elderly. Dementia, unrecognized infection, and even medication toxicity (sometimes secondary to the anti-cholinergic agents used to induce drowsiness in over-the-counter sleep remedies) are common source of delirium. Cardiovascular dysfunction leading to orthopnoea, paroxysmal nocturnal dyspnoea (PND), or nocturnal angina; chronic obstructive pulmonary disease; hyperthyroidism, and urinary frequency also can produce insomnia.
- Primary sleep disorders make up approximately 10-20% of DIMS. Ask the patients be partner for observations of cessation of respiration (sleep aponea) or twitching of legs (nocturnal myoclonus or restless legs syndrome). These produce poor quality sleep and lead to the complaint of "insomnia".

Physical Examination

- A full examination should be conducted to exclude medical causes of insomnia.
- The effects of alcoholism and addictive drugs if any should be noted.

Investigations

These will depend on the nature of medical problems detected.

Management

Treatment options:
Acute insomnia

Sleep onset difficulties:

1. Cognitive behavioral therapy (CBT): CBT has been shown to effectively treat insomnia over the long term and incorporates elements of stimulus control therapy, sleep restriction therapy and cognitive restructuring.

2. **Hypnotics** are considered safe and effective—new generation hypnotics-zolpidem, Ramelteon, Doxepin

Doses: Zolpidem 5 mg orally once daily at bedtime when required.
Zalepron 5-10 mg orally once daily
Eszopiclone 2-3 mg orally once daily
Ramelteon 8 mg orally once daily

Doxepin 3-6 mg orally once daily
Note: alprazolam, ativan, diazepam should not be used
3. first line---sleep hygiene and relaxation techniques including biofeedback.
Treat the secondary cause of insomnia

CBT for insomnia

(1) Stimulus Control Therapy (SCT)

1. lie down intending to go to sleep only when sleepy,
2. avoid any behavior in the bed or bedroom other than sleep or sexual activity,
3. leave the bedroom if awake for more than 15 minutes,
4. Return to the bed only when sleepy.

Items 3 and 4 are repeated as needed

(2) Sleep Restriction Therapy (SRT)

FIGURE 3.1. Sleep restriction.

(3) Sleep Hygiene Education

Relaxation Training

- This type of intervention may be most suitable for patients who characterize their insomnia as an "inability to relax" (e.g., the patient may say: "I feel like my heart is racing when I am trying to fall asleep"), and/or for patients who present with multiple somatic complaints (e.g., deep muscle pain, headaches, gastric problems, etc.).
- There are essentially four forms of relaxation therapy.
- Progressive muscle relaxation is used to diminish skeletal muscle tension.
- Diaphragmatic breathing is used to induce a form of respiration that is slower, deeper, and mechanically driven from the abdomen as opposed to the thorax. (It is interesting to note that this form of respiration resembles what occurs naturally at sleep onset.)
- Autogenic training focuses on increasing blood flow by having subjects imagine, in a systematic way, that each of their extremities feels warm.
- Imagery training entails the patient selecting a relaxing image or memory and evoking the image and engaging with it from a multisensory perspective

Therapeutic Recommendations

- If the DIMS is related to affective disorders, begin a sedating tricyclic antidepressant, such as amitriptyline 25mg, to be taken an hour before bedtime every night for at least a month. Increase the dose as needed.
- If the DIMS is related to anxiety or other personality disorder, offer psychiatric consultation and treatment, require close adherence to good sleep hygiene, If the insomnia persists and daytime anxiety is also a problem, begin therapy with a before-bed dose of flunazepam (15mg).
- If the DIMS is related to drugs, alcohol, or other substance use, clearly inform the patient that improvement is based on proper substance withdrawal and the maintenance of abstinence. Supervise withdrawal; support the patient's effort at maintaining abstinence. Try to avoid treating "dry" alcoholics with sedatives, as there may rekindle their drinking.

- Treat any underlying medical DIMS; a brief course of benzodiazepine therapy after treatment can re-establish the sleep pattern and boost patient confidence.
- Use reduced dose and caution when prescribing sedative for the elderly.
- Withdraw benzodiazepine therapy slowly in tapering fashion over 1-2 weeks to avoid.
- Rebound insomnia if drug therapy has been used daily for more than 6-8 weeks.
- Refer patients with primary sleep disorders, or those who are refractory to all efforts, for evaluation by a sleep laboratory.

Indications for referral

- Referral to a sleep laboratory if primary sleep disorder (sleep apnoea, or nocturnal myoclonus) is suspected, or careful workup fails to reveal the source of DIMS.
- Psychiatric consultation is indicated only when character problems interfere with diagnosis or management, or if the nature of a suspected mental or emotional problem is obscure.

Reference

1. Weilburg JB, Approach to the patient with insomnia. in: Goroll et al: Primary CAre Medicine 3rd ed. 1985; 1062-1066.
2. Fleming J A E & Warneboldt R B, Multiple Sleep Pathologies Presenting as Depression. Can Fam Physician 1990, 36:1185-9.
3. Diploma in Family Medicine module by Dr Win Lwin Thein.et., al, 2017
4. Michael L.Perlis et.al: Cognitive behavioral Treatment for insomonia, 1 st Ed.Springer,2005

19. MEDICALLY UNEXPLAINED PHYSICAL SYMPTOMS (MUPS)

Introduction

- In Myanmar, we come across so many patients brought to us together with a bunch of medical record books concerning with various specialist's consultations. For example, when a patient suffered from dizziness, he/she was concerned about stroke and directly came to neurologist.
- At the same time, he/she also suffered from chronic abdominal pain thereby went to gastroenterologist. And so on, he/she went to various specialists for various complaints. Thus, finally he/she came to Family physician's office with thick files of medical records.
- Actually, it is nothing but MUPS case. To work up this sort of problem efficiently in daily practice is a MUST competency which Myanmar Family Medicine doctors have.

Relevance to general practice/ family medicine:

Physical symptoms such as headache and dizziness prompt almost 50% of all primary care consultations.

- Shown to have organic origin in only 10-15% of patients followed up for 1 year
  - *Katon J Clin Psychiatry 1998;59 (supplement 20):15-21*
- Patient diagnosed with MUPs after appropriate assessment unlikely to show later evidence of underlying organic disease
- **Prevalence** of medically unexplained episodes in frequent attenders categorised by referral complaint (stratified by age). Figures are number of medically unexplained symptoms/number of referrals

Referral complaint	18-45 yrs	46-65 yrs
Abdominal pain/bowel habit	25/30	14/23
Pelvic pain	7/20	0/6
Headache	13/18	4/9
Back pain	14/19	15/23
Joint pain	4/21	6/39
Chest pain	25/31	15/52

Types of MUPS



Figure 1. List of functional somatic symptoms showing link to common factor and intermediate syndrome groupings (after Deary[24]).

Ref: BJGP March 2003

Functional somatic syndromes	
Medical specialty	Somatic syndromes
Gasteroenterology	Irritable bowel syndrome, functional dyspepsia
Gynaecology	Pre-menstrual syndrome, chronic pelvic pain
Rheumatology	Fibromyalgia
Cardiology	Atypical or non-cardiac chest pain
Respiratory medicine	Hyperventilation syndrome
Infectious disease	Chronic fatigue syndrome
Neurology	Tension headache, non-epileptic attacks, functional gait disorders
Dentistry	Temporomandibular joint dysfunction, atypical facial pain
ENT	Globus syndrome
Allergy medicine	Multiple chemical sensitivity

Ref:

Davidson's principles and practice of medicine 23rd edition Somatic fixation:

- It is a personal distress in the form of somatic and refused to believe that no organic disease is present.
- Somatic Fixation is unnecessary to avoid thick file $ or Fat envelope $.
- Symptomatic management is not enough.
- Fragmented care should be discouraged instead organized care or holistic care should be applied.
- Defragmentation is essential in FM. Holistic approach must be applied in such cases.

WORK UP

General management
General management principles for MUPS
• Take a full sympathetic history • Exclude disease but avoid unnecessary investigation or referral • Seek specific treatable psychiatric syndromes • Demonstrate to patients that you believe their complaints • Establish a collaborative relationship • Give a positive explanation for the symptoms, including but not over-emphasizing psychological factors • Encourage a return to normal functioning

1. The disorder should be treated as a chronic illness, with the focus on functioning rather than symptom cure.
2. Gradual change should be expected, with periods of improvement and relapse. Physicians should practice secondary prevention, especially of iatrogenic harm.
3. When new symptoms arise, at least a limited physical examination should be performed. However, invasive diagnostic and therapeutic procedures should be permitted only on the basis of objective evidence, not subjective complaints.
4. The need for unnecessary tests and procedures can be avoided by having the patient feel "known" by the physician.

Specific issues

Patient-Centered Care

- Feelings of illegitimacy by patients and common physician attitudes toward patients contribute to power differentials and struggles.
- These can be avoided by practicing the relational behaviors patients prefer from their providers.
- Physicians should speak with patients as equals, listen well, ask lots of questions, answer lots of questions,
- Explain things understandably, and allow patients to make decisions about their care. A collaborative relationship should be developed in which the physician works together with the patient to understand and manage patient problems.
- "Common ground" shared by the physician and the patient should be monitored and differences discussed.

Office Visits

- Regular, brief appointments should be scheduled, thus avoiding "as-needed" medications and office visits that make medical attention contingent on symptoms.
- Practical time-related strategies include negotiating and setting the agenda early in the visit, paying attention to the emotional agenda, listening actively rather than in a controlling manner, soliciting the patient's attributions for the problems, and communicating empathetically.

Psychosocial Issues

- Reassurance should be provided to the patient, but not too soon. Psychosocial questions should be interspersed with biomedical ones to explore all issues: physiologic, anatomic, social, family, and psychological.
- The physician should inquire about trauma and abuse. As trust builds, the patient should be encouraged to explore psychological issues that may be related to symptoms.
- In this way, symptoms can be linked to the patient's life and feelings. The term *stress* should not be overused. Eventually and subtly, patients are likely to reveal their personal side and concerns.

Family Involvement

- Family members should be invited to participate in patients' visits. An occasional family conference can be valuable.
- Each person's opinion about the illness and treatment can be solicited, and family members can be asked how family life would be different if the patient were without symptoms.
- Physicians should solicit and constantly return to the patient's and family's strengths and areas of competence.

Pharmacotherapy

- Because these patients may be extremely sensitive to side effects, psychopharmacologic agents generally, should not be used unless the patient has a demonstrated pharmacologically responsive mental disorder such as major depression, generalized anxiety disorder, panic disorder, or obsessive-compulsive disorder.
- Selective serotonin reuptake inhibitors (SSRIs), other nontricyclic antidepressants, and benzodiazepines are the medications most frequently used for coexisting psychiatric conditions. Treatment should be initiated at subtherapeutic doses and increased very gradually, as described elsewhere.
- Contrary to standard placebo effect-enhancing practice (i.e., enthusiastic recommendation of a medication), psychopharmacologic agents should be recommended with a degree of

pessimism, with the notion that it is unlikely to be very beneficial but may be worth a try. Hypochondriasis and body dysmorphic disorders are similar to obsessive-compulsive disorder and patients with these disorders may benefit directly from higher doses of SSRIs, if side effects are tolerated.

- Those with transitorily extreme dysmorphic concerns may benefit from temporary treatment with an atypical antipsychotic medication.

Consultation or Referral

- Involvement of a mental health clinician may be helpful to diagnose comorbid mental conditions, offer suggestions for psychotropic medications, and engage some patients in psychotherapy.
- However, patients are unlikely to see the value of consultation or may experience referral as an accusation that their symptoms are not authentic. Pressuring the patient to accept a consultation is unlikely to be effective and may render the consultant encounter unproductive.
- Trust must first be established and psychological issues must be made a legitimate subject for discussion.
- The idea of referral can be reintroduced later. When possible, it can be more effective to see the patient along with the mental health clinician so that a comprehensive approach continues to be emphasized, the patient does not feel abandoned, and doubts that the patient's concerns are not taken seriously are alleviated. Extreme distress or preoccupations worsening to delusional levels may require inpatient hospitalization.

Psychotherapeutic Interventions

- Standardized group or individual cognitive-behavioral therapies can be an effective treatment for chronic somatoform disorders, reducing somatic symptoms, distress, impairment, and medical care utilization and costs.
- Cognitive interventions train the patient to identify and restructure dysfunctional beliefs and assumptions about health.
- Behaviorally, the patient is encouraged to experiment with activities that are counter to usual practices, such as avoidance, "doctor shopping," or excess seeking of reassurance.
- In addition, patients learn relaxation and meditation techniques to manage symptoms of anxiety. With high emotional distress respond more rapidly to psychotherapy and patients able to at least partially attribute symptoms to psychological factors show better therapeutic outcomes than patients who firmly believe that their physical symptoms have a physical cause .

Reference:

1. Robert.E.Rakel et.al. Essential Family Medicine fundamentals and cases, 3rd Ed., 2006
2. Diploma in Family Medicine Module, by Dr Win Lwin Thein.,2017
3. Michael Bluminfield, Psychosomatic Medicine, Lipincott William & Wilkins, 2006.
4. Davidson's Principles and Practice of Medicine, 23rd Ed, Elsievier, 2018.

20. RED EYE

Relevance to general practice

- The red ye is the most common eye problem encountered by the primary care physician.
- Patients present with a wide range of conditions that are characterized by a red eye. Most are fortunately self-limiting or easily treatable conditions.
- There is a need to be alert for the occasional serious red eye.

Causes

These can be classified into lid or eye conditions and of gradual or sudden onset (see Table 1)

Table 1. Causes of the Red Eye

RED EYE OF GRADUAL ONSET

Conjunctivitis

- viral, bacterial or chlamydial conjunctivitis
- allergic conjunctivitis
- prolonged wearing of contact lens

Problems of the eye lid

- blepharitis
- stye
- Meibomian cyst, chalazion
- entropion and ectropion
- dacryocystitis or dacryoadenitis

Keratitis

- viral or bacterial keratitis
- marginal keratitis
- iritis and anterior uveitis
- episcleritis

RED EYE OF SUDDEN ONSET

- Spontaneous subconjunctival haemorrhage
- Foreign body
- Arc eye
- Acute glaucoma
- Blunt trauma
- Chemical burns

Source: Khunti K. Update Jun I, 1995:751 (Arranged in order of frequency as seen in general practice)

RED EYE OF GRADUAL ONSET

Conjunctivitis

- Conjunctivitis is the most common cause of a red eye.

Viral conjunctivitis

- Viral conjunctivitis is characterized by watery, sometimes mucoid discharge, often beginning in one eye but spreading to the other eye several days later.

- It may be associated with fever and pharyngitis particularly in children. Periauricular adenopathy is common.

Bacterial conjunctivitis

- Bacterial conjunctivitis is characterized by a mucopurulent discharge and usually occurs unilaterally without pre-auricular adenopathy. The eyelids have a thick crust on them after a night's sleep. Pneumococcus, streptococcus, staphylococcus and haemophilus are common causal agents.

Allergic conjunctivitis

- Allergic or atopic conjunctivitis is characterized by itching, tearing and redness of both eyes and may be associated with atopic dermatitis or vasomotor rhinitis.

Contact lens conjunctivitis

- This is common as the number of contact lens users are increasing, it is usually a bacterial conjunctivitis.

Chemical keratoconjunctivitis

- Chemical keratoconjunctivitis is a common industrial injury due to a splash of an irritant solution. The conjunctiva is uniformly red, the pupil constricted, vision decreased, the cornea may be hazy and the eye painful because of spasm of the iris. Alkaline solutions are more dangerous than acidic ones.

Malingering

- Occasionally the doctor may come across one who fakes a diseased red eye by rubbing his eye with irritant substances such tobacco. The eye is red and may have chemosis. The cue is that there is much tearing that is clear and not mucoid or purulent; however, allergic conjunctivitis can also appear like this.

Eyelid conditions

- Included are blepharitis, stye, meibomian abscess, chalazion, ectropion and entropion and orbital cellulitis.

Blepharitis

- Blepharitis is inflammation of the lid margin. In the mild squamous variety, skin scale and grease line the lid margin which is slightly inflamed. In the ulcerative variety, the lash follicles are inflamed and the lid margin is ulcerated.

Stye

- A stye is an inflamed lash follicle.

Meibomian abscess

- A meibomian abscess may form in a meibomian gland forming a visible swelling on the eyelid.

Chalazion

- After the acute inflammation in Meibomian gland has subsided, a Meibomian cyst may form. This is called a chalazion. Some may resolve spontaneously so some period of observation is in order.

Entropion and ectropion

- An entropion or ectropion can cause a red eye. Entropion may do so because of conjunctival and corneal irritation by in-turned lashes and ectropion because the everted conjunctiva and stagnant pool of teas become secondarily infected.

Keratitis and corneal ulcers

- Some conjunctivitis is associated with corneal involvement, There are many causes of keratitis and corneal ulcer: bacterial ulcers secondary to foreign body, blunt injury or contact lens wear, exposure secondary to facial palsy, thyrotoxic eye disease and herpes simplex infection.

Iritis and Uveitis

- There may be secondary to systemic disease or more likely, of unknown cause. One or both eyes may be affected. Photophobia and impaired vision are prominent complaints. There is ciliary injection, altered iris colour, smaller pupillary size with sluggish light response in the affected eye.

Episcleritis and scleritis

- Episcleritis is usually a benign inflammation of superficial episcleral vessels. Sometimes seen in association with collagen diseases, gout, allergic conditions and psoriasis.
- The patient complains of tender irritated eyes, the conjunctiva shows local raised areas of redness. Scleritis is inflammation of deeper layers of the sclera. In most cases no specific cause is found by it may occur as a feature of systemic lupus erythematosus, rheumatoid arthritis or polyarteritis nodosa.

RED EYE OF SUDDEN ONSET

Subconjunctival haemorrhage

- The cause is a rupture of subconjunctival vessels either spontaneously, or as the result of strain at stools or from coughing, often in an elderly person. In patients receiving anticoagulant medications, spontaneous subconjunctival haemorrhage may be a sign of overdose.

Foreign body

- Foreign body on the bulbar conjunctiva or under either upper or lower lid may result in copious tearing and conjunctival injection.

Acute glaucoma

- Acute glaucoma is an ocular emergency that presents as a painful, red eye with prominent ciliary flush. The patient reports cloudy vision, coloured rings around lights, unilateral headache, nausea and vomiting.

WORKUP

History

- The patient should be asked specifically about the onset and progression of the red eye. Key symptoms to ask are the presence if any, of visual impairment, discharge, pain, photophobia, grittiness and itch.
- A past history of eye problems and any recent injury or foreign body entry should be sought. The patient should be asked if any of the family is affected.

Physical examination

If the diagnosis is not obviously a lid problem, bilateral conjunctivitis or a subconjunctival haemorrhage, then a complete examination of the eye using a bright light is important. The distribution of the red eye should be noted.

- The lid margins should be inspected for crusting, ulceration, ectropion or entropion, and infection as well as localized lesions such as stye, dacryocystitis or dacryoadenitis. Bilateral eyelid oedema may be caused by an allergy.

- The upper and lower eyelids should be retracted to and the eye carefully examined to exclude any foreign bodies.
- The conjunctiva should be inspected for redness, ciliary flush and foreign body. The palpebral conjunctiva should not be overlooked.
- Corneal ulcer, hypopion and corneal opacity should be looked for.
- The pupil size should be checked. Abnormality is seen in iritis or glaucoma,
- If there is any suggestion of visual impairment or if there is any diagnostic doubt, it is essential to measure the visual acuity.
- Fundoscopy should be done if there is history of injury by a flying foreign body.

Table 2 summarises the chief features in differentiating conjunctivitis from iritis, keratitis and acute glaucoma.

Table 2. The Red Eye

Clinical features	Conjunctivitis	Iritis	Keratitis (corneal inflammation or foreign body	Acute glaucoma
Vision	Normal or intermittent blurring that clears on blinking	Slightly blurred	Slightly blurred	Marked blurring
Pain	None or minor and superficial	Moderately severe and aching	Sharp, severe, foreign body sensation	very severe, frequently nausea and vomiting
Photophobia	Nil	++	+	Nil
Discharge	Usually significant with crusting of eye lashes	None	None to mild	None
Pupil size	Normal	Constricted	Normal or constricted	Semi-dilated and fixed
Conjunctival injection	Diffuse	Circumcorneal	Circumcorneal	Diffuse with predominant circumcorneal
Cornea	Clear	Clear or slightly hazy	Opacification present; altered light reflex; positive fluorescein staining	Hazy; altered light reflex
Pupillary response to light	Normal	Minimal further constriction	Normal	Minimal or no reaction if dilated pupil
Anterior chamber dept	Normal	Normal	Normal	Shallow

Investigation

- For purulent discharges, culture and sensitivity should be done.

Management

The management if the patient general practitioner can provide symptomatic relief or specific treatment for the following:

- **Viral conjunctivitis** – hydrocortisone or betamethasone eye drops. Steroid eye drops are contraindicated if corneal ulcer is present; consider referring such patients to the ophthalmologist for further management.
- **Bacterial conjunctivitis** – antibiotic eye drops.
- **Allergic conjunctivitis** – antihistamine eye drops or mild steroid eye drops.
- **Contact lens conjunctivitis** – advice on proper care of the lens and avoid lens wear until conjunctivitis subside.
- **Stye, cellulitis, meibomian inflammation** – systemic antibiotics with or without incision and drainage may be necessary.
- **Superficial foreign body** – dislodging and removing this with moistened cotton bud may be tried initially for a very superficial foreign body.
- Removal of a lightly embedded foreign body may be attempted by the use of a syringe needle tip under good lighting if one is sufficiently experienced; if that fails the patient should be referred.

Indications for referral

- Red eye associated with eye pain, visual disturbance, signs of acute glaucoma or iritis should be referred immediately.
- Corneal ulcer – particularly, the dendritic ulcer should be regarded as an emergency.
- Gonococcal infection of the newborn is a serious potentially blinding condition which requires intensive treatment. It is characterized by profuse mucopurulent discharge.
- Foreign bodies and more than superficial eye injuries should also be immediately referred.
- A conjunctivitis that is not recovering after initial treatment of 2-3 days or even earlier; if in doubt, one should not hesitate to refer.

References

1. Khunti K. Eight-minute consultation: The red eye Update 1995 Jun: 751-752
2. Steinert RF. Evaluation of the red eye, in: Goroll et al. Primary Care Medicine, 3rd ed. Philadelphia Lippincott, 1995:956-960
3. Dobson PM, Harton RC, Inflammatory eye disease Update 1989, 1003-1008
4. Glasspool MG. Incision of eyelid cysts. Update 1989: 44-47.

CHAPTER (3) CARDIOVASCULAR PROBLEMS

Hypertension

Hyperlipidaemia

Angina

Acute Coronary Syndrome

Acute Pulmonary Oedemia

Atrial Fibrillation

Supraventricular Tachycardia

Bradycardia

Chronic Heart Failure

Rheumatic Fever (RF) and Rheumatic Heart Disease (RHD)

Deep Vein Thrombosis (DVT)

HYPERTENSION

SCOPE OF PROBLEM and related guidelines

- Hypertension is 4th leading risk factor of death and disability in Myanmar (GBD – Global Burden Study 2015)
- Most cases of hypertension are diagnosed and managed by General Practitioners
- Disease prevalence in Myanmar
    - Male – 24.7%, Female 28%, both sexes 26.4% (2014 WHO step survey Myanmar)
    - www.searo.who.int/myanmar/areas/ncd_steps_survey/en

Treatment Goals

The recommended target BP treatment levels BP <140/90 mmHg.
In fragile elderly individuals, the systolic BP goals should be adapted to individual tolerability.

Diagnosis of hypertension

Definition of hypertension at office

- Hypertension is defined as **persistent elevation** of systolic BP of 140 mmHg or greater and/or diastolic BP of 90 mmHg or greater in 3 visits within one week (at Office).
- If blood pressure measured in the clinic is 140/90 mmHg or higher, take a second measurement during the consultation. If the second measurement is also high, take a third measurement within one week.
- Exception: Patients with symptoms and target organ damage need frequent visits.

Definitions of hypertension in HBPM[7]

- BP 2 times in the morning (1 min apart) and 2 times in the evening (1 min apart) for 4 to 7 days. Discard 1st day readings. Average remaining measurements.
- Patients with an average BP ≥135/85 mmHg measured repeatedly at rest at home may be regarded as hypertensive.
- Home BP monitoring is an important tool in self-monitoring and self management.

Classification

Table 1. Classification of blood pressure (BP)

Category	Systolic BP	Diastolic BP
Normal BP	<120 mmHg and	<80 mmHg
Prehypertension	120 to 139 mmHg or	80 to 89 mmHg
Hypertension, Stage 1	140 to 159 mmHg or	90 to 99 mmHg
Hypertension, Stage 2	≥160 mmHg or	≥100 mmHg

Blood pressure measurement

Blood pressure measuring devices

- **Automatic digital blood pressure monitor (Preferable)**
- Manual blood pressure monitor (Sphygmomanometer)
- Aneroid sphygmomanometer (not acceptable)

Step (1) – properly prepare the patient

1. Have the patient relax, sitting in a chair (feet on floor, back supported) for >5 min.
2. The patient should avoid caffeine, exercise, and smoking for at least 30 min before measurement.
3. Ensure patient has emptied his/her bladder.
4. Neither the patient nor the observer should talk during the rest period or during the measurement.
5. Remove all clothing covering the location of cuff placement.
6. Measurements made while the patient is sitting or lying on an examining table do not fulfill these criteria.

Step (2) – use proper technique for BP measurements.

1. Use a BP measurement device that has been validated, and ensure that the device is calibrated periodically.
2. Support the patient's arm (e.g., resting on a desk).
3. Position the middle of the cuff on the patient's upper arm at the level of the right atrium (the midpoint of the sternum).
4. Use the correct cuff size, such that the bladder encircles 80% of the arm, and note if a larger- or smaller-than-normal cuff size is used
5. Either the stethoscope diaphragm or bell may be used for auscultatory readings.



Step (3) - Take the proper measurements needed for diagnosis and treatment of elevated BP/hypertension

1. At the first visit, record BP in both arms. Use the arm that gives the higher reading for subsequent readings.
2. Separate repeated measurements by 1–2 min.
3. For auscultatory determinations, use a palpated estimate of radial pulse obliteration pressure to estimate SBP. Inflate the cuff 20–30 mm Hg above this level for an auscultatory determination of the BP level.
4. For auscultatory readings, deflate the cuff pressure 2 mm Hg per second, and listen for Korotkoff sounds.

Step 4: Properly document accurate BP readings

1. Record SBP and DBP. If using the auscultatory technique, record SBP and DBP as onset of the first Korotkoff sound and disappearance of all Korotkoff sounds, respectively, using the nearest even number.
2. Note the time of most recent BP medication taken before measurements.

Step 5: Average the readings

- Use an average of ≥2 readings obtained on ≥2 occasions to estimate the individual's level of BP.

Step 6: Provide BP readings to patient

- Provide patients the SBP/DBP readings both verbally and in writing,

Causes of hypertension

- Primary Hypertension (90-95%)
- Secondary Hypertension (5-10%)

When to suspect secondary hypertension

- *Drug resistant/induced hypertension*
- *Abrupt onset of hypertension*
- *Onset of hypertension at 30 years*
- *Exacerbation of previously controlled hypertension*
- *Disproportionate target organ damage for degree of hypertension*
- *Accelerated or malignant hypertension*
- *Onset of diastolic hypertension in older adults (age >65 years)*
- *Unprovoked or excessive hypokalaemia*

Causes of secondary hypertension

- Common causes
  - Renal parenchyma disease (e.g. chronic kidney disease CKD)
  - Renovascular disease (e.g. renal artery stenosis)
  - Primary hyperaldosteronism
  - Obstructive sleep apnoea
  - Drug or alcohol induced*
- Uncommon causes
  - Phaeochromocytoma
  - Cushing's syndrome
  - Hypothyroidism, Hyperthyroidism
  - Primary hyperparathyroidism
  - Coarctation of aorta
  - Congenital adrenal hyperplasia
  - Mineralocorticoid excess syndrome other than primary aldosteronism
  - Acromegaly

** Several non-prescribed and illicit substances cause hypertension, e.g., licorice, cocaine, amphetamine, crystal methamphetamine, and 3,4- methylenedioxy-methamphetamine (MDMA, 'Ecstasy')*

Assessment of the Overall Cardiovascular Risk

Risk Assessment is obligatory

1. **Cardiovascular risk factors for atherosclerosis**

Non-modifiable	**Modifiable**
Age (men ≥55 years, women ≥65 years)	Sedentary lifestyle
family history of premature cardiovascular	Smoking
disease (men ≤55 years, women ≤65 years)	Poor dietary habits
	Abdominal obesity
	Level of SBP and DBP (Grade 1&2)
	Dysglycaemia
	Dyslipidaemia
	Stress
	Non-adherence

2. **Search for target organ damage**
   - **Cerebrovascular disease**
     - transient ischemic attack
     - ischemic or hemorrhagic stroke
   - **Hypertensive retinopathy**
   - **Left ventricular dysfunction**
   - **Left ventricular hypertrophy**
   - **Coronary artery disease**
     - myocardial infarction
     - angina pectoris
     - congestive heart failure
   - **Chronic kidney disease**
     - hypertensive nephropathy (eGFR <60 ml/min/1.73 m2)
     - albuminuria
   - **Peripheral artery disease**
     - intermittent claudication
3. **Search for exogenous potentially modifiable factors that can induce/aggravate hypertension**
   - Prescription Drugs:
     - NSAIDs, including coxibs
     - Corticosteroids and anabolic steroids
     - Oral contraceptive and sex hormones
     - Vasoconstricting/sympathomimetic decongestants
     - Calcineurin inhibitors (cyclosporin, tacrolimus)
     - Erythropoietin and analogues
     - Antidepressants: Monoamine oxidase inhibitors (MAOIs), SNRIs, SSRIs
   - Other:
     - Licorice root
     - Stimulants including cocaine
     - Salt
     - Excessive alcohol use

WHO/ISH risk assessment chart (see annex) could be used in cardiovascular risk assessment.

Routine Laboratory Tests

1. Random blood sugar
2. Standard 12-leads ECG
3. Urinalysis/Urine RE
4. Blood cholesterol (Lipid profile if available)
5. Creatinine (if available)

Treating high blood pressure[7]

Treatment goal

The recommended target BP treatment levels is:

1. BP < 140/90 mmHg

In fragile elderly individuals, the systolic BP goals should be adapted to individual tolerability.

Algorithm for treatment of hypertension



Non-pharmacological therapy (Lifestyle modification)

Table 2. Lifestyle Modification (LM)[7]

Modification	Recommendation	Approximate SBP Reduction (Range)**
Reduce weight	Maintain normal body weight (body mass index 18.5-24.9 kg/m^2)	5-20 mmHg/ 10Kg
Adopt DASH* eating plan	Consume a diet rich in fruits, vegetables, and low fat dairy products with a reduced content of saturated and total fat	8-14 mmHg
Lower sodium intake	a. Consume no more than 2,400 mg of sodium/day***; b. Further reduction of sodium intake to 1,500 mg/day is desirable since it is associated with even greater reduction in BP; and c. Reduce intake by at least 1,000 mg/day since that will lower BP, even if the desired daily sodium intake is not achieved;	2-8 mmHg
Physical activity	Engage in regular aerobic physical activity such as brisk walking (at least 30 min per day, most days of the week	4-9 mmHg
Moderation of alcohol consumption	Limit consumption to no more than 2 drinks (e.g., 24 oz beer, 10 oz wine, or 3 oz 80-proof whiskey) per day in most men, and to no more than1 drink per day in women and lighter weight persons	2-4 mmHg

**DASH, dietary approaches to stop hypertension*
***The effects of implementing these modifications are dose and time dependent, and could be greater for some individuals*
****2400 mg Sodium = 1 teaspoon (5-6 g table salt)*

Pharmacological treatment

Choice of antihypertensive drugs

The choice of antihypertensive drug should be tailored to the individual patient, taking into account the following factors, in addition to risk profile and cost:

1. Side effects
2. Drug-drug interactions
3. Patient preference

Non-compelling indication

Begin antihypertensive treatment with any one, or an appropriate combination of the four drug classes, namely:

1. Angiotensin-converting enzyme inhibitor (ACE inhibitor)
2. Angiotensin II receptor blocker (ARB)
3. Calcium-channel blocker (CCB)
4. Diuretic (thiazide, thiazide-like,)

Other classes of antihypertensive drugs, such as beta-blockers, methyldopa, hydralazine, and α-adrenergic receptor blockers (peripheral α-1 blockers such as prazosin, doxazosin; central α-2 blockers (like clonidine) may be used in combination treatment.

Table 3- Antihypertensive drugs information[7]

Drug Class	Agent of Choice	Comments
Diuretics	**HCTZ 12.5-50mg***, chlorthalidone* 12.5-25mg, indapamide 1.25-2.5mg* triamterene 100mg *K+ sparing* – spironolactone 25-50mg*, amiloride 5-10mg*, triamterene 100mg furosemide 20-80mg twice daily*, torsemide 10-40mg	Monitor for hypokalemia Most SE are metabolic in nature Most effective when combined w/ ACEI Stronger clinical evidence w/chlorthalidone Spironolactone - gynecomastia and hyperkalemia Loop diuretics may be needed
ACEI/ARB	*ACEI:* lisinopril, benazapril, fosinopril and quinapril 10-40mg, ramipril 5- 10mg*, trandolapril 2-8mg, Pernidopril 5-10mg* Enalapril 5mg* *ARB*: candesartan 8-32mg*, valsartan 80-320mg, losartan 50-100mg*, olmesartan 20-40mg*, telmisartan 20-80mg*	SE: Cough (ACEI only), angioedema (more with ACEI), hyperkalemia Losartan lowers uric acid levels; candesartan may prevent migraine headaches
β-Blockers	metoprolol succinate 50-100mg* and tartrate 50-100mg twice daily, nebivolol 5-10mg*, propranolol 40-120mg twice daily*, carvedilol 6.25-25mg twice daily*, bisoprolol 5-10mg, labetalol 100-300mg twice daily*,	Not first line agents – reserve for post-MI/CHF Cause fatigue and decreased heart rate Adversely affect glucose; mask hypoglycemic awareness
Calcium channel blockers	*Dihydropyridine*s: amlodipine 5-10mg*, nifedipine ER 30-90mg*, Felodipine 5-10mg* Cilnidipine 5-10 mg* *Non-dihydropyridine*s: diltiazem ER 180-360 mg*, verapamil 80-120mg 3 times daily or ER 240-480mg *	Cause edema; dihydropyridines may be safely combined w/ B-blocker Non-dihydropyridines reduce heart rate and proteinuria
Vasodilators	hydralazine 25-100mg twice daily, minoxidil 5-10mg terazosin 1-5mg*&, doxazosin 1-4mg* given at bedtime	Hydralazine and minoxidil may cause reflex tachycardia and fluid retention – usually require diuretic + B-blocker Alpha-blockers may cause orthostatic hypotension
Centrally-acting Agents	clonidine 0.1-0.2mg twice daily methyldopa 250-500mg twice daily* guanfacine 1-3mg	Clonidine available in weekly patch formulation for resistant hypertension

**Available in Myanmar*

Compelling Indication

Table 4. Compelling and possible indications, contraindications, and cautions for the major classes of antihypertensive drugs

Compelling and possible indications, contraindications, and cautions for the major classes of antihypertensive drugs				
Class of drug	**Compelling indications**	**Possible indications**	**Caution**	**Compelling contra-indications**
Alpha-blockers	Benign prostatic hypertrophy		Postural hypotension, heart failure	Urinary incontinence
ACE-inhibitors	Heart failure, LV dysfunction, post MI or established CVD, Type I diabetic nephropathy, 2^{o} stroke prevention	Chronic renal disease, Type II diabetic nephropathy, proteinuric renal disease	Renal impairment PVD	Pregnancy, renovascular disease
ARBs	ACE inhibitor-intolerance, Type II diabetic nephropathy, hypertension with LVH, heart failure in ACE-intolerant patients, post MI	LV dysfunction post MI, intolerance of other antihypertensive drugs, proteinuric renal disease, chronic renal disease, heart failure	Renal impairment PVD	Pregnancy, renovascular disease
Beta-blockers	MI, Angina	Heart failure	Heart failure, PVD, Diabetes (except with CHD)	Asthma/COPD, Heart block
CCBs (dihydropyridine)	Elderly, ISH	Angina	-	-
CCBs (rate limiting)	Angina	Elderly	Combination with beta-blockade	Heart block Heart failure
Thiazide/thiazide-like diuretics	Elderly ISH Heart failure 2 ^{o} stroke prevention			Gout

Combination Therapy

When blood pressure is more than 20 mmHg above systolic goal or 10 mmHg above diastolic goal or stage 2 hypertension, initial combinations of two drugs should be given.

*Start with the lowest effective dose, two-drug combinations may be either 2 separate drugs, or a fixed two-drug combination tablet.

Figure 2. Paring the major drug classes



ACE = angiotensin-converting enzyme.

- Green continuous lines: preferred combinations; green dashed line: useful combination (with some limitations); black dashed lines: possible but less well-tested combinations; red continuous line: not recommended combination.

Table 5. Evidence-Based Dosing for Antihypertensive Drugs available in Myanmar

Antihypertensive Medication	Initial Daily Dose, mg	Target Dose in RCTs Reviewed, mg	No. of Doses per Day
ACE inhibitors			
Enalapril	5	20	1-2
Ramipril	1.25, 2.5	10	1-2
Lisinopril	10	40	1
Perindopril	2,4,5	10	1
Angiotensin receptor blockers			
Candesartan	4	12-32	1
Losartan	50	100	1-2
Valsartan	40-80	160-320	1
Irbesartan	75	300	1
Telmisartan	20	160	1
β-Blockers			
Atenolol	25-50	100	1
Metoprolol (XL)	50	100-200	1-2
Bisoprolol	2.5	10	1
Carvedilol	3.125	25 BD	1
Calcium channel blockers			
Amlodipine	2.5	10	1
Diltiazem extended release	120-180	360	1
Nifedipine	10	20	1-2
Cilnidipine	2.5	10	1
Thiazide-type diuretics			
Chlorthalidone (Diruton)	12.5	12.5-25	1
Hydrochlorothiazide	12.5-25	25-100	1-2
Indapamide SR	1.25	1.25-2.5	1

Caution of using Antihypertensive drugs

Thiazide

Recheck creatinine and electrolytes 1 month after starting a thiazide then repeat annually.

- 30% is acceptable provided it remains <200 umol/1.
  If eGFR is <30 ml/min/1.73m^2, Frusemide 500mg is given and if eGFR>30 ml/min/1.73m^2, Thiazide is given.
  Older thiazide can lead to electrolyte imbalance and new Diabetes. New thiazide is lipid neutral.

Calcium-channel blockers (CCBS)

- Short-acting nifedipine is not recommended in hypertension because of the possibility of an increased risk of myocardial infarction in patients who have CHD.

ACE inhibitors and related drugs

Starting them:

- The first dose should be taken at night. Even then, first-dose hypotension due to once-daily agents may not occur until 6-8 hours after the first dose, and may last for 24 hours;
- Recheck serum creatinine and electrolytes after starting the drug, and after any dose increase, then annually.
- Use an angiotensin II receptor antagonist in patients who need an ACE inhibitor but cannot tolerate it because of cough.

β-blockers

- Warn the patient not to stop a beta-blocker suddenly, especially one without ISA (Intrinsic Sympathomimetic Activity) (e.g. atenolol)
- Atenolol cause new onset of Diabetes Mellitus
- Bisoprolol and Carvedilol are used more.

Primary Prevention of CVD in Hypertensive Patient

Aspirin

- Aspirin (75 mg/day) is recommended for all patients at high risk of developing CVD (20% risk over 10-years), provided the blood pressure is controlled to <150/90 mmHg.

Statin

- It is appropriate to initiate statin therapy in people with a 10-year CVD risk of 20% and type 1 diabetes and chronic kidney disease.

Table 6. Frequency of recommended tests/actions[5]

Recommended test/action	Recommended frequency
BP monitoring Risk level* • Low added risk • Medium to very high risk	 6 monthly to annually 3 to 6 monthly
BMI Fasting glucose Fasting lipid profile Serum electrolytes, urea, creatinine Urine-albumin measurement	Annually or more frequently, as per individual risk profile
ECG	As per individual risk and cardiac profile
Patient education Lifestyle modification and Medication adherence	At each visit

**Goal BP achieved.*

Annually* - Follow up visits can be adjusted according to patient condition and severity.

Lifestyle modification, medication adherence and patient education should be done depending on clinical judgment.

Follow up and Monitoring

Once antihypertensive drug therapy is initiated, most patients should return for follow up and adjustment of medications at approximately monthly intervals until the BP goal is reached. More frequent visits will be necessary for patients with stage 2 hypertension or with complicating co morbid conditions.

- Serum potassium and creatinine should be monitored at least 1–2 times/year.
- After BP is at goal and stable, follow up visits can usually be at 3- to 6-month intervals.
- Comorbidities, such as heart failure, associated diseases such as diabetes, and the need for laboratory tests influence the frequency of visits.
- If not at goal, 1 month interval. Other cardiovascular risk factors should be treated to their respective goals, and tobacco avoidance should be promoted vigorously.

Antihypertensive Medication Adherence Strategies

1. In adults with hypertension, dosing of antihypertensive medication **once daily** rather than multiple times daily is beneficial to improve adherence
2. **Use of combination pills** rather than free individual components can be useful to improve adherence to antihypertensive therapy

Referral

1. Conditions needing *emergency or urgent treatment*, e.g. malignant hypertension, hypertensive heart failure, or other impending complications
2. Hypertension that is *difficult to manage*, e.g. unusually labile BP, or hypertension refractory to multiple drugs in different pharmacological classes
3. *Secondary hypertension*, i.e. hypertension due to an underlying cause, such as hyperaldosteronism
4. Hypertension in *special circumstances*, e.g. pregnancy, and young children.

Treating blood pressure in special conditions[5]

Table 7. Antihypertensive therapy in Diabetes mellitus

Diabetes mellitus with nephropathy (130/80)		
Initial Therapy	***2nd line therapy***	***Notes &/or cautions***
ACEIs or ARBs	Addition of thiazide diuretics, cardio-selective β blockers, long-acting CCBs	A loop diuretic in the place of low-dose thiazide if serum Cr is >15umol/L & volume control is required
Diabetes mellitus without nephropathy (140/90)		
ACEIs, ARBs, dihydropyridine CCBs or thiazide diuretics	Combinatio0n of 1st line drugs or (if 1st line drugs intolerant) addition of cardio-selective β blockers &/or long acting non-dihydropyridine CCBs	Normal ACR <2.0mg/mmol in men and <2.8mg/mmol in women Combination of ACEI with ARB – not recommended.

Table 8. Antihypertensive therapy in non-diabetic chronic kidney disease

Target <130/80 mmHg		
Initial therapy	***2nd line therapy***	***Notes &/or cautions***
ACEIs (or ARBs if ACEI intolerant) if there is proteinuria.	Combinations of additional agents	Avoid ACEIs or ARB if bilateral renal artery stenosis or unilateral disease with solitary kidney.

Thiazide diuretics as additional therapy		Careful monitoring of serum Cr & K+ in ACEI or ARB treatments. Combinations of ACEIs or ARB – not recommended without proteinuria

Table 9. Antihypertensive therapy in Ischaemic Heart Disease

Target <140/90 mmHg		
Initial therapy	***2nd line therapy***	***Notes &/or cautions***
Coronary Artery Disease		
ACEIs β blockers for stable angina	Long acting CCBs	Avoid short acting nifedipine. Combination of ACEI with ARB – not recommended without co-existing systolic heart failure.
Recent ST-elevation MI or Non ST-elevation MI		
β blockers & ACEIs (ARBs if ACEIs intolerant)	Long acting CCBs in post-MI when β -blockers are contraindicated or not effective.	Avoid non-dihydropyridine CCBs (Diltiazem, Verapamil) in heart failure with pulmonary congestion.

Table 10. Antihypertensive therapy in Heart failure

Target <140/90 mmHg		
Initial therapy	***2nd line therapy***	***Notes &/or cautions***
ACEIs (ARBs if ACEIs intolerant) & b-blockers namely carvedilol; metoprolol-XL; bisoprolol; spironolactone in patients with NYHA class III or IV symptoms B blockers for stable angina	Hydralizine/isosorbide dinitrate combination (ACEIs or ARBs is CI or intolerant) Thiazide or loop diuretic as additive therapy	Titrate doses of ACEI & ARB to those used in clinical trials. Avoid non-dihydropyridine CCBs (Diltiazem, Verapamil) Careful monitor K^{++} and renal function if combining ACEI with ARB

HYPERTENSION IN PREGNANCY

Table 11. Pregnancy with either pre-existing or gestational hypertension

For severe hypertension		
Target <160/110mmHg		
Initial therapy	***2nd line therapy***	***Notes &/or cautions***
Labetalol Nifedipine capsules Nifedipine PA tablets or Hydralazine	Long acting CCBs	Continuous FHR monitoring until BP is stable.
For non-severe hypertension		
Without comorbid conditions: Target <130/80-105 mmHg *With comorbid conditions:* Target <130-139/80-89 mmHg		
Methyldopa Labetalol Other β-blockers CCBs		ACEIs & ARBs – should not be used. Atenolol & prazosin – no recommended.

STROKE

- Where systolic BP is above 140 mmHg but below 220 mmHg within the first two weeks of onset of acute ischaemic stroke, lowering of high BP should be based on individual clinical judgment after careful consideration of all the contraindications.
- Use any of the first line pharmacological classes of antihypertensive drugs for stroke prevention in patients after the acute phase of stroke, provided that the BP is effectively lowered

ANTIHYPERTENSIVE THERAPY IN THE ELDERLY

- Highly beneficial in giving Indapamide for systolic hypertension
- No significant difference in lowering BP & CV protection between younger & elderly patients (>65 years)
- Therefore, no drug of choice guided by age. Thiazide diuretics, ACEIs, Ca^{++} antagonists, angiotensin receptor antagonists, & β-blockers can be considered. Drug treatment can be initiated on SBP >140 mmHg. Target SBP <140mmHg.

Management of OSA-related hypertension[11]

- OSA-related hypertension is characterized by nocturnal hypertension, marked BP variability, and a non-dipping pattern of nighttime BP, all of which are important cardiovascular risk factors.
- Lifestyle changes including weight reduction, avoidance of alcohol intake, increase in physical activity, and smoking cessation are an integral part of the management of all patients with OSA.
- CPAP and antihypertensive therapy have limited effects on BP in patients with OSA and hypertension. Renal sympathetic denervation (RDN) seems to be an effective and promising intervention for the permanent control of BP in patients with OSA, especially those with resistant hypertension.

COVID-19 and hypertension[11]

- Almost all available evidence suggests that hypertension increases the risk of severe COVID-19, defined as admission to intensive care, clinically defined severity or a combination of these; or mortality.
- Concerns regarding use of angiotensin-converting enzyme inhibitors (ACEIs) in these patients were raised due to identification of angiotensin-converting enzyme 2 (ACE2), the monocarboxy-peptidase that inactivates angiotensin II and thereby counters the activation of the classic renin–angiotensin–aldosterone system (RAAS), as the functional receptor for the severe acute respiratory syndrome coronavirus 2.
- The WHO conducted a rapid review of evidence related to the use ACEIs or ARBs in COVID patients which identified 11 observational studies. No studies were found that were designed to directly assess whether ACEIs or ARBs increase the risk of acquiring COVID-19. Discontinuation of ACEIs or ARBs may yield worse outcomes than continuation of their use in patients with a diagnosis of COVID-19.
- In contrast to the uncertainty about the potential benefit of initiating RAAS blocker use in patients with COVID-19, there is a clear potential for harm in withdrawing these agents in high-risk COVID-19 patients with established myocardial injury, HTN or heart failure. Most of the world's professional societies either recommend or strongly encourage continuing ACEIs/ ARBs

in COVID-19- infected patients

Resistant Hypertension: Diagnosis, Evaluation, and Treatment[2]

Confirm treatment resistance

1) Office SBP/DBP ≥130/80 mmHg and Patient prescribed ≥3 antihypertensive medications at optimal doses, including a diuretic, if possible or
2) Office SBP/DBP <130/80 mmHg but patient requires ≥4 antihypertensive medications

↓

Exclude pseudo-resistance
Ensure accurate office BP measurements
Assess for nonadherence with prescribed regimen
Obtain home, work, or ambulatory BP readings to exclude white coat effect

↓

Identify and reverse contributing lifestyle factors
(Obesity, Physical inactivity, Excessive alcohol ingestion, High-salt, low-fiber diet)

↓

Discontinue or minimize interfering substances – NSAIDs, Sympathomimetic
(e.g., amphetamines, decongestants) Stimulants, Oral contraceptives, Licorice Ephedra

↓

Screen for secondary causes of hypertension
Primary aldosteronism (low serum K+, elevated aldosterone/renin ratio)
CKD (eGFR <60 mL/min/1.73 m2)
Renal artery stenosis (young female, known atherosclerotic disease, worsening kidney function)
Pheochromocytoma (episodic hypertension, palpitations, diaphoresis, headache)
Obstructive sleep apnea (snoring, witnessed apnea, excessive daytime sleepiness)

↓

Treat accordingly or Refer to specialist
Refer to appropriate specialist for known or suspected secondary cause(s) of hypertension
Refer to hypertension specialist if BP remains uncontrolled after 6 months of treatment

HYPERTENSIVE EMERGENCIES AND URGENCY

Definition:

Hypertensive emergency: Marked hypertension with rapid progression of acute organ damage such as the brain, heart, kidney and large vessels.

Hypertensive urgency: Marked hypertension with no rapid progression of acute organ damage ≥180/120 mmHg

Hypertensive emergencies are

1. Accelerated-malignant hypertension with papilloedema
2. Hypertensive encephalopathy
3. Severe hypertension associated with acute organ damage
    - Atherothrombotic brain infarction
    - Brain hemorrhage
    - Subarachnoid hemorrhage
    - Head trauma
    - Acute aortic dissection
    - Acute LVF
    - Acute coronary syndrome
    - Acute or rapidly progressive renal failure
4. Severe hypertension after thrombolytic therapy for brain infarction
5. Excess circulating catecholamines
    - Interactions of MAOI with foods or drugs
    - Use of sympathomimetic drugs
    - Rebound hypertension after sudden cessation of antihypertensive drugs
    - Automatic hyperreflexia after spinal cord injury
6. Eclampsia
7. Hypertensive emergencies related to surgery
    - Severe hypertension in patients requiring emergency surgery
    - Postoperative hypertension
    - Postoperative bleeding from vascular suture lines
8. Hypertension after coronary bypass surgery
9. Severe body burns
10. Severe epistaxis

Principles of treatment

Hypertensive urgency

- BP control by oral medication
- Treatment-resistance-case should be referred to a specialist.

Hypertensive emergency

- Prompt diagnosis & immediate referral
- Hospitalization
- Target BP reduction: not >25% during the first 1 hour
    - **(SUBLINGUAL NIFEDIPINE IS CONTRAINDICATED)**
- To a BP level of 160/100–110 mmHg within the next 2–6 hours

Clinical quality improvement

The recommended target BP levels in antihypertensive treatment are

- Below 140/90 mmHg in patients*
- In elderly patients with good physical and mental status, if treatment is well tolerated.
- The greater the total cardiovascular disease risk, the more rigorously the BP should be controlled.
- The BP level attainable with treatment is influenced by medication side effects and other co-morbidities, such as diabetes, chronic kidney disease, CAD and cerebrovascular disease.
- Good clinical judgment should therefore be exercised for every patient.

Summary

- This guideline is to reflect and modify the current practice which is mainly based on targeting numbers rather than risks, hence this guideline should emphasize more on CVD risks including numbers.

References:

1. *www.searo.who.int/myanmar/areas/y.pdf*
2. *2017ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults*
3. *Manual on Hypertension, CVD project, WHO-MOHS*
4. *MOH Clinical Practice Guidelines on Hypertension 1/2017(Singapore)*
5. *Clinical Practice Guidelines on Management of Hypertension (Malaysia)*
6. *JNC 7 Hypertension Guideline*
7. *JNC 8 Hypertension Guideline*
8. *CHEPP, Hypertension Canada*
9. *Alex Khot, Andrew Polmear-Practical General Practice -Guides for effective Clinical Management*
10. *WHO/ISH risk prediction chart*
11. *LOTHIAN HYPERTENSION GUIDELINES 2022*

Annex

Annex 1: WHO/ISH Risk prediction charts [8]

WHO/ISH Risk prediction charts for SERA D.10-year risk of a fatal or non-fatal cardiovascular events by gender, age, systolic blood pressure, total blood cholesterol, smoking status and presence or absence of diabetes mellitus



This chart can only be used for countries of the WHO Region of South-East Asia, Sub-region D, in settings where blood cholesterol can be measured.

Annex 2: WHO/ISH Risk prediction charts[8]

WHO/ISH Risk prediction charts for SERA D.10-year risk of a fatal or non-fatal cardiovascular event by gender, age, systolic blood pressure, smoking status and presence or absence of diabetes mellitus

Risk Level <10% 10% to <20% 20% to <30% 30% to <40% ≥40%





This chart can only be used for countries of the WHO Region of South-East Asia, Sub-region D, in settings where blood cholesterol CANNOT be measured.

- Instructions on how to use WHO/ISH (World Health Organization/International Society of hypertension) risk prediction charts
- The charts provide approximate estimates of cardiovascular disease (CVD) risk in people who do not have established coronary heart disease, stroke or other atherosclerotic disease. They are useful as tools to help identify those at high cardiovascular risk, and to motivate patients, particularly to change behaviour and, when appropriate, to take antihypertensive, lipid-lowering drugs and aspirin.

How do you use the charts to assess cardiovascular risk?

First make sure that you select the appropriate charts using information

- If blood cholesterol cannot be measured due to resource limitations, use the charts that do not have total cholesterol
- Before applying the chart to estimate the 10-year cardiovascular risk of an individual, the following information is necessary
    - Presence or absence of diabetes1
    - Gender
    - Smoker or non-smoker
    - Age
    - Systolic blood pressure2
    - Total blood cholesterol (if in mg/dl divide by 38 to convert to mmol/l)
- Once the above information is available proceed to estimate the 10-years cardiovascular risk as follows.

Step 1 Select the appropriate chart depending on the presence or absence of diabetes1
Step 2 Select male or female tables
Step 3 Select smoker or non-smoker boxes3
Step 4 Select age group box (if age is 50-59 years select 50, if 60-69 years select 60 etc)
Step 5 Within this box find the nearest cell where the individuals systolic blood pressure (mm Hg) and total blood cholesterol level (mmol/l) 4 cross. The colour of this cell determines the 10-year cardiovascular risk.

---

1. *A person who has diabetes is defined as someone taking insulin or oral hypoglycaemic drugs, or with a fasting plasma glucose concentration above 7.0 mmol/l (126 mg/dl) or a postprandial (approximately 2 hours after a main meal) plasma glucose concentration above 11.0 mmol/l (200 mg/l)on two separate occasions). For very low resource settings urine sugar test may be used to screen for diabetes if blood glucose assay is not feasible. If urine sugar test is positive a confirmatory blood glucose test need to be arranged to diagnose diabetes mellitus.*

2. *Systolic blood pressure, taken as the mean of two readings on each of two occasions, is sufficient for assessing risk but not for establishing a pretreatment baseline.*

3. *All current smokers and those who quit smoking less than 1 year before the assessment are considered smokers for assessing cardiovascular risk.*

4. *The mean of two non-fasting measurements of serum cholesterol by dry chemistry, or one non-fasting laboratory measurement, is sufficient for assessing risk.*

Practice points

Please note that CVD risk may be higher than indicated by the charts in the presence of the following:

- already on antihypertensive therapy
- premature menopause
- approaching the next age category or systolic blood pressure category
- obesity (including central obesity);
- sedentary lifestyle;
- family history of premature coronary heart disease (CHD) or stroke in first degree relative (male

< 55 years, female < 65 years);

- raised triglyceride level (>2.0 mmol/l or 180 mg/dl);
- low HDL (high density lipoprotein) cholesterol level (< 1 mmol/l or 40mg/dl in males, <1.3 mmol/l or 50 mg/dl in females);
- raised levels of C-reactive protein, fibrinogen, homocysteine, apolipoprotein B or Lp(a), or fasting glycaemia, or impaired glucose tolerance;
- microalbuminuria (increases the 5-year risk of diabetics by about 5%);
- raised pulse rate.
- socioeconomic deprivation

Risk levels

- The colour of the cell indicates the 10-year risk of combined myocardial infarction and stroke risk (fatal and non-fatal) as shown below.

10-year combined myocardial infarction and stroke risk (fatal and non-fatal)

- Green <10%
- Yellow 10% to <20%
- Orange 20% to <30%
- Red 30% to <40%
- Deep Red > 40%

HYPERLIPIDAEMIA

Definition:

- Dyslipidaemia is the presence of an abnormal lipid/lipoprotein profile in the serum and can be classified as:
  - Predominant hypertriglyceridaemia
  - Predominant hypercholestrolaemia
  - Mixed pattern with elevation of both cholesterol and triglyceride (TG)
- Average cholesterol level in a population is a predictor of CVD risk and dependent on diet but, on an individual level, it is a much poorer predictor.
- Lowering LDL and raising HDL decrease progression of coronary atherosclerosis—whatever the age of the patient—and is a valuable tool for both primary and secondary prevention of CVD.

CHOLESTEROL

- Fatty substance manufactured by the body (mainly liver) which plays a vital role in functioning of cell membranes. Total plasma cholesterol consists of:
  - LDL (low-density lipoprotein) cholesterol: High levels are associated with increased risk CVD
  - HDL (high-density lipoprotein) cholesterol: Low levels are associated with increased risk CVD
  - Triglycerides (TGs): Independent risk factor for CVD. If >5 mmol/L, refer for specialist opinion
  - Ratio of total cholesterol: HDL used to predict risk. No threshold—the higher the ratio, the greater the risk. High risk if ≥6

SECONDARY HYPERLIPIDAEMIA

Conditions associated with secondary hyperlipidaemia include:

Drugs: • Steroids • β-blockers • Thiazides • COC pill • Isotretinoin • Antipsychotics • Tamoxifen • Antiretrovirals	• Obesity • DM* • Excess alcohol • Smoking (lowers HDL) • Pregnancy • Hypothyroidism** • Renal failure • Nephrotic syndrome • RA/SLE	• HIV • Cholestasis • Cushing's syndrome • Porphyria • Myeloma • Lipodystrophies • Glycogen storage disease

** Treatment of hyperglycaemia in DM decreases secondary hyperlipidaemia.*

*** Patients with hypothyroidism should receive adequate thyroid replacement before assessing need for lipid-lowering treatment. Correction of hypothyroidism may resolve the lipid abnormality, and untreated hypothyroidism increase risk of myositis with statins.*

DIAGNOSIS

Measure Plasma Lipids

- Total cholesterol (TC)
- High-density lipoprotein cholesterol (HDL-C)
- Non-HDL-C: TC - HDL-C

- Triglycerides (TG)
- Low-density lipoprotein cholesterol (LDL-C) is derived by Friedewald formula: LDL-C (mmol/L) = TC - HDL-C - [TG x 0.45] or LDL-C (mg/dL) = TC - HDL-C - [TG x 0.2]

Considerations

- Fasting or a non-fasting plasma lipid profile can be used in screening and in risk estimation
- Non-fasting samples can be used to document baseline lipid levels before initiation of statin therapy in patients with clinical atherosclerotic cardiovascular disease (ASCVD)
- Fasting lipid profile is recommended for initial evaluation in patients with a family history of premature ASCVD, genetic hyperlipidemia or for follow-up of patients with hypertriglyceridemia
- TC and HDL-C can be measured accurately at any time of the day
- TG levels are affected by food resulting to a higher plasma level of about 0.3 mmol/L (27 mg/dL), by alcohol intake within 24 hours prior to measurement and by smoking during the fasting state.
- Non-HDL cholesterol can be computed even from a non-fasting lipid profile

Dyslipidemia Screening

- More frequent assessments are needed for all patients with cardiovascular disease (CVD) risk factors and those with a family history of premature CVD (definite myocardial infarction or sudden death prior to age 55 years in father or other male 1st-degree relative, or before age 65 years in mother or other female 1st-degree relative)
- Women should be screened in the same way as men
- Adults >65 Years of Age
    - Evaluate annually those with 0-1 cardiovascular disease risk factor
- Adult with Diabetes Mellitus (DM)
    - All adult patients with diabetes mellitus should be screened annually for dyslipidemia

Dyslipidemia Screening Tests

- Fasting Lipid Profile
    - Used to ensure that the most accurate lipid assessment is achieved
- For lipid screening, both fasting and non-fasting specimens may be utilized
    - Includes plasma or serum TC, LDL-C, HDL-C and TG

LDL-C

- Recommended as the primary lipid analysis method for screening, diagnosis and management of dyslipidemia
- Direct measurement of LDL-C in certain high-risk patients (eg patients with diabetes mellitus, vascular disease, fasting TG level >2.9 mmol/L or >250 mg/dL) is recommended.
- Estimation by Friedewald equation is valid only for values obtained in the fasting state, and is largely inaccurate in TG levels >2.3 mmol/L (>200 mg/dL) and is invalid when TG levels are >4.5 mmol/L (>400 mg/dL)

HDL-C

- HDL-C >1.6 mmol/L (>60 mg/dL) is an independent negative risk factor for dyslipidemia in both sexes.
- In women, very low HDL-C (<1.03 mmol/L or <40 mg/dL) is an independent risk factor for development of cardiovascular disease and mortality, even in the presence of normal LDL-C and/or TG levels or TC level <5.2 mmol/L (<200 mg/dL)
- Women with low HDL-C have a cardiovascular disease risk elevated to almost 3-fold (as compared with women with high HDL-C)
- Considered as an alternative risk marker, especially in combined hyperlipidemias, diabetes, metabolic syndrome or chronic kidney disease (CKD)

Non-HDL-C (TC minus HDL-C)

- In patients with moderately increased TG (2.3-5.6 mmol/L or 200-500 mg/dL), diabetes mellitus and/or established cardiovascular disease, or if insulin resistance is suspected, measure non-HDL-C
- Provides a better risk assessment than LDL-C alone in patients with moderately elevated TG
- Shows the total atherogenic burden including particles contained within VLDL, intermediate-density lipoproteins (IDL), LDL, chylomicron remnants and lipoprotein(a) [Lp(a)]
- Can be considered as an additional therapeutic target for residual CV risk reduction after the LDL-C has been reached

Triglycerides

- TG levels >1.7 mmol/L (>150 mg/dL) may help identify those at risk for insulin resistance syndrome.
- TG levels ≥2.3 mmol/L (≥200 mg/dL) may point to a significant increase in the risk for cardiovascular disease.
- Very high triglyceride level is associated with increased risk of pancreatitis.

Apolipoprotein B

- Target apo B level to <90 mg/dL (<0.9 g/L) for those at risk of cardiovascular disease (including those with diabetes mellitus)
- Target apo B level to <80 mg/dL (<0.8 g/L) for those with established cardiovascular disease or those with diabetes mellitus who have ≥1 additional risk factors
- May help evaluate the success of LDL-C lowering therapy
- Can be considered as an additional therapeutic target to further reduce CV event in individuals on statin therapy who have achieved their LDL-C goal
- Recommended for risk assessment in patients with high TG levels, DM, obesity, metabolic syndrome or very low LDL-C levels
- Considered as an alternative risk marker, especially in combined hyperlipidemias, diabetes, metabolic syndrome or chronic kidney disease
- Apo B and/or Apo B/Apo A1 ratio calculation and evaluation in patients with TG ≥150, HDL-C <40, prior atherosclerotic cardiovascular disease (ASCVD) event, type 2 diabetes mellitus, and/or insulin resistance syndrome may help in determining the best treatment strategy
- Apo B reflects LDL particle number and is considered a more potent measure of cardiovascular disease risk as compared with LDL-C and LDL particle size
- Measurement of Apo B-100 provides a more accurate evaluation of atherogenicity since all atherogenic particles (VLDL, IDL, LDL) contain 1 Apo B-100 molecule

Lipoprotein(a) [Lp(a)]

- A LDL particle with an Apo(a) moiety that has pro-atherogenic effects attributed to its pro-coagulant and pro-inflammatory effects
- Should be measured at least once in a person's lifetime to identify people who have inherited an elevated Lp(a) level of ≥430 nmol/L (≥180 mg/dL) and have a very high lifetime risk of ASCVD
- Should be considered in patients with an estimated 10-year risk of ASCVD that is near the threshold between high and moderate risk

Risk Stratification

- Evaluation of lipid profile must be performed in parallel with risk assessment for cardiovascular disease
    - LDL-C is used as primary lipid analysis for screening and risk estimation
    - ASCVD risk assessment is not necessary in secondary prevention, in individuals with LDL-C ≥190 mg/dL, or in those 40-75 years old with diabetes mellitus
    - SCORE can be used in different populations when recalibrated by adjusting for secular changes in CVD mortality and risk factor prevalence

- Identify patients with established cardiovascular disease or with cardiovascular disease risk equivalents: Diabetes mellitus, peripheral artery disease (PAD) or abdominal aortic aneurysm
- Major independent risk factors for cardiovascular disease
    - Cigarette smoking
    - Hypertension (elevated blood pressure or on antihypertensive medication)
        - History of preeclampsia or pregnancy-induced hypertension in women
    - Low HDL cholesterol (<40 mg/dL)
    - Increased total serum cholesterol level
    - Increased non-HDL-cholesterol levels
    - Increased LDL-cholesterol levels (≥190 mg/dL)
    - Family history of premature atherosclerotic cardiovascular disease (male 1st-degree relative <55 years; female 1st-degree relative <65 years)
    - Age (men ≥45 years; women ≥55 years)
    - CKD stage 3/4
    - Diabetes mellitus
        - For individuals with high HDL cholesterol (>60 mg/dL), subtract 1 risk factor from the total
    - History of gestational diabetes in women
- Additional risk factors
    - Dyslipidemic triad (hypertriglyceridemia, low HDL-C and excess of small, dense LDL)
    - Obesity, abdominal obesity
    - Elevated apo B
    - Elevated LDL particle number
    - Fasting/postprandial hypertriglyceridemia
    - Family history of hyperlipidemia
    - Polycystic ovarian syndrome (PCOS) in women
    - Elevated small, dense LDL-C
    - Microalbuminuria/proteinuria
    - History of premature menopause
    - South Asian ancestry
- Nontraditional risk factors
    - Elevated lipoprotein (a)
    - Elevated clotting factors
    - Elevated inflammation markers
    - Elevated triglyceride-rich remnants
    - Elevated homocysteine levels
    - Apo E4 isoform
    - Elevated uric acid

CARDIOVASCULAR DISEASE RISK CATEGORIES			
Risk Category	**ACC/AHA 2019**	**ESC 2021**	
	10-Year ASCVD Risk[1]	**Apparently Healthy Individuals[2]**	**Patients with Risk Factors**
Very High Risk	No recommendation	• <50 years: ≥7.5% • 50-69 years: ≥10% • ≥70 years: ≥15%	• Documented clinical ASCVD (eg previous acute myocardial infarction, acute coronary syndrome, coronary revascularization and other arterial revascularization procedures, TIA and stroke, aortic aneurysm and PAD) or unequivocally documented

			ASCVD finding (eg significant plaque) on imaging that does not include some increase in continuous imaging parameters (eg intima-media thickness of the carotid artery) • T2DM with established ASCVD and/or severe target organ damage (TOD)[3] • Without diabetes or ASCVD but with severe CKD [estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m^2] or eGFR 30-44 mL/min/1.73 m^2 and albumin-to-creatinine ratio (ACR) >30
High Risk	≥20%	• <50 years: 2.5-<7.5% • 50-69 years: 5-<10% • ≥70 years: 7.5-<15%	• T2DM without ASCVD and/or severe TOD with moderate risk criteria not met[3] • Without diabetes or ASCVD but with moderate CKD (eGFR 30-44 mL/min/1.73 m^2) and ACR <30 or eGFR 45-59 mL/min/1.73 m^2 and ACR 30-300 or eGFR ≥60 mL/min/1.73 m^2 and ACR >300 • Familial hypercholesterolemia associated with markedly increased levels of cholesterol
Moderate Risk	No recommendation	• <50 years: <2.5% • 50-69 years: <5% • ≥70 years: <7.5%	• Patients with <10-years of well-controlled T2DM without TOD or other ASCVD risk factors[3]
Intermediate Risk	7.5% to <20%	No recommendation	
Borderline Risk	5% to <7.5%	No recommendation	
Low Risk	<5%	• <50 years: <2.5% • 50-69 years: <5% • ≥70 years: <7.5%	

- T2DM = Type 2 Diabetes Mellitus
- ASCVD risk estimator (http://tools.acc.org/ldl/ascvd_risk_estimator/index.html#!/calculate/estimator/) estimates the 10-year ASCVD risk for asymptomatic individuals 40-75 years old.
- Based on SCORE2 and SCORE2-Older Persons (SCORE2-OP)
  SCORE2 estimates the 10-year risk of fatal and non-fatal CVD events (eg stroke, MI) in apparently healthy individuals 40-69 years old with risk factors that are not treated or have been stable for several years; can be accessed in the ESC CVD Risk Calculation app.
  SCORE2-OP estimates the 5- and 10-year fatal and non-fatal CVD events (eg stroke, MI) adjusted for competing risks in apparently healthy individuals ≥70 years old.

[3]Patients >40 years old with type 1 DM may also be classified according to these criteria.

References:

1. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the primary prevention of cardiovascular disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019.
2. Visseren FLJ, Mach F, Smulders YM, et al; ESC National Cardiac Societies, ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021.

METABOLIC SYNDROME

- Non-HDL-C is secondary target of therapy (LDL-C lowering is primary)

Clinical Identification

- Any 3 or more of the following (including those on treatment):
  - Increased waist circumference (Asian cut off: ≥80 cm for females; ≥90 cm for males)
  - Raised TG level ≥1.7 mmol/L (≥150 mg/dL) or specific treatment for this lipid abnormality
  - Reduced HDL cholesterol <1 mmol/L (<40 mg/dL) in males and <1.3 mmol/L (<50 mg/dL) in females or specific treatment for this lipid abnormality
  - Raised blood pressure [systolic blood pressure (SBP) ≥130 mmHg or diastolic blood pressure (DBP) ≥85 mmHg] or treatment of previously diagnosed hypertension
  - Disorders of glycemia:
    - Type 2 diabetes mellitus, *or*
  - Impaired glucose tolerance (IGT): Fasting plasma sugar <7 mmol/L (<125 mg/dL) and 2 hours post-75 g glucose load 7.8-11.1 mmol/L (140-200 mg/dL), *or*
  - Impaired fasting glucose (IFG): Fasting plasma sugar 6.1-7.0 mmol/L (110-125 mg/dL)

Manage the Underlying Causes

- Obesity and physical activity
  - Weight loss and increased physical activity will reduce all of the above risk factors

Lipid Treatment Goals

- Targeted approach to lipid management is primarily aimed at reducing atherosclerotic risk by substantially lowering LDL-C levels
- Currently, no specific treatment goals for HDL-C or TG levels have been established in clinical trials.

Lipid Treatment Goals Based on Cardiovascular Disease Risk			
Risk Categories	LDL-C	Non-HDL-C	Apolipoprotein B
Very High Risk	<1.4 mmol/L (55 mg/dL)	<2.2 mmol/L (<85 mg/dL)	<1.6 mmol/L (<65 mg/dL)
High Risk	<1.8 mmol/L (<70 mg/dL)	2.6 mmol/L (<100 mg/dL)	<2 mmol/L (<80 mg/dL)
Moderate Risk	<2.6 mmol/L (<100 mg/dL)	<3.4 mmol/L (<130 mg/dL)	<2.6 mmol/L (<100 mg/dL)

Low Risk	<3 mmol/L (<116 mg/dL)	--	--
Reference: Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020.			

Pharmacotherapy

LDL-C-Lowering Pharmacological Therapy

- *LDL-C is the primary target of lipid management*
- The greater the LDL-C level is reduced, the more significant is the amount of CV risk reduction
- Assess patient's response to LDL-C-lowering therapy and lifestyle modifications with a repeat lipid profile 4-12 weeks after starting statin therapy or dose adjustment then every 3-12 months as needed.

Statins [Beta-hydroxy-beta-methylglutaryl-Coenzyme A (HMG-CoA) Reductase Inhibitors]

- Reduce risk for acute coronary syndromes, coronary procedures and other coronary outcomes in both primary and secondary coronary heart disease prevention.
- Recommended for the following:
    - Adults ≥21 years old with clinical atherosclerotic cardiovascular disease (ASCVD)
    - Adults ≥21 years old with LDL-C ≥190 mg/dL
    - Adults 40-75 years of age without ASCVD but with diabetes mellitus (especially type 2 diabetes mellitus) and LDL-C levels of 70-189 mg/Dl
    - Adults 40-75 years of age without ASCVD and diabetes mellitus but with LDL-C levels of 70-189 mg/dL and estimated 10-year risk of ≥7.5% for ASCVD
        - If decision to start statin therapy is uncertain, measure coronary artery calcium (CAC); statin therapy is favored with a CAC score of 1-99 and is indicated with a CAC score of ≥100 Agatston units or ≥75th percentile
    - Adults 40-75 years of age without diabetes mellitus but with risk-enhancing factors and estimated 10-year ASCVD risk of 7.5-19.9%
- Effective in patients with nephrotic syndrome
- Inhibit HMG-CoA reductase which is the rate-limiting step in cholesterol biosynthesis
- Most effective class of drugs at lowering LDL-C levels, with moderate effects on lowering TG and elevating HDL-C: Decreases LDL-C in a dose-dependent manner by 20-55%, decreases TG by up to 35%, increases HDL-C by 2-10%
- The drugs of choice for LDL lowering and in reducing CVD risk in high-risk patients (eg DM) with hypertriglyceridemia
    - Statin dose may be increased or non-statin drug (eg Ezetimibe, fibrates, or Nicotinic acid) may be added if TG levels remain at >2 mmol/L (>200 mg/dL) after achieving the LDL-C target level
- High-intensity statins: Atorvastatin (80 mg), Rosuvastatin (20 mg)
    - Statin regimen that helps lower LDL-C by ≥50%
    - Recommended to be given at the highest tolerated dose to achieve the LDL-C goals set for a specific risk group
    - Recommended as 1st-line treatment for patients <75 years old with clinical ASCVD
    - May be used for patients ≥21 years old with LDL-C ≥190 mg/dL or TG ≥500 mg/dL especially those trying to achieve at least 50% LDL-C level reduction
        - A non-statin drug may be added if LDL-C goal has not been achieved with high-intensity regimen
    - For ≥75-year-old patients with ASCVD without contraindications

    - For 40-75-year-old patients with diabetes mellitus with ≥7.5% 10-year ASCVD risk
    - For 40-75-year-old patients with diabetes mellitus or LDL-C ≥190 mg/dL
- Moderate-intensity statins: Atorvastatin (10 mg), Rosuvastatin (10 mg), Simvastatin (20-40 mg), Pravastatin (40 mg), Lovastatin (40 mg), Fluvastatin (40 mg 12 hourly), Pitavastatin (1-4 mg)
    - Daily dose helps lower LDL-C by 30-49%
    - Alternative treatment for patients with clinical ASCVD with contraindications against high-intensity statins or with side effects from statin therapy
    - For ≥75-year-old patients with ASCVD with contraindications/intolerance to high-intensity statins
    - For 40-75-year-old patients with diabetes mellitus with or without 5- ≤7.5% 10-year ASCVD risk
    - For 40-75-year-old patients with diabetes mellitus and LDL-C 70-189 mg/dL
    - For 40-75-year-old patients with diabetes mellitus or LDL-C ≥190 mg/dL with contraindications/intolerance to high-intensity statins
    - For 40-75-year-old patients without diabetes mellitus but LDL-C ≥70 mg/dL and ≥7.5% 10-year ASCVD risk
- Low-intensity statins: Simvastatin (10 mg), Pravastatin (10-20 mg), Lovastatin (20 mg), Fluvastatin (20-40 mg)
    - Daily dose helps lower LDL-C by <30%
- Treatment with statin is associated with the risk of developing statin-associated muscle symptoms (SAMS) or new-onset DM but benefits of statin therapy for CV risk reduction outweigh the risk
- Risk of developing a first ASCVD event, defined as nonfatal myocardial infarction or coronary heart disease (CHD) death or fatal or nonfatal stroke, over a 10-year period among people free from ASCVD at the beginning of the period.

BEFORE STARTING TREATMENT

- Assess:
    - Non-fasting lipid profile (total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides)
    - Fasting blood glucose (FBS)
    - Renal function (creatinine)
    - Liver function (transaminases) (ALT)
    - TSH if dyslipidaemia is present

FACTORS TO CONSIDER BEFORE STARTING A STATIN

- Statins are contraindicated in pregnancy, breastfeeding, and for those with active liver disease. Transaminases that are increased but <3times upper limit of normal are not a contraindication
- Important drug interactions-increase effect warfarin; increase risk of myositis when taken with other lipid-lowering drugs, macrolide antibiotics (e.g. erythromycin) calcium channel blockers, or ciclosporin
- Statins are most effective taken in the evening

ADVERSE EFFECTS OF STATINS

- Myositis
    - The most important adverse effect of statins (11/100,000 person years). Ask patients to report unexplained muscle pain/weakness. If this occurs check Creatinine kinase if >5 times upper limit of normal, withdraw therapy.
- Peripheral neuropathy
    - Stop statins and seek specialist advice if unexplained peripheral neuropathy develops.
- Abnormal liver function
    - Discontinue if serum transaminase increase (and stays at) more than 3 times normal.

Selective Cholesterol-Absorption Inhibitor

- Eg **Ezetimibe**
- 1st optional non-statin to consider for patients with poor tolerance to statins.
- 1st option to add onto maximally tolerated statin therapy in patients who are less responsive to statins and failed to reach LDL-C goals
    - May be added to a maximally tolerated statin therapy in patients with very high-risk ASCVD when LDL-C level remains ≥70 mg/dL
    - Combination is a strategy to prevent side effects associated with statin monotherapy
    - Combination products of selective cholesterol-absorption inhibitor+statin, eg Ezetimibe/Simvastatin, Ezetimibe/Atorvastatin, are available and may be used to reduce LDL-C, apo B, TG and non-HDL-C and to increase HDL-C
    - If the addition of Ezetimibe to a statin achieved therapy goals, the combination therapy may be continued with continuous monitoring of treatment response
- Beneficial in patients with homozygous familial hypercholesterolemia
- Ezetimibe/statin combination is recommended in patients with CKD stage 3-5 not dependent on dialysis
- Selective potent inhibitor of cholesterol absorption in the intestinal lumen and reduces the overall delivery of cholesterol to the liver
- Causes moderate reduction in LDL-C level
    - When used alone, Ezetimibe decreases LDL by 10-20% with favorable effects on HDL and TG
    - When used in combination with statins, there is an additional reduction in LDL-C by 18-25% with favorable effects on HDL and TG, with Fenofibrate 20-22% reduction in LDL-C

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors

- Eg **Alirocumab, Evolocumab**
- As human monoclonal PCSK9 antibody, it binds to PCSK9 which then increases LDL receptor density
- May be given alone or in combination with a maximally tolerated statin dose and/or other lipid-lowering therapies, eg Ezetimibe
- Recommended as adjunct to diet and maximally tolerated statin therapy plus Ezetimibe for the treatment of heterozygous familial hypercholesterolemia with very high risk or clinical ASCVD that needs further reduction of LDL-C
- Given also to patients with very high and high CV risk with intolerance to statin therapy
- Addition of a PCSK9 inhibitor is recommended to patients with very high-risk ASCVD or severe primary hypercholesterolemia with multiple risk factors for ASCVD events if the LDL-C level remains above goal on maximally tolerated statin and Ezetimibe therapy
- Addition of a PCSK9 inhibitor is also recommended in patient with ACS whose LDL-C goal is not achieved after4-6 weeks of maximal tolerated statin therapy plus Ezetimibe
- Evolocumab may also be given in combination with other LDL-lowering agents (eg statins, Ezetimibe, LDL apheresis) to treat homozygous familial hypercholesterolemia needing further reduction of LDL-C
- Lowers LDL-C levels by 48-71%, TC by 36-42%, apo B by 42-55%, and non-HDL-C by 49-58%

Bile Acid Sequestrants

- Eg; **Cholestyramine(4-16g), colestipol (5-20g), cholesevelam (2.6-3-8g)**
- Have been shown to reduce risk for CVD; considered in patients who have contraindications or intolerance to statin therapy
- Also effective in LDL lowering in patients with diabetes mellitus
- Bind bile acids in the intestine through anion exchange
- Cause moderate reduction in LDL-C levels
    - LDL-lowering potential increases when combined with other agents (eg statins)

- May raise TG levels in some patients
- Decrease LDL-C by 15-25%; increase HDL-C by 4-11%

Nicotinic Acid

- Favorably affects all lipid and lipoproteins when given in the proper dosage
  - Lower doses increase HDL-C
  - 2-3 g/day are needed to lower LDL-C
- Moderate reduction in CVD risk
- Alter lipid levels by inhibiting lipoprotein synthesis and decreasing the production of VLDL particles by the liver
- Most effective at raising HDL levels among lipid-modifying drugs
  - Decrease LDL-C by 5-25%
  - Increase HDL-C by 10-35%
  - Decrease TG by 20-30% in a dose-dependent manner
- May be combined with statins in managing DM patients with hypertriglyceridemia
- May increase blood glucose levels

Intensified LDL-C-Lowering Pharmacotherapy

- Dose increase
- Combination therapy eg; statin with Ezetimibe with or without a PCSK9 inhibitor, statin with PCSK9 inhibitor, Ezetimibe with PCSK9 inhibitor, statin with bile acid sequestrant

Triglyceride-Lowering and HDL-C-Raising Pharmacological Therapy

Fibrates

- Eg**; Gemfibrozil (600mgBD), Fenofibrate (200mg), Clofibrate (100mg BD)**
- Primary use is for lowering TG
  - Decrease TG by 20-50%
  - May be combined with statins in managing diabetes mellitus patients with hypertriglyceridemia and low HDL-C
  - If TG is not elevated, fibrates may lower LDL-C by 5-20%
- Also useful in combined/mixed dyslipidemia and in increasing HDL-C by 6-35%
- Recommended for patients with very high TG (>4.5 mmol/L) who are at risk for pancreatitis
- Moderately reduce risk for CHD
- Favorably lower LDL in patients with diabetes mellitus
- Down-regulate the apolipoprotein C-III (apoC-III) gene and up-regulate genes for apolipoprotein A-1, fatty acid transport protein, fatty acid oxidation and possibly lipoprotein lipase
- Primarily target atherogenic dyslipidemia including diabetic dyslipidemia
  - Fenofibrate with or without statin therapy reduces progression of diabetic retinopathy
- When used in combination with LDL-lowering drugs, it improved the overall lipoprotein compared to either agent alone
  - In combination with statin, Fenofibrate is the preferred fibrate to use due to lower risk of myopathy and rhabdomyolysis
- Provide an alternative treatment in statin-intolerant patients with mild to moderate hypercholesterolemia
- In patients in whom a fibrate is recommended, Nicotinic acid can also be considered
- May be used to treat patients with hypertriglyceridemia and to prevent CV events in those with hypertriglyceridemia

Nicotinic Acid

- *Please see discussion under LDL-C-Lowering Pharmacological Therapy*

Omega-3 Fatty Acids

- **Total eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) at dosages between 2 to 4 g/day** can lower serum TG levels
    - Studies showed EPA reduced serum TG levels by up to 45% in a dose-dependent manner
- **Icosapent ethyl (IPE)** is a highly purified, non-oxidized form of EPA and is indicated for patients with TG levels ≥150 mg/dL with established ASCVD or diabetes with ≥2 ASCVD risk factors and on maximally tolerated statins to prevent ASCVD morbidity and mortality

Treatment of Specific Dyslipidemias

Very High LDL Cholesterol [≥4.9 mmol/L (≥190 mg/dL)]

- Usually caused by genetic forms of hypercholesterolemia
- For patients at very high risk and with persistent high risk, use a maximally tolerated statin and, if necessary, Ezetimibe to lower LDL-C levels; if still not at treatment goal, a PCSK9 inhibitor may be added
- May consider addition of a bile acid sequestrant in patients 20-75 years old with an LDL-C level of ≥4.9 mmol/L (≥190 mg/dL) with <50% reduction in LDL-C and TG ≤3.4 mmol/L (≤300 mg/dL) while on maximally tolerated statin and Ezetimibe therapy

Elevated Triglycerides

- Strong association between high TG levels and CHD risk
- TG levels ≥2.3 mmol/L (≥200 mg/dL) indicate the need to identify non-HDL-C level, which is the secondary target of lipid-lowering therapy in these patients (LDL-C is still the primary goal of therapy)
    - Non-HDL-C is more representative of all atherogenic lipoproteins than LDL-C
        - Non-HDL-C (mmol/L) = TC-HDL-C; non-HDL-C levels can be calculated from non-fasting serum
- Acquired causes: Obesity, physical inactivity, excess alcohol intake, high carbohydrate diet
    - Secondary causes (eg diabetes mellitus, chronic renal failure, nephrotic syndrome, chronic liver disease, hypothyroidism, Cushing's disease, various medications, etc)
    - Genetic causes
- Elevated TG can often be effectively treated through lifestyle changes; however, fibrates, Niacin, and combination therapy with statins may be appropriate options for many patients
- Very high TG [>5.6 mmol/L (≥500 mg/dL)]
    - Treatment should be likened to an emergency to avoid acute pancreatitis
        - Fibrate (preferably Fenofibrate), prescription omega-3 fatty acids, or Nicotinic acid should be started
    - Lifestyle modifications
        - Fish oils can replace some long-chain TG in diet.
- If LDL-C is still elevated despite a fibrate, consider adding a statin
    - Decision must be individualized
    - Must be started only when it is strongly indicated
    - The recommended fibrate to be combined with a statin is Fenofibrate
- High TG [2.3-5.6 mmol/L (200-499 mg/dL)]
    - Lifestyle modifications
    - If LDL-C or non-HDL-C levels are high or ASCVD risk ≥5%: Start statin
        - Consider combination therapy with Fenofibrate if LDL-C is at goal but TG level remains >200 mg/dL in primary prevention or high-risk patients.
        - Consider combination therapy with Icosapent ethyl if TG level is between 135-499 mg/dL despite statin therapy in patients at high risk (or above)
- Borderline high TG [1.7-2.2 mmol/L (150-199 mg/dL)]
    - Lifestyle modifications
    - Medications are rarely required unless LDL-C is elevated above target level.

- Low HDL-C [<1 mmol/L (<40 mg/dL)]
    - Low HDL-C is a strong, independent predictor of CHD
    - Excluding secondary causes of low HDL-C and in the presence of other risk factors (eg; borderline LDL-C, personal history of CAD, or a family history of premature CAD, HDL-C levels should be raised by as much as possible to levels of at least >40 mg/dL in both men and women.
    - Raising HDL-C levels alone in patients without accompanying risk factors is not recommended.
- Low HDL-C without Hypertriglyceridemia
    - Causes: Obesity, physical inactivity, cigarette smoking, type 2 DM, certain drugs, etc
    - Treatment in patients with CHD or CHD-risk equivalents when lifestyle modifications fail to increase HDL include fibrates or Nicotinic acid
- Low HDL-C with Hypertriglyceridemia
    - HDL-C is low and TG is high and LDL-C is not significantly elevated: Start fibrates or Nicotinic acid
- Elevated Lipoprotein(a)
    - Aggressive reduction of LDL-C will help lower Lp(a)
- Agents that have shown to reduce Lp(a) by approximately 20-30% include high-dose Niacin, PCSK9 inhibitors, Estrogen and Aspirin
    - Niacin reduces Lp(a) by an average of 25% and may be given to patients with elevated Lp(a) and hypercholesterolemia with elevated LDL-C despite maximum tolerated statin therapy and Ezetimibe
- Atherogenic Dyslipidemia [Triglycerides ≥1.7 mmol/L (≥150 mg/dL) and HDL-C <1 mmol/L (<40 mg/dL)]
    - The patient likely has metabolic syndrome
    - Attempt adequate trial of lifestyle modification to meet LDL-C goals.
    - Add LDL-lowering drug therapy if lifestyle modification fails to reach LDL-C goals
- TG <2.3 mmol/L (<200 mg/dL): Drug therapy to lower TG is not necessary
    - If patient has CHD or CHD-risk equivalents, consider using drug therapy to raise HDL-C (eg fibrates or Nicotinic acid)
- TG 2.3-5.7 mmol/L (200-499 mg/dL):
    - If non-HDL-C remains elevated after adequate LDL-C lowering therapy: May consider higher dose of statin or statin + TG-lowering drug (fibrate or Nicotinic acid)
- Apolipoproteins
    - Target apo B level at <90 mg/dL for patients at risk of CAD, including those with diabetes mellitus
    - Target apo B level at <80 mg/dL for patients with established CAD or DM plus ≥1 additional risk factor

FAMILIAL HYPERCHOLESTEROLEMIA

- Common autosomal dominant genetic disease that causes LDL-C level elevation
- Causes early-onset CHD
- Dutch Lipid Clinic Network criteria are used for the diagnosis of heterozygous familial hypercholesterolaemia in adults and include the following:
    - Family history
        - 1st degree relative with known premature* coronary or vascular disease, or 1st-degree relative with known LDL-C >95th percentile = 1 point
        - 1st degree relative with tendinous xanthomata and/or arcus cornealis, or children <18 years old with LDL-C >95th percentile = 2 points
    - Clinical history
        - Premature* coronary artery disease = 2 points
        - Premature* cerebral or peripheral vascular disease = 1 point

- Physical examination
  - Presence of tendinous xanthomata = 6 points
  - Presence of arcus cornealis before 45 years old = 4 points
- LDL-C levels (without treatment)
  - LDL-C ≥8.5 mmol/L (≥325 mg/dL) = 8 points
  - LDL-C 6.5-8.4 mmol/L (251-325 mg/dL) = 5 points
  - LDL-C 5.0-6.4 mmol/L (191-250 mg/dL) = 3 points
  - LDL-C 4.0-4.9 mmol/L (155-190 mg/dL) = 1 point
- DNA analysis
  - Functional mutation in the *LDLR, apoB,* or *PCSK9* genes = 8 points
- Definite diagnosis of familial hypercholesterolemia can be made if the score is >8 points, probable if 6-8 points, possible if 3-5 points

Treatment of familial hypercholesterolemia includes the following:

- Lifestyle modification that includes intervention on smoking, diet and physical activity
- Initiation of cholesterol-lowering drugs that include statins (maximal potent dose), Ezetimibe, PCSK9 inhibitors (Alirocumab, Evolocumab), bile acid-binding resins, Bempedoic acid or Evinacumab
- *Premature = <55 years old in men, <60 years old in women

COVID-19 AND LIPID-LOWERING THERAPY

- Current evidence shows that lipid-lowering therapy is safe in patients with COVID-19 infection
  - Lipid-lowering therapy should be continued in patients with confirmed COVID-19 diagnosis and abnormal liver function tests (LFTs) unless alanine transaminase (ALT) or aspartate transaminase (AST) progressively increases, a significant drug-drug interaction between the lipid-lowering agents and COVID-19 drugs has been identified, or patient is critically ill and/or cannot take oral medications

NON-DRUG THERAPY

Lifestyle Modification

- Patients with dyslipidemia are advised to have lifestyle modification regardless of their risk profile
  - ASCVD risk is reduced by a healthy lifestyle in all age groups.

Dietary Recommendations

- Recommended LDL-C-lowering diet:
  - Increase vegetables, fruits, whole grain products, low-fat dairy products, poultry, fish, legumes, non-tropical vegetable oil, and nuts
  - Limit red meat, sweetened beverages, chocolates and sweets
- Dietary fat should range from 20-30% of total calories
  - Saturated fat should be <10% of total calories
  - Cholesterol should be <300 mg/day
  - Polyunsaturated fat can be up to 6-10% of total calories
  - Monounsaturated fats: Total Fats - (Saturated + Polyunsaturated fats)
    - May comprise up to 20% of caloric intake
  - Reducing trans-fat (<1% of total calories) may decrease LDL-C
- Reduce sodium consumption to ≤2,400 mg/day
  - Decreasing sodium intake to 1,150 mg/day may reduce blood pressure in 30- to 80-year-old patients with or without hypertension by up to 4/2 mmHg
  - When reduced to 1,000 mg/day, studies showed decrease in cardiovascular disease (CVD) events by 30%

- Carbohydrates should range from 45-55% of total energy intake
    - Lower carbohydrate intake if with high triglycerides and low HDL-C
    - Source of carbohydrates should be mainly from complex carbohydrates
    - Includes grains (especially whole grains), fruits and vegetables
- Fiber: 25-40 g/day of total dietary fiber
- Protein should be 15-20% of total calories
- Total calories should be enough to balance energy intake and expenditure to maintain body mass index (BMI) for Asian adults of 18.5-23 kg/m^2 or BMI for European adults of 20-25 kg/m^2
- Moderate intake of fatty fish that is boiled, broiled or baked but not fried
    - Up to 2 servings of fatty fish per week for the general population is recommended while coronary artery disease (CAD) patients should consume 1 gram of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) through fatty fish or high-quality dietary supplements
    - Omega-3 fish oil supplements may be considered to treat severe hypertriglyceridemia (triglycerides >500 mg/dL) and for secondary prevention of CVD.

Increase Physical Activity

- Physical activity can reduce risk for CV
- Reduce sedentary time
- Moderate aerobic exercise (eg; brisk walking, swimming, jogging, cycling) 3-4 days/week (ideally daily) for 30-40 minutes at each session is recommended
- Aerobics may reduce LDL-C levels in adults by 3-6 mg/dL and non-HDL-C by 6 mg/dL
- Studies show that resistance training helps lower LDL-C, triglycerides and non-HDL-C levels by 6-9 mg/dL
- Especially helpful in patients with metabolic syndrome
- Muscle-strengthening exercise is recommended ≥2 days/week in addition to aerobic exercises
- Studies have shown that weight and resistance training may benefit patients with insulin resistance syndrome regardless of body fat or aerobic fitness

Weight Loss

- Achieved mainly by dietary changes and exercise
- Weight loss should be gradual
    - 10% of body weight in 6 months
- Waist circumference maintained at <90 cm for men and <80 cm for women

Moderate Alcohol Intake

- ≤2 drinks/day (up to 20 g/day) for men
- ≤1 drink/day (up to 10 g/day) for women

Smoking Cessation

- Patient must quit immediately
- Has beneficial effect on overall cardiovascular risk and specifically on HDL-C levels

Intensifying Lifestyle Modifications

Increasing Viscous Fiber

- Therapeutic option to help lower LDL-C
- Viscous (soluble) fiber is found in oats, pectin-rich fruit, barley, psyllium, beans, et
    - 5-10 g/day can reduce LDL-C levels by ~5%

Plant Stanols/Sterols

- Sterols are isolated from soybean and tall pine tree oils
- Lipids are needed to solubilize stanol or sterol esters
    - Found in commercial margarines, where available
- 2 g/day lower TC and LDL-C by 7-10%
- Help reduce cholesterol absorption

Referral to Dietitian

- Consultation with qualified professional for medical nutrition therapy
- List foods rich in omega-3 fatty acids EPA and DHA

PRIMARY PREVENTION

- This includes a lipid profile. There are a number of potential problems with this strategy:
    - Those with increased cholesterol levels may assume a sick role
    - Repeat lipid levels with attention to diet if lipid levels are found to be high. Only treat with statin if lipids remain high despite low cholesterol diet and 10year CVD risk is >20%. Continue to offer opportunistic screening to those with other risk factors for CVD or signs of increase cholesterol (e.g. corneal arcus <50 yr, xanthelasma, xanthomata).
    - Start a statin, e.g. atorvastatin 20 mg nocturnal.
    - There is no target level for total or LDL cholesterol for primary prevention
    - Check liver function 3 months and 1 year after initiating the statin; do not recheck again unless clinically indicated
    - Do not recheck lipid levels
    - Review drug therapy at least annually; if statins are not tolerated, consider a fibrate, anion exchange resin, or ezitimibe

SECONDARY PREVENTION AND DM

- For all those who have proven CVD, check cholesterol levels annually.

CALCULATING CARDIOVASCULAR DISEASE (CVD) RISK

- Always consider increased cholesterol in the context of other risk factors for CVD
    - Start statin, e.g. atorvastatin 20 mg od; if acute coronary syndrome, a higher intensity statin may be used
    - Measure total cholesterol (non-fasting) 3 months after starting treatment or after any dose change; if stable measure 6-12 monthly
    - Consider increase dose of statin if target lipid levels are not met
    - Check liver function 3 months and 1year after initiating statin therapy. Do not recheck again unless clinically indicated.
- If statins are not tolerated, consider ezetimibe, fibrate, anion exchange resin, nicotinic acid (not for DM)
    - <50% will achieve total cholesterol <4 mmol/L or LDL cholesterol <2 mmol/L
    - *For each mmol/L* decrease *in LDL*
- ↓ Major coronary events 23%
- ↓ First stroke 17%
- ↓ CHD death 19%
- ↓ Overall death rate 12%

Referral

- Familial hypercholesterolaemia
- High triglyceride level (>2.3 mmol/L)

- Hypercholesterolaemia resistant to treatment or difficult to treat

Figure 1A: Estimation of 10-year CVD Points for MEN

(Framingham Point Scores)

Points	Age, Y	HDL-C	TC	SBP (not treated)	SBP (treated)	Smoker	Diabetes
-2		1.6+		<120			
-10		1.3-1.6					
0	30-34	1.2-<1.3	<4.2	120-129	<120	No	No
1		0.9-<1.2	4.2-<5.2	130-139			
2	35-39	<0.9	5.2-<6.3	140-159	120-129		
3			6.3-<7.4	160+	130-139		Yes
4			>7.4		140-159	Yes	
5	40-44				160+		
6	45-49						
7							
8	50-54						
9							
10	55-59						
11	60-64						
12	65-69						
13							
14	70-74						
15	75+						
Points allotted							

Grand Total : ( ) points

Total Points	10-year Risk %	Total Points	10-year Risk %
≤-3 or less	<1	8	6.7
-2	1.1	9	7.9
-1	1.4	10	9.4
0	1.6	11	11.2
1	1.9	12	13.2
2	2.3	13	15.6
3	2.8	14	18.4
4	3.3	15	21..6
5	3.9	16	25.3
6	4.7	17	29.4
7	5.6	18+	>30

Figure 2A: Estimation of 10-year CVD Points for WOMEN

(Framingham Point Scores)

Points	Age,Y	HDL-C	TC	SBP (not treated)	SBP (treated)	Smoker	Diabetes
-3				<120			
-2		1.6+					
-1		1.3-1.6			<120		
0	30-34	1.2-<1.3	<4.2	120-129		No	No
1		0.9-<1.2	4.2-<5.2	130-139			
2	35-39	<0.9		140-159	120-129		
3			5.2-<6.3		130-139	Yes	
4	40-44		6.3-<7.4	150-159			Yes
5	45-49		>7.4	160+	140-149		
6					150-159		
7	50-54				160+		
8	55-59						
9	60-64						
10	65-69						
11	70-74						
12	75+						
Points allotted							

Grand Total : ( ) points

Figure 1B: CVD Risk for Women

Total Points	10-year Risk %	Total Points	10-year Risk %
≤-2	<1	10	6.3
-1	1.0	11	7.3
0	1.2	12	8.6
1	1.5	13	10.0
2	1.7	14	11.7
3	2.0	15	13.7
4	2.4	16	15.9
5	2.8	17	18.5
6	3.3	18	21.5
7	3.9	19	24.8
8	4.5	20	28.5
9	5.3	21+	>30

Reference

1. Oxford handbook of General Practice (4th Edition)
2. Alex Khat, Andrew Polmear-Practical General Practice -Guides for effective Clinical Management
3. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019 Jun 25;73(24):3168-3209. doi: 10.1016/j.jacc.2018.11.002. Accessed 29 Jan 2019. PMID: 30423391
4. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. ESC. http://www.escardio.org. 31 Aug 2019. Accessed 09 Sep 2019.
5. Iqbal Z, Ho JH, Adam S, et al. Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: an expert panel position statement from HEART UK. Atherosclerosis. 2020 Nov;313:126–136. doi: 10.1016/j.atherosclerosis.2020.09.008. Accessed 22 Feb 2021. PMID: 33045618

ANGINA

Definition

- This is due to myocardial ischaemia and presents as a central chest tightness or heaviness, which is brought on by exertion and relieved by rest. It may radiate to one or both arms, the neck, jaw or teeth.
- Other precipitants: emotion, cold weather, and heavy meals. Associated symptoms dyspnoea, nausea, sweatness, faintness.
- Incidence increases with age.

The most common cause

- Coronary artery disease

Rarer causes

- HOCM, valve disease, hypoperfusion during arrhythmia, arteritis, anaemia, or thyrotoxicosis.
- Mortality (usually sudden death or after acute coronary syndrome or LVF) is 0.5 - 4%/year - doubled if coexistent left ventricular dysfunction.

Work up

Presentation of stable angina

Diagnosis is usually made on history:

1. **Pain**: Episodic central-crushing or band-like chest pain that may radiate to jaw/neck and/or one or both arms. Pain in the arms/neck may be the only symptom. Ask about frequency, severity, duration, and timing.
2. **Precipitating factors**: Precipitated by exertion, cold, emotion, and/or heavy meals.
3. **Relieving factors**: Pain stops with rest or glyceryl trinitrate (GTN) within 5 minutes

   All three features → typical angina
   Two features → Atypical angina
   1-0 feature → Non-angina, chest pain

   Associated symptoms: Pain may be associated with palpitations, sweating, nausea, and/or breathlessness during attacks

   Presence of risk factors: Smoking history; family history; history of other vascular disease, e.g. CVA/TIA, peripheral vascular disease

Examination:

- There are usually no physical signs although anaemia may exacerbate symptoms.
- Check BMI and BP.
- Look for murmurs (especially ejection systolic murmur of aortic stenosis) and evidence of peripheral vascular disease and carotid bruits (especially in patients with DM).

First-line investigations

- 12-lead resting ECG provides information on rhythm, presence of heart block, previous MI, myocardial hypertrophy, and/or ischaemia

- Blood FBC, fasting lipid profile, fasting blood glucose.
- ESR (to exclude arteritis) and
- TFTs if clinical suspicion of thyrotoxicosis
- A normal ECG does not exclude coronary artery disease, but an abnormal ECG identifies those at higher risk of cardiac events in the next year—consider referral for further investigation.

Management of patients with stable angina

General advice

- Information about angina and its treatment
- Occupation: May not be able to undertake heavy work—give advice/ support.

Non-drug treatment

- Aimed at secondary prevention of CHD:
- Identify or stratify the risk factors and treatment. (SNAP)
  - **S**moking cessation
  - **N**utrition: Advise healthy diet (oily fish, low cholesterol, fruit and vegetables, salt) and, if obese, aim to decrease weight until BMI <25kg/m^2
  - **A**lcohol: excess consumption. *Targets:* <2 U/day
  - **P**hysical exercise aerobic exercise within the limits set by the disease state
- Hypertension: Check BP and treat if >140/90
- Diabetes: Treat any underlying DM
- Cardiac rehabilitation: May be helpful for patients with angina and/or after surgery

Drug treatment

Symptom control

- *As required medication*
- The acute attack

Nitrates:

- glyceryl trinitrate (nitroglycerine GTN) 600 µg tab or 300 µg (½ tab) sublingually (SL) *or* repeat after 5 minutes if pain persists (maximum two doses) *or*
- isosorbide dinitrate 5 mg sublingually; repeat every 5 minutes if pain persists (maximum 3 tablets)

- Aspirin 150 mg per oral.

Regular treatment

- Drugs for regular symptomatic treatment
  - Within any drug class use the cheapest preparation that the patient can tolerate, will comply with, and which controls symptoms. Assess response every 2–4wk after initiating/changing drug therapy.
  - First-line agent: β-blocker (e.g. atenolol 50 mg bd, or bisoprolol 5-10 mg bd) or calcium channel blocker (e.g. amlodipine 5 mg od, diltiazem) —choice depends on co-morbidites, contraindications, and patient preference
  - If treatment is ineffective/not tolerated:

Switch to whichever first-line agent has not been tried and/or combine a β-blocker and dihydropyridine calcium channel blocker, e.g. amlodipine, felodipine

- Aspirin (if not tolerated or resistant → clopidogrel)

Alternative regular treatments

- Long-acting nitrates, ivabradine, nicorandil.
    - Consider: Monotherapy if both first-line agents (β-blockers; atenolol, bisoprolol, metoprolol, and calcium channel blockers; amlodipine, diltiazem, verapamil) are contraindicated or not tolerated
    - In combination with a first-line agent if symptoms are not controlled with one first-line agent alone and the other first-line agent is contraindicated or not tolerated
    - As a third anti-anginal agent if symptoms are not controlled with two anti-anginal drugs and the person is either not suitable for coronary revascularization with bypass surgery (CABG)/ percutaneous intervention (PCI) or is awaiting CABG/PCI

Secondary prevention

Aspirin:

- decrease mortality by 34%. Unless contraindicated, give 75mg od to *all* patients with angina. Consider clopidogrel 75 mg od if aspirin intolerant.

Statin:

- decrease in total cholesterol and LDL by 25–35% using statin therapy, decrease CHD mortality by 25–35%. Trial data suggest *all* patients with proven CHD benefit from decrease in total cholesterol and LDL irrespective of initial cholesterol concentration

ACE inhibitors:

- Significantly decrease cardiovascular deaths and all-cause mortality even in the absence of left ventricular dysfunction.

Referral to Hospital

- Unstable angina/rapidly progressive symptoms
- Aortic stenosis with angina
- Angina following MI
- Abnormal ECG at diagnosis
- Angina not controlled by medication with two drugs
- If diagnosis is in doubt
- Strong family history
- Other factors, e.g. occupation affected

ISCHEMIC HEART DISEASE

- Cardiovascular disease (CVD) is the leading cause of global morbidity and mortality, contributing to over 30% of deaths worldwide
- Cardiovascular events are highly preventable, through population and individual-level interventions such as smoking cessation, weight reduction, physical activity and exercise, and blood pressure and lipid lowering therapies.
- High-quality primary care is critical to CVD prevention, due to the opportunity to assess risks and to provide lifestyle and pharmacological interventions.

Aetiology

- A repetitive mismatch between myocardial oxygen supply and demand.
- This most frequently is seen when long-standing atherosclerotic obstruction within the epicardial coronary arteries results in poor flow and ischemia distally.
- Coronary artery vasospasm, microcirculation dysfunction, or congenital anomalies can cause the same supply-demand mismatch and result in chronic repetitive ischemia

Types

- Stable ischemic heart disease
- Acute coronary syndrome (ACS), where a more acute presentation with troponin elevation (i.e., myocardial infarction)
- Unstable angina- high-risk chest pain without troponin elevation

Stable ischemic heart disease patients can develop chronic, slow worsening of their angina symptoms, which is often managed medically, or may go on to develop ACS and require urgent intervention.

Symptoms

- Chest pain or discomfort often left-sided and substernal, which may travel into the shoulder, arm, back, neck, or jaw.
- Usually, symptoms occur with exercise or emotional stress, last less than a few minutes, and relieved with rest or nitroglycerin
- The description of the chest discomfort itself can vary from heaviness to pressure, squeezing or tightness.



Definition of Stable Angina

- Episodes of reversible myocardial demand/supply mismatch, related to ischaemia or hypoxia, which are usually inducible by exercise, emotion or other stress and reproducible-but which may also be occurring spontaneously.
- Such episodes of ischaemia/hypoxia are commonly associated with transient chest discomfort. (angina pectoris)

Clinical classification of suspected angina

Typical angina (definite)	Meets all three of the following characteristics: • Substernal chest discomfort of characteristic quality and duration; • Provoked by exertion or emotional stress; • Relieved by rest and/or nitrates within minutes
Atypical angina (probable)	Meets two of these characteristics.
Non-aginal chest pain	Lacks or meets only one or none of the characteristics.

Classification of Angina

Canadian Cardiovascular Society Classification System

Class I	Ordinary physical activity does not cause angina Angina occurs with strenuous or rapid or prolonged exertion
Class II	Slight limitation of ordinary activity Climbing stairs rapidly, walking uphill
Class III	Marked limitation of ordinary physical activity Walking ½ streets on the level or climbing 1 flight of stairs
Class IV	Inability to carry on any physical activity without discomfort Angina symptoms may be present at rest

Major Risk Factors

- Cigarette smoking (including passive smoking)
- Elevated total or LDL-cholesterol
- Hypertension (BP >140/90 mmHg or on antihypertensive medication)
- Low HDL cholesterol (<40 mg/dL)†
- Family history of premature CHD
    - CHD in male first degree relative <55 years
    - CHD in female first degree relative <65 years
- Age (men >45 years; women >55 years)
- Diabetes Mellitus
- HDL cholesterol ≥60 mg/dL counts as a "negative" risk factor; its presence removes one risk factor from the total count.

Other Recognized Risk Factors

- Obesity: Body Mass Index (BMI)
    - Weight (kg)/height (m^2)
    - Weight (lb)/height (in^2) x 703
    - Obesity BMI ≥30 kg/m^2
    - Overweight defined as 25-<30 kg/m^2
    - Abdominal obesity involves waist circumference ≥40 in. in men, ≥35 in. in women
- Physical inactivity: most experts recommend at least 30 minutes moderate activity at least 4-5 days/week

Diagnosis and Assessment

- Confirmation of the presence of ischaemia in patients with suspected stable angina
- Identification or exclusion of associated conditions or precipitating factors
- Risk stratification
- To plan treatment options
- Evaluation of the efficacy of treatment

Cardiovascular risk categories

- **Very-high risk**
  - People with any of the following:
    - Documented ASCVD, either clinical or unequivocal on imaging.
    - Documented ASCVD includes previous ACS (MI or unstable angina), stable angina, coronary revascularization (PCI, CABG, and other arterial revascularization procedures), stroke and TIA, and peripheral arterial disease.
    - Unequivocally documented ASCVD on imaging includes those findings that are known to be predictive of clinical events, such as significant plaque on coronary angiography or CT scan (multivessel coronary disease with two major epicardial arteries having ≥50% stenosis), or on carotid ultrasound.
    - DM with target organ damage, or at least three major risk factors, or early onset of T1DM of long duration (>20 years).
    - Severe CKD (eGFR <30 ml/min/1.73m2).
    - A calculated SCORE ≥10% for 10-year risk of fatal CVD.
    - FH with ASCVD or with another major risk factor
    - Symptomatic peripheral arterial disease (history of claudication with ABI<8.5, previous revascularization or amputation)
- **High-risk**
    - Age ≥65 years
    - People with: Markedly elevated single risk factors, in particular TC >8 mmol/L (>310 mg/dL), LDL-C >4.9 mmol/L (>190 mg/dL), or BP >180/110 mmHg.
    - Patients with FH without other major risk factors.
    - Patients with DM without target organ damage, with DM duration >10-years or another additional risk factor.
    - Moderate CKD (eGFR 30-59 mL/min/1.73 m2).
    - A calculated SCORE ≥5% and < 10% for 10-year risk of fatal CVD.
    - Current smoking
    - History of congestive HF
- **Moderate-risk**
    - Young patients (T1DM <35 years, T2DM<50years) with DM duration <10years, without other risk factors.
    - Calculated SCORE ≥1% and <5% for 10- years risk of total CVD
- **Low-risk**
    - Calculated SCORE <1% for 10-years risk of total CVD

Investigation

Laboratory investigation

- Full blood count
- Fasting lipid profile
- Fasting blood sugar
- Urea- electrolyte, Creatinine

- Markers of myocardial damage; Troponin if ACS suspect
- Thyroid function test if indicated
- OGTT, HbA1c, Hs CRP (high sensitivity C-reactive protein), NT-BNP (N-terminal brain natriuretic peptide)

Cardiac Investigation

- Resting ECG,
- Exercise ECG,
- Holder ECG
- CXR
- Echocardiogram
- Exercise testing with echocardiography
- Exercise testing with myocardial perfusion scan
- CT angiogram
- Coronary angiogram

Role of ECG

- ECG remains the key test for the diagnosis of acute and chronic coronary artery disease.
- The finding varies considerably depending on various factors
    1. The duration of ischemic process (acute vs chronic)
    2. Its extent (size and transmural location)
    3. Its topography (anterior vs inferior)
    4. The presence of other abnormalities (LBBB or WPW)

Normal ECG and waves



Normal 12 lead ECG



Recommendation for resting ECG

- A resting ECG is recommended in all patients at presentation.
- A resting ECG is recommended in all patients during or immediately after an episode of chest pain suspected to indicate clinical instability of CAD.
- Ambulatory ECG monitoring is recommended in patients with SCAD (stable coronary artery disease) and suspected arrhythmia.

Indication for Exercise ECG

- Diagnosis of CAD
- Post MI evaluation
- Pre and post revascularization
- Peri-operative evaluation in some patient
- Evaluation of valvular heart disease

Contraindication for Exercise ECG

- Myocarditis or pericarditis
- Symptomatic severe aortic stenosis
- Severe uncontrolled hypertension
- Decompensated heart failure
- Significant resting arrhythmia (e.g., uncontrolled atrial fibrillation or complete heart block)
- Known severe left main disease
- Physical disability impairing ability to exercise
- ECG abnormality rendering interpretation of ST segment difficult (e.g., LBBB, LVH with strain or digoxin effect, WPW/pre-excitation)

Exercise ECG- Criteria for positive test

- Flat and down sloping ST depression at least 1 mm
- Failure of BP to rise or hypotension during exercise.
- Ventricular arrhythmias
- Typical ischemic symptom during exercise
- Inability to increased heart rate

ECG changes during exercise test



Recommendation for Exercise ECG

- Exercise ECG is recommended as the initial test for establishing a diagnosis of SCAD in patients with symptoms of angina and intermediate PTP (pretest probability) of CAD

- An imaging stress test is recommended as the initial test for diagnosing SCAD if the PTP is between 66–85% or if LVEF is <50% in patients without typical angina.
- An imaging stress test is recommended in patients with resting ECG abnormalities which prevent accurate interpretation of ECG changes during stress.

Recommendation for CXR

- CXR is recommended in patients with atypical presentation or suspicion of pulmonary disease.
- CXR should be considered in patients with suspected heart failure.

Recommendation for Echocardiogram

- A resting transthoracic echocardiogram is recommended in all patients for:
  a) exclusion of alternative causes of angina;
  b) regional wall motion abnormalities suggestive of CAD;
  c) measurement of LVEF for evaluation of diastolic function

Myocardial perfusion scanning

- The evaluation of patients with an equivocal or uninterpretable exercise test and those who are unable to exercise.
- Thallium and tetrofosmin are taken up by viable perfused myocardium.
- A perfusion defect present during stress but not at rest provides evidence of reversible myocardial ischaemia
- Persistent perfusion defect seen during both phases of the study is usually indicative of previous MI

Coronary angiography

- The test is performed to delineate the exact coronary anatomy in patients being considered for revascularization
- Coronary angiography should be performed only when the benefit in terms of diagnosis and potential treatment outweighs the small risk of the procedure (a mortality rate of < 1 in 1000 cases).
- Lesions with complex morphology appear to identify a subgroup of stenoses associated with disease progression and adverse clinical outcomes
- This is occasionally useful in patients with chest pain where the diagnosis is unclear.

Three major steps for decision-making

Step I Clinical assessment of the probability of SCAD (determination of PTP)

↓

Step II Non-invasive testing to establish the diagnosis of SCAD

↓

Step III Stratification for risk of subsequent events, optional medical therapy is instituted

Clinical Pretest Probability for patients with stable chest pain

	Typical angina		Atypical angina		Non-anginal pain	
Age	Men	Women	Men	Women	Men	Women
30-39	59	28	29	10	18	5
40-49	69	37	38	14	25	8
50-59	77	47	49	20	34	12
60-69	84	58	59	28	44	17
70-79	89	68	69	37	54	24
>80	93	76	78	47	65	32

Clinical Pretest Probability for CAD



Management

Aim of management

- To reduce symptoms (relief of angina)
- To improve prognosis (event prevention)

Components of management

- Lifestyle modification
- Control of CAD risk factors
- Evidence-based pharmacological therapy and education
- Revascularization

General Management

- Education about nature of disease, treatment option and effective use of medication, management of emergency condition
- Healthier Life style
- Increase physical activity
- Weight reduction
- Stress management
- Cessation of smoking
- Alcohol (moderate consumption)

Patients with angina and/or dyspnoea and coronary artery disease (Lifestyle recommendations)

Smoking cessation	Use pharmacological and behavioural strategies to help patients quit smoking. Avoid passive smoking
Healthy diet	Diet high in vegetables, fruits and wholegrains' Limit saturated fat to <10% of total intake Limit alcohol to <100 g/week or 15 g/day
Physical activity	30-60 min moderate physical activity most days, but even irregular activity is beneficial.
Healthy weight	Obtain and maintain a healthy weight (<25 Kg/m2), or reduce weight through recommended energy intake and increased physical activity
Other	Take medications as prescribed. Sexual activity is low risk for stable patients not symptomatic at low-to-moderate activity levels.

ESC European Society of Cardiology

Patient with angina and/or dyspnoea and coronary artery disease – (Health diet characteristics

• Increase consumption of fruits and vegetable (≥200 g each per day)
• 35-45 g of fibre per day, preferably from wholegrains.
• Moderate consumption of nuts (30 g per day, unsalted).
• 1-2 servings of fish per week (one to be oily fish).
• Limited lean meat, low-fat dairy products, and liquid vegetable oils.
• Saturated fats to account for <10% of total energy intake; replace with poly saturated fats.
• As little intake of trans unsaturated fats as possible, preferably no intake from process food and <1% of total energy intake.
• ≤5-6 g of salt per day.
• If alcohol is consumed, limiting intake to ≤100 g/week or <15 g/day is recommended.
• Avoid energy-dense foods such as sugar-sweetened soft drinks.
ESC European Society of Cardiology

Modification of risk factors: Diabetes, Hypertension, Dyslipidaemia

Recommendations for diabetes mellitus in chronic coronary syndromes

- Risk factor (BP, LDL-C, and HbA1c) control to targets is recommended in patients with CAD and diabetes mellitus. (I A)
- BP-<130/80mmhg, HbA1c-<7%, LDL-C <1.8mmo/l (<70mg/dl)
- In asymptomatic patients with diabetes mellitus, a periodic resting ECG is recommended for cardiovascular detection of conduction abnormalities, AF, and silent MI. (I C)
- ACE inhibitor treatment is recommended in CCS patients with diabetes for event prevention. (I B)
- The sodium-glucose co-transporter 2 inhibitors empagliflozin, canagliflozin, or dapagliflozin are recommended in patients with diabetes and CVD. (I A) to reduce risk of CV event.
- A glucagon-like peptide-1 receptor agonist (liraglutide or semaglutide) is recommended in

patients with diabetes and CVD (I A) to reduce CV event.

- In asymptomatic adults (age >40 years) with diabetes, functional imaging or coronary CTA may be considered for advanced cardiovascular risk assessment. (IIb B)

Recommendations for hypertension treatment in chronic coronary syndromes

- It is recommended that office BP is controlled to target values: systolic BP 120 - 130 mmHg in general and systolic BP 130 - 140 mmHg in older patients (aged >65 years). (I A)
- In hypertensive patients with a recent MI, betablockers and RAS blockers are recommended. (I A)
- In patients with symptomatic angina, betablockers and/or CCBs are recommended. (I A)
- The combination of ACE inhibitors and ARBs is not recommended. (III A)

Chronic coronary syndromes in specific circumstances: Blood pressure thresholds

Category	Systolic BP (mmHg)		Diastolic BP (mmHg)
Office BP	≥140	and/or	≥90
≥80 years of age	≥160	and/or	≥90
Ambulatory BP			
Daytime (or awake)	≥135	and/or	≥85
Night-time (or sleep)	≥120	and/or	≥70
24 hours	≥130	and/or	≥80
Home BP	≥135	and/or	≥85

ESC European Society of Cardiology

Recommendations for treatment goals for low-density lipoprotein cholesterol

- For patients with ASCVD who experience a second vascular event within 2 years (not necessarily of the same type as the first event) while taking maximally tolerated statin-based therapy, an LDL-C goal of <1.00mmo/l (<40mg/dl) may be considered. (IIb B)
- In patients at high risk, an LDL-C reduction of >_50% from baselined and an LDL-C goal of <1.8mmo/l (<70mg/dl) are recommended. (IA)
- In individuals at moderate risk, an LDL-C goal of <2.6mmol/l (<100mg/dl) should be considered. (IIa A)
- In individuals at low risk, an LDL-C goal of <3.0mml/l (<116mg/dl) should be considered. (IIb A)

General considerations

- Medical treatment of symptomatic patients requires one or more drug(s) for angina/ischaemia relief in association with drug(s) for event prevention. (IC)
- It is recommended that patients are educated about the disease, risk factors, and treatment strategy. (IC)
- Timely review of the patient's response to medical therapies (e.g. 24 weeks after drug initiation) is recommended. (IC)

Drug treatment of angina

Drug	Treatment notes
β-blockers May accumulate in patients with renal failure - decreased dose	• Effective for symptom control and to prevent vascular events. • Check fully -blocked by monitoring heart rate-resting heart rate: ≤ 65bpm; post- exercise (e.g. walking up two flights of stairs) heart rate: ≤90bpm • Further increase in dose once adequately • β-blocked are usually unhelpful • Warn patients not to stop suddenly or run out. If the patient needs to stop the drug, tail off over 4 wks • In patients with asthma/COPD in whom β -blockade is essential, use cardio-selective • β-blockers (e.g. atenolol, bisoprolol, metoprolol, nebivolol) with care • In patients with left ventricular failure, start at very low dose and titrate dose over weeks/months
Dihydropyridine calcium channel blockers	• e.g. amlodipine, felodipine • All equally effective in symptom control. No evidence of cardioprotective effect • Contraindications: vary. Do not use if aortic stenosis, < l month post-Ml or uncontrolled heart failure except with specialist advice
Rate-limiting calcium channel blockers	• e.g. diltiazem, verapamil • Contraindications: avoid if heart block or heart failure • Do not combine with β-blockers
Long-acting nitrates	• e.g. isosorbide mononitrate (ISMO) • Oral and patch preparations (dosages ≥ 10mg/24h) are available. Start with a low dose and increase as tolerated. • Side effects are common • Side effects: headache, postural hypotension, and dizziness-wear off with use. Reflex tachycardia may decrease coronary blood flow and worsen angina • Tolerance: many patients rapidly develop tolerance with decrease therapeutic effect. To avoid this, allow a nitrate-free period of 4-8 hr/day overnight by removing patches at night or giving the 2nd dose of ISMO at 4 p.m. • Contraindications: HOCM, aortic stenosis, constrictive pericarditis, mitral stenosis, severe anaemia, closed-angle glaucoma
Potassium channel activator	• e.g. nicorandil • Headache is common-usually transitory • Contraindications: left ventricular failure; hypotension
Ivabradine	• Lowers the heart rate by its action on the sinus node Contraindications: avoid if heart rate <60bpm, heart block, or heart failure

Medical management of patients with stable coronary artery disease



I. To decrease anginal symptoms

Recommendation for Angina/ischaemic relief

- Short-acting nitrates are recommended for immediate relief of effort angina. (I B)
- First-line treatment is indicated with beta-blockers and/or CCBs to control heart rate and symptoms. (I A)
- If angina symptoms are not successfully controlled on a beta-blocker or a CCB, the combination of a beta-blocker with a DHP-CCB should be considered. (IIa C)
- Initial first-line treatment with the combination of a beta-blocker and a DHP-CCB should be considered. (IIa B)
- Long-acting nitrates should be considered as a second-line treatment option when initial therapy with a beta-blocker and/or a non-DHP-CCB is contraindicated, poorly tolerated, or inadequate to control angina symptoms. (IIa B)
- When long-acting nitrates are prescribed, a nitrate-free or low-nitrate interval should be considered to reduce tolerance. (IIa B)
- Nicorandil, ranolazine, ivabradine, or trimetazidine should be considered as a second-line treatment to reduce angina frequency and improve exercise tolerance in subjects who cannot tolerate, have contraindications to, or whose symptoms are not adequately controlled by beta-blockers, CCBs, and long-acting nitrates. (IIa B)
- In subjects with baseline low heart rate and low BP, ranolazine or trimetazidine may be considered as a first-line drug to reduce angina frequency and improve exercise tolerance. (IIb C)
- In selected patients, the combination of a beta-blocker or a CCB with second-line drugs (ranolazine, nicorandil, ivabradine, and trimetazidine) may be considered for first-line treatment according to heart rate, BP, and tolerance. (IIb B)
- Nitrates are not recommended in patients with hypertrophic obstructive cardiomyopathy or co-administration of phosphodiesterase inhibitors. (III B)

II. Medical treatment to improve prognosis (life expectancy) (Event prevention)

Recommendations for event prevention

- Antithrombotic therapy in patients with CCS and in sinus rhythm
  - Aspirin 75-100 mg daily is recommended in patients with a previous MI or revascularization. (I A)
  - Clopidogrel 75 mg daily is recommended as an alternative to aspirin in patients with aspirin intolerance. (I B)
  - Clopidogrel 75 mg daily may be considered in preference to aspirin in symptomatic or asymptomatic patients, with either PAD or a history of ischaemic stroke or transient ischaemic attack. (IIb B)
  - Aspirin 75-100 mg daily may be considered in patients without a history of MI or revascularization, but with definitive evidence of CAD on imaging. (IIb C)
  - Adding a second antithrombotic drug to aspirin for long-term secondary prevention should be considered in patients with a high risk of ischaemic events and without high bleeding risk. (II a)
  - Adding a second antithrombotic drug to aspirin for long-term secondary prevention may be considered in patients with at least a moderately increased risk of ischaemic event and without high bleeding risk (IIb A)
- **Lipid-lowering drugs**
  - Statins are recommended in all patients with CCS. (I A)
  - If a patient's goal is not achieved with the maximum tolerated dose of statin, combination with ezetimibe is recommended. (I B)
  - For patients at very high risk who do not achieve their goal on a maximum tolerated dose of statin and ezetimibe, combination with a PCSK9 inhibitor is recommended. (I A)
- **ACE inhibitors**
  - ACE inhibitors (or ARBs) are recommended if a patient has other conditions (e.g. heart failure, hypertension, or diabetes). (I A)
  - ACE inhibitors should be considered in CCS patients at very high risk of cardiovascular events. (IIa A)
- **Other drugs**
  - β-blockers are recommended in patients with LV dysfunction or systolic HF. (I A)
  - In patients with a previous STEMI, long-term oral treatment with a beta-blocker should be considered. (IIa B)

Indications for revascularization

- Medical therapy is unsuccessful in controlling symptoms to the patient's satisfaction
- Non-invasive tests reveal a substantial area of myocardium at risk
- There is a high likelihood of success and acceptable risk of morbidity and mortality

Indications for coronary bypass surgery

- left main stem disease
- 3 vessel disease with objective large ischaemia
- 3 vessel disease with poor Left Ventricular function
- 2-3 vessel disease including severe disease of the proximal LAD
- Angina CCS class I to IV with multi vessel disease (Diabetes)

PRINZMETAL (VARIANT) ANGINA

Definition:

- Angina at rest resulting from coronary artery spasm. ECG shows ST elevation.
- Refer to cardiology to exclude MI and atherosclerosis angina.
- GTN alleviates immediate episodes. Calcium channel blockers (CCB) are used to prevent angina.

Referral of patients with suspected stable angina

For patients with new onset intermittent chest pains, refer to prompt specialist assessment to:

- Confirm/refute angina
- Perform an exercise ECG and/or other investigations as appropriate, and
- Provide information on treatment options available, including the merits of revascularization for the individual

! Patients with pre-existing cardiac disease (e.g. previous MI, valve disease, cardiomyopathy) are referred directly to cardiology.

Reference

1. *Oxford handbook of General Practice (4th Edition)*
2. *John Murtagh's General Practice (6th Edition)*
3. *Oxford handbook of Clinical Medicine, 10th Edition)*
4. *2019 ESC guideline on the diagnosis and management of chronic coronary syndrome*

UNSTABLE ANGINA

Definition:

- Pain on minimal or no exertion, pain at rest (may occur at night), or angina which is rapidly worsening in intensity, frequency, or duration. 15% suffer MI in <1month.

Management

Urgent referral to cardiology:

- Admit if attacks are severe pain, occur at rest or last >10min even with sublingual GTN
- Surgical intervention:
- Consider referral for coronary revascularization with bypass surgery (CABG) or percutaneous intervention (PCI) if symptoms are not controlled with anti-anginal drug intervention (two drugs).
- Both procedures decrease symptoms, but CABG confers a survival advantage if DM, age >65years, left anterior descending (LAD) artery disease, or complex 3-vessel disease.

Management of NSTEMI



EMS = emergency medical services; PCI = percutaneous coronary intervention.

Diagnosis and risk stratification

1st step: Initial Evaluation

- Quality of chest pain
- Assessment of likelihood of CAD

- ECG (ST elevation or other ECG abnormalities)

2nd step: Validation & Risk Assessment

- Biochemistry
- Responsiveness to antianginal treatment
- ECG (repeat, continuous monitoring)
- Echocardiography
- Risk score
- Treatment

3rd step: Invasive Management

- Emergent
- Early
- No/elective

4th step: Revascularization

5th step: Long-term management

Pharmacological Management for UAP/NSTEMI

Oral antiplatelet therapy

Aspirin: recommended for all patients without contraindications at an initial oral loading dosed of 150- 300 mg (in aspirin-naïve patients) and a maintenance dose of 75-100 mg/day long-term P2Y12 inhibitor - in addition to aspirin, for 12 months

Clopidogrel (300-600 mg loading dose, 75mg daily dose)

Parenteral anticoagulation: at the time of diagnosis according to both ischemia and bleeding risks

Fondaparinux (2.5mg s.c daily) (most favourable efficacy)
UFH-70-100 IU/kg i.v.
Enoxaparin (1mg/kg s.c twice daily) for 6 – 8 Days

Surgical intervention:

- Consider referral for coronary revascularization with bypass surgery (CABG) or percutaneous intervention (PCI) if symptoms are not controlled with anti-anginal drug intervention (two drugs).
- Both procedures decrease symptoms, but CABG confers a survival advantage if DM, age >65years, left anterior descending (LAD) artery disease, or complex 3-vessel disease.

ACUTE CORONARY SYNDROME

The acute coronary syndrome (ACS) means **Myocardial infarction:** Both ST segment elevation MI (STEMI) and non-ST segment elevation MI (NSTEMI), and **Unstable angina.** Initial primary care management is the same for STEMI, NSTEMI, and unstable angina.

1. WORK UP

CLINICAL PRESENTATION

May be new onset or a rapid deterioration in stable angina.
Presenting features include;

- Sustained central chest pain (>15min)—typically described as central crushing/pressure, band-like pain
- Pain radiating to the arms, jaw, back, or upper abdomen (may be the only symptom)
- Variable pain; may be mistaken for indigestion.
- Symptoms resulting from sympathetic autonomic stimulation, e.g. nausea, vomiting, sweating
- Symptoms relating to shock, e.g. breathlessness, hypotension, collapse

Other factors to consider

- Does the patient have risk factors for cardiac disease?
- Has the patient had previous investigations for chest pain? If so, what investigations were done, when, and what were the results?
- Does the patient have a history of ischaemic heart disease? If so, what is the current treatment and what has been tried in the past?
- Diagnosis of acute coronary syndrome (ACS) is sometimes difficult (e.g. patients with DM may have silent MI): have a high index of suspicion.
- Elderly patients may also have silent myocardial infarct.

Features of STEMI, NSTEMI and Unstable angina			
	STEMI	NSTEMI	Unstable angina
Chest pain present?	Yes	Yes	Yes
ECG changes	ST elevation (≥1mm in ≥2 adjacent limb leads or ≥2mm in ≥2 adjacent anterior chest leads) or New LBBB	Normal or Signs of myocardial ischaemia: • ST segment depression • T wave inversion/ Flattening	Normal or Signs of myocardial ischaemia: • ST segment depression • T wave inversion/ flattening
Troponin levels*	Raised	Raised	Normal

*Usually done in hospital. Indicate myocardial muscle necrosis. Becomes +ve 3–6 hours after onset of pain and may remain positive for 7–14 days.

Examination

There may be no abnormal sign or pale/grey, clammy, dyspnoeic, restlessness and apprehensive.

- Pulse, BP, JVP, heart sounds (mild cardiac failure-third or fourth heart sound) , chest (basal crackles-pulmonary oedema)
- **ECG:** Do not do an ECG if it delays transfer of the patient to hospital.
- Normal ECG does not exclude ACS. If an ECG is done, send it to the receiving hospital with patient.

ECG changes

- Hyperacute (tall) T waves, ST elevation or new LBBB
- T wave inversion, pathological Q waves (hrs to days)
- ST depression, T wave inversion, non-specific changes
- But, in 20% of MI, ECG may be normal initially

Inferior	II, III, aVF	Right coronary
Lateral	I, aVL (+V5-6)	Left circumflex (or LAD)
Anterior	V1-2 septum, V3-4 apex, V5-6 ant/lat	LAD
Posterior	ST depression in V1-3	Left circumflex or right coronary

- Point of care troponin testing if available

MANAGEMENT

- If ACS is suspected, arrange immediate transfer to hospital.
- For reperfusion interventions (thrombolysis or percutaneous coronary intervention) to be effective, they must be carried out as soon as possible after the onset of pain.
- Seeing the patient before arranging transfer introduces unnecessary delays.
- If possible, attend the patient once the ambulance has been called:
- Give pain relief with either sublingual GTN or IV/IM opioid (e.g. morphine 5–10 mg—half dose if elderly/frail) or both
- Give aspirin 300mg per oral (unless contraindicated)
- Give Clopidogrel 300 mg per oral
- Consider giving IV/IM antiemetic (e.g. metoclopamide 10mg)
- Measure oxygen saturation with pulse oximeter—only give oxygen if saturations are <94%. Aim for saturations of 94–98% (88–92% if known COPD and at risk of CO2 retention)

Management of STEMI



DI-DO=door-in to door-out time; DTB=door-to-balloon time; EMS=emergency medical service; FMC=first medical contact; FMCTB=first-medical-contact-to balloon time; PCI=percutaneous coronary intervention; STEMI=ST-segment elevation myocardial infarction

Immediate management within the first 12 hrs

- Aspirin 300 mg & Clopidogrel 300 mg
- Sublingual glyceryl trinitrate 0.3-1mg. (can Repeat)

- ** **Need admit to hospital urgently**
  - Attach ECG monitor and record 12 lead ECG
  - O2 2~4 L with nasal canula
  - IV assess & blood for markers (FBC, Cholesterol, U & E, Creatinine, RBS)
- Brief history, any CI to thrombolysis?
  - (State & Division Hospitals)
- Physical Examination
- Morphine 5~10mg IV + Anti-emetics
- Beta-blocker (if no CI) for ongoing chest pain, hypertension, tachycardia
- Primary PCI or Thrombolysis
- Primary PCI (not for state & division level)

Thrombolysis

- Immediate thrombolysis if Primary PCI cannot be done within 120 min of FMC (First Medical center)
- ECG criteria for thrombolysis
  - ST elevation >1mm in 2 or more limb leads OR
  - ST elevation >2mm in 2 or more chest leads.
  - LBBB (new onset)
  - Posterior changes: Deep ST depression and tall R waves in leads V1 to V3.
- Contraindications

    - Internal or heavy vaginal bleeding
    - Acute pancreatitis or severe liver disease
    - Active lung disease with cavitation
    - Recent trauma or surgery (< 2 weeks)
    - Severe hypertension (>200/120mmHg)
    - Suspected aortic dissection
    - Previous allergic reaction
    - Recent haemorrhagic stroke
    - Oesophageal varices
    - Cerebral neoplasm
- **Relative Contraindications**
    - Severe hypertension
    - Peptic ulcer
    - History of CVA
    - Bleeding diathesis
    - Pregnancy/recent delivery
    - Anticoagulants taking
    - Prolonged CPR
- **Drugs used in Thrombolysis**
    - **Streptokinase**
        - Dose: 1.5 million Units in 100ml 0.9% saline IVI over 1 hour.
        - SE: nausea, vomiting, haemorrhage, stroke, dysrhythmias, hypotension, allergy
    - **Tenecteplase**
    - **Alteplase**
    - **Reteplase**
- **Complications of MI**
    - Arrhythmias
    - Post infarct angina
    - Acute circulatory failure
    - Pericarditis
    - Mechanical complications
    - Rupture of the papillary muscle
    - Rupture of the interventricular septum
    - Rupture of the ventricle
    - Embolism
    - Impaired ventricular function, remodelling and ventricular aneurysm
    - Dressler's syndrome
- **Prognosis**
    - 50% of deaths – within 2 hr of onset of symptoms.
    - Up to 7% - die before discharge.
    - Worse prognosis if :
    - Elderly, LV failure, and ST changes.
- **Follow up**
    - Review at 5 wks post-MI to review symptoms.
    - Review at 3 months.

After myocardial Infarct

Modification of risk factors (secondary prevention)

- **Cholesterol:** All patients with proven coronary heart disease (CHD) benefit from reduction in total cholesterol and LDL, irrespective of initial cholesterol concentration

- **β blocker:** Unless contraindicated, start all patients on an oral β blocker (e.g. metoprolol XL) soon after myocardial infarct and continue indefinitely. (Rate limiting CCB e.g. diltiazem or verapamil is an alternative)
- **ACE inhibitors:** Reduce myocardial work and deaths <1 month post-myocardial infarct. Effects are greater for patients with heart failure.
- **Antiplatelets:** Start aspirin 75 mg od <24 hr after myocardial infarct unless contraindicated, continue life-long. clopidogrel 75 mg od in addition to aspirin 12 month if NSTEMI/unstable angina/STEMI with drug eluting stent
- **Statin:** titrate to achieve target LDL-C level <1.8mmol/L (<70mg/dl)
- **Aldosterone antagonist/Eplerenone:** If depressed LV function (LVEF ≤ 35) and either DM or HF without significant renal dysfunction.

Follow up

Monitoring Health

- Continue regular reviews at least annually life-long check for symptoms and signs of cardiac dysfunction (Breathlessness, palpitations, angina), depression, carer stress.

Monitoring drug therapy

- Ongoing prescription of drugs, monitoring of compliance and side effects, changing medication if clinical circumstances or best practice later.

Secondary Prevention

- **Smoking cessation:** reduce risk of death by 50% over 15 years
- **Hypertension:** Check BP. Treat if >140/90
- **Diet:** Advice healthy diet (low cholesterol, ↑ fruit and vegetables, ↓ salt) and if obese, aim to reduce weight until BMI <25
- **Alcohol:** Reduce excess consumption, target <2U/d
- **Exercise:** increase aerobic exercise within the limits set by the disease state.
- **Diabetes:** Treat any underlying DM. Reinforce information given during cardiac rehabilitation.

Dressler Syndrome (Post MI syndrome)

Develops 2-10 weeks after MI or Heart surgery as a result of autoantibodies to heart muscle. Presents with recurrent fever and chest pain ± pleural and/or pericardial effusion.

Management

- Refer urgently. Treatment is with Steroids and NSAIDs.
- Clopidogrel 75 mg od – prescribe in addition to aspirin.
- 1 month STEMI with no coronary stenting
- 3 month STEMI with bare metal stenting
- 12 month if Non-STEMI/unstable angina
- Anticoagulation occasionally required if atrial fibrillation, left ventricular aneurysm or if clopidogrel/aspirin are not tolerated.

Heart failure/Left Ventricular Dysfunction

- After MI, patients with signs and symptoms of heart failure and left ventricular systolic dysfunction (ejection on fraction <0.4), treated with spironolactone 25 gm od increasing in <1 month to 50 mg od. Should be initiated within 3-14 days of MI preferably after ACEI therapy.

Cardiac Rehabilitation

- Reduce risk of death by 20-25%. Component include: psychological support, information about CHD, Structured exercise programme, modification of other risk factor.

Support after discharge

Return to work

- One month after uncomplicated MI with sedentary workers
- Two months after uncomplicated MI with light manual
- Three months after uncomplicated MI with heavy workers

Physical Activities

- Advice gradual increase in activity
- Ensure goals given match those given by local cardiac rehabilitation guide
- up to 2 weeks – stroll in garden or street
- from 2-6 weeks – walk 0.5 miles/day aiming to increase to 2 miles/day by 6 weeks
- from 6 weeks – increase speed of walking, aim 2 miles in <30 minutes

Sexual activity

- Resume after 6 weeks.

Psychological effects

- About 50% are depressed 1 week after MI and 25% after 1 year.
- Educate about CHD. Check for depression, counsel and treat as needs.

Flying:

- 2 weeks after MI

Referral

- All acute coronary syndrome cases must be referred to hospital urgently.

REFERENCE:

1. *Oxford Handbook of General Practice, 4th Edition*
2. *John MURTAGH'S Handbook of General Practice, 6th Edition*
3. *2020 ECS guideline for the management of ACS in patient presenting without persistent ST elevation*

ACUTE PULMONARY OEDEMA

Definition

- Pulmonary oedema occurs when fluid leaks from the pulmonary capillary network into the lung interstitium and alveoli, and the filtration of fluid exceeds the ability of the lymphatics to clear the fluid.
- Acute pulmonary oedema (APO) is a life-threatening emergency that requires immediate intervention with a management plan and an evidence-based treatment protocol.

Clinical presentation

- Severe dyspnoea
- Distress
- Pallor
- Sweating
- Tachycardia and
- Poor peripheral perfusion.

Causes of acute pulmonary oedema

- **Primary cardiac causes**
  - Acute coronary syndrome/myocardial infarction
  - Arrhythmia
  - Pericarditis
  - Acute valve dysfunction (aortic stenosis, mitral regurgitation)
  - Endocarditis
- **Fluid overload**
- **Drugs**
  - (e.g. nonsteroidal anti-inflammatory drugs [NSAIDs], non dihydropyridine calcium channel blockers
- **Non-compliance with:**
  - heart failure management medications
  - restrictions on fluid intake or alcohol intake
- **Pulmonary embolus**
- **Acute renal failure**
- **High output states**
  - Septicaemia
  - Anaemia
  - Thyrotoxicosis

Assessment of Acute Pulmonary Oedema

- **Initial**
  - Call for help (other GPs, nurses, clinic staff)
  - Commence oxygen
  - Insert 16-gauge intravenous cannula
  - Commence definitive treatment while assessing patient
- **History**
  - Focused cardiorespiratory history (Note: nocturnal dyspnoea and orthopnoea are specific but not sensitive for heart failure)
  - Check past medical history, medications, compliance
  - Consider third party information

- **Examination**
  - Five vital signs
    1. temperature
    2. pulse (rate, rhythm)
    3. blood pressure
    4. respiration (rate, pattern)
    5. oxygen saturation
- **Focused cardiorespiratory examination, particularly:**
  - colour
  - diaphoresis
  - jugular venous pulse
  - apex beat (shift, loading)
  - heart sounds (gallop rhythm?)
  - Murmurs (e.g. mitral regurgitation, aortic stenosis)
  - Peripheral perfusion and oedema
  - Air entry, crepitations, rhonchi
- **Monitoring**
  - Blood pressure
  - Continuous ECG (lead II) – if available
  - Oxygen saturation
  - Automated external defibrillator on standby
  - Consider urinary catheter if managing in rural hospital/area

Investigations depending on availability

- 12 lead electrocardiogram (ECG) as soon as possible: look for signs of myocardial ischaemia or arrhythmia (APO is and an acute coronary syndrome until proven otherwise). **An ECG should not delay** the treatment of pulmonary oedema.
- Chest X-ray (portable, if available) signs vary depending on the severity of pulmonary oedema. In early stage, dilatation of vessels in upper lobes then perihilar haze and thickening of septa. In advanced stage, prominent opacities in hilar and perihilar regions and pleural effusion. Can exclude other lung disease such as pulmonary infection.
- Point-of-care pathology tests (if available)
  - Troponin
  - B-type natriuretic peptide (BNP) or NT-pro BNP
- Other pathology tests: urea and electrolytes, liver function tests, glucose, urinalysis, full blood examination (FBE), arterial blood gases
- Echocardiogram at earliest opportunity (depending on access and patient stability)

Management Acute Pulmonary Oedema

Reassurance and explanation

- Reassurance and explanation to patient and relatives

Posture

- Patient supported in sitting up position
- Supine position if unconscious or in cardiogenic shock

Oxygen

- Corrects hypoxaemia. Align centre of flow-meter ball to required flow rate 10–15 L/min via Hudson type mask and reservoir bag

- This is initial treatment even in patients with known COPD who are at risk of hyperoxic hypercapnia as oxygenation is the priority. Monitor conscious state, respiratory rate and oxygenation
- When stable, reduce to 2–6 L/min via nasal prongs or 5–10 L/min via mask
- Patients with COPD should ideally receive controlled oxygen therapy via a 28% mask (flow rate 4 L/min)
- Titrate to achieve oxygen saturation of 94–98% (non-COPD) or 88–92% (COPD)

Drug treatment

Action

- If severe call for emergency ambulance support
- Sit the patient up
- Be reassuring – it is very frightening to be very short of breath
- Give oxygen if available SPO_2 94-98% (88-92% for COPD)
- Give i.v. furosemide 20-80 mg slowly
- Give GTN 400 mg sublingual every 5 minutes

Glyceryl trinitrate

- (venodilator, reduces preload) 400 µg sublingual every 5 minutes (up to three doses)
- Maintain systolic blood pressure (SBP) above 100 mmHg
- Contraindicated within 48 hours of PDE5 Inhibitor
- Double infusion rate every 5 minutes according to clinical response (maintain SBP above 90 mmHg)

Frusemide

- (loop diuretic, reduces fluid overload; possible vasodilator effect) 20–80 mg IV bolus
- After bolus, consider continuous IV infusion at 5–10 mg/hour (total dose <100 mg in first 6 hours, and <240 mg in the first 24 hours).
- Consider repeating a bolus dose after 30–60 minutes if there has been no clinical improvement and no diuresis. Risk of hypovolaemia; avoid if no clear fluid overload
- Admit once the patient is sufficiently stable, for fuller assessment and for continuing treatment.

Checklist for post-acute care

- **Structured management plan**: patient and GP define problems, goals and actions
- **Team based care** according to needs and access (Medicare primary care items may apply). This may involve the GP, cardiologist and/or hospital, health worker, dietician or exercise physiologist
- **Education and support** for patient and care-giver
- Home assessment and community support
- **Lifestyle**
  - smoking cessation
  - diet: no added salt
  - fluid restriction: maximum 2 L/day (1.5 L/day if severe CHF)
  - alcohol: no more than one unit per day
  - exercise: individualised program
- **Investigations**
  - echocardiogram: mandatory for all patients post-AHF
  - full cardiac ‘workup’: ECG, lipid profile, glucose, renal function, liver function, thyroid function, iron studies, Full Blood Count
- **Monitoring**: patient self-monitoring (symptoms, weight, BP)
- **GP review** (frequency determined by severity and stability of CHF):
  - symptoms, weight, BP, cardiorespiratory status

    - risk factor management
    - co-morbidities (especially ischaemic heart disease, diabetes, COPD, renal impairment, sleep apnoea, obesity, depression, osteoarthritis)
    - mental state
    - medication review
    - pathology (urea, creatinine, electrolytes, FBE)
- **Medications indicated** (improves prognosis as well as symptoms)
    - angiotensin converting enzyme inhibitor (ACEI): all patients with CHF (if not tolerated use angiotensin II receptor blocker)
    - beta blocker: patients with systolic failure; COPD is not a contraindication (bisoprolol, carvedilol, metoprolol, nebivolol)
    - frusemide: symptoms of fluid overload
    - spironolactone: add on if symptom control inadequate
    - digoxin: consider for atrial fibrillation, or as add on therapy for sinus rhythm with severe CHF inadequately controlled with the above
- **Medications** (contraindicated or caution):
    - verapamil and diltiazem
    - NSAIDs or cyclo-oxygenase-2 inhibitors
    - corticosteroids
- **Vaccinations**: influenza, pneumococcal vaccination
- **Device** therapy for patients with moderate or severe CHF
  (Cardiologist would assess and recommend if appropriate):
    - cardiac resynchronisation therapy (e.g. if QRS is greater than 120 ms)
    - implantable cardioverter defibrillator.

Referral

- Since acute pulmonary oedema is a medical emergency, all cases must be referred urgently.

Reference

1. *John MURTAG's Handbook of General Practice, 6th Edition*
2. *Andrew Baird's article, a General Practitioner*
3. *Oxford Handbook of General Practice, 4th Edition*
4. *Acute heart failure: diagnosis and management. Clinical guideline [CG187] Published date: October 2014;* updated: May 17, 2022 by Dr Paula Zaininger
5. *MSF medical guidelines Clinical guidelines - Diagnosis and treatment manual; Last updated: April 2021*

ATRIAL FIBRILLATION

Definition:

- Atrial Fibrillation is a common disturbance of cardiac rhythm that may be episodic (paroxysmal), characterized by rapid irregularly irregular narrow QRS complex tachycardia with absence of P waves.
- Associated with 5 times increased risk of stroke

ECG changes in atrial fibrillation

1. Variable R-R interval
2. Narrow QRS (normal QRS = 80-100 msec: 2 small squares
3. Absent P waves



https://image.slidesharecdn.com/ecg-170415060629/95/ecg-62-638.jpg?cb=1492236423

Causes:

- No cause (isolated AF) 12%
- Coronary heart disease
- Increase BP (especially if LVH)
- Cardiomyopathy
- Valvular heart disease (especially mitral valve disease
  Acute AF may be precipitated by acute infection, high alcohol intake, surgery, electrocution, MI, pericarditis, pulmonary embolism, or hyperthyroidism.

WORK UP

Symptoms

- Often asymptomatic but may cause palpitations, chest pain, stroke/TIA, dyspnoea, fatigue, light-headedness, and/or syncope.

Examination

- **General examination:** Check for anaemia, thyrotoxicosis, anxiety, and other systemic disease
- **Cardiovascular examination:** Heart size, pulse rate/rhythm (apex rate > radial pulse rate if in AF), JVP, BP, heart sounds/murmurs, LVF

Investigations

- Routine investigations:
  - Resting ECG, CXR if paroxysmal AF is suspected but not captured on ECG consider 24 hr ECG monitoring, or cardiac memo
  - CXR to evaluate the size of the heart and identify lung disease
  - *Blood:* TFTs, FBC, U&E/eGFR, TFTs (anaemia, hyperthyroidism or electrolyte imbalance trigger AF; renal function affects drug choice)
- Echocardiography: to check left atrial size and left ventricular function

Management

Aims:

- To relieve symptoms, e.g. palpitations, fatigue, dyspnoea;
- Prevent thromboembolism and decrease risk of stroke; and
- Maintain cardiac function.

Initial Management Decision

Atrial Fibrillation → Unstable → Refer for urgent cardioversion

Atrial Fibrillation → Stable → Rate or Rhythm control → stable → Anticoagulants

- *'Pill-in-the-pocket' approach to paroxysmal AF.* Consider self-medication with a β-blocker prn (e.g. atenolol 50–100 mg od) if infrequent symptomatic paroxysms *and* no history of LV dysfunction or valvular/ischaemic heart disease; systolic BP >100mmHg and resting heart rate >70bpm; able to understand when and how to take the medication.

Refer

- Fast rate and compromised by arrhythmia, chest pain, decreased BP or more than mild heart failure
- Candidate for DC or chemical cardioversion
- Uncertainty about diagnosis or treatment
- Symptoms are uncontrolled by standard treatment
- Paroxysmal AF for consideration of sotalol or other anti-arrhythmic drugs when standard β-blockers have failed.

Management of AF in primary care



Two treatment approaches

Rhythm control:

Consider referral/ admission for **DC or chemical** cardioversion to restore sinus rhythm if

- Symptomatic or CCF
- First presentation with lone AF
- Age ≤ 65y
- AF 2° to a treated/corrected precipitant.

After treatment, medication (e.g. β-blocker) may be needed to maintain sinus rhythm.

Rate control : Consider controlling ventricular rate with a ß blocker (e.g. atenolol 50–100 mg od) or rate-limiting calcium channel blocker (e.g. verapamil 40–120 mg tds) if:

Age >65y

• Long duration of AF (>12months)

• No CCF

• Coronary artery disease

• **Structural heart disease** which makes AF likely, e.g. mitral stenosis, large left atrium

• History of multiple failed attempts at cardioversion/relapses

• Contraindications to anticoagulation

• Ongoing but reversible cause of AF, e.g. thyrotoxicosis

Aim for a ventricular rate of 60–80bpm at rest and 90–115bpm during moderate exercise. If ineffective during normal activities, combine ß blocker with digoxin;

if ineffective during exercise combine a rate-limiting calcium antagonist with digoxin.

If still ineffective/poorly tolerated—refer for consideration of other anti-arrhythmic agents, e.g. sotalol, propafenone, or amiodarone.

Consider digoxin as monotherapy for predominantly sedentary patients.

Recommendations for lifestyle interventions and management of risk factors and concomitant diseases in patients with AF

- Identification and management of risk factors and concomitant diseases is recommended as an integral part of treatment in AF patients.
- Modification of unhealthy lifestyle and targeted therapy of intercurrent conditions is recommended to reduce AF burden and symptom severity.
- Opportunistic screening for AF is recommended in hypertensive patients.
- Attention to good BP control is recommended in AF patients with hypertension to reduce AF recurrences and risk of stroke and bleeding.
- In obese patients with AF, weight loss together with management of other risk factors should be considered to reduce AF incidence, AF progression, AF recurrence.
- Advice and management to avoid alcohol excess should be considered for AF prevention and in AF patients considered for OAC (oral anticoagulant therapy)
- Physical activity should be considered to help prevent AF incidence or recurrence, with the exception of excessive endurance exercise, which may promote AF.
- Opportunistic screening for AF should be considered.
- Optimal management of OSA (Obstructive sleep apnea) may be considered, to reduce AF incidence, AF progression, AF recurrences, and symptoms.

Offer people with atrial fibrillation a personalised package of care. Package of care includes:

- stroke awareness and measures to prevent stroke
- rate control
- rhythm control.

When to offer rate or rhythm control

Rate control

- Choose the drugs based on the person's symptoms, heart rate, co-morbidities and preferences when considering drug treatment.
    - a standard β-blocker (that is, a beta-blocker other than sotalol) or
    - a rate-limiting calcium-channel blocker as initial monotherapy
    - Consider digoxin monotherapy for people with non-paroxysmal atrial fibrillation only if they are sedentary (no or very little physical exercise).
- If monotherapy does not control symptoms, and if continuing symptoms are thought to be due to poor ventricular rate control, consider combination therapy with any 2 of the following:
    - a β-blocker
    - diltiazem
    - digoxin
- **Do not offer** amiodarone for long-term rate control.

Rhythm control

- Consider pharmacological and/or electrical rhythm control for people with atrial fibrillation whose symptoms continue after heart rate has been controlled or for whom a rate-control strategy has not been successful.

Cardioversion

- For people having cardioversion for atrial fibrillation that has persisted for longer than 48 hours, consider amiodarone therapy starting 4 weeks before and continuing for up to 12 months after electrical cardioversion to maintain sinus rhythm, and discuss the benefits and risks of

amiodarone with the person.

- For people with atrial fibrillation of greater than 48 hours' duration, in whom elective cardioversion is indicated.

Drug treatment for long-term rhythm control

- Assess the need for drug treatment for long-term rhythm control, taking into account the person's preferences, associated co-morbidities, risks of treatment and likelihood of recurrence of atrial fibrillation.

Beta-blockers

- If drug treatment for long-term rhythm control is needed, consider a standard beta-blocker (i.e. a β-blocker other than sotalol) as first-line treatment unless there are contraindications.
- Amiodarone for people with left ventricular impairment or heart failure.

Pill in the pocket

- Where people have infrequent paroxysms and few symptoms, or where symptoms are induced by known precipitants (such as alcohol, caffeine), a 'no drug treatment' strategy or a 'pill-in-the pocket' strategy should be considered and discussed with the person, who have no history of left ventricular dysfunction, or valvular or ischaemic heart disease **and** have a history of infrequent symptomatic episodes of paroxysmal atrial fibrillation **and** have a systolic blood pressure greater than 100 mmHg and a resting heart rate above 70bpm **and** are able to understand how to, and when to, take the medication.

Left atrial ablation and a pace and ablate strategy

Left atrial ablation

- If drug treatment has failed to control symptoms of atrial fibrillation or is unsuitable:
  - offer left atrial catheter ablation to people with paroxysmal atrial fibrillation consider left atrial catheter
  - or surgical ablation for people with persistent atrial fibrillation,
  - discuss the risks and benefits with the person.

Pace and ablate strategy

- Pacing and atrioventricular node ablation for people with permanent atrial fibrillation and symptoms or left ventricular dysfunction thought to be caused by high ventricular rates.
- Left atrial catheter ablation before pacing and atrioventricular node ablation for people with paroxysmal atrial fibrillation or heart failure caused by non-permanent (paroxysmal or persistent) atrial fibrillation.

Assessing stroke risk

- Use the CHA2DS2-VASc stroke risk score to assess stroke risk in people with any of the following symptomatic or asymptomatic paroxysmal, persistent or permanent atrial fibrillation, atrial flutter a continuing risk of arrhythmia recurrence after cardioversion back to sinus rhythm.

Scoring the patient's stroke risk using CHADS2

CHA2DS2-VASc score			
	Condition	**Points**	**Score**
C	Congestive heart failure or LVEF <40%	1	**0 - *Low risk*** - no antithrombotic therapy or aspirin 75mg od **1 - *Moderate risk*—**aspirin, or oral anticoagulation depending
H	Hypertension	1	
A	Age >75 years	2	
A	Age 65–74 years	1	
D	DM	1	
S	Sex category-Female*	1	

S	Prior stroke/TIA	2	on patient preference **≥2—*High risk*—oral anticoagulation unless contraindicated** *Target INR for warfarin:* 2–3
VASc Vascular disease e.g. MI, peripheral arterial disease, aortic plaque		2	

** For women <65 yr with no other risk factors, CHA2DS2-VASc score = 0*

- In all cases weigh benefit of treatment against potential harms.
- The HAS-BLED score may help with decision making:
  - Hypertension (uncontrolled, systolic >160mmHg)—1 point
  - Abnormal liver function (cirrhosis, bilirubin >2x normal, ALT/AST/alk phos >3x normal) 1 point
  - Abnormal renal function (dialysis, Cr >200μmol)—1 point
  - Stroke history—1 point
  - Prior major bleed or predisposition to bleeding—1 point
  - Labile INR (<60% of the time in therapeutic range)—1 point
  - Elderly (age ≥65y)—1 point
  - Drugs predisposing to bleeding (e.g. antiplatelet agents, NSAIDs)—1 point
  - Alcohol use—1 point
- score ≥ 3 indicates 1-year bleed risk on anticoagulation sufficient to justify caution before prescribing or more regular review

Assessing bleeding risk

- Use the HAS-BLED score to assess the risk of bleeding in people who are starting or have started anticoagulation. Offer modification and monitoring of the following modifiable risk factors:
  - uncontrolled hypertension, concurrent medication, for example concomitant use of aspirin or a non-steroidal anti-inflammatory drug, harmful alcohol consumption and alcohol dependence
- When discussing the benefits and risks of anticoagulation, explain to the person that: for most people the benefit of anticoagulation outweighs the bleeding risk for people with an increased risk of bleeding the benefit of anticoagulation may not always outweigh the bleeding risk, and careful monitoring of bleeding risk is important.
- **Do not withhold** anticoagulation solely because the person is at risk of having **preventing stroke**
- **Do not offer** stroke prevention therapy to people aged under 65 years with atrial fibrillation and no risk factors other than their sex (that is, very low risk of stroke equating to a CHA2DS2-VASc score of 0 for men or 1 for women).
- **Do not offer** aspirin monotherapy solely for stroke prevention to people with atrial fibrillation

Reference

1. *NICE Atrial fibrillation updated December (2016)*
2. *Oxford handbook of General Practice , (4th Edition)*
3. *2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)*

SUPRAVENTRICULAR TACHYCARDIA

Definition

- Supraventricular tachycardia (SVT) is a general term describing a group of arrhythmias whose mechanism involves or is above the atrioventricular (AV) node.

Classifications of SVT

- Atrioventricular Nodal Reentrant Tachycardia (AVNRT)
  - AVNRT is the most commonly encountered paroxysmal SVT.
- Atrioventricular Reentrant Tachycardia (AVRT)
  - Accessory pathways are anomalous, extranodal conduction pathways between atrium and ventricle
- Atrial Tachycardia
  - Atrial tachycardia describes a group of atrial arrhythmias whose mechanisms may be focal or macro reentrant.
- Atrial Flutter
  - Typical atrial flutter is a form of macro reentrant atrial tachycardia that deserves special mention because it is common, may result in stroke and cardiomyopathy, and is highly amenable to catheter ablation.

ECG features of SVT



Supracentricular Tachycardia (SVT)

- **Rhythm** Regular
- **Rate** 140-220 beats/min
- **QRS complex** usually normal
- **P Wave** Often buried in preceding T wave
- **P-R Interval** Depends on site of supraventricular pacemaker
- Impulses stimulating the heart are not being generated by the sinus node, but instead are coming from a collection of tissue around and involving the atrioventricular (AV) node

https://image.slidesharecdn.com/ecgasanaidfordiagnoses-140614092828-phpapp02/95/ecg-as-an-aid-for-diagnoses-29-638.jpg?cb=1403057427

- SVT usually exhibits a narrow QRS complex tachycardia, although wide complex tachycardia may occur in the case of SVT with pre-existing or rate-related bundle branch block.

Acute management of SVT

- Vagal Maneuvers
  - Valsalva maneuver
  - Carotid Sinus Massage
- If failure above → Refer

Vagal maneuvers

- Vagal maneuvers (carotid sinus massage, Valsalva manoeuvre) transiently increase the AV block and may unmask underlying atrial rhythm are an appropriate first treatment option in

patients with hemodynamically stable SVT.

- Several studies have suggested that vagal maneuvers are more effective in the termination of AVRT compared to AVNRT

Carotid Sinus massage



Fig. Stimulation of carotid sinus triggers baroreceptor reflex and increased vagal tone, affecting SA and AV nodes

Valsalva maneuver

- The Valsalva maneuver is performed by attempting to forcibly exhale while keeping the mouth and nose closed. It is used as a diagnostic tool to evaluate the condition of the heart and is sometimes done as a treatment to correct abnormal heart rhythms or relieve chest pain.
- Instruction: Take a deep breath, close your mouth and pinch your nose with the thumb and index finger and attempt to breathe out gently, keeping your cheek muscles tight, not allowing them to bulge out

Contraindications for Valsalva maneuver

- Severe coronary heart disease or recent heart attack
- Severely increased or decreased blood pressure
- Aortic aneurysm
- Severe dehydration or bleeding (hypovolemia)

Pharmacologic Treatment in hospital

- Before refer to hospital, get i.v. access and give oxygen if SPO2 <90% (if available)
- Pharmacologic therapy if vagal maneuver fails.
- The preferred initial agents are intravenous (IV) adenosine or a nondihydropyridine calcium channel blocker (verapamil or diltiazem)
- The ECG should be continuously recorded during adenosine administration to document the effect of the drug on SVT and to monitor for the rare occurrence of proarrhythmia.
- Adenosine is contraindicated in patients with WPW and atrial fibrillation
- **Synchronized DC cardioversion** is recommended if drug therapy fails to convert or control the tachycardia

Direct-Current Cardioversion

- The use of direct-current cardioversion is generally limited to cases of haemodynamically unstable SVT, a rare phenomenon.

Long-Term Management of SVT

Expectant Management

- (ACC/AHA/ESC) guidelines recommend expectant management for patients with infrequent episodes of haemodynamically stable SVT, normal left ventricular function, and a normal resting ECG.
- Both long-acting calcium channel blockers and beta blockers improve symptoms in 60%-80% of patients with SVT.

Catheter Ablation

- Catheter-based radiofrequency ablation was found to have a superior efficacy and safety profile compared to direct current ablation.
- Catheter ablation is recommended in patients with persistent atrial flutter or in the presence of depressed LV systolic function due to tachycardiomyopathy.
- Catheter ablation is recommended for symptomatic, recurrent AVNRT.

REFER

- REFER to hospital as an emergency if the attack continues.
- Urgent referral if chest pain, dizziness, or breathlessness during attacks including ECG trace during an attack if available.

Reference:

1. *Oxford Handbook of General Practice, 4th Edition*
2. *John MURTAGH'S Handbook of General Practice, 6th Edition*
3. *Therapeutic Manual -Internal Medicine (Myanmar Medical Association, Internal Medicine Society), 1st Edition*
4. *2019 ESC Guideline for the management of patients with supraventricular tachycardia*

BRADYCARDIA

Definition:

- Heart rate less than 60 beats per minutes

WORK UP

Presentation

- Often an incidental finding but may present with faints or blackouts, drop attacks, dizziness, breathlessness, or lack of energy.

Examination:

- Slow pulse rate; normal/low BP ± evidence of secondary heart failure. There may also be symptoms/signs of associated disease.

Investigations

- ECG 12-lead resting ECG; -is recommended to document rhythm, rate, and conduction, and to screen for structural heart disease or systemic illness.(eg, left ventricular hypertrophy, diagnostic Q waves, prolonged corrected QT interval, findings suggestive of hyperkalemia)
- Ambulatory ECG may help with diagnosis of intermittent bradycardia. (e.g. sick sinus syndrome)
- Blood TFTs, FBC, ESR, U&E, LFTs, digoxin levels (if taking digoxin)

The evaluation of patients with bradycardia

- requires a ***complete history and physical as well as an ECG. Symptom-rhythm correlation*** is critical to good clinical decision making.
- The history should outline the frequency, timing, duration, severity, longevity, circumstances, triggers and alleviating factors of symptoms suspicious for bradycardia or conduction disorders.
- The relationship of the symptoms to medications, meals, medical interventions, emotional distress, physical exertion, positional changes, and triggers (eg, urination, defecation, cough, prolonged standing, shaving, tight collars, and head turning) can help narrow the broad differential diagnosis.
- A complete history should include comprehensive cardiovascular risk assessment, family history, travel history, and review of systems. Like the medical history, the physical examination should not only focus on manifestations of bradycardia but also signs of underlying structural heart disease and systemic disorders.

SINUS BRADYCARDIA

- Constant bradycardia. P-waves present and P-R interval <0.2s (one large square).

Causes:

- Hypothyroidism
- Hypothermia
- increase ICP
- Jaundice
- Physiological e.g. athletes

- Vasovagal attack
- Drugs e.g. β blocker, digoxin
- Inferior myocardial infarct
- Sick sinus syndrome

Management

- Admit acutely if symptomatic.
- Refer for cardiology opinion if asymptomatic but HR <40bpm despite treatment of reversible causes.

AV NODE BLOCK (HEART BLOCK)

Causes:

- IHD
- Drugs (digoxin, verapamil)
- Myocarditis
- Cardiomyopathy
- Fibrosis
- Lyme disease (rare)

Types of heart block



- 1st degree block Fixed P-R interval >200ms (one large square)
- 2nd degree block
- Mobitz type I (Wenckebach)—progressively lengthening P-R interval followed by a dropped beat.
- Mobitz type II—constant P-R interval with regular dropped beats
- (e.g. 2:1—every second beat is dropped; consider drug toxicity).
- 3rd degree block (complete heart block)—P-P intervals are constant and R-R intervals are constant but not related to each other

Management

- Untreated 2nd and 3rd degree heart block have a mortality of 83.5%.
- Refer all patients to cardiology, even if asymptomatic.
- If symptomatic (BP <90mmHg systolic, left ventricular failure, heart rate <40bpm), admit as an emergency and give O2 (if available) whilst awaiting admission.

STOKES-ADAM ATTACKS

- Cardiac arrest due to AV block results in sudden loss of consciousness ± some limb twitching due to cerebral anoxia.
- The patient becomes pale and pulseless, but respiration continues.
- Attacks usually last 30s although occasionally are fatal. On recovery the patient becomes flushed.

SICK SINUS SYNDROME

- Due to sinus node dysfunction causing bradycardia ± asystole, sinoatrial block (complete heart block), AF, or SVT alternating with bradycardia (tachy/brady syndrome).
- Common amongst elderly patients. If symptomatic, heart rate <40bpm, or pauses >3s on ECG refer to cardiology for pacemaker insertion.

NOCTURNAL BRADYARRHYTHMIAS

- Common cause for nocturnal bradyarrhythmias is sleep disordered breathing.
- The 2018 Bradycardia Guideline gives a class I recommendation for the screening of sleep apnoea in patients with nocturnal bradycardia and documented or suspected sleep-disordered breathing.
- Patients who screen positive should be considered for polysomnography and/or specialty consultation.
- The prevalence of sinus bradycardia in patients with sleep apnea can be as high as 40%, with episodes of 2nd or 3rd degree AV block in up to 13% of patients.
- Treatment of underlying sleep apnoea can result in a near 90% reduction in bradycardia events.
- Patients with bradycardia that is exclusively nocturnal and not associated with symptoms almost never require permanent pacing.

PACEMAKERS

- Electrically stimulate the heart to beat.

Indications:

- Symptomatic bradycardia
- 2nd or 3rd degree heart block
- Suppression of resistant tachycardia

Reference

1. *Oxford Handbook of General Practice, 4th Edition*
2. *2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients with Bradycardia and Cardiac Conduction Delay*

CHRONIC HEART FAILURE

Definition

- Chronic heart failure occurs when output of the heart is inadequate to meet the needs of the body.
- It is the end stage of all diseases of the heart. Prevalence increases with age.

WORK UP

Causes

- **High output**
- The heart is working at normal or increase rate but the needs of the body are increased beyond that which the heart can supply, e.g.
    - Hyperthyroidism
    - Anaemia
    - Paget's disease
    - AV malformation
- **Low output**
    - Decreased heart function.
        - Increased pre-load, e.g. mitral regurgitation, fluid overload
        - Pump failure
        - Cardiac muscle disease: IHD (46%), cardiomyopathy
        - Decreased expansion of heart and restricted filling—restrictive cardiomyopathy, constrictive pericarditis, tamponade
        - Inadequate heart rate: β-blockers, heart block, post-MI
        - Arrhythmia: AF is the most common
        - Decreased power: negatively inotropic drugs, e.g. verapamil, diltiazem
        - Chronic excessive after load, increased BP, aortic stenosis

History

- Shortness of breath (on exertion, orthopnoea, Proximal Nocturnal Dyspnoea)
- Decreased exercise tolerance, lethargy, fatigue
- Nocturnal cough (may bring up pink froth or have haemoptysis)
- Swelling of ankles
- Abdominal discomfort due to liver distension
- Cerebral symptoms, e.g. confusion, dizziness
- Weight ↑ or ↓ ± wasting
- Past history of MI, AF, or increased BP
- Wheeze
- Nausea/anorexia

Clinical Criteria for diagnosis of heart failure (Framingham Criteria)

- The diagnosis of heart failure requires **2 major** or **1 major + 2 minor** criterias

Major Criteria

- PND
- Raised JVP, Distended Neck Vein

- Creptitations in lung fields
- Cardiomegaly on CXR
- Acute pulmonary oedema
- S3 gallop rhythm
- Hepatojugular reflux
- Weight loss >4.5 Kg in 5 days in response to treatment of heart failure

Minor Criteria

- Bilateral ankle oedema
- Nocturnal cough
- Dyspnoea on ordinary exertion
- Hepatomegaly
- Pleural effusion
- Tachycardia >120/min
- Decrease in vital capacity by one third

Examination

- Increased RR ± cyanosis
- Increased pulse rate
- Increased JVP
- Cardiomegaly; displaced apex beat
- Right ventricular heave
- Basal crepitations ± pleural effusion and/or wheeze
- Pitting oedema of the ankles
- Ascites
- Cachexia and muscle wasting
- Pulsus alternans
- 3rd heart sound
- Hepatomegaly

Classification

- Left ventricular **systolic dysfunction** decreased left ventricular ejection fraction (LVEF) (HFrEF) on echocardiography (Ejection fraction <40%)
- Heart failure with improved ejection fraction (HFimpEF) Previous LVEF <40% and a follow-up measurement of LVEF >40%
- Heart failure with mildly reduced ejection fraction (HF mrEF) (Ejection fraction 41-49%)
- Heart failure with preserved ejection fraction (HFpEF) also termed **diastolic dysfunction** signs/symptoms of heart failure with normal LVEF on echocardiogram (Ejection fraction >50%)

Investigation

- To exclude aggravating factors/other causes of symptoms:
  - urinalysis, blood (FBC, U&E, creatinine, eGFR, TFTs, FBG/ HbA1c), ECG, CXR, and PEFR/spirometry,
- B-type Natriuretic Peptide (BNP) /NT-proB-type Natriuretic Peptide (NT-pro BNP) level (if available)
- Echocardiogram (if available)

Grading of severity
(The New York Heart Association (NYHA) classification)

I. **No limitation:** ordinary physical exercise does not cause undue fatigue, dyspnoea, or palpitations
II. **Slight limitation of physical activity:** comfortable at rest, but ordinary activity results in fatigue, palpitations, or dyspnoea
III. **Marked limitation of physical activity:** comfortable at rest, but less than ordinary activity results in symptoms
IV. **Unable to carry out any physical activity without discomfort:** symptoms of heart failure are present even at rest with increased discomfort with any physical activity

Differential diagnosis

- Obesity
- Respiratory disease
- Venous insufficiency in lower limbs
- Drug-induced ankle swelling (e.g. calcium channel blockers) or fluid retention (e.g. NSAIDs)
- Intrinsic renal or hepatic disease
- Pulmonary embolic disease
- Hypoalbuminaemia
- Depression and/or anxiety
- Bilateral renal artery stenosis
- Intrinsic renal or hepatic disease
- Severe anaemia
- Thyroid disease

Management of chronic heart failure

- Always look for the underlying cause and treat wherever possible.
- Review the basis for historical diagnosis, and arrange echo to confirm if diagnosis is in doubt.

Regular review

- Every 6 month or more often as needed. Check:
    - Clinical state Functional capacity, fluid status, cardiac rhythm, cognitive and nutritional status
    - Screen for depression Affects >40%
    - Manage co-morbidities
    - Medication: Ensure drug record is up to date, review compliance and side effects, change if clinical circumstances/best practice alter
    - Blood U&E, creatinine, and eGFR

Non-drug measures

- Educate about the disease, current/expected symptoms, and need for treatment.
- Discuss prognosis. Support with written information
- Discuss ways to make life easier, e.g. benefits, mobility aids.
- Consider referral to social services for assessment for services, such as home care
- Diet: Adequate calories, ↓ salt, ↓ weight if obese, restrict alcohol, limit caffeine to 1-2 cups coffee/tea a day
- Lifestyle measures - Smoking cessation; regular exercise, weight reduction if patient obese
- Restrict fluid intake if severe heart failure
- Vaccination: Pneumococcal and annual influenza vaccination

Drug treatment

- ***Diuretics***
  - Relieve congestive symptoms/fluid retention in all types of heart failure. Choose a loop diuretic, e.g. furosemide 20–40mg Add a thiazide if continued problems with oedema or hypertension. Titrate dose, increase or decrease according to need.
  - Monitor for decreased K+ and co-treat with amiloride or K+ supplements as needed.
  - First-line medication for heart failure with reduced ejection fraction (HFrEF) (left ventricular systolic dysfunction)
- Start all patients on an ACE inhibitor and a β-blocker. Use clinical judgement to decide which drug to start first.
- ***ACE inhibitors***
  - Improve symptoms, increase exercise capacity, decrease progression of disease, decrease hospital admissions, and increase survival in symptomatic and asymptomatic patients. Start at low dose (e.g. ramipril 1.25 mg od) and titrate upwards.
- Check U&E and Creatinine before starting, at first follow-up, and after each increase in dose. Use ARB if not tolerated.
- *ARNi*
  - An ARNi is composed of an ARB and an inhibitor of neprilysin, an enzyme that degrades natri- uretic peptides, bradykinin, adrenomedullin, and other vasoactive peptides
  - In patients with HFrEF and NYHA class II to III symptoms, the use of ARNi is recommended to reduce morbidity and mortality.
  - In patients with chronic symptomatic HFrEF NYHA class II or III who tolerate an ACEi or ARB, replacement by an ARNi is recommended to further reduce morbidity and mortality.
- If neither an ACE inhibitor nor ARB is tolerated first-line, combination of hydralazine with a nitrate is an alternative - seek specialist advice.
- ***β-blockers***
  - Start a β-blocker for heart failure (e.g. bisoprolol 1.25 mg morning) in all those with left ventricular dysfunction regardless of whether symptoms persist.
  - Use in a 'start low, go slow' manner with assessment of pulse, BP, and clinical status after each titration.
- ***Mineralocorticoid receptor antagonist***
  - Reduce the mortality by 30% when added to conventional therapy
  - e.g. spinorolactone 25 mg/24 hr po
  - Heart failure with preserved ejection fraction (HFpEF)
- ***An SGLT2 inhibitor*** (dapagliflozin or empagliflozin)
  - Reduce the risk of HF hospitalization or CV death (recommended in patients with HFmrEF and HFpEF)

- Treat any co-morbidities, e.g. DM, hypertension, IHD.

Other drugs to consider

- ***Anticoagulation****:*
  - If heart failure + AF, or history of thromboembolism, left ventricular aneurysm, or intrathoracic thrombus
- ***Aspirin***
  - 75–150mg od if heart failure + atherosclerotic arterial disease (including CHD)
- ***Statins***
  - Only if other indications
- ***Amlodipine****:*
  - Treatment for angina and increased BP.
  - Avoid verapamil, diltiazem, or short-acting dihydropyridine agents

Treatment of causes and precipitating factors

- Determination and treatment of the causes
- Precipitating factors that should be treated include:
  - Arrhythmias (e.g. atrial fibrillation)
  - Electrolyte imbalance, especially hypokalaemia
  - Anaemia
  - Myocardial ischaemia, especially myocardial infarction
  - Dietary factors (e.g. malnutrition, excessive salt or alcohol intake)
  - Adverse drug reactions (e.g. fluid retention with NSAIDs and COX-2 agents)
  - Infection (e.g. bronchopneumonia, endocarditis)
  - Hyper and hypothyroidism
  - Lack of compliance with therapy
  - Fluid overload

Avoid Drugs that can aggravate CHF

- NSAIDs including COX-2 inhibitors
- Corticosteroids
- Tricyclic antidepressants
- Calcium-channel blockers (verapamil and diltiazem)
- Selected anti-arrhythmics (e.g. quinidine)
- Macrolide antibiotic
- Type 1 antihistamines
- H2-receptor antagonists
- Thiazolidinediones (glitazones)
- TNF-alpha inhibitors

Referral

- Consider if:
  - Making the initial diagnosis of heart failure
  - Heart failure unable to be managed at home
  - Severe heart failure
  - Heart failure not controlled by first-line medication
  - Angina, AF, or other symptomatic arrhythmia
  - Heart failure due to valve disease or diastolic dysfunction
  - Co-morbidity that may impact on heart failure, e.g. COPD, renal failure, anaemia, thyroid disease, PVD, urinary frequency, gout
  - Woman with heart failure planning pregnancy

Treatment under specialist supervision

Left ventricular systolic dysfunction

- Second-line agents that may be started under specialist supervision include:
  - Aldosterone antagonists, e.g. spironolactone
  - Combination of hydralazine and nitrate
  - **Digoxin** is anti-arrhythmic and a positive isotropic. It is used for worsening or severe heart failure due to left ventricular systolic dysfunction despite first- and second-line treatment.
  - **Amiodarone*:*** May be used to treat arrhythmias associated with heart failure. It requires specialist initiation and close monitoring with TFTs and LFTs at least every 6month once established on a maintenance dose.

Prognosis

- Progressive deterioration to death; 50% die suddenly, probably due to arrhythmias.
- Mortality
- Mild/moderate heart failure – 20 - 30% 1 yr mortality
- Severe heart failure - >50% 1yr mortality

Reference

1. *Oxford Handbook of General Practice, 4th Edition*
2. *John MURTAGH's Handbook of General Practice, 6th Edition*
3. *Oxford Handbook of Clinical Medicine, 10th Edition*
4. *2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure*
5. *ESC Clinical Practice Guidelines, 25 Aug 2023*
6. *2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure:*

RHEUMATIC FEVER (RF) & RHEUMATIC HEART DISEASE (RHD)

Introduction

- Pharyngeal infection with Lancefield Group A β-haemolytic streptococci triggers rheumatic fever 2-4 weeks later.
- Rheumatic Heart Disease - Non-suppurative complications of Group A streptococcal pharyngitis due to a delayed immune response (an antibody to the carbohydrate cell wall of the streptococcus cross reacts with valve tissue, antigenic mimicry, and cause permanent damage to the heart valves).
- Peak incidence: 5-15 yrs
- True infection (rising antibody response) or carrier state (no rising antibody)
- True infection: at risk of developing RF and of spreading the organism to close contacts
- Socioeconomic & environmental factors play an indirect but important role in the magnitude and severity of RF & RHD

Diagnosis of Rheumatic Fever

- Major & minor categories based on the prevalence and specificity of manifestations

Modified Jones' Criteria

Major	**Minor**
• Carditis • Polyarthritis • Chorea • Erythema marginatum • Subcutaneous nodules	Clinical – • Fever • Polyarthralgia Lab – • Elevated acute phase reactants (ESR, WBC count, CRP)
Supporting Evidence	
A preceding infection within 45 days: • Prolonged PR interval, • Elevated or rising ASO or • Other streptococcal antibody, • Positive throat culture, • Rapid antigen test for group A streptococcal, • Recent scarlet fever	

Diagnostic Categories	**Criteria**
Primary episode of RF	2 major or 1 major & 2 minor+evidence of a preceding infection
Recurrent attack of RF without established RHD	same
Recurrent attack of RF with established RHD	2 minor + evidence of a preceding infection
Rheumatic chorea Insidious onset Rheumatic Carditis	Other major manifestations or evidence of Group A streptococcal infection are not required
Chronic valvular RHD (1st time Mitral or Aortic valvular lesion)	Diagnosis do not require any other criteria as having RHD

WHO Criteria for diagnosis Rheumatic Fever& Rheumatic Heart Disease

Never Diagnose as Rheumatic Fever on account of raised ASO titre alone

Clinical features of rheumatic carditis

- Pericarditis: (in primary episode or recurrence of RF) – rub supported by echo evidence of pericardial effusion and simultaneous valvular involvement
- Myocarditis: unexplained CHF or cardiomegaly, almost always associated with valvular involvement. RHD patients – CHF, minor criteria, increased ASO provide Rheumatic carditis
- Endocarditis/valvulitis: Apical PSM ± MDM (Carey Coombs), basal EDM in patients who do not have RHD
- ?Patients with previous RHD, change in the character of murmur or the appearance of a new significant murmur indicates the presence of carditis
- Role of Echo in diagnosis of carditis is essential

Medical Management of Rheumatic fever

- General:
- Hospital admission - to confirm the diagnosis
- Bed rest – to monitor closely for the onset of carditis
- Rest period at least 4 weeks for carditis

Investigations:

- throat culture, ASO, Acute phase reactants (ESR, CRP), CXR, ECG, Echo, blood culture to exclude IE

Antimicrobial Treatment:

- Eradication of the pharyngeal streptococcal infection
- Two throat cultures before starting antibiotics
- Suppression of the inflammatory process
- Should avoid premature administration of salicylates
    - Aspirin 100 mg/kg/day divided into 4-5 doses (125 mg/kg/day in children) for adequate response but avoid toxicity
    - Reduce to 60-70 mg/kg/day for 3-6 weeks
    - Naproxen 10-20 mg/kg/day if intolerant or allergic to aspirin
    - Corticosteroids: Not respond to Aspirin or for pericarditis or HF
    - Prednisolone 2 mg/kg/day (80 mg/day) or methylprednisolone 2-3 weeks, overlap with aspirin
- HF in RF: bed rest, steroids, if severe symptoms, Diuretics, ACEI, digoxin
- For chorea: self-limiting benign disease, treatment is usually unnecessary. It may need neuroleptics, benzodiazepines, anti-epileptics (Haloperidol, Diazepam, Carbamazepine) if patient become more severe.
- **Steroids are not beneficial for chorea**

- Primary prevention of RF: Recommended Treatment for streptococcal pharyngitis

Benzathine benzyl penicillin	IM 1,200,000 units / 60,000 units for < 27 kg	Preferable to oral pen: Patient adherence
Phenoxymethylpenecillin	250 mg QID or 500 mg BD, 250 mg BD or TDS for children – 10 days	Penicillin resistance by group A streptococcal has never been reported
Amoxicillin	25-30 mg/kg/day or 750-1500 mg/day – 10 days	Acceptable alternative
1st generation Cephalosporins	Varies with agents 10 days full course	Acceptable alternative
Erythromycin	4 times/day for 10 days	Alternative for penicillin allergy, high rates of macrolides resistance

Secondary prevention of RF

Definition:

- Continuous administration of specific antibiotics to patients with a previous attack of RF or a well-documented RHD
- To prevent upper respiratory tract infection with group A streptococcal and development of recurrent attacks of RF
- Mandatory for all patients who had an attack of RF ± residual RHD

Antibiotics used in secondary prophylaxis of RF

Benzathine benzyl penicillin	IM 1,200,000 units /60,000 units for children (3-4 weekly)
Penicillin V	250 mg BD
Sulphonamide e.g. Sulphadoxine, Sulphadiazine	1 gm daily 500 mg daily for children
Erythromycin	250 mg BD

Suggested duration of secondary prophylaxis

Patients without proven carditis	For 5 yrs after the last attack or until 21 yrs of age (whichever is longer)
Patients with carditis (mild MR or healed carditis)	For 10 yrs after the last attack or at least until 40 yrs of age (whichever is longer)
More severe valvular disease	Lifelong
After valve surgery	Lifelong

Surgical referrals

- Chronic rheumatic valve disease
- Determined by the severity of patient's symptoms and significantly impaired cardiac function
- To prevent irreversible damage to the LV and irreversible pulmonary hypertension
- Echo is essential for an assessment and follow up of valvular disease

Treatment options

- Balloon valvotomy (commissurotomy)
- Surgical treatment;

- Closed mitral commissurotomy
- Valve repair
- Valve replacement

Referral for further assessment

- NYHA Class II. (Note: with AS, all symptomatic patients)
- Progressive LV enlargement on clinical or CXR
- Cardiac failure not due to episode of rheumatic carditis
- PHT with clinical signs and ECG evidence of RVH, and CXR evidence of pulmonary artery dilatation
- TR complicates mitral valve disease
- Development of AF
- Thromboembolism
- Endocarditis is suspected to contribute to cardiac decompensation

Reference:

1. *Therapeutic Manual of Internal Medicine, Myanmar Medical Association, 2017*
2. *Oxford Handbook of Clinical Medicine, 10th Edition*

DEEP VEIN THROMBOSIS (DVT)

Definition:

- DVT may be proximal, involving veins above the knee or isolated to the calf veins. It may also occur in the cerebral sinus and veins of the arms, retina, and mesentery.

Risk factors

- Age >40 years
- Smoking
- Obesity
- Immobility
- Recent long-distance travel
- Pregnancy
- Puerperium
- Combined Hormonal Contraceptives (CHC)/Hormonal Replacement Therapy (HRT) use
- Surgery
- Recent trauma
- Malignancy
- Heart failure
- Nephrotic syndrome
- Inflammatory bowel disease
- PMH of venous thromboembolism
- Inherited thrombophilic clotting disorders
- Other chronic illness
- Central venous catheters are a common cause of upper limb DVT

Presentation

- Unilateral leg pain, swelling and/or tenderness ± mild fever, pitting oedema, warmth, and distended collateral superficial veins

Differential diagnosis

- Cellulitis
- Arthritis/muscle tear
- Ruptured Baker's cyst
- Superficial thrombophlebitis
- Chronic venous insufficiency
- Venous obstruction
- Post-thrombotic syndrome
- Acute arterial ischaemia
- Lymphoedema
- Fracture
- Hypoproteinaemia
- Clinical diagnosis is unreliable. <50% with clinically suspected DVT have diagnosis confirmed on diagnostic imaging.
- If there will be a delay in investigation to exclude DVT, provide anticoagulation with low molecular weight heparin (LMWH).

Clinical prediction rules

- To decide whether patients fall into high or low probability groups for DVT.

Wells' score for DVT

Cancer	+1
Paralysis or recent plaster cast	+1
Bed rest >3 days or surgery <4 wks	+1
Pain on palpation of deep veins	+1
Swelling of entire leg	+1
Diameter difference on affected calf >3cm	+1
Pitting oedema (affected side only)	+1
Dilated superficial vein (affected side)	+1
Alternative diagnosis at least as probable as DVT	-2

(0) *Low risk,* ***(1-2)*** *Intermediate risk,* ***(≥3)*** *High risk*

Diagnostic algorithm for clinically suspected DVT/PE



CUS = Compression Ultrasonography

Summary of consensus statements

DVT diagnosis

- Revised. Clinical prediction rule (two-level modified Wells score, Supplementary material online, Table S1) should be used to stratify patients with suspected DVT
- Revised. ELISA D-dimer or highly sensitive immunoturbidimetric tests should be measured in 'unlikely' clinical probability patients to exclude DVT diagnosis
- Venous US is recommended as first-line imaging method for DVT diagnosis
- Venous CT scan should be reserved to selected patients only
- Venous US may be proposed also in case of confirmed PE, for initial reference venous imaging, useful in case of DVT recurrence suspicion or further stratification in selected patients
- Venous US may be considered for further severity stratification in selected patients with concomitant suspected PE.

Management of patients with confirmed DVT

- Initial anticoagulation is with LMWH followed by oral anticoagulation (usually warfarin as an outpatient)
- LMWH should be continued for at least 4 days and until INR is in therapeutic range for ≥2 days.

- Target INR 2. 5 (range 2–3)
- Oral anticoagulants decrease risk of further thromboembolism and should be continued for 3–6months after a single DVT
- Treatment of deep vein thrombosis: compression therapy
    - Compression therapy is used for both upper and lower extremity DVT. Compression therapy is a non-invasive treatment option, which is readily available and is associated with few complications.
    - Adverse events in compression trials for DVT are usually mild and mainly involve itching and minor skin changes, reported in 2% - 6% with knee length compression. More adverse effects are reported with thigh length compression (25% - 40.7%).
    - Contraindications to compression are limited to two categories of patients: patients with severe lower extremity arterial disease (ankle brachial index < 0.50 or absolute ankle pressure < 60 mmHg), and patients with severe congestive heart failure as there might be a risk of systemic fluid overload.
    - For patients with proximal deep vein thrombosis, early compression at 30 - 40 mmHg with either multilayer bandaging or compression hosiery, applied within 24 hours, is recommended to reduce pain, oedema, and residual venous obstruction.
    - For patients with proximal deep vein thrombosis, use of below knee compression stockings should be considered in order to reduce the risk of post-thrombotic syndrome
    - Graduated elastic compression stockings should be worn for >2years as they decrease risk post-thrombotic leg syndrome by 12-50%.
- If a patient has a DVT and there is no obvious cause:
    - If <45 years, consider thrombophilia – long term treatment of anticoagulation.
    - If >45 years, consider undiagnosed cancer - LMWH during the first 3-6 months, then anticoagulant as long as the cancer is consider active

Summary of consensus statements
Initial and long-term DVT management

- Patients with proximal DVT should be anticoagulated for at least 3 months.
- Patients with isolated distal DVT at high risk of recurrence should be anticoagulated, as for proximal DVT; for those at low risk of recurrence short LMWH(low molecular weight heparin) treatment (4–6 weeks), even at lower anticoagulant doses, or ultrasound surveillance may be considered.

In non-cancer patients

- NOACs (nonvitamin K antagonists and anticoagulants) should be preferred as first-line anticoagulant therapy in absence of contraindications
- New. If a parenteral agent is used, LMWH should be preferred over UFH (unfractionated heparin) for the initial treatment

New. In cancer patients:

- LMWH should be preferred over UFH for initial treatment
- LMWH is recommended over VKA (vitamin K antagonist) for long-term treatment
- Edoxaban and rivaroxaban should be considered as an alternative to LMWH for initial and long-term treatment in patients without gastrointestinal or urothelial cancer. Caution should be made for any potential drug interaction with anti-cancer therapy
- Apixaban should be considered as an alternative to LMWH for initial and long-term treatment in patients without primary or metastatic brain cancer or acute leukaemia. Caution should be made for any potential drug interaction with anti-cancer therapy.
- LMWH is preferred over NOACs for initial and long-term treatment in cancer patients, with unstable clinical situations, such as low platelet count, nausea, and vomiting, and a risk of expected drug interactions with the anti-cancer therapy as well as those undergone surgery

involving the upper gastrointestinal tract. New. Anticoagulant choice should include patient's preference, and may include cost, mode of administration, and monitoring options

- Revised.
    - Adjuvant catheter-directed thrombolysis should not be routinely performed and be reserved for individual and very severe cases and performed in experienced centers. Primary acute DVT stenting or mechanical thrombus removal alone are not recommended
- Revised.
    - Vena cava filters should be considered if anticoagulation is absolutely contraindicated or in case of recurrent VTE event under adequate therapeutic anticoagulation.
- Revised.
    - In patients with proximal DVT, immediate (<24 h from diagnosis) compression therapy associated with early mobilization and walking exercise may be proposed to relieve acute venous symptoms.

Extended management (>first 3 months) of DVT (without PE)

- Revised.
    - When deciding for extended anticoagulation, individual risk assessment should be proposed for all DVT patients, also taking into account patients' preferences, compliance, and impact of long-term DVT complications. For this purpose scores may be helpful in risk stratification

Complications of DVT

- Pulmonary embolus (PE): Without treatment 20% with proximal DVT develop PE
- Post-thrombotic syndrome: Occurs after DVT. Results in chronic venous hypertension causing limb pain, swelling, hyperpigmentation, dermatitis, ulcers, venous gangrene, and lipodermatosclerosis
- Recurrent venous thromboembolism:
    - Patients with history of DVT or PE have increased risk of recurrence in high-risk situations (trauma, surgery, immobility, pregnancy) and should receive prophylaxis with heparin/oral anticoagulants in such situations

Prevention of venous thromboembolism (VTE)

- Give all patients at high risk of VTE, life style advice to reduce that risk.
- Prevention of VTE for passengers on long howl flight.

Referral

- All cases of suspected DVT should be referred to specialist hospital.
- Consider referring the following to do investigation for thrombophilia
- DVT aged under 40years
- Recurrent DVT or superficial thrombophlebitis
- Unusual DVT: e.g. mesenteric vein thrombosis
- Skin necrosis in association with venous thrombosis
- Those with a VTE and first degree relative who has had a VTE
- Recurrent fetal loss
- Unexplained neonatal thrombosis
- Dealing with patients on warffarin is essential

Reference

1. *Oxford Handbook of General Practice, 4th Edition*
2. *Alex Khot, Andrew Polmear - Practical General Practice – Guides for effective Clinical Management*
3. *Second consensus document on diagnosis and management of acute deep vein thrombosis: updated document elaborated by the ESC*

4. *https://www.healthline.com/health/dvt/home-treatment*
5. *European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis*

CHAPTER 4

RESPIRATORY PROBLEMS

Chapter (4)

Respiratory Problem

1. Asthma In Adults
2. Chronic Obstructive Pulmonary Disease
3. Acute Respiratory Infection (ARI)
4. Pneumonia In Adults
5. Bronchiectasis
6. Pleural Effusion
7. Pneumothorax
8. Pulmonary Embolism
9. Respiratory Failure
10. Lung Cancer

ASTHMA IN ADULTS

DEFINITION

Asthma is a condition of paroxysmal reversible airways obstriction and has three characteristic features

- Airflow limitation - usually reversible spontaneously or with treatment
- Airway hyper -responsiveness to a wide range of stimuli
- Inflammation of bronchi.

DIAGNOSIS OF ASTHMA

Clinical features that increase probability of asthma > **1** of the following:

- **Wheeze**
- **Breathlessness**
- **Chest tightness**
- **Cough particularly if symptoms are worse:**
  - **o at night/early morning**
  - **o with exercise, allergen and/or cold air exposure o after aspirin/ blocker**
- **Past History of atopy**
- **Family History of asthma and/or atopy**
- **Widespread wheeze**
- **Unexplained low FEV l or PEFR**
- **Unexplained eosinophilia**

Diagnosis of Asthma



Ref: https://www.nature.com/articles/s41533-023-00330-1/figures/1

Symptoms/Signs of a Severe Asthma Attack

- PEFR 30-50% predicted or best
- 02 saturation≥92%
- unable to talk in sentences
- intercostal recession
- tachypnoea, respiratory rate >25 breaths/min
- tachycardia, heart rate ≥**110** bpm

Life-Threatening Signs

- PEFR <33% predicted or best
- 02 saturation <92%
- Arrhythmia
- Hypotension
- Cyanosis
- Exhaustion
- Poor respiratory effort
- Silent chest (inaudible wheeze)
- Altered consciousness

Differential Diagnosis

Airflow obstruction = FEV 1 / FVC <0.7

Airflow obstruction

- COPD
- Bronchiectasis
- Inhaled foreign body
- Obliterated bronchiolitis
- Large airway stenosis
- Lung cancer
- Sarcoidosis

No airflow obstruction

- Chronic cough syndrome
- Hyperventilation syndrome
- Vocal cord dysfunction Rhinitis
- Gastro-oesophageal reflux
- Heart failure
- Pulmonary fibrosis

Asthma Management In Practice

The aim of asthma management is to prevent exacerbations and asthma deaths, and to relieve and control symptoms

treatment to:

- Reduce symptoms and impact on lifestyle (e.g., absence from work/school)
- Minimize the need for reliever medication
- Prevent severe attacks/exacerbations

Management Of Acute Asthma

Non-pharmaceutical measure

In addition to medicals, other therapies and strategies may be considered where relevant, to assist in symptom control and risk reduction. Some examples with consistent high-quality evidence are:

- ***Smoking cessation advice*:** at every visit, strongly encourage smokers to quit. Provide access to counselling and resources. Advise parents and carers to exclude smoking in rooms/cars used by children with asthma
- **Physical Activity:** encourage people with asthma to engage in regular physical activity because of its general health benefits; it may have a small management of exercise-induced bronchoconstriction
- **Investigation for occupational asthma:** ask all patients with adult-onset asthma about their work history. Identify and remove occupational sensitizers as soon as possible. Refer patients for expert advice, if available
- **Identify aspirin-exacerbated respiratory disease**, and before prescribing NSAIDs including aspirin, always ask about previous reaction

  Although allergens may contribute to asthma symptoms in sensitized patients, allergen avoidance is not recommended as a general strategy for asthma. These strategies are often complex and expensive, and there are no validate methods for identifying those who are likely to benefit.

Drug treatment of asthma

- Use a stepwise approach
- Start at the step most appropriate to the initial severity of symptoms. The aim is to achieve early control of the condition.

STARTING TREATMENT

in adults and adolescents with a diagnosis of asthma

Track 1 is preferred if the patient is likely to be poorly adherent with daily controller ICS-containing therapy is recommended even if symptoms are infrequent, as it reduces the risk of severe exacerbations and need for OCS.

FIRST ASSESS:

- Confirm diagnosis
- Symptom control and modifiable risk factors, including lung function
- Comorbidities
- Inhaler technique and adherence
- Patient preferences and goals

START HERE IF:

CONTROLLER and **PREFERRED RELIEVER** (Track 1). Using ICS-formoterol as reliever reduces the risk of exacerbations compared with using a SABA reliever

Symptoms less than 4–5 days a week

STEPS 1 – 2
As-needed low dose ICS-formoterol

Symptoms most days, or waking with asthma once a week or more

STEP 3
Low dose maintenance ICS-formoterol

Daily symptoms, or waking with asthma once a week or more, and low lung function

STEP 4
Medium dose maintenance ICS-formoterol

Short course OCS may also be needed for patients presenting with severely uncontrolled asthma

STEP 5
Add-on LAMA
Refer for phenotypic assessment ± anti-IgE, anti-IL5/5R, anti-IL4R
Consider high dose ICS-formoterol

RELIEVER: As-needed low-dose ICS-formoterol

START HERE IF:

CONTROLLER and **ALTERNATIVE RELIEVER** (Track 2). Before considering a regimen with SABA reliever, check if the patient is likely to be adherent with daily controller therapy

Symptoms less than twice a month

STEP 1
Take ICS whenever SABA taken

Symptoms twice a month or more, but less than 4–5 days a week

STEP 2
Low dose maintenance ICS

Symptoms most days, or waking with asthma once a week or more

STEP 3
Low dose maintenance ICS-LABA

Daily symptoms, or waking with asthma once a week or more, and low lung function

STEP 4
Medium/high dose maintenance ICS-LABA

Short course OCS may also be needed for patients presenting with severely uncontrolled asthma

STEP 5
Add-on LAMA
Refer for phenotypic assessment ± anti-IgE, anti-IL5/5R, anti-IL4R
Consider high dose ICS-LABA

RELIEVER: As-needed short-acting β2-agonist

GINA 2021, Box 3-4Bi

Adults & adolescents 12+ years

Personalized asthma management
Assess, Adjust, Review
for individual patient needs



Confirmation of diagnosis if necessary
Symptom control & modifiable risk factors (see Box 2-2B)
Comorbidities
Inhaler technique & adherence
Patient preferences and goals

Symptoms
Exacerbations
Side-effects
Lung function
Patient satisfaction

Treatment of modifiable risk factors and comorbidities
Non-pharmacological strategies
Asthma medications (adjust down/up/between tracks)
Education & skills training

CONTROLLER and **PREFERRED RELIEVER** (Track 1). Using ICS-formoterol as reliever reduces the risk of exacerbations compared with using a SABA reliever

STEPS 1 – 2
As-needed low dose ICS-formoterol

STEP 3
Low dose maintenance ICS-formoterol

STEP 4
Medium dose maintenance ICS-formoterol

STEP 5
Add-on LAMA
Refer for assessment of phenotype. Consider high dose maintenance ICS-formoterol, ± anti-IgE, anti-IL5/5R, anti-IL4R, anti-TSLP

RELIEVER: As-needed low-dose ICS-formoterol

See GINA severe asthma guide

CONTROLLER and **ALTERNATIVE RELIEVER** (Track 2). Before considering a regimen with SABA reliever, check if the patient is likely to be adherent with daily controller

STEP 1
Take ICS whenever SABA taken

STEP 2
Low dose maintenance ICS

STEP 3
Low dose maintenance ICS-LABA

STEP 4
Medium/high dose maintenance ICS-LABA

STEP 5
Add-on LAMA
Refer for assessment of phenotype. Consider high dose maintenance ICS-LABA, ± anti-IgE, anti-IL5/5R, anti-IL4R, anti-TSLP

RELIEVER: As-needed short-acting beta$_2$-agonist

Other controller options for either track (limited indications, or less evidence for efficacy or safety)

Low dose ICS whenever SABA taken, or daily LTRA, or add HDM SLIT

Medium dose ICS, or add LTRA, or add HDM SLIT

Add LAMA or LTRA or HDM SLIT, or switch to high dose ICS

Add azithromycin (adults) or LTRA. As last resort consider adding low dose OCS but consider side-effects

GINA 2022, Box 3-5A

Ref: https://twitter.com/bigcatdoc/status/1389823874385199104/photo/1

ASTHMA TREATMENT TRACKS FOR ADULTS AND ADOLESCENTS

The option for ongoing treatment for adults and adolescents have been obtained in the main treatment figure (Box) by showing two treatment tracks. The key difference between the tracks is the medication that is used for symptom relief: as-needed low dose ICS-formoterol in Track 1 (preferred) and as-needed SABA in Track 2

TRACK 1: THE RELIEVER IS AS-NEEDED LOW DOSE ICS-FORMOTEROL

This is the preferred approach recommended by GINA for adults and adolescents. Using low dose ICS-formoterol as reliever reduces the risk of severe exacerbations compared with regimens with SABA as reliever, with similar symptom control. With the approach:

- When as patient at any treatment step has asthma symptoms, they use low dose ICS-formoterol in a single inhaler for symptom relief.
- In steps 3-5, patients also take ICS-formoterol as their regular daily treatment. This is called ‘maintenance and reliever therapy (MART)

ICS-formoterol should not be used as the reliever by patients taking any other ICS-LABA

TRACK 2: THE RELIEVER IS AS-NEEDED SABA.

This is an alternative approach when Track 1 is not possible or is not preferred by a patient who has no exacerbations on their current therapy.

- **In step 1**, the patient takes a SABA and a low dose ICS together for symptom relief when a symptom occurs, either in combination inhaler or with the ICS taken right after the SABA
- **In Steps 2-5**, a SABA (alone) is used for symptom relief, and the patient takes ICS-containing controller medication regularly every day.

Before prescribing a regimen with SABA reliever, consider whether the patient is likely to be adherent with their ICS-containing controller therapy, as otherwise they will be at higher risk of exacerbations.
During ongoing treatment, treatment can be stepped up or down along one track, using the same reliever at each step, or it can be switched between tracks, according to the individual patient’s needs.

Before stepping up, check for common problems such as incorrect inhaler technique, poor adherence, and environmental exposures, and conform that the symptoms are due to asthma (See Box 5) be scheduled. The frequency of review depends on the patient’s initial level of symptom control, their risk factors, their response to initial treatment, and their ability and willingness to engage in self-management with an action plan.

STEPPING UP ASTHMA TREATMENT

Asthma is a variable condition, and periodic adjustment of controller treatment by the clinician and/or patient may be needed.
Sustained step-up (for at least 2-3 months), if symptoms and/or exacerbations persist despite 2-3 months of controller treatment, assess the following common issue before considering a step-up

- Incorrect inhaler technique
- Poor adherence
- Modifiable risk factors, e.g., smoking
- Are symptoms due to comorbid conditions, e.g., allergic rhinitis

Short-term step-up (for 1-2 weeks) by clinician or by patient with written asthma action plan, e.g., during viral infection or allergen exposure

Day-today adjustment by patient with as-needed low dose ICS-formoterol for mild asthma, or ICS-formoterol as maintenance and reliever therapy. This is particularly effective in reducing severe exacerbations.

STEPPING DOWN TREATMENT WHEN ASTHMA IS WELL-CONTROLLED

Consider stepping down treatment once good asthma control has been achieved and maintained for 3 months, to find the lowest treatment that controls both symptoms and exacerbations, and minimizes side-effects.

- Choose an appropriate time for step-down (no respiratory infection, patient not travelling, not pregnant)
- Assess risk factors, including history of previous exacerbations or emergency department visit, and low lung function
- Document baseline status (symptom control and lung function), provide a written asthma action plan, monitor closely, and book a follow-up visit
- Step down through available formulations to reduce the ICS dose by 25-50% at 2-3-month intervals (see box 3-9 in full GINA 2021 report for details of how to step down different controller treatments)
- If asthma is well-controlled on low dose ICS or LTRA, as-needed low dose ICS-formoterol is a step-down option, based on three large studies in mild asthma. Smaller studies have shown that low dose ICS taken whenever SABA is taken (with combination or separate inhalers) is more effective as a step-down strategy than SABA alone.
- Do not completely stop ICS in adults or adolescents with asthma unless this is needed temporarily to confirm the diagnosis of asthma.
- Make sure a follow-up appointment is arranged.

BACKGROUND – THE RISKS OF "MILD" ASTHMA

- Patients with apparently mild asthma are still at risk of serious adverse events
  - 30-37% of adults with acute asthma
  - 16% of patients with near-fatal asthma
  - 15-27% of adults dying of asthma

  } had symptoms less than weekly in previous 3 months (Dusser Allergy 2007, Bergstrom 2008

- Exacerbation triggers are un predicable (viruses, pollens, pollution, poor adherence)
- Even 4-5 lifetime OCS courses increase the risk of osteoporosis, diabetes, cataract (*Price et al J Asthma Allerg 2018)*

(Global Initiative for Asthma www.ginasthma.org)

WHY NOT TREAT WITH SABA ALONE?

INHALED SABA HAS BEEN FIRST-LINE TREATMENT FOR ASTHMA FOR 50 YEARS

- Asthma was thought to be a disease of bronchoconstriction
- Role of SABA reinforced by rapid relief of symptoms and low cost
- Regular use of SABA, even for 1–2 weeks, is associated with increased AHR, reduced bronchodilator effect, increased allergic response, increased eosinophils (*e.g., Hancox, 2000; Aldridge, 2000)*
- Can lead to a vicious cycle encouraging overuse
- Over-use of SABA associated with ↑ exacerbations and ↑ mortality (*e.g., Suissa 1994, Nwaru 2020)*
- Starting treatment with SABA trains the patient to regard it as their primary asthma treatment
- The only previous option was daily ICS even when no symptoms, but adherence is extremely poor
- GINA changed its recommendation once evidence for a safe and effective alternative was available

OTHER CHANGES IN MEDICATION RECOMMENDATIONS FOR ≥12 YEARS

- Long-acting muscarinic antagonists (LAMA) should not be used as monotherapy for asthma (i.e. without ICS) because of increased risk of severe exacerbations (*Baan, Pulm Pharmacol Ther 2021)*
- Adding LAMA to ICS-LABA: GRADE review and meta-analysis (*Kim, JAMA 2021)* confirms previous findings
- Small increase in lung function (mean difference 0.08 L)
- No clinically important benefits for symptoms or quality of life → don't prescribe for dyspnea
- Modest overall reduction in exacerbations compared with ICS-LABA (risk ratio 0.83 [0.77, 0.90])

Source	Mean annualized exacerbation rate[a] Triple	Dual	Incidence rate ratio (95% CI)	Weight, %
Kerstjens et al,[46] 2012	0.53	0.66	0.80 (0.66-0.96)	21
Kerstjens et al,[55] 2020[b]	0.26	0.33	0.78 (0.61-1.00)	12
Kerstjens et al,[55] 2020[b]	0.38	0.41	0.93 (0.74-1.17)	14
Lee et al,[56] 2020[b]	0.38	0.41	1.04 (0.82-1.31)	14
Lee et al,[56] 2020[b]	0.39	0.38	0.92 (0.69-1.23)	9
Pearl Therapeutics,[57] 2017	0.44	0.55	0.79 (0.58-1.09)	8
Virchow et al,[45] 2019	0.27	0.35	0.77 (0.64-0.93)	22
Overall: $I^2 = 0\%$			0.85 (0.78-0.92)	100



- Patients with exacerbations should receive at least medium dose ICS-LABA before considering add-on LAMA
- Chromone pMDIs (sodium cromoglycate, nedocromil sodium) have been discontinued globally

HOW TO INVESTIGATE UNCONTROLLED ASTHMA

Most patients can achieve good asthma control with ICS-containing treatment, but some patients do not, and further investigation is needed.

Box 5. How to investigate uncontrolled asthma in primary care

Watch patient using their inhaler. Discuss adherence and barriers to use	Compare inhaler technique with a device-specific checklist, and correct errors, recheck frequently. Have an empathic discussion about barriers to adherence.
↓	
Confirm the diagnosis of asthma	If lung function normal during symptoms, consider halving ICS dose and repeating lung function after 2-3 weeks
↓	
Remove potential risk factors. Assess and manage comorbidities	Check for risk factors or inducers such as smoking, beta0blockers, NSAIDs, allergen exposure. Check for comorbidities such as rhinitis, obesity, GERD, depression/anxiety.
↓	
Consider treatment step-up	Consider step-up to next treatment level. Use shared decision-making, and balance potential benefits and risks.
↓	
Refer to a specialist or severe asthma clinic	If asthma still uncontrolled after 3-6 months on Step 4 treatment, refer for expert advice. Refer earlier if asthma symptoms severe or doubts about diagnosis.

REVIEW AND MONITORING

Aim to review all patients with asthma at least annually

- Check symptoms last seen. Use objective measures
  In the last month
  1. Have you had any **difficulty sleeping** because of your asthma symptoms (including cough)?
  2. Have you had your usual asthma **symptoms during the day** (cough, wheeze, chest tightness, or breathlessness)?
  3. Has your asthma **interfered with usual activities**, e.g., house work, work/school etc.?
- Record smoking status and advice smokers to stop.
- Record any **exacerbations/acute attacks** since last seen
- Check **medication-inhaler** technique, problems, side effects.
- Check influenza/pneumococcal vaccination received.
- Review objective measures of lung function, e.g., home PEFR chart, PEFR/ spirometry at review.
- Address any problems or queries and educate about asthma.
- Agree management goals and date for further Review

Table 1. Levels of asthma control

Characteristics	Controlled (all of the following)	Partly controlled (any present in any week)	Uncontrolled
Daytime symptoms	≤ 2 per week	>2 per week	2-3 features of partly controlled asthma present in any week
Limitation of activities	None	Any	
Nocturnal symptoms/awakening	None	Any	

Need for rescue/reliever treatment	≤ 2 per week	>2 per week	
Lung function (PEF or FEV1)	Normal	<80% predicted or personal best (if known) on any day	



Ref: GINA guideline 2022

WRITTEN ASTHMA ACTION PLANS

All patients should be provided with a written asthma action plan appropriate for their level of asthma control and health literacy, so they know how to recognize and respond to worsening asthma.

Box 10. Self-management with a written action plan



The written asthma action plan should include:

- the patient's usual asthma medications
- when and how to increase medications, and start OCS if needed
- how to access medical care if symptoms fail to respond.

COVID-19 AND ASTHMA

- **Are people with asthma at increased risk of COVID-19, or severe COVID-19?**
  - People with asthma do not appear to be at increased risk of acquiring COVID-19, and systematic reviews have not shown an increased risk of severe COVID-19 in people with well-controlled, mild-to-moderate asthma
- **Are people with asthma at increased risk of COVID-19-related death?**
  - Overall, studies to date indicate that people with well-controlled asthma are not at increased risk of COVID-19-related death (*Williamson, Nature 2020; Liu et al JACI IP 2021)* and in one meta-analysis, mortality appeared to be lower than in people without asthma (*Hou, JACI IP 2021).*
  - However, the risk of COVID-19 death was increased in people who had recently needed OCS for their asthma (*Williamson, Nature 2020; Shi, Lancet RM 2022)* and in hospitalized patients with severe asthma (*Bloom, Lancet RM 2021).*
- **What are the implications for asthma management?**
  - It is important to continue good asthma management (as described in the GINA report), with strategies to maintain good symptom control, reduce the risk of severe exacerbations and minimise the need for OCS
- **Have there been more asthma exacerbations during the pandemic?**
  - No: in 2020–21, many countries saw a *decrease* in asthma exacerbations and influenza-related illness
  - The reasons are not precisely known, but may be due to public health measures such as handwashing, masks and social/physical distancing that reduced the incidence of other respiratory infections, including influenza (*Davies, Thorax 2021)*

COVID-19 AND ASTHMA MEDICATION

- Advise patients to continue taking their prescribed asthma medications, particularly inhaled corticosteroids
  - For patients with severe asthma, continue biologic therapy or OCS if prescribed
- Are inhaled corticosteroids (ICS) protective in COVID-19?
  - In one study of hospitalized patients aged ≥50 years with COVID-19, ICS use in those with asthma was associated with lower mortality than in patients without an underlying respiratory condition (*Bloom, Lancet RM 2021)*
- Make sure that all patients have a written asthma action plan, advising them to:
  - Increase controller and reliever medication when asthma worsens (see GINA report Box 4-2)
  - Take a short course of OCS when appropriate for severe asthma exacerbations
- When COVID-19 is confirmed or suspected, or local risk is moderate or high, avoid nebulizers where possible, to reduce the risk of spreading virus to health professionals and other patients/family
  - For bronchodilator administration, pressurized metered dose inhaler via a spacer is preferred except for acute severe asthma
  - Add a mouthpiece or mask to the spacer if required

COVID-19 AND ASTHMA – INFECTION CONTROL

- In healthcare facilities, follow local COVID-19 testing recommendations and infection control procedures if spirometry or peak flow measurement is needed (*e.g., Virant, JACI in Practice 2022)*
  - Use of an in-line filter minimizes the risk of transmission *during* spirometry, but many patients cough *after* performing spirometry; coach the patient to stay on the mouthpiece if they feel the need to cough
  - If spirometry is not available due to local infection control restrictions, and information about

lung function is needed, consider asking patients to monitor lung function at home

- Follow local infection control procedures if other aerosol-generating procedures are needed
  - Nebulization, oxygen therapy (including nasal prongs), sputum induction, manual ventilation, non-invasive ventilation and intubation
- Follow local health advice about hygiene strategies and use of personal protective equipment, as new information becomes available in your country or region

COVID-19 VACCINE AND ASTHMA

- Have COVID-19 vaccines been studied in people with asthma?
  - Yes. Many types of COVID-19 vaccines have been studied and are being used worldwide
- Are COVID-19 vaccines safe in people with allergies?
  - In general, allergic reactions to vaccines are rare
  - Patients with a history of severe allergic reaction to a COVID-19 vaccine ingredient (e.g., polyethylene glycol for Pfizer/BioNTech or Moderna, or polysorbate 80 for AstraZeneca or J&J/Janssen), should receive a different COVID-19 vaccine. More details from ACIP in *https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/covid-19.html*
  - People with allergies to food, insect venom or other medications can safely receive COVID-19 vaccines
  - As always, patients should speak to their healthcare provider if they have concerns
  - Follow local advice about monitoring patients after COVID-19 vaccination
- Usual vaccine precautions apply, for example:
  - Ask if the patient has a history of allergy to any components of the vaccine
  - If the patient has a fever or another infection, delay vaccination until they are well
- Based on the risks and benefits, and with the above precautions, GINA recommends people with asthma should be up to date with COVID-19 vaccination (including booster doses, if available)
- COVID-19 vaccination and biologic therapy
  - We suggest that the first dose of asthma biologic therapy and COVID-19 vaccine should not be given on the same day, so that adverse effects of either can be more easily distinguished
- Influenza vaccination
  - Remind people with asthma to have an annual influenza vaccination
  - CDC now recommends that influenza vaccine and COVID-19 vaccine can be given on the same day
- After COVID-19 vaccination
  - Current advice from the United States Centres for Disease Control and Prevention (CDC) is that where there is substantial transmission of COVID-19, people will be better protected, even if they are fully vaccinated, if they wear a mask in indoor public settings; this will also reduce risk to others.

GINA will update advice about COVID-19 and asthma as new data become available



Fig 2. Holding Breathing

https://buteykoclinic.com/wp- content/ uploads/ 2016107/ holding_breath.png



https://www.fabhow.com/wp-content/uploads/2017/03/buteyko-breathing-for-relief-from-asthma-1.jpg

DIFFICULT ASTHMA

Persistent symptoms and/or frequent exacerbations despite treatment at step 4/5. Check diagnosis and exacerbating factors.

Assess adherence to medication. Find out about family, psychological, or social problems that may be interfering with effective management.

REFERENCE:

1. *GINA Guideline2022*
2. *Oxford handbook of General Practice 4th edition*

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

DEFINITION

Chronic obstructive pulmonary disease (COPD) is a slowly progressive disorder characterized by airflow obstruction **(FEV1<80% predicted; FEV1/FVC<0.7)** with little or no reversibility. It includes chronic bronchitis and emphysema.

Aetiology, Pathobiology and Pathology of COPD leading to Airflow Limitation and Clinical Manifestation



PATHWAY TO DIAGNOSIS OF COPD



FIGURE 2.1

KEY INDICATORS FOR CONSIDERING A DIAGNOSIS OF COPD

Consider COPD, and perform spirometry, if any of these indicators are present in an individual over age 40. These indicators are not diagnostic themselves, but the presence of multiple key indicators increases the probability of a diagnosis of COPD. Spirometry is required to establish a diagnosis of COPD.

Dyspnea that is:	Progressive over time. Characteristically worse with exercise. Persistent.
Chronic Cough:	May be intermittent and may be unproductive. Recurrent wheeze.
Chronic Sputum Production:	Any pattern of chronic sputum production may indicate COPD.
Recurrent Lower Respiratory Tract Infections	
History of Risk Factors:	Host factors (such as genetic factors, congenital/developmental abnormalities etc.). Tobacco smoke (including popular local preparations). Smoke from home cooking and heating fuels. Occupational dusts, vapors, fumes, gases and other chemicals.
Family History of COPD and/or Childhood Factors:	For example low birthweight, childhood respiratory infections etc.

TABLE 2.1

OTHER CAUSES OF CHRONIC COUGH

INTRATHORACIC

- Asthma
- Lung Cancer
- Tuberculosis
- Bronchiectasis
- Left Heart Failure
- Interstitial Lung Disease
- Cystic Fibrosis
- Idiopathic Cough

EXTRATHORACIC

- Chronic Allergic Rhinitis
- Post Nasal Drip Syndrome (PNDS)
- Upper Airway Cough Syndrome (UACS)
- Gastroesophageal Reflux
- Medication (e.g. ACE Inhibitors)

TABLE 2.2

CONSIDERATIONS IN PERFORMING SPIROMETRY

PREPARATION

- Spirometers need calibration on a regular basis.
- Spirometers should produce hard copy or have a digital display of the expiratory curve to permit detection of technical errors or have an automatic prompt to identify an unsatisfactory test and the reason for it.
- The supervisor of the test needs training in optimal technique and quality performance.
- Maximal patient effort in performing the test is required to avoid underestimation of values and hence errors in diagnosis and management.

BRONCHODILATION

- Possible dosage protocols are 400 mcg short-acting beta$_2$-agonist, 160 mcg short-acting anticholinergic, or the two combined.[a] FEV_1 should be measured 10-15 minutes after a short-acting beta$_2$-agonist is given, or 30-45 minutes after a short-acting anticholinergic or a combination of both classes of drugs.

PERFORMANCE

- Spirometry should be performed using techniques that meet published standards.[b]
- The expiratory volume/time traces should be smooth and free from irregularities. The pause between inspiration and expiration should be < 1 second.
- The recording should go on long enough for a volume plateau to be reached, which may take more than 15 seconds in severe disease.
- Both FVC and FEV_1 should be the largest value obtained from any of three technically satisfactory curves and the FVC and FEV_1 values in these three curves should vary by no more than 5% or 150 ml, whichever is greater.
- The FEV_1/FVC ratio should be taken from the technically acceptable curve with the largest sum of FVC and FEV_1.

EVALUATION

- Spirometry measurements are evaluated by comparison of the results with appropriate reference values based on age, height, sex, and race.
- The presence of a postbronchodilator FEV_1/FVC < 0.70 confirms the presence of airflow limitation.

a Pellegrino et al. Eur Respir J 2005; 26(5): 948-68;
b Miller et al. Eur Respir J 2005; 26(2): 319-38.

The GOLD guidelines classify patients into four different categories: GOLD 1 (mild), GOLD 2

(moderate), GOLD 3 (severe), or GOLD 4 (very severe) based on their level of airflow limitation. This is assessed by evaluating

CLASSIFICATION OF AIRFLOW LIMITATION SEVERITY IN COPD (BASED ON POST-BRONCHODILATOR FEV_1)

In patients with FEV1/FVC < 0.70:

GOLD 1:	Mild	$FEV_1 \geq 80\%$ predicted
GOLD 2:	Moderate	$50\% \leq FEV_1 < 80\%$ predicted
GOLD 3:	Severe	$30\% \leq FEV_1 < 50\%$ predicted
GOLD 4:	Very Severe	$FEV_1 < 30\%$ predicted

MODIFIED MRC DYSPNEA SCALE[a]

PLEASE TICK IN THE BOX THAT APPLIES TO YOU | ONE BOX ONLY | Grades 0 - 4

mMRC Grade 0.	I only get breathless with strenuous exercise.	☐
mMRC Grade 1.	I get short of breath when hurrying on the level or walking up a slight hill.	☐
mMRC Grade 2.	I walk slower than people of the same age on the level because of breathlessness, or I have to stop for breath when walking on my own pace on the level.	☐
mMRC Grade 3.	I stop for breath after walking about 100 meters or after a few minutes on the level.	☐
mMRC Grade 4.	I am too breathless to leave the house or I am breathless when dressing or undressing.	☐

[a] Fletcher CM. BMJ 1960; 2: 1662.

TABLE 2.5

CAT™ ASSESSMENT

For each item below, place a mark (x) in the box that best describes you currently.
Be sure to only select one response for each question.

EXAMPLE: I am very happy	0 (X) 2 3 4 5	**I am very sad**	**SCORE**
I never cough	0 1 2 3 4 5	I cough all the time	
I have no phlegm (mucus) in my chest at all	0 1 2 3 4 5	My chest is completely full of phlegm (mucus)	
My chest does not feel tight at all	0 1 2 3 4 5	My chest feels very tight	
When I walk up a hill or one flight of stairs I am not breathless	0 1 2 3 4 5	When I walk up a hill or one flight of stairs I am very breathless	
I am not limited doing any activities at home	0 1 2 3 4 5	I am very limited doing activities at home	
I am confident leaving my home despite my lung condition	0 1 2 3 4 5	I am not at all confident leaving my home because of my lung condition	
I sleep soundly	0 1 2 3 4 5	I don't sleep soundly because of my lung condition	
I have lots of energy	0 1 2 3 4 5	I have no energy at all	

TOTAL SCORE: ◯

Reference: Jones et al. ERJ 2009; 34 (3); 648-54.

FIGURE 2.3

What is CAT score in COPD?

Table

CAT score	Impact level
<10	Low
10-20	Median
20-30	High
>30	Very High

THE REFINED ABCD ASSESSMENT TOOL

Spirometrically Confirmed Diagnosis › Assessment of airflow limitation › Assessment of symptoms/risk of exacerbations

Post-bronchodilator $FEV_1/FVC < 0.7$

Grade	FEV_1 (% predicted)
GOLD 1	≥ 80
GOLD 2	50-79
GOLD 3	30-49
GOLD 4	< 30

Moderate or Severe Exacerbation History

- ≥2 or ≥ 1 leading to hospital admission
- 0 or 1 (not leading to hospital admission)

C	D
A	B
mMRC 0-1 CAT < 10	mMRC ≥ 2 CAT ≥ 10

Symptoms

Spirometry as the gold standard for accurate and repeatable measurement of lung function. Evidence is emerging that when spirometry confirms a COPD diagnosis, doctors initiate more appropriate treatment.

Spirometry is the cornerstone of COPD diagnosis. According to GOLD guidelines, persistent airflow limitation is defined as a **post-bronchodilator ratio of FEV1 to Forced Vital Capacity (FEV1/FVC) of less than 0.7**

ROLE OF SPIROMETRY

- **Diagnosis**
- **Assessment of severity of airflow obstruction (for prognosis)**
- **Follow-up assessment**
  - » Therapeutic decisions.
    - – Pharmacological in selected circumstances (e.g., discrepancy between spirometry and level of symptoms).
    - – Consider alternative diagnoses when symptoms are disproportionate to degree of airflow obstruction.
    - – Non-pharmacological (e.g., interventional procedures).
  - » Identification of rapid decline.

TABLE 2.6

DIFFERENTIAL DIAGNOSIS OF COPD

DIAGNOSIS	SUGGESTIVE FEATURES
COPD	Onset in mid-life. Symptoms slowly progressive. History of tobacco smoking or exposure to other types of smoke.
Asthma	Onset early in life (often childhood). Symptoms vary widely from day to day. Symptoms worse at night/early morning. Allergy, rhinitis, and/or eczema also present. Family history of asthma. Obesity coexistence.
Congestive Heart Failure	Chest X-ray shows dilated heart, pulmonary edema. Pulmonary function tests indicate volume restriction, not airflow limitation.
Bronchiectasis	Large volumes of purulent sputum. Commonly associated with bacterial infection. Chest X-ray/CT shows bronchial dilation, bronchial wall thickening.
Tuberculosis	Onset all ages. Chest X-ray shows lung infiltrate. Microbiological confirmation. High local prevalence of tuberculosis.
Obliterative Bronchiolitis	Onset at younger age, nonsmokers. May have history of rheumatoid arthritis or acute fume exposure. Seen after lung or bone marrow transplantation. CT on expiration shows hypodense areas.
Diffuse Panbronchiolitis	Predominantly seen in patients of Asian descent. Most patients are male and nonsmokers. Almost all have chronic sinusitis. Chest X-ray & HRCT show diffuse small centrilobular nodular opacities & hyperinflation.

These features tend to be characteristic of the respective diseases, but are not mandatory. For example, a person who has never smoked may develop COPD (especially in the developing world where other risk factors may be more important than cigarette smoking); asthma may develop in adult and even in elderly patients.

MANAGEMENT OF COPD



MANAGEMENT CYCLE



FIGURE 4.3

INITIAL PHARMACOLOGICAL TREATMENT

≥ 2 moderate exacerbations or ≥ 1 leading to hospitalization	**Group C** LAMA	**Group D** LAMA or LAMA + LABA* or ICS + LABA** *Consider if highly symptomatic (e.g. CAT > 20) **Consider if eos ≥ 300
0 or 1 moderate exacerbations (not leading to hospital admission)	**Group A** A Bronchodilator	**Group B** A Long Acting Bronchodilator (LABA or LAMA)
	mMRC 0-1, CAT < 10	mMRC ≥ 2, CAT ≥ 10

FIGURE 4.2

FOLLOW-UP PHARMACOLOGICAL TREATMENT

1. **IF RESPONSE TO INITIAL TREATMENT IS APPROPRIATE, MAINTAIN IT.**
2. **IF NOT:**
   - ✓ Consider the predominant treatable trait to target (dyspnea or exacerbations)
     - Use exacerbation pathway if both exacerbations and dyspnea need to be targeted
   - ✓ Place patient in box corresponding to current treatment & follow indications
   - ✓ Assess response, adjust and review
   - ✓ These recommendations do not depend on the ABCD assessment at diagnosis



eos = blood eosinophil count (cells/µL)
** Consider if eos ≥ 300 or eos ≥ 100 AND ≥2 moderate exacerbations / 1 hospitalization*
*** Consider de-escalation of ICS or switch if pneumonia, inappropriate original indication or lack of response to ICS*

FIGURE 4.4

NON-PHARMACOLOGIC MANAGEMENT OF COPD*

PATIENT GROUP	ESSENTIAL	RECOMMENDED	DEPENDING ON LOCAL GUIDELINES
A	Smoking Cessation (can include pharmacologic treatment)	Physical Activity	Flu Vaccination Pneumococcal Vaccination Pertussis Vaccination Covid-19 Vaccination
B, C and D	Smoking Cessation (can include pharmacologic treatment) Pulmonary Rehabilitation	Physical Activity	Flu Vaccination Pneumococcal Vaccination Pertussis Vaccination Covid-19 Vaccination

*Can include pharmacologic treatment.

TABLE 4.8

FOLLOW-UP OF NON-PHARMACOLOGICAL TREATMENT

1. IF RESPONSE TO INITIAL TREATMENT IS APPROPRIATE, MAINTAIN IT AND OFFER:

- Flu vaccination every year and other recommended vaccinations according to guidelines
- Self-management education
- Assessment of behavioral risk factors such as smoking cessation (if applicable) and environmental exposures

Ensure

- Maintenance of exercise program and physical activity
- Adequate sleep and a healthy diet

2. IF NOT, CONSIDER THE PREDOMINANT TREATABLE TRAIT TO TARGET

• DYSPNEA •

- Self-management education (written action plan) with integrated self-management regarding:
- Pulmonary rehabilitation (PR) program and/or maintenance exercise program post PR
- Breathlessness and energy conservation techniques, and stress management strategies

• EXACERBATIONS •

- Self-management education (written action plan) that is personalized with respect to:
- Avoidance of aggravating factors
- How to monitor/manage worsening of symptoms
- Contact information in the event of an exacerbation

All patients with advanced COPD should be considered for end of life and palliative care support to optimize symptom control and allow patients and their families to make informed choices about future management

OXYGEN THERAPY AND VENTILATORY SUPPORT IN STABLE COPD

OXYGEN THERAPY

- The long-term administration of oxygen increases survival in patients with severe chronic resting arterial hypoxemia **(Evidence A)**.
- In patients with stable COPD and moderate resting or exercise-induced arterial desaturation, prescription of long-term oxygen does not lengthen time to death or first hospitalization or provide sustained benefit in health status, lung function and 6-minute walk distance **(Evidence A)**.
- Resting oxygenation at sea level does not exclude the development of severe hypoxemia when traveling by air **(Evidence C)**.

VENTILATORY SUPPORT

- NPPV may improve hospitalization-free survival in selected patients after recent hospitalization, particularly in those with pronounced daytime persistent hypercapnia ($PaCO_2 \geq 52$ mmHg) **(Evidence B)**.

INTERVENTIONAL THERAPY IN STABLE COPD

LUNG VOLUME REDUCTION SURGERY

- Lung volume reduction surgery improves survival in severe emphysema patients with an upper–lobe emphysema and low post–rehabilitation exercise capacity **(Evidence A)**.

BULLECTOMY

- In selected patients, bullectomy is associated with decreased dyspnea, improved lung function and exercise tolerance **(Evidence C)**.

TRANSPLANTATION

- In appropriately selected patients with very severe COPD, lung transplantation has been shown to improve quality of life and functional capacity **(Evidence C)**.

BRONCHOSCOPIC INTERVENTIONS

- In select patients with advanced emphysema, bronchoscopic interventions reduce end-expiratory lung volume and improve exercise tolerance, health status and lung function at 6-12 months following treatment. Endobronchial valves **(Evidence A)**; Lung coils **(Evidence B)**; Vapor ablation **(Evidence B)**.

GOALS FOR TREATMENT OF STABLE COPD

- **Relieve Symptoms**
- **Improve Exercise Tolerance**
- **Improve Health Status**

→ **REDUCE SYMPTOMS**

and

- **Prevent Disease Progression**
- **Prevent and Treat Exacerbations**
- **Reduce Mortality**

→ **REDUCE RISK**

TABLE 4.1

INTERVENTIONAL BRONCHOSCOPIC AND SURGICAL TREATMENTS FOR COPD

Overview of various therapies used to treat patients with COPD and emphysema worldwide. Note that all therapies are not approved for clinical care in all countries. Additionally, the effects of BLVR on survival or other long term outcomes or comparison to LVRS are unknown.



Definition of Abbreviations: BLVR, Bronchoscopic Lung Volume Reduction, EBV, endobronchial Valve, LVRS, Lung volume reduction surgery, LVRC, Lung volume reduction coil, VA, Vapor ablation

*at some but not all centers

FIGURE 4.6

KEY POINTS FOR THE USE OF NON-PHARMACOLOGICAL TREATMENTS

EDUCATION, SELF-MANAGEMENT AND PULMONARY REHABILITATION

- Education is needed to change patient's knowledge but there is no evidence that used alone it will change patient behavior .
- Education self-management with the support of a case manager with or without the use of a written action plan is recommended for the prevention of exacerbation complications such as hospital admissions **(Evidence B)**.
- Rehabilitation is indicated in all patients with relevant symptoms and/or a high risk for exacerbation **(Evidence A)**.
- Physical activity is a strong predictor of mortality **(Evidence A)**. Patients should be encouraged to increase the level of physical activity although we still don't know how to best insure the likelihood of success.

VACCINATION

- Influenza vaccination is recommended for all patients with COPD **(Evidence A)**.
- Pneumococcal vaccination: the PCV13 and PPSV23 are recommended for all patients> 65 years of age, and in younger patients with significant comorbid conditions including chronic heart or lung disease **(Evidence B)**.
- Covid-19 vaccination in line with national recommendations **(Evidence B)**.
- Tdap (dTaP/dTPa) vaccination for adults with COPD who were not vaccinated in adolescence to protect against pertussis (whooping cough) **(Evidence B)**.

NUTRITION

- Nutritional supplementation should be considered in malnourished patients with COPD **(Evidence B)**.

END OF LIFE AND PALLIATIVE CARE

- All clinicians managing patients with COPD should be aware of the effectiveness of palliative approaches to symptom control and use these in their practice **(Evidence D)**.
- End of life care should include discussions with patients and their families about their views on resuscitation, advance directives and place of death preferences **(Evidence D)**.

TREATMENT OF HYPOXEMIA

- In patients with severe resting hypoxemia long-term oxygen therapy is indicated **(Evidence A)**.
- In patients with stable COPD and resting or exercise-induced moderate desaturation, long term oxygen treatment should not be routinely prescribed. However, individual patient factors may be considered when evaluating the patient's needs for supplemental oxygen **(Evidence A)**.
- Resting oxygenation at sea level does not exclude the development of severe hypoxemia when travelling by air **(Evidence C)**.

TREATMENT OF HYPERCAPNIA

- In patients with severe chronic hypercapnia and a history of hospitalization for acute respiratory failure, long term noninvasive ventilation may be considered **(Evidence B)**.

INTERVENTION BRONCHOSCOPY AND SURGERY

- Lung volume reduction surgery should be considered in selected patients with upper-lobe emphysema **(Evidence A)**.
- In selected patients with a large bulla surgical bullectomy may be considered **(Evidence C)**.
- In select patients with advanced emphysema, bronchoscopic interventions reduce end-expiratory lung volume and improve exercise tolerance, quality of life and lung function at 6-12 months following treatment. Endobronchial valves **(Evidence A)**; Lung coils **(Evidence B)**; Vapor ablation **(Evidence B)**.
- In patients with very severe COPD (progressive disease, BODE score of 7 to 10, and not candidate for lung volume reduction) lung transplantation may be considered for referral with at least one of the following: (1) history of hospitalization for exacerbation associated with acute hypercapnia (Pco_2 >50 mm Hg); (2) pulmonary hypertension and/or cor pulmonale, despite oxyqen therapy; or (3) FEV_1 < 20% and either DLCO < 20% or homogenous distribution of emphysema **(Evidence C)**.

TABLE 4.10

IDENTIFY & REDUCE RISK FACTOR EXPOSURE

- Smoking cessation interventions should be actively pursued in all COPD patients **(Evidence A)**.
- Efficient ventilation, non-polluting cooking stoves and similar interventions should be recommended **(Evidence B)**.
- Clinicians should advise patients to avoid continued exposures to potential irritants, if possible **(Evidence D)**.

KEY POINTS FOR THE USE OF BRONCHODILATORS

- LABAs and LAMAs are preferred over short-acting agents except for patients with only occasional dyspnea **(Evidence A)**, and for immediate relief of symptoms in patients already on long-acting bronchodilators for maintenance therapy.
- Patients may be started on single long-acting bronchodilator therapy or dual long-acting bronchodilator therapy. In patients with persistent dyspnea on one bronchodilator treatment should be escalated to two **(Evidence A)**.
- Inhaled bronchodilators are recommended over oral bronchodilators **(Evidence A)**.
- Theophylline is not recommended unless other long-term treatment bronchodilators are unavailable or unaffordable **(Evidence B)**.

KEY POINTS FOR INHALATION OF DRUGS

- The choice of inhaler device has to be individually tailored and will depend on access, cost, prescriber, and most importantly, patient's ability and preference.
- It is essential to provide instructions and to demonstrate the proper inhalation technique when prescribing a device, to ensure that inhaler technique is adequate and re-check at each visit that patients continue to use their inhaler correctly.
- Inhaler technique (and adherence to therapy) should be assessed before concluding that the current therapy requires modification.

KEY POINTS FOR THE USE OF ANTI-INFLAMMATORY AGENTS

- Long-term monotherapy with ICS is not recommended **(Evidence A)**.
- Long-term treatment with ICS may be considered in association with LABAs for patients with a history of exacerbations despite appropriate treatment with long-acting bronchodilators **(Evidence A)**.
- Long-term therapy with oral corticosteroids is not recommended **(Evidence A)**.
- In patients with severe to very severe airflow limitation, chronic bronchitis and exacerbations the addition of a PDE4 inhibitor to a treatment with long acting bronchodilators with/without ICS can be considered **(Evidence B)**.
- Preferentially, but not only in former smokers with exacerbations despite appropriate therapy, macrolides, in particular azithromycin, can be considered **(Evidence B)**.
- Statin therapy is not recommended for prevention of exacerbations **(Evidence A)**.
- Antioxidant mucolytics are recommended only in selected patients **(Evidence A)**.

KEY POINTS FOR THE USE OF OTHER PHARMACOLOGICAL TREATMENTS

- Patients with severe hereditary alpha-1 antitrypsin deficiency and established emphysema may be candidates for alpha-1 antitrypsin augmentation therapy **(Evidence B)**.
- Antitussives cannot be recommended **(Evidence C)**.
- Drugs approved for primary pulmonary hypertension are not recommended for patients with a pulmonary hypertension secondary to COPD **(Evidence B)**.
- Low-dose long acting oral and parenteral opioids may be considered for treating dyspnea in COPD patients with severe disease **(Evidence B)**.

ACUTE EXACERBATIONS OF COPD

PRESENTATION

Worsening of previous stable condition. *Features:* 2:1 of:

- increase dyspnoea- marked dyspnoea, tachypnoea (>25 breaths/min), use of accessory muscles at rest and purse lip breathing are signs of severe exacerbation
- decrease exercise tolerance-marked decrease in activities of daily living is a sign of severe exacerbation
- increase fatigue
- increase fluid retention-new-onset oedema is a sign of severe exacerbation
- increase wheeze
- Chest tightness
- increase cough
- increase sputum purulence
- increase sputum volume
- Upper airways symptom e.g., colds, sore throats,
- New-onset cyanosis-severe exacerbation
- Acute confusion-severe exacerbation

Fever and chest pain are uncommon presenting features-consider alternative diagnosis.

CAUSES OF EXACERBATIONS

30% have no identifiable cause

- Infections Viral upper and lower respiratory tract infections, e.g., common cold, influenza; bacterial lower respiratory tract infections
- Pollutants, e.g., nitrous oxide, sulphur dioxide, ozone

DIFFERENTIAL DIAGNOSIS

- Pneumonia
- LVF/pulmonary oedema
- Lung cancer
- Pleural effusion
- Recurrent aspiration
- Pneumothorax
- PE
- Upper airway obstruction

INVESTIGATIONS

- **Pulse oximetry:** can be used to assess severity (saturation: S92% breathing after suggests hypoxaemia- consider admission) and to monitor progress
- **CXR:** Consider if diagnostic doubt and/or to exclude other causes of symptoms
- **Sputum culture:** Not recommended routinely in the community.

DECIDING TO TREAT EXACERBATIONS AT HOME OR IN HOSPITAL

The more features in the 'treat in hospital' column, the more likely the need for admission.

	Treat at home	Treat in Hospital*
Ability to cope at home	Yes	No
Breathlessness	Mild	Severe
General condition	Good	Poor-deteriorating
Level of activity	Good	Poor/Confined to bed
Cyanosis	No	Yes
Worsening peripheral oedema	No	Yes
Level of consciousness	Normal	Impaired
Already receiving LTOT	No	Yes
Social circumstances	Good	Living alone/not coping
Acute confusion	No	Yes
Rapid rate of onset	No	Yes
Significant co-morbidity e.g., cardiac disease, DM	No	Yes
Changes on CXR (if available)	No	Present

DIFFERENTIAL DIAGNOSIS OF COPD EXACERBATION

WHEN THERE IS CLINICAL SUSPICION OF THE FOLLOWING ACUTE CONDITIONS, CONSIDER THE FOLLOWING INVESTIGATIONS:

PNEUMONIA
- Chest radiograph
- Assessment of C-reactive protein (CRP) and/or procalcitonin

PNEUMOTHORAX
- Chest radiograph or ultrasound

PLEURAL EFFUSION
- Chest radiograph or ultrasound

PULMONARY EMBOLISM
- D-dimer and/or Doppler sonogram of lower extremities
- Chest tomography – pulmonary embolism protocol

PULMONARY EDEMA DUE TO CARDIAC RELATED CONDITIONS
- Electrocardiogram and cardiac ultrasound
- Cardiac enzymes

CARDIAC ARRHYTHMIAS – ATRIAL FIBRILLATION/FLUTTER
- Electrocardiogram

POTENTIAL INDICATIONS FOR HOSPITALIZATION ASSESSMENT*

- Severe symptoms such as sudden worsening of resting dyspnea, high respiratory rate, decreased oxygen saturation, confusion, drowsiness.
- Acute respiratory failure.
- Onset of new physical signs (e.g., cyanosis, peripheral edema).
- Failure of an exacerbation to respond to initial medical management.
- Presence of serious comorbidities (e.g., heart failure, newly occurring arrhythmias, etc.).
- Insufficient home support.

*Local resources need to be considered.

MANAGEMENT OF SEVERE BUT NOT LIFE-THREATENING EXACERBATIONS*

- Assess severity of symptoms, blood gases, chest radiograph.
- Administer supplemental oxygen therapy, obtain serial arterial blood gas, venous blood gas and pulse oximetry measurements.
- Bronchodilators:
  - » Increase doses and/or frequency of short-acting bronchodilators.
  - » Combine short-acting beta 2-agonists and anticholinergics.
  - » Consider use of long-active bronchodilators when patient becomes stable.
  - » Use spacers or air-driven nebulizers when appropriate.
- Consider oral corticosteroids.
- Consider antibiotics (oral) when signs of bacterial infection are present.
- Consider noninvasive mechanical ventilation (NIV).
- At all times:
  - » Monitor fluid balance.
  - » Consider subcutaneous heparin or low molecular weight heparin for thromboembolism prophylaxis.
  - » Identify and treat associated conditions (e.g., heart failure, arrhythmias, pulmonary embolism etc.).

*Local resources need to be considered.

KEY POINTS FOR THE MANAGEMENT OF EXACERBATIONS

- Short-acting inhaled beta$_2$-agonists, with or without short-acting anticholinergics, are recommended as the initial bronchodilators to treat an acute exacerbation **(Evidence C)**.
- Systemic corticosteroids can improve lung function (FEV_1), oxygenation and shorten recovery time and hospitalization duration. Duration of therapy should not be more than 5-7 days **(Evidence A)**.
- Antibiotics, when indicated, can shorten recovery time, reduce the risk of early relapse, treatment failure, and hospitalization duration. Duration of therapy should be 5-7 days **(Evidence B)**.
- Methylxanthines are not recommended due to increased side effect profiles **(Evidence B)**.
- Non-invasive mechanical ventilation should be the first mode of ventilation used in COPD patients with acute respiratory failure who have no absolute contraindication because it improves gas exchange, reduces work of breathing and the need for intubation, decreases hospitalization duration and improves survival **(Evidence A)**.

INDICATIONS FOR RESPIRATORY OR MEDICAL INTENSIVE CARE UNIT ADMISSION*

- Severe dyspnea that responds inadequately to initial emergency therapy.
- Changes in mental status (confusion, lethargy, coma).
- Persistent or worsening hypoxemia (PaO_2 < 5.3 kPa or 40mmHg) and/or severe/worsening respiratory acidosis (pH < 7.25) despite supplemental oxygen and noninvasive ventilation.
- Need for invasive mechanical ventilation.
- Hemodynamic instability - need for vasopressors.

*Local resources need to be considered.

INTERVENTIONS THAT REDUCE THE FREQUENCY OF COPD EXACERBATIONS

INTERVENTION CLASS	INTERVENTION
Bronchodilators	LABAs LAMAs LABA + LAMA
Corticosteroid-containing regimens	LABA + ICS LABA + LAMA + ICS
Anti-inflammatory (non-steroid)	Roflumilast
Anti-infectives	Vaccines Long Term Macrolides
Mucoregulators	N-acetylcysteine Carbocysteine Erdosteine
Various others	Smoking Cessation Rehabilitation Lung Volume Reduction Vitamin D Shielding measures (e.g., mask wearing, minimizing social contact, frequent hand washing)

KEY POINTS FOR THE MANAGEMENT OF STABLE COPD DURING COVID-19 PANDEMIC

PROTECTIVE STRATEGIES

- Follow basic infection control measures
- Wear a face covering
- Consider shielding/sheltering-in-place
- Have the COVID-19 vaccination in line with national recommendations

INVESTIGATIONS

- Only essential spirometry

PHARMACOTHERAPY

- Ensure adequate supplies of medications
- Continue unchanged including ICS

NON-PHARMACOLOGICAL THERAPY

- Ensure annual influenza vaccination
- Maintain physical activity

Table 1. Comparison of COPD and asthma

	COPD	Asthma
Symptoms <35y	Rare	Common
Smoking history	Nearly all	Maybe
Breathlessness	Persistent and progressive Good response to inhaled therapy is typical	Variable throughout the day, and from day to day. Poor response to inhaled therapy if good reconsider diagnosis
Chronic productive cough	Common	Uncommon
Waking at night with cough/wheeze	Common	Uncommon

REVERSIBILITY TESTING

Can be misleading. Not routinely recommended:

- >400 ml increase in FEVl following trial of bronchodilator or prednisolone (30 mg od for 2 week) suggests asthma
- Clinically significant COPD is *not* present if FEVl and FEVl/FVC return to normal after drug therapy

PEAK EXPIRATORY FLOW RATE (PEFR)

- Patients with COPD have little variability in PEFR. Serial home PEFR measurements can help distinguish between asthma and COPD. PEFR may underestimate severity of airflow limitation and a normal PEFR does not exclude airflow obstruction.

OTHER INVESTIGATIONS ORGANIZED IN PRIMARY CARE

- CXR
  - Indicated to exclude other diagnoses, e.g., lung cancer
- FBC
  - To identify polycythaemia or anaemia
- BMI
- al-antitrypsin : if early onset COPD or family history
- ECG/echo: if Cor pulmonale is suspected
- Sputum culture: if purulent sputum is persistent

MANAGEMENT

SMOKES: a consultation checklist for obstructive pulmonary diseases

S Smoking cessation
M Medication-inhaled bronchodilator, vaccines (influenza, pneumococcus), corticosteroids (if indicated)
0 Oxygen-is it needed?
K Komorbidity-cardiac dysfunction, sleep apnoea, osteoporosis, depression, asthma
E Exercises and rehabilitation
S Surgery-bullectomy, lung volume reduction surgery, single -lung transplantation

Record values of spirometric tests performed at diagnosis and review. At each review record current

symptoms, problems since last seen, exercise tolerance, and smoking status. Calculate BODE score if possible. Educate the patient/family about COPD, medication, and self-help strategies.

NON-DRUG THERAPY

- Smoking cessation: Most important. Improves outcome
- Vaccination: Offer pneumococcal and annual influenza vaccination
- Exercise: Lack of exercise decrease FEVl. Pulmonary rehabilitation is of proven benefit-refer directly or via respiratory physicians
- Nutrition: Weight decrease in obese patients improves exercise tolerance

SMOKING AND COPD

FEV as % of value aged 25 yr	Age 60 yrs	Age 75 yrs
Non-smoker	85%	80%
Ex-smoker: quit aged 40 yr	60%	45% (symptoms)
Ex-smoker: quit aged 60 yr	33% (severe symptoms)	15% (severe disability)
On-going smoker	33% (severe symptoms)	Dead

REFERENCE:

1. GOLD Guideline 2022
2. Oxford handbook 4th edition

ACUTE RESPIRATORY INFECTIONS (ACUTE VIRAL INFECTIONS)

INTRODUCTION AND RELEVANCE TO GENERAL PRACTICE

- Acute respiratory infections range from self-limited conditions such as uncomplicated upper respiratory infections (URI, common cold) to serious life-threatening conditions like pneumonia. URI and acute bronchitis are among the most common reasons for visits in ambulatory care; they account for significant morbidity and absenteeism from work and school.
- Management of these infections has been complicated by recent evidence indicating a rise in the prevalence of antibiotic-resistant pathogens. The vast majority of antibiotics prescribed in ambulatory settings are for respiratory tract infections. The injudicious use of antimicrobial agents creates an environment for developing resistance, placing the population and individual patient at risk.
- Consequently, appropriate treatment of acute respiratory tract infections has become a challenge to the clinician. Acute Respiratory infection specifically URTI stands for second ranking in USA family practice and third ranking in Australia general practice regarding most frequently managed disorders.

CLASSIFICATION OF ARI

- Infections localized in respiratory structures above the larynx can be conceptualized as URI, and correspondingly those below the larynx as lower respiratory tract infections.
- An advantage to focusing on different primary sites of infection is that different pathogens are more common at certain sites than others thereby providing a guide for treatment.

Sinus And Nasal Problems

- Generally, viruses are the most common causes of respiratory complaints, and the history and physical examination are meant to detecting other reasons for these symptoms. The most common causes of noninfectious nasal discharge include allergic rhinitis and foreign bodies.
- **Key historical findings** that suggest causes other than infection for a runny nose include unilateral nasal discharge (as seen with a foreign body or necrotic tumor) or a clear nasal discharge that has persisted for several weeks (suggesting allergy).
- Differentiating bacterial from viral URI is very difficult. Evidence suggests that many of the symptoms that are typically ascribed to bacterial sinusitis occur just as often with sinus inflammation associated with common colds.
- **Two studies** have been helpful in identifying clinical cues that can be used to differentiate these two conditions. Combined, these studies suggest that patients with sinusitis are more likely to have a constellation of maxillary toothache, purulent nasal discharge by history or examination, poor sinus transillumination, and a lack of response to decongestants, along with a phenomenon termed "double sickening".
- **Double sickening** refers to patients who say they started with the symptoms of a common cold, but a few days later they "got sicker". One or two of these symptoms alone are not predictive of a sinusitis, but the presence of the entire spectrum increases the likelihood of a secondary sinusitis.

Sore Throats

- **Sore throats or hoarseness** may be caused by a limited number of other conditions. These are primarily laryngeal inflammation from acute insults such as smoke inhalation, chronic abuse from smoking, or singing.
- **Vocal cord neoplasm** may also be suspected in patients with chronic hoarseness, especially if risk factors such as cigarette smoking or alcohol use are present.
- Pharyngeal infections are even more difficult to differentiate into bacterial- or viral-based on clinical criteria. **Decision rules (CENTOR SCORE)** using fever, tonsillar exudate, cervical adenopathy, and the lack of either a runny nose or cough have been evaluated to identify patients with streptococcal pharyngitis, but have had mixed success.
- Another difficulty in evaluating decision rules is that a large segment of the population (up to 20%) can be colonized with group A Streptococcus; so, a positive culture may not indicate infection with this agent in a fairly large group of patients.
- However, at this time either rapid or conventional throat cultures remain the best way to differentiate a strep throat from pharyngitis associated with a cold.

Cough And Lower Respiratory Symptoms

- For **lower respiratory symptoms** such as cough, additional noninfectious causes should be considered. Congestive heart failure, aspiration of gastric contents or foreign bodies, lung neoplasms, asthma, and other inflammatory pulmonary conditions can produce a cough and shortness of breath.
- **Congestive heart failure and pulmonary embolism** also can cause pulmonary infiltrates and effusions that can be confused with pneumonia. Medications, most notably angiotensin-converting enzyme inhibitors, may cause a cough as well.
- If **a lower respiratory infection** is suspected, several possible conditions should be considered. First, it is important to differentiate acute bronchitis, a self-limited condition, from pneumonia.
- The presence of **rales and/or a localized decrease in breath sounds** suggest pneumonia, but may not be sensitive. Patients who appear to be ill yet have no abnormal physical findings on lung examination that suggest pneumonia should have a chest radiograph.
- In addition to pneumonia, other infectious conditions can cause rales and productive cough. Pulmonary abscesses may produce undulating fevers, shortness of breath, and cough.
- **Abscesses** are associated with certain types of pneumonia-causing organisms such as Staphylococcus sp. Bronchiectasis is a bronchial wall disease that allows accumulation of large amounts of secretions in the diseased bronchus.
- The **copious secretions** result in a chronic productive cough. Furthermore, these pooled secretions often become infected and can produce a fever, shortness of breath, and purulent sputum production consistent with pneumonia.

DIFFERENTIAL DIAGNOSIS

UNCOMPLICATED URI/COMMON COLD

- URI, or the "**common cold,**" are common infectious conditions often seen in the ambulatory care setting. Adults typically have two to four URI annually, and children in day care have as many as six or seven.
- Although **URI are mild, self-limited,** and of short duration, they are a leading cause of acute morbidity, and industrial and school absenteeism. Each year, URI account for 170 million days

of restricted activity, 23 million days of school absence, and 18 million days of work absence. And while colds may be viewed as benign, the impact of URI on quality of life is similar in magnitude to such chronic illnesses as chronic lung disease, depression, or osteoarthritis.

- The **mechanisms of transmission** suggest that URI can be spread through contact with inanimate surfaces as well as direct hand-to-hand contact. URI have a seasonal variation, with an increased prevalence in the United States between September and March. It is unclear why this variation exists although it may be related to increased crowding of indoor populations in the colder months.
- **Temperature** is not the key to seasonal variation without the presence of a pathogen. Evidence from Antarctica showed that spacious well-ventilated rooms reduced transmission of URI compared to crowded poorly-ventilated rooms regardless of temperature.
- **One study** was able to identify the specific virus believed to cause a URI in 69% of all URI cases. Rhinoviruses were the most prevalent virus and were seen in 52% of the patients. Coronaviruses were the second most common group of causative agents, followed by influenza A or B virus. Identified bacterial pathogens were Chlamydia pneumoniae, Haemophilus influenza, Streptococcus pneumoniae, and Mycoplasma pneumoniae. None of the patients had beta-hemolytic group A Streptococcus. In terms of bacterial pathogens, infections without evidence of a viral infection occurred in only 0.05% of the cases.

- **Uncomplicated URI** are characterized by rhinorrhea, nasal congestion, sneezing, sore or "scratchy" throat, and cough. The incubation period varies between 48 and 72 hours. In some cases, a low-grade fever is present, but temperature elevation is rare in adults. The early symptoms may be minimal and limited to malaise and nasal symptoms.

- The **nasal discharge** is initially clear and watery. There is a subsequent transition period where the nasal discharge becomes viscous, opaque, and discolored (white, yellow, green). The color of the secretions alone is not predictive of a bacterial infection.

- The clinical presentation is similar in both adults and children. The episode tends to be self-limited. The median duration of a cold is **1** week, with most patients improving by day 10, but lingering symptoms may last up to two weeks.

ACUTE SINUSITIS

- Because **sinusitis** usually is a complication of upper respiratory viral infections, the incidence peaks in the winter. Among children, sinusitis is frequently found as a comorbidity with otitis media.

- **Children** are also more likely to have posterior ethmoidal and sphenoid inflammation, while adults have mainly maxillary and anterior ethmoidal sinusitis.
- Some **medical conditions** may increase the risk for sinusitis. These include cystic fibrosis, asthma, immunosuppression, and allergic rhinitis. Cigarette smoking may also increase the risk of bacterial sinusitis during a cold because of reduced muco-ciliary clearance.
- **Sinus inflammation** can be caused by viral, fungal, and bacterial infections as well as allergies. Most acute sinusitis is caused by viral infection. The inflammation associated with viral infections clears without additional therapy.
- **Cultures from patients with sinusitis** show that the most prevalent organisms are S. pneumoniae and, especially in smokers, H. influenza. These two organisms are present in 70% of bacterial acute sinusitis cases. When antibiotics are used to treat bacterial sinusitis, selection criteria should include sufficient coverage of these two organisms.
- **Fungal sinusitis** is very rare and usually occurs in immunosuppressed individuals or those with diabetes mellitus.

- Acute sinusitis has considerable overlap in its constellation of signs and symptoms with URI. One half to two thirds of patients with sinus symptoms seen in primary care are unlikely to have sinusitis. UR is often precursors of sinusitis, and at some point, symptoms from each condition may overlap.

- Sinus inflammation from a URI without bacterial infection is also common. In a series of 60 children undergoing computerized tomography (CT) for non-sinus-related diagnoses, 47% had evidence of sinus inflammation with no clinical signs of sinusitis, and with complete resolution following their viral illness.

- Acute sinusitis tends to start with a URI that leads to sinus ostial obstruction. The signs and symptoms that increase the likelihood that the patient has acute sinusitis are a "double sickening" phenomenon, maxillary toothache, purulent nasal discharge, poor response to decongestants, and a history of discolored nasal discharge (4,23). Other authors have stressed that the symptoms need to persist longer than 1 week to distinguish sinusitis from a URI (24). It should be pointed out that the commonly used sign of facial pain or swelling has low sensitivity for acute sinusitis.

ACUTE BRONCHITIS

- **Acute bronchitis** in the otherwise healthy adult is one of the most common medical problems encountered in primary care. The prevalence of acute bronchitis peaks in the winter and is much less common in the summer.
- **Viral infection** is the primary cause of most episodes of acute bronchitis. A wide variety of viruses have been shown as causes of acute bronchitis including influenza, rhinovirus, adenovirus, coronavirus, parainfluenza, and respiratory syncytial virus. Nonviral pathogens including Mycoplasma pneumoniae and Chlamydia pneumoniae have also been identified as causes.
- The etiologic role of bacteria like **H. influenza and S. pneumoniae** in acute bronchitis is unclear because these bacteria are common upper respiratory tract flora. Sputum cultures for acute bronchitis are therefore difficult to evaluate since it is unclear whether the sputum has been contaminated by pathogens colonizing the nasopharynx.
- **Acute bronchitis** is an inflammatory condition of the tracheobronchial tree usually associated with a generalized respiratory infection. Cough begins early in the course of the illness and is the most prominent feature of the condition. An initially dry cough may later result in sputum production, which characteristically changes from clear to discolor in the later stages of the illness. The cough may last for a significant time. Although the duration of the condition is variable, one study showed that 50% of patients had a cough for more than 3 weeks, and 25% had a cough for more than 4 weeks.
- **Patients with acute bronchitis** usually have a viral respiratory infection with transient inflammatory changes that produce sputum and symptoms of airway obstruction. Acute bronchitis is essentially a diagnosis of exclusion. The history should include information on cigarette use, exposure to environmental toxins (e.g., dust, beryllium, volatile organic compounds, asbestos), as well as medication history (e.g., use of angiotensin converting enzyme inhibitors). The chronicity of the cough should be established to distinguish acute bronchitis from chronic bronchitis since they have different treatments.
- Both **acute bronchitis and pneumonia** can present with fever, constitutional symptoms, and a productive cough. While patients with pneumonia often have rales, this finding is neither sensitive nor specific for the illness. When pneumonia is suspected because of a high fever, constitutional symptoms, severe dyspnea, and certain physical findings or risk factors, a chest radiograph should be obtained to confirm the diagnosis.
- **Asthma and allergic bronchospastic disorders** can mimic the productive cough of acute bronchitis. When obstructive symptoms are not obvious, mild asthma may be misdiagnosed as

acute bronchitis. Further, since respiratory infections can trigger bronchospasm in asthma, patients with asthma that occurs only in the presence of respiratory infections may present as patients with acute bronchitis.

- **Asthma** should be considered in patients with repetitive episodes of acute bronchitis. Patients who repeatedly present with cough and wheezing can be given pulmonary function testing with and without a bronchodilator. For patients for whom routine pulmonary function testing is equivocal but asthma is highly suspected, further or provocative testing with a methacholine challenge test may help differentiate asthma from recurrent bronchitis.

BRONCHIOLITIS

- **Acute bronchiolitis** is a distinct syndrome occurring in young children with a peak incidence at 6 months of age. It is an acute respiratory illness resulting from inflammation of small airways and characterized by wheezing.

- Children generally acquire the infection from family members or other children in day care who are infected with an upper respiratory tract infection. Bronchiolitis is not uncommon, with approximately 15% of children experiencing this illness during the first 2 years of life.
- **Respiratory syncytial virus (RSV**) is the most common cause of bronchiolitis accounting for between 50% and 90% of cases. The majority of the cases occur during the winter and early spring mirroring the prevalence of the viral pathogens in the community.
- **The diagnosis of** bronchiolitis is based on clinical findings and on the knowledge of the prevalence of viral pathogens prevalent in the community. The classic signs of bronchiolitis are wheezing and hyperexpansion of the lungs.
- **Bronchiolitis begins** as a URI, but soon the patient develops a cough, audible wheezing, irritability, listlessness, dyspnea, and cyanosis. Chest radiographs may reveal atelectasis, hyperinflation, or both. Untreated, infants with bronchiolitis can die from hypoxemia, dehydration, or apnea; less than **1**% of affected infants die, however. Most recover but suffer recurrent wheezing episodes, usually precipitated by viral infections

INFLUENZA

- Approximately **10% to 20%** of the population in the United States develops influenza annually, with influenza season usually peaking between late December and early March.

- In Myanmar, influenza season starts from mid-May to end of August, that is, rainy season. In recent influenza seasons, especially when influenza A type **H3N2** predominated, **80% to 90%** of influenza-related deaths occurred in individuals older than 65 years of age. It is the fifth leading cause of death in individuals over 65, and the most common infectious cause of death in this country.

- Rates of disease are increased in individuals 65 years of age or older and in those with underlying health problems, such as diabetes mellitus and coronary artery disease. Influenza is caused by highly infectious RNA viruses of the orthomyxovirus family.

- **Influenza A viruses** are classified into subtypes based on two surface antigens- hemagglutinin (H) and neuraminidase (N). Changes in the H or N antigen account for the epidemiologic success of these viruses. Infection with one subtype however, provides little protection against infection with other subtypes, and infection or vaccination with one strain does not result in immunity to distantly related strains of the same subtype because of antigenic drift. Consequently, major epidemics of respiratory disease are caused by influenza virus strains not represented in that year's vaccine.
- Occasionally, there are **major shifts in the antigenic composition** of the influenza virus. Such

shifts are believed to be associated with the deadly pandemic of influenza in 1917-1918 as well as pandemics in 1957 and 1968. What made the 1918 influenza pandemic so remarkable was the high fatality rate in young to middle-age adults. Concerns about emerging antigen shifts associated with avian flu viruses compare possible consequences to the 1918 pandemic, although there is no evidence that an avian strain was associated with this prior epidemic.

- During the initial evaluation of an influenza-like illness, the following entities must be considered in the differential: respiratory syncytial virus, parainfluenza, adenovirus, enterovirus, mycoplasma, chlamydia, and streptococcal disease. Influenza is extremely contagious and is transmitted from person to person through small particles of virus-laden

  respiratory secretions that are propelled into the air by infected persons during coughing, sneezing, and talking.

- **The abrupt onset of fever, myalgia, sore throat, and a nonproductive cough** characterize the typical influenza infection. Symptoms usually last 1 to 5 days. Unlike other common respiratory illnesses, influenza viruses cause severe malaise lasting several days. The symptoms vary by age, with children commonly presenting with cough, rhinorrhea, and croup, while adults present with cough, myalgia, sore throat, and headache. The elderly usually complains of cough alone or in combination with headache. A key to diagnosis is being aware of influenza outbreaks in the community at the time of presentation.
- **The availability of rapid tests** to identify influenza has made it possible to evaluate patients quickly for this disorder. However, the cost-benefit of this approach is questionable. Most studies show that during flu season when influenza is highly likely, it is most economical to simply treat the patient. The value of office-based testing is probably during the "shoulders" of flu season when the probability of influenza is lower.

CLINICAL EVALUATION (DIAGNOSTIC WORK UP)

- Patients with acute respiratory infections need a focused history that includes current and recent symptoms, duration of episode, prior episodes and treatment, other family members affected, risk factors, and smoking history.
- In addition, several red flags in the history and physical examination may alert the clinician to noninfectious or life-threatening emergencies

HISTORY AND PHYSICAL EXAMINATION

- **Fever is a nonspecific sign**, but can be used to discriminate mild, **self-limited problems,** such as acute bronchitis, from more significant infections such as pneumonia. Both the height of the temperature and the pattern of its development can give clues to the diagnosis. For example, URI ("colds") generally cause little or no fever in older children and adults.

- However, a child with symptoms of a common cold but who also has a high fever might be suspected of having otitis media, sinusitis, or another bacterial infection. Fever also can be used to discriminate between different types of virally-mediated illnesses such as the common cold and influenza, since influenza generally produces a high fever.
- **Rhinorrhea**, either watery or purulent, indicates inflammation in the nasal cavities from either an infectious or noninfectious source. Although viral illnesses commonly cause runny noses, noninfectious conditions such as allergic rhinitis (hay fever) and a foreign body in the nose can also present with rhinorrhea. **In viral illnesses**, the nose is usually red and swollen with patchy areas of exudates. In contrast, in allergic rhinitis, the mucosa usually is swollen (boggy) and often pale with a clear, glistening surface and little exudate. With foreign bodies, generally only one nostril is affected and the drainage is usually purulent and foul-smelling.

- **Headache** is another symptom that can arise from respiratory and nonrespiratory structures. Frontal headache, particularly if it gets worse by bending over, suggests sinus inflammation from either a cold or sinusitis. Facial pain is another symptom of sinus disease, since portions of the sinuses, the ear, and the skin of the face are all supplied by the trigeminal nerve.
- However, as noted below, facial pain alone is not a good discriminator of sinusitis since many patients with common colds also have sinus inflammation. Sinus inflammation also can cause maxillary toothache because the superior alveolar nerve passes through that sinus.

Red Flags of History and Physical Examination

Red Flag	Other Condition to consider
Unilateral purulent nasal drainage	Occult nasal foreign body
Severe sore throat with deviation of the uvula laterally	Peritonsillar abscess
Difficulty swallowing with stridor	Epiglottitis
Hoarseness persisting greater than 30 days	Laryngeal cancer or nodule
Cough persisting greater than 30 days	Lung cancer
Hemoptysis	Bronchial lung cancer
Cough with unilateral wheezing	Bronchial foreign body
Early morning cough with hoarseness	Reflux esophagitis
Shortness of breath with unilateral decreased breath sounds	Spontaneous pneumothorax

- **Sore throats** can result from direct inflammation of the throat caused by a variety of different pathogens. The type of pain associated with streptococcal pharyngitis is not helpful in differentiating strep throat from virally mediated infections. However, very severe pain with difficulty swallowing may be indicative of a peritonsillar abscess. Severe pain and swallowing difficulty also is common with herpangina, a Coxsackie viral infection of the throat, palate, and posterior tongue.
- **Pharyngeal inflammation** also can cause referred pain to the ear because the middle ear shares innervation from the glossopharyngeal nerve.
- **Hoarseness** generally indicates narrowing of the airway in the region of the larynx. Typically, the cause is inflammation of the vocal cords from laryngitis. In small children, narrowing of the same air passage leads to stridor.
- **Cough** is the most common symptom observed in lower respiratory tract infections, but is common in URI as well; Inflammation of the trachea, bronchi, bronchioles, or alveoli causes cough regardless of the etiology of the inflammation.
- Infections also cause hypersecretion of and production of infectious exudates that are cleared with coughing. Some infections, such as mycoplasma influenza and other viral infections, produce inflammation without a great deal of exudate and are typified by a nonproductive or dry cough. The degree of cough provides little indication of disease severity; many viral respiratory infections cause severe, persistent cough, even when they are largely resolved.
- **Chest pain** can occur with some respiratory infection, but it is a rare symptom in isolation. Usually chest pain is present with coughing, shortness of breath, fever, or some other sign of infection. Chest pain with infection is usually pleuritic in nature and represents pleural inflammation from the infectious process.
- **The pleuritis** can be mild as seen in some cases of acute bronchitis, severe as with some Coxsackie B virus infections, or associated with significant pleural effusions and respiratory compromise in pneumonias. Because other conditions, such as a pulmonary embolism, can cause chest pain and low grade fever, clinicians should consider non-infectious causes as well as respiratory infections when patients complain of chest discomfort.

- Finally, **cough can lead to chest pain** by straining or otherwise injuring the muscles and bones of the chest wall or by irritating an inflamed trachea or bronchi. Red flags in the history that suggest other disorders are shown in Table described above.
- For patients with respiratory tract disease, a thorough physical examination often confirms the diagnosis that was suspected after a careful history. When evaluating a patient with a potential respiratory infection, **a first step** is to assess the overall appearance of the patient, and his or her vital signs. Patients who are comfortable, breathing easily, and afebrile are unlikely to have a life-threatening disease.
- However, tachycardia, tachypnea, and alterations in mental status are ominous signs that are associated with much higher death rates from respiratory infections such as pneumonia.
- **After initial assessment,** careful attention should be paid to the ears, nose, throat, neck, and chest. As noted earlier, the appearance of the nasal mucosa may be helpful in determining if rhinorrhea is caused by infection as opposed to allergy.
- **Palpation of the sinuses** is sometimes performed, but since this maneuver offers little value in differentiating sinusitis from a common cold and is likely to be highly operator-dependent, it is of little value. Transillumination of the sinuses has a much higher value in differentiating a sinusitis from a cold.
- **Pharyngeal findings** of erythema, tonsillar enlargement, and exudate are useful in identifying a likely infection.
- **Exudative tonsillitis** is common with streptococcal pharyngitis, but is seen just as frequently in adenoviral throat infections; exudative tonsillitis also is a feature of mononucleosis. Uvular deviation is another important sign to look for during the pharyngeal examination. Deviation of the uvula is an early sign of a peritonsillar abscess; in these cases, the uvula points away from the side with the abscess.
- **Cervical adenopathy**, which is common with streptococcal pharyngitis and mononucleosis, should be searched for during the neck examination. Palpation of the neck also may be useful in detecting an enlarged thyroid or other mass that may be compressing the trachea and producing stridor.
- A complete lung examination is crucial in patients with suspected lower respiratory infections. Auscultation over all areas of the lungs is important to detect rales or a rub from pleuritis. Percussion of the lower lung fields may be useful in detecting pleural effusions.

DIAGNOSTIC TESTING

- Routine laboratory testing is not indicated for the vast majority of respiratory infections. The most helpful tests for URI are a throat culture and serum testing for mononucleosis.
- Because of delays in the appearance of anti-mononucleosis antibodies, the commonly used mononucleosis tests may be falsely negative in the first week of symptoms, so testing should be delayed until symptoms have been present for a week or longer.
- Sinus radiographs or CT scans offer little benefit over clinical criteria for sinusitis and should be reserved only for patients with very confusing clinical pictures or fever without a clear origin.
- For lower respiratory infections, the most valuable test is a chest radiograph. This is useful in differentiating pneumonia from acute bronchitis or other causes of shortness of breath and cough. The appearance of the infiltrate on the chest radiograph is sometimes helpful in predicting the etiologic agent as well.
- However, clinicians should be wary of false negative chest radiographs, which can occur in patients who are dehydrated or neutropenic.
- Sputum cultures are less helpful. Cultures are often unreliable or contaminated. Many studies have found that only about one third of hospitalized patients with pneumonia are able to produce adequate specimens for culturing. Empiric treatment based on the age of the patient, severity of illness, and other risk factors is the most cost-effective strategy.

MANAGEMENT OF UTRI

- Patient management and treatment is based on the condition. The following table summarizes the evidence for treatment options for most acute respiratory infections.
- Uncomplicated URI/Common Cold
- **The most effective symptomatic treatments** are over the counter decongestants. Preparations containing pseudoephedrine are effective in treating the nasal congestion associated with the common cold. However, several states have begun regulating the purchase of pseudoephedrine because of its integral role in the illicit manufacture of methamphetamine.
- Despite the viral etiology of common colds, several studies have shown that the majority of common cold cases seen by physicians are treated with antibiotics. It should be noted that many individuals do not seek care from physicians for colds and therefore are limited in their ability to use antibiotics.
- Controlled trials of antibiotic treatment of URI have consistently demonstrated no benefit.
- In seven trials of antimicrobial treatment of URI, six found no difference in improvement or further complications between the groups. Complications tend to be minimal and occur at a rate of 1%-15%. One trial found a slight benefit in decreasing purulent rhinitis. Similarly, an additional trial attempted to isolate "bacterial colds," for which antibiotics might be effective treatments. Although there was some indication of patient improvement at day 5, the differences were gone by day 10. It should be noted that the normal presentation of a URI is 1 to 2 weeks.
- In addition, it is important to emphasize that the use of antibiotics for URI does not prevent bacterial complications such as otitis media.
- Many alternatives to antibiotics for URI have been investigated and have their advocates, if not strong evidence of effectiveness. Zinc gluconate lozenges are available without a prescription and have been suggested as effective in decreasing the duration of the common cold. However, one meta-analysis of eight randomized trials and another of seven trials.
- It is concluded that **zinc lozenges were not effective** in reducing the duration of cold symptoms.
- Echinacea has shown mixed results as a treatment for URI in both children and adults. Although several smaller studies have observed some benefit, larger studies have tended to find no significant benefit for using Echinacea. Several recent studies have found echinacea beneficial when compounds are used that mix echinacea with other treatments such as vitamin C or tea.
- **Vitamin C** also has been advocated for URI; systematic reviews of the literature, however, provide only weak support for its effectiveness. Antihistamines, with a few exceptions, have not been shown to be effective treatments.
- Other treatments also are being evaluated for use in URI. Ipratropium bromide has demonstrated use in controlling congestion and rhinorrhea, but its cost has limited its usefulness to date.
- Other treatments that are being investigated for URI include acupuncture, nitric oxide, vitamin E, and North American ginseng. Some appear promising, but it is premature to recommend them as treatments because of limited evidence of their benefits.

ACUTE SINUSITIS

- Antibiotics are commonly prescribed for adult patients who present with complaints consistent with acute sinusitis. The effectiveness of antibiotics is unclear, although some evidence supports their use. Four recent placebo-controlled, double-blind, randomized trials of antibiotics for acute sinusitis encountered in general practice settings have yielded mixed results.
- Two of these trials showed no beneficial effect of antibiotics, but two demonstrated significant effects of penicillin and amoxicillin. The trials demonstrating effects suggested that patients with more severe signs and symptoms, as well as radiographic or CT confirmation, may benefit from an antibiotic.
- A meta-analysis of 32 randomized trials of antibiotics versus placebo and antibiotics of different

classes captured in computerized databases such as MEDLINE and studies from pharmaceutical companies indicated that acute maxillary sinusitis may benefit from treatment with penicillin or amoxicillin for 7 to 14 days.

- If an antibiotic is used, evidence using trimethoprim/sulfamethoxazole suggests that short duration treatment (e.g., 3 days) is as effective as longer treatment (76). Further, a meta- analysis indicates that narrow spectrum agents are as effective as broad spectrum agents.

ACUTE BRONCHITIS

- Antibiotic treatment for acute bronchitis is quite common, with evidence indicating that 60%-75% of adults visiting a doctor for acute bronchitis receive an antibiotic. Clinical trials of the effectiveness of antibiotics in treating acute bronchitis have had mixed results.
- One reason for the lack of consensus is that in each of the nine trials, different antibiotics were used as well as different outcomes. In an effort to quantitatively review the data, three different meta-analyses were recently conducted. In one meta-analysis, neither resolution of cough nor clinical improvement at reexamination was affected by antibiotic treatment. Importantly, the side effects were more common in the antibiotic groups compared to placebo.
- The other two meta-analyses concluded that antibiotics may be modestly effective for acute bronchitis. All of the meta-analyses agreed that the benefits of antibiotics in a general population are marginal and should be weighed against the impact of excessive use of antibiotics on the development of antibiotic resistance.
- Data from clinical trials suggests that bronchodilators may provide effective symptomatic relief to patients with acute bronchitis. Treatment with bronchodilators demonstrated significant relief of symptoms including faster resolution of cough, as well as return to work.
- However, one study evaluated the effect of albuterol in a population of patients with undifferentiated cough and found no beneficial effect. Since a variety of conditions present with cough, there may have been some misclassification in generalizing this to acute bronchitis.
- The mainstay of therapy consists of respiratory support, nutrition, and hydration. Bronchodilators have been suggested as treatments for bronchiolitis, but a meta-analysis of eight trials of bronchodilators versus placebo indicated that bronchodilators produce only limited short-term improvement in clinical scores. This small benefit must be weighed against the costs of these agents.
- The use of antivirals in the treatment of RSV infections remains controversial. Ribavirin is the only antiviral agent licensed for the treatment of RSV infections and should be considered in severely affected children. Patients undergoing therapy should be placed in negative pressure rooms with frequent air exchanges and scavenging systems to decrease ribavirin exposure of health care providers and to minimize release into the surrounding environment.
- Uncontrolled trials show that early therapy with ribavirin aerosol may be beneficial. In a systematic review of 10 trials of ribavirin for RSV, it was concluded that the trials lack sufficient power to provide reliable estimates of the effects. The cumulative results of three small trials show that ribavirin reduces length of mechanical ventilator support, and may reduce days of hospitalization.
- Vaccines against RSV are under development but not currently available. Hand washing is currently the most effective preventive measure.
- Cough nor clinical improvement at reexamination was affected by antibiotic treatment. Importantly, the side effects were more common in the antibiotic groups compared to placebo. The other two meta-analyses concluded that antibiotics may be modestly effective for acute bronchitis.
- All of the meta-analyses agreed that the benefits of antibiotics in a general population are marginal and should be weighed against the impact of excessive use of antibiotics on the

development of antibiotic resistance.

- Data from clinical trials suggests that bronchodilators may provide effective symptomatic relief to patients with acute bronchitis. Treatment with bronchodilators demonstrated significant relief of symptoms including faster resolution of cough, as well as return to work. However, one study evaluated the effect of albuterol in a population of patients with undifferentiated cough and found no beneficial effect. Since a variety of conditions present with cough, there may have been some misclassification in generalizing this to acute bronchitis.

INFLUENZA

- **Treatment of influenza infection** is targeted toward symptoms, with spontaneous recovery within 5 to 7 days. The typical therapy includes bed rest, oral hydration, acetaminophen or NSAIDs to reduce fever, headache, and myalgias, over the counter throat lozenges, intranasal anticholinergics, and systemic antihistamines and anticholinergics. Preventative measures along with antiviral drugs are used to shorten the disease course and decrease secondary complications.
- In addition to symptomatic medications, influenza may be treated with antiviral agents. First generation antiviral agents effective against influenza A are amantadine hydrochloride and rimantadine hydrochloride.
- These drugs have no effect on influenza B viruses, however. A meta-analysis of the randomized and quasi-randomized trials indicate that both amantadine or rimantadine are effective in reducing the severity and duration of symptoms, particularly if given within 48 hours of illness onset. Unfortunately, these drugs have shown substantial rates of adverse events.
- Two neuraminidase inhibitors, zanamivir and oseltamivir, have been successful against both influenza A and B. An analysis of six randomized placebo-controlled trials of zanamivir indicated a decrease in illness duration ranging from 1 to 3 days in different populations.
- The greatest benefit was found in patients >50 years of age. Randomized trials of oseltamivir have also demonstrated reduced duration of illness. The treatments must be given within 36 hours, and preferably within 24 hours, of onset for maximum effectiveness.

PREVENTION

- **Vaccination for influenza** is the **most common** and effective way to prevent influenza. Each year's vaccine contains three virus strains representing the viruses that are predicted to circulate in the United States during the upcoming influenza season.

- Unfortunately, sometimes the supply of influenza vaccine is delayed or insufficient to cover all patients recommended for immunization.
- It is recommended that the following individuals receive the influenza vaccine:
    - persons aged 65 years and older
    - residents at least 6 months of age in nursing homes or chronic care facilities
    - individuals 6 months or older who have underlying medical conditions
    - individuals 6 months to 18 years of age who receive long-term aspirin therapy and have an increased risk for developing Reye's syndrome after being infected with influenza virus
    - women who will be at or beyond 14 weeks gestation during the influenza season or at any stage, if underlying medical conditions may result in secondary complications
    - Employees of hospitals, outpatient settings, nursing homes, and other chronic care facilities that care for high-risk patients.
    - Because of the decline of immunity during the year and antigen variation from year to year within the influenza virus, individuals should receive the vaccine every year. The optimal time for vaccination is May to June.

Drug	Dosage	Adverse effects	Cost per course ($)*	Comments
Amantadine	100 mg BID for 3-5 days Reduce dose in elderly (100 mg/D) Dose in children 5 mg/kg/D in 2 divided doses	Confusion, insomnia, depression, nervousness, nausea, anorexia, dry mouth	$	Start within 48 hrs: Type A only shortens symptoms by 1 day
Rinantidine	100 mg BID for 3-5 days Reduced dose in elderly (100 mg/D) Dose in children under 10 is 5 mg/kg/D once a day	Nausea, dizziness	$	Start within 48 hrs: Type A only shortens symptoms by 1 day
Zanamivir	2 inhalations Q12 hrs for 5 days Approved in children 0.5-≤7 yrs of age	Cough	NA	Start within 30 hrs: Type A & B shortens symptoms by 1.5 days
Oseltamivir	75 mg BID for 5 days Approved in children 0.5-1 yr of age, >15 kg-30 kg, 45 mg BID; >24-40 kg, 60 mg BID; >40 kg, 75 mg BID	Nausea and vomiting; Insomnia; vertigo; bronchitis	$$$	Initiate treatment within 2 days of symptoms; Type A & B shortens symptoms by 1.5 days

$ = <$ 33, $$ = $ 34-66, $$$ = > $ 67

Evidence supporting management of common respiratory tract infections

Treatment strategy	Strength of recommendation (SOR)	Recommendation/conclusion
Antibiotic therapy	A	No benefits seen and complications higher in treated groups
Use of decongestants	A	Assist in symptom control, no effect on duration of illness
Echinacea products	B	Early trials demonstrated modest benefit, better controlled trials show no benefit
Zinc lozenges	A	Effectiveness in adults not shown; one randomized trial shown no benefit in children
Antihistamine therapy	A	No benefit at relieving symptoms or altering duration of disease
Acute bronchitis		
1. Use of routine Antibiotics	A	Meta-analyses show weak/modest benefit ; no evidence of effectiveness in single trials of individual drugs
Use of short acting bronchodilators	A	Two randomized trials showed benefit in cough duration
Influenza		
Use of amantadine/rimantadine	A	Useful in influenza A only if started in first 48 hours
Use of neuraminidase inhibitors	A	Useful in influenza A and B but only if started in first 30-36 hours

		Beneficial in preventing complications in high-risk patients
Sinusitis		
Antibiotics	A	Useful, but benefit limited to small number of patients; highly dependent on accurate diagnosis
http://www.aafp.orglafpsort.xml.		

REFERENCE:

1. *Essentials of Family Medicine by D.Sloane et.al, fifth edition, Limpincott William & Walkins publishing.*

PNEUMONIA IN ADULTS

Pneumonia
An acute lower respiratory tract infection associated with fever, symptoms and signs in the chest, and abnormalities on the chest x-ray.

CLASSIFICATION AND CAUSES

1. Community-acquired pneumonia
2. Hospital-acquired.
3. Aspiration:
4. Immunocompromised patient:

COMMUNITY ACQUIRED PNEUMONIA

DEFINITION

A syndrome of infection that is usually bacterial, with symptoms and signs of consolidation of parts of the lung parenchyma. Community-acquired pneumonia is the most common type of pneumonia. It occurs outside of hospitals or other health care facilities. It may be caused by:

- Bacteria.
- Bacteria-like organisms
- Fungi.
- Viruses, including COVID-19.

COMMON CAUSATIVE ORGANISMS

- Pneumococcus (*S. pneumoniae* -36%)
- *H. influenza* (10%) - more common amongst the elderly
- *Influenza A and B* (8%) – annual epidemics during the winter months - 73% develop pneumonia
- *Mycoplasma pneumonia* (1.3%) - less common in the elderly;
- Gram (-)ive enteric bacteria (1.3%)
- *C. psittaci* (1.3%) - 20% have history of bird contact
- *S. aureus* (0.8%) - more common in the winter months; may be associated with viral infection, e.g., flu
- *Legionella* spp. (0.4%) - most common in September/October; >50% related to travel

RISK FACTORS FOR CAP

- Aspiration
- Alcoholism and diabetes
- Oral steroids/immunosuppression
- Cigarette smoking
- COPD
- Nursing home residents

CLINICAL FEATURES

1. Fever
2. Cough
3. Sputum
4. SOB
5. Pleuritic chest pain
6. Non-specific features in elderly - confusion, hypothermia

EXAMINATION

1. Raised RR (may be the only sign in the elderly)
2. Tachycardia
3. Localizing signs on chest examination. Reduced chest expansion on the affected side, with signs consistent with consolidation9reduced air entry, with bronchial breathing, reduced percussion note, increased vocal resonance) crackles. A normal chest examination makes the unlikely.

DIAGNOSIS

- Symptoms and signs of an acute lower respiratory tract infection
- New focal chest signs
- New radiographic shadowing
- At least one systemic feature
- No other explanation for illness

SEVERITY

'CURB-65'is a simple, validated severity scoring system one point for each of:

- Confusion (abbreviated mental test ≤8)
- Urea >mmol/L
- Respiratory rate ≥30/min
- BP <90systolic and/or 60mmHg diastolic
- Age ≥65
    - 0-1, po antibiotic/home treatment
    - 2- hospital therapy
    - ≥3 severe pneumonia indicates mortality 15-40% -consider ITU

COMPLICATIONS

- Respiratory failure
- Hypotension
- Atrial fibrillation
- Pleural effusion
- Empyema
- Lung abscess
- Septicaemia
- Pericarditis and myocarditis
- Jaundice –cholestatic and may be due to sepsis

MANAGEMENT

- Consider the need for admission
- Have a low threshold for admission if ill but apyrexial, concomitant illness (e.g., heart failure, chronic lung, renal or liver disease, DM, cancer), or poor social situation. If life-threatening

infection or considerable delay (>2h) consider administering antibiotics before admission

If a decision is made to treat at home

- Advise not to smoke, to rest, and drink plenty of fluids
- Start antibiotics, e.g., amoxicillin 500 mg- 1 g tds, or doxycycline 100-200 mg od, or clarithromycin 500 mg bd for 5 days course
- Treat pleuritic pain with simple analgesia, e.g., paracetamol 1 g qid
- Review within 48 hr. Reassess clinical state. If deteriorating or not improving consider CXR or admission
- Most antibiotics are used empirically at diagnosis of CAP in the absence of microbiological information
- Early antibiotic administration is associated with an improved outcome

It is vital there is no delay in the administration of the first antibiotic dose in patients with confirmed CAP. Confirmation of pneumonia with CXR and antibiotic administration should occur within 4 hours of admission.

CAP: ANTIBIOTICS

Suggested empirical antibiotics for CAP treatment

	Preferred treatment	alternative
Community treatment	Amoxicillin 500mg-1 g tds PO	Doxycycline 100mg od (after 200mg loading dose0po OR Clarithromycin 500mg bd PO
Hospital treatment: low severity (CURB-65=0-1)	Amoxicillin 500mg tds PO (or same dose IV if oral treatment impossible)	Doxycycline 100mg od (after 200mg loading dose po OR Clarithromycin 500mg bd PO
Hospital treatment: moderate severity (CURB-65= 2)	Amoxicillin 500mg-1 g tds PO Clarithromycin 500mg bd PO If oral treatment. If oral treatment is impossible, amoxicillin 500mgtds IV or benzylpenicillin 1.2g qds IV and clarithromycin 500mgbd IV	Doxycycline 100mg od (after 200mg loading dose) PO or levofloxacin 500mg od PO or moxifloxacin 400mg od PO
Hospital treatment: high severity (CURB-65= 3-5)	Co-amoxiclav 1.2gtds IV and clarithromycin 500mgbd IV (add levofloxacin if Legionella strongly suspected)	Benzylpenicillin 1.2g qds IV and either levofloxacin 500mg bd IV or Ciprofloxacin400mgbd IV or Cefuroximine 1.5mgtds IV cefotaxime1g tds IV /ceftriaxone2g od IV (add levofloxacin if Legionella strongly suspected)

Length of treatment

There is no evidence to guide treatment length, but consensus suggests

- 7 days --- non-severe, uncomplicated pneumonia
- 7-10 days --- severe, microbiologically undefined pneumonia
- 14-21 days --- if Legionella, staphylococcal disease, or Gram-negative enteric bacteria suspected

PREVENTION

- Influenza vaccination:

- Pneumococcal vaccination

VACCINATION

Influenza vaccination
This reduces hospital deaths from pneumonia and influenza by about 65% and respiratory deaths by45%
Recommended for high-risk individuals

- Chronic lung disease
- Cardiac, renal, and liver disease
- Diabetes
- Immunosuppression
- Those aged over 65
- Long- stay residential care
- Health care workers

Pneumococcal vaccination
Recommended for;

- Those aged over 65
- Chronic Cardiac, renal, and liver disease
- Diabetes
- Immunodeficiency or immunosuppression (due to disease including HIV infection or drugs)

REFERENCE

1. *Oxford Handbook of General Practice, 4th Edition,*
2. *John M URTA GH 's Handbook of General Practice, 6th Edition*
3. *Oxford Handbook of Clinical Medicine*

BRONCHIECTASIS

Chronic inflammation of the bronchi and bronchioles leading to permanent dilatation and thinning of these airways.
Main organisms; *H. influenzae; Strep. pneumonia; Staph. aureus; Pseudomonas aeruginosa.*

CAUSES

- Congenital
  - Cystic fibrosis
  - Kartagener syndrome
- Post-infection
  - TB
  - pertussis
  - measles
  - pneumonia
- Other Bronchial obstruction
- Aspergillosis
- Hypogammaglobulinaemia
- Gastric aspiration

CLINICAL FEATURES

Symptoms; Persistent cough, copious purulent sputum, intermittent haemoptysis

Signs; finger clubbing, coarse inspiratory crepitations, wheeze

Complications; pneumonia, pleural effusion, pneumothorax, haemoptysis, cerebral abscess, amyloidosis

INVESTIGATIONS

- CXR
- Sputum-Microscopic, C&S
- Spirometry- often shows an obstructive pattern
- Bronchoscopy to locate site of haemoptysis; exclude obstruction and obtain samples for culture.

MANAGEMENT

- **Airway clearance techniques and mucolytics.** physiotherapy (to aid the sputum expectoration and mucus drain.
- Antibiotics
- Bronchodilators
- Corticosteroids (e.g**.,** prednisolone) and itraconazole for ABPA
- vaccination (influenza and pneumococcal)
- Surgery.

PLEURAL EFFUSION

DEFINITION

A pleural effusion is fluid in the pleural space. Effusion can be divided by their protein concentration into transudates (25g/L) and exudates (35g/L). The accumulation of frank pus is termed empyema, that of blood is haemothorax and that of chyle is chylothorax. Both blood and air in the pleural space is called a haemopneumothorax.
In general, pleural fluid accumulates as a result of either increased hydrostatic pressure or decreased osmotic pressure ('transudative effusion', as seen in cardiac, liver or renal failure) or from increased microvascular pressure due to disease of the pleural space itself or injury in the adjacent lung (exudative effusion).

KEY POINTS

- normal pleural space has 10-20ml fluid
- can be detected on X-ray if > 300ml fluid in pleural space.
- can be detected clinically if -500 ml fluid
- can be sub pulmonary-simulates a raised diaphragm.
- may be asymptomatic
- dyspnea common with large effusion
- chest pain in setting of pleuritis, infection or trauma
- Signs
    - Pleural effusion >500ml
    - Trachea - towards opposite side (if massive)
    - Chest wall movement -decreased (unilateral)
    - Percussion note - stony dull
    - Breath sounds - absent or decreased
    - Vocal fremitus - absent or decreased
    - Adventitious sounds (crackles, wheeze, pleural rubs and stridor) -none
    - The fluid may be transudate or exudates (diagnosed by aspirate)
        - If blood stained - malignancy, pulmonary infarction, TB

TRANSUDATE

- May be due to increase venous pressure (cardiac failure; Constrictive pericarditis, fluid overload) or Hypoproteinaemia (cirrhosis. nephrotic syndrome malabsorption),
- Also occur in hypothyroidism and Meigs' syndrome, Ovarian tumour- right-sided effusion (Meig's syndrome (right pleural effusion and ovarian fibroma)

EXUDATE

- Are mostly due to increased leakiness of pleural capillaries secondary to infection, inflammation, or malignancy.

CAUSES

- Infection
  - bacterial pneumonia
  - Pleurisy
  - Empyema
  - TB
  - viral
- Malignancy
  - Bronchogenic carcinoma
- Pulmonary infarct
- Connective tissue diseases
  - SLE
  - RA
- Acute pancreatitis
- Lymphoma
- Sarcoidosis
- HIV with parasitic pneumonia

TESTS

- CXR:
- Ultrasound
- Diagnostic aspiration:
- Pleural biopsy

MANAGEMENT

Treat the underlying cause.

- Drainage
- Pleurodesis
- Intra-pleural alteplase and dornase alfa
- Surgery

REFER

- For drainage if symptomatic. Repeated drainage ± pleurodesis may be necessary

PNEUMOTHORAX

DEFINITION

Pneumothorax is the present of air in the pleural space which can occur spontaneously or result from iatrogenic injury or trauma to the lung or chest wall.
Primary spontaneous pneumothorax occurs in patients with no history of lung disease in whom smoking, tall stature and the present of apical subpleural blebs are additional risk factors.

CLASSIFICATION OF PNEUMOTHORAX

SPONTANEOUS

PRIMARY

- No evidence of overt lung disease. Air escape from the lung into the pleural space through rupture of a small subpleural emphysematous bullae or pleural bleb, or the pulmonary end of a pleural adhesion.

SECONDARY

- Underlying lung disease, most commonly COPD and TB; also seen in asthma, lung abscess, pulmonary infarcts, bronchogenic carcinoma, all forms of fibrotic and cystic lung disease.

TRAUMATIC

- Iatrogenic (e.g., following thoracic surgery or biopsy) or chest wall injury.

TYPES OF SPONTANEOUS PNEUMOTHORAX

- Closed type
- Open type
- Tension (valvular) type

CLINICAL FEATURE

- sudden onset unilateral pleuritic chest pain
- breathlessness
- pallor ± or tachycardia

PHYSICAL EXAMINATION

- normal in small pneumothorax,
- tracheal shift to opposite side
- hyper-resonance on percussion and obliteration of cardiac dullness
- decreased or absent breath sound in large pneumothorax

INVESTIGATION

- Chest X-ray

MANAGEMENT

- Primary pneumothorax in which lung edge is less than 2 cm from the chest wall and the patient is not breathless normally resolves without intervention. 50% collapse takes 40 days to be resolved.
- In young patients presenting with a moderate or large spontaneous pneumothorax, acute respiratory distress, chest pain, percutaneous (16-l 8G cannula through the 2nd intercostal space just above the 3rd rib at mid clavicular line) aspiration of air is a simple and well-tolerated alternative to intercostal tube drainage, with a 60-80% chance of avoiding the needle for a chest drain.
- When needed, intercostal drains are inserted in the 4th' 5th or 6th intercostal space in the mid-axillary line connected to an underwater seal or one-way Heimlich valve and secured firmly to the chest wall or refer depending upon clinical judgement.
- Smoking cessation reduces risk of recurrence.

REFER

- Tension pneumothorax is the medical emergency. It was indicated/categoraized as urgent referral.

REFERENCE

1. *Davison's Principles and Practice of Medicine, 22nd Edition*

PULMONARY EMBOLISM

DEFINITION

Venous thrombi, usually from a deep vein thrombosis in the leg pass into the pulmonary circulation and block blood flow to the lungs. The source is often occult. Always suspect pulmonary embolism in sudden collapse 1-2 weeks after surgery. Without treatment, 20% with proximal deep vein thrombosis develop pulmonary embolus (PE).

RISK FACTORS

- Immobility: long flight or bus journey, post-op, plaster cast, bed-ridden
- Smoking
- Surgery –especially pelvic and lower limb
- Pregnancy or puerperium, OCP, HRT.
- Malignancy, Myeloproliferative disorder
- Past history or family history of DVT, PE, or clotting tendency

SYMPTOMS

- Acute dyspnoea
- Pleuritic chest pain
- Haemoptysis
- Syncope
- Large clots can be rapidly fatal

SIGNS

- Hypotension
- Tachycardia, gallop rhythm
- Cyanosis, loud P2, right ventricular heave
- Increased JVP
- Tachypnoea
- Pleural rub

Look for a source of emboli - although DVT may not be clinically obvious, have a high level of suspicion. Patients may have minimal symptoms/ signs apart from some pleuritic pain and dyspnoea. PE in the community can be associated with surgical procedures done 2-3wk previously.

DIFFERENTIAL DIAGNOSIS

- Pneumonia and pleurisy
- Acute coronary syndrome
- Other causes of acute breathlessness- acute LVF, asthma, exacerbation of COPD, pneumothorax, shock (e.g., due to anaphylaxis), arrhythmia, hyperventilation
- Other causes of acute chest pain - aortic dissection, rib fracture, musculoskeletal chest pain, pericarditis, oesophageal spasm, shingles

INVESTIGATION

- Chest X-ray and ECG
- U&E FBC, baseline clotting
- ABG
- Serum D –dimmer
- CT Pulmonary angiogram.

Well Score for DVT

Cancer	**+l**
Paralysis or recent plaster cast	**+l**
Bed rest >3 days or surgery <4 weeks	**+l**
Pain on palpation of deep veins	**+l**
Swelling of entire leg	**+l**
Diameter difference on affected calf >3cm	**+l**
Pitting oedema (affected side only)	**+l**
Dilated superficial vein (affected side)	**+l**
Alternative diagnosis at least as probable as DVT	-2

(0) *Low risk,* ***(1-2)*** *Intermediate risk, (3) High risk*

Diagnostic algorithm for clinically suspected DVT/PE



CUS = *compression ultrasonography*

MANAGEMENT

IMMEDIATE ACTION

Most of the pulmonary embolism deaths occur within 1 hour.

- It is an acute medical emergency.
- Give i.v. access for haemodynamic instability patient before refer to hospital.
- If suspected, give oxygen as soon as possible (aim to keep Sp02 at 94-98%).
- Needs supportive medical care and anti-coagulation
- Initial anticoagulation with LMWH and warfarin, then followed by oral anticoagulant
- LMWH should be continued for at least 4 day and anti INR is in therapeutic range for 2:2 day. Target INR 2.5 (Range 2-3)

- Oral anticoagulants reduce risk of further thromboembolism and should be continued for 3-6 months after a single DVT
- If a patient has a DVT and there is no obvious cause
  - If <45 years, consider thrombophilia
  - If >45 years, consider undiagnosed cancer

FURTHER MANAGEMENT

- In all cases of proven PE, anticoagulation is started in hospital before discharge to general practice.
- Warfarin should be continued for 2:3 months. Aim to keep the INR 2.5 (range 2-3)
- Malignancy: continue treatment with LMWH for 6 months or until cure of cancer
- Pregnancy: LMWH is continued until delivery or end of pregnancy

REFER

- All suspected DVT/PE cases must be referred to hospital (urgently).

REFERENCE:

1. *Oxford Handbook of General Practice, 4th Edition*
2. *John MURTAGH's Handbook of General Practice, 5th Edition*

RESPIRATORY FAILURE

The term respiratory failure is used when pulmonary gas exchange fails to maintain normal arterial oxygen and carbon dioxide levels. Respiratory failure occurs when gas exchange is inadequate, result in in hypoxia. It is defined as a PaO2<8kPa and subdivided into two types according to PaCO2 LEVEL. It is classified into Type I and Type II depending on the absence or presence of hypercapnia (raised PaC02)

TYPE I RESPIRATORY FAILURE

Defined as hypoxia (PaO2<8kPa) with normal or **low PaCO2**. It is caused primarily by ventilation/perfusion mismatch, hypoventilation, abnormal diffusion, right to left cardiac shunt. Examples of ventilation/perfusion mismatch;

- Pneumonia
- Pulmonary oedema
- PE
- Asthma
- Emphysema
- Pulmonary fibrosis
- ARDS

TYPE II RESPIRATORY FAILURE

Defined as hypoxia (PaO2<8kPa) with hypercapnia **(PaCO2>6.0kPa)** This is caused by alveolar hypoventilation, with or without ventilation/perfusion mismatch.

Cause includes;

- Pulmonary disease: Asthma, COPD, pneumonia, end-stage pulmonary fibrosis, obstructive sleep apnoea
- Reduced respiratory drive: Sedative drugs. CNS tumour or trauma
- Neuromuscular disease: cervical cord lesion, diaphragmatic paralysis, poliomyelitis, myasthenia grevis, Gullian-Barre' syndrome
- Thoracic wall disease: Flail chest, kyphoscoliosis

BLOOD GAS ABNORMALITIES IN RESPIRATORY FAILURE

Type I			Type II	
Hypoxia [Pa0 2 <8.0kPa (60mmHg), Normal or low PaC02 (<6.6kPa (50mmHg)]			Hypoxia [Pa02 <8.0 kPa (60mmHg) Raised PaC02 (>6.6 kPa (50mmHg)]	
	Acute	Chronic	Acute	Chronic
H+	-7 or j	-7	i	-7 or j
Bicarbonate	-7	-7	-7	i
Causes	• Acute asthma • Pulmonary oedema • Pneumonia • Lobar collapse • Pneumothorax • Pulmonary embolus • ARDS	• Emphysema • Lung fibrosis • Lymphangitis carcinomatosa • Right-to-left shunts • Brain-stems lesion	• Acute severe asthma • Acute exacerbation COPD • Upper airway obstruction • Acute neuropathies/ paralysis • Narcotic drugs • Primary alveolar hypoventilation • Flail chest injury	• COPD • Sleep apnoea • Kyphoscoliosis • Myopathies/ muscular dystrophy • Ankylosing spondylitis

CLINICAL FEATURES

Are those of underlying cause together with symptoms and signs of hypoxia, with or without hypercapnia
Hypoxia – dyspnea, restlessness, agitation, confusion, central cyanosis. If long standing hypoxia; polycythemia, pulmonary hypertension, cor-pulmonale
Hypercapnaea –headache, peripheral vasodilatation, tachycardia, bounding pulse, tremor/flap, papilloedema, confusion drowsiness, coma

INVESTIGATIONS

are aim at determining the underlying cause

- Blood test –FBC, U&E, CRP, ABG
- Radiology –CXR
- Microbiology - sputum and blood culture
- Spirometry (COPD, neuromuscular disease, Guillian-Barre' syndrome)

MANAGEMENT – DEPEND ON CAUSES.

MANAGEMENT OF ACUTE RESPIRATORY FAILURE

Prompt diagnosis and management of the underlying cause is crucial to the management.
In type I respiratory failure, high concentrations of oxygen (40-60% by mask) will usually relieved

hypoxia.

Acute type II respiratory failure is an emergency, which requires immediate interventions. The most common cause of chronic type II respiratory failure is severe COPD.

Assessment and management of 'acute on chronic' type II respiratory failure
Initial assessment
Patient may not appear distressed in spite of being critically ill • Conscious level (respond to commands, ability to cough) • C02 retention (warm periphery, bounding pulses, flapping tremor) • Airways obstruction (wheeze, prolong expiration, hyperinflation, intercostal indrawing, pursed lips) • Cor-pulmonale (peripheral oedema, raised JVP, hepatomegaly, ascites) • Background functional status and quality of life • Signs of precipitating causes.
Investigations
• Arterial blood gas (severity of hypoxaemia, hypercapnia, acidaemia, bicarbonate) • Chest X-ray
Management
• Maintenance of airway • Treatment of specific precipitating cause • Frequent physiotherapy+ /- pharyngeal suction • Nebulized bronchodilators • Controlled oxygen therapy Start with 24% Venturi mask Aim for a Pa02 >7kPa (52mmHg) (a Pa02 <5 (37mmHg) is dangerous) • Antibiotics • diuretics
Progress
• If PaC02 contributes to rise or patient cannot achieve a safe Pa02without severe hypercapnia and acidaemia, mechanical ventilator support may be required.

LUNG CANCER

Lung cancer is the most common cancer.
Incidence increased with age-85% are aged >65 years and 1% <40 years at presentation.
M : F = 2:1 but incidence is increasing in women.

RISK FACTORS

- Cigarette smoking (causes 90% of lung cancer)
- Other passive smoking
- Asbestos. chromium, arsenic, iron oxides and radiation

HISTOLOGY

Clinically the most important division is small cell and non-small cell lung cancer.

Squamous cell (35%); adenocarcinoma (27%) large cell (10%); adenocarcinoma in situ (rare 1%);

Small cell (oat cell) (20%).

Most 70% of small cell lung cancer are disseminated at the time of presentation.

CLINICAL FEATURES

SYMPTOMS:

- Cough (80%)
- Haemoptysis (70%)
- Dyspnea (60%)
- Chest pain (40%)
- Recurrent or slowing resolving pneumonia, lethargy, anorexia, weight loss.

SIGNS

- Cachexia, anaemia, clubbing, HOPA (causing wrist pain), supraclavicular or axillary nodes
- Chest signs: none or consolidation, collapse and pleural effusion
- Metastases: bone tenderness, hepatomegaly, confusion, fits, focal CNS signs, cerebellar syndrome, proximal myopathy, peripheral neuropathy.

COMPLICATIONS

- Local: recurrent laryngeal nerve palsy, phrenic nerve palsy, SVC obstruction, Horner's syndrome, (Pancoast's tumour), rib erosion. Pericarditis, AF.
- Metastatic: brain, bone, liver, adrenal (Adison)
- Non-metastatic neurological: confusion, fits, cerebellar syndrome, proximal myopathy, neuropathy, polymyositis
- Most present between 50 and 70 years (mean 67 years)
- Only l0-25% asymptomatic at time of diagnosis
- If symptomatic - usually advanced and not resectable

Tests

- CXR;
- Cytology
- Fine needle aspiration or biopsy
- Bronchoscopy
- Radio-nuclide bone scan

Presentation

>90% have symptoms at the time of diagnosis. Common presenting features:

- Cough (56%)
- Chest/shoulder pain (37%)
- Haemoptysis (7%)
- Dyspnoea
- Hoarseness
- Weight decrease
- Finger clubbing
- General malaise
- Distant metastases
- Incidental finding on CXR

Referral For Suspected Lung Cancer Immediate Referral/ Acute Admission

- Stridor
- Superior vena cava obstruction (swelling & congestion of face/neck with fixed increase JVP)

Urgent Referral

- Persistent haemoptysis (in smokers/ex-smokers aged 2:40 years)
- CXR suggestive of lung cancer (including pleural effusion and slowly resolving consolidation)
- May be normal CXR where there is high suspicion of lung cancer
- History of asbestos exposure and recent onset of chest pain, shortness of breath, or unexplained systemic symptoms where a CXR indicates pleural effusion, pleural mass, or any suspicious lung pathology

Urgent Referral For CXR

- Haemoptysis
- Any of the following if unexplained or present for >3 weeks,
  - Cough
  - Chest/shoulder pain
  - Weight loss
  - Hoarseness of voice
  - Cervical or supraclavicular lymphadenopathy
  - Dyspnoea
  - Chest signs
  - Finger clubbing
  - Features suggestive of metastases from a lung cancer, e.g., secondaries in the brains, bone, liver and skin

- But do not delay for 3 weeks if high suspicious of lung cancer
  - smoker/ex-smoker
  - COPD
  - History of asbestos exposure
  - Previous history of cancer (especially head and neck cancer)

PREVENTION

- **Smoking cessation:** 90% of lung cancer patients are smokers or ex-smokers. The younger a person is when he/she starts smoking the greater the risk of developing lung cancer. Risk also increased with amount smoked (duration of smoking and number of cigarettes smoked/day)
- **Diet:** increase consumption of fruit, carrots, and green vegetables may decrease incidence, but there is no evidence that vitamin supplements are beneficial and they might be harmful.

PANCOAST SYNDROME

- Apical lung cancer + ipsilateral Homer's syndrome.
- *Cause:* invasion of the cervical sympathetic plexus.
- *Other features:* shoulder and arm pain (brachial plexus invasion C8-T2) ± hoarse voice/bovine cough (unilateral recurrent laryngeal nerve palsy and vocal cord paralysis).

PARANEOPLASTIC SYNDROMES

- (E.g., ectopic ACTH production, SIADH, hypercalcaemia, hypercoagulability) Affect 10- 20% of patients with lung cancer-particularly small cell. Have a high index of suspicion and refer for specialist management if suspected.

MANAGEMENT

- Once the diagnosis has been confirmed, or suspected, refer to chest physician. Active treatment options depend on type and extent of tumour and include surgery, radiotherapy, and/or chemotherapy.
- Follow-up regularly. 80% die in < lyr.

PALLIATIVE RADIOTHERAPY

Radiotherapy is a key component of symptomatic treatment for:

- Haemoptysis
- Chest pain
- Breathlessness due to bronchial occlusion
- Pain from bone metastasis
- Symptoms from brain metastasis

Radiotherapy may be combined with palliative chemotherapy, particularly for patients with non-small cell lung cancer.

REFERENCE

1. *Oxford Handbook of General Practice 4th Edition*
2. *Oxford Handbook of Clinical Medicine*

CHAPTER 5

GASTRO-INTESTINAL AND HEPATO-BILIARY PROBLEMS

ACUTE GASTROENTERITIS/ DIARRHOEA

DEFINITION OF DIARRHOEA

- Passage of unusually loose or watery stools usually at least three times in a 24-hour period. (14 day or fewer in duration)
- (consistency of stool is more important than number)

CAUSATIVE AGENTS

Bacteria	Viruses	Parasites
• *Diarrheagenic Escherichia coli* • *Campylobacter jejuni* • *C. coli* • *C. upsaliensis* • *Vibrio cholerae O1* • *V cholerae 0139* • *V parahaemolyticus* • *Shigella species* • *Bacteroides fragilis* • *Nontyphoidal Salmonellae* • *Clostridium difficile* • *Yersinia enterocolitica* • *Y. pseudotuberculosis*	• *Rotavirus* • *Norovirus (calicivirus)* • *Adenovirus* • *Astrovirus* • *Cytomegalovirus*	**Protozoan** • *Cryptosporidium parvum* • *Giardia intestinalis* • *Microsporida* • *Entamoeba histoly tica* • *Jsospora belli* • *Cyclospora cayetanensis* • *Dientamoeba fragilis* • *Blastocystis hominis* **Helminths** • *Strongyloides stercoralis* • *Angiostrongylus costaricensis* • *Schistosoma mansoni,* • *Schistosoma japonicum*

Clinical manifestations

- Episodes of diarrhoea can be classified into three categories.

Category	Clinical manifestations
Acute diarrhea	Presence of three or more unusually loose or watery stools in the preceding 24 hours
Dysentery	Presence of visible blood in stools
Persistent diarrhea	Acutely starting episode of diarrhea lasting more than 14 days

Linking the main symptoms to the causes of acute diarrhea

Symptoms	Causes of acute diarrhoea
Fever	Common and associated with invasive pathogens Initially present in the majority of children with rotavirus diarrhea
Bloody stools	Invasive and cytotoxin-producing pathogens Suspect *(entero-haemorrhagic E. coli)* EHEC infection in the absence of fecal leucocytes Not with viral agents and enterotoxins producing bacteria
Vomiting	Frequently in viral diarrhea and illness caused by ingestion of bacterial toxins (e.g. Staphylococcus aureus) Common in cholera

Clinical evaluation

The initial clinical evaluation of the patient should focus on:

- Assessing the severity of the illness and the magnitude (degree) of dehydration
- Determining likely causes on the basis of the history and clinical findings, including stool characteristics

Medical assessment of diarrhoea

Patient history	Physical examination
• Onset, stool frequency, type and volume • Presence of blood • Vomiting • Dark yellow or scant urine, decreased skin turgor, orthostatic hypotension • Food history, recent and remote travel history, occupational exposure • Medicines received • Past medical history • Underlying conditions	• Body weight • Temperature • Pulse/heart and respiratory rate • Blood pressure

Character of symptoms

- Diarrhea of small bowel origin is typically watery, of large volume, and associated with abdominal cramping, bloating, and gas. Weight loss can occur if diarrhea becomes persistent. Fever is rarely a significant symptom and occult blood or inflammatory cells in the stool are rarely identified.
- In contrast, diarrhea of large intestinal origin often presents with frequent, regular, small volume, and often painful bowel movements. Fever and bloody or mucoid stools are common, and red blood cells and inflammatory cells can be seen routinely on stool microscopy.
- These inflammatory signs associated with large bowel infection (fever, bloody or mucoid stools) suggest invasive bacteria (eg, Salmonella, Shigella, or Campylobacter), enteric viruses (eg, cytomegalovirus [CMV] or adenovirus), Entamoeba histolytica, or a cytotoxic organism such as C. difficile. Visibly bloody acute diarrhea is relatively uncommon and raises the possibility of Shiga toxin-producing E. coli (STEC) (eg, E. coli O157:H7) infection.
- Other bacterial causes of visibly bloody diarrhea are Shigella, Campylobacter, and Salmonella species. Bloody diarrhea can also reflect non-infectious aetiologies such as inflammatory bowel disease or ischemic colitis
- Syndromes that begin with diarrhea but progress to fever and systemic complaints, such as headache and muscle aches, should raise the possibility of other aetiologies, including a typhoidal illness (particularly in travelers from resource-limited settings) or infection with Listeria monocytogenes (particularly if a stiff neck is also present or the patient is a pregnant woman).

Food history

- Consumption of unpasteurized dairy products, raw or undercooked meat or fish, or organic vitamin preparations may suggest certain pathogens.
- Although it is often difficult to know which food exposure was the potential source, the timing of symptom onset following exposure to the suspected offending food can be an important clue to the diagnosis.
- Within six hours: suggests ingestion of a preformed toxin of Staphylococcus aureus or Bacillus cereus, particularly if nausea and vomiting were the initial symptoms
- At 8 to 16 hours: suggests infection with Clostridium perfringens
- At more than 16 hours: suggests either viral or other bacterial infection (e.g., contamination of food with enterotoxigenic or STEC or other pathogens)

Other exposures

- Exposure to animals (poultry, turtles, petting zoos) has been associated with Salmonella infection.
- Travel to a resource-limited setting increases the risk of bacterial diarrhea and also informs the risk of certain parasitic infections.
- Occupation in daycare centers has been associated with infections with Shigella, Cryptosporidium, and Giardia. Rotavirus is a potential consideration, but in countries that routinely immunize infants against rotavirus, infection due to rotavirus has decreased substantially.

Medical history

- It is also important to ask about recent antibiotic use (as a clue to the presence of C. difficile infection), other medications (such as proton pump inhibitors, which can increase the risk of infectious diarrhea), and to obtain a complete past medical history (eg, to identify an immunocompromised host or the possibility of nosocomial infection).

Physical examination

- The examination focuses on evaluating volume status and identifying complications.
- Volume depletion can be suggested by dry mucous membranes, diminished skin turgor, postural or frank, reductions in blood pressure, and altered sensorium. These signs can be mild or absent with early hypovolemia
- The abdominal examination should evaluate for findings that can suggest ileus or peritonitis, including abdominal distension, pain with gentle percussion, abdominal rigidity, or rebound tenderness

Clinical assessment of hydration status

- Assessment of patients' hydration status is based on the presence of the symptoms and signs outlined in the following table. The presence of one of these signs or symptoms immediately classifies the patient as a more severe case.

Classification of dehydration

Severe dehydration

- Consider hospitalization depend on patient's condition
- Lethargic, unconscious
- Incapable of drinking
- Weak radial pulse
- Supine hypotension
- Skin pinch goes back very slowly
- Decrease in the urine output (oliguria)

Moderate dehydration

- Sunken eyes with ocular hypo-tony
- Dryness of the oral mucosa, tongue, and mucous membrane
- Intense thirst; drinks eagerly
- Skin pinch goes back slowly

No signs of dehydration

- None of the above

Investigations

- Blood
- Full blood count
- Urea, creatinine and electrolytes
- ESR (increased in cancer, inflammatory bowel disease)
- CRP (increased in infection, inflammatory bowel disease)
- Blood cultures (in patients with high fevers or who appear systemically ill)
- Stool/ Rectal swab
- Microbiological investigation is indicated in patients who are dehydrated or febrile or have blood or pus in their stool. A fecal specimen or rectal swab should be obtained for analysis in cases of severe, bloody, inflammatory, or persistent diarrhoea, or if cholera is suspected.

Management

- Rehydration
- Antibiotics
- Diet
- Anti-diarrhoeal agents
- Zinc supplement
- Probiotic, prebiotic

Rehydration

- The first line of treatment in acute diarrhoea is prevention and treatment of fluid and electrolyte depletion.

No signs of dehydration

- Oral rehydration salt (ORS) solution ad lib at home (liquid should be administered in small amounts frequently, every 15-30 minutes)

Moderate dehydration

- ORS + IV Ringer's lactate solution 10 ml/kg/hour

Severe dehydration

- Life-threatening condition
- Two or more IV lines should be installed.
- IV Ringer's lactate solution should be given rapidly until radial pulse is palpable and BP is raised above 90/60 mmHg.
- Then subsequent fluid therapy depends on the amount of ongoing stool loss.
- Ringer's lactate solution is the first option. If it is not available, isotonic saline solution (0.9%) can be used.
- Never use glucose solution.
- ORS should also be given at the same time.
- Closely monitor fluid balance during this phase in order to guarantee sufficient replenishment of volume.

Antibiotics

- Antibiotics are indicated if history and physical examination suggestive of bacterial infection (i.e. diarrhoea is severe and prolonged, fever, look toxic).

Cause	**Antibiotics** First choice *I Alternative(s)*
Cholera	Doxycycline 300 mg once *Azithromycin* 1.0 g as a single dose, only once *Ciprofloxacin* 500 mg 12-hourly for 3 days, or 2.0 grams as a single dose, only once
Shigellosis	Ciprofloxacin 500 mg bd/day for 3 days, or 2.0 g as a single dose only once *Ceftriaxone* 2-4 g as a single daily dose for 2-5 days
Amoebiasis	Metronidazole 750 mg tds/day for 5 days (10 days for severe disease)
Giardiasis	Metronidazole 250 mg tds/day for 5 days *Tinidazole* single dose 50 mg/kg orally; maximum dose 2 g *Ornidazole* single, 2-g dose
Campylobacter	Azithromycin 500 mg od/day for 3 days *Fluoroquinolones* such as ciprofloxacin 500 mg od/day for 3 days

Anti-diarrhoeal agents

Antimotility agents

- (Loperamide 4-6 mg/day is the agent of choice for adults)
- Should be used mostly for mild to moderate traveler's diarrhea (without clinical signs of invasive diarrhea)
- Inhibits intestinal peristalsis and has mild antisecretory properties
- Should be avoided in bloody or suspected inflammatory diarrhea (febrile patients)
- Significant abdominal pain also suggests inflammatory diarrhea (this is a contraindication for loperamide use)

Diet

- Normal feeding should be continued for those with no signs of dehydration, and food should be started immediately after correction of moderate and severe dehydration, which usually takes 2-4 hours. Adequate nutrition during an episode of acute diarrhea is important to facilitate enterocyte renewal. Boiled starches and cereals (eg, potatoes, noodles, rice, wheat, and oat) with salt are indicated in patients with watery diarrhea.
- Foods with high fat content should be avoided until the gut function returns to normal after a severe bout of diarrhea.

- Dairy products (except yogurt) may be difficult to digest in the presence of diarrheal disease. This is due to secondary lactose malabsorption, which is common following infectious enteritis and may last for several weeks to months. Thus, temporary avoidance of lactose-containing foods is reasonable.

Zinc supplement

- Zinc deficiency is widespread among children in developing countries. Routine zinc therapy, as an adjunct to ORT is useful in modest reduction of the severity but more importantly reduce diarrhea episodes. It is not routinely recommended in adults.

Probiotics and Diarrhea

- Probiotics are considered to be beneficial to the host's health and contain a sufficient amount of non-pathogenic specific live bacteria preparations, such as Lactobacillus, Yeast, Bifidobacterium, Enterococcus, and Bacillus.
- Probiotics with beneficial bacteria that assist in maintaining or recolonizing the intestine with non-pathogenic flora can also be used as alternative therapy.
- Many different probiotics are available, and each probiotic has different activity, so only specific probiotics may be useful.
- Lactobacillus GG has been shown to decrease duration of childhood infectious diarrhea and Saccharomyces boulardii may be effective in decreasing the duration of C. difficile infection.

Prebiotics

- Prebiotics are defined as "substrates that are selectively utilized by host microorganisms to confer health benefits" (Gibson et al., 2017).
- Consumption of prebiotics can improve the gut microbiota, which is beneficial to health. Some prebiotics, such as fructo-oligosaccharide, inulin, pectin oligosaccharides, etc., can resist the colonization of pathogen by acting as soluble decoy receptors that mimic the binding site of pathogens, thereby promoting the eliminating of pathogens from the intestine (Pujari and Banerjee, 2021) Previous studies have shown that prebiotics can shorten the duration of acute watery diarrhea and has a good therapeutic effect on diarrhea (Rigo Adrover et al., 2017).

Prevention of diarrhoea

- Safe water supply and water sanitation
- Food sanitation
- Hand washing habit
- Safe disposal of stool
- Fly control

Persistent diarrhea (more than 14 but fewer than 30 days in duration)

- Work-up and management for patients with persistent diarrhea or diarrhea that does not respond to empiric treatment includes testing for parasitic organisms and other evaluation for noninfectious processes.
- The spectrum of parasites associated with persistent diarrhea can vary based on exposures or populations.
- In general, Giardia, Cryptosporidium, and E. histolytica are the most common parasitic pathogens in patients with persistent diarrhea.

- Persistent diarrhea following travel to certain locations, such as mountainous regions, is associated with Giardia, Cryptosporidium, or Cyclospora. Persistent diarrhea with exposure to infants in daycare centers has been associated with Giardia and Cryptosporidium. Microsporidium should be a consideration in immunocompromised patients with persistent diarrhea.
- Most of these pathogens can be diagnosed by microscopy for ova and parasites. Three specimens should be sent on consecutive days (or each specimen separated by at least 24 hours) for ova and parasite examination since parasite excretion may be intermittent.
- Non-infectious aetiologies also become more likely when acute diarrhea persists or does not respond to empiric therapy. The evaluation of patients for a non-infectious etiology should be pursued in those patients in whom evaluation fails to identify a pathogen (eg, bacterial, viral, or protozoal) and the diarrhea worsens or becomes chronic. In some cases, this will include endoscopy, for example, to distinguish inflammatory bowel disease from infectious diarrhea.

Reference

1. *Oxford Handbook of General Practice, 4th Edition*
2. *Oxford Handbook of Clinical Medicine, 10th Edition*
3. *https://www.uptodate.com/contents/search source=RELATED_SEARCH& search=Gastroenteritis Approach to the adult with acute diarrhea in resource-rich settings*
4. *Gut Microbiota and Diarrhea:An Updated Review, Front. Cell. Infect. Microbiol. 11:625210. www.frontiersin.org*

CHRONIC DIARRHOEA

Definition

- Diarrhoea persisting >4 weeks. Patients' perceptions of diarrhoea vary widely. Clarify what is meant.

Causes of chronic diarrhea

	Colonic	Malabsorption	Small bowel
Clinical features	Blood and mucus in stool	Steatorrhoea	Large-volume, watery stool
	Cramping lower abdominal pain	Undigested food in the stool Weight loss and nutritional disturbances	Abdominal bloating Cramping mid-abdominal pain
Some causes	Inflammatory bowel disease	Pancreatic	VIPoma (neuroendocrine tumour that secrete Vasoactive intestinal Peptide)
	Neoplasia	Chronic pancreatitis	Drug-induced
	Ischaemia	Cancer of pancreas	NSAIDs
	Irritable bowel syndrome	Cystic fibrosis	Aminosalicylates
		Cystic fibrosis	Aminosalicylates
		Enteropathy Coeliac disease	Selective serotonin re- uptake inhibitors (SSRIs)
		Tropical sprue	
		Lymphoma	
		Lymphangiectasia	
Investigations	Colonoscopy with biopsies	Ultrasound, CT and Magnetic Resonance Cholangiopancreatography (MRCP)	Stool volume
		Small bowel biopsy	Gut hormone profile
		Barium follow-through	Barium follow-through

(Davidson 's Principles and Practice of Medicine 22nd Edition)

Symptoms suggestive of organic disease

- History of <3 months duration
- history of gastrointestinal cancer, or symptom onset after the age of 50 years.
- Mainly nocturnal or continuous (as opposed to intermittent) diarrhoea
- Significant weight loss
- awakening by symptoms
- Liquid stools with blood and/or mucus

Examination and investigation

- Full examination: Look for signs of systemic disease and examine abdomen thoroughly.
- Physical exam of the abdomen may reveal localized tenderness or masses serve as an argument for further diagnostic evaluations. Measurement of blood pressure and heart rate and inspection of mucous membranes to detect anemia or dehydration.

- Check:
- Blood- FBC, ESR, Ca++, LFTs, haematinics (Fe, folic acid, B12), TFTs,
- Stool-Microscopy, C&S

Management

- If obvious identifiable cause, e.g. GI infection, constipation, drug side effect, then treat and review.
- Treat the underlying cause is the main stay of treatment.
- Clear explanation of the symptoms and diagnosis and reassurance about the benign nature of chronic functional diarrhoea are important.
- Dietary restrictions of food components, such as fructose, sorbitol, caffeine, or other precipitating foods, are generally proposed as a first approach.
- Pharmacotherapy can be considered as a first-line treatment in those who have symptoms with major impact on their quality of life or can be added in those who fail to respond sufficiently to reassurance and dietary measures.
- Antidiarrheal agents may be classified as intestinal transit inhibitors (opioids, tricyclic antidepressants and 5-HT antagonists), intraluminal agents (cholestyramine, medicinal fiber, clays, activated charcoal, and bismuth), proabsorptive agents (clonidine), and antisecretory drugs (octreotide).

Further Evaluation of Patients with Chronic Secretory Diarrhea

- Patients with chronic watery diarrhea who have little or no osmotic gap as calculated from stool electrolytes should be evaluated with three sets of investigations:
- Although bacterial infection rarely causes chronic diarrhea, it can be excluded by stool culture, including culture on special media for Aeromonas and Pleisiomonas. In addition, the stool should be examined microscopically for ova and parasites, with special tests for Cryptosporidium, Microsporidium, and Giardia. Giardia antigen, measured in stool by enzyme-linked immunosorbent assay, is the most sensitive test for giardiasis. An aspirate of small bowel contents for quantitative culture or breath tests with glucose or isotopically labeled xylose can be used to establish the presence of small bowel bacterial overgrowth but is likely to be meaningful only in patients with disorders predisposing them to bacterial overgrowth.
- Structural disease should be excluded by radiography of the small bowel, sigmoidoscopy, or colonoscopy with multiple biopsies of the colonic mucosa, computerized tomography of the abdomen, and endoscopic biopsy of the proximal small bowel mucosa. A small bowel follow-through examination is preferable to an enteroclysis study for the radiographic evaluation of patients with chronic diarrhea.
- Selective testing for plasma peptides such as gastrin, calcitonin, vasoactive intestinal polypeptide, and somatostatin, as well as urine excretion of 5-hydroxyin_dole acetic acid, metanephrine, or histamine and other tests of endocrine function, such as measurement of thyroid-stimulating hormone and serum thyroxine levels or an adrenocorticotropin-stimulation test for adrenal insufficiency, can be valuable. Because peptide secreting tumor syndromes causing chronic diarrhea are very rare, measurement of serum peptide concentrations (e.g., gastrin, vasoactive intestinal polypeptide, calcitonin) should be done only when a tumor syndrome seems likely from the clinical presentation or findings on radiographic studies.

Further Evaluation of Patients with Chronic Osmotic Diarrhea

- Most osmotic diarrhea not associated with steatorrhea is caused by ingestion of poorly absorbable carbohydrates or magnesium salts.
- A low stool pH suggests carbohydrate malabsorption, and a high stool magnesium concentration or output suggests magnesium ingestion.
- If carbohydrate malabsorption is suspected, a careful dietary history and judicious use of breath hydrogen testing with lactose as the test sugar or measurement of lactase in a mucosal biopsy specimen can be diagnostic. Patients with high stool magnesium outputs should be evaluated for inadvertent ingestion of magnesium in mineral supplements or antacids and for surreptitious laxative abuse.

Further Evaluation of Chronic Inflammatory Diarrhea

- Patients with blood and pus in the stool should undergo radiographic evaluation of the small bowel with barium (small bowel follow-through examination) and sigmoidoscopy or colonoscopy with biopsies of the colonic mucosa.
- Stool culture and analysis of stool for Clostridium difficile toxin may identify infectious causes of inflammation.

Evaluation of Chronic Fatty Diarrhea

- Patients with evidence of steatorrhea should undergo small bowel follow-through radiographic study to exclude structural problems. Small bowel biopsy specimens and an aspirate of small bowel contents for quantitative culture should be obtained, and pancreatic exocrine insufficiency should be assessed by direct tests, such as the secretin test, or by indirect tests, such as measurement of stool chymotrypsin activity or a bentiromide test.
- Studies such as D-xylose absorption tests and the Schilling test have little application in the evaluation of these patients.

Empirical Therapy for Chronic Diarrhea

- Empirical therapy is used in three situations:(1) as a temporizing or initial treatment before diagnostic testing,(2) after diagnostic testing has failed to confirm a diagnosis, and (3) when a diagnosis has been made, but no specific treatment is available or specific treatment fails to effect a cure.
- Empirical trials of antimicrobial therapy may be justified if the prevalence of bacterial or protozoal infection is high in a specific community or situation.
- An empirical trial of bile acid–binding resins, such as cholestyramine, may be the least expensive way to diagnose bile acid–induced diarrhea.
- Opiates are the most effective nonspecific antidiarrheal agents. Octreotide should be reserved as a secondary agent.
- Adequate hydration is an essential part of the treatment of diarrheal diseases, and oral rehydration solutions may be necessary in some instances. Some patients, particularly those with postresection diarrhea, may need long-term intravenous fluid administration
- Parenteral nutrition should be reserved for patients who are unable to maintain an adequate nutritional status because of the diarrheal disease.

Antibiotic associated diarrhoea

- Diarrhoea is a common adverse effect of antibiotic treatments. The frequency of antibiotic associated diarrhoea depends on the definition of diarrhoea, the inciting antimicrobial agents, and host factors. Almost all antibiotics, particularly those that act on anaerobes, can cause diarrhoea, but the risk is higher with aminopenicillins, a combination of aminopenicillins and clavulanate, cephalosporins, and clindamycin. Host factors for antibiotic associated diarrhoea include age over 65, immunosuppression, being in an intensive care unit, and prolonged hospitalisation.
- Clinical presentations of antibiotic associated diarrhoea range from mild diarrhoea to fulminant pseudomembranous colitis. The latter is characterised by a watery diarrhoea, fever (in 80% of cases), leucocytosis (80%), and the presence of pseudomembranes on endoscopic examination.
- Severe complications include toxic megacolon, perforation, and shock.
- Antibiotic associated diarrhoea results from disruption of the normal microflora of the gut by antibiotics. Antibiotics disturb the composition and the function of this flora and enable overgrowth of microorganisms that induce diarrhoea.
- Clostridium difficile has emerged as the major enteropathogen of antibiotic associated diarrhoea. Other infectious agents reported to be responsible for antibiotic associated diarrhoea include C perfringens, Staphylococcus aureus, Candida spp, Klebsiella oxytoca, and Salmonella spp.
- Antibiotic associated diarrhoea can also result from a decrease in metabolism of carbohydrates and bile acids.
- Managing the diarrhoea depends on presentation and the inciting agent. In mild to moderate diarrhoea conventional measures include rehydration or discontinuation of the inciting agent or its replacement by an antibiotic with a lower risk of inducing diarrhoea, such as quinolones, co-trimoxazole, or aminoglycosides.
- In 22% of cases of diarrhoea related to C difficile, withdrawal of the inciting agent will lead to resolution of clinical signs in three days.
- In cases of severe or persistent antibiotic associated diarrhoea, the challenge is to identify C difficile associated infections since this is the most common identifiable and treatable pathogen. Treatment of C difficile related diarrhoea is based on oral metronidazole (250 mg four times daily) or oral vancomycin (125 mg four times daily) for 10 days. Vancomycin should be reserved for those with severe illness, intolerance to metronidazole, failure to respond to metronidazole, or pregnancy.
- Antiperistaltic agents should be avoided because of the risk of retention of toxins in the lumen. About 20% of patients with C difficile related diarrhoea will relapse. The key measure for preventing antibiotic associated diarrhoea, is to limit antibiotic use.
- Probiotics have proved useful in preventing diarrhoea, Lactobacillus rhamnosus GG and Saccharomyces boulardii appear to be the most efficacious
- Choice for preventing antibiotic-associated diarrhoea, Lactobacillus casei may be the best for specifically preventing severe C. difficile-related diarrhoea

***REFER** to gastroenterologist:*

- If treatment does not relieve symptoms.
- If symptoms suggestive of functional bowel disease and <45 yr with normal investigations, irritable bowel syndrome is likely. Reassure, offer advice, and review as necessary.
- If atypical symptoms appear or the patient is unhappy with the diagnosis.
- Otherwise refer to gastroenterologist for assessment.

- Speed of referral depends on age and severity of symptoms

Refer urgently if:

•Any age with:

- Right lower abdominal mass consistent with involvement of large bowel
- A palpable rectal mass (intraluminal, not pelvic; a pelvic mass outside the bowel would warrant an urgent referral to a urologist)
- Unexplained iron deficiency anaemia (Hb≤11g/dL for male: ≤10g/dL for a non-menstruating female)
- •Aged ≥ 40 yr
- Reporting rectal bleeding with a change of bowel habit towards looser stools and/or increased stool frequency persisting ≥ 6 weeks.
- •Aged ≥ 60 yr with:
- Rectal bleeding persisting for ≥ 6 weeks without a change in bowel habit and without anal symptoms
- Change in bowel habit to looser stools and/or more frequent stool persisting for ≥ 6 weeks without rectal bleeding.
- • In a patient with equivocal symptoms who is not unduly anxious, it is reasonable to 'treat, watch and wait'.

Reference

1. *Gastroenterol Clin N Am 41 (2012) 629-637*
2. *Fine KD, Schiller LR. AGA technical review on the evaluation and management of chronic diarrhea. Gastroenterology 1999;116: 1464–1486*
3. *https://www.nchi.nlm.nih.gov/articles/PMC1123310/*

ACUTE GASTRITIS

Definition

- Mucosal inflammation of the stomach with no ulcer
- Type A: affects the entire stomach; associated with pernicious anaemia; pre-malignant
- Type B: affects antrum ± duodenum; associated with H. pylori
- Type C: due to irritants, e.g. NSAIDs, alcohol, bile reflux
- Other causes -stress (secondary to mucosal ischemia) and autoimmune gastritis.
- Rare causes - phlegmonous gastritis (a rare bacterial infection).

Presentation

- COMMON SYMPTOMS
- retrosternal or epigastric pam, fullness, bloating, wind, heartburn, nausea, and vomiting.

Examination

- usually normal
- Clinical anaemia
- Epigastric tenderness.
- Epigastric mass/hepatomegaly, and lymph nodes in the neck.

Investigation

- Helicobacter pylori urea breath test
- H pylori fecal antigen test
- CBC
- Endoscopy
- Gastric mucosal histology
- Serum vitamin B12

Management

- Lifestyle:reduce alcohol, stop smoking
- Mucosal coating (sucralfate, antacids) agents or short-term histamine-2 antagonists and proton-pump inhibitor (PPI) for 4-8weeks can stabilize mild to moderate cases in the short term.
- Administer fluids and electrolytes as required, particularly if the patient is vomiting.
- Treat the cause where possible: (e.g. vitamin B12 injections; H. pylori eradication; avoidance of nonsteroidal anti-inflammatory drugs, caffeine, alcohol)
- Re-endoscope to confirm healing
- Consult a gastroenterologist in complicated cases.
- Surgical intervention is not necessary for gastritis, except in the case of phlegmonous gastritis or acute necrotizing gastritis.

Complications

- Haemorrhage, gastric atrophy ± gastric cancer (type A only)

Prevention

- In patients with gastritis, it is recommended to eradicate *H pylori* infection before starting nonsteroidal anti-inflammatory drug (NSAIDs)/aspirin treatment for the first time, as this will decrease the possibility of inducing gastroduodenal ulceration.

Reference

1. *Oxford Handbook of General Practice, 4th Edition*
2. *https://bestpractice.bmj.com/topics/en-us/8163*
3. *https://emedicine.medscape.com/article/175905-treatment*

PEPTIC ULCERATION

Definition

- Peptic ulceration (PU) is a term which includes both gastric and duodenal ulceration. Most patients present with dyspepsia
- **Gastric** – referring to the stomach.
- **Duodenal** – referring to the beginning of the small intestine or duodenum.

Features of gastric and duodenal ulcers

	Gastric Ulcer (GU)	Duodenal Ulcer (DU)
Population	Typically affects middle-aged/elderly male	Typically affects young-middle-aged male, although can affect any adult. M > F
Risk factors	*H pylori* (70-90%) NSAID use (increased risk x3-4) Delayed gastric emptying Reflux from the duodenum (increased by smoking)	*H pylori* (>90%) NSAID use Gastric hyperacidity Rapid gastric emptying Smoking Stress
Presentation	May be asymptomatic Epigastric pain worsened by food and helped by antacids or lying flat ± weight loss With complications	May be asymptomatic or spontaneously relapse and remit Epigastric pain typically relieved by food and worse at night ± weight increased ± waterbrash (saliva fills the mouth) With complications
Examination	In uncomplicated gastric ulceration, examination is usually normal, though there may be epigastric/left upper quadrant tenderness.	In uncomplicated duodenal ulceration, examination is usually normal, though there may be epigastric tenderness.
Investigation	As for dyspepsia	
Complications	***Bleeding:*** Acute GI bleeding, iron deficiency anaemia ***Perforated peptic ulcer:*** DU > GU; GUs may perforate posteriorly into the lesser sac; DUs usually perforate anteriorly into the peritoneal cavity. There may not be a past history of indigestion. Presents with sudden onset severe epigastric pain which rapidly becomes generalized. When a GU perforates into the lesser sac symptoms may remain localized or be confined to the right side of the abdomen. *Examination:* Generalized peritonism with 'board-like rigidity'. *Management:* acute surgical admission ***Pyloric stenosis in adults:*** duodenal stenosis secondary to scarring from a chronic DU. Characterized by copious vomiting of food l-2 days old. There may not be a past history of indigestion. *Examination:* if prolonged vomiting may be evidence of dehydration ± weight decreased. Succussion splash may be audible. *Management:* surgical referral for confirmation of diagnosis and surgical relief	

Management

*For patients not taking NSAIDs***want to big font*

- Eradicate H. pylori if present
- Speeds ulcer healing and decrease relapse; confirm eradication with a urea breath test (duodenal ulcer) or repeat endoscopy (gastric ulcer), and retreat if still present
- If H. pylori negative: Treat with full-dose PPI (e.g. omeprazole 20 mg od) for 1-2 month.
- If gastric ulcer, re-endoscope to check ulcer is healed

For patients taking NSAIDs

- Stop NSAIDs where possible. If not possible consider changing to a safer alternative (e.g. paracetamol, decreased dose of NSAID, COX2-selective NSAID) and adding gastric protection with a PPI or misoprostol
- Offer full-dose PPI or H2 receptor antagonist (H2RA) therapy for 2months
- Check eradication with repeat endoscopy (gastric ulcer) or urea breath test (duodenal ulcer).

Medical Management of NSAID Ulcers

- According to the ACG (American College of Gastroenterology) guideline, all patients who are beginning long-term NSAID therapy should first be tested for **H pylori**. NSAIDs should be immediately discontinued in patients with positive **H pylori** test results if clinically feasible.
- The 2017 ACG guidelines for the treatment of **H pylori** infection (HPI) have reaffirmed testing for HPI before initiating NSAID therapy.
- For patients who must continue with their NSAIDs, PPI maintenance is recommended to prevent recurrences even after eradication of **H pylori**. If NSAIDs must be continued, changing to a cyclooxygenase (COX)-2 selective inhibitor is an option.
- For patients with a known history of ulcer and in whom NSAID use is unavoidable, the lowest possible dose and duration of the NSAID and co-therapy with a PPI or misoprostol are recommended.
- Thus, the 2009 ACG guideline recommends that patients who are treated with NSAIDs and also require low-dose aspirin therapy for cardiovascular disease be treated with naproxen plus misoprostol or a PPI. Patients at moderate risk for gastrointestinal complications and at high risk for cardiovascular disease should avoid NSAIDs or COX-2 inhibitors entirely and receive alternative therapy.

For all patients

- Lifestyle measures
- Avoid foods (or alcohol) which exacerbate symptoms; eat little and often; avoid eating <3 hours before bed
- Stop smoking
- If symptoms recur following initial treatment, offer a PPI at lowest dose to control symptoms, with a limited number of repeat prescriptions. Discuss using the treatment on a pm basis
- Offer H2RA therapy If there is an inadequate response to a PPI
- In patients with unhealed ulcer or continuing symptoms despite adequate treatment, exclude non-adherence, malignancy, failure to detect H. pylori, inadvertent NSAID use, other ulcer-inducing medication, and rare causes, e.g. Zollinger-Ellison syndrome.

- Once symptoms are controlled, review at least annually to discuss symptom control, lifestyle advice, and medication.

Long-Term Monitoring

- Maintenance therapy with antisecretory medications (eg, H2 blockers, PPIs) for 1 year is indicated in high-risk patients. High-risk patients include those with recurrent ulcers and those with complicated or giant ulcers. If **H pylori** eradication is not achieved despite repeat treatment, maintenance antisecretory therapy should be recommended.
- Consider maintenance therapy with half of the standard doses of H2-receptor antagonists at bedtime in patients with recurrent, refractory, or complicated ulcers, particularly if cure of **H pylori** has not been documented or if an **H pylori** – negative ulcer is present.
- Patients with refractory ulcers may continue receiving once-daily PPI therapy indefinitely.
- In this setting, if **H pylori** is absent, consider a secondary cause of duodenal ulcer, such as Zollinger-Ellison syndrome

- Peptic ulcer rebleeding is extremely rare after **H pylori** eradication. The use of maintenance antisecretory therapy is not necessary if **H pylori** eradication has been achieved. However, NSAID use may cause rebleeding even in patients in
- **H pylori** has been eradicated.

Patient Education

- • Patients with peptic ulcer disease should be warned about known or potentially injurious drugs and agents.
- Some examples are as follows:
- Nonsteroidal anti-inflammatory drugs (NSAIDs)
- Aspirin
- Alcohol
- Tobacco
- Caffeine (eg, coffee, tea, colas)
- • Obesity has been shown to have an association with peptic ulcer disease, and patients should be counseled regarding benefits of weight loss. Stress reduction counseling might be helpful in individual cases but is not needed routinely.
- • A special diet is not indicated for patients with duodenal ulcers. It is a common-sense approach to avoid any food or beverages that may aggravate symptoms. Although the link between duodenal ulcers and alcohol is inconclusive, moderation of alcohol intake may be recommended for other health reasons.

Deterrence and prevention

- Primary prevention of NSAID-induced ulcers includes the following:
  - Avoid unnecessary use of NSAIDs
  - Use acetaminophen or nonacetylated salicylates when possible
  - Use the lowest effective dose of an NSAID and switch to less toxic NSAIDs, such as the newer NSAIDs or COX-2 inhibitors, in high-risk patients without cardiovascular disease
- Consider prophylactic or preventive therapy for the following patients:
  - Patients with NSAID-induced ulcers who require chronic, daily NSAID therapy
  - Patients older than 60 years
  - Patients with a history of peptic ulcer disease or a complication such as gastrointestinal bleeding

    - Patients taking concomitant steroids or anticoagulants or patients with significant comorbid medical illnesses.
- Prophylactic regimens that have been shown to dramatically reduce the risk of NSAID-induced gastric and duodenal ulcers include the use of a prostaglandin analog or a PPI according to the following regimens:
    - Misoprostol 100-200 mcg PO 4 times per day
    - Omeprazole 20-40 mg PO every day
    - Lansoprazole 15-30 mg PO every day

Refer

- If gastric ulcer fails to heal or if symptoms do not respond to medical treatment.
- Possible surgical procedures include: gastrectomy, vagotomy, and drainage procedure;highly selective vagotomy
- Alarm features that warrant prompt gastroenterology referral include the following:
    - Bleeding or anemia
    - Early satiety
    - Unexplained weight loss
    - Progressive dysphagia or odynophagia
    - Recurrent vomiting
    - Family history of gastrointestinal cancer

Reference

1. *Oxford Handbook of General Practice, 4th Edition*
2. *https://emedicine.medscape.com/article/181753-treatment*

DYSPEPSIA AND H.PYLORI

Definition

Functional dyspepsia (FD) is defined as the presence of one or more of the followings bothersome postprandial fullness, bothersome early satiation, bothersome epigastric burning and no evidence of structural disease (including at upper endoscopy) to explain symptoms. (Rome IV 3)

Causes

- Gastro-oesophageal reflux disease (GORD) 15-25%
- Peptic ulcer (PU)l5-25%
- Stomach cancer 2%
- The remaining 60% are classified as non-ulcer dyspepsia (NUD, 'functional' dyspepsia) manage as for uninvestigated dyspepsia
- Rarer causes: oesophagitis from swallowed corrosives, oesophageal infection (especially in the immunocompromised)

Differential diagnosis

- Cardiac pain (difficult to distinguish)
- Gallstone pain
- Pancreatitis
- Bile reflux

Presentation

- Clinical history taking in dyspepsia
- The patient should be asked about all possible upper gastrointestinal symptoms, including ‘red flags’,
- or alarm symptoms and signs.

Common symptoms

- Retrosternal or epigastric pain or burning, early satiation, postprandial fullness, heartburn, bloating, wind, heartburn, nausea, vomiting, belching, regurgitation, dysphagia, including the level at which food sticks, and rumination, ensuring the patient understands what he/she means.
- Weight loss is reported frequently by patients with FD. Depending on the patient’s age, this may be considered an alarm symptom, so attention should be paid to obtaining objective evidence of this.

Alarm – symptoms

- Anaemia
- Loss of weight
- Anorexia
- Recent onset of progressive symptoms
- Masses & Melaena/haematemesis
- Swallowing difficulty

Examination

- usually normal
- epigastric tenderness
- clinical anaemia, epigastric mass/hepatomegaly, and lymph nodes in the neck.

Investigation

- A full blood counts
- Testing for H. pylori and eradicating the bacterium in patients with dyspepsia in primary care who are found to be infected is logical. This is termed a 'test and treat' strategy and can be done via faecal antigen or carbon-urea breath testing, where available, which have a similar accuracy to rapid urease testing of biopsies obtained at endoscopy.

Endoscopy

- endoscopy only in patients aged ≥55 years with dyspepsia with evidence of weight loss. Non-urgent endoscopy can be considered in patients aged ≥55 years with treatment-resistant dyspepsia or dyspepsia with either a raised platelet count or nausea or vomiting.
- In patients from areas at high risk of gastric cancer, or those with a family history of gastrooesophageal malignancy, the age limit for endoscopy should be reduced to >40 years.
- In those with aged ≥60 years with abdominal pain and weight loss urgent CT scanning should be considered to exclude pancreatic cancer.
-
- • Definite referral criteria for urgent endoscopy to assess for gastro-oesophageal cancer
- People of any age with dysphagia
- People aged ≥55 years with weight loss and any of the following:
- Dyspepsia.
- Upper abdominal pain.
- Reflux.
- • Probable referral criteria for non-urgent endoscopy to assess for gastro-oesophageal cancer
- People with haematemesis.
- People aged ≥55 years with:
- Treatment-resistant dyspepsia.
- Dyspepsia with raised platelet count or nausea or vomiting.
- Upper abdominal pain with low haemoglobin, raised platelet count or nausea or vomiting.
- Reflux with raised platelet count, or nausea or vomiting.
- Nausea or vomiting with any of the following: weight loss, reflux, dyspepsia, or upper abdominal pain.

Managing New Dyspepsia



Management of dyspepsia in primary care

- It is important to build rapport and trust in the doctor–patient relationship by adopting the principles of empathic listening to optimise the consultation.

First-line treatment of FD

- All patients with FD are advised to take regular aerobic exercise (recommendation: strong, quality of evidence: very low).
- Insufficient evidence to recommend dietary therapies, including a diet low in fermentable oligosaccharides, disaccharides and monosaccharides, and polyols in FD (recommendation: weak; quality of evidence: very low).
- Eradication therapy is an efficacious treatment for H. pylori positive patients with FD.
- Adverse events are more common than with a control therapy (recommendation: strong; quality of evidence: high).
- Histamine-2 -receptor antagonists may be an efficacious treatment for FD. These drugs are well tolerated (recommendation: weak, quality of evidence: low).
- Proton pump inhibitors (PPIs) are an efficacious treatment for FD. There does not appear to be a dose response, so the lowest dose that controls symptoms should be used. These drugs are well tolerated (recommendation: strong, quality of evidence: high).
- Some prokinetics may be an efficacious treatment for FD. However, efficacy varies according to drug class, these drugs are well tolerated (recommendation: weak,

quality of evidence: low for acotiamide, itopride, and mosapride, recommendation: strong, quality of evidence: moderate for tegaserod).

Second-line treatment of FD

- Tricyclic antidepressants (TCAs) used as gut–brain neuromodulators are an efficacious second-line treatment for FD. They can be initiated in primary or secondary care, but careful explanation as to the rationale for their use is required, and patients should be counselled about their side effect profile.
- They should be commenced at a low dose (eg, 10 mg amitriptyline once daily) and titrated slowly to a maximum of 30–50 mg once daily (recommendation: strong, quality of evidence: moderate).
- Antipsychotics, such as sulpiride 100 mg four times a day or levosulpiride 25 mg three times a day, may be efficacious as a second-line treatment for FD. There should be careful explanation as to the rationale for be counselled on their side effect profile (recommendation: weak, quality of evidence: low).
- Pregabalin 75 mg once daily may be an efficacious second line treatment for FD but further randomised controlled trials (RCTs) are needed and given its controlled drug status we advise this drug is only used in specialist settings (recommendation: weak, quality of evidence: low).
- Mirtazapine 15 mg once daily may be an efficacious second line treatment for patients with FD with early satiation and weight loss, but further RCTs are needed (recommendation: weak, quality of evidence: very low)
- Hypnotherapy may be an efficacious treatment for global symptoms in FD (recommendation: weak, quality of evidence: very low).

Gut–brain behavioural therapies in FD

- Interpersonal psychodynamic informed psychotherapy may be an efficacious treatment for global symptoms in FD (recommendation: weak, quality of evidence: very low).
- Cognitive–behavioural therapy (CBT) and metacognitive therapy may be an efficacious treatment for global symptoms in FD (recommendation: weak, quality of evidence: very low).
- Stress management approaches may be an efficacious treatment for global symptoms in FD (recommendation: weak, quality of evidence: very low).

Management of severe or refractory FD

- A multidisciplinary support team should be involved for patients with severe or refractory FD (recommendation: strong, quality of evidence: low).
- Opioids and surgery should be avoided in patients with severe or refractory FD to minimize iatrogenic harm (recommendation: strong, quality of evidence: very low).
- Patients with severe or refractory FD presenting with weight loss and food restriction are assessed for eating disorders and disordered eating, including avoidant restrictive food intake disorder (ARFID) (recommendation: strong, quality of evidence: very low).
- Early dietitian involvement in patients with severe or refractory FD to avoid an overly restrictive diet (recommendation: strong, quality of evidence: very low)

Helicobacter pylori

Helicobacter pylori continues to be a major health problem worldwide, causing considerable morbidity and mortality due to peptic ulcer disease and gastric cancer. H. pylori infection usually persists for life, unless it is treated with antibiotics or autoeradication occurs when long-standing infection causes widespread gastric mucosal atrophy and metaplasia with achlorhydria. Transient infection may occur in some infants.

Infection is associated with:

- GI disease-peptic ulcer disease; gastric cancer; non-ulcer dyspepsia; oesophagitis
- Non-GI disease-ranging from cardiovascular disease and haematological malignancy to cot death
- Testing for H pylori
- 'Test and treat' all patients with dyspepsia who do not meet referral criteria.
- In practice choice of test is limited by availability, ease of access, and cost.
- Options in the community are: serology, urea breath test, and faecal antigen test.
- *Urea breath tests* (UBTs) are very useful and have higher diagnostic accuracy than other noninvasive tests for identifying H. pylori (in patients without a history of gastrectomy).
- Most commercial urease tests appear to be accurate to a sensitivity of about 95%.
- A 2 week wash out period following proton pump inhibitor (PPI) use is necessary before testing for H pylori with a breath test or a stool antigen test.
- Eradication: Clears 80-85% H pylori infections.

Options:

- PAC500 regimen:
- Full-dose PPI (e.g. omeprazole 20mg bd) +Amoxicillin lg bd +
- Clarithromycin 500 mg bd for 1week, or
- PMC250 regimen:
- Full-dose PPI (e.g. omeprazole 20mg bd) + Metronidazole 400mg bd +
- Clarithromycin 250mg bd for 1week
- Do not re-test even if dyspepsia remains unless there is a strong clinical need.
- Re-test if needed using a urea breath test.

Triple therapies and quadruple-therapy combinations—typical composition, dosage, and duration

Triple therapies	**1**	**2**	**3**	
All twice daily for 7–14 days	PPI PPI PPI	Amoxicillin 1 g Metronidazole 400 mg Amoxicillin 1 g	Clarithromycin 500 mg Clarithromycin 500 mg Metronidazole 400 mg	
All twice daily for 10–14 days	PPI	Amoxicillin 1 g	Levofloxacin 500 mg	
All twice daily for 7–10 days	PPI	Amoxicillin 1 g	Rifabutin 150 mg	
Quadruple therapies	**1**	**2**	**3**	**4**
For 7–14 days	PPI twice daily	Bismuth 120 mg four times daily	Metronidazole 400– 500 mg three times daily	Tetracycline 500 mg four times daily
	(Amoxicillin 500–1000 mg three times daily has been substituted for tetracycline)			
All twice daily for 7–14 days	Bismuth 240 mg	PPI	Amoxicillin 1 g	Clarithromycin 500mg

Treatment considerations when local resistance rates are not well defined, individual patient testing is not available, and there are low resource

First–line therapies		
PPI-AC	In regions where clarithromycin resistance rate is thought to be low or moderate (< 20%)	If prior clarithromycin use in monotherapy or combination, assume resistance and avoid in first-line therapy 7-day minimum duration, likely higher eradication success with 10–14 days (consider costs) Use quality generic drugs to minimize costs Encourage compliance with full course
Quadruple therapy	In regions where clarithromycin resistance rates are likely > 20%	Avoid PPI-AC first-line Quadruple therapy overcomes MR; unaffected by CR May be more difficult to take and "nuisance"; adverse effects are common Encourage compliance with full course Generic drugs may be less expensive than triple therapy
PPI-AC or quadruple therapies	In regions with unknown clarithromycin resistance rates	Avoid clarithromycin if past personal patient exposure PPI-AC otherwise a reasonable choice Quadruple therapy also a good option
Second–line therapies		
•Quadruple therapy •Levofloxacin triple therapy	After failure of clarithromycin containing regime	Avoid repeating the same treatment Avoid using clarithromycin again, as secondary resistance will be high and eradication success very low Levofloxacin triple therapy a good option if no prior personal exposure and resistance thought to be low or moderate
•Clarithromycin or levofloxacin triple therapy	After failure of quadruple therapy	Check compliance Levofloxacin preferred if likely high CR region or past personal exposure

A, amoxicillin; C, clarithromycin; CR, clarithromycin resistance; MR, metronidazole resistance; PPI, proton-pump inhibitor

Lifestyle advice

- Give advice on healthy eating, weight reduction, and smoking cessation.
- Advise patients to avoid precipitating factors, e.g. alcohol, coffee, chocolate, fatty foods.
- Raising the head of the bed and having a main meal well before going to bed may help some people.
- Promote continued use of antacids.

Reference

1. *Oxford Handbook of Clinical Medicine, 10th Edition*
2. *Oxford handbook of General Practice, 4th Edition*
3. *World Gastroenterology Organisation Global Guidelines Helicobacter pylori May 2021*

GASTRO- OESOPHAG EAL REFLUX

GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)

Def: Retrograde flow of gastric contents into the esophagus through an incompetent gastro-oesophageal junction

Risk factors

- Smoking
- Alcohol
- Coffee
- Fatty food
- Big meals
- Obesity
- Hiatus hernia
- Tight clothes
- Pregnancy
- Systemic sclerosis

Conditions caused by GORD

- Oesophagitis (defined by mucosal breaks) ± oesophageal ulcer
- Benign oesophageal stricture
- Intestinal metaplasia: Barrett's oesophagus
- Oesophageal haemorrhage
- Anaemia

Presentation

- Heartburn:most common symptom.
- Burning retrosternal or epigastric pain which worsens on bending, stooping or lying, and with hot drinks. Relieved by antacids
- Other symptoms:
- Waterbrash-mouth fills with saliva
- Reflux of acid into the mouth especially on lying flat
- Nausea and vomiting
- Nocturnal cough/wheeze due to aspiration of refluxed stomach contents
- Examination:usually normal.
- Check for clinical anaemia, epigastric mass/hepatomegaly, and lymph-nodes in the neck

Complication

- Oesophagitis, ulcers, benign stricture, iron deficiency, metaplasia dysplasia neoplasia.
- GORD may lead to Barrett's oesophagus.

Investigation

Endoscopy if indicated

- Upper endoscopy is the most widely used objective test for evaluating the esophageal mucosa. For patients with GERD symptoms who also have alarm symptoms such as dysphagia, weight loss, bleeding, vomiting, and/or iron deficiency anemia, epigastric mass, endoscopy should be performed as soon as feasible. The endoscopic findings of EE and Barrett's esophagus are specific for the diagnosis of GERD.
- Symptoms are poorly correlated with endoscopic findings.
- Reflux may remain silent in patients with Barrett's oesophagus but heartburn can severely affect quality of life of patients with negative endoscopy results.

Esophageal manometry (HRM)

- HRM can be used to assess motility abnormalities associated with GERD, but HRM is not alone a diagnostic test for GERD. Weak lower esophageal sphincter (LES) pressure and ineffective esophageal motility often accompany severe GERD, but no manometric abnormality is specific for GERD.

Reflux monitoring

- Ambulatory reflux monitoring (pH or impedance-pH) allows for assessment of esophageal acid exposure to establish or refute a diagnosis of GERD and for correlating symptoms with reflux episodes using the symptom index (SI) or symptom association probability (SAP).
- The main methods of reflux testing include a wireless telemetry capsule (Bravo Reflux Capsule; Medtronic, Minneapolis, MN) attached to the esophageal mucosa during endoscopy and transnasal catheter-based testing, and there are strengths and weaknesses to each approach.

Diagnosis of GERD in pregnancy

- Heartburn is the only GERD symptom that has been studied in pregnancy, and the diagnosis of GERD is almost always symptom-based. Endoscopy and pH monitoring are rarely needed..

Initial management

- In all cases, give lifestyle advice (reduce weight, smoking cessation, small and regular meals, reduce hot drinks, alcohol, citrus fruit, tomatoes, onion, fizzy drinks, spicy food, caffeine, chocolate, avoid eating <3 hr before bed, raised the bed-head)
- If diagnosis is clinical (i.e. patient presents with 'reflux-like' symptoms), treat as for uninvestigated dyspepsia (see figure in dyspepsia)

Medications

- The backbone of pharmacologic therapy for GERD are medications that are directed at neutralization or reduction of gastric acid. Agents in this class include antacids, H2RA, and PPIs. Antacids are used exclusively for on-demand symptom relief.

- For patients with reflux confirmed on endoscopy, offer treatment with a PPI (e.g. omeprazole 20 mg od) for 1-2months.
- Optimization of PPI therapy includes verifying compliance, confirming that the PPI is taken 30–60 minutes before the first meal of the day for daily dosing and before the first and dinner meal for twice-daily dosing. Twice-daily PPI therapy is superior to once-daily double-dose PPI therapy in maintaining gastric pH above 4 during a 24-hour monitoring period.
- If oesophagitis at endoscopy and the patient remains symptomatic on PPI, double the dose of PPI for a further l month.
- If inadequate response to PPI, try an H2 receptor antagonist (e.g. ranitidine 150 mg bd) and/or add a prokinetic (e.g. domperidone 10 mg tds) for l month
- H2RA taken at bedtime
- Use of a bedtime H2RA may be beneficial if dosed on an as-needed basis for patients with nocturnal symptoms and for patients with objective evidence of nocturnal acid reflux on pH monitoring despite PPI treatment.

Baclofen

- Baclofen, a GABAB agonist, reduces the transient LES (Lower esophageal sphincter) relaxations that enable reflux episodes. Baclofen decreases the number of postprandial acid and nonacid reflux events, nocturnal reflux activity, and belching episodes. A trial of baclofen at a dosage of 5–20 mg 3 times a day can be considered in patients with objective documentation of continued symptomatic reflux despite optimal PPI therapy.
- Sucralfate is a mucosal protective agent, but few data document its efficacy in GERD.

Long-term management of endoscopically /barium-confirmed GORD

- Patients who have had dilatation of an oesophageal stricture should remain on long- term full-dose PPI therapy
- For all other patients, if symptoms recur following initial treatment, offer a PPI at the lowest dose possible to control symptoms, with a limited number of repeat prescriptions. Discuss using the treatment on an as-required basis to manage symptoms
- Refer for consideration of surgery if quality of life remains significantly impaired despite optimal treatment.
- Surgery of any type is >90% successful although results may deteriorate with time

Surgery

- Identifying patients with true refractory GERD is crucial because surgery (or endoscopic treatment) may truly be best in this group. GERD that fails to respond to medical therapy is another valid indication for antireflux procedures, but one that requires meticulous preprocedure evaluation to achieve good surgical outcomes.

Fundoplication

- Fundoplication especially Nissen fundoplication, is widely regarded as the "gold standard" among the antireflux procedures for its efficacy in improving the physiologic parameters of GERD such as LES pressure and esophageal acid exposure time. Fundoplication creates a barrier to the reflux of all gastric material (acidic and nonacidic) and therefore should be an effective treatment for any GERD symptom that is reflux-related.

Magnetic sphincter augmentation (MSA)

MSA with the LINX Reflux Management System, a necklace of titanium beads with magnetic cores that encircles the distal esophagus to bolster the LES and prevent reflux, was developed as a less invasive and more readily reversible GERD treatment than fundoplication.

Roux-en-Y gastric bypass (RYGB)

GERD is strongly associated with obesity. RYGB can control GERD in obese patients, presumably because the small gastric pouch fashioned during RYGB produces far less acid than an intact stomach, and because the accompanying long alimentary loop prevents the reflux of bile.

Endoscopic antireflux therapies

- Presently, the only endoscopic GERD treatments still widely available are radiofrequency antireflux treatment (Stretta; Restech, Houston, TX) and TIF (endogastric solutions).

Treatment of GERD during pregnancy

- Approximately two-thirds of pregnant women experience heartburn. It has been recommended that treatment of GERD during pregnancy should start with lifestyle modifications. When lifestyle modifications fail, antacids (aluminum-, calcium-, or magnesium-containing), alginates, and sucralfate are the first-line therapeutic agents. All histamine H2- blockers are FDA category B, and all PPIs are FDA category B except omeprazole, which is FDA category C.

HIATUS HERNIA

- Common (30% of over 50s); 50% have GORD.
- Obesity is a risk factor. The proximal stomach herniates through the diaphragmatic hiatus into the thorax
- 80% have a 'sliding' hiatus hernia where the gastro-oesophageal junction slides into the chest
- 20% have a 'rolling' hernia where a bulge of stomach herniates into the chest alongside the oesophagus. The gastro-oesophageal junction remains in the abdomen

Management

- Treat as for GORD.
- BARRETT'S OESOPHAGUS
- Usually found incidentally at endoscopy for symptoms of GORD and caused by chronic GORD. The squamous mucosa of the oesophagus undergoes metaplastic change, and the squamocolumnar junction appears to migrate away from the stomach.
- The length affected varies. It carries a 40 times increased risk of adenocarcinoma of the oesophagus, so regular endoscopy is essential.
- Treatment is with long-term PPIs (e.g. omeprazole 20-40mg od) ± laser therapy ±resection.

Reference

1. *Oxford handbook of General Practice, 4th Edition*
2. *ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease,Am J Gastroenterol 2022;117:27–56. https://doi.org/10.14309/ajg.0000000000001538; published online November 22, 2021*
3. *The American Journal of GASTROENTEROLOGY, VOLUME 117 | JANUARY 2022 www.amjgastro.com*

MALABSORPTION

Definition

- Malabsorption: defective mucosal uptake and transport of adequately digested nutrients including vitamins and trace elements.
- Presents with chronic diarrhoea, weight loss, steatorrhoea, vitamin/iron deficiencies, and/or oedema due to protein deficiency.

Causes

- Pancreatic
- Chronic pancreatitis Cancer of pancreas Cystic fibrosis
- Enteropathy Coeliac disease Tropical sprue Lymphoma
- Lymphangiectasia
- Blind loops, systemic sclerosis, and diverticula, where small intestinal bacterial overgrowth (SIBO) can occur. Intestinal bacteria may use up dietary vitamin B12 and other nutrients, perhaps interfere with enzyme systems, and cause mucosal injury.
- Cirrhosis and cholestasis reduce hepatic bile synthesis or delivery of bile salts to the duodenum, causing malabsorption.

Symptoms suggestive of malabsorption

- Pale and /or offensive stools
- Steatorrhoea-excess fat in faeces. The stool is pale-coloured and foul-smelling and floats ('difficult to flush')
- Severe vitamin and mineral deficiencies occur in advanced malabsorption; symptoms are related to the specific nutrient deficiency.
- Vitamin B12 deficiency may occur in blind loop syndrome or after extensive resection of the distal ileum or stomach.
- Iron deficiency may be the only symptom in a patient with mild malabsorption.
- Amenorrhea may result from undernutrition and is an important manifestation of celiac disease in young women.

Refer to gastroenterologist for investigation/treatment of the cause.

WHIPPLE'S DISEASE

- A cause of malabsorption which usually occurs in male >50 yr.
- Other features: arthralgia, pigmentation, weight loss, lymphadenopathy, ± cerebellar or cardiac signs.
- Cause: Tropheryma whippelii.
- Refer for gastroenterology assessment. Jejunal biopsy is characteristic.
- Treatment: long-term broad-spectrum antibiotics.

FACTITIOUS DIARRHOEA

- Responsible for 4% referrals to gastroenterology departments and 20% of tertiary referrals.
- Due to laxative abuse or adding of water or urine to stool samples.
- Difficult to spot-have a high index of suspicion especially in patients with history of eating disorder or somatization.

Suggested evaluation for malabsorption



Reference

1. *Gastroenterol Clin N Am 41 (2012) 629-637*
2. *https://www.msdmanuals.com/professional/gastrointestinal-disorders/malabsorption-syndromes/overview-of-malabsorption*

IRRITABLE BOWEL SYNDROME

Definition

- IBS is a chronic and sometimes disabling functional bowel disorder.
- IBS is diagnosed on the basis of recurrent abdominal pain related to defecation or in association with a change in stool frequency or form.

Rome (IV) criteria for IBS

- Recurrent abdominal pain, on average, at least 1 day/week in the last 3 months, associated with two or more of the following criteria:
- Related to defecation
- Associated with a change in frequency of stool
- Associated with a change in form (appearance)
- Criteria fulfilling for the last 3 months with symptoms onset at least 6 months before diagnosis.

Prevalence

- It is most common in women and young people.
- The diagnosing IBS accurately can minimize the invasive investigations and can recommend effective treatment to reduce the societal and economic effects of the disease.

Classification

- On the basis of the Rome IV criteria, IBS is classified into four subtypes
- IBS with diarrhea (IBS-D)
- IBS with constipation (IBS-C)
- IBS with mixed symptoms of constipation and diarrhea (IBS-M)
- Undefined subtype (IBS-U) - unclassified; the symptoms cannot be categorized into one of the above three subtypes (IBS-U)

Diagnosis

- Patients with suspected IBS have symptoms of abdominal pam; the absence of abdominal pain precludes the diagnosis.
- Disordered bowel habits also need to be present. Abdominal bloating is not required but is frequently present and supports the diagnosis.
- A detailed history should be obtained to rule out disorders that can mimic IBS (e.g. carbohydrate malabsorption, celiac disease, ovarian cancer, and microscopic colitis).
- Physical examination in patients with IBS generally reveals no abnormalities other than lower abdominal tenderness.
- The presence of ascites, hepatosplenomegaly enlarged lymph nodes, or a mass → an alternative diagnosis.
- A digital rectal examination to exclude overlapping pelvic-floor dyssynergia.
- In the absence of warning signs, the Rome IV criteria should be applied to make a positive diagnosis.
- The clinician may order appropriate limited diagnostic testing to rule out other, less common, causes of similar symptoms.
- The Bristol Stool Form Scale can be used to accurately classify the patient.
- Treatment should be initiated as soon as the diagnosis is made and should focus on the predominant symptoms.

Bristol Stool Chart



Investigation

- Complete blood count to exclude IBD (Inflammatory Bowel Disease)
- C Reactive Protein (CRP)
- Thyroid Function Test (TFT),
- Serum Ca++ (for hyperparathyroidism)
- IBS-D
- Serology testing to exclude coeliac disease
- 23-seleno-25-homotaurocholicacid (75SeHCAT) testing
- serum 7a-hydroxy-4-cholesten-3-one [C4, a bile acid precursor] testing
- IBS- C
- Anorectal manometry-Pelvic floor dyssynergia
- USG (abdomen) (transvaginal) to exclude ovarian mass
- Fecal calprotectin testing- in IBS mixed, can reduce the use of colonoscopy novel biomarkers
- two serum biomarkers
- o (antibodies to a bacterial toxin produced by Campylobacter jejuni and vinculin),which distinguished IBS from IBD with good specificity (92% for C. jejuni and 84% for vinculin) but low sensitivity (44% for C. jejuni and 33% for vinculin).

TREATMENT

Therapy	Study outcome	Reported efficacy	Quality of evidence	Limitation of data	Side effect
Antispasmodic drugs (e.g. dicyclomine, 20-40 mg qid daily	Global symptoms, abdominal pain, diarrhoea	May be effective but class dependent	Low	No high-quality trials, only a small number of RCTs, assessing each drug and few trials with FDA-approved end points: none of the drugs identified as effective are available in the US	Abdominal pain, constipation, drug mouth, and dry eyes
Pepermint oil [e.g. colpermin (McNeil Products, two capsules tds daily)]	Global symptoms	Effective	Moderate	Few RCTs and no FDA-approved end points	Heartburn, dyspepsia, headache, and dry mouth
Rifaximin 550 mg tds	Global symptoms, abdominal pain, diarrhoea	Effective	Moderate	Few RCTs and only a modest benefit over placebo	Heartburn, nausea, abdominal pain, and diarrhoea
Soluble fibre (e.g. psyllium, one sachet tds daily)	Global symptoms,	Effective, start at a low dose and increase slowly	Moderate	Only one trial of high quality and no FDA-approved end point	Diarrhoea, constipation, bloating, and flatulence
Low fermentable oligo-dimono-saccharides and polylos (FODMAP) diet	Global symptoms, abdominal pain, bloating	May be effective; nutritionist's guidance helpful	Very low	Fre RCTs, may if cross over design with a small number of participants, and no FDA- approved end points	Potential effect on the colonic microbiome, with unknown long-term consequences

An individualized approach to management

- An effective doctor-patient relationship increases patient satisfaction and reduces the number of subsequent consultations.
- Reassurance, explanation, and a positive diagnosis are essential steps in management.
- Start with dietary modifications (slowly increasing soluble fiber if the patient has IBS with constipation or instituting a low-FODMAP diet temporarily if the patient has IBS with diarrhea or the mixed subtype of IBS).
- We also recommend increased exercise and stress reduction.
- A probiotic may be added, especially if bloating is prominent.
- Pain may be ameliorated with an antispasmodic agent or a tricyclic antidepressant, diarrhea with loperamide or a bile acid sequestrant (e.g., colestipol),

- constipation with polyethylene glycol
- 1-month trail of above Treatment
- Antihistamine-Ebastine is also effective
- Persistent and troublesome IBS-C symptoms, linaclotide or lubiprostone may help.
- IBS-D -alosetron, eluxadoline, or rifaximin
- Pain is often a predominant concern, and at least one psychiatric disorder is usually present.

Refractory IBS

- A multidisciplinary team approach to providing patient support is ideal.
- Opiates should be avoided, since their use increases the risk of the narcotic bowel syndrome.
- Patients with symptoms that are difficult to manage may request fecal microbial transfer.



*Selection of the medication should be based on the clinical features and needs of the patient.

TCA, tricyclic antidepressant; SNRI, serotonin-norepinephrine reuptake inhibitor; PEG, polyethylene glycol; CBT, cognitive behavioral therapy

Referral

- passing blood (except if from an anal fissure or haemorrhoid.
- Abdominal, rectal or pelvic mass
- Unintentional/unexplained weight loss
- Positive inflammatory markers and/or anorexia
- >40 years with new symptoms
- Change in symptoms especially if >40 years
- Atypical features
- Family history of bowel or ovarian cancer
- Patient is unhappy to accept a diagnosis of IBS despite explanation

Reference

1. *NEJM (June 29, 201 7)*
2. *Irritable Bowel Syndrome (IBS) Guidelines. Updated: Feb 15, 2022,Author: Jenifer K Lehrer, MD; Chief Editor: BS Anand, MD more...*

ACUTE HEPATITIS

Definition

- Acute inflammation of the liver that lasts less than six months, usually defined by features of acute liver insufficiency as well as by absence of features of chronic liver insufficiency and portal hypertension.

Causes

- Viral Hepatitis- Hepatitis A virus (HAV), Hepatitis B virus (HBV), Hepatitis C virus (HCV), Hepatitis E virus (HEV), Cytomegalovirus (CMV)
- Bacterial infection-Leptospirosis, Sepsis
- Alcoholic hepatitis
- Drugs induced hepatitis- Acetaminophen, Anti-Tuberculosis drugs (isoniazid, rifampicin and pyrazinamide), Antiepileptic drugs (phenytoin, carbamazepine, lamotrigine)

Clinical presentation

- Typical example of acute hepatitis is acute viral hepatitis. Onset is usually insidious but may be abrupt.
- Symptomatic acute viral hepatitis can present with three phases but more likely to be asymptomatic in children.

In the early phases:

- Tiredness, Fatigue, slight fever
- Nausea, poor appetite
- Pain in right hypochondrium
- Aching muscles and joints, headache, skin rash

In the jaundiced phase:

- Yellowish discoloration of sclerae, skin and mucous membranes
- Dark urine
- Light-coloured stools
- The symptoms in early phase subsided around this time.

In the recovery phase:

- Tiredness that can last for weeks.
- The whole Illness typically lasts 2 to 4 weeks and ultimately resolves. In a very few, there is a potential of developing fulminant form (acute liver failure and death)
- In Fulminant forms- Signs of Hepatic Encephalopathy (personality change, aggressive behavior, sleep pattern changes and coma) can supervene rapidly. Widespread hemorrhage due to coagulopathy may develop.

Investigation

- In addition to History and physical examination, the following investigations should be done to arrive the diagnosis.
- Liver panel (ALT, GGT, Total & Direct bilirubin, ALP)
- Coagulopathy (prothrmbin time, INR)
- Viral serology (Anti-HAV IgM, HBsAg, Anti-HBc IgM, Anti- HCV)
- Ultrasound Abdomen

Diagnostic Algorithm for Acute Hepatitis



Treatment

General measure

- In most people, special treatment is not necessary.
- Bed rest, avoidance of alcohol and strenuous physical exertion is helpful.
- Stopping of causative drugs is also important.
- IV 10% glucose should be given if nausea, vomiting and reduced oral intake are pronounced.
- Regarding dietary management, palatable meals as tolerated, without overfeeding.
- Severe restrictions of diet or activity are unnecessary, and vitamin supplements may be helpful in malnourished patients.
- People with severe acute hepatitis (hepatic Encephalopathy, INR > 1.6) may require hospitalization.

Specific treatment

- There is no specific treatment for hepatitis A. Most cases of hepatitis A resolve themselves spontaneously.
- The only treatment for hepatitis B is rest, combined with a high protein/high carbohydrate diet to repair damaged liver cells and protect the liver. Spontaneous recovery occurs after acute infection with HBV occurs in 95-99% of previously healthy adults.

Follow up

- All patient with acute hepatitis will need regular follow up depend on severity and stage of hepatitis.

Prevention

- Personal hygiene and hand washing is important.
- 2 doses of Hepatitis A vaccine should be given within 6 to 12 months period before the age of 30 years.
- 3 doses of the hepatitis B vaccine should also be given to prevent hepatitis B infection.

Reference

1. *Therapeutic manual on internal medicine, 1st Edition, MMA*

HEPATITIS B (ENVELOPED DNA VIRUS)

- Common, Endemic in much of Asia and the Far East
- National -wide prevalence 6.5% (5/2015, Dept of Medical Research and Dept. of Public Health)
- The virus has 3 major structural antigens: HBsAg, HBcAg, HBeAg. Spread is via infected blood, sexual intercourse, from mother to newborn baby, or via human bites.
- Incubation period is 6- 23 weeks (average 17weeks)
- HBV infection can be either acute or chronic and the associated illness ranges in severity from asymptomic to symptomic, progressive disease (cirrhosis, HCC).
- Antiviral agents active against HBV are available, and have been shown to suppress HBV replication, prevent to progression cirrhosis and reduce the risk of HCC and liver related deaths.
- However, currently available treatments fail to eradicate the virus in most of those treated, necessitating potentially lifelong treatment.
- (In detail, please see in Infection and Infestation Chapter)

HEPATITIS C (RNA VIRUS)

- HCV is a major cause of acute and chronic hepatitis.
- National wide prevalence survey HCV -2.7% (Dept of Medical research and Dept of public health 5/2015)
- Should be tested anybody attending clinic for any illness or patient's desire.
- (In detail, please see in Infection and Infestation Chapter)

FATTY LIVER DISEASE (HEPATIC STEATOSIS)

Key highlight:

- Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the world.
- It is projected to become a leading indication for liver transplantation, superseding hepatitis C.
- The diagnosis of hepatic steatosis is based on exclusion of other etiologies, such as alcohol use along with histology.
- Associated with obesity and features of the metabolic syndrome in most cases. May progress to steatohepatitis and end-stage liver disease.
- There are no currently recommend drug treatment. Lifestyle modification remains the first line of the therapy.

Definition

- Non-alcoholic liver disease (NAFLD) is a clinicohistopathologic activity that includes a spectrum of condition characterized histologically by macrovesicular hepatic steatosis in those who do not consume alcohol in amounts generally considered harmful to liver.

Clinicopathological classification of NAFLD

- Steatosis
- Steatohepatitis (NASH-nonalcoholic steatohepatitis)
- NASH associated fibrosis
- NASH associated cirrhosis
- NASH associated end stage liver disease

High-Risk Groups

- Obesity (excessive body mass index [BMI] and visceral obesity) is the most common and well documented risk factor for NAFLD. In fact, the entire spectrum of obesity, ranging from overweight to obese and severely obese, is associated with NAFLD.
- Type 2 diabetes mellitus (T2DM): There is a very high prevalence of NAFLD in individuals with T2DM.
- Dyslipidemia: High serum triglyceride (TG) levels and low serum high-density lipoprotein (HDL) levels are also common in patients with NAFLD.
- Age and sex: both the prevalence of NAFLD and stage of liver disease appear to increase with age. The prevalence of NAFLD in men is 2 times higher than in women.
- Individuals with persistently abnormal aminotransferase levels in the absence of other causes of liver disease (eg, viral hepatitis and excessive alcohol use)
- Screen children and adolescents with type 2 diabetes for NAFLD using age appropriate liver enzyme tests.

Diagnosis of NAFLD in Adults

- Clinicians should consider persons with obesity and/or features of Metabolic Syndrome, those with prediabetes or T2D, and those with hepatic steatosis on any imaging study and/or persistently elevated plasma aminotransferase levels (over 6 months) to be “high risk” and screen for NAFLD and advanced fibrosis.

- Clinicians should use **liver fibrosis prediction calculations** to assess the risk of NAFLD with liver fibrosis. The preferred noninvasive initial test is the **fibrosis-4 index (FIB-4)*.**
- ***FIB-4- Fibrosis-4 index** An index to estimate the risk of hepatic cirrhosis calculated from the computation of age, plasma aminotransferases (AST and ALT), and platelet count. This noninvasive estimate of liver scarring is used to assess the need for biopsy. **The score is calculated using a person's age, AST level, platelet count (PLT), and ALT level**.
- **FIB-4 score** = age (years) x AST (U/L)/[PLT (10^9 /L) x ALT ½ (U/L).
- To stage the risk of fibrosis in persons with NAFLD, clinicians should prefer the use of VCTE as best validated to identify advanced disease and predict liver-related outcomes.
- (**VCTE - Vibration-controlled transient elastography**, A technique for liver stiffness measurement that is correlated with the severity of liver fibrosis on histology)
- The current "**gold standard"** for the diagnosis of steatohepatitis is a **liver biopsy.** Although safe, it is an **invasive procedure** associated with potential adverse effects, such as pain, bleeding, and infection. In addition, it has other limitations, including reduced acceptability, intraobserver and interobserver variability, sampling variability, and cost.
- Patients with **low-risk FIB-4** are managed with a focus on cardiometabolic disease prevention (weight management, diabetes, hypertension, lipids). High risk patients or indeterminate patients who need further evaluation are referred to the liver specialist."

Management of Non-alcoholic fatty liver disease

- Clinicians must manage persons with NAFLD for obesity, Metabolic Syndrome, prediabetes, diabetes mellitus, dyslipidemia, hypertension, and CVD based on the current standards of care.

Treatment options

- Non alcoholic fatty liver disease (NAFLD) with diabetes
- **First line:** Lifestyle modification (weight loss, diet, exercise) to lower fibrosis and hepatic steatosis
- **Weight loss in obese and overweight** patients through reduced caloric intake, increased exercise, or a combination of both.
- eight loss should be gradual, approximately 0.5 to 1.0 kg I week through dietary restrictions and regular exercise (30) minutes 3-5 times per week

Adjunctive therapy

- Roux-en-Y gastric bypass.
- Morbidly obese patients (BMI >35kg/m^2) should be considered for more aggressive weight loss measures including bariatric surgery
- Weight loss pharmacotherapy
- ORLISTAT prevents the absorption of fats from the GI tract.
- Clinicians must consider treating diabetes with pioglitazone and/or GLP-1 RAs when there is an elevated probability of having NASH based on elevated plasma aminotransferase levels and noninvasive tests.
- To offer cardiometabolic benefit in persons with T2D and NAFLD, clinicians must consider treatment with GLP1 RAs, pioglitazone, or SGLT2 inhibitors; however, there is no evidence of benefit for treatment of steatohepatitis with SGLT2 inhibitors.

- Two antidiabetic agents have proven to be safe and effective to reverse NASH in persons with obesity, prediabetes, or T2D: pioglitazone and GLP-1 RA.
- For chronic weight management in individuals with a BMI of 27 kg/m2 and NAFLD or NASH, clinicians should give preference to semaglutide 2.4 mg/week (best evidence) or liraglutide 3 mg/day.

NAFLD with Dyslipidaemia

- First line
- Lifestyle modification
- Adjunctive therapy
- ORLISTAT
- Lipid lowering therapy
- Roux- en-Y gastric bypass



Diabetes Management in NAFLD

Fibrosis Risk Stratification

	 Low Risk FIB-4: <1.3 LSM <8 kPa ELF <7.7	 Indeterminate Risk FIB-4: 1.3 - 2.67 LSM 8 - 12 kPa ELF 7.7 - 9.8	 High Risk[1] FIB-4: >2.67 LSM >12 kPa ELF >9.8
General goal	Optimize glycemic control using preferred agents that reverse steatohepatitis, whenever possible. Prefer GLP-1 RA and SGLT2i in CVD. Prefer SGLT2i in CKD and HF.		
Dietary recommendations	Glycemic load reduction via emphasis on whole food carbohydrates (vegetables, legumes, fruit) versus sugar/processed carbohydrates.		
Individualize A1c target	≤6.5% for persons without concurrent serious illness and at low hypoglycemic risk (>6.5% otherwise).		In advanced cirrhosis[1], caution with risk of hypoglycemia and avoid oral agents[2]
Preferred diabetes pharmacotherapy	Consider agents that reduce liver fat (pioglitazone, GLP-1 RA, SGLT2i).	Strongly consider agents with efficacy in NASH: Pioglitazone and/or GLP-1 RA[3]. No evidence that SGLT2i improve steatohepatitis.	Strongly consider agents with efficacy in NASH: Pioglitazone and/or GLP-1 RA[3]. No efficacy data in cirrhosis.
Metformin, sulfonylurea, DPP-4i, acarbose and insulin	May continue but limited benefit on liver histology in NAFLD.	May continue but limited benefit on liver histology in NAFLD.	May continue (F2-F3) but avoid oral agents if advanced cirrhosis present. Cannot avoid insulin in patients with advanced liver cirrhosis – often only option

Abbreviations: CKD = Chronic kidney disease, CVD = Cardiovascular disease, DPP-4i = Dipeptidyl peptidase 4, GLP-1 RA = Glucagon-like peptide-1 receptor agonists, HF = Heart failure, NASH = Nonalcoholic steatohepatitis, SGLT2i = Sodium-glucose cotransporter-2 inhibitors.

1. Advanced cirrhosis is defined as persons with cirrhosis based on biopsy and Child class B or C with clinical evidence of comorbidities (varices, portal hypertension, ascites, etc.).
2. Limited data on oral diabetes medications and GLP-1 RA in persons with cirrhosis. Avoid metformin, GLP-1 RA appear safe, insulin preferred. Avoid oral agents in advanced cirrhosis.
3. Among GLP-1 RAs, semaglutide has the best evidence of benefit in persons with steatohepatitis and fibrosis.

Algorithm Figure 4

AACE.

Weight Management in NAFLD

Fibrosis Risk Stratification

	 Low Risk FIB-4: <1.3 LSM <8 kPa ELF <7.7	 Indeterminate Risk FIB-4: 1.3 - 2.67 LSM 8 - 12 kPa ELF 7.7 - 9.8	 High Risk FIB-4: >2.67 LSM >12 kPa ELF >9.8
General lifestyle changes	Decrease sedentary time and increase daily movement. Stress reduction through exercise and other methods.		
Dietary recommendations	Creating an energy deficit is the priority with reduction of saturated fat, starch, & added sugars. Persons with cirrhosis need an individualized nutritional assessment and treatment plan.		
Exercise	To improve cardiometabolic health, support weight loss and mitigate sarcopenia. Aerobic exercise for 30-60 min (3-5 days/week) + resistance training 20-30 min (2-3 times/week).		
Alcohol intake	Minimize	Minimize	Avoid if F3 or cirrhosis (F4)[1]
Weight loss goal to treat NAFLD (if overweight or obesity)[2]	Greater weight loss associated with greater liver and cardiometabolic benefit.		
Weight loss tools	Behavioral modification counseling. In person or remote programs.	Greater intensity of weight loss to reverse steatohepatitis and fibrosis.	Specialized obesity management, with a structured program, anti-obesity medications, bariatric surgery.
Medical therapy to treat obesity	Phentermine, phentermine/topiramate ER, naltrexone/bupropion, orlistat, liragluitde 3 mg/d, semaglutide 2.4 mg/wk	GLP-1 RA preferred for NASH.[3,4]	GLP-1 RA preferred for NASH.[3,4]
Bariatric surgery	Consider to treat obesity and comorbidities.	Strong consideration to treat steatohepatitis and fibrosis.	Stronger consideration to treat steatohepatitis and fibrosis. Avoid in decompensated cirrhosis.

Abbreviations: GLP-1 RA = Glucagon-like peptide-1 receptor agonists, HCC = Hepatocellular carcinoma, NASH = Nonalcoholic steatohepatitis

1. Persons with confirmed cirrhosis based on biopsy or high likelihood based on LSM >13.6kPa from vibration controlled transient elastography (FibroScan®), ELF ≥9.8 or >5.0 kPa on MRE) should undergo HCC surveillance. Varices screening is recommended if LSM >20 kPa or platelet count of <150,000/mm^3.
2. These goals should only be taken as a broad guidance. NAFLD/NASH may also improve by changes in macronutrient content, exercise and other factors beyond magnitude of weight loss. All high-quality studies available limited to a maximum of 12 month duration.
3. No high-quality evidence for pharmacotherapy in persons with NASH cirrhosis. Treatment should be individualized and used with caution only by liver specialists.
4. Among GLP-1 RAs, semaglutide has the best evidence of benefit in persons with steatohepatitis and fibrosis.

Algorithm Figure 3

AACE.

Atherogenic Dyslipidemia Management in NAFLD

Lipid risk levels are similar in the presence of NAFLD or NASH

General goal	Early intensive management of dyslipidemia needed to reduce cardiovascular risk. Intensify therapy until lipid goal is reached.		
Dietary recommendations	Increase fiber intake (>25 g/d), prioritize vegetables, fruits whole grains, nuts, reduce saturated fat & added sugars (e.g., Mediterranean diet).		
Lipid risk levels	**High CV Risk[1]** ≥2 risk factors and 10-year risk 10-20% Diabetes or CKD ≥3 with no other risk factors	**Very high CV Risk[1]** Established CVD or 10-year risk >20% Diabetes with >1 risk factor, CKD ≥3, HeFH	**Extreme CV Risk[1]** Progressive CVD CVD + diabetes or CKD ≥3 or HeFH FHx premature CVD (<55 yrs male <65 yrs female)
LDL-C goal (mg/dL)	<100	<70	<55
Non-HDL-C goal (mg/dL)	<130	<100	<80
Triglycerides goal (mg/dL)	<150	<150	<150
Apo B goal (mg/dL)	<90	<80	<70
First line pharmacotherapy: Statins	Use a moderate-to-high intensity statin[2], unless contraindicated. Statins are safe in NAFLD or NASH but do not use in decompensated cirrhosis (Child C).		
If LDL-C not at goal[3]: Intensify statin therapy	Use higher dose or higher potency statin.		
If LDL-C not at goal (or statin intolerant)[4]: add 2nd agent, then add 3rd agent	Ezetemibe, PCSK9 inhibitor, bempedoic acid, colesevelam, inclisiran.		
If triglycerides > 500 mg/dL	Fibrates, Rx grade omega 3 FA, icosapent ethyl (if diabetes, optimize glycemic control and consider pioglitazone).[5]		
If TG 135-499 mg/dL on max statin dose	Emphasize diet (as above).	Add icosapent ethyl.[6]	Add icosapent ethyl.[6]

Adapted from Handelsman Y, et al. Endocr Pract. 2020;26:1196-1224.

Abbreviations: CKD = Chronic kidney disease, CVD = cardiovascular disease, FA = Fatty acids, HeFH = Heterozygous familial hypercholesterolemia, HTN = Hypertension, Rx = Prescription
1. Major risk factors: age >40, DM, HTN, FHx of early CVD, low HDL C, elevated LDL, Smoking, CKD 3,4
2. High intensity statin therapy: rosuvastatin 20, 40 mg/d, atorvastatin 40, 80 mg/d.
3. Other lipid modifying agents should be used in combination with maximally tolerated statins if goals not reached: ezetimibe, PCSK9 inhibitor, bempedoic acid, colesevelam, or inclisiran.
4. Assess adequacy and tolerance of therapy with focused laboratory evaluations and patient follow up.
5. Niacin may lower triglycerides but does not reduce CVD and worsens insulin resistance. It may promote hyperglycemia in a population at high-risk of diabetes.
6. Icosapent ethyl 4g/d is recommended as an adjunct to maximally tolerated statin therapy to reduce risk of cardiovascular disease in high-risk persons.

Algorithm Figure 6

AACE.

Hypertension Management in NAFLD

Fibrosis Risk Stratification

	 FIB-4: <1.3 LSM <8 kPa ELF <7.7	 FIB-4: 1.3 - 2.67 LSM 8 - 12 kPa ELF 7.7 - 9.8	 FIB-4: >2.67 LSM >12 kPa ELF >9.8
General goal	Optimize BP control and improve cardiovascular health using preferred agents, whenever possible. Assess every 3 months and intensify therapy until goal achieved.		
Goal (individualize)[2,3,4]	Systolic < 130 mm Hg / Diastolic < 80 mm Hg	Systolic < 130 mm Hg / Diastolic < 80 mm Hg	Systolic < 130 mm Hg / Diastolic < 80 mm Hg; individualize if decompensated cirrhosis
Dietary recommendations	In addition to general dietary recommendations, reduce sodium & increase high potassium foods (e.g., DASH diet).		
Pharmacotherapy for hypertension[5]	First-line therapy: ACEIs and ARBs.	First-line therapy: ACEIs and ARBs.	Same but avoid ACEI or ARB if decompensated cirrhosis.
Intensification of therapy	Second agent: CCB, BB[6] or thiazide diuretic (as additional agents as needed).		Same but individualize if decompensated cirrhosis. Use diuretics with caution (risk of excessive diuresis).
Additional options	Additional BP medication choices: alpha blockers, central agents, vasodilators, aldosterone antagonist.		Same but individualize if decompensated cirrhosis.

Abbreviations: ACEIs = Angiotensin-converting enzyme inhibitors, ARBs = angiotensin II receptor blockers, BB = beta blockers, CCB = calcium channel blockers.
1. Advanced cirrhosis defined as persons with cirrhosis based on biopsy and Child class B or C and clinical evidence of comorbidities (varices, portal hypertension, ascitis, etc.).
2. AACE recommends that BP control be individualized, but that a target of <130/80 mm Hg is appropriate for most persons.
3. Less-stringent goals may be considered for frail persons with complicated comorbidities or those who have adverse medication effects.
4. A more intensive goal (e.g., <120/80 mm Hg) should be considered for some persons if this target can be reached safely without adverse effects from medication.
5. If initial BP > 150/100 mm Hg start with dual therapy. (ACEI or ARB + CCB, BB or thiazide diuretic).
6. Prefer weight neutral beta-blockers: carvedilol, nebivolol.

Algorithm Figure 5

AACE.



-
- Vitamin E can be considered for the treatment of NASH in persons without T2D, but there is not enough evidence at this time to recommend for persons with T2D or advanced fibrosis.

Drugs used in NAFLD

Drug	Benefits	Avoid Use	Recommend Use
Pioglitazone	• Improves insulin sensitivity • Anti-atherosclerotic and anti-inflammatory properties • Decreases liver steatosis and fibrosis	Patient without diabetes	• Biopsy proven nonalcoholic steatohepatitis (NASH) • Patients with diabetes
GLIP-1 agonists • *Liraglutide* • *Semaglutide*	• Cardiometabolic benefit • Weight management • Decreases liver steatosis • Normalizes aminotransferases levels	• Patient without diabetes • BMI <27 kg/m2	Obesity (≥27 kg/m^2) • *Semaglutide 2.4 mg weekly* • *Liraglutide 3 mg daily* Type 2 diabetes • *Semaglutide 2 mg weekly* • *Liraglutide 1.8 mg daily*
SGLT-2	Cardiometabolic benefit	Patient without diabetes Steatohepatitis	Patients with diabetes
Statin	• Anti-oxidant • Antithrombotic • Anti-inflammatory effect • Reduce cardiovascular mortality	• Significant liver disease • Unexplained elevated serum transaminase	• NASH • High ASCVD risk or clinical ASCVD
Vitamin E	Improvement in liver histology	Patient with diabetes	NASH

NASH associated end stage liver disease

Liver transplant and transjugular intrahepatic portosystemic shunt (TIPS)

Reference:

1. *Ludwig J et al. Non-alcoholic steatohepatitis: Mayo ClinProc.1980;55:434-438*
2. *Epocrates, Athena gp. 2018*
3. *Clinical Practice Guidelines American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD)2022*
4. *https://www.sciencedirect.com/science/article/pii/S1530891X22000908*

LIVER CIRRHOSIS

- A pathological condition of liver fibrosis generated by continuous scar formation and recovery due to chronic liver injury, eventually leading to the development of regenerative nodules around the fibrotic scar.

Common aetiology

- Viral hepatitis (B and C)
- Alcohol
- NASH
- Metabolic (e.g. haemochromatosis, Wilson's disease)
- Primary biliary cirrhosis
- Autoimmune hepatitis
- Toxins and drugs (e.g. methotrexate, amiodarone)

Diagnosis

- Clinically classified as compensated and decompensated (cases with ascites, variceal bleeding, hepatic encephalopathy or jaundice)

Imaging

- Abdominal ultrasound (coarse echo pattern by fibrosis and regeneration)
- CT
- MRI

Evaluation of the cause, severity, and staging

- History taking (drug use, blood transfusion, alcohol use, history suggestive of chronic liver disease)
- Physical examination (jaundice, ascites, spider angioma, hepatomegaly or splenomegaly)
- Laboratory tests (whole blood count including platelet count, liver function test including albumin, prothrombin time)
- Endoscopy should be carried out to confirm the presence or absence of esophageal varices which are indicator of portal hypertension.
- Tests for hepatitis B or C virus infection
- The Child-Pug score to assess the severity
- alpha fetoprotein
- Presence of one condition of following findings suggest the diagnosis of liver cirrhosis
- nodularity of the liver surface,
- a platelet count of less than 100,000/mm3,
- albumin less than 3.5 g/dL
- an international normalized ratio of ≥ 1.3
- Pathological diagnosis of liver cirrhosis
- liver biopsy--- gold standard for confirming the diagnosis, invasive and not
- routinely used

Child-Turcotte-Pugh Classification for Severity of Cirrhosis			
Clinical and Lab Criteria	Point		
	1	**2**	**3**
Encephalopathy	None	Mild to moderate (grade 1 or 2)	Severe (grade 3 or 4)
Ascites	None	Mild to moderate (diuretic responsive)	Severe (diuretic refractory)
Bilirubin (mg/dl)	<2	2-3	>3
Albumin (g/dl)	>3.5	2.8-3.5	<2.8
Prothrombin time			
Seconds prolonged	<4	4-6	>6
International normalized ratio	<1.7	1.7-2.3	>2.3
+Child-Turcotte-Pugh Class obtained adding score for each parameter (total points) Class A = 5 to 6 points (least severe liver disease) Class B = 7 to 9 points (moderately severe liver disease) Class C = 10 to 15 points (most severe liver disease)			

Management

- Treatment of the underlying disease
- (antiviral therapy for chronic hepatitis B to reduce liver fibrosis from virus proliferation, DAA treatment for chronic hepatitis C, abstinence of alcohol in alcoholic cirrhosis, improving insulin resistance, removing risk factors of metabolic syndrome, lifestyle modifications, drug therapy for nonalcoholic fatty liver disease, prednisolone and azathioprine for autoimmune hepatitis, phlebotomy for haemochromatosis)
- Treatment of complications
- Give flu and pneumococcal vaccination

Treatment of the underlying disease

Recommendations

- The cause of cirrhosis should be treated to improve liver fibrosis.
- In patients with liver cirrhosis due to chronic hepatitis B, antiviral therapy with sustained suppression of viral replication is needed.
- In patients with liver cirrhosis due to chronic hepatitis C, antiviral therapy with DAA and ribavirin should be considered.
- In patients with alcoholic liver cirrhosis, strict abstinence is recommended to prevent worsening of disease.
- In patients with nonalcoholic fatty liver disease, losing weight, diet therapy and exercise can be recommended.
- In patients with primary biliary cirrhosis, high dose ursodeoxycholic acid is recommended.
- Trientine and zinc for Wilson disease

Treatment of complications

Variceal bleeding

Recommendations for screening

- It is recommended that all patients undergo endoscopy when they are at first diagnosed of liver cirrhosis.

- For patients with compensated liver cirrhosis, endoscopy every 2 to 3 years should be considered and for patients with decompensated liver cirrhosis endoscopy every 1 to 2 years should be considered.
- Patients with compensated liver cirrhosis with small varices not using nonselective beta-blocker,endoscopy every 2 years is recommended.
- The frequency of endoscopy can be adjusted according to the cause and progression of liver cirrhosis.

Recommendations for acute variceal bleeding

- Initially be administered vasoconstrictor (e.g. Somatostatin, octreotide) and antibiotic treatment.
- Endoscopic treatment is recommended for patients with acute variceal bleeding.
- Balloon tamponade can be used as a rescue therapy if active variceal bleeding cannot be controlled.

Recommendations for prevention of variceal bleeding

- Nonselective beta-blockers should be considered for patients with varices.
- In patients with large varices in which bleeding has never been observed, nonselective beta-blockers and endoscopic variceal ligation (EVL) are recommended.

Ascites

Recommendations for ascites

- Paracentesis should be performed when Grade 2 or 3 ascites occurs.
- When the initial paracentesis is performed, a total cell count and differential, albumin, and total protein tests should be performed. A culture of ascitic fluid in blood culture bottles at the bedside is recommended.
- If serum-ascites albumin gradient is greater than or equal to 1.1 g/dL, it indicates ascites by portal hypertension.
- Patients with cirrhotic ascites should be advised to take in less than 5 g of salt a day.
- When the serum sodium is normal, restriction of water intake is not necessary.
- Bed rest is not recommended for the treatment of ascites.
- The first-choice diuretic for patients with cirrhotic ascites is aldosterone antagonist. Loop diuretics can be used along with aldosterone antagonist.
- Spironolactone can be used with a starting dose of 50-100 mg/day up to400 mg/day.
- To increase the diuretic effects and maintain a normal serum potassium level, 20-40 mg of furosemide should be used with spironolactone (40:100) at the initial stage.
- The rate of weight loss should be up to 1 kg/day for patient with peripheral edema and 0.5 kg/day for patients without edema.
- In cases of severe hyponatremia, kidney dysfunction, encephalopathy, or severe muscle spasms, diuretics should be stopped.
- In cases of hypokalemia, loop diuretic should be reduced or stopped, and if hyperkalemia occurs, the dose of aldosterone antagonist should be adjusted.
- Therapeutic large volume paracentesis is recommended as the first-line treatment for tension-type ascites.
- Patients with refractory ascites should be referred to specialist center.
- Serial therapeutic paracenteses are a treatment option for patients with refractory ascites.
- Post-paracentesis albumin infusion may not be necessary for a single paracentesis of less than 4 to 5 L.
- For large-volume paracenteses, an albumin infusion of 6-8 g per liter of fluid removed is recommended.

The older system
1+ is minimal and barely detectable
2+ is moderate
3+ is massive but not tense
4+ is massive and tense
The International Ascites Club grading (2003)
Grade 1: mild ascites detectable only by US
Grade 2: moderate ascites manifested by moderate symmetrical abdominal distension
Grade 3: large or gross ascites with marked abdominal distension

Spontaneous bacterial peritonitis (SBP)

The diagnosis is made in the presence of an elevated ascitic fluid neutrophil count (>250 cells/mm3) without an evident intra-abdominal, surgically treatable source of infection.

Recommendations for SBP

- Empirical antibiotics should be started immediately following the diagnosis of SBP.
- The first line antibiotic treatment is third-generation cephalosporins for 7 days.
- Alternative options include amoxycillin/clavulanic acid and quinolones for 7 days.
- Patients who have recovered from an episode of SBP should be considered for treatment with norfloxacin (400 mg once daily), ciprofloxacin (500 mg once daily, orally) or co-trimoxazole (800 mg sulfamethoxazole and 160 mg trimethoprim daily, orally) to prevent further episode of SBP. (Quality of evidence: low; Recommendation: weak)
- Patients who recover from an episode of SBP have a high risk of developing recurrent SBP.
- The prophylactic antibiotics reduce the risk of recurrent SBP.
- Ciprofloxacin (500 mg/day, orally) is the treatment of choice. Norfloxacin 400 mg once a day also as secondary prophylaxis,
- Patients presenting with gastrointestinal bleeding and underlying ascites due to cirrhosis should receive prophylactic antibiotic treatment (cefotaxime has been widely studied but the antibiotic should be chosen based on local data) to prevent the development of SBP. (Quality of evidence: strong, Recommendation: strong)
- Primary prophylaxis should be offered to patients considered at high risk, as defined by an ascitic protein count <1.5 g/dL. However, it is important that the potential risks and benefits and existing uncertainties are communicated to patients. (Quality of evidence: low; Recommendation: weak)
- Give prophylaxis for high-risk patients (↓ albumin, ↑PT/INR, low ascetic albumin) or those who have had a previous episode: ciprofloxacin 500 mg po daily.

Hepatic encephalopathy

- A broad range of neurologic and neuropsychiatric impairments seen m patients with significant underlying liver disease

West-Haven criteria for hepatic encephalopathy

Grade	Consciousness	Intellect and behavior	Neurologic finding
0	Normal	Normal	Normal examination: if impaired psychomotor testing then MHE
1	Mild lack of awareness	Shortened attention span: impaired addition or subtraction	Mild asterixis or tremor
2	Lethargic	Discontented: inappropriate behavior	Obvious asterixis: slurred speech

3	Somnolent but arousable	Gross disorientation: bizarre behavior	Muscular rigidity and clonus; hyperreflexia
4	Coma	Coma	Decerebrate posturing

- Precipitating factors of hepatic encephalopathy are gastrointestinal bleeding, infection, constipation, excessive intake of protein, dehydration, renal function disorder, electrolyte imbalance, psychoactive medication,and acute hepatic injury.

Recommendations for treatment

- Nonabsorbent disaccharides (e.g., lactulose, lactitol and rifaximin) are recommended.
- Nonabsorbable disaccharides can be used to adjust the bowel movement-loose stool (2-3 times/day).
- L-omithine-L-aspartate (LOLA) 20 g can be injected daily for 1-2 weeks or LOLA of 6 g can be given orally 3 times per day for 1-2 weeks.
- In patients with a history of hepatic encephalopathy, nonabsorbable disaccharide can be used until patients have loose stools 2-3 times a day.

Renal failure

- Reduced hepatic clearance of immune complex leads to trapping in kidneys (:.IgA nephropathy ± hepatic glomerulosclerosis).
- Renal dysfunction worsens the prognosis of patients with Liver cirrhosis
- Presently, the combined administration of noradrenaline and albumin has been suggested. (Recommendation: weak, 73% agreed, evidence level B)
- In appropriately selected patients, transjugular intrahepatic portosystemic shunts (TIPS) improves renal function, reduces ascites, and can be expected to improve prognosis.
- Liver transplantation (LT) improves the prognosis for liver and kidney syndrome.

Follow up

- Patient with liver cirrhosis needs regular follow up depending on stage and severity of disease (maximum interval of four months).
- Hepatocellular carcinoma surveillance is needed for every patient with liver cirrhosis.

Reference

1. *Aithal GP, et al. Gut 2020;0:1–21. doi:10.1136/gutjnl-2020-321790*
2. *Evidence-based clinical practice guidelines for Liver Cirrhosis 2022, J Gastroenterol (2021) 56:593–619 https://doi.org/10.1007/s00535-021-01788-x, J Gastroenterol (2021) 56:593–619*

Algorithm for management of cirrhosis



Source: J Gastroentero Hepatol 2009 Blackwell Publishing

**Large volume paracentesis, ** Transjugular intrahepatic porto systemic shunt*

CHOLELITHIASIS (GALL STONES)

- Gallstones are increasingly common. 9% of 60 years old have them and prevalence increase with age.

Risk factors

- Gender (F > M)
- Body weight-prevalence increase with weight; also associated with rapid decreased weight
- Affluency
- Pregnancy (and possibly HRT but not COC pill)
- Diet-vegetarian diet is protective
- Associated conditions like:
- Haemolysis
- DM
- Hypertriglyceridaemia
- Cirrhosis
- Crohn's disease
- Partial gastrectomy

Drugs which cause gallstones: Clofibrate (and other fibric acid derivatives); octreotide (somatostatin analogue).

Pathophysiology

- Gallstones are conveniently classified into cholesterol or pigment stones, although the majority are of mixed composition.
- Cholesterol stones are most common in developed countries, whereas pigment stones are more frequent in developing countries.

Presentation

- Gallstones are blamed for many digestive symptoms. They are probably innocent in most cases. 70% of stones in the gall bladder do not cause symptoms. Common presentations as follows:

Table 13.19 Presentation and management of gallstone disease

	Presentation	Management
Biliary colic	• Clear-cut attacks of severe upper abdominal pain which may radiate back/shoulder tip, lasting ≥:30min and causing restlessness ± jaundice ± nausea or vomiting • *Examination:* tenderness ± guarding in the right upper quadrant (increase on deep inspiration - Murphy's sign)	• Treat acute attacks with pethidine (50mg IM/po) or naproxen (500mg po) + prochlorperazine 12.5 mg IM or domperidone 10mg po/PR for nausea • Admit if: uncertain of diagnosis, inadequate social support, persistent symptoms despite analgesia, suspicion of complications, and/or concomitant • medical problems (e.g. dehydration, pregnant, DM, Addison's) • Investigate: for gallstones with abdominal USS to prove diagnosis when the episode has settled. • Differential diagnosis: any cause of acute abdomen • Treat gallstones to prevent recurrence

Acute cholecystitis/ cholangitis	• Pain and tenderness in the right upper quadrant/epigastrium ± vomiting • Examination: tenderness ± guarding in the right upper quadrant ± fever ± jaundice	• Treatment: broad-spectrum antibiotic (e.g. ciprofloxacin) and analgesia as for biliary colic • Admit if: generalized peritonism, diagnosis uncertain, very toxic, concomitant medical problems (e.g. dehydration, DM, Addison's, pregnancy), inadequate social support, or not responding to medication • Empyema occurs when the obstructed gall bladder fills with pus. Presents with persistent swinging fever and pain. Usually requires cholecystectomy ± surgical drainage • Investigate and follow up to prevent recurrence as for biliary colic
Pancreatitis	• Poorly localized, continuous, boring epigastric pain which increase over l hour, often worse lying down ± radiation to the back • (50%) Nausea ± vomiting	• Admit as an acute surgical emergency. Prior to transfer, give analgesia with pethidine.
Gallstone ileus	• Occurs usually after an attack of cholecystitis. • A stone perforates from the gall bladder into the duodenum and impacts in the terminal ileum causing bowel obstruction	• Admit as surgical emergency.
Chronic cholecystitis	• Vague intermittent abdominal discomfort, nausea, flatulence, and intolerance of fats	• Investigate for gallstones with abdominal USS to prove the diagnosis • Differential diagnosis: reflux, IBS, upper GI tumour, PU • Refer for treatment of gallstones
Jaundice	• Obstructive jaundice ± right upper quadrant pain	• Refer for same day or urgent specialist surgical assessment (depending on clinical state)

Ultrasound is the primary modality for diagnosing gallstones.

Complications

- Pancreatitis
- Bile duct stones
- Acute cholecystitis
- Gallbladder empyema, necrosis
- Gallbladder cancer
- Cholecystoenteric fistula

Management

- The management of gallstones depends on patient symptoms. Only 50% of patients with stones will develop symptoms. Asymptomatic patients should be educated on a low-fat diet, exercise, and weight loss.
- Advise the patient to stick to a low-fat diet
- The primary clinicians should educate the patient that weight loss and regular exercise also lead to a much-lowered risk of gallstones.
- Definitive treatment for symptomatic stones is cholecystectomy
- Refer for surgical review ± further evaluation (e.g. ERCP-endoscopic retrograde cholangiopancreatography)

- Gallstones can be removed by cholecystectomy (laparoscopic or open) or ERCP or may be dissolved with ursodeoxycholic acid (stones <5mm diameter---40% recur in <5years) or shattered with lithotripsy for non-calcified gallstones is another option.
- (1:3 develop biliary colic afterwards)
- Persistent digestive symptoms after surgery are common (50% after cholecystectomy) and difficult to treat.

References:

1. *Oxford Handbook of General Practice, 4th Edition*
2. *Davidson's Principles and Practice of Medicine, 22"dEdition 22nEdition*
3. *https://www.ncbi.nlm.nih.gov/books/NBK470440/*

PANCREATITIS

ACUTE PANCREATITIS

- Premature activation of pancreatic enzymes results in autodigestion and tissue damage. Most episodes are mild and self-limiting but 1:5 patients have a severe attack. Overall mortality is 5-10%. It may be recurrent.

Causes

- In 10% patients no cause is identified.
- Common causes (80%): gallstones, alcohol
- Rarer causes:
- Drugs (e.g. azathioprine)
- Trauma
- Pancreatic tumours
- Post-ERCP
- Viral infection (mumps, HIV, Coxsackie B)
- Mycoplasma infection
- Hypercalcaemia
- Hyperlipidaemia
- Pancreas divisum (normal variant in 7-8% of the white population)
- Familial pancreatitis
- Vasculitis
- Ischaemia or embolism
- Pregnancy
- End-stage renal failure

Presentation

- Poorly localized, continuous, boring epigastric pain which increase over 1 hr, often worse on lying down ± radiation to the back (50%)
- Nausea ± vomiting

Examination

- General: Tachycardia, fever, shock, jaundice
- Abdominal: Localized epigastric tenderness or generalized abdominal tenderness; abdominal distension ± decreased bowel sounds; evidence of retroperitoneal haemorrhage (periumbilical and flank bruising-rare)
- The diagnosis of AP is most often established by the presence of two of the three following criteria:
  (i) abdominal pain consistent with the disease
  (ii) serum amylase and/or lipase greater than three times the upper limit of normal, and/or
  (iii) characteristic findings from abdominal imaging.
- (Strong "We recommend", Moderate)
- Transabdominal ultrasound should be performed in all patients with acute pancreatitis.
- (Strong "We recommend", Low)
- In the absence of gallstones and/or history of significant history of alcohol use, a serum triglyceride should be obtained and considered the etiology if >1,000 mg/dl. (Conditional (weak) "We suggest", Moderate)

- In a patient older than 40 years, a pancreatic tumor should be considered as a possible cause of acute pancreatitis. (Conditional (weak) “We suggest”, Low)
- Endoscopic investigation in patients with acute idiopathic pancreatitis should be limited, as the risks and benefits of investigation in these patients are unclear. (Conditional (weak) “We suggest”, Low)

Management

- Admit as an acute surgical emergency. Prior to transfer, give analgesia with pethidine (morphine may induce spasm of the sphincter of Oddi).

Initial assessment and risk stratification

- Hemodynamic status should be assessed immediately upon presentation and resuscitative measures begun as needed. (Strong “We recommend”, Moderate)
- Risk assessment should be performed to stratify patients into higher- and lower-risk categories to assist triage, such as admission to an intensive care setting. (Conditional (weak) “We suggest”, Moderate)

Initial management

- Aggressive hydration, defined as 250-500 ml per hour of isotonic crystalloid solution should be provided to all patients, unless cardiovascular and/or renal comorbidities exist.
- Early aggressive intravenous hydration is most beneficial the first 12–24 h, and may have little benefit beyond. (Strong “We recommend”, Moderate)

The role of antibiotics in acute pancreatitis

- Antibiotics should be given for an extrapancreatic infection, such as cholangitis, catheter-acquired infections, bacteremia, urinary tract infections, pneumonia. (Strong “We recommend”, High)
- Routine use of prophylactic antibiotics in patients with severe acute pancreatitis is not recommended. (Strong “We recommend”, Moderate)

The role of surgery in acute pancreatitis

- In patients with mild AP, found to have gallstones in the gallbladder, a cholecystectomy should be performed before discharge to prevent a recurrence of AP. (Strong “We recommend”, Moderate)
- In a patient with necrotizing biliary AP, in order to prevent infection, cholecystectomy is to be deferred until active inflammation subsides and fluid collections resolve or stabilize. (Strong “We recommend”, Moderate)
- The presence of asymptomatic pseudocysts and pancreatic and/or extrapancreatic necrosis do not warrant intervention, regardless of size, location, and/or extension. (Strong “We recommend”, Moderate)

Complications

- Delayed complications may present in general practice- suspect if persistent pain or failure to regain weight or appetite.Complications include:
- Pancreatic necrosis
- Pseudocyst-localized collection of pancreatic secretions
- Fistula/abscess formation
- Bleeding or thrombosis

Prevention of further attacks

- Avoid factors that may have caused pancreatitis, e.g. alcohol, drugs
- Advise patients to follow a low-fat diet
- Treat reversible causes, e.g. hyperlipidaemia, gallstones

CHRONIC PANCREATITIS

- Chronic inflammation of the pancreas results in gradual destruction and fibrosis of the gland ± loss of pancreatic function causing malabsorption and DM.

Causes

- Alcohol is responsible for most cases.
- More rarely: familial; CF; haemochromatosis; pancreatic duct obstruction (gallstones/ pancreatic cancer); hyperparathyroidism.

Presentation

Constant or episodic epigastric pain, radiating to the back and relieved by sitting forwards

- Vomiting
- Weakness
- Jaundice
- Steatorrhoea
- Weight loss
- DM
- Chronic poor health
- Natural History and Clinical Symptoms of Chronic Pancreatitis (CP)
- Alcohol and smoking cessation are recommended for all patients with CP.
- Progression to CP can be predicted by the identification of disorders of underlying pancreatic inflammation, such as acute pancreatitis and recurrent acute pancreatitis.
- The risk for development of diabetes mellitus (DM) due to pancreatic enzyme failure is thought to be related to the duration of CP disease.
- Other risks for DM development include a high body mass index (BMI) and tobacco use.
- There is no evidence to support the routine screening of CP patients for malignancy.

Investigation

- Ultrasound +/- CT (pancreatic calcifications confirm the diagnosis)
- MRCP (magnetic resonance cholangio-pancreatography + ERCP(endoscopic retrograde cholangio-pancreatography) (risks acute attack),
- Abdominal XR: speckled calcification

Management

Refer to gastroenterologist Treatment:

- Diet Low-fat, high-protein,high-calorie diet with fat-soluble vitamin supplements.
- Pancreatic enzyme supplementation (e.g. Creon (pancrelipase) capsules pre-meals) may improve diarrhoea
- Alcohol abstinence
- Smoking cessation.
- Pain control: Provide analgesia-beware of opioid abuse.
- Diabetes management
- Surgery -Pancreatectomy or pancreatico-jejunostomy for pancreatic duct stricture,
- obstructive jaundice, unremitting pain, or weight loss.
- Management of Exocrine Pancreatic Insufficiency in Chronic Pancreatitis

- To improve associated nutritional complications, pancreatic enzyme replacement therapy (PERT) is recommended for individuals with CP and Exocrine Pancreatic Insufficiency.
- Periodic evaluation for malnutrition and related complications, such as osteoporosis and fat-soluble vitamin deficiency, is recommended

PANCREATIC INSUFFICIENCY

- Global decreased function of the pancreas.

Causes:

- Child- Cystic fibrosis
- Adult - Chronic pancreatitis, pancreatic tumour, pancreatectomy, total gastrectomy

Presentation

- Malabsorption (frequent loose, odorous stools ± abdominal pain), weight loss or failure to thrive,
- DM.

Management

- Take specialist advice.
- Treat the underlying cause.
- Treat associated DM.
- Supplement digestive enzymes

Reference

1. *Oxford handbook of General Practice, 4th Edition*
2. *https://www.guidelinecentral.com/summaries/american-college-of-gastroenterology-guideline-management-of-acute-pancreatitis/*
3. *Gardner, T. B., Adler, D. G., Forsmark, C. E., Sauer, B. G., Taylor, J. R., & Whitcomb, D. C. (2020). ACG Clinical Guideline: Chronic Pancreatitis. The American journal of gastroenterology, 115(3), 322–339.*

ROUTINE LIVER BIOCH EMICAL TESTS AND CLINICAL USEFULNESS

Biochemical tests can be used to detect acute and chronic diseases of the liver before development of symptoms.
Single laboratory test is generally not useful in evaluating the severity of acute or chronic liver diseases.
A combination of tests such as serum bilirubin, aminotransferases, alkaline phosphatase, albumin and prothrombin time is referred to "liver function tests" or a "liver panel." These tests can provide an initial characterization of the etiology and severity of liver disease.
Traditionally liver diseases have been characterized as primarily hepatocellular or cholestatic based on the predominance of elevated aminotransferases or alkaline phosphatase.

Routine liver function tests

1.SERUM BILIRUBIN
- Unconjugated (Indirect) bilirubin Conjugated (Direct) bilirubin

2.SERUM AMINOTRANSFERASES
- Aspartate aminotransferase (AST, SGOT [serum glutamic oxaloacetic transaminase]) Alanine aminotransferase (ALT, SGPT [serum glutamic pyruvic transaminase])

3.SERUM ALKALINE PHOSPHATASE
4.GAMMA GLUTAMYL TRANSFERASE (GGT)
5.SERUM PROTEINS
- Albumin
- Prothrombin time (PT)/ INR

Serum bilirubin

- With the van den Bergh method, the normal serum bilirubin concentration is usually
- <1mg/dL (18 mmol/L).
- As much as 30% or 0.3 mg/dL (5.1 mmol/L) of the total is direct bilirubin.
- Jaundice clinically apparent when serum bilirubin exceeds 3 mg/dL; often the first evidence of liver disease.

Causes of hyperbilirubinemia

a.Unconjugated (Isolated hyperbilirubinemia, nearly always <7 mg/dL)
Overproduction → hemolysis, ineffective erythropoiesis, resorption of hematoma
Defective uptake and storage of bilirubin → Gilbert's syndrome
b.Conjugated
Hereditary → Dubin-Johnson and Rotor's syndromes, bile transport protein defects
Cholestasis
Intrahepatic → cirrhosis, hepatitis,primary biliary cirrhosis, drug-induced
Extrahepatic → biliary obstruction: choledocholithiasis,stricture, neoplasm, biliary atresia, sclerosing cholangitis
Serum enzyme tests can be grouped into two categories:
enzymes whose elevation in serum reflects generalized damage to hepatocytes; and
enzymes whose elevation in serum primarily reflects cholestasis

Serum aminotransferases

- Aspartate aminotransferase (AST, SGOT [serum glutamic oxaloacetic transaminase])
- Found in liver as well as skeletal muscle, heart, kidney, brain, and pancreas
- Alanine aminotransferase (ALT, SGPT [serum glutamic pyruvic transaminase])
- Highest concentration in liver (more sensitive and specific than AST)
- These intracellular enzymes are the most useful marker of hepatic injury (inflammation or cell necrosis).
- Normal levels of ALT are up to 30 U/L in men and up to 19 U/L in women.
- Aminotransferase → mainly viral, alcoholic, autoimmune, or drug-induced hepatitis.
- In alcoholic hepatitis, the serum AST is usually no more than 2 - 10 times the upper limit of normal, and the ALT is normal or nearly normal with an AST:ALT >2.
- In nonalcoholic fatty liver disease, ALT is typically higher than AST until cirrhosis develops.
- Aminotransferase <500 U/L 7 in obstructive jaundice.

Causes of elevated serum aminotransferase levels

Mild elevation (<5 × normal) ALT predominant	**Marked elevation (>15× normal)**
Chronic viral hepatitis (B,C)	Acute viral hepatitis (A–E, herpes)
Acute viral hepatitis (A–E, Epstein-Barr virus, cytomegalovirus)	DILI
NAFLD(nonalcoholic fatty liver disease)	Ischemic hepatitis
Haemochromatosis	Autoimmune hepatitis
DILI (drug-induced liver injury)	Wilson disease
Autoimmune hepatitis	Acute bile duct obstruction
Alpha-1 antitrypsin deficiency	Acute Budd–Chiari syndrome
Wilson disease	Hepatic artery ligation
Celiac disease	

Serum alkaline phosphatase

- This test is sensitive for detection of biliary tract obstruction; may be intrahepatic or extrahepatic.

Isolated elevation of alkaline phosphatase

- This may indicate infiltrative liver disease: tumor, abscess, granulomas, or amyloidosis.
- High levels → biliary obstruction, sclerosing cholangitis, primary biliary cirrhosis, sepsis, acquired immunodeficiency syndrome, cholestatic drug reactions, and other causes of vanishing bile duct syndrome.
- Non-hepatic sources of alkaline phosphatase are bone, intestine, kidney, and placenta and also elevated in → Paget' s disease of the bone, osteoblastic bone metastases, small bowel obstruction, growing children and normal pregnancy.
- Hepatic origin of an elevated alkaline phosphatase level is suggested by simultaneous elevation of serum gamma glutamyl transferase (GGT).

Gamma glutamyl transferase (GGT)

- It is a very sensitive indicator of hepatobiliary disease but is not specific.
- Elevated levels → renal failure, myocardial infarction, pancreatic disease, diabetes mellitus, phenytoin or alcohol in the absence of other clinical evidence of liver disease.

- Many patients with isolated serum GGT elevation have no other evidence of liver disease; an extensive evaluation is usually not warranted. Patients should be retested after avoiding alcohol and other hepatotoxins for several weeks.

Serum proteins

- reflect the synthetic capability of the liver.

Albumin

- Normal in acute viral hepatitis, drug related hepatoxicity, and obstructive jaundice.
- Hypoalbuminemia (<3 g/dL) is common in chronic liver disease (an indicator of severity).
- It is not specific for liver disease and may also reflect glomerular or gastrointes- tinal losses.

Prothrombin time (PT)/International normalized ratio (INR)

- Prothrombin time is useful in assessing the severity and prognosis of acute liver disease.
- Deficiency of one or more of liver-produced coagulation factors results in a prolonged prothrombin time.
- Prolongation of the prothrombin time in cholestatic liver disease may result from vitamin K deficiency.
- The international normalized ratio (INR) is used to standardize prothrombin time determinations performed in different laboratories.

Distinguishing different types of jaundice

Types of jaundice	Pre-hepatic	Hepatic	Post-hepatic
Type of bilirubin elevated	Unconjugated bilirubin	Both conjugated & unconjugated bilirubin	Conjugated bilirubin
Serum bilirubin Van den Bergh test	Indirect positive	Biphasic	Direct positive
Urine Conjugated bilirubin	Absent	++	+++
Urobilinogen	+++	+ early, obst, -dee	Absent
Bile salt	Absent	+	++
Urine colour	Normal-Acholuric	Dark-Cho luric	Dark-Choluric
Stool colour	Dark brown colour	N/decreased	Clay coloured stools
AST & ALT	Normal	Very high	increased
ALP level	Normal	2-3 times increased	10-12 times increased

The followings are the common stepwise approach to the patients with abnormal LFT.

1. Approach to the patient with an elevated ALT



In young patients, check for Acute Hepatitis A (Anti HAV IgM).

Fig. Approach to patients with an elevated serum alanine aminotransferase (ALT) level. AAT, alpha- I antitrypsin; ANA, antinuclear antibodies; anti-HBc, antibody to hepatitis B core antigen; anti-HCV, antibody to hepatitis C virus; CT, computed tomography; HBsAg, hepatitis B surface antigen; IgG, immunoglobulin; SMA, smooth muscle antibodies; TIBC, total iron binding capacity; US, ultrasonography.

2. Approach to the patient with mild diffuse liver test abnormalities



Fig. Approach to a patient with mild diffuse liver biochemical test abnormalities. ANA, antinuclear antibodies; CT, computed tomography; LFT, liver function test; IgG, immunoglobulin; MRCP, magnetic resonance cholangiopancreatography; NAFLD, nonalcoholic fatty liver disease; SMA, smooth muscle antibodies; US, ultrasonography.

3. Approach to a patient with isolated serum alkaline phosphatase elevation



Fig. Approach to a patient with isolated serum alkaline phosphatase elevation. ACE, angiotensin- converting enzyme; AMA, antimitochondrial antibodies; ERCP, endoscopic retrograde cholangiopancreatography; MRCP, magnetic resonance cholangiopancreatography; MRI, magnetic resonance imaging; THC, transhepatic cholangiography; US, ultrasonography.

Reference

1. *Therapeutic Manual (Internal Medicine) 1st Edition 2016*

COLORECTAL CANCER (CRC) SCREENING:

Introduction and relevance to GP:

- Colorectal cancer is the third most common cancer and the second most common cause of cancer related death in US. Most CRC arise from preexisting adenomatous polyps. Adenomatous polyps occur in 30% of adults 50 years and older and the incidence increases with advancing age. The goal of CRC screening is to identify early cancers and adenomatous polyps by mass screening of all average -risk adults 50 years and older up to 75 years of age (USPSTF recommendation)
- CRC screening in overview and recommendations:
- AAFP: strongly recommends that adults 50 years and older be screened for CRC.
- CRC screening is cost-effective, regardless of the screening method, and it has been estimated that routine screening could save 18,800 lives per year.

Methods of screening:

1.Fecal occult blood test (FOBT)

- It should be performed using testing cards sent home with the patient. Office testing of stool samples obtained by DRE has not been shown to reduce mortality. Single FOBT performed by DRE will miss 95% of CRC and is not recommended for screening. Rather, patients should take home three cards with two testing windows on each card, and be instructed to use one card a day for three consecutive days. Rehydration of stool cards with water before development may improve sensitivity, but is also lead to increased false-positive results.
- A Cochrane systematic review showed a reduction in CRC mortality of 16% with FOBT.
- Fecal immunochemical testing is a newer way to detect occult blood in stool. Unlike FOBT, fecal immunochemical testing does not require dietary restriction before testing.
- A positive test should be followed up with a colonoscopy.

2.Flexible sigmoidoscopy

- Flexible sigmoidoscopy every five years is an accepted modality for CRC screening by most recommending organizations. USPSTF recommends combining sigmoidosopy every 5 years with high sensitivity FOBT every 3 years.

3.Colonoscopy

- Several organizations recommend colonoscopy every 10 years for CRC screening in average risk persons. Colonoscopy carries a greater risk of perforation and other serious complications than sigmoidoscopy.

4.Double-contrast barium enema

- This method is still used as a screening tool, particularly in the right side of the colon following an incomplete colonoscopy.

5.CT colonography

- Studies of this method have reported sensitivities 55-100% and specificities of 86-98% for detection of polyps larger than 10mm

6.Fecal DNA testing

- In a large prospective study, it was four times more sensitive than FOBT for detecting invasive cancer. Also, patients have been shown to prefer fecal DNA testing to FOBT and colonoscopy.

7.Pillcam colon

- It involves ingestion of a capsule that wirelessly acquires colonic images for later viewing. The sensitivity and specificity of Pillcam Colon was inferior to that of colonoscopy.

Primary and secondary prevention

- Following risk factors should be reduced for prevention of CRC.

Obesity

- A large cohort study showed that an association between increasing BMI and relative risk of CRC mortality.

Fat intake

- There is evidence that high fat intake increases the risk of developing adenomatous polyps.

Red meat

- There is conflicting evidence about red meat and CRC risk.

Fiber

- A systematic review failed to show any benefit of increased dietary fibre intake for reducing incidence or recurrence of adenomatous polyps.

Aspirin, NSAIDs, and COX21

- Although there is poor evidence of reducing CRC mortality, risk of GI bleeding and other harms outweighs the benefit. So the USPSTF recommends against using them for chemoprevention.

Calcium

- There was insufficient evidence to recommend the general use of calcium supplementation to prevent CRC.

Vitamin D

- Vitamin D alone or combined with Calcium may reduce the risk of CRC. However, little evidence to support Vitamin D as chemo prevention was seen in analysis of cohort and case-control studies.

HRT

- There is contradictory evidence regarding whether HRT reduces the risk of CRC.

Anti-oxidants

- There was no benefit of anti-oxidants in decreasing CRC. Vitamin E was found to increase of adenomatous polyps.

Statins

- A population-based case-control study found that CRC was less likely to occur in patients who took a statin for at least 5 years.

Key recommendation for practice (summary)		
Clinical recommendation	Evidence ratio!!	Comments
CRC screening		
1. All adults 50 yrs and older should be screened	A	Most CRCs arise from adenomatous polyps
2. Routine screening for CRC should continue until 75 yrs of age	A	The USPSTF recommends against continued routine screening in previous screened adults 75-85 yrs of age and against any screening in adults older than 85 yrs
3. Options for screening:		
a. Annual FOBT	A	Decreased mortality from CRC, but not all-cause mortality
b. 5 yrs flexible sigmoidoscopy (with or without FOBT)	A	Decreased mortality from CRC, effect on all-cause mortality unknown.
c. 10 yrly colonoscopy	B	Mortality benefit not proven. Greater single test-accuracy than FOBT or sigmoidoscopy, but higher risk of serious complucations.
Primary prevention of CRC		
1. Fibre supplementation should not be recommended to decrease the risk of CRC.	A	Not recommended for chemoprevention, no evidence of benefit.
2. Aspirin and NSAID should not be routinely used for chemoprevention of CRC.	A	Increased harms, such as GI bleeding and renal impairment, limit routine use.
3. Risks and benefits should be considered when recommending hormone therapy for women to decrease risk for CRC.	B	Good evidence of benefit to decrease the risk of colon cancer, inconsistent evidence of rectal cancer. Increased risk of more advanced colon cancers with oestrogen use; and associated with VTE and breast cancer.
4. Antioxidants should not be recommended to decrease the risk of CRC.	A	Not recommneded for chemoprevention; vitamin E associated with increased risk of adenomatous polyps.

CHAPTER (6) ENDOCRINE PROBLEMS

1. Diabetes Mellitus
2. Thyroid Disorders
    a. Hypothyroidism
    b. Hyperthyroidism (Thyrotoxicosis)
    c. Thyroid crisis (Thyroid storm)
    d. Thyroid Nodules
    e. Thyroid Carcinoma
3. Pituitary Disorders
    a. Pituitary Tumours
    b. Over secretion of pituitary disorder
    c. Disorder of posterior pituitary disorders
    d. Adrenal disorder
    e. Primary Hyperaldosteronism
    f. Phaeochromocytoma
4. Calcium Disorders

DIABETES MELLITUS

Classification of diabetes mellitus

The features most useful in discrimination of type 1 diabetes include younger age at diagnosis (<35 years) with lower BMI (<25 kg/m^2), unintentional weight loss, ketoacidosis, and glucose >360 mg/dL at presentation.

Type 1 diabetes	Type 2 diabetes	Specific types of diabetes due to other causes	Gestational diabetes mellitus
• Due to autoimmune β-cell destruction, usually leading to absolute insulin deficiency, including (LADA)	• non-autoimmune progressive loss of adequate β-cell insulin secretion frequently on the background of insulin resistance and • metabolic syndrome	• Monogenic diabetes syndromes (neonatal diabetes and MODY) • Diseases of the exocrine pancreas (cystic fibrosis and pancreatitis) • Drug- or chemical-induced diabetes (glucocorticoid use, in the treatment of HIV/AIDS, or after organ transplantation	• Diabetes diagnosed in the second or third trimester of pregnancy that was not clearly overt diabetes prior to gestation

LADA = latent autoimmune diabetes of adulthood, MODY = maturity-onset diabetes of the young

Criteria for screening for diabetes or prediabetes in asymptomatic adults

1. Adults with overweight or obesity (BMI ≥ 25 kg/m^2 or ≥ 23 kg/m^2 in Asian American individuals) who have one or more of the following risk factors: - First-degree relative with diabetes - High-risk race/ethnicity (e.g., African American, Latino, Native American, Asian American, Pacific Islander) - History of CVD - Hypertension (≥ 140/90 mmHg or on therapy for hypertension) - HDL cholesterol level <35 mg/dL (0.90 mmol/L) and/or a triglyceride level >250 mg/dL (2.82 mmol/L) - Individuals with polycystic ovary syndrome - Physical inactivity -Other clinical conditions associated with insulin resistance (e.g., severe obesity, acanthosis nigricans)
2. People with prediabetes should be tested yearly
3. People who were diagnosed with GDM should have lifelong testing at least every 3 years
4. For all other people, testing should begin at age 35 years.
5. People with HIV

Criteria for the diagnosis of diabetes and prediabetes

CRITERIA FOR THE DIAGNOSIS OF DIABETES
FPG ≥ 126 mg/dL (7.0 mmol/L). Fasting is defined as no caloric intake for at least 8 h.*
OR
2-h PG ≥ 200 mg/dL (11.1 mmol/L) during OGTT.

The test should be performed as described by WHO, using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water. *
OR
A1C ≥ 6.5% (48 mmol/mol). The test should be performed in a laboratory using a method that is NGSP certified and standardized to the DCCT assay. *
OR
In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose ≥ 200 mg/dL (11.1 mmol/L).
CRITERIA FOR THE DIAGNOSIS OF PREDIABETES
FPG 100 mg/dL (5.6 mmol/L) to 125 mg/dL (6.9 mmol/L) (IFG)
OR
2-h PG during 75-g OGTT 140 mg/dL (7.8 mmol/L) to 199 mg/dL (11.0 mmol/L) (IGT)
OR
A1C 5.7–6.4% (39–47 mmol/mol)

DCCT = Diabetes Control and Complications Trial; FPG = fasting plasma glucose; OGTT= oral glucose tolerance test; NGSP= National Glycohemoglobin Standardization Program; WHO = World Health Organization; 2-h PG = 2-h plasma glucose; IFG = impaired fasting glucose; IGT, impaired glucose tolerance. *In the absence of unequivocal hyperglycemia, diagnosis requires two abnormal test results from the same sample or in two separate test samples.



Diabetic Treatment Strategy in Family Medicine Clinic	
A	**A**ssess Glycaemic Status, Hb**A**1c
B	**B**MI **B**P (Hypertension)
C	**C**VD Risk Assessment, **C**holesterol
D	**D**etection of Comorbidity and Complications Working **D**iagnosis
E	**E**vidence-Based, Updated Management Patient **E**mpowerment

Comprehensive medical evaluation and assessment of comorbidities

	Initial visit	3-monthly OR Every follow-up visit	At annual visit
Physical examination			
Weight	✓	✓	✓
Waist circumference	✓	✓	✓
BMI	✓		✓
BP	✓	✓	✓
Eye			
Visual acuity	✓		✓
Fundoscopy/Fundus camera	✓	If indicated	✓
Feet			✓
Pulses/ABI	✓	If indicated	✓
Neuropathy	✓	If indicated	✓
Dental check-up	✓		✓
ECG	✓	If indicated	✓
Laboratory investigations			
HbA1C	✓	✓	✓
Lipid profile	✓	If indicated	✓
Creatinine, urea + eGFR	✓	✓	✓
Urine microscopy	✓	If indicated	✓
spot morning UACR	✓	If indicated	
LFT (AST, ALT)	✓	✓	✓

✓ = conduct test

GLYCEMIC TARGET

HbA1c	**<7%***
Pre-prandial Glucose	**80 - 130 mg/dl***
Post-prandial Glucose	**<180 mg/dl***

*More or less stringent individualized glycemic target should be based on duration of diabetes, age/life expectancy, comorbid conditions, known CVD or advanced microvascular complications, hypoglycemia unawareness, and individualized considerations.

PHARMACOLOGIC APPROACHES TO GLYCEMIC TREATMENT

1. *Glycemic management of out patients*

Lifestyle modification to all patients ††

↓

Glycemic management

HbA1c <8.5% OR FPG <150 mg/dl, RBS <250 mg/dl	**HbA1c 8.5 - 10.0% OR FPG 150 – 250 mg/dl, RBS 250 – 350 mg/dl**	**HbA1c >10.0% OR FPG >250 mg/dl, RBS >350 mg/dl**
Mono therapy	**Dual combination therapy**	**Triple combination therapy++ or Insulin if osmotic symptoms or weight loss present**
Follow-up with Blood Glucose level after 2-4 weeks. •Optimize dose of OAD/ addition of another OAD in subsequent 2-4 weeks. •HbA1c every 3-6 months.	Follow-up with Blood Glucose level after 2-4 weeks. •Optimize dose of OAD/ addition of another OAD in subsequent 2-4 weeks. •HbA1c every 3-6 months.	Follow-up with Blood Glucose level after 2-4 weeks, •Optimize dose of OAD/ addition of another OAD in subsequent 2-4 weeks. •HbA1c every 3-6 months.
If Blood Glucose level is satisfactory and/or HbA1c reach individualized target, continue therapy.*	If Blood Glucose level is satisfactory and/or HbA1c reach individualized target, continue therapy.*	If Blood Glucose level is satisfactory and/or HbA1c reach individualized target, continue therapy.*

†† 150 min or more of moderate- to vigorous-intensity aerobic activity per week, spread over at least 3 days/week, with no more than 2 consecutive days without activity

++Rescue Therapy: For symptomatic hyperglycemia, consider insulin or sulfonylurea and review when blood glucose has been achieved
**If Blood glucose level and HbA1c is discordant, look for the reasons of discordance or seek advice from Endocrinologists*

Use of glucose-lowering medications in the management of type 2 diabetes

LIFESTYLE MODIFICATION + METFORMIN
Unless intolerant or contraindicated/ ½ dose at DKD stage 3B, stop at DKD stage 4-5)

If HbA1c does not reach individualized target/Blood Glucose level is not satisfactory



**In terms of choosing between SGLT-2i or GLP1-RA, SGLT-2i should be prioritized according to Myanmar situation.*
**DKD Stage 1-3: eGFR >30 ml/min DKD Stage 4-5: eGFR <30 ml/min*
**Sulfonylurea and Repaglinide should not be used together because of similar site of action*

Oral Anti- diabetic drugs and injectable non-Insulin Agents

Drugs	Formulation	Minimum dose	Maximum dose
Biguanides			
Metformin SR	500/750/850/1000 mg	Initial dose: 500 mg OD	850 mg TDS 2000 mg OD
Metformin	500/850/1000 mg	Initial dose 500 mg OD	Usual: 850 BD/100 BD Exception: 1000 TDS
Sulphonylureas			
Gliclazide	80 mg	40 mg OD	160 mg BD
Gliclazide MR	60/30 mg	30 mg OD	120 mg OD
Glipizide	5 mg	2.5 mg OD	10 mg OD
Glimepiride	2/3 mg	1 mg OD	8 mg OD
Meglitinides			
Repaglinide	0.5/1/2 mg	0.5 mg with main meal	4 mg with main meals (not exceeding 16 mg daily)
Nateglinide	60/120 mg	60 mg with meals	180 mg with meals
α-glucosidase inhibitor			
Acarbose	50/100 mg	Initial dose 50 mg OD Usual dose: 50-100 mg take at 1st bite of main meals	100 mg TDS
Voglibose	0.2/0.3 mg	0.2 mg TDS (with meal)	0.3 mg TDS (with meals)
Thiazolidinedione			
Pioglitazone	15/30 mg	15 mg OD	45 mg OD
DPP4-inhibitors			
Sitagliptin	25/50/100 mg	25 mg OD	100 mg OD
Vildagliptin	50 mg	50 mg OD	50 mg OD
Teneligliptin	20/40 mg	20 mg OD	40 mg OD
Linagliptin	5 mg	5 mg OD	5 mg OD
SGLPT2-inhibitors			
Dapagliflozin	5/10 mg	5 mg OD	10 mg OD
Canagliflozin	100/300 mg	100 mg OD	300 mg OD
Empagliflozin	10/25 mg	10 mg OD	25 mg OD
GLP1-RA			
Liraglutide	6 mg/ml	0.6 mg OD	1.8 mg OD

Efficacy of Anti-diabetic Drugs

	MET	SU	GLN	AGI	TZD	DPP4-i	SGLT2-i	GLP1-RA	Insulin
HbA1c ↓%	1.0-1.5	0.4-1.6	1.0-1.2	0.5-0.8	0.5-1.4	0.5-0.8	0.2-0.8	0.5-1.4	>1.5
FPG vs. PPG	FPG	Both	PPG	PPG	FPG	Both	Both	Both	Both
Hypoglycemia	↔	↑↑	↑	↔	↔	↔	↔	↔	↑↑
Weight change	↓	↑↑	↑	↔	↑↑	↔	↓-↓↓	↓↓	↑↑
GI symptoms	↑↑	↔	↔	↑↑	↔	↑	↔	↑↑	↔
CHF	↔	↔	↔	↔	↑	↔	↓↓	↔	↔
CVD	↓	↔	↔	↔	↔	↔	↓↓	↓↓	↔
Bone loss	↔	↔	↔	↔	↑	↔	↔	↔	↔
DKD	Avoid*	Hypo	Hypo	↔	Fluid retent[n]	Dose adjust[m]	↓↓[a]	↓↑	

**Avoid if eGFR <30ml/min/1.73m²; ↑avoid if eGFR <15ml/min/1.73m²; a SGLT2-i can be used until dialysis is initiated and has proven reno-protection although glucose-lowering efficacy is reduced.*

Increased risk | *Mild-moderate risk* | *Neutral* | *Possible benefit* | *Beneficial*

Dosage of oral anti-diabetic drugs in Renal Failure

Generic Name	Usual dose*	Dose adjustment in renal failure			
		Mild (CKD 2) (GFR 60-89)	Moderate (CKD 3) (GFR 30-59)	Severe (CKD 4-5) (GFR <30)	
Biguanide					
Metformin	500-1000 mg BD	Continue	45-60: No dose adjustment	Avoid	
Metformin SR	500-100 mg BD 750 mg TDS 850 mg BD		<45: 50% dose reduction		
Sulphonylurea*					
Gliclazide	80 mg OD – 160 mg BD	No dose adjustment		Caution	
Gliclazide MR	30-120 mg OD	No dose adjustment		Caution	
Glimepiride	1-8 mg OD	Initiate with 1 mg OD		≥15: Caution	<15: Avoid
Glipizide	2.5 mg OD – 10 mg BD	No dose adjustment		Caution	
Meglitinides					
Repaglinide	0.5-4 mg TDS	No dose adjustment		Initiate at 0.5 mg with meals	
Nateglinide	60-120 mg TDS	No dose adjustment		Initiate at 60 mg with meals	
α-glucosidase inhibitor					
Acarbose	25-100 mg TDS			Avoid	
Voglibose	0.2-0.3 mg TDS	No dose adjustment			
Thiazolidinedione					
Pioglitazone	15-45 mg OD	No dose adjustment (caution with fluid retention risk)			
DPP4-inhibitors					
Sitagliptin	100 mg OD	No dose adjustment	≥50: No dose adjustment	25 mg OD	
			30-<50: 50 mg OD		
Vildagliptin	50 mg OD-BD	No dose adjustment	≥50: No dose adjustment		
			<50: 50 mg OD (limited data)		
Teneligliptin	20-40 mg OD	No dose adjustment			
Linagliptin	2.5-5 mg OD	No dose adjustment			
GLP1-RA					
Liraglutide	1.2 to 1.8 mg OD (Initial 0.6 mg OD x one week)	No dose adjustment	No dose adjustment	≥15: No dose adjustment	<15: Avoid
SGLPT2-inhibitors					
Dapagliflozin	5-10 mg OD	No dose adjustment	45-60: No dose adjustment	Avoid Exception: can give up to eGFR 25 in HF and CKD	
			<45: not recommended in DM		
Canagliflozin	100-300 mg OD	No dose adjustment	45-60: 100 mg OD	Avoid	
Empagliflozin	10-25 mg OD	No dose adjustment			

Dose should be adjusted based on frequent monitoring to balance goals of glycemic control with avoiding hypoglycaemia.

INSULIN THERAPY

Indications for Insulin therapy in T2DM

- Newly diagnosed patients (with severe osmotic symptoms) if
  - ✓ *RBS >300mg/dl or*
  - ✓ *FBS >250mg/dl or*
  - ✓ *HbA1c of ≥ 10%*
- Acute clinical conditions (e.g. AMI, Sepsis, Severe Pneumonia, Extensive Koch's Lung etc.)
- Pregnancy (pre-pregnant or GDM)
- Diabetes patients already on OAD therapy (Poor glycaemic control despite maximal tolerable dose of two or three OADs over three months, with HbA1c >7%)

↓

Start Basal Insulin
Starting dose: 10 units (0.2 units/kg/day)
Continue lifestyle management + other anti-diabetic agents

↓

Repeat HbA1c 3 monthly

Target HbA1c reached → Continue basal insulin, Repeat HbA1c

↓

Titration based insulin

If above HbA1c target

↓

Pre-mixed Insulin
TDD = 0.5 units/kg/day (or) unit per unit at the same total insulin dose
Premixed insulin before breakfast and dinner

Basal Bolus Insulin

Basal Insulin Therapy

BASAL INSULIN

Intermediate acting (Insulin N): NPH insulin (*Insulatard, Insunova N, Wolsulin N, Gensulin N*)

Long-acting Analogue (Insulin G): Insulin Glargine (*Glaritus, Insunova G, Lantus*)
Detemir (*Levemir*)

- *Basal insulin is best starting insulin choice.*
- *Intermediate and long-acting insulin are comparable in HbA1c lowering effect but less hypoglycaemia with long-acting analogue insulin.*
- *Start one of the intermediate-acting or long-acting insulins listed above at bedtime.*
- *When starting basal insulin: Continue OAD*
- *Note: if NPH causes nocturnal hypoglycaemia, consider switching NPH to long-acting insulin.*
- *Let the patient know that food intake is not recommended with basal insulin.*
- *Before up-titrating the dose, check the diet first and correct accordingly.*

↓

STARTING DOSE:
Start dose: 10 units (0.2 units/kg/day)

↓

TITRATE:

Adjust insulin doses after 3 consecutive FBS values obtained (every 3 – 7 days)

- <80 mg/dL (>1 value) → reduce dose by 2 units
- 80 – 130 mg/dL (all value) → maintain current dose
- >130 mg/dL (>1 value, no hypos) → increase by 2 units

Maximum dose for basal insulin = 0.5/kg/day. If needing more than that, change to other regimen.

↓

Assess adequacy of basal insulin dose

Consider clinical signals of overbasalization (e.g. Basal insulin >0.5 units/kg/day, elevated bedtime-morning and/or post-preprandial differential, hypoglycaemia (aware or unaware), high variability) and need for adjunctive therapies

↓

Once fasting glucose at goal, evaluate post-meal glucose pattern

PREMIXED INSULIN THERAPY

PREMIXED INSULIN

Conventional: Combination of short and intermediate acting (30% short + 70% NPH)
(*Mixtard 30, Insunova 30/70, Wolsulin 30/70, Gensulin M30*)

Analogue: Combination of rapid acting & protaminated analogue (*Novomix 30*),
Combination of Aspart 30% & Degludec 70% (*Ryzodeg*)

1. Premixed insulin is an option for patients who are unable to do multiple injections and who have fixed meal schedules.
2. Premixed insulin is more likely to cause hypoglycemia compared to basal and prandial insulins.
3. Start one of the mixed insulins listed above. Given twice daily, before breakfast and before dinner (or before other meals depending on the main meals, food intake and lifestyle). For analogue insulin, can increase to three times daily before each meal if not well controlled with twice daily regimen.
4. Analogue insulins should be just before meal. Conventional insulin needs to be taken 30 minutes before meals.
5. When starting pre-mixed insulin: Stop secretagogues. Continue metformin. Stop all other insulins.
6. Before up-titrating the dose, check the diet first and correct accordingly.

↓

STARTING DOSE:

Total Daily dose: 0.5 units/kg/day (or) unit per unit at the same total insulin dose

Conventional: Morning 2/3, Evening 1/3
Analogue: Morning 50%, Evening 50%

↓

TITRATE

Adjust insulin doses after 3 consecutive days blood glucose values obtained (every 3 – 7 days)

- <80 mg/dL (>1 value) → reduce dose by 2 units
- 80 – 130 mg/dL (all value) → maintain current dose
- >130 mg/dL (>1 value, no hypos) → increase by 2 units

- Pre-lunch and Pre-dinner blood glucose determines morning premixed dose adjustment.
- Bedtime and Pre-breakfast blood glucose determines evening premixed dose adjustment

Screening and management of complications

(A) Cardiovascular Disease and Risk Management

Atherosclerotic cardiovascular disease (ASCVD)—defined as coronary heart disease (CHD), cerebrovascular disease, or peripheral arterial disease presumed to be of atherosclerotic origin—is the leading cause of morbidity and mortality for individuals with diabetes.

Cardiovascular Disease Screening	
Consider investigations for coronary artery disease (eg ECG, CT coronary calcium score, pharmacologic stressed ECHO) in the presence of any of the following: 1. atypical cardiac symptoms (e.g., unexplained dyspnea, chest discomfort); 2. signs or symptoms of associated vascular disease including carotid bruits, transient ischemic attack, stroke, claudication, or peripheral arterial disease; 3. electrocardiogram abnormalities (e.g., Q waves).	
Treatment of Cardiovascular Disease	
Lifestyle	Intensive lifestyle intervention focusing on weight loss (Preferably >10%)
Glucose lowering therapies	• SGLT 2 inhibitor or GLP 1 receptor agonist with demonstrated CV disease benefit is recommended in people with T2DM who have established CV disease or established heart failure with either preserved or reduced ejection fraction or established CKD or multiple risk factors for ASCVD.
ACEI/ARB/ MRA	• For people with T2DM and CKD with albuminuria treated with maximum tolerated doses of ACEI or ARB, addition of MRA is recommended to improve CV outcomes and reduce the risk of CKD progression. • In people with known ASCVD, particularly coronary artery disease, ACE inhibitor or ARB therapy is recommended to reduce the risk of cardiovascular events
Beta blocker	• In prior myocardial infarction or heart failure with reduced EF (beta-blocker with proven CV outcomes benefit)

Hypertension/BP control

BP monitoring	At every routine clinical visit
How to diagnose?	Systolic blood pressure ≥ 130 mmHg or a diastolic blood pressure ≥ 80 mmHg based on an average of ≥ 2 measurements obtained on ≥ 2 occasions (1-2 week apart) Individuals with BP ≥ 180/110 mmHg and cardiovascular disease could be diagnosed with hypertension at a single visit.
Threshold for pharmacologic therapy	Confirmed office-based blood pressure ≥130/80 mmHg
Blood pressure target/goal	<130/80 mmHg. Multiple-drug therapy is generally required to achieve blood pressure targets in DM.

Recommendations for the Treatment of Hypertension in People with Diabetes



*An ACEi or ARB is suggested to treat hypertension for people with coronary artery disease (CAD) or urine albumin-to-creatinine ratio (ACR) 30–299 mg/g creatinine and strongly recommended for individuals with urine albumin-to-creatinine ratio ≥ 300 mg/g creatinine.

**Thiazide-like diuretic; long-acting agents shown to reduce cardiovascular events, such as chlorthalidone and indapamide, are preferred.

***Dihydropyridine calcium channel blocker (CCB)

For patients treated with an ACEi, ARB or diuretic, serum creatinine/estimated glomerular filtration rate and serum potassium levels should be monitored at least annually.

LIPID MANAGEMENT

When to Obtain a Lipid Profile (total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides)?	
1. at the time of diagnosis 2. at the initial medical evaluation, and at least every 5 years thereafter in patients <40 years of age	3. immediately before initiating statin therapy 4. 4–12 weeks after initiation of statin therapy, 5. after any change in dose of statin therapy

Primary Prevention	
For aged 40–75 years • **without ASCVD risk*** → moderate-intensity statin therapy in addition to lifestyle therapy • **with one or more ASCVD risks*** → use high intensity statin therapy with target LDL cholesterol goal of <70 mg/dL • with multiple ASCVD risks* and LDL cholesterol >70 mg/dL → may be reasonable to add ezetimibe to maximum tolerated statin therapy.	**For aged 20–39 years with** • additional ASCVD risks* → may be reasonable to initiate statin therapy in addition to lifestyle **For aged >75 years** • if already on statin therapy, it is reasonable to continue statin treatment • if not already on statin therapy, it is reasonable to initiate moderate-intensity statin therapy after discussion of potential benefits and risks
Secondary Prevention	
For people of all ages with diabetes and ASCVD, • **high intensity statin** therapy should be added to lifestyle therapy. • Target LDL cholesterol: reduction of >50% from baseline and goal of <55 mg/dL. • If lipid goal is not achieved on maximum tolerated statin therapy, add ezetimibe.	
Treatment of other Lipoprotein	
• For individuals with fasting TG levels ≥ 500 mg/dL, evaluate for secondary causes of hypertriglyceridemia and consider medical therapy (fibric acid derivatives and/or fish oil) and reduction in dietary fat to reduce the risk of acute pancreatitis. • In individuals with ASCVD or other CV risk factors on a statin with controlled LDL cholesterol but elevated TG (135–499 mg/dL), the addition of icosapent ethyl can be considered to reduce CV risk.	

High-Intensity Statin Therapy Lowers LDL by ≥50% from baseline	**Moderate-Intensity Statin Therapy** Lowers LDL by 30 - 49% from baseline
Atorvastatin 40-80 mg Rosuvastatin 20-40 mg	Atorvastatin 10-20 mg Rosuvastatin 5-10 mg Pitavastatin 2-4 mg

*ASCVD risk (family history of CVD, obesity, hypertension, smoking, dyslipidemia, or albuminuria)

ANTI-PLATELET THERAPY

Primary prevention
• May be consider in patient **aged ≥50 years** and at least one additional **major CV risk factor** (family history of premature ASCVD, hypertension, dyslipidemia, smoking, or CKD/albuminuria) who are not at increased risk of bleeding (e.g., older age, anemia, renal disease)

Secondary prevention	
1. Use **aspirin** therapy (75–162 mg/day) in all patients with ASCVD. In documented aspirin allergy, clopidogrel should be use. 2. **Dual antiplatelet therapy** (with low-dose aspirin and clopidogrel,) is reasonable for a year after ACS and may have benefits beyond this period. 3. Long-term treatment with dual antiplatelet therapy should be considered for individuals with prior coronary intervention, high ischemic risk, and low bleeding risk.	4. **Combination therapy with aspirin plus low-dose rivaroxaban** (2.5 mg twice daily) should be considered for individuals with stable coronary and/or peripheral artery disease and low bleeding risk to prevent major adverse limb and cardiovascular events

CHRONIC KIDNEY DISEASE AND RISK MANAGEMENT

Diagnosis of Diabetic Kidney Disease (DKD)

DKD is usually clinical diagnosis based on serum creatinine for eGFR ≤ 60 ml/min or 2 or 3 out of 3 UACR ≥ 2.0 mg/mmol at 3 months in the absence of signs or symptoms of other primary causes of kidney damage.

Screening

At least annually

→ urinary albumin (e.g., spot urinary albumin-to-creatinine Ratio-UACR)

→ estimated glomerular filtration rate(eGFR) should be assessed.

When to Screen

→ Type 1 diabetes with duration of >5 years

→ Type 2 diabetes regardless of treatment.

Treatment

Kidney-Heart Risk Factor Management



Management of Diabetic Kidney Disease



For people with non–dialysis dependent stage 3 or higher CKD, dietary protein intake should be aimed to a target level of 0.8 g/kg body weight per day.

For patients on dialysis, higher levels of dietary protein intake should be considered since protein energy wasting is a major problem in some individuals on dialysis.

Referral to Nephrologist

1. *Continuously increasing urinary albumin levels*
2. *Continuously decreasing eGFR and if the eGFR rate is <30 mL/min/1.73 m²*
3. *Uncertainty about the etiology of kidney disease*
4. *Difficult management issues*
5. *Rapidly progressing kidney disease.*
6. *Haematuria*
7. *Resistant hypertension (failure to achieve target BP despite 3 antihypertensive agents including a diuretic)*

RETINOPATHY, NEUROPATHY, AND FOOT CARE

Diabetic retinopathy

Definition
Diabetic retinopathy is clinically defined, diagnosed and treated based on the extent of retinal vascular disease detected by ophthalmoscopy
Screening
• Adults with **type 1** diabetes → within **5 years** after the onset of diabetes • Patients with **type 2** diabetes→ **at the time of the diabetes diagnosis** • If there is no evidence of retinopathy for one or more annual eye exams and glycemia is well controlled, then screening every 1–2 years may be considered. →If any level of diabetic retinopathy is present, subsequent dilated retinal examinations should be repeated at least annually by an ophthalmologist or optometrist. →If retinopathy is progressing or sight-threatening, then examinations will be required more frequently.
Treatment
- Optimize glycemic control to reduce the risk or slow the progression of diabetic retinopathy. - Optimize blood pressure and serum lipid control to reduce the risk or slow the progression of diabetic retinopathy. - The presence of retinopathy is **NOT a contraindication to aspirin** therapy for cardioprotection, as aspirin does not increase the risk of retinal hemorrhage

Urgency of referral	**Ocular features**
Emergency (same day referral)	Sudden severe visual loss Symptoms or sign of acute retinal detachment
Appointment within 1 week	Presence of retinal new vessels Retinal hemorrhage Viterous hemorrhage Rubeosis iridis
Appointment within 4 weeks	Unexplained drop in visual acuity Any form of maculopathy Severe NPDR Worsening retinopathy

NPDR = non proliferative diabetic retinopathy

Diabetic neuropathy and foot care

Screening of neuropathy

- ***Type 2 Diabetes patients at diagnosis***
- ***Type 1 Diabetes 5 year after diagnosis***
- ***And then Annually thereafter***

Neuropathic Pain

Positive Symptoms **(Due to excessive activities)**	
Symptoms	Definition
Spontaneous pain	Painful sensations felt with no evident stimulus
Allodynia	Pain due to a stimulus that does not normally provoke pain

	(eg, touching, movement, cold, heat)
Hyperalgesia	An increased response to a stimulus that is normally painful (eg, cold, heat, pinprick)
Dysesthesia	An unpleasant abnormal sensation, whether spontaneous or evoked (eg, shooting sensation)
Paresthesia	An abnormal sensation, whether spontaneous or evoked (eg, tingling, buzzing, vibrating sensations)

Negative Symptoms (Due to deficit of function)	
Symptoms	**Definition**
Hypoesthesia	Diminished sensitivity to stimulation
Anesthesia	A total loss of sensation (especially tactile sensitivity)
Hypoalgesia	Diminished pain in response to a normally painful stimulus
Analgesia	Absence of pain in response to stimulation that would normally be painful

Diagnosis of Diabetic Peripheral Neuropathy

1. History
2. Neurological Examination- Pinprick, Temperature, Vibration, 10 g monofilament test, Distal Reflexes
3. Rule out other causes – B12 deficiency, Hypothyroid, Uremic Syndrome, Peripheral Vascular Disease

Treatments

STEP – 1	**Initiate treatment with one or more first-line treatments** α2δ ligands (gabapentin, pregabalin) SNRIs (duloxetine, venlafaxine) TCAs* (nortriptyline, desipramine)
↓	
STEP – 2	If there is partial pain relief, add another first-line medication If there is no or inadequate pain relief, switch to another first-line medication
↓	
STEP – 3	If first-line medications alone and in combination fail, consider second-line medications (opioids, tramadol) or third-line medications (bupropion, citalopram, paroxetine, carbamazepine, lamotrigine, oxcarbazepine, topiramate, valproic acid, topical capsaicin, dextromethorphan, memantine, mexiletine) or referral to pain specialist.

FOOT CARE

Perform a comprehensive foot evaluation at least annually to identify risk factors for ulcers and amputations.

History Taking	**Examination**
Prior history of ulceration, amputation, Charcot foot, angioplasty or vascular surgery - cigarette smoking - retinopathy - renal disease	1. *look skin, foot deformities* 2. *Neurological assessment (10-g monofilament testing with at least one other assessment: pinprick, temperature, vibration),* 3. *Vascular assessment- pulses in the legs and feet. capillary refill time, rubor on*

- assess current symptoms of neuropathy (pain, burning, numbness) - vascular disease (leg fatigue, claudication).	*dependency, pallor on elevation, and venous filling time.* 4. *Multidisciplinary approach - for individuals with foot ulcers and high-risk feet* 5. *Provide general preventive foot self-care education to all people with diabetes*
Referral Criteria to do ankle–brachial index and for further vascular assessment	**Refer to Foot care Specialist.**
1. *history of leg fatigue, claudication, and rest pain relieved with dependency* 2. *decreased or absent pedal pulses*	1. *Smoker* 2. *history of prior lower-extremity complications,* 3. *loss of protective sensation,* 4. *structural abnormalities, or peripheral arterial disease*

International working group on the Diabetic Foot risk stratification system and corresponding foot screening frequency

Category	Ulcer risk	Characteristic	Examination frequency
0	Very low	No LOPS & No PAD	Annually
1	Low	LOPS or PAD	Every 6-12 month
2	Moderate	LOPS + PAD or LOPS + Foot deformity, or PAD + Foot deformity	Every 3-6 month
3	High	LOPS or PAD and one or more of the following - H/O foot ulcer - Amputation - ESRD	Every 1-3 month

LOPS = loss of position sensation, PAD = Peripheral artery disease

References

1. *American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2021. Diabetes care. 2021 Jan 1;44(Supplement_1): S111-24.*
2. *Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA1c: analysis of glucose profiles and HbA1c in the Diabetes Control and Complications Trial. Diabetes care. 2002 Feb 1;25(2):275-8.*
3. *The National Institute for Health and Care Excellence. Type 2 Diabetes in adults: Management; [updated 2020]. Available from: https://www.nice.org.uk/guidance/ ng28/chapter/ Recommendations #blood-glucose-management*
4. *Joint Formulary Committee. British National Formulary. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; [updated 2022 Mar].*
5. *Ministry of Health Malaysia and Malaysia Endocrine and Metabolic Society. Management of Type 2 Diabetes Mellitus (6th edition): Quick Reference Guide for Healthcare Professionals; [updated 2020]. Available from: https://www.moh.gov.my/moh/resources/ Penerbitan/CPG/Endocrine/ CPG_T2DM_6th_Edition_2020_13042021.pdf*
6. *American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2023. Diabetes care. 2023 Jan 1;46(Supplement_1):S140-57.*
7. *KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease – 2022 Nov. 102 (Suppl 5S), S1–S127.*

THYROID PROBLEMS

HYPOTHYROIDISM

Hypothyroidism is the syndrome caused by thyroid hormone deficiency

Common, in women, with a prevalence of about 2% (compared with 0.1% for men).
The prevalence of subclinical hypothyroidism is about 7.5% in women and 3% in men, and increases with age.
Congenital hypothyroidism is one of the most common congenital defects (about 1 in 5000 births).

Causes of hypothyroidism

Primary Hypothyroidism (>95% of cases)

- ***Chronic lymphocytic (Hashimoto's) thyroiditis***
- ***Radioactive iodine treatment or external neck radiation***
- ***Thyroidectomy***
- ***Transient (during recovery from painless thyroiditis or subacute thyroiditis***
- **Drugs (amiodarone, lithium, interferon-α and interferon-β, interleukin-2, thalidomide, bexarotene, and sunitinib, thionamide drugs etc;)**
- ***Severe iodine deficiency***
- ***Congenital hypothyroidism***

Secondary (Central) Hypothyroidism

- ***Any Pituitary or Hypothalamic causes***

Others

- ***Consumptive hypothyroidism due to vascular tumours expressing deiodinase***

Diagnosis

Clinical features

Symptoms	Signs
Cold intolerance	Delayed tendon reflex relaxation
Lethargy, fatigue	Facial and periorbital puffiness
Weight gain (modest)	Bradycardia
Dry skin, hair loss	Poor memory, dementia
Constipation	Non pitting oedema (Myxedema)
Myalgia, arthralgia	Pleural and pericardial effusion
Menorrhagia	Carpel tunnel syndrome
Hoarseness of voice	Deafness
	Hypoventilation, Hypothermia

- The most specific findings are cold intolerance (feeling cold when others are comfortable) and delayed relaxation of tendon reflexes.
- Hypothyroidism does not cause marked obesity.
- Laboratory findings may include hyponatremia and elevated plasma levels of cholesterol, triglycerides, and creatine kinase.
- Primary hypothyroidism may cause hyperprolactinemia.
- The electrocardiogram (ECG) may show low voltage and T- wave abnormalities

Clinical scoring systems should not be used to diagnose hypothyroidism

Investigations (Thyroid function test)	
Free T4 & TSH	
Primary hypothyroidism (T4 ↓, TSH ↑)	
Plasma TSH is the best initial diagnostic test. A normal value excludes primary hypothyroidism, and a markedly elevated value (>20 µU/mL) confirms the diagnosis	
Secondary hypothyroidism (T4 ↓ TSH → ↑) Procced MRI-brain	
Plasma TSH levels are usually within the reference range in secondary hypothyroidism and cannot be used alone to make this diagnosis. Plasma free T_4should be measured.	
Subclinical hypothyroidism (T4 →, TSH ↑)	
Anti-thyroid peroxi- dase antibody (TPOAb) measurements should be considered	
Hypothyroid in pregnancy	
Total or free T4, TSH (Trimester specific value of TSH)	
Nonthyroidal illness	
Mild elevation of plasma TSH (<20 µU/mL) may be caused by nonthyroidal illness.The test should be repeated with measurement of plasma free T_4 to confirm the diagnosis.	
Anti TPO measurement	
Primary hypothyroid (To confirm Dx- Hashimoto) Subclinical hypothyroidism To identify autoimmune thyroiditis	
Treatment	
Levothyroxine	
1.6 mcg/kg orally daily, and most patients require doses between 75 and 150 mcg daily	
How to take	
Levothyroxine should be taken 60 minutes before a meal, since dietary fiber and soy products interfere with its absorption. It should not be taken together with medications that inhibit its absorption including calcium or iron supplements, cholestyramine, sucralfate, and aluminum hydroxide.	
Initiation of therapy	
Young healthy adult	1.6 mcg/kg daily.
Elderly	50 ug/day
Cardiac disease	25-50 ug/day
Monitoring	
Primary Hypothyroid	
Plasma TSH after 6-8 weeks	Dose adjustment 12-25 ug at 6-8 weeks until TSH normal
After TSH normal	Annual TSH measurement
Secondary hypothyroidism	
plasma TSH cannot be used to adjust therapy	to maintain the plasma free T_4 near the middle of the reference range
Side effects	
Iatrogenic hyperthyroidism, Atrial fibrillation, osteoporosis	
Problems with treatment – Difficult to achieve a dose to normalize TSH	
Poor or erratic medication compliance Drugs interaction Pregnancy	

Gradual failure of endogenous thyroid function (Eg. After RAI treatment of hyperthyroid)

Special situations

Subclinical hypothyroidism



Hypothyroid in pregnancy

In pregnancy, the upper limit of the normal range should be based on trimester-specific ranges for that laboratory.
If trimester-specific reference ranges for TSH are not available in the laboratory, the following upper normal reference ranges are recommended:

1st trimester- 2.5 mIU/L
second trimester- 3.0 mIU/L
third trimester- 3.5 mIU/L

LT4 therapy is recommended for

- TPOAb-positive women with a TSH greater than the pregnancy-specific reference range
- TPOAb-negative women with a TSH greater than 10.0 mU/L

Hypothyroid in severely ill patient

In severe nonthyroidal illness, the diagnosis of hypothyroidism may be difficult
Plasma TSH is the best initial diagnostic test. A normal TSH value is strong evidence that the patient is euthyroid
Marked elevation of plasma TSH (>20 μ U/mL) establishes the diagnosis of primary hypothyroidism.
Moderate elevations of plasma TSH (<20 μ U/mL) may occur in euthyroid patients with nonthyroidal illness and are not specific for hypothyroidism

When to refer

A nodular thyroid, suspicious thyroid nodules, or compressive symptoms
Pregnancy
Underlying cardiac disorders
Age younger than 18 years
Secondary or tertiary hypothyroidism
Unusual constellation of thyroid function test
Inability to maintain TSH in the target range
Unresponsiveness to treatment

Myxoedema coma

Myxedema coma is a severe and life-threatening form of de-compensated hypothyroidism with an underlying precipitating factor.
The mortality rates may be as high as 25–60% even with best possible treatment.
It is a medical emergency and requires immediate specialist input.
Definition: Severe Hypothyroidism with

- Altered mental state
- Hypothermia
- Other organ failure
- Typically triggered by underlying illness or event

Clinical features: Usual symptoms & signs of hypothyroidism, Plus:

- Hypothermia (80 % of cases)
  - If temp: is normal, consider infection present
- Hypotension / bradycardia
- Hypoventilation / respiratory failure
- Ileus
- Depressed mental status

Laboratory Abnormalities
Hyponatraemia
Hypoglycaemia
Anaemia
Elevated creatinine
Elevated creatinine kinase
Elevated transaminases
Hypercapnoea
Hypoventilation
Hyperlipidaemia
Leucopenia
Respiratory acidosis
Elevated aPTT

Treatment of myxedema crisis should be prompt and multi-dimensional with attention to the following principles:
(a) intensive care treatment with ventilator support, central venous pressure monitoring, and pulmonary capillary wedge pressure if feasible in patients with cardiac disease,
(b) appropriate fluid management and correction of hypotension and dyselectrolytemia,
(c) aggressive management of precipitating factors and steroid supplementation if required,
(d) thyroid hormone replacement.

- Initial thyroid hormone replacement for myxedema coma should be levothyroxine given intravenously.
- A loading dose of 200–400 lg of levothyroxine may be given, with lower doses given for smaller or older patients and those with a history of coronary disease or arrhythmia.

Prolong bleeding time	• A daily replacement dose of 1.6lg/kg body weight, reduced to 75% as long as it is being intravenously administered, can be given thereafter.

THYROTOXICOSIS

Hyperthyroidism	Thyrotoxicosis
Due to an inappropriately high synthesis and secretion of thyroid hormone (TH) by the thyroid	A clinical state that results from inappropriately high thyroid hormone action in tissues generally due to inappropriately high tissue thyroid hormone levels

Causes of thyrotoxicosis

Thyrotoxicosis assicated with a normal or elevated radioactive iodine (RAI) uptake over the neck[a]

- *GD*
- *TA or TMNG*
- *Trophoblastic disease*
- *Thyroid-stimulating hormone (TSH)-producing pituitary adenomas*
- *Resistance to thyroid hormone (T_3 receptor β mutation [THRB])[b]*

Thyrotoxicosis associated with a near-absent RAI uptake over the neck

- *Painless (silent) thyroiditis*
- *Amiodarone-induced thyroiditis*
- *Subacute (granulomatous, deQuervain's) thyroiditis*
- *Palpation thyroiditis*
- *Iatrogenic thyrotoxicosis*
- *Factitious ingestion of thyroid hormone*
- *Struma ovarii*
- *Acute thyroiditis*
- *Extensive metastaese from follicular thyroid cancer*

[a] In iodine-induced or iodine-exposed hyperthyroidism (including amiodarone type 1), the uptake may be low.
[b] Patients are not uniformly clinically hyperthyroid.

Common symptoms

- Nervousness
- Anxiety
- Increased perspiration
- Heat intolerance
- Hyperactivity
- Palpitations

Common signs

- Tachycardia or atrial arrhythmia
- Systolic hypertension
- wide pulse pressure
- Warm, moist, smooth skin
- Lid lag
- Stare
- Hand tremor
- Muscle weakness
- Weight loss despite increased appetite
- oligomenorrhea

Presentations of thyrotoxicosis

Younger patients tend to exhibit symptoms of sympathetic activation (e.g., anxiety, hyperactivity, tremor)
Older patients have more cardiovascular symptoms (e.g., dyspnoea, atrial fibrillation) and unexplained weight loss
Patients with Grave's disease often have more marked symptoms than patients with thyrotoxicosis from other causes
Ophthalmopathy (e.g., periorbital oedema, diplopia, or proptosis) and pretibial myxoedema dermopathy specifically occur with Grave's disease
Elevated thyroid hormone levels associated with subacute thyroiditis may occur as part of a post-viral syndrome (subacute granulomatous thyroiditis) or within a year of the end of a pregnancy (postpartum subacute thyroiditis)

Investigations and Diagnosis

Thyroid function test	**To find out the aetiology of thyrotoxicosis**
The most reliable screening measure of thyroid function is the thyroid-stimulating hormone (TSH) level. ***Hyperthyroidism and thyrotoxicosis*** - suppressed TSH & elevated T3 and FT4 ***Milder hyperthyroidism*** - elevation of T3 only with a suppressed TSH ***Subclinical hyperthyroidism*** - decreased TSH and normal T3 and FT4	• ***TSH-receptor antibody (TRAb)***: 63-81% of Grave's disease; diagnostic & specific for GD • ***^{123}I or ^{99m}Tc pertechnetate uptake scan*** (when clinically suggests TA or TMNG or Subacute thyroiditis) • ***Thyroidal blood flow on USG***



Fig. 1. Algorithm for investigating a patient with suspected Graves' hyperthyroidism.

Treatment

Symptomatic management (Beta-adrenergic blockade)	Propranolol (20–40 mg 6 h) or longer acting (i.e., atenolol/bisoprolol) recommended in all with symptomatic thyrotoxicosis, especially • Elderly • Resting HR >90/minute or • Coexistent cardiovascular disease If not tolerate or severe asthma, CCB (verapamil or diltiazem) can be used.
Grave's disease	▪ *Patients with newly diagnosed Graves' hyperthyroidism should be treated with ATD. RAI therapy or thyroidectomy may be considered in patients who prefer this approach.* ▪ *Methimazole (MMI) or Carbimazole (CBZ) should be used in every non-pregnant patient.* ▪ *The initial dose of MMI: 10–30 mg once daily depending on severity of hyperthyroidism (CBZ 15–40 mg/day).* ▪ *Propylthiouracil (PTU): 100 mg TID, divided doses throughout the course.* ▪ *Gradually reduced (titration regimen) as thyrotoxicosis improves.* ▪ *Patients should be informed of potential side effects of ATD and the necessity of informing the physician promptly if they should develop jaundice, light-colored stools, dark urine, fever, pharyngitis, or cystitis.* ▪ *In patients taking ATD, a differential white blood cell count should be obtained during febrile illness and/or pharyngitis, and liver function should be assessed in those who experience jaundice, light-colored stools, or dark urine.*
	Table: Advert effects if anti-thyroid drugs
	Common (1.0-5.0%) - *Skin rash* - *Urticaria* - *Arthralgia, Polyarthritis* - *Fever,* - *Mild Leukopenia* **Rare (0.2-1.0%)** - *Gastrointestinal* - *Abnormalities of taste and smell* - *Agranulocytosis* **Very rare (<0.1%)** - *Aplastic anaemia (PTU, CBZ)* - *Thrombocytopenia (PTU, CBZ)* - *Vasculitis, lupus-like, ANCA + (PTU)* - *Hepatitis (PTU)* - *Hypoglycaemia (Anti-insulin Abs, PTU)* - *Cholestatic Jaundice (CBZ, MMI)*
	PTU= propylthiouracil, MMI = methimazole, CBZ = carbimazole, ANCA = anti-neutrophil cytoplasmic antibody
	▪ *MMI is administered for 12–18 months then discontinued if the TSH and TRAb are normal.* ▪ *Measurement of TRAb levels prior to stopping ATD therapy is recommended, as it aids in predicting which patients can be weaned from the medication, with normal levels indicating a greater chance of remission.* ▪ *Patients with persistently high TRAb at 12–18 months can continue MMI therapy, repeating the TRAb measurement after an additional 12 months, or opt for RAI or thyroidectomy.*



Fig. 2. Algorithm for the management of a patient with Graves' hyperthyroidism. GD, Graves' disease; MMI, methimazole; CBZ, carbimazole; GO, Graves' orbitopathy; RAI, radioactive iodine; Tx, total thyroidectomy.

Toxic nodular goitre	Control hyperthyroidism with antithyroid drugs, then surgery or RAI. Long term remissions on antithyroid drugs in a toxic nodular goitre are rare.
Subacute thyroiditis (SAT)	▪ Thyrotoxicosis temporary following surge of thyroxine after viral-type illness ▪ Self-resolving, and the treatment is also symptom relief. ▪ Pain &/or tenderness over the goitre (esp. on swallowing) & fever. ▪ Rest, analgesics (aspirin 600mg (po) 4-6 hourly) and soft foods. ▪ beta-blockers can be used to control symptoms ▪ Rarely, when pain is severe, corticosteroids may be used. ▪ Antithyroid drugs not indicated.



When to refer

- Doubt about the diagnosis
- Severe hyperthyroidism, especially if there is coexisting thyrocardiac disease
- Pregnant patients with hyperthyroidism
- Progression of exophthalmos
- Ideally all cases

THYROID CRISIS (THYROID STORM)

- *Rare disorder characterized by multisystem involvement*
- *Mortality rates in the range of 8%–25% in modern series*
- *Clinical features are marked anxiety, weight loss, weakness, proximal muscle weakness, hyperpyrexia, tachycardia (>150/ minute), heart failure and arrhythmias.*
- *It is usually precipitated by surgery or an infection in an undiagnosed patient.*
- *Dx made clinically in severely thyrotoxic patient + systemic decompensation.*
- *Referral is required for urgent intensive hospital management.*

2.

THYROID NODULES AND THYROID CARCINOMAS

Prevalence of palpable thyroid nodules are 5% in women and 1 % in men in iodine sufficient part of the world (ATA 2015)
Thyroid cancers are found in 7 -15 % of cases depending on age, sex, radiation exposure history, family history and other factors
Differentiated thyroid cancer (DTC), which includes papillary and follicular cancer, comprises the vast majority (>90%) of all thyroid cancers and <3 % are poorly differentiated tumors

Risk factors for Malignancy

1. Prior irradiation
2. Family history
3. Male sex
4. Nodules in individuals age less than 15 year and above 45 year
5. Symptoms of invasiveness: development of hoarseness, progressive dysphagia or dyspnea

Investigations of Thyroid nodules

1. Ultrasound imaging by TIRADS
2. Thyroid function tests (TSH)



Thyroid USG (TIRADS)

Diagram



Source: ACR White Paper 2017

Diagram



Source: ACR White Paper 2017

From findings on USG or USG guided FNA

- **Follicular neoplasm- 80% of these nodules-benign & 20 %- thyroid carcinoma**
- **Papillary carcinoma- accuracy of FNA approaches 100 %**

General features of thyroid cancers derived from follicular and para-follicular cells

Type	Prevalence	Age (years)	Distant Metastasis	5 years survival rate
Papillary	85-90%	20-50	5-7%	>90%
Follicular	<10%	40-60	20%	>90%
Poorly differentiated	<5%	50-60	20-80%	>50%
Anaplastic	1-2%	60-80	20-50%	1-17%
Medullary thyroid carcinoma	1-2%	40-50	10-15%	65-89%

Preoperative staging with diagnostic imaging and laboratory tests

- USG (Neck)
- CT/ MRI/ PET
- serum Tg or anti-Tg

Treatment of Thyroid carcinoma (DTC)

- Surgery
  - For cytology "diagnostic of" or "suspicious for" papillary thyroid cancer, surgery is recommended.
  - If FNAB cytology is indeterminate, use of molecular markers such as BRAF, RAS, RET/PTC, Pax8-PPARɣ, or galectin-3 may be considered to guide management
  - Iodine-123 (^{123}I) thyroid scan - considered if the cytology report documents a follicular neoplasm, especially TSH -in the low-normal range
- Tumor >1 cm and <4 cm, no extrathyroidal extension-Total Thyroidectomy
- Tumor >4 cm, or with gross extrathyroidal extension _ Near total _Total Thyroidectomy

An alternative active surveillance management approach can be considered in:

A) patients with very low risk tumors
B) patients at high surgical risk because of co-morbid conditions,
C) patients expected to have a relatively short remaining life span

Follow p after Surgery after FNA

DTC (PTC, FTC)
↓
TSH, Tg, USG
↓
RAI Therapy
Life-long T4 with Risk Assessment

MTC
↓
Assessment of associated MEN's $
↓
Follow up
Calcitonin, CEA

Long term management

1. Repeat RAI scan 6-12 months after ablation & every 2 years thereafter
2. Tg- every 6-12 months for at least 5 years

3. Annual measurement of unstimulated Tg and periodic neck USG
4. A patient who has had a thyroidectomy without parathyroid preservation requires vitamin D and calcium supplementation for life.
5. Patients require lifelong thyroid hormone replacement therapy, especially after total thyroidectomy (levothyroxine in a dosage of 2.5-3.5 mcg/kg/d)

Standard Treatment of Thyroid Cancer

Thyroid Nodules – Physical Examinations and USG (TIRADS) / and FNAC

↓

FNAC finding - Thyroid Ca

↓

Total Thyroidectomy

↓

RAI Ablation - detect and destroy any metastasis and residual tissue in the thyroid.

↓

Suppression Therapy -Minimum T4 to suppress TSH without thyrotoxicosis

- *TSH target - <0.1 mU/L in High-risk TC*
- *TSH -0.1-0.5 in intermediate risk TC*
- *TSH -0.5- 2 mU/L in Low-risk TC*

↓

Whole body Scan, USG, Tg assay -to detect any metastasis and residual tissue in the thyroid.

References

3. *American Thyroid Association (ATA) (2015)*
4. *National Comprehensive Cancer Network (NCCN) (2014)*
5. *European Society for Medical Oncology (ESMO)*
6. *American Association of Clinical Endocrinologists/Association of Medicine Endocrinologist /European Thyroid Association (AACE/AME/ETA)*

PITUITARY DISORDERS

Pituitary Tumours

Types of Pituitary tumours	Symptoms	Investigation	Treatment
- Prolactinomas (49%) - Acromegaly (12%) - Cushing's $ (7%) - TSHomas (<1%) - Non-functioning adenoma (28%) - Incidental tumours (~10%) - Pituitary carcinoma very rare (<0.1%)	*Mass effects* - Headache, nausea and vomiting - Visual field defects (uni- or bitemporal quadrantanopia or hemianopia) - Ophthalmoplegia - Apoplexy (rarely) - May also manifest symptoms of pituitary hormone deficiencies or overproduction, depending on the size and type of tumour	Refer to endocrinologists/ physicians to proceed - Pituitary imaging: MRI/CT - Visual assessment - Pituitary function assessment	Refer to neurosurgeons for Transphenoidal surgery Based on the type and size of the tumour, - observation - medical therapy, or - radiation therapy may be possible treatment options

PITUITARY HORMONE DEFICIENCIES (HYPOPITUITARISM)

- Hypopituitarism refers to either partial or complete deficiency of anterior and/or posterior pituitary hormones.

Common Causes

- *Sellar and parasellar tumours (e.g. pituitary adenomas, craniopharyngiomas, meningiomas, 2° deposits (e.g. breast, lung))*
- *Surgery to remove a pituitary tumour*
- *Radiotherapy for pituitary, cranial, nasopharyngeal tumours*
- *Vascular: Pituitary infarction (apoplexy), Subarachnoid haemorrhage (SAH), or severe blood loss during childbirth (Sheehan's Syndrome)*
- *Infection (e.g. tuberculosis (TB))*
- *Traumatic brain injury (TBI)*

Signs and symptoms of hypopituitarism

- The signs and symptoms vary from person to person, depending on which pituitary hormones are affected and to what degree. They usually develop gradually and can get worse over time but develop suddenly for others. These are listed in the Fact Sheet.

FACT SHEET – HYPOPITUITARISM

Deficient Hormone	Symptoms	Investigation	Hormone Replacement Therapy
Adreno cortico-trophic hormone (ACTH)	Pale, ↓BP, dizziness, tiredness, weight loss, stomach pain, depression, low tolerance to stresses, reduced QOL	- 8–9 AM cortisol levels (perform at least 18–24 hours after the last hydrocortisone (HC) dose) -a corticotropin stimulation test	- HC, usually 15–20 mg total daily dose/ Prednisolone (3.75-10 mg) in single or divided doses to be taken the highest dose in the morning at awakening - treat patients with suspected adrenal crisis due to secondary AI with an immediate parenteral injection of 50–100 mg HC
Thyroid Stimulating Hormone (TSH)	Weight gain, lethargy, cold intolerance, constipation, dry skin	- fT4 level↓ with ↓or ↔ TSH usually	- L-T4 in doses (~1.6 µg/kg/d) sufficient to achieve serum fT4 levels in the mid to upper half of the reference range - dose adjustments based on clinical context, age, and fT4 levels
Follicle Stimulating Hormone (FSH) / Luteinising Hormone (LH) in ♀	Irregular or loss of periods, low libido, hot flushes, vaginal dryness (pain during sex), sleep disturbance	-estradiol (E2), FSH, and LH	- hormone replacement therapy in premenopausal women with central hypogonadism, provided there are no contraindications
FSH/LH in ♂	Erectile dysfunction, low libido (sex drive), low sperm count, infertility, loss of facial and body hair	- serum Testosterone (T), FSH, and LH (in the absence of illness and before 10 AM after overnight fast)	-T replacement for adult males in order to prevent anemia related to T deficiency; reduce fat mass and improve bone mineral density (BMD), libido, sexual function, energy levels, sense of wellbeing, and muscle mass and strength
Growth Hormone (GH)	Lack of growth and sexual development (in children), excessive tiredness, muscle weakness, ↓bone density, ↑body fat, ↓QOL	- IGF-1 level - GH stimulation testing	- GH replacement to those patients with proven GHD and no contraindications

PITUITARY HORMONE OVERPRODUCTION

Prolactinoma

Definition

A prolactinoma is a benign pituitary tumor causing hyperprolactinaemia.

Epidemiology

- *Prolactinomas are the commonest functioning pituitary tumour.*
- *(microprolactinomas >macroprolactinomas),*

- ♀ *preponderance of microprolactinomas*

Clinical features

- ***Hyperprolactinaemia (microadenomas <1cm and macroadenomas ≥1cm)***
  - *Galactorrhoea (up to 90% ♀, <10% ♂)*
  - *♀ : presents with menstrual disturbance (up to 95%)—amenorrhoea, oligomenorrhoea, or with infertility and reduced libido*
  - *♂ : presents with loss of libido and/or erectile dysfunction*
  - *a long-term risk of ↓ BMD*
  - ***Mass effects (macroadenomas only)***
  - *Headaches and visual field defects (usually uni- or bitemporal field defects)*
  - *Hypopituitarism*
  - *Invasion of the cavernous sinus may lead to cranial nerve palsies and even temporal lobe epilepsy.*
- ***Other Causes of Hyperprolactinaemia***
  - *Physiological: Pregnancy, Stress*
  - *Pituitary Stalk section—head injury*
  - *Cranial irradiation.*
  - *Drug treatment: metoclopramide, domperidone. Opiates. Cocaine.*
  - *Neuroleptics: haloperidol, chlorpromazine, risperidone. Antidepressants: tricyclics amitriptyline, SSRIs, MAOIs, Protease inhibitors (PIs): ritonavir, indinavir,*
  - *Others: Oestrogens, omeprazole, H_2 antagonists,*
  - *Metabolic: Hypothyroidism, CRF, Severe liver disease, PCOS*
  - *'Idiopathic' hyperprolactinaemia*

Investigations

- ***Serum Prolactin (PRL):*** *Serum PRL <2000mU/L- a tumour—either a microprolactinoma or a non-functioning macroadenoma compressing the pituitary stalk. Serum PRL >3000mU/L - diagnostic of a macroprolactinoma.*
- ***Imaging:*** *MRI*

Management

- ***(Refer to endocrinologist/physician for medical therapy and neurosurgeons for operation)***
- ***Drug therapy****—dopamine agonists:*
  - ***Cabergoline****: 0.25 mg 2 times a week*
  - ***Bromocriptine****: 1.25-2.5 mg once a day, may increase the dose by 2.5 mg every 2 to 7 days as needed and tolerated (maximum dose- 10 mg/day)*
  - *Side effects: nausea, vomiting, stomach upset or pain, constipation, dizziness,*
  - *psychological manifestations: impulse control disorders (viz. Hypersexuality, Compulsive shopping, Compulsive eating, Pathological gambling),*
  - *Cardiac valvulopathy - risk appears to be low in prolactinoma patients on standard doses of cabergoline (<2mg/week)*
- ***Surgery****:* ***Transsphenoidal surgery*** *indicated for patients who are resistant to, or intolerant of, dopamine agonist treatment.*
- ***Radiotherapy*** *useful in the treatment of macroprolactinomas once the tumour has been shrunken away from the chiasm, only if the tumour is resistant.*



Figure 1. Algorithm for investigating hyperprolactinaemia.

OVER-SECRETION PITUITARY DISORDERS

	Acromegaly	*8. Cushing's disease*
Definition	*Acromegaly is the clinical condition resulting from prolonged excessive GH, and hence IGF-1 secretion in adults.*	*Cushing's disease is the clinical condition resulting from excess cortisol secretion due to pituitary adenoma.*
Epidemiology	• *Rare. Equal sex distribution. Mean age at diagnosis 49 years.* • *Prevalence 40–86 cases/million population.* *13.*	• *Rare; annual incidence ~2/million.* • *More common in ♀ (♀:♂, 3–15:1).* • *Age—most commonly, 20–40 years.*

Causes	**Causes of acromegaly**
	• *Pituitary adenoma (>99% of cases):*
	  ○ *Macroadenomas 60–80%*
	  ○ *Microadenomas 20–40%*
	• *GHRH secretion:*
	  ○ *Hypothalamic secretion.*
	  ○ *Ectopic GHRH e.g. carcinoid tumour (pancreas, lung) or other neuroendocrine tumours (NETs)*
	• *Ectopic GH secretion. Very rare (e.g. pancreatic islet cell tumour, lymphoreticulosis)*
		Causes of Cushing's syndrome
		• *Pseudo-Cushing's syndrome:*
		  ○ *Alcoholism*
		  ○ *Severe depression 1%*
		• *ACTH-dependent:*
		  ○ ***Pituitary adenoma 68% (Cushing's disease)***
		  ○ *Ectopic CRH/ACTH secretion ~12%*
		• *ACTH-independent:*
		  ○ *Adrenal adenoma 10%*
		  ○ *Adrenal carcinoma 8%*
		  ○ *Nodular (macro- or micro-) hyperplasia 1%*
		  ○ *Carney complex*
		• *Exogenous steroids*

Clinical features	***Symptoms*** • *↑ sweating—>80% of patients* • *Headaches—independent of tumour effect* • *Tiredness and lethargy* • *Joint pains. Change in ring or shoe size.* **Signs** • *Facial appearance. Coarse features, oily skin, frontal bossing, enlarged nose, deep nasolabial furrows, prognathism, and ↑ interdental separation* • *Deep voice* • *Tongue enlargement—macroglossia* • *Enlargement of hands and feet, osteoarthritis (OA), generalized myopathy*	• *Facial appearance—round plethoric complexion, acne and hirsutism, thinning of scalp hair* • *Weight gain—truncal obesity, buffalo hump, supraclavicular fat pads* • *Skin—thin and fragile due to loss of SC tissue, purple striae on abdomen, breasts, thighs, and axillae, easy bruising, tinea versicolor, occasionally pigmentation due to ACTH.* • *Proximal muscle weakness.* • *Mood disturbance—labile, depression, insomnia, psychosis* • *Menstrual disturbance* • *Low libido and impotence* • *High incidence of venous thromboembolism (VTE)*

	Acromegaly	*8. Cushing's disease*
	• *Entrapment neuropathies such as carpal tunnel syndrome (40% of patients)* • *Goitre and other organomegaly—liver, heart, kidney* *18.* **Complications** • *Hypertension (40%).* • *Insulin resistance and impaired glucose tolerance (40%)/DM (20%).* • *Obstructive sleep apnoea* • *↑ risk of colonic polyps and colonic carcinoma* • *CVD and cerebrovascular disease.* • *CCF and possible ↑ prevalence of regurgitant valvular heart disease.* • *Higher frequency of vertebral fractures.* **Effects of tumour** • *Visual field defects.* • *Hypopituitarism.*	• *Overall mortality greater* • *Growth arrest in children* **Associated features** • *Hypertension (>50%)* • *Impaired glucose tolerance (IGT)/DM (30%).* • *Osteopenia and osteoporosis (leading to fractures of spine and ribs).* • *Vascular disease due to metabolic syndrome.* • *Susceptibility to infections.*
. ***Investigations***	• *IGF-1.* • *GH Oral glucose tolerance test (OGTT)* • *MRI pituitary* • *Pituitary function testing*	• *Overnight dexamethasone suppression test* • *24h Urinary Free Cortisol* • *Low-dose dexamethasone suppression test* • *ACTH*
. ***Management***	Refer to endocrinologist/ physician	Refer to endocrinologist/ physician

DISORDERS OF POSTERIOR PITUITARY HORMONES

DIABETES INSIPIDUS AND SIADH

Diabetes insipidus	SIADH
High urine output	Low urine output
Low level of ADH	High level of ADH
Hypernatremia	Hyponatremia
Dehydrated	Over hydrated
Lose too much fluid	Retain too much fluid

DIABETES INSIPIDUS

Definition	Impaired secretion of vasopressin (antidiuretic hormone) from the posterior pituitary
Clinical features	polyuria, nocturia and compensatory polydipsia resulting in the passage of 3-20 L of dilute urine per day.
Causes	• Postoperative (hypothalamic- pituitary), transient only • Cranial DI - tumours, infections and infiltrations. • Nephrogenic DI - insensitive to vasopressin. (e.g. lithium, hypercalcaemia, pyelonephritis, hydronephrosis)
Diagnostic criteria	Serum Sodium >145mEq/L **AND** Serum osmolality >295 mOsm/ kg **AND** Urine Osmolality <300 mOsm/ kg

SIADH

Definition	SIADH is a disorder of impaired water excretion caused by the inability to suppress the secretion of antidiuretic hormone (ADH). Results in impaired water excretion, and subsequently hyponatremia and hypo-osmolality.
Clinical features	STADH: signs and symptoms → Decreased/low urine output Signs of hyponatremia: lethargy, apathy, disorientation, muscle cramps, anorexia, agitation Signs of water toxicity: nausea, vomiting, personality changes, confused, combative If Na <110 mEq/L, seizures, bulbar palsies, hypothermia, stupor, coma
Causes	Malignant disease - Bronchogenic carcinoma Pulmonary disorders - Viral and bacterial pneumonias ,Tuberculosis Neurologic disorders – Encephalitis, Meningitis

	Trauma Stroke Alcohol withdrawal HIV/AIDS
Diagnostic Criteria	• Decreased serum osmolality (<275 mOsm/kg) • Urine osmolality >100 mOsm/kg in the setting of serum hypotonicity • In the setting of normal dietary sodium intake, urine sodium >40 mmol/L • Normal thyroid, adrenal, renal, cardiac function • No recent use of diuretics
Treatment	Fluid restriction and referral to endocrine team

Approach to a patient with high urine output

High urine output (>4ml/kg/hr)

↓

Rule out other causes of polyuria
- osmotic diuresis secondary to mannitol hyperglycaemia
- diuretics
- appropriate diuresis following large IV fluid load intra operatively
- large volumes of contrast media during angiography/embolisation

↓

SEND
Serum Sodium
Serum Osmolality
Urine Sodium Urine Osmolality/Urine Specific Gravity

↓

SERUM SODIUM HIGH >145 mmol/l
Has the serum Na risen rapidly with the diuresis?
Is the serum osmolality >295?
Is there a negative fluid balance?
Is the urine colourless with a very low urine Na?
If all 4 criteria are met then polyuria is probably Diabetes Insipidus, contact Endocrine team.

The points of difference between Diabetes Insipidus & SIADH have been summarized below.

Characteristics	Diabetes Insipidus	SIADH
Definition	A disorder of water and salt metabolism marked by heavy urination and intense thirst.	A disorder in which increased levels of a hormone causes the body to retain water.
ADH	Inadequate ADH	Excess ADH
Types	2 forms of DI include Cranial diabetes insipidus (CDI) Nephrogenic diabetes insipidus (NDI)	4 forms include Type A SIADH, Type B SIADH, Type C SIADH and Type D SIADH
Urinary Output (Osmolarity)	Higher urinary output (polyuria)	Lower urinary output (Oliguria)
Sodium content	High	Low

Risk	Hypovolemic shock	Seizures
Plasma volume	Euvolemic	Euvolemic or slightly hypervolemic
Diagnostic criteria	Diagnostic criteria Serum Sodium >145mEq/L AND Serum osmolality >295 mOsm/ kg AND Urine Osmolality <300 mOsm/ kg	• Concentrated urine Na >20 mmol/L • Hyponatremia <125 mmol/L • Plasma osmolarity <260 mmol/kg In the absence of hypokalaemia, oedema or diuretics
Treatment	Vasopressin/ Desmopressin Chlorpropamide/HCTZ	Normal saline Fluid restriction Demeclocycline

ADRENAL DISORDERS

- The adrenal glands are located on the top of the kidneys
- The adrenal glands are made up of two parts, the cortex and the medulla
- The adrenal cortex, zona glomerulosa layer produces aldosterone, zona fascicular and reticularis layer produce cortisol and androgen



Hypothalamo–pituitary–adrenal axis (HPA axis)



	Adrenal Insufficiency (AI)	Cushing's Syndrome
Definition	Adrenal insufficiency is a chronic medical condition in which the adrenal glands do not produce enough of the necessary hormones (cortisol and aldosterone) to respond to stressors such as illness and injury	○ Cushing's syndrome comprises a large group of signs and symptoms, results from chronic exposure to excess glucocorticoids, which can be from either exogenous corticosteroids or

	Adrenal Insufficiency (AI)	Cushing's Syndrome
		endogenous source of cortisol
Epidemiology	Rare Prevalence - 5 in 10,000 Usually effects 30-50 years old, but can be seen in all ages Affects women more frequently than men	○ Estimated incidence of 0·2–5·0 per million people per year ○ A prevalence of 39–79 per million in various populations ○ Median age of onset/diagnosis was 41·4 years ○ Female-to-male ratio of 3:1
Causes	Primary (high ACTH) Addison's disease • Autoimmune (80%) (sporadic or polyglandular failure, APS1 and APS2) • Adrenal infection (TB, HIV, CMV, cryptococcosis, histoplasmosis, coccidioidomycosis) • Adrenal infiltration (Metastases, lymphomas, sarcoidosis, amyloidosis, hemochromatosis) • Bilateral adrenalectomy • Adrenoleukodystrophy (ALD) Secondary (low ACTH) • Pituitary tumors (endocrine adenomas, rarely carcinoma) • Mass lesions affecting the HP region (craniopharyngioma, meningioma, metastases) • Pituitary irradiation • Pituitary apoplexy/hemorrhage • Pituitary infiltration (TB, actinomycosis, sarcoidosis, Wegener's granulomatosis, metastases) • Glucocorticoid-induced AI (long-term administration of exogenous glucocorticoids)	○ Exogenous / Iatrogenic (Oral, injection or inhaled steroid) • the most common cause of Cushing's syndrome ○ Endogenous • ACTH dependent (80%) • Pituitary adenoma (Cushing's disease) • Ectopic ACTH or CRH secreting tumor • ACTH independent (20%) • Adrenal adenoma • Adrenal carcinoma
Clinical features	Symptoms and Signs Caused by Glucocorticoid Deficiency: • Chronic fatigue • Weight loss, anorexia • Myalgia, joint pain	○ Symptoms and Signs Caused by Glucocorticoid Excess: • Facial appearance— round plethoric complexion, acne and hirsutism, thinning of scalp hair

	Adrenal Insufficiency (AI)	Cushing's Syndrome
	• Low blood pressure, postural hypotension • Fever • Anemia, eosinophilia and lymphocytosis • Hypoglycemia, Hyponatremia due to loss of feedback inhibition of ADH release • Symptoms and Signs Caused by Mineralocorticoid Deficiency (Primary AI Only) • Abdominal pain, nausea, vomiting • Dizziness, postural hypotension • Salt craving • Low blood pressure, postural hypotension • Hyponatremia • Hyperkalemia • Hyperpigmentation, especially mucous membranes of mouth and hard palate, skin creases of hands • Signs and Symptoms Caused by Adrenal Androgen Deficiency • Lack of energy • Dry and itchy skin (in women) • Loss of libido (in women) • Loss of axillary and pubic hair (in women)	• Weight gain—truncal obesity, buffalo hump, supraclavicular fat pads • Skin—thin and fragile due to loss of SC tissue, purple striae on abdomen, breasts, thighs, and axillae, easy bruising, tinea versicolor, occasionally pigmentation due to ACTH. • Proximal muscle weakness. • Mood disturbance—labile, depression, insomnia, psychosis • Menstrual disturbance • Low libido and impotence • High incidence of venous thromboembolism (VTE) • Overall mortality greater • Growth arrest in children • Associated features • Hypertension (>50%) • Impaired glucose tolerance (IGT)/DM (30%). • Osteopenia and osteoporosis (leading to fractures of spine and ribs). • Vascular disease due to metabolic syndrome. • Susceptibility to infections.
Investigations	• Morning cortisol level (8:00 AM) • Random cortisol in ill patient • ACTH level • ACTH stimulation test • DHEAS • Adrenal Autoantibodies • Anti-21-OH-hydroxylase antibody (80%) • ACA—adrenal cortex antibody	• Overnight dexamethasone suppression test (1mg DST) • 24h Urinary Free Cortisol (UFC) (at least two measurements) • Late night salivary cortisol (two measurements) • Low-dose dexamethasone suppression test (2mg/day for 48 hr) • ACTH
Diagnosis	• Low basal serum cortisol: Highly likely if serum cortisol <138 nmol/L (5µg/dl) • Elevated plasma ACTH: >2-foldover URL • Corticotropin stimulation test:250µg iv, cortisol at baseline and after 30 min) for confirmation - peak cortisol below 500–550 nmol/l (18µg/dl)	• Serum cortisol greater than 1.8 g/dl (50 nmol/liter) after 1 mg dexamethasone (1-mg DST) • UFC greater than the normal range • Late-night salivary cortisol greater than 145 ng/dl
Management	• Glucocorticoid replacement therapy • Hydrocortisone (15 –25 mg), 2-3 times divided daily	• In exogenous Cushing's syndrome, gradual withdrawal of the glucocorticoid is

	Adrenal Insufficiency (AI)	Cushing's Syndrome
	• Prednisolone (3-5 mg) once or twice daily • Do not use dexamethaxone • Monitor energy level, BP, body weight, sign of Cushing • No biochemical or hormonal monitoring recommended • Mineralocorticoid replacement • fludrocortisone in confirmed aldosterone down, starting with 100µg/d • Monitor clinical sign, electrolytes and plasma renin • DHEA replacement therapy • Treating depression, low energy and libido • Initial dose 25–50 mg • Discontinue after 6 months if no benefit • Measurement of DHEAS	important because most patients on long-term therapy will have some degree of HPA-axis suppression with resultant adrenal insufficiency if therapy is abruptly discontinued • In ACTH-independent Cushing's syndrome, Patients should be referred for adrenalectomy • In ACTH-dependent Cushing's disease, a transsphenoidal microadenectomy is the treatment of choice for patients with a clearly circumscribed pituitary microadenoma
Sick day rules for patients with known AI	• Double the normal dose of hydrocortisone for a fever of more than 37.5 C or for infection/sepsis requiring antibiotic. • For severe nausea (often with headache), take 20mg hydrocortisone orally and sip rehydration/electrolyte fluids • On vomiting, use the emergency injection (100mg hydrocortisone) immediately. Then call a doctor, saying Addison's emergency.	• Refer to endocrinologist/ physician

ADDISONIAN CRISIS

- It is a life-threatening medical emergency condition
- Severe hypotension (shock)
- Unexplained fever, diarrhea, vomiting
- Hyperkalemia
- Hyponatremia
- Hypoglycemia
- Could cause coma and death
- Precipitated by infection, surgery or intercurrent disease

Acute Management of Addisonian Crisis

- IV fluid (normal saline 1L/h) - Infusion rate 1 litre per hour until SBP >100mg Hg, then reduced rate according to clinical state
- IV Hydrocortisone 100 mg bolus then 200 mg over 24h (infusion or multiple injections (50mg 6hrly) until GI symptoms improve then start oral therapy

- If hypoglycaemic (blood glucose <4.0 mmol/L) -100ml 20% dextrose over 10-15 minutes stat and Intravenous infusion 10% dextrose at 100ml/hr if hypoglycaemia persists, Monitor blood glucose hourly
- Mineralocorticoid replacement can be initiated once the daily hydrocortisone dose has been reduced to <50 mg
- Treat Precipitating causes



Algorithm for withdrawal from chronic GC (Exogenous Cushing/GC induced

Step 1 Decrease glucocorticoid dose from supraphysiologic to physiologic

↓

Step 2 Switch to a.m. hydrocortisone or alternate day therapy

↓

Step 3 Measure morning cortisol level

<3µg/dl	3-20 µg/dl	>20 µg/dl
Patient adrenally insufficient. Continue glucocorticoid. Retest in 4-6 weeks	Need further testing • *Insulin tolerance test* • *CRH stim* • *Cortisol stim* • *Metarapone test*	Recover HPA axis Can withdraw glucocorticoid therapy

Physiologic dose of prednisolone 5-7.5mg/day

PRIMARY HYPERALDOSTERONISM

Primary hyperaldosteronism is due to unilateral or bilateral cortical adrenal hyperproduction of aldosterone. It may be caused by adenoma, hyperplasia or carcinoma of adrenal gland. Among them, aldosterone producing macro or micro adenoma called Conn's syndrome is most common one.

When to suspect Conn's syndrome

- Resistant hypertension
- Patients with BP ≥150 (systolic) and /or 100(diastolic) on ≥3 measurements
- Hypertension and hypokalemia
- Hypertension and adrenal incidentaloma
- Hypertension and sleep apnoea syndrome
- Hypertension and a family history of early onset hypertension or stroke (before 40 years of age)
- Hypertensive first degree relatives of patients with primary aldosteronism
- Hypertension with atrial fibrillation

How to diagnose Conn's syndrome

- For screening, Aldosterone Renin Ratio (ARR) need to be done. Before ARR, the following drugs that affect ARR need to be stopped for at least four weeks.

Drugs	Effect on ARR
• ACEI	• Decrease
• ARB	• Decrease
• MRB (aldosterone)	• Decrease
• Diuretics	• Decrease
• CCB	• Normal or increase
• NSAID	• Normal or increase
• Beta blockers	• Normal or increase
• Clonidine	• Normal or increase
• Methyldopa	• Normal or increase

- When ARR test is positive, confirmatory test should be done and refer to Endocrinologist for them.
- After confirming the diagnosis, imaging with contrast CT with adrenal protocol or MRI need to be done for localization.
- Adrenal venous sampling for lateralization can be done if tumour is bilateral or sugery is desired.

Treatment

- For unilateral disease and surgery is desired, unilateral adrenalectomy can be done.
- For bilateral disease or surgery is not indicated, mineralocorticoid receptor antagonists should be given to control the deleterious effect of aldosterone on cardiovascular system.


Patients with Hypertension that are at Increased Risk for PA
PA Unlikely
–
ARR to Detect Cases (1|⊕⊕○○)
+
Patient Unwilling/
Unable to Proceed
↓K+, renin ↓↓↓
PAC >20 ng/dL
+
PA Unlikely
–
Confirmatory Testing (1|⊕⊕○○)
+
No Need for
Confirmatory
Testing
(2|⊕○○○)b
Treat with MR
Antagonist
(2|⊕⊕○○)a
Adrenal CT (1|⊕⊕⊕○)
If Surgery Desired
Subtype
Testing
If Surgery
Not Desired
AVS (1|⊕⊕⊕○)
Marked PA, Young Age, and + CT (2|⊕○○○)c
Bilateral
Unilateral
Treat with MR Antagonist
(1|⊕⊕⊕○)
Treat with Laparoscopic
Adrenalectomy (1|⊕⊕⊕○)

PHEOCHROMOCYTOMA

- Pheochromocytoma is a tumour arising from adrenomedullary chromaffin cells that commonly produces one or more catecholamines such as epinephrine, norepinephrine and dopamine.

When to suspect Pheochromocytoma

If the patient has signs and symptoms of Pheochromocytoma and the following score can be used.

• Pallor	+1 point
• Hyperhidrosis	+1 point
• Palpitaitons	+1 point
• Tremor	+1 point
• Nausea	+1 point
• BMI <25	+1 point
• Heart rate of 85bpm or higher	+1 point
• BMI >30	-1 point

If score is 3 or more, the probability is 5.8 folds higher.

- Other signs and symptoms are postural hypotension, anxiety, panic attack, sense of doom, weakness, abdominal or chest pain, constipation, fasting hyperglycemia, paresthesia, flushing, dyspnoea and visual disturbances.
- In some patients, signs and symptoms appear and lead to crisis after taking following drugs.

Dopamine receptor antagonists	Metoclopramide, chlorpromazine
Beta adrenergic receptor blockers	Propranolol, sotalol, timolol, labetolol
Sympathomimetics	Ephedrine, fenfluramine, phentermine
Opoid analgesics	Morphine, pethidine, tramadol
Norepinephrine reuptake inhibitors	Amitriptyline, imipramine
Serotonin reuptake inhibitors	Paroxetine, fluoxetine
Monoamine oxidase inhibitors	Phenelzine
Corticosteroids	Dexamethasone, prednisolone, hydrocortisone
Peptides	ACTH, glucagon
Neuromuscular blocking agents	Succinylcholine, tubocurarine, atracurium

How to diagnose Pheochromocytoma

1. 1.Gold standard is measurement of plasma free metanephrines by using liquid chromatography with tandem mass spectrometry method. Supine position for at least 20 minutes is required before taking blood. More than 2 folds increase above reference interval upper cut off is high suspicion. Major medications that may cause falsely elevated tests are acetaminophen, methyldopa, tricyclic antidepressant, phenoxybenzamine, sulphasalazine, cocaine and levodopa. Physiological stress associated with extreme illness may have effect on the test. So, confirmation with clonidine suppression test need to be done for above conditions.
2. Imaging studies with contrast CT with adrenal protocol or MRI can be done for localization.
3. Genetic testing with shared decision making.

Treatment

1. Surgery is treatment of choice.
2. Before surgery, alpha-adrenoreceptor blockade should be given for 2 to 14 days to prevent cardiovascular emergency and crisis. Blood pressure target before surgery is <130/80 mmHg and heart rate target before surgery is 60 to 70 bpm in a seated position and 70 to 80 bpm for upright position. Phenoxybenzamine is best and doxazosin can be used. Beta blockers should not be used before alpha blockade.



PHEOCHROMOCYTOMA CRISIS

When to suspect crisis

- Unexplained shock or left ventricular failure
- Multiorgan failure
- Hypertensive crisis
- Unexplained lactic acidosis especially if also febrile.
- When crisis is suspected, refer to endocrinologist.

CALCIUM DISORDER

	Hypercalcemia	Hypocalcemia
Definition	Corrected calcium >10.5 mg/dl (2.63mmol/L)	Corrected calcium<8.8 mg/dl (2.2mmol/L)
Causes	Common • Hyperparathyroidism: • Primary • Tertiary • Malignancy • Humoral hypercalcaemia • Multiple myeloma • Bony metastases Uncommon • Familial hypocalciuric hypercalcemia • Sarcoidosis and other granulomatous diseases • Thiazide diuretics • Lithium • Immobilization • Vitamin D intoxication • Hyperthyroidism • Renal failure • Addison's disease • Vitamin A intoxication	Hypoparathyroidism Destruction of parathyroid glands: • Surgical. • Autoimmune. • Radiation. • Infiltration. Failure of parathyroid development: • Isolated, e.g. X-linked. • With other abnormalities, e.g. di George syndrome (with thymic aplasia, immunodeficiency, and cardiac anomalies). Failure of PTH secretion: • Magnesium deficiency. • Overactivity of Ca-sensing r/c Failure of PTH action: • Pseudohypoparathyroidism—due to G protein abnormality. Failure of release of calcium from bone Osteomalacia: • Vitamin D deficiency. • Vitamin D resistance. • Renal failure. Inhibition of bone resorption: • Drugs linked to hypocalcaemia, e.g. cisplatin, calcitonin, PO PO4, • IV bisphosphonates, denosumab. • ↑ uptake of Ca into bone: • Osteoblastic metastases (e.g. prostate). • Hungry bone syndrome. • Imatinib mesylate Complexing of calcium from the circulation • ↑albumin-binding in alkalosis. • Acute pancreatitis:

		• Formation of Ca soaps from autodigestion of fat. • Abnormal PTH and vitamin D metabolism. • PO4 infusion. • Multiple blood transfusions—complexing by citrate.
Clinical features	**Renal** • Polyuria • Polydipsia • Stones GI • Anorexia • Vomiting • Constipation • Abdominal pain CNS • Confusion • Lethargy • Depression Other • Pruritus • Sore eyes	Acute • Neuromuscular irritability (Tetany) • Paresthesias (peri-oral, extremities) • Muscle twitching • Carpopedal spasm • Trousseau's sign • Chvostek's sign • Seizures • Laryngospasm • Bronchospasm Cardiac Prolong QT interval Hypotension Heart failure Arrhythmia Papilledema Chronic • Ectopic calcification (basal ganglia) • Extrapyramidal signs • Parkinsonism • Dementia • Subcapsular cataracts • Abnormal dentation • Dry skin
Evaluation	• Careful history and physical examination • Repeat serum calcium • Calculate corrected calcium level if needed or check ionized calcium • Stop causative medication if possible and recheck again	• repeat the measurement to confirm that there is a true decrease in the serum calcium concentration • corrected calcium • serum calcium to add by 0.8 mg/dL (0.2 mmol/L) for every 1 g/dL (10 g/L) fall in the serum albumin concentration
Investigations	• intact parathyroid hormone • magnesium • U & E, creatinine • phosphate • vitamin D • alkaline phosphatase.	• intact parathyroid hormone • magnesium • U & E, creatinine • phosphate • vitamin D • alkaline phosphatase.
Management	Management in hospital Moderate hypercalcemia (<3.5 mmol/L, <14 mg/dl)	Management in hospital • (Corrected calcium ≤7.5mg/dl, 1.9mmol/L and symptomatic)

	• Rehydration • Normal saline 4-6 L/day Recheck serum calcium after 24 hours • If >3 mmol/L (12 mg/dl) → treat as severe hypercalcemia Severe Hypercalcemia ≥ 3.5 mmol/L (≥14mg/dl) • IV Bisphosphonate If Malignancy • IVI Zoledronic acid 4 mg in NS 100cc over 15 minutes If not Malignancy • IVI Pamidronate (in 100 ml-500 ml NS over 2 hours) • 60-90 mg if adjusted Ca >3 mmol/L • 30-60 mg if adjusted Ca <3 mmol/L Recheck serum calcium after 48 hours Calcium >4 mmol/L (≥16 mg/dl) • SC inj Calcitonin 100 units 3 times per day for 24-48 hours If no response in 5 days after adequate hydration and Pamidronate • consider giving Zoledronic Acid 4 mg in 50 ml saline over 15 minutes. *Refer to Endocrinologist	• Initially, 10–20mL of 10% calcium gluconate diluted in 50–100mL of • 5% glucose and infused over about 10min. Repeat if symptoms not resolved. Cardiac monitoring is advisable. In order to maintain the plasma Ca, a Ca infusion is required; • 100mL of 10% calcium gluconate (ten vials) should be added to 1L of saline • or glucose solution and infused at 50–100mL/h. The plasma Ca should be checked regularly (not less than 6-hourly), and the infusion rate adjusted in response to the change in concentration. **Oral calcium** supplementation • 1 to 2 g of elemental calcium given as calcium carbonate or calcium citrate daily, in divided doses. As an example, calcium carbonate is 40 percent elemental calcium, so that 1250 mg of calcium carbonate contains 500 mg of elemental calcium. oral magnesium, • typically, 300 to 400 mg daily divided into three doses For patients with acute hypoparathyroidism, • calcitriol (in a dose of 0.25 to 0.5 mcg twice daily) and oral calcium (1 to 4 g of elemental calcium carbonate daily in divided doses) should be initiated as soon as possible. *Refer to Endocrinologist



Abbreviation
PTH=Parathyroid Hormone;
pHPTH=primary hyperthyroidism;
PTHrp=Parathyroid Hormone-related peptide;
1,25D=1,25-dehydroxy-vitamin D;
25D=25-hydroxy-vitamin D

Management of Primary Hyper-Parathyroidism



HEMATOLOGY

ANAEMIA

- Anaemia is defined by the World Health Organization (WHO) as a condition in which the number of red blood cells and their oxygen carrying capacity is insufficient to meet the body's physiologic needs. Hemoglobin (Hb) levels to diagnose anaemia varies according to age, sex, location (especially altitude) and smoking status. Generally, at sea level, anaemia can be diagnosed in men (15 years of age and above) if Hb is ≤ 12.9 g/dL; in non-pregnant women (≥ 15 years) if Hb is ≤ 11.9 g/dL; and in pregnant women if Hb is ≤ 10.9 g/dL.[1]
- Both Hb concentration and hematocrit (HCT), also known as packed cell volume (PCV), are commonly used to diagnose anaemia. The red blood cell (RBC) indices – such as mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC) and red cell distribution width (RDW) – are useful in detecting the underlying cause of anaemia. In Myanmar, Hb concentration is usually expressed in g/dL unit (it can be multiplied by 0.62 to convert to mmol/L).[2] HCT or PCV is usually reported in percentage.

Approach to Anaemia

- First of all, it is important to note that there are several conditions in which the ranges of Hb values provided by the laboratories may not apply. The causes of lower Hb values include pregnancy, old age and intense physical exercise whereas smoking, hemoconcentration and high altitude are the causes of higher Hb values. [2]
- The proper approach to diagnose anaemia divide patients into different categories and then the probability of particular diagnoses in each category are considered. The following figure is the simplified algorithm for evaluation of anaemia in ambulatory patients. [2]

Figure 1. Evaluation of anaemia in ambulatory patients



(ACD: anaemia of chronic disease; MCV: mean corpuscular volume)

ANAEMIA IN CHILDREN

- According to the World Bank data, the prevalence of anaemia among Myanmar children of 6 months to 5 years old was around **50%** in 2019.[3] The cut-off values of hemoglobin to define anaemia in children vary with age.
- The threshold to diagnose anaemia in children is HCT or Hb value at or below the 2.5th percentile for age and sex based upon normative data from healthy individuals, but that kind of data is still limited locally. Iron deficiency should be screened in children of **6 months to 6 years** old with Hb **<11 g/dL**, in **6 to 12 years** old children with Hb **<11.2 g/dL** and in children of **12 to <18 years** old with Hb **<11.4 g/dL (for girls)** or with Hb **<12.4 g/dL (for boys)**.[4]
- The first step of approach to anaemia in children is to detect whether the child has isolated anaemia or the other cell lines (white blood cells and platelets) are also affected. Then, the second step is to classify the anaemia according to MCV. Iron deficiency and thalassemia are the most common causes of microcytic anaemia in children. To differentiate IDA from thalassemia, the RDW index can be used: RDW is high in IDA and normal in thalassemia.[4]
- In children with normocytic anaemia, the following diagnoses should be considered first: hemolytic anaemia, blood loss, infection, medication, and anaemia of chronic disease. To differentiate between possible diagnoses, the reticulocyte count (RC) is helpful: high RC in blood loss (except acute blood loss: low RC) or hemolysis and low or normal RC in bone marrow suppression (e.g., due to infection, infiltrations or medications).[4]
- For the children with macrocytic anaemia, the common causes include the exposure to some drugs (e.g., antiseizure medications and immunosuppressives), vitamin B12 or folate deficiency, liver disease, hypothyroidism and aplastic anaemia. Children with Down syndrome can also present with isolated macrocytosis.[4]
- After narrowing down the possible underlying etiology/ pathology, further evaluation and confirmatory tests can be done accordingly:
    - Review medications and/ or diet history
    - Serum ferratin, iron, TIBC
    - Serum vitamin B12, folate levels
    - Infection screening tests
    - Serum indirect bilirubin, LDH and haptoglobin
    - Bone marrow aspirate/ biopsy (refer to hematology first).[4]

IRON DEFICIENCY ANAEMIA

- Iron deficiency anaemia (IDA) is the most common form of anaemia, accounting for nearly 50% of anaemia cases globally.[5] Iron deficiency is also the most common nutritional disorder worldwide. In Myanmar, it was recently estimated that about two in five pregnant women and one in three women of reproductive age (15- 49 years of age) could be iron deficient.[6, 7]

Management

- In a patient with anaemia, serum ferratin value lower than 45 ng/mL (or 45 mcg/L) can be used to diagnose iron deficiency, with the sensitivity of 85% and specificity of 92%. However, serum ferratin test is less accurate in patients with chronic kidney disease or any other inflammatory disorders. In such cases, additional tests – serum iron, transferrin saturation (TSAT) and C-reactive protein (CRP) – can be used to confirm the diagnosis of IDA.[8] According to a 2022 review, serum ferratin level cut-off for IDA is <100 mcg/L if there is inflammation and TSAT cut-off for IDA is <20%.[9]
- Investigations are based on the history and physical examination, including the rectal examination. If gastrointestinal (GI) bleeding is suspected, the esophagogastroduodenoscopy (OGDS) and

colonoscopy, small bowel biopsy, small bowel enema and the fecal occult blood test should be done.

- Typical findings of hematological investigations are as follows:
    - Microcytic, hypochromic red cells
    - Anisocytosis (variation in size), poikilocytosis (shape)- pencil-shaped rods
    - Low serum iron level
    - Raised iron-binding capacity and reduced transferrin saturations (TSAT)
    - Serum ferritin level low (the most useful index)
- As transferrin is a negative acute phase protein, it can be normal or reduced in patients with inflammatory disorders. Thus, it is better to check both serum ferratin level and TSAT in any case of inflammation.

Treatment

- Patients with IDA should be treated with the aim to refill iron stores and maintain hemoglobin to a normal level (for respective age and sex).[9]
- Evaluation and treatment of underlying causes of IDA is essential to achieve the above aim. For example, *Helicobacter pylori* infection is commonly associated with IDA and thus, *H. pylori* eradication therapy can improve the benefit of iron supplementation among infected patients. Besides, other nutritional deficiencies, covert blood loss and malabsorption syndromes should be excluded (if required resources are available) or treated accordingly if present.
- Iron supplementation: Oral iron, e.g., ferrous sulphate, can be given to most patients with IDA. The preferred dosing regimen is a single daily dose of 40- 60 mg or alternate-day dose of 80- 100 mg to optimize the absorption of elemental iron and lessen the side effects.[9]
- Hb should be increased by lg/dL per week. The response to treatment should be confirmed 2 to 3 weeks after starting. Treatment should be continued for 3 months after correction of the iron deficiency to allow replenishment of the iron stores.
- If a patient is not responding to one type of oral iron supplements, change to another formulation, or intravenous iron should be used as an alternative.[9]
- Sideroblastic anaemia should be considered if the patient has high serum ferritin with hypochromic microcytic anaemia and is not responding to iron.

Failure to respond

- In case of failure to respond to iron supplementation, the following causes should be considered: *H. pylori* infection (test/ treat), continuing bleeding, or non-compliance with iron supplements. Besides, the diagnosis should be reviewed: the patient may have anaemia mixed with other cell line disorders, or may have underlying chronic infection, vasculitis, rheumatoid arthritis (RA), malignancy or renal failure.

When to refer

- If the patient presents with dyspepsia and iron deficiency anaemia, refer him/her to gastroenterologist for gastroscopy.
- If Hb <11 g/dL in a man or <10 g/dL in a non-menstruating woman, refer him/ her for suspected lower GI cancer.
- Refer to hematologist for coordinated care if the patient fails to respond to iron supplementation and the initial tests for underlying causes are not conclusive.

Follow-up

- Once normal, monitor Hb, MCH, and MCV every 3months for 1 year, and then annually. Give further iron supplements if Hb, MCH, or MCV fall below normal levels. Investigate further if iron supplementation is unable to maintain Hb.

NON-ANEMIC IRON DEFICIENCY

- Iron deficiency without anaemia (low serum ferratin) is 3 times as common as iron deficiency anaemia but it is usually not recognized and treated. According to recent studies, iron deficiency (ID) is associated with colorectal cancers. Thus, in addition to giving iron supplements to replenish iron stores, iron deficient patients should be investigated for GI cancers, regardless of hemoglobin level.[10]

VITAMIN B12 DEFICIENCY

- Vitamin B12 is an essential cofactor for enzymes in DNA synthesis. It is found in animal liver & kidney, fish, chicken, meats, dairy products and eggs. Intrinsic factor is required for B12 absorption in the terminal ileum.
- Vitamin B12 is necessary for effective erythropoiesis, and it becomes deficient only when the hepatic stores are depleted. Vitamin B12 deficiency is usually defined as the value of serum B12 concentration <148 pmol/L (200 pg/mL). Sometimes, serum B12 levels may correlate poorly with deficiency, especially in pregnancy.[11]
- Prevalence of B12 deficiency is relatively low: ranging from <1% in children to about 6% in the elderly (>60 years of age), and the national data for B12 deficiency prevalence in Myanmar is still unknown.[12]
- The three main causes of B12 deficiency include autoimmune cause (pernicious anaemia), malabsorption (e.g., tapeworm infestation, bypass surgery or coeliac disease) and dietary insufficiency.[11]

PERNICIOUS ANAEMIA

- Pernicious anaemia (PA) is a rare autoimmune condition associated with gastric atrophy and anti-intrinsic factor antibodies or gastric parietal cell antibodies.
- Patients with PA have autoimmune gastritis due to antibodies to both parietal cells and intrinsic factor, which causes B12 deficiency and consequently, macrocytic megaloblastic anaemia.
- Although the prevalence of PA is very low (0.1%) in the community, it should be considered as a differential diagnosis if macrocytic anaemia is incidentally detected in the complete blood count (CBC) analysis.[13]

Management

- Generally, it is recommended to treat all people with confirmed vitamin B12 deficiency. In treating B12 deficiency, it is first to check whether the patient has the following conditions: symptomatic or severe anaemia (<8 g/dL), neurologic symptoms, possible malabsorption or concern about adherence or follow-up.[14]
- For patients with severe clinical features (mentioned above), treat with 1000 mcg hydroxocobalamin IM once daily or 1- 3 times weekly, then 1000 mcg per week for 4 weeks. If the neurological symptoms are improving but still present, the duration of initial treatment can be extended up to 3 months.
- To monitor for improvement in anaemia or resolution of neurological symptoms, close follow-up should be planned, and CBC (with reticulocyte count) should be repeated at 2 or 3 weeks. After initial treatment, maintenance therapy should be continued: either IM 1000 mcg hydroxocobalamin every 2 months, or oral/ sublingual methyl-cobalamin 1000 mcg daily. Then, CBC can be rechecked every 6 months for the first year, then yearly.[14]
- For patients without severe features, treat with 1000 mcg of hydroxocobalamin IM weekly for 4 weeks followed by 1000 mcg every 2 months; or treat with oral or sublingual methyl-cobalamin 1000 to 2000 mcg daily.[14]

- If the expected response to treatment is not achieved, the patient should be re-evaluated for other causes of anaemia and neurologic symptoms or the need to increase the dosing.
- If the cause of B12 deficiency is irreversible, the maintenance dose may be continued indefinitely.[14]
- Refer the patient if malabsorption or PA is suspected.[14]

FOLATE DEFICIENCY

- Folate is required for protein metabolism and synthesis of DNA and RNA. It is found in the highest concentrations in liver and yeast but is also in spinach, other green vegetables, nuts and fruits. The daily requirement for folate varies with age and pregnancy is the time when daily folate requirement is the highest (about 600 mcg per day).[14]
- The cut-off value for folate deficiency is defined as the serum folate less than 4.5 nmol/L (2 ng/mL).
- Both folate and B12 deficiencies may coexist in some cases and so serum B12 level should be checked together.
- The causes of folate deficiency include inadequate dietary intake, malabsorption, excess use (pregnancy & lactation, prematurity, malignancy and hemolysis) and drugs induced (anticonvulsant, trimethoprim).[14, 15]

Management

- Initial screening test is the CBC with blood film report. If macrocytic anaemia is found, serum B12 and folate levels should be detected.
- If the levels of serum B12 and folate are in the borderline range, methylmalonic acid (MMA) and homocysteine levels can be checked (if local resources are available).
- In folate deficiency, both serum B12 and MMA levels are normal and only homocysteine level is raised, while B12 deficiency shows elevated MMA and homocysteine levels.[15]
- All patients with folate deficiency should be evaluated for possible underlying causes and treated accordingly.
- Usual treatment for folate deficiency is oral folic acid 1- 5 mg daily for 1- 4 months if the cause of deficiency is reversible.
- For those with chronic or irreversible cause of folate deficiency, folic acid supplementation should be continued for long-term.
- For individuals with macrocytic anaemia, vitamin B12 should be given together with folic acid before the laboratory results are available.
- Besides, vitamin B12 should also be administered to those who develop neurologic symptoms after taking folic acid.[14]
- In addition to supplementation, it is important to encourage all patients with folate deficiency to eat more fruits and vegetables.[15]
- If the folate deficiency is due to malabsorption, further evaluation should be done to confirm the cause of malabsorption and in even such case, folic acid 5 mg daily dose is sufficient. For prevention of folate deficiency, the individuals, who have severe malnutrition, chronic haemolytic anaemia, renal dialysis or other diseases with high cellular turnover, can take oral folic acid 1 to 5 mg daily.[14]

Folate supplements in pregnancy

- As the folate requirement is the highest during pregnancy, it is recommended to provide folic acid tablet 0.4 mg once a day to all women of childbearing age, starting at least one month before planning conception and continuing throughout pregnancy to prevent neural tube defect as well as to fulfill the growth and developmental needs of the fetus.
- High dose prophylaxis (folic acid 1- 4 mg daily) should be prescribed if there is any personal or family history of neural tube defect in either parent or first degree relative of either parent (*high risk*), or if the mother has coeliac disease, diabetes, obesity (BMI >30), or is taking anticonvulsants (*moderate risk*).[16]

ANAEMIA OF CHRONIC DISEASE

- Anaemia of chronic disease (ACD), also known as anaemia of chronic inflammation, is the most common cause of anaemia in hospitalized patients.[17]
- Due to the increasing prevalence of chronic communicable and non-communicable diseases, the number of people with ACD is rising in the community.
- ACD is usually a type of normocytic anaemia, but it can become hypochromic microcytic anaemia over a period of time.[18]

Management

- The main aims of management are to detect and treat underlying disorders, such as chronic infections, chronic kidney disease, and hematologic or other malignancies, and to improve hemoglobin concentration of blood.[18]
- The following laboratory tests should be done in patients with ACD:
    - Complete blood count, reticulocyte count and peripheral blood film report
    - Iron studies: serum iron (low), TIBC (low) and ferritin (normal or high);
    - Liver function tests: serum bilirubin, ALT, AST and alkaline phosphatase;
    - Renal function tests (serum creatinine & eGFR), together with blood glucose test;
    - Serum lactate dehydrogenase (LDH) test and if needed, serum electrophoresis.
- After proper history taking and physical examination of patients with ACD, together with the results of initial tests, any recently diagnosed chronic diseases or inflammatory conditions should be treated accordingly. Since ageing is a pro-inflammatory process, some of the elderly patients may have unexplained anaemia, even after detailed investigations. It is also important to provide cancer screening tests, appropriate to the patient's age (if resources are available).[18, 19]
- Erythropoiesis-stimulating agents (ESAs) are not commonly used now and generally reserved for patients with chronic kidney disease (CKD), inflammatory bowel disease or rheumatologic disorders who are not responding to iron supplementation. This is because some studies have reported that ESAs could increase the mortality due to increased risk of thromboembolism.[19]
- Although iron supplementation is not usually prescribed in ACD, it can be given to those with absolute iron deficiency.
- Oral or parenteral iron can also be used together with erythropoietin to reach the target hemoglobin concentration (10- 12 g/dL) in some patients with functional iron deficiency.[18, 19]
- Transfusion of packed red cells should be given only for those with severely symptomatic or life-threatening anaemia.
- For symptomatic patients, the hemoglobin threshold for transfusion is 10 g/dL for ill patients with acute myocardial ischemia or hemodynamic instability, and 7- 8 g/dL for hemodynamically stable patients in hospitals.[19]

When to refer

- Patients with ACD should be referred for admission to a hospital if they are severely symptomatic, when there is acute drop in Hb/ HCT, if transfusion is needed or if detailed or invasive investigations are required.[18]

HAEMOLYTIC ANAEMIA

- Hemolytic anaemia is a type of normocytic anaemia due to premature RBC and hemoglobin breakdown. Hemolytic anaemia can be classified based on severity (mild to life-threatening), chronicity (acute to chronic), or etiology (hereditary or acquired).[20]
- The causes of hemolytic anaemia include:
    - Hereditary/ Genetic (intrinsic) RBC defects:
    - Hemoglobinopathies (e.g., Sickle cell disease and Thalassemia)
    - Abnormalities of RBC membrane (e.g., Hereditary spherocytosis and elliptocytosis)
    - RBC enzyme disorders (e.g., glucose-6-phosphate dehydrogenase (G6PD) deficiency)
    - Immune-mediated (extrinsic) causes:
    - Warm autoimmune hemolytic anaemia (AIHA)
    - Cold agglutinin disease
    - Drug-induced (or toxin-induced) hemolytic anaemia
    - Systemic diseases (infections including COVID-19, liver disease, renal disease)
- Less common causes:
    - Microangiopathic hemolytic anaemia (e.g., thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome)
    - Hemolytic transfusion reactions
    - Paroxysmal nocturnal hemoglobinuria (PNH)[20]

Approach to Hemolytic Anaemia

- General principles for evaluation of anaemia should be followed when approaching to patients with hemolytic anaemia.
- The clinical features of hemolysis (such as jaundice, dark urine, splenomegaly, increased reticulocyte count, different sizes and shapes of RBC on peripheral smear, elevated indirect bilirubin and increased serum LDH) are usually seen in many patients with hemolytic anaemia.[20]
- All children with unexplained hemolytic anaemia should be referred immediately to pediatric hematologist because of the increased risk of developing acute life-threatening hemolysis.[21]
- For adult patients with hemolytic anaemia, it is first to exclude the conditions for immediate medical attention: hemodynamic instability (rapid thready pulse with signs of pending shock), active bleeding, acute thrombosis, acute kidney injury, Hb level <7 g/dL, and schistocytes on blood film. If any of the above conditions are detected, the primary care physician can provide pre-hospital emergency care to stabilize the patient and refer him/ her to hospital immediately.[20]
- If there is no urgent conditions, the next step is to check whether the patient received a transfusion within the last four weeks. If ‘yes’, the patient should be evaluated for acute and delayed transfusion reactions. Refer the patient to a hematologist (or an internal medicine specialist).[20]
- If there is no transfusion history, the other causes of hemolysis should be evaluated based on history, examination, blood film report and direct antiglobulin (Coombs) test (if available).[20, 21]
- Management of hemolytic anaemia will vary according to the underlying cause and every patient should have consultation with a hematologist.

HAEMOGLOBINOPATHY

THALASSAEMIA

- Thalassaemia (or thalassemia) is a group of inherited (autosomal recessive) hemoglobinopathies with impaired production of normal alpha- or beta-globin chains, leading to ineffective erythropoiesis, hemolysis, and anaemia.[22]
- Prevalence of alpha thalassemia is higher in Asian countries than that of beta thalassemia. Hemoglobin E (HbE) is also prevalent in South-East Asia.[23]
- In Myanmar, alpha thalassemia is the most common hemoglobinopathy (10% - 56.9%) followed by HbE (1% - 28.3%) and beta thalassemia (0.5% - 4%).[24]

Approach to Thalassemia Patients

- Evaluation of a suspected case of thalassemia usually starts with CBC and peripheral blood film. In all patients with low Hb and reduced MCV (microcytic anaemia), iron deficiency should be excluded first with iron studies (mainly serum ferratin level), before confirming the diagnosis of thalassemia. The findings of peripheral blood film seen in thalassemia patients are as follows:
    - Hypochromic and microcytic cells
    - Aniso-poikilocytosis
    - Increased percentage of reticulocytes
    - Target cells, and
    - Heinz bodies.[23]
- Patients with the above findings, especially all pregnant mothers with microcytic anaemia, should be tested with hemoglobin electrophoresis (if resources are available).
- However, hemoglobin electrophoresis should not be repeated in patients who have a prior result and who do not require therapeutic intervention or monitoring of hemoglobin variant levels.[22]

Management

- Management depends on the type and severity of thalassemia. The overview of management includes treatment of anaemia, reduction of ineffective erythropoiesis, prevention of excess iron stores and treatment of complications due to iron overload.[22, 23]
- Patients with alpha-thalassemia trait (normal HbA_2) and those with beta-thalassemia trait (increased HbA_2) are usually asymptomatic and do not require any treatment (as long as they have hemoglobin level >7 g/dL). [22, 23]
- Patients with alpha-thalassemia intermedia (deletional HbH disease) can require treatment for mild to moderate anaemia, ineffective erythropoiesis and skeletal abnormalities.
- In patients with more severe phenotype (non-deletional HbH disease), transfusion therapy is usually required.[22] They should be referred urgently to hematologists (or to internist or pediatrician if there is no hematologist in some rural areas).
- Alpha-thalassemia major (with Hb Bart's disease) is usually fatal (hydrops fetalis).[22] The babies with this phenotype are almost impossible to survive in the local setting of Myanmar.
- Patients with beta-thalassemia intermedia may sometimes need transfusions and should be referred to a specialist, too.[22]
- Patients with beta-thalassemia major, similar to those with other types of transfusion-dependent thalassemia (TDT) (e.g., severe HbE/beta thalassemia and non-deletional HbH disease), require regular transfusions, usually every two to five weeks. All patients with TDT should be referred to a hematologist.[22]

Role of primary care physicians

- Being the primary care physicians in the community, family physicians (FP) and general practitioners (GP) can be part of the multi-disciplinary management team for thalassemia patients, especially those from sub-urban or rural areas, who cannot frequently visit the hematology clinics.
- FP/ GP can help thalassemia patients in the following ways:
    - Monitoring for any side-effects from iron chelation therapy,
    - Addressing any physical and psychosocial problems related to the patients and their families which can affect the treatment outcomes,
    - Monitoring for any complications of thalassemia and transfusion-related complications,
    - Coordinating with specialists and providing treatments for cardiac complications, endocrine disorders, leg ulcers (if any), osteoporosis, transfusion-related infections, prophylactic anticoagulation (in high-risk patients for thrombosis), and
    - Providing reproductive health care and family planning for those in child-conceiving age.[22]

GLUCOSE-6-PHOSPHATE DEHYDROGENASE (G6PD) DEFICIENCY

- Glucose-6-phosphate dehydrogenase (G6PD) is an intracellular enzyme found in every cell and it plays a significant role in prevention of cell damage from oxidation processes due to reactive oxygen species.
- G6PD deficiency is an X-linked recessive disorder, in which boys are mostly affected and girls are usually the carriers. It is the most common enzyme disorder of RBC detected in nearly 500 million people globally.[26, 27]
- Most forms of G6PD are mild and G6PD deficient people do not usually have any symptoms. Symptoms develop when they are either exposed to certain foods or drugs (*See the prevention section below*), when they are severely ill, or when exposed to noxious substances. Symptoms may develop when rapid breakdown of RBCs occurs and usually disappear when the offending food or drug is stopped.
- Typical presenting symptoms include acute onset of pallor, jaundice and dark-colored urine with sudden fall in Hb levels by 3- 4 g/dL, after a few hours or days of exposure to the triggering factors.[27]

Diagnosis

- When patients present themselves with acute jaundice and pallor, G6PD deficiency should be considered as a possible differential diagnosis, since prevalence of G6PD deficiency can be as high as 30% in some ethnic groups of Myanmar.
- In children, most cases are not detected until the child develops a health problem.[28]

Investigation for G6PD deficiency

- It should be done in the following cases:
    - Neonatal jaundice;
    - Unexplained hemolytic anaemia after exclusion of other possible causes;
    - Asymptomatic patients from high-risk populations before prescribing certain drugs, and
    - Asymptomatic family members of G6PD deficient patients (if needed).[27]
- Screening for G6PD deficiency can be done with qualitative G6PD assay. If the screening test is positive, it should be confirmed by quantitative G6PD assay at the reference laboratories.
- Timing for the G6PD enzyme assays is also important.
- The test may be false-positive in patients during the time of acute hemolysis because the RBCs with reduced G6PD enzyme activity have hemolyzed and are not be measured in the G6PD assay. Thus, if the screening test is negative and G6PD deficiency is still suspected, then the G6PD assay should be repeated about 3 months after the resolution of hemolysis.[27]

Treatment

- For the majority of cases, treatment is as simple as avoiding the triggering factors. Severely ill children may need hospitalization, oxygen support and intravenous fluids.
- In neonatal jaundice, treatment for those with G6PD deficiency is similar to treating those without deficiency.
- Mild cases do not usually require treatment; intermediate cases are treated by phototherapy and severe cases may need therapeutic plasma exchange.[27]
- Most of the neonatal jaundice cases are now diagnosed and treated in hospitals and hence, it is less likely to see such cases in primary care clinics.
- Treatment for acute hemolysis include the removal of any possible causes as soon as possible, adequate hydration, and transfusion for severe anaemia.
- Mild cases of hemolysis due to G6PD deficiency are usually self-limiting and may recover soon after discontinuation of the trigger for hemolysis.

- For moderate cases, supportive treatment to maintain adequate hydration and to improve symptoms should be given and transfusion will be required for those with severe hemolysis and sudden pallor.[27,28]

When to refer

- Immediately refer the patient to a general physician or hematologist if he/ she experiences:
  - severe exhaustion or pale skin or any of the persisting symptoms become worse;
  - very dark, red, red-brown, brownish or tea colored urine; and
  - urine output has noticeably reduced recently (oliguria or anuria).

Prevention

- It is important to avoid the foods and drugs below.
  - Antibiotics: Sulphonamides, Co-trimoxazole (Septrin), Dapsone, Chloramphenicol,
  - Nitrofurantoin, Nalidixic acid, Fluoroquinolones
  - Antimalarials: Chloroquine, Hydroxychloroquine, Primaquine, Quinine, Mepacrine
  - Chemicals: Moth Balls, naphthalene, Methylene blue
  - Food: Fava beans - also called broad beans
  - Other drugs: Aspirin, Phenacetin, Sulphasalazine, Methyldopa, Hydralazine, Quinidine, Large doses of Vitamin C, Procainamide, Rasburicase and some chemotherapy agents
- Tips to help patient get the most from a visit to healthcare provider:
  - Know the reason for their visit and what they want to happen;
  - Before their visit, write down questions they want answered;
  - Bring someone to help them ask questions and remember what their provider tells them;
  - During the visit, write down the name of a new diagnosis, and any new medicines, treatments, or tests;
  - Also write down any new instructions their provider gives them;
  - Know why a new medicine or treatment is prescribed, how it will help them, and what the side effects are;
  - Ask if their condition can be treated in other ways;
  - Know why a test or procedure is recommended and what the results could mean;
  - Know what to expect if they do not take the medicine or have the test or procedure;
  - If they have a follow-up appointment, write down the date, time, and purpose for that visit;
  - Know how they can contact their provider if they have questions.

APLASTIC ANAEMIA

- Aplastic anaemia is a rare disorder of bone marrow failure characterized by pancytopenia and bone marrow aplasia. Its incidence is as low as about two per million per year and nearly half of all diagnosed cases are usually younger than 30 years of age.
- The causes of aplastic anaemia include certain drugs (phenytoin, carbamazepine, sulfonamides, indomethacin, methimazole, propylthiouracil), toxins, ionizing radiation and infection.
- Primary care physicians may often find bicytopenia or pancytopenia incidentally in CBC and blood film reports. In such cases, possible causes of aplastic anaemia should be excluded and the patients with pancytopenia should be referred urgently to a hematologist.
- Treatment depends on the underlying cause and severity, and the patients should be under the care of hematologist.
- Supportive treatment involves transfusions and prophylaxis/treatment of infection.
- Definitive treatment includes the hemopoietic cell transplant and the immunosuppressive therapy.[29]

HAEMOPHILIA

- Hemophilia is the X-linked recessive disorder which causes prolonged bleeding due to deficiency of certain clotting factors. Common types include haemophilia A (factor VIII deficiency) and haemophilia B (factor IX deficiency- Christmas disease).[30]

Diagnosis

- The important point in diagnosis and evaluation is to differentiate haemophilia from other bleeding disorders as well as to confirm the severity and type of haemophilia. Severity of haemophilia can be classified as mild, moderate and severe based on the residual factor level as follows:
    - mild haemophilia with factor level between >5% and <40% of normal;
    - moderate haemophilia with factor level between ≥1% and ≤5%; and
    - severe haemophilia with factor level <1%.[31]
- In all patients with prolonged bleeding, haemophilia should be included in the list of differential diagnoses and personal bleeding history and family history should be taken thoroughly.
- Initial tests for all suspected cases of haemophilia include the prothrombin time (PT), activated partial thromboplastin time (aPTT), and platelet count.
- In moderate and severe hemophilia, the PT and platelet count are normal with prolonged aPTT while those with mild hemophilia (Hemophilia B) can have normal aPTT. Thus, for those with isolated prolonged aPTT (which corrects in mixing studies) and those with normal PT, aPTT and platelet count who have a relevant clinical history or family history for hemophilia should be tested for factor activity levels.[31]
- In every individual with suspected hemorrhagic disorders, screening tests for HIV, Hepatitis B and Hepatitis C infections should be ordered to get the baseline status before transfusions and to provide vaccination for Hepatitis B if not previously vaccinated.
- Low platelet count should suspect HIV infection associated with immune thrombocytopenic purpura (ITP).

Management

- The management of haemophilia includes the treatment of acute bleeding and prophylaxis.[30]
- It is important to follow the guidelines for management of hemophilia (3rd edition) published by the World Federation of Hemophilia (WFH) and individualized care should be provided (based on the available resources).
- During an acute bleeding episode,
    - patient should be immediately admitted to a hospital with hematology unit for transfusion of clotting factor concentrates (CFCs), even if the diagnostic tests are pending.
    - The transfusion of factor VIII concentrate (FVIII) for Hemophilia A or factor IX concentrate (FIX) for Hemophilia B must be done as soon as possible after bleeding has started.
    - In areas where CFCs are not available, fresh frozen plasma and cryoprecipitate can be provided as emergency care.
    - Symptomatic treatment includes proper rest, adequate analgesia and physiotherapy for bleeding into muscles/ joints (hematoma).[30]

Prophylaxis

- The WFH recommends regular long-term prophylaxis (regular factor infusions) as the standard of care for hemophilia patients. Even in resource-limited setting, the use of less intensive prophylaxis should be considered because it is more effective than on-demand therapy.[32]
- Tranexamic acid can be used to prevent or control superficial soft tissue and mucosal bleeds, and for invasive dental procedures (pre- and post-operatively). It can be given orally (25 mg/kg/dose) 3-4 times daily or by IV infusion (10 mg/kg/dose) 2-3 times daily.

- ***However, tranexamic acid is contraindicated in patients with hemophilia B receiving prothrombin complex concentrates.***[32]
- Desmopressin (DDAVP)- increases the plasma level of factor VIII (but not factor IX) and can be used, under close supervision, as a treatment option for mild or moderate hemophilia A.[32]
- Prophylaxis with standard half-life clotting factor:
    - for Hemophilia A, 10-15 IU FVIII/kg (low-dose) or 15-25 IU FVIII/kg (intermediate-dose) 3 days per week;
    - for Hemophilia B, 10-15 (low-dose) or 20-40 IU FIX/kg (intermediate-dose) twice a week.
- Prophylaxis is essential to prevent joint damage in children with haemophilia.
- The dose of prophylactic therapy can be increased if the patient still experience some breakthrough bleeds and high-dose prophylaxis can be used if the resources are available in the local area.[32]

VON WILLEBRAND DISEASE (VWD)

- Von Willebrand disease (VWD) is a common bleeding disorder, affecting up to 1% of population in the United States.
- Bleeding in VWD patients is usually a mild problem with an excellent prognosis.
- There are three types of VWD:
    - autosomal dominant type 1
    - autosomal dominant type 2 (type 2A is the most common variant) and
    - autosomal recessive type 3 (with severe bleeding).[33]
- Regarding the local incidence, there were only nineteen patients with VWD reported in 2018 and hence majority of people with VWD may still remain undiagnosed in Myanmar.[34]
- Most people with VWD are asymptomatic and only a small percentage of them presents with recurrent bruising, prolonged bleeding from skin cuts or from mucosal surfaces (e.g., menorrhagia and epistaxis). They can be diagnosed after proper evaluation and investigations. In severe cases, bleeding may occur in joints. Bleeding tendency can be exacerbated by aspirin.[33]

Diagnosis

- CBC shows normal platelets.
- Coagulation screening results will be as follows: increased bleeding time, normal PT and normal/ prolonged aPTT (aPTT may be prolonged if there is associated factor VIII deficiency).
- Von Willebrand (VW) factor antigen test is indicated for quantitative defect.
- VW factor activity test can be done for quantitative defect.
- VW factor level <30% is required to confirm the diagnosis.[33]

Management

- Refer to a hematologist in easily accessible areas for the patients.
- Mild cases are managed with tranexamic acid and desmopressin (DDAVP) trial.
- Type 1 VWD patients generally have good response to DDAVP trial, while type 3 VWD does not response.
- Severe cases (those with type 3 VWD or severe variants of type 1 & 2) may require VW factor replacement therapy.[33]

THROMBOCYTOPENIC PURPURA

- Bleeding is inevitable if platelet count decrease to <5-10 x 10^9/L. Purpura due to thrombocytopenia can be classified into two groups as follows:
    - ***Non-immune thrombocytopenic purpura***
        - caused by conditions that damage the bone marrow, e.g., drugs (chemotherapy), aplastic anaemia, leukemia, myeloproliferative disorders
    - ***Immune thrombocytopenic purpura***
        - Primary immune thrombocytopenic purpura (ITP) or
        - Secondary to SLE, transfusions or drug reactions (drug-induced ITP).

IMMUNE THROMBOCYTOPENIC PURPURA

- Immune thrombocytopenic purpura (ITP) is an acquired autoimmune disorder caused by anti-platelet antibodies.
- Most patients with thrombocytopenia may be asymptomatic and underdiagnosed.
- Patients with ITP can present with skin/ mucosal bleeding and low platelet count.[35]

Diagnosis

- ITP is the diagnosis of exclusion – meaning all other possible causes of thrombocytopenia should be excluded before confirming the diagnosis of ITP.
- Clinical presentations of acute ITP include generalized purpura in otherwise healthy children, easy bruising, oral mucosal bleeds, epistaxis, conjunctival hemorrhage, menorrhagia or hematuria.[35]
- Initial investigations for suspected cases of ITP include
    - CBC,
    - peripheral blood film,
    - reticulocyte count,
    - direct antiglobulin test and
    - serum immunoglobulin levels (if available).
- For further evaluation and diagnosis, refer any children with suspected ITP to a pediatric hematologist, and adult patients with isolated thrombocytopenia should also consult with a hematologist.
- Bone marrow examination of ITP patients will reveal normal marrow with normal or increased megakaryocytes.
- Platelet Coomb's test can detect anti-platelet antibodies fixed on the platelets of the patient.[35, 36]

Management

- The aim of ITP management is to prevent or treat significant bleeding, and not just to merely increase the platelet count.
- In managing patients with ITP, it is first to consider whether each patient is indicated for treatment. Then, the next step is to determine the urgency of treatment.[37]
- The risk of severe bleeding is highest in those with:
    - previous bleeding history,
    - older age >60 years, and
    - platelet count <10,000/microliter.
- The indications for specific therapy are based on the rapid clinical assessment which includes the following points:
    - Bleeding site, acuity and severity (if bleeding is present at the time of assessment),
    - Platelet count (Severe or critical bleeding occurs with platelets <20,000/microliter),

    - Other bleeding risk factors,
    - Previous treatments given for bleeding or thrombocytopenia and their effectiveness
    - Treatment given for the current bleeding episode
- All patients with suspected ITP, who have high risk of severe or critical bleeding or who present with bleeding, should be urgently referred to a hospital with a hematology unit.
- Most patients with minor bleeding or asymptomatic patients may not require any treatment, however, they should be scheduled for regular follow-up and informed about the risks of bleeding and treatment plan if there is acute bleeding.[37]
- ITP often resolves spontaneously within 3 months in children, but a minority of children can develop chronic ITP (thrombocytopenia >12 months since presentation) and they should be referred to a pediatric hematologist for further evaluation and management.[38]
- Patients with critical bleeding, which includes ***intracranial, intraspinal, intraocular, retroperitoneal, pericardial, or intramuscular bleeding with compartment syndrome,*** require immediate treatment with platelet transfusion, intravenous immune globulin (IVIG) infusion, glucocorticoids and other necessary treatments.
- Patients with severe bleeding, which causes reduction in Hb of ≥2 g/dL or requires blood transfusion (≥2 units) but do not have features of critical bleeding, will need urgent treatment with IVIG, glucocorticoids and other supportive care.[37]
- Antifibrinolytic therapy is useful for mucosal bleeding (oral, gastrointestinal, or gynecologic). Tranexamic acid can be given orally (1 g three to four times per day) or intravenously (10 mg/kg three times a day).[37]
- In managing patients with ITP, it is also important to detect and treat the underlying conditions which can cause secondary ITP. The causes of secondary ITP include:
    - ***Autoimmune diseases:*** Antiphospholipid syndrome, Systemic lupus erythematosus, Rheumatoid arthritis, Inflammatory bowel disease
    - ***Immunodeficiency:*** HIV, Selective IgA deficiency, Common variable immune deficiency
    - ***Infections:*** Cytomegalovirus (CMV), Hepatitis C virus, Varicella zoster virus, *H. pylori*
    - ***Lymphoma and Chronic lymphocytic leukemia (CLL)***
    - ***Alemtuzumab or some other monoclonal antibodies, and***
    - ***Mumps, measles and rubella (MMR) vaccine***
- There are some reported cases of ITP with COVID-19 vaccination. However, the risk is low and individuals with ITP can also receive COVID-19 vaccines after consultation with a hematologist. In patients with acute flare of ITP, doctors should postpone the vaccination until the flare is controlled.[37]

LEUKEMIA

- Leukemia is a group of hematological malignancies caused by an acquired malignant transformation in the haemopoietic stem cells.
- Acute leukemia has a rapidly fatal course if untreated, while chronic leukemia has a variable chronic course with an inevitable fatal outcome.
- Globally, the estimated number of deaths due to leukemia was over 334,000 in the year 2019.[39]

ACUTE LEUKEMIA

- Patients with acute leukemia usually have blast cells >20% in the peripheral blood smear or bone marrow.
- Acute leukemia is more commonly diagnosed in children and adolescents than in adults.[40]

ACUTE LYMPHOBLASTIC LEUKEMIA

- Acute lymphoblastic leukemia (ALL), or recently called lymphoblastic lymphoma (LBL), is the most common malignancy in children. It accounts for about 30% of all childhood cancers.[41]
- Clinical signs and symptoms of ALL/ LBL are non-specific and may be difficult to differentiate with other diagnoses. The common clinical findings in patients with ALL/ LBL include:
    - Hepatomegaly and/ or splenomegaly (the most common signs in >60% of the patients);
    - Lymphadenopathy (in about 50% of the patients);
    - Fever (in >50% of the patients): either due to infection or leukemia itself;
    - Hematologic abnormalities: bleeding with reduced platelet count, features of anaemia (pallor or fatigue) and low, normal or high white cell count (WCC >50,000/microL in 20%); and
    - Musculoskeletal pain: the affected child can present with a limp or refusal to bear weight.

Diagnosis

- Diagnosis of ALL/ LBL in children requires a high level of clinical suspicion since major clinical findings are not specific.
- The laboratory tests for suspected patients with ALL/ LBL includes the ***complete blood count (CBC) and differential count, peripheral blood smear, and bone marrow examination***.
- If lymphadenopathy is the first or main clinical finding, diagnostic evaluation should start with the excisional or core needle biopsy of the suspected lymph node.[41]
- The morphologic evaluation of cells from a peripheral blood film, bone marrow or other affected tissues (e.g., lymph nodes) together with immunophenotyping and karyotyping are usually required to confirm the diagnosis of ALL/ LBL. Thus, all suspected patients should be referred to a hemato-oncologist (or pediatric oncologist) for detailed investigations to confirm the diagnosis.[41]

Treatment

- Treatment of ALL/ LBL includes multidrug regimen divided into different phases, namely induction, consolidation or intensification and maintenance therapy.
- The treatment protocols may vary based on the immunophenotype and risk category and it usually takes about two or three years to complete the treatment.[42]
- All patients with suspected or confirmed ALL/ LBL should be referred to an oncologist (hemato-oncologist) on the same day to receive all necessary investigations and specific treatments.
- At the time of diagnosis, majority of the patients with ALL/ LBL require supportive care with transfusion, treatment for infections with broad-spectrum antibiotics, and treatment for metabolic changes due to fast cellular turnover (e.g., allopurinol can be used for hyperuricemia to prevent tumor lysis syndrome in ALL/ LBL patients).[42]

ACUTE MYELOID LEUKEMIA

- Acute myeloid leukemia (AML) is characterized by the clonal proliferation of myeloid precursor cells. It is the most common form of acute leukemia in adults.
- The incidence of AML increases with age and the median age at the time of presentation is approximately 68 years.[40, 43]
- The risk factors for AML consist of environmental factors such as:
    - exposure to smoking, radiation, chemicals or
    - previous chemotherapy/ radiotherapy and
    - genetic factors such as trisomy 21 (Down syndrome), Fanconi anaemia and Bloom's syndrome.[43]
- Most patients may not exactly know the onset of AML because they only experience subtle and non-specific symptoms (e.g., fatigue and weakness) at the beginning of the disease, probably several weeks or months before diagnosis.
- Common presenting features of AML are as follows:
    - Fatigue – in the majority of patients;
    - Pallor and weakness;
    - Fever, almost always due to infections;
    - Hemorrhage – gingival bleeding, epistaxis, ecchymoses, or menorrhagia, and
    - Any combination of the above clinical signs and symptoms.[43]

Diagnosis

- Similar to ALL/ LBL, the initial laboratory tests for patients with suspected AML include CBC, peripheral blood smear and reticulocyte count.
- CBC results may be normal or shows reduced Hb and platelet counts and WCC may vary (20% of patients have WCC >100,000/microliter; 25- 40% have WCC <5000/microL).
- Provisional diagnosis of AML can be made if there are ***any myeloid precursor cells detected in the peripheral blood smear examination***.
- To confirm the diagnosis of AML, ***evidence of bone marrow infiltration*** (from adequate bone marrow aspiration and biopsy) as well as ***demonstration of myeloid cells*** (with the presence of Auer rods, cytochemical reaction for myeloperoxidase or presence of myeloid markers in immuno-phenotyping) are required.[43]
- Impairment of renal function can be found in patients with AML if the WCC is very high. Mediastinal mass and/or lytic bone lesions may be detected in chest X-ray of some patients.

Management

- All suspected cases of AML should be referred to a hemato-oncologist within one day for early diagnosis and treatment.
- The management of AML ***aims to control disease activity and to achieve complete remission, if possible.*** The individual goals of treatment should be made by share decision-making by patients, their family members and clinicians.[44, 45]
- Pretreatment evaluation should include:
    - thorough history taking,
    - physical examination, and
    - the following laboratory tests:
    - CBC with differential count,
    - coagulation studies,
    - serum chemistries and viral serologies.
- Flow cytometry (immunophenotyping), karyotyping and molecular analysis (if needed) will be required to classify the subtypes of AML.[44]
- The ideal treatment outline for AML patients consists of
    - induction therapy (for complete remission),

    - followed by consolidation and/ or maintenance therapy to strengthen the remission and increase response duration.
- Before starting the definitive treatment, it is recommended to take time to prepare the patients physically and psychosocially to stabilize them and also to determine the best treatment option for individual patients.[44]
- AML is the most common indication for allogenic hemopoietic cell transplantation (HCT).
- Finding and matching with possible donors, specific indications, timing of HCT and preparation for HCT should be consulted with the experienced hemato-oncologists in well-equipped tertiary hospitals.[44]

Prognosis of Acute Leukemia

- Prognosis of acute leukemia varies significantly according to
    - the subtypes of ALL and AML,
    - chromosomal abnormalities,
    - genetic mutations,
    - age and
    - presenting features at the time of diagnosis,
    - underlying comorbid conditions (multimorbidity), and
    - treatment responses.[40]
- Due to the availability of newer therapies and person-centered comprehensive care, overall five-year survival rate of patients with acute leukemia has increased up to nearly 70%.[40,46]
- Prognosis is usually poor if any prognostic factors listed in Table-1 are present.

Table-1. Poor prognostic factors for Acute Leukemia

For ALL/ LBL[47]	**For AML[48]**
Personal: Age ≤1 year (infants) or ≥10 years at diagnosis	Personal: older age (>55 yrs.) and poor performance status (due to comorbidities)
Cytogenetics*: t(9:22)/BCR::ABL1, t(4:11), Hypodiploidy, etc.	Cytogenetics*: t(6;9), t(9:22), del(5q), complex karyotype, monosomal karyotype, etc.
T-cell immunophenotype	Acute promyelocytic leukemia (PML-RARA)
White cell count >50,000/microL; CNS or testicular involvement at diagnosis	Therapy-related AML; prior myelodysplastic syndrome or other hematological disorder
Delayed disappearance/ reappearance of measurable residual disease (MRD)	[Role of MRD detection is still unclear in AML prognosis]

** for detailed information, check the two cited references; CNS: central nervous system*

CHRONIC LEUKEMIA AND MYELOPROLIFERATION

CHRONIC LYMPHOCYTIC LEUKEMIA

- Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in the western hemisphere. It is commonly detected in the elderly, with the median age of 70 years.
- CLL has pathologic and immunophenotypic features identical to small lymphocytic lymphoma (SLL).
- When the disease manifestations are primarily in the blood, it is diagnosed as CLL while SLL is diagnosed when the primary involvement is nodal.[49, 50]

Diagnosis

- Many patients with CLL are asymptomatic and they usually present with an incidental finding in CBC result showing abnormal lymphocytosis.

- On physical examination, up to 90% of such patients may have ***localized or generalized lymphadenopathy,*** most commonly found in triangles of neck, supraclavicular and axillary region. ***Spleen*** can be palpable in 25 to 55% of the patients and ***hepatomegaly*** is found at the time of diagnosis in 15- 25% of cases.[49, 50]
- Skin is the most common non-lymphoid tissue that is already infiltrated by CLL cells at the time of diagnosis. Thus, it is important to examine the skin for any skin lesions ***(leukemia cutis)***, and if present, can refer the patient for skin biopsy.[49]
- The initial investigations include ***CBC and peripheral blood smear***. The threshold of absolute lymphocyte count for diagnosis of CLL is >5 x 10^9/L of B lymphocytes and it can be as high as >100 x 10^9/L in some cases. The peripheral blood film usually shows small lymphocytes with a darkly stained nucleus and narrow rim of basophilic cytoplasm, and smear cells or smudge cells can also be detected.[49, 50]
- ***Immunophenotyping*** by flow cytometry is essential for the diagnosis of CLL.
- The three main immunophenotypic findings of CLL include:
    - expression of B-cell associated antigens (CD19, CD20, CD23),
    - expression of CD5 and
    - expression of low levels of surface membrane immunoglobulin.
- Bone marrow aspirate and biopsy are not usually needed for CLL diagnosis.[49]

Management

- Refer to a hematologist, depending on age and clinical state of the patient
- Once diagnosis has been confirmed, well patients with low levels of lymphocytosis are often managed in primary care with regular FBC and clinical review (at least every 6 months).
- Treat any infections promptly.
- Refer to a hematologist for expert management if any of the following is present:
    - Symptomatic disease (fevers, sweats, weight loss);
    - Lymphadenopathy and/or hepatosplenomegaly;
    - Rising lymphocyte count (increase >50% in 2 months or doubling time of <6 months);
    - Anaemia or thrombocytopenia
- Splenectomy is indicated in patients with massive symptomatic splenomegaly and refractory cytopenia. It should be consulted with a hematologist.
- Explain the diagnosis of CLL, its benign nature and often good prognosis (>10 years).
- Stem-cell transplantation may have a role in carefully selected patients.

CHRONIC MYELOID LEUKEMIA

- Chronic myeloid leukemia (CML) is the myeloproliferative disorder caused by uncontrolled proliferation of mature and premature granulocytes with relatively normal differentiation.
- CML accounts for approximately 20% of leukemias in adults, with the median age of 50 years at the time of presentation.[51]
- Nearly half of patients with CML are initially asymptomatic and they can be incidentally detected with routine blood tests.
- Non-specific systemic symptoms such as fatigue, weight loss and excessive sweating, and bleeding due to platelet dysfunction are common in symptomatic patients.[51]

Diagnosis

- If CBC result shows marked leukocytosis (>50 x 10^9/L) with/ without anaemia and if numerous granulocytes (from myeloblasts to segmented neutrophils) are found in peripheral blood smear, CML should be suspected.
- The diagnosis of CML is confirmed by cytogenetic analysis (***demonstration of Philadelphia chromosome BCR::ABL1 fusion gene***).[51]

Management

- **Refer urgently to a hematologist** (by using teleconsultation service in remote areas).
- Treatment is determined by the phase of the disease.
- Initial treatment is BCR::ABL1 tyrosine kinase inhibitors (TKI) if there is no contraindication.
- Other medications like hydroxyurea and interferons may be used sometimes.
- Allogeneic hematopoietic cell transplantation (HCT) can be considered for medically fit patients if there is a suitable donor.[51]

LYMPHOMA

NON-HODGKIN'S LYMPHOMA

- Non-Hodgkin's lymphoma (NHL) is a group of hematologic malignancies which includes all lymphomas without Reed-Sternberg cells.
- NHL can be found in all ages and socioeconomic status.[52]
- The clinical features and presenting symptoms may vary based on different histologic types of NHL and sites of involvement.
- Typical presentations of NHL can be divided into two groups as follows:
    - ***Aggressive NHLs*** usually present with constitutional symptoms ("B" symptoms) such as fever, weight loss and night sweats; rapidly growing mass; and tumor lysis syndrome.
    - ***Indolent cases*** often present with slow-growing lymph nodes over several months or years, hepatomegaly, splenomegaly, with/ without cytopenia.[52]

Diagnosis

- Initial investigations are the CBC with differential count, coagulation tests, serum electrolytes, renal function (blood urea nitrogen & creatinine) and liver function tests, serum LDH and uric acid.
- CBC may be normal if there is no bone marrow involvement. Increased LDH may be associated with poor prognosis.[52]
- In patients with suspected NHL, a biopsy should be taken from an involved lymph node.
- The patients should not recently take glucocorticoids before biopsy, as steroids are lymphocytolytic. Diffuse large B cell lymphoma (DLBCL) is the most common histologic subtype.[52]

Management

- All patients with suspected NHLs should be urgently referred to an oncologist or hematologist for diagnosis confirmation, pretreatment evaluation, staging and specific treatments.[52]
- Fitness for treatment can be evaluated by clinical examination and performance status.[52]
- Serum protein electrophoresis should be done in selected cases.[52]
- Infection screening: for HIV in all patients and for HBV and HCV in some cases.[52]
- Imaging can be done depending on the histologic subtypes.[52]

Prognosis

- The prognosis of NHL varies widely between different histopathological types.
- DLBCL can be cured in nearly 50% of patients with current standard therapy, especially for those who have complete remission with the first-line treatment.
- Younger, fitter patients with less widespread disease do better.
- Socioeconomic conditions, performance status and underlying comorbidities can also influence the prognosis to a certain extent.
- Poor prognostic factors are as follows:
    - Age >60 years,
    - Increased serum LDH,
    - Eastern Cooperative Oncology Group (ECOG) performance status ≥2,
    - Clinical stage III or IV, and
    - >1 extranodal disease stie.[53]

HODGKIN'S LYMPHOMA

- Hodgkin's lymphoma (HL) is a relatively rare lymphoid malignancy characterized by the histologic finding of multi-nucleated Reed-Sternberg cells mixed with non-neoplastic inflammatory cells.
- HL can be divided into two main types:
    - Classic HL (90%)- Reed Sternberg cells are present; and
    - Nodular lymphocyte predominant HL (NLPHL).[54]
- Typically, the majority of patients with classic HL present with asymptomatic/ painless lymph node enlargement or an incidental finding of a mass in chest X-ray (CXR).
- About 40% of patients also develop systemic "B" symptoms such as fever, weight loss and night sweats.[54]
- In 60-80% of cases, lymphadenopathy is found in the neck (cervical nodes) or supraclavicular region. Mediastinal nodes are sometimes involved in about 60% of cases.
- Bone marrow and liver involvement as extranodal sites are less common in classic HL.[54]

Diagnosis

- Initial investigations for all patients should include:
    - Complete blood count (CBC) with differential count and erythrocyte sedimentation rate (ESR),
    - Serum electrolytes, renal and liver function tests and serum albumin, and
    - HIV testing,
    - Serum LDH and uric acid.[54]
- Classic HL should be suspected in any patients with lymphadenopathy or mediastinal mass on CXR.
- Imaging can be used to find out potential sites for lymph node biopsy and for other organ involvement. PET/CT is used for staging.[54]

Staging

- Staging for Hodgkin's lymphoma is important for specific treatment and prognosis.
- Ann Arbor staging is summarized in Table-2.
- Recently there is another modified staging, known as Lugano classification, derived from Ann Arbor staging.[55]

Table-2. Staging (Ann Arbor Staging)

Stage	Description
Stage I	Confine to single lymph node region.
Stage II	Involvement of two or more nodal area on the same side of diaphragm
Stage III	Involvement of nodes on both side of diaphragm
Stage IV	Spread beyond lymph nodes (e.g.; liver or bone marrow)
Each stage is either: A: no systemic symptoms except pruritus or B: presence of B symptoms: weight loss >30% in last 6 months, unexplained fever >38°C, sweating (needing change of clothes) Localized extranodal extension does not advance stage but is indicated subscripted 'E'.	

Management

- All patients with classic HL or NLPHL should be consulted with a hemato-oncologist for diagnostic confirmation, pretreatment evaluation, staging and specific treatments.[56]
- For patients with ***early staging,*** treatment should be aimed for eradication of the disease.[56]
- For ***Stage I and II patients***, combination of chemotherapy and involved-field radiotherapy can be used for higher disease-free survival.[56]

- For patients with ***advanced classic HL*** (stage III or IV), combination chemotherapy with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) is the treatment of choice.[57]
- Patients should receive individualized treatment from the specialist team.[56]
- One month after the completion of planned treatment, the patients should be evaluated for treatment response and regularly followed for any relapse.[56]

Prognosis

- Prognosis of HL depends on several factors, including
    - age at onset,
    - staging,
    - WCC,
    - serum LDH,
    - albumin and hemoglobin level.
- Nodular sclerosis type of classic HL has better prognosis than other types of HL. 5-year overall survival of early stages of HL (Stage 1 and 2A) is nearly 90% while that of advanced HL (Stage 4) is about 60%.[58]

References

1. *World Health Organization (WHO). Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System. Geneva, World Health Organization, 2011 (WHO/NMH/NHD/MNM/11.1). https://apps.who.int/iris/bitstream/handle/10665/85839/WHO_NMH_NHD_MNM_11.1_eng.pdf*
2. *Means RT Jr, Brodsky, RA. Diagnostic Approach to Anaemia in Adults. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2022. Accessed August 7, 2022.*
3. *World Bank. Prevalence of anaemia among children (% of children ages 6-59 months) – Myanmar. World Health Organization, Global Health Observatory Data Repository/World Health Statistics. Accessed September 12, 2022. https://data.worldbank.org/indicator/SH.ANM.CHLD.ZS?locations=MM.*
4. *Powers JM, Sandoval C. Approach to the child with anaemia. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2022. Accessed September 12, 2022.*
5. *Stoltzfus RJ. Iron deficiency: global prevalence and consequences. Food Nutr Bull. 2003 Dec;24(4 Suppl):S99-103. doi: 10.1177/15648265030244S206. PMID: 17016951.*
6. *United Nations Children's Fund. Ministry of Health and Sports and UNICEF present Frameworks of Action for Complementary Feeding and Maternal Nutrition in Myanmar. Published February 14, 2020. Accessed August 7, 2022. https://www.unicef.org/myanmar/press-releases/ministry-health-and-sports-and-unicef-present-frameworks-action-complementary*
7. *United Nations Children's Fund. The State of the World's Children 2021: On My Mind – Promoting, protecting and caring for children's mental health, UNICEF, New York, October 2021.*
8. *Sonoda, K. Iron Deficiency Anaemia: Guidelines from the American Gastroenterological Association. American Family Physician. August 2021;104(2):211-212.*
9. *Kumar A, Sharma E, Marley A, et al. Iron deficiency anaemia: pathophysiology, assessment, practical management. BMJ Open Gastroenterology 2022;9:e000759. doi: 10.1136/bmjgast-2021-000759*
10. *Majeed T, Solomon J, Ali RS, Chitsabesan P. Non-anaemic iron deficiency should be investigated with the same priority as iron deficiency anaemia in fast-track colorectal clinics-retrospective cohort study. J Gastrointest Oncol. 2020 Aug;11(4):609-615. doi: 10.21037/jgo-19-451.*
11. *Ankar A, Kumar A. Vitamin B12 Deficiency. [Updated 2022 Jun 5]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK441923.*
12. *Allen LH. How common is vitamin B-12 deficiency?, The American Journal of Clinical Nutrition, Volume 89, Issue 2, February 2009, Pages 693S–696S, https://doi.org/10.3945/ajcn.2008.26947A*
13. *Rodriguez NM, Shackelford K. Pernicious Anaemia. [Updated 2022 Jul 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK540989.*
14. *Means RT Jr, Fairfield KM. Treatment of vitamin B12 and folate deficiencies. In: UpToDate, Post, TW*

(Ed), UpToDate, Waltham, MA, 2022. Accessed September 19, 2022.
15. *Khan KM, Jialal I. Folic Acid Deficiency. [Updated 2022 Jun 27]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK535377.*
16. *Goetzl LM. Folic acid supplementation in pregnancy. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2022. Accessed September 19, 2022.*
17. *Badireddy M, Baradhi KM. Chronic Anaemia. [Updated 2022 May 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK534803.*
18. *Madu AJ, Ughasoro MD. Anaemia of Chronic Disease: An In-Depth Review. Med Princ Pract. 2017;26(1):1-9. doi: 10.1159/000452104. Epub 2016 Sep 28. PMID: 27756061; PMCID: PMC5588399.*
19. *Camaschella C, Weiss G. Anaemia of chronic disease/anaemia of inflammation. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2022. Accessed September 20, 2022.*
20. *Barcellini W. Diagnosis of hemolytic anaemia in adults. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2022. Accessed September 24, 2022.*
21. *Despotovic JM. Overview of hemolytic anaemias in children. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2022. Accessed September 24, 2022.*
22. *Baird DC, Batten SH, Sparks SK. Alpha- and Beta-thalassemia: Rapid Evidence Review. Am Fam Physician. 2022;105(3):272-280. https://www.aafp.org/pubs/afp/issues/2022/0300/p272.html*
23. *Bajwa H, Basit H. Thalassemia. [Updated 2022 Jun 7]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK545151.*
24. *Win S. Epidemiology and current status of case management of Thalassemia in Myanmar – Country Report. Myanmar Medical Journal. December 2016;58(4):43-51.*
25. *Benz EJ Jr, Angelucci E. Management of thalassemia. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2022. Accessed September 22, 2022.*
26. *Richardson SR, O'Malley GF. Glucose 6 Phosphate Dehydrogenase Deficiency. [Updated 2022 Jun 21]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470315.*
27. *Glader B. Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2022. Accessed September 24, 2022.*
28. *Li Q, Yang F, Liu R, Luo L, Yang Y, Zhang L, Liu H, Zhang W, Fan Z, Yang Z, Cui L, He Y. Prevalence and Molecular Characterization of Glucose-6-Phosphate Dehydrogenase Deficiency at the China-Myanmar Border. PLoS One. 2015 Jul 30;10(7):e0134593. doi: 10.1371/journal.pone.0134593. Erratum in: PLoS One. 2015;10(9):e0138038. PMID: 26226515; PMCID: PMC4520570.*
29. *Moore CA, Krishnan K. Aplastic Anaemia. [Updated 2022 Jul 18]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK534212.*
30. *Mehta P, Reddivari AKR. Hemophilia. [Updated 2022 Jun 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK551607.*
31. *Hoots WK, Shapiro AD. Clinical manifestations and diagnosis of hemophilia. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2022. Accessed September 27, 2022.*
32. *Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020:26(Suppl 6):1-158. https://doi.org/10.1111/hae.14046.*
33. *Sabih A, Babiker HM. Von Willebrand Disease. [Updated 2022 Jul 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459222.*
34. *World Federation of Hemophilia. Report on the Annual Global Survey 2018. 2019. Available from: https://www1.wfh.org/publications/files/pdf-1731.pdf. Assessed September 27, 2022.*
35. *Justiz Vaillant AA, Gupta N. ITP-Immune Thrombocytopenic Purpura. [Updated 2022 Jul 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537240*
36. *Bussel, JB. Immune thrombocytopenia (ITP) in children: Clinical features and diagnosis. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2022. Accessed September 29, 2022.*
37. *Arnold DM, Cuker A, Kelton JG. Initial treatment of immune thrombocytopenia (ITP) in adults. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2022. Accessed September 29, 2022.*

38. *Bussel, JB. Immune thrombocytopenia (ITP) in children: Management of chronic disease. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2022. Accessed September 29, 2022.*
39. *Sharma, R., Jani, C. Mapping incidence and mortality of leukemia and its subtypes in 21 world regions in last three decades and projections to 2030. Ann Hematol 101, 1523–1534 (2022). https://doi.org/10.1007/s00277-022-04843-6*
40. *Chennamadhavuni A, Lyengar V, Shimanovsky A. Leukemia. [Updated 2022 May 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560490*
41. *Horton TM, Steuber CP, Aster JC. Overview of the clinical presentation and diagnosis of acute lymphoblastic leukemia/lymphoma in children. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2022. Accessed September 29, 2022.*
42. *Horton TM, Steuber CP. Overview of the treatment of acute lymphoblastic leukemia/lymphoma in children and adolescents. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2022. Accessed September 29, 2022.*
43. *Schiffer CA, Gurbuxani S. Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2022. Accessed September 30, 2022.*
44. *Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345-1377. doi:10.1182/blood.2022016867*
45. *Kolitz JE. Overview of acute myeloid leukemia in adults. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2022. Accessed September 30, 2022.*
46. *The Cancer.Net Editorial Board. Leukemia - Acute Myeloid - AML: Statistics. April 2022. Available from https://www.cancer.net/cancer-types/leukemia-acute-myeloid-aml/statistics. Accessed September 30, 2022.*
47. *Horton TM. Prognostic factors and risk group stratification for acute lymphoblastic leukemia/lymphoblastic lymphoma in children and adolescents. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2022. Accessed September 30, 2022.*
48. *Schiffer CA. Prognosis of acute myeloid leukemia. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2022. Accessed September 30, 2022.*
49. *Rai KR, Stilgenbauer S, Aster JC. Clinical features and diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2022. Accessed September 30, 2022.*
50. *Mukkamalla SKR, Taneja A, Malipeddi D, et al. Chronic Lymphocytic Leukemia. [Updated 2022 Jul 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470433*
51. *Etten RAV. Clinical manifestations and diagnosis of chronic myeloid leukemia. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2022. Accessed September 30, 2022.*
52. *Freedman AS, Friedberg JW, Aster JC. Clinical presentation and initial evaluation of non-Hodgkin lymphoma. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2022. Accessed September 30, 2022.*
53. *Freedman AS, Aster JC. Prognosis of diffuse large B cell lymphoma. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2022. Accessed October 1, 2022.*
54. *LaCasce AS, Ng AK, Aster JC. Clinical presentation and diagnosis of classic Hodgkin lymphoma in adults. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2022. Accessed October 1, 2022.*
55. *McClain KL, Kamdar K. Overview of Hodgkin lymphoma in children and adolescents. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2022. Accessed October 1, 2022.*
56. *Hoppe RT, LaCasce AS. Treatment of favorable prognosis early (stage I-II) classic Hodgkin lymphoma. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2022. Accessed October 1, 2022.*
57. *Yahalom J, LaCasce AS. Initial treatment of advanced (stage III-IV) classic Hodgkin lymphoma. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2022. Accessed October 1, 2022.*
58. *Kaseb H, Babiker HM. Hodgkin Lymphoma. [Updated 2022 Jul 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK499969.*

CHAPTER (8) RENAL PROBLEMS

1. Acute Kidney Injury/Acute Renal Failure
2. Chronic Kidney Disease (CKD)
3. Urinary Tract Infections
4. Renal stones or Urolithiasis
5. Bladder stones
6. Benign Hyperplasia of Prostate Glands (BPH)



ACUTE KIDNEY INJURY / ACUTE RENAL FAILURE

Definition

Acute kidney injury is defined as the sudden loss of kidney function over hours to days resulting in the inability to maintain electrolyte, acid-base, and water balance. Or Acute kidney injury (AKI) is defined as any of the following:

- Increase in Serum Creatinine (SCr) by ≥0.3 mg/dl (≥26.5 µmol/1) within 48 hours; or
- Increase in SCr to ≥1.5 times baseline, which is known or presumed to have occurred within the prior 7 days; or
- Urine volume <0.5 ml/kg/h for 6 hours.

Symptoms

- feeling sick or being sick
- diarrhoea
- dehydration
- peeing less than usual
- confusion
- drowsiness

Risk factors for Acute Renal Injury

Nonmodifiable	Modifiable
AIDS	Anaemia
Chronic kidney disease	Hypercholesterolemia
Chronic liver disease	Hypertension
Chronic heart failure	Hypoalbuminemia
Diabetes Mellitus	Hyponatremia
Older age (>65 years)	Mechanical ventilation
Peripheral vascular diseases	Nephrotoxic drug use
Prior kidney surgery	Rhabdomyolysis
Renal artery stenosis	Sepsis

Stages of Acute kidney injury

Stage	Urine output	Serum creatinine
1	<0.5 ml/kg/h for 6-12 hours	1.5 - 1.9 times baseline Or ≥ 0.3 mg/dl (≥ 26.5 µmol/1) increase
2	<0.5 ml/kg/h for ≥12 hours	2.0 - 2.9 times baseline
3	<0.3 ml/kg/h for ≥ 24 hours Or Anuria for ≥ 12 hours	3.0 times baseline Or Increase in serum creatinine to ≥ 4.0 mg/dl (≥ 353.6

		µmol/1) Or Initiation of renal replacement therapy Or In patients <18 years, decrease in eGFR to <35 ml/min per 1.73 m^2

Causes

Commonest causes:

- Sepsis
- Major surgery
- Cardiogenic shock
- Other hypovolaemia
- Drugs
- Hepatorenal syndrome
- Obstruction
- It is essential to identify treatable cause to prevent further renal deterioration.

Causes of renal failure

	Pathology	**Examples**
Pre-renal	Decreased vascular volume	Haemorrhage, Diarrhoea &Vomiting, burns, pancreatitis,
	Decreased Cardiac	Cardiogenic shock, MI
	Systemic vasodilation	Sepsis, drugs
	Renal vasoconstriction	NSAIDs, ACEI, ARB, hepatorenal syndrome
Renal	Glomerular	Glomerulonephritis, Acute Tubular Necrosis (ATN) (prolonged renal hypoperfusion causing intrinsic renal damage)
	Interstitial	Drug reaction, infection, infiltration (e.g. sarcoid)
	Vessels	Vasculitis, Haemolytic uremic syndrome (HUS), Thrombotic thrombocytopenic purpura (TTP), Disseminated intravascular coagulation (DIC)
Post-renal	Within renal tract	Stone, renal tract malignancy, stricture, clot
	Extrinsic compression	Pelvic malignancy, prostatic hypertrophy, retroperitoneal fibrosis

For Early Diagnosis

Think of and investigate for acute kidney injury in patients with acute illness, if any of the following are present:

- chronic kidney disease
- history of acute kidney injury
- symptoms or history of urological obstruction, or conditions that may lead to obstruction
- symptoms or signs of nephritis (such as oedema or haematuria)
- oliguria (urine output less than 0.5 ml/kg/hour)
- those with limited access to fluids (e.g. young age, neurological impairment or disability)
- hypovolaemia
- hypotension
- sepsis
- severe diarrhoea (children and young people with bloody diarrhoea are at particular risk)
- heart failure
- liver disease
- haematological malignancy
- use of drugs with nephrotoxic potential (such as NSAIDs, aminoglycosides, ACE inhibitors, ARBs and diuretics) within the past week, especially if hypovolaemic

Consider critical care referral

RAPID ASSESSMENT AND TREATMENT OF LIFE-THREATENING EMERGENCY SITUATIONS

Physiological parameters	Score 3	2	1	0	1	2	3
Respiration rate	≤8		9-11	12-20		21-24	≥ 25
Oxygen Saturations	≤91	92-93	94-95	≥96			
Any supplemental oxygen		Yes		No			
Temperature	≤35.0		35.1-36.0	36.1-38.0	38.1-39.0	≥39.1	
Systolic BP	≤90	91-100	101-110	111-219			≥220
Heart rate	≤40		41-50	51-90	91-110	111-130	≥130
Level of consciousness				A			V.P or U

The NEWS initiative flowed from the Royal College of Physicians' NEWSDJG, and was jointly developed and funded in collaboration with the Royal College of Physicians, Royal College of Nursing, National Outreach Forum and NHS Training for Innovation.

- Early warning scores are tools to aid assessment. They do not replace clinical judgment: use yours and respect the clinical opinion of others.
- Refer to local early warning scores where available.
- Hyperkalaemia (ECG showing tall T especially with widening QRS complex)
- Fluid overload l pulmonary oedema
- Hypotension or shock
- Urinary tract obstruction, especially in patient with anuria; but always consider it although there is urine output. Urgent US is mandatory. It is surgical emergency.

Investigation

- The history and physical examination are important in determining the etiology of acute kidney injury.
- The physical examination should focus on evaluating intravascular volume status.
- Skin rashes may indicate an underlying condition (e.g., systemic lupus erythematosus, atheroembolism/vasculitis) or exposure (e.g., drug rash suggesting acute interstitial necrosis) leading to acute kidney injury.
    - Urgent:
    - Urine REME (routine examination and microscopic examination),
    - Blood urea, creatinine and creatinine clearance, electrolytes
    - ECG
    - USG abdomen

Treatment

Treatment of AKI depends on what's causing your illness and how severe it is.
The patient may need:

- to increase your intake of water and other fluids if you're dehydrated
- antibiotics if you have an infection
- to stop taking certain medicines (at least until the problem is sorted)
- a urinary catheter, a thin tube used to drain the bladder if there's a blockage
- treat acute pulmonary oedema as in other causes
- treat hyperkalemia
- treat metabolic acidosis
- nutrition
- A total energy intake of 20-30 kcal/kg/d should be given in patients with any stage of AKI.
- Protein 0.5 g/kg/day. Avoid potassium rich food and drug

may need to go to hospital for some treatments.

Prevention

- Nephrotoxic medications like aminoglycosides, NSAID including COX2 inhibitors and ACEI or ARB should not be used if possible in patients at risk for AKI or with AKI.
- To keep the patient normal hydration as a whole.
- In the absence of hemorrhagic shock, isotonic crystalloids rather than colloids (albumin or starches) should be used as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI.

Referral criteria

- National early warning score for adult patient >1
- Anuria for more than12 hours
- A lack of a clear precipitating cause of AKI.
- Clinical suspicion for a diagnosis that may require specialist treatment (for example vasculitis, myeloma, glomerulonephritis, interstitial nephritis)
- Chronic kidney disease stage 4 or 5
- AKI requiring Renal Replacement Therapy

Refer urologist when one or more of the following is present:

- pyonephrosis
- an obstructed solitary kidney
- bilateral upper urinary tract obstruction with acute kidney injury.

Indications for Dialysis (Peritoneal Dialysis, Haemodialysis, Haemofiltration)

- Refractory hyperkalaemia:Potassium >7 (persistently >6) (check ECG to exclude any error during sampling)
- Uncontrolled fluid overload or pulmonary oedema
- Severe acidosis: pH <7.15, HC03 <15 mmol/1
- Uraemic complications such as pericarditis and encephalopathy

Reference

1. *Oxford handbook of Clinical Medicine, 10th Edition*
2. *https://www.google.com/search?q=acute+renal+failure+aafp&oq=acute+renal+failure+&aqs=chrome.1.69i59l3j0i512l7.8679j0j7&sourceid=chrome&ie=UTF-8*
3. *https://www.nhs.uk/conditions/acute-kidney-injury/*

CHRONIC KIDNEY DISEASE (CKD)

DEFINITION

- CKD is defined as abnormalities of kidney structure or function, present for >3 months, with implications for health.

***Criteria for CKD** (either of the following present for >3 months)*	
Markers of kidney damage (one or more)	• Albuminuria (AER ≥30 mg/24 hours; ACR ≥30 mg/g) • Urine sediment abnormalities • Electrolyte & other abnormalities due to tubular disorders • Abnormalities detected by histology • Structural abnormalities detected by imaging • History of kidney transplantation
Decreased GFR	• <GFR 60ml/min/1.73m^2 (GFR categories G3a-G5)

Abbreviations: AER- albumin excretion rate; A CR- albumin creatinine ratio; GFR- glomerular filtration rate.

STAGING OF CKD

Stage	GFR (ml/min/1.73 m^2)	Terms
1	≥ 90	Normal or high
2	60 -89	Mildly decreased
3a	45 – 59	Mildly to Moderately decreased
3b	30 – 44	Moderately to severely decreased
4	15 – 29	Severely decreased
5	<15	Kidney failure

Symptoms	*Signs*
• No symptoms in early stage • At a more advanced stage, symptoms can include: • tiredness • swollen ankles, feet or hands • shortness of breath • feeling sick • blood in urine • Weight loss, poor appetite, difficult in sleeping, headache • Nausea, anorexia, lethargy, itch, nocturia, impotence. muscle cramps • Later: oedema, dyspnoea, chest pain (from pericarditis), vomiting, confusion, fits, hiccups, neuropathy, coma	• pallor, • lemon tinge to skin, • pulmonary/peripheral oedema, • pericarditis,pleural effusion, • metabolic flap, • Hypertension, • retinopathy

Markers of kidney damage

- Proteinuria
- Albuminuria
- Presence of hematuria, cellular casts, chronic pyuria, tubular concentrating defects, insufficient renal acidification

Investigations

Blood: Hb (normochromic normocytic anemia), ESR, U&E, glucose, Ca, P04, alkaline phosphate, PTH,
Urine: Dipstick, MC&S, albumin, creatinine ration or protein : creatinine ration
Imaging: In CKD, kidneys are usually small (<9cm), but enlarged in infiltrative disorders (amyloid, myeloma), APKD and DM. If asymmetrical, consider renogram
Histology: consider renal biopsy if unclear cause or rapidly progressive or normal sized kidneys

Assessment of Patient at risk of CKD

(algorithm see next page)

Retarding progression to ESRD

Antihypertensive therapy

- Hypertension is an important risk factor for progression of kidney disease and is a common cause of ESRD.
- Recommended target BP is ≥ 130/80 mmHg in CKD.
- Choice of antihypertensives may depend on the presence or absence of co- morbidities:
- ARB or ACEI is recommended to be used in both diabetics and non-diabetics with CKD
- In addition, the following drugs can be used alone or in combination:
- Calcium channel blocker (preferably non dihydropyridine).
- Beta blocker (preferably vasodilating group).
- Centrally acting agent (methyl dopa).
- Alpha blocker (prazosin/ doxazosin).
- Diuretics: low dose spironolactone (be careful of hyperkalaemia), thiazides (chlorthalidone, indapamide), loop diuretics (particularly in CKD 4-5).

Control of diabetes mellitus (DM)

- Diabetic nephropathy is the most common cause of ESRD in the developed world, and its incidence is rising in Myanmar.
- Tight glycaemic control may minimize the rate of decline of renal function and a target HbAl c 7.0% is recommended.

Renoprotection with ACEI/ARB

- Use of ACEI or ARB should be reviewed or discontinued if serum creatinine >265 umol/L or a 20% rise from baseline levels or development of hyperkalemia.



*—Monitoring guidelines are available in the 2012 Kidney Disease: Improving Global Outcomes recommendations (see Guide to Frequency of Monitoring [number of times per year] by GFR and Albuminuria Category in chapter 2.1.4 at http://www.kdigo.org/clinical_practice_guidelines/pdf/CKD/KDIGO_2012_CKD_GL.pdf).

†—Markers of kidney damage include, but are not limited to: structural renal disease (i.e., atrophic kidneys, thin [< 1 cm] renal cortices, hyperechoic kidneys on ultrasonography), hematuria (microscopic or otherwise), presence of cellular casts, chronic pyuria, tubular concentrating defects, and insufficient renal acidification.

Dietary protein restriction

- It is suggested to avoid high protein intake (>1.3 g/kg/d) in adults with CKD at risk of progression.
- Protein intake of 0.8 g/kg/d is recommended in CKD stage 4-5, but a protein intake of 1.2-1.3 g/kg/d is recommended for patients on regular HD (due to risk of malnutrition).

Salt intake

- Salt intake is recommended to be <2 g/d of sodium or <5 g/d of sodium chloride in adults, unless contraindicated.

Lifestyle

- Be encouraged to undergo physical activity compatible with cardiovascular health and tolerance (30 minutes x 5 times/week), achieve a healthy weight (BMI 20-25), and stop smoking.
- Diet -potassium restriction if hyperkalemic, avoidance of high phosphate foods (milk, cheese, eggs)
- Cardiovascular modification -in CKD 1 and 2, risk from cardiovascular death is higher. Give statins to CKD with raised lipid, give aspirin

Managing complications of CKD

Anaemia

- Treatment of renal anaemia should start when Hb <10.0 g/dl, not to intentionally increase >13.0 g/dl
- Check haematinics and replace iron, B12 and folate if necessary. If still anaemic, consider recombinant human erythropoietin, (Erythropoietin stimulating agents (Inj. Erythropoietin /EPO) can be used to maintain the Hb concentration effectively, and the recommended starting dose is 50-150 IU/kg/week (4000-8000 IU/week), and SC Erythropoietin dose is 15-30% lower than iv dose.)
- If Hb falls despite this, and no infection, hemolysis or blood loss, suspect red cell aplasia. Stop at once and get help from haematology.

Hyperphosphataemia

- Dietary phosphate restnct10n of ≤ 30-40 mmol/d (avoid dairy products, nuts, chocolate & tinned fish).
- Phosphate binders taken a few minutes before a meal, and calcium containing binders are more appropriate than aluminium hydroxide. Non-calcium, non- aluminium containing binders (sevelamer) and lanthanum carbonate are safer but expensive.
- Give vitamin D supplement (e.g. Colecalciferol, ergocalciferol) if deficient.
- If increased PTH persist or is increasing, treat with an activated vitamin D analogue (e.g. l alpha calcidol or calcitriol).

Metabolic acidosis

- Acidosis is common in all forms of CKD and can worsen uraemic osteodystrophy and protein malnutrition.
- Early treatment with oral sodium bicarbonate (650-1300 mg bd/ tds) may prevent this and a serum bicarbonate level of <20 mEq/L is recommended.

Oedema

- High dose of loop diuretics may be needed (furosemide 250 mg - 2 g/24hr with or without metalazone 5-10 mg/24hr each morning) and restriction of fluid and salt intake.

Restless legs/cramps

- Check ferritin (low level worsen symptoms) clonazepam or gabapentin, pregabalin or quinine sulphate may help.

Nephrologist referral

Delayed referral to a nephrologist is associated with increased morbidity& mortality.
Consider if

- GFR <30 ml/min/1. 73m2 (CKD stage 4-5)
- develop AKI or abrupt sustained fall in GFR.
- Significant albuminuria (ACR >70 mg/mmol)
- Persistent microscopic haematuria and <50 year (to urologist if >50)
- functional consequences of CKD (anaemia -Hb <11 g/dl, bone disease
- hypertension refractory to treatment with antihypertensive agents (>140/90 on 4 agents)
- known or suspected rare or genetic causes of CKD
- Suspected renal artery stenosis

Renal replacement therapy (RRT)

Choice of RRT

End Stage Renal Disease (ESRD or CKD stage 5) reflects progression of CKD to a point where RRT may be required to maintain life (fatal & irreversible)
There are a variety of options for RRT to choose:

- Continuous ambulatory peritoneal dialysis (CAPD)
- Automated peritoneal dialysis (APD)
- Haemodialysis (HD)*
- Haemodiafiltration (HDF)
- Renal transplantation*

(* = these are the only options available in Myanmar, but CAPD may develop later)

Haemodialysis (HD)

Indications for HD include

- Acute on chronic conditions of kidneys such as
- metabolic acidosis (HCO3 <10 mmol/L)
- electrolyte imbalance unresponsive to conservative treatment.
- fluid overload not responding to diuretics.
- creatinine clearance <5-10 ml/min/1.73 m^2
- uraemic signs & symptoms not responding to conservative treatment (serum creatinine >8-10 mg%)

Renal transplantation

- Renal transplantation can be done using cadaveric, live related & live unrelated donors (only live related transplantation is possible in Myanmar).
- All patients with ESRD should be considered for renal transplantation as it offers a better life expectancy and quality of life than dialysis.

Absolute contraindications are:

1. Uncontrolled cancer (especially with metastasis).
2. Active systemic infections.
3. Any condition with a life expectancy <2 years.

Reference

1. *Oxford handbook of Clinical Medicine, 10th Edition*
2. *https://www.aafp.org/pubs/afp/issues/2017/1215/p776.html*
3. *https://www.nhs.uk/conditions/kidney-disease/diagnosis/*

URINARY TRACT INFECTIONS

Definition

The presence of a pure growth of $>10^5$ organisms per ml of fresh MSU.
Lower UTI: urethra (urethritis), bladder (cystitis), prostate (prostatitis)
Upper UTI: renal pelvis (pyelonephritis)

Presentations of UTI

Cystitis: frequency, dysuria, urgency, strangury, low abdominal pain, incontinence of urine, acute retention of urine, cloudy or offensive urine and /or haematuria
Pyelonephritis: loin pain, fever, rigors, malaise, vomiting and/or haematuria
Organisms involved: E. coli, Proteus spp, Pseudomonas spp, Streptococci, Staphylococci, Chlamydia in young people
Risk factors: Prior infection, DM, Stones, pregnancy, dehydration, GU instrumentation, catheterization, menopause, sexual intercourse, GU malformation, Urinary stasis/ obstruction, Delayed micturition

Initial investigation



- If symptoms are present, test urine with leucocyte and nitrite dipstick, if positive, treat empirically, if negative with symptomatic, send MSU for MC&S to confirm (take MSU prior to starting antibiotic)

Causes of urinary tract infections (UTIs)

UTIs are common infections that happen when bacteria, often from the skin or rectum, enter the urethra, and infect the urinary tract.
The infections can affect several parts of the urinary tract, but the most common type is a bladder infection (cystitis). Women have a shorter urethra than men.
This means bacteria are more likely to reach the bladder or kidneys and cause an infection.
the risk of bacteria getting into the **bladder** include:

- having sex
- pregnancy
- conditions that block the urinary tract – such as kidney stones
- conditions that make it difficult to fully empty the bladder – such as an enlarged prostate in men and constipation in children
- urinary catheters (a tube in bladder used to drain urine)
- having a weakened immune system – for example, people with diabetes or people having chemotherapy
- not drinking enough fluids
- not keeping the genital area clean and dry

Reason to send MSU for MC&S

- Unresolved infection after antibiotics
- Recurrent UTI
- Uncatheterized man with UTI
- Catheterized man or woman with symptomatic UTI
- Child
- Pregnant woman
- Suspected pyelonephritis
- Haematuria

A pure growth of $>\mathbf{10^5}$ organisms/ml is diagnostic.
If $<10^5$ organisms/ml and pyuria (>20 WBC/mm3), treat if symptomatic.

Further investigation

- FBC, CRP, and blood culture if systematic unwell,FBS,
- Blood test (U&E, Cr, eGFR, and/or PSA if >40 years old and male) and/or radiology (renal tract USS, KUB) if
- UTI in man, child,
- Recurrent UTI in women

PYELONEPHRITIS

- Unclear diagnosis (persisting symptoms but negative MSU)
- Unusual infecting organism
- Sterile pyuria

Management

SYMPTOM MANAGEMENT

- Increase fluid intake (>3L/24hr)
- Alkalinize urine (potassium citrate solution)

Table – Urinary Tract Infection in adults

Category	Diagnostic criteria	Principal pathogens	First-line therapy	Comments
Acute uncomplicated cystitis	Urinalysis for pyuria and hematuria (culture not required)	*Escherichia coli* *Staphylococcus saprophyticus* *Proteus mirabilis* *Klebsiella pneumoniae*	TMP-SMX DS (Bactrim, Septra) Trimethoprim (Proloprim) Ciprofloxacin (Cipro) Ofloxacin (Floxin)	Three-day course is best Quinolones may be used in areas of TMP-SMX resistance or in patients who cannot tolerate TMP-SMX
Recurrent cystitis in young women	Symptoms and a urine culture with a bacterial count of more than100 CFU per mL of urine	Same as for acute uncomplicated cystitis	If the patient has more than three cystitis episodes per year, treat prophylactically with postcoital, patient-directed* or continuous daily therapy (see text)	Repeat therapy for seven to10 days based on culture results and then use prophylactic therapy
Acute cystitis in young men	Urine culture with a bacterial count of 1,000 to 10,000 CFU per mL of urine	Same as for acute uncomplicated cystitis	Same as for acute uncomplicated cystitis	Treat for seven to 10 days
Acute uncomplicated pyelonephritis	Urine culture with a bacterial count of100,000 CFU per mL of urine	Same as for acute uncomplicated cystitis	If gram-negative organism, oral fluoroquinolone If gram-positive organism, amoxicillin If parenteral administration is required, ceftriaxone (Rocephin) or a fluoroquinolone If Enterococcus species, add oral or IV amoxicillin	Switch from IV to oral administration when the patient is able to take medication by mouth; complete a 14-day course
Complicated urinary tract infection	Urine culture with a bacterial count of more than 10,000 CFU per mL of urine	*E. coli* *K. pneumoniae* *P. mirabilis* *Enterococcus species* *Pseudomonas aeruginosa*	If gram-negative organism, oral fluoroquinolone If Enterococcus species, ampicillin or amoxicillin with or without gentamicin (Garamycin)	Treat for 10 to 14 days

Asymptomatic bacteriuria in pregnancy	Urine culture with a bacterial count of more than 10,000 CFU per mL of urine	Same as for acute uncomplicated cystitis	Amoxicillin Nitrofurantoin (Macrodantin) Cephalexin (Keflex)	Avoid tetracyclines and fluoroquinolones Treat for three to seven days
Catheter-associated urinary tract	Symptoms and a urine culture with a bacterial count of more than100 CFU per mL of urine	Depends on duration of catheterization	If gram-negative organism, a fluoroquinolone	Remove catheter if possible, and treat for seven to 10 days
			If gram-positive organism, ampicillin or amoxicillin plus gentamicin	For patients with long-term catheters and symptoms, treat for five to seven days

Source*: https://www.aafp.org/pubs/afp/issues/1999/0301/p1225.html*

Disease management

For non pregnant women with lower UTI

- Trimethoprim 200mg bd PO or nitrofurantoin 50 mg/6 hourly PO for 3- 6 days, amoxicillin 500 mg/8 hourly PO,
- Alternative: cefalexin l g bd for 7 days
- Second line: co-amoxiclav PO for 7 days

For non pregnant women with upper UTI:

- co-amoxiclav IV 1. 2g/8hourly then PO for 7 days

For pregnant women:

- cephalexin 250 mg tds and get expert Opinium.

For men:

- 7 days course of trimethoprim or quinolone (ciprofloxacin 500 mg bd)

Asymptomatic bacteriuria in elderly men (>65 years):

- antibiotic therapy is not recommended.

All men with upper UTI, recurrent UTI or fail to respond antibiotic therapy:

- should be referred to urologist.
- Intermittent self catheterization (to insert catheter into his or her bladder four to five times per day to drain urine) in catheterized patient.

For children:

- trimethoprim bd for 3 days for lower UTI and 7 days for upper UTI

Recurrent Cystitis in Young Women

Up to 20 percent of young women with acute cystitis develop recurrent UTIs.

During these recurrent episodes, the causative organism should be identified by urine culture and then documented to help differentiate between relapse (infection with the same organism) and recurrence (infection with different organisms).

Multiple infections caused by the same organism require longer courses of antibiotics and possibly further diagnostic tests.

The most recurrent UTIs in young women are uncomplicated infections caused by different organisms.

These infections are generally not associated with underlying anatomic abnormalities and do not require further work-up of the genitourinary tract.

Women who have more than three UTI recurrences within one year can be managed using one of three preventive strategies

Acute self-treatment with a three-day course of standard therapy.

Postcoital prophylaxis with one-half of a trimethoprim-sulfamethoxazole double-strength tablet (40/200 mg) if the UTIs have been clearly related to intercourse.

Continuous daily prophylaxis with one of these regimens for a period of six months: trimethoprim-sulfamethoxazole, one-half tablet per day (40/200 mg); nitrofurantoin, 50 to 100 mg per day; norfloxacin,

200 mg per day; cephalexin (Keflex), 250 mg per day; or trimethoprim, 100 mg per day.

Complicated UTI

A complicated UTI is one that occurs because of **anatomic, functional or pharmacologic factors** that predispose the patient to persistent infection, recurrent infection or treatment failure.
These **factors** include conditions often encountered in elderly men, such as **enlargement of the prostate gland, blockages and other problems** necessitating the placement of indwelling urinary devices, and the presence of bacteria that are resistant to multiple antibiotics.

Treatment

- most often includes a **fluoroquinolone**, administered orally if possible.

In patients who are unable to tolerate oral medication or who require hospitalization for concomitant medical problems, appropriate initial therapy may be parenteral administration of one of the following:

- a third-generation cephalosporin with antipseudomonal activity such as ceftazidime (Fortaz) or
- cefoperazone (Cefobid), cefepime (Maxipime), aztreonam (Azactam), imipenemcilastatin (Primaxin) or
- the combination of an antipseudomonal penicillin (ticarcillin [Ticar], mezlocillin [Mezlin], piperacillin [Pipracil]) with an aminoglycoside.

UTI in Men

- Urinary tract infections most commonly occur in older men with prostatic disease, outlet obstruction or urinary tract instrumentation.
- These infections occur in young men
  - who participate in anal sex (exposure to *E. coli* in the rectum),
  - who are not circumcised (increased *E. coli* colonization of the glans and prepuce) or
  - whose sexual partner is colonized with uropathogens.
- In men (unlike in women), a urine culture growing **more than 1,000 CFU of a pathogen per mL of urine is the best sign of a urinary tract infection**, with a sensitivity and specificity of 97 percent.
- Men with urinary tract infections should receive **a minimum of seven days of antibiotic therapy** (either trimethoprim-sulfamethoxazole or a fluoroquinolone).
- More extensive courses may be required in, men with associated urinary tract infection and prostatitis.
- Among young men with acute cystitis who respond to seven days of treatment, diagnostic work-ups beyond cultures are generally unrewarding.
- Urologic evaluation should be performed routinely in adolescents and men with pyelonephritis or recurrent infections.
- When bacterial prostatitis is the source of a urinary tract infection, eradication usually requires antibiotic therapy for six to 12 weeks and in rare instances even longer

Refer to urology

If any abnormalities detected on further investigation or unable to resolve symptoms

Prevention of recurrent cystitis

- **General advice**: advise patient to urinate frequently, double void
- wipe from front to back when go to the toilet
- keep the genital area clean and dry
- drink plenty of fluids, particularly water – so that regularly urinate during the day and do not feel thirsty
- wash the skin around the vagina with water before and after sex
- urinate as soon as possible after sex

- promptly change nappies or incontinence pads if they're soiled
- Prophylactic antibiotic: either post-coitally (e.g. nitrofurantoin 50mg stat) or continuously (trimethoprim 1 mg hs or nitrofurantoin 50mg hs)
- Men with BPH: finasteride or dutasteride and/or doxazosin
- HRT: topical oestrogens

Reference

1. Oxford handbook of Clinical Medicine, 10th Edition
2. *Oxford hand book of General Practice 4th Edition*
3. *https://www.nhs.uk/conditions/urinary-tract-infections-utis/*
4. *https://www.aafp.org/pubs/afp/issues/1999/0301/p1225.html*

RENALSTONES

INCIDENCE

- About **12%** of Male and **3%** of Female will develop a renal stone at some point; peak age 20- 50 years. Symptoms are not dependent on size of the stone.



Risk factors

- Family history: increased risk 3 times. *Specific conditions:* X-linked nephrolithiasis, cystinuria, hyperoxaluria
- Anatomically abnormal kidneys, e.g. horseshoe kidney, medullary sponge kidney
- Metabolic disease, e.g. gout, hypercalcaemia / hypercalciuria, cystinuria, renal tubular acidosis or other acidosis (ileostomy, adenomatous polyp), oxaluria, aminoaciduria
- Dehydration
- Immobilization
- Chronic UTI

Composition of kidney stones in developed country

Stone type	Children (%)	Adult (%)
Calcium	50 - 90	64 - 92
Calcium oxalate	60 - 90	32 - 46
Calcium phosphate	10 - 20	3 - 5
Both calcium oxalate & phosphate	-	29 - 40
Cystine	1 - 5	1
Struvite (Magnesium ammonium phosphate)	1 -18	2 - 15
Uric acid	*1- 0*	3 -16
Other	4	1

Causes

- Kidney stones often have no definite, single cause, although several factors may increase your risk.
- Kidney stones form when your urine contains more crystal-forming substances — such as calcium, oxalate and uric acid — than the fluid in your urine can dilute.
- At the same time, your urine may lack substances that prevent crystals from sticking together, creating an ideal environment for kidney stones to form

Drugs predisposing patients to stone formation

- Acetazolamide, allopurinol, aspirin, steroids, indinavir, nelfinavir, loop diuretics, probenecid, quinolones, sulfonamides, theophylline, thiazides, triamterene, antacids, calcium/vitamin D supplements,high-dose vitamin C.

Types of kidney stones

Calcium stones

- Most kidney stones are calcium stones, usually in the form of calcium oxalate. Oxalate is a substance made daily by your liver or absorbed from your diet. Certain fruits and vegetables, as well as nuts and chocolate, have high oxalate content.
- Dietary factors, high doses of vitamin D, intestinal bypass surgery and several metabolic disorders can increase the concentration of calcium or oxalate in urine.
- **Struvite stones.** Struvite stones form in response to a urinary tract infection. These stones can grow quickly and become quite large, sometimes with few symptoms or little warning.
- **Uric acid stones.** Uric acid stones can form in people who lose too much fluid because of chronic diarrhea or malabsorption, those who eat a high-protein diet, and those with diabetes or metabolic syndrome.
- **Cystine stones.** These stones form in people with a hereditary disorder called cystinuria that causes the kidneys to excrete too much of a specific amino acid.

Risk factors

- **Family or personal history.**
- **Dehydration.** Not drinking enough water each day can increase your risk of kidney stones.
- **Certain diets.** Eating a diet that's high in protein, sodium (salt) and sugar may increase your risk of some types of kidney stones.
- **Obesity.** High body mass index (BMI), large waist size and weight gain have been linked to an increased risk of kidney stones.
- **Digestive diseases and surgery.** Gastric bypass surgery, inflammatory bowel disease or chronic diarrhea can cause changes in the digestive process that affect your absorption of calcium and water, increasing the amounts of stone-forming substances in your urine.
- **Other medical conditions** such as renal tubular acidosis, cystinuria, hyperparathyroidism and repeated urinary tract infections also can increase your risk of kidney stones.
- **Certain supplements and medications,** such as vitamin C, dietary supplements, laxatives (when used excessively), calcium-based antacids, and certain medications used to treat migraines or depression, can increase risk of kidney stones.

Presentation

- A kidney stone usually will not cause symptoms until it moves around within the kidney or passes into one of the ureters.
- If a kidney stone becomes lodged in the ureters, it may block the flow of urine and cause the kidney to swell and the ureter to spasm, which can be very painful.

- Usually presents with pain ± nausea/vomiting. Location and type of pain gives clues about the site of the stone:
    - Loin pain - kidney stone
    - Renal colic - ureteric stone
    - Renal colic (Sign and symptoms)
- Severe sharp pain with waves of increased severity. Usually starts abruptly as flank pain, below the ribs which then radiates around the abdomen to the groin as stone progresses down the ureter.
- Pain that comes in waves and fluctuates in intensity
- May be referred to testis/ tip of penis in men or labia majora in women.
- Pain or burning sensation while urinating
- Patient is obviously in pain - usually unable to sit still and keeps shifting position to try to get comfortable (in contrast to peritonitis where patients tend to keep still).
- May be pale and sweaty.
- May be mild tenderness on deep abdominal palpation or loin tenderness, though often minimal signs. If fever suspect infection.
- Pink, red or brown urine
- Cloudy or foul-smelling urine
- A persistent need to urinate, urinating more often than usual or urinating in small amounts
- Nausea and vomiting
- Fever and chills if an infection is present

Other presentations

- UTI, haematuria, retention, renal failure (rare).
- Pain caused by a kidney stone may change — shifting to a different location or increasing in intensity — as the stone moves through your urinary tract.

DIFFERENTIAL DIAGNOSIS

- Pyelonephritis
- ruptured Aneurysm of Abdominal Aorta
- Cholecystitis
- Pancreatitis
- Appendicitis
- Diverticulitis
- intestinal obstruction
- strangulated hernia
- testicular torsion
- pethidine addiction

Immediate investigation

- Dipstick urine if possible. Absence of RBCs does not exclude renal colic but consider alternative diagnosis.

Immediate management

- Stones usually pass spontaneously. Give pain relief (diclofenac 75mg IM/ l00mg PR)±antiemetic.

When to refer

- Any of the following:
- stone >5 mm in diameter
- high-grade obstruction
- gross hydronephrosis

- fever/UTI
- unremitting pain
- stone fails to progress
- Pregnant
- Strangury - bladder stone
- Interruption of flow - urethral stone

Investigation

- Blood U&E, creatinine, eGFR, Ca2+, P043-, alkaline phosphatase, uric acid, albumin
- Urine M, C&S; RBCs., Ca2+, P04 3-, uric acid, and sodium excretion
- Radiology X-ray of kidneys, ureters, and bladder - 90% of renal stones are radio- opaque only urate and xanthine stones are radio-translucent;
- High-speed or dual energy computerized tomography (CT) may reveal even tiny stones.
- Renal tract USS
- Analysis of passed stones

Management

Treatment for kidney stones varies, depending on the type of stone and the cause.

Small stones with minimal symptoms

- Most small kidney stones won't require invasive treatment. You may be able to pass a small stone by:
- **Drinking water.** Encourage drinking as much as 2 to 3 quarts (1.8 to 3.6 liters) a day will keep your urine dilute and may prevent stones from forming. Sieve urine for stones.
- **Pain relievers.** Passing a small stone can cause some discomfort. To relieve mild pain, your doctor may recommend pain relievers such as ibuprofen (Advil, Motrin IB, others) or naproxen sodium (Aleve).
- Monitor/review pain relief and for complications.
- Diclofenac 75 mg IM injection then 50 mg (oral) tds for 1 week.
- Several clinical trials have shown that NSAIDs by IM injection, including ketorolac (10-30 mg IM), are effective and at least as efficacious as opioids
- **Medical therapy.** a medication to help pass your kidney stone.
- This type of medication, known as an alpha blocker, relaxes the muscles in your ureter, helping you pass the kidney stone more quickly and with less pain. Alpha blockers include tamsulosin (Flomax) and the drug combination dutasteride and tamsulosin (Jalyn)

Large stones and those that cause symptoms

- Kidney stones that are too large to pass on their own or cause bleeding, kidney damage or ongoing urinary tract infections may require more-extensive treatment.
- **Using sound waves to break up stones.** For certain kidney stones — depending on size and location — may recommend a procedure called extracorporeal shock wave lithotripsy (ESWL).
- ESWL uses sound waves to create strong vibrations (shock waves) that break the stones into tiny pieces that can be passed in your urine. The procedure lasts about 45 to 60 minutes and can cause moderate pain, so it may be under sedation or light anesthesia to make you comfortable.
- **Surgery to remove very large stones in the kidney.** A procedure called percutaneous nephrolithotomy,
- involves surgically removing a kidney stone using small telescopes and instruments inserted through a small incision in back.
- **Using a scope to remove stones.** To remove a smaller stone in your ureter or kidney, doctor may pass a thin lighted tube (ureteroscope) equipped with a camera through your urethra and bladder to your ureter.

Urine alkalinization:

- The mainstay for medical management of uric acid stones is alkalinization (increasing the pH) of the urine.
- Uric acid stones are among the few types amenable to dissolution therapy, referred to as chemolysis. Chemolysis is usually achieved through the use of oral medications
- Diuretics:
- One of the recognized medical therapies for prevention of stones is the thiazide and thiazide-like diuretics, such as chlorthalidone or indapamide.
- These drugs inhibit the formation of calcium-containing stones by reducing urinary calcium excretion.
- Allopurinol: For people with hyperuricosuria and calcium stones, allopurinol is one of the few treatments that have been shown to reduce kidney stone recurrences.

Medical expulsive therapy

- The use of medications to speed the spontaneous passage of stones in the ureter is referred to as medical expulsive therapy. alpha adrenergic blockers (such as tamsulosin) and calcium channel blockers (such as nifedipine), have been found to be effective.

- *Antispasmodics to facilitate stone passage**

Alpha blockers	
Doxazosin (Cardura)	4 mg orally per day
Tamsulosin (Flomax)	0.4 mg orally per day
Calcium channel blocker	
Nifedipine (Procardia, SR)	30 mg orally per day

- 50% recur in 5-7years. Give general advice on prevention of stones (see Table 2).
- If investigations show any loss of renal function, renal obstruction, or remaining stones - refer to urology.
- Dependent on composition of stones, give dietary advice/refer to dietician (see Table 14.6).

HYPEROXALURIA

- May be 1° (autosomal recessive condition) or s to gut resection/malabsorption or dietary excess of spinach or vitamin C.
- Take specialist advice on management. There are two types of p hyperoxaluria:
- Type 1 hyperoxaluria -Calcium oxalate stones are widely distributed throughout the body. Presents as renal stones and nephrocalcinosis in children. 80% have chronic renal failure in <20years.
- Type 2 hyperoxaluria- More benign but less common - nephrocalcinosis but no chronic renal failure.

CYSTINURIA

- Most common aminoaciduria. Usually presents with stones at age 10 -30years. If the *Urine - increased the* cystine, omithine, arginine and lysine. Take specialist advice on management.

HYPERCALCAEMIA

- Hypercalciuria may occur without hypercalcaemia and is found in 80% of patients with calcium oxalate stones

Table 1:Prevention of renal stones

Type of stone	Preventative measures
All types	increase fluid intake (>2-2.5L/24h), especially in hot weather decrease weight if obese; decrease animal protein and increase fruit/ vegetables in diet; decrease salt intake
Calcium oxalate	Urinary alkalinization with potassium citrate; avoid chocolate, tea, rhubarb and spinach, nuts, beans, beetroot; decrease citrus fruits; bendroflumethiazide 2.5mg od may help if hypercalciuria; hyperoxaluria is treated with pyridoxine
Calcium phosphate	Low Ca2+ diet; avoid vitamin D supplements. Bendroflumethiazide 2.5mg od may help if hypercalciuria
Staghorn/ triple phosphate (calcium, magnesium, and ammonium	Associated with UTI due to *Proteus* species and urinary stasis, e.g. due to anatomical abnormality. Treat UTI with antibiotics
Urate	Avoid beer as has uricosuric effect; allopurinol; urinary alkalinization with potassium citrate (pH >6.5)
Cystine	Urinary alkalinization with potassium citrate

THE DIETARY ADVICE FOR RECURRENT URINARY CALCULI INCLUDES:

- Drink at least 2L of water every day, or more if there is increased fluid loss: this is the most important step.
- Minimise consumption of foods that contain oxalate or uric acid. Foods that contain oxalate include:
- chocolate
- coffee
- cola and similar 'soft' drinks
- rhubarb
- tea
- Foods that contain uric acid include:
- beer
- red wine
- red meat
- organ meats
- Avoid milk in tea - calcium precipitates oxalate.
- Avoid processed meats, organ meats (e.g. brain, kidney, liver and sweetbread), yeast spreads and other high-salt foods. Restrict salt intake.
- Reduce animal protein consumption: restriction to one major meat meal a day (includes chicken and fish).
- Add citrate-containing fruit juices to the diet, including grapefruit, apple and orange Juice.
- Eat a healthy diet of vegetables and fruit with a high fibre content.
- Drink at least 2L of water every day, or more if there is increased fluid loss: this is the most important step.

Minimise consumption of foods that contain oxalate or uric acid. Foods that contain oxalate include:

- Chocolate
- Coffee
- cola and similar 'soft' drinks
- rhubarb
- tea
- Foods that contain uric acid include:
- beer
- red wine
- red meat

- organ meats
- Avoid milk in tea - calcium precipitates oxalate.
- Avoid processed meats, organ meats (e.g. brain, kidney, liver and sweetbread), yeast spreads and other high-salt foods. Restrict salt intake.
- Reduce animal protein consumption: restriction to one major meat meal a day (includes chicken and fish).
- Add citrate-containing fruit juices to the diet, including grapefruit, apple and orange juice.
- Eat a healthy diet of vegetables and fruit with a high fibers content.

REFERENCES

1. John Murtagh 'S General Practice-5th Edition
2. *Oxford Handbook of General Practice _4th Edition*
3. *LYNDA FRASSETTO, MD, et.al, University of California School of Medicine, San Francisco, California,, American Family Physician, Volume 84, Number I]December 1, 201*
4. https://www.urologyhealth.org/urology-a-z/k/kidney-stones
5. *https://www.mayoclinic.org/diseases-conditions/kidney-stones/symptoms-causes/syc-20355755*

BLADDER STONES

Bladder stones are hard lumps of minerals that can form inside the bladder when it's not completely empty of urine.
They may not cause any symptoms if they're small enough to be passed out of the bladder when urination
But most people with bladder stones do experience symptoms because the stones either irritate the wall of the bladder or block the flow of urine.

Typical symptoms

lower abdominal pain, which can often be severe (men may also have pain in or around their penis)
pain or difficulty when peeing
peeing more frequently (particularly at night)
cloudy or dark-coloured urine
blood in the urine
Most cases of bladder stones affect men aged 50 or older because of the link with prostate enlargement.
But both men and women can get bladder stones. It's rare for bladder stones to affect children.
In children, they can lead to bedwetting, and some boys may experience priapism, a persistent and often painful erection that can last for hours.

Causes bladder stones

Bladder stones usually form when you can't completely empty your bladder of urine.
A common reason for this in men is having an enlarged prostate gland that blocks the flow of urine.
If urine sits in the bladder for a long time, chemicals in the urine form crystals, which harden into bladder stones.

Treatment

Surgery is usually needed to remove the stones from the bladder.
The most common procedure is a cystolitholapaxy, where a thin tube (cystoscope) with a camera at the end is used to find the bladder stones.
The cystoscope will then use stone-crushing devices, lasers or ultrasound to break up the stones before they're removed.
Where possible, it's important to treat the underlying causes of bladder stones to prevent new stones developing in the future.

Preventing bladder stones

If you have had bladder stones, they can come back.
increase your daily fluid intake to 2 to 3 litres to lower the concentration of your urine
regularly empty your bladder without delaying
urinate again 10 to 20 seconds after your first attempt (if you're unable to empty your bladder completely first time); this is called double voiding and helps empty the bladder more efficiently
avoid constipation (regular laxatives may be recommended)

Reference

1. *https://www.nhs.uk/conditions/bladder-stones/*
2. *https://www.urologyhealth.org/urology-a-z/k/kidney-stones*

BENIGN PROSTATIC HYPERPLASIA (BPH)

Benign prostatic hyperplasia—also called BPH—is a condition in men in which the prostate gland is enlarged and not cancerous. Benign prostatic hyperplasia is also called benign prostatic hypertrophy or benign prostatic obstruction.



Causes

The cause of benign prostatic hyperplasia is not well understood.
Occurs mainly in older men.
Benign prostatic hyperplasia does not develop in men whose testicles were removed before puberty.
Throughout their lives, men produce testosterone, a male hormone, and small amounts of estrogen, a female hormone.
As men age, the amount of active testosterone in their blood decreases, which leaves a higher proportion of estrogen.
Benign prostatic hyperplasia may occur because the higher proportion of estrogen within the prostate increases the activity of substances that promote prostate cell growth.
Another theory focuses on dihydrotestosterone (DHT), a male hormone that plays a role in prostate development and growth. It was indicated that even with a drop in blood testosterone levels, older men continue to produce and accumulate high levels of DHT in the prostate.
This accumulation of DHT may encourage prostate cells to continue to grow.
BPH is the most common prostate problem for men older than age 50. Benign prostatic hyperplasia affects about 50 percent of men between the ages of 51 and 60 and up to 90 percent of men older than 80.

Risk factor

Men with the following factors are more likely to develop benign prostatic hyperplasia:

- age 40 years and older
- family history of benign prostatic hyperplasia
- medical conditions such as obesity, heart and circulatory disease, and type 2 diabetes
- lack of physical exercise
- erectile dysfunction

Symptoms

Lower urinary tract symptoms suggestive of benign prostatic hyperplasia may include

- urinary frequency—urination eight or more times a day
- urinary urgency—the inability to delay urination
- trouble starting a urine stream
- a weak or an interrupted urine stream
- dribbling at the end of urination
- nocturia—frequent urination during periods of sleep

- urinary retention
- urinary incontinence—the accidental loss of urine
- pain after ejaculation or during urination
- urine that has an unusual color or smell
- Symptoms of benign prostatic hyperplasia most often come from
- a blocked urethra
- a bladder that is overworked from trying to pass urine through the blockage

Complications

acute urinary retention
chronic, or long lasting, urinary retention
blood in the urine
urinary tract infections (UTIs)
bladder damage
kidney damage
bladder stones
Seeking to Medical Care
Men with the following symptoms should seek immediate medical care:
complete inability to urinate
painful, frequent, and urgent need to urinate, with fever and chills
blood in the urine
great discomfort or pain in the lower abdomen and urinary tract

Diagnosis

A health care provider diagnoses benign prostatic hyperplasia based on
a personal and family medical history
a physical exam - performs a digital rectal exam
medical tests



Digital rectal exam

Medical Tests

Urinalysis
a prostate-specific antigen (PSA) blood test - men who have prostate cancer may have a higher amount of PSA in their blood. However, a high PSA level does not necessarily indicate prostate cancer.
urodynamic tests
Cystoscopy
transrectal ultrasound
Biopsy

Treatment

lifestyle changes
Medications
minimally invasive procedures
Surgery

Lifestyle Changes

Lifestyle changes can include
reducing intake of liquids, particularly before going out in public or before periods of sleep
avoiding or reducing intake of caffeinated beverages and alcohol
avoiding or monitoring the use of medications such as decongestants, antihistamines, antidepressants, and diuretics
training the bladder to hold more urine for longer periods
exercising pelvic floor muscles
preventing or treating constipation

Medications

alpha blockers
phosphodiesterase-5 inhibitors
5-alpha reductase inhibitors
combination medications

Alpha blockers.
These medications relax the smooth muscles of the prostate and bladder neck to improve urine flow and reduce bladder blockage:
terazosin (Hytrin)
doxazosin (Cardura)
tamsulosin (Flomax)
alfuzosin (Uroxatral)
silodosin (Rapaflo)

Phosphodiesterase-5 inhibitors.
Urologists prescribe these medications mainly for erectile dysfunction

5-alpha reductase inhibitors.
These medications block the production of DHT, which accumulates in the prostate and may cause prostate growth:
finasteride (Proscar)
dutasteride (Avodart)
These medications can prevent progression of prostate growth or actually shrink the prostate in some men. Finasteride and dutasteride act more slowly than alpha blockers and are useful for only moderately enlarged prostates.

Combination medications
The combinations include
finasteride and doxazosin
dutasteride and tamsulosin (Jalyn), (a combination of both medications that is available in a single tablet)
alpha blockers and antimuscarinics

Minimally Invasive Procedures

These procedures include:
transurethral needle ablation
transurethral microwave thermotherapy
high-intensity focused ultrasound
transurethral electrovaporization
water-induced thermotherapy
prostatic stent insertion
Minimally invasive procedures can destroy enlarged prostate tissue or widen the urethra, which can help relieve blockage and urinary retention caused by benign prostatic hyperplasia.

Surgery

For long-term treatment of benign prostatic hyperplasia, a urologist may recommend removing enlarged prostate tissue or making cuts in the prostate to widen the urethra. Urologists recommend surgery when
medications and minimally invasive procedures are ineffective
symptoms are particularly bothersome or severe
complications arise
Although removing troublesome prostate tissue relieves many benign prostatic hyperplasia symptoms, tissue removal does not cure benign prostatic hyperplasia.
TURP. Transurethral resection of the prostate
Laser surgery
Open prostatectomy

Reference

1. *https://www.mayoclinic.org/diseases-conditions/benign-prostatic-hyperplasia/symptoms-causes/syc-20370087*
2. *https://www.nhs.uk/conditions/prostate-enlargement/*
3. *https://my.clevelandclinic.org/health/diseases/9100-benign-prostatic-hyperplasia*
4. *https://www.urologyhealth.org/urology-a-z/b/benign-prostatic-hyperplasia-(bph)*

CHAPTER (9)
MUSCULOSKELETAL PROBLEMS

1. Low Back Pain
2. Neck Pain
3. Shoulder Problems
4. Knee Problems
5. Elbow Problems
6. Ankle Problems
7. Foot Pain
8. Fibromyalgia Syndrome
9. Gout
10. Osteoarthritis
11. Osteoporosis
12. Rheumatoid Arthritis
13. Systemic Lupus Erythematosus

LOW BACK PAIN

Definition

Acute low back pain: New episode of low back pain of < 6weeks duration.
Common-lifetime prevalence 58%
Chronic low back pain: Back pain lasting >3months

Causes of back pain

Age (Yr)	Causes		
15-30	Postural Medical Prolapse disc	Trauma Fracture Ankylosing spondylosis	Spondylolisthesis Pregnancy
30-50	Postural Prolapse disc	Discitis Spondyloarthropathies	Degnerative joint disease
>50	Postural Malignancy (Lung, Breast, Prostate, Thyroid, Kidney)	Myelanoma	Paget's disease
Other causes	Referred pain Spinal stenosis	Cauda equina tumours	Spinal infection

History

- Circumstances of pain-history of injury; duration
- Nature/severity of pain-pain/stiffness mainly at rest/at night, easing with movement suggests inflammation, e.g. discitis, spondylarthropathy
- Associated symptoms-numbness, weakness, bowel/bladder symptoms
- PMH-past illnesses (e.g. cancer), previous back problems
- Exclude pain not coming from the back (e.g. GI or GU pain)

Examination

- Deformity, e.g. kyphosis (typical of ankylosing spondylitis), loss of lumbar lordosis (common in acute mechanical back pain), scoliosis
- Palpate for tenderness, step deformity, and muscle spasm
- Assess flexion, extension, lateral flexion, and rotation whilst standing
- Ask to lie down-this gives a good indication of severity of symptoms
- In lower limbs look for muscle wasting and check power, sensory loss, and reflexes (knee jerk and ankle jerk) see table 1
- Assess Straight Leg Raise (SLR) - sciatica is present if SLR on one side elicits back/buttock pain (usually ipsilateral but can be either side) compared to SLR on the other side

Straight leg raising (SLR) test

- This test is a passive test by the practitioner. The patient lies supine with both knees extended and the ankle dorsiflexed. The affected leg is raised slowly, keeping the knee extended. If sciatica with dural irritation is present, 20° to 60° of elevation causes reproduction of pain.

'Red flags'

- <20 or >55 years
- Non-mechanical pain
- Pain that worsens when supine
- Night-time pain
- Thoracic pain
- Past history of cancer
- HIV
- Immune suppression
- IV drug use
- Taking steroids
- Unwell
- Weight decrease
- Structural deformity
- Widespread neurology (table 1)

Table 1: Neurology with lumbosacral nerve root entrapment

Root	Sensory changes	Motor weakness	Reflex changes
L2	Front of thigh	Hip flexion/adduction	None
L3	Inner thigh	Knee extension	Knee
L4	Knee extension	Foot dorsiflexion	Knee
L5	Outer shin Dorsum of foot	Knee flexion Foot inversion Big toe dorsiflexion	None
SJ	Lateral side of foot/sole	Knee flexion Foot plantarflexion	Ankle

Management of acute pain in the community

- Triage according to history and examination-see Figure 1
- FOR PATIENTS WHO DO NOT REQUIRE IMMEDIATE REFERRAL
- Prescribe analgesia, e.g. paracetamol ± NSAIDs ±amitriptyline (10-25 mg nocte) and use the Keele STarT back screening tool.

Keele STarT Back Pain Scoring Tool

- Ask patients to consider the following statements and state whether they agree or disagree with them. Thinking about the past 2weeks:
- My back pain has spread down my leg(s) at some time in the last 2 week
- I have had pain in the shoulder or neck at some time in the last 2 weeks
- I have only walked short distances because of my back pain
- In the last 2 weeks, I have dressed more slowly than usual because of back pain
- It's not really safe for a person with a condition like mine to be physically active
- Worrying thoughts have been going through my mind a lot of the time
- I feel that my back pain is terrible and it's never going to get any better
- In general, I have not enjoyed all the things I used to enjoy.
- (If the patient agrees with a statement, score 1; if disagrees, score 0)
- Overall, how bothersome has your back pain been in the last 2 weeks?
- (Not at all, slightly, or moderately- score 0, Very much or extremely- score 1)

- If total score: ≤3, explain likely natural history of the pain and advise to avoid bed rest and maintain normal activities as far as possible (decrease chance of chronic pain). Suggest self-help exercises
- If total score is ≥4, check question 5-9 sub-score:
- If: ≤3 - if not resolved in 4weeks, refer for physical therapy. Options include: back exercise classes, physiotherapy, chiropractic osteopathy, or acupuncture, if available.
- If ≥4 - if not resolved in 4weeks, refer directly for specialist intervention, sooner if worsening or severe pain
- In all cases, challenge any 'yellow flag' factors (see Figure 1) that may inhibit recovery and delay return to normal functioning
- Do not X-ray for back pain routinely
- X rays require a high radiation dose, and clinically meaningful findings are rare. Exceptions:
- Young (<25 years) - X-ray SI joints to exclude ankylosing spondylitis
- Elderly-if vertebral collapse/malignancy suspected
- History of trauma

CAUDA EQUINA SYNDROME:

- Compression of the cauda equina below L2, e.g. by disc protrusion at L4/5 presents with:
- Numbness of the buttocks and backs of thighs
- Urinary/faecal incontinence
- Lower motor neurone weakness:
- L4 -loss of dorsiflexion of the foot (and toes-L4/5)
- S1 - loss of ankle reflex, plantarflexion, and eversion of the foot

Management

- Refer/admit as a neurological emergency.
- Rapid surgical intervention increases the chance of full motor and sphincter recovery.

SPINAL CORD COMPRESSION

- Affects 5% of cancer patients -70% in the thoracic region
- Maintain a high level of suspicion if history of cancer and new back pain-especially if known bony metastases or tumour likely to metastasize to bone.

Presents with:

- Back pain, worse on movement-often appears before neurology
- Neurological symptoms/signs-
- can be non-specific, e.g. constipation, weak legs, urinary hesitancy.
- Lesions above L1 (lower end of spinal cord) produce upper motor neurone signs (e.g. increased tone/reflexes) and a sensory level;
- lesions below L1 produce lower motor neurone signs (decreased tone/reflexes) and perianal numbness (cauda equina syndrome)

Management

- Prompt treatment (<24--48 h from first neurological symptoms) is needed; once paralysed, <5% walk again.
- Treat with oral dexamethasone 16 mg/day and refer for same-day assessment and surgery/ radiotherapy unless in final stages of disease.

OSTEOPOROTIC VERTEBRAL COLLAPSE

- Causes pain, decreased height, and kyphosis
- Pain can take 3-6months to settle and requires strong analgesia.
- Calcitonin is useful for pain relief for 3months after vertebral fracture if other analgesics are ineffective.

SCOLIOSIS

- Lateral curvature of the spine associated with rotation of vertebrae ± ribs or wedging of vertebrae.
- Early treatment prevents progression and complications, e.g. cardiopulmonary disturbance.

Clinical features

- Difference in shoulder height;
- Spinal curvature;
- Difference in the space between the trunk and upper limbs.
- Scoliosis which disappears on bending is postural and of no clinical significance.

Management

- In all cases where structural scoliosis is suspected, refer for an orthopaedic opinion.
- If associated with pain, especially at night, consider spinal tumour and refer urgently.



Fig: 1 Triage of Acute Back Pain

LOW BACK PAIN

Causes

- Mechanical low back pain,
- Malignancy - primary or secondary, infection (e. spinalTB)
- ankylosing spondylosis,
- pyelonephritis or kidney stone or
- referred pain e.g. AAA

Red Flags (referred to criteria within Oxford guidance)

- Unexplained weight loss
- Previous or suspected malignancy
- Drug abuse, HIV, immunosuppression or corticosteroids use.
- Abnormal bloods (ESR >50) or fever
- Thoracic pain or night pain
- Trauma
- <20, >50 years onset (worsening or new onset)
- Disturbed gait or progressive neurological deficit
- Co-morbidity or unwell patient
- Abnormal function /controlled of bladder or bowel or saddle anesthesia
- Known osteoporosis and suspected crush fracture
- Severe morning stiffness
- Consider couda equina syndrome if on examination there is gait disturbance, urinary retention, abnormal perianal sensation or anal tone with lower limbs weakness

Yellow Flags (Psychological factors)

- A negative attitude that back pain is harmful or potential severe disabling
- Fear avoidance behaviour and reduced activity levels
- An expectation that passive, rather than active, treatment will be beneficial.
- History of depression, low mood and social withdrawal
- Social or financial problems
- <20 years – Consider HLAB27 testing for AS if morning stiffness and pain awakens the patient
- 55 years -Consider an ESR, electrophoresis (myeloma screen), urine dipstick, palpating for AAA, PSA in men and CA125 in women.
- So, should all >55 years with new onset back pain have an urgent MRI if they have no other red flags and bloods are normal. This is where clinical judgement comes in and follow local guidance.

Oxford CCG guidance	
Cauda equina and widespread neurological deficit or infection	Refer as an emergency to the spinal team
Red Flags symptoms (No mention age)	Direct referral to Urgent limited MRI
Suspected osteoporotic crush fracture only	Lateral X ray then routine MRI
No red flags and persistent pain> weeks	Review diagnosis, conservative Rx and refer to MSK assessment team
Progressive deformity(kyphosis) Intractable pain Deteriorating neurology	Review diagnosis and refer to MSK assessment team if patient will consider surgery and is a surgical candidates
Occasionally, an MRI will report that it cannot exclude malignancy in which case consider a bone scan. For simple back pain offer analgesia and exercise. Give realistic prognosis.	

-

NECK PAIN

- Neck pain is common (lifetime incidence 50%) and contributes to 2% of GP consultations. Prevalence is highest in middle age.
- Most neck pain is acute and self-limiting (within days/weeks) but 1 in 3 have symptoms lasting >6months or recurring pain.

History

- Pain-onset, site, radiation, aggravating and relieving factors, timing
- Stiffness-timing (continuous? worse in the mornings?)
- Deformity (e.g. torticollis)-onset, changes
- Neurological symptoms-numbness, paraesthesiae, weakness
- Other symptoms-weight loss, bowel/bladder dysfunction, sweats
- ! Pain is often poorly localized and neck problems commonly present with shoulder pain and/or headache (cervicogenic headache).

Examination

- Look- Posture; deformity, e.g. torticollis, asymmetry of scapulae; arms and hands-wasting, fasciculation? Leg weakness?
- Feel- Tenderness? Midline tenderness may be due to supraspinous or spinous process damage following a whiplash injury. Paraspinal tenderness± spasm radiating into the trapezius ± crepitation is common with cervical spondylosis
- Move/measure -Normal ranges: flexion/extension-130 ° total range; lateral flexion--45° in each direction from a neutral position; rotation-80 ° in each direction from a neutral position
- Neurology: Weakness in the upper limbs in a segmental distribution, with loss of dermatomal sensation and altered reflexes indicates a root lesion. If cervical cord compression is suspected, examine the lower limbs looking for up-going plantars and hyperreflexia

Red flags

- A Red Flag specific for neck pain is evidence of cervical myelopathy (the equivalent of the cauda equine syndrome). Neck pain may be absent but the syndrome should be suspected when any of the following features are present:
- sensory disturbances in upper and lower limbs;
- weakness in upper and lower limbs;
- clumsiness and gait disturbance:
- spasticity of lower limbs (upper limbs may be normal, spastic or flaccid);
- increase tendon reflexes;
- Lhermitte's sign: paraesthesiae in limbs on neck flexion indicates neck instability and warrants immediate admission.
- Refer patients with one or more Red Flags urgently for a specialist opinion.

CERVICAL SPONDYLOSIS

Clinical features

- Degenerative disease of the cervical spine can cause pain, but minor changes are normal (especially >40 yr) and usually asymptomatic.
- Pain is generally intermittent and related to activity.

Examination

- Reveals decreased neck mobility. Severe degeneration can cause nerve root signs.

Treatment

- With analgesia ± cervical collar.
- X-ray only if conservative measures fail, troublesome pain, nerve root signs, or the patient has psoriasis (? psoriatic arthropathy).

NERVE ROOT IRRITATION OR ENTRAPMENT

- Secondary to degeneration, vertebral displacement/collapse, disc prolapse, local tumour, or abscess.

Clinical feature:

- Neck stiffness, pain in arms or fingers, decreased reflexes, sensory loss, and decreased power.
- The level of entrapment can usually be determined clinically.

Treatment

- With analgesia ± cervical collar.
- ray cervical spine -lateral or oblique views.

Refer

- For physiotherapy
- Refer for further investigations (e.g. MRI) if conservative management fails and there is objective evidence of a root lesion.

Table 1. Neurology associated with cervical nerve root entrapment

Root	Sensory changes	**Motor weakness** Shoulder	Reflex changes
C5	Lateral arm	abduction/flexion Elbow flexion	Biceps
C6	Lateral forearm Thumb Index finger	Elbow flexion Wrist extension	Biceps Supinator
C7	Middle finger	Elbow extension Wrist flexion Finger extension Finger flexion	Triceps
C8	Medial side of lower forearm		None
Tl	Ring and little fingers Medial side ofupper forearm		None



https://www.physio-pedia.com/File:Screen_Shot_2017-10-12_at_15.59.19.png



Fig 1. Cervical Spine contains 8 nerves, each innervating specific areas of the upper limbs

http:I/www.painn eck.com/images/cervical-nerves.jpg

Refer urgently if there are signs of spinal cord compression:

- Root pain and lower motor neurone signs at the level of the lesion, *and*
- Spastic weakness, brisk reflexes, upgoing plantars, loss of coordination and sensation below the lesion

SPASMODIC TORTICOLLIS (WRY NECK)

- Common.
- Sudden onset of painful stiff neck due to spasm of trapezius and sternocleidomastoid muscles.
- Self-limiting.
- Heat, gentle mobilization, muscle relaxants, and analgesia can speed recovery.
- A cervical collar may help in the short term but can prolong symptoms. Often caused by poor posture, e.g. computer-seating position; carrying heavy, uneven loads.

CERVICAL RIB

- Congenital condition of C7 vertebra costal process enlargement.
- Usually asymptomatic but can cause thoracic outlet compression → hand or forearm pain, weakness or numbness, and thenar or hypothenar wasting.
- Radial pulse may be weak.
- X-ray of thoracic outlet may show cervical rib-but symptoms are sometimes due to fibrous bands that are not seen on X-ray.

REFER to upper limb orthopaedic surgeon for further assessment.

WHIPLASH INJURIES

- Neck pain resulting from stretching or tearing of cervical muscles and ligaments due to sudden extension of the neck-often due to a RTA.
- Pain and decreased neck mobility typically starts several hours or days after injury.
- Pain may radiate to shoulders, arms, and head.

Management

- Examine carefully to exclude bony tenderness requiring X-ray.
- Treat with analgesia and early mobilization-collar may help initially but avoid long- term use.
- Recovery is often slow and 40% patients suffer long-lasting symptoms.
- As a general rule of thumb, the quicker the symptoms develop, the longer they will take to disappear.
- Early physiotherapy, if available, can improve recovery rate.
- Psychological problems and medicolegal issues can affect progress.
- Daily Stretching and Strengthening Exercises: Advise the patient to hold the neck for 10 seconds in each of the six positions (right and left lateral flexion and rotation, flexion and extension within the pain range. Repeat 10 times.

Reference:

1. *Oxford handbook of General Practice, 4th Edition*
2. *Alex Khat Andrew Polmear Practical General Practice, 4th Edition*

SHOULDER PROBLEMS

Relevance to GP

- Shoulder pain is responsible for approximately 16% of all musculoskeletal complaints and has a yearly incidence of 15 new episodes per 1,000 patients seen in the primary care setting; an estimated20% of the population will suffer an episode of shoulder pain during their lifetime.
- Shoulder pain is second only to low back pain in patients seeking care for musculoskeletal ailments in the primary care setting.
- Peak incidence of shoulder pain occurs during the fourth through sixth decades but can affect all patients, young and old, particularly athletes

Definition:

- Shoulder pain is defined as pain that is localized to the shoulder joint. It can have a primary (shoulder joint) or secondary (referred or systemic) etiology.



Fig. Anatomy of the shoulder joint.

History

- Pain and stiffness joint pain is felt anteriorly and may radiate down the arm; pain on top of the shoulder suggests acromioclavicular joint problems or cervical spine disorders.
- Pain in the shoulder may be referred from the neck, heart, mediastinum, or diaphragm
- Deformity, swelling of the shoulder; prominence of the acromioclavicular (AC) joint;
- winging of the scapula
- Loss of function Difficulty reaching behind back (e.g. doing up brastrap), brushing hair, or dressing

Examination

- Look: Posture; asymmetry; muscle wasting; swelling (large effusions can be seen anteriorly); scars
- Feel: Tenderness; warmth; swelling; crepitus

- Move/measure: Compare sides. Check range of movement; complex movements (e.g. scratching opposite scapula in 3 ways, hands behind head, arm across front of chest to top of opposite shoulder); power

Special test

- Liff off test (to diagnose rotator cuff problems)
- Drop arm test (to diagnose rotator cuff problems)
- Empty can test (supraspinatous tendon problems)
- Yergason' s test (bicep tendonitis)
- *General rules:* Intra-articular disease - painful limitation of movement in all directions; tendonitis - painful limitation of movement in one plane only; tendon rupture or neurological lesions - painless weakness.

Differential Diagnosis of the Patient with Shoulder Pain

Diagnosis	Typical Features	Frequency in Family Diagnosis Typical Features Medicine Clinic
Rotator cuff disorders (tendinopathy, partial tears, complete tears)	Often associated with repetitive overhead shoulder activities (Partial tears most common at older than age 40 years (10) • *Complete tears most common at older than age 60 years (10)* • *Pain localized to the deltoid region* • *Pain worse with overhead activities and at night (11)* • *Pain and or weakness of the rotator cuff muscles on manual testing* • *Positive impingement tests*	Very common
Adhesive capsulitis	Pain with progressive loss of both active *and* passive range of motion • Associated with diabetes, females, and middle decades of life (40–60 years)	Common
Shoulder joint arthritis	Acromioclavicular joint arthritis: • All ages with history of repetitive overhead lifting or heavy arthritis: common weight training • Pain localized to superior aspect of shoulder (acromioclavicular joint) • Pain worse at night and with cross body movements • Tenderness at acromioclavicular joint on exam as well as with cross body adduction testing	Acromioclavicular joint : common
	Glenohumeral joint arthritis: • Most common over age of 60 years • History of trauma, rheumatologic disease • Deep, diffuse pain localized to shoulder region • Loss of passive range of motion in more advanced cases, can be confused for adhesive capsulitis	Glenohumeral arthritis: rare
Shoulder instability	• Most common in young patients and athletes • Often prior history of acute shoulder injury or fall with frank young patients and dislocation or sensation of "pop" or "shift" in the shoulder athletes • Dislocation/subluxation most commonly occurs with arm in an abducted and externally rotated position • Positive apprehension test	Common, particularly young patients and athletes

Referred Shoulder Pain

• Hand	• Carpal tunnel
• Neck	• Cervical radiculopathy, muscle spasm
• Thoracic spine	• Myofascial pain (trapezius, rhomboid, levator scapulae)

• Chest	• Cardiac pain from MI (referred to left shoulder)
	• Pneumothorax (patient also c/o acute onset of dyspnoea)
	• Aortic dissection/aneurysm (pain between the scapulae)
• Abdomen	• Diaphragmatic irritation (gall bladder to right scapula, diffuse process to shoulder)
• Other	• Polymyalgia rheumatic, completx regional pain syndrome)

•

Red Flags for Patients with Shoulder Pain Indicating More Serious Disease

• Red Flags	• Associated Conditions
• Fever, chills, redness of joint, intravenous drug use, immune deficiency	• Glenohumeral joint infection
• Anorexia, Weight Loss	• Malignanc y (primary or metastatic)
• Persistent shoulder pain in children <8 years or in elderly without history of trauma or overuse	• Malignancy, especially sarcoma in elderly (rare)
• Profound shoulder weakness	• Massive rotator cuff tear
• Fall or trauma	• Fracture or large rotator cuff tear (particularly in elderly)
• Multiple joint involvement with effusion	• Auto-immune etiology
• Numbness, tingling or radiation of pain past elbow	• Cervical etiology
• Muscle atrophy	• Peripheral nerve injury

Causes of a stiff, painful shoulder joint

- Adhesive capsulitis- primary or secondary to DM or intrathoracic pathology
- Inflammation - inflammatory arthritis (e.g. RA, psoriatic), infection
- Osteoarthritis
- Prolonged immobilization, e.g. haemiplegia, strapping after dislocation
- Polymyalgia rheumatic

SHOULDER OA

- Often occurs after a history of trauma. Less common than knee or hip OA. Often associated with crystal-induced inflammation and secondary causes of OA (e.g. gout, haemochromatosis).
- Imaging for synovitis (USS/MRI) is important to rule out disease that may benefit from
- Steroid injection.
- Shoulder replacement may be considered in severe cases.

FROZEN SHOULDER (ADHESIVE CAPSULITIS)

- Over diagnosed in primary care. Affects patients aged 40-60years.
- Painful, stiff shoulder with global limitation of movement -notably external rotation. Pain is often worse at night.
- Cause unknown, but increased in diabetics and those with intrathoracic pathology (MI, lung disease) or neck disease.

Management

- If not known to be diabetic, check fasting blood glucose.
- NSAIDs, physiotherapy, and local steroid injection can all be helpful. May take > 1year to recover and long-term outcome is uncertain.
- If restricted movements are slow to return consider orthopaedic referral.

ROTATOR CUFF INJURY

- The shoulder is the most mobile joint in the body and relies on the musculo-tendinous rotator cuff to maintain stability.
- Disorders of the rotator cuff account for most shoulder pain.
- *Acute tendinitis* Often caused by excessive use/trauma in patients<40years.
- Presents with severe pain in the upper arm. Patients hold the arm immobile and are unable to lie on the affected side. Usually starts to resolve spontaneously after a few days. In middle age can be causedby inflammation around calcific deposits-requires steroid injection
- *Rotator cuff tears* may accompany subacromial impingement pain and is difficult to diagnose clinically unless the tear is large-suspect if impingement pain is recurrent. Refer
- Subacromial impingement. Pain occurs in a limited arc of abduction (60-120°-
- *painful arc syndrom e)* or on internal rotation due to acromial or ligament pressure on a damaged rotator cuff tendon. In patients<40years, associated with glenohumeral instability from generalized connective tissue laxity or labral injury. In older patients, often due tochronic rotator cuff tendinitis or functional cuff weakness/tear

Investigations:

- X-ray may show calcification of the supraspinatus tendon in acute tendinitis and irregularities/cysts at the humeral greater tuberosity if chronic cuff tendinitis.

Treatment

- Rest followed by mobilization and physiotherapy, NSAIDs, and/or subacromial steroid injection.
- If conservative measures fail, refer for imaging, arthroscopy, and consideration for surgery.

SHOULDER DISLOCATION

- Usually due to fall on arm or shoulder - anterior dislocation is most common. Shoulder contour is lost (flattening of deltoid) and the head of the humerus is seen as an anterior bulge.
- Axillary nerve may be damaged. It cause absent sensation on a patch below the shoulder.
- Refer to A&E for X-ray and reduction.
- In young patients, 30% have recurrent dislocations afterwards due to labral tear. Dislocation is associated with rotator cuff tear in 25% of elderly patients.

Recurrent dislocation:

- Usually anterior and follows trauma- but 5%recurrent dislocations are in teenagers with no trauma but general joint laxity. Refer for specialist physiotherapy and consideration of surgery.

ACROMIOCLAVICULAR JOINT PROBLEMS

- Pain on the top of the shoulder or in the suprascapular area suggests a problem with the acromioclavicular (AC) joint or neck.
- AC joint pain is usually due to trauma or OA - joint tenderness and pain are present on palpation and passive horizontal adduction.

Management:

- NSAIDs ± local steroid injection.

SHOULDER PAIN

- The three joints of the shoulder – Sternoclavicular, acromioclavicular and glenohumeral joint.
- The four rotator cuff muscles:
- Supraspinatus (initiation of adduction)
- Infraspinatus (external rotation)
- Subscapularis (internal rotation)
- Teres minor (external rotation)
- These joint together to form the rotator cuff tendon which travels through the sub-acromial space.
- Rotator cuff tendonitis
- It is where inflammation which causes impingement (where the tendon becomes trapped.) reduces the range of movement, hence a painful arc.
- For example, if there is a supraspinatus tendonitis there is compression of supraspinatus tendon between the humeral head and acromion

Causes

- Tendonitis secondary to an injury or repetitive strain or calcium deposits.
- Subacromial space narrowing: bony spurs from wear and tear or enlargement of bursa.
- As USS may be helpful to diagnose and guide a steroid injection.
- It may also diagnose tears in the rotator cuff tendons, some of which may require surgical repair.
- Most tendonitis settles with rest. Physio and NSAID/ steroid injection. Occasionally, (e.g if chronic /bony spur) arthroscopic decompression is necessary.

FROZEN SHOULDER (ADHESIVE CAPSULITIS)

- It is generalized inflammation within the capsule, which cause pain and limits any ROM of the glenohumeral joint.
- It usually affects the non dominant shoulder. Frozen shoulder may occur after rotator cuff injury or spontaneously and cause is unknown.
- There are typically three phases:
- Painful freezing stage – most painful stage with gradual loss of movement, may last up to 9 months.

- Frozen/Adhesive stage – reduced movement but less painful, last up to 1 year
- Thawing/ Recovery phase -gradual return to normal function which may take 1-3 years.
- Tell patients that symptoms may last between 1 months and 3 years, although the vast majority of patients have recovered by 2 years.
- The treatment is physiotherapy.
- A steroid injection may be helpful within the first 8 weeks.
- Patients with diabetes or thyroid conditions have an increased risk of a bilateral frozen shoulder.
- Osteoarthritis:
- In an older patient it may be helpful to see if there is OA present.
- Dislocations
- usually occur after an impact injury.
- Consider referred pain from the diaphragm (ruptured ectopic pregnancy) or heart (MI).
- If you are ever giving a PII then describe what is on it!
- If unable to abduct the shoulder the first 10 degrees, consider a complete tear of the supraspinatus and speak to a specialist about ranging a clinical appointment.

References

1. *Chantal Simon; et.al, Oxford handbook of General Practice-Fourth edition,2014*
2. *Philip D. Sloane MD; et.al, Essential of Family Medicine- Sixth edition,2012*

-

ELBOW PROBLEMS

DIAGNOSTIC WORKUP

History

- Pain and stiffness: Joint pain is diffuse; pain well localized over the medial or lateral epicondyles may be due to tendinitis
- Deformity: Swelling? Nodules? Structural deformity?
- Loss of function: May be limitation of flexion, extension, pronation, and/or supination. This can affect function, e.g. causing difficulty eating (can't get hand to mouth) or with personal care.
- Neurology: Numbness and paraesthesiae distal to the elbow - particularly in the ulnar nerve distribution

Examination

- Look Carrying angle (11o for male 13° for female). Effusion may be visible either side of the olecranon. A discrete swelling over the olecranon could be RA nodule, gouty tophus, olecranon bursa, or other nodule. Check for muscle wasting
- Feel: Tenderness? Swellings? Warmth? If indicated test neurology and check pulses distal to the elbow.
- Move Active and passive movements. Compare both sides. Normal range is from 0° in full extension to 145° in full flexion. Check pronation/supination. Normal range is 75° and 80° respectively.

TENNIS ELBOW AND GOLFER'S ELBOW (EPICONDYLITIS)

- Common extensor tendon inflammation at the epicondyle
- CAUSE: repeated strain.
- Tennis elbow - tenderness over the lateral epicondyle and lateral elbow pain on resisted wrist extension

Lateral tennis elbow: typical clinical profile

- Age:40-60 years
- Occupation: Carpenter, bricklayer, housewife, gardener, dentist, violinist, Sport Tennis, squash
- Symptoms: Pain at outer elbow, referred down back of forearm. Rest pain and night pain (severe cases). Pain in the elbow during gripping hand movements (e.g. turning on taps, turning door handles, picking up objects with grasping action, carrying buckets, pouring tea, shaking hands)
- Signs: No visible swelling
- Localised tenderness over lateral epicondyle, anteriorly Pain on passive stretching wrist
- Pain on resisted extension wrist and third finger

Normal elbow movement



https://upload.wikimedia.org/wikipedia/commons/b/bb/Tennis_Elbow.png



https://blog. wimi-fitness .com/ wp-content /uploads/ 20 16/ 06/ tennis-elbow-test- 2. jpg
https://blog.wimi-fitness .com/ wp-content /uploads/ 20 16/ 06/ tennis-elbow-test-3.jJpg

- Course: 6 to 24 months

Management basic:

- rest from offending activity
- RICE and oral NSAIDs if acute (RICE: rest, ice, compression, elevation)
- exercises-stretching and strengthening
- Additional (if refractory):
- corticosteroid/LA injection (max. two)
- Manipulation
- Surgery

GOLFER'S ELBOW

- Tenderness over the medial epicondyle and medial elbow pain on resisted wrist pronation.
- The pain is felt on the inner side of the elbow and does not radiate far.
- The main signs are localised tenderness to palpation and pain on resisted flexion of the wrist.



https://upload. wikimedia .org/ wikipedia/commons/3/31/ Golfers-Elbow_ SAG.jpg

Management

- Stop trigger movements if possible. Often settles with time ± NSAIDs. Recovery is speeded by local steroid injection although relapse is more common after injection. Physiotherapy may help, as may an epicondylar clasp.
- Exercises: Stretching and strengthening exercises for the forearm muscles represent
- the best management for tennis elbow. Three options are presented:
- With the arm extended, grasp the towel with the affected side placed in neutral.
- Then exert maximum wring pressure: first flexing the wrist for 10 seconds, then extending the wrist for 10 seconds. This is an isometric 'hold' contraction. This exercise should be performed only twice a day, initially for 10 seconds in each direction. After each week increase the time by 5 seconds in each twisting direction until 60 seconds is reached (week This level is maintained indefinitely.
- Note: Despite severe initial pain, the patient must persist, using as much force as possible. Review at 6 weeks to check progress and method.
- *'Weights' exercise.* The muscles are strengthened by the use of hand-held weights or dumbbells.
- A suitable starting weight is 0.5 kg, building up gradually (increasing by 0.5 kg) to 5kg, depending on the patient.

Method

- To perform this exercise the patient sits in a chair beside a table.
- The arm is rested on the table so that the wrist extends over the edge.
- The weight is grasped with the palm facing downwards in lateral epicondyltis and upwards in medial epicondylitis
- The weight is slowly raised and lowered by flexing and extending the wrist.
- The flexion/extension wrist movement is repeated 10 times, with a rest for 1
- minute, and the program is repeated twice.
- The pronating exercise. A suitable stretching exercise is to rhythmically rotate the hand and wrist inwards with the elbow extended and the forearm pronated.

DISLOCATED ELBOW

- Usually due to fall on outstretched hand with flexed elbow. Ulna is displaced backwards,
- elbow is swollen and held in fixed flexion. May have associated fracture. Refer to hospital for reduction.

OLECRANON BURSITIS

- Olecranon bursitis presents as a swelling localised to the bursa (which has a synovial membrane) over the olecranon process. The condition may be caused by trauma, arthritic conditions (rheumatoid arthritis and gout) or infection.
- Traumatic bursitis may be caused by a direct injury to the elbow or by chronic friction and pressure as occurs in miners (beat elbow), truck drivers or carpet layers.
- Acute olecranon bursitis with redness and warmth can occur in rheumatoid arthritis, gout, pseudogout, haemorrhage and infection (sepsis). Septic bursitis must be considered where the problem is acute or subacute in onset. Aspiration of the bursa contents with appropriate laboratory examination is necessary (smear, Gram stain, culture and crystal examination).
- Treatment depends on the cause.

ULNAR NEURITIS

- Narrowing of the ulnar grove (from OA, RA, or post-fracture) causes pressure on the ulnar nerve and ulnar neuropathy.
- Clumsiness with the hand is often the first symptom, then weakness wasting of hand muscles innervated by the ulnar nerve and decreased sensation in the little finger and medial half of the ring finger. Rule out metabolic and autoimmune causes of a mononeuritis and refer for consideration of surgical decompression ± nerve conduction studies if entrapment is likely

PULLED ELBOW

- Common in children <5years.
- Traction injury to elbow causes subluxation of radial head.
- Often occurs when the child is pulled up suddenly by the hand. Child will not use the arm. No clinical signs. M > F. Left arm > right.
- Xrays are unhelpful.

Management

- Apply anterior pressure with the thumb on the radial head whilst supinating and extending the forearm. Immediate recovery is seen after reduction.

Reference

1. *Oxford handbook of General Practice (4th Edition)*
2. *John Murtagh 's General Practice (6th Edition)*

KNEE PROBLEMS

- DIAGNOSTIC WORKUP

History

- Trauma: History of injury - ask about degree and direction of force.
- Pain/stiffness: Attempt to distinguish well-localized mechanical pain and diffuse inflammatory/degenerative pain
- Deformity: Swelling? If injury, time of onset of swelling in relation to history (immediate effusion suggests haemarthrosis; post-traumatic effusions appear later). Knock-knees or bow-legs?
- Age-related causes of painful knee
- First decade (0-10 year)
- Infection
- Juvenile chronic arthritis
- Second decade (10-20 years)
- Patellofemoral syndrome
- Subluxation/dislocation of patella
- Slipped femoral epiphysis (referred)
- 'Hamstrung' knee
- Osteochondritis dissecans
- Osgood-Schlatter disorder
- Anserinus tendonopathy
- Third decade (20-30 years)
- Bursitis
- Mechanical disorders
- Fourth and fifth decades (30-50 years)
- Cleavage tear of medial meniscus
- Radial tear of lateral meniscus
- Sixth decade and older (50 years & over)
- Osteoarthritis
- Osteonecrosis
- Paget disease (femur, tibia or patella)
- Anserinus bursitis
- Chondrocalcinosis and gout
- Osteoarthritis of hip (referred pain)

Examination

- Always compare the two knees.
- Look: Watch the patient walk. Look at the knees whilst standing - varus/valgus deformity?
- Ask: the patient to lie down. Note quadriceps wasting, scars, skin changes, swelling, and deformity. A space under the knee viewed laterally suggests a fixed flexion deformity. With legs extended, lift both feet off the bed to demonstrate hyperextension.
- Feel: Feel the quadriceps for wasting and palpate the knee for warmth. Check the joint line, collateral ligaments, tibial tubercle, and femoral epicondyles for tenderness.
- Palpate: the popliteal fossa for a Baker's cyst. Check for an effusion. Test for patellofemoral lesions by sliding the patella sideways across the underlying femoral condyles.

- Move: With the patient lying on his back check active and passive range of movement
- pain reproduced on movement? Crepitus? Test the medial and lateral collateral ligaments and cruciate ligaments.
- NB. Knee pain can be referred from the hip so examine the hip as well.

OSTEOARTHRITIS OF THE KNEE

- Very common

Symptoms

- Usually appear in middle life or later. It is more common in women, the obese, and in those with knee deformities (e.g. genu varum) or previous trauma, especially meniscal tears.
- The degenerative changes may involve either the lateral or the medial tibiofemoral compartment, the patellofemoral joint or any combination of these sites.

Diagnosis

- Confirmed by X-ray (weight-bearing view)

Treatment:

- Education
- Relative rest
- Weight loss
- Analgesics and/or judicious use of NSAIDs
- Walking aids and other supports
- Physiotherapy (e.g. hydrotherapy, quadriceps exercises, mobilisation and stretching techniques
- Intra-articular injections of corticosteroids are generally not recommended but a single injection for severe pain can be very effective.
- Surgery is indicated for severe pain and stiffness and, especially for the medial compartment with focal arthritis and varus deformity.

INFECTION OF THE KNEE JOINT (SEPTIC ARTHRITIS)

- Most commonly infected joint. Septic (pyogenic) arthritis should be suspected when the patient complains of intense joint pain, malaise and fever.

Signs:

- Hot, red, swollen, painful knee.

Differential diagnosis:

- Reiter's disease,
- gout,
- pseudo gout,
- traumatic effusion,
- RA.
- If infection is suspected refer as an emergency to rheumatology or orthopaedics.

RHEUMATOID ARTHRITIS

- The knee is frequently affected by rheumatoid arthritis (RA) although it rarely presents as monoarticular knee pain.
- RA shows the typical features of inflammation - pain and stiffness that is worse after resting. Morning stiffness is a feature.
- *Note:* The spondyloarthropathies have a similar clinical pattern to RA. Synovectomy is a
- useful option with persistent boggy thickening of synovial membrane but without destruction of the articular cartilage.

BIPARTITE PATELLA

- Detected on X-ray. Usually asymptomatic incidental finding but can cause pain due to excessive mobility of a patella fragment.
- If troublesome refer for fragment excision.

PATELLAR DISLOCATION

- Lateral dislocation of the patella and tearing of the medial capsule/quadriceps can occur due to trauma. More common in young people and if joint hypermobility syndrome, patient is in pain and unable to flex knee.
- REFER to Accident and Emergency Department or orthopaedics for reduction.

RECURRENT SUBLUXATION OF THE PATELLA

- Medial knee pain+ knee 'gives way' due to lateral subluxation of the patella Most common in girls with valgus knees
- ASSOCIATIONS: familial, hypermobility, high-riding patella.

Signs:

- increased lateral patella movement and +ve apprehension test (pain and reflex contraction of quadriceps on lateral patella pressure).

Refer

- to physiotherapy for vastus medialis exercises.
- If that is unhelpful, refer to rheumatology to exclude a hereditary connective tissue disorder and/or to orthopaedics for consideration of lateral retinacular release.

PATELLA TENDINITIS

- Small tear in the patella tendon causes pain. Most commonly seen in athletes.

Differential

- includes inferior patellar pole enthesitis (spondylarthropathies), fat-pad syndrome, anterior cartilage lesion, and bursitis.

Diagnosis *is with USS.*

Treatment

- is with rest,
- NSAIDs ±steroid injection around (not into) the tendon.

BURSITIS

- Prepatellar bursitis (housemaid's knee) is associated with excess kneeling.
- Vicar's knee (infrapatellar bursitis) is associated with upright kneeling.
- Educate to avoid aggravating activity, and refer orthopaedics. .

BAKER'S CYST

- A popliteal cyst (Baker cyst) is a herniation of a chronic knee effusion between the heads of the gastrocnemius muscle and usually is associated with osteoarthritis (most common), rheumatoid arthritis or internal derangement of the knee.
- It presents as a mass behind the knee and may or may not be tender or painful. It tends to fluctuate in size.
- A Baker's cyst indicates intra-articular pathology and indicates a full assessment of the knee joint
- Rupture may result in pain and swelling in the calf, mimicking DVT.
- Treat underlying knee inflammation (synovitis). Surgical removal of the cyst is advisable for persistent problems.

COLLATERAL LIGAMENT INJURY

- Common in contact sports. Causes knee effusion if severe ± tenderness over the injured ligament. Collateral ligaments provide lateral stability to the knee.
- Normally there is <5° of movement - if >5° the ligament may be ruptured.
- TREAT with rest, knee support, analgesia.
- REFER to orthopaedic surgeon if rupture is suspected.

CRUCIATE LIGAMENT INJURY

- Cruciate ligaments provide anterior/ posterior knee stability.
- Assessment can be difficult.

ANTERIOR CRUCIATE TEARS

- Result from a blow to the back of tibia ± rotation when the foot is fixed on the ground.
- Signs: effusion and positive drawer test (supine with foot fixed and knee at 90°, pull the tibia forward test is positive if the tibia moves forward on the femur)

POSTERIOR CRUCIATE TEARS

- Cause: e.g. when the knee hits the dashboard in car accidents.
- Reverse drawer test is positive (supine with knee at 90°; apply pressure to push the tibia backwards-test is positive if the tibia moves backward on the femur)

Management

- Refer to orthopaedics if suspected.
- Splinting and then physiotherapy helps most (60%) but some require reconstructive surgery-consider urgent referral if keen sportsman.

LOOSE BODIES IN THE KNEE

- May result in locking of the joint and/or effusion.
- CAUSES: OA, chip fractures, osteochondritis dissecans, synovial chondromatosis.
- If problematic refer for removal.

OSTEOCHONDRITIS DISSECANS

- Necrosis of articular cartilage and underlying bone can cause loose body formation. Cause is unknown.
- Seen in young adults and pain after exercise and intermittent knee swelling ± locking. Predisposes to arthritis.
- REFER for expert management.

MENISCAL LESIONS

- Twisting with the knee flexed can cause medial (bucket handle) meniscal tears and adduction with internal rotation can cause lateral cartilage tears.

Symptoms/signs:

- Locking of the knee-extension is limited due to cartilage fragment lodging between the condyles
- Giving way of the knee
- Tender joint line
- Positive McMurray's test-rotation of the tibia on the femur with flexed knee followed by knee extension causes pain and a click, as the trapped cartilage fragment is released. X ray reliability of this test is debated

Management

- Refer for investigation and treatment.

MENISCAL CYST

- Pain+ swelling over the joint line due to a meniscal tear. Lateral cysts are more common than medial. The knee may click and give way.
- Refer to orthopaedics.

CHONDROMALACIA PATELLAE

- Common in teenage girls. Pain on walking up or down stairs or on prolonged sitting.
- SIGNS: pain on stressing the undersurface of the patella.
- TREAT with analgesia+ physiotherapy (vastus medialis strengthening decrease pain in 80%). If persistent, exclude spondylarthropathy and refer to orthopaedics.

OSGOOD-SCHLATTER DISEASE

- Seen in athletic teenagers. Pain and tenderness ± swelling over the tibial tubercle. X-rays not required.
- Avoid aggravating activities.

- Usually settles over a few months. If not settling refer to orthopaedics or rheumatology for further assessment.

BOW-LEGS AND KNOCK-KNEES IN CHILDREN

GENUVARUM (BOW-LEGS)

- Outward curving of the tibia usually associated with internal tibial torsion. Except in severe cases always resolves spontaneously.
- Severe cases raise the possibility of rickets or other rare developmental disorders-refer for orthopaedic opinion.

GENUVALGUM (KNOCK-KNEES)

- Common amongst 2--4years olds.
- Innocent if symmetrical and independent of any other abnormality. Severe, progressive cases suggest rickets-refer for X-ray.

Principles of management

- Most painful knee conditions are not serious and, providing a firm diagnosis is made and internal knee disruption or other serious illness discounted, a simple management plan as outlined leads to steady relief For more serious injuries the primary goal is to minimise the adverse consequences of forced inactivity.
- First aid: RICE (avoid heat in first 48 hours).
- Lose weight if overweight.
- Adequate support for ligament sprains- supportive elastic tubular (Tubigrip) bandage or a firm elastic bandage over Velband.
- Simple analgesics-paracetamol (acetaminophen).
- Judicious use ofNSAIDs and corticosteroid injections.
- Physiotherapy to achieve strength and stability.
- Attend to biomechanical abnormalities, inappropriate footwear and athletic techniques.
- Orthotics and braces to suit the individual patient.
- Quadriceps exercises: these simple exercises are amazingly effective.

Quadriceps exercises (examples)

- Instruct the patient to tighten the muscles in front of the thighs (as though about to lift the leg at the hip and bend the foot back but keeping the leg straight). The patient should hold the hand over the lower quadriceps to ensure it is felt to tighten. This tightening and relaxing exercise should be performed at least 6 times every 2 hours or so until it becomes a habit.
- It can be done sitting, standing or lying.
- Sitting on a chair the patient places a weight of 2-5 kg around the ankle (e.g. a plastic bag with sand or coins in a sock) and lifts the leg to the horizontal and then gently lowers it (avoid in patellofemoral problems).

When to refer

- Early referral is required for knees 'at risk' following acute injuries where one or more of the followings are present:
- locked knee
- Haemarthrosis
- Instability
- Clinical evidence of a tom cruciate ligament, third degree tear of the collateral ligaments or tom meniscus

- Undiagnosed acute or chronic knee pain
- Recurrent subluxation or dislocation of the patella
- Suspected septic arthritis
- Presence of troublesome intra-articular loose body
- Severe pain and stiffness and, especially for the medial compartment with focal arthritis and varus deformity of OA knee.
- Knee pain
- Osteoarthritis

Diagnosis

- Diagnose osteoarthritis clinically without investigations if a person:
- Is 45 or over and
- Has activity-related joint pain and
- Has either no morning joint-related stiffness or morning stiffness that lasts no longer than 30 minutes
- Atypical features include history of trauma, prolonged morning joint related stiffness, rapid worsening of symptoms or the presence of a hot swollen joint.

Differential diagnosis

- Gout
- Septic arthritis
- Inflammatory arthritis
- Malignancy
- Injury from trauma
- NICE advises a holistic assessment of a person with OA:
- social situation and impact,
- health beliefs,
- mood,
- quality of sleep,
- support network,
- other MSK pain,
- attitudes to exercise,
- influence of comorbidity and
- a full pain assessment.

GP management options include:

- NSAIDs
- Muscle strengthening exercise
- Advice about aerobic fitness and foot wear
- Physiotherapy
- Steroid injections
- Consider additional needs for TENS or aid.

When to consider surgery

- Mechanical locking or loose bodies on X ray for arthroscopic larvae and debridement.
- After at least three core (non-surgical) treatment option
- (Basic core treatment – weight loss, appropriate exercise, suitable footwear)
- Symptoms causing a significance impact on life or ongoing functional limitation

ANTERIOR CRUCIATE LIGAMENT INJURY

Mechanism

- Most commonly associated with a non-contact mechanism – knee in and toe out.
- The risk is greater in female.

Injury triad

- Anterior cruciate ligament + medial collateral ligament +medial meniscus
- Acute injury
- Refer acute injuries to orthopaedics for assessment, imaging and management options.
- NB: Immediate effusions following trauma / injury are often due to haemarthrosis which is associate with more significant joint injuries.
- Have a low threshold for referral of such cases (possibly same day or urgently to trauma /fracture clinic).
- If presenting as a chronic injury, you may be able to refer for direct access MRI to guide diagnosis and management.
- Check local protocols.

Reference

1. *Oxford handbook of General Practice, 4th Edition*
2. *John Murtagh's General Practice, 6th Edition*

ACUTE ANKLE INJURY

- The Ottawa Ankle Rule reduces the need for X-rays following ankle injury by 30-40% (see Table). Note that the rule is very good at identifying patients who do not need an X-ray (high sensitivity). It is poor at identifying those who have a fracture (low specificity). An ankle X- ray is required if there is any pain in the malleolar zone and:
- there is bone tenderness at the posterior edge or tip of the lateral malleolus; or
- there is bone tenderness at the posterior edge or tip of the medial malleolus; or
- the patient is unable to weight bear both at injury and when seen.

Figure 5. The Ottawa Ankle Rules for ankle and midfoot injuries.



a) An ankle x-ray series is only required if:
There is any pain in malleolar zone and any of these findings:
i) bone tenderness at A ***or***
ii) bone tenderness at B ***or***
iii) inability to bear weight both immediately and in the ED

b) A foot x-ray series is only required if:
There is any pain in midfoot zone and any of these findings:
i) bone tenderness at C ***or***
ii) bone tenderness at D ***or***
iii) inability to bear weight both immediately and in the ED

Reproduced with permission from: Michael JA, Steill IG. Ankle injuries. In: Tintinalli JE, Kelen GD, Stapczynski JS, eds. *Emergency Medicine: A Comprehensive Study Guide*. New York: McGraw-Hill; 2000:1828. Figure 268-2.

Figure 5.The Ottawa Ankle Rules for ankle and midfoot injuries.

- An ankle x-ray series is only required if:
- There is any pain in malleolar zone and any of these findings:
- bone tenderness at A or
- bone tenderness at B or
- inability to bear weight both immediately and in the ED
- b)A foot x·ray series is only required if:
- There is any pain in midfoot zone and any of these finding!.:
- bone tenderness at C or
- bone tenderness at D or
- inability to bear weight both immediately and in the ED
- Reproduced with permission from:Michael JA,SteiiiiG. Ankle Injuries. In:Tlntlnalll JE. Kelen GO.Stapczynskl JS,eds.Emergency
- Mea/cine:A Comprehensive Stuay Gulae.New York: McGraw-Hill;2000:1828.Figure 268-2 .
- https://meds .queensu. ca/central/assets/moduleslreproducibility !The_Ottawa_Ankle_ RulesJar_ ankle_and_midfo ot_injuries_Emegency_Medicine _Practice _l.JPG

Table: Reliability of the Ottawa Ankle Rules for identifying ankle and foot fractures or avulsion fractures			
Patients Groups	Sensitivity (95%Cl)	Specificity (Interquartile Range)	LR-
All patients	96% (94 to 99 %)	26% (19 to 34 %)	0.10
Ankle injuries	98% (96 to 99 %)	40% (30 to 48 %)	0.08
Midfoot injuries	99% (97 to 100 %)	38% (25 to 70 %)	0.08
LR - is the likelihood ratio for a negative result.			

- A foot X-ray is required if there is pain in the midfoot zone and:
- there is bone tenderness at the navicular; or
- there is bone tenderness at the base of the 5th metatarsal; or
- patient is unable to weight bear both at injury and when seen.
- The immediate treatment of an ankle sprain (as for any injured joint or limb) is RICE (rest, ice, compression, elevation). Of these, compression appears to be the most important and, with elevation, must be maintained for at least 48 hours. Ice should be applied no more than 20 minutes at a time, three times a day and the skin should be separated from the ice by a wet towel. It is an approach based on experience rather than evidence.
- Analgesia, support with mobilization, immobilization and surgical repair are all used in inversion injuries of the ankle. There is no robust evidence to guide the clinician in their use although the use of support and early mobilization seems to result in faster recovery and better long-term outcome.
- Rehabilitation after ankle injuries
- Recommend active mobilization to restore proprioception. This can be achieved by regular exercises:
- imagine writing the alphabet with the foot, first capitals then small letters;
- balance on the injured leg while moving the free leg forward and backward and side- to-side; initially with eyes open then with eyes shut;
- use a wobble board.

FOOT PAIN

Differential diagnosis of foot pain

• Soft tissue	• Chronic heel pad inflammation	• Warm dull throbbing pain over weight bearing area of the heel → worse when first getting up
	• Acute synovitis	• Throbbing pain made worse by • Movement → rule out systemic causes
	• Acute inflammation of anterior metatarsal heads	• Common in women wearing slip-on / heeled shoes → burning and throbbing on walking
	• Planter metatarsal bursitis	• Throbbing pain under metatarsal head → persist at rest and exacerbated when the area if first loaded
• Bone	• Fracture	• Has there been impact? Use the Ottawa rules.
	• Stress fracture (march fracture)	• Palpable tender lump
	• Osteoarthritis	• Common at first MPjt, tarsus joint and mid foot
	• Rhematoid arthritis	• Swelling and deformity, may describe walking on pebbles due to swelling/subluxation
	• Sever's disease	• e.g boys 8 -13 years and exacerbated by jumping
	• Hallux valgus	• Great toe moves towards /overlies the 2nd toe
	• Bunion	• Inflamed and painful metatarsal head
• Red hot	• Gout / septic arthritis	• Requires urgent aspiration /culture/ Rx
• Nerve	• Morton/s neuroma	• Burning and numbness → often the 3rd /4th toe → Metatarsal squeeze test (mulder's click)
	• Peripheral neuropathy	• e.g tarsal tunnel or secondary to decrease B12, alcohol or DM
• Arterial	• ischaemia	• Absent pulses, signs of Peripheral Vascular Disease (PVD) and check ABPIs.

Reference

1. *Oxford handbook of General Practice, 4th Edition*

FIBROMYALGIA SYNDROME

Definition

- Fibromyalgia syndrome is a distinct syndrome ofwidespread, chronic pain .The mechanism for pain is thought to be driven by central sanitization.

Clinical features

- The main diagnostic features are:
- history of widespread pain (neck to low back)
- pain in 11 of 18 tender points on digital palpation
- These points must be painful, not tender. Smythe and Moldofsky have recommended 14 of these points on a map as a guide for management. These are:
- *Occiput:* suboccipital muscle insertions.
- *Low cervical:* anterior aspects of the intertransverse space at C5-C7.
- *Trapezius:* midpoint of upper border.
- *Supraspinatus:* origin, above the scapula spine near medial border.
- *Second rib:* at the second costochondral junction on uppersurface.
- *Lat eral epicondyle:* 2 em distal to epicondyle.
- *Gluteal:* in upper outer quadrants of buttocks in anterior fold of muscle.
- *Greater trochanter:* posterior to the trochanteric prominence,
- *Knee:* the medial fat 1 pad of proximate the joint line.



- https://upload.wikimedia.org/wikipedia/commons/2/23/Fibromyalgia.jpg

- symptoms have been present for over 3 months Other features
- Female to male ratio= 4:1
- Usual age onset 29-37 years: diagnosis 44-53 years
- Poor sleep pattern
- Dermatographia
- Fatigue (similar to chronic fatigue syndrome)
- Psychological disorders (e.g. anxiety, depression, tension headache, irritable digestive system)
- This disorder is very difficult to treat and is usually unresponsive in the long term to passive physical therapy or injections.
- Limited investigations to exclude other causes of widespread pain are usually undertaken at presentation (thyroid function tests, full blood count, inflammatory markers, serum calcium and alkaline phosphatase, biochemical profile, creatinnie kinase, random blood glucose).
- There is no diagnostic test for fibromyalgia.

Cause

- No single pathophysiological causative mechanism has been identified, and fibromyalgia is a multifactorial syndrome characterized by abnormal processing of pain, known as central sensitization.



Treatment

- Explanation, reassurance and counselling
- Attention to sleep disorders, stress factors and physical factors
- Relaxation program
- Rehabilitation: graduated exercise program (e.g. walking, water exercises, swimming or cycling)
- Use paracetamol for first-line analgesia
- Find out the patient's concerns, worries and answer appropriately. A patient centered approach has been found to be associated with less pain and less distress 1 year later.
- Advise: gradually increasing aerobic exercise of the sort recommended for cardiovascular fitness.
- In severe unremitting cases, consider referral to a multidiscipline team.
- Consider referral for cognitive behaviorual therapy.

Medication (often disappointing)

- Antidepressants (of proven short-term value); start low then monthly increments as tolerated: amitriptyline 10-75 mg PO (every night) may help with sleep/pain. Pregabalin (150- 300 mg/12 hr) PO can be alternative).
- SSRI (Selective Serotinin Reuptake Inhibitor) e.g. sertraline 25-50 mg od, may help anxiety, depression, and sleep
- Or
- duloxetine 30 mg (o) (morning), increasing to 60 mg over 2 weeks Stop if no improvement after a month's trial
- Note: NSAIDs are of no proven benefit.

Reference:

1. *ABC Rheumatology*
2. *John Murtagh's General practice, 4th Edition*
3. *Alex Khat Andrew Polmear Practical General Practice, 6th Edition*

GOUT (MONOSODIUM URATE CRYSTAL DISORDERS)

Definition:

- Gout is an abnormality of uric acid metabolism resulting in hyperuricaemia and urate crystal deposition. Urate crystals deposit in:
- joints - acute gouty arthritis
- soft tissue - tophi and tenosynovitis
- urinary tract - urate stones
- Four typical stages of gout are recognised:
- Stage 1 -asymptomatic hyperuricaemia
- Stage 2 -acute gouty arthritis
- Stage 3 -intercritical gout (intervals between attacks)
- Stage 4 -chronic tophaceous gout and chronic gouty arthritis
- Asymptomatic hyperuricaemia:
- 10 times more common than gout
- Elevated serum uric acid (>0.42 mmol/L in men,> 0.36 mmol/L in women)
- Absence of clinical manifestations
- Usually does not warrant treatment

Clinical features

- Typical clinical features of gout include:
- mainly a disorder of men (5-8% prevalence)
- onset earlier in men (40-50) than women (60 +)
- acute attack: excruciating pain in great toe, early hours of morning
- skin over joint- red, shiny, swollen and hot
- exquisitely tender to touch
- relief with colchicine, NSAIDs, corticosteroids
- can subside spontaneously (3 to 10 days) without treatment

Causes/precipitating factors

- Alcohol excess (e.g. binge drinking)
- Surgical operation
- Starvation
- Drugs (e.g. frusemide, thiazide diuretics)
- Chronic kidney disease
- Myeloproliferative disorders
- Lymphoproliferative disorders (e.g. leukaemia)
- Sugary soft drinks
- Cytotoxic agents (tumour lysis)
- Hypothyroidism
- Low-dose aspirin
- Others
- THE ARTHRITIS
- Monoarthritis in 90% of attacks:
- MTP joint great toe - 75%
- other joints- usually lower limbs: other toes, ankles, knees
- Polyarticular onset is more common in old men and may occur in DIP and PIP joints offingers. No synovial joint is immune.

- Other features
- Prone to recurrence
- Tophi in ears, elbows (olecranon bursa), big toes, fingers, Achilles tendon (take many years)
- Can cause patellar bursitis
- Can get cellulitis (does not respond to antibiotics)

NODULAR GOUT

- Develops in postmenopausal women with kidney impairment taking diuretic therapy who develop pain and tophaceous deposits around osteoarthritic interphalangeal (especially DIP) joints of fingers.

Diagnosis

- Blood: increased WCC; increased ESR;
- Elevated serum uric acid: (up to 30% can be within normal limits with a true acute attack)
- Synovial fluid aspirate: typical uric acid crystals using compensated polarized
- microscopy; this should be tried first (if possible) as it is the only real diagnostic feature
- X-ray: Not usually required, shows soft tissue swelling only, unless severe disease when an erosive pattern is seen

Management

- Management of gout includes these principles:
- good advice and patient education information
- provision of rapid pain relief
- preventing further attacks
- prevention of destructive arthritis and tophi
- dealing with precipitating factors and comorbid conditions (e.g. alcohol dependence, obesity, CKD, polycythaemia vera, diabetes, hypertension)
- The acute attack
- Resolves in <2week-often after 2-7days if treated.
- Exclude infection
- Rest and elevate joint - apply ice packs
- NSAIDs are helpful - e.g. naproxen 500mg bd - caution if GI problems
- Note: Any other NSAID can be used.
- Alternatively, if NSAIDs are contraindicated, try colchicine
- Colchicine: 0.5 mg (o) stat, then 0.5 mg every 6 or 8 hours until pain relief (usually 24-28 hours) or diarrhoea develops (max. 6 mg/24 hours)
- Note:
- Must be given early
- Avoid if kidney impairment
- Avoid use with macrolide antibiotics e.g. clarithromycin especially in CKD
- Avoid long-term use

Consider:

- corticosteroids: intra-articular following aspiration and culture (gout and sepsis can occur together); a digital anaesthetic block is advisable. An oral course can be used: start with prednisolone 40 mg/day for 4 days then decrease gradually over 10 days

- corticotrophin (ACTH) IM in difficult cases (e.g. synthetic ACTH: tetracosactrin 1 mg IM)
  Note:
- Avoid aspirin and urate pool lowering drugs (probenecid, allopurinol, sulphinpyrazone)
- Monitor kidney function and electrolytes
- Long-term therapy
  When acute attack subsides preventive measures (life style modification and dietary advice) include:
- weight reduction
- a normal, well-balanced diet
- avoidance of purine-rich food, such as organ meats (liver, brain, kidneys,
- sweetbread), tinned fish (sardines, anchovies, herrings), shellfish and game
- reduced intake of alcohol
- reduced intake of sugary soft drinks
- good fluid intake (e.g. water-2 litres a day)
- avoidance of drugs such as diuretics (thiazides, frusemide) and salicylates/low- dose aspirin
- wearing comfortable shoes.
- mcrease exercise
- control of co-morbidities(eg; hypertension, hyperlipidaemia)
- Prevention (drug prophylaxis)
-
  Allopurinol (a xanthine oxidase inhibitor) is the drug of choice: dose 100-300 mg daily. Febuxostat (80 mg/24 hr) is an alternative. Indications:
  frequent acute attacks (> 1 attack in 12 months)
  tophi or chronic gouty arthritis
  kidney stones or uric acid nephropathy
  hyperuricaemia Adverse effects:
  rash (2%)
  severe allergic reaction (Steven Johnson's Syndrome) Precautions:
  beware of kidney insufficiency and elderly patients - use lower doses
  beware of drug interactions:
  azathioprine and 6 mercaptopurine - potentially lethal
  amoxicillin - prone to rashes

Method: treatment of intercritical and chronic gout

- Commence 6-8 weeks after last acute attack.
- Start with 50 mg daily for the first week and increase by 50 mg weekly to maximum 300 mg.
- Check uric acid level after 4 weeks: aim for level <0.38 mmol/L.
- Add colchicine 0.5 mg bd for 6 months (to avoid precipitation of gout) or NSAIDs.
- Probenecid (uricosuric agent)
- Good for hyperexcretion of unic acid by blocking renal tubular reabsorption.
- Dose: 500 mg/day (up to 2 g)
- *Note:* Aspirin antagonises effect.
- Gout may be linked to increased risk of hypertension and coronary heart disease - screen patients

Refer to rheumatologist

- Any patient with gout and kidney stones or recurrent UTI to Urology
- Recurrent attacks, tophi (urate deposits) in pinna, tendons and joints, and joint damage
- Suspected septic arthritis
- Uncertained diagnosis
- Suspicious underlying systemic illness (e.g. rheumatoid arthritis, connective tissue disorder
- Gout occurs during pregnancy or under 25 yr of age.

Risk factors

- Thiazides, ACEI, alcohol, obesity
- Do not start allopurinol during an acute attack
- Do not stop allopurinol or debuxostat during an acute attack if treatment is already established.

Acute medication

- 1st line NSAID (Diclofenac, indomethacin or naproxen)
- 2nd line colchicine
- 3rd line if NSAID contraindicated – consider systemic corticosteroids
- When initiating allopurinol consider a course of NSAID or colchicine. If in 2/12 you need to increase the allopurinol give another overlap of colchicine to prevent an acute attack as the urate levels decrease again.
- Uric acid levels measure 4-6 weeks after an acute attack.
- Aim for normal levels of uric acid if the decision has been made to start allopurinol.

Self-management

- Rest
- Avoid trauma
- Keep the joint cool
- Lifestyle
- Reduce alcohol
- Weight control
- Dietary changes
- Avoid dehydration

Reference

1. *John Murtagh's Handbook of General Practice,6th Edition*
2. *Oxford Handbook of General Practice, 4th Edition*

-

OSTEOARTHRITIS

Definition

- Osteoarthritis (OA) is the most important cause of locomotor disability. It used to be considered 'wear and tear' of the bone/cartilage of synovial joints but is now recognized as a metabolically active process involving the whole joint i.e. cartilage, bone, synovium, capsule, and muscle.

Important risk factors for osteoarthritis

Risk Factor	Notes
Genetics	Hand, knee and hip OA show strong heritabilit y (40-60%): this probabl y results
Race	Knee OA is prevalent across the world, whereas hip OA is particularly prevalent in
Age	Although not an inevitable consequence of ageing, OA is strongly age-related; this
Sex	Women have a higher prevalence and radiographic severit y ofOA at all joints sites
Obesity	This is an important risk factor for knee OA, but a more modest risk factor for hip
Bone density	High density is a risk factor for development of knee, hip and hand OA; low density
Abnormal joint, shape and alignment	Acetabular dysplasia is a recognized cause of hip OA, and distal femoral dysplasia (often overlooked)may contribute to knee OA; varus or valgus mal alignment may be a risk for development and more rapid progression
Joint trauma and usage	Major joint injury is an important factor at the knee (especially if it causes subchondral fracture, meniscal injury or ligament rupture)and can cause OA at any site; recognized occupational hazards include farming (hip OA), underground mining (knee OA),professional soccer (knee OA) and some

- Primary OA is usually symmetrical and can affect many joints.
- In primary OA all the synovial joints may be involved, but the main ones are:
- first carpometacarpal (CMC) joint of thumb
- first metatarsophalangeal (MTP) joint of great toe
- distal interphalangeal (DIP) joints of hands
- Other joints that are affected significantly are the proximal interphalangeal joints, the knees, hips, acromioclavicular joints and joints of the spine, especially the facet joints of the cervical (CS-6, C6-7) and lumber regions (L3-4, L4-5, L5-SI).

Clinical features

- Pain: worse by the end of the day, aggravated by use, relieved by rest, worse in cold and damp
- Variable morning stiffuess
- Variable disability

Signs

- Hard and bony swelling
- Crepitus
- Signs of inflammation (mild)
- Restricted movements
- Joint deformity
- Note: There should be no sys temic manifestations.
- Crystal arthropathy can complicate OA, especially in the fingers of people taking diuretics (e.g. nodular gout).

Differentiation from an inflammatory arthropathy

- OA does not exhibit the typical inflammatory pattern. The clinical diagnosis based on:
- Gradual onset of pain after activity (worse towards the end of the day)
- The pattern of joint involvement
- The lack of soft tissue swelling
- The transient nature of the joint stiffness or gelling
- Takes <30 minutes to settle after rest while inflammatory arthritis takes at least 30 minutes

Diagnosis

- The diagnosis is clinical and radiological but the degree of changes on X-ray do not always parallel levels of symptoms.

RAY findings

- Joint space narrowing with sclerosis of subchondral bone
- Formation of osteophytes on the joint margins or in ligamentous attachments
- Cystic areas in the subchondral bone
- Altered shape ofbone ends
- Exclude other causes of pain, e.g. check FBC and ESR if inflammatory arthritis is suspected (normal or mildly increase in OA, ESR >30mm/h suggests RA or psoriatic arthritis).
- Mnemonics of X-ray finding (LOSS)
- loss of joint space
- Osteophytes
- subarticular sclerosis
- subchondral cyst

Management of osteoarthritis in primary care

- The goals of medical management of OA are to:
- provide patient education and information access;
- relieve pain;
- (c) optimize function; and
- minimize disease progression

Patient education and information access

- This is a professional responsibility, but education also improves outcome and is a treatment in its own right and use of educational programme to help patients understand OA and develop self management strategies.

Exercise

- Local quadriceps-strengthening exercise can reduce pain and disability and improve the physiological accompaniments of knee OA (muscle weakness, impaired proprioception and balance, tendency to fall). Aerobic activity also reduces pain and disability from OA, improves well-being and sleep-quality, and is beneficial for common co-morbidities. Both forms of exercise need to be prescribed. Increased activity and exercise can be accomplished in a variety of ways (e.g. home exercise, group classes), tailored to the patient's wishes and lifestyle.

Reduction of adverse biomechanical factors

- Spreading physically hard jobs (e.g. housework, mowing the lawn) at intervals through the day, with breaks in between ("pacing") can reduce sustained mechanical loading. Weight reduction can improve function and reduce pain in obese and overweight patients and may slow progression of knee and hip OA. Appropriate footwear (thick soft sole, no raised heel, broad forefoot and deep soft uppers) can reduce impact loading in people with knee and hip OA, and wedged in soles can counteract knee varus deformity . Walking sticks and other walking aids reduce loading across OA joints.

Pharmacological treatment

- Pain is the main reason patients seek help.
- Paracetamol should be the first oral analgesic (1-2 qid regularly) to try, based on its excellent safety and reasonable efficacy.
- Topical non-steroidal anti-inflammatory drugs (NSAIDs) and topical capsaicin
- are also safe and are particularly useful for hand and knee OA.
- Oral NSAIDs including highly selective COX inhibitors, and weak opioids (e.g. codeine, tramadol) may be considered for those patients who obtain insufficient relief from paracetamol and/or topical agents.
- The increased risk of gastrointestinal ulceration and bleeding from traditional NSAIDs can be decreased by concomitant prescription of a proton pump inhibitor or misoprostol.
- Oral NSAIDs and selective COX inhibitors therefore should be given at the lowest effective dose on an as-required, rather than regular, basis . Weak opioids, either alone or in combination with paracetamol, may provide good pain relief, but central nervous system side effects (e.g. constipation, headache, confusion) often limit their usefulness.
- Low-dose antidepressants, e.g. amitriptyline 10-75 mg, are a useful adjunct especially for pain causing sleep disturbance
- Intra-anticular corticosteroid injection is a valuable treatment that often gives quick effective relief of pain that may last just a few weeks to a few months. It is particularly useful to tide a patient over an important event (e.g. family wedding, holiday) and to improve pain during initiation of other interventions such as an exercise programme.

Surgery

- The success of prosthetic joint replacements has greatly advanced management of end-stage hip and knee OA.
- The criteria for referral for consideration of joint replacement include:
- Uncontrolled pain and
- Severe impairment of function despite conservative treatment
- Age, in itself, is not a contraindication.
- Psychological factors
- Psychological factors have a major impact on the disability from OA. Seek and treat depression and anxiety with screening tools.

Refer

- To rheumatologist:
- to confirm diagnosis if coexistent psoriasis (psoriatic arthritis mimics OA and can be missed by radiologists);
- rule out secondary causes of OA (e.g. pseudo gout, haemochromatosis) if young OA or odd distribution
- To orthopaedic surgeon:
- if symptoms are severe for joint replacement
- as an emergency if you suspect joint sepsis
- To physiotherapist
- for advice on exercises especially isometric exercises for the less mobile

Reference

1. *Oxford handbook of General Practice, 4th Edition*
2. *Oxford handbook of Clinical Medicine, 10th Edition*

-

OSTEOPOROSIS

Definition

- Osteoporosis, which literally means porous bone, is **reduced bone mass** per unit volume thus predisposing the person with it to an increased risk of fracture. It also refers to the increased bone fragility that accompanies ageing and many illnesses.

Key facts and checkpoints

- Osteoporosis is silent, common, measurable, treatable and potentiallylethal (analogous to hypertension).
- Osteoporosis is commonest in postmenopausal women.
- Up to 50% of women will develop fractures in their lifetime and 30% of all women reaching 90 years of age will suffer a hip fracture.
- Osteoporosis leads to reduced bone strength and susceptibility to fracture, even with minor trauma.
- Osteoporosis usually causes pain when complicated by fracture.
- First presentation is usually a fracture (Colles, femoral neck and vertebra) or height shrinkage.
- Vertebral collapse is the hallmark of osteoporosis.
- The disorder is of low bone mass.
- For osteoporosis in a vertebra including a pathological fracture, multiple myeloma needs exclusion.
- The first step in prevention is regular exercise, an adequate dietary intake of calcium (1500 mg per day) and maintenance of adequate serum vitamin D levels.

Classification

- PRIMARY (AGE RELATED)
- Typ e 1:
- Postmenopausal (vertebral or distal forearm fractures between the ages of 51 and 75)
- Due to increased osteoclast activity
- 6 times more common in women than men
- Typ e 2:
- Involutional or senile osteoporosis (fracture of proximal femur and other bones).
- It affects patients over 60 years and is twice as common in women as in men.
- Idiopathic osteoporosis: Occurs in children and young adults of both sexes with normal gonadal function.
- SECONDARY
- Secondary to various endocrine disorders, malabsorption and malignancies. Various causes and risk factors are presented in Table 1.

- Table 1. Osteoporosis: risk factors and/or causes

- Constitutional and non-modifiable
- Female sex
- Ageing
- Thin build; low BMI <18; short stature
- Race: Asian, Caucasian
- Family history (e.g. maternal hip fracture <75 yrs)
- Premenopausal oestrogen deficiency (e.g. amenorrhoea)
- Late menarche

- Early menopause <45 years (natural or surgical)
- Modifiable lifestyle factors
- Cigarette smoking
- High alcohol intake >2 standard drinks per day
- Low calcium intake
- Lack of vitamin D
- Physical inactivity
- Medical causes
- Eating disorders (e.g. anorexia nervosa)
- Malabsorption syndrome (e.g. coeliac disease)

- Endocrine disorders:
- Cushing syndrome
- diabetes mellitus
- hyperparathyroidism
- thyrotoxicosis
- amenorrhoea in elite athletes
- hypogonadism/sex hormone deficiency
- acromegaly
- Connective tissue disorders (e.g. RA)
- Chronic organ failure (kidney, liver, heart, lungs)
- Drugs causing bone loss:
- corticosteroids
- anti-epileptic drugs, especially hepatic enzyme inducers
- thiazolidinediones for diabetes
- long-term heparin
- excessive thyroid hormone
- prostate cancer hormone therapy
- breast cancer hormone therapy
- Prolonged immobilization
- Plasma calcium, phosphate and alkaline phosphatase (usually normal).
- Thyroid stimulating hormone.

- Consider tests for multiple myeloma in an osteoporotic area.
- Densitometry can predict an increased risk of osteoporosis and fracture, the best current modality being dual energy X-ray absorptiometry (DEXA scan) in a facility with high-standard quality control. The spine and femoral neck are targeted: the femoral neck is the most useful index.

Osteoporosis risk factors (SHATTERED)

- **S** = Steroid use of more than 5 mg per day of prednisolone **H** = Hyperthyroidism, hyperparathyroidism, hypercalciuria, **A**= Alcohol and tobacco use increased
- **T** =**T**hin
- BMI <18.5
- **T** = reduced Testosterone, anti-androgen in carcinoma prostate treatment
- **E** = Early menopause
- **R** =Renal or liver failure
- **E** = Erosive inflammatory bone disease, e.g. myeloma, rheumatoid arthritis
- **D** = Dietary reduced calcium, malabsorption, diabetes mellitus type I,

Investigations

- Plain radiography is oflimited value (low sensitivity, low specificity) Osteoporosis is not detectable until40-50% ofbone is lost.

- 25-hydroxy vitamin D (most useful test): normal range 75-250 nmol/L

Dexa, T scores and Z scores

- Dual energy X-ray absorptiometry (DEXA) is the current gold standard for the diagnosis of osteoporosis. It assesses both whole-body and regional bone mass (lumbar spine and proximal femur). Bone mass is measured as bone mineral density (BMD) in g/cm 2 and the lower the BMD, the higher the risk of fracture. There are actually different normal ranges of BMD for each bone and for each type of DEXA measuring machine.
- The BMD 'T score' is the number of standard deviations (SD) away from the mean BMD of a 30-year-old adult (Table 2). Osteopenia (low bone density) is -1-2.5 SDs below the young adult standard mean. Osteoporosis is > -2.5 SD below this mean. This is a strong indicator of bone fragility. Consider treatment ifT score is < -2.5.
-
- Table 2. Interpretation ofT scores (WHO criteria)
- T score Interpretation

≥ (-)1	Normal
(-)1 – (-)2.5	Osteopenia
≤(-)2.5	Osteoporosis
<(-)2.5	With fracture severe osteopososis

- The BMD 'Z score' is the number of SDs away from the **age- and sex-matched mean BMD.** The Z score is used to express bone density in patients <50 years, premenopausal women, younger men and children. If low (<-2) it indicates prompt investigation for underlying causes of a bone deficit.
- BMD is recommended for healthy women aged over 50 with all the risk factors for osteoporosis of:
- postmenopause
- fracture after age 40 with minimal trauma
- family history of osteoporosis, smoking habit or low BMI (< 18)

Treatment

- The goal of treatment is to prevent osteoporosis or reduce further loss. Eliminate risk factors where possible and focus on optimal lifestyle measures as a baseline for management. No treatment has been shown to replace lost bone effectively. Anabolic agents such as nandrolone decanoate may reduce further loss but the side effects are problematic.

Medications of value in decreasing further loss

- The following medications may be valuable in preventing further bone loss, possibly reversing the osteoporosis process and preventing further fractures.
- **1. bisphosphonates** (decrease bone absorption) can be used alone or combined with other agents (take care with potential adverse effects of oesophagitis and osteonecrosis of jaw):
- alendronate 10 mg (o) daily or 70 mg (o) once weekly (take care with potential side effect of oesophagitis)
- If intolerant,
- etidronate 400 mg (o) for 14 days then calcium carbonate 1250 mg (o) for 76 days
- risedronate 5 mg (o) daily or 150 mg (o) once monthly or 35 mg (o) once weekly or in combination therapy with calcium carbonate ± vitamin D zoledronic acid, single annual IV injection

- decrease bone loss and fracture rate. Mainstay of treatment for osteoporosis. Avoid if severe CKD or woman of child bearing age (possible teratogenic effects).
- Instructionsfor use:
- Take on an empty stomach first thing in the morning, 2:30 min before food/other medication; take in an upright position washed down with plenty of water; sit upright for 30min after taking.
- Atypical femoral fracture
- Prolonged bisphosphonate treatment >5years cause over suppression of bone turnover and increase bone fragility. Acute sub-trochanteric or mid-shaft femoral fractures are most common. To prevent this, a 'drug holiday' of 1-5years has been proposed for low-risk patients after 5years use-follow local guidance.
- **2. Strontium ranelate** has been shown to both increase osteoblastic bone formation and reduce osteoclastic bone resorption. Given at 2 grams daily orally, it may be used as first line therapy in high risk patient or in those intolerant of bisphosphonates. It is indicated in post-menopausal osteoporosis for reduction of fracture risk in hip and vertebrae but increased risk of cardiac problems.
- **3. HRT** (long-term use is not recommended but weigh potential benefits versus harms with the patient)
- **4. Raloxifene, selective estrogen receptor modulators (SERM)** is recommended as 2nd line of medical treatment. It is effective for prevention and treatment of vertebral fracture in post-menopausal women. Prescribed dosage is 60 mg once daily.

Recommendations for prevention

- Adequate dietary intake of calcium: 1200-1300 mg per day in both men and women.
- Dairy food is the main source of dietary calcium. Calcium-rich foods include low-fat calcium-enriched milk (500 mL contains 1000 mg), other low-fat dairy products (e.g. yoghurt or cheese), fish (including tinned fish such as salmon with the bone), citrus fruits, sesame and sunflower seeds, almonds, brazil nuts and hazel nuts. Oral calcium supplements will be necessary in postmenopausal women or where a person's diet does not meet their daily calcium requirements. Calcium citrate is better absorbed than carbonate. Recommend: 3 calcium citrate 2.38 g (= 500 mg elemental calcium) daily *or* calcium carbonate 1.5 g (= 600 mg elemental calcium) daily with food
- Vitamin D deficiency and sunlight: there is evidence we need significant exposure to sunlight of the face, arms and hands to produce natural vitamin D (e.g. 15-30 minutes a day in all climates, up to 50 minutes a day in winter in temperate climates). 6 Refer to regional recommendations. Measure serum 25-hydroxy vitamin D and maintain it at 75 11mol/L. If supplementation is required use colecalciferol 25-50 meg (1000- 2000 IU) oral daily until target 25-0H vitamin D level ?.75 11mol/L.
- Exercise: moderate exercise against gravity- walking (brisk walking for 30 minutes four times a week), jogging or tennis-may make a small contribution to retarding bone loss.
- Lifestyle factors: stop smoking and limit alcohol and caffeine intake.
- Adequate nutrition: keep BMI >18.
- Attention to falls prevention, including avoiding sedative medication.
- Provide 'hip protectors' especially to osteoporotic patients at increasing risk of fractures after falling, but adherence is poor.

Monitoring osteoporosis treatment

- Recommendations are to measure BMD at the lumbar spine and hip:
- 2 years after therapy begins
- 1-2 years after therapy changes significantly
- more frequently in patients at higher risk of bone loss

OSTEOPOROSIS IN CHILDREN

- The main problem in children is secondary osteoporosis, which is usually related to chronic inflammatory disorders and their treatment with corticosteroids and also to reduced mobility. Other medical causes are malignancy, malabsorption syndromes, poor nutrition, anorexia nervosa and hypogonadism. Use DEXA to assess and monitor BMD and Z scores. Refer for treatment, which may be based on bisphosphonates.

OSTEOPOROSIS IN MEN

- Currently only bisphosphonates and teriparatide (recombinant PTH, increased risk of renal malignancy) are recommended for treatment of osteoporosis in men.

WHEN TO REFER

- Refer postmenopausal women and older men to a specialist according to individual needs
- Osteoporosis appears to be secondary to an underlying illness
- Advice is required about the management of a patient with pathological osteoporotic fractures or loss of height
- Fragility fracture on treatment.

Osteoporosis (NICE Guideline)

Risk factors (low)	Female, BMI <18.5, smoking, Alcohol (units>14/week for female and >21/week for male. Previous fracture or history of falls, immobility, FH osteoporosis or hip fracture, medical mobility.
Risk factors (medium)	Corticosteroids, premature menopause, previous osteoporotic fracture
Risk factors (high)	>7.5 mg prednisolone daily for 3 months (current or recent) Previous major osteoporotic fracture Multiple fragility fracture

Who do we screen

- Female, >65 years or <65 years with any risk factor
- Male >75 years or <75 years with any risk factor
- Anyone <50 years with a medium or high-risk factors or <40 years with a high-risk factor

How do we screen?

- History – is the patient risk?
- Calculate the FRAX score if age 4o – 90 years or Q fracture if age 30 – 84 years
- Once the data is inserted into the tool, use the link to NOGG to guide management – lifestyle advise (low risk)
- DEXA scan (intermediate risk) – recalculate with BMD(Bone Mineral Density.
- Start treatment (High risk).
- Above the upper age limits defined by the tools, consider people to be a high risk.
- >80 years predicted 10 year fracture risk may underestimate their short-term fracture risk.
- Assessment tools underestimate risk in: multiple fractures or vertebral fracture, alcohol use, steroid treatment or comorbidities.

T score	
≥-1.0	Normal
Between -1 and -2.5	Osteopenia
< -2.5	Osteoporosis
≤-2.5	With feacture, severe osteoporosis

- **For reversible causes** - consider testing of:
- TSH for hyperthyroidism
- PTH for hyperparathyroidism
- Ca2+ for Osteomalacia
- vitamin D,
- Testerone – hypogonadism
- LH and FSH

Who should have calcium and vitamin D replacement?

- Due to new studies demonstrating risks of calcium treatment, consider vitamin D replacement alone if dietary calcium intake is < 700 mg/day.
- If calcium intake is inadequate: Prescribe 10 micrograms (400 IU) of vitamin D with at least 1000 mg calcium daily.
- Prescribe 20 microgram (800IU) of vitamin D with at least 1000 mg of calcium daily for elderly people who are housebound or living in a nursing home.

Who should have bisphosphonates?

- NOGG guidance has indicated treatment is required or following a confirmed osteoporosis diagnosis.
- Only alendronate (OD tablets) and risedronate (once weekly tablets) are licensed for use in men.

Management of Osteopenia

- Lifestyle
- Smoking
- Exercise and weight bearing exercise
- Test bone profile
- Blood test – Albumin, U&E, LFT, FBC, ESR, TSH
- Rescan 2-3 years
- To allow calcium intake calculation consultation

Reference

1. *John Murtagh's General Practice, 6th Edition*
2. *Oxford handbook of General Practice, 4th Edition*
3. *Oxford handbook of Clinical Medicine, 10th Edition*
4. *Therapeutic manual (Internal Medicine), 1st Edition (2016)*

RHEUMATOID ARTHRITIS

Definition

- Rheumatoid arthritis (RA) is the most common disorder of connective tissue. It is an immunological disease, triggered by environmental factors, in patients with genetic predisposition. Disease course is variable with exacerbations and remissions.

Clinical features

- Insidious onset but can begin acutely (explosive RA)
- Age 10-75 years, peak 30-50 years but bimodal25-50 (peak age) and 65-75
- Female to male ratio= 3:1
- Joint Pain: Worse on walking, nocturnal pain, disturbed sleep: relieved with activity
- Morning stiffness can last hours.
- Rest stiffness - (e.g. after sitting)
- General: malaise, weakness, weight loss, fatigues
- Disability according to involvement

Signs

- Soft swelling (effusion and synovial swelling) especially ofwrist, MCP and PIP joints
- Warmth
- Tenderness on pressure or movement
- Limitation of movement
- Muscle wasting
- Later stage: deformity, subluxation, instability or ankylosing.
- Look for swan necking, boutonniere and Z deformities, ulnar deviation.
- Cheek for a number of everyday functions
- Power grip (lifting a jug of water)
- Precision grip (using a key or pen), undoing buttons
- Hook grip

Extra-articular manifestation

- Anaemia, inflammatory to eye, sjogren's syndrome (dry eyes, dry mouth),
- Lymphadenopathy
- Pulmonary (pleural effusion, fibrosing alveolitis, nodules - caplan syndrome, vasculitis (pupura) nail fold infections and skin ulcer, cervical spine (atlentoaxial subluxation).
- Cardiac (pericarditis, myocarditis), splenomegaly (felty syndrome), subcutaneous nodules, bursitis, tenosynovitis, capal tumel syndrome, Raynaud's phenomenon, Baker cyst (popliteral fossa) peripheral sensory neuropathy, mononeuritis mulptiplex.

Diagnosis

- According to ACR I EULAR (2010) RA criteria
- A score of >6/ 10 is needed to diagnose definite RA.

No.	Symptom	Score
A	Joint involvement (0-5)	
	1 medium-large joint	0
	2-10 medium-large joint	1
	1-3 small joints (with or without involvement of large joint)	2
	4-10 small joints (with or without involvement of large joint)	3
	> 10 joints (at least one small joint)	5
B	Serology (0-3)	
	Negative RF and negative anti-citrullinated protein antibodies	0
	Low positive RF or low positive anti-citrullinated protein antibodies	2
	High positive RF or high positive anti-citrullinated protein antibodies	3
c	Acute phase reactants	
	Normal CRP and normal ESR	0
	Abnormal CRP or abnormal ESR	1
D	Duration of symptoms	
	< 6 week	0
	>= 6 week	1

Severity Assessment

- Disease Activity: Modified Disease Activity Score (DAS 28)

DAS 28 = $0.56 \times \sqrt{TJC28} + 0.28 \times \sqrt{SJC28} + 0.7 \times \log_{nat}(ESR) + 0.014 \times GH$

TJC = Tendon Joint Count, SJC = Swollen Joint Count, GH = Global Health, ESR = Erythrocyte Sedimentation Rate.

- Can use DAS28 on-line
- <2.6 =Remission, 2.6-3.2 =Low Disease Activity, 3.2-5.1 =Moderate Activity, >5.1 =High Activity
- Poor prognostic factor
- Functional limitation (Functional Health Status III or IV)
- Extra articular manifestation
- Positive rheumatoid factor or anti-cyclic citrullinated peptide antibodies
- Bony erosions by radiograph
- Function Health Status (FHS)
- No handicap (Can perform activity of daily life (ADL), Vocational &
- A vocational works)
- Can perform ADL and vocational works.
- Can do ADL (self-care without assistant, may need minimal help sometimes)
- Need assistant for self-care, chair bound.
- Duration of symptoms
- <6 months or >6 months

Management

- Early referral from primary care for suspected RA for early diagnosis
- Early intervention with Disease Modifying Anti-Rheumatic Drug (DMARD) in the window of opportunity before joint erosion occur

Patient assessment

- Assess the impact on the patient's mental health, sleep, fatigue, acts of daily living and social function.
- Screen for and treat cardiovascular risk factors
- Check for extra- articular manifestations including constitutional upset

Pharmacological treatment

- Pain Control
- ***NSAIDs and simple analgesics:*** (e.g. regular paracetamol) provide symptomatic relief but do not alter the course of disease. NSAIDs is started with the least gastric- toxic, e.g. ibuprofen 200-400 mg tds and alter as necessary, e.g. to naproxen 500mg bd. If the patient has a history of indigestion/gastric problems consider adding gastric protection, e.g. PPI, or, if there is no history of CVD, using a COX2 inhibitor, e.g. celecoxib 100 mg bd.
- It is customary to try a patient on one NSAID or coxib for a period of several weeks and then to switch to an alternatives if it is ineffective. If NSAIDS or coxibs are needed for the long term, prescribe the lowest effective dose
- **Steroids:** Daily low-dose oral steroids relieve symptoms and there is some evidence that they can modify disease progression, but concerns about adverse side effects have limited use. Consider using systemic steroid in the following situation
- **1)** bridging disease control between different DMARD therapies
- to achieve rapid control of symptoms but only once the diagnosis has been established.
- Prednisolone 2.5- 10 mg per day
- * Recommend local steroid injection for localized flare ups.

DMARD

- They include antimetabolites, antimalarials and biologic agents (e.g. infliximab, rituximab, initiated by specialist). The choice ofDMARD will be made by the patient and consultant. Methotrexate has emerged as the most commonly prescribed DMARD closely followed by sulfasalazine.
- Preparations before starting DMARD
- Clinical background
- Alcohol consumption Smoking
- Diabetes Hypertension
- Coronary Heart disease Menstrual history Contraception

Investigations

- CRP or ESR, Cholesterol, Blood sugar, FBC, LFT, ALT, Urea and Creatinine
- HBs Ag, Anti-HCV
- Tuberculin test in those with history of close contact to open case ECG
- Chest X-ray (PA)

Vaccinations

- Influenza vaccine Pneumococcal vaccine Hepatitis B vaccine
- In immunosupressed patients not immune to measles or varicella consider using immunoglobulins after significant contact exposure. Avoid using live vaccines in patients taking immunosuppressive drugs. Withhold DMARDs/biologics if necessary and contact secondary care team.

- Methotrexate: 7.5- 15mg weekly+ folic acid 5mg weekly Leflunomide
- Body wt < 160 lb **-7** 60 mg od x 3 DS
- > 160 lb **-7** 100 mg od x 3DS Followed by 20 mg od
- CQ: 150 mg od
- Adjunctive Rx
- Omega 3 Fatty acid Lipid - Lowering Agent
- Prophylactic Rxfor osteoporosis (see in osteoporosis guideline)

THE GP's role

- Support patients during the initiation of therapy. There may be no benefit for 2-6 months, counsel patient to report potential adverse effect promptly.
- **Pre-pregnancy Counselling:** Ensure patients know about the danger to conception. Several DMARDs are contraindicated in pregnancy. Both male and female patient may need to delay conception until a period has elapsed after stopping cytotoxics. The period depends on the DMARD e.g. 3 months for MTX, 2 years for women on leflunomide.
- Follow local protocols for monitoring the advance effect of these drugs, as protocols vary between institutions.

Antidepressants

- Ask about sleep disturbance and fatigue. Prescribe an antidepressant to aid sleep and reduce pain as well as to treat depression if present

Non-drug management

- Education, physiotherapy and related intervention remain at the centre of care.
- Education
- Education improve knowledge, symptom control, adherence and self management.
- Consider every consultation an opportunity to educate the patient.
- Provide information leaflets.
- Exercise
- Advise patient to keep active and exercise. This improves mood and encourage self-sufficiency. Advise the patient to pace activities to a realistic level. Explain the benefits of the different forms of exercise.
- range of movement or stretching exercise relieve stiffness and maintain flexibility
- strengthening exercise maintain muscle strength, need for function and joint support
- aerobic exercise improve cardiovascular risk, aids weight control and overall function
- Osteoporosis: Patients with RA are at an increased risk of osteoporosis. Calculate the patient's fracture risk.
- Management outline: see algorithm

Follow up

- Timing
- At week 4, week 12, week 24, week 36, week 52, then 24 weekly (6 monthly later)
- Monitor - Disease activity
- Functional Health Status
- Blood Test
- Atweek4 At week 12
- At week 24 ATweek36 At week 52
- FBC, ALT

- FBC, LFT, ALT, CRP
- FBC, ALT, CRP, CXR, (PA) FBC, ALT
- FBC, LFT, ALT, CRP, Urea, Creatinine, Cholesterol, Sugar, CXR (PA) Bone mineral density (DEXA scan)

Surgery

- Surgery can be highly effective in selected cases and covers tendon transfers, arthroplasties (including upper limb and small joints) and arthrodeses.

MULTISECTORAL PLAN FOR MANAGEMENT OF RHEUMATOID ARTHRITIS





PPF* = poor prognostic factors: Anti-CCP positive, RA (+), FHS III or IV
MTX=Methotrexate, HCQ=chloroquine, LEF=Leflunomide

- **Fig. Rheumatoid arthritis management algorithm**

Criteria for referral

- All suspected cases of rheumatoid arthritis to rheumatology for early treatment with disease- modifying drugs which can significantly alter disease progression.
- Refer urgently if:
- Small joints of the hands/feet are affected
- > 1joint is affected
- There has been a delay of 2:3 months between onset of symptoms and seeking medical advice:
- Pregnancy
- Fibrotic lung Disease
- Liver disease
- Vasculitis
- Moderate or High disease activity at 3 months follow up after combination of 2 DMARDs

References

1. *Alex Khat, Andrew Polmear: Practical General Practice*
2. *Oxford handbook of General Practice, 4th Edition*
3. *Therapeutic Manual, Internal Medicine Society, MMA, 1st Edition, 2016*

SYSTEMIC LUPUS ERYTHEMATOSUS

Definition

- SLE (lupus), which is the commonest of the connective tissue disorders
- It is a multisystem autoimmune disorder with a wide variety of clinical features that are due to vasculitis. Arthritis is the commonest feature of SLE (90% of cases). Milder manifestations outnumber more severe forms.

Clinical features

- Mainly affects women in 'high oestrogen' period (90% of cases)
- Peak onset between 15 and 40 years
- Fever, malaise, tiredness common
- Multiple drug allergies e.g. sulfonamides

System	% of patients	Presenting complaints	
Joints	95	• Arthritis • Arthralgia	• Myalgia • Tenosynovitis
Skin	80	• Photosensitivity • Facial 'butterfly' rash • Vasculitic rash	• Hair loss • Urticaria • Discoid lesions
Lungs	50	• Pleurisy • Pneumonitis	• Pleural effusion • Fibrosing alveolitis
Kidney	50	• Proteinuria • increased BP	• Glomerulonephritis • Renal failure
Heart	40	• Pericarditis	• Endocarditis
CNS	15	• Depression • Psychosis • Infarction	• Fits • Cranial nerve lesions
Blood	95	• Anaemia (very common) • Thrombocytopenia	• Splenomegaly
Fatigue	95		

Diagnostic criteria

- Polyarthritis + fatigue + skin lesions -7 SLE

Classification criteria

- Systemic Lupus International Collaborating Clinics Classification (SLICC)
- The favourite differential diagnosis, SLE mimics other illnesses, with wide vanatwn in symptoms that may come and go unpredictably. Diagnose SLE in an appropriate clinical setting if 4 criteria (at least 1 clinical and 1 laboratory) or biopsy-proven lupus nephritis with positive ANA or anti-DNA.

Clinical criteria

- *Acute cutaneous lupus:* Malar rash/butterfly. Fixed erythema, flat or raised over the malar eminences, tending to spare the nasolabial folds. Occurs in up to 50%. Bullous lupus, toxic epidermal necrolysis variant of SLE, maculopapular lupus rash,

photosensitive lupus rash, or subacute cutaneous lupus (non-indurated psoriasiform and/or annular polycyclic lesions that resolve without scarring).

- *Chronic cutaneous lupus:* Discoid rash, erythematous raised patches with adherent keratotic scales and follicular plugging ± atrophic scarring. Think of it as a three-stage rash affecting ears, cheeks, scalp, forehead, and chest: erythema -7 pigmented hyperkeratotic oedematous papules -7 atrophic depressed lesions.
- *Non scarring alopecia:* (In the absence of other causes.)
- *Oral/nasal ulcer:* (In the absence of other causes)
- *Synovitis:* (Involving two or more joints or two or more tender joints with >30 minute of morning stiffness.)
- *Serositis:* a) Lung (pleurisy for > 1 day, or pleural effusions, or pleural rub; b) pericardia! pain for > 1 day, or pericardia! effusion, or pericardia! rub, or pericarditis on
- ECG.
- *Urinanalysis:* Presence of proteinuria (>0.5 g/d) or red cell casts.
- *Neurological features:* Seizures; psychosis; mononeuritis multiplex; myelitis; peripheral or cranial neuropathy; cerebritis/acute confusional state in absence of other causes.
- 9. Haemolytic anaemia.
- *Leucopenia:* (WBC <4.) At leaset once or lymphopenia (lymphocytes < 1) at least once.
- *Thrombocytopenia:* (Platelets < 100.) At least once.
- Laboratory criteria
- positive ANA (positive in >95%)
- Anti-double stranded DNA (Anti-dsDNA)
- Anti-Smith antibodies present
- Antiphospholipid antibodies present
- Low complement (C3, C4 or C50)
- positive Direct Coombs test
- Adapted from 'Derivation and validation of the Systemic Lupus Int ernational Collaboration Clinics classification criteria for systemic lupus erythematosus'. PetriM et al., Arthritis abd Rheumatism, val. 64, Issue 8 (2012) 26 772686.

Diagnosis

- ESR/CRP - elevated in proportion to disease activity
- ANA test- positive in 95% (perform first) (key test)
- dsDNA antibodies- 90% specific for SLE but present in only 60% (key test)
- ENA antibodies, especially Sm - highly specific
- Rheumatoid factor- positive in 50%
- LE cell test - inefficient and not used
- The diagnosis cannot be made on blood tests alone. Supportive clinical evidence is necessary. For suspected SLE, the recommended approach is to perform an ANA test. If positive, order
- dsDNA and ENA antibodies.



- https:// i1.yp. com/ www. mvli(eria .com/ wp-content / uploads/20 1 7/ 02/ tcara-merawat-sle-anda-tanda- sle.jpg ?resize=300 %2C215

Management

- Refer to rheumatologist.
- Appropriate explanation, support and reassurance, use of sunscreens

Treatment for sunburn

- Hydrocortisone 1% ointment or cream for severe sunburn on face, early.
- Use hydrocortisone 1% or 0.02% betamethasone valerate for other areas.
- Repeat in 2-3 hours and then the next day.
- Hydrocortisone is not useful after 24 hours and should be used for unblistered erythematous skin, not on broken skin.
- Oral aspirin eases pain. Oil in water baths or bicarbonate of soda paste may help and wet applications such as oily calamine lotions or simply cool compresses may give relief

Prevention of sunburn

- Avoid direct exposure to summer sunlight during peak UV periods (10 am to 3 pm).
- Use natural shade- beware of reflected light from sand or water and light cloud. Use a sunscreen with a minimum of SPF 30.
- Wear broad-brimmed hats and protective clothing.
- Refer to consultant rheumatologist for shared care in a multidisciplinary team

Treatment

- Based on severity and organ involved Mild (Facial rash + Arthritis)
- PO Hydroxychloroquine (HCQ) 200 mg odor Chloroquine (CQ) 150 mg od
- PO Prednisolone 5 mg od
- Moderate (Truncal rash)
- PO Hydroxychloroquine 200 mg odor Chloroquine 150 mg or liz tablet od
- PO leflunamide/methotrexate

- PO Prednisolone 5-10 mg or methyl prednisolone 4-8 mg em Treatment of organ threatening (Severe) SLE
- REFER to hospital Vaccination
- Pneumococcal vaccination stat. and 5 yrly
- Influenza vaccination stat. and yearly
- Hepatitis B vaccine stat and followed by at 1 & 6 month Family Planning
- Ask for patient's family planning and advice rightfully
- 3 month depo injection to all reproductive age patient who have potential to become pregnant
- cvs
- Check cardiovascular risk factor and correct accordingly Follow up
- Check blood for CP, ESR, ALT, Potassium, Creatinine, RBS, Urine RE monthly
- Check lipid profile 6 monthly
- Check Bone Mineral Density(BMD) after 6 month of steroid therapy
- Yearly visual field examination to detect CQ and HCQ related changes SLE and Pregnancy
- Check Anti-Phospholipid Antibodies 12 weeks apart
- Choose HCQ or Azathioprine ifDMARD is needed.
- Steroid and aspirin are safe
- Use aspirin and low molecular weight heparin (LMWH) for anti-phospholipid antibodies positive.

References

1. *John Mutagh 's General Practice, 6th Edition*
2. *Oxford handbook of General Practice 4th Edition*
3. *Therapeutic Manual (Internal Medicine) 1st Edition*

-

ACR mnemonic of SLE diagnostic criteria

- The following are the ACR diagnostic criteria in SLE, presented in the "**SOAP BRAIN MD"** mnemomc:
- **S**erositis - Pleurisy, pericarditis on examination or diagnostic electrocardiogram (ECG) or 1magmg
- **O**ral ulcers - Oral or nasopharyngeal, usually painless; palate is most specific
- **A**rthritis - Nonerosive, 2 or more peripheral joints with tenderness or swelling
- **P**hotosensitivity - Unusual skin reaction to light exposure
- **B**lood disorders- Leukopenia(< 4 x 10^3 cells/11L on >1 occasion), lymphopenia(< 1500 cells/ 11L on >1 occasion), thrombocytopenia(< 100 x 10^3 cells/11L in the absence of offending medications), hemolytic anemia
- **R**enal involvement- Based on presence of proteinuria (>0.5 g/day or 3+ positive on dipstick testing) or cellular casts (including red blood cells [RBCs], hemoglobin, granular, tubular, or mixed) or based on the opinion of a rheumatologist or nephrologist
- **A**ntinuclear antibodies (ANAs)- Higher titers generally more specific (> 1:160); must be in the absence of medications associated with drug-induced lupus
- **I**mmunologic phenomena- dsDNA; anti-Smith (Sm) antibodies; antiphospholipid antibodies (anticardiolipin immunoglobulin G [IgG] or immunoglobulin M [IgM] or lupus anticoagulant); biologic false-positive serologic test results for syphilis, lupus erythematosus (LE) cells (omitted in 1997 revised criteria)
- **N**eurologic disorder - Seizures or psychosis in the absence of other causes
- **M**alar rash - Fixed erythema over the cheeks and nasal bridge, flat or raised
- **D**iscoid rash- Erythematous raised-rimmed lesions with keratotic scaling and follicular plugging, often scarring
- https://emed icine.medscap e.com/ar ticle/332244-workup
-

CHAPTER (10)
NEUROLOGICAL PROBLEMS

1. Epilepsy
2. Facial Nerve (Bell) Palsy
3. Headache
4. Parkinsonism
5. Stroke
6. Trigeminal Neuralgia (Tic Douloureux)

7 Peripheral Neuropathy

EPILEPSY

Definition

- A seizure is defined by transient (***paroxysmal event***) due to abnormal excessive or synchronous neuronal activity in the brain.

Provoked seizure

- It is a seizure associated with a clear precipitant or triggering factor (such as: drugs, fever, acute head injury, acute cerebra-vascular,acute metabolic imbalance)

Unprovoked seizure

- Itis a seizure not associated with a clear precipitant or triggering factor.

Epilepsy

- Epilepsy is defined as recurrence of at least 2 unprovoked seizures occurring more than 24 hours apart.
- It is a clinical phenomenon rather than a single disease entity, since there are many forms and causes of epilepsy.

Status Epilepticus

- *Status epilepticus refers to continuous seizures or repetitive, discrete seizures with impaired consciousness in the interictal period.*
- *More practical definition is a situation in which the duration of seizures (for generalized tonic-clonic epilepsy usually last more than 5 minutes) prompts the acute use of anticonvulsant therapy.*

Causes of Epilepsy

1. Unknown cause (Idiopathic epilepsy) - 60-75%
   - Genetic (hereditary) factors may play a role in some cases.
2. Symptomatic epilepsy - 25-40% Some causes include:
   - Congenital disorders
     - Inborn error of metabolism
     - Neuro-Phakomatoses (e.g. neurofibromatosis)
     - Cortical dysgenesis
   - Cerebral anoxia of any cause
   - Head trauma
   - CNS Infection (meningitis, AIDS and viral encephalitis)
   - Vascular Disease (e.g. post-stroke, AV malformation,Aneurysm)
   - Brain tumor
   - Drugs and alcohol

Triggering factors for seizures

- Sleep deprivation
- Missed doses of anti-epileptic drugs in treated patients
- Alcohol (particularly withdrawal)
- Recreational drug misuse
- Physical and mental exhaustion
- Flickering lights, including TV and computer screens (generalized epilepsy syndromes only)
- Intercurrent infections and metabolic disturbances
- Uncommon:
  - loud noises, music, reading, hot baths

Phases of seizure in Generalized Epilepsy

- ***Prodromal Phase-*** lasting hours or days, may rarely precede the seizure. It is not part of the seizure itself: the patient or others notice a change in mood or behaviour.
- ***Aura Phase-*** is part of the seizure of which the patient is *aware*, and may precede its other manifestations. The aura may be a strange feeling in the gut, or an experience such as ***dejavu*** (disturbing sense of familiarity), or strange smells or flashing lights. It implies a partial (focal) seizure, often, but not necessarily, from the temporal lobe.
- ***Post-ictal Phase-*** there may be headache, confusion, myalgia, and a sore *tongue;* or temporary weakness after a focal seizure in motor cortex (Todd's *palsy)*, or dysphasia following a focal seizure in the temporal lobe.

Classification of seizures



Generalised Seizures

- *Generalized seizures are thought to arise at some point in the brain but immediately and rapidly engage neuronal networks in both cerebral hemispheres.*
- *Several types of generalized seizures have features that place them in distinctive categories and facilitate clinical diagnosis.*

Typical absence seizures

- *characterized by sudden, brief lapses of consciousness without loss of postural control.*
- *The seizure typically lasts for only seconds, consciousness returns as suddenly as it was lost, and there is no postictal confusion.*
- *It always starts in childhood. Occur so frequently (20-30 times a day) that they are mistaken for daydreaming or poor concentration in school.*
- *Triggers: hyperventilation and flashing lights*



Atypical absence seizures

- *Different from typical absence seizure.*
- *The lapse of consciousness is usually of longer duration and less abrupt in onset and cessation, and the seizure is accompanied by more obvious motor signs that may include focal or lateralizing features.*
- *They are usually associated with diffuse or multifocal structural abnormalities of the brain and less responsive to antiseizure medications.*

Tonic-clonic seizures

- *The most common seizure type. Initial 'aura' then becomes rigid (tonic) and unconscious. During this phase, breathing stops and central cyanosis may occur.*
- *The limbs produce jerking (clonic) movements for a variable time. Afterwards, there is a flaccid state of unresponsiveness, which can persist for some minutes.*
- *After regaining consciousness, the patients may be confused, disorientated and/or amnesic.*
- *Urinary incontinence and tongue-biting may occur.*

Atonic seizures

- *It is characterized by sudden loss of postural muscle tone lasting 1–2 s Consciousness is briefly impaired, but there is usually no postictal confusion.*
- *A very brief seizure may cause only a quick head drop or nodding movement, while a longer seizure will cause the patient to collapse or fall.*
- *Atonic seizures are usually seen in association with known epilepsy syndromes.*

Myoclonus seizures

- *A sudden and brief muscle contraction that may involve one part of the body (usually in the arms) or the entire body.*
- *They are more marked in the morning or on awakening from sleep, and tend to be provoked by fatigue, alcohol or sleep deprivation.*
- *Myoclonic seizures usually coexist with other forms of generalized seizures but are the predominant feature of juvenile myoclonic epilepsy (JME).*

Focal seizures

- *Focal seizures arise from a neuronal network either discretely localized within one cerebral hemisphere or more broadly distributed but still within the hemisphere.*

Focal seizures without dyscognitive features (previously known as Simple partial)

- *Focal motor seizures usually are clonic type.*
- *It can also manifest as changes in somatic sensation (e.g., paresthesias), vision (flashing lights or formed hallucinations), equilibrium (sensation of falling or vertigo), or autonomic function (flushing, sweating, piloerection).*
- *Focal seizures arising from the temporal or frontal cortex may also cause alterations in hearing, olfaction, or higher cortical function (psychic symptoms).*

Focal seizures with dyscognitive features (previously known as Complex partial)

- *It is accompanied by a transient impairment of the patient's ability to maintain normal contact with the environment.*
- *The patient is unable to respond appropriately to visual or verbal commands during the seizure and has impaired recollection or awareness of the ictal phase.*
- *The seizures frequently begin with an aura, that is stereotypic for the patient. A sudden behavioral arrest (automatism) or motionless stare are common aura.*

Evolution of focal seizures to generalized seizures (previously known as secondary generalization)

- *Focal seizures can spread to involve both cerebral hemispheres and produce a generalized seizure, usually of the tonic-clonic variety.*
- *This is observed frequently following focal seizures arising from a focus in the frontal lobe.*
- *A focal seizure that evolves into a generalized seizure is often difficult to distinguish from a primary generalized-onset tonic-clonic seizure*

Currently Unclassifiable Seizures

Epileptic spasms:

- These are characterized by a very brief sustained flexion or extension of predominantly proximal muscles, including truncal muscles, *but recurring in clusters of 5-50, often on awakening.*
- *Occur mainly in infancy.*

Disorders That May Mimic Epilepsy

Cardiovascular events (syncope)

- Vasovagal attacks (vasodepressor syncope),
- Arrhythmias (Stokes-Adams attacks)

Movement disorders

- Paroxysmal choreoathetosis
- Myoclonus, *tics,* habit spasms

Migraine –

- *Brainstem migraine*

Sleep disorders

- *Parasomnias*

Metabolic disorders

- Hypoglycemia,

Psychological disorders

- *Functional seizures*

Diagnosis

History Taking

- Should be obtained from ***both patients and witnesses*** including;
- The clinical ***context,*** including medical and family history, and circumstances under which the episode occurred

Specific triggers or provoking factors

A detailed clinical description that entails four components:

- What is the first ***symptom or sign*** (presence and type of aura, evidence of focal seizure at onset)?
- How does it ***evolve after onset*** (what happens during the seizure proper, what are the signs or symptoms, how long does it last)?
- How does ***it end*** (gradually or abruptly)?
- Are there ***any neurologic deficits*** after the seizure ends?
- What type of seizure is it-partial or generalized?
- ***Physical and neurological examination***
- Routine examination of all the systems.
- Scars, *bruises*, skin pigmentation, adenoma *sebaceum*, haemangioma, congenital anomalies
- Signs of drug *toxicity*, e.g., ataxia, drowsiness, sleepiness, nystagmus

Differential diagnosis

- Vasovagal syncope
- *Functional seizures*
- Tics
- Panic attack
- Hypoglycaemic attack
- Normal phenomenon (e.g. deja vu)
- Cardiac arrhythmias
- Other cardiac disorders (e.g. Aortic stenosis)
- HOCM
- TIA
- Migranous aura

Investigation

- ***Blood tests*** - Blood sugar, full blood count, ESR, urea & electrolytes, creatinine, *calcium*, ***magnesium***, liver function *test*, pregnancy test
- *EEG*

Refer to neurologist for further management. Drug choice is a specialist decision

Pharmacological treatment

Initiation of Antiseizure Medication Treatment

- should be ***individualized*** according to the seizure *type*, epilepsy *syndrome*, concurrent ***medications*** and ***co-morbidity, lifestyle,*** and the preferences of the person and their ***family and/or carers.***
- generally recommended after a second epileptic seizure.
- should be considered even after a first unprovoked seizure

1) *abnormal neurological examination*
2) *the EEG shows unequivocal epileptic activity*

3) *the risk of having a further seizure is high*
4) *status epilepticus as the first seizure presentation*
5) *brain imaging shows a structural abnormality*

Principle Of AED

How to start first drug

- Start with ***one of the first-line drug:***
- Start at a ***low dose:*** increase gradually ***until*** effective control is achieved
- If seizure is ***not controlled with monotherapy,*** check *compliance*, dose frequency, timing and drug interactions

When to use second drug

- If seizure control is ***not achieved*** with maximum tolerant dose of first drug
- ***Optimise*** second drug, then try ***to withdraw first drug*** (alternative monotherapy)
- *Monotherapy should be the goal whenever possible.*

When to use combination therapy

- *After trying 2 drugs as monotherapy*
- *In multiple seizure types*
- *In poor prognosis epilepsy syndromes*

When to withdraw AED

- *Complete medical control of the seizure for 1-5 years*
- *Single seizure type, either focal or generalized*
- *Normal neurologic examination including intelligence*
- *Normal EEFG*
- *With patient's informed agreement*
- *One drug at a time in cases of polytherapy*
- *Withdraw slowly over 3-6 months*
- *Most recurrences occur in the first 3 months after discontinuing therapy, and patients should be warned*

Choice of ASMs according to Seizure Type

GENERALISED ONSET TONIC CLONIC	FOCAL	TYPICAL ABSENCE	ATYPICAL ABSENCE MYOCLONIC, ATONIC
First-Line			
Valproic acid Lamotrigine Topiramate	Lamotrigine Carbamazepine Oxcarbazepine Phenytoin Levetiracetam	Valproic acid Ethosuximide	Valproic acid Lamotrigine Topiramate
Alternatives			
Zonisamide* Phenytoin Carbamazepine Oxcarbazepine Phenobarbital Primidone Felbamate	Topiramate Zonisamide* Valproic acid Tiagabine* Gabapentin* Lacosamide* Phenobarbital Primidone Felbamate	Lamotrigine Clonazepam	Clonazepam Felbamate

*As adjunctive therapy

- *Sodium valproate is first-line treatment in-patients with newly diagnosed GTC seizures.*
- *Carbamazepine or lamotrigine is first-line treatment in patients with newly diagnosed focal seizures.*
- *Do not offer lamotrigine in myoclonic seizures, and carbamazepine and oxcarbazepine in myoclonic or absence seizures. (may beworsen seizures)*

Dosage guidelines for established ASMs in adolescent and adult

Drug	Starting dose (per day)	Standard Maintenance Dose (per day)	Dosage interval	Common side effects
Sodium valporate	200 mg	500-2000mg	od - qid	Weight gain, Tremor, Hair Loss, Teratogenesis
Carbamazepine	200 mg	400-1800mg	od - bid	Rash, Diplopia, Dizziness, Headache, Nausea, Teratogenesis,
Phenobaribitone	60 mg	60-180mg	od - bid	Fatigue, Listlessness, Depression
Phenytoin	200 mg	100 - 400 mg	od - bid	Ataxia, Drowsiness, Hirsutism, Gum hypertrophy, Teratogenesis
Lamotrigine	25 mg	100 - 500 mg	od - bid	Rash, Nausea, Headache, Insomnia
Topiramate	25 mg	100 - 400 mg	od - bid	Nausea, vomiting, Diarrhoea, Constipation, Dyspepsia, Dry mouth, Abdominal pain, Dizziness, Cognitive impairment
Levetiracetam	250 mg	250 -3000 mg	od - bid	Anorexia, Weight change, Abdominal pain, Dyspepsia, Diarrhoea, Dizziness
Oxycarbazepine	300 mg	900-2400 mg	od - bid	Rash, Diplopia, Dizziness, Headache, Nausea, Teratogenesis,
Lacosamide	100 mg	200-400 mg	od - bid	GI irritation Cardiac conduction (PR interval prolongation)

- Serious skin reaction including Stevens-Johnson's syndrome and toxic epidermal necrolysis is rare but potentially fatal. Warn the patients to see doctor immediately if rash or signs and symptoms of hypersensitivity develop

Referral to the Tertiary Centre

Referral should be considered when one or more of the following criteria are present:

- management is unsuccessful after two drugs
- unacceptable side effects from medication
- suspected of structural brain lesion
- psychological and/or psychiatric co-morbidity
- diagnostic doubt as to the nature of the seizures and/or seizure syndrome

Considerations in women

Menstruation

- Some women experience a marked increase in seizure frequency around the time of menses (catamenial epilepsy)
- This is believed to be mediated by either the effects of estrogen and progesterone on neuronal excitability
- or changes in antiepileptic drug levels due to altered protein binding or metabolism.
- Some patients may benefit from increases in antiseizure drug dosages during menses

Contraception

- Enzyme-inducing antiepileptic drugs (e.g. carbamazepine, phenytoin, phenobarbital, oxcarbazepine, topiramate) that reduce estrogen levels by enhancing its metabolism require patients to be treated with higher doses of pill (containing 50- 100 µg ethinyloestradiol) or alternative methods of contraception.

Pregnancy

- *Most women with epilepsy who become pregnant will have an uncomplicated gestation and*

deliver a normal baby

- *Epilepsy poses some important risks to a pregnancy.*
- *Seizure frequency during pregnancy will remain unchanged in ~50% of women, increase in 30%, and decrease in 20%*
- *Changes in seizure frequency are due to endocrine effects on the CNS, variations in antiepileptic drug pharmacokinetics (such as acceleration of hepatic drug metabolism or effects on plasma protein binding), and changes in medication compliance.*
- Risk of fetal malformation is minimized if a single first-line AED with folic acid (5mg/day) supplementation is used.
- Antiepileptic drugs should not be discontinued
- Valproate should be *avoided*, if possible. It is Valproic acid is strongly associated with an
- *increased risk of adverse fetal outcomes (7–20%).*
- Carbamazepine and *Lamotrigine* have the lowest incidence of major fetal malformations.
- *Enzyme-inducing drugs such as phenytoin, carbamazepine, oxcarbazepine, topiramate, phenobarbital, and primidone cause a transient and reversible deficiency of vitamin K–dependent clotting factors in ~50% of newborn infants*
- *Neonatal hemorrhage is uncommon, the mother should be treated with oral vitamin K (20 mg/d, phylloquinone) in the last 2 weeks of pregnancy, and the infant should receive intramuscular vitamin K (1 mg) at birth.*

Breast Feeding

- *Given the overall benefits of breast-feeding and the lack of evidence for long-term harm to the infant by being exposed to antiepileptic drugs, mothers with epilepsy can be encouraged to breast-feed.*
- *This should be reconsidered, if there is any evidence of drug effects on the infant such as lethargy or poor feeding.*



FACIAL NERVE (BELL) PALSY

- ***Bell Palsy is an acute unilateral lower motor neuron paresis or paralysis of the facial nerve (cranial nerve 7). It is the most common cranial neuropathy.***
- ***The annual incidence of this idiopathic disorder is ~25 per 100,000 annually, or about 1 in 60 persons in a lifetime and common in age group between 10 and 40.***
- The classic type is Bell palsy, which is usually idiopathic although attributed to an inflammatory swelling involving the facial nerve in the bony facial canal.
- In Ramsay-Hunt syndrome, which is due to infection with herpes zoster causing facial nerve palsy, vesicles may be seen on the ipsilateral ear.
- *Herpes simplex virus (HSV) type 1 DNA was frequently detected in endoneurial fluid and*
- *posterior auricular muscle, suggesting that a reactivation of this virus in the geniculate ganglion may be responsible for most cases.*
- *Reactivation of varicella zoster virus is associated with Bell's palsy in up to one-third of cases, and may represent the second most frequent cause*

Clinical features

- Abrupt onset (can worsen over 2-5 days)
- ***Pain behind the ear may precede the paralysis for a day or two.***
- *Weakness in the face (complete or incomplete)*
- Impaired blinking
- *Bell phenomenon - when closing the eye, it turns up under the half-closed lid*

Bell's Palsy



- Less common:
  - difficulty eating
  - loss of taste-anterior two-thirds of tongue
  - *hyperacusis*

Prognosis

- *70% of patient have a complete recovery, 13% have had insignificant sequelae, the remainder have permanent deficit*
- *Approximately 80% of patients recover within a few weeks or months.*
- *The presence of incomplete paralysis in the first week is the most favorable prognostic sign.*

Management

- ***Prednisolone*** 1mg/kg/day in divided doses for 3 days within 72 hrs of onset, then taper to zero over next 14 days (start within 3 days of onset)
- *Prednisolone therapy modestly shortens the recovery period and improves the functional outcome.*
- *For Ramsey-Hunt syndrome, antiviral agent is added.*
    - Although two larges recently published randomized trials found no added benefit of antiviral agents ***valacyclovir*** (1000 mg daily for 5–7 days) or ***acyclovir*** (400 mg five times daily for 10 days) compared to prednisolone alone, the overall weight of evidence suggests that the combination therapy with prednisone plus valacyclovir/acyclovir may be marginally better than prednisone alone, especially in patients with severe clinical presentations.
- ***Patient education andreassurance***
- ***Adhesive patch*** or paper tape to cover over eye if corneal exposure (e.g. windy or dusty conditions, during sleep)
- ***Artificial tears*** if eye is dry and at bedtime
- Massage and facial exercises during recovery
- ***Note:*** At least 70-80% achieves full spontaneous *recovery*, higher if mild.
- *Electromyography and nerve excitability or conduction studies are a prognostic guide only.*
- *No evidence that surgical procedures to decompress the nerve are beneficial*
- *Refer to physiotherapy for better outcome*

Refer

- If recovery is not starting after 3 weeks
- For tarsorrhaphy if complete or long-standing palsy
- If unacceptable cosmetic result may benefit from plastic surgery

HEADACHE

Introduction

- *Everyday* many patients visit to the doctors with the complaint of headache.
- *Chief skill is interpreting the history to get to the diagnosis.*

Causes

COMMON CAUSES OF HEADACHE

PRIMARY HEADACHE		SECONDARY HEADACHE	
TYPE	**%**	**TYPE**	**%**
Tension-type	69	Systemic infection	63
Migraine	16	Head injury	4
Idiopathic stabbing	2	Vascular disorders	1
Exertional	1	Subarachnoid hemorrhage	<1
Cluster	0.1	Brain tumor	0.1

Source: After J Olesen et al: *The Headaches*. Philadelphia, Lippincott, Williams & Wilkins, 2005.

Acute Single Episode

- ***Meningitis:*** *Acute, severe headache with stiff neck and fever suggests meningitis. Lumbar puncture is mandatory.*
- *Often there is striking accentuation of pain with eye movement.*
- ***Encephalitis:*** Fever, odd behaviour, *seizure,* or reduced consciousness
- ***Tropical illness:*** *Malaria,* flu like illness
- ***Intracranial Hemorrhage:*** Acute, severe headache with stiff neck but without fever suggests subarachnoid hemorrhage. A ruptured aneurysm, arteriovenous malformation, or intraparenchymal hemorrhage may also present with headache alone.
- ***Sinusitis:*** Dull constant aching pain over the affected frontal or maxillary sinus, with tender overlying skin with or without post nasal drip, often accompanied by coryza
- ***Head injury:*** Cuts, *bruises,* reduced consciousness and lucid interval

Acute Recurrent Attack

- ***Migraine:*** if aura present, usually, seeing spots, *zigzag* lines, Vomiting, Nausea, Throbbing type and usually last up to 72 hours
- ***Cluster headache:*** Strictly unilateral, and typically associated with severe pain and congestion of eye, tearing, nasal congestion on the affected side, tearing, lasts for about 4-8 weeks then feels resolve for next several months then reoccur intermittently. Usually last for 90 to 120 minutes and majority occur at last in night.
- ***Glaucoma:*** Glaucoma may present with a prostrating headache associated with nausea and vomiting. The headache often starts with severe eye pain. On physical examination, the eye is often red with a fixed, moderately dilated pupil.

Subacute Headache

- ***Temporal (Giant) cell arteritis:*** *Temporal (giant cell) arteritis is an inflammatory disorder of arteries that frequently involves the extracranial carotid circulation.*
  - *It is a common disorder of the elderly*
  - *The average age of onset is 70 years, and women account for 65% of cases.*
  - *About half of patients with untreated temporal arteritis develop blindness due to*

involvement of the ophthalmic artery and its branches.
  - *Typical presenting symptoms include headache, polymyalgia rheumatica, jaw claudication, fever, and weight loss.*
  - *Headache is the dominant symptom and often appears in association with malaise and muscle aches.*
  - *Scalp tenderness is often present, The ESR is often, though not always, elevated; a normal ESR does not exclude giant cell arteritis*
- ***Venous sinus thrombosis:*** cavernous sinus thrombosis due to
  - spread of facial pustules or
  - folliculitis causing *headache*,
  - chemosis,
  - *proptosis*,
  - painful ophthalmoplegia
- ***Saggittal sinus thrombosis:***
  - *Headache*,
  - *vomiting*,
  - seizures,
  - *papilloedema*
- ***Brain tumor:***
  - *Approximately 30% of patients with brain tumors consider headache to be their chief complaint.*
  - *The head pain is usually nondescript—an intermittent deep, dull aching of moderate intensity, which may worsen with exertion or change in position and may be associated with nausea and vomiting*

Chronic Headache

- ***Chronic daily headache:*** The presence of a headache on 15 days or more per month for at least 3 months.
- ***Tension Headache:*** *tension-type headache (TTH) is commonly used to describe a chronic head-pain syndrome characterized by bilateral tight, bandlike discomfort.*
  - *The pain typically builds slowly, fluctuates in severity, and may persist more or less continuously for many days. The headache may be episodic or chronic (present >15 days per month).*
  - *A useful clinical approach is to diagnose TTH in patients whose headaches are completely without accompanying features such as nausea, vomiting, photophobia, phonophobia, osmophobia, throbbing, and aggravation with movement.*

CLASSIFICATION OF CHRONIC DAILY HEADACHE

PRIMARY		
>4 h DAILY	**<4 h DAILY**	**SECONDARY**
Chronic migraine[a]	Chronic cluster headache[b]	Posttraumatic Head injury Iatrogenic Postinfectious
Chronic tension-type headache[a]	Chronic paroxysmal hemicrania	Inflammatory, such as Giant cell arteritis Sarcoidosis Behçet's syndrome
Hemicrania continua[a]	SUNCT/SUNA	Chronic CNS infection
New daily persistent headache[a]	Hypnic headache	Medication-overuse headache[a]

[a]May be complicated by analgesic overuse.
[b]Some patients may have headache >4 h/d.
Abbreviations: SUNA, short-lasting *u*nilateral *n*euralgiform headache *a*ttacks with cranial autonomic symptoms; SUNCT, short-lasting *u*nilateral *n*euralgiform headache attacks with conjunctival injection and *t*earing.

1.

Other chronic headache

- ***Chronically increased ICP:*** e.g. brain *tumour*, worse in the morning *waking*, projectile vomiting
- Analgesic induced headache: rebound headache on stopping taking analgesics
- ***Paget's disease:*** most commonly presents with bone pain but can come with headache
- ***Depression***
- ***Dental and occular disease***
- ***Temporomandibular joint dysfunction***
- ***Trigeminal neuralgia***

How to get diagnosis of headache

Thorough history taking is essential

- ***onset:*** *acute*, subacute, *chronic*, recurrent
- ***duration:*** hours or days, episodic
- ***severity:*** severe at *onset*, first and worse headache ever, thunderclap headache is SAH
- ***site and radiation:*** commonly bi-temporal in tension *headache*, unilateral in *migraine*, frontal in raised intracranial pressure,
- ***associated features:***
  - neck stiffness, photophobia m meningitis, disorientation m encephalitis
  - *nausea*, lacrimation, seeing spots in migraine
  - *vomiting*, headache worse on waking up, diplopia in brain tumor
  - periorbital oedema, chemosis, ophthalmoplegia in cavernous sinus thrombosis

Diagnostic workup

History

- Complete systemic examination (need to emphasize on CNS examination)
- Fundoscopic and retinal examination (may need eye referral for glaucoma cases)

Basic laboratory exam

- Full blood count (neutrophil leucocytosis in pyogenic *meningitis*, lymphocytosis in viral and tuberculous meningitis)
- ESR raised in Giant Cell Arteritis
- Urea and electrolytes, liver function test for metabolic causes of encephalopathy
- Skull X-ray and Sinus X-ray if there is evidence of head injury, sinusitis
- Lumbar puncture if there is no papilloedema on fundoscopy
- Essential for diagnosis of meningitis, encephalitis and subarachnoid haemorrhage
- CT head scan: to exclude space occupying lesion

Management

Depends on the underlying cause

- If there is suspicious signs of increase intracranial pressure and meningitis, should refer to hospital immediately.
- If no emergency symptoms like severe headache, *vomiting*, neurological *deficit*, can do investigation and can be treated atoutside clinic.

Symptomatic Management

- *Simple pain killers (paracetamol or **simple analgesics)** first, then step up to **potent NSAIDs** if symptom not controlled.*
- ***Antiemetics** like metoclopramide should be added in cases of Migraine.*
- *If headache tends to be **chronic and long term NSAID usage is needed,** should consider to add **proton pump inhibitor** to prevent gastritis or erosion*
- *If pain still continues, can use narcotic-based compounds (co-codamol) or tramadol.*

Specific Management

Migraine acute treatment

- ***Oral triptan** combined with either NSAID or paracetamol (NICE)*
- ***High dose Aspirin** 900mg 6 hrly after food or paracetamol 1 gram 6 hourly after metoclopramide therapy*
- ***Alternatives:** Sumatriptan, Zolmitriptan, Ergotamine*
- *Breathing into paper bag may abort some attacks*
- *Some people find warm or cold packs to the head helps ease the pain*

Migraine prophylaxis treatment

- ***Stop Oral Contraceptive pills** if the migraine produces focal neurology, such as hemiplegia*
- *Patients with an increasing frequency of migraine attacks, or with attacks that are either unresponsive or poorly responsive to abortive treatments, are good candidates for preventive agents.*
- *A preventive medication should be for patients with five or more attacks a month*
- *Drugs must be taken daily, and there is usually a lag of at least 2–12 weeks before an effect is seen.*
- *If one drug **doesn't work** after 2-3 months **try another***
- *60% ofpatients can expect some benefits*
- *Drugs:*
    - *Propranolol 40-80 mg 8 hrly,*
    - *Topiramate 25-50 mg 12 hrly (teratogenic in pregnancy),*
    - *Pizotifen 500 µg 8 hrly PO, or 1.5 mg PO at night,*
    - *Amitryptyline 10-50 mg at night (contraindicated if IHD, coronary spasm, uncontrolled hypertension and recent lithium SSRI or Ergotamine use)*
    - *Second line drugs: **sodium valproate,** verapamil, **gabapentin** and clonidine*

Referral

- *Should refer to emergency if any fever, signs of increase intracranial pressure, neck stiffness, sensorium changes present, unilateral headache with eye pain, recent head injury (<3 month)*
- *Seek specialist opinion if headache recurrent, not responding to maximal dose of pain killers and neurological involvement*
- *New onset in patient with a history of HIV or cancer*
- *Headache with atypical aura (>1 hr ± motor weakness)*
- *Aura for first time and using COC*

TREATMENT OF ACUTE MIGRAINE

Drug	Dosage
Simple analgesics	
Paracetamol, aspirin, caffeine combination	Two tablets or caplets q6h (max 8 per day)
NSAIDs	
Naproxen	220-550 mg BD
Ibuprofen	400 mg TDS-QID
5-HT1 Agonists	
Avamigran	One or two tablets at onset, then one tablet q1/2h (max 6 per day, 10 per week)
Sumatriptan	50–100 mg tablet at onset; may repeat after 2 h (max 200 mg/d)
Zolmitriptan	2.5 mg tablet at onset; may repeat after 2 h (max 10 mg/d)
Dopamine Antagonists	
Metoclopramide	Oral 5–10 mg/d, or IV 10 mg
Prochlorperazine	Oral 1–25 mg/d, or IV 10 mg

Preventive Treatments in Migraine

Drug	Dose	Selected side effects
Propranolol	40-120 mg BD	Reduced energy Tiredness Postural symptoms Contraindicated in asthma
Amitriptyline	10-75 mg HS	Drowsiness
Topiramate	25-200 mg/day	Paresthesias Cognitive symptoms Weight loss Glaucoma Caution with nephrolithiasis
Valproate	400-600 mg BD	Drowsiness Weight gain Tremor Hair loss Fetal abnormalities Hematologic or liver abnormalities
Gabapentin	900-3600 mg/day	Dizziness Sedation
Flunarizine	5-15 mg/day	Drowsiness Weight gain Depression Parkinsonism

PARKINSONISM

SYNDROME OF PARKINSONISM

- *a general term that is used to define a symptom complex manifest by bradykinesia with rigidity and/or tremor.*
- *Among the different forms of parkinsonism, PD is the most common (approximately 75% of cases).*

Atypical parkinsonism:

- *a group of neurodegenerative conditions present with a parkinsonism (rigidity and bradykinesia) but typically have a slightly different clinical picture than PD, reflecting differences in underlying pathology.*
- *They are often characterized by early speech and gait impairment, absence of rest tremor, no asymmetry, poor or no response to levodopa, and an aggressive clinical course.*
- *In the early stages, they may show some modest benefit from levodopa and be difficult to distinguish from PD.*
- *Common forms of atypical parkinsonism are (1) multisystem atrophy, (2) progressive supranuclear palsy and (3) corticobasal degeneration.*

Secondary parkinsonism:

- *It can be associated with drugs, stroke, tumor, infection, or exposure to toxins such as carbon monoxide or manganese.*
- *Dopamine-blocking agents such as the neuroleptics are the commonest cause of secondary parkinsonism. These drugs are most widely used in psychiatry, but be aware that drugs such as metoclopramide and chloropyrazine, which are primarily used to treat gastrointestinal problems, are also neuroleptic agents and common causes of secondary parkinsonism and tardive dyskinesia*

DIFFERENTIAL DIAGNOSIS OF PARKINSONISM

Parkinson's Disease	Atypical Parkinsonisms	Secondary Parkinsonism	Other Neurodegenerative Disorders
Genetic	Multiple-system atrophy	Drug-induced	Wilson's disease
Sporadic	Cerebellar type (MSA-c)	Tumor	Huntington's disease
Dementia with Lewy bodies	Parkinson type (MSA-p)	Infection	Neurodegeneration with brain iron accumulation
	Progressive supranuclear palsy	Vascular	SCA 3 (spinocerebellar ataxia)
	Corticobasal ganglionic degeneration	Normal-pressure hydrocephalus	Fragile X–associated ataxia-tremor-parkinsonism
	Frontotemporal dementia	Trauma	Prion disease
		Liver failure	Dystonia-parkinsonism (DYT3)
		Toxins (e.g., carbon monoxide, manganese, MPTP, cyanide, hexane, methanol, carbon disulfide)	Alzheimer's disease with parkinsonism

Treatment of Drug-induced Parkinsonism

- If *possible*, stop the implicated drug. If on an antipsychotic for schizophrenia, do not stop *treatment*, but add an anticholinergic drug (e.g. Trihexyphenidyl 2 mg tds).
- Consider switching to an atypical antipsychotic drug -take specialist advice.

PARKINSON DISEASE

Definition

- *Incurable, progressive,* degenerative disease affecting the dopaminergic neurons of the substantia nigra in the brainstem, resulting in ***deficiency of dopamine*** and relative excess of acetylcholine transmitters

Clinical Features

Symptoms

- *PD is a most common and disabling chronic neurological disorder.*
- *The mean age of onset is between 58 and 62 years.*
- The incidence rises sharply over 70 years of *age*.
- The diagnosis is based on the history and examination.
- Always think of PD in an older person presenting with falls.
- Non-motor automatic dysfunctions: cognition, behavior, *mood*. Hemi-Parkinsonism can occur; all the signs are confined to one side and thus must be differentiated from hemiparesis. In fact, most cases of PD start *unilaterally*.
- Always consider drug-induced Parkinsonism. The usual drugs are phenothiazines, butyrophenones and reserpine. Tremor is uncommon but rigidity and bradykinesia may be severe.

THREE MAJOR TRAPS IN MISSING EARLY DIAGNOSIS:

- *Age:* 10-15% are <50 years at onset
- Belief that it is a disease of men:
- Absence of resting tremor (only 50% have it at onset).

Signs

- *Power,* reflexes, and sensation are usually normal.
- The earliest abnormal physical signs to appear are loss of dexterity of rapid alternating movements and absence of arm swing, in addition to increased tone with distraction.
- Positive frontal lobe signs, such as grasp and glabellar taps (only allow three blinks), *are* more common with Parkinsonism.

The Classic Tetrad of PD

- tremor (at rest)
- *rigidity*
- bradykinesia (poverty of movement)
- *postural instability*

CLINICAL FEATURES OF PARKINSON'S DISEASE

CARDINAL FEATURES	OTHER MOTOR FEATURES	NONMOTOR FEATURES
Bradykinesia	Micrographia	Anosmia
Rest tremor	Masked facies (hypomimia) equalize	Sensory disturbances (e.g., pain)
Rigidity	Reduced eye blink	Mood disorders (e.g., depression)
Gait disturbance/postural instability	Soft voice (hypophonia)	Sleep disturbances
	Dysphagia	Autonomic disturbances
	Freezing	Orthostatic hypotension
		Gastrointestinal disturbances
		Genitourinal disturbances
		Sexual dysfunction
		Cognitive impairment/dementia

PARKINSON DISEASE: SYMPTOMS AND SIGNS (CHECK-LIST)

General	Tiredness Lethargy Restlessness Trouble getting out of chair or car and turning over in bed
Tremor	Present at rest
Rigidity	Slow rate--4 to 6 cycles per second Alternating, especially arms Pill-rolling (severe cases) *Note:* may be absent or unilateral 'Cogwheel' - 'juddering' on passive extension of the forearm-feels like going through c o g s Lead pipe-limbs resist passive extension through movement (constant resistance)
Bradykinesia/hypokinesia	Slowness of initiating a movement Masked facies Relative lack of blinking Impaired convergence of eyes Excessive salivation (late) Difficulty turning over in bed and rising from a chair Slow, monotonous s p e e c h /dysarthria
Gait disorder	No arm swing on one or both sides Start hesitation Slow and shuffling Short steps *(petit pas)* Slow turning circle ('tum by numbers') 'Freezing' when approaching an obstacle Festination
Disequilibrium	Poor balance Impaired righting reflexes Falls-may be first thing that leads to presentation
Posture	Progressive forward flexion of trunk (stooped) Flexion of elbow at affected side
Autonomic symptoms	Constipation (common) Postural hypotension-may be induced by treatment Depression (early) Progressive dementia in 30-40% usually after 10 years
Psychiatric	Hallucination – either with Lewy body dementia or treatment

PRINCIPLES OF MANAGEMENT

1. Provide appropriate explanation and education.
Explain that PD is slowly progressive disease, and it may improve some but not cured by treatment.
Support systems are necessary for advanced PD.
Walking sticks (which spread the centre of gravity) with appropriate education into their use may be necessary to help prevent falls, and constant care is required, so that admission to a nursing home for end-stage disease may be appropriate.
Reduce symptoms and increase quality of life
Reduce rate of disease progression
Limit side effects of treatment

SCREENING FOR DEPRESSION

REFERRAL

- Refer all patients to Neuro-Physician for confirmation of diagnosis, advise on management and to access a multidiscipline specialist rehabilitation team.

REHABILITATION

- Liaise closely with specialistrehabilitation team

DRUG TREATMENT

- *The medical treatment of early PD should be started when functional disability appears, which is a different threshold for each patient.*
- *For patients below 65 years old, or above 65 years old but with preserved mental function and with no severe comorbidity, initial monotherapy with a dopamine agonist is advisable.*
- *Non–levodopa medications eventually will be insufficient to effectively ameliorate motor symptoms, and patients will need to be treated with levodopa (levodopa rescue).*

Dopamine Receptor Agonist

- *Dopamine agonists directly stimulate dopamine receptors, bypassing degenerating dopaminergic neurons in the brain.*
- *Non–ergot dopamine agonists are used as both monotherapy and adjunctive therapy in the treatment of Parkinson disease. They have longer half-lives (greater than 6 hours) than levodopa*
- *They also have a higher incidence of psychiatric side effects, including hallucinations and impulse control disorders as well as potential "sleep attacks" (i.e., episodes of sudden onset of sleep).*
- *Dopamine agonists include pramipexole, ropinirole rotigotine (transdermal formulation), and apomorphine, which is for subcutaneous use as a rescue medication for acute off periods.*

Levodopa (L-dopa)

- *Levodopa is the gold standard for dopamine replacement therapy in Parkinson disease.*
- *It is administered with a dopa decarboxylase inhibitor (carbidopa) to reduce its peripheral breakdown and lessen nausea.*
- *Levodopa is particularly effective in treating akinesia and rigidity, with more variable effects on tremor.*
- *Clinical research suggests that levodopa treatment does not worsen disease*
- *Progression*

COMT Inhibitors

- *COMT inhibitors reduce the breakdown of levodopa to 3-O-methyldopa and increase the plasma half-life of levodopa.*
- *COMT inhibitors are used in conjunction with levodopa to improve end-of-dose wearing-off time*
- *They may increase dyskinesia.*
- *Currently available COMT inhibitors include* ***entacapone and tolcapone.***

MAO-B (Monoamine Oxidase B) inhibitors

- *MAO-B inhibitors prevent levodopa degradation in the brain and limit its reuptake.*
- *Selegiline is a selective and irreversible MAO-B inhibitor approved as adjunctive medication to levodopa in patients with motor fluctuations.*
- *Rasagiline, a second-generation MAO-B inhibitor, lacks the amphetamine metabolites of selegiline and may be used as monotherapy and adjunct therapy.*
- *Safinamide is another potent, reversible MAO-B inhibitor as adjunct therapy in patients with Parkinson disease with motor fluctuations*

Amantadine

- *Amantadine is an N-methyl-D-aspartate (NMDA) receptor antagonist and has antidyskinetic*

properties.

- *It also improves bradykinesia, tremor, and rigidity.*

Anti-cholinergic drugs

- *Anticholinergic medications such as trihexyphenidyl and benztropine are used to treat tremor in younger patients with Parkinson disease*
- *Useful for drug-induced parkinsonism.*

NON-MOTOR FEATURES OF PARKINSON'S DISEASE

DEPRESSION

- Management of depression in people with PD should be tailored to the individual to their co-existing therapy.
- SSRI e.g.,
  - Escitalopram (5-20 mg/D)
  - Fluoxetine 20-60 mg/D
  - Sertraline 25-200 mg/D
  - Venlafaxine 37.5-187.5 mg/D

PSYCHOTIC SYMPTOMS

- Rule out secondary cause
- *Mild psychotic symptoms may not need to be actively treated if well tolerated by the patient and carers.*
- Eliminate PD medication in order of anticholinergic, *amantadine,* dopamine agonists and MAOI.
- Atypical *antipsychotics*
  - Quetiapine immediate release (50 mg tablet) 12.5-200 mg HS.
  - Clozapine (25 mg tablet) 6.25-50 mg HS can be used.

COGNITIVE IMPAIRMENT

- Compensatory strategies (e.g. *Cueing,* simplifying complex tasks)
- Cholinesterase inhibitors: Rivastigmine 1.5 mg bd (3 mg/day) titrate every 4 weeks to 6 mg bd as tolerated or Donepezil 5 mg/day after 4 weeks to 10 mg/D

SLEEP DISTURBANCES

- Good sleep hygiene should be advised such *as*
  - avoidance of stimulants (for *example,* coffee, *tea,* caffeine) in the evening
  - establishment of a regular pattern of sleep
  - comfortable bedding and temperature
  - provision of assistive devices, such as a bed lever or rails to aid with moving and *turning,* allowing the person to get more comfortable
  - restriction of daytime nap
  - advice about taking regular and appropriate exercise to induce better sleep
  - *a review of all medication and avoidance of any drugs that may affect sleep or alertness, or may interact with other medication (e.g. selegiline, antihistamines, H2 antagonists, antipsychotics and sedatives).*

Drug treatment for sleep disturbances

- *Tricyclic antidepressants*
  - *Amitriptyline 12.5-25 mg HS*
- *Non benzodiazepine hypnotic-*
  - *Zolpidem 5-10 mg HS*
- *Benzodiazepine –*
  - *Lorazepam 0.5-1 mg HS*
- *Atypical antipsychotic-*
  - *Quetiapine 12.5-50 mg HS*

RAPID EYE MOVEMENT BEHAVIOR DISORDER (RBD)

- *Mild-not need medication, ensure safety of sleeping environment.*
- *Moderate or severe-Clonazepam 0.25 mg HS and titrate according to response and tolerability up to 4 mg/day*
- *Consider melatonin (3 mg HS titrate 3 mg every week as necessary and tolerated up to 12 mg).*

CONSTIPATION

- *Dietary fiber and fluid intake*
- *Laxatives - lactulose 15-30 ml daily or bd,*
- *Stimulant laxative - Bisacodyl (Dulcolax) 5-15mg HS*

PD related pain

- *Amitriptyline*
- *Gabapentin*

TABLE. PHARMACEUTICAL TREATMENTS FOR MOTOR SYMPTOMS OF PARKINSON'S DISEASE

ACTION	DRUGS	AVAILABLE FORMULATIONS	COMMON SIDE EFFECTS
Dopamine precursor with metabolic inhibitor	Levodopa/carbidopa	Tablets (IR, ER) Dissolving tablets	Nausea, vomiting, orthostatic hypotension, vivid dreams, hallucinations, delusions
MAO inhibitors reduce levodopa and dopamine degradation	Rasagiline	Tablets	Hypertension, orthostatic hypotension, potentiation of levodopa-related side effects
	Selegiline	Tablets, capsules, orally disintegrating tablets	
	Safinamide	Tablets	
COMT inhibtors reduce levodopa and dopamine degradation	Entacapone	Tablets	Potentiaiton of levodopa-related side effects, diarrhea, orange color of urine
	Tolcapone	Tablets	Potentiation of levodopa-related side effects, hepatotoxicity,
Dopamine receptor agonists	Pramipexole	Tablets, ER tablets	Nausea, vomiting, orthostatic hypotension, hallucinations, psychosis, impulse control disorders, peripheral edema
	Ropinirole	Tablets, ER tablets	
	Rotigotine	Transdermal patches	
	Apomorphine	Subcutaneous injection	
Other/Unknown	Anticholinergics (trihexyphenidyl, benztropine)	Tablets	Dry mouth, dry eyes, confusion, hallucinations, constipation, urinary retention
	Amantadine	Tablets, capsules, ER tablets	Dry mouth, dry eyes, livedo reticularis, confusion, hallucinations, constipation, urinary retension, peripheral edema

Abbreviations: COMT, catechol-*o*-methyltransferase; ER, extended release; IR, immediate release; MAO, monoamine oxidase.

Symptoms	Treatment
Depression	• Norepinephrine antidepressants such as: Amitriptyline, imipramine, nortriptyline, and desipramine • SSRI's such as fluoxetine and nefazodone • Second generation non-ergot agonists, for example, Pramipexole and ropinirole • Psychotherapy
Anxiety	• Buspirone and SSRI • Cognitive Behavioral Therapy
Apathy	• Piribedil • Dopamine enhancing medication, for example, Pramipexole and ropinirole
Dementia	• Rivastigmine
Front Executive Dysfunction	• Cholinesterase inhibitors
EDS	• Correct timing of medication • CNS stimulants: Modafinil, Ritalin • Avoid benzodiazepine
MCI	• Cholinesterase inhibitors
RBD	• Clonazepam • Donepezil • Melatonin • Pramipexole
Incontinence	• Anticholinergic drugs • α-Blockers • Pelvic floor muscle therapy • Lifestyle changes
Hyperhidrosis	• Dopamine agonist therapy • Apomorphine
Drooling	• Anti-Parkinson's drug therapy • Speech and language therapy • Chewing gum • Trihexyphenidyl • Amitriptyline
Sexual dysfunction	• ED: Phosphodiesterase inhibitors, for example, Sildenafil • Hypersexuality: Pergolide mesylate with L-DOPA • Counseling
Postural hypotension	• Fludrocortisone
Non-motor symptom fluctuation	• COMT inhibitors • IMAOB • Apomorphine infusion • Subthalamic deep brain stimulation • Amatine • Free salt intake • Increased fluid intake
Pain	• Musculoskeletal pain: NSAIDS, physical therapy and exercise program • Dystonic pain: deep brain stimulation, trihexyphenidyl • Pain from akathisia: managed with dopaminergic treatments • Central pain: analgesics, opiates, and atypical neuroleptics
Speech dysfunction	• Behavioral speech therapy • LSVT LOUD
Constipation	• Diet of high fiber foods and fluids • Exercise • Reduction of anticholinergic medication

EDS: Excessive day time sleepiness; MCI: Mild cognitive impairment; PLMS: Periodic limb movements of sleep; RBD: REM behavioral disorder; RLS: Restless leg syndrome.

Symptoms	Treatment
	• Macrogol • Milk of magnesia • Psyllium • Polyethylene glycol • Laxatives and enemas as a last resort
Dysphagia	• Softening solid food and thickening liquids before consumption • Gastrostomy
Ocular dysfunction	• Artificial tears • Bifocal and progressive lenses
RLS	• Pramipexole, ropinirole • Pregabalin • Simplify psychoactive medications with atypical neuroleptics, for example, clozapine • Gabapentin enacarbil to treat PLMS • Oxycodone with naloxone

EDS: Excessive day time sleepiness; MCI: Mild cognitive impairment; PLMS: Periodic limb movements of sleep; RBD: REM behavioral disorder; RLS: Restless leg syndrome.

STROKE

Definition

A focal neurological deficit lasting longer than 24 hours caused by intracerebral hemorrhage or infarction.

Completed stroke: The deficit has become fixed and maximal, usually within 6 hrs.
Stroke in evolution: An enlarging neurological deficit, presumably due to infarction, which increases over 24-48 hours.
Transient cerebral ischaemic attack (TIA): A transient focal neurological deficit due to cerebral ischemia, lasting not more than 24 hr. of initial symptoms, but most TIAs last <1 h. The causes of TIA are similar to the causes of ischemic stroke, but because TIAs may herald stroke they are an important risk factor that should be considered separately.
Patients with a history of TIA have a 20% risk of stroke in the following month with higher risk in the first 72 hr. Risk can be predicted using the ABCD2 scoring system.
Amaurosis fugax: Amaurosis fugax, or transient monocular blindness, is a form of TI occurs from emboli to the central retinal artery of one eye. This may indicate carotid stenosis as the cause or local ophthalmic artery disease.

ACUTE STROKE

Definition of CNS infarction:

CNS infarction is brain, spinal cord, or retinal cell death attributable to ischemia, based on

1. *pathological, imaging, or other objective evidence of cerebral, spinal cord, or retinal focal ischemic injury in a defined vascular distribution; or*
2. *clinical evidence of cerebral, spinal cord, or retinal focal ischemic injury based on symptoms persisting ≥24 hours or until death, and other etiologies excluded.*

Definition of ischemic stroke:

- *An episode of neurological dysfunction caused by focal cerebral, spinal, or retinal infarction.*

Definition of silent CNS infarction:

- *Imaging or neuropathological evidence of CNS infarction, without a history of acute neurological dysfunction attributable to the lesion.*

Definition of intracerebral hemorrhage:

- *A focal collection of blood within the brain parenchyma or ventricular system that is not caused by trauma.*

Definition of stroke caused by intracerebral hemorrhage:

- *Rapidly developing clinical signs of neurological dysfunction attributable to a focal collection of blood within the brain parenchyma or ventricular system that is not caused by trauma.*

Classification of stroke



RISK FACTORS FOR STROKE

Modifiable risk factors	Non-modifiable risk factors
Hypertension	Age
Cardiac disease	Gender
Diabetes	Race
Hyperlipidaemia	Ethnicity
Cigarette smoking	Family history of stroke
Alcohol consumption	
Illicit drug use	
Lifestyle factors: obesity, lack of physical activity and poor diet	
Oral contraceptive	
Migraine	
Atrial fibrillation	
Transient ischaemic attack	

PRESENTATION:

Symptoms strongly associated with stroke are sudden onset of:

- Change in speech
- Visual loss or diplopia

- Paralysis or weakness
- Numbness or tingling
- Non-orthostatic d i z z i n e s s

History: Sudden onset of CNS symptoms or stepwise progression of symptoms over hours or days

Examination: Conscious level may be reduced or normal: Neurological signs (including dysphagia and incontinence): BP, heart rate and rhythm, heart murmurs; carotid bruits; Systemic signs of infection or neoplasm.

MANAGEMENT OF ACUTE STROKE

- Admit all patients to an acute stroke unit unless there is a reason why that would be inappropriate, for *instance*, the patient is already in the terminal stage of another illness.

Assessment of patient by using BEFAST (Balance Eye Face Arm Speech Time)

To look for:

- A new symptom of trouble with balance and/or coordination
- A new symptom of suddenly blurred or double vision or a sudden loss of vision in one or both eyes without pain
- A new symptom of asymmetry of mouth; (acute facial paresis)
- A new symptom of inability to hold one arm out for 5 seconds compared to the other arm: (arm drift)
- A new symptom of slurred speech or new inability to understand or say words. (abnormal speech)

Patients who are candidates for brain imaging within hour of the onset of symptoms are:

- Those who are candidates for thrombolysis
- Patients on anticoagulants or with a bleeding tendency;
- Those with depressed level of consciousness (Glasgow Coma Score< 13);
- Those with progressive or fluctuating symptoms
- Those with signs of alternative pathology: neck stiffness, papilledema, fever

Those whose stroke begins with severe headache of sudden onset.

Assess the urgency or referral using ABCD2 (TIA)

Score the patient' risk of stroke in the next 30 days as follows:

- *score is a risk assessment tool designed to improve the prediction of short-term stroke risk after a transient ischemic attack (TIA).*
- The score is optimized to predict the risk of stroke within 2 days after a TIA, but also predicts stroke risk within 90 days.
- *The ABCD2 score is calculated by summing up points for five independent factors.*

Risk factor	Points	Score
Age • ≥ 60 years	1	
Blood Pressure • Systolic BP ≥ 140 mmHg or Diastolic BP ≥ 90 mmHg	1	
Clinical features of TIA (choose one) • Unilateral weakness with or without speech impairment OR • Speech impairment without unilateral weakness	2 1	
Duration • TIA duration ≥ 60 minute • TIA duration 10-59 minutes	2 1	
Diabetes	1	
Total		

High risk (6-7 points) Median risk (4-5 points) Low risk (0-3 points)
Admit if score is >l in <l week
Between 2-4 (median & high-risk group) must be assessed by a specialist within 24 hours

PREVENTION OF STROKE

SECONDARY PREVENTION

The risk of recurrence is 8% per year with the additional risk of other manifestation of cardiovascular disease.

Set up a cardiovascular disease register.

- *Lifestyle changes:* Assist smokers to stop and urge weight reduction, dietary *change,* reduction of alcohol intake to within sensible limits and exercise where appropriate.
- *Antiplatelet drugs:* Aspirin 75 mg daily or clopidogrel 75 mg daily *or* cilostazol 50 to 100 mg BD unless the stroke is likely to have been hemorrhage.
- *Blood pressure:* Once the initial phase of stroke is over (usually about 2 weeks), control any hypertension to < 140/85 or 130/80 in patients ***Atrial fibrillation:***
- Arrange anticoagulation with warfarin whether valvular heart disease is present or not.
- *Co- incidental cardiac disease: either;*
  - arranges *echocardiography*
  - anticoagulated
- *Raised cholesterol:* Use a statin and diet to lower cholesterol as recommended in the prevention of coronary heart *disease*
- *Carotid artery surgery for symptomatic extracranial carotid artery severe stenosis (70-99%).* Check that patient has been considered for carotid endarterectomy or angioplasty *if* the stroke was in the appropriate carotid artery territory.
- *With diabetes:* Treatment with Perindopril 4mg *daily+/-* a thiazide reduces the risk of further stroke by 28%.
- *ACE inhibitor:* Give an ACE inhibitor (e. g. ramipril 2.5mg daily increasing to ***10*** mg daily)

PRIMARY PREVENTION OF STROKE

Prevention should be targeted towards patients with one or more of these factors.

- *Hypertension:* Control BP to< 140/85 mmHg.
- *Atrial fibrillation:* Advise the patient about anticoagulation or antiplatelet treatment according

to risk.

- *Aspirin:* Recommend aspirin in primary prevention only high- risk patients.
- *Cholesterol:* Assess the patient's risk from all occlusive artery disease Treatment with atorvastatin 20 mg daily prevents stroke in patients at high risk. In this case high risk was defined as having occlusive cardiovascular disease other than stroke, or diabetes or hypertension in men aged at least 65.
- *ACE inhibitor:* Ramipril decreases the risk of stroke by 32% despite lowering the BP by only 4/3 mmHg
- *Alcohol* -Advise the patient to keep alcohol consumption of < 14 units per week. Regular light to moderate consumption of alcohol seems to decrease the risk of ischaemic stroke by reducing atherothrombotic events.
- *Smoking:* Encourage smokers to stop.
- Encourage *lifestyle and behavior modification:* (including moderate exercises for 30 mins on 5 days a week) that are effective in the prevention of cardiovascular disease and stroke. Weight (a BMI >28 and a large girth (waist circumference>99cm) are independent risk factors for stroke, at least in older men.

SPECIFIC MANAGEMENT

For Cerebral Infarct

- Thrombolytic therapy IV rtPA (IV tissue plasminogen activator)
- *Antiplatelet*
- Anticoagulant heparin, warfarin

For Intracerebral Heamorrhage

- Control hypertension
- Reduce the cerebral edema by mannitol infusion and dexamethasone injection
- ***REFER for*** urgent neurosurgical clot evacuation
- Antiplatelet drugs and anticoagulants are contraindicated.

Neurological Rehabilitation Problems

Principle of rehabilitation & elderly case

Use of Assessments/measures

Central to the management of frailty disability use validated measures by all team members (e.g. disability scores, PHQ-9). Reassess regularly

Team Works

Good outcomes are associated with clinicians working as a team towards a common goal with patients and their families (or carers) included as team members

Goal Setting

Goal must be meaningful, challenging but achievable. Use short and long term goals involve the patient ± carer(s). Regularly renew, review, and adapt

Underlying approach to therapy

All approaches focus on modification of impairment with everyday activities & improvement in function

Intensity/duration of therapy

How much therapy is needed? Is there minimum threshold below which there is no benefit at all?

BOWEL PROBLEMS

Dysphagia:

- Common. Fluids are more difficult to swallow than semisolids.
- Formal assessment by trained staff is essential. Feeding through NG tube or percutaneous endoscopic gastrostomy (PEG) may be needed long or short term in terminal disease (e.g., MND). Weigh provision of nutrition against prolongation of poor-quality life.

Constipation

- Difficulty with defecation or bowel open <2 times/wk.
- Increase fluid intake and increased fiber in diet, if no *improvement,* use laxative po ± regular suppositories/enema.

Incontinence

- Exclude overflow due to constipation.

BLADDER PROBLEM

UTI

- *If suspected, check urine dipstick ± send MSU for microscopic examination, C&S and start antibiotics. If >3 proven UTI in* ***1*** *year,* ***REFER*** *to urology).*

Urgency

- *Modify environment, e.g., provide commode, try anticholinergic e.g., tolterodine 2mg bd. If not better, REFER to urology.*

SKIN BREAKDOWN

- *Prevented by positioning, mobilization, good skin care, management of incontinence, pressure relieving aids (e.g., special mattress/cushion).*

FATIGUE

- *Consider & treat factors that might be responsible depression, disturbed sleep, chronic pain. poor nutrition*

Action

- *Review support, diet and medication, encourage graded aerobic exercise.*

DEPRESSION AND ANXIETY

- *Common. Diagnosis can be difficult. Standard questionnaires e.g.* ***(PHQ9)*** *are helpful for screening.*

2. ***Action***
   - *Give opportunities to talk about the impact of the illness on lifestyle. Jointly identify areas where positive changes could be made e.g. referral to day care to widen social contact. Consider antidepressant medication or REFER.*

RESPIRATORY INFECTION

- *Common. Treat with antibiotics unless in terminal stages of disease. Advice pneumococcal and influenza vaccination.*

MOTOR IMPAIRMENT

- *Aim to maintain physical independence, involve physiotherapy. Often only 2-3 visits are needed.*
- *Involve OT (occupational therapy)*
- *A task-oriented approach is used (e.g., learning how to dress). Can also supply/advice on aids and appliances, e.g., wheelchairs.*
- *REFER for social services OT assessment for aids, equipment or adaptations are needed for the home.*
- *Give information about driving/employment where appropriate. Spasticity ± muscle & joint contractures*

- *Treat with physiotherapy (usually involving exercise ± splintage) ± drugs. Antispasticity drug include baclofen 5 mg bd, or tizanidine 2 mg od.*

PATIENT HEALTH QUESTIONNAIRE-9
(P H Q - 9)

Over the last 2 weeks, how often have you been bothered by any of the following problems? (Use ✔ to indicate your answer)	**Not at all**	**Several days**	**More than half the days**	**Nearly every day**
1. *Little interest or pleasure in doing things*	0	1	2	3
2. *Feeling down, depressed, or hopeless*	0	1	2	3
3. *Trouble falling or staying asleep, or sleeping too much*	0	1	2	3
4. *Feeling tired or having little energy*	0	1	2	3
5. *Poor appetite or overeating*	0	1	2	3
6. *Feeling bad about yourself – or that you are a failure or have let yourself or your family down?*	0	1	2	3
7. *Trouble concentrating things, such as reading the newspaper or watching television*	0	1	2	3
8. *Moving or speaking so slowly that other people could have noticed? Or the opposite – being so fidgety or restless that you have been moving around a lot more than usual*	0	1	2	3
9. *Thoughts that you would be better off dead or of hurting yourself in some way*	0	1	2	3
FOR OFFICE CODING	0	+	+	+
			= Total Score	

If you checked off any problems, how difficult have these problems made it for you to do your work, take care of things at home, or get along with other people?

Not difficult at all	**Somewhat difficult**	**Very difficult**	**Extremely difficult**
☐	☐	☐	☐

TRIGEMINAL NEURALGIA (TIC DOULOUREUX)

- Trigeminal neuralgia is among the most excruciating of pain syndromes seen in office practice. Most patients are middle-aged or elderly. Some have found the pain so intolerable that they consider suicide. The primary physician needs to know how to use available medical therapies and when to send the patient for a neurosurgical consultation.

Clinical Presentation and Natural History

- The illness is characterized by paroxysms of unilateral lancinating facial pain involving the jaw, gums, lips, or maxillary region (areas corresponding to branches of the trigeminal nerve).
- The pain seldom lasts more than a few seconds or a minute or two.
- The paroxysms, experienced as single jabs or clusters, tend to recur frequently, both day and night, for several weeks at a time.
- They may occur spontaneously or with movements of affected areas evoked by speaking, chewing, or smiling.
- The maxillary and mandibular divisions are affected more frequently than the ophthalmic division. Minor, repeated contact with a **trigger zone** often precipitates an attack, setting off fierce pain that usually lasts up to a few minutes.
- Repeated paroxysms pain may continue for several weeks. The disease is strictly unilateral and there is demonstrable sensory or motor deficits, features that distinguish it from trigeminal pain with other causes, such as tumor.
- The condition can be chronic, although spontaneous remissions are not uncommon. Women (60%) are more often affected than men, and the incidence rises with age.
- The etiology of the condition is unknown. Despite much speculation, no definitive evidence links it to herpes simplex virus. The pathologic lesion found in some electron micrographs appears to be a breakdown of myelin.
- Compression of the trigeminal nerve root by a blood vessel, most often the superior
- cerebellar artery or on occasion a tortuous vein, is the source of trigeminal neuralgia in a substantial proportion of patients.
- In cases of vascular compression, age-related brain sagging and increased vascular thickness and tortuosity may explain the prevalence of trigeminal neuralgia in later life.
- Trigeminal neuralgia may be a symptom of multiple sclerosis, which should be considered in a young adult with bilateral trigeminal neuralgia, BUT it is infrequent as the initial or sole manifestation of this disease. Similarly, trigeminal neuralgia is uncommonly the isolated symptom of a cerebellopontine angle tumor.
- Both diseases can be demonstrated by magnetic resonance imaging (MRI).

Differential Diagnosis

- Although few conditions absolutely mimic the lancinating pain of trigeminal neuralgia, pain referable to structures of the face may be similar.
- Conditions that should be excluded include dental disease, temporomandibular joint dysfunction, temporal arteritis, sphenoid sinusitis, and cluster headache.
- The preemption pain of herpes zoster, which occurs in the distribution of the ophthalmic division of the trigeminal more frequently than in the distribution of the other two divisions, and postherpetic neuralgia, which follows the skin eruption by a few weeks, are two other entities to be considered.
- Physical examination should be normal without evidence of sensory loss in the distribution of the trigeminal nerve.

Principles Of Management

- **Treatment is symptomatic**.
- Because drug therapy may provide adequate control of symptoms, surgical intervention should be reserved for refractory cases.
- Pharmacologic agents found particularly useful in the condition include carbamazepine, oxcarbazepine, and baclofen.

Pharmacologic Therapy

Carbamazepine

Drug therapy with carbamazepine is effective in ~50– 75% of patients.

- Carbamazepine should be started as a single daily dose of 100 mg taken with food and increased gradually (by 100 mg daily in divided doses every 3–4 days) until substantial (>50%) pain relief is achieved.
- Most patients require a maintenance dose of 200 mg qid. Doses >1200 mg daily provide no additional benefit.
- Dizziness, nausea, diarrhea, imbalance, sedation, and rare cases of agranulocytosis are the most important side effects of carbamazepine.
- Skin rash often precedes other serious side effects; it may be erythematous and pruritic. The onset of a skin rash is an early indication to halt therapy
- If treatment is effective, it is usually continued for several months and then tapered as tolerated.
- Unfortunately, by 3 years, 30% of patients no longer obtain relief by taking carbamazepine.

Oxcarbazepine

- Oxcarbazepine (300–1200 mg bid) is an alternative to carbamazepine, has less bone marrow toxicity, and probably is equally efficacious.
- Serum sodium must be followed carefully because this is a common metabolic derangement with oxcarbazepine.
- The starting dose is 300 mg in the evening and the daily dose can be titrated upward to a target daily dose of 900 to 1800 mg in three divided doses.
- If these agents are not well tolerated or are ineffective, lamotrigine 400 mg daily or phenytoin, 300–400 mg daily, are other options

Baclofen

- Baclofen, an agent that enhances synaptic transmission of GABA and, has been used with success in a high percentage of cases.
- It can be administered, either alone or in combination with an anticonvulsant.
- Some now consider it the drug of choice for trigeminal neuralgia. The initial dose of 10 mg twice daily is increased slowly.
- The usual maintenance dose is 60 to 80 mg/day (divided into TDS or QID).
- Sedation and nausea are the most common limiting side effects.
- Abrupt cessation of therapy can lead to hallucinations and seizur*es; therefore, discontinuation must be gradual.*

Combination Therapy and Use of Other Agents

- Combination therapy may be necessary because trigeminal neuralgia tends to increase in severity.
- Carbamazepine and Baclofen or Either with Phenytoin
- *These agents in combination or either in conjunction with phenytoin can provide additional relief*
- The usual daily dose of phenytoin that achieves therapeutic serum levels is 300 to 400 mg. Although phenytoin is not as effective as carbamazepine as monotherapy, it may be a useful add-

on *treatment*, and parenteral phenytoin is sometimes used emergently for patients who are having a flurry of severe attacks and cannot take medicine orally.

Gabapentin

- This drug may be prescribed if other medicines are failed, but sedation can be a limiting side effect if high doses are needed.
- If need to use, gabapentin may be started at a dose of 300 mg at bedtime and then increased by 300 mg every 4 days until a total of 1,800 mg is being taken divided into three doses daily.

Narcotics

- Narcotics should be avoided because they are unlikely to be helpful for long-term control of pain and may lead to drug dependency.

Tricyclics

- Amitriptyline, although useful for postherpetic neuralgia and other forms of neuropathic *pain,* is not helpful for trigeminal *neuralgia*.

Surgical Approaches (If available)

- Surgical approaches can be considered when drug therapy proves inadequate and pain is incapacitating.

Percutaneous Radiofrequency Rhizotomy

- This is the least invasive procedure that produces the greatest relief of symptoms and the least loss of sensation.
- The small pain fibers are destroyed, whereas the more heavily myelinated touch fibers that supply the relevant zone are spared.
- The procedure has produced short-term relief in 80% of those treated *once;* only 5% have experienced an undesirable loss of sensation.
- Late recurrences occur in up to 50% at 5 *years,* but pain relief is achieved with a repeated procedure in these patients.
- *It is used less often now than in the past.*

Microvascular Decompression

- *The most widely used method currently and is to relieve pressure on the trigeminal nerve as it exits the pons*
- This procedure affords the best chance of long-term pain relief without sensory deficit, but entails much more complicated surgery, reserving it for younger patients.
- *It requires general anesthesia and a suboccipital craniotomy.*
- *More than 90% of operated patients have compression of the trigeminal nerve by an artery or vein.*
- Muscle tissue or synthetic material is used to decompress the nerve with 85% I -year success rate.

Gamma knife radiosurgery

- *It is also utilized for treatment and results in complete pain relief in more than two-thirds of patients and a low risk of persistent facial numbness; the response is sometimes long-lasting.*
- *Recurrent pain develops over 2–3 years in half of patients.*
- *Compared with surgical decompression, gamma knife surgery appears to be somewhat less effective but has few serious complications.*

Patient Education

- The patient needs to be told that the condition can be controlled and is often self-limited. This knowledge can prevent a distraught sufferer from attempting suicide. The physician must keep in mind the anguish these patients may experience; they require close support. Obvious ways to prevent attacks, such as avoiding repetitive contact with the trigger *zone*, have usually been discovered by the *patient*, but they are worth mentioning. Patients treated with carbamazepine must be informed of the risk for marrow suppression and the importance of regular monitoring of the complete blood cell count.

PERIPHERAL NEUROPATHY: DIFFERENTIAL DIAGNOSIS AND MANAGEMENT

Definition

- Peripheral nerves serve different motor, sensory, and autonomic functions.
- The term peripheral neuropathy is usually used to describe symmetric and universal damage to adjacent nerves. The damage and clinical manifestations are usually located distally with a proximal *progression*.

Relevance to general practice

- One study estimated that the prevalence of peripheral neuropathy in the family medicine setting is 8% in persons 55 years and older. The prevalence in the general population may be as high as 2.4%. A community-based study estimated the prevalence of peripheral neuropathy in patients with type 2 diabetes mellitus to be 26.4 percent.

Diagnosis workup

- Peripheral neuropathy can be caused by a variety of systemic *diseases*, toxic exposures, medications, infections, and hereditary disorders. Several disorders can damage peripheral nerves and cause peripheral *neuropathy;* it is important to differentiate actual neuropathy from other disorders that can have a similar clinical presentation.

Causes

Table 1. Causes of Peripheral Neuropathy Based on Clinical Presentation

Conditions causing mononeuropathy • Acute (trauma-related) • Chronic (nerve entrapment)	**Conditions causing neuropathy with autonomic Features** • Alcoholism • Amyloidosis • Chemotherapy-related neuropathy • Diabetes • Heavy metal toxicity • Paraneoplastic syndrome • Porphyria • Primary *dysautonomia* • Vitamin B12 deficiency
Disorders causing mononeuropathy *Acute* • Diabetes mellitus* • Multifocal motor neuropathy • Vasculitic syndromes *Chronic* • Acquired immunodeficiency syndrome • Leprosy* • Sarcoidosis	**Conditions causing painful neuropathy** • Alcoholism • Amyloidosis • Chemotherapy (heavy metal toxicity) • Diabetes • Idiopathic polyneuropathy • Porphyria

May cause symmetric peripheral neuropathy.

The most common treatable causes are diabetes, hypothyroidism and nutritional deficiencies



General Approach

In approaching a patient with a neuropathy, the clinician has three main goals:
(1) identify where the lesion is,
(2) identify the cause, and
(3) determine the proper treatment.
The first goal is accomplished by obtaining a thorough history, neurologic examination, and electrodiagnostic and other laboratory studies

APPROACH TO NEUROPATHIC DISORDERS: SEVEN KEY QUESTIONS	
1.	**What systems are involved?**
	Motor, sensory, autonomic, or combinations
2.	**What is the distribution of weakness?**
	Only distal versus proximal and distal
	Focal/asymmetric versus symmetric
3.	**What is the nature of the sensory involvement?**
	Temperature loss or burning or stabbing pain (e.g., small fibre)
	Vibratory or proprioceptive loss (e.g., large fibre)
4.	**Is there evidence of upper motor neuron involvement?**
	Without sensory loss
	With sensory loss
5.	**What is the temporal evolution?**
	Acute (days to 4 weeks)
	Subacute (4-6 weeks)
	Chronic (>6 weeks)
6.	**Is there evidence for a hereditary neuropathy?**
	Family history of neuropathy
	Lack of sensory symptoms despite sensory signs
7.	**Are there any associated medical conditions?**
	Cancer, diabetes mellitus, connective tissue disease or other autoimmune diseases, infection (e.g., HIV, Lyme disease, leprosy)
	Medications including over-the-counter drugs that may cause a toxic neuropathy
	Preceding events, drugs, toxins

Information from History and Physical examination
Pattern Recognition Approach To Neuropathic Disorders

Pattern 1: Symmetric proximal and distal weakness with sensory loss
Consider: inflammatory demyelinating polyneuropathy (GBS and CIDP)
Pattern 2: Symmetric distal sensory loss with or without distal weakness
Consider: cryptogenic or idiopathic sensory polyneuropathy (CSPN), diabetes mellitus and other metabolic disorders, drugs, toxins, hereditary (Charcot-Marie-Tooth, amyloidosis, and others)
Pattern 3: Asymmetric distal weakness with sensory loss
With involvement of multiple nerves
Consider: multifocal CIDP, vasculitis, cryoglobulinemia, amyloidosis, sarcoid, infectious (leprosy, Lyme, hepatitis B or C, HIV, CMV), hereditary neuropathy with liability to pressure palsies (HNPP), tumor infiltration
With involvement of single nerves/regions
Consider: may be any of the above but also could be compressive mononeuropathy, plexopathy, or radiculopathy
Pattern 4: Asymmetric proximal and distal weakness with sensory loss
Consider: polyradiculopathy or plexopathy due to diabetes mellitus, meningeal carcinomatosis or lymphomatosis, hereditary plexopathy (HNPP, HNA), idiopathic
Pattern 5: Asymmetric distal weakness without sensory loss
With upper motor neuron findings
Consider: motor neuron disease
Without upper motor neuron findings
Consider: progressive muscular atrophy, juvenile monomelic amyotrophy (Hirayama disease), multifocal motor neuropathy, multifocal acquired motor axonopathy
Pattern 6: Symmetric sensory loss and distal areflexia with upper motor neuron findings
Consider: Vitamin B_{12}, vitamin E, and copper deficiency with combined system degeneration with peripheral neuropathy, hereditary leukodystrophies (e.g., adrenomyeloneuropathy)
Pattern 7: Symmetric weakness without sensory loss
With proximal and distal weakness
Consider: spinal muscular atrophy
With distal weakness
Consider: hereditary motor neuropathy ("distal" SMA) or atypical CMT
Pattern 8: Asymmetric proprioceptive sensory loss without weakness
Consider causes of a sensory neuronopathy (ganglionopathy):
Cancer (paraneoplastic)
Sjögren's syndrome
Idiopathic sensory neuronopathy (possible GBS variant)
Cisplatin and other chemotherapeutic agents
Vitamin B_6 toxicity
HIV-related sensory neuronopathy
Pattern 9: Autonomic symptoms and signs
Consider neuropathies associated with prominent autonomic dysfunction:
Hereditary sensory and autonomic neuropathy
Amyloidosis (familial and acquired)
Diabetes mellitus
Idiopathic pandysautonomia (may be a variant of Guillain-Barré syndrome)
Porphyria
HIV-related autonomic neuropathy
Vincristine and other chemotherapeutic agents

Abbreviations: CIDP, chronic inflammatory demyelinating polyneuropathy; CMT, Charcot-Marie-Tooth disease; CMV, cytomegalovirus; GBS, Guillain-Barré syndrome; HIV, human immunodeficiency virus; HNA, hereditary neuralgic amyotrophy; SMA, spinal muscular atrophy.

Clinical Pearls

- When a patient presents with symptoms of distal numbness, tingling and pain, or weakness, the first step is to d**etermine whether the symptoms are the result of peripheral neuropathy or of a lesion in the CNS,** and whether a **single nerve root, multiple nerve roots, or a peripheral nerve plexus** is involved.
- **CNS lesions** may be associated with other features, such as speech difficulty, double vision, ataxia, cranial nerve involvement, or, in cases of **myelopathy**, impairment of bowel and bladder functions. Deep tendon reflexes are usually brisk, and muscle tone is spastic.
- Lesions of the peripheral nerve **roots** are typically **asymmetric**, follow a **dermatomal pattern** of sensory symptoms, and may have associated neck and low back pain.
- Lesions of the **plexus** are **asymmetric** with sensorimotor involvement of **multiple nerves in one extremity**.
- The neuropathies must be further characterized by **onset and chronicity** of symptoms, the pattern and extent of involvement, and the type of nerve fibers involved (i.e., sensory, motor, or autonomic).
- In the early stages of peripheral neuropathy, patients typically present with progressive symptoms, including sensory loss, numbness, and pain or burning sensations in distal limbs in a "stocking and glove" distribution. Over time, the numbness may extend proximally, and mild distal muscle weakness and atrophy may occur.
- In disorders that cause acute peripheral neuropathy, such as those produced by toxic exposures, patients may present with similar but more fulminant symptoms, and **pain predominates; symptoms also typically have a faster progression.**
- In other disorders, such as acute inflammatory demyelinating disorder (i.e. Guillain- Barre syndrome) and chronic inflammatory demyelinating polyneuropathy, weakness rather than sensory loss typically predominates and may be the earliest sign of the disease.
- The presence of neuropathic symptoms, decreased ankle reflexes, and decreased distal sensations, regardless of distal muscle weakness and atrophy, makes the diagnosis of peripheral neuropathy likely.
- Some causes of peripheral neuropathy are characterized by mononeuropathy, some involve multiple *nerves,* and others have ***autonomic dysfunction*** or pain prominence.
- Risk factors and medical comorbidities associated with peripheral neuropathy

Diagnostic Testing

The evaluation of a patient with peripheral neuropathy starts with simple blood tests, including

- a complete blood *count,*
- *comprehensive metabolic profile,*
- *erythrocyte sedimentation rate and*
- fasting blood glucose,
- vitamin B12, and
- *thyroid stimulating hormone levels.*

Additional tests, if clinically indicated, may include a paraneoplastic panel to evaluate for occult malignancy;

- anti-myelin-associated glycoprotein antibodies to evaluate for sensorimotor *neuropathies;*
- antiganglioside antibodies;

- cryoglobulins;
- cerebrospinal fluid analysis to evaluate for chronic inflammatory demyelinating neuropathy;
- anti-sulfatide antibodies to evaluate for autoimmune polyneuropathy; and
- genetic testing if hereditary peripheral neuropathy is suspected
- lumbar puncture and CSF analysis may be helpful in diagnosing Guillain-Barre syndrome and chronic inflammatory demyelinating *neuropathy;* CSF protein levels may be elevated in patients with these conditions *(albumin cytologic dissociation)*

Tests Indicated in Patients with Peripheral Neuropathy in complete resource setting

Tests	*Clinical disorders*
Routine	
*Complete blood count	
*Comprehensive metabolic panel -	
*Erythrocyte sedimentation rate –	
*Fasting blood glucose level	
*Thyroid-stimulating hormone level	
*Vitamin Bl2 level	
If indicated by clinical suspicion	
*Glucose tolerance test, Al C level	Diabetes mellitus
* HIV antibodies	HIV
*Hepatic panel	Liver disorders
Lyme antibodies	Lyme disease
*Rapid plasma regains, VDRL	Syphilis
*Urinalysis (including 24-hour urine collection)	Heavy metal toxicity, porphyria
For multiple myeloma	
*Urine and serum protein electrophoresis with Immunofixation	Demyelinating neuropathy
Angiotensin-converting enzyme levels	Sarcoidosis
*Antinuclear antibodies, P-ANCA, C-ANCA	Vasculitis
Tests for uncommon conditions	
*Paraneoplastic panel	Underlying malignancy
Anti-myelin-associated glycoprotein and antiganglioside antibodies	Sensorimotor neuropathy
Anti-sulfatide antibodies	Autoimmune polyneuropathy
Cryoglobulins	Cryoglobulinemia
Salivary flow rate, Schirmer test, rose Bengal test, labial gland biopsy	Sjogren syndrome
*Cerebrospinal fluid analysis	Acute or chronic inflammatory demyelinating neuropathy
Genetic testing	Hereditary neuropathy

C-ANCA = cytoplasmic antineutrophil cytoplasmic antibodies; HIV = human immunodeficiency virus; P-ANCA = perinuclear antineutrophil cytoplasmic antibodies. VDRL = Venereal Disease Research Laboratory.

Principles of Treatment

Treatment of peripheral neuropathy has two goals:

1. controlling the underlying disease process
2. treating troublesome symptoms.

1. Controlling the underlying disease process

- Eliminating offending agents, such as toxins or medications; correcting a nutritional deficiency; or treating the underlying disease *(e.g.,* corticosteroid therapy for immune- mediated

neuropathy). These steps are important to halt the progression of neuropathy, and they may improve symptoms.

- Acute inflammatory neuropathies require more urgent and aggressive management with intravenous immunoglobulin or plasmapheresis.

Treating troublesome symptoms

- It is important to help patients control troublesome symptoms of peripheral neuropathy, such as severe numbness and pain, as well as to alleviate disability resulting from weakness.
- Several pharmacologic options exist to treat neuropathic pain, including some antiseizure medications (e.g., gabapentin, topiramate, carbamazepine, pregabalin) and antidepressants (e.g., amitriptyline).
- Topical patches and sprays containing lidocaine (Lidoderm patch or capsaicin (also may relieve pain in some *patients*.
- Other supportive measures, such as foot care, weight reduction, and shoe selection, may also be helpful.
- Narcotics may have a role in the treatment of chronic neuropathic pain in selected patients; candidates initially should be evaluated for their risk of substance abuse and addiction, and several nonnarcotic regimens should be tried *first*.
- A second opinion regarding the patient's diagnosis and management also should be considered before initiating long-term opioid therapy.

TREATMENT OF PAINFUL SENSORY NEUROPATHIES

THERAPY	ROUTE	DOSE	SIDE EFFECTS
First-Line			
Lidoderm 5% patch	Apply to painful area	Up to 3 patches qd	Skin irritation
Tricyclic antidepressants (e.g., amitriptylin, nortriptyline)	p.o.	10–100 mg qhs	Cognitive changes, sedation, dry eyes and mouth, urinary retention, constipation
Gabapentin	p.o.	300–1200 mg TID	Cognitive changes, sedation, peripheral edema
Pregabalin	p.o.	50–100 mg TID	Cognitive changes, sedation, peripheral edema
Duloxetine	p.o.	30–60 mg qd	Cognitive changes, sedation, dry eyes, diaphoresis, nausea, diarrhea, constipation
Second-Line			
Carbamazepine	p.o.	200–400 mg q 6–8 h	Cognitive changes, dizziness, leukopenia, liver dysfunction
Phenytoin	p.o.	200–400 mg qhs	Cognitive changes, dizziness, liver dysfunction
Venlafaxine	po	37.5–150 mg/d	Asthenia, sweating, nausea, constipation, anorexia, vomiting, somnolence, dry mouth, dizziness, nervousness, anxiety, tremor, and blurred vision as well as abnormal ejaculation/orgasm and impotence
Tramadol	p.o.	50 mg qid	Cognitive changes, GI upset
Third-Line			
Mexiletine	p.o.	200–300 mg tid	Arrhythmias
Other Agents			
EMLA cream 2.5% lidocaine 2.5% prilocaine	Apply cutaneously	q.i.d.	Local erythema
Capsaicin 0.025%–0.075% cream	Apply cutaneously	q.i.d.	Painful burning skin

CHAPTER (11) MENTAL HEALTH

Chapter (11)
Mental Health

1. Mental Health
    a. Psychiatric emergency
    b. Schizophrenia
    c. Mood disorders
    d. Depressive disorders
    e. Anxiety and related disorders
    f. Obsessive Compulsive and related disorders
    g. Trauma and stressor related disorders
    h. Somatic Symptom and related disorders
2. Substance Misuse
    a. Alcohol use disorder
    b. Tobacco use disorder
    c. Substance use disorders



PSYCHIATRIC EMERGENCY

Introduction

- Psychiatric emergency is a condition wherein the patient has acute disturbances of thought, affect and psychomotor activity which if untreated leading to a threat to his existence (suicide), or threat to the people in the environment (homicide).

Objectives of Psychiatric Emergency Intervention

- To safeguard the life of patient
- To reduce the anxiety of the family members
- To provide the emotional security to others in the environment
- To educate the client and family members

Factors precipitating psychiatric emergencies

- Certain condition or stressor predisposes the client family members to seek immediate intervention as they feel discomfort.
- Disharmony between client and his environment
- Sudden unexpected disorganization in person
- Unable to cope with the stressful situation or family in handling the stressors

Features Indicating a Possibility of Medical Illness

- Acute Onset
- Old Age
- First Episode
- Non-auditory hallucinations
- Disorientation/Confusion
- Memory impairment
- Catatonic state
- Neurological symptoms like unconsciousness, seizures, and visual problems.
- Head injury

Initial approaches during psychiatric emergency

- The initial approach to the patient should be warm, direct and concerned.
- A quick evaluation to identify the nature of the condition and to institute care on the basis of seriousness is essential.
- The emergency staff should have been trained for handling psychiatric emergencies.
- The security must be adequate to control violent and dangerous patients.
- Medicolegal cases need to be registered separately and informed to the concerned officer. History and clinical findings should be recorded clearly in the emergency file.
- Patient's conditions and plans of management should be explained in simple language to the patient and family members.

Evaluation of Psychiatric Emergencies

- The nature and availability of support system and capacity of the patient to use it.
- Dangerousness: suicidal or homicidal ideation, substance intoxication
- Psychiatric history and current psychiatric status, including patient's ways of coping with similar stressors previously.

- Ability to care for oneself.
- Motivation and capacity to participate in the treatment process.
- The request(s) of patient and family.
- Co-morbid medical conditions

EMERGENCY PSYCHIATRIC MANAGEMENT

SUICIDE ATTEMPTS AND SUICIDAL IDEATION

- Suicidal attempt is one of the commonest psychiatric emergencies. Suicide is a type of deliberate self-harm and is defined as an intentional human act of killing oneself.

Aetiology

1.Psychiatric Disorders

Major depression:

- The commonest conditions associated with a high risk of suicide. It is due to pervasive and persistent sadness, delusions of guilt, helplessness, hopelessness and worthlessness. The risk of suicide is more when the acute phase has passed and the patient has more energy to carry out his suicidal plans.

Schizophrenia:

- The major risk factors among schizophrenics include the presence of associated depression, young age and high levels of premorbid functioning (especially during college education). People in this risk group are more likely to see suicide as a reasonable alternative.

Mania:

- Manic patients may occasionally commit suicide as the result of grandiose ideation. They may carry out some dangerous activity that can cost them their life.

Drug or alcohol abuse:

- Due to depression in the withdrawal phase. Also, the loss of friends and family, self-respect, status, and a general realization of the havoc alcohol has created in his life.

Dementia, delirium:

- Organic conditions such as delirium and dementia due to changes of mood like anxiety and depression may also induce suicidal tendency.

Personality disorder:

- Individuals with histrionic and borderline traits may occasionally attempt suicide.

2. Physical Disorders:

- Patients with incurable or painful physical disorders like, cancer and AIDS.

3.Psychosocial Factors:

- Failure in board exam
- Marital problems
- Loss of loved object
- Isolation and alienation from social groups
- Financial and occupational difficulties

Risk factors for suicide

- Age:
  - Males above 40 years of age

- Females above 55 years of age

- Sex:
  - Men have greater risk of completed suicide
  - Women have higher rate of attempted suicide.
- Being unmarried, divorced widowed, or separated
- Having a definite suicidal plan
- History of previous suicidal attempts
- Recent losses

Assessment of Suicidality

Table 1

SBQ-R Suicide Behaviours Questionnaire-Revised

Patient Name _____Date of visit_____

Instructions: Please check the number beside the statement or phrase that best applies to you

1. Have you ever thought about or attempted to kill yourself? (check one only)

☐ 1. Never
☐ 2. It was just a brief passing thought
☐ 3a. I have had a plan at least once to kill myself bout did not try to do it
☐ 3b. I have had a plan at lease once to kill myself and really wanted to die
☐ 4a. I have attempted to ill myself, but did not want to die
☐ 4b. I have attempted to kill myself, and really hoped to die

2. How often have you thought about killing yourself in the past year? (check one only)

☐ 1. Never
☐ 2. Rarely (1 time)
☐ 3. Sometimes (2 times)
☐ 4. Often (3-4 times)
☐ 5. Very Often (5 or more times)

3. Have you ever told someone that you were going to commit suicide, or that you might to do it? (check one only)

☐ 1. No
☐ 2a. Yes, at one time, but did not really want to die
☐ 2b. Yes, at one time, and really wanted to die
☐ 3a. Yes, more than once, but did not want to do it
☐ 3b. Yes, more than once, and really wanted to do it

4. How likely is it that you will attempt suicide someday? (check one only)

☐ 0. Never
☐ 1. No chance at all
☐ 2. Rather unlikely
☐ 3. Unlikely
☐ 4. Likely
☐ 5. Rather likely
☐ 6. Very likely

Table 2

SBQ-R-Scoring

Item 1: taps into lifetime suicide ideation and/or suicide attempts			
Selected response 1	Non-Suicidal subgroup	1 point	
Selected response 2	Suicide Risk Ideation subgroup	2 points	
Selected response 3a or 3b	Suicide Plan subgroup	3 point	
Selected response 4a or 4b	Suicide Attempt subgroup	4 points	Total point ( )
Item 2: assesses the frequency of suicidal ideation over the past 12 months			
Selected Response:	Never	1 point	
	Rarely (1 time)	2 points	
	Sometimes (2 times)	3 points	
	Often (3-4 times)	4 points	
	Very Often (5 more times)	5 points	Total points ( )
Item 3: taps into the threat of suicide attempts			
Selected response 1		1 point	
Selected response 2		2 points	
Selected response 3a or 3b		3 points	
Item 4: evaluates self-reported likelihood of suicidal behaviour in the future			
Selected Response:	Never	0 point	
	No chance at all	1 point	
	Rather unlikely	2 points	
	Unlikely	3 points	
	Likely	4 points	
	Rather likely	5 points	
	Very Likely	6 points	Total points ( )
Sum all the scores circled/checked by the respondents. The total score should range from 3-18			Total Score ( )

Psychometric Properties			
	Cutoff score	**Sensitivity**	**Specificity**
Adult General Population	≥7	93%	95%
Adult Psychatric Inpatients	≥8	80%	91%

Management

- All psychiatric patients need to be asked about suicidal ideation as a part of routine assessment. Asking about suicidal attempt does not provoke the patient to commit suicide or instil the idea to do so.
- Clinicians should consider screening patients with possible suicidal ideation for depression, anxiety, and alcohol use to help determine symptom severity. (SOR B)
- Direct inquiry about suicidal ideation in patients with risk factors is associated with more effective treatment and management. (SOR B)
- Be aware of certain signs which may indicate that the individual may commit suicide, such as:
    - Suicidal threat
    - Writing farewell letters
    - Giving away treasured articles
    - Making a will
    - Closing bank accounts
    - Appearing peaceful and happy after a period of depression
    - Refusing to eat or drink, maintain personal hygiene.
- Patients who have expressed suicidal ideation but deny current suicidal intent, have no plan or means in place, and have good social support may be treated as an outpatient therapy
- Patients with specific plans for suicide who have the means to complete their plan should be offered inpatient admission.

Monitoring the patient's safety needs and further management:

- Take all suicidal threats or attempts seriously and notify psychiatrist.
- Search for toxic agents such as drugs / alcohol.
- Do not leave the drug tray within reach of the patient, make sure that the daily medication is swallowed.
- Remove sharp instruments such as razor, blades, knives, glass bottles from his environment.
- Remove straps and clothing such as belts, neckties.
- Do not allow the patient to bolt his/her door on the inside, make sure that somebody accompanies to the bathroom.
- Patient should be kept in constant observation and should never be left alone.
- Have good vigilance especially during morning hours.
- Spend time with him, talk to him, and allow him to ventilate his feelings.
- Encourage him to talk about his suicidal plans/methods.
- If suicidal tendencies are very severe, sedation should be given as prescribed. In schizophrenia, atypical antipsychotics such as clozapine are effective.
- Encourage verbal communication of suicidal ideas as well as his/ her fear and depressive thoughts.
- Enhance self-esteem of the patient by focusing on his strengths rather than weaknesses. His positive qualities should be emphasized with realistic praise and appreciation. This fosters a sense of self-worth and enables him to take control of his life situation.
- Antidepressants are often the first-line treatment for mood disorders, but warning has been issued because of increased risk of suicidality among adolescents and young adults in the early months after starting selective serotonin reuptake inhibitor therapy
- After initial stabilization and improvement of suicidal ideation, patients will need follow-up care with mental health clinicians or community mental health care programs.

Management of Attempted Suicide

- Assess for vital signs, check airway, if necessary clear airway.

- If pulse is weak, start IV fluids.
- Tum patient's head and neck to one side to prevent regurgitation and swallowing of vomitus.
- Emergency measures to be instituted in case of self-inflicted injuries.
- Management of shock.
- Transfer the patient to medical centre immediately.

Management of completed suicide

- If there is no evidence of life, leave the body in the same position/room in which it was found Inform authorities, record the incident accurately
- Once the patient is transferred to mortuary or police custody clean the place with disinfectant solution
- A completed suicide causes stress for the patient's loved ones and physician. Bereavement reaction of survivors after suicide is more likely to feel shame and to blame themselves for the loss. The physician should be prepared to empathetically support the family members through this difficult transition without assigning blame.

VIOLENT OR AGGRESSIVE BEHAVIOR OR EXCITEMENT

- This is a severe form of aggressiveness. During this stage, patient will be irrational, uncooperative, delusional and assaultive.
- The risk of violence is especially high in those societies where there is easier access to firearms and prevalence of alcohol/drug misuse.

Aetiology

- Organic psychiatric disorders like, delirium, dementia, Wernicke-Korsakoff syndrome or psychosis.
- Other psychiatric disorders like schizophrenia, mania, agitated depression, withdrawal from alcohol and drugs, epilepsy, acute stress reaction, panic disorder and personality disorders.
- The use of alcohol also predisposes to violence.

Signs of Impending Assault

- Anger, excitement, loud voice,
- Demanding immediate attention
- Staring eyes, flared nose, flushed face, hands clenched or gripped
- Pacing about in the room, pushing furniture, slamming objects
- Possessing weapons

The assault cycle

- One recognized method of identifying behaviors that can lead to violence is the assault cycle. Learning and understanding the phases of the assault cycle will help healthcare workers to identify the patterns of escalating behavior and assist them to respond appropriately.
- The Assault Cycle is divided into five separate, distinct and observable phases.
- **Phase I: The Triggering Event** - This phase includes any event that an individual perceives as a serious threat to well-being. The event may be observable (name calling by another person, a disturbing phone call, loss of a privilege) or not observable (a flashback or memory, a delusion or hallucination, a reaction to medication).
- **Phase II: Escalation** - The person's mind and body prepare to do battle with the cause of the triggering event. The person's muscles become increasingly tense and active; his/her ritual behaviours of combat occupy more and more space in the overall behavioural pattern. (See above -Signs of Impending

Assault)

- **Phase III: Crisis** - The behavioural pattern explodes into one or more physical assaults on the perceived source of the threat. The individual will threaten injury, hit, kick, throw objects at people, etc. An individual cannot sustain this level of energy forever.
- **Phase IV: Recovery** - With the battle over, the muscles become progressively more relaxed and ritual combat behaviours become less frequent. It is important to note, however, that the individual is not yet at baseline and is vulnerable to reescalation.
- **Phase V: Post-Crisis Depression** - The physical and emotional symptoms of fatigue and/or depression dominate the behavioural pattern. Observable behaviours frequently include crying, hiding, sleeping, curling up in a fetal position or self-blame.

Fig. 1. **Assault Cycle showing the escalating behaviours and appropriate interventions**



Managing Violence and Aggressions

Staff Training

- Health and social care provider organizations should consider training staff working in community and primary care settings in methods of avoiding violence, including anticipation, prevention, de-escalation and breakaway techniques, depending on the frequency of violence and aggression in each setting.

Anticipating and reducing the risk of violence and aggression

- To recognize the early signs of agitation, irritation, anger and aggression (See above)
- To understand the likely causes of aggression or violence.
- Establish a close working relationship with service users at the earliest opportunity and sensitively monitor changes in their mood or composure that may lead to aggression or violence.
- To use skills, methods and techniques to reduce or avert imminent violence and defuse aggression when it arises (for example, verbal de-escalation)

De-escalation

- The use of techniques (including verbal and non-verbal communication skills) aimed at defusing anger and averting aggression. There are three components in de-escalation.
- ***Self-control:***
    - Use emotional regulation and self-management techniques to control verbal and non-verbal expressions of anxiety or frustration (for example, appear calm, voice low and monotonous, safe and open body posture (relax, arms at the side, hands outward) and avoiding prolonged eye contact when carrying out de-escalation.
- ***Stance (Self-protection):***
    - To recognise the importance of personal space: stand between the door and the patient two-arm length away, at the same eye level. Never see a potentially violent person alone. If a patient is carrying a weapon, ask them to place it in a neutral location rather than handing it over.
    - If a patient who is at risk of becoming violent or aggressive is in a room or area where there are objects that could be used as weapons, remove the objects or relocate the patient.
- ***De-escalation process:***
    - Use techniques for distraction and calming, and ways to encourage relaxation. Use a wide range of verbal and non-verbal skills and interactional techniques to avoid or manage known 'flashpoint' situations without provoking aggression.
    - Communicate with respect and empathy with the patient at all stages of De-escalation. Listen intently to the patient and offer choices and optimism.
    - P.r.n. medication can be used as part of a de-escalation strategy but p.r.n. medication used alone is not de-escalation.

Using p.r.n. (pro re nata) Medication (Chemical Restraints)

- The use of medication as part of a strategy to de-escalate or prevent from violence or aggression. It does not refer to p.r.n. medication used on its own for rapid tranquillisation during an episode of violence of aggression.
- If the patient is willing to take medication;
    - Olanzapine 5mg sublingual not more than 20mg/day (or)
    - Clonazepam 0.5 mg PO, not more than 4 mg/day (or)
    - Risperidone 0.5 mg PO not more than 3 mg/day (or)
    - Lorazepam 2mg PO, not more than 10 mg/day can be given.
- If parenteral route is preferred and patient does not have the evidence of cardiovascular disease;
    - intramuscular haloperidol 5 mg hourly prn, not to exceed 18 mg/day.
- If the patient has the evidence of cardiovascular disease;
    - intramuscular lorazepam 2mg hourly prn can be used with the limit of 20mg/day (or)
    - intramuscular diazepam 10 mg 6-12 hourly, not more than 30 mg/8 hours.
- Ensure that the maximum daily dose is specified and all p.r.n medications does not inadvertently exceed the maximum daily dose.

Breakaway techniques

- A set of physical skills to help separate or break away from an aggressor in a safe manner. They do not involve the use of restraint.

Restrictive interventions

- Interventions that include observation, seclusion, manual restraint, mechanical restraint and rapid tranquillization.
- If the patient is not calmed down by de-escalation and refuses p.r.n medication, restraints may become necessary. That may infringe a person's human rights and freedom of movement.

1.Observation

- A minimally restrictive intervention of varying intensity in which a member of the healthcare staff observes and maintains contact with a patient to ensure the patient's safety and the safety of others.

2. Seclusion

- The supervised confinement of a patient in a room, which may be locked. Its sole aim is to contain severely disturbed behaviour that is likely to cause harm to others.

3. Manual restraint

- A skilled, hands-on method of physical restraint **used by trained healthcare professionals** to prevent patients from harming themselves, endangering others or compromising the therapeutic environment.
- *Community mental health teams should not use manual restraint in community settings. In situations of medium risk, staff should consider using breakaway techniques and de-escalation. In situations of high risk, staff should remove themselves from the situation and, if there is immediate risk to life, contact the police. (NICE guideline Published: 28 May 2015)*

4. Mechanical restraint

- A method of physical intervention involving the use of **authorized equipment,** for example handcuffs or restraining belts, applied in a skilled manner by **designated healthcare professionals**.
- Use mechanical restraint only as a last resort and its purpose is to safely immobilize or restrict movement of part(s) of the body of the patient to prevent from an extreme violence directed at other people or limiting self-injurious behaviour.

5. Rapid tranquillization

- Use of medication by the parenteral route (usually intramuscular or, exceptionally, intravenous) if oral medication is not possible or appropriate and urgent sedation with medication is needed.
- If there is evidence of cardiovascular disease, including a prolonged QT interval, or no electrocardiogram has been carried out, avoid intramuscular haloperidol combined with intramuscular promethazine and use intramuscular lorazepam instead. (NICE guidelines 2015)

Patient-centered care

- Once the patient is sedated, arrange the patient for referral.
- If the referral is not feasible, following measures should be taken:
- In particular check for history of convulsions, fever, recent intake of alcohol, fluctuations of consciousness.
- Carry out complete physical examination.
- Look for evidence of **dehydration and malnutrition.** If there is severe dehydration, IV drip may be started.
- Following application of restraints, observe patient every 15 minutes to ensure that nutritional and elimination needs are met. Also observe for any numbness, tingling or cyanosis in the extremities. It is important to choose the least restrictive alternative as far as possible for these patients.

Reference:

Violence and aggression: short-term management in mental health, health and community settings NICE guideline Published: 28 May 2015 www.nice.org.uk/guidance/ng10

PANIC ATTACKS (SEE ALSO PANIC DISORDER)

- Episodes of intense fear characterized by a constellation of symptoms including palpitations, sweating, tremors, feelings of choking, trembling or shaking, sense of shortness of breath or smothering, chest pain, nausea, abdominal distress, fear of losing control or going crazy, feeling dizzy, unsteady, light-headed, or faint, fear of dying, paraesthesia, chills or hot flashes.
- These symptoms develop rapidly, reach a peak of intensity in about 10min, and generally do not last longer than 20–30min (rarely over 1hr).
- Attacks may be either **spontaneous/unexpected** ('out of the blue') or **situational/expected** (usually **where** attacks have occurred previously).

Emergency Management of an ACUTE PANIC ATTACK

- Talking down#: Explain the nature of symptoms to the patient and why they come.
- Maintain a reassuring and calm attitude (most panic attacks resolve spontaneously within 30min). (See Panic First Aid below)
- If symptoms are severe and distressing consider prompt use of benzodiazepines* (immediate relief of anxiety may help reassure the patient, provide confidence that treatment is possible, and reduce subsequent 'emergency' presentations).
- If first presentation, exclude medical causes (may require admission to hospital for specific tests).
- If panic attacks are recurrent, consider differential diagnosis for panic disorder and address underlying disorder (may require psychiatric referral).
- **Benzodiazepines (e.g. alprazolam or clonazepam) are not recommended by NICE. They should be used with caution (due to potential for abuse or dependence and cognitive impairment), but may be effective for severe, frequent, incapacitating symptoms. Use for 1–2wks in combination with an antidepressant may offer symptomatic relief until the antidepressant becomes effective.*
- #"Talking down"
  - Explain the nature of the symptoms to the patient
  - Racing of the heart is due to adrenalin produced by the panic.
  - Paresthesia/feelings of dizziness are secondary to over breathing due to panic
  - Breathing exercises - Count breaths in and out gently slowing breathing rate
  - Propranolol 10 -20 mg stat may be helpful (Contraindicated in Asthma/heart failure, verapamil or diltiazem can be tried)

Move to stop PANIC: PANIC FIRST AID

- **Be still: resist escaping.**
  - ***I will still be safe if I don't run.***
- **Go with your body's reaction: don't fit it.**
  - ***All the sensations I am feeling now will pass. I can allow this to wash over me***
- **Stay in the present: don't futurize. Keep your attention only on what's happening now, rather than what could happen in the future**
- **Deflate the danger: tell yourself the facts.**
  - ***All the sensations of panic are harmless, no matter how intense -the response is protective in nature.***
- **Dampen down the reaction:**
  - ***Breathe slowly into your belly***
  - ***Relax your muscles***
  - ***Stabilize your energy***
- **Be consistent: don't resort to bad habits.**

When Panic Attacks by Dr Aine Tubridy
http ://wellbeingfoundation.com/jirs taid-pa nic.html

Differential Diagnosis of ACUTE PANIC ATTACK

- Dysthymia (persistent mild depression),
- Asthma
- Anaphylaxis
- Thyrotoxicosis
- Hypoglycemia
- Temporal lobe epilepsy

CATATONIC STUPOR

- **Stupor** is a clinical syndrome of akinesis and mutism but with relative preservation of conscious awareness. The patient is conscious but there is non-responsiveness to the surroundings.
- Catatonic stupor is a subtype of stupor presenting with signs and symptoms including immobility, mutism, negativism, ambitendency, catalepsy and waxy flexibility, echolalia, echopraxia, automatic obedience, posturing, mannerisms, stenotypes, etc.,

Causes

- The most important causes include:
  - **Psychiatric (Functional)**
    - Schizophrenia
    - Mood disorders (bipolar disorders, major depressive disorder)
    - Antipsychotic drugs
  - **Organic**
    - Encephalitis
    - Carbon monoxide poisoning
    - Serum potassium imbalance (periodic paralysis)

Management

- Ensure patent airway
- Administer IV fluids
- Collect history and perform physical examination
- Draw blood for investigations before starting any treatment
- Withhold antipsychotic medication if the patient was taking
- Trial of lorazepam 1-2 mg every 4-12 hours PO up to 6 days and gradual reduction.
- *Zolpidem challenge test* after treatment with BZD had failed. 7.5 -40 mg PO/day
- Other care is same as that for an unconscious patient.

GRIEF AND BEREAVEMENT

- Grief is areaction of an individual to a significant loss including person, things, experiences such as relationship and job.
- Bereavement is a period of mourning or a state of intense grief following the death of a loved one.

Factors affecting GRIEF reaction:

- Abruptness of loss.
- Extent of loss.
- Preparation of loss.
- Significance of the lost person /object to the individual.

- Past experience of grief
- Cultural background.
- Personality traits.

UNCOMPLICATED GRIEF

- The clinical features of uncomplicated grief are sadness, yearning for the deceased, crying, anger, insomnia, poor appetite, loss of interest, guilt, social withdrawal. and death wish.
- Stages:
  - ***Hours to days***: Shock and disbelief.
  - ***Weeks to months***: Anger, resentment, depression
  - ***Six months to a year***: Acceptance of reality

Management

- Evaluation to find out any primary psychiatric disorder. Those without underlying mental disorders do not usually require any specific treatment, such as medication or grief counseling.
- Early intervention is *not* recommended because it may interfere with the grieving process. Patients with extended grief or grief complicated by depression may receive greater benefit from counseling.

Crisis intervention

- Most reviews recommend tailoring the intervention to the cues and perceived needs of the bereaved. Patient is encouraged to talk about his feeling concerning the deceased in privacy.
- Responding to patients' cues can provide appropriate support after a loss. Kind, compassionate words spoken with empathy and a short phone call a couple days after the visit to check in or a personal note can be of tremendous comfort.
- Patients can be reassured that their emotions, feelings, and pain are normal and that everyone experiences grief and loss a little differently.
- The patient can be assured that the intensity of these emotions will subside significantly by six months and diminish by one year.
- The family physician should encourage the patient to get enough exercise and sleep, to eat well, avoid excessive alcohol intake and lower the risk of associated morbidity, including myocardial infarction.
- Maintaining social interactions can be helpful for patients and should be also encouraged.

Ref: Helping Patients Cope with Grief: Am Fam Physician. 2019;100(1):54-56

Pharmacotherapy

- Avoid drug treatment, as far as possible. Prescribe nighttime sedatives on as-needed (SOS) basis.
- Refer to psychiatric services for primary psychiatric condition, if necessary.

COMPLICATED GRIEF (UNRESOLVED GRIEF)

Prevalence

- 10% to 20% after the loss of a romantic partner and even higher after the loss of a child
- During the first few months after a loss, many signs and symptoms of normal grief are the same as those of complicated grief.
- Complicated grief is like being in an ongoing, heightened state of mourning that keeps the patients from healing. It can be diagnosed when grieving continues to be intense, persistent and debilitating beyond **12 months**.

Signs and symptoms of complicated grief

may include:

- Intense sorrow, pain and rumination over the loss of the loved one
- Extreme focus on reminders of the loved one or excessive avoidance of reminders
- Problems accepting the death

- Numbness or detachment
- Inability to enjoy life or think back on positive experiences with the loved one
- Having trouble carrying out normal routines
- Isolation from others and withdrawal from social activities
- Depression, deep sadness, guilt or self-blame
- Believing that he/she did something wrong or could have prevented the death
- Feeling life isn't worth living and suicidality.

Management

- Referral for complicated grief psychotherapy.
- If psychotherapy is not feasible, the family doctor should try to:
    - explain about complicated grief including grief reactions, grief symptoms and how to overcome
    - help the patient to adjust to the loss and redefining the life goals
    - encourage the patient to hold imagined conversations with the loved one and retell the circumstances of the death to help him/her become less distressed by images and thoughts of the loved one
    - teach how to explore the thought patterns, identify dysfunctional thoughts (catastrophic thinking) and reframe the thoughts into more positive ones to change subsequent emotions and behaviours.
    - help to improve coping skills
    - reduce feelings of blame and guilt
- Medications:
    - antidepressants may be helpful in people who have clinical depression as well as complicated grief.
- Hospitalization for the patients with physical illnesses and suicidality.

HYSTERICAL ATTACKS

- Hysteria or conversion disorder is a disorder whereby a person expresses emotional turmoil by converting it into a bodily symptom. **The term "hysteria" is no longer used.**
- Conversion disorder may present as an affliction of organs of special senses i.e. as hysterical deafness, hysterical blindness. It may also affect the voluntary nervous system and patients may present with hyperventilation, convulsions, paraesthesias, hysterical paraplegia, ataxia etc.
- The symptoms and signs of conversion hysteria are **not consciously simulated** as opposed to malingering.
- Neurological examination of the affected part of the body reveals an intact neuromuscular apparatus with normal reflexes.

Management

- All presentations are marked by a dramatic quality and sadness of mood.
- Hysterical fit must be distinguished from genuine fits (epileptic seizures).
- As hysterical symptoms can cause panic among relatives. The family physician should explain to the relatives the psychological nature of symptoms and reassure that no harm would come to the patient.
- Help the patient realize the meaning of symptoms, and help him find alternative ways of coping with stress such as:
    - Concentrate on the present instead of focusing on yesterday or tomorrow
    - Engage in breathing exercises
    - Write in a journal
    - Get physically active

    - Develop a consistent sleep schedule
- Secondary hysteria due to anxiety and depression- anxiolytics and antidepressants may help

TRANSIENT SITUATIONAL DISTURBANCE (DSM II) (RENAMED AS ADJUSTMENT DISORDER- SINCE DSM III)

- A state of subjective distress and emotional disturbance, usually interfering with social functioning and performance, and arising in the period of adaptation to a significant life change or to the consequences of a stressful life event (WHO, 1992)
- Onset of symptoms is usually **within one month** of the onset of the stressful event according to ICD-10 (WHO, 1992) or within three months and **do not last longer than 6 months** according to DSM-5. (More than 6 months= persistent/ chronic adjustment disorder)
- Symptoms can vary from mild to severe, depending on the intensity of the triggering situation and the personal significance for the patient.

Common Physical and Emotional Symptoms

- Insomnia
- Headaches, body aches and soreness
- Palpitations.
- Sweating hands.
- Symptoms of anxiety and depression including being anxious or agitated, feeling trapped, hopeless, poor concentration, lacking energy, loss of self-esteem, loss of interest.
- Abusing alcohol or drugs.
- Having suicidal thoughts or behaviors.

Management

- Reassurance as many people with adjustment disorders find treatment helpful, and they often need only brief treatment.
- Allowing the patient to ventilate his/her feelings to a trusted person.
- Counselling by a professional or referral for psychotherapy
- Medications such as antidepressants (SSRI/SNRI) and anxiolytics (short term BZD) may be added to help with symptoms of depression and anxiety.

DELIRIUM TREMENS (SEE ALSO IN ALCOHOL USE DISORDER)

- Delirium tremens (DTs) is the most severe form of ethanol withdrawal, manifested by altered mental status (global confusion) and sympathetic overdrive (autonomic hyperactivity), which can progress to cardiovascular collapse.
- Minor alcohol withdrawal is characterized by tremor, anxiety, nausea, vomiting, and insomnia.
- Major alcohol withdrawal signs and symptoms include visual hallucinations and auditory hallucinations, whole body tremor, vomiting, diaphoresis, hypertension and seizures.
- *https://emedicine.medscape.com/article/166032-overview*

Management

- Keep the patient in a calm, quiet, safe and well-lit environment.
- Sedation is usually given with diazepam 10mg or lorazepam 4mg IV, followed by oral administration.
- Ongoing reassessment and maintain fluid and electrolyte balance.
- Thiamine: to prevent from Wernicke encephalopathy and Korsakoff syndrome.
- Reassure patient and family.

EPILEPTIC FUROR

- Following epileptic attack, patient may have a sudden outburst of rage or excitement during which an irrational act of violence may be committed.

Management

- Sedation: Inj. Diazepam 10 mg IV [or] Inj. Phenobarbital (Luminal) 10 mg IV followed by oral anticonvulsants
- Haloperidol 10 mg IV helps to reduce psychotic behavior.

ACUTE DRUG-INDUCED EXTRAPYRAMIDAL SYMPTOMS

- Extrapyramidal Side effects (EPS), commonly referred to as drug-induced movement disorders are among the most common adverse drug effects patients experience from dopamine-receptor blocking agents.

Highest incidence:

- Haloperidol and phenothiazine (61.6%) (Centrally acting dopamine-receptor blocking agents, the first-generation antipsychotics).

Less frequently:

- Atypical antipsychotics
- Antiemetics (metoclopramide 4-25%, droperidol, and prochlorperazine 25-57%)
- Lithium
- Serotonin reuptake inhibitors (SSRIs)
- Stimulants
- Tricyclic antidepressants (TCAs).

Symptoms and Signs

- On physical exam, dystonia manifests with involuntary muscle contractions resulting in abnormal posturing or repetitive movements,
- The back and extremities- opisthotonus
- Neck – torticollis
- Jaw – trismus
- Eyes - oculogyric crisis
- Abdominal wall and pelvic muscles - tortipelvic crisis
- Facial and tongue muscles - buccolingual crisis
- The clinician must evaluate these patients for pain and particularly difficulty in breathing, swallowing, and speech.
- Neuroleptic malignant syndrome is rare but most serious of these symptoms and occurs in a small minority of patients taking neuroleptics, especially high-potency compounds.

Management

- Dystonic reactions are rarely life-threatening, and the clinician should discontinue the offending agent and manage pain if present.
- Emergency airway intervention if laryngeal and pharyngeal dystonic reactions may increase the risk of imminent respiratory arrest.
- Treatment is symptomatic and includes cooling the patient, maintaining fluid and electrolyte balance.
- If the causative medication is a typical first-generation antipsychotic, switching to an atypical antipsychotic may be trialed.

- Administration of an antimuscarinic agent (benztropine, trihexyphenidyl) or diphenhydramine may relieve dystonia within minutes.
- In cases of tardive dystonia, administration of benzodiazepine, trial of muscle relaxant (e.g., baclofen).

DRUG TOXICITY

- Drug toxicity generally occurs over time, while drug overdose happens when too much of a substance is consumed at once.
- Drug toxicity is typically accidental, while drug overdose can be either accidental or intentional.
- In either case all attempts must be made to find out the drug consumed. A detailed history should be collected and symptomatic treatment instituted.
- A very common drug is lithium.
- The symptoms include drowsiness, vomiting, abdominal pain, confusion, blurred vision, acute circulatory failure, stupor and coma, generalized convulsions, oliguria and death.

Diagnosis of Drug Toxicity

- Acute drug toxicity is more easily diagnosed as the symptoms follow the taking of the medication just one time. Blood tests can also screen for levels of the medication in the bloodstream.
- Chronic drug toxicity is harder to identify. Stopping the medication, then "re-challenging" it later is one method of testing whether the symptoms are caused by the medicine.

Management

- Administer Oxygen
- Start i/v line
- Assess for cardiac arrhythmias
- Acute overdose: gastric lavage, activated charcoal, consider antidote
- Refer for haemodialysis
- Administer anticonvulsants as appropriate

VICTIMS OF DISASTER

- Victims of disaster are people, who have survived a sudden, unexpected, overwhelming stress. This is beyond what is normally expected in life, like in an earthquake, flood, riots and terrorism.
- Anger, frustration, guilt, numbness and confusion are common features in these people.

Management

- Treatment for life threatening physical problems

Crisis Management Briefing (CMB)

- An efficient and effective way for the people to get clear, concise, and regular communication during a critical incident. It is designed to provide information about the incident, control rumors, educate about symptoms of distress, inform about basic stress management, and identify resources available for continued support. The communication is mostly one-sided.
- It can be delivered to a small or large group that include all kinds of participants, from survivors to spectators.
- CMBs can, and frequently should, be done in the course of a critical incident.
- CMB can be given by someone who has taken a level of responsibility for the incident such as leadership within an organization or response managers.
- A CMB can lose some of its effectiveness if the speakers are overly emotionally invested in the events.
- A CMB moves quickly through 4 phases of communication; Introduction, Fact, Teaching, and Re-Entry (Mitchell 2006). Most CMBs will take less than an hour.

Fig.2 Crisis Management Briefing



Introduction Phase

- The introduction is the part of the briefing where audience members are introduced to the people involved in giving the briefing and the reason for the briefing.

Fact Phase

- This phase is about getting everyone on the same page as to what has happened and where the situation stands at the moment. It is beneficial to put the known facts in chronological order.
- Facts should be delivered in a business tone, with little emotional reaction from the speaker.

Teaching Phase

- It is often the longest portion of the briefing, where the voice of communication will change from **what has happened to what will happen**. It should address physical, emotional, mental, and spiritual expectations and resources.

Re-Entry Phase

- This phase concludes the CMB. Start this phase by normalizing and validating the struggle that the events have caused,
- CBM may be especially useful in response to community violence / terrorism and can be tailed to smaller group applications.
- By doing CBM, the need for CISD can be assessed.

Critical Incident Stress Debriefing (CISD)

- CISD is a special technique to help normal people deal with abnormal situations. It is a structured group discussion concerning the critical incident which follows a structure of 7 phases. Debriefing allows those involved with the incident to process the event and reflect on its impact.
- Only trained individuals should initiate a CISD. Untrained individuals can cause more harm than good if they do not understand the reasons behind and steps involved in a Debriefing.
- CISD should be done **after the first 24 hours** of the incident to 10 days.
- **CISD includes seven phases:** Introduction, Fact, Thought, Reaction, Symptom, Teaching and Re-entry.
- In selected cases benzodiazepines for short term are prescribed to reduce anxiety and induce sleep.
- Referral to mental health service, if required

RAPE VICTIM (SEE MORE DETAILS IN SEXUAL VIOLENCE, CHAPTER 17)

- Rape is a perpetuation of an act of sexual intercourse with a female against her will and consent.

Signs and Symptoms

- Acute disorganization characterized by self-blame, fear of being killed, feeling of being killed, feelings of degradation and loss of self-esteem, feelings of depersonalization, unable to remember important parts of the event (dissociative amnesia) and serialization of recurrent intrusive thoughts are commonly seen.
- Long term psychological effects like post-traumatic stress disorders (PTSD), anxiety and depression can occur in some cases.

Management

- Be supportive, reassuring and non-judgmental
- Physical examination for any injuries
- Give morning after pill to prevent possible pregnancy. Send sample for STD and HIV infection.
- Explain to the patient the possibility of PTSD, sexual problems like vaginismus (vaginism) and anorgasmia may appear later.

SCHIZOPHRENIA SPECTRUM AND OTHER PSYCHOTIC DISORDERS

Schizophrenia Spectrum and Other Psychotic Disorders includes the following.

A. Schizophrenia
B. Other psychotic disorders, and
C. Schizotypal (personality) disorder.

They are defined by abnormalities in one or more of the following five domains:

- Delusion
- Hallucinations
- disorganized thinking (speech)
- grossly disorganized or abnormal motor behavior (including catatonia), and
- negative symptoms. {a lack of normal function and include diminished emotional expression, alogia (diminished speech output), avolition (i.e., reduced goal-directed activity due to decreased motivation), asociality (apparent lack of interest in social interactions), and anhedonia (decreased ability to experience pleasure from positive stimuli)}

Two negative symptoms are particularly prominent in schizophrenia: diminished emotional expression and avolition.

SCHIZOPHRENIA

Schizophrenia is the most common psychotic mental disorder. According to a 2019 data, schizophrenia is the third leading diagnosis among mental health problems in Myanmar.[1]

The age of highest tendency to have a syndromic phase

- Men - between 18 and 25 years of age.
- Women - two peaks; the first between 25 and mid-30s, and the second after 40 years of age.
- Initial presentation before 15 years of age is possible but rare.

Etiology

It is a multifactorial process involving the interaction of genetic predisposition and environmental factors (the polygenic threshold model).

Environmental factors that increase the risk of schizophrenia

1. During fetal development and early life infections (e.g., rubella, influenza, Toxoplasma gondii, herpes simplex virus type 2)
2. Nutritional deficiencies (e.g., folic acid, iron, vitamin D)
3. Pregnancy and birth complications, neonatal hypoxic events
4. Childhood trauma
5. Substance use disorder especially cannabis use
6. Socioeconomic status.

Clinical Presentation

It is important to identify schizophrenia early in the course of disease because those who are treated early have better long-term outcomes. Primary care physicians must be vigilant in identifying people with psychotic symptoms, using current diagnostic criteria (e.g. DSM-5) or specialty care referral to aid in diagnosis.

Schizophrenia is characterized by two sets of categorical symptoms, with at least **one positive symptom** (delusion, hallucinations, disorganized thinking) and either **one negative symptom** (see

above) or **grossly disorganized** or **catatonic behavio**r present for at least six months.
Symptoms must be present for at least six months and be significantly debilitating for at least one month (or less if receiving clinical treatment).
Other psychiatric disorders and medical conditions that mimic schizophrenia should be ruled out when patients present with symptoms are reviewed.

Psychiatric Conditions That Can Mimic Schizophrenia

Conditions	Distinguishing features
Bipolar disorder with psychotic features	Psychotic symptoms during manic or depressive episodes
Brief psychotic disorder	Delusions, hallucinations, and other psychotic symptoms lastir more than one day but less than one month
Delusional disorder	Fixation on false beliefs or nonbizarre delusions without other psychotic symptoms
Major depressive disorder with psychotic features	Psychotic symptoms with mood disturbances qualifying for concomitant major depressive disorder diagnosis
Obsessive-compulsive disorder	Significant obsessions, compulsions, and preoccupations
Posttraumatic stress disorder	Symptoms related to reliving inciting traumatic event
Schizoaffective disorder	Mania or depression occurring concomitantly with psychotic symptoms; psychotic symptoms without mood disturbance
Schizophreniform disorder	Psychotic symptoms lasting at least one month, but less than six months
Schizotypal personality disorder	No hallucinations or delusions with personality Features

Medical Conditions That Can Present with Psychosis

1. Cushion syndrome
2. Delirium
3. Dementia
4. Intracranial tumor
5. Paraneoplastic and non-paraneoplastic autoimmune syndromes with psychosis
6. Porphyria
7. Substance abuse
8. Systemic lupus erythematosus
9. Thyroid disorders
10. Vitamin B12 deficiency
11. Wilson disease



Algorithm for the Diagnosis of Schizophrenia

Am Fam Physician.October 2022 ◆ Volume 106, Number 4

Treatment

The primary goal for initial treatment of schizophrenia should be to reduce acute positive symptoms by using first or second-generation antipsychotics allowing the patient to return to a baseline level of function and prevent long-term disability. (Recommendation A)

Treatment for schizophrenia should continue for life. Primary care physicians who are comfortable prescribing antipsychotics can play a vital role in treating patients in resource-constrained environments.

Patients with a first episode of psychosis who receive a formal diagnosis of schizophrenia should be treated in a coordinated specialty care program (Recommendation B)

Person centered medication

The factors a family physician should consider in selection of medication include:

- individual preference
- prior treatment response
- adherence history
- relevant medical history and risk factors
- adverse effects, and
- long-term treatment planning, including cost and access to medication.

Antipsychotics

First generation antipsychotics

- Dopamine receptor antagonists.
- More incidence of extrapyramidal symptoms
- Chlorpromazine, fluphenazine, perphenazine and haloperidol are available.

Second-generation antipsychotics

- Serotonin receptor antagonists
- Generally preferred as first-line agents

- Associated with the development of metabolic syndrome
- Aripiprazole, olanzapine, quetiapine and risperidone are available.

Antipsychotic Medications and Adjunctive Treatments for Schizophrenia

Medication	Initial dosage (mg/day)	Typical dosage range (mg/day)	Common adverse effects
First-generation antipsychotics			
Chlorpromazine	25 to 100	200 to 800	Dry mouth, elevated prolactin levels, extrapyramidal symptoms, glucose intolerance, postural hypotension, somnolence, weight gain
Fluphenazine	2.5 to 10	6 to 20	Akathisia, parkinsonism, dystonia, hyperproteinemia
Haloperidol	1 to 15	5 to 20	Dry mouth, extrapyramidal symptoms, galactorrhea, hyperprolactinemia, hypotension, somnolence, tachycardia
Perphenazine	8 to 16	8 to 32	Dry mouth, extrapyramidal symptoms, galactorrhea, hyperprolactinemia, hypotension, somnolence, tachycardia
Second-generation antipsychotics			
Aripiprazole	10 to 15	10 to 15	Anxiety, constipation, dizziness, headache, insomnia
Clozapine	12.5 to 25	300 to 450	Hyperlipidemia, diabetes mellitus, orthostasis, seizures
Olanzapine	5 to 10	10 to 20	Weight gain, hyperlipidemia, diabetes, akathisia, hyperprolactinemia, postural hypotension
Quetiapine	Immediate release: 50 Extended release: 300	400 to 800	Hyperlipidemia, agitation, dizziness, dry mouth, hypotension, somnolence, weight gain
Risperidone	2	2 to 8	Anxiety, hyperprolactinemia, hypotension, insomnia, metabolic changes, nausea, weight gain

Maintenance Therapy

Patients with schizophrenia should continue maintenance therapy while being monitored for treatment effectiveness and adverse effects. The goal of maintenance therapy is to prevent relapse into active phase schizophrenia and maximize social function and quality of life.

Primary care physicians should be aware that patients with schizophrenia have an increased risk of cardiovascular disease as well as overall mortality.

Treatment-resistant Schizophrenia

Treatment-resistant schizophrenia is the persistence of significant symptoms despite adequate pharmacologic treatment.

Schizophrenia refractory to first- and second-generation antipsychotics should be treated with clozapine. (Recommendation B)

Clozapine has an FDA boxed warning in the US, highlighting the risk of severe neutropenia (e.g., agranulocytosis), myocarditis, cardiomyopathy, seizures, and profound hypotension. Oral and long-acting injectable clozapine require additional training for the physician.

Adjunctive treatments

The psychosocial therapies should be offered as adjunctive treatments, such as:

- cognitive behavior therapy for psychosis
- psychoeducation

- supported employment services
- assertive community care, and
- family interventions

(Recommendation B).

However, electroconvulsive therapy (ECT) was associated with memory impairment (NNH = 4) and headache (NNH = 8) even though ECT adjunctive treatment with clozapine is superior to clozapine monotherapy for treatment-resistant schizophrenia (NNT = 3).

Relapse was reduced with family interventions, psychoeducation, illness self-management, and early interventions following the first episode of psychosis.

Prognosis

The clinical course and prognosis of people with schizophrenia are marked with heterogeneity and the unpredictable disease course.

People with schizophrenia have mortality rates two to four times greater than the general population. Most deaths are related to an increased rate of cardiovascular disease with concomitant renal disease, respiratory diseases, stroke, cancer, and thromboembolic events.

People with schizophrenia should be screened by a primary care physician for cardiovascular disease and receive at least annual metabolic screening and counseling with interventions to prevent weight gain and attempt to mitigate other factors, such as smoking. A large cohort study found that maintenance therapy with antipsychotic medications reduces rates of suicide and overall mortality.

References

1. Our World in Data: Burden of disease from each Category of mental illness, Myanmar, 2019. https://ourworldindata.org/grapher/burden-disease-from-each-mental-illness?country=~MMR
2. Diagnostic and Statistical Manual of Mental Disorders; Fifth Edition (DSM-5), American Psychiatric Association.
3. Schizophrenia; American Family Physician. Volume 106, Number 4 ◆ October 2022.

MOOD DISORDERS

- Bipolar and related disorders
- Dysthymic disorder
- Depressive disorders

BIPOLAR AND RELATED DISORDERS

- Bipolar disorders are common, recurrent mental health conditions of variable severity.
- Bipolar disorders are difficult to diagnose.
- Affected individuals have higher rates of other mental health disorders, substance use disorders, and comorbid chronic medical illnesses.
- Physicians should consider bipolar disorder in any patient presenting with depression.

Categories and Types of Bipolar Disorders

Bipolar I disorder: Manic or mixed feature episode with or without psychosis and/or major depression

Bipolar II disorder: Hypomanic episode with major depression; no history of mania, but can have a history of hypomania

Cyclothymia: Hypomanic and depressive symptoms that do not meet bipolar II disorder criteria, no major depressive episodes, occurring over two years, with no more than two months free of symptoms

Bipolar disorder, not otherwise specified: Does not meet criteria for major depression, bipolar I disorder, bipolar II disorder, or cyclothymia (e.g., less than one week of manic symptoms, without psychosis or hospitalization)

Substance-induced mania (include name of substance: e.g. steroids, alcohol, cocaine, or prescription antidepressants).

Manic Episode

- A distinct period of abnormally and persistently elevated, expansive, or irritable mood and abnormally and persistently increased **goal-directed** activity or energy, **lasting at least 1 week** and present most of the day, nearly every day (or any duration if hospitalization is necessary). (Presence of psychotic symptoms like delusion of grandeur, auditory hallucinations)

Hypomanic Episode

- A distinct period of abnormally and persistently elevated, expansive, or irritable mood and abnormally and persistently increased activity or energy, lasting at least 4 consecutive days and present most of the day, nearly every day.
- **Mood:** predominately elevated, irritable
- **Speech &thought:** pressured, flight of ideas, poor attention
- **Behaviour:** Insomnia, loss of inhibitions: sexual promiscuity, overspending, risk-taking, compulsive gambling, increased appetite.

Major Depressive Episode (See in Depressive Disorders)

Assessment of Acute Manic Episode

- Lookfor
  - Several days of:
    - marked elevated or irritable mood

        - Excessive energy and activity
        - Excessive talking
        - Recklessness
- Past history:
    - Depressed mood
    - Decreased energy and activity
- People who suffer only manic episodes (without depression) are also classified as having bipolar disorder.
- Complete recovery between episodes is common in bipolar disorder.

Differential diagnosis

- Hypoglycemia
- Alcohol or drug abuse
- Steroid side effects
- Temporal lobe epilepsy
- Frontal lobe dysfunction (d/t tumor or stroke)
- Thyrotoxicosis

Look for concurrent conditions

- Alcohol use or drug use disorders
- Suicide/ self-harm
- Dementia
- Concurrent medical illness e.g. stroke, diabetes, hypertension, HIV/AIDS, cerebral malaria, or steroid use

Management of Bipolar Disorders

- Patients with acute mania require hospitalization because of risk of harm to self or others. If acute mania is suspected, exclude other physical causes and refer promptly for specialist assessment, diagnosis and management.
- Alcohol/drug misuse is common co-morbidity.
- Sedation whilst awaiting admission may be required - try oral medication first, Olanzapine 10mg po (5-20mg/d).
- Only if oral treatment is not feasible, consider i/m haloperidol 1.5 - 3mg (typically effective dose 3-20 mg)
- The first-line treatment for bipolar disorders should be pharmacotherapy including mood stabilizers, such as lithium, anticonvulsants(valproate), and antipsychotics such as quetiapine, olanzapine, risperidone which should be continued indefinitely because of the risk of patient relapse.
- Monotherapy with antidepressants is **contraindicated** during episodes with mixed features, manic episodes, and in bipolar I disorder.
- Ongoing management involves monitoring for suicidal ideation, substance use disorders, treatment adherence, and recognizing medical complications of pharmacotherapy.
- Psychotherapy is a useful adjunct to pharmacotherapy.
- Patients and their families should be educated about the chronic nature of this illness, possible relapse, suicidality, environmental triggers (e.g., seasonal light changes, shift work, other circadian disruption), and the effectiveness of early intervention to reduce complications.

DEPRESSIVE DISORDERS

- Serious medical illness that negatively affects how you feel, how you think, and how you act.
- These disorders are common and 30-50% cases are not detected although most are mild cases and more likely to resolve spontaneously.

Types of Depressive Disorders

- **Disruptive mood dysregulation disorder**
- **Major depressive disorder (including major depressive episode)**
- **Persistent depressive disorder (dysthymia)**
- **Premenstrual dysphoric disorder**
- **Substance/medication-induced depressive disorder**
- **Depressive disorder due to another medical condition**
- **Other specified depressive disorder, and unspecified depressive disorder.**

MAJOR DEPRESSIVE DISORDERS

Diagnostic criteria (DSM-5)

A. Five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning: at least one of the symptoms is either 1) depressed mood or 2) loss of interest or pleasure.
Note: Do not include symptoms that are clearly attributable to another medical condition.

1) Depressed mood most of the day (e.g., feels sad, empty, hopeless, appears tearful, in children and adolescents- can be irritable mood.)
2) Markedly diminished interest or pleasure.
3) Significant weight loss when not dieting, or weight gain (e.g. more than 5% of body weight)
4) Insomnia or hypersomnia nearly every day.
5) Psychomotor agitation or retardation nearly every day
6) Fatigue or loss of energy nearly every day.
7) Feelings of worthlessness or excessive or inappropriate guilt.
8) Diminished ability to think or concentrate, or indecisiveness, nearly every day.
9) Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a specific plan, or a suicide attempt or a specific plan for committing suicide.

B. The symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.

C. The episode is not attributable to the physiological effects of a substance or to another medical condition.

Screening questions for Depression

The Patient Health Questionnaire-2 (PHQ -2)

1. During the past 2 weeks, have you often been bothered by **feeling down, depressed, or hopeless?**
2. During the past 2 weeks, have you often bothered by having **little interest or pleasure in doing things?**

If positive response to either question, investigate further, e.g., with PHQ9 to confirm diagnosis and assess severity.

Severity Assessment of Depression

Table. 3

THE PATIENT HEALTH QUESTIONNAIRE (PHQ-9)

Patient Name:_____Date of Visit:_____

Over the past 2 weeks, how often have you been bothered by any of the following problems?	**Not At all**	**Several Days**	**More than half the days**	**Nearly Every Day**
1. Little interest or pleasure in doing things	0	1	2	3
2. Feeling down, depressed or hopeless	0	1	2	3
3. Trouble falling asleep, saying asleep, or sleeping too much	0	1	2	3
4. Feeling tired or having little energy	0	1	2	3
5. Poor appetite or overeating	0	1	2	3
6. Feeling bad about yourself - or that you're a failure or have let yourself or your family down	0	1	2	3
7. Trouble concentrating on things, such as reading the newspaper or watching television	0	1	2	3
8. Moving or speaking so slowly that other people could have noticed. Or, the opposite being so fidgety or restless that you have been moving around a lot more than usual	0	1	2	3
9. Thoughts that you would be better off dead or of hurting yourself in some way	0	1	2	3
10. If you checked off any problems, how difficult have those problems made it for you to do your work, take care of things at home, or get along with other people? □Not difficult at all □Somewhat difficult □Very difficult □Extremely difficult				

- *Sub threshold depressive symptoms (<5)*
- *Mild (5-9)*
- *Moderate (10-14)*
- *Moderately severe (15-19)*
- *Severe (symptoms markedly interfere with functioning+/- psychotic symptoms) (≥20)*

Biopsychosocial assessment

- Important to exclude differential diagnosis and treatment options
- Current symptoms (nature, onset, duration, severity)
- Past history of depression and or mood elevation (? Bipolar disorder)
- Family history of mental illness
- Quality of relationships
- Living conditions- social support
- Employment/financial worries
- Alcohol/substance misuse
- Suicidal ideation
- Treatment options
- Past experience of response to treatment
- Co- morbid mental/ physical health problems
- Awareness of sources of help
- The patient's views about the cause of his /her symptoms
- Need for follow-up

Management of Depression

- Assess suicide risk with Suicide Behaviors Questionnaire-Revised (See above in Assessment of Suicidality)
- **If high risk,**
  - refer as emergency to mental health specialist center or hospital.
- **If low risk**
  - Remove means of self-harm
  - Create secure and supportive environment, if possible, offer separate, quiet room while waiting.
  - Do not leave the person alone
  - Supervise and assign a family member to ensure safety.
  - Attend mental state, and emotional distress.
  - Maintain regular contact and follow-up for as long as the suicidal risk persists.

Pharmacological Treatment

- Medication is required for moderate/severe depression (or) mild/sub-threshold depression not responded to non--pharmacological treatment.
- SSRI (fluoxetine 10- 20mg od /sertraline 50-150mg od/ escitalopram 10-20mg od)
- SNRI (venlafaxine 75 – 225 mg od/ duloxetine20-60mg od)
- Start low dose, go slow to titrate.
- Time to response- 4-6wks

Side-effects:

- Dyspepsia, GI Bleeding especially co-administering with NSAIDS
- Increased anxiety/agitation within 2wk of treatment
- Hyponatremia in elderly people those taking SSRI or SNRI (Highest risk in the first 2-4 weeks and seems to diminish over time) (Lower risk with mirtazapine)

Patient- centered Approach for depression

- Discuss choice of drug and non-pharmacological therapy.
- Cognitive therapy is equally effective as antidepressant in mild/ moderate depression.
- Combined therapy is more effective than either treatment alone.
- Discuss side effects, not all side effects undesirable (SSRI may help premature ejaculation). Warn that there may be an initial worsening of symptoms in the first few weeks before therapeutic effects are seen.
- Assess after 4-6 wks.
- If effective, continue for at least 4-6 months after recovery, if stopped too soon 50% relapse.
- If no effect seen, increase dose and review in 2weeks.
- If still no response, increase dose unless poorly tolerated. Review in 2weeks. If no response or poor tolerability, switch to an alternative class of antidepressant.
- **Recurrent depression:** of those who have one episode of major depression 50-85% will have further episodes. Continuing antidepressants lowers the odds of relapse by 65% which is about half the absolute risk.

Psycho-Education Points

- Depression is a very common problem that can happen to anybody.
- Depressed people tend to have unrealistic negative options about themselves, their life and their future.
- Effective treatment is possible. It tends to take at least a few weeks before treatment reduces the symptoms of depression. Adherence to any prescribed treatment is important.
- The following need to be emphasized:

- Continue activities that used to be interesting or give pleasure
- Maintain a regular sleep cycle, (establish regular sleep/wake times, avoid excess eating, smoking, or alcohol before sleep, create a proper environment for sleep, take regular physical activity)
- Regular social activity (participation in communal social activities
- Structured physical activity program (exercises)
- Recognizing thoughts of self-harm or suicide and coming back for help when these occur

- In older people, to seek help for physical health problems.
- Offer the person an opportunity to talk, preferably in a private space. Explore idea of symptoms, their concerns and their expectations.
- Ask about current psychosocial stressors and address to the extent.

Referral to Mental Health Specialists

- URGENT
  - High suicide risk
  - Severe self-neglect
  - Depression complicated by psychotic symptoms
- ROUTINE or SOON
  - Depression complicated by psychotic co-morbidity or psychosocial factors
  - Inadequate response to multiple treatments.

SSRI Discontinuation reactions

- Occur once a drug has been used ≥ 8wk.
- Usually become apparent <5days after stopping the drug.
- Reduced risk by tapering dose (4 - 6wks).
- Symptoms: GI disturbances, headache, Nausea, paraesthesia, dizziness, anxiety, tinnitus, sleep disturbances, flu like symptoms. (FINISH-See below)
- Follow-up: if patient do not attend appointments. Give patient and or Family/carers clear advice on what to do if patient's mood deteriorates and how to access urgent support, both in and out of hours.

Table. 4

FINISH: A mnemonic for discontinuation Symptoms
F – Flu-like symptoms
I – Insomnia
N – Nausea
I – Imbalance
S – Sensory disturbance
H – Hyperarousal

PERSISTENT DEPRESSIVE DISORDERS (DYSTHYMIA)

- Dysthymia is a milder, but long-lasting form of depression.
- People with this condition may also have bouts of major depression at times.
- The people with this condition may be described as having a gloomy personality, constantly complaining or incapable of having fun.
- Though persistent depressive disorder is not as severe as major depression, because of the chronic nature of persistent depressive disorder, coping with depression symptoms can be challenging,

Diagnostic criteria (DSM-5)

A. Depressed mood for most of the days, as indicated by either subjective account or observation by others, for **at least 2 years.**
(In children and adolescents, mood can be irritable and duration must be at least 1 year).
B. Presence, while depressed, of ***two (or more) of the following***:

1. **Poor appetite or overeating.**
2. **Insomnia or hypersomnia.**
3. **Low energy or fatigue.**
4. **Low self-esteem.**
5. **Poor concentration or difficulty making decisions.**
6. **Feelings of hopelessness.**

C. During the 2-year period (1 year for children or adolescents) of the disturbance, the individual has never been without the symptoms in Criteria A and B for more than 2 months at a time.

*Note: Criteria for a major depressive episode include four symptoms that are **absent** from the symptom list for persistent depressive disorder (dysthymia).*

Management

For adults: a combination of psychotherapy and medication can be effective.
For children and adolescents; psychotherapy may be the first line recommendation, but sometimes antidepressants are also needed.

Medications

Following antidepressants are used.

- Selective serotonin reuptake inhibitors (SSRIs)
- Tricyclic antidepressants (TCAs)
- Serotonin and norepinephrine reuptake inhibitors (SNRIs)

ANXIETY AND RELATED DISORDERS

Anxiety disorders include disorders that share features of excessive fear and, anxiety and related behavioral disturbances. *Fear* is the emotional response to real or perceived imminent threat, whereas *anxiety* is anticipation of future threat.

Classification of Anxiety Disorders (DSM-5)

- Generalized anxiety disorder
- Panic disorder
- Phobia e.g. Agoraphobia
- Social anxiety disorder
- Separation anxiety disorder
- Selective mutism

GENERALIZED ANXIETY DISORDERS

Diagnostic criteria (DSM-5)

A. Excessive anxiety and worry occurring more days than not for **at least 6 months**, about a number of events or activities (such as work or school performance).
B. The individual finds it difficult to control the worry.
C. The anxiety and worry are associated with three (or more) of the following six symptoms (Only one item is required in children.)
    i. Restlessness or feeling keyed up or on edge.
    ii. Being easily fatigued.
    iii. Difficulty concentrating or mind going blank.
    iv. Irritability.
    v. Muscle tension.
    vi. Sleep disturbance (difficulty falling or staying asleep, or restless, unsatisfying sleep).
D. The symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.
E. The disturbance is not attributable to the physiological effects of a substance (drugs, caffeine, medications) or another medical condition (e.g., hyperthyroidism, temporal lobe epilepsy) or another mental disorder (e.g., panic disorder, social anxiety disorder)

(Anxiety +3 somatic symptoms and present for 6mth)

Clinical symptoms

Can present in various ways:

- Insomnia
- poor concentration
- goose flesh
- butterflies in the stomach
- Hyperventilation
- Headache
- sweating
- palpitation
- poor appetite
- nausea
- lump in throat unrelated to swallowing
- difficulty in getting to sleep
- excessive concern about self and bodily functions
- repetitive thoughts and activities

Children's symptoms

- Thumb-sucking; nail biting, bed wetting, food fads

Associations

- Anxiety is often accompanied by ***depression, dysthymia*** and other anxiety disorders including simple phobias, social phobia and panic disorder. Also may be a feature of ***early schizophrenia.***

Assessment

- Check Thyroid Functions.
- Use GAD- 2 screening tool.
- The first two items (core anxiety symptoms) of GAD-7 screening tool (See below). 86% in sensitivity and 83% in specificity for cut-off of 3.
- **GAD-2**

  Ask:
  - Over the last 2 weeks, how often have you been bothered by the following problems?
  - Feeling nervous, anxious, or on edge
    - (0) Not At all, (1) Several Days, (2) More than half the days, (3) Nearly every day
  - Not being able to stop or control worrying
    - (0) Not At all, (1) Several Days, (2) More than half the days, (3) Nearly everyday Interpretation: 0 – 2 = Negative, 3 – 6 = GAD
  - (< 3 and still suspicious 7 Ask *"Do you find yourself avoiding places or activities and does this cause you problems?" If the answer is* **yes, Consider anxiety disorder.)**

GAD-7 Scale

- The GAD-seven scale works by measuring the severity of anxiety symptoms.
- It is administered at the beginning of treatment to get a baseline measure of anxiety symptoms.
- It can then be given periodically throughout treatment to track changes in anxiety levels.

Table. . Generalized Anxiety Disorder-7

Generalized Anxiety Disorder-7 Scale				
Over the last 2 weeks, how often have you been bothered by the following problems? (Use – to indicate your answer)	Not at all	Several days	More than half the days	Nearly every day
1. Feeling nervous, anxious or on edge	0	1	2	3
2. Not being able to stop or control worrying	0	1	2	3
3. Worrying too much about different things	0	1	2	3
4. Trouble relaxing	0	1	2	3
5. Being so restless that it is hard to sit still	0	1	2	3
6. Becoming easily annoyed or irritable	0	1	2	3
7. Feeling afraid as if something awful mght happen	0	1	2	3
For office coding: Total Score	( )	( )	( )	( )

Scoring instructions

Scores of 5, 10 and 15 are taken as the cutoff points for mild, moderate and severe anxiety respectively.

0-4: Minimal anxiety 5-9: Mild anxiety

10-14: Moderate anxiety 15-21: Severe anxiety

Management of GAD

- Avoid caffeine, excess alcohol, and illicit drugs
- Use a stepped treatment approach

Stepped Treatment Approach

Step 1. Identification and assessment, education and active monitoring Symptom control:

- Listening is a good way to reduce anxiety.
- Explain that headache is not from tumor, and that palpitations are harmless. Anything done to enrich patient's relationship with others may well help.
- Regular exercise
- CBT and relaxation appear to be the best specific measures with 50-60% recovering over 6 months.

Step 2. Offer low intensity psychological interventions

- Individual non-facilitated self-help (self-administered intervention intended to treat GAD involved a self-help resource, e.g. book or workbook), individual guided, Self – help, psycho educational groups

Step 3. Offer high intensity psychological intervention

- (e.g. CBT, Applied relaxation and/or drug treatment)

Step 4. Offer referral for specialist treatment

Step 1 and 2 = ***Normally primary care***
Step 3 = ***Normally primary care with review every 2-4 weeks in the first 3 months then every 3 months thereafter.***
Step 4 = ***Normally in specialist service, secondary care will initiate treatment and primary care will continue.***

Drug Treatment

SSRI and SNRI are recommended as first-line treatment for GAD (Strength of Recommendation A)

- SSRI (sertraline 50 to 150mg od, escitalopram 5-20 mg od)
- SNRI (venlafaxine 37.5 to 225mg od /day)
- caution: <30yr-increased suicidal thought in 1wk
- Follow up <**1**wk, weekly for 1 month
- If drug treatment is effective, continue for 6 to 12 months after achieving treatment response to reduce the rate of relapse. (SOR B)
- If no benefit, consider alternative SSRI/ SNRI or add a psychological therapy
- Pregabalin is an option if unable to tolerate.
- Do not offer antipsychotic medication.
- Avoid benzodiazepines to use as first-line therapy (SOR B) except for acute crises; restrict use to <4wk due to potential for dependence.
- Psychotherapy is as effective as medication for GAD (SOR A)
- Physical activity reduces symptoms of anxiety (SOR B)

Referral

- If severe anxiety with marked functional impairment and
- Risk of self-harm/suicide
- Significant co-morbidity (e.g. Substance misuse, personality disorder or complex physical health problems)
- Self-neglect
- Inadequate response to drug treatment

PANIC DISORDERS

DSM-5 Criteria for PANIC DISORDER

- Experiencing of **recurrent panic attacks**, with 1 or more attacks, followed by at least 1 month of fear of another panic attack or significant maladaptive behavior related to the attacks which often includes avoiding situations that might induce an attack.
- A **panic attack** is an abrupt period of intense fear or discomfort accompanied by 4 or more of the following 13 systemic symptoms:
    - Palpitations, pounding heart, or accelerated heart rate
    - Sweating
    - Trembling or shaking
    - Shortness of breath or feeling of smothering
    - Feelings of choking
    - Chest pain or discomfort
    - Nausea or abdominal distress
    - Feeling dizzy, unsteady, lightheaded, or faint
    - Chills or heat sensations
    - Paresthesias (ie, numbness or tingling sensations)
    - Derealization (ie, feeling of unreality) or depersonalization (ie, being detached from oneself)
    - Fear of losing control or going crazy
    - Fear of dying

Association

- Depression (56%), GAD, agoraphobia, substance misuse, suicide

Differential Diagnosis of PANIC DISORDER

- Social phobia or another specific (simple) phobia, OCD, PTSD or separation anxiety disorder.
- Alcohol withdrawal,
- drug misuse/withdrawal,
- other psychiatric disorders (e.g. psychosis),
- hyperthyroidism,
- temporal lobe epilepsy,
- cardiac arrhythmia,
- labyrinthitis,
- hypoglycaemia,
- hyperparathyroidism,
- pheochromocytoma.

Management of Acute Panic Attack (See above in Psychiatric Emergency)

Management of Panic Disorder

Psychotherapy

- Psychotherapy can be as effective as medication for panic disorder. Cognitive behavior has the best level of evidence (SOR A)
- The aim is to **help** the patient **understand panic attacks and panic disorder and learn how to cope with them**.

Medication

- Selective serotonin reuptake inhibitors are considered first-line therapy for panic disorder (SOR B)
- To avoid relapse, medication should be **continued for 12 months** after symptoms improve before tapering. (SOR C)
- Physical activity is a cost-effective treatment for panic disorder. (SOR B)
- Benzodiazepines can be used as augmentation, but only for short term because they are associated with tolerance. (SOR B)

OBSESSIVE COMPULSIVE AND RELATED DISORDERS

- Obsessive Compulsive Disorder
- Body Dysmorphic Disorder
- Trichotillomania
- Excoriation Disorder
- Hoarding Disorder

OBSESSIVE-COMPULSIVE DISORDERS

- Obsessive-compulsive disorder (OCD) is a chronic illness that can cause marked distress and disability.
- It is a complex disorder with a variety of manifestations and symptom dimensions, some of which are under recognized.
- Early recognition and treatment with OCD-specific therapies may improve outcomes, but there is often a delay in diagnosis. (The average time it takes to receive treatment after meeting diagnostic criteria is 11 years)

Table 6. Common Symptoms in Patients with OCD

Obsession	Examples	Associated compulsive behaviour
Aggressive	Fear of harming others, recurrent violent images	Monitoring the news for reports of violent crimes, asking for reassurance about being a good person
Contamination	Fear of being contaminated or contaminating others: • fear of being contaminated by germs, infections, or environmental factors, • fear of being contaminated by bad or immoral persons	Washing or cleaning rituals
Pathologic doubt, completeness	Recurrent worries about doing things incorrectly or incompletely, thereby negatively affecting the patient or others	Checking excessively, performing actions in a particular order
Religious	Thoughts about being immoral and eternal damnation	Asking forgiveness, praying, reassurance seeking
Self-control	Fear of making inappropriate comments in public	Avoiding being around others
Sexual	Recurrent thoughts about being a pedophile or sexually deviant, recurrent thoughts about acting sexually inappropriate toward others	Avoiding situations that trigger the thoughts, performing mental rituals to counteract the thoughts
Superstition	Fears of certain “bad” numbers or colours	Counting excessively
Symmetry and exactness	Recurrent thoughts of needing to do things in a balanced or exact fashion	Ordering and arranging

Am Fam Physician 2015;92(10):896-903

Diagnosis

- Physicians should consider the possibility of OCD in patients with general complaints of anxiety or depression with additional clues such as alluding to intrusive thoughts or repetitive behaviors,

avoidance of particular locations or objects, excessive concerns about illness or injury, and repetitive reassurance-seeking behavior.

- If OCD is suspected, the use of simple initial screening questions (see below) can be helpful for primary care physicians.

- Do you wash or clean a lot?
- Do you check things a lot?
- Is there any thought that keeps bothering you that you would like to get rid of but cannot?
- Do your daily activities take a long time to finish"
- Are you concerned about putting things in a special order, or are you very upset by mess?
- Do these problems trouble you?
- *Note: If a person answers "yes" to any of these questions and the symptom causes distress, a diagnostic interview or patient symptom inventory should be administered*

Table 7. OCD Initial Screening Questions

Am Fam Physician. 2015;92(10):896-903

- The diagnosis of OCD should be confirmed with DSM-5 criteria or through psychiatric referral.

Comorbidities

The most common psychiatric comorbidities of OCD are:

- **Anxiety disorders** (75.8%), including panic disorder, social phobia, other specific phobias and PTSD
- **Mood disorders** (63.3%) including major depressive disorder (40.7%), impulse control disorders (55.9%) and substance use disorders (38.6%).

Management

- Patients with OCD should be monitored for psychiatric comorbidities and suicide risk. (Strength of Recommendation C).
- Cognitive behavior therapy, specifically exposure and response prevention, is the most effective psychotherapy method for treating OCD. (SOR A)
- SSRIs are recommended as first-line pharmacologic therapy for OCD. (SOR A)
- Fluoxetine, fluvoxamine, paroxetine, and sertraline have been approved for the treatment of OCD. There are dose limitations for citalopram because of concerns about QT prolongation.
- A trial of SSRI therapy should continue for 8 to 12 weeks, with at least 4 to 6 weeks at the maximal tolerable dosage. (SOR C)
- Patients with OCD require a higher dosage of an SSRI compared with other indications.
- Indefinite SSRI therapy should be considered to prevent OCD relapse. At a minimum, SSRIs should be continued for 1 to 2 years before attempting to discontinue. (SOR C)
- Augmenting SSRI therapy with an atypical antipsychotic is effective in some patients with OCD who have inadequate response to SSRI therapy. (SOR B)

(Table 8) Obsessive-Compulsive–Related Disorders

Disorder	Diagnostic criteria	Clinical features	Preferred treatment
Body dysmorphic disorder	Preoccupation with perceived defects or flaws in physical appearance that leads to repetitive behaviors or mental acts in response to the apparent concerns	Poor insight Seeks care from dermatologists and cosmetic surgeons to address perceived defects Symptom onset during adolescence Waxing and waning course	Cognitive behavior therapy (exposure and response prevention) Some SOR for SSRIs

Excoriation (skin-picking) disorder	Recurrent skin picking resulting in skin lesions Repeated attempts to decrease or stop skin picking	More common in females Symptom onset at the beginning of puberty	Habit reversal therapy Limited studies evaluating response to pharmacotherapy
Hoarding disorder	Persistent difficulty discarding or parting with possessions because of strong urges to save items and/or distress with discarding items Accumulation of possessions to a degree that the space where possessions accumulate cannot be used as intended	75% of patients with hoarding disorder have comorbid mood or anxiety disorders The hoarding causes significant distress or impairment in function Symptom onset between 11 and 15 years of age, equally in men & women Symptoms or hoarding behaviors progressively worsen	Behavior therapy targeted toward removal of hoarded items and reduction in accumulation of new items No data to support pharmacotherapy
Trichotillomania (hair-pulling disorder)	Recurrent pulling of hair from any part of the body resulting in hair loss Repeated attempts to decrease or stop hair pulling	More common in females Symptom onset at the beginning of puberty	Habit reversal therapy Mixed to poor response to SSRIs

TRAUMA AND STRESSOR RELATED DISORDERS

- Acute Stress Disorder
- Post-Traumatic Stress Disorder (PTSD)
- Adjustment Disorder
- Reactive attachment disorder
- Disinhibited social engagement disorder

ACUTE STRESS DISORDER

Diagnostic criteria (dsm5)

- **A.** The significant symptoms of acute stress begin after RECENT (within approximately one month) exposure to actual or threatened death, serious injury, or sexual violation in one (or more) by directly experiencing or witnessing the events or learning from a close family member or a close friend.
- **B.** Presence of nine (or more) of the following symptoms from any of the five categories.
    - *Intrusion symptoms* – recurrent distressing memories or dreams, dissociative reactions (e.g. flash backs).
    - *Negative mood* –inability to experience to positive emotions
    - *Dissociative symptoms* - seeing oneself from another's perspective, dissociative amnesia
    - *Avoidance symptoms*- efforts to avoid distressing memories or thoughts or external reminders.
    - *Arousal symptoms*- sleep disturbance, irritable behavior and angry outbursts, hypervigilance, problems with concentration
- **C.** Symptoms typically begin immediately after the trauma, but persistence for at least **3 days and up to a month.**

Management

- Psychological first aid.
- Listen, DO NOT pressure the person to talk
- Assess needs and concerns
- Help the person to address immediate basic physical needs (e.g. shelter)
- Help people connect to services, family, social supports, and accurate information
- As far as possible, help protect the person from further harm
- Assess for current stressors and/or ongoing abuse
- Consider stress management; Breathing exercises, Progressive muscle relaxation
- Help people to identify and strengthen positive coping methods and social support
- Do not prescribe benzodiazepines or antidepressants for acute stress symptoms
- Ask the person to return if the symptoms become more severe or no improvement by one month after the event. (To assess for PTSD)

Ref: mhGAP Intervention Guide Module

POST-TRAUMATIC STRESS DISORDER (PTSD)

- May occur in 25-30% of those who have experienced/witnessed an actual or threatened death, serious injury, or sexual violence **at least a month ago** e.g. major accident, fire, assault, military combat, natural disasters (e.g. cyclone, earthquake), rape.

Symptoms

- **Re-experiencing (Intrusion) symptoms**; repeated and unwanted recollections of the event as though occurring in the here and now (e.g. frightening dreams, flashbacks or intrusive

memories accompanied by intense fear or horror)

- **Avoidance symptoms;** deliberate avoidance of thoughts, memories, activities or situations that remind the person of the event
- **Hyperarousal symptoms-** related to a sense of heightened current threat; hypervigilance or exaggerated startle responses

Associations

- Depression
- Anxiety
- Drug/alcohol abuse and dependence

Diagnosis

A person is likely to have **PTSD** if she/he meets **all of the** following criteria:

- Has experienced a potentially traumatic event at least a month ago
- Has at least one re-experiencing symptom
  and
  One avoidance symptom
  and
  One hyper-arousal symptom
- Has difficulties in day-to-day functioning

Management

- Assess for and if possible, address current stressors and/or ongoing abuse
- Offer psychoeducation
- Explain the course of symptoms – beginning of some stress-related reactions in the first few days to weeks, symptoms of PTSD after one month and many people recover from PTSD over time without treatment. However, treatment may speed up the recovery process.
- Explain the nature of PTSD – easily startled(jumpy) and constantly on the watch for danger; unwanted recollections of the event (re-experiencing symptoms); trying to avoid any reminders of the event and which can cause problems in their lives (e.g. going to work); trying to avoid thinking about something usually results in thinking about it more; may sometimes have concurrent problems like aches and pains, low energy, irritability and depressed mood.
- Explain that the effective treatment is available – but likely to take several weeks to reduce the symptoms
- If trained therapists are available, consider referral for cognitive behavioral therapy with a trauma focus (CBT-T), or Eye Movement Desensitization and Reprocessing (EMDR)
- Consider stress management (see 10-tips for chronic stress relief below)
- Help people to identify and strengthen positive coping methods (ask them what is going well. How do they keep going? How have they previously coped with hardship?) and social support (identify people who give emotional support- Hand technique)
- Encourage resumption of social activities and normal routine
- In adults, consider antidepressants when stress management, CBT-T and EMDR prove ineffective or are unavailable.
- To recognize the thoughts of suicide and come back for help when these occur

Refer

- If severe acute stress symptoms <4wk or ongoing intrusive symptoms >4wk after trauma which require advanced psychological interventions such as CBT-T or EMDR

Self-help Stress Management Strategies

10 tips for chronic stress relief

1. Ensure you get enough sleep and rest–avoid using sleeping tablets to achieve this
2. Look after yourself and your own health, e.g. don't skip meals, sit down to eat, take time out to spend time with family and friends, make time for hobbies and relaxation, do not ignore health worries.
3. Avoid using nicotine, alcohol, or caffeine as a means of stress relief
4. Work off stress with physical exercise -reduce levels of adrenaline release and increase release of natural endorphins which increase a sense of well-being and enhanced sleep
5. Try relaxation techniques; breathing exercises, progressive muscle relaxation
6. Avoid interpersonal conflicts - try to agree more and be more tolerant
7. Learn to accept what you can't change
8. Learn to say 'no'
9. Manage your time better -prioritize and delegate; create time buffers to deal with unexpected overruns and emergencies
10. Try to sort out the cause of the stress, e.g. talk to line manager at work, arrange marriage or debt counseling, arrange more childcare

Time management made easy;

- This technique aims to transform and overwhelming volume of work into a series of manageable tasks.
- Make a list of all the things you need to do
- List them in order of genuine importance
- Note whether you really need to do the tasks, what you need to do personally, and what can be delegated to others
- Note a timescale in which each task needs to be done, e.g. immediately, within a day, within a week, within a month, etc.

SOMATIC SYMPTOM AND RELATED DISORDERS

Classification (DSM-5)

- Somatic symptom disorder
- Conversion disorder (functional neurological symptom disorder)
- Psychological factors affecting other medical conditions
- Factitious disorder
- Other specified somatic symptom and related disorder
- Unspecified somatic symptom and related disorder.
- All of the disorders in this category share a common feature: **the prominence of somatic symptoms associated with significant distress and impairment.**

Individuals with disorders with prominent somatic symptoms are commonly encountered in primary care and other medical settings but are less commonly encountered in psychiatric and other mental health settings.

- These disorders should be considered early in the evaluation of patients with unexplained symptoms to prevent unnecessary interventions and testing.
- Treatment success can be enhanced by:
    - discussing the possibility of a somatic symptom and related disorder with the patient early in the evaluation process
    - limiting unnecessary diagnostic and medical treatments
    - focusing on the management of the disorder rather than its cure
    - using appropriate medications and psychotherapy for comorbidities
    - maintaining a psycho-educational and collaborative relationship with patients and
    - referring patients to mental health professionals when appropriate.
- The unexplained symptoms of somatic symptom disorders often lead to general health anxiety; more frequent office visits, unnecessary laboratory or imaging tests, or costly and potentially dangerous invasive procedures.
- The main feature of these disorders is a concern with physical symptoms that are attributed to a nonpsychiatric disease. This concern can manifest as one or more somatic symptoms that result in excessive thoughts, feelings, or behaviors related to those symptoms and that are distressing or result in significant disruption of daily life.

Table 9. SORT: Key Recommendation for practice

Clinical Recommendation	*SOR Rating*	*Comments*
Fostering a strong physician-patient relationship is integral to managing somatic symptom and related disorders.	C	Recommendations from clinical practice settings
Cognitive behavior therapy is effective in treating patients with somatic symptom related disorders.	B	Consistent findings from randomized controlled trials
Psychiatric consultation helps improve the effects of somatic symptom related disorders.	B	Consistent findings from randomized controlled trials

Diagnosis

- The challenge in working with somatic symptom disorders in the primary care setting is to simultaneously exclude medical causes for physical symptoms while considering a mental health diagnosis.
- There are no specific physical examination findings or laboratory data that are helpful in confirming these disorders; it often is the lack of any physical or laboratory findings to explain the patient's excessive preoccupation with somatic symptoms that initially prompts the physician to consider the diagnosis.

Diagnostic Criteria

- One of the following criteria must be present:
  - Significant thoughts about the seriousness of the symptoms;
  - A high level of anxiety about the symptoms; or
  - Excessive energy spent regarding symptomatic concern.
- Although somatic symptoms need not be continuously present, they must be persistent (present for **more than six months**).
- Two specifiers of this condition in the DSM-5 are “with predominant pain” and “persistent.”
- Somatic symptom disorders can be mild, moderate, or severe.
- ***Note: Malingering** must be excluded before diagnosing a somatic symptom disorder.*
  - **Malingering:** the purposeful feigning of physical symptoms for external gain (e.g., financial or legal benefit, avoidance of undesired situations).
- **In somatic symptom disorders,** there are **no obvious gains or incentives** for the patient, and the physical symptoms are not willfully adopted or feigned; rather, anxiety and fear facilitate the initiation, exacerbation, and maintenance of these disorders.
- One screening tool is used in primary care settings, the Patient Health Questionnaire (PHQ 15), to screen somatic symptom disorders.

Table 10

The Patient Health Questionnaire - 15			
During the past four weeks, how much have you been bothered by the following symptoms?			
Symptoms	**Not at all**	**A little**	**A lot**
Back pain	0	1	2
Chest pain	0	1	2
Constipation, loose bowels, or diarrhoea	0	1	2
Dizziness	0	1	2
Fainting	0	1	2
Feeling tired or having low energy	0	1	2
Feeling your heart pound or race	0	1	2
Headache	0	1	2
Menstrual cramps or other problems with your periods (women only)	0	1	2
Nausea, gas, ir indigestion	0	1	2
Pain in your arms, legs, or joints	0	1	2
Pain or problems during sexual intercourse	0	1	2
Shortness of breath	0	1	2
Stomach pain	0	1	2
Trouble sleeping	0	1	2

The more recently developed Somatic Symptom Scale-8 (*Table 11*) shows promise in measuring somatic symptom burden. A study determines it is a reliable and valid self-report measure of somatic symptom burden.

Table 11: The Somatic Symptom Scale-8

Somatic Symptom Scale - 8					
During the past four weeks, how much have you been bothered by the following symptoms?					
Symptoms	**Not at all**	**A little bit**	**Some what**	**Quite a bit**	**Very much**
Back pain	0	1	2	3	4
Chest pain	0	1	2	3	4
Dizziness	0	1	2	3	4
Feeling tired or low energy	0	1	2	3	4
Headache	0	1	2	3	4
Pain in your arms, legs, or joints	0	1	2	3	4
Stomach and Bowel problems	0	1	2	3	4
Trouble sleeping	0	1	2	3	4
Score = ( )					
Scoring: Non to minimal (0-3), low (4-7), medium (8-11), high (12-15), very high (16-32)					

SOMATIC SYMPTOM RELATED DISORDERS

Table 12. Subsets of Somatic Symptom Disorder

Subset	Description
Conversion disorder	One or more symptoms of altered voluntary motor or sensory function inconsistent with a known condition. The symptoms typically do not conform to known anatomic pathways or physiologic mechanisms (Pseudo-neurologic).
Factitious disorder	Falsification of physical or psychological symptoms, or induced injury or disease; can be with regard to self or imposed on others, although not for personal gain (as with malingering)
Illness anxiety disorder	Preoccupation with getting or having a serious medical disorder; the two types include care-seeking and care-avoidant; previously included in **hypochondriasis.**
Psychological factors affecting other medical conditions	A medical condition must exist, and psychological factors must negatively affect the condition
Other specified somatic symptom and related disorders	Symptoms consistent with somatic symptom disorder are present, but do not meet full criteria for any of the above disorders (e.g. Pseudocyesis)
Unspecified somatic symptom and related disorders	Symptoms consistent with somatic symptom disorder are present, but do not meet criteria for any of the above disorders; should be used only when there is insufficient information to make a more specific diagnosis. (e.g. chronic fatigue which cannot be fully explained by a known medical condition)

Pain disorder, which was previously included in DSM-IV TR is removed in DSM-5. Which should be diagnosed as ‘somatic symptom disorder with predominant pain’ or ‘psychological factors affecting other medical condition' or an ‘adjustment disorder’ appropriately.

Differentia diagnosis

- Depression,
- Panic disorder
- Generalized anxiety disorder,

- Substance use disorder,
- Syndromes of unclear etiology (e.g. Nonmalignant pain syndrome, chronic fatigue syndrome), and
- Non-psychiatric medical conditions.

Management

- The management of somatic symptom disorders requires a multifaceted approach tailored to the individual patient.
- The primary care clinicians should keep in mind psychological, social, and cultural factors that influence somatic symptoms to choose the correct treatment plan.
- General treatment tenets for the primary care clinician include:
    - scheduling regular, short-interval visits to avoid the need for symptoms to get an appointment
    - establishing a collaborative, therapeutic alliance with the patient
    - acknowledging and legitimizing symptoms once the patient has been evaluated for other medical and psychiatric diseases
    - limiting diagnostic testing and reassuring the patient that serious medical diseases have been ruled out
    - educating patients about coping with physical symptoms
    - setting a treatment goal of functional improvement rather than cure
    - appropriately referring patients to subspecialists and mental health professionals.
- CARE MD treatment approach was developed to help primary care clinicians work more effectively with patients who have somatic symptom disorder. (See below)

Table 13: CARE MD Approach to Somatic Symptom Disorder

Component	Description
Consultation (psychiatry or cognitive behaviour therapy	Consult and collaborate with mental health professionals
Assessment	Evaluate for other medical and psychiatric diseases
Regular visits	Schedule short-interval follow-up to stop overuse of medical care (e.g., inappropriate emergency department visit, excessive calls) and avoid the need for symptoms to get an appointment; stress coping rather than cure
Empathy	Spend most of the time listening to the patient and acknowledge that what he or she is feeling is real
Medical-psychiatric interface	Emphasize the mind-body connection; avoid comments such as “there is nothing medically wrong with you”
Do no harm	Limit diagnostic testing and referrals to subspecialist; reassure the patient that serious medical diseases have been ruled out

Cognitive Behavioral Therapy

- *SOR: multicenter RCT, reviews of controlled clinical show;*
    - Effective for treatment of somatic symptom disorder and medically unexplained symptoms.
    - “Health anxious” patients had sustained symptomatic benefit over two years, with no significant effect on total costs.
    - Reduced physical symptoms, psychological distress, and disability.

Mindfulness-Based Therapy

- *SOR: Meta-analysis of RCTs show;*
    - May be effective in treating some aspects of somatic symptom disorder
    - Significant and sustained improvements in clinical outcomes (overall symptom severity, depression, and anxiety) compared with control groups

Pharmacotherapy

- *SOR: Systematic reviews of controlled trials show;*
  - Amitriptyline shows benefit for one or more of the following outcomes: fatigue, functional symptoms, global improvement, morning stiffness, pain, sleep, and tender points.
  - Fluoxetine (Prozac) shows benefit for functional status, global well-being, morning stiffness, pain, sleep, and tender points
  - Monoamine oxidase inhibitors, bupropion (Wellbutrin), antiepileptics, and antipsychotics showed no benefit and should not be used.

St. John's Wort

- *SOR: Randomized, double-blind, placebo-controlled trials (lower-quality studies) show;*
  - More effective than placebo for improvement in self-reported somatic symptoms;
  - Well-tolerated and safe

A strong, positive relationship between the physician and the patient is essential and should be coupled with frequent, supportive visits, while avoiding the temptation to medicate or test when these interventions are not clearly indicated.

Considering referral

- Collaboration with a psychiatrist or other mental health professional may help with the subtleties between these disorders and their psychiatric comorbidities, the severity of disorders, and improvements in symptom severity, social functioning, and health care use when multiple interventions are employed.
- Avoiding confrontation
- Avoid unnecessary medical tests and specialty referrals, and be cautious when pursuing new symptoms with new tests and referrals
- Focus treatment on function, not symptom, and on management of the disorder, not cure
- Address lifestyle modifications and stress reduction, and include the patient's family if appropriate and possible
- Treat comorbid psychiatric disorders with appropriate interventions
- Use medications sparingly and always for an identified cause
- Schedule regular, brief follow-up office visits with the patient (five minutes each month may be sufficient) to provide attention and reassurance while limiting frequent telephone calls and "urgent" visits
- Collaborate with mental health professionals as necessary to assist with the initial diagnosis or to provide treatment

References

1. *American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, D.C.: American Psychiatric Association, 2013.*
2. *de Waal MW, Arnold IA, Eekhof JA, van Hemert AM Somatoform disorders in general practice: prevalence, functional impairment and comorbidity with anxiety and depressive disorders. Br J Psychiatry. 2004;184:470---6*
3. *Hiller W, Fichter MM, Rief W A controlled treatment study of somatoform disorders including analysis of healthcare utilization and cost-effectiveness. J Psychosom Res. 2003;54:369-80.*
4. *17. McCarron RM. Somatization in the primary care setting. Psychiatr Times. 2006;23(6):32-34*
5. *Murray AM, Toussaint A, Althaus A, Löwe B. Barriers to the diagnosis of somatoform disorders in primary care: protocol for a systematic review of the current status. Syst Rev. 2013;2:99*
6. *Greenberg DB, Dimsdale J, Solomon D. Somatization:epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis.*
7. *Somatic Symptom Disorder; American Family Physician; January 1, 2016 ◆ Volume 93, Number 1*

ALCOHOL USE DISORDER

- Alcohol misuse is **a major public health and social concern for Myanmar**.
- The readily available cheap alcohol has created a national problem for Myanmar's underfunded public health system.
- Per capita consumption (liters of pure alcohol per person ages 15+ per year) is increasing, from 2.9L in 2010 to 4.8L in 2016.
- Excessive drinkers with noticeable social, physical and psychological problems are supposed to require medical treatment.

Spectrum of Alcohol Use Disorder

- Acute intoxication/ Binge drinking
- Risky drinking or hazardous alcohol use
- Alcohol dependence
- Chronic dependence

Diagnostic Criteria for Alcohol Use Disorder (DSM-5)

■ A problematic pattern of alcohol use leading to clinically significant impairment or distress, as manifested by at least two of the following, occurring within a 12-month period:

- Alcohol is often taken in larger amounts or over a longer period than was intended.
- There is a persistent desire or unsuccessful efforts to cut down or control alcohol use.
- A great deal of time is spent in activities necessary to obtain alcohol, use alcohol, or recover from its effects.
- Craving, or a strong desire or urge to use alcohol.
- Recurrent alcohol use resulting in a failure to fulfill major role obligations at work, school, or home.
- Continued alcohol use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of alcohol.
- Important social, occupational, or recreational activities are given up or reduced because of alcohol use.
- Recurrent alcohol use in situations in which it is physically hazardous.
- Alcohol use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by alcohol.
- Tolerance, as defined by either of the following:
  - A need for markedly increased amounts of alcohol to achieve intoxication or desired effect.
  - A markedly diminished effect with continued use of the same amount of alcohol.
- Withdrawal, as manifested by either of the following:
  - The characteristic withdrawal syndrome for alcohol.
  - Alcohol (or a closely related substance, such as a benzodiazepine) is taken to relieve or avoid withdrawal symptoms.

ALCOHOL ACUTE INTOXICATION

- The degree of intoxication is determined by the amount of alcohol ingested, the duration of the ingestion, and the patient's tolerance.
- Usually after consuming **4 or more drinks** (female), or **5 or more drinks** (male) **in about 2 hours.**

Table. 14. Blood alcohol level and clinical symptoms

At the level of:	Clinical Symptoms
20 mg/dL	mild euphoria, mild impairment of coordination, and mood alterations
20 - 80 mg/dL	generally accepted as an unsafe level for motor vehicle operation
80 - 100 mg/dL	delayed reaction times and slurred speech
100 - 200 mg/dL	ataxia, grossly slurred speech, and incoordination occur
>400 mg/dL	coma, respiratory depression, hypothermia, and death

Diagnostic Criteria of ALCOHOL INTOXICATION (DSM-5)

A. Recent ingestion of alcohol.

B. Clinically significant problematic behavioral or psychological changes (e.g. inappropriate sexual or aggressive behavior, mood lability, impaired judgement) that developed during, or shortly after, alcohol ingestion.

C. One (or more) of the following signs or symptoms developing during, or shortly after, alcohol use:

1. Slurred speech.
2. Incoordination.
3. Unsteady gait.
4. Nystagmus.
5. Impairment in attention or memory.
6. Stupor or coma.

D. The signs or symptoms are not attributable to another medical condition and are not better explained by another mental disorder, including intoxication with another substance.

Management

- Protecting the airway, keep in left lateral position
- Careful monitoring of vital signs.
- Performing basic resuscitation, if necessary.
- The patient should be placed in a warm protective environment.
- Thiamine and glucose should always be administered. (Chronic alcoholism is associated with hypoglycemia and thiamine deficient states)
- Refer to hospital if necessary.
- If methanol poisoning is suspected, refer to hospital for emergency management.
- Should look for additional drug use (consider urine toxicology screen)

RISKY ALCOHOL USE (AT-RISK USE)

- Exceeding the recommended limits of:
  - ***For all women and men 65 years or older: No more than 3 drinks per day and no more than 7 drinks per week***
  - ***For men (21 to 64 years): No more than 4 drinks per day and no more than 14 drinks per week***

(NIAA = National Institute on Alcohol Abuse and Alcoholism)

Fig. 3. Standard Drink



1 Unit = one small glass of wine = one half pint of beer = 25ml of 40% alcohol Myanmar unit one peg (တပတ်) = 62.5 ml = 2.5 Unit

HAZARDOUS USE

A pattern of substance use that increases the risk of harmful consequences; in contrast to harmful use, hazardous use refers to patterns of use that are of **public health significance**, despite the absence of a current alcohol use disorder in the individual user. (WHO)

HARMFUL USE

A pattern of drinking that is already causing damage to health; the damage may be either physical (e.g., liver damage from chronic drinking) or mental (e.g., depressive episodes secondary to drinking) (WHO)

UNHEALTHY USE

Either hazardous use or harmful use. {American Society of Addiction Medicine (ASAM)}
Any alcohol use is considered unhealthy in pregnant women and adolescents.

SCREENING FOR UNHEALTHY ALCOHOL USE

- The USPSTF recommends screening for **unhealthy alcohol use in primary care settings** in adults 18 years or older, including pregnant women, and providing persons engaged in risky or hazardous drinking with **brief behavioral counseling interventions** to reduce unhealthy alcohol use. (SOR B)
- Of the available screening tools, the USPSTF determined that 1-item to 3-item screening instruments have the best accuracy for assessing unhealthy alcohol use in adults 18 years or older.

Single alcohol screening question (sasq)

The SASQ is a 1-item screening instrument. It has adequate sensitivity and specificity across the unhealthy alcohol use spectrum and requires less than 1 minute to administer.

Single Alcohol Screening Question

How many times in the past year have you had five (for men<65) or four (for women and all adults older than 65 years) or more drinks in a day?

An answer of one or more is considered a positive screen
Sn= 73-88%, Sp=74-100%

Table 15. Alcohol Use Disorder Identification Test-Consumption (AUDIT-C)

Questions	0	1	2	3	4	Score
1. *How often do you have a drink containing alcohol:*	Never	Monthly or less	2-4 times a month	2-3 times a week	4 or more times a week	
2. *How many drinks containing alcohol do you have on a typical day when you are drinking?*	1 or 2	3 or 4	5 or 6	7 to 9	10 or more	
3. *How often do you have six or more drinks on one occasion?*	Never	Less than monthly	Monthly	Weekly	Daily or almost daily	
					Total	

- *0-3 Low-risk drinking (advise no use)*
- *4-5 Moderate-risk drinking (advise no use and provide brief counseling intervention or consider referral to a specialist addiction service)*
- *≥6 High-risk drinking (definite referral to a specialist addiction service)*
- *Sn=74%, Sp=83%*

CAGE Questionnaire

1. *Ever felt ought to **C**ut down on your drinking?*
2. *Have people **a**nnoyed you by criticizing your drinking?*
3. *Ever felt bad or **g**uilty about your drinking?*
4. *Ever had an **e**ye-opener to steady nerves in the morning?*

- **2** or more "**yes**" means Dependency.
- Although the **CAGE** questionnaire is easy and widely used screening tool for alcohol dependency in primary care, its accuracy varies in ambulatory setting. It detects **only alcohol dependence** rather than the full spectrum of unhealthy alcohol use.
- (Sensitivity 91%, Specificity 87.8% for alcohol dependence and 87.5% and 80.9% for alcohol misuse)

Interventions

- Primary care settings often used the **S**creening, **B**rief **I**ntervention, and **R**eferral to **T**reatment (**SBIRT**) approach.
- Brief (five- to 10-minute) multi-contact counseling interventions seem to have the best SOR of effectiveness.
- A recent meta-analysis found that brief interventions reduced unhealthy alcohol use with a decrease of 1.6 drinks per week.
- Counseling interventions include personalized **normative feedback**.
  - Discussing the patient's alcohol use compared with national norms.
  - patient-specific adverse alcohol effects, and
  - mutual agreements to specific drinking amounts
- Personalized normative feedback was often combined with motivational interviewing or more extensive cognitive behavioral counseling.
- **Other cognitive behavioral strategies** frequently used:
  - Drinking diaries

- Action plans
- Alcohol use “prescriptions”
- Stress management
- Problem-solving

ALCOHOL DEPENDENCE (AD)

- DSM5 combines alcohol abuse and dependence into a single Alcohol Use Disorder; mild, moderate and severe.
- AD is at the moderate to severe spectrum of alcohol use disorder.

Screening alcohol dependence:

- AUDIT-C score ≥6
- CAGE score ≥2

Treatment of AD

- Alcohol dependent patients are appropriate to refer to the treatment center to provide:
- Detoxification
- Medical treatment (See below)
- Professional rehab or counseling
- Self-help group support

Counseling and Rehabilitation

- State clearly the results of the assessment and explain both the short-term risks of continuing use at the current level.
- Have a short discussion about the person's motivations for their alcohol use (not having alcohol at home, not going to pubs)
- Motivate complete cessation of alcohol.
- Advise daily consumption of thiamine 100mg.
- **If the person is willing to stop using alcohol,**
  - facilitate alcohol cessation.
  - Determine the appropriate setting to cease alcohol.
  - Set a definite day to quit
  - Plan the cessation of alcohol.
  - Discuss correct way to avoid or cope with high risk situation for relapse drinking
  - Make specific plans to avoid drinking. eg how to respond invitation for drinking
  - Discuss with family members for support, encouragement and understanding of patient's behavior during detoxification
  - Arrange detoxification if necessary
- **For those not willing to stop now,**
  - do not reject or blame
  - Try to motivate the patient to take treatment
- **For those who brought by relatives to stop drinking,**
  - Discuss about problems related to alcohol consumption
  - Try to motivate the patient to take treatment
  - If the patient agrees to take treatment, follow the line for those willing to stop now

ALCOHOL WITHDRAWAL SYNDROME (AWS)

- The patients who have alcohol dependence are at risk of developing alcohol withdrawal syndrome if they abruptly abstain from alcohol use.
- Alcohol withdrawal syndrome begins six to 24 hours after the last intake of alcohol or even 6 days after.

- Alcohol withdrawal also occurs following cessation of heavy alcohol consumption for >2 weeks.
- Alcohol withdrawal affects the central nervous system, autonomic nervous system, and cognitive function.
- If AWS is not treated or is undertreated, delirium tremens can occur. This condition is a severe hyperadrenergic state and life threatening.

Table. 16. Stages of Alcohol Withdrawal Syndrome

Stage	Symptoms
1.Mild	Anxiety, tremor, insomnia, headache, palpitations, gastrointestinal disturbances
2. Moderate	Mild symptoms + diaphoresis, increased systolic blood pressure, tachypnea, tachycardia, confusion, mild hyperthermia
3.Delirium tremens	Moderate symptoms + disorientation, impaired attention, visual and/or auditory hallucinations, seizures

LOOK FOR

- Tremor in hands
- Sweating
- Vomiting
- Increased pulse and blood pressure
- Agitation

ASK ABOUT

- Headache
- Profound insomnia
- Transient illusion and hallucination, e.g. insects crawling under the skin
- Nausea
- Anxiety
- Seizures and confusion may occur in severe cases.
- Past episodes of severe alcohol withdrawal including delirium and seizures. Other medical or psychiatric problems or benzodiazepine dependence.

Treatment of AWS

Treatment Goals:

- To reduce withdrawal symptoms
- To prevent seizures, delirium tremens, and death
- To prepare the patient for long-term abstinence from alcohol use.

Treat where?

- Outpatient treatment is appropriate in patients with mild or moderate AWS, if there are no contraindications (SOR C)
- Patients who have not had alcohol in at least five days may also receive outpatient treatment.
- The self-completed,10-item SAWS (Short Alcohol Withdrawal Scale) has been validated in the outpatient setting to assess the severity and decide where to treat.

Table.17

Short Alcohol Withdrawal Scale (SAWS)				
Item	None (0 point)	Mild (1 point)	Moderate (2 points)	Severe (3 points)
Anxious				
Feeling confused				
Restless				
Miserable				
Problems with memory				
Tremor (shakes)				
Nausea				
Heart pounding				
Sleep disturbance				
Sweating				

Patients indicate how they have felt in the past 24 hours.
Mild AWS <12 points; Moderate to severe AWS ≥12 points. (Consider hospital treatment if >12)

Contraindications to Outpatient Treatment (HOME DETOX) of AWS

- Abnormal laboratory results
- Absence of a support network (Physician's expertise, family)
- Acute illness
- High risk of delirium tremens
- History of a withdrawal seizure
- Long-term intake of large amounts of alcohol
- Poorly controlled chronic medical conditions (e.g., diabetes mellitus, COPD, CHF)
- Serious psychiatric conditions (e.g., suicidal ideation, psychosis)
- Severe alcohol withdrawal symptoms (SAWS >12)
- Urine drug screen positive for other substances

General Management of AWS & Detoxication

- Nursing care
- Frequent monitoring of vital signs, mostly daily
- Correct fluid and electrolytes requirements. (typically K+, Mg++)
- Treat immediately with diazepam (Benzodiazepines)
- Take precaution in liver failure and older patients

Medications

- Thiamine (100- 300mg daily) and folic acid (1 mg daily)
- (Thiamine supplementation lowers the risk of Wernicke encephalopathy)
- Long-acting benzodiazepines (diazepam, chlordiazepoxide) should be administered early to reduce psychomotor agitation.
- Intermediate-acting BD (lorazepam, oxazepam) are safer for patients with hepatic dysfunction and older patients.

Table. 18: Benzodiazepine Regimen for Alcohol Detoxication (Moderate Dependence)

Day	Morning	Noon	Evening	Night	Total Dose
1	2 tabs	2 tabs	2 tabs	2 tabs	C80/D40
2	2 tabs	0 tab	2 tabs	2 tabs	C60/D30
3	2 tabs	0 tab	0 tab	2 tabs	C40/D20
4	0 tab	0 tab	0 tab	2 tabs	C20/D10
5	0 tab	0 tab	0 tab	2 tabs	C20/D10

C = Chlordiazepoxide 10 mg, D = Diazepam 5 mg

Benzodiazepines can be administered using a fixed-dose or symptom-triggered schedule.
A front-loading, or loading-dose, schedule is not recommended.

Points for HOME DETOX (community detoxication)

- Helping a patient through home alcohol detoxification has high patient satisfaction rates and is hugely rewarding for the family doctors.
- New SORs show that the majority of dependent drinkers can detox safely and successfully at home and do not require hospital admission.
- Home detox has better outcome, more acceptability and cheaper cost.
- A non-judgemental approach and the use of motivational interviewing techniques are essential
- Daily review by a family doctor or nurse is important for at least the first four days.
- Ongoing psychosocial support is essential for recovery.
- {Home detox – supporting patients to overcome alcohol addiction (Chris Davis Australian Prescriber, 3 December 2018)}
  https://www.nps.org.au/australian-prescriber/articles/home-detox-supporting-patients-to-overcome-alcohol-addiction

ACUTE CONFUSION OR CLOUDING OF CONSCIOUSNESS WITH RECENT HISTORY OF HEAVY ALCOHOL CONSUMPTION

Look for

- Wernicke's encephalopathy (**NOA**=nystagmus, ophthalmoplegia, ataxia) (Oculomotor dysfunction, abnormal mentation, ataxia)
- Head injury (bleeding from head or lacerations)
- Alcohol withdrawal delirium (Delirium Tremens),
- (**CAT** – *confusion and* disorientation, *autonomic hyperactivity:* tachycardia, hypertension, *Tremors* or body shakes)

ACUTE WERNICKE'S ENCEPHALOPATHY

- Treat all suspected cases with i/v. or i/m. thiamine 100 mg stat and refer.
- *Head injury should be excluded*
- Monitor GCS and stabilize patient, and refer

ALCOHOL WITHDRAWAL DELIRIUM

- i/v. or i/m. thiamine 100mg, refer

Medications for maintaining abstinence in AUD

Table.19

Drugs	Dosage
Acamprosate (Campral)	Two 333-mg enteric-coated tablets three times per day
Disulfiram (Antabuse)	250 mg once per day; if not effective, increase to 500 mg once per day
Fluoxetine (Prozac)	Begin with 20 mg per day; may increase to 60 to 80 mg per day
Gabapentin (Neurontin)	300 mg twice per day or once-daily dosages up to 1,800 mg at bedtime
Naltrexone (Revia [oral], Vivitrol [injectable])	Oral: 50 to 100 mg per day
Ondansetron (Zofran)	Not more than 8mg twice per day
Sertraline (Zoloft)	Begin with 50 mg per day; may increase to 200 mg per day
Topiramate (Topamax)	Begin with 25-mg dose; increase to a total of 300 mg given twice per day

Detox and Counseling

- Detox without counseling or motivational interviewing has poor drinking outcome.
- Counseling for alcohol addiction can change perceptions, feelings and behaviors to help individuals identify drinking problems.
- People can also learn to take the steps needed to combat triggers and cravings that can lead to relapse.

(Alcohol Addiction Counseling | Types of Therapy for Alcoholism)
https://www.drugrehab.com/addiction/alcohol/counseling/

Prevention

- Health education
- The pricing of alcohol beverages
- Control on sale

Reference

1. *American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders.5th ed. Washington, D.C.: American Psychiatric Association, 2013*
2. *WHO Mental Health Gap Action Programme (mhGAP) 2017*
3. *Myanmar: Rising Mental Health Issues Linked to Alcohol Posted on August 11, 2019, Movendi International.*
4. *WHO Global Alcohol Status Report 2018*
5. *National Institute on Alcohol Abuse and Alcoholism (NIAAA) resources*
6. *Screening and Behavioral Counseling Interventions to Reduce Unhealthy Alcohol Use in Adolescents and Adults: Recommendation Statement by USPSTF:American Family Physician, June 15, 2019*
7. *Identification of and Treatment for Unhealthy Alcohol Use in Primary Care Settings: Elizabeth Salisbury-Afshar, Michael Fleming: American Family Physician June 15, 2019*
8. *Outpatient Management of Alcohol Withdrawal Syndrome: American Family Physician, November 1, 2013*
9. *Medications for Alcohol Use Disorder: American Family Physician, March 15, 2016*

TOBACCO USE DISORDER

- Tobacco use disorder is common among individuals who use cigarettes and smokeless tobacco daily and is uncommon among individuals who do not use tobacco daily or who use nicotine medications.

Diagnostic criteria (DSM-5)

- A problematic pattern of tobacco use leading to clinically significant impairment or distress, as manifested by at least two of the following, occurring **within a 12-month period**:
  1. Tobacco is often taken in larger amounts or over a longer period than was intended.
  2. There is a persistent desire or unsuccessful efforts to cut down or control tobacco use.
  3. A great deal of time is spent in activities necessary to obtain or use tobacco.
  4. Craving, or a strong desire or urge to use tobacco.
  5. Recurrent tobacco use resulting in a failure to fulfill major role obligations at work, school, or home (e.g., interference with work).
  6. Continued tobacco use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of tobacco (e.g., arguments with others about tobacco use).
  7. Important social, occupational, or recreational activities are given up or reduced because of tobacco use.
  8. Recurrent tobacco use in situations in which it is physically hazardous (e.g., smoking in bed).
  9. Tobacco use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by tobacco.
  10. Tolerance, as defined by either of the following:
      - A need for markedly increased amounts of tobacco to achieve the desired effect.
      - A markedly diminished effect with continued use of the same amount of tobacco.
  11. Withdrawal, as manifested by either of the following:
      - The characteristic withdrawal syndrome for tobacco (Irritability, frustration, or anger, anxiety, difficulty concentrating, increased appetite. etc., with clinically significant distress)
      - Tobacco (or a closely related substance, such as nicotine) is taken to relieve or avoid withdrawal symptoms.

SMOKING

- Smoking is the **greatest single cause of illness** and premature death. Half of all regular smokers will die as a result of smoking.
- Worldwide, more than 7 million people die annually of tobacco-related illnesses, including cancer, cardiovascular disease, and chronic obstructive pulmonary disease.
- Primary care physicians have an opportunity to offer office-based smoking cessation interventions to the smokers who visits their offices.
  - **Light smoker:** <half pack/day,
  - **Heavy smoker:** >1 pack/day (1 pack = 20 cigarettes)
- Smoking is associated with increased risk of
  - Cancers: lung, lip, mouth, stomach, colon, bladder
  - Cardiovascular disease: CHD, CVD, peripheral vascular disease
  - Chronic lung disease: COPD, recurrent chest infection, exacerbation of asthma Problems in pregnancy: (PET, IUGR, preterm delivery, neonatal and late foetal death)
  - Diabetes mellitus
  - Thrombosis
  - Osteoporosis
  - Dyspepsia and/or gastric ulcer

- Passive smoking is associated with
  - increased risk of coronary heart disease and lung cancer (increased by 25%)
  - increased risk of cot death, bronchitis, and otitis media in children



Table 21. SORT: Key Recommendations for Practice

Clinical Recommendation	SOR rating
All adults should be screened routinely for tobacco use.	**A**
All smokers should be encouraged to quit at every clinical contact.	**A**
Motivational interventions should be used with patients who are not yet ready to quit smoking.	**A**
Physicians should encourage appropriate patients to use effective medications for treatment of tobacco dependence to improve quit rates.	**A**
Heavy smokers should be encouraged to use higher dosages of a nicotine replacement therapy, or more than one form ("patch plus" regimen).	**B**
Pregnant smokers should be offered person-to-person psychosocial interventions that exceed minimal advice to quit.	**B**
Sustained-release bupropion (Zyban) or a nicotine replacement therapy (particularly gum and lozenges) may be more appropriate for smokers who are concerned about weight gain after quitting.	**C**

Management plan for Smoking Cessation

5A's framework

- **Ask**
  - about tobacco use at every visit.
  - *Include questions about tobacco use when assessing the patient's vital signs.*
  - *Placing tobacco-use status stickers on patient charts, noting tobacco use in electronic medical records.*
- **Advise**
  - to quit through clear personalized messages.
  - *Advice to patients should be clear (direct expression of the need for smoking cessation), strong (highlighting the importance of cessation), and personalized (linking the patient's health goals to cessation)*
- **Assess**
  - willingness to quit.
  - *Willingness to quit and barriers to quitting should be assessed, as well as smoking history and current level of nicotine dependence;*

- *Patients should be asked about their timeline for quitting and about previous attempts.*
- *"Have you ever tried to cut back on or quit smoking?"*
- *"Are you willing to quit smoking now? What keeps you from quitting?"*
- *"How soon after getting up in the morning do you smoke?" (<30 minutes?)*
- *"Do you ever smoke in prohibited area?"*

- **Assist**
  - effort to quit or refer
  - Offer support and additional resources if available (e.g., referral to counseling);
  - Help patients to anticipate difficulties and encourage them to prepare their social support systems and their environment for the impending change
  - Help to set a quit date. Remove cigarettes, matches. Explain friends and family. Reward for accomplishment.
  - *"Are you worried about anything in particular when it comes to quitting? Do you worry about cravings or irritability? Or weight gain?"*
  - *"I would like to help you quit. Can I tell you about some of the things we know can increase your odds of success?"*
  - Explain - Nicotine withdrawal symptoms:
    - *urges to smoke (70%),*
    - *increased appetite (70% mean 3-4kg increased),*
    - *depression (60%),*
    - *restlessness (60%),*
    - *poor concentration (60%),*
    - *irritability /aggression (50%),*
    - *nighttime awakenings (25%),*
    - *light headedness (usually first few days after quitting- I 0%)*
- **Arrange** follow-up and support
  - Follow-up plans should be set;
    - For patients who have recently quit, it is important to elicit the benefits of quitting and ask patients to anticipate and problem solve about situations that might lead to relapse;
    - Follow-up contacts should also readjust the dosages of therapeutic agents that may be altered by smoking cessation (e.g., beta blockers, antipsychotics, insulin, benzodiazepines)
  - Abstinence by the quit date is highly predictive of long-term success.
  - *"I would like to see you in the office (or talk to you by phone) on your quit date."*
  - *"What problems have you had? Are there situations you worry about confronting without cigarettes?"*

Aids to Smoking Cessation

Nicotine Replacement Therapy (NRT)

- (**Adhesive patch, chewing gum, lozenges*, nose spray and inhaler)**
  - Increase the chance of quitting successfully by50-70%. All preparations are equally effective. Skin patches deliver nicotine to the brain slower than smoking cigarettes, and other forms deliver faster. (Lozenges available in Myanmar)
  - Start with higher doses for patients who are highly dependent. Continue treatment for 3months, tailing off dose gradually over 2weeks before stopping (except gum which can be stopped abruptly).
  - Contraindication: immediately post-MI, stroke, or TIA, and for patients with arrhythmia.
- **Bupropion**
  - (>18 years) 1-2weeks before-quite date
  - 150 mg cm x 3d

- 150mg bd 12 weeks to 6 months -maintenance dose depend on patient
- *Contraindicated in epilepsy*

- **Varenicline**
  - (Chantix- selective alpha$_4$-beta$_2$ nicotine receptor partial agonist) (>18yr) lwk before quite date
  - 0.5 mg po for 3d
  - 0.5 mg po bd for 4d
  - 1mg bd for 11wk - 12wk for reduced chance of relapse.
  - Increases the chance of a successful quit two to three folds.
  - *Contraindicated in psychiatric illness*
  - *AE- neuropsychiatric symptom? increased risk of coronary events*
- **Behavioural Interventionist**
  - A variety of behavioral interventions are effective for smoking cessation. However, most of them are not yet initiated in Myanmar. The behavioral interventions may include following;
    - Providing individual counseling
    - Group counseling
    - Guaranteed financial incentives
    - Text message–based counseling
    - Telephone counseling
    - Printed self-help materials
    - Internet-based intervention
- All of the interventions provide additional benefit even when smoking cessation pharmaco-therapy is prescribed. There are no apparent harms of behavioral interventions. (SOR: A)
- Greater frequency and duration of contact are more effective.

References:

1. *American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders.5th ed.Washington, D.C.: American Psychiatric Association, 2013*
2. *Hartmann-Boyce J, Livingstone-Banks J, Ordóñez-Mena JM, et al.; Behavioural interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2021;(1):CD013229.*
3. *Tobacco product use among adults—United States, 2019. Centers for Disease Control and Prevention. Last reviewed October 31, 2021. Accessed April 6, 2021.*
4. *How to quit smoking. Centers for Disease Control and Prevention. Last reviewed June 21, 2021. Accessed March 23, 2021.*
5. *Promoting Smoking Cessation: American Family Physician March 15, 2012 ◆ Volume 85, Number 6*
6. *Fiore MC, Jaén CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Rockville Md.: Public Health Service; 2008*

SUBSTANCE USE DISORDERS

- The essential feature of a substance use disorder is a cluster of cognitive, behavioral, and physiological symptoms indicating that the individual continues using the substance despite significant substance-related problems. (DSM5)
- An important characteristic of substance use disorders is an underlying change in brain circuits that may persist beyond detoxification, particularly in individuals with severe disorders.

Diagnostic Criteria in general for all Substance Use Disorders (DSM-5)

- **Criterion A**
- **Impaired control**
  - The individual may take the substance in larger amounts or over a longer period than was originally intended.
  - The individual may express a persistent desire to cut down or regulate substance use and may report multiple unsuccessful efforts to decrease or discontinue use.
  - The individual may spend a great deal of time obtaining the substance, using the substance, or recovering from its effects
  - Craving is manifested by an intense desire or urge for the drug.
- **Social impairment**
  - Recurrent substance use may result in a failure to fulfill major role obligations at work, school, or home.
  - The individual may continue substance use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of the substance.
  - Important social, occupational, or recreational activities may be given up or reduced because of substance use.
- **Risky use**
  - Recurrent substance use in situations in which it is physically hazardous.
  - The individual may continue substance use despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance.
- **Pharmacological criteria**
  - Tolerance is signaled by requiring a markedly increased dose of the substance to achieve the desired effect or a markedly reduced effect when the usual dose is consumed.
  - Withdrawal is a syndrome that occurs when blood or tissue concentrations of a substance decline in an individual who had maintained prolonged heavy use of the substance.
- **Severity and Specifiers**
  - Substance use disorders occur in a broad range of severity; mild, moderate and severe,
  - As a general estimate of severity, a mild substance use disorder is suggested by the presence of two to three symptoms, moderate by four to five symptoms, and severe by six or more symptoms.

Causes

- Alcohol
- Caffeine
- Cannabis
- Hallucinogen (phencyclidine and others)
- Inhalant
- Opioid
- Sedative, hypnotic, or anxiolytic
- Stimulant or
- Tobacco categories

SUBSTANCE-INDUCED DISORDERS

- ACUTE INTOXICATION
- WITHDRAWAL

Opioid Overdose or other Sedative Overdose or Mixed Drug with or without Alcohol Overdose

- Unresponsive or minimally response
- Slow respiratory rate
- Pinpoint pupils (opioid overdose)

Treatment

- Before urgent referral, take care airway, breathing, and circulation
- Inj: naloxone 0.4 - 2 mg IM/IV/SC, repeat every 2-3 minutes PRN, not to exceed 10 mg.

Managing Acute Methamphetamine or other Stimulant Intoxication or Overdose

- **Step one: observe clinical signs of toxicity**
  - During this stage observing signs of toxicity have higher priority than trying to determine the methamphetamine dose consumed. (Some individuals may experience toxicity symptoms after relatively low doses)
  - Symptoms which may alert clinicians to potential toxicity and overdose include:
    - Chest pain
    - Rapid increase in body temperature
    - Psychotic features (such as hallucinations, paranoia or delusions)
    - Behavioural disturbances which may put the individual or others at risk
    - Seizures
    - Uncontrolled hypertension
    - Dilated pupils.
- **Step two: monitor vital signs.**
  - Check pulse, blood pressure and temperature
- **Step three: attempt verbal calming of the situation if required**
  - Talk quietly and calmly to the patient
  - Do not raise voice or become agitated
  - Take the person to a quiet place where there are no distractions or potential weapons
  - If acute behavioural disturbance is a feature of toxicity, using a physical restraint is not recommended as it may worsen the situation.
- **Step four: sedation if necessary**
  - A titrated dose of a short acting benzodiazepine is recommended until acute behavioural disturbance is controlled.
  - Patient should not be sedated to the point where they are unconscious.
- **Step five: regular hydration and observation**
  - For significantly elevated vital signs, more intensive intervention may be required, including intravenous hydration line and cardiac monitoring.
  - For mild cases of serotonin toxicity, supportive care, regular observation and consideration of sedation with a benzodiazepine or antipsychotic may be required.
  - For more serious serotonin toxicity, supportive care in an emergency department setting with an emergency medicine specialist is advised.
- **Managing aggressive or agitated behaviour and delirium**
  - Clinicians and service providers must be aware and informed about the safety procedures and appropriate response to manage patients who present in an agitated or aggressive

condition.

- **Suggested sedatives to manage difficult behavior**
  - Administer 10-20 mg of diazepam (oral if possible) every 30 minutes until the patient is lightly sedated.
  - Do not provide more than 120mg of diazepam in a 24-hour period without the capacity for continuous monitoring.
  - Intravenous (IV) use of benzodiazepines should be reserved for epileptic seizures. (Resuscitation equipment should be available)
- **Managing methamphetamine/amphetamine-induced acute psychotic symptoms**
  - If there is evidence that the person has recently taken amphetamine-type stimulants (ATS) and is *still experiencing the stimulant effects of ATS* (such as raised pulse and blood pressure, sweating, agitation and rapid movements), ***then the first line of treatment should be benzodiazepines.***
  - If there is *no recent history of ATS*, ***antipsychotics*** should be used.
  - ***Olanzapine***
    - Initial dose: 10 or 15 mg orally once a day
    - Maintenance dose: 5 to 20 mg orally once a day
  - ***Haloperidol***
    - Oral: initial dose: 0.5 to 5 mg orally 2 to 3 times a day. Maintenance dose: 1 to 30 mg/day in 2 to 3 divided doses.
    - Parenteral: 2 to 5 mg IM or IV for prompt control. May repeat every 4 to 8 hours

ACUTE OPIOID WITHDRAWAL

- History of opioid dependence, recent heavy use ceasing in the last days
- Muscle aches and pain, abdominal cramps, headaches
- Nausea, vomiting, diarrhea
- Dilated pupils
- Raised pulse and blood pressure
- Yawning, running eyes and nose, pilo-erection(gooseflesh)
- anxiety, restlessness

Treatment

- Opioid Substitution Therapy (OST) e.g. buprenorphine.
- Methadone maintenance treatment (MMT) (See below)

MANAGING METHAMPHETAMINE OR OTHER STIMULANTS WITHDRAWAL

Table 22. Time course of methamphetamine and ATS withdrawal

Phase	Time since last stimulant use	Common signs and symptoms
Crash	Typically commences 12-24 hours after last amphetamine use and subsides by 2-4 days	• Exhaustion, fatigue, agitation and irritability, depression, muscle ache • Sleep disturbances (typically increased sleep, although insomnia or restless sleep may occur)
Withdrawal	Typically commences 2-4 days after last use, peaks in severity over 7-10 days and then subsides over 2-4 weeks	• Strong craving • Fluctuating mood and energy level, alternating between irritability, restlessness, anxiety and agitation • Fatigue, lack of energy
Extinction	Weeks to months	• Gradual resumption of normal mood with

Phase	Time since last stimulant use	Common signs and symptoms
		episodic fluctuation in mood and energy level, alternating between irritability, restlessness, anxiety, agitation, fatigue, lack of energy • Episodic craving • Disturbed sleep

Protracted phase

- One to three months, sometimes longer sleep patterns improve, energy levels get better, mood settles, slowly resolving anhedonia, (Being unable to feel pleasure)
- Managing withdrawal from methamphetamine consists
  - primarily of psychosocial interventions, which may be supplemented with:
  - medications, such as benzodiazepines (for example diazepam), to reduce symptoms of insomnia and anxiety during the first few days.
- The use of medications should be determined on an individual basis according to what symptoms are prominent.
- Methamphetamine withdrawal is relatively safe and most commonly can occur as an outpatient or home detoxification. However, treatment completion rates as an outpatient or during home detoxification remain poor and rates of relapse immediately after withdrawal are high.
- For a person with evidence of significant polydrug use, psychotic symptoms, severe depression, or potential medical complications, an in-patient setting may be more appropriate,

HARM REDUCTION FOR PATIENT WITH SUBSTANCE USE DISORDER

- Patients engaged in high-risk activities are often ambivalent about changing their behavior.
- Harm reduction is an approach that focuses on limiting harm and improving quality of life for patients who persist with high-risk behaviors.
- The foundations of harm reduction are pragmatism and compassion.
- Acknowledging the complexity of high-risk behavior and using a supportive, practical approach to address the situation can decrease friction between the patient and physician and build trusting therapeutic relationships.
- The leading harm reduction interventions target **prevention of overdose** and **infection**, and also **reproductive issues**.
- Harm Reduction measures can decrease criminal activities to finance drug habit.

Overdose education and naloxone distribution (including usage of naloxone kits)

- Medications for opioid use disorder to reduce opioid overdose and acute care use.
- (Methadone, buprenorphine, extended-release naltrexone)
- *{Methadone available in Methadone Maintenance Treatment (MMT) Programs in Drug Treatment Centers (DTC)*}*

Prevention of Infections

- Testing for hepatitis B, C, HIV and STIs
- Diagnosis of tuberculosis
- Needle and syringe program to prevent hepatitis B, C and HIV infection.

Reproductive health

- Long-acting reversible contraception for women of reproductive age to decrease unintended pregnancy.
- Use of condom, use of lubricants

The combination of motivational interviewing and harm reduction can decrease risk, improve the therapeutic relationship and prevent physicians from feeling helpless.

Warning Signs and Symptoms suggesting Drug Misuse

- Inappropriate behaviour
- Lack of self-care
- Unexplained nasal discharge
- evidence of injecting (e.g., marked veins)
- Hepatitis or HIV infection
- Unusually constricted/dilated pupils
- Social factors: Family disruption, criminal history

The Role of Primary Health Care Team

- Primary health Care team has a vital role in identifying drug misuse.
- Assess health and willingness to modify drug abuse (see motivational model of Change for Addiction)
- Appropriate referral for specialist assessment and treatment. *It is imperative that people who use opioids be enrolled in opioid substitution treatment programs to cut the vicious cycle of addiction and halt the spread of infectious diseases such as HIV.*

Motivational model of change



Other education for HARM REDUCTION

- Safer route of drug administration e.g. Smoking/rectal administration for heroin abusers.
- Discourage IM/Subcutaneous administration.
- Specific risks of drugs (e.g. psychosis with amphetamines; local risks; such as contaminated street drugs
- Safe injecting advice and overdose prevention
- Safe sexual practice/condom use
- Driving and drug misuse
- **Safe injecting advice**
    - Never inject alone
    - Always inject with the blood flow and rotate sites - avoid neck, groin, penis, axilla, foot and hand veins, and any infected areas/swollen limbs - even if veins are distended.
    - Use sterile, new injecting equipment with the smallest bore needle possible and dispose of all equipment safely after use
    - Avoid unsuitable preparations e.g. crushed tablets and/or injecting cocktails of drugs (injection of heroin and cocaine together is known as 'speed balling' or 'snowballing')
    - Learn basic principles of first aid and CPR (provide information on courses available). Encourage calling for an ambulance. Educating about usage of naloxone if feasible

- **Preventing overdose, be aware of risk factors:**
    - Injecting heroin
    - Longer injecting career
    - High levels of alcohol use
    - Lowered tolerance after detoxification/imprisonment
    - Depression, suicidal thoughts
    - Multiple drug use - particularly CNS depressants
    - Sharing equipment/other high risk injecting behavior - indicate low concern about personal risk
    - Not being on a treatment programme or premature exit from a methadone maintenance treatment programme
    - Recent non-fatal overdose
    - High levels of use/intoxication

References:

1. *American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, D.C.: American Psychiatric Association, 2013*
2. *Harm Reduction for Patients with Substance Use Disorders: American Family Physician: January 2022 ◆ Volume 105, Number 1*
3. *Guidelines for the Management of Methamphetamine Use Disorders in Myanmar: Department of Medical Services, Ministry of Health and Sports, The Republic of the Union of Myanmar October 2017*
4. *Client satisfaction to methadone maintenance treatment program in Myanmar:Sun Tun, Balasingam Vicknasingam, Darshan Singh & Nyunt Wai*
   https://substanceabusepolicy.biomedcentral.com/articles/10.1186/s13011-021-00429-z
5. **Guidelines on Methadone Therapy and Treatment of Drug Dependence in Myanmar: Department of Health, Ministry of Health, The Republic of the Union of Myanmar 2012.*

CHAPTER (12) CARE OF OLDER ADULT

Care of Older Adult

Functional Assessment of an Older Adult

Illness in Older People

Management of Common Geriatric Problem

Chronic Disease Management

Prescribing in Older People

Geriatric Rehabilitation and Pain Management in Elderly

CARE OF OLDER ADULT

General Principle of Geriatric Care

- The following principles help in caring for older adult.
    - Many disorders are multifactorial in origin and are best managed by multifactorial interventions.
    - Diseases often present atypically.
    - Not all abnormalities require evaluation and treatment.
    - Complex medication regimens, adherence problems, and polypharmacy are common challenges.

Assessment of the older adult

- Comprehensive assessment address three topics in addition to conventional assessment of symptoms and diseases: prognosis, values, and preferences, and ability to function independently. Comprehensive assessment is warranted before major clinical decisions (e.g., whether major surgery should be performed, or whether a patient should be admitted to hospital)
    - Assessment of prognosis
    - Assessment of Values and Preferences
    - Assessment of Function

Assessment of prognosis

- When an older patient's clinical situation is dominated by a single disease process (e. g. , lung cancer metastasis to brain) prognosis can be estimated well with a disease specific instrument.
- When an older patient's clinical situation is not dominated by a single disease process prognosis can be estimated initially by considering the patient's age, sex and general health.
- The prognosis of older persons living at home can be estimated by considering age, sex, comorbid conditions and function.

Assessment of Values and Preferences

- Although patients vary in their values and preferences, most frail older patients prioritize maintain their independence over prolonging survival or relieving pain or other symptoms, Values and preferences can be assessed most readily in the context of a specific medical decision. For example, the clinician might ask a patient considering hip replacement, "How would like your hip pain and function to be different? Tell me about the risk and discomfort you are willing to go through to achieve that improvement."

Assessment of Function

- People often lose function in multiple domains as they age, with the results that they may not be able to do some activities as quickly or capably and may need assistance with other activities.
- About one-fourth of patients over 65 have impairments in their IADLs (instrumental activities of daily living) or ADLs (basic activities of daily living)

- In general persons who need help only with IADLs can usually live independently with minimal supports, such as financial services or a chore worker. If institutional care is needed, residential care, board-and-care or assisted living is usually sufficient. While many persons who need help with ADLs may require a nursing home level of care, most live at home with care givers and other community services (day care).

Caregiver issues

- Most elders with functional impairment live in the community with help of an ”informal” caregiver, most commonly a spouse or daughter. An older patient’s need for nursing home placement is predicted better by the caregiver’s ability and stress than the severity of the patient’s illness.

Functional Screening Instrument

- Functional screening should include assessment of ADL and IADL and questions to detect weight loss, falls, incontinence, depressed mood, self-neglect, fear for personal safety, and common serious impairments (e.g., hearing, vision, cognition and mobility).

FUNCTIONAL ASSESSMENT OF AN OLDER ADULT

NORMAL AGEING

What is ageing?

- Ageing is a gradual series of changes over time that lead to the loss of function of organs and cells, with the eventual outcome of death. Individuals vary greatly in the rate at which they age. Several factors seem to influence this:
    - Genetic make-up
    - Psychological health
    - Socio-economic factors
    - Environment
    - Lifestyle-diet, physical exercise, smoking

NORMAL CHANGES OF AGEING

System	Clinical/functional effects
Cardiovascular	• Cardiac enlargement/left ventricular hypertrophy • Decreased cardiac output -7 decreased exercise capacity • Decreased response of heart rate to exercise • Systolic hypertension • Left ventricular failure
Respiratory	• Decreased FEVl/FVC and increased residual volume • Increased susceptibility to infection • Increased susceptibility to aspiration
Endocrine	• Decreased insulin sensitivity -7 impaired glucose regulation • Decreased thyroid hormone production
Gastrointestinal	• Increased in gastric acid production • Constipation
Genito-urinary	• Decreased glomerular filtration rate not reflected by increased creatinine • Benign enlargement of the prostate (25-50% of men >65 yr) -7 prostatism • Slowing of sexual function; erectile dysfunction • Dry vagina and increase susceptibility to urinary infections (♀)
Musculoskeletal	• Sarcopenia-decreased muscle strength/power, • Decreased lean body mass (30-40%), increase fat body mass • Decreased mobility • Increased likelihood of falls • Increased osteoporosis /susceptibility to fractures
Nervous	• Slower thought processes/reaction times • General decline in performance • Dementia is not a normal change of ageing

Vision	• Presbyopia (difficulty focusing on near objects); decrease visual acuity; cataract; impaired dark adaptation
Hearing	• High frequency hearing loss/presbycusis-deafness affects 80% of 80 years old • Degenerative changes in the inner ear -7 impairment of balance causing
Immune	• Atrophy of the thymus • Reduced immune function resulting in increased infectious disease, reactivation of latent disease (e.g., TB, shingles), increased cancer, and increased autoimmune disease
Skin/hair	• Dry skin, wrinkles, tendency to bruise easily, and slower healing • Greying of the hair decreased sweating, heat generation, and heat conservation → heat stroke; • hypothermia decreased sensitivity to touch, pain, and temperature discrimination → burns, pressure sores

- **Primary** ageing-usually due to interactions between genetic (intrinsic 'nature' and environmental (extrinsic, nurture)
- **Secondary ageing** -Adaptation to changes of primary ageing. These are commonly behavioral)

ILLNESS IN OLDER PEOPLE

FEATURES OF ILLNESS IN OLDER PEOPLE

Table 1. Examples of assessment of the four domains of the aging phenotype

Approach to assessment	Body Composition	Energetics	Homeostatic Regulation	Neurodegeneration
Self-report		Self-reported questionnaires investigating physical activity, sense of fatigue/exhaustion, exercise tolerance		
Physical examination	Muscle strength testing (isometric and isokinetic) Anthropometrics (weight, height, DMI, waist circumference, arm and leg circumference, skin golds)	Performance-based tests of physical function		Objective assessment of gait balance, reaction time, coordination Standard neurologic examination including assessment of global cognition*
Laboratory value	Biomarkers (24 h creatinuria or 3-methyl histidine)		Nutritional biomarker (e.g., vitamin, anti-oxidants Baseline level of biomarkers and hormone level Inflammatory marker (e.g., ESR, CRP, IL-6, INF- α)	
Imaging	CT and MRI DEXA	Magnetic resonance spectroscopy		MRI, fMRI, PET, and other dynamic imaging techniques
Others	Hydrostatic weighing	Resting metabolic rate, Treadmill testing of oxygen consumption during walking, Objective measures of physical activities, accelerometer, double-labeled water	Stress response Response to provocative test, such as oral glucose tolerance test, dexamethasone test and others	Evoked potentials Electroneurography and Electromyography

- Mini-Mental State Montreal Cognitive Assessment

- CRP = C-reactive Protein, DEXA = dual energy x-ray absorptiometry, fMRI = functional MRI, IL-6 = Interleukin-6, PET = position emission tomography, TNF- α = tumour necrosis factor-α



- **Figure: A unifying model of aging, frailty, and the geriatric syndrome**

Illness in older people

- Features of illness in older people
- Present atypically and non-specifically
- Cause greater morbidity and mortality
- May progress much more rapidly
- Health, social, and financial sequelae
- Co-pathology is common
- Lack of physiological reserve
- Difficulties assessing the elderly
- Communication problems-hearing, cognition, speech
- Multiplicity of cause-one symptom may be caused by different, concurrent processes, e.g., breathlessness as a result of COPD + heart failure
- Non-specific symptoms/signs-confusion, falls, or 'off legs' may be the only overt sign of underlying disease, e.g., UTI, MI, stroke
- Symptoms may be absent despite disease, and signs harder to elicit

- Poly-pharmacy may result in side effects and interactions
- Laboratory tests may be unreliable-especially white cell counts and ESR (always check CRP)
- Disease
- The ageing process is compounded by overt disease. This may affect functional capacity, quality of life and independence, cause frailty, decrease well-being and independence, and result in increased care and mobility needs.
- Multiple Morbidity
- Older people are more likely to have several ongoing chronic illnesses that can act in combination to cause disability greater than either illness alone and/or result in:
- Direction of care at some problems with relative neglect of others
- Poly-pharmacy
- Involvement of multiple specialist teams which can cause inconvenience to the patient and family, and result in conflicting advice, and opposing opinions on cause/effect of symptoms
- Frailty
- Many elderly people are described as being 'frail'. This term is used to describe individuals who are physically weak and fragile. It can occur on a background of natural ageing or be precipitated by a disease process. It is not a disease or disability in itself, but a vulnerability or inability to withstand physical/psychological stressors. Common features of frailty include:
- Unintentional weight loss (>5 kg in a year)
- Feeling of exhaustion
- Weakness-measured by grip strength
- Slow walking speed
- Low levels of physical activity

Clinical assessment of older people

- The geriatric assessment is a multidimensional, multidisciplinary assessment designed to evaluate an older person's functional ability, physical health, cognition and mental health, and socio environmental circumstances. It is usually initiated when the physician identifies a potential problem. Specific elements of physical health that are evaluated include nutrition, vision, hearing, faecal and urinary continence, and balance.

- Clinical assessment of older people
    - General physical examination
    - Assess gait in an older person
- Common patterns
    - **Leaning back** -common with pseudo-Parkinson's
    - **Leaning forward and grabbing furniture –** common in patients with multiple falls and loss of confidence
    - **Veering to one side** - consider stroke or balance problem
    - **Limping /antalgic** - consider hip or knee or foot problem
    - **Unsteady on turning –** Consider ENT pathology
    - **Difficulty setting off** - consider Parkinson's
    - **Wide based** – Consider cerebellar, subcortical disease and normal pressure hydrocephalus

- **Freezing/halting** - consider anxiety and feeling of falling, Parkinson's disease or frontal brain lesions
- **Foot drop**
- **Difficult rising from chair** - consider proximal muscle weakness

Functional assessment of Older Adult

- Functional assessment gauges a patient's ability to manage tasks of self-care,
- household management, and mobility. This can be assessed by the ADL and IADL scores activities of daily living (ADL) and instrumental activities of daily living (IADL).
- ADL are self-care activities that a person performs daily (e.g., eating, dressing, bathing, transferring between the bed and a chair, using the toilet, controlling bladder and bowel functions).
- IADL are activities that are needed to live independently (e.g., doing housework, preparing meals, taking medications properly, managing finances, using a telephone).
- Physicians can acquire useful functional information by simply observing older patients as they complete simple tasks, such as unbuttoning and buttoning a shirt, picking up a pen and writing a sentence, taking off and putting on shoes, and climbing up and down from an examination table.
- Deficits in ADL and IADL can signal the need for more in-depth evaluation of the patient's socio-environmental circumstances and the need for additional assistance.
- Loss of IADL predicts mild cognitive impairment from normal cognitive function
- Shopping
- Balancing check book
- To assess cognitive dysfunction Mini-Cognitive assessment instrument is the preferred test.
- Mini-Cog
- Name 3 items to remember
- Clock drawing test: 11:10
- Recall 3 items to remember
- 3 items correct- normal
- 3 items wrong- dementia
- 1 or 2 items recalled correctly: o If clock is normal- normal
- If clock is abnormal- dementia

Mini-Cognitive Assessment Instrument

- Step 1. Ask the patient to repeat three unrelated words, such as "ball", "dog", and "window".
- Step 2. Ask the patient to draw a simple clock set to 10 minutes after eleven o'clock (11:10). A correct response is drawing of a circle with the numbers placed in approximately the correct positions, with the hands pointing to the 11 and 2.
- Step 3. Ask the patient to recall the three words from Step 1. One point is given for each item that is recalled correctly.

- Interpretation

Number of items correctly recalled	*Clock drawing test result*	*Interpretation of screening for dementia*
0	*Normal*	*Positive*
0	*Abnormal*	*Positive*
1	*Normal*	*Negative*
1	*Abnormal*	*Positive*
2	*Normal*	*Negative*
2	*Abnormal*	*Positive*
3	*Normal*	*Negative*
3	*Abnormal*	*Negative*

- *Adapted with permission from Ebel! MH Brief screening instruments for dementia in primary care. Am FamPhysicia*

Investigations

- Simple investigations
- Full blood count, ESR
- Urea, creatinine, and electrolytes
- Glucose
- Liver function tests
- Calcium and phosphate
- CRP
- Thyroid function tests
- CXR
- ECG
- Urinalysis
- Different reference range in older patients
- *ESR* may be as high as 30mm/hr for men and 35 mm/hr for women
- *Haemoglobin* reference range should probably
- Abnormal result but common and rarely imply important new disease
- Thyroid stimulating hormone (TSH)
- Low blood sodium
- Alkaline phosphatase
- Normochromic normocytic anaemia
- Bacteriuria
- High creatinine/low estimated glomerular filtration rate
- False negative results
- Creatinine -low muscle mass can mask poor renal function
- Urea - as creatinine

Reference

- *Oxford handbook of General Practice, 4th Edition*

MANAGEMENT OF COMMON GERIATRIC PROBLEMS

- **Dementia**
- **Depression**
- **Delirium**
- **Immobility**
- **Falls and Gait Disorders**
- **Urinary incontinence**
- **Undernutrition & Frailty**
- **Pressure ulcers**
- **Pharmacotherapy and Polypharmacy**
- **Vision impairment**
- **Hearing impairment**
- **Elderly Mistreatment & Self Neglect**

DEMENTIA

Essentials of Diagnosis

- Progressive decline of intellectual function.
- Loss of short-term memory and at least one other cognitive deficit
- Deficit severe enough to cause impairment of function.
- Not delirious.
- Not due to delirium or psychiatric disease
- Age is the main risk factor, followed by family history and vascular disease risk factors.

General Considerations

- Dementia is an acquired persistent and progressive impairment in intellectual function, with compromise of memory and at least one other cognitive domain, most commonly
    - **aphasia** (typically, word finding difficulty),
    - **apraxia**(inability to perform motor tasks, such as cutting a loaf of bread, despite intact motor function)
    - **agnosia** (inability to recognize objects)
    - **and impaired executive function** (poor abstraction, mental flexibility, planning and judgment).
- The diagnosis of dementia requires a significant decline in function that is severe enough to interfere with work or social life.

Causes are:

- Alzheimer's disease
- Vascular dementia
- Dementia with Lewy Bodies and
- Fronto-temporal dementia
- Some of the risk factors for Alzheimer disease are older age, family history, lower education level, and female sex. Risk factors for vascular dementia are those for stroke, i.e., older age, hypertension, cigarette use, atrial fibrillation, diabetes mellitus and hyperlipidaemia. Depression and delirium are also common in elders, may coexit with dementia. Depression is a common concomitant of early dementia.

Clinical findings

- Screening
- Cognitive impairment
    - Although there is no consensus at present on whether older patients should be screened for dementia, the benefits of early detection include early identification of potentially reversible causes, planning for the future (including discussing values and completing advance care directives), and providing support and counseling for the caregiver.
    - The combination of a clock drawing task with three-item word recall("mini-cog") is a simple screening test that is fairly quick to administer. scores are classified as normal, almost normal and abnormal. When patient is able to draw a clock normally and can remember all 3 objects, dementia is unlikely.
- Decision-making capacity—
- While no single test of capacity exists, the following five elements should be considered in a thorough assessment;
- ability to express a choice.
- understanding relevant information about the risk and benefits of planned therapy and the alternatives, in the context of one value, including no treatment.
- comprehension of problem and its consequences
- ability to reason; and
- consistency.
- Sensitivity must be used in applying these five components to people of various cultural backgrounds.

Symptoms and Signs

- The clinician can gather important information about the type of dementia that may be present by asking about the:
- the rate of progression of the deficits as well as their nature (including any personality or behavioral changes.
- the present of other neurologic symptoms, particularly motor symptoms.
- risks factors for HIV;
- family history of dementia; and
- medications, with particular attention to recent changes

- Work-up is directed at identifying any potentially reversible cause of dementia.
- Symptoms depend on area of the brain affected **short- term memory loss**
    - **Word-finding difficulty**
    - **Visuospatial dysfunction**
    - **Executive dysfunction**
    - **Apathy or Apraxia**

Physical examination

- The neurologic examination emphasizes assessment of mental status but should also include evaluation for sensory deficits, possible previous strokes, parkinsonism or peripheral neuropathy.

Neuropsychological assessment

- The FOLSTEIN Mini Mental State Exam is commonly used and can be administered in approximately 5 minutes.
- **MINI-MENTAL STATE EXAMI NATION**



https://disinherited.com/wp-content/uploads/2018/04/Mental-capacity-exam.jpg

Interpretation of MMSE scores

- Mini-Mental State Examination (MMSE): good sensitivity but only fair specificity in detecting cognitive impairment and dementia
- 27-30: Normal cognitive, no dementia
- 24-26: Possible cognitive impairment
- 19-23: Mild dementia
- 10-18: Moderate dementia
- 0-9: Severe dementia

- *Note:* In clinical trials, the MMSE for inclusion of mild-to-moderate AD is 14 to 26.

Diagnostic criteria for dementia (DSM-V)

Memory impairment: impaired ability to learn new information or to recall old information
One or more of the following: *aphasia* (language disturbance) *apraxia* (impaired ability to carry out motor activities despite intact motor function) *disturbance in executive functioning* (impaired ability to plan, organize, sequence, abstract)
The cognitive deficits results in functional impairment (social/occupational)
The cognitive deficits do not occur exclusively solely during a delirium
NOT due to other medical or psychiatric conditions

Investigations in dementia

- Full blood count
- Urea and electrolytes
- Glucose
- Liver function tests
- Calcium
- Erythrocyte sedimentation rate (ESR) or plasma viscosity
- Vitamin B12 and folate
- Thyroid function tests
- Laboratory findings
- Laboratory studies include a- serum level of B12, Free T4 and thyroid-stimulating hormone, complete blood count, serum Electrolyte Blood glucose, calcium and creatinine HIV testing.
- Most patients should receive neuroimaging as part of the diagnostic work-up to rule out subdural haematoma, tumor, previous stroke, and hydrocephalus. In older patients with a more classic picture of Alzheimer disease in whom neuroimaging is desired, a non-contrast CT scan is sufficient.

Types of dementia

- Alzheimer's disease (AD)
- Vascular dementia (subtypes: acute onset, multi-infarct, subcortical)
- Dementia with Lewy bodies (DLB)
- Pronto-temporal dementia syndromes (e.g., Pick's disease)
- Other dementias
    - e.g., metabolic 'dementias ' like vitamin Bl2 and thyroid deficiency, Creutzfeldt-Jakob disease, Huntington's disease, Parkinson's disease, AlDS-related dementia

Reversible causes of dementia

- Approximately 13% of cases. The commonest causes of reversible or partially reversible dementia are:
- Drugs

- Depression
- Metabolic: Thyroid disease, vitamin Bl2 deficiency, Calcium disturbance,
- Liver diseases
- Normal pressure hydrocephalus
- Subdural hematoma
- Neoplasm
- Differential Diagnosis
    - **Mild cognitive impairment**
    - **Delirium**
    - **Many medications –** have been associated with delirium and other types of cognitive impairment in older patients.

Treatment

- Patients and families should be made aware of the Alzheimer's Association as well as the wealth of helpful community.
- Collaborative care models and disease management programs appear to improve the quality of care for patients with dementia.

Cognitive Impairment

- Because demented patients have greatly diminished cognitive reserve, they are a high risk for experiencing acute cognitive or functional decline in the setting of new medical illness.
- Consequently, fragile cognitive status may be best maintained by ensuring that comorbid diseases such as congestive heart failure and infections are detected and treated.

Acetylcholinesterase inhibitors

- Many experts recommend considering a trail of acetylcholine esterase inhibitors (eg. Donepezil, galantamine, rivastigmine) in most patients with mild to moderate Alzheimer disease.
- Starting doses, respectively, of donepezil, galantamine, and rivastigmine, are 5 mg orally once daily (maximum 10 mg once daily), 4 mg orally twice daily (maximum 12 mg twice daily) and 1. 5 mg orally twice daily (maximum 6 mg twice daily)
- The doses are increased gradually as tolerated.
- The most bother side effects include diarrhea, nausea. anorexia, weight loss, and syncope.
- In those patients who have had no apparent benefit, experience side effects, or for whom the financial outlay is a burden, the drug should be discontinued.

Memantine –

- In clinical trials, patients with more advanced disease have been shown to have statistical benefit from the use of memantine, an *N-methyl-D-aspartate (NMDA)* antagonist, with or without concomitant use of an acetylcholinesterase inhibitor. Long –term and meaningful functional outcomes have yet to be demonstrated.

Behavioral Problems

- Nonpharmacologic
- Behavioral problems in demented patients are often best managed with a nonpharmacologic approach.

- Initially, it should be established that the problems is not unrecognized delirium, pain, urinary obstruction, or fecal impaction.
- Aerobic exercise (45 minutes most days of the week) and frequent mental stimulation may reduce the rate of functional decline and decrease the demented patient's caregiving needs and these interventions may reduce the risk of dementia in normal individual.

Pharmacologic approaches –

- There is no clear consensus about pharmacological approaches to behavioral problems in patients who have not benefited from nonpharmacological therapies.
- The target symptoms –depression, anxiety, psychosis, mood lability, or pain – may suggest which class of medications might be most helpful in a given patient.
- Patients with Lewy bodies have shown clinically significant improvement in behavioral symptoms when treated with rivastigmine (3- 6 mg orally twice daily)
- For those with Alzheimer disease and agitation, no agents have demonstrated consistent efficacy.
- Despite the lack of strong evidence, antipsychotic medications have remained a mainstay for the treatment of behavioral disturbances.
- The newer atypical antipsychotic agents (risperidone, olanzapine, quetiapine clozapine, ziprasidone) are reported to be better tolerated than older agents but should be avoided in patients with vascular risk factors due to an increased risk of stroke, they can cause weight gain and are also associated with hyperglycaemia in diabetic patient.
- Starting and target dosages should be much lower than those used in schizophrenia (e.g., haloperidol, 0. 5-2 mg orally, risperidone, 0. 25-2mg orally).

Driving

- Experts agree that patients with very moderately severe or more advanced dementia should be counseled to stop driving.
- Caregivers of patients with at least a 30% decline in their IADLs score unable to drive safely than other.

Advance Financial Planning

- Difficulty in managing financial affairs often develop in early in the course of dementia.
- The patient's caregiver may seek advice from the patient's primary care clinician.
- No gold standard test is available to identify when a patient with dementia no longer has financial capacity.
- Patients with dementia are also at increased risk for becoming victims of financial abuse.
- When financial abuse is suspected, clinicians should be aware of the reporting requirements in their local jurisdictions.

Prognosis

- Life expectancy after a diagnosis of Alzheimer disease is typically 3- 15 years; it may be shorter than previous reported.
- Other neurodegenerative dementias, such as dementia with Lewy bodies, show more rapid decline.

When to Refer

- Referral for neuropsychological testing may be helpful in the following circumstances; to distinguish dementia from depression, to diagnose dementia in persons of very poor education or very high premorbid intellect, and to aid diagnosis when impairment is mild.

DEPRESSION

Essentials of Diagnosis

- Depressed elders may not admit to depressed mood
- Depression screening in elders should include a question about anhedonia.

General considerations

- Geriatric patients with depression are more likely to have somatic complaints, less likely to report depressed mood and more likely to experience delusions than younger patients.

Clinical Findings

- A simple two-question screen----- which consists of asking
- 'During the past 2 weeks, have you felt down, depressed or hopeless?" and
- "During the past 2 weeks, have you felt little interest or pleasure in doing things?" --- is highly sensitive for detecting major depression in persons over age 65.
- Positive responses can be followed up with more comprehensive, structured interviews, such as the Geriatric Depression Scale or the PHQ-9.
- Elderly patients with depressive symptoms should be questioned about medication use, since many drugs (e.g., Benzodiazepines, corticosteroids) contribute to the clinical picture.
- Similarly, several medical problems can cause fatigue, lethargy, or hypoactive delirium, all of which may be mistaken for depression.

Treatment

- Choice of antidepressant agent in elders is usually based on side effect profile and cost.
- Citalopram and sertraline are often used as first-line agents because of their low side-effect profiles.
- In general, fluoxetine is avoided because of its long duration of action and tricyclic depressants are because of their high cholinergic side effects. Mirtazapine is often used for patient with weight loss, anorexia or insomnia. Venlafaxine can be useful in patients who have neuropathic pain.
- Recommend starting elders at a relatively low dose, titrating to full dose slowly, and continuing for a longer trial.

When to refer

- Patients who have not responded to an initial antidepressant drug trial.
- Patients with have symptoms of mania, suicidality, or psychosis.

DELIRIUM

Essentials of diagnosis

- Rapid onset and fluctuating course.
- Primary deficit in attention rather than memory.
- May be hypoactive or hyperactive
- Dementia frequently coexists.

General considerations

- Delirium is an acute, fluctuating disturbance of consciousness, associated with change in cognition or the development of perceptual disturbances.
- It is the pathophysiological consequences of an underlying general medical condition such as infection, coronary ischaemia, hypoxemia, or metabolic derangement.
- Cognitive impairment is an important risk factor for delirium. Other risk factors are male sex, severe illness, hip fracture, fever or hypothermia, hypotension, malnutrition, polypharmacy and use of psychoactive medications, sensory impairment, use of restrains, use of intravenous line, or urinary catheters metabolic disorders, depression, and alcoholism.

Clinical Findings

- The confusion assessment method (CAM), which requires
- acute onset and fluctuating course.
- inattention and either
- Disorganized thinking or
- Altered level of consciousness
- A key component of delirium work-up is review of medications because large number of drugs, the addition of a new drug, or discontinuation of a medication known to cause withdrawal symptoms are all associated with development of delirium.
- Medications that are particularly likely to increase the risk of delirium include opioids, benzodiazipines, dihydropyridines and antihistamines.
- Laboratory evaluation of most patients should include a complete blood count, electrolytes, blood urea nitrogen (BUN), and serum creatinine, glucose, calcium, albumin, liver function studies, urinalysis and electrocardiography.
- In selected cases, serum magnesium, serum drug level, blood gas measurements, blood cultures, chest radiography, urinary toxin screen, head CT-Scan and lumber puncture may be helpful.

Prevention

- Prevention is best approach in the management of delirium. Measures include improving cognition (frequent reorientation, activities, socialization with family and friends when possible), sleep (massage, noise reduction, minimizing interruption at night). mobility, vision (visual aids and adaptive equipment), hearing and hydration status, (volume repletion).

Treatment

- Management of established episodes of delirium is largely supportive and includes reassurance and reorientation treatment of underlying causes, eliminating unnecessary medications and avoidance of indwelling catheters and restraints.
- Antipsychotic agents (such as haloperidol, 0. 5-1mg, or quetiapine, 25mg, at bedtime or twice daily) are considered the medication of choice when drug treatment of delirium is necessary.

When to refer

- If initial evaluation does not reveal the cause of delirium or if entities other than delirium are in the differential diagnosis, referral to a neuropsychologist, neurologist should be considered.
- Immobility
- Although common in older people, reduced mobility is never normal and is often treatable if its causes are identified.
- Bed rest is an important cause of hospital-induced functional decline.
- The hazards of bed rest in older adults are multiple, serious, quick to develop, and slow to reverse. Pressure sores, deep vein thrombosis and pulmonary embolism are additional serious risks.

Prevention & Treatment

- When immobilization cannot be avoided, several measures can be used to minimize its consequences. Skin, particularly areas over pressure points should be inspected at least daily. If the patient is unable to shift position, staff should do so every 2 hours. To minimize the cardiovascular deconditioning, patients should be positioned as close to the upright position as possible, several times daily. To reduce the risk of contracture and weakness, range of motion and strengthening exercises should be started immediately and continue as long as the patient is in bed. Whenever possible, patients should assist with their own positioning, transferring, and self-care. As long as the patient remains immobilized, antithrombotic measures should be used. Advice for a physical therapist is often helpful.

FALLS & GAIT DISORDERS

- About one-third of people over age 65 fall each year and frequency of falls increases markedly with advancing age. About 10% of falls result in serious injuries such as fractures, soft tissue injuries and traumatic brain injuries. Complications of falls are the leading cause of death from injury in persons over age 65. Hip fractures are common precursors to functional impairment, nursing home placement, and death.
- Assessment of patients who fall should include postural blood pressure and pulse, thorough cardiac examination, evaluation of strength, range of motion, cognition proprioception and examination of feet and footwear.
- A thorough gait assessment should be performed in all older people. gait and balance can be readily assessed by the “Up and Go Test”, in which the patient is asked to stand up from a sitting position without use of hands, walk 10 feet, turn around, walk back, and sit down. Patients who take < 10 seconds are usually normal, patients who take longer than 30 seconds tend to need assistance with many mobility tasks and those in between tend to vary widely with respect to

gait, balance and function. The ability to recognize common patterns of gait disorders is an extremely useful clinical skill to develop. Examples of gait abnormalities and their causes are listed---

Causes of Falls

- With age, balance mechanisms can become compromised and postural sway increases. These changes predispose the older person to a fall.
- A fall may be the clinical manifestation of an occult problem, such as pneumonia or myocardial infarction, but much more commonly falls due to the interaction between an impaired patient and an environmental risk factor. Dizziness may be closely related to the deficits associated with falls, gait abnormalities, or dizziness Sedative/ hypnotics, antidepressants and benzodiazipines were class of drugs most likely to be associated with falling. . The use of multiple medications simultaneously has also been associated with an increased fall risk.

Falls assessment

- The timed get- up- and- go test
- May use usual walking aid.
    - Start with the patient sitting in a straight- backed chair of comfortable height with arms
    - Ask the patient to rise from the chair, walk to a line 10 feet (3m) away, turn around, return to the chair, and sit down again
    - Start timing while the patient is sitting; end timing when the patient has sat down again
    - A time of ≥13sec predicts increase falls risk
- Falls assessment If available, refer to a specialist falls service. *Record*:
    - Frequency and history of circumstances around any previous falls
- Drug therapy: polypharmacy, hypnotics, sedatives, diuretics, antihypertensives may all cause falls
    - Assessment of gait and balance, including abnormalities due to foot problems or arthritis, and motor disorders, e.g., stroke, PD
    - Examination of basic neurological function, including vision, mental status (impaired cognition and depression), muscle strength, lower extremity peripheral nerves, proprioception, and reflexes
    - Assessment of basic cardiovascular status including BP (exclude postural hypotension), heart rate, and rhythm
    - Assessment of environmental risk factors, e.g., poor lighting particularly on the stairs, loose carpets or rugs, badly fitting footwear or clothing, lack of safety equipment such as grab rails, steep stairs, slippery floors, or inaccessible lights or windows

Complications of Falls

- The most common fractures resulting from falls are of the wrist, hip, and vertebrae.
- Fear of falling again is a common, serious, but treatable factor.
- Patients who are unable to get up from a fall are at risk for dehydration, electrolyte imbalance, pressure sores, rhabdomyolysis, and hypothermia.

Prevention and Management

- The risk of falling and consequent injury, disability, and potential institutionalization can be reduced by modifying those factors.
- Emphasis is placed on treating all contributory medical conditions (e.g., cataract) minimizing environmental hazards and eliminating medications.
- Also important are strength, balance, and gait training as well as screening and treatment for osteoporosis, if present.
- Falls and fracture s may be prevented by prescribing vitamin D at a dose of 800 international units daily or higher.
- Assistive devices such as canes and walkers, are useful for many older adults
- Early surgery for patients with cataracts may reduce falls, but eyeglasses, particularly bifocal or graduated lens may increase the risk of falls, particularly the early weeks of use.

- Table: Fall risk factors and targeted interventions and best evidence for fall prevention

• **Risk factor**	• **Targeted intervention**
• Postural hypotension (>20 mmHg drop in systolic blood pressure, or systolic pressure <90 mmHg)	• Behavioral recommendation such as hand clenching; elevation of head of bed; discontinuation or substitution of high-risk medications
• Use of benzodiazepine or hypnotic-sedative agent	• Education of sleep hygiene; discontinuation or substitution of medications
• Use of multiple prescription medications	• Review of medications
• Environmental hazards	• Appropriate changes; installation of safety equipment (e.g., grab bar)
• Gait impairment	• Gait training, assistive devices, balance or strengthening exercise
• Impairment of transfer or balance	• Balance exercises, training in transfers, environmental alterations (e.g., grab bars)
• Impairment in leg and arm muscle strength or limbs range of motion	• Exercise with resistance bands or putty, with graduated increase in resistance
• **Best Evidence of Fall Prevention[1]**	• **Numbers of Trails and Risk Ratio**
• Exercise of physical therapy	• 16 Randomized controlled trials • Risk ratio for fall 0.87 (confidence interval 0.81-0.94)
• Vitamin D supplementation	• 9 Randomized controlled trials • Risk ratio for fall 0.83 (confidence interval 0.77-0.89)
• Multifactorial intervention	• 19 Randomized controlled trials • Risk ratio for fall 0.97 (confidence interval 0.84-1.02)

- [1]*Adapted with permission from Michael YL et.al., Primary care relevant interventions to prevent falling in older adults: systemic evidence review for the U.S Preventive Services Task Force, Ann Intern Med 2010 Dec 21, 153(12):815-25,(PMID: 21173416)*

- *The timed get-up-and-go test* 0 May use usual walking aid.
- Start with the patient sitting in a straight-backed chair of comfortable height with arms
- Ask the patient to rise from the chair, walk to a line 10 feet (3m) away, turn around, return to the chair, and sit down again



- Start timing while the patient is sitting; end timing when the patient has sat down again
- A time of ≥13sec predicts if falls risk

When to Refer

- Patients with a recent history of falls should be referred for physical therapy, eye examination, and home safety evaluation.

URINARY INCONTINENCE

Essentials of Diagnosis

- Involuntary loss of urine
- *Stress incontinence*: leakage of urine upon coughing, sneezing, or standing.
- *Urge incontinence*: urgency and inability to delay urination.
- *Overflow incontinence*: may have variable presentation

General Considerations

- Incontinence in older adults is common, and interventions can improve most patients.
- A simple question about involuntary leakage of urine is a reasonable screen: (Do you have a problem with urine leaks or accidents?

Classification

- Transient Causes
- Use of the mnemonic (**DIAPPERS**) may be helpful in remembering the categorie4s of transient incontinence. Transient or potentially reversible causes of incontinence.
    - **Delirium**
    - **Infection**
    - **Atrophic urethritis or vaginitis**
    - **Pharmaceuticals –** Drugs are one of the most common causes of transient incontinence. Typical offending agents include potent diuretics, anticholinergics, psychotropics, opioid analgesics, α-blockers (in women)**, α**-agonists (in men) and calcium channel blockers.
    - **Psychological factors** –severe depression with psychomotor retardation may impede the ability to reach a toilet.
    - **Excess urinary output**
    - **Restricted mobility**
    - **Stool impaction**

Established causes

- **Detrusor overactivity (urge incontinence)**
    - Detrusor overactivity refers to uninhibited bladder contractions that cause leakage.
    - The single best question to ask when diagnosing:
    - **urge incontinence -** *"Do you have a strong and sudden urge to void that makes you leak before reaching the toilet?"*
- **Urethral incompetence (stress incontinence)**

- **Detrusor underactivity (overflow incontinence)**
- Detrusor underactivity is the least common cause of incontinence. It may be idiopathic or due to sacral lower motor nerve dysfunction.

Types of urinary incontinence in older people

- There are five **main** types of urinary incontinence in older people:
- urge incontinence (or over-active/unstable bladder)
- stress incontinence
- mixed incontinence (both urge and stress)
- voiding problems (due to obstruction or a neurogenic bladder)
- functional incontinence (due to an inability to get to the toilet tor confusion).

Type of incontinence	Definition	Causes	Symptoms
Urge	The complaint of involuntary leakage of urine accompanied or immediately preceded by urgency	Overactive bladder (OAB)	Frequency, urgency, nocturia.Unable to delay voiding
Stress	Involuntary leakage of urine on effort or exertion, coughing or sneezing	Weak pelvic floor muscles, incompetent urethra. Raised intra- abdominal pressure	Leaks urine on exertion, coughing, laughing, sneezing
Mixed	The complaint of involuntary leakage associated with urgency and also with effort or exertion	OAB and weak pelvic floor	Combination of the above
Voiding problems	The generic term for obstruction during voiding, characterised by increased detrusor pressure and a reduced urinary flow rate	Prostatic hypertrophy, detrusor failure (neurogenic bladder), faecal impaction	Hesitancy, poor stream, post-micturition dribble. May have large residual urine volume. Impaired bladder sensation
Functional incontinence	Inability to toilet independently	Extrinsic factors such as immobility, confusion, inability to access toilet facilities, medications etc.	Incontinent if carer unavailable or unable to communicate needs, or cannot get to toilet

Treatment

Transient causes

- Each identified transient cause should be treated.

Established causes

- **Detrusor overactivity**
  - The cornerstone of treatment is bladder training.
  - Life style modifications including weight loss and caffeine reduction may also improve the incontinence symptoms.
  - Pelvic floor muscle (Kegel) exercises, with or without biofeedback, can reduce the frequency of incontinence episode.
  - If behavioral approaches prove insufficient, drug therapy with antimuscarinic agents may provide additional benefit.
  - The combination of behavioral therapy and antimuscarinics appear to be more effective.
  - Available regimens of antimuscarinics are tolterodine and oxybutynin.
- **Urethral incompetence (stress incompetence)**
  - Life style modifications including limiting caffeine intake and timed voiding, may be helpful for some women.
  - Pelvic floor muscle exercises are effective for women with mild to moderate stress incontinence;
- **Urethral obstruction**
  - Surgical decompression is the most effective treatment for obstruction
- **Detrusor underactivity**
  - For the patients with a poorly contractile bladder, augmented voiding techniques(eg. double voiding, suprapubic pressure) often prove effective.
  - If further emptying is needed, intermittent or indwelling catheterization is the only option.

When to Refer

- Men with urinary obstruction who do not respond to medical therapy should be referred to urologist.
- Women who do not respond to medical and behavioral therapy should be referred to a urogynecologist or urologist.

UNDER-NUTRITION & FRAILTY

General Considerations

- Undernutrition affects substantial numbers of elderly.
- Frailty may be accompanied by physiologic changes in inflammatory and neuroendocrine systems.
- Frailty is not a disease or disability in itself, but a vulnerability or inability to withstand physical/psychological stressors.

Clinical Findings

- Useful laboratory and radiologic studies for the patient with weight loss include complete blood count. serum chemistries (including glucose, TSH, creatinine, calcium) urinalysis and chest radiograph.
- **Frailty** Many elderly people are described as being ‘frail’. This term is used to describe individuals who are physically weak and fragile. It can occur on a background of natural ageing

or be precipitated by a disease process. It is not a disease or disability in itself, but a vulnerability or inability to withstand

- physical/psychological stressors.

Common features of frailty include:

- Unintentional weight loss (>5kg in a year)
- Feeling of exhaustion
- Weakness—measured by grip strength
- Slow walking speed
- L ow levels of physical activity
- The most widely recognized definition of frailty requires that the patient exhibit at least three of five following criteria:
- slow gait speed
- low hand grip strength.
- exhaustion
- weight loss and
- low energy expenditure

Treatment

- Oral nutritional supplement of200 to 1000 kcal/d can increase weight and improve outcome in malnourished hospitalized elder.
- For those who have lost the ability to feed themselves, assiduous hand feeding allows maintenance of weight. Although artificial nutrition and hydration (tube feeding) may seem a more convenient alternative.
- The ideal strategies for preventing the frailty syndrome are unknown.
- At present, treatment is largely supportive, multifactorial, and individualized based on patient goals, life expectancy and comorbidities.

PRESSURE ULCERS

Essentials of Diagnosis

- Pressure ulcers should be described by one of six stages:
- Blanchable hyperemia (stage I)
- Extension through epidermis. (stage II)
- Full thickness skin loss (stage III)
- Full thickness wounds with extension into muscle, bone or supporting structures(stageIV)
- If eschar or slough overlies the wound, the wound is unstageable
- Suspected deep tissue injury is an area of discolored or blistered skin

General Considerations

- The primary risk factors for pressure ulcer is immobility. Other contributing factors include reduced sensory perception and moisture (urinary and fecal incontinence) poor nutritional status and friction and shear forces.
- Ulcers in which the base is covered by slough (yellow, tan, gray, green or brown) and /or eschar (tan, brown or black) are considered unstageable.

Prevention

- Using specialized support surfaces (including mattress, beds and cushions), patient repositioning, optimizing nutritional status, moistening sacral skin are strategies that has been shown to reduce pressure ulcer.

Evaluation

- Evaluation of pressure ulcers should include patient risk factors and goals of care, wound stage, size, depth, present or absent of exudate, type of exudate present, appearance of wound bed and whether there appears to be surrounding infection, inus tracking, or cellulitis.
- In poorly healing or atypical pressure ulcers, biopsy should be performed to rule out malignancy or other less common infections such as a pyoderma gangrenosum.

Treatment

- Treatment is aimed toward removing necrotic debris and maintain a moist wound bed that will promote healing and formation of granulation tissue.
- The type of dressing that is recommended depends on the location and depth of the wound, whether necrotic tissue or dead space is present and the amount of exudate
- Pressure reducing devices (e.g., air-fluid beds and low air loss beds) are associated with improved healing rates.
- Although poor nutritional status is a risk factor for the development of pressure ulcer, the
- results of trials of nutritional supplementation in the treatment of pressure ulcers have been disappointing.
- In patient with end-stage disease who is receiving palliative care, appropriate treatment might toward comfort (including minimizing dressing changes and odour) rather than efforts directed at healing.

Table: Treatment of Pressure Ulcer

Ulcer type	Dressing type and consideration
Stage I and suspected deep injury	Polyurethane film Hydrocolloid wafer Semi-permeable foam dressing
Stage II	Hydrocolloid wafer Semi-permeable foam dressing Polyurethane film

Stage III/IV	For highly exudative wound, use highly absorptive dressing or packing, such as calcium alginate Wound with necrosis must be debrided. Debridement can be autolytic, mechanical (wet to moist) or surgical Shallow clean wound can be dressed with hydrocolloid wafer, semi-permeable foam or polyurethane film Deep wound can be packed with gauze; if the wound is deep and highly exudative, and absorptive packing should be used.
Heel ulcer	Do not remove eschar on heel ulcer because it can help promote healing (eschar in other location should be debrided)
Unstageable	Debride before deciding on further therapy

Complications

- Pressure ulcers are associated with increased mortality rates, although a causal link has not been proven.
- Complications include pain, cellulitis, osteomyelitis, systemic sepsis and prolongation of lengths of stay in the inpatient or nursing home setting.

When to Refer

- Ulcers that are large or nonhealing should be referred to plastic or general surgeon or dermatologist for biopsy, debridement, and possible skin grafting.

PHARMACOTHERAPY & POLYPHARMACY

- There are several reasons for the greater incidence of iatrogenic drugs reactions in elderly population, the most important of which is high number of medications that elder take.
- Drugs metabolism is impaired due to a decrease in glomerular filtration rate as well as reduced hepatic clearance.
- Since older adults have a decrease in total body water and relative increase in body fat, water-soluble drugs become more concentrated and fat- soluble drugs have longer half-lives.

Precautions in Administering Drugs

- Non- pharmacologic interventions can often be a first-line alternative to drugs(e. g. , diet for mild hypertension or type 2 diabetes mellitus).
- Therapy is begun with less than the usual adult dosage and the dosage increased slowly, consistent with its pharmacokinectics in older patients.
- A number of single interventions can help improve adherence to the prescribed medical regimen.
- When possible, the provider should keep the dosing schedule simple, the number of pills low, the medication changes as infrequent as possible, and encourage the patient to use a single pharmacy.
- Pillboxes or “medi-sets” helps some patient with adherence.

- Having the patient or care-giver bring all medications at each visit can help the provider perform medication reconciliation and reinforce reasons for drug use, dosage, frequency of administration, and possible side effects.
- The risk of toxicity goes up with the number of medications prescribed.
- Certain combinations of medications are particularly likely to cause drug-drug interactions and should be watch carefully.

When to Refer

- Patients with poor or uncertain adherence may benefit from referral to a pharmacist or a home health nurse.

VISION IMPAIRMENT

- Although visual loss is not severe in many elders, visual impairment is an independent risk factor of falls; it also has a significant impact on quality of life.
- The prevalence of serious and correctable visual disorders in elders is sufficient to warrant a complete eye examination by an ophthalmologist or optometrist annually or biannually for most elders.

HEARING IMPAIRMENT

- Over one-third of persons over age 65 and half of those over age 85 have some hearing loss. . This deficit is correlated with social isolation and depression.
- A reasonable screen is to ask patients if they have hearing impairment. Those who answer “yes” should be referred for audiometry.
- Those who answer “no” may still have hearing impairment and can be screened by a handheld audio-scope or the whispered voice test.
- Caregivers or family members often have important information on the impact of hearing loss on the patient’s social interaction.
- Hearing amplification can improve hearing-related quality of life in patients with hearing loss.
- In general, facing the patient and speaking slowly in a low tone is a more effective communication strategy than yelling for patients with age-related hearing loss.

ELDER MISTREATMENT & SELF NEGLECT

- Elder mistreatment is defined as” actions that cause harm or create a serious risk of harm to an older adult by a caregiver or other person who stands in a trust relationship to the older
- adult or failure by a giver a caregiver to satisfy the elder’s basic needs or to protect the elder from harm”.
- Self-neglect is the most common form of elder mistreatment.
- According to the best available estimates, the prevalence potential neglect and psychological and financial abuse, are each about 5%, with other forms of abuse being less common.
- Clues to possibility of elder abuse include behavioral changes in the present of the caregiver, delays between occurrence of injuries and sought treatment, inconsistencies between an

observed injury and associated explanation, lack of clothing or hygiene, and not filling prescriptions.

- Many elders with cognitive impairment become targets of financial abuse.
- Both elder abuse and self-neglect are associated with an increased rate of mortality.
- It is helpful to observe and talk with every older person alone for at least part of a visit in order to ask questions directly about possible abuse and neglect.

Table: Phrases and actions that may be helpful in situation of suspected abuse or neglects

Question for the Elder
• Has anyone hurt you? • Are you afraid of anybody? • Is anyone taking or using your money without your permission?
Question for the caregiver
• Are you dad's needs more than you can handle?
• Are you worried that you might hit your dad? • Have you hit your dad?
If abuse is suspected
• Tell the patient that you are concerned, want to help and will call Adult Protective Services to see if there is anything that they can do to help. • Document any injury • Document the patient's words • Document whether or not the patient is decision making capacity using a tool such as Aid to Capacity Evaluation.

- When self-neglect is suspected, it is crucial to establish whether a patent has decision making capacity in order to determine what course of action needs to be taken.

When to Refer

- The law in most state require health care providers to report suspected abuse or neglect to Adult Protective Agencies.

Reference

- *Current Diagnosis and Treatment LANGE*
- *Oxford handbook of General Practice, 5th Edition*

CHRONIC DISEASE MANAGEMENT

- Long- term conditions frequently managed in general practice include:
- Back pain
- Cancer
- DM
- Dementia
- Renal or liver failure
- Irritable bowel syndrome
- Inflammatory bowel disease
- Cardiovascular disease, e.g., increase BP, heart disease, stroke
- HIV
- Arthritis of all types
- Chronic lung disease
- Chronic neurological conditions, e.g., Parkinson's disease, MS
- Psychiatric illness, e.g., depression, psychosis

Common elements of effective chronic illness management

- Involvement of the whole family Chronic diseases do not only affect the patient but everyone in a family
- Collaboration between service providers, patients, and carers
- Negotiate and agree a definition of the problem; agree targets and goals for management; develop an individualized self- management plan
- Personalized written care plan Take into account patients'/ carers' views and experience and the current evidence base
- Tailored education in self- management A patient with diabetes spends 3h/ year with a health professional— the other 8757h he or she manages his/ her own condition. Helping patients with chronic disease understand and take responsibility for their conditions is vital
- Planned follow- up Proactive follow- up according to the care plan— use of disease registers and call– recall systems is important.

Monitoring of outcome and adherence to treatment

- Use of disease/treatment markers; monitoring of concordance, e.g., prescription frequency; medicine management programmes—
- Tools and protocols for stepped care
    - Provide a framework for using limited resources to greatest effect; step professional care in intensity—
    - start with limited professional input and systematic monitoring, then augment care for patients not achieving an acceptable outcome
- Targeted use of specialist services
    - For those patients who cannot be managed in primary care alone
- Monitoring of process
    - Continually monitor management through clinical governance mechanisms

DEPRESSION AND CHRONIC DISEASE

- Depression is common among people with chronic disease. It is reported to affect 30– 50% of those with epilepsy, CVD, dementia, cancer, type 2 DM, and arthritis.
- Interaction between depression and chronic physical illness
- Depression in those with chronic medical illnesses adversely affects prognosis.
- Conversely, treatment of depression can improve prognosis.
- Depression is associated with:
    - increased mortality, morbidity, disability, and poorer quality of life
    - increase prevalence of smoking and sedentary lifestyles
    - Poorer chronic disease outcome measures, e.g., higher HbA1c levels
    - increase use of services and healthcare costs
    - Poor concordance with medication and management plans

Detection of depression

- Use NICE depression screening questions:
- During the last month, have you often been bothered by feeling down, depressed, or hopeless?
- During the last month, have you often been bothered by having little interest or pleasure in doing things?
- A positive response to either of these questions should prompt further assessment with the following 3 questions: *During the last month have you often been bothered by*:
- Feelings of worthlessness?
- Poor concentration?
- thoughts of death?

Reference

- *Oxford handbook of General Practice, 5th Edition*

PRESCRIBING IN OLDER PEOPLE

- Most of older people are on regular medication
- Pharmacokinetics and pharmacodynamics are **different** in this age group
- Older people are much more likely to suffer from the **side effects** of drugs
- **Polypharmacy** and problems with **concordance** are particular issues m geriatric medicine
- Drug trials **tend not to include** people over the age of 80
- Two-thirds of people over the age of 60 are taking regular medication,and over half of those with repeated prescriptions are taking **more than four drugs.** People in care homes are even more likely to be taking several regular medications. Adverse drug reactions account for up to 17% of hospital admissions.

Pharmacology in older patients

- Administration challenges include:
  - Packing
  - Labels
  - Tablets may be large and difficult to swallow or have an unpleasant taste
  - Liquid formulation
  - Multiple tablets
  - Absorption
  - Increased gastric pH
  - Delayed gastric emptying
  - Reduced intestinal motility and blood flow
  - Absorption of drugs is largely unchanged with age -exceptions include iron and calcium which are absorbed
- Hepatic metabolism
  - Specific hepatic metabolic pathways (e.g., conjugation) are unaffected by age
  - Reducing hepatic mass and blood flow can impact on overall function which slows metabolism of drugs.
  - Many factors interact with liver metabolism (e.g., nutritional state, acute illness, smoking, other medications etc.
- Renal excretion
  - Renal function declines with age
  - Drugs or drugs with active metabolites,that are mainly excreted in the urine include digoxin, gentamycin, lithium, furosemide, and tetracycline
  - Where there is narrow therapeutic index (e.g., digoxin, aminoglycosides)
  - Impair renal function is exacerbated by dehydration and urinary sepsis

PRESCRIBING FOR THE ELDERLY

- Use of medicines increase as people get older. 90% of prescriptions are for repeat medication. Adverse drug events are common reasons for hospital admission in the over-75 age group; many are avoidable. Regular review is essential.

POLYPHARMACY

- Elderly people often have multiple problems.
- Before prescribing a new drug, consider whether it is necessary oBalance the potential risks of the drug against the benefits
- Review medication regularly

Pharmacoki netic differences

- **Age-related changes** lead to differences in absorption, distribution, metabolism and elimination of drugs.
- There is a **reduced volume of distribution** for many drugs because of reduced total body water and an increase in the percentage of body weight as fat. As a result, dose requirements are less than in younger people.
- For example, digoxin is a water-soluble drug, and lower loading doses may be required.
- Diazepam is a lipid-soluble drug and the relative increase in body fat may lead to accumulation, causing toxicity.
- **Liver metabolism is reduced,** leading to slower drug inactivation.
- **Reduced liver blood flow** is made worse by cardiac failure, potentially leading to increased drug concentrations, although this is rarely of clinical significance. However, care should be taken when prescribing drugs that are metabolised in the liver and have a narrow therapeutic index: warfarin,theophylline and phenytoin.
- Plasma levels of these drugs should be monitored.
- Perhaps the most clinically significant difference is that renal blood flow and mass reduce significantly with age, leading to a **reduction in the clearance of many drugs,** especially water-soluble ones.

Pharmacodynamic differences

- Some commonly prescribed drugs should be reduced to account for **reduced renal function** (as measured by GFR). Examples are ciprofloxacin, gentamicin,digoxin and lithium.
- There is an **increased sensitivity to drugs** in general, and lower doses are often required compared to younger adults, for example, a patient started on treatment for hypertension may develop dizziness due to reduced baroreceptor sensitivity causing postural hypotension.

Adverse drug reactions

- More common and complex with increasing age
- Altered drug handling and sensitivity occur with age, worse by poor appetite, nutrition and fluid intake.
- Frailty and multiple diseases make drug-disease interactions more common, for example

- Anticholinergics may precipitate urine retention in a patient with prostatic hypertrophy.
- Benzodiazipine may precipitate delirium in a patient with dementia
- These relationships become even more complex when large numbers of drugs that are prescribed for multiple conditions interact with the disease as well as each other.
- Errors in drug taking make adverse reaction more likely mistakes increase with:
- Increasing age
- Increasing number of prescribed drugs
- Cognitive impairment
- Living alone

- **Table 1. Illustrates examples of diseases in old age and the disease-drug interactions that can occur with commonly prescribed medications**

Disease in older age	Drugs	Potential effect
Dementia	Benzodiazepines Antimuscarinics, (some) anticonvulsants Levodopa	Worsening confusion
Parkinson's disease	Antimuscarinics Metoclopramide	Worsening symptoms Deteriorating movement disorder
Seizure disorder/epilepsy	Antibiotics Analgesics Antidepressants Antipsychotics Theophyllines Alcohol	Reduced seizure threshold/ seizures

GUIDELINES FOR PRESCRIBING FOR THE ELDERLY

- Think before prescribing
- Is the drug needed?
- Is there another non-pharmacological way of managing the problem?
- Are you treating the underlying condition or the symptoms of it?
- What are the pros and cons of the patient taking this drug?
- What is the evidence base for its use in this age group?
- Will the patient be able to take the drug (formulation; packaging)?
- Will the patient be concordant?
- Will the patient comply with any necessary monitoring?
- Limit the range of drugs you use
- Prescribe from a limited array of drugs that you know well.
- Repeats and disposal
- Tell patients how to get more tablets, and monitor frequency of repeat prescriptions
- Review repeated prescriptions regularly
- Tell patients what to do with any leftover if a drug is stopped
- Decrease the dose
- Start with 50% of the adult dose
- Avoid drugs likely to cause problems (e.g., long-acting antidiabetic agents such as glibenclamide)

- Review regularly
- Consider on each occasion whether each drug could be stopped or the regime simplified
- Consider lowering dosage of drugs if renal function is deteriorating
- Involve carers, community pharmacists, and other PHCT members
- Simplify regimes
- Use OD or BD regimes wherever possible
- Avoid polypharmacy
- Explain clearly
- Put precise instructions on the drug bottle-avoid 'use as directed'
- Give written instructions about how the drug should be taken
- Ensure explanations are given to carers as well as patients where appropriate
- Consider method of administration
- Bottles with childproof tops are often impossible for arthritic hands to open. Suggest the patient asks the chemist for a standard screw cap
- Drug administration boxes, in which the correct tablets are stored in slots marked with the day and time of administration can be helpful. Available from pharmacists and can be filled by the patient, a carer, friend or relative,or the pharmacist
- Medication reminder charts can also be helpful

Reference

- *Oxford handbook of General Practice, 4th Edition*

GERIATRIC REHABILITATION & PAIN MANAGEMENT IN THE ELDERLY

- Ageing, disability, and pain
- Ageing – a progressive physiologic multi-organic decline that promotes the onset of functional limitation and disability.
- Frailty– a condition characterized by a gradual physiologic decline in multiple body systems, by loss of function, loss of physiologic reserve, and increased vulnerability to disease and death.
- Rehabilitation can play an essential role to counteract impairments and to improve abilities.
- The main goal of rehabilitative intervention in the elderly is to maintain independent mobility and activities of daily living (ADL)
- Chronic pain is one of the most common conditions encountered by healthcare professionals, particularly among older (≥65 years) patients.
- Pain is associated with substantial disability reduced mobility avoidance of activity falls depression and anxiety sleep impairment, and isolation
- Its negative effects extend beyond the patient, to disrupt both family and social relationships. Chronic pain poses a significant economic burden on society.

Common Pain Conditions in Elderly

- Musculoskeletal condition such as arthritis
- Cancer
- Neuropathies
- Shingles
- Sciatica
- Spinal Stenosis
- Muscle Pain



- Elements of a comprehensive geriatric pain assessment
- Sensory
- Please tell me all of the places you experience pain or discomfort. What does it feel like? What words come to mind?
- Is your pain or discomfort with you all of the time or does it come and go? How long has it been present? What makes it better, what makes it worse?
- Emotional impact (Effective)
- Has pain affected your mood, sense of wellbeing, energy level?
- Are you worried about your pain or what may be causing it?
- Functional impact
- Has pain affected your ability to do every day activities? To do things you enjoy?
- How about relating with others? If so, how?
- Sleep
- Has pain affected your sleep?

- Do you have trouble falling asleep or need to take drugs to help you sleep on account of your pain?
- **Attitudes and beliefs (Cognitive)** Do you have any thoughts or opinions about experiencing pain at this point in your life that you believe would be important for me to know? Do you have any thoughts or opinions about specific pain treatments that you believe would be important for me to know?
- **Coping styles** What things do you do to help you cope with your pain? This could be listening to your favorite music, praying, sitting still, or isolating yourself from others
- **Treatment expectations and goals** What do you think is likely to happen with the treatment I have recommended? What are the most important things you hope will happen as a result of the treatment?
- **Resources** Is there anyone at home or in the community that you can turn to for help and support when your pain is really bad?

Treatment approach

- **To treat the whole patient (Holistic and comprehensive health care) with multidisciplinary team approach**
- not just the specific injury or condition
- in order to improve overall recovery
- prevent recurrence of pain or other source of dysfunction
- needs to focus on Functional, vocational, and socioeconomic and psychological status

Goals of treatment

- to restore the patient's normal function and
- improve quality of life for patients from a physical, emotional, psychosocial and vocational perspective.
- Rehabilitation programs and goals in the elderly
- Prescription of appropriate physical therapy including aerobic exercises focused on balance, gait, mobility, and flexibility.

Prevention of falls

- Prevention of complications of mobility limitation and immobility
- Maintaining functional independence
- Assessment and prescription for equipment and devices

Prevention and treatment of pain

- Patient and family education
- Maintaining social participation
- Improvement of quality of life

Treatment option

- Pharmacological
- Analgesic, NSAIDs, muscle relaxants, anti- epileptics, tranquilizers, etc.
- Non-Pharmacological

- Health education
- Postural care
- Physical Modalities
- Physical activity and therapeutic exercise
- Bio-psychosocial approach
- prevention of recurrence
- Social integration and return back to work
- Cognitive behavioral therapy
- The use of CBT is promising.
- CBT is used to enhance patients' control over pain, based on the premise that an individual's beliefs, attitudes, and behaviors play a central role in the experience of pain.
- Standard CBT protocols instruct patients in the use of specific cognitive and behavioral techniques, teach them how certain thoughts, beliefs, attitudes, and emotions influence pain, and highlight the patient's own role in controlling and adapting to chronic pain.

Reference

- *GERITRIC CONFERENCE MAY 2018 Professor/Head Dr. Khin Myo Hla PRESENTATION*

CHAPTER 13 DERMATOLOGY

Contents

- *Bee and Wasp Stings*
- *Flea Bites*
- *Fire Ant Stings*

- ***7. Fungal infections***
    - *Tinea Pedis*
    - *Tinea of the Groin (Tinea Cruris, Jock Itch)*
    - *Tinea of the Body (Tinea Corporis) (Tinea circinata)*
    - *Tinea of Hand (Tinea Manuum)*
    - *Tinea Incongnito*
    - *Tinea Facei/Tinea Facialis*
    - *Tinea Capitis*
    - *Tinea barbae*
    - *Tinea Versicolor or Pityriasis versicolor*
    - *Candidiasis (Moniliasis)*
    - *Candidial Balantitis*
    - *Diaper dermatitis*
    - *Candida intertrigo*
    - *Tinea of the Nail*
    - *Candida onychomycosis*
- ***8. Acne vulgaris and Rosacea***
    - *Acne Vulgaris*
    - *Rosacea*
- ***9. Dermatosis***
    - *Dermatitis / Eczema*
    - *Atopic Dermatitis*
    - *Seborrhoeic Dermatitis*
    - *Discoid or Nummular Eczema*
    - *Dyshidrotic Eczema / Pompholyx / Hand and Foot Eczema*
    - *Stasis Dermatitis*
    - *Venous Leg Ulcer*
    - *Xerotic Eczema*
    - *Icthyosis Vulgaris*
    - *Keratosis Pilaris*
    - *Pityriasis Alba*
    - *Contact Dermatitis*
    - *Irritant Contact Dermatitis (ICD)*
    - *Allergic Contact Dermatitis (ACD)*
    - *Lichen Simplex Chronicus*
    - *Prurigo Nodularis (PN)*
- ***10. Urticaria***

- ***11. Psoariasis***

- ***12.Miscellaneous Inflammatory Disorders***
    - *Lichen Planus-*
    - *Pityriasis Rosea -*
- ***13. Benign skin tumors***

- *Dermatofibroma*
- *Keratoacanthoma*
- *Skin Tags*
- *Sebaceous Hyperplasia*
- *Syringoma*
- *Seborrheic Keratosis*
- *Hypertrophic Scar*
- *Pilar Cyst (Trichilemmal cyst)*
- *Epidermal Cyst (Epidermoid Cyst)*
- *Nevous Sebaceous*
- *Chondrodermatitis*
- *Clear Cell Acanthoma*
- *Keloid*
- *Milium*
- *Digital Myxoid Cyst*

14. Vascular Tumor and Malformations

- *Hemangiomas of Infancy*
- *Vascular Malformation*
- *Capillary Malformation*
- *Spider Angioma (Nevus Araneus)*
- *Cherry Angioma*
- *Angiokeratoma*
- *Pyogenic Granuloma*
- *Venous Malformation*
- *Venous Lake*
- *Lymphatic Malformation*
- *Lymphangioma*
- *Kaposi's sarcoma*

- ***Capillary / Venous Malformation***

-Telangiectasis

- ***15. Precancerous Lesions***

  - *Actinitic (Solar) Keratosis or Keratosis Senilis*
  - *Arsenical Keratosis*
  - *Bowen's Disease*
  - *Cutaneous Horn*
  - *Cutaneous T cell lymphoma*
  - *Leucoplakia*

- ***16. Cutaneous Melanomas***

  - *Melanoma*
  - *Nevi*
  - *Mongolian spot*
  - *Nevus of Ota*
  - *Becker Nevus*

- ***17. Skin Cancers***

  - *Basal cell Carcinoma*
  - *Basal cell nervous syndrome*
  - *Squamous Cell Carcinoma*
  - *Paget disease of Breast*
  - *Extra mammary Paget's disease*

- ***18. Photosensitivity and Photo Induced Disorders***

- *Skin Reactions to Sunlight*
- *Acute Sun Damage (Sunburn)*
- *Drug or chemicalinduced photosensitivity*
- *Phototoxic Drug / Chemical induced photosensitivity*
- *Photoallergic Drug/ Chemical induced Photosensitivity*
- *Polymorphous light Eruption*
- *Solar Urticaria*

- ***Metabolic Photosensitivity – The porphyria***

  - *Causes of Aging Skin (Intrinsic and Extrinsic aging)*
  - *Types of skin damage from exposure to UVR*
  - *Chronic Photodamage*
    - ***Photo aging or dermatoheliosis***
      - ***Solar lentigo***
      - ***Solar Elastosis***
      - ***Actinic keratosis***

- ***19. Pigmentary Disorders***

  - *Vitiligo -*
  - *Poikiloderma of Civatte*
  - *Melasma*
  -

- ***20. Immunobullonus diseases***

  - *Pemphigus Vulgaris*
  - *Bullous Pemphigoid*
  - *Pemphigus Foliaceus*
  - *Herpes Gestations*
  - *Dermatitis Herpetiformis*

- **21. Connective Tissue Diseases**
  - *Cutaneous Lupus Erythematous*
  - *Scleroderma*
  - *Morphea*

- ***22. Hair Diseases***

  - *Alopecia areata*

- ***23.Cutaneous Manifestation of Internal Diseases***

  - *Cutaneous Manifestation of Leprosy*
  - *Cutaneous Tuberculosis*
  - *Cutaneous Manifestation of Diabetes Mellitus*
  -

1. TYPES OF SKIN LESIONS

Primary Lesions: these lesions represent the early stage of the lesion, how they look when they start, and prior to evolving. Secondary Lesions: these lesions represent a later stage after the lesion has evolved or been altered. This may help you to determine where in the skin the process is occurring (epidermis, dermis, fat)

TYPES OF PRIMARY SKIN LESIONS



https://www.nclexquiz.com/wp-content/uploads/2016/11/skin.png

Bulla - fluid filled blister more than 0.5 cm.
Macule - less than l cm flat non-palpable lesion.
Nodule - elevated bump more than 0.5 cm, frequently in the dermis or fat and deeper than a plaque
Patch - more than 1 cm flat non-palpable lesion
Papule - elevated bump less than 0.5 cm
Plaque - plateau like lesion more than 0.5 cm
Pustule - cloudy fluid filled lesion containing many inflammatory cells (pus in it)
Vesicle - fluid filled blister less than 0.5 cm
Wheal - special plaque composed only of fluid (hives)
Large nodules, more than 2 cm are often referred to as **tumors**
Cyst - papule or nodule filled fluid or semisolid material
Telangiectasia - dilated superficial vessels (not broken blood vessels)

SECONDARY LESION

- ***Crust - Dried fluid and keratinocytes arising from broken vesicles and bullae***
- ***Scale - thickened stratum corneum (scale occurs in the epidermis)***
- ***Induration - Increased firmness and thickening of the dermis (need to feel to determine this)***
- ***Erosion - Loss of the epidermis***
- ***Ulceration - Loss of the epidermis and some or all of the dermis and sometimes subcutaneous tissue***
- ***Atrophy - Loss of dermis or fat (sunken in) or thinning of the epidermis (finely wrinkled translucent skin)***

SHAPE AND CONFIGURATION

- ***Annular - Making a circle, clear in the center round or oval***
- ***Grouped (herpetiform) - Occurring in crops***
- ***Linear - Making a line***
- ***Dermatomal - Going along the nerves:***

DIRECTION

A series of pictures displaying various morphologies and patterns will follow, try to think about how you should describe these lesions to your residents and attendees and then see how these lesions are appropriately described.

T2. TOPICAL STEROID

A topical steroid is an anti-inflammatory preparation used to control eczema (dermatitis and many other skin conditions). Topical steroids are available in creams, ointments, solutions and other vehicles. Topical steroids are also called topical corticosteroids, glucocorticosteroids, and cortisone.

ACTION OF TOPICAL STEROID

- ***Anti-inflammatory***
- ***Immunosuppressive***
- ***Anti-proliferative***
- ***Vasoconstrictive.***

The potency of a topical steroid depends on:

- ***The specific molecule***
- ***Amount that reaches the target cell***
- ***Absorption through the skin (0.25%-3%)***

FORMULATIONS OF TOPICAL STEROID

Several formulations are available for topical steroids, intended to suIt the type of skin lesion and its location.

CREAMS

A cream is an emulsion of oil and water in approximately equal proportions. It penetrates the stratum corneum outer layer of skin well. Cream is thicker than lotion, and maintains its shape when removed from its container

LOTION

Lotions are similar to solutions but are thicker and tend to be more emollient in nature than solution. They are usually oil mixed with water, and more often than not have less alcohol than solutions Creams and lotions are general purpose and are the most popular formulations.

OINTMENT

An ointment is a homogeneous, viscous, semi-solid preparation, most commonly greasy, thick oil (oil 80% - water 20%) with a high viscosity that is intended for external application to the skin or mucous membranes. It is more suitable formulation for dry, non-hairy skin, no requirement for preservative, reducing risk of irritancy and contact allergy and occlusive, increasing risk of folliculitis and miliaria.

GEL OR SOLUTION

Gels are thicker than a solution. Gels are often a semisolid emulsion in an alcohol base. Some will melt at body temperature. Gel tends to be cellulose cut with alcohol or acetone. Gels tend to be drying. It is useful in hair-bearing skin, has an astringent (drying) effect and stings inflamed skin.

As a general rule, use the weakest possible steroid that will do the job. It is often appropriate to use a

potent preparation for a short time to ensure the skin condition clears completely.
Topical steroid is sometimes combined with another active ingredient, including antibacterial, antifungal agent or calcipotriol.

Topical corticosteroid / antibiotic preparations should be used rarely, and short-term (e.g., three times daily for one week for a small area of infected dermatitis), to reduce the risk of antimicrobial resistance.

CLASSIFICATION OF TOPICAL CORTICOSTEROID

Potency Class	Topical Corticosteroid		Formulation
Ultra-high	I	Clobetasol propionate	Cream, 0.05%
		Diflorasone diacetate	Ointment, 0.05%
High	II	Amcinonide	Ointment, 0.1%
		Betamethasone dipropionate	Ointment, 0.05%
		Fluocinonide	Cream, ointment or gel 0.05%
		Halcinonide	Cream 0.1%
	III	Betamethasone dipropionate	Cream, 0.05%
		Betamethasone valerate	Ointment, 0.1%
		Diflorasone diacetate	Cream, 0.05%
		Triamcinolone acetonide	Ointment, 0.1%
Moderate	IV	Desoximetasone	Cream, 0.05%
		Fluocinolone acetonide	Ointment, 0.025%
		Fludroxycortide	Ointment, 0.05%
		Hydrocortisone valerate	Ointment, 0.2%
		Triamcinolone acetonide	Cream 0.1%
	V	Betamethasone dipropionate	Lotion, 0.02%
		Betamethasone valerate	Cream, 0.1%
		Fluocinolone acetonide	Cream, 0.025%
		Fludroxycortide	Cream, 0.05%
		Hydrocortisone butyrate	Cream, 0.1%
		Hydrocortisone valerate	Cream, 0.2%
		Triamcinolone acetonide	Lotion, 0.1%
Low	VI	Betamethasone valerate	Lotion, 0.05%
		Desonide	Cream, 0.05%
		Fluocinolone acetonide	Solution, 0.01%
	VII	Dexamethasone sodium phosphate	Cream, 0.1%
		Hydrocortisone acetate	Cream, 0.1%
		Methylprednisolone acetate	Cream, 0.25%

Very potent or super potent Class I, is up to 600 times as potent as hydrocortisone) e.g., Clobetasol propionate, Betamethasone dipropionate (in optimised vehicle).
Potent, Class II is 100-150 times as potent as hydrocortisone, such as Betamethasone valerate, Betamethasone dipropionate (cream, ointment, gel), Mometasone furoate and Methylprednisolone aceponate.
Moderate, class III or IV is 2 -25 times as potent as hydrocortisone such as Clobetasone butyrate and Triamcinolone acetonide.

Mild form is Hydrocortisone and Hydrocortisone acetate.
Class I topical corticosteroids are the most potent and Class VII are the least potent. Efficacy and side-effects are greatest with the Class I ultra-high-potency preparations which should only be used for limited time periods (2-3 weeks).

CUTANEOUS SIDE EFFECTS

Local side effects may arise when a potent topical steroid is applied daily for long periods of time (months). Most reports of side effects describe prolonged use of unnecessarily potent topical steroid for inappropriate indications.

- ***Skin thinning (atrophy)***
- ***Stretch marks (striae) in armpits or groin***
- ***Easy bruising (senile / solar purpura) and tearing of the skin***
- ***Enlarged blood vessels (telangiectasia)***
- ***Localised increased hair thickness and length (hypertrichosis)***

Topical steroid can cause, aggravate or mask skin infections such as impetigo, tinea, herpes simplex, and malassezia folliculitis and molluscum contagiosum.
Note: topical steroid remains the first-line treatment for infected eczema.
Potent topical steroid applied for weeks to months or longer can lead to:

- ***Periorificial dermatitis (common)***
- ***Steroid rosacea***
- ***Symptoms due to topical corticosteroid withdrawal***
- ***Pustular psoriasis.***
- ***Stinging frequently occurs when a topical steroid is first applied, due to underlying inflammation and broken skin.***
- ***Contact allergy to steroid molecule, preservative or vehicle is uncommon, but may occur after the first application of the product or after many years of its use.***

OCULAR SIDE EFFECTS

Topical steroid should be used cautiously on eyelid skin, where It commonly results in periocular dermatitis. Potentially, excessive use over weeks to months might lead to glaucoma or cataracts.

TOPICAL STEROID IN PREGNANCY

Mild and moderate-potency topical steroids can be safely used in pregnancy. Caution should be used for potent and ultra-potent topical steroids used over large areas or under occlusion, of which a proportion will be absorbed systemically.

USAGE OF TOPICAL STEROID

Topical steroid is applied once daily (usually at night) to inflamed skin for a course of 5 days to several weeks. After that, It is usually stopped, or the strength or frequency of application is reduced.
Emollients can be applied before or after the application of topical steroid, to relieve irritation and dryness or as a barrier preparation. Infection may need additional treatment.

FINGERTIP UNIT

The fingertip unIt guides the amount of topical steroid to be applied to a body site. One unIt describes the amount of cream squeezed out of its tube onto the volar aspect of the terminal phalanx of the index

finger.
The quantity of cream in a fingertip unit, varies with gender, age and body part.

- ***Adult male: one fingertip unit provides 0.5 g***
- ***Adult female: one fingertip unit provides 0.4 g***
- ***Child aged 4 years: approximately 1/3 of adult amount***
- ***Infant 6 months to 1 year: approximately 1/4 of adult amount***
- ***One hand: apply 1 fingertip unit***
- ***One arm: apply 3 fingertip units***
- ***One foot: apply 2 fingertip units***
- ***One leg: apply 6 fingertip units***
- ***Face and neck: apply 2.5 fingertip units***
- ***Trunk, front & back: 14 fingertip units***
- ***Entire body: about 40 units***



https://hermnetnz.org/topics/fingertip-unit

3. BACTERIAL INFECTIONS

1. Impetigo





https://www.nhs.uk/conditions/impetigo
https://hermnetnz.org/cme/bacterial-infections/impetigo

Highly contagious superficial skin infection caused by *staphylococcus* or *streptococcus*.

- ***Highly contagious infection characterized by pustules and honey-coloured crusted erosion. Kissing lesions are arise where two skin surfaces are in contact.***
- ***Common in young children.***
- ***Infection of the epidermis with crusted lesion***
- ***Two types - Bullous impetigo and non-bullous impetigo or school sores.***

Treatment

- ***Fusidic acid cream bd for 7 days***
- ***2% mupirocin ointment or bactroban 3 time for l0 days***
- ***Widespread non-bullous impetigo (>3 lesions) or topical fail, oral is recommended.***
- ***Dicloxacillin 250 mg qid for 5-10 days or***
- ***Flumox 250 mg tds for 5-7 days or***
- ***Cephalexin 250 mg qid for 5-10 days or***
- ***Azithromycin 500 mg on day l, 250 mg on day 2 to day 5.***

2. Ecthyma



http://www.antimicrobe.org/new/photolink/gangrenosum.asp

A deeper infection than impetigo caused by *Staphyloccous*

- ***Infection of the epidermis which may extend into dermis with crusted deep erosions or ulcers***

Treatment

- ***A topical antiseptic such as povidone iodine or H_2O_2 solution***
- ***Fusidic acid cream bd for 7 days***
- ***2% mupirocin ointment or bactroban 3 time for 10 days***
- ***Dicloxacillin 250 mg qid for 5-10 days or***
- ***Flumox 250 mg tds for 5-7 days or***
- ***Cephalexin 250 mg qid for 5-10 days or***
- ***Azithromycin 500 mg on day 1, 250 mg on day 2 to day5.***



https://www.pcds.org.uk/clinical-guidance/erysipeloid

3. Cellulitis

Infection of dermis and subcutaneous tissue characterized by fever, erythema, edema and pain. Caused by *streptococcus and Staph.* Related to underlying Diabetes Mellitus.
Doctors typically diagnose cellulitis by a physical examination and looking at the affected skin. It usually affects the lower legs. It is associated with lymphangitis and lymphadenitis.



https://podiatryhq.com.au/are-you-suffering -from-ce

Treatment

- ***Pain relieved by cool Burrow's wet dressing***
- ***Elevation of affected limb***
- ***Amoxicillin + Clavulanate 500 mg bd 5-7 days***
- ***Dicloxacillin 500-1000 mg qid for 7 days or***
- ***Cephalexin 250-500 mg qid for 5-10 days or***
- ***Azithromycin 500 mg on day l, 250 mg on day 2 to day 5.***

4. Erysipelas

An acute inflammatory form of cellulitis that differs from other types of cellulitis in that It is superficial with lymphatic involvement (streaking) prominent.
It is a tender, intensely erythematous indurated plaque with a sharply demarcated border. It has well defined margin.
It is caused by a beta-hemolytic Streptococcus and Staphlococcus aureus.
The affected skin has a very sharp, raised border. It is bright red, firm and swollen.



https://en.wikipedia.org/wiki/Erysipelas

- ***Erythema, well define and sign of inflammation***
- ***Most often in face and common in lower limbs***

Treatment

- ***Bed rest, elevate limbs, cold pack***
- ***Oral or Intravenous penicillin is the antibiotic of first choice.***
- ***Pencillin V 500 mg qid x -10 days***
- ***Erythromycin 500 mg qid x 10-14 days***
- ***Dicloxacillin 500 mg qid for 10 days or***
- ***Allergy to penicillin – Ceftriazone or cefazolin.***

5. Erysipeloid

Acute infection of skin and soft tissue caused by *Erysipelothrix rhusiopathiae.*
Local pain, itching, burning and swelling usually on fingers or hand. It has clearly defined bright red to purple lesions with smooth, shiny surfaces.
Lesions may be warm and tender and cause pain or burning.

A purplish red plaque, with demarcated raised borders
Contact with poultry, fish, crab or pig.

Treatment

- ***Penicillin V 250 - 500 mg qid for 2 weeks.***
- ***Cephalexin 250 - 500 mg qid for 5-10 days***

6. Folliculitis

An inflammation of the hair follicle, caused by *staphylococcus*. Folliculitis can be due to infection, occlusion (blockage) or irritation. Deep folliculitis is called furunculosis which healed with scarring.
KOH examination to exclude the fungal infection



https://www.bajajfinservmarkets.in/insurance/health-insurance/health-problems/folloculitis.html

Treatment

- ***2% mupirocin ointment for 7 days***
- ***Dicloxacillin 250 mg qid for 5-10 days or***
- ***Flumox 250 mg tds for 5-7 days***
- ***Cephalexin 250 mg qid for 5-10 days or***
- ***Pityrosporum folliculitis - Clotrimazole cream***

7. Pseudofolliculitis (Pseudofolliculitis barbae)

Razer bumps, ingrowth hairs.
Is popular and pustular foreign body inflammatory reaction that can affect hair who shaves closely on a regular basis



https://www.pinterest.com/pin/137289488747443750/

Treatment

- ***Imbedded hair shaft must be dislodged.***
- ***Shaving must be discontinued until inflammation is under control***
- ***Topical clindamycin ointment***
- ***Dicloxacillin 500-1000 mg qid for 7days or***
- ***Cephalexin 250-500 mg qid for 5-10 days***
- ***Intralesional triamcinolone acetonide 2.5 mg /ml for persist papule***
- ***Avoidance of close shaving***
- ***A moisturizing lotion /gel (Aveeno) after shaving***

8. Furuncles (boil)



https://www.vinmec.com/en/oncology-radiotherapy/health-news/boils-on-thighs-what-you-ar-need-to-know/

A boil is a deep form of bacterial folliculitis (infection of a hair follicle).
Boil is a walled off, deep and painful, firm or fluctuant mass enclosing a collection of pus.
It evolves from a superficial folliculitis. It is caused by *Staph, Ecoli,* Pseudomonus, Strept.

Treatment

- ***Warm, moist dressing are applied to the lesion***
- ***Antiseptic or antibiotic ointment***
- ***Incision and drain***
- ***Dicloxacillin 250 mg qid for 5-10 days or***
- ***Cephalexin 250 mg qid for 5-10 days or***
- ***Augmentin 875 mg bd for 10 days or***
- ***Clindamycin 150 - 300 mg tds for 10 days***

9. Carbuncle

A carbuncle is a cluster of boils that form a connected area of infection.
It is also an extensive infection of a group of contagious follicles caused by *Staphyloccous.* Carbuncles cause a deeper and more severe infection and more likely to cause scars.
Predisposing factor - DM, prolong steroid therapy, malnutrition, generalized dermatosis



https://www.vinmec.com/en/oncology-radiotherapy/health-news/boils-on-thighs-what-

Treatment

- ***Warm, moist dressing are applied to the lesion***
- ***Incision and drainage***
- ***Dicloxacillin 250 mg qid for 5-10 days or***
- ***Flumox 250 mg tds for 5-7 days or***
- ***Cephalexin 250 mg qid for 5-10 days or***
- ***Augmentin 875 mg bd for 10 days or***
- ***Clindamycin 150-300 mg tds for 7days***

10. Staphylococcal Scalded Skin Syndrome (Ritter's Disease)

It is a serious skin infection caused by exotoxin of *Staphyloccous aureus* GP 2, Type 71 and 55.
The exfoliative toxin that causes the outer layer of skin to blister and peel.
Most common in neonate during first 3 months. It is rare. It can be serious and painful, but It is usually not deadly.
Early erythematous areas are very tender
Localized form - bullous impetigo
Generalized form - exfoliation toxin induced changes

Nikolsky sign positive, acantholysis
Tender red skin, denuded skin
No scarring after



https://www.pcds.org.uk/clinical-guidance/staphylococcal-scalded-skin-syndrome

Complication

Cellulitis, pneumonia

Treatment

- ***Bacitracin or silver sulphadiazine***
- ***Refer to hospital for systemic antibiotics***
- ***Antibiotics - i.v. flucloxacillin, or i.v. clindamycin***

11. Toxic Shock Syndrome

Toxic shock syndrome is a rare but life-threatening condition caused by toxin producing bacteria such as Staphylococcus aureus and Group *A Streptococcus (GAS).*
It can affect anyone.
It is a multisystem disease caused by an exotoxin produced most often by S. *Aureus.* Staphylococcal TSS and Streptococcal TSS
Rapid onset of fever and hypotension
Skin finding - early - generalized skin and mucosa erythema
Late - desquamation in early convalescence
Organ hypo-perfusion and multisystem failure



https://emedicine.medscape.com/article/169177-clinical

Treatment

- ***Refer to hospital for systemic antibiotics***
- ***Supportive***

12. Scarlet Fever

- It is a bacterial illness mainly affects children.
- It is caused by ***Group A Streptococcus (GAS)***
- The first sign of scarlet fever can be flu like symptoms including high temperature, sore throat and swollen neck glands.
- A rash appears 12 - 48 hours later. It looks like small, raised bumps and starts on the chest and tummy, then spread.
- The rash makes the skin feel rough, like sand paper.
- A white coating appears on the tongue. The peel, leaving the tongue red, swollen and covered in little bumps called strawberry tongue.
- Severe infection – toxin production causes streptococcus



https://www.gponline.com/management-scarlet-fever-paediatric-medicine/paediatrics/article/1087062

Treatment

- ***Antibiotics (oral amoxicillin for 10 days)***
- ***Alternative – Erythromycin or cephalexin)***
- ***Supportive – antihistamine, calamine lotion***

13. Cutaneous Anthrax



https://acpinternist.org/archives/2018/02mksap-quiz-5-day-historv-of-a-lesion-html

- Caused by Bacillus anthracis
- Zoonosis, Toxin mediated, can occur anywhere.
- A group of small blisters or bumps that may itch
- Black eschar surrounded by edema and purple vesicles
- A painless skin sore (ulcer), blackened, necrotic eschar and may
- or may not present regional lymphadenopathy

Treatment

- ***Doxycycline 100 mg bd or ciprofloxacin 500 mg bd for 8 weeks***

14. Meningococcal Infection



https://www.meningitisnow.org/meningitis-explained/signs-and-symptoms/glass-

- Caused by Neisseria meningitides
- Commonly carried in the nasopharynx
- Release of endotoxin
- **Medical Emergency** - Seek medical attention immediately If the child develops symptoms of meningococcal disease.
- **Two common types** – meningitis and septicemia
- Fever, chills, nausea, headache, neck stiffness, vomiting, myalgias, stupor, confusion hemorrhagic lesion, hypotension, meningitis
- Early exanthem- pink papules/macules (Maculopapular rash) distributed on trunk, lower limbs and mucus membrane, petichae may coalesce into haemorrhagic bullae or undergo necrosis and ulcerate.
- Later lesions - petechiae appear center of macules, lesion become meningococcemia and meningitis.
- Fulminant meningococcaemia infection can cause septicaemia and death within hours of the first symptoms
- Most common cutaneous sign of meningococcal disease is localized acral purpura. The typical meningococcal rash doesn't disappear when pressure, this is known as a **blanching rash.**
- The **meningitis glass test** – the rash does not fade under pressure



https://www.meningitisnow.org/fight-for-now/wtf-meningitis/ identifying-disease/meningitis-rash/

Complication

- Intercurrent infection
- CNS damage, necrosis of skin
- Arthritis, pneumonia
- Sinusitis, urethritis
- Endocarditis, pericarditis, Chronic Meningococcemia Case fatality rate – 20 - 40%

Treatment

- ***Acute meningococcemia - Cefotaxime 2 gm iv 8 hourly or***
- ***Pen G 4 million U iv 4 hourly***
- ***Refer***

Prophylaxis

- ***Ciprofloxacilin 500mg single dose, or injection ceftriaxone.***

15. Pseudomonas Folliculitis

- Caused by **Pseudomonas**, gram negative bacterial infection of hair follicles
- Hot tub folliculitis or spa pool folliculitis
- Sudden eruption of scattered red macules that evolve into papules and pustules centred on hair follicle.



https://www.medicalnewstoday.com/articles/324721#gallary-open

Treatment

- ***Antiseptic cleanser – e.g., Hydrogen peroxide***
- ***Topical Antibiotics – Mupirocin or erythromycin cream***
- ***Wet dressing of acetic acid 5% is applied for 20 min bd or silver sulfadiazine cream***
- ***Oral Antibiotics – Ciprofloxacin 500 mg bd for 7-10 days***
- ***Dicloxacillin 250 mg qid for 7-10 days***
- ***Cephalexin 500 mg bd 10 days***

16. Necrotizing Soft Tissue Infection

- Rapid progression of infection with extensive necrosis of subcutaneous tissue and overlying skins.
- It is **serious life-threatening** condition, can destroy skin, muscle and soft tissue.
- Severe spontaneous pain, indurated edema, bullae, cyanosis, skin pallor, absence lymphangitis, skin hyperesthesia
- May associated with toxic shock syndrome



http://faoj.org/2008/04/01/necrotizing-soft-tissue-infection-of-the-foot-a-case-report/

Management

- ***Refer to hospital***

17. Lymphangitis

An acute inflammatory process involving the subcutaneous lymphatic channel by infection.

- Acute - Most often due to GAS and Staphylococcus aureus
- Red linear streaks and palpable lymphatic cords



https://www.sciencephoto.com/keyword/lymphangitis

Treatment

- ***2% mupirocin ointment or bactroban 3 time for 10 days***
- ***Dicloxacillin 250 mg qid for 5-10 days or***
- ***Flumox 250 mg tds for 5-7 days or***
- ***Cephalexin 250 mg qid for 5-10 days or***
- ***Azithromycin 500 mg on day 1, 250 mg on day 2 to day5.***
- ***Clindamycin 300mg tds 5-7 days***

18. Erythrasma

Overgrowth of *Corynebacterium minutissimum* in the honey layer of epidermis



https://healthjade.net/erythrasma/

- Asymptomatic infection
- Intertriginous areas of web spaces of feet, groins, axillae, sub-mammary areas
- Well demarcated red or tan patches with fine scales
- Distinguish from dermatophytosis and non-infectious intertrigo.
- Wood lamp examination shows coral red fluorescence.

Treatment

- ***2.5% Benzoyl peroxide gel daily for 7 days***
- ***Fusidic acid cream***
- ***Topical erythromycin or clindamycin bd for 7 days***
- ***Tetracycline 250 mg qid for 7 days or***
- ***Doxycycline 100 mg bd for 7 days***
- ***Topical miconazole cream***

19. Pitted Keratolysis

- Caused by Kytococus sedentarius, Dermatophilus Congolensis and Corynebacterium spp
- Planter feet, web-space feet
- Defects in thickly keratinized skin,
- Have small holes in the top layer of skin
- With eroded pIt of variable depth
- Itchiness and smelly feet
- Hyperhidrosis –excessive sweating of feet
- Maceration
- Pain and itching while walking



https://www.medicalnewstoday.com/articles/326911

Treatment

- ***2.5% Benzoyl peroxide gel daily for 7 days***
- ***Fusidic acid cream***
- ***Topical erythromycin or clindamycin bd for 7 days***
- ***Topical miconazole cream***
- ***Tetracycline 250 mg qid for 7 days or***
- ***Doxycycline 100 mg bd for 7 days***

20. Nonspecific Intertrigo

- Non-specific inflammation of opposed skin (Infra-mammary regions, axillae, groins, gluteal folds, redundant skin fold of obese individual.
- Clinical feature
- Erythema ± symptoms of pruritus, tenderness or increased sensitivity, excluding infectious causes.
- Rule out infectious intertrigo; bacterial or fungi and dermatoses

Treatment

- ***Zinc oxide ointment***
- ***Antifungal (e.g., clotrimazole powder) or antibacterial powders***

21. Lyme Disease

It is vector borne illness caused by infection with the spirochaetes of *Borrelia burgdorferi* and transmitted by the bite of genus *Ixodesscapularis* and related ticks.



https://healingartsvalpo.com/lyme-disease-and-tick-borne-illness/ https://www.nejm.org/doi/full/10.1056/NEJMp1915891

- Occur in the forest area
- Start with Flu like symptoms
- A small erythematous macules or papule appear at the site of bite, annular lesion with central clearing or a roundish smooth erythematous patch look like a bull's eye with circles around the middle.
- Erythema migrans is an early sign of localized disease.
- The rash usually resolves in days to weeks, but may persist for years.
- Symptoms such as a rash, fever, headache and fatigue
- Disseminated lyme - AV block, rheumatological and neurological manifestation

Treatment

- ***Doxycycline 100 mg bd for 21 days***
- ***Amoxicillin or cefuroxime for pregnant woman and children.***

22.Scrub Typhus



Scrub typhus, also known as bush typhus, is an acute, febrile, infectious illness disease caused by a bacteria called *Orientia tsutsugamushi***.**

Scrub typhus is **spread to people through bites of infected chiggers** (larval mites). The most common symptoms include fever, headache, body aches, and sometimes rash

Symptoms of scrub typhus usually **begin** within 10 days of being bitten. Signs and symptoms may include:

- Fever and chills
- Headache
- Body aches and muscle pain
- **A dark, scab-like region at the site of the chigger bite**
- (also known as **eschar**)
- Mental changes, ranging from confusion to coma
- Enlarged lymph nodes
- Rash
- People with severe illness may develop organ failure and bleeding,
- which can be fatal If left untreated.
- Scrub typhus lasts for 14 to 21 days without treatment.

Treatment

- ***Doxycycline (100 mg orally or intravenously twice daily) is the drug of choice for this illness.***
- ***Azithromycin has been advocated as an alternative agent.***

23. Acute Rheumatic Fever

- Acute rheumatic fever (ARF) is caused by a reaction to a bacterial infection with particular strains of group **A streptococcus.** ARF only follows streptococcal pharyngitis (sore throat).
- It usually affects children aged 5–15 years.



https://www.orthobullets.combasic-science9045acute-rheumatic-fever.jpg

- Fever
- Abdominal pain
- Muscle aches
- Polyarthritis (multiple inflamed joints)
- Carditis (inflammation of the heart)
- Sydenham chorea
- Erythema marginatum rheumaticum – This is a characteristic type of annular erythema that occurs in about 10% of first attacks of ARF in children.
- The rash appears as pink or red macules (flat spots) or papules (small lumps), which spread outwards in a circular shape
- Subcutaneous nodules (small lumps under the skin)

Treatment

- ***Oral Penicillin V 250 mg tds for 10 days for acute fever***
- ***Clindamycin 20 mg/kg/day for 3 divided dose for 10 days (If sensitive to Pen)***
- ***Azithromycin 12 mg /kg/day for 5 days (If sensitive to Pen)***
- ***Continuous Penicillin (Inj; Benzathine Pen G every 4 weeks for 10 years) is recommended for established rheumatic heart disease.***

4. VIRAL INFECTION OF SKINS

1. Molluscum Contagiosum



https://step2.medbullets.com/dermatology/120053/molluscum-contagiosum

- caused by Molluscum contagiosum virus
- Self-limited epidermal viral infection.
- Risk group include children, sexually active adult, immunocompromised, HIV|AIDS
- Presents as localized clusters of small rounded bumps (papules) especially in armpit, groin or behind knees
- Size from 1- 6 mm and may be white, pink or brown, often a waxy, pinkish look with a small **central pIt or umbilicated.**
- Spread skin to skin, sex is possible in adult
- Papules from row is known as koebnerized molluscum
- Direct microscopic exam; Giemsa stain - central semisolid core reveals molluscum bodies (Inclusion body)

Treatment

- ***No specific treatment is necessary. Untreated lesions resolve spontaneously after 12- 18 months.***
- ***Soft white core can be squeezed out***
- ***Antiseptics such as hydrogen peroxide cream or povidone iodine solution***
- ***Cryotherapy, Minor surgery, Curettage***
- ***5% Imiquimod cream at bed time x 3-5 times x 1-3 months***
- ***Wart paints containing salicylic acid or phodophyllin***

2. Herpes *Simplex* (Cold sores, Fever Blisters)



https://stamfordskin.com/en/news/76085-2/
https:/ /newsnetwork.mayoclinic.org/discussion/mayo-clinic-q-and-a-direct-contact-with-cold-s

- It is caused by double strand **DNA herpes simplex virus.**
- Type 1 is associated with vesicular ulcerative oral and facial lesions and type 2 is the genital and rectal infection.
- Primary infection - after the established in the nerve ganglion
- Secondary infection -recurrent disease at the same site
- Can spread by respiratory droplets, direct contact with an active lesion or virus containing fluid such as saliva or cervical secretions
- 3-7 days after the contact
- **Recurrent** – Type 1 (HSV-1) can occur any site mostly on face and lips.
- Type 2 (HSV-2) can occur any site mostly effect on genital area.
- Clinical diagnosis is enough. If there is clinical doubt, do lab. Test.

Laboratory

- Tzanck smear from base of the vesicle, characteristic - multinucleated giant cells
- Rapid Direct Florescent Antibody test
- PCR detect HSR DNA.
- Serology can perform for type 1 or 2.

Types

- Herpes simplex labialis is most common
- Herpetic whitlow (the finger tip)
- Herpes gladiatorum (athletes, wrestlers)

Treatment

- ***Symptomatic relief e.g., analgesic mouthwashes e.g., benzydamine***
- ***If seen less than 48hours after onset, oral antivirals acyclovir 200 mg five times per day for 5 days. (or)***
- ***Valaciclovir — 500 mg twice daily for five days (or)***
- ***Famciclovir — as a single dose of 3 x 500 mg***
- ***Recurrent - 5% acyclovir 200 mg five times per day for 5 days If needed.***

3. Eczema Herpeticum (Kaposi's Varicelliform Eruption)

- Associated with Atopic Dermatitis, HSV or Darier disease commonly seen in infants and children with atopic dermatitis.
- Most of the cases are due to **HSV type 1 and 2**
- Is a disseminated viral infection characterized by fever and clusters of itchy blister or punched-out erosions.
- Most cases, primary infection is herpes infection, this infection can spread rapidly over wide areas, may be camouflaged and heralded
- More common on corticosteroid treated skin
- Eczema herpeticum is also called Kaposi varicelliform eruption
- Lesions heal over 2-6 weeks.
- Can be diagnosed clinically with atopic dermatitis history.



https://perridermatology.com/viruses-eczema-herpeticum/

Treatment

- ***Tetracaine (Cepacol Viractin) cream 1.8% can reduce the healing time of recurrent herpes labialis lesions by two days***
- ***Abreva (Docosanol) also reduce the healing time herpes labialis lesions***
- ***Topical acyclovir is not approved for use in core sore of immunocompetent patient***
- ***Wet dressing with cold water decreases erythema***
- ***Antibiotics for secondary bacterial infection.***
- ***Consult an ophthalmologist when eye or eyelid involvement is suspected.***
- ***Oral therapy is most effective when administered within 48 hours of the onset of sign***
- ***Acyclovir***
- ***Initial episode 200 mg 5 time for 7-10 days (or)***
- ***Acyclovir 400 - 800 mg 3 time for 7-10 days***
- ***Suppressive therapy, 400 mg bd for 1 year***
- ***Fanciclovir***
- ***Initial episode - 250 mg 3 time for 7-10 days***
- ***Recurrent, 125 mg bd for 5 days***
- ***Suppressive therapy, 250 mg bd for 1 year OR***
- ***Valacyclovir***
- ***Initial episode - 1000 mg bd for 7-10 days***
- ***Recurrent, 500 mg bd for 3 days***
- ***Suppressive therapy, 100 mg of for 1 year***

4. Varicella (Chicken Pox)

- A highly contagious infection caused by the **Varicella Zoster** virus and results in lifelong immunity.
- Primary infection is caused by varicella zoster virus and sometime
- called human herpes virus type 3.
- Incubation period is 14-16 days
- The virus can be spread from person to person by direct contact,
- inhalation of aerosols from vesicular fluid of skin lesions of acute varicella or zoster, and possibly through infected respiratory secretions that also may be aerosolized
- Lesions are centripetal
- Patients are contagious from 2 days before the onset of the rash until all lesions have crusted.
- There is simultaneous presence of lesions (Vesicles, Pustules and crusts) in all stages
- The rash begins on the trunk and spreads to the face and
- extremities
- Crusts fall off in about 7 days and usually heal without scarring.
- Pneumonia is most common complication.
- Hepatitis is most common complication in immunocompromised patients.
- Bacterial superinfection with staphylococcus or streptococcus
- Ataxia, thrombocytopenia, associate with Reye syndrome, ocular involvement.
- Maternal infection during the first 20 weeks of gestation poses the Foetal Congenital Varicella Syndrome is 2%.



https://en.wikipedia.org/wiki/Chickenpox



https://www.clinicaladvisor.com/slideshow/slides/varicella-zoster-virus/

- The blisters clear up within one to three weeks but may leave a few scars. These are most often depressed (anetoderma), but they may be thickened (hypertrophic scars).
- Scarring is prominent when the lesions get infected with bacteria
- Vaccination is available for chickenpox and is highly recommended.

Treatment

- ***Oral antihistamine and calamine lotion may help control excoriation***
- ***Use bland anti-pruritus lotion***
- ***Recommended that certain group at increased risk for moderate to severe varicella be considered for oral acyclovir or valacyclovir treatment.***
- ***These high-risk groups include:***
- ***Healthy people older than 12 years of age***
- ***People with chronic cutaneous or pulmonary disorders***
- ***People receiving long-term salicylate therapy***
- ***People receiving short, intermittent, or aerosolized courses of corticosteroids***
- ***For maximum benefit, oral acyclovir or valacyclovir therapy should be given within the first 24 hours after the varicella rash starts.***
- ***Acyclovir (Oral)***
- ***> 40 kg 800 mg 4 times for 5 days***
- ***< 40 kg 20 mg /kg per dose 4 times for 5 days***
- ***Intravenous route for severe disease (e.g., disseminated VZV such as pneumonia, encephalitis, thrombocytopenia, severe hepatitis) and for varicella in immunocompromised patients.***

- ***Adult 20 mg /kg x divided by 3 dose for 5 -7 days***
- ***Children,>2 years 10 mg/kg/day for 3 time for 7-10 days***

5. Herpes Zoster (Shingles)

- **Herpes Zoster** is a localised, blistering and painful rash of acute dermatomal infection associated with reactivation of **Herpes Zoster** virus or varicella virus.
- Following primary infection or vaccination VZV remains latent in the sensory dorsal root ganglion cells. The virus begins to replicate at some later time, when immunity to VZV decline, travelling down the sensory nerves into the skin.
- Affected on Thoracic region 55%, Cranial - 20%, Lumbar region- 15%, Sacral - 5%
- The first sign of herpes zoster is usually localised pain without tenderness or any visible skin change.
- Within one to three days of the onset of pain, a blistering rash appears in the painful area of skin. It starts as a crop of red papules. New lesions continue to erupt for several days within the distribution of the affected nerve,
- 3 clinical stage - Prodromal, Active infection, chronic (post herpatic neuralgia)
- Prodromal stage - neuropathic pain or paresthesia precedes for 2-3 weeks
- Acute vesiculation - 3-5 days
- Crust formation days - 2-3 weeks
- Post herpetic neuralgia -persistence or recurrence of pain more than a month after the onset of shingles
- Chronic or Post-herpetic neuralgia phase pain is burning or ice-burning or shooting
- The first sign is pain, which may be severe, patient feels quite unwell with fever and headache. Lymph node often may enlarge
- Within 1-3 days of onset of fever, blistering rash appears in the painful area.



https://www.msdmanuals.com/home/multimedia/image/shingles-rash-on-the-chest



https://www.hmpgloballearningnetwork.com/site/thederm/feature-story/treating-zoster-associated-pain-and-postherpetic-neuralgia

- It starts as a crop of closely grouped red bumps in a continuous and on the area of skin.
- Facial nerve palsy is most common
- In uncomplicated cases, recovery is complete within 2–3 weeks in children and young adults, and within 3–4 weeks in older patients.

Ophthalmic Zoster

- Involvement of any branch of the ophthalmic nerve is called herpes zoster ophthalmicus with zoster ophthalmic nerve, the rash extends from eye level to the vertex of the skull but does not cross the midline.
- Vesicles on the side or tip of the nose (Hutchinson's sign) are associated with most serious complication.
- Ramsay Hunt syndrome (herpes zoster oticus) occurs when a shingles outbreak affects the facial nerve near one of the ears. The two main signs and symptoms of Ramsay Hunt syndrome are: A painful red rash with fluid-filled blisters on, in and around one ear and facial weakness or paralysis on the same side as the affected ear

Investigation



https://www.aao.org/eyenet/article/herpes-zoster-ophthalmicus-pearls

- Tzank smear - nonspecific for HSV and VZV - formation of multinucleated giant cells to confirm diagnosis.
- Test is rapid but accuracy rate 60-90%, False positive rate 3-13%
- Direct Fluorescent Antibody method - more accurate
- Viral culture, more difficult for HSV
- PCR most reliable method, more sensitive than Viral culture
- ELISA can test specific infection of HSV 1, HSV2 and VZV

Treatment

Goal of treatment

- ***Relieve constitutional symptoms,***
- ***Minimize pain,***
- ***Reduce viral shedding,***
- ***Prevent secondary bacterial infection,***
- ***Speed crusting of lesions and healing***
- ***Ease physical, psychological and emotional discomfort***
- ***Prevent dissemination or other complication***



If seen the lesions less than 48hours after onset,

- ***oral -Acyclovir 800 mg po 4 times daily for 7-10 days (or)***
- ***Valacyclovir 1000 mg tds for 7 days (or)***
- ***Famciclovir 500 mg 3times daily for 7 days (or)***
- ***Acyclovir resistant VZV - Foscamet***

Immunosuppressed patient – iv acyclovir and recombinant interferon alpha 2a to prevent dissemination of HZ

Supportive

- ***Bed rest***
- ***Non-steroidal anti-inflammatory drug***
- ***Suppression of pain -early control of pain is narcotic analgesic***
- ***Gabapentin: 300 mg three times daily***
- ***Tricyclic antidepressants such as sedation - Doxepin 10-100 mg at bed time***
- ***Inflammation and Infection***
- ***Cool tap water wed dressing***
- ***Dressing - application of moist dressing***
- ***Chronic pain - Capsaicin cream 4 hourly***
- ***Topical anesthetic such as EMLA or 5 % lidocaine, or nerve block to area of allodynia***

Prevention

- ***VZV immunization***
- ***Most effective in aged 60-69 years***
- ***HZ in immunocompromised host***
- ***May involve several contiguous dermatomes***
- ***Have more extensive cutaneous necrosis***
- ***Have wide hematogenous dissemination to mucocutaneous structures and viscera***
- ***Symptoms of typical zoster, but the lesions may be more ulcerative, necrotic and may more severe.***

- ***Multidermatosomal zoster***
- ***Visceral dissemination***
- ***Associated with SIADH***
- ***Persistent dermatomal infection, cutaneous or haematogenous***
- ***In HIV/AIDS -acute retinal necrosis - blindness (loss of vision)***

6. Hand, Foot and Mouth Disease (HFMD)

- Usually caused by Coxsackie A 16 virus and other virus Enterovirus 71, CVA6, CVA5, A7
- Oral aphthae like lesion varies, irregularly distributed in oral cavity.
- The vesicle appears on the palms, soles dorsal aspect of fingers and toes, face, buttock and legs.
- Square blisters and small painful ulcers on throat and tonsil.
- Characterized by blisters on the hands, feet and in the mouth and other symptoms like fever, headache, sore throat and runny nose.
- Very infectious and epidermics are most common.
- Most often infects children under age of 10 and most are under 5 years of age.
- Sign and symptoms usually clear up in 7 to 10 days.
- There is no specific treatment. Give symptomatic.



https://www.fvhospital.com/learn-more/hand-foot-and-mouth-disease/
https://story.motherhood.com.my/blog/hfmd-treatments-prevention/
https://www.merckmanuals.com/en-pr/professional/infectious-diseases/enteroviruses/hand-foot-and-mouth-disease-hfmd

7. Erythema infectiosum (Slapped Cheeks)

- Human parvovirus B19 or EVB 19
- Single stranded DNA virus and known as fifth disease
- Droplet aerosal
- Is a common childhood infection causing edematous erythematous plaques on the cheeks (slapped cheeks) and a rash.
- Erythematous lacy eruption on the trunk and extremities
- Erythematous macules with ring formation on the upper arm. Mostly
- mild childhood infection.



http://www.yogavanahill.com/slap-cheek

Treatment

- ***Symptomatic***

8. Gianotti-Crosti Syndrome

- Also called papular acrodermatitis or infantile papular acrodermatitis or acrodermatitis papulose infantum. It is a rare skin disease.

Causal agents are -

- ***Virus - EBV, CMV, HBV, HCV, HAV, HIV, Rota Virus,***
- ***Adenovirus, Poliovirus, Poxvirus***
- ***Bacteria - Mycoplasma pneumonia, Borrelia burgdorferi***
- ***Vaccine - Influenza, Tetanus, Diphtheria***
- ***6 months to 12 years***
- ***Exanthem- discrete, non-pruritus, erythematous, monomorphic papules***
- ***Usually found on face, buttocks, arms or leg. The blisters consist of large, flat-topped, fluid filled sacks.***
- ***The rash resolves over several weeks. The rash is self-limiting.***

Treatment

- ***Symptomatic***





https://www.pcds.org.uk/clinical-guidance/gianotti-crosti-syndrome-syn-papular-acrodermatitis-of-childhood

9. Human Papilloma Virus Infection

- Also called WARTS.
- HPV - DNA virus
- Subtype 150
- Local spread by autoinoculation
- Transmission by contact
- Type of warts
- Common warts - HPV 2,4,7
- Planter warts - HPV 1,4 (Verrucas)
- Genital Warts - HPV-1,2,6,10.11.16.18.31. 32.33.34
- Genital Human Papilloma Virus subtype 16, 18 and 31 are risk subtypes
- account for 75% of invasive Ca
- Butcher's wart - common in butchers, meat packers and fish handlers
- Mucosal wart – condyloma acuminatum (Genital warts)



https://www.healthline.com/health/skin/wart



https://quizlet.com/553146266/27-human-pa

- Flesh colour papules evolve into dome shaped, gray to brown, hyperkeratotic discrete and rough papules, often with black dots on the surface
- Black dots are thrombosed capillaries
- Common site are hands, periungual skin, elbows, knees and planter surface
- Filiform warts are growths with finger like fresh colour projections
- Common warts (Verruca Vulgaris)
- Firm papules, red or brown dots
- Linear arrangement
- Annular warts
- Planter warts- Kissing warts, Verruca plana



http://medwarts.com/warts-on-face-all-possible-locations-their-causes-and-effective-treatment/

https://www.aafp.org/pubs/afp/issues/2014/0901/p312.html

Treatment

- ***Small lesion -10-20% salicylic acid and lactic acid in collodion***
- ***Large lesion - 40% salicylic acid plaster for 1 week, then application of salicylic acid and lactic acid in collodion***
- ***Podophyllin –apply once a day for 3 days a week for 2 weeks***
- ***5% Imiquimod cream-3 time per week for 6-12 weeks***
- ***Cryosurgery***
- ***Electrosurgery (curettage and cautery)***
- ***Ablative laser***
- ***Surgery***
- ***Vaccine against HPV are available to prevent anogenital warts.***

10. Rubella (German measles)

- Rubella virus, an RNA togavirus
- A viral infection of children and adult
- Characteristic exanthema and lymphadenopathy and fever
- Pink papule, macules initially on forehead, spreading to face, trunk and extremities.
- By second day, facial exanthems fade. By third day, exanthems fade complete without residual pigmentary changes.
- Infection to pregnant mother may result in the congenital rubella syndrome with serious chronic fatal infection and malformation.
- Characters of childhood congenital rubella syndrome are congenital heart defects, cataracts, microphthalmia, microcephaly, hydrocephaly and deafness.
- Rubella is part of TORCH complex.
- Childhood immunization is highly effective for prevention of infection.
- MMR vaccine among preschool children
- There is no specific treatment.



https://www.nhs.uk/conditions/rubella/



https://www.nhs.uk/conditions/rubella/

11. Measles

- Caused by measles virus, RNA virus. It is a notifiable disease.
- Droplet aerosol. I.P is 7 – 14 days.
- A highly contagious childhood viral infection, characterized by fever, coryza cough, an exanthema, conjunctivitis, koplik spots.
- Fever, malaise, upper respiratory tract infection, photophobia, conjunctivitis.
- On fourth febrile day, erythematous macules and papules appear on the forehead at hairline, behind ears, spread centrifugally and inferiorly to involve the face and trunk, extremities, palm and sore reaching the feet by third day. Initial lesions become confluent on face, neck and shoulder.
- Lesions gradually fade in order of appearance and exanthema resolves in 4-6 days.
- There is no specific treatment for measles. Supportive and symptomatic.
- MMR vaccine among preschool children



httpswww.cdc.govmeaslessymptomsphotos.html

12. DHF

- Flavivirus infection (DENV 1- 4)
- Transmitted by bite of Aedes mosquito. I.P 4 -10 days
- Classical fever- arthralgia-rash syndrome with abrupt onset of fever and muscle and joint pain usually with retro-orbital pain, photophobia and lymphadenopathy.
- DHF characterized by high fever, haemorrhagic phenomena and often hepatomegaly.
- DSS with circulatory failure, can be fatal.
- Initial rash 1-2 days after onset of symptoms, erythema/flashing of face, neck and chest. Later rash 4-7 days after onset of symptoms; morbiliform eruption beginning on trunk, spreading to extremities and face in uncomplicated dengue, lasting for 1-5 days, petichiae, island of sparing (White islands in sea of red).
- Mucosal lesions- conjunctival, epistasis, bleeding gums, nose, GI tract.

Dengue fever with warning signs:

- Abdominal pain or tenderness
- Persisting vomiting
- Mucosal bleeding (from nose and gum)
- Lethargy (somnolence or restlessness) Hepatomegaly
- Increase haematocrIt (a feature of fluid loss)
- Thrombocytopenia (low platelet count)
- Pleural or peritoneal effusion (fluid in the lining of the lungs or abdominal organs)



https://www.bansalglobalhospital.com/dengue-hemorrhagic-fever-sign-and-causes/

Severe dengue

- Dengue fever plus at least one of the following
- Kidney failure
- Acute pulmonary oedema
- Shock feature
- Severe bleeding

- Heart failure AST or ALT > 1000 IU
- Altered consciousness level

Diagnosis

- The presence of IgM against dengue virus (IgM is an antibody produce in acute infection)
- The increase in IgG titres against dengue virus in two different blood samples.(IgG is an antibody produced when the person has been infected before.)

Treatment

- ***Symptomatic***

13. Monkey Pox

- Monkeypox is a rare disease that is caused by infection with monkeypox virus. Monkeypox virus belongs to the *Orthopoxvirus* genus in the family *Poxviridae*.
- The natural reservoir of monkeypox remains unknown.
- The symptoms of monkeypox are similar to but milder than the symptoms of smallpox.
- Monkeypox begins with fever, headache, muscle aches, and exhaustion, swollen lymph nodes and chills.
- Incubation Period is 7−14 days, range from 5−21 days.
- Virus can spread in direct contact with the virus from an infected animal, infected person, or materials contaminated with the virus.
- The virus can also cross the placenta from the mother to her fetus.
- It also can be spread by respiratory secretions during prolonged, face-to-face contact.
- Monkeypox virus have a mild, self-limiting disease course in the absence of specific therapy.
- The illness typically lasts for 2−4 weeks.
- People with severe disease (e.g., hemorrhagic disease, confluent lesions, sepsis, encephalitis, or other conditions required hospitalization)

https://island.lk/us-cdc-suspects-monkeypox-virus-to-be-airborne-advises-public-to-wear-masks/

Antiviral Medication

- ***Tecovirimat (also known as TPOXX)***
- ***Cidofovir (also known as Vistide)***
- ***Brincidofovir (also known as Tembexa)***

Prevention

- ***Avoid contact with animals that could harbor the virus (including animals that are sick or that have been found dead in areas where monkeypox occurs).***
- ***Avoid contact with any materials, such as bedding, that has been in contact with a sick animal.***
- ***Isolate infected patients from others who could be at risk for infection.***
- ***Practice good hand hygiene after contact with infected animals or humans.***
- ***E.g., washing your hands with soap and water or using an alcohol-based hand sanitizer.***
- ***Use personal protective equipment (PPE) when caring for patients.***

5. ARTHROPOD INSECT BITES AND CUTANEOUS INFECTIONS

1. Scabies

Is a parasitic infestation of the skin caused by mite Sarcoptes scabiei
Intensely pruritic eruption and may be the seven years itch.
Skin to skin contact; fomites



https://my.clevelandclinic.org/health/diseases/4567-scabies



https://step2.medbullets.com/dermatology/120061/scabies



https://www.cmaj.ca/content/181/5/289



Manifestation

Generalized intractable pruritus especially at night and a pimple like (popular) itch rash is most common symptom.
Often minimal cutaneous finding. Burrows under stratum corneum, scabetic nodule, eczematous dermatitis
Burrows found in finger webs, wrists, side of the hands and feet, lateral fingers and toes and genitalia including gland penis, buttocks and scortum.
Scabies rash cause little bumps that often form a line. The bumps look like hives, tiny bites, knots under the skin, or pimple.
Scratching the itchy rash can cause sores. Crusts form in severe type.
A common sign of crusted scabies is widespread crusts on the skin.
Crusted form scabies is called Norwegian scabies.

Classical scabies

a dozen of female mite but crusted scabies or Norwegian scabies- > 1 million mites may be present or up to 4700 mites/g skin, associated with HIV/AIDS.
Nodular scabies develops in 7-10 % of patient
Pruritus is Id or Auto sensitization type reaction.
Mineral oil applied to burrow, vesicles and papules to preserve the mite feces.

Investigation

by KOH and Heat, and Ink test

Treatment

- ***Antihistamine to control itch***
- ***5% Permethrin cream applied to all areas of the body from the body from neck to down.***
- ***Wash after 8-12 hour after application.***
- ***10% and 25% Benzyl benzoate lotion- swabbing only once; two applications separated by 10 min or two applications with a 24 hour***
- ***Benzyl benzoate with sulfiram***
- ***0.5% Malathion lotion is used If permethrin is ineffective***

- ***10% Crotamiton cream applied thinly to the entire body***
- ***Lindanel % (gumma benzene hexachloride) lotion is effective m most area but resistance reported and Seizures and Aplastic anaemia had reported. Lindane should be avoided because of CNS toxicity.***
- ***Systemic - Ivermectin - (Stromectol 6 mg scored tablets) 200µg /kg PO single dose, two to three doses separated by 1-2 weeks usually required for heavy infection or Norwegian Scabies.***
- ***Caution for elderly patients.***
- ***Need to repeat the treatment 1 week later***
- ***Everyone in the home needs to be treated at the same time, even If they do not have symptoms***
- ***Anyone that have had sexual contact with in the 8 weeks should be treated.***
- ***Wash all bedding and clothing in the house on the first day of treatment***
- ***Put the clothing that cannot be washed in a sealed bag for 3 days until the mite die.***
- ***Do not share bedding, clothing or towels with someone with scabies.***

2. Lice (Pediculosis)

- Lice are small wingless insects that infest the hair of the scalp, body and pubic region
- Lice attach to the skin and feed on blood. They lay eggs or nits on hair shafts.
- Head lice- Pediculus capitis
- Body lice – Pediculus corporis
- Pubic lice – Phthirus pubics
- It is highly contagious, direct contact is the primary source of transmission
- Lice have a blood meal every 3-6 hours
- They live for about 1 month
- Female lays 7-10 eggs a day
- Nits are small white eggs firmly cemented to the hair shafts.
- Red-brown spots on the skin are due to excreted digested blood.
- Infestation - mild itch
- Scratching can cause crusting and scale on the scalp.


https://www.marksimonianmd.com/lice

Treatment

- ***Physical methods – comb down the hair shaft towards the scalp.***
- ***NIt combs used in wet hair are effective way.***
- ***The most commonly used for topical insecticides for head lice is 0.5%malathion.***
- ***1% Permethrin rinse, rinse out in 10 min. Additional, 1-2 treatment per week is also required.***
- ***Synergized Permethrin cream and shampoo, 2-3 treatment a week.***
- ***5% Permethrin for treatment failure.***
- ***0.5% Malathion lotion is rapidly pediculicidal and ovicidal, lotion applied for 8-12 hours***
- ***For Head lice -web combing***
- ***Pubic lice - Shaving and Lindane should be applied***
- ***Systemic - Ivermectin - (Stromectol 6 mg scored tablets) 200 µg/Kg PO single. For adult 12 mg as a single dose and can repeated in 10 days.***

3.Cutaneous Larva Migrans (Creeping Eruption)

Is a parasitic skin infection caused by hookworm larvae.

Human can be infested with the larvae by walking barefoot.

Common type of hookworms by *Ancylostoma braziliense*

Clinical features

A non-specific eruption occurs at the site of penetration
A serpiginous red to purple lesion with a 3 mm wide tract
Commonly affected in feet, web spaces, hand, knee and buttocks
Itching to moderate to intense
Worm migrates about 2 cm daily
Loeffler syndrome is a possible complication



https://benthamopen.com/FULLTEXT/TODJ-14-1/FIGURE/F1/
https://www.dermcoll.edu.au/atoz/cutaneous-larva-migrans/

Treatment

- ***Albendazole 400mg I day or 200 mg bd for 3 days***
- ***Ivermectin 200 µg/kg (12 mg) single dose***
- ***Thiabendazole orally 50 mg /kg/d in two divided dose for 2-5 days***
- ***Thiabendazole 15% in liquid or cream applied topically tds for 5 days***
- ***Antihistamine and topical corticosteroids to relief itch.***

Prevention

- ***It is a key and involves avoidance of direct skin contact with faecally contaminated soil.***

6. INSECT BITES AND STINGS

1. Bee and Wasp Stings


https://www.westernexterminator.com/blog/mythbusters-allergic-to-bee-stings-and-wasp-stings/

- Honey bees can cause severe allergic reaction
- Localized or systemic allergic reaction may develop.
- Allergic anaphylactic reaction involved itching, hives, shortness of breath, wheezing, nausea and abdominal cramps. It can occur within minutes to hours.
- Fatal in hypersensitivity person.
- Delayed onset up to one week.
- Multiple stings can cause death. The medium lethal dose of bee venom is 500-1500 stings.

Treatment

- ***For ordinary bee stings that do not cause allergic reaction- need home treatment***
- ***Multiple stings or allergic reaction, can be medical emergency that require immediate treatment.***
- ***Remove the stinger, remove It by scraping over It with fingernail or a piece of gauze.***
- ***Apply Ice and Cold pack***
- ***An antihistamine e.g., Benadryl 25-50 mg Oral or IM***
- ***Severe generalized reactions are treated with Epinephrine (Adrenalin) 1:1000 (0.3-0.5 ml) SC, 20 min interval is needed.***
- ***If hypotensive – IV 1:10000 dilution of epinephrine can used.***
- ***Inj: Adrenalin***
- ***Oxygen***
- ***EpiPen (Bee sting kits -If available)***

2. Flea Bites

- Fleas are tiny red brown hard body's wingless insects but have 3 pairs of leg that are capable of jumping 60 cm.
- Main symptom of flea bite is intense itching
- Red to purpuric papules sometime central blister
- Persistent scratching


https://pestseek.com/how-to-get-rid-of-flea-bites/

Treatment

- ***Oral antihistamine***
- ***Anti-pruritus lotion e.g., Sama***
- ***Mild to moderate steroid cream***
- ***Anaphylaxis has not been reported.***

3. Fire Ant Stings

- Are wingless Hymenoptera species
- Main symptoms are pain, itching, hive, pimples, swelling
- Initially burning and sharp pain occur at the site of sting. A single ant can inflict multiple stings
- A systemic allergic reaction can occur, occasionally resulting death from anaphylactic shock

Clinical features

- Skin finding - two pinpoint red papules (the bite) Surrounded by a ring of pustules (the sting)
- Edema and itching are accompanied by a wheal of 5-10 mm

https://www.pinterest.com.mx/pin/424956914831026465/
https://plasticsurgerykey.com/bites-and-stings-4/

Treatment

- ***Cool wet dressing***
- ***Topical anti-pruritus cream Sama lotion***
- ***1% Hydrocotisone cream***
- ***Pain medication - paracetamol***
- ***Oral antihistamine -Benadryl***
- ***Short course of Prednisolone***
-

7. FUNGAL INFECTIONS

- Dermatophytes infection which include Trichophyton, Epidermophyton and Microsporum species occur 90% fungal infection of hair, nails, and skin.
- Less frequently superficial skin infections are caused by nondermatophyte fungi e.g., Candida species and Malassezia furfur or pityrisporum ovalae, they cause normal skin.
- Deeper chronic cutaneous fungi infections can occur after cutaneous inoculation of Mycetoma, Chromomycosis, and Sporotrichosis species.
- Systemic fungal infection mostly occurred in immunocompromised host.

DERMATOPHYTOSES OF EPIDERMIS

1. Tinea Pedis

- Dermatophytic infection of the feet. It is also called athlete's foot.



https://www.semanticscholar.org/paper/Foot-bacterial-intertrigo-mimicking-interdigital-Lin-Shih/4f9cd9c992931229ffc580f58541e1a28a170d9a
https://www.durbanskindoctor.co.za/services/tinea-pedis-fugal-infections-of-the-foot/,
https://healthjade.net/tinea-pedis/

Causal organism -

Trichophyton rubrum, T. interdigitale and Epidermophy floccosum

Types

(a) ***Interdigital tinea pedis (toe web infection) - dry, scale and fissure, white, macerated and soggy***
(b) ***Chronic scaly infection of the planter surface- often present with dry silvery white scaling surface***
(c) ***Acute vesicular tinea pedis - the burning and itching that accompany the formation of the vesicle***

Clinical finding -

Tinea of feet may present with the classical ringworm pattern nut most infection is found in the toe webs or on the sole.
Itchy erosions and/or scales between the toes, especially between 4th and 5th toes
Scale covering the sole and sides of the feet (hyperkeratotic/moccasin type)
Small to medium-sized blisters, usually affecting the inner aspect of the foot (vesiculobullous type).
uncommonly cause oozing and ulceration between the toes (ulcerative type), or pustules asymmetrical, and may be unilateral
Erythema, scaling, maceration and or bulla formation
Itching is most intense; skin is pink and tender

Laboratory

Diagnosis is mainly by clinically

Potassium hydroxide wet mount (KOH) (10%-20%)

Dermatophyte appears as translucent, branching, rod shape filaments (hyphae) of uniform width with line of separation (septa) spanning with and appearing at irregular intervals.

Treatment

- ***Terbinafine cream or Econazole cream bd for 2- 4 weeks***
- ***For acute or extensive lesions***
- ***Terbinafine250 mg / day for 14 days orally or***
- ***Itraconazole 200 mg / bd for 7days OR 200 mg /day for 14days or***
- ***Fluconazole 150-200 mg l daily for 4-6 weeks***
- ***Antibiotic for bacterial infection and cool wet dressing, sock change***
- ***Patients with the hyperkeratotic variant of tinea pedis may benefIt from the addition of a topical keratolytic cream containing salicylic acid or urea***

Prophylaxis

- ***Daily washing of feet while bathing with benzoyl peroxide or antifungal powder or alcohol gels.***

2. Tinea of the Groin (Tinea Cruris, Jock Itch)

- Subacute or chronic dermatosis of the groin, pubic regions and thighs.
- Always associated with tinea pedis, the source of infection.
- Male > female.
- Itching becomes worse as moisture accumulate.
- Predisposing factors
- warm, humid environment, obesity and steroid therapy.



https://nursingfile.com/nursing-care-plan/ nursing-interventions/ nursing-interventions-for-tinea-cruris .html

Etiology

- *T rubrum, T mentagrophytes.*
- Predisposing factors for tinea cruris include:
- Longstanding tinea pedis
- Previous episodes of tinea cruris
- Occlusive clothing
- Obesity
- Excessive sweating (hyperhidrosis)
- Diabetes mellitus
- Topical steroid use.

Symptoms

- Often bilateral, begins in the crural fold.
- A half -moon shaped plaque forms with well-defined scaling and sometime a vascular border advanced out of the crural fold onto the thigh.
- Ringworm pattern of infection with multiple round superficial plaques with scaling borders.
- The entire surface of the lesions is dry and scaling.

- Acute tinea cruris may present as a moist and exudative rash.
- Chronic tinea cruris presents as a large well-demarcated scaly plaque with a raised border and central clearing.
- Scale is most prominent at the leading edge of the plaque.
- Tinea cruris is usually itchy.
- Involvement of scrotum is unusual. Rarely involve scortum and penis.
- Distribution - groins and thighs may extend to buttock.



Treatment

- General and preventative measures
  - ***Careful toweling after washing to avoid transfer of fungi from the feet***
  - ***Loose fitting clothing***
  - ***Treatment of triggers such as hyperhidrosis or obesity***
  - ***Topical antifungal powder after bathing***
- Specific
  - ***Terbinafine cream or Econazole cream bd for 2-4 week***
  - ***Terbinafine 250 mg / day for 14 days or***
  - ***Itraconazole 200 mg / bd for 7 days or 200 mg /day for 14 days or***
  - ***Fluconazole 150-200 mg l daily for 4-6 weeks***
  - ***Antibiotic for bacterial infection.***
  - ***Absorbent powders help to control moisture and prevention and reinfection.***

3. Tinea of the Body (Tinea Corporis) (Tinea circinata)





- Etiology – T. rubrum most commonly, M canis, T. tonsurans
- Transmission - autoinoculation from other part of the body
- e.g., T. pedis, T. capatis

Skin lesion

- Lesions varying in size, degree of inflammation and depth of involvement.
- There are two general clinical patterns round annular lesions (Classical ring worm and deep inflammatory lesions).

Classical ringworm

- ***Lesions begin as flat, scaly papules which slowly develop a raised border that extends at variable rates in children***
- ***Advancing, scaly border may have red raised papules and vesicles***
- ***The central area becomes brown or hypo pigmented and less scaly***
- ***as active border progress outward***
- ***Red papules may occur in the central area***

- Several annular lesions may enlarge to cover large areas of the body surface
- It is commonly called **'ringworm'** as It presents with characteristic
- ring-shaped lesions.
- Larger lesions tend to be mildly itchy or asymptomatic

Deep inflammatory lesions

- The round, intensely inflamed lesion has a uniformly elevated, red, boggy, pustular surface
- The pustules are follicular and represent deep penetration of fungus into the hair follicle
- Secondary infection can occur such as *Staphylococcus aureus*
- Majocchi's granuloma is a deep fungal infection of the hair follicle, typically occurring on the lower legs, more often in women, shaving and superficial trauma are believed to play a role.
- Tinea corporis initially presents as a solitary circular red patch with a raised scaly leading edge.
- A lesion spreads out from the centre forming a ring-shape with central hypopigmentation and a peripheral scaly red rim (ringworm).
- The border can be papular or pustular.
- Itch is common.

Medical risk factors

- Previous or concurrent tinea infection
- Diabetes mellitus
- Immunodeficiency
- Hyperhidrosis
- Xerosis
- Ichthyosis

Course and prognosis

- With treatment the scale resolves before the erythema fades.
- Post inflammatory depigmentation blends away over several months
- Reinfection is common

Diagnosis

- Diagnosis is mainly by clinically
- Potassium hydroxide wet mount (KOH) (10%-20%) with skin scrapings taken from the scaly lesion edge
- Dermoscopy may assist the clinical diagnosis

Treatment

- ***Antifungal cream - clotrimazole or econazole or miconazole, or Terbinafine cream bd for 2 weeks***
- ***Continue treatment at least one week after resolution of the infection***
- ***Extensive lesions or those with red papules require oral therapy.***
- ***Terbinafine 250 mg /day for 2-4 week or***
- ***Itraconazole 100 mg /day for 15 days***
- ***Fluconazole 150-300 mg /week for 4 weeks***
- ***Antibiotic for bacterial infection.***
- ***Short course of prednisone considered for highly inflamed lesions.***

Tinea of Hands (Tinea manuum)

- A fungal infection of the hand
- Children are rarely affected
- May be insidious and progress slowly
- Itching is moderate, minimal or absent

- UNILATERAL, mostly common on the dominant hand
- Usually associated with tinea pedis
- Tinea involving the dorsal hand has all of the feature of classical ringworm lesions of the body
- A raised, red, scaly advancing border is typical.
- Papules or vesicles may be present at the border or in the
- Well demarcated scaling patches and scaling confirm to palmar crease, fissures on the hand.
- *Tinea manuum* causes a slowly extending area of peeling, dryness and mild itching on the palm of one hand (hyperkeratotic tinea). Skin markings may be increased
- Hyperkeratotic tinea of the palms may be unaware of the infection
- Erythema and scaling of the right hand, which was associated with bilateral tinea pedum;
- "ONE HAND, TWO FEET" syndrome distribution is typical epidermal dermatophytosis.



https://www.facebook.com/GLUQUINEEZ/posts/tinea-manuum-is-a-fungal-infection-of-the-hands-tinea-an/624428371296727/

Complications

- Spread of the fungal infection to other skin sites
- Spread of the fungal infection to others

Treatment

- ***Antifungal cream - ketoconazole 2% cream, or clotrimazole 1 % cream, or econazole 1% cream, or miconazole 2% cream, or terbinafine cream bd for 2 weeks***
- ***Continue treatment at least one week after resolution of the infection***
- ***Extensive lesions or those with red papules require oral therapy.***
- ***Terbinafine250 mg /day for l4 days or***
- ***Itraconazole 200 mg /day for 7 days***
- ***Fluconazole 150 mg - 200 mg/days for 2- 4 weeks***
- ***Antibiotic for bacterial infection.***

Prophylaxis

- ***Daily washing of hand while bathing with benzoyl peroxide or antifungal powder or alcohol gels.***

Tinea incongnito

- It is a localized cutaneous fungal infection, of the groin, pubic region and thighs, scortum and penis rarely involved.
- Cortisone cream applied to cutaneous fungal lesions alter the usual clinical presentation.
- Trichophyton rubrum is the most common organism
- The clinical appearance has been altered by inappropriate treatment, usually a topical steroid cream.
- The result is that the original infection slowly extends
- Always associated with tinea pedis
- The alter clinical picture is called tinea incongnito.
- Large scale, well demarcated dull red / tan brown plaques.
- It is a localized cutaneous fungal infection.

- The appearance of which has been altered by application of topical corticosteroid leading to atypical eruption.
- Commonly seen in groin, face and dorsal aspect of the hand.
- Scaling at the margin may be absent. Is less scaly.
- Diffuse erythema, diffuse scale, scattered pustules and brown hyperpigmentation may result.
- Has a less raised margin, and more extensive and more pustular
- No well define border and more irritable
- It is also known as steroid-modified tinea.
- Tinea incognita can also be caused by systemic steroids.







Treatment

- ***Discontinue Topical Steroid***
- ***Antifungal cream - ketoconazole 2% cream, or clotrimazole 1% cream, or econazole 1% cream, or miconazole 2% cream, or terbinafine cream bd for 2 weeks***
- ***Continue treatment at least one week after resolution of the infection***
- ***Extensive lesions or those with red papules require oral therapy.***
- ***Terbinafine250 mg /day for 2 week or***
- ***Itraconazole 100 mg /day for 15 days***
- ***Fluconazole 150-300mg /week for 4 weeks***
- ***Antibiotic for bacterial infection.***

Tinea faciei/Tinea facialis





https://perridermatology.com/fungus-tinea-faciei/
https://plasticsurgerykey.com/diseases-resulting-from-fungi-and-yeasts/

- Dermatophytosis of the glabrous facial skin.
- Well circumscribed macule to plaque or erythematous patch.
- It may be acute or chronic
- Of variable size: elevated border and central regressions
- Etiology – Tinea tonsurans
- There are round or oval red scaly patches, often less red and scaly in the middle or healed in the middle.
- Symptoms -mostly asymptomatic
- Scaling minimal
- Pink to red colour
- In black patient, it is hyperpigmentation

Treatment – the SAME as other Tineas

8. DERMATOPHYTOSIS OF HAIR

Dermatophytes are capable of invading hair follicles and hair shaft causing dermatophytic trichomycosis, such as

- Dermatophytic folliculitis
- Tinea capitis
- Tinea barbae
- Majochi granuloma

Dermatophytic folliculitis

Ectothrix - mycelia and arthroconidia are seen on the surface of the hair follicle.
Endothrix type - hyphae and arthroconidia occur within the hair shaft.

Tinea Capitis



https://www.researchgate.net/figure/Grey-patch-type-of-Tinea-capitis-with-Tinea-facieii_fig3_235729586

Dermatophytic trichomycosis of the scalp.
Tinea capitis is a fungal infection of the scalp, involving both the skin and hair.

Clinical presentation may

Non inflammatory of the scaling, scaling and broken off hairs

- Grey patch:
- Black dot
- Diffuse scale: severe painful inflammatory with painful, boggy nodules that drain pus and result of scarring alopecia.
- Diffuse pustular
- Kerion
- Favus

Etiology

Trichophyton tonsurans (90% of cases), less common – M. canis

Transmission

Person to person via fomite
Animal to person
Spores are present on asymptomatic carrier

Skin Finding

Four clinical patterns

- Seborrheic dermatitis type
- Inflammatory tinea capitis (KERION)
- Black dot pattern
- Pustular type

Seborrheic dermatitis type

The most common type resembles seborrheic dermatitis
There is diffuse, or patchy, fine white adherent scale on the scalp.
KOH test often negative

Inflammatory tinea capitis (KERION)

One or many Painful, inflammatory, purulent, boggy, nodules and plaque tender areas
Caused by - T.verrucosum, T, mentagrophytes, M. canis
Extremely painful, drains pus from multiple opening like honeycomb
Scaring alopecia may occur
Fever, occipital adenopathy and leucocytosis may occur
Hair do not break off but hair fall off, can be pull without pain
Involvement of entire skull
Heal with scarring alopecia.

Black dot pattern

Uncommon
Large areas of alopecia are present
Broken off hairs near surface give appearance of DOT in dark hair patients.
DOTs occur as affected hair breaks at surface of scalp. Tends to be diffuse and poorly circumscribed.
Trichophyton tonsurans and *T.violaceum* isolated
Grey patch tinea capitis, partial alopecia, often circular in shape, showing numerous broken off hairs dull grey form



https://dermnetnz.org/topics/tinea-capitis
https://dermnetnz.org/topics/wood-lamp-skin-examination

Pustular type

There are pustules or scabbed area without scaling or significant hair loss.
Tinea capitis favus - Extensive hair loss with atrophy, scaring and so called scutullae.
Grey yellowish adherent crusts present on the scalp remaining hairs pierce the scutula.
Usually *T.schoenleinii* was isolated.

Laboratory

Wood lamp - bright green hair shaft by *M. canis* and *M. audouinii*
No fluorescent - *T.tansurans*
Dermoscopy- findings characteristic of tinea capitis with a high predictive value but not seen in every case
Fungal culture - dermatophytes can be cultured

Treatment

- ***Shampoo with selenium sulphite 1% or ketoconazole 2% every other day***
- ***Topical antifungal is INEFFECTIVE in Tinea capitis.***
- ***Base line Liver function is needed.***
- ***Terbinafine, itraconazole, and fluconazole are at least as effective as griseofulvin for trichophyton infections***

For Childern

- ***Itraconazole 5 mg/kg/day east 6 weeks to several weeks***
- ***Ultramicrosized 10 mg /kg l day***

For Adult
(Gray patch Tinea Capitis)

- ***Terbinafine, itraconazole, and fluconazole are at least as effective as griseofulvin for trichophyton infections 6 weeks***

Black Dot Tinea Capitis

- ***Terbinafine, itraconazole, and fluconazole are at least as effective as griseofulvin for trichophyton infections 6 weeks or longer period***

KERION

- ***Terbinafine 250 mg /day for 4 week or according to weight in children***
- ***Itraconazole 100 mg /day for 6-8 weeks, (Paediatric dose - 5 mg/kg/day or Adult 200 mg /day)***
- ***Fluconazole 100 mg or 150 mg per day 6-week (Paediatric dose) 6mg/Kg/day for 2-4 weeks or Adult 200mg /day***
- ***Ketoconazole (Paediatric dose 5mg /Kg /day for 4-6 weeks or Adult 200mg - 400 mg/day for 4-6 weeks)***
- ***Adjunctive therapy - prednisolone 1 mg/kg/day for 14 days for children for kerion.***
- ***Antibiotic for bacterial infection.***

Tinea barbae

Dermatophytic trichomycosis by *T. verrucosum or T. mentagrophytes var. equinum* involving the beard and moustache areas.
Ring worm pattern and follicular pattern
Ring worm pattern – resembles the annular plaques of tinea corporis with sharp define border
It is usually very inflamed with red lumpy areas, pustules and crusting around the hairs
Follicular pattern - deep follicular infection resembles bacterial folliculitis.



https://quizlet.com/220415924/tinea-barbae-flash-cards/

Treatment

- ***Terbinafine 250 mg daily for 2- 4 weeks or***
- ***Itraconazole 200mg every day for 2- 4 week***
- ***Fluconazole 150 mg once a week for 3 - 4 week.***

Tinea Versicolor or Priasisity Versicolor



It is a common yeast infection of the skin, in which flaky discoloured patches appear on the chest and back.
Etiology - Malassezia furfur (*Pityrosporumovale, P.orbiculare*)
It is part of normal skin flora
Excessive heat and humidity predispose to infection
Oily skin
Immune deficiency
Corticosteroid treatment
The white or hypopigmented type of pityriasis versicolor is thought to be due to a chemical produced by malassezia that diffuses into the epidermis and impairs the function of the melanocytes.
The pink type is mildly inflamed, due to dermatitis induced by Malassezia or its metabolites

Skin finding



Numerous small, circular, white, scaling papules on the upper trunk.
May extend to involve the upper arms, neck and abdomen.
Facial involvement is more common
Powdery scale
usually asymptomatic, but in some people, It is mildly itchy.
Lesions are hypo pigmented in tanned skin and pink or brown color in untanned skin.
Colour is uniform in each person
Wood light examination shows hypo pigmented areas of infection and a faint yellow green florescence.

Laboratory

Dermoscopy of pityriasis versicolor — pallor, background faint pigment network, and scale.
Wood lamp (black light) examination — yellow-green fluorescence may be observed in affected areas
KOH examination- The scale shows numerous hyphae that tend to break into short, rod shape fragment intermixed with round spores in grape like cluster called SPAGHETTI and MEATBALL.

Differential Diagnosis



Vitiligo, Guttate psoriasis
Post inflammatory following nummular eczema, or pityriasis rosea

Treatment

- ***Topical agents***
- ***Mild case***
- ***Topical medications are considered the first-line therapy for pityriasis versicolor.***
- ***Selenium sulphite 2.5% lotion or shampoo - applied daily for 10-15 min followed by shower for 1 week. or Ketoconazole shampoo***

- ***Ketoconazole is the most common topical treatment used to treat pityriasis versicolor. cream or econazole cream or miconazole or ciclopirox olamine 1%, clotrimazole cream applied daily bd for 2 weeks. or***
- ***Terbinafine 1 % solution bd for 7 days.***
- ***Systemic therapy***
- ***Oral medications are viewed as a second-line of treatment for pityriasis versicolor in the event of widespread, severe.***
- ***Itraconazole 400 mg stat or and 200mg od for 7 days or***
- ***Fluconazole 400 mg stat or and 150 mg or 300mg per week for two -four weeks.***
- ***Oral terbinafine is not effective in the treatment of pityriasis versicolor.***
- ***Oral Ketoconazole no longer approved due to its potential hepatotoxic side effects.***

Prophylaxis

- ***It is commonly recurrent superficial fungal infection of the skin. The patients need effective follow-up care to implement a relapse prevention strategy.***
- ***Ketoconazole shampoo once or twice a week or 2.5% Selenium sulphite***
- ***Oral Itraconazole is also used for prophylaxis of recurrences***

CANDIASIS (Moniliasis)

Etiology –



candida albicans (Yeast) is most common organism
Other C. parapsilosis, glabrata, C. tropicalis
C. parapsilosis
The organisms lived among the normal flora of the mouth, vagina tract and lower gastrointestinal tract.
Superficial infection
Disseminated candidemia in immunocompetent patients.
With balanitis Candida can transmIt from sexual partners. o

Host factor -



Immunocompromised patient such as HIV,
D.M, Cushing syndrome
Obesity
Hyperhydrosis
Systemic and topical corticosteroid
General debility e.g, from cancer or malnutrition
Underlying skin diseases e.g., Psoriasis, lichen planus

Skin finding

The yeast infects outer layers of the epithelium of mucus membrane and skin
Primary lesion is pustule and peel It away
Erythematous papules with a few pustules becoming confluent on the media thigh.
Small peripheral satellite papules and pustules that have become confluent, creating large erode area
Tender pinpoint red papules and pustules

Laboratory



KOH preparation - budding yeast forms and sausage likes pseudo hyphal forms.

Treatment

- ***Keep inter trigonous area dry***
- ***Washing with benzyl peroxide bar may reduce Candida colonization***
- ***Power with imidazole applied daily***
- ***Topical - Castellani paint immediate relief of symptoms***
- ***Glucocorticoid preparation - judicious short-term use speed up resolution of symptoms.***
- ***Topical antifungal cream -nystatan, imidazole cream***
- ***Oral antifungal agents - nystatan***
- ***Fluconazole 200 mg po once followed by 100 mg/d for 2-3 weeks***
- ***Increase 400-800 mg in resistant infection.***
- ***Itraconazole 100 mg po, od or bd for 2 weeks. Can increase in resistance case.***

- ***Ketoconazole 200 mg po, od or bd for 1-2 weeks***
- ***Clotrimazole oral tablet (lozenges) 10 mg, one tablet 3 time daily may be effective.***

Oral candidiasis or Thrush

Predisposing factors



https://medcraveonline.com/JOENTR/diagnosis-and-management-of-pseudomembranous-candidiasis.html

Infancy, old age, antibiotic therapy, steroid and other immunosuppressive drugs, xerostomia, anaemia, endocrine disorders, and immunodeficiency. It is a common finding in people with HIV infection.

The most common presentations of oral candidiasis are:

Pseudomembranous candidiasis (syn. thrush)

white patches on the surface of the oral mucosa.

Lesions develop into confluent plaques that resemble milk curds and can be wiped off to reveal a raw erythematous and sometimes bleeding base

Candidiasis in the mouth and throat can have many different symptoms, including:

- ***White patches on the inner cheeks, tongue, roof of the mouth, and throat***
- ***Cotton-like feeling in the mouth***
- ***Loss of taste***
- ***Pain while eating or swallowing***
- ***Cracking and redness at the corners of the mouth***

Erythematous candidiasis –

erythematous areas found generally on the dorsum of the tongue, palate, or buccal mucosa are characteristic.

Lesions on the dorsum of the tongue present as depapillated areas.

Red areas often are seen on the palate of individuals with HIV infection

Thrush is often treated with antifungals in the form of lozenges, tablets, or liquid mouthwash that you swallow.

Treatment

- ***Topical antifungal cream -nystatan, imidazole cream***
- ***Oral antifungal agents - nystatan***
- ***Fluconazole 200 mg po once followed by 100 mg/d for 2-3 weeks***
- ***Increase 400-800 mg in resistant infection.***
- ***Itraconazole 100mg po, od or bd for 2 weeks. Can increase in resistance case.***
- ***Ketoconazole 200 mg po, od or bd for 1-2 weeks***
- ***Clotrimazole oral tablet (lozenges) 10 mg, one tablet 3 time daily may be effective.***
- ***The treatment for candidiasis in the esophagus is usually fluconazole.***

Candidial Balantitis

A localized acute infection of the fore skin and gland penis caused by candida species.

Occur more frequently in uncircumcised penis
DM is risk factor
Inflammation intense, causing fissure

- ***Topical therapy is usually sufficient***
- ***Miconazole, or clotrimazole cream or econazole cream***



https://www.pcds.org.uk/clinical-guidance/candida-infection# introgallery-3

Diaper dermatitis

Irritant contact diaper dermatitis
Most commonly red, scaly, erode, painful plaque on the convex surface or groin and buttock.

Treatment

- ***Barrier ointments such as petrolatum or zinc oxide are useful.***
- ***1% hydrocortisone cream twice daily for until inflammation is controlled.***
- ***Candida infection is well treated with miconazole or ketoconazole or clotrimazole.***
- ***Localized bacterial cream mupirocin cream***



Candida intertrigo

Yeast thrives in intertriginous areas where skin touches skin.
Red, moist, glistering plaques extend to or just beyond the limits of the opposing skin fold.
Satellite papules dot the normal skin just beyond the plaques.
There is tendency of painful fissuring



https://www.msdmanuals.com/professional/dermatologic-disorders/fungal-skin-infections /intertrigo

Treatment

- ***Wet dressing applied several times for 20-30 min o Antifungal cream***
- ***Fluconazole cream 100-200 mg daily for 7 days***

Tinea of the Nail

Is a fungal infection of the nail plate of the fingers or toe caused by the many different species of the fungus?
Once It established - It tends to be chronic and asymptomatic o Lifelong infection, with no spontaneous remission
Predispose factor is trauma o 4 distinct clinical patterns
Nail infection may occur simultaneously with hand or foot tinea

- Distal subungual onychomycosis
- White superficial onychomycosis
- Proximal subungual onychomycosis
- Candida onychomycosis

Distal subungual onychomycosis

Most common pattern
Distal nail plate turns yellow or white as accumulation of hyperkeratotive debris cause the nail to rise and separate from the underlying bed.



https://dermnetnz.org/cme/fungal-infections/tinea-unguium
https://step1.mebdullets.com/dermatology/112095/onychomycosis

White superficial onychomycosis

The nail surface is soft, dry and powdery and can easily be scrapped.
Nail plate is not thickened and adhere to the nail bed

Proximal subungal onychomycosis

Microorganisms enter the posterior cuticle area of the nail fold and invade the nail plate from below.
The surface of the nail plate remains intact.
Trichophyton rubrum is the most common cause.
Commonly seen in HIV patients



Candida onychomycosis

It generally involves all of the finger nails
Nail plate thickens and turns yellow to brown
Rare disease

Differential Diagnosis

Psoriasis
Leukonychia
Eczema

Course and prognosis

Indication for treatment include - pam with thick nails, functional limitations, secondary bacterial function, and diabetes and cosmetics.
Oral therapy has highest success rate with nail infection in young persons
Systemic therapy is more effective.
Relapse rate 15-20%

Treatment

- ***Topical antifungal treatment***
- ***Terbinafine 250 mg daily for fingernail 6 weeks, toe nails for 12 weeks***
- ***Itraconazole 200mg od for 6 weeks for finger nails and 12 weeks to toe nail.***
- ***Nail clipper with plier's handles may be used to remove substantial amounts of hard, thick debris.***

Pulse Therapy for Onychomycosis

- ***Ltraconazole (Three- or four-month cycles of 200 mg of itraconazole twice daily for one week (400 mg daily for one week), followed by three weeks off and the drug for 3 or 4 pulse doses)***
- ***Terbinafine***
- ***Terbinafine 250 mg Pulse dose twice daily for 1 week on and 3 weeks off.***
- ***Fluconazole***
- ***Fluconazole 300 mg once a week for 6-9 month or until the nail is normal.***

Table: Summary of Treatment of Fungal infections

Candiasis Moniliasis	HE	Anti-fungal cream	Antipruritic drugs	Antifungal powder / Suspension(Oral)	Antifungal drug	Steroid Cream	Antibiotics cream	Shampoo
Oral Candidiasis	✓			✓	✓			
Candidial Balanitis	✓	✓	✓					
Diaper dermatitis	✓	✓	✓	✓		✓	✓	
Candidal Intertrigo	✓	✓	✓	✓	✓			
Tinea Versicular	✓	✓			✓			✓

Table: Summary of Treatment of Fungal Infections

	HE	Antipruritic drugs	Anti-fungal cream	Anti-fungal drugs	Anti-fungal powder	Antibiotics	Short-course PNLD	Shampoo	Surgery
Tinea pedis	✓	✓	✓	✓	✓	+/-			+/-
Tinea cruris or Tinea groin	✓	✓	✓	✓	✓				
Tinea corporis or Tinea of the body	✓	✓	✓						
Tinea manuum	✓	✓	✓						
Tinea faciei	✓	✓	✓						
Onychomycosis	✓	✓		✓			✓		✓
Tinea incognito	✓		✓	✓					
Tinea capitis	✓			✓		✓	✓	✓	✓
Tinea barbae	✓	✓	✓	✓					

8. ACNE VULGARIS AND ROSACEA

Acne Vulgaris (Acne)

Acne vulgaris is chronic inflammatory disease of the pilosebaceous follicle characterized by comedones, papules, pustules, and nodules and often scar.
Acne vulgaris and rosacea are very common yet and heavy emotional burden for its victims
Acne vulgaris is the most common of all skin disorder.
It is a chronic inflammatory process that affects the pilosebaceous unIt every adolescent and in many adults and pre pubertal children.
Acne is very common among adolescents and young adults, but can persist into adulthood
Nearly 85% of teenagers are affected by acne at some point during their teenage years
Permanent scarring, poor self-image, depression, and anxiety can result from acne
More severe in male than female.

Pathogenesis



Multifactorial pathogenesis
Possibly linked to keratin plugging of follicles due to abnormal or follicular hyper keratinization
Androgen-induced increase in sebum secretion and
Secondary proliferation or colonization of *Propionibacterium acnes,* an anaerobic organism normally resides in the follicles
Key pathological feature is follicular plugging and distension and perifollicular inflammation.
Role of androgen must be carefully considered.
Telltale signs of hyper androgenism as hirsutism
Hyperandrogenism secondary to polycystic ovary syndrome.

Acne Lesion

Primary lesion of AV is microcomedo, the microscopic bulging mass that results from a combination of hyperproliferative comeocytes and sebum and lead to follicular plugging.
Microcomedo is the closed comedo (white head) is the first visible acne lesion.
It is a non-inflammatory lesion that evolves from the microcomedo and appear as a white dot ranging from 0.1 to 3.0.mm in diameter.
The open comedo (black head) is a 0.1 to 3.0 mm non-inflammatory lesion that like black dot.
The dark color is blockage of light transmission through the occluded.
Open comedo is inflammatory acne lesions include papules, pustule, nodules and cysts.
A papule is a pink to red raised, papule lesion with no visible accumulation of fluid which can range from 1 to 4 mm in diameter.
A pustule is a raised accumulation of purulent materials on the skin's surface and similar size to papules.
Nodule is a tender firm lesion that may persist for weeks.

Cysts may be as large as several centimeters in diameter and they may drain creamy, yellowish materials.
Darkly pigmented skin affected by acne tends to develop significant post-inflammatory hyperpigmentation.

Classification

Superficial lesions

Open and closed comedones (blackheads and whiteheads)
Papules (small, tender red bumps)
Pustules (white or yellow "squeezable" spots)



Deeper lesions

Nodules (large painful red lumps)
Pseudocysts (cyst-like fluctuant swellings)

Secondary lesions

Excoriations (picked or scratched spots)
Erythematous macules (red marks from recently healed spots, best seen in in fair skin)
Pigmented macules (dark marks from old spots, mostly affecting those with dark skin)
Scars or various types



Ref: https://www.pinterest.com/pin/types-of-acne--326229566743521926

Individual acne lesions usually last less than 2 weeks but the deeper papules and nodules may persist for months. Many acne patients also have oily skin (seborrhoea).

Acne Grading

Acne may be classified as mild, moderate or severe. Comedones and inflammatory lesions are usually considered separately.
(Mild acne)

- < 20 comedones
- < 15 inflammatory lesions
- Or, total lesion count <30

(Moderate acne)

- 20-100 comedones
- 15-50 inflammatory lesions
- Or, total lesion count 30-125

(Severe acne)

- >5 pseudocysts
- Total comedo count > 100
- Total inflammatory count >50
- Or total lesion count > 125



Mild **Moderate** **Severe**
https://www.studocu.com/en-gb/document/lancaster-university/medicine-and-surgery/acne-vulgaris-and-rosacea/14243784

Some dermatologists assess the severity of a patient's acne more precisely by using a grading scale. The inflammatory lesions are compared with a set of standard photographs to determine the grade, which may be 1 (very mild) to 12 (exceptionally severe) for example

Treatment

- ***Treatment for acne depends on the patient's age and sex, the extent and the severity of the acne, how long It has been present, and response to previous treatments.***
- ***Treatment for mild acne includes topical anti-acne preparations, lasers and lights***
- ***Treatment for moderate acne includes antibiotics such as tetracyclines and/or antiandrogens such as birth control pill***
- ***Treatment for severe acne may require a course of oral isotretinoin***
- ***Topical treatment for acne is available as washes, solutions, lotions, gels and creams. They may have single or multiple active ingredients.***

Treatment algorithm of Acne for adolescents and young adults (aad guideline)

First line treatment options			
Mild	Benzoyl peroxide (BP)	Topical retinoid	Topical combination therapy*: BP + antibiotic; or Retinoid + BP; or Retinoid + BP + antibiotic
Moderate	Topical combination therapy*: BP + antibiotic; or Retinoid + BP; or Retinoid + BP + antibiotic	Oral antibiotic + topical retinoid + BP	Oral antibiotic + topical retinoid + BP + topical antibiotic
Severe	Oral Antibiotic + topical combination therapy: BP + antibiotic; or Retinoid + BP; or Retinoid + BP + antibiotic	Oral isotretinoin	

* *May be prescribed as a fixed combination product or as separate component.*

	Alternative options			
Mild	Add topical retinoid or BP (If not on already)	Consider alternate retinoid	Consider topical dapsone	
Moderate	Consider alternate combination therapy	Consider change in oral antibiotic	Add combined oral contraceptive or oral spironolactone (females)	Consider oral isotretinoin
Severe	Consider change in oral antibiotic	Add combined oral contraceptive or oral spironolactone (females)	Consider oral isotretinoin	

https://www.aad.org/member/clinical-quality/guidelines/acne

When to refer

Non responsive acne vulgaris may evolve to cystic acne, scarring, hyperpigmentation

Pyogenic granuloma
Very severe acne condition needs to treat with systemic isotretinoin treatment

Acne scar and Hyperpigmentation

Many people develop one or more of the following after getting acne.
Acne scars: When an acne breakout clears, It can leave a permanent scar.
Some scars cause depressions in the skin. Others are raised.
It's impossible to predict who will develop scars when the acne clears, but the following increases your risk:
Living with acne for an extended amount of time because you don't treat It or treatment doesn't work
Having one or more close blood relatives who developed acne scars

Dark spots on the skin:
As an acne breakout clears, some people see a spot where the acne once was. This completely flat spot can be pink, red, purple, black, or brown, and it's often mistaken for a permanent acne scar.
As the acne clears, It can leave long-lasting dark spots on the skin.


https://www.researchgate.net/figure/Acnean d-Postinflammatory-Hyperpigmentation-Cou rtesy-of-Valerie-Callender-MD-Callender_fig2 _313792481

Drugs for acne

- *Azelaic acid (Azelex) - for post-inflammatory dyspigmentation*
- *A dicarboxylic acid 20%*
- *Effect is anti-inflammatory*
- *Azithromycin and cephalexin are alternative to moderate to severe.*
- *Monotherapy with systemic antibiotics is NOT recommended*



Antibiotics

- *Moderate to severe acne*
- *Front line antibiotics - Tetracycline 250-500 mg qid for 6-8 weeks*
- *or minocycline 50-l 00 mg od or bd or doxycycline 100 mg bd 6-8 weeks*
- *Erythromycin - second line drug, 250-500 mg bd or qid for 6-8 weeks or Clindamycin 150 mg tds for 6-8 weeks*
- *Others - septrin, dapsone, amoxicillin, clindamycin*

Isotretionoin

- *Most effective therapy for severe nodulocystic and scarring acne*
- *Dose 0.5-1 mg / kg / day in od or bd I day long duration (6 month)*
- *Side effect - dry skin, eyes, lips, muscle joint pain.*
- *Fetal abnormality If use in pregnancy*
- *Possibility of depression and suicide*

Hormonal Therapy

- *Oral contraceptive pills improve acne, by decreasing the amount of circulating androgen.*
- *It may improve acne for many women. They could be used alone or in combination with other acne treatments.*

- *Recommended for Estrogen-containing combined oral contraceptives for inflammatory acne in females*
- *Currently four FDA-approved combined oral contraceptives for the treatment of acne*
- *Acne reduction with these agents can take time*
- *Appropriate for women with moderate acne*
- *These agents block both adrenal and ovarian androgens.*
- *As pregnancy while on antiandrogen treatment will result in feminization of a male fetus. 50-100 mgl day*

Dexamethasone

- *Reduce the androgen excess and may alleviate cystic acne. Corticosteroids (CS) are effective in the treatment of adult-onset adrenal hyperplasia.*

Prednisolone

- *It is generally only given to the patients with severe inflammatory acne during the first few weeks of treatment with isotretinoin, for initial reduction of inflammation and to reduce isotretinoin induce flares.*

Other hormonal agents

- *Finasteride, flutamide, estrogen, gonadotropin releasing agonist, and metformin - beneficial effect on acne but due to side effect and expenses.*
- *Spironolactone can be useful in the treatment of acne in select females, though evidence of its efficacy is limited*

Intralesional Corticosteroid

- *Injection Kenalog 10 is best dilute with sterile water normal saline, less than 0.1 ml directly into the center of the nodule.*

Role of diet in acne

- *No specific dietary changes are recommended in the management of acne*
- *Emerging data suggests that high glycemic index (GI) diets may be associated with acne*
- *Limited evidence suggests that some dairy, particularly skim milk, may influence acne*
- *There is limited evidence to recommend the use and benefIt of physical modalities for the routine treatment of acne including:*
- *Comedo removal*
- *Pulsed dye laser*
- *Potassium titanyl phosphate (KTP) laser*
- *Fractionated and non-fractionated infrared lasers*
- *Fractionated CO2 laser*
- *Photodynamic therapy (PDT)*
- *Glycolic acid peels*
- *Salicylic acid peels*

Rosacea

Rosacea is a cutaneous vascular disorder.
It appears on the central face (Cheeks, chin and nose, forehead) where inflammatory papules and pustules erupt on a background of erythema and telangiectasias.

This occurs more in fair skinned, fair-haired people.
Rosacea is more common in women.
It occurs after age of 30 years, peak 40-50 years
Etiology is unknown
It tends to appear in patients who are flushers and blushers.
The flushing and blushing reaction, which is sometimes called pre-rosacea, may response to emotional, psychological or environmental.
Rosacea is not curable.



https://www.everydayhealth.com/rosacea/is-it-something-else/
https://www.nhs.uk/conditions/rosacea/

Diagnosis

Primary feature (Must present one or more)
Flushing (transient erythema)
Non-transient erythema: persistent redness of the central face - the most common sign of rosacea.
Papules and pustules which appear in cluster
Telangiectasias: common but required for diagnosis
Secondary Feature
Burning or stinging
Plaques
Dryness: itchiness, scaly skin resembling dry skin
Edema
Ocular manifestation
Peripheral location including chest, neck, scalp, or back
Phymatous changes

Subtype

Erythematotelangiectatic - redness, flushing, visible blood vessels
Papulopsutular - redness, swelling, and acne-like breakouts
Phymatous - skin thickens and has a bumpy texture
Ocular - eyes red and irritated, eyelids can be swollen, and the person may have what looks like a sty
No medical test can tell whether you have rosacea

Treatment

Find your triggers.

- ***Many things you do can cause rosacea to flare. Common triggers for rosacea include becoming overheated, having cold wind blowing on your face, and eating spicy foods.***
- ***Minimize sun exposure***
- ***Apply a broad-spectrum sunscreen with an SPF 30 (or higher) every day before you head outdoors***
- ***Think sun protection 24/7.***
- ***Use a moisturizer***
- ***Use only gentle skin care product***
- ***Cover up the face when you go out***

Practice rosacea friendly skin care

- *Avoid the midday sun*
- *Seek shade when outdoors*
- *Slip on a wide-brimmed hat when outdoors to protect your face and neck from the sun*
- *Wear sun-protective clothing and sunglasses*
- *Care of eye*
- *Avoid spicy food*
- *Mild case topical alone*

Azelaic acid:

- *Most patients apply this medicine twice a day — in the morning and evening*
- *Metronidazole cream (Metrogel 0.75%, or Metrolotion 0.75% can used)*

Metronidazole:

- *Available as a gel or cream, has been used for more than 60 years*
- *to treat the acne-like breakouts of rosacea*

Retinoid:

- *It can irritate skin with rosacea. Applying a retinoid can help you prevent flare-ups*
- *Sodium sulphacetamide topical (Klaron or sulfacet cream) used to safely treat the acne-like breakouts of rosacea for more than 60 years.*

Systemic treatment

- *Oral antibiotics*
- *Tetracycline 250-500 mg bd up to 12 weeks*
- *Doxycycline 50-100 mg bd*
- *Minocycline 50-100 mg bd*
- *Tetracycline - It can quickly reduce the acne-like breakouts and redness*
- *Minocycline, doxycycline, or erythromycin, can also effectively treat rosacea*
- *Not response use oral isotretinoin, but side effect -teratogenic Other*
- *Electrosurgery*
- *Laser surgery*
- *Dermabrasion*

Laser or light therapy

9. DERMATOSIS

Dermatosis is a term that refers to diseases of the integumentary system.

Dermatitis

Any sort of inflammation of the skin which usually produce a rash.

Eczema

Eczema is a chronic (persistent) skin condition with symptoms such as itching which creates inflammation, rashes and redness which causes the skin to swell.

Stages of Eczema

(1) Acute Eczema
(2) Subacute Eczema
(3) Chronic Eczema

Acute Eczema

It is characterized by clinically erythema, edema, and vesicle. Weeping or oozing from lesion is typical. Pruritus is often severe.


https://clinicalgate.com/eczema-basic-principles contact-dermatitis/

Skin Finding

Erythema, edema, vesiculation, weeping, inflammation can be moderate to tense, vesicle and bullae can be seen

Type of reaction –

Id reaction (Autoeczematization)

Duration

within week
Examples - poison ivy, poison oak, poison Sumac

Treatment

- ***Cool and wet dressing with Burrow's solution***
- ***Topical steroid Group II to III***
- ***Oral Antihistamine - such as diphenyl hydramine or cetrine***
- ***Infection for Antibiotics, e.g., dicloxacillin 10-14d or flucloxacillin 250 mg tds x 7d***
- ***Oral corticosteroid is reserve for Severe cases. (C.S 0.5-lmg/kg/day)***

Subacute Eczema

It is characterized by clinically itchy, red and scaling patches, papule and plaque in various configurations.



Duration

Over one week

Skin Finding

Erythema and scaling occur. Indistinct border. Redness may be faint or intense.
Type of Reaction - Autoeczematization
Examples - Atopic dermatitis

Treatment

- ***Wet dressing should be avoided.***
- ***Topical steroid cream Group II-V***
- ***Oral Antihistamine such as diphenylhydramine or loratidine***
- ***Immune modulators Tacrolimus ointment 0.1-0.03% applied bd***
- ***Tar oilment and creams***
- ***Infection for Antibiotics, e.g., dicloxacillin 10-14 d***
- ***Moisturizes are essential, apply bd, e.g., Aveeno or DML***

Chronic Eczema

Affected skin is inflamed, red, scaling and lichenified.





Duration

month to year

Skin Finding

Intense itching, inflamed, itchy skin thickens and surface markings become more prominent. Lichenification present, hyperpigmentation and hypopigmentation present

Treatment

Cool and wet dressing.
Emollients (petrolatum)(white soft paraffin)(vaseline cream)
Topical steroid Group I or II are used with plastic occlusion for 8 hrs.
Steroid impregnated tape, e.g., cordran tape for 12 hrs.
Immune modulators Tacrolimus ointment 0.1-0.03% applied bd
Intralesional injection, e.g., Kenalog l 0 mg/ml for 3-4 weeks interval can use.

Common Types of Eczema

Atopic dermatitis
Seborrhoeic dermatitis

Discoid / nummular
Dyshidrotic/ Pompholyx
Stasis eczema
Venous leg ulcer
Xerotic dermatitis - caused by extremely dry skin made worse by dry winter
Contact dermatitis - in response to allergen
Lichen Simplex Chronicus
Plurigo Nudularis
Pityriasis Alba



Atopic Dermatitis (Atopic means sensitive to allergen)

AD is a chronic, inflammatory skin disease that is characterized by pruritus and a chronic course of exacerbation s and remission.

Characteristics

Dry Skin, crack and scaly
Pruritus or itchy
Rubbing lead to increased inflammation
Red
Broken skin
Thicken
Crack
Itch scratch cycle



https://www.singhealth.com.sg/patient-care/conditions-treatments/atopic-dermatitis

Predisposing factors

Genetic, family tendency
Environmental component
Food e.g., cow's milk, egg, soybean
Infection
Season
Clothing
Emotional stress
Hormonal changes
Exercises
Auto allergens

Clinical presentation


https://www.dermatologyinfo.net/english/chapters/DSC02390.JPG

1 month to 2 years (Infantile type)

Hallmark - Pruritus
Characteristic lichenified appearance
Erythema and scaling of cheeks and eruption may extend to scalp, neck, forehead, wrist and extremities.
Secondary effects from scratching, rubbing and infection - Crust, infiltration and pustules
Sparing of naso-labial fold in face
Disappear in end of second year of life.


https://www.pcds.org.uk/clinical-guidance/atopic-eczema

2 years to 10 years (Childhood Type)

Pruritus is characterized feature
Classical location is antecubital and popliteal fossa
Lichenified and indurated plaque
Lichenification and secondary infection
Change of itch to pain due to scratching (Itch -scratch cycle)

Adolescent I Adult (Adult type)

May occur as a localized erythematous, scaly, papular, exudative or lichenified
Location is antecubital and popliteal fossa and front and side of neck, forehead and area around the eye
Lichenification and prurigo like lesions are common
Infection such as *Staphlococcus*
Hyper or hypopigmentation seen
Associated Finding
White demographism is a special and unique features of involved skin
Ichthyosis vulgaris and keratosis pilaris occur in 10%.
Flare up
During the flare up, the skin may be itchy, red, hot, dry and scaly, wet, weeping and swollen and infected with bacteria.


https://www.amboss.com/us/knowledge/Atopic_dermatitis

Diagnosis Criteria

Major Criteria (must have three of the following)

Pruritus
Typical morphology and distribution (flexural lichenification in adult or facial and extensor involvement in infancy)
Chronic or chronically relapsing dermatitis
Personal or Family history of atopic diseases (asthma, allergic rhinitis, atopic dermatitis)

Minor (must have 3 of the following.)

Chelitis
Recurrent conjunctivitis

Orbital darkening
Pityriasis alba
Icthyosis
Nipple eczema
Elevate Serum IgE
Xerosis
IgE reactivity
Early age onset

Treatment in Primary Care

Dry skin - Emollients are first line, such as emulsifying ointment BP, three time per day (white soft Paraffin gel or Vaseline petroleum,)
Use bath oil such as oilatum or oilatum plus
Avoid soaps and shampoo but you can use Soap like Eucerine wash and Physiological shower cream
Cooling the skin
Antihistamine such as diphenhydramine 5mg/kg/d for child, 25-50 mg qid
Topical steroid such as 1% hydrocortisome cream should be used
Immunomodulator such as tacrolimus 0.03% for children and 1% for adult
Skin infection -Topical fucidin or systemic Antibiotics such as erythromycin 10 – 14 days
UVA-UVB phototherapy
Cyclosporine treatment in all over treatment failure.

Seborrhoeic Dermatitis

SD is common chronic, superficial, inflammatory disease characterized by redness and scaling and occurring in regions where the sebaceous glands are most active such as face, scalp, trunk, pre sternal area, body fold, groin and gluteal crease.


https://www.dermacaredirect.co.uk/advice/skincare-sd/

Co factor - SD linked to *pityrosporum ovale*
Linked to T cell depression
Increase sebum production
It affects areas rich in sebaceous glands
Activation of complement pathway
SD caused by immunologic abnormalities and activation of complements.
May worsen in Parkinson diseases and in AIDS and neurologic disease (head trauma, stroke)
SD is aggravated by changes in Humidity, seasonal changes and emotional stress.
Age -onset -infancy (within first month of life), usual onset with puberty, most 20-50 years, peak 40 years
Increase activity is seen in winter and early spring.

Skin Finding

The disease is characterized by scale on erythematous based.
The scale has a yellow, greasy appearance or the papules are moist, transparent to yellow, greasy and scaling, among coalescing red patches and plaques.
Characteristic locations are seen on the eye-brown, the base of eyelashes, nasolabial folds and

paranasal skin and external ear canal.
Red, sharply marginated macules / patches covered with greasy-looking yellowish scales
Head - Scalp, eyebrows, eyelashes, beard - Erythema and yellow orange scales and crusts
Vertex of infant - yellow, greasy adherent scale on the vertex of the scalp (Cradle cap) with minimal underlying redness.
Face - Flush (butterfly) areas, on forehead (Corona seborrhoica), nasolabial folds eyebrow, glabella.
Diaper area -yellow crusts and psoriform lesions. More redness than scaling.

Dermatopathology

KOH rule out for Dermatophytes
Hyperkeratosiis, Acanthosis, Accentuated Rete ridges, Focal spongiosis, Parakeratosis

Treatment

Early Treatment of flare
(Infants) – (For cradle cap)

- ***Removal of crusts with warm olive oil compress***
- ***Follow by baby shampoo (2% ketoconazole shampoo)***
- ***Application of 1- 2.5% cortisone cream and 2% ketoconazole cream***
- ***1% pimiecrolimus cream***

(Face and Trunk)

- ***2% ketoconazole shampoo and***
- ***2% Glucocorticoid cream and lotion***
- ***2% ketoconazole cream and***
- ***1% Pimiecrolimus cream***

(Adult) – (Scalp)

- ***2.5 %Selenium Sulphide or 2% ketoconazole shampoo for 2-3 weeks OR***
- ***Zinc pyrithioneand***
- ***2% Glucocorticoid cream and lotion OR***
- ***2% ketokonazole cream***
- ***1% Pimiecrolimus cream or 0.03% Tacrolimus***
- ***Antibiotics for secondary infection***
- ***Itraconazole 200 mg bd for 2 weeks***

Discoid or Nummular Eczema

NE is a chronic, pruritus, inflammatory dermatitis occurring in the form of coin shaped plaque composed of small papules and vesicles on a erythematous based.
One of the difficult forms of eczema to treat.

can occur in association with atopic eczema, eczema craquelé, and secondary eczematisation.


https://dermnetnz.org/topics/discoid-eczema
https://www.theindependentpharmacy.co.uk/eczema-dermatitis/ guides/discoid-eczema

Skin finding

Symptom - Pruritus often intense
Sharply demarcated, scaling, round eczematous plaques appear on the trunk and extremities.
Weeping lesions and vesiculation can flare.
Secondary infection with Staphylococcus.

Distribution

Generalized or regional cluster or Scatter
Lower leg, trunk, hands and finger

Laboratory

Patch testing
Rule out Staph infection

Differential Diagnosis

Ringworm or Tinea infection
Psoriasis
Cutaneous T cell lymphoma

Treatment

- ***Moisturizer such as Petrolatum cream bd or***
- ***Emollient -Vaseline or Aveeno***
- ***Topical corticosteroid medium to high potency, twice a day for 3-4 weeks***
- ***Dicloxacillin 250 mg qid for secondary infection***
- ***Antihistamine such as loratadine***
- ***Coal tar 2-5 % ointment daily***
- ***UVB for light therapy***

Dyshidrotic Eczema/Pompholyx/Hand and Foot Eczema

Pompholyx is a common type of eczema affecting the hand (Cheriopompholyx) and the feet (Pedopompholyx).
It is also called Dyshidrotic eczema or Vesicular Eczema.


https://www.nhs.uk/conditions/pompholyx/
https://www.healthline.com/health/dyshidrotic-eczema

Pompholyx is characterized by sudden eruption of usually highly pruritus, symmetric vesicles on the palm, lateral fingers and planter feet.
Sudden onset of much deep-seated pruritus, clear tapioca like vesicles.
Hand alone involvement occurs in 80%.
It is a distinctive, chronic relapsing vascular eczematous dermatitis of unknown etiology.
More common in women.

Clinical Feature

Vesicles are 1-5 mm in diameter, are monomorphic, deep seated, filled with clear fluid and resemble TAPIOCA, wet and weeping
Vesicles erupt suddenly and symmetrically on the palm or lateral fingers or on the planter feet.
Dry and scaling
Depending on the phase of the disease, the physician may see BROWN SPOT. Brown spots are site of previous vesiculation.

Course and prognosis

Vesicle resolved slowly over 1-3 weeks, recurrent maybe a month or a few time a year. Secondary bacterial infection and paronychia can get.

Treatment

- ***Cool compresses - Soaks and compresses using weak solution of CONDY's crystal (Potassium permangate), aluminum acetate, applied 15 min 4 time a day***
- ***Emollients - dimethicone barrier cream.***
- ***Topical corticosteroid cream (high potency) or***
- ***Intralesional injection of triamcinolone 3 mg / ml***
- ***Systemic steroid -PNLD 0.5-1 mg / kg/day***
- ***Tacrolimius ointment (protopic 0.1%)***
- ***UVA therapy for refractory cases.***
- ***Others - methotraxate or azathioprine***

Stasis Dermatitis

Stasis Dermatitis is an eczematous dermatitis of the legs, associated with edema, varicose and dilated veins and hyper-pigmentation.
It is chronic problem and commonly relapses.
It is also known as 'stasis eczema' and 'gravitational dermatitis.

History

prior history of DVT, surgical trauma, ulceration
Family history or personal history of varicose vein the legs are swollen at the end of the day
Prolong standing or walking

Skin finding


https://www.triage.com/health/en/clinician/stasis-dermatitis

The affected skin is red and scaly, and may ooze, crust and crack.
Irregular haemosiderin pigmentation is usually present.
Dilated and tortuous veins are frequently present.
Edema, brown discoloration, erosion, or ulceration
Pruritus
White scars on medial calf indicate previous ulceration
Inflammation, skin is scaling, thicken from itching and both legs are swelling.
Secondary infection may be present

Treatment

- ***Elevate feet when sitting or lying***
- ***Wear graduated compression stockings long term***
- ***Don't stand for long periods***
- ***Take regular walks***
- ***Cool water dressings***
- ***Emollients e.g., vaseline***
- ***Oral Antihistamine - e.g., hydroxyzine 10-25 mg qid***
- ***Topical corticosteroid G II to V twice a day for 2-3 weeks***
- ***Antibiotics e.g., dicloxacillin***
- ***Oral steroid for 3 week and taper***
- ***Compressing 20-30 mg is accompanying with stocking***

Venous Leg Ulcer

A venous leg ulcer is chronic non-healing ulcer typically located on the medial aspect of the lower leg associated with chronic venous insufficiency.
They are flat, have sharp or slightly sloping borders and are typically shallow with covering granulation tissues. Pitting edema is common.
Ache and swollen legs by the patient complaints

Treatment



- ***Elevation of legs***
- ***Exercise***
- ***Stop smoking***
- ***Treatment of underlying disease such D.M.***
- ***Compression with Ace wraps. But must not use in arterial diseases.***
- ***Corticosteroid cream group III-V***
- ***Heavy moisturizers e.g., Aveeno cream***
- ***Neomycin topical Antibiotics***
- ***Pentoxifylline 400 mg tds***
- ***Careful assessment of ulcer (Arterial or venous ulcer)and ulcer therapy***
- ***Special wound dressing***
- ***Metro gel cream***
- ***Hydrocolloid dressings***
- ***Asprin 300 mg I day***
- ***Continuous wet saline dressing***

Refer

- ***A large ulcer sizes***
- ***Long ulcer duration***
- ***Ulcer size do not decrease***

Xerotic Eczema

Xerotic Eczema is also called
Eczema Craquele,
Pruritus hiemalis,
Asteatotic Eczema or winter Itch.





https://dermnetnz.org/topics/asteatotic-eczema
https://healthjade.net/xerotic-eczema/

- ***a common type of dermatitis that occurs as a result of dry skin.***

The most common site is the shins, but asteatotic eczema may occur elsewhere including upper limbs and trunk.
Desiccation dermatitis and winter Eczema is a form of Eczema that is characterized by changes
that occur when skin becomes abnormally dry, itchy and cracked.
The sites are legs, arms and hands but also trunk.
May worse in winter when the humidity was reduced.

Symptoms

The primary lesion is an erythematous patch covered with adherent scale.
It has a distinctive crazy-paving appearance. Diamond-shaped plates of skin are separated from each other by red bands forming a network.
The dehydrated skin showing redness, dry scaling, and fine cracking that may resemble cracked porcelain or the fissure in the bed of a dried lake or pond.
The erythematous, scaling lesions are pruritus. There may also be scratch marks.

Treatment

- ***Life style changes to avoid the temperature, humidity and exacerbation factors***
- ***Bathe only once every 1-2 days (Tepid water bath), Use bath oil such as QV or Hamilton's Alphaker.***
- ***Keep the nails cut short or wear a covering the hands (gloves and socks)***
- ***Wear cotton clothing***
- ***Use low allergic washing powders such as DOVE***
- ***Moisturizer twice a day with such as QV and Dermaveen, or Lubriderm or Oils such as olive oil can be used.***
- ***Topical immunomodulators such as pimecrolimus and tacrolimus may be used***
- ***Topical steroid such as Group III-V (Medium potency) for short term.***
- ***Topical antibiotics cream for secondary bacterial infection.***

Icthyosis Vulgaris

It is autosomal dominant traIt of a disorder of keratinization characterized by dry, rectangular scales resembling a cracked pavement especially on extremities.

Finding

Dry, small, rectangular scales appear on the lower extremities particularly the anterior shin.
Affected skin has the appearance of cracked pavement or fish scale.

It is also called fish scale disease," or "fish skin disease.
Characteristically spare on flexor surfaces.
Usually, asymptomatic may become pruritus or chapped in the winter.
Associated with Keratosis Pilaris and may also be present.
This condition may result from a defect in the synthesis of epidermal proteins
, profilaggrin and filaggrin (FLG).
Most often It appears after about 2 months and in most cases before the age of 5. Symptoms may worsen up to puberty, and sometimes improve with age.


https://bestpractice.bmj.com/topics/en-us/584

Differential Diagnosis

Acquired icthyosis - more sudden onset, generalized
Infection with HIV virus, Sarcoidosis, Malignancy, drugs and metabolic disorder, Bone marrow disorder,
X-linked ichthyosis - large scales are dart brown colour, flexural may be involved. (Patient may have dry skin in the summer months that evolves into large, brown, quandricular scales during the winter months.

Treatment

- ***Often improve with age***
- ***Bathe in salt water increased environment humidity and warmth result in resolution or improvement***
- ***Regular application of Moisturizers cream or lotion after bathing***
- ***Emollients containing Lactic acid, Urea, AHA***
- ***Ammonium Lactate 12% (Lac Hydrin cream)***
- ***Oral retinoids such as acitretin or isotretinoin can be prescribed in severe cases.***

Keratosis Pilaris

KP consists of rough, monomorphic, tiny, follicle-based scaling papules most commonly on the posterolateral aspect of upper arms but occasionally more widespread including the anterior and lateral thigh and the buttocks.
Keratosis pilaris is a very common, dry skin condition caused by keratin accumulation in the hair follicles.
Common in young, peaking in adolescent
asymptomatic

Finding

goosebump' or 'chicken skin' appearance of their skin. These small bumps can be skin-coloured, red, or brown.
The skin can feel rough, dry, and can occasionally be itchy.
It has been associated with other skin diseases such as atopic eczema and ichthyosis.
Small, pinpoint follicular papules and occasionally pustules, remain in the same area for years
The skin feels rough, like sandpaper
A red halo appears at the periphery of the keratotic papules.

Differential Diagnosis

Acne
Bacterial folliculitis - typical bacterial folliculitis is haphazard distribution.
KP often improves or resolve by adulthood.

Treatment


https://www.healthline.com/health/keratosis-pilaris-treatment

- ***There is no cure for keratosis pilaris, however, It often clears up during adult life.***
- ***Moisturizing cream that contains urea, salicylic acid, lactic acid or alpha hydroxy acids***
- ***Ammonium Lactate 12% (Lac Hydrin cream)***
- ***Topical retinoid cream***
- ***Low potency C.S cream***
- ***Emollients***

Pityriasis Alba

It refers to the characteristic fine scale, and alba to its pale colour (hypopigmentation).


https://stamfordskin.com/en/dermatology/pityriasis-alba/

- ***Asymptomatic, hypo pigmented, slightly elevated fine scales patches with indistinct borders, typically on the lateral cheeks.***
- ***Affect lateral cheeks, lateral upper arms, and thigh***
- ***prevalence in children of around 5%***
- ***mainly affects children and adolescents aged 3 to 16 years, but can occur in older and younger people.***
- ***cause of pityriasis alba is unknown.***
- ***Pityriasis alba often coexists with dry skin and atopic dermatitis.***

Skin finding

White macules are round to oval and vary m size, 2-4 cm in diameter.
A fine scale surface may be seen
More obvious in summer and in the darker

Treatment

- ***Usually, no treatment***
- ***Reassurance***
- ***Hypopigmentation fade with time***
- ***A moisturizing cream may improve the dry appearance.***
- ***A mild topical steroid (0.5-1% hydrocortisone) may reduce redness and itch If present.***
- ***Calcineurin inhibitors (pimecrolimus cream and tacrolimus ointment) may be as effective***
- ***Treated with cosmetic reason***

Contact Dermatitis

CD is a generic term applied to acute or chronic inflammatory reactions to substances that come in contact with the skin.
Types of Contact Dermatitis based on etiologic background-

Irritant contact dermatitis (Icd)
Allergic Contact dermatitis (Acd)
Photo contact dermatitis
Contact urticaria
Reaction to pharmacologically active agents



Irritant Contact Dermatitis (ICD)



https://drclementlo.com/refer/index.php/dermatology-jean-l?view=article&id=102&catid=19

ICD is a localized disease confined to areas exposed to irritants
It is produced by a substance that has a direct toxic effect on the skin.
After exposure to an irritant a skin reaction can occur immediately or gradually after repeated exposure. e.g., Common irritants - acids (certain toilet bowel and drain cleaners, dish washer detergents), hand sensitizers, alkalis (ammonia, dye), cement, turpentine and paint thinners.

Symptoms

Itching and burning
Typically, redness, swelling and oozing
The longer the contact or more concentrated
The agents the more severe the reaction.
Irritant contact dermatitis is an eczematous
Dermatitis often caused by repeated exposure to
Mild irritants such as water, soaps, heat and frictions.
About 80% of cases of contact dermatitis involve irritant contact dermatitis.
It does not require Sensitization.

Clinical Finding

The hands are most often affected; both dorsal and palmar surfaces can be affected.
Eyelids are another irritant prone site.
Chronic lip lickers will develop an Irritant dermatitis from repeated Wet-Dry cycle
Erythema, dryness, painful cracking or fissuring and scaling are typical.
Vesicle may be present. May shows juicy papules, weeping and edema
Persistent, Chronic irritants dermatitis is characterized by lichenification, patches of erythema, fissures, excoriation and scaling.

Laboratory

KOH examination for tinea infection
Patch testing for ACD
Blood test -Acanthosis, hyperkeratosis, and lymphyocyte infiltration

Treatment

- ***Removal or avoidance or the substances causing irritation***
- ***Cleaning the area with water and mild soap (mildest cleaner - Dove or Cataphil)***
- ***Application of bland emollients such as Vaseline***
- ***Appropriate protective gloves should be worn.***

- ***Corticosteroid ointment or cream 2-3 weeks (Low potency for face, medium potency for arms, legs and trunk and high potency for hands and feet.***
- ***Corticosteroid tablets- 3 weeks then tapering.***

Contact Dermatitis (CD)

CD is a reaction which occurs when skin comes in contact with certain substances.
Two mechanisms

- Allergic contact dermatitis (allergic reaction)
- Irritant contact dermatitis or

Common irritants:

- Soap, detergents, acids, alkalis and organic solvents e.g., nail varnish remover due to warm, moist condition in the shoes and socks

Seen in around the hands or areas that touched were exposed to the irritants / allergens
Laundry soaps is irritants such as sodium silicate, sodium phosphate, sodium carbonate, rosin
Chemical irritants such as chlorine, cleansers, detergents and soap, fabric softeners, glues used on artificial nails, perfumes and topical medications

Allergic Contact Dermatitis (ACD)

The reaction does not occur the first time one is exposed to a particular substance but on subsequent exposures, which can cause dermatitis in 4 to 24 hours.
Allergic Contact Dermatitis
Is red, itchy, weepy reaction where the skin has come into contact with a substance that immune system recognizes as a foreign such as poison ivy, or certain preservatives in creams and lotion.
Red, bumpy, scaly, itchy and swollen skin are symptoms


https://gladskin.com/blogs/resources/types-of-eczema-contact-dermatitis

Allergic phytodermatitis or RHUs dermatitis

is also called Toxicodendron dermatitis.
It is also allergic contact dermatitis exposed to members of Toxicodendron
Lesions appear within 12-24 hours
New lesion appears on 2-3 weeks


https://healthjade.net/phytophotodermatitis/

Allergic Contact Dermatitis

Nickel allergy
Nickel containing items such as ear rings, in jewelry such as necklaces, necklace clip, earrings, watch strap (especially low carat goal)
In clothing - metal zip, bra hook
Lipstick holder, powder compacts, handbag, cigarette lighter, razors,


https://sso.uptodate.com/contents/image?imageKey=PI%2F62784

key rings
Mental items – cupboard handles, kitchen utensils, toaster, metal teapots, scissors, needles, pins, torches
Silver coins contains cupro-nickel

Hives or Urticaria

Are red, itchy, swollen areas of the skin that can range in size and appear anywhere on the body.
Caused by infections, drugs, food or latex
Hives are caused by a chemical called Histamine and are responsible for many of the symptoms of the skin.


https://www.allergyuk.org/types-of-allergies/urticaria-hives-other-skin-allergy/

Angioedema

It is a swelling of a deeper layers of the skin, sometime occurs with hives. It is not itchy or red and often occurs in soft tissue such as eyelids, mouth and genitals.
It is results from the actions of these chemicals in the deeper layers of the skin.
The mast cells which are cells heavily involved in allergic reactions.
Medication such as aspirin, NSAID such as Ibuprofan, ACE inhibitors, codeine, foods
Allergic Contact Dermatitis (Clinically)
When an allergen comes and contact with previously sensitized skin (Cell mediated hypersensitivity or delay type) or eczematous delay type hypersensitivity reaction.
The time required for previously sensitized person to develop clinically apparent inflammation is about 12 -48 hours.


https://coreem.net/core/angioedema/

Allergic contact dermatitis

is characterized by Vesicles, edema redness and often pruritus.
Itch and swelling are key components of history.
In ivy poison - vesicles, blister and linear lesions present
The hands, forearms and face and foot.
Irritant and ACD can be Impossible to distinguish clinically.


https://alrustom-laser.com/ allergic-contact-rashes/

Laboratory

Blood - spongiosis
Patch test
Contact Dermatitis (Sensitizer type)
CD can occur any part of the body but usually affects hands, feet and groin
Does not spread from one person to another
This type of allergic contact dermatitis usually occurs anywhere from 5-7 days occasionally as long as 20 days after the initial or sensitizing contact, at the site of contact.
There are no circulatory or detectable antibodies produced, although there is a local tissue allergy.

The most common sensitizers are plants, paraphyenylenediamine, nickel, rubber and dichromates.
Commonly occurs - hair dyes, nail polishers, perfumes, lipsticks, tooth paste and sun creams, Rubber, Elastic in hair net, Adhesive tapes, Latex, Non-rubber.
CD to Soaps and detergents, dishwashers, contact with clothing washed in strong soaps or detergents
CD from clothing natural fiber clothing, made from wool, cotton, linen or dark clothing
Fabric finishes
Footwear
Diaper rash

Treatment

- ***Removal or avoidance or the substances causing irritation***
- ***Cleaning the area with water and mild soap***
- ***Manganese sulphate solution to reduce itching***
- ***Antihistamine***
- ***Corticosteroid ointment or cream 2-3 weeks (Low potency for face, medium potency for arms, legs and trunk and high potency for hands and feet.***
- ***Corticosteroid tablets 3 weeks then tapering.***

Lichen Simplex Chronicus

A special localized form of lichenification, occurring in circumscribed plaques.
Result from repetitive rubbing and scratching
Lichenification is a characteristic feature of atopic dermatitis whether generalized or localized
LSC can last for decades
Skin symptoms consist of pruritus, often in paroxysm
Lichenified skin is like an Ergoneous zone
It became pleasure to scratch
The rubbing becomes automatic and reflexive and unconscious habit.



https://www.mdedge.com/familymedicine/article/140009/dermatology/itchy-rash-neck
https://plasticsurgerykey.com/42-lichen-simplex-chronicus-and-prurigo/

Skin Lesions

A solid plaque of lichenification, arising from the confluence of small papules, scaling is minimal except on lower limbs.
Lichenified skin is palpably thickened
Nuchal area, scalp, ankles, lower legs, upper thighs, exterior forearm, vulva, pubis, anal area, scortum and groin.
In black skin-special lichenification pattern - Follicular pattern

Treatment

- ***Rubbing and scratching must be stopped***
- ***Topical Corticosteroid, or TAR preparation***
- ***Combination of 55 Crude coal tar in zinc oxide paste plus class II Corticosteroid cream***
- ***Occlusive dressing is effective***

- ***Adhesive plastic tape.***
- ***Intralesional Triamcinolone 3 mg/ml***
- ***Oral hydroxyzine 25-50 mg***

Prurigo Nodularis (PN)

Idiopathic form, popular or nodular form of lichen simplex chronicus
Nodular prurigo is a skin condition characterized by very itchy firm lumps.
It is the most severe form of prurigo.
PN - pruritic firm papules and nodules and secondary to repeated localized scratching and picking.
Onset gradually and primarily on adult.
The individual prurigo nodule is a firm lump, 1–3 cm in diameter, often with a raised warty surface
Nodular prurigo lesions are usually grouped and numerous but may vary in number from 2–200.
Nodular prurigo tends to be symmetrically distributed.
Extensor arms and legs are typically affected, lumbosacral area, nape of neck, dorsal hands
The small papules and nodules are red or brown, hard and often dome shape with a smooth, crusted or warty surface. Nodules are often eroded, excoriated and sometimes even in ulcerative as patient dip into them with their nails.
Hypo pigment or hyperpigmentation and scratch marks, often resistance to treatment and last years


https://en.drmakise.com/prurigo-nodularis/

Treatment

- ***Emollients***
- ***Oral antihistamine***
- ***High potency Corticosteroid group II - IV cream or***
- ***C.S impregnant tape (Cordan)***
- ***Intralesional steroid kenalog***
- ***Coal Tar ointment as a steroid alternative***
- ***Calcipotriol ointment (topical vitamin D3), can be applied twice daily***
- ***Pramoxine with hydrocortisome***
- ***UVB or UVA therapy***
- ***Cryotherapy***

Overall Treatment

- ***Health Education***
- ***Chronicity of eczema, Association of other conditions: AR, asthma***
- ***Vast number of sensitizing chemicals used currently in our soaps, shampoos, detergents, foods, etc.***
- ***Detailed sensitizers/triggers***
- ***Moisturize daily***
- ***Wear cotton, avoid wool and tight clothes***
- ***Take lukewarm showers, using mild soap or non -soap cleansers***

- ***Pat dry - do not rub***
- ***Avoid extremes of heat/humidity and perspiration***
- ***Learn triggers and how to avoid them***
- ***Keep fingernails short***
- ***Remove carpets and pets from the home***

Conservative Therapy

- ***Education (chronicity, prevention, and trigger id)***
- ***Use of astringents and emollients/moisturizers***
- ***OTC products (hydrocortisone, benadryl, calamine, etc.)***

Steroid - Low to mid potency steroid creams or High potency steroid creams
Immunomodulators - Elidel and Protopic creams
PO therapy: antipruritic,
Cyclosporine, methotrexate
Coal Tar
PUVA therapy (phototherapy)

Summar of Treatment of Dermatitis

	HE	Emollients / moisturizers	Antipruritic creams	Antipruritic drugs	Anti-fungal cream	Steroid Cream	Steroid oral / Injection	Antibiotics	Immune modulator	Cyclo / meth	Coal Tar	PUVA
Atopic Dermatitis	✓	✓	✓	✓		✓		✓	✓	✓	✓	✓
Seborrhoeic Dermatitis	✓	✓		✓	✓	✓		✓	✓			
Pompholyx	✓	✓	✓	✓		✓	✓		✓	✓	✓	✓
Nummular Eczema	✓	✓	✓	✓	✓	✓	✓	✓			✓	✓
Stasis Dermatitis	✓	✓	✓	✓		✓	✓	✓				
Lichen Simplex Chronicus	✓	✓	✓	✓		✓	✓		✓		✓	
Prurigo Nodularis	✓	✓	✓	✓		✓	✓		✓		✓	✓
Icthyosis Vulgaris	✓	✓										
Pityriasis Alba	✓	✓				✓			✓			
Xerotic Eczema	✓	✓		✓	✓	✓		✓	✓			
Contact Dermatitis	✓	✓			✓	✓	✓					

10. URTICARIA

Urticaria (hives) is a vascular reaction of the skin characterized by wheals surrounded by a red halo or flare (area of erythema)



https://www.theharleystreetdermatologyclinic.co.uk/conditions/hives-urticaria/

Cardinal symptom PRURITUS (itch)

Urticaria is caused by swelling of the epidermis

Angioedema can be caused by the same pathogenic mechanisms as urticaria, but the pathology is in the deep dermis and subcutaneous tissue and swelling is the major manifestation.

Angioedema commonly affects the face or a portion of an extremity. Involvement of the lips, cheeks, and periorbital areas is common, but angioedema also may affect the tongue, pharynx, larynx and bowels

Urticaria and Angioedema, both are not a disease but a cutaneous reaction pattern.

Urticaria and angioedema may occur in any location together or individually.

It is self-limited and benign, It can cause significant discomfort, continue for months to years, and uncommonly represent a serious systemic disease or life-threatening allergic reaction.

Angioedema and/or urticaria may be the cutaneous presentation of anaphylaxis,

Assessment of the respiratory and cardiovascular systems is vital.

Urticaria is a common dermatologic condition that typically presents with intensely pruritic, well-circumscribed, raised wheals ranging from several millimeters to several centimeters or larger in size.

Urticaria can occur with angioedema, which is localized non-pitting edema of the subcutaneous or interstitial tissue that may be painful and warm.

The intense pruritus can cause significant impairment in daily functioning and disrupt sleep.

Types of Urticaria

Acute urticaria, new onset urticaria, (<6 weeks duration, and often gone within hours to days)

Chronic urticaria, recurrent urticaria, (> 6 weeks duration, with daily or episodic wheals)

Chronic urticaria may be spontaneous or inducible. Both types may co-exist.

Causative Factors (6 IS)

Ingestants - medication, food, additives

Inhalants - dust, feather, pollen

Injectants- drugs, stings, bite

Infections -bacteria virus, fungal

Internal diseases such as chronic infection, LE, erythematous, Occult cancer

Idiopathic

Genetic

Stress

Urticaria is caused by immunoglobulin E- and non–immunoglobulin E-mediated release of histamine and other inflammatory mediators from mast cells and basophils.

Chronic urticaria is idiopathic in 80% to 90% of cases.

Classification

Immunologic


https://www.aafp.org/pubs/afp/issues/2011/0501/p1078.html

IgE mediated urticaria
Complement mediated urticarial
Autoimmune urticaria
Immune Contact urticarial

Physical

Dermographism
Cold urticaria
Cholinergic urticaria
Contact urticaria
Delayed pressure urticaria
Solar urticaria
Heat urticaria
Vibratory urticaria
Aquagenic urticaria
Due to mast cell releasing agents, pseudo-allergens, ACEI

Idiopathic

Nonimmune Contact urticaria
Associated with vascular/connective tissue autoimmune disease
Distinct Angioedema syndrome
Hereditary angioedema
Angioedema urticarial eosinophilia syndrome

History - ASK -6 IS

Physically, Urticaria is characterized by the following:
Blanching, raised, palpable wheals, which can be linear, annular (circular), or arcuate (serpiginous)
Wheals small (< l cm) to large (>8cm),
large areas of erythematous, raised lesions that blanch with pressure
Lesions are transient
Angioedema - skin coloured, transient enlargement of the portion of face
Localized or regional or generalized in solar, pressure, vibration, cold...
Dermographism (urticarial lesions resulting from light scratching)
Potentially life-threatening,
Angioedema of the lips, tongue, or larynx
Individual urticarial lesions that are painful, long-lasting, or ecchymotic or that leave residual hyperpigmentation or ecchymosis upon resolution
Hypotension
Respiratory distress
Stridor

GI disturbance

Etiology

Immunoglobulin E (IgE) often mediates this release, but non-IgE and nonimmunologic mast cell activation also can occur.

Proteases from aeroallergens and activation of the complement system have been proposed as examples of non-IgE triggers

Systemic Sign or Symptoms

Scleral icterus, hepatic enlargement, or tenderness

Thyromegaly

Pneumonia or bronchospasm (asthma)

Cutaneous evidence of bacterial or fungal

Table: Assessment of disease activity in urticaria patients

Score	Wheal	Pruritus
0	None	None
1	Mild (<20 wheals /24 hours)	Mild (present but not annoying or troublesome)
2	Moderate (20-50 wheals/24 hr)	Moderate (troublesome but does not interfere with normal daily activity or sleep)
3	Intense (>50 heals /24 hours or large confluent areas of wheals	Intense (severe pruritus, which is sufficiently troublesome to interfere with normal daily activity or sleep)

Sum of score: 0-6

Urticaria is a clinical diagnosis

A detailed history and physical exam should be performed

Many times, patients will not present with urticaria during their clinic visit

Treatment

- ***Discontinue the all-suspected triggers. The mainstay of treatment is avoidance of triggers, If identified.***
- ***Antihistamine e.g., hydroxyzine 10 -25 mg / per day***
- ***The first-line pharmacotherapy is second-generation H_1 antihistamines, which can be titrated to greater than standard doses.***
- ***Non-sedating Antihistamine e.g., cetrizine, or loratadine 7-10 days***
- ***H_1 blocker such as cimetidine 400 mg bd or ranitidine 150 mg/day 7-10 days.***
- ***First-generation H_1 antihistamines, H_2 antihistamines, leukotriene receptor antagonists and high-potency antihistamines.***
- ***Montelukast 10 mg hs for 7 -10 days***
- ***Doxepin, tricyclic antidepressant and antihistamine can be given***
- ***Oral prednisolone can use the condition of difficult to control (adjunctive treatment) with antihistamine.***

Treatment of Chronic urticaria (AAFP)



NOTE: *If symptoms are severe, a short course (3 to 10 days) of systemic corticosteroids (e.g., oral prednisone, 0.5 to 1 mg per kg per day) may be added at steps 1, 2, or 3.*

- ***https://www.aafp.org/pubs/afp/issues/2017/0601/p717.html***
- ***When to ReferReferral to a dermatologist and biopsy should be performed in patients with one or more of the following features:***

Individual lesions that persist beyond 48 hours, are painful rather than pruritic, or have accompanying petechial characteristics

Systemic symptoms, Lack of response to antihistamines

Lesions that leave pigmentation changes upon resolution

11. PSORIASIS

Psoriasis is an inflammatory immunological reaction and It is a noncontagious skin disorder most commonly appears as inflamed, edematous skin lesion covered with silvery white scale. or
A common chronic inflammatory genodermatosis which appear to be due to abnormal T lymphocyte function.
Site - Scalp, nails, extensor surface of the limbs, umbilical regions and sacrum

CHARACTERISTIC OF LESION



Circumscribed, erythematous, dry, scaling plaques of various sizes and covered with silvery white lamellar scales.
Sex - more common in female.
Race- more common in white.
Age - 10-15% new cases in younger child than 10 years, mean age onset is 28 years
Frequency - 2 and 2.6 % of US affected.
Flare -may be related to systemic or environmental factors. e.g., stress or infections
Heredity- Polygenic trait. Associated with HLA B13, Bl 7, Bw57
Trigger factors - Physical trauma (Koebner phenomenon), infection, stress, drugs, alcohol

TYPES

Plaque or discoid psoriasis



https://emedicine.medscape.com/article/1108072-overview
https://www.dermatologyadvisor.com/home/topics/psoriasis/long-term-plaque-pso-treatment-clinician-recommendations/
https://www.aad.org/public/diseases/psoriasis/what/symptoms

Is most common type, characterized by patches on the scalp, trunk, and limbs.
Red sharply defined, scaling papules that coalesce to form stable round to oval plaques. Deep rich colour is a characteristic feature.
Scale is adherent, when removed reveal bleeding (Auspitz sign).
Most common on extensor surface of knee, elbow, scalp and trunk.

Guttate psoriasis


https://www.pcds.org.uk/clinical-guidance/guttate-psoriasis

Sudden appearance of numerous monomorphic psoriasis papules (Salmon pink papules or
small red drop/dots (Rain drop) appear on the arms, trunks and legs.
May have some scales. Triggered by URTI (streptococcal infection).
Guttate lesion may resolve spontaneously within a few weeks but usually become recurrent
and may evolve into chronic stable plaques. Age start at 30 years.

Inverse psoriasis (Intertriginous)

Occur on the flexural surface, armpit, groin, ear, axilla, navel, and intergluteal crease, penis, under the breast and in the skin fold.
It is characterized by smooth, inflamed lesions without scaling.
Super- imposed candidal infections in DM patients and with topical steroid use.
Napkin psoriasis is seen in
diaper area of infant of 2- 8 months old.


https://www.healthline.com/health/inverse-psoriasis#gallery-open

Pustular psoriasis

Presents as sterile pustules appearing on the hands and feet or at time diffusely
and may cycle through erythema, pustules and scaling.
Characterized by pustules not papules, arising on normal or
inflamed, erythematous skin.


https://www.verywellhealth.com/what-are-the-different-types-of-pustular-psoriasis-3876679
https://dermnetnz.org/images/generalised-pustular-psoriasis-images

Two types, palmoplanter pustulosis and generalized acute pustular psoriasis (Von Zumbush) which is medical emergency.

Erythrodermic Psoriasis

Presents generalized erythema, pain, itchy and fine scaling. There is total body redness with weakness, fatigue with chills, It is called RED Man Syndrome.
Massive scaling can lead to protein loss and maximal dilation of skin capillaries to considerable heat dissipation and high output cardiac failure.
One of the medical emergencies. May be drug related.


https://www.uptodate.com/contents/image/print?imageKey=DERM%2F111552~DERM%2F111553~DERM%2F111554

Nail Psoriasis

Pitting is the most characteristic sign of psoriasis of the nail plate. Onycholysis is separation
of the nail from the nail bed.
Accumulation of parakeratotic debris and serum under
the nail bed creates a light brown spot called an oil spot lesion.



https://www.uptodate.com/contents/image/print?imageKey=DERM%2F111552~DERM%2F111553~DERM%2F111554
https://www.researchgate.net/figure/Nail-pitti

Scalp Psoriasis

Affected 50% of patients, presents as

- Erythematous raised plaques with Silvery white scales on the scalp.



https://www.everydayhealth.com/psoriasis/guide/scalp-psoriasis/

Psoriasis Arthritis

10% with skin symptoms, 5 clinical patterns,
Oligoarthritis with swelling and tenosynovitis of one or a few hand joints (70%)
Asymmetrical distal interphalangeal joint involvement (16%)
Symmetrical polyarthritis like rheumatoid arthritis with claw hands (15%)
Ankylosing spondylitis alone or with peripheral arthritis (5%)
Arthritis mutilans with osteolysis of phalanges and metacarpals (5%)



https://www.orthobullets.com/basic-science/9050/psoriatic-arthritis

Oral Psoriasis

May present with lesions on the buccal mucosa which may appear to change day to day. May
present as a severe chelosis with extension onto the surrounding skin.



https://www.healthline.com/health/psoriasis/psoriasis-on-the-tongue#pictures

Causes

Lesions of psoriasis are caused by increase in the turnover rate of dermal cells from the
normal 23 days to 3 - 5 days in affected area. Silver scale is due to a layer of dead skin cells.
Gene locus
Trigger factors - immunologic events, stress, drug induced

After respiratory tract infection
Autoimmune function
Superantigens and T cells

Pathogenesis

Hyperproliferative disorder
The proliferative disorder is driven by a mixed T helper THI and THI 7 inflammatory diseases.
It is clear that immune factors and inflammatory cytokines (messenger proteins) such as IL1β and TNFα are responsible for the clinical features of psoriasis.
Current theories are exploring the TH17 pathway and release of the cytokine IL17
T cells and cytokins play the pivotal role in psoriasis.

Laboratory Diagnosis

Punch biopsy - shows Acanthosis, Parakeratosis, Hyperkeratosis and Munro microabscesses.
ASO titre for streptococcal pharyngitis
Potassium hydroxide - candida infection (fungal studies)
HIV test especially extensive psoriasis.
Rheumatoid factors
Uric acid - elevate in psoriasis arthritis
Latex fixation test
ESR
Radiographs
Bone scan

Differential Diagnosis

Seborrheic dermatitis
Dyshidrotic eczema
Tinea capitis
Pityriasis rosea

Treatment

All patients should be given basic information, consultation, consider features of diseases and patients characteristics.
Goals of treatment

- ***Controlling itch, discomfort and scaling***
- ***Cleaning psoriasis patches***
- ***Limiting the extent of the diseases***
- ***preventing complications such as erythroderma or generalized psoriasis***
- ***Preventing recurrent***

Emergency Department care

- ***Patients with Guttate, Erythroderma or Pustular psoriasis may present to emergency care***
- ***Restoration of the barrier functions is important.***
- ***Do cleaning and bandaging.***
- ***Solar or UV radiation may be helpful.***

- *Oatmeal baths may be helpful.*

Therapy to consider

- *A step-by-step guide to medical management*
- *PASI Score <20 % of body surface area affected - use topical*
- *PASI Score >20% of body surface area affected - refer to hospital*

General Treatment

- *Life style modification*
- *Behavior or life style change*
- *Relaxation therapy*
- *Psychotherapy*
- *Exercise*
- *Avoidance of exacerbating factors*
- *Assistant to supports group for the patients*

Adjunct to treatment

- *Moisturizers*
- *Scale removing agents containing salicylic acid*
- *Sunshine*

Initial treatment

- *Topical corticosteroids group (I-V) - reduce the plaque formation and have anti- inflammatory affect. e.g., - Triamcinolone acetonide 0.1% cream, but not affective in nail psoriasis.*
- *Calcipotriene (Dovonex) – A synthetic vitamin D3 analog that regulates skin cell production and development. It can be used in chronic plaque psoriasis and scalp psoriasis. It can apply once or twice daily.*
- *Coal tar1 -10% (DHS tar) - useful in hair bearing area, It has antipruritic and antibacterial action. It is particularly affective for scalp psoriasis.*
- *Keratolytic agents – Anthralin 0.1-1% (Dithranol cram), use to remove scale, to smooth the skin and to treat hyperkeratosis, especially chronic plaque psoriasis.*
- *Topical retinoids - Tazarotene (Tazorac) aqueous gel 0.05% to 0.1%, It is converted to its active form in the body and modulates differentiation and proliferation of epithelial tissues, and It has anti-inflammatory and immunomodulatory. The most common side effect is skin pain and local irritation. Contraindicated in -pregnancy.*
- *Calcineurin inhibitors (Tacrolimus)*
- *They are steroid sparing agents on sensitive sites where the skin is thinner (Face, genital are) usually used under occlusion.*

Failure of Topical treatment

- *Affecting more than 20 % of body surface area*
- *UVB therapy, it is generally reserved for topical therapy was ineffective. It is very effective for psoriasis, usually 2-3 treatment per week for 20-30 treatment. Not effective for scalp and flexural site.*
- *Combination of topical therapy and phototherapy.*

Oral therapy

- ***Failure of topical and phototherapy, repeated hospitalization, extensive chronic plaque, severe psoriatic arthropathy, erythrodermic or generalized pustular psoriasis***
- ***Methotrexate***
- ***Cyclosporin***
- ***Combination therapy***
- ***Biological therapies***

Treatment of Localized Psoriasis

Algorithm for the treatment of localized psoriasis.



https://www.aafp.org/pubs/afp/issues/2000/0201/p725.html

- Treatment of localized psoriasis is initiated using topical corticosteroids, alone or in combination with coal tar or calcipotriene.
- Patients with resistant lesions may benefIt from the addition of anthralin or tazarotene.

In special situation (Scalp psoriasis)

- ***Difficult to treat***
- ***Corticosteroid lotion or tar gel (Linotar, coal tar gel) or shampoo (Neutrogena T shampoo) or spray or foams to treat mild to moderate scalp psoriasis.***

Genital Area

- ***Mild corticosteroid (with or without calcitriol ointment)***

- ***Medium-strength or potent corticosteroid (used for a short time)***
- ***Mild coal tar (use this only If a doctor recommends it)***
- ***Calcipotriene cream***
- ***Pimecrolimus cream or tacrolimus ointment***
- ***Stronger medicine such as cyclosporine, methotrexate, or a biologic***
- ***Body wash (QV wash or Halmiton's body wash)***
- ***Colloidal oat meal in the bath***
- ***Moisturizers***

Nail

- ***General nail care***
- ***Moisturize your nails and the skin around your nails.***
- ***Keep your nails trimmed short.***
- ***Apply a nail hardener polish.***
- ***Cut off hangnails.***
- ***A corticosteroid cream, ointment or nail polish.***
- ***injection triamcinolone acetonide (Kenacort Al O) 2-3 monthly***

Complication

- secondary infection
- Psoriatic arthritis
- Mitral valve prolapsed

Prevention

- Avoid injury to skin
- Avoid sunburn
- Physical trauma

Prognosis

- ***Life-long involvement***
- ***Usually benign***
- ***May be refractory to treatment***

Pitfall

- Abrupt stopping steroid therapy in psoriasis or adding known irritant drugs - may cause worsening of the psoriasis
- Many of therapies for psoriasis manipulate the function of the immune system and expose the risk of infection.

12. MISCELLANEOUS INFLAMMATORY DISORDERS

Lichen Planus (LP)

LP in an acute or chronic inflammatory dermatosis involving skin and or mucous membrane.
Characterized by flat-topped (Latin, planus -flat), pink to violaceous, shiny, pruritus, polygonal papules.
6 Ps - Papule, Purple, Polygonal, Pruritus, Planter (Flat top), Plaque
Flat top with interspersed lacy white line.
It is thought to be an abnormal immune reaction provoked by a viral infection e.g., VHC or a drug.
Cell mediated immunity plays in a major role.



https://statmed.org/knowledge/lichen_planus
https://dermnetnz.org/topics/lichen-planus
https://almostadoctor.co.uk/encyclopedia/lichen-planus

Lichen planus may cause a small number of skin lesions or less often affect a wide area of the skin and mucous membranes.
85% of cases It clear from skin surface within 18 months but may persist longer.
Age of onset -30-60 years
Female > male
Onset - Acute (Days) or insidious
Mucous membrane lesions are painful especially when ulcerated.
Skin Lesion -Papules, flat topped,1 - 10 mm, sharp defined, shiny.
Violaceous with white lines (Wickham striae)
Grouped, Annular< disseminated scattered discrete lesions when generalized.



https://dermnetnz.org/topics/lichen-planus

Classical Lichen Planus

Characterized by shiny, flat topped, firm papules varying from pin point size (guttate) to larger than 1 cm.
There are a purple colour and often are crossed by white lines (Wickham line).
They may be
Liner lichen planus - group in line
Annular lichen planus -ring
Hypertrophic LP (Very thick scaly patches are particularly itchy.

Variants

Hypertrophic - Large thick plaques arise on the foot, dorsum of hands and shin. Typical LP papule is smooth, hypertrophic lesion become hyperkeratotic
Atrophic - White bluish, well demarcated papules and plaque
Follicular - Individual keratotic follicular papules and plaques that lead to cicatricial alopecia. Cicatrical alopecia of scalp is called Graham little syndrome.
Vesicular - Vesicular or bullous lesions may develop within LP patches.
Pigmentosus - Hyperpigmented, dark brown macules lesions in sun exposed areas.
Actinicus - Papular LP lesions arised in sun exposed areas site.
Ulcerative type - LP lead to therapy resistant ulcers on the soles.
Mucous Membranes
Reticular (Net-like) - pattern of lacy white hyperkeratosis on buccal mucosa, tongue, gingiva, most common pattern
Erosive or Ulcerative - Superficial erosion with or without overlying fibrin clot; occur on tongue and buccal mucosa.
Genitalia - Papular,annular, or erosive lesions arise on penis., scortum, labia majoria, vagma
Hair and Nails, Scalp - Follicular LP, atrophic scalp skin with scarring alopecia.
Nails- destruction of nail fold and nail bed with longitudinal splintering.

Classical lichen pianos

Classical lichen planus is characterised by shiny, flat-topped, firm papules (bumps) varying from pin point size ('guttate') to larger than a centimetre.

Oral lichen pianos

The mouth is involved in 50% of cases and is often the only affected area.
The usual areas affected are the inside of the cheeks and the sides of the tongue, but the gums and lips may also be involved. The most common features are:
Painless white streaks in a lacy or fem-like pattern
Painful and persistent ulcers (erosive lichen planus)
Diffuse redness and peeling of the gums (desquamative gingivitis)



https://dermnetnz.org/topics/erosive-lichen-planus
https://www.aaom.com/oral-lichen-planus

Vulval lichen pianos

As in the mouth, lichen planus may cause painless white streaks.
Erosive lichen planus affects the labia minora (inner lips) and introitus (entrance to the vagina).
The affected mucosa is bright red and raw.
The labia minora can shrink and stick to each other or to the labia majora (the outer lips).
Erosive lichen planus can be very painful, preventing sexual intercourse. It can also scar, closing over the vagina.

Vaginal lichen pianos

Sometimes lichen planus affects deeper within the vagma where It causes desquamative vaginitis.
The surface cells in the vagina peel off and cause a mucky discharge. The eroded vagina may bleed easily on contact.

Penile lichen pianos

Classical papules are the most common form of lichen planus on the penis and mostly occur in a ring around the glans (the tip of the penis).
White streaks and erosive lichen planus are much less common on the penis.

Other mucosal sites

Erosive lichen planus uncommonly affects the eyelids, external ear canal, oesophagus, larynx, bladder and anus.

Lichen planopilaris

Follicular lichen planus, also known as lichen planopilaris, results in tiny red spiny papules around a cluster of hairs.
Sometimes no follicular scaling or inflammation is present but bald areas of scarring slowly appear, often looking rather like footprints in the snow.
This is known as 'pseudopelade'. When the cause is unknown, It is called pseudopelade of Brocq.
Frontal fibrosing alopecia is thought to be a limited form of lichen planopilaris.



Lichen planus affecting the scalp Lichen planopilaris

https://dermnetnz.org/topics/lichen-planopilaris ,
https://www.drbatras.com/lichen-planus-and-hair-loss

Lichen pianos of the nails

Lichen planus affects one or more nails in 10% of cases, sometimes without involving the skin surface.
If all nails are abnormal and nowhere else is affected It is called twenty nail dystrophy.

The nail plate tends to thin and may become grooved and ridged. The nail may darken, thicken up or ift off the nail bed (onycholysis). Sometimes the cuticle is destroyed and forms a scar (pterygium). The ails may shed, stop growing altogether and rarely, completely disappear.



https://www.medicaljournals.se/acta/content/html/10.2340/00015555-1957
https://dermnetnz.org/images/nail-lichen-planus-images

Lichen pianos pigmentosos

In some patients ill-defined oval greyish brown marks appear on the face and neck or trunk and limbs without an inflammatory phase.
In some cases, lichen planus pigmentosus is provoked by sun exposure. In others, It arises in sun-protected sites such as the armpits. It has diffused, reticulate and diffuse patterns.
Lichen planus pigmentosus may be the same or similar to erythema dyschromicum perstans.
Skin biopsy of lichen planus pigmentosus reveals lichenoid features which are absent in a similar condition called idiopathic macular pigmentation.

Actinic lichen pianos

Actinic lichen planus only affects sun exposed sites such as face, neck and the backs of the hands.
Bullous lichen pianos
Bullous lichen planus is rare; blisters appear within lichen planus papules or by themselves, generally on the lower legs.

Skin biopsy

The diagnosis of lichen planus is often made by a dermatologist, oral surgeon or dentist by the typical appearance.

- However, a biopsy is often recommended to confirm or make the diagnosis and to look for cancer.
- The histopathological signs are of a 'lichenoid tissue reaction' affecting the epidermis (the skin cell layer). Typical features include:

Irregularly thickened epidermis
Degenerative skin cells
Liquefaction degeneration of the basal layer of the epidermis
Band of inflammatory cells just beneath the epidermis
Melanin (pigment) beneath the epidermis
Direct staining by immunofluorescent techniques may reveal deposits of immunoglobulins at the base of the epidermis.

Treatment

- ***Treatment is not always necessary.***
- ***Potent and ultrapotent topical steroids Topical steroids such as clobetasol propionate and betamethasone propionate ointments are generally applied for 4 -6-week courses.***
- ***In the mouth, steroid pastes or inhalant powders may be easier to apply to affected sites. Hydrocortisone foam can be used inside the vagina.***
- ***Steroid injections into affected areas may be useful for localized disease.***
- ***Systemic steroids in extensive cases systemic steroids such as prednisone may be prescribed for a few weeks or longer.***
- ***This will lessen the itch and often clear up the lichen planus completely. However, It may recur later.***
- ***Systemic Retinoids (Acitretin)***
- ***PUVA Photochemotherapy***
- ***Other treatments include long term antibiotics, oral antifungal agents, phototherapy, acitretin, methotrexate and hydroxychloroquine.***
- ***The immune modulating drugs that inhibIt calcineurin, tacrolimus ointment and pimecrolimus cream, may be useful for oral and genital lichen planus.***

Pityriasis Rosea

Is an acute exanthematous eruption with a distinctive morphology and often with characteristic of self-limited course.
Initially, a single (Primary or herald) plaque lesion develops usually on the trunk.
1 to 2 weeks later a generalized secondary eruption develops in a typical distribution pattern.
The entire process remits spontaneously in 6 weeks
Reactivation of HHV 6 and 7 is the most probable cause.
Onset - 10-43 years
Etiology - Good evidence that PR is associated with HHV 6 and HHV 7.

Clinical manifestation

A single herald patch precedes the exanthematous phase; which develops over a period of 1-2 weeks.
PRURITUS absents in 25%, mild in 50% and severe in 25%
Skin lesion - Herald Patch in 80 % of the patients.
Oval, slightly raised plaque or patch 2-5 cm. Salmon red, fine Collarette scale at periphery, may be multiple.
Exanthem -fine scaling papules and plaques with marginal collarette.
Dull pink or Tawny
Oval scattered, with characteristic distribution with long axes of the oval lesions following the lines of cleavage in a CHRISTMAS TREE pattern.
Lesions confirm to trunk and proximal aspects of the arms and legs.
Atypical pityriasis rosea lesions may be present only on the face and neck. This usually results from irritation and sweating. called Pityriasis rosea irritate.



https://step2.medbullets.com/dermatology/120085/pityriasis-rosea
https://patient.info/childrens-health/viral-skin-infections-leaflet/pityriasis-rosea
https://www.penndermspecialists.com/pityriasis-rosea/

Pityriasis rosea is a viral rash which lasts about 6-12 weeks.
It is characterized by a herald patch followed by similar, smaller oval red patches that are located mainly on the chest and back.
Pityriasis rosea most often affects teenagers and young adults. However, It can affect males and females of any age.

Systemic symptoms

Many people with pityriasis rosea have no other symptoms, but the rash sometimes follows a few days after a upper respiratory viral infection (cough, cold, sore throat or similar).

The herald patches

The herald patch is a single plaque that appears 1-20 days before the generalized rash of pityriasis rosea.
It is an oval pink or red plaque 2-5 cm in diameter, with a scale trailing just inside the edge of the lesion like a collaret.

Secondary rash

A few days after the appearance of the herald patch, more scaly patches (flat lesions) or plaques (thickened lesions) appear on the chest and back.
A few plaques may also appear on the thighs, upper arms and neck but are uncommon on the face or scalp.
These secondary lesions of pityriasis rosea tend to be smaller than the herald patch. They are also oval in shape with a dry surface.
Like the herald patch, they may have an inner collaret of scaling. Some plaques may be annular (ring-shaped).
Pityriasis rosea plaques usually follow the relaxed skin tension or cleavage lines (Langer's lines) on both sides of the upper trunk.
The rash has been described as looking like a fir tree. It does not involve the face, scalp, palms or soles.
Pityriasis rosea may be very itchy, but in most cases, It doesn't itch at all.
Pityriasis rosea clears up in about six to twelve weeks.
Pale marks or brown discoloration may persist for a few months in darker skinned people but eventually the skin returns to its normal appearance.
Second attacks of pityriasis rosea are uncommon (1-3%), but another viral infection may trigger recurrence years later.

Complications

Pityriasis rosea during early pregnancy has been reported to cause miscarriage in 8 of 61 women studied.
Premature delivery and other perinatal problems also occurred in some women.
Atypical pityriasis rosea due to reactivation of herpes 6/7 in association with a drug can also lead to the severe cutaneous adverse reaction, drug hypersensitivity syndrome.

General advice

Bathe or shower with plain water and bath oil, aqueous cream, or other soap substitute.
Apply moisturizing creams to dry skin.
Expose skin to sunlight cautiously (without burning).

Treatment

- ***Oral antihistamine***
- ***Antipruritic lotion***
- ***Topical Corticosteroid - reduce the itch while waiting for the rash to resolve.***
- ***UVB therapy - Extensive or persistent cases can be treated by phototherapy.***
- ***Short course of PNLD - helpful***

To speed up clearance of pityriasis rosea:

- ***A 7-day course of high-dose acyclovir***
- ***A 2-week course of oral erythromycin has also been reported to help, probably because of a nonspecific anti-inflammatory effect.***
- ***Other studies have found that erythromycin and azithromycin are not effective in pityriasis rosea.***

13. BENIGN SKIN TUMOURS

Dermatofibroma

Common benign indolent dermal papule, occurs on the legs of adults.
Mostly asymptomatic, may be pruritus and tenderness.
Aetiology unknown
Discrete firm pink dermal papules of 3-5 mm in diameter are typical, most are dome shape but some are depressed, fixed with skin
On palpation, lesions feel firm button
Typical fresh color to pink with define ring of tan to brown pigmentation due to melanin and hemosiderin
DIMPLE Sign- Dimpling (Retract) of the lesion is seen when pinched between two fingers.


https://www.msdmanuals.com/en-sg/home/quick-facts-skin- sorders /noncancerous-skin-growths/dermatofibromas

- ***Surgical excision with primary closure, or cryosurgery with cotton-tip applicator.***

Keratoacanthoma

A rapidly evolving tumor composed of keratinizing squamous cells originating in the pilocebaceous follicles and resolving spontaneously If untreated.
A dome-shaped nodule with central keratotic plug or depression conceals a deep keratinous cavity.
Aetiological factors: HPV 9, 16, 19, 25 & 37 and UV rays, industry pitch and tar
Characteristic is volcano-like lesion, color is slightly red or tan or brown, firm but hard, always appear on sun damage area, skin, cheeks, nose, ears and hands
Like molluscum contagiosum
3 growth phases (1) Proliferative phase (2) Mature phase (3) Resolving phase
Spontaneous healing takes 3 months.
Resolved or progressive into invasive squamous cell carcinoma.


https://www.sciencephoto.com/media/1273804/view/keratoacanthoma

- ***Excisional biopsy, surgical excision, complete excision with margin or electro- desiccation and curettage***

Skin Tags

Common benign soft skin color or tan or brown, round or oval or loose fibrous tissue
pedunculated papilloma
Mainly on axillae, neck, eyelids, and major flexures such as axillae, inframammary, groins.
More common in females and obese patients

May be part of Birt-Hogg-Dube Syndrome which also includes Trichodiscomas and
Fibro-folliculoma of the face.
May be associated with Renal Cell Carcinoma, Colonic Adenoma, pulmonary cyst, Ca thyroid.


https://www.firstderm.com/skin-tags/

- ***Simple snipping with scissors,***
- ***Electrodessication or Cryosurgery or Electro cautery.***

Sebaeceous Hyperplasia

Prominently enlarged sebaceous glands of unknown aetiology
Common in older person, both sex
Can confuse with Basal Cell Carcinoma
Begins as a 1-2 mm soft pale yellow to skin colored minimally elevated papules, may be solitary but are more commonly multiple and on the forehead, nose and cheeks


https://www.l-formulaclinic.co.uk/sebaceous-hyperplasia

- ***Treatment is not required but may be cosmetic reason Biopsy, CO_2 laser ablation, electrodesiccation***

Syringoma

Benign adenomatous eccrine ducts of sweat glands.
Small, firm, skin colored papules, most common in women, around the eyelids, upper chest, on vulva.
Specific histological pattern: many small ducts in the dermis with comma like tail with the appearance of tadpoles.


https://www.iskin.com.hk/syringomas-sebaceous-hyperplasia-seborrhoeic-keratosis/

- ***Electrosurgery, cryotherapy, laser therapy***

Seborrheic Keratosis (SK) (Dermatosis Papulosa Nigra)

Commonest benign epithelial tumors
Unusual before age 30 years
Most people develop at least one SK in their lifetime
Usually asymptomatic, but can be irritation, trauma and bleeding
Multiple lesions, at any site except palms, sole and lips
Flat or raised, sharply demarked, rounded to oval or asymmetric


https://skinsurgeryclinic.co.uk/treatments/seborrhoeic-keratosis-removal/

Surface: smooth, velvety or verrucous
Color: variable including white, pink, brown and black and color may be vary in a single lesion
Characteristic: STUCK-ON appearance and waxy texture
Dermatosis Papulosa Nigra is darkly pigmented seborrheic keratosis of face seen in African –American people and myriad of tiny black lesions.

STUCCO Keratosis is small white, firm SK more commonly found on the lower legs and ankle of older Caucasian people.
Leser Trelat (sudden onset, numerous SK in association with internal malignancy).
Flat SK may mimic pigmented AK

- ***Biopsy -Acanthosis, hyperkeratosis and papillomatosis***
- ***Cryosurgery is effective for Flat and minimal raised SK, best***

Hypo or Hyper pigmentation are possible side effect of removal

Hypertrophic Scar



Exuberant fibrous repair tissues after a cutaneous injury
Confined to site of original injury. Papule to nodules.
Unknown etiology

- ***Intralesional injection Triamicinolone 10-40 mg/ml every months, can combine with cryotherapy, or surgical excision***

Silicone cream and gel not very effective

Pilar Cyst (Trich Ilemmal Cyst)

A cyst containing keratin originating from epithelial cell of outer root sheet of the hair follicle.
Second most common type of cutaneous cyst, commonest on scalp (90%)
Smooth, mobile, firm and rounded nodule
Larger lesion may be lobular and multiple cysts
Cyst wall may be fused with the epidermis to form crypt
No central punctum

- ***I&D with LA or elective excision.***



https://www.pcds.org.uk/clinical-guidance/pilar-cyst-syn-trichilemmal-cyst

Epidermal Cyst

A firm subcutaneous keratin filled nodule originating from true epidermis
Common anywhere on the skin, on the trunk, post- auricular fold and posterior neck and scrotum
Usually solitary, firm, domed shaped, pale yellowish intradermal or subcutaneous
Mobile but are tethered to the overlying skin through a small punctum that open appear as a comedo.
Multiple cysts occurring on the face, scalp and back shoulder should suspect Gardner Syndrome (rare autosomal dominant associated with Colonic polyposis and adenocarcinoma of the colon)
Cysts on the face may rupture, yellow white keratinous foul- smelling debris extruding from a ruptured



https://www.researchgate.net/figure/The-epidermoid-cysts-multiplex-of-the-scrotum_fig1_263863774

epidermal cyst, and lead to scarring,

- ***I&D under LA, or complete surgical excision with narrow margins is curative.***

Nervous Sebaceus

Congenital lesions of the scalp, head and neck and composed of skin and appendageal components
As a single lesion on the scalp, forehead or post- auricular area
A linear to oval, yellowish to flesh coloured plaque
A triad of nervous sebaceous, epilepsy and mental retardation can occur.
Depending on location, It can be quite noticeable and even disfiguring


https://www.healthline.com/health/nevus-sebaceous

- ***Excision of entire lesions is recommended***

Choncromermatitis (Nodularis-Helicis)

Is an inflammatory condition of the helical of the ear cartilage
Tender papules on the most lateral edge of the helix
Primary lesion is a firm, tender, red to pink papule of 2-4 mm with a central keratotic punctum, which has firm, adherent crust or scale resembling a small cutaneous horn.


https://www.pcds.org.uk/clinical-guidance/chondermatitis-nodularis-helicis

- ***Intralesional steroid, or Surgical removal***

Clear Cell Acanthoma

A scaly plaque or nodule that has a characteristic accumulation of clear, glycogen containing cells in the epidermis
Solitary, slightly elevated to dome shaped plaque or nodule with an abrupt margin and wafer like scale adherent at the periphery which leaves a moist or bleeding surface when removed.
Characteristically red with vascular puncta and It blanches on diascopy


https://drclementlo.com/refer/index.php/dermatology-jean-l?view=article&id =192&catid=98

- ***Treatment - Excision***

Keloid

Feature of hypertrophic scars with added feature of thick, eosinophilic, acellular bands of collagen, but may arise spontaneously without history of injury
May extend in a claw-like fashion far beyond the original injury, may continue to expand in size for decades
Earlobe, shoulder, back, chest


https://www.thenationalskincentre.com/keloid.html

- ***No treatment is highly effective***

Milium

1-2 mm superficial, white to yellow, keratin containing epidermal cyst.
Can occur at any age, even in infant, small chalk white or yellow papule on the cheek.
Milia arises around the eye or in association with various dermatoses with subepidermal bullae


https://www.tuasaude.com/como-tirar-milium-da-pele/

- ***Surgical Incision***

Digital Myxoid Cyst

Pseudocyst occurring over the distal interphalangeal joint and base of the nail of the finger or toe, often associated with Heberden's node
Solitary cyst, rubbery, translucent.
A clear gelatinous viscous fluid may be extruded.
Older patient >60 years
When the Myxoid cyst is over the nail matrix, a nail plate dystrophy occurs.


https://www.healthline.com/health/myxoid-cyst

- ***Surgical excision, I&D***

14. VASCULAR TUMORS AND MALFORMATION

HEMANGIOMAS OF INFANCY

Benign red, purple or blue vascular neoplasms, endothelial cell hyperplasia
Most common vascular tumor in infancy
Nascent (Early) hemangioma may appear flat and pale white with a few telangiectasia and large dilated blood vessels
Growth phase -they are bright red or blue and feel firm and rubbery
Infant with located near the eye, ears and mouth can threaten function of those organs
Infant with located near or on the mandible (Beard distribution) can be associated with glottis hemangiomas
Large segments facial haemangioma can be associated with malformation of other organs (PHACES)
Large perineal haemangioma can be associated with underlying malformation with GI Tract.


https://childrenswi.org/medical-care/birthmarks-and-vascular-anomalies-center/conditions

- ***Skin Biopsy, should be followed closely to reassure that they are benign, Pulse dye laser, Systemic PNLD 2-5 mg/Kg/day, propanolol 2 mg/kg/day to complicated haemangioma***
- ***Embolization, surgical resection and radiation are used for complicated Haemangioma.***

VASCULAR MALFORMATION

Abnormalities of blood and lymphatic vessels due to abnormal development and morphologicies
Occurs in normal endothelial cells

Classification

- ***Vessel types (capillary, venous, arterial, lymphantic, mixed, arteriovenous)***
- ***Flow characteristics (slow flow and fast flow)***

Capillary Malformation

Macuar staining occur on eyelids -Angle kiss
Forehead & Nuchal area- Stroke bite
Nevus FlammeusNuchae (Stroke bite, erythema nuchae, salmon patch) occurs in one third of infants on nape of neck and tend to regress spontaneously.
Capillary Haemangioma has remained Stable for years
PORT-WINE Stain: an irregular shaped red or violaceous, macular capillary malformation that is present at birth and never disappear.
Malformation is confined to the skin


https://step2.medbullets.com/dermatology/120083/port-wine-stain

Sturge-Weber Syndrome: the association of PWS in the trigeminal distribution with vascular malformation in the eyes and leptomeningies and superficial calcification of brain.
Klippel-Trenaunary Weber syndrome: have associated with PWS overlying the deeper vascular

malformation of soft tissue and bone.

Spider Angioma (Nevus Araneus)

Is an asymptomatic blanchable pink papule due to central dilated arteriole and very fine radial branches
Very common red, focal telangiectatic network of dilated capillaries radiating from a central arteriole (Punctum), is the site of the feeding arterioles with macular radiating telangiectasia vessels.
Most common occur in face, forearms and hands.
Pulsation on the central papule with firm pressure may be associated with hyperestrogenic states such as pregnancy.
Spider angioma arising in childhood and pregnancy may regress spontaneously


https://twitter.com/SmartEnglish3/status/830003380391129088

- ***Treated with Electro or laser surgery***

Cherry Angioma

Common asymptomatic bright red to violaceous or even black, domed vascular lesions or occurring as myraids of tiny red popular spots simulating petechiae.
Discrete, size 0.5-5 mm, smooth dome shape to polypoid papules, early lesions are cherry red and deeper larger lesions are maroon.
Primarily on the trunk. First appears at about age of 30 and increase in number over the years.
Associated with Bromide exposure, Sulpha mustard gas and glycol ether
A sudden appearance may warrant for Malignancy


https://contourclinics.com.au/treatment/cherry-angioma-removal/

- ***Electrosurgery or laser or Cryosurgery***

Angiokeratoma

Is scaly papules coloured red to purple, formed by dilation of superficial blood vessels and epidermal thicken OR
Vascular tumor with keratotic elements. Capillaries and post capillaries venules are packed into the post papillary body just beneath and bulging into the epidermis.
Solitary lesion and dark violaceous to black often keratotic papules or small plaques hard upon palpitation.


https://hemedicalclinic.com/scrotal-angiokeratoma/

Clinical Variants

- ***Angiokeratoma of Fordyce***
- ***Angiokeratoma of solitary or Papular***
- ***Angiokeratoma of Mibelli***
- ***Angiokeratoma of Corporis Diffusum***

Angiokeratoma of Fordyce


https://www.researchgate.net/figure/Vascular-papules-of-angiokeratoma-of-Fordyce-on-the-scrotum-of-the-same-patient_fig1_7194136

Most common
Asymptomatic multiple angiokeratomasymmetrically distributed on the scortum and vulva
Associated with Hernia, varicosities of legs, varicole
Vulvular angiokeratoma may develop a younger age in pregnant woman

Angiokeratoma of solitary or Papular


https://www.thedermatologyclinic.london/skin-conditions/angiokeratoma-treatment-london/

Occur equally in both sex
Common single lesion on the legs of young adult
Papular angiokeratoma are larger than other variants

Angiokeratoma of Mibelli


https://healthjade.net/angiokeratoma/

Pink to dark, symmetric group, multiple, occurring on the backs of finger and toes and It is autosomal dominant
Lesions are more common on female

Angiokeratoma of Corporis Diffusum (Fabry Disease)


https://www.sciencephoto.com/media/642200/view/fabry-s-disease

It is X-link recessive inborn error of metabolism
Boys are more affective
Deep red to maroon, blue to black papule 0.5 - 1.0 cm

- ***Symptoms of Fabry disease should be refer, Eye and CNS consultation are need, can be treated with Electrosurgery, Laser surgery***

Pyogenic Granuloma

It is an exophytic dome shaped papule made up of proliferating capillaries separated by thick fibrous bands and surrounded by epithelial collarette
Not infectious, followed by minor *trauma,lobular haemangioma*
Cause is unknown
Yellow to deep red glistering, dome shaped to polypoid, papules 3-10 mm, grow rapidly, bleed profusely, not larger than 1 cm, can fall off and regrowth, common on head and neck and finger


https://www.ebmedicine.net/content.php?action=showPage&pid=351

- ***Most resolve with a single crateriform scar, recurrent occur***
- ***Biopsy, Multiple PG should be referred, electrodesiccation and curettage***

VENOUS MALFORMATION

Usually are blue and sponge appearance
Tend to be enlarge in valsava maneuver
Venous malformation appears at birth as flat, irregular, red to purple patches. Later, they may become popular, simulating a cobblestone surface
Phleboliths (small calcified nodules) commonly found and are felt as hard nodules

Venous Lake

Is a dilated vein that occurs on the sun damage areas as a small blanchable dark blue to purple of elderly patients is a dark blue violaceous asymptomatic soft papule resulting from a dilated venule, occurring on the face, lips and ears of patients
Soft papule of 2-10 mm that blanches with pressure
Multiple lesions may be present on the mucosa surface of the lips, especially on lower lateral vermilion border
Occur after 50 years of age
Due to dark blue or black colour, lesions can confuse with nodular melanoma or pyogenic granuloma


https://healthjade.net/venous-lake/

- ***Treated with electro surgery, laser***

LYMPHATIC MALFORMATION

Small (microscopic) and large (macrocystic) channel and can be localized or diffuse
Lymphangioma circumscripta (micro) and Cystic hygroma (macro)

Lymphangioma

Lymphatic malformation
Lymphangioma circumscripta is malformation (like frog spawn), microcystic lymphatic like confluent grouped vesicles filled with a serosanguineous fluid
Present at birth or appears in infancy or childhood
May occurred as solitary or cover large areas and associated with Capillary venous lymphatic malformation


https://medicoapps.org/m-lymphangioma/

- ***Treated with sclerotherapy***

CAPILLARY/VENOUS MALFORMATIONS

Deep vascular malformation characterized by soft, compressible deep tissue swelling lesions are not apparent at birth but become so during childhood
Manifest as soft tissue swelling, dome shape or multinodular and slow-flow-lesions
They are easily compressed and filled promptly when pressure is released
May be complicated by ulceration and bleeding, scaring and secondary infection
No satisfactory Treatment

Variants

Vascular Hamartomas
Klippel-Trenaunay Syndrome
Blue Rubber Bleb Nevus
Marfucci Syndrome
Parkes-Weber Syndrome

KAPOSI'S SARCOMA

Malignant of lymphatic endothelial cells associated with y Herpes virus, HHV 8
4 Clinical Variants: (1) Clinical, (2) Endemic, (3) Immunosuppression associated and (4) Transplant associated
Classical Kaposi's Sarcoma is sporadic and slowly progressive and occurs in 50-70 years old man
People receiving immunosuppressive therapy and organ transplant recipients are risk for Kaposi's sarcoma
A variety of morphologies (macules, patches, papules, plaque, nodules) and the lesions can vary depending on clinical variant


https://en.wikipedia.org/wiki/Kaposi%27s_sarcoma

Early Kaposi's sarcoma nodules can feel soft, older nodules can feel firm
Lesions in AIDS associated KS have a predilection for the face the tarso and oral mucosa. Also linked with systemic involvement
Immunosuppression associated Kaposi's sarcoma is morphologically similar to classical Kaposi's sarcoma
Classical Kaposi's sarcoma starts with purple patches on the distal lower extremities that progress proximally and become multifocal. Individual lesions darken and thicken becoming brown and verrucous
Most affected organs are lymph node, GIT and lungs

- ***Skin Biopsy, CD 4 count, combination therapy with surgery, radiation and chemotherapy***

TELANGIECTASIAS

Common, asymptomatic, dilation of capillaries, venules and arterioles within the sub- papillary plexus.
Primary telangiectasis

Hereditary Haemorrhagic Telangiectasia (Osler-Rendu-Weber Syndrome)

Hereditary, A Dominant in which Telangiectasia are found on mucosa, skin, and internal organ
Earliest sign - recurrent epistasis in child
Prominent in tongue, palate, nasal mucosa, palms, sole and nail beds
At risk for life threatening


https://www.msdmanuals.com/professional/hematology-and-oncology/bleeding-due-to-abnormal-blood-vessels/hereditary-hemorrhagic-telangiectasia

Hereditary Benign Telangiectasia

Hereditary, A dominant
No associate with bleeding

Ataxia Telangiectasia (Louis Bar Syndrome)


https://www.contemporarypediatrics.com/view/ataxia-telangiectasia

A recessive with progressive cerebellar ataxia, Telangiectasia and immune dysfunction
Cardial sign – Ataxia appear on conjunctiva, face, and upper trunk
Cafe-au-laIt macules, skin ulcerations, poikiloderma, premature gray hair, dry skin, scleroderma skin changes, eczema
Generalized Essential Telangiectasia
First appear on legs, then gradually progressively, symmetrically extend to involve the trunk and arm

Unilateral Nevoid Telangiectasia

Trigeminal (V), III and IV cervical nerves are the most commonly affected dermatomes

Secondary Telangiectasia

Are seen in BCC, Rosacea, collagen vascular disease, corticosteroid atrophy, chronic graft versus host disease
Also occur in CREST and SCLERODERMA as a T MATS
The skin of the fingers feels WAXY, and Raynaud's phenomenon, cutaneous calcinosis and ulceration may be present.
Dilated dermal vessel with diameter of 1 mm or less, not palpable and easily blanched
Occur in occult liver disease
Cosmetically, T may be ablated with Laser surgery or pinpoint electro surgery.

15. PRECANCEROUS LESIONS

Actinic Keratosis (AK) or Solar Keratosis

Hyperkeratotic lesions occurring in sun exposed adult skin
Malignant potential, precursor or early lesion of SCC, only 10% of AK change to SCC only 1% per annum.
Single or multiple, discrete, dry, rough, adherent scaly lesion
Face, head, neck and dorsal hand and temples
Solar keratosis is usually a collection of telangiectatic capillaries 1-2 mm, dry, rough, adherent and often yellow or brown colour scales.
AK are rough sandpaper like red to pink patches and papules


https://skintechmedical.com.au/actinic-keratosis-statistics-risks-and-treatments

Treatment

- ***Cryothreapy, cautery or diathermy,***
- ***Topical 5 fluorouracil is useful bd x 3-4 weeks, (or) Imiquimod twice weekly for 16 weeks (or)***
- ***Topical retinoids,***
- ***Diclofenac gel***
- ***Laser surgery***
- ***Facial peel***
- ***Photodynamic therapy***
- ***Systemic -Acitretion or isotretinion, Suncream, Low fat diet***
- ***Avoidance of sunlight***

Arsenical Keratosis

Appear after the chronic arsenic ingestion, have a potential to become invasive SCC

- ***Treatment -same as Actinic Keratosis***

Bowen's Disease

A persistent, progressive, non-elevated, red, scaly or crusted plaque which is due to an intradermal Ca, and is potentially malignant, intraepidermal SCC
Occur anywhere on the skin surface or mucosal surface
Typically solitary, raised red or pink patches or plaques with dry adherent scales
Full thickness replacement of epidermis with tumour cells
Erythroplasia of Querat (Penile Bowen's disease) is a variant in situ of gland penis


https://healthjade.com/bowens-disease/

- ***Cryotherapy, Curettage and Excision,***
- ***Topical chemotherapy with 5 Fluorouracil cream***

Cutaneous Horn

Appearance of an animal horn with a popular or nodular base and a keratotic cap of various shape and length
Represent hypertrophic solar keratosis
Face, ear, dorsum of hands, forearm and shins
White, black, or yellow, straight, curved or spiral shape


https://stamfordskin.com/wp-content/uploads/2020/02/2-600x338.jpg

- ***Surgical excision***

Cutaneous T Cell Lymphoma

Helper T cell lymphoma of the skin
May invade into lymph nodes and internal organ
Sezary Syndrome is leukaemic form of T cell lymphoma
Stages: (a) Patch stage (b) Plaque stage and (c) Tumour stage (d) End stage



https://i0.wp.com/oncohemakey.com/wp-content/uploads/2017/07/A322077_1_En_12_Fig2_HTML.jpg?w=960

- ***Referral to dermatologist or Oncologist***

Leukoplakia

Leukoplakia is a descriptive clinical term, not a definitive diagnosis
Leucoplakia begins as a single small well-defined, translucent to white, slightly elevated papule or patch
Oral hairy leukoplakia is seen in advanced HIV patient
Solar keratosis that occurs on the vermiliform border with a history of recurrent sunburn of the lips, predominantly on the lower lip


https://www.healthline.com/health/leukoplakia

- ***Treatment -Removal of affected area***

Erythroplasia Of Queyrat

SCC is situ of the gland penis or prepuce, penile shaft also occurs
Single or multiple, fixed, well circumscribed, erythematous, moist, velvety or smooth, red surface plaques on the gland penis.


https://www.pagepress.org/journals/index.php/dr/article/view/8566/8321

- ***Treat with 5% 5FU cream 3-12 weeks***

16.CUTANEOUS MELANOMA

Two types

- ***Dysplastic nevomelanotic nevi***
- ***Congenital nevomelanotic nevi***

Dysplastic nevomelanotic nevi

Specialized type of acquired, circumscribed, pigmented lesions that represent disordered proliferation of atypical melanocyte
Arise DE NOVO or as part of compound melanocyte nevus
Appears OUT OF STEP, e.g., a mix of large and small flat and raised tan and very dark lesions

- ***Treat with Surgical Excision***

Congenital nevomelanotic nevi

Pigmented lesions of the skin usually present at birth
Size may vary, Benign
Giant congenital nevomelanocytic nevus

CLASSIFICATION OF MELANOMA

De noy melanoma	(a) Melanoma in situ
	(b) Letingomaligna melanoma
	(c) Superficial spreading melanoma
	(d) Nodular melanoma
	(e) Acral lentiginous melanoma
	(f) Melanoma of mucous membrane
	(g) Demoplastic melanoma
Menoma arising from precursors	(a) Melanoma arising in Dysplastic nevomelanocytic nevi
	(b) Melanoma arising in congenital nevomelanocytic nevi
	Melanoma arising in common NMN

Major risk factors for Melanoma (TRANSK)

Atypical (Dysplastic) >5
Common moles (numerous >50)
Red hair and freckling (often these persons have few or no moles)
Inability to tan (Skin photo types 1 and 2)
Sunburn - Severe bum especially before age 14
Family History of melanoma

Risk factor for development of melanoma

Genetic markers
Skin Type I/II

Family History of dysplastic nevi or melanoma
Personal history of melanoma
UV
Number >50 and size >5 mm
Congenital nevi
Number of dysplatic nevi >5
Dysplatic melanocytic nevus syndrome

SIX SIGNs of Melanoma (ABCDE RULE)

A = Asymmetry in shape
B = Border is irregular
C = Colour is not uniform, mottled
D = Diameter is usually large
E = Elevation is always present and is irregular



Major type of melanoma

Type	Frequency %	Site	Radial growth	Vertical growth
Superficial spreading	70	Any site	Mth -years	Delayed
Nodular	15	Any site	No	immediate
Letingo MM	5	Face neck hand	Years	Much delayed
Acral Lentigious M	5-10	Palm sole	Mth-years	Early but recognition delayed

Melanoma in situ


https://media.sciencephoto.com/image/c0401005/800wm/C0401005-Melanoma_in_situ.jpg

Also called Letingo Maligna.
Large very irregular and asymmetric macule, striking variegation of pigmentation (tan, brown, dark brown)

Letingomaligna melanoma

Focal popular and nodular areas signal a switch from the radial to the vertical growth phase and invasion into the dermis.
Superficial spreading melanoma
The pigment variegation of SSM is similar to, but more striking than, the variety of color present in most LMM. The color display is a mixture of brown, dark brown, black, blue and red with slate gray or gray regions in areas of tumor regression.

Nodular Melanoma

Uniformly elevated and presents as a thick plaque or an exophytic polypoid or dome shaped lesions.
Acral lentiginous melanoma
Special presentation of cutaneous melanoma; palm, sole, fingernail or toe nailbed.

Melanoma of Mucous Membrane

Major site are the vulva and vagina, nasal and oral cavity

Demoplastic melanoma


https://www.your-doctor.net/derma_atlas/images/Desmoplastic_melanoma.jpg

Connective tissue proliferation.
A flat skin color nodule with a speck of brown in the center
That appeared on the forehead.
Total excisional biopsy, incisional or punch biopsy, surgical removal, chemothreapy, radiational therapy

NEVI

Nevi are benign skin tumors composed of melanocyte derived nervous cells.
After 30 years of age
Melanocyte nevi are composed of organized cluster of nerve cells arranged at various levels in skin

- Junctional Nevi
- Nevus Spilus
- Blue Nevi
- Recurrent Nevi
- Intradermal Nevi
- Compound Nevi
- Halo Nevi

- Spitz Nevus



https://upload.medbullets.com/topic/112094/images/screen%20shot%202017-12-06%20at%2011.21.13%20am.jpg

Junctional Nevi

Flat or slightly raised brown to tan macules, most commonly found in Children
Nevi of palms, soles, genitalia and mucosa are junctional nevi.

Nevus Spilus



https://upload.wikimedia.org/wikipedia/commons/thumb/4/4e/Naevus-spilus.jpg/450px-Naevus-spilus.jpg

Is a sharply define tan to brown background patch similar to cafe-au-laIt spot
The appearance is reminiscent of a chocolate chip cookie

Blue Nevi

https://media.cheggcdn.com/media/e2f/e2f7b237-ad3e-4154-9cda-f284215bde67/dp0204a07g001-14AF06131D945877453.jpg?height=160

Solitary bluish macules or papules most commonly on head and neck, or on buttock
Commonly present in early childhood

Recurrent Nevi

Occur at the site of a previously partially removed nerves

Intradermal Nevi



https://media.sciencephoto.com/image/c0402849/800wm/C0402849-Intradermal_nevus.jpg

Papules, most commonly elevated, fleshy and slightly or moderately pigmented, dark to brown to normal skin color.
Seen mainly after the adolescent
Nests and cords of nerves cells are found.

Compound Nevi

Slightly or markedly raised pigmented papules, surface may be smooth or slightly papillomatous, center tend to be more heavily pigmented than peripheral.



https://uploads-ssl.webflow.com/5e9e5f7613f2f323fec92b3f/60f8cbc20d271d64567d9a24_compound_naevus-sq-p-800.jpeg

Halo Nevi

Occur primarily during adolescent. A pre-existing nevus
Develops a surrounding rim of hypopigmentation that
Heralds the gradual disappearance of the nevus over several month



https://www.chandigarhayurvedcentre.com/wp-content/uploads/2021/10/1-26.jpg

Spitz Nevus

Spindle cell nevus is usually a reddish pink, dome shape, smooth surface, most occur on face, scalp or legs
Suspected nevi should be BIOPSY
ABCDE are useful grade



google.com/search?q=Spitz+Nevus&tbm

Mongolian Spot

Congenital gray-blue macular lesions characteristically located on the lumbosacral area but can occur on back, scalp or anywhere on the skin.
Underlying pathology is dispersed spindle shapes melanocytes within the dermis. (Dermalmelanocytosis)
Pigments cells have been interrupted in their migration from the neural crest to the epidermis
May disappear in early childhood

https://media.springernature.com/m312/springer-static/image/chp%3A10.1007%2F978-1-4614-6654-3_6/MediaObjects/310620_1_En_6_Fig4_HTML.jpg?as=webp

Nevus of Ota

Pigmentary disorder, very common in Asia
Pigments can be quite subtle or marked disfiguring consists of a motted dusky admixture of blue and brown hyperpigmentation of skin.
The blue hue results from the present of ectopic melanocytes in the dermis.



https://sifsof.com/wp-content/uploads/2022/03/Nevus-of-Ota-and-Laser-Treatment.jpg

It can occur in the conjunctiva, sclera and tympanic membrane
May be bilateral, congenital, not hereditary

- ***Treatment with laser***

Becker Nevus


https://healthjade.net/wp-content/uploads/2020/04/Beckers-nevus.jpg

Is asymptomatic clinical lesion that is a pigmented hamartoma
Only in males and in all races, before 15 years of age
Predominantly a macule but with popular verrucous surface not like the lesion of acanthosis nigricans
Common location is shoulders and back. The increase hair growth follows the onset of pigmentation and localized to the areas that are pigmented.
Hypertrichosis can be of cosmetic concern.

17. SKIN CANCER

Basal Cell Carcinoma (BCC)

Most common cancer in humans
Caused by UVR, PTCH gene mutations
Derived from the basal layer of the keratino- cytes of the epidermis
Rarely can metastasize


https://www.skindoctor.co.za/images/basal_cell_carcinoma.jpg

Different clinical types

- ***Nodular bcc (most common)***
- ***Pigmented bcc***
- ***Superficial bcc***
- ***Morphea form bcc***
- ***Sclerosing bcc (cicatricial)***
- ***Ulcerating bcc (rodent)***

In general: pink, violaceous or pearly white papules or nodules, frequently bleed, become erosive, crusted and ulcerated at center
Nodular bcc: papule or nodule, translucent or pearly, skin coloured or reddish, smooth surface with telangiectasia, well define and firm.
Pigmented bcc: may be brown, blue or black. Smooth, glistening surface, hard, firm, stippled pigmentation can be seen in any type of bcc.
Superficial multicentric bcc: appear as a thin plaque, pink or red, characteristic - fine thread border and telangiectasia.
Ulcerating bcc ulcer: often cover with a crust with rolled border (rodent ulcer) which against is translucent, pearly, smooth with telangiectasia and firm.
Morphea and sclerosing bcc: the most subtle and least common form of bcc.
Both forms tend to occur aggressively.
Morphea form: waxy, firm, flat or slightly raised and either pale white or yellowish.
Sclerotic bcc: with a flat and atrophic scar like central patch and other more elevated nodule and hemorrhagic crust within.

Treatment

- ***Excision with primary closure, skin flaps of grafts***
- ***Cryosurgery***
- ***Electro surgery for very small lesion and not in the danger sites***
- ***In the danger area such as nasolabial area, around the eye, in the ear canal - mohs surgery (microscopically controlled surgery) is the best.***
- ***Radiation is alternate***
- ***Topical 5 fu ointment and imiquimod cream 5 times a week x 6 weeks***

Basal Cell Nevous Syndrome (Gorlin Syndrome)

Autosomal dominant condition of BCC and multiple associated abnormalities of the skin, skeleton and CNS

Appear in early in life of BCC and palmar pitting

Caused by gene mutation

Skeletal abnormalities: odontogenic cysts, frontal bossing, bifid ribs, kyphosclerosis, kymphosis, sclerosis

CNS: calcification of falx cerebri and development of medulloblastoma, blindness, deafness and seizures



https://www.clinicaladvisor.com/wp-content/uploads/sites/11/2018/12/ca0611cancer_basal_177473.jpg

- ***Treatment Option: Cryotherapy, Electrosurgery***

Squamous Cell Carcinoma

It is invasive, primary cutaneous malignancy arising from keratinocytes of the skin and mucosal surface, full thickness involvement

Most on face, head, neck or hands of elderly, arise from Actinic Keratosis may arise de novo

Second most common cancer, 20% of all cutaneous Ca, SCC in sun exposed areas.

Appearance of hypertrophic Actinic Keratosis

Typical: pink to dull red, firm, poorly define dome shape nodule with an adherent yellow white scale

Palpation of LN is important



https://upload.medbullets.com/topic/121592/images/squamous%20cell%20carcinoma.jpg

- ***Treatment: Mohs micrographic surgery, Radiation therapy***

Paget's Disease of The Breast

Intraductal Ca of the breast, more common cutaneous lesion of Breast Cancer

Misdiagnosed with NIPPLE ECZEMA

pink to red, sharply demarcated irregular shaped scaly patch or plaque on the aerola or nipple

The process appears eczematous but will not response to topical steroid

The nipple, aerola and surrounding breast may be involved

Most is unilateral, regional LN rarely palpable



https://assets.nhs.uk/nhsuk-cms/images/C0131062.width-1534.jpg

- ***Refer to Breast surgeon, 5year survival rate >90%***

Extramammary Paget's Disease


https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2017/nejm_2017.376.issue-17/nejmicm1610755/20180122/images/img_large/nejmicm1610755_f1.jpeg

Intraepidermal malignancy involving the anogenital or axillary skin, occur in areas of apocrine glands
A red to white patch or plaque is sharply demarcated and has irregular borders
The lesions may appear inflamed, eczematous or lichenified
Light scale to heavy crusting erosion and serious exudate may occur
Regional LN may palpable
Urogenital and rectal Ca is the most common origin
Skin Biopsy, Mohs surgery, Radiotherapy and 5% imiquimod cream

18. PHOTOSENSIVITY AND PHOTO-INDUCED DISORDERS

Skin Reaction to Sunlight

Abnormal response to sunlight, within minutes, hours, or days of exposure and lasting up to weeks, months and even long.

3 broad types of photosensitivity

- ***Sunburn type, erythema, edema, and bullae.***
- ***Rash type - Macules, papules, or plaques***
- ***Urticarial type, occur in erythropoietic porphyria***

Chronic photosensitivity: Chronic repeated sun exposure over time result in polymorphic skin changes such as dermatoheliosis or photoaging

UnIt of measurement of sunburn is the minimum erythema dose (MED) - which is the minimum UV exposure that produce a clearly marginated erythema in the irradiated site 24 hour after a single exposure.

Skin Phototypes



SPT I - Pale white, do not Tan
SPT II - White, Tan with difficulty, bum easily
SPT III - White, Tan easily but may bum initially
SPT IV - Light brown/olive, Tan easily, hardly bum
SPT V - Brown, Tan easily, usually do not bum
SPT VI Black, become darker, do not bum

- *Skin Reaction to Sunlight*

Phototoxicity (Sunburn)
Photoallergy (Drug or chemical induced)
Idiopathic (Polymorphic light reaction)
Metabolic and nutritional
DNA deficiency photodermatoses
Photoexacerbated dermatoses
Chronic Photogamage
Photo aging
Solar lentigo
Actinic keratosis
Skin cancer

Acute Sun Burns (Damage)

Acute delayed and transient inflammatory response of normal skin after exposure to UVR from sunlight or artificial sources

By nature, It is a phototoxic reaction

Sunburn is characterized by erythema, If severe by vesicles and bullae, edema, Tenderness and Pain.


https://uploads-ssl.webflow.com/5f60c8810f2457c2c942df3e/5f9b02bc3dd9ad84f09f0202_barbara2-300x252.jpeg

Prevention:

Avoid sun bathing between 11AM to 2 PM, UV screening clothing, Sun- screen:
lotion, gel, cream,

Treatment:

- ***Topical cool wet dressing, Topical CS, Systemic - Acetylsalicylic***

Drug/Chemical Induced Photosensivity

Two mechanism (1) phototoxic reaction (2) Photoallergic reaction (Type 4 Reaction)

Phototoxic reaction

is an irritant (Toxic) contact dermatitis or sunburn. Phototoxic reactions are photochemical reaction leading to skin pathology is an allergic eczematous contact dermatitis.

Photoallergic reaction

photoallergen is formed that initiates an immunologic response and manifests in skin as Type 4 immunologic Reaction)

PHOTOTOXIC DRUG / CHEMICAL INDUCED -PHOTOSENSITIVITY

It is adverse reaction of the skin that results from simultaneous exposure to certain drugs (injection, ingestion, or topical application) and to UVR or visible light.
These chemicals may be therapeutic, cosmetic, industrial or agricultural
There are two types of reaction:
Systemic phototoxic dermatitis: systemically exposed to a photosensitizing agent (Drug) and UVR
Local phototoxic dermatitis: topically exposed to the photosensitizing agent and UVR
Both are exaggerated sunburn response (Erythema, edema, vesicles and bullae)

Systemic phototoxic dermatitis

Systemic phototoxic dermatitis occurs in all exposed site, local phototoxic dermatitis only in topical application sites.


https://media.springernature.com/m312/springer-static/image/chp%3A10.1007%2F978-3-319-40221-5_15-2/MediaObjects/322814_0_En_15-2_Fig6_HTML.jpg?as=webp

Systemic Phototoxic Agents
Antianxiety drugs Anticancer drug Antidepressants Antifungals Antimalarials Antimicrobials Antipsychotics Cardiac Medications Diuretics
Formation of toxic photoproducts such as free radicals or reactive oxygen species such as singlet oxygen.

The principal site of damage is nuclear DNA or cell membranes. The action spectrum is UVA.
An exaggerated sunburn after solar or UVR exposure, that normally would not elicIt a sunburn in that particular individual. Occur within hours after exposure, with some agents such as psoralens after 24 hours.
Early lesions: exaggerated sunburn, erythema, edema, vesicles and bulla formation.
Pseudo porphyria can occur in some drugs
Nail: subungual hemorrhagic
Pigmentation: Marked brown epidermal pigmentation in some cases.

Topical Phototoxic Dermatitis


https://www.healthline.com/health/skin-disorders/phytophotodermatitis

Contact or therapeutic application of a photosensitizer followed by UVA irradiation
Common topical are Rose Bengal, Fluorescein, furocoumarins and Tar.
Symptoms are smarting, stinging and burning rather than itching.

Phytophoto dermatitis

Is an inflammation of the skin caused by contact with certain plants during recreational or occupational exposure to sunlight.
The inflammatory response is a phototoxic reaction to photosensitizing chemicals in several plants.
Common types of PPD are due to exposure to Limes, Celery and Meadow grass
Acute erythema, edema, vesicles and bullae. Smarting, sensation of sunburn, pain, later pruritus.
Wet dressing and topical Corticosteroid cream

PHOTOALLERGIC DRUG/CHEMICAL INDUCED PHOTOSENSITIVITY

This result from interaction of a photo allergen and UVA.
In sensitized individuals' exposure to a photo allergens and sunlight results in a pruritic eczematous eruption confined to exposed sites.
In most patients the eliciting drug/chemical has been applied topically but systemic elicitation also occurs.


https://slideplayer.com/slide/10392080/

Some topical photo allergens
Sunscreens: (Para-Aminobenzoic Acid), (PABA), Benzophenones
Fragrances: 6 Methylcoumarin
Antibacterial: Dibromosalicylanilide
Antifungal: Buclosamide
Others: Chlorpromazine
Corticosteroid cream
In severe case - Azathioprine and CS or oral cyclosporine

Polymorphus Light Eruption


https://www.healthline.com/health/polymorphous-light-eruption

A group of heterogenous idiopathic acquired acute recurrent eruption characterized by delayed abnormal reactions to UVR.
Manifested by varied lesions, including erythema, macules, papules and vesicles. The eruption is monomorphus
Most frequent morphologic types are popular and papulovesiclar eruptions

Treatment:

- ***Sunblock***
- ***Beta carotene 60 mg tds for 2 weeks***
- ***Oral prednisolone 20 mg/d two day before and 2 days after the exposure.***
- ***PUVA phototherapy***
- ***Narrow band UVB 311 mm***

Solar Urticaria


https://dermnetnz.org/assets/Uploads/reactions/solar-urticaria1__ProtectWyJQcm90ZWN0Il0_FocusFillWzI5NCwyMjIsIngiLDFd.jpg

Uncommon sunlight induced whealing confined to exposed body sites
Eruption occurs within minutes of exposure and resolves in a few hours.

- ***Very disabling and sometimes life-threatening immediate type 1 hypersensitivity response to cutaneous ± circulating photo allergens***
- ***Multiple phototherapy sessions in low but increasing doses on the same day***
- ***Oral immunosuppressive agents***
- ***Prevention: sun avoidance, sunscreen***

METABOLIC PHOTOSENSITIVITY

Porphyria cutanea tarda

Mostly in adult
Do not present with characteristic photosensitivity but with complaints of fragile skin, vesicles and bullae particularly on the dorsa of the hands after minor trauma


http://www.yogavanahill.com/uploads/images/original/b742d61852e9f63512583caaa005b0d4.jpg

Confirmed by the presence of a pinkish-red fluorescence in the urine when examined with wood lamp
Do not have acute life-threatening attacks
Tense bullae and erosion, normal appearing skin, slow heal to form pink to atrophic scars, milia on dorsa of hands and feet, nose, forehead or scalp
Purple red suffusion (heliotrope) of central facial skin.
Brown hypermelanosis diffuse on exposed areas.
Scleroderma like changes

Management

- ***Avoid ethanol, stop drugs that could be inducing Porphyria Cutanea Tarda***
- ***Phelotherapy is done by removing 500 ml of blood at weekly or biweekly intervals***
- ***until the Hb is decreased to 10 gm.***
- ***Low dose chloroquine***

Variegate Porphyria

Is a serious autosomal dominant of heme biosynthesis
Skin lesion similar to PCT
Acute attack of abdominal pain, neuropsychiatric manifestation

Erythropoietic protoporphyria

Hereditary metabolic disorder
Characterized by an acute sunburn like photosensitivity
Symptoms occur rapidly within minutes of sun exposure, and consist of stinging and burning
Skin signs are erythema, edema, and purpura.

- ***There is no treatment.***

1. CHRONIC PHOTODAMAGE

TYPE OF SKIN DAMAGE FROM EXPOSURE TO UVR

(a) ***Wrinkles (Premature aging of skin and Photoaging)***
(b) ***Freckles/Sun spot***
(c) ***Sun Tan***
(d) ***Eye damage***

Wrinkles

UVA penetrate deep into our skin and damage the collagen
UVA break down the collagen structure which result in wrinkles
Once collagen is damage, It cannot rebuild itself which results in wrinkles.
Up to 80% of skin aging is by the Sun

Freckles (ephelides)

- ***Freckles and sun spot are sign of skin damage***
- ***small, 1-2 mm, sharply defined macular lesions of uniform color, most often found on face, neck, chest and arms***
- ***Subsequent increase in melanization, freckles which result from increase melanin production***
- ***As a result of too much sun exposure***
- ***Found on face, legs, and buttock of hand***


https://i.insider.com/612d4ba712b9cc0019636fb7?width=1136&format=jpeg

Sun Tan (Brown Spot)

When exposed to sun's ray, our skin melanocytes produce Melanin, the dark pigment that creates a tan.
A Tan of our skin attempt to protect UV rays from doing further damage

Eye Damage

- ***Cataract***
- ***Retina damage***
- ***Macula damage***

Chronic Photodamage

- ***Photoaging or dermatoheliosis***
- ***Solar lentigo***
- ***Solar Elastosis***
- ***Actinic keratosis***

Dermatoheliosis (Photoaging)


https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2012/nejm_2012.366.issue-16/nejmicm1104059/production/images/img_medium/nejmicm1104059_f1.jpeg

Repeated solar injuries over many years, a polymorphic response of various components of the skin to prolonged and or excessive sun exposure
Severity depends upon the duration and intensity of sun exposure and on indigenous skin colour and the capacity to the skin tan
Lesions: A combination of atrophy (of epidermis), hypertrophy (of papillary dermis due to elastosis), telangiectasis, spotty depigmentation and hyperpigmentation on light exposed areas.
Skin appears wrinkled, wizened, leathery, PREMATURE AGED.
Both fine, cigarette paper like and deep furrow like wrinkle; skins is waxy, popular with a yellowish hue.
Solar lentigines: macular hypopigmentation Guttate hypomelanosis <3 mm diameter

- ***Treat with Tretinion in lotions, gels, and cream, Topical Tazarotene, OR 5 FU***

Solar Lentigo/Lentigines

Is a circumscribed 1-3 cm brown macule resulting from a localized proliferation of melanocytes due to acute or chronic exposure to sunlight. As large as 5 cm.


https://doctorhoogstra.com/en/wiki/lentigo-solar/

Light yellow or light brown or dark brown. Vary in color from light yellow to dark brown and them often a variegated appearance
Multiple lesions usually arise in sun exposed areas.
Macule, 1-3 cm, hyper pigmented, well circumscribed lesions on sun exposed surfaces of the skin
The face, hands, forearms, chest, back and shins are the most common location eruption after acute or chronic UV exposure.
>40 years
Called Liver spot, tend to become more numerous with repeated sun exposure and with advancing age
Result from a local proliferation of Basal melanocytes and subsequent increase in melanization, differing from freckles which result from increase melanin production
Systemic Disorder

- ***Treatment - CRYOTHREAPY or laser surgery***

Not more than 10 sec of Nitrogen therapy should not be used.

Peutz Jeghers Syndrome

(GI Hamartomas, Buccal, lip, perioral or digital macules: onset at birth or early childbirth.)

Leopard Syndrome

Multile Lentigines
ECG abnormalities
Occular hypertension
Pulmonic Stenosis
Abnormal geniitalia
Retard Growth
Deafness of sensorineural

Lamb Syndrome

Multiple Lentigines
Atrial and/or mucocutaneous myxomas
Mixed neurofibromas, Ephelides
Blue nevi

Treatment

Laser therapy: Neodymium-doped yttrium aluminum garmet (ND: YAG) Laser
Chemical peels: 30-50% Trichloroacetic acid (Trichlor)
Cryothreapy
Hydroxyquinone: (Eldoquin Forte) 3-4% topical
Retinoid: Tarazotene 0.1% cream, adapalene 0.1% or 0.3% gel
Combination of Mequinol & tretinoin: 2% Mequinol + 0.01% Tretinoin

Prevention

Avoid Sun exposure
Using sunscreen

Solar Elastosis

UVR break down the collagen and elastic fibres which lies deeper layer of skin (Dermis)
Without Connective tissue, the skin loses its strength and flexibility
Called Solar Elastosis which is characterisez by VERTICAL CREASES, deep wrinkle and loose or SAGGING Skin
SPF 15 = 1115 = 6.7%
93.3 % = UVprotection
6.7% = absorbed with no skin protection
30 % is better SUN protection.


https://www.medwebplus.com/wp-content/uploads/2020/02/Solar-Elastosis.jpg

19. PIGMENTARY DISORDERS

Vitiligo

Vitiligo is a disease that cause areas of skin to lose color, resulting in sports and patches of lighter skin.
Some people develop a few spots. Others have more widespread color loss.


https://assets.nhs.uk/nhsuk-cms/images/S_1017_vitiligo_M2900105.width-1534.jpg

Acquired depigmented cell loss of skin in which melanocytes are lost
Persistent white milky patch
1% of population affected
Autoimmune disease, associated with DM, Thyroid diseases. SLE, Rheumatoid, Psoriasis, Alopecia areata, Addison disease and may be drug induced
Theory - Cell injury theory, Autoimmune Theory, auto toxic theory
Start with single patch, hypo or hyperpigmentation
Exposed site, injury site
Follow by emotion
Multiple halo nevi
Poliosis
Vitiligo can affect the quality of life.


https://www.medicalnewstoday.com/articles/245081

Type of vitiligo

localized vitiligo – the lesion develops a few spots or patches that appear in one or a few places on your body.
generalized vitiligo -when vitiligo causes scattered patches of color loss on different areas of the body.
universal vitiligo- some people lose most of their skin color.
Segmental (unilateral vitiligo)
Mixed (rare type)
Unclassified


https://sa1s3optim.patientpop.com/assets/docs/276883.jpg

Assessment

VASI (Vitiligo Area Scoring Index) - 6 sites - hand, upper extremities, trunk, lower extremities, feet, neck
Lip-tip - prognosis bad

Diagnosis

Clinically
Wood lamp examination
Skin biopsy

Treatment

While vitiligo cannot be cured, treatment may restore lost skin color.

Unsatisfactory

General measure

- ***Wear sun protecting clothing***
- ***seek shade***
- ***Apply sunscreen - broad-spectrum protection, water-resistance, and an SPF 30 or higher to all skin not covered by clothing***
- ***Avoid tanning***
- ***There is currently no way to prevent vitiligo.***
- ***If you have vitiligo, the sooner vitiligo treatment starts, the more effective It tends to be.***
- ***Left untreated for years, vitiligo may be difficult to treat.***

Topical

- ***Corticosteroid creams - for trunk area up to 3 months, not for face,***
- ***If not progress stop it. Don't use potent corticosteroid for thin skin area.***
- ***Calcinerun inhibitors (pimecrolimus cream) or Tacrolimus ointment for face, neck, armpits and groin***
- ***Phototherapy - UBV or UBA***
- ***Not Response – Refer***

Poikiloderma Of Civatte

- ***Common, benign skin condition mainly on the sides of the neck, mainly women.***
- ***It characteristically spares the shaded area under the chin. The skin in the affected skin is red-brown with prominent hair follicles.***
- ***The term "poikiloderma" refers to a change in the skin where there is thinning, increased pigmentation and dilation of the fine blood vessels (telangiectasia).***



Ref: https://dermnetnz.org/topics/poikiloderma-of-civatte

Civatte was a French dermatologist who first described a common weathering change that affects the skin of the sides and front of the neck.
The exact cause is unknown. Contributing factors are:
Fair skin and accumulated sun exposure
Photosensitising components of cosmetics and toiletries, especially perfumes
Hormonal factors

Treatment

- ***There is no specific medical treatment for this condition.***

- ***The patient should be educated about avoiding sun exposure and the correct use of sunscreens. The results of treatment may be disappointing in many cases.***
- ***Sun protection including daily broad-spectrum SPF 50+ sunscreen***
- ***Avoid all perfumes on or near the affected area, including those in soap***
- ***Hydroquinone-containing preparations may help fade the pigmentation***
- ***Exfoliants including long term use of alpha hydroxy-acids and /or tretinoin***
- ***Pulsed dye laser (PDL) and intense pulsed light (IPL) treatments seem the best way to reduce the telangiectasia and pigmentation***

Melasma


https://www.skincarenetwork.co.uk/wp-content/uploads/2017/11/pigmentation.jpg

Known as chloasma or mask of pregnancy
It is brown darkening of facial skin or grey brown patch on the face,
Dark patches usually occur on the cheeks, forehead, nose and chin.
Occurs by combination of factors
Exposure to sunlight
An increase in female hormones estrogen and progesterone
Common in women

Triggers factors or Melisma

Sun exposure - this is the most important avoidable risk factor
Pregnancy - in affected women, the pigment often fades a few months after delivery
Hormone treatments - oral contraceptive pills containing oestrogen and/or progesterone, hormone replacement, intrauterine devices and implants are a factor in about a quarter of affected women
Certain medications, scented or deodorant soaps, toiletries and cosmetics - these may cause a phototoxic reaction that triggers melasma, which may then persist long term
Hypothyroidism (low levels of circulating thyroid hormone)
Melasma commonly arises in healthy, non-pregnant adults and persists for decades.
Exposure to ultraviolet radiation (UVR) deepens the pigmentation because It activates the melanocytes to produce more melanin.

Clinical features

Melasma presents as macules (freckle-like spots) and larger flat brown patches. These are found on both sides of the face and have an irregular border. There are several distinct patterns.
Centrofacial pattern: forehead, cheeks, nose and upper lips
Malar pattern: cheeks and nose
Lateral cheek pattern
Mandibular pattern: jawline
Reddened or inflamed forms of melasma (also called erythrosis pigmentosa faciei)
Poikiloderma of Civatte: reddened, photoaging changes seen on the sides of the neck, mostly affecting patients older than 50 years
Brachial type of melasma affecting shoulders and upper arms (also called acquired brachial cutaneous dyschromatosis).
Melasma is sometimes separated into epidermal (skin surface), dermal (deeper) and mixed types. A Wood lamp that emits black light (UVAl) may be used to identify the depth of the pigment.

Type of melasma	Clinical Features	
Epidermal	Well defined border Dark brown colour Appear more obvious under black light Responds well to treatment	 https://skinbase.co.uk/wp-content/uploads/2017/09/melasma.jpg
Dermal	The most common type Ill-defined border Light brown or bluish in colour Unchanged under black light Responds poorly to treatment	
Mixed	Combination of bluish light and dark brown patches Mixed pattern seen under black light Partial improvement with treatment	

Diagnosis of melasma

The characteristic appearance of melasma means diagnosis is usually straightforward and made clinically. Other disorders that may be considered include:

Post-inflammatory pigmentation

Solar lentigines and other forms of lentigo

Drug-induced pigmentation, e.g., due to minocycline

Lichen planus

Naevus of Ota

Guttate hypomelanosis, in which pale spots are prominent

Occasionally, skin biopsy may be performed to make or confirm the diagnosis of melasma. Histology varies with the type of melasma. But some degree of each of the following features is usually found.

Melanin deposited in basal and suprabasal keratinocytes

Highly dendritic (branched) deeply pigmented melanocytes

Melanin in the dermis within melanophages

Solar elastosis and elastic fiber fragmentation

The extent and severity of melasma can be described using the Melasma Area and Severity Index (MASI).

Treatment of melasma

- ***Melasma can be very slow to respond to treatment.***
- ***Treatment may result in irritant contact dermatitis in patients with sensitive skin, and this can result in post-inflammatory pigmentation.***
- ***Generally, a combination of the following measures is helpful.***

General measures

- ***Discontinue hormonal contraception.***
- ***Year-round sun protection. Use broad-spectrum very high protection factor (SPF 50+) sunscreen applied to the whole face every day. It should be reapplied every 2 hours If outdoors during the summer months.***
- ***Alternatively, or as well, use a make-up that contains sunscreen.***
- ***Wear a broad-brimmed hat.***
- ***Use a mild cleanser, and If the skin is dry, a light moisturizer.***
- ***Cosmetic camouflage (make-up) is invaluable to disguise the pigment.***

Topical therapy

- ***Tyrosinase inhibitors are the mainstay of treatment. The aim is to prevent new pigment formation by inhibiting formation of melanin by the melanocytes.***
- ***Hydroquinone 2-4% as cream or lotion, applied accurately to pigmented areas at night for 2-4 months. This may cause contact dermatitis (stinging and redness) in 25% of patients. It should not be used in higher concentration or for prolonged courses as It has been associated with ochronosis (a bluish grey discoloration).***
- ***Azelaic acid 20% cream, lotion or gel can be used long term, and is safe even in pregnancy. This may also sting.***
- ***Kojic acid is often included in formulations, as It binds copper, required by L-DOPA (a cofactor of tyrosinase). Kojic acid can cause irritant contact dermatitis and less commonly, allergic contact dermatitis.***
- ***Ascorbic acid (vitamin C) also acts through copper to inhibIt pigment production. It is well tolerated but highly unstable, so is usually combined with other agents.***
- ***New agents under investigation include mequinol, arbutin and deoxyarbutin (from berries), licorice extract, rucinol, resveratrol, 4-hydroxy-anisole, 2,5-dimethyl-4- hydroxy-3(2H)-furanone and/or N-acetyl glucosamine***

Other active compounds used for melasma include:

- ***Topical corticosteroids such as hydrocortisone. These work quickly to fade the colour and reduce the likelihood of contact dermatitis caused by other agents.***
- ***Soybean extract, which is thought to reduce the transfer of pigment from melanocytes to skin cells (keratinocytes) and to inhibIt receptors.***
- ***Tranexamic acid, a lysine analogue that inhibits plasmin and is usually used to stop bleeding. It reduces production of prostaglandins, the precursors of tyrosine.***
- ***Superficial or epidermal pigment can be peeled off. Peeling can also allow tyrosinase inhibitors to penetrate more effectively.***
- ***Topical alpha hydroxy acids including glycolic acid and lactic acid, as creams or as repeated superficial chemical peels, remove the surface skin and their low pH inhibits the activity of tyrosinase.***
- ***Topical retinoids, such as tretinoin (a prescription medicine) are effective. Tretinoin can be hard to tolerate and sometimes causes contact dermatitis. Do not use during pregnancy.***

- ***Retinoids (e.g., tretinoin 0.05% or 0.1% cream; adapalene 0.1% or 0.3% gel [Differin]) all have some effectiveness.***
- ***Salicylic acid, a common peeling ingredient in skin creams, can also be used for chemical peels but It is not very effective in melasma.***
- ***The most successful formulation has been a combination of hydroquinone, tretinoin, and moderate potency topical steroid.***
- ***A triple-combination treatment of fluocinonide 0.01% / hydroquinone 4% / tretinoin 0.05% cream (Tri-Luma) showed significantly greater effectiveness at improving dyspigmentation than treatment.***
- ***This has been found to result in improvement or clearance in up to 60-80% of those treated.***
- ***Many other combinations of topical agents are in common use, as they are more effective than any one alone. However, these products are often expensive.***

Devices for melasma

- ***Machines can be used to remove epidermal pigmentation but with caution over-treatment may cause post-inflammatory pigmentation. Patients should be pretreated with a tyrosinase inhibitor (see above).***
- ***Fractional lasers and intense pulsed light (IPL) appear to be the most suitable options. Several treatments may be necessary and post-inflammatory hyperpigmentation may complicate recovery.***
- ***Carbon dioxide or erbium: YAG resurfacing lasers, pigment lasers (Q-switched ruby and Alexandrite devices).***
- ***Mechanical dermabrasion and microdermabrasion should be used with caution in the treatment of melasma.***

Outcome of treatment of melasma

- ***Results take time and the above measures are rarely completely successful.***
- ***Unfortunately, even in those that get a good result from treatment, pigmentation may reappear on exposure to summer sun and/or because of hormonal factors.***

Radiation Dermatitis

Skin changes resulting from exposure to ionizing radiation
Reversible effect: are pain, erythema, epilation, suppression of sebaceous gland and pigmentation
Irreversible effects: atrophy, sclerosis, telangiectasis, ulceration and radiation induced cancer.

20. IMMUNOBULLOUS DISEASES

Immunobullous diseases refer to a group of blistering skin condition with an autoimmune origin.
Immunobullous disorders are not contagious.
The most common types are (1) Pemphigus vulgaris (2) Bullous pemphigoid (3) Pemphigus foliaceus (4) Herpes gestations, and (5) Dermatitis herpetiformis
Depending on the type of skin condition, blisters or erosions may develop on the skin, eyes, or mucous membranes including the mouth.
The chance of developing pemphigus vulgaris or bullous pemphigoid increases with age. Correct diagnosis requires skin biopsies.
Typical treatment consists of oral immunosuppressive therapy including steroids.

Pemphigus Vulgaris

It is a blistering disease, most patients first present with lesions on the mucous membranes such as the mouth and genitals.
Several months later blisters on the skin may develop or in some cases mucosal lesions are the only manifestation of the disease.
The blisters of pemphigus are very shallow and rupture easily, therefore skin erosions rather than frank blisters are usually seen.
Blisters most commonly begin in the mouth (approximately 60% of cases).
The most common mucosal area affected is the inside of the mouth but others include the conjunctiva, oesophagus, labia, vagina, cervix, penis, urethra and anus.
Without treatment, the blisters and painful sores can become widespread,

Common features of oral mucosal pemphigus include:


https://assets.nhs.uk/nhsuk-cms/images/C0548786-Pemphigus_vulgaris_copy.width-1534.png

50-70% of patients get oral lesions
blistering superficial and often appears as erosions
widespread involvement in the mouth
painful and slow to heal
may spread to the larynx causing hoarseness when talking
may make It difficult to eat or drink
Skin lesions appear as thin-walled flaccid blisters filled with clear fluid that easily rupture causing painful erosions.
Erosions in the skin folds may develop into vegetative lesions which are granular and crusty looking (known as pemphigus vegetans).
Pemphigus vulgaris is most common for individuals in their fifth to sixth decades of life.


https://www.pcds.org.uk/imager/gallery/clinical/pemphigus-foliaceus/11736/Pem_fol_1_fee391183f15cb4d62773032fe0be92d.jpg

Diagnosis

A skin biopsy, which shows typical features of rounded- up separated keratinocytes (called acantholytic cells) within the blisters just above

the basal layer of the epidermis.
It is confirmed by direct immunofluorescence staining of the skin biopsy sections to reveal antibodies. Circulating antibodies can be detected by a blood test (indirect immunofluorescence test). The level of antibodies fluctuates and may reflect
the effectiveness of treatment.

Assessment

The severity of pemphigus can be scored using PDAI: (Pemphigus Disease Area Index)

Treatment

The aim of treatment is to decrease blister formation, prevent infections and promote healing of blisters and erosions.

Corticosteroid cream

- ***Oral corticosteroids such as methyl prednisolone or methylprednisolone are the mainstay of treatment***
- ***for controlling the disease. Corticosteroid can clear the blister and sore.***
- ***Mortality rate dropped from 99% to 5-15% by treatment***
- ***They are not a cure for the disease but improve the patient's quality of life by reducing disease activity.***
- ***Higher doses may result in serious side effects and risks.***

Other **immunosuppressant medication** is used to minimize steroid use.
These include:

- ***Azathioprine***
- ***Cyclophosphamide***
- ***Dapsone***
- ***Tetracyclines***
- ***Nicotinamide***

Biologics: This is a newer treatment option. One biologic, rituximab, appears to offer safe treatment

- ***Wound care – heal blister and sore.***
- ***Taking both a corticosteroid like prednisone, and an immunosuppressant medication like azathioprine to quiet the immune system, may deliver better results.***

Bullous Pemphigoid (Bp)

Bullous pemphigoid is a rare skin condition that mainly affects older people. It usually starts with an itchy, raised rash.
As the condition develops, large blisters can form on the skin.
It is characterized by tense blisters on the skin, firm and do not break easily.
The most common form of autoimmune subepidermal blistering disease.
It is the result of an attack on the basement membrane of the epidermis by

- IgG +/- IgE immunoglobulins (antibodies) and activated
- T lymphocytes (white blood cells).

The mouth and other mucosal surfaces are typically not involved.

Common areas of blisters are the trunk, thighs, and groin.
The elderly are more commonly affected, although children, usually younger than 1 year old, are also a group that may be affected by bullous pemphigoid. People over 80 years of age, and mostly affects people over 50.
The blisters of BP are deeper than pemphigus vulgaris.
It causes severe itch and (usually) large, tense bullae (fluid-filled blisters), which rupture forming crusted erosions.
Early BP is sometimes confused with hives.
It can be mild but also chronic (meaning that there is no cure). If the disease is found early, treatment can be effective.



https://dermnetnz.org/assets/Uploads/immune/s/bulpem6__WatermarkedWyJXYXRlcm1hcmtlZCJd.jpg


https://www.mayoclinic.org/-/media/kcms/gbs/patient-consumer/images/2013/08/26/10/41/ds00722_im02463_r7_bullouspemphigoidthu_jpg.jpg

When typical bullae are present, the diagnosis is suspected clinically, the diagnosis will be confirmed by a skin biopsy of an early blister.
The diagnosis can also be made from non-blistered, inflamed skin.
Pathological examination of bullous pemphigoid shows a splIt under the epidermis. A dermal neutrophilic infiltrate is usual but not always present. Eosinophils may be prominent.
Direct immunofluorescence staining of a skin biopsy taken adjacent to a blister highlights antibodies along the basement membrane that lies between the epidermis and dermis.
Blood tests include an indirect immunofluorescence test for circulating pemphigoid BP 180 antibodies.
The Bullous Pemphigoid Disease Area Index (BPDAI) has separate scores for skin and mucous membrane activity.

Treatment

- ***To skin heal, stop new patches or blisters appearing, and reduce the chance of the skin getting infected.***
- ***Steroid creams -treatment usually begins with topical corticosteroids such as clobesterol cream.***
- ***Steroid tablets - extensive skin involvement may require oral steroids e.g., prednisolone 0.5 mg/kg/day***
- ***Immunosuppressive medications including azathioprine or methotrexate or intravenous immunoglobulin.***
- ***Antibiotics – tetracycline usually doxycycline 200 mg bd/day or, niacinamide or dapsone.***
- ***Pain relief.***
- ***Emollients***
- ***Antihistamine***
- ***Do not burst the blisters – the skin might get infected. If a blister is in an annoying place (like the bottom of foot), doctor can drain It with a needle.***

Pemphigus Foliaceus

The pemphigus families are rare autoimmune blistering diseases affecting skin and/or mucous membranes.
It is a rare relatively benign form of pemphigus.
It is the least severe of these disorders. Typically, the protein that causes the blistering is only found

on the top (superficial) layer of skin.



https://www.frontiersin.org/files/Articles/422553/fmed-05-00315-HTML/image_m/fmed-05-00315-g001.jpg

Pemphigus foliaceus affects people of all races, age and sex.
It appears most commonly between the ages of 50-60 years.
These blisters are soft and easily broken.
They may begin on the scalp and move to other parts of the body including the chest, back and face.
Spontaneous remission may occur in some patients whilst in others the problem may persist for several years.
The primary aim of treatment is to prevent new areas from developing infections and promote healing of affected areas.
Topical treatment with corticosteroids and antibiotics is usually all that is necessary for mild cases of pemphigus foliaceus.
For more severe cases treatment is similar to that for pemphigus vulgaris or refer.

Pemphigoid Gestations

It is known as pemphigoid gestations, is an autoimmune blistering disease that occurs in women during pregnancy.



https://dermnetnz.org/assets/Uploads/immune/pemgest1__WatermarkedWyJXYXRlcm1hcmtlZCJd.jpg

A rare pregnancy-associated autoimmune blistering skin condition
It is very rare; 1 in 50,000 pregnancies and usually begins during the second and third trimesters of pregnancy or the immediate postpartum period.
Skin blisters usually begin around the belly button or extremities. Itching is often severe.
The rash spreads to other parts of the body, including the trunk, buttocks, and arms.
The face, scalp, palms, soles, and mucous membranes are not usually affected
This condition is closely related to bullous pemphigoid and is not related to the herpes virus.
Herpes gestation is usually resolves after pregnancy but flares with birth control use or future pregnancies.

Treatment

- ***requires steroids, topical for limited disease, and oral steroids for more significant skin involvement.***
- ***Minimum effective doses should be used to reduce the risk of side effects to both mother and fetus.***
- ***Oral antihistamines may be used to relieve itching.***
- ***Dapsone may be effective.***
- ***Immunosuppressive medications such as azathioprine or ciclosporin may also be used successfully but their safety in pregnancy or during breast feeding must be carefully considered.***
- ***Intravenous immunoglobulin has also been reported to be effective.***
- ***Pemphigoid gestation is usually recurs with subsequent pregnancies, although there may be unaffected pregnancies in between.***

Dermatitis Herpetiformis (Duhring- Brocq Disease)

It is an extremely itchy, blistering disease, immunobullous disease closely related to gluten-sensitive enteropathy or celiac disease of the gut), a gluten- sensitive enteropathy.



The name herpetiformis is derived from the tendency for blisters to appear in clusters, resembling herpes simplex.

But not viral disease.

Predominantly affects Caucasians aged 15–40 years but may occur in those younger or older.

Dermatitis herpetiformis and coeliac disease are due to intolerance to the gliadin fraction of gluten found in wheat, rye and barley.

Gluten triggers production of IgA antibodies and an autoimmune process that targets the skin and gut.

In coeliac disease, gluten causes intestinal inflammation resulting in diarrhoea, tiredness, weight loss and abdominal discomfort.



https://www.rcemlearning.co.uk/wp-content/uploads/Dermatitis-herpetiformis.jpg

The majority (> 90%) of patients with dermatitis herpetiformis also have gluten-sensitive enteropathy.

Gastrointestinal symptoms may be mild to severe; some patients remain symptom-free.

The skin rash consists of red bumps that have been scratched.

The condition usually appears on the scalp, buttocks, elbows, and backs of arms and legs.

The skin condition flares with gluten intake (all grains except rice and com).

It is characterized by prurigo (extremely itchy papules) and vesicles on normal or reddened skin.

They often appear in groups or serpiginous clusters.

Blisters are often eroded and crusted due to immediate scratching.

Diagnosis

is confirmed by IgA staining in skin biopsy.

Treatment

Gluten-free diet

- ***Gluten-free diet for life is strongly recommended in patients with dermatitis herpetiformis, as it:***
- ***Reduces the requirement for medication to control dermatitis herpetiformis***
- ***Improves associated gluten-sensitive enteropathy***
- ***Enhances nutrition and bone density***
- ***May reduce the risk of developing other autoimmune conditions***
- ***May reduce the risk of intestinal lymphoma.***

Medication

- ***Dapsone is the treatment of choice for dermatitis herpetiformis, as It usually reduces itch within 3 days.***
- ***Dose varies from 25 mg to 300 mg daily.***
- ***Dapsone has potential side effects and monitoring requirements.***
- ***It may be gradually weaned off in those who have been on a stable gluten-free diet.***
- ***If intolerant or allergic to dapsone, the following may be useful:***

- ***Ultra-potent topical steroids***
- ***Systemic steroids***
- ***Sulfapyridine***

21. CONNECTIVE TISSUE DISEASES

Cutaneous lupus erythematosus

Cutaneous lupus erythematosus (LE) is a diverse group of autoimmune connective tissue disorders localised to the skin that can be associated with systemic lupus erythematosus (SLE) to varying degrees.

Cutaneous lupus erythematosus (CLE) is classified as:

- ***Acute (ACLE)***
- ***Subacute (SCLE)***
- ***Intermittent (lupus tumidus)***

Chronic (CCLE) eg, discoid lupus (DLE), lupus profundus, chilblain lupus erythematosus.



ACUTE (ACLE)

https://dermnetnz.org/assets/Uploads/immune/lupus-erythematosus/2537__WatermarkedWyJXYXRlcm1hcmtlZCJd.jpg



SUBACUTE (SCLE)

https://www.dermatologyadvisor.com/wp-content/uploads/sites/20/2019/03/ch1174.fig1_.jpg



INTERMITTENT (LUPUS TUMIDUS)

https://ars.els-cdn.com/content/image/1-s2.0-S1578219011001053-gr1.jpg



DISCOID LUPUS (DLE)

https://media.sciencephoto.com/image/c0522480/800wm/C0522480-Discoid_lupus_erythematosus.jpg



LUPUS PROFUNDUS

https://ars.els-cdn.com/content/image/1-s2.0-S2352647517300400-gr1.jpg

CHILBLAIN LUPUS ERYTHEROMATOSUS

https://dermnetnz.org/assets/Uploads/immune/s/lupus-chilb__WatermarkedWyJXYXRlcm1hcmtlZCJd.jpg

Each is a different type of lupus. Cutaneous lupus affects the skin. SLE can affect the skin and other parts of your body, including the joints, lungs, and kidneys.

A person can have cutaneous lupus without having SLE. If you have lupus on your skin, however, It can be a sign that lupus is affecting other parts of your body.

Discoid lupus

It often looks like a raised, thick, scaly patch. Most patches develop on the face, scalp, or ears.

Discoid lupus in the mouth

Lifelong skin cancer screenings are essential If discoid lupus forms in your mouth or on your lips.

Subacute cutaneous lupus

Some people develop a red, scaly rash that usually appears on the chest, upper back, or neck.
This type of cutaneous lupus can also cause a rash that has a ring-like pattern.
The skin can be so light sensitive that sunlight and even fluorescent light bulbs can trigger a flare.

Acute cutaneous lupus (ACL)

A common sign of ACL is the butterfly rash, which can last for hours or days.



LUPUS PANNICULITIS

https://sso.uptodate.com/contents/images/DERM/85711/Lupuspannicfaclipoatro.jpg

Lupus panniculitis

In time, the inflammation often destroys the fat cells.
This causes deep, recessed scars as shown on this woman's face.

Drug-induced lupus

Medicine can cause this type of lupus. The lupus usually clears when the drug is stopped.



https://ars.els-cdn.com/content/image/1-s2.0-S2352647519300887-gr1.jpg

Causes

All types of lupus are autoimmune diseases. .
When a person has systemic lupus erythematosus (SLE), the immune system may attack different
parts of the body, including the skin, kidneys, and lungs.
What causes people to develop this type of autoimmune disease isn't certain. It may be a combination
of genes, environmental triggers, and hormones.
Anything that triggers immune system to attack itself can cause lupus to flare, common triggers for lupus are:
Sunlight
Ultraviolet (UV) light from tanning beds and fluorescent light bulbs
An infection
Some medicines
Stress
Surgery or a serious injury
SLE is female predominance with CLE particularly affecting women 20 to 50 years of age
All age groups and both sexes can be affected.



https://images.rxlist.com/images/image_collection/skin/acute-systemic_lupus-erythematosus.jpg

Skin of colour is an important predisposing factor.
Causes of cutaneous lupus erythematosus- The pathogenesis is multifactorial:
Genetic susceptibility
High incidence among family members
Environmental factors
Cigarette smoking
Sun exposure
Medications
Innate and adaptive immune responses
autoantibodies.

Clinical features of cutaneous lupus erythematosus

Acute cutaneous lupus erythematosus typically presents as transient erythematous patches associated with a flare of systemic lupus erythematosus.
Lupus-specific skin changes:

- ***Localised acute CLE: malar 'butterfly' rash – redness and swelling over both cheeks, sparing the nasolabial folds, lasting hours to days***
- ***Generalised acute CLE: diffuse or papular erythema of the face, upper limbs (sparing the knuckles), and trunk resembling a morbilliform drug eruption or viral exanthem***
- ***Toxic epidermal necrolysis-like acute CLE: is associated with lupus nephritis or cerebritis, and must be distinguished from drug-induced toxic epidermal necrolysis in a patient with SLE.***

Subacute cutaneous lupus erythematosus

It is less commonly associated with SLE with approximately 50% having a mild form of SLE.
It is thought 20–40% have drug-induced SCLE.
It comprises 10–15% of cutaneous LE presentations.
The skin changes are more persistent than those of ACLE.


SUBACUTE CUTANEUOUS LUPUS ERYTHEMATOSUS
https://www.dermatologyadvisor.com/wp-content/uploads/sites/20/2019/03/ch1174.fig2_.jpg

Skin lesions of SCLE:

- ***Occur on the trunk and upper limbs, triggered or aggravated by***
- ***sun exposure***
- ***Present as a psoriasiform papulosquamous rash orannular, polycyclic***
- ***plaques with central clearing***
- ***Resolve to leave dyspigmentation and telangiectases, but no scarring***


SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS
https://images.ctfassets.net/1ny4yoiyrqia/3kzZIZMGGUANUayD37nO7c/ee962af01bb7d5fff19a6410133fcf71/lupus-symptoms-subacute-cutaneous.png?w=450&h=450

Intermittent cutaneous lupus erythematosus

It is better known as lupus tumidus, a dermal form of lupus erythematosus.
Skin lesions of lupus tumidus:
Occur on sun-exposed areas of skin, such as the face, neck, and upper anterior chest
Present as erythematous, round or annular, papules and plaques with a smooth surface
Resolve in winter without scarring.



https://i0.wp.com/post.healthline.com/wp-content/uploads/2022/02/discoid-lupus-erythematosus-face-body1.jpg?w=1155&h=1528

Chronic cutaneous lupus erythematosus

Chronic cutaneous lupus erythematosus is the most common form of CLE, and about 25% of SLE patients have some form of CCLE.
Discoid lupus erythematosus (DLE) is the most common form of CCLE (80%) and is particularly prevalent and severe in patients with skin of colour. Only 1–2% of patients with localised DLE progress to SLE.

Skin lesions of DLE:

The most commonly located on the scalp, ears, cheeks, nose, and lips
Present as destructive scaly plaques with follicular prominence (carpet tack sign) which can result in scarring alopecia. Discoid lupus erythematosus adherent scale with similitude to signs carpet tack, cat tongue, and tin tacks. (Perforation of paper with pen: Simple technique to explain the carpet.)
Heal slowly leaving post-inflammatory dyspigmentation and scarring.



https://www.researchgate.net/profile/Richard-Sontheimer/publication/26890374/figure/fig1/AS:394219878404102@1471000751559/Chronic-cutaneous-lupus-erythematosus-Discoid-lupus-erythematosus-demonstrating.png

https://www.jaad.org/cms/attachment/4e8f1d4c-c63a-420b-9681-bc38188b60bc/gr1.jpg



https://encrypted-tbn0.gstatic.com/images?q=tbn:ANd9GcQAVIcRj2mZAkDz8i9005KNptc0d9598q8OD6GNOtTW_Uvzerw&s

Diagnosis

Skin biopsy — diagnostic histopathology and direct immunofluorescence is seen only in specific-LE lesions
Blood tests — full blood count, renal function test, inflammatory markers
Serology — including ANA, ENA – are often negative in chronic CLE
Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI)
The Cutaneous Lupus Erythematosus Disease Area and Severity Index scores activity and damage in each of 12 anatomical locations.*(see Cutaneous LE Diaease Area and Severity Index CLASI chart)*
The total activity score:
Degree of redness (0-3) and scale (0-2)
Mucous membrane involvement (0-1)

Recent hair loss (0-1), nonscarring alopecia (0-3)
Total damage score:
Degree of dyspigmentation (0-2) and scarring (0-2)
Persistence of dyspigmentation more than 12 months doubles the dyspigmentation score
Scalp scarring (0, 3, 4, 5, 6).

Treatment for cutaneous lupus erythematosus

General measures

- ***Sun protection** and avoidance: SPF 50+ broad spectrum **sunscreen**, UPF 50+ sun-protective clothing*
- ***Smoking cessation***
- ***Vitamin D supplement***
- ***Life style changes***
- ***Specific measures***

Local therapy

- ***Topical steroids - to reduce the inflammation and clear the skin.e.g., fluocinolone acetonide***
- ***or hydrocortisone butyrate.***
- ***Intralesional steroids - to clear a thick patch on the skin or area of hair loss.***
- ***Topical calcineurin inhibitor like tacrolimus (Protopic, Prograf) or pimecrolimus (Elidel) may be prescribed to avoid steroid side effects.***

Systemic therapy

- ***Antimalarials, usually hydroxychloroquine - First-line systemic therapy for patients with all subtypes of CLE. It is also effectively treated lupus on the skin.***
- ***Immune modulators such as methotrexate, mycophenolate, dapsone, ciclosporin, cyclosporine, dapsone and mycophenolate mofetil.***
- ***Systemic corticosteroids - doses of prednisone of 0.5 to 1.0mg/kg/day & tapered over 2-4 weeks***
- ***Chronic CLE tends to follow a chronic relapsing course for years, with flares in spring and summer, and resolution with scarring if untreated.***
- ***If the discoid lupus, clearing skin can reduce the risk of scars, permanent hair loss, and discolored skin prevent lupus rash flare-ups.***
- ***About 40% to 70% of people with lupus have symptom flare-ups after exposure to ultraviolet (UV) light.***
- ***To minimize flare-ups, people with lupus need to take extra caution around sunlight or artificial light.***
- ***To prevent lupus butterfly rash flare-ups and protect yourself from UV exposure:***
- ***Apply a broad-spectrum sunscreen with at least SPF 30 every day.***
- ***Avoid sunlight when the sun is strongest, between 10 a.m. and 4 p.m.***
- ***Don't use tanning beds.***
- ***LimIt your time around indoor fluorescent lights.***
- ***Wear sun-protective clothing, such as wide-brimmed hats and long sleeves.***
- ***In addition to avoiding sun exposure, you may also want to:***
- ***Eat a diet full of nutritious foods, such as fruits, vegetables and whole grains.***
- ***Exercise moderately as often as you can.***
- ***Manage stress with healthy coping tools.***
- ***Sleep at least seven to eight hours per night.***

- ***Take all medications as prescribed.***
- ***If you smoke, stop as It can make the rash worse. Smoking may also make medications that treat the rash less effective.***
- ***Most people who have cutaneous lupus can lead active and productive lives. Treatment helps because It can clear the skin and reduce the effects that lupus has on life. There is currently no cure for cutaneous lupus.***

Cutaneous LE Disease Area and Severity Index (CLASI) ©

Select the score in each anatomical location that describes the most severely affected cutaneous lupus-associated lesion

activity ⟵ ⟶ **damage**

Anatomical Location	Erythema	Scale/ Hypertrophy	Dyspigmentation	Scarring/ Atrophy/ Panniculitis	Anatomical Location
	0-absent 1-pink; faint erythema 2- red; 3-dark red; purple/violaceous/ crusted/ hemorrhagic	0-absent; 1-scale 2-verrucous/ hypertrophic	0-absent, 1-dyspigmentaton	0 – absent 1 – scarring 2 – severely atrophic scarring or panniculitis	
Scalp				See below	Scalp
Ears					Ears
Nose (incl. malar area)					Nose (incl. malar area)
Rest of the face					Rest of the face
V-area neck (frontal)					V-area neck (frontal)
Post. Neck &/or shoulders					Post. Neck &/or shoulders
Chest					Chest
Abdomen					Abdomen
Back, buttocks					Back, buttocks
Arms					Arms
Hands					Hands
Legs					Legs
Feet					Feet

Mucous membrane

Mucous membrane lesions (examine if patient confirms involvement)	
0-absent; 1-lesion or ulceration	

Dyspigmentation

Report duration of dyspigmentation after active lesions have resolved (verbal report by patient – tick appropriate box)
☐ Dyspigmentation usually lasts less than 12 months (dyspigmentation score above remains) ☐ Dyspigmentation usually lasts at least 12 months (dyspigmentation score is doubled)

Alopecia

Recent Hair loss (within the last 30 days / as reported by patient) 1-Yes 0-No		NB: if scarring and non-scarring aspects seem to coexist in one lesion, please score both

Divide the scalp into four quadrants as shown. The dividing line between right and left is the midline. The dividing line between frontal and occipital is the line connecting the highest points of the ear lobe. A quadrant is considered affected if there is a lesion within the quadrant.

Alopecia (clinically not obviously scarred)		Scarring of the scalp (judged clinically)	
0-absent 1-diffuse; non-inflammatory 2-focal or patchy in one quadrant; 3-focal or patchy in more than one quadrant		0- absent 3- in one quadrant 4- two quadrants 5- three quadrants 6- affects the whole skull	

Total Activity Score
(For the activity score please add up the scores of the left side i.e. for Erythema, Scale/Hypertrophy, Mucous membrane involvement and Alopecia)

Total Damage Score
(For the damage score, please add up the scores of the right side, i.e. for Dyspigmentation, Scarring/Atrophy/Panniculitis and Scarring of the Scalp)

Ref: https://www.semanticscholar.org/paper/Cutaneous-lupus-and-the-Cutaneous-Lupus-Disease-and-Klein-Morganroth/b6f5cd0fa8967c9fea0a4c1cd9ba33a1c401e5b9

Scleroderma

Scleroderma means "hard skin." Most people have hardening and tightening on their skin. But this disease can affect more than the skin.
Joints, muscles, and even internal organs like the kidneys and lungs can harden and tighten.
Many people who have scleroderma lead normal—or almost normal—lives.

Type of scleroderma

- *Localized - **Morphea***

1 or a few patches of thickened skin, which are usually red or purple.
The patches can itch but are usually painless. Sometimes the excess collagen develops deep in the skin.
In rare cases, morphea affects muscle.
Gerneralized morphea: Patches of morphea can develop on different areas of the body.



https://www.healthline.com/health/morphea
https://www.atlasdermatologico.com.br/disease.jsf;jsessionid=12B7270274A0A1B77AFCA039FC1197E3?diseaseId=256

Linear scleroderma: Often beginning in childhood or the teenage years, this type causes a line of thickening skin, usually on an arm or leg.

En coup de sabre: A line of thickened skin forms on the scalp, face, or both, and the tissue beneath disappears.
Localized variant associated with CREST syndrome (calcinosis,Raynaud's disease,esophageal dysmotility, Sclerodactyly and telangiectasia)

Systemic scleroderma

Limited cutaneous scleroderma (Sores and calcium deposits on fingers).
Diffuse cutaneous scleroderma: In just a few weeks or months, hard, thickened skin can develop on many areas of the body.
Peak age 30-50 year.
The disease may remain localized on the hands for many years. Systemic sclerosis is rare.



https://images.ctfassets.net/1ny4yoiyrqia/5pbkpQWqGdrjkOidomMwIA/96ddd3222daf5b152f2406c1aac830d4/scleroderma-overview-diffuse-cutaneous.png?fm=webp&w=450&h=450



https://www.birpublications.org/cms/10.1259/bjrcr.20150203/asset/images/medium/bjrcr.20150203.g004.jpg



https://images.ctfassets.net/1ny4yoiyrqia/VAqbmvSl8avmBQ00fCtIN/cb4dc5ec47a29648be2f371f90af6947/Limited-cutaneous-scleroderma.png?fm=webp&w=450&h=450

Signs of scleroderma

Hard, thickening, or tight skin
Hair loss and less sweating
Dry skin and itch
Skin color changes
Salt-and-pepper look to the skin
Stiff joints and difficulty moving them
Muscle shortening and weakness
Loss of tissue beneath the skin
Bone may not grow as It should
Sores and pitted scars on the fingers
Calcium deposits beneath the skin
Hard, thickening, or tight skin
Hair loss and less sweating
Dry skin and itch
Visible blood vessels near the surface of the skin
Extreme sensitivity to cold, stress, or both
When scleroderma affects internal organs
Problems swallowing, Heartburn, Diarrhea, Constipation,
Bloated feeling after eating
Weight loss without trying, High blood pressure



https://healthjade.net/wp-content/uploads/2018/03/scleroderma.jpg



https://cdn.todaysrdh.com/wp-content/uploads/2022/04/Scleroderma-Figure1.png?strip=all&lossy=1&ssl=1



https://www.selfmanagescleroderma.com/images/01.png

Diagnosis

symptoms, health, and medical history is important.
Examine skin for signs of hardening and thickening.
Blood test - elevated antinuclear antibodies.
A skin biopsy can be helpful

Treatment

- ***Started early, treatments like phototherapy (light therapy) and***
- ***Medicines that work on the immune system like methotrexate and cyclosporine can help diminish scleroderma.***
- ***Physical and occupational therapy can help you keep your ability to straighten and bend joints and maintain daily life.***
- ***Working with a physical therapist can help:***

- ***Keep the ability to move a joint (i.e., jaw, finger, or wrist) when thickened skin covers it***
- ***Minimize tightening of skin over joints***
- *Swelling and patches of hard-feeling skin:* ***If you have only a few patches of morphea (a type of scleroderma) on your skin, the following medicines can be effective:***
- ***Calcipotriene (may also reduce discolored skin and visible blood vessels)***
- ***Calcipotriene + a strong corticosteroid***
- ***Imiquimod***
- ***Tacrolimus ointment***
- ***Itch: To treat this, your dermatologist may recommend moisturizer, camphor, or menthol.***
- ***Dry skin: A moisturizer can help heal the dry skin.***
- ***Calcium deposits beneath the skin: Soaking in warm water can help reduce these.***
- ***A strong corticosteroid like prednisone can treat large calcium deposits that develop beneath the skin. Laser treatment can also be helpful.***
- ***Morphea on the top layers of your skin: A type of light treatment called narrowband UVB treatment can be helpful.***

22. HAIR DISEASES

Alopecia Areata

Alopecia areata, one or more round bald patches appear suddenly, most often on the scalp. Alopecia areata is also called autoimmune alopecia.

Alopecia areata can affect males and females at any age. It starts in childhood in about 50%, and before the age of 40 years in 80%. Lifetime risk is 1-2% and is independent of ethnicity.

A family history of alopecia areata and/or of other autoimmune conditions is present in 10-25% of patients.

https://www.birminghamdermatologyclinic.co.uk/_webedit/cached-images/113-0-0-1111-10000-8889-1280.jpg



https://cancerhomoeoclinic.co.in/wp-content/uploads/2017/01/alopecia-areata-707x409.jpg

At least 8 susceptibility genes have been detected.

Patients with alopecia areata have higher than expected rates of thyroid disease, vitiligo and atopic eczema.

There is increased prevalence in patients with chromosomal disorders such as Down syndrome.

It's possibly drug-induced when arising in patients on biologic medicines

Causes

Alopecia areata is classified as an autoimmune disorder.

It is histologically characterised by T cells around the hair follicles.

These CDS (+) NK group 2D-positive (NKG2D(+)) T cells release pro-inflammatory cytokines and chemokines that reject the hair.

The exact mechanism is not yet understood.

The onset or recurrence of hair loss is sometimes triggered by:

Viral infection

Trauma

Hormonal change

Emotional/physical stressors

Clinical features

Most patients have no symptoms, and a bald patch or thinning hair is noted incidentally, often discovered by a hairdresser.

Other patients describe a burning, prickly discomfort in the affected areas-this is known as trichodynia.

Patchy alopecia areata

Patch alopecia areata can affect any hair-bearing area, most often the scalp, eyebrows, eyelashes and beard.

Patchy alopecia areata has three stages.

Sudden loss of hair
Enlargement of bald patch or patches
Regrowth of hair
The bald areas may have a smooth surface, completely devoid of hair or with scattered "exclamation mark" hairs.
Exclamation mark hairs are 2 to 3-mm in length, broken or tapered, with a club- shaped root. Microscopy shows a thin proximal shaft and normal caliber distal shaft.
Regrowing hairs are often initially coloured white or grey; they may be curly when previously straight. It may take months and sometimes years to regrow all the hair.
One patch can be falling out while another is regrowing.

Alopecia totalis


https://www.medicalnewstoday.com/articles/320504#causes

- ***Affects up to 5% of patients with autoimmune hair loss.***
- ***All or nearly all scalp hair is lost***

Alopecia universalis


https://nn.neurology.org/content/nnn/5/3/e454/F1.medium.gif

- ***Affects less than 1% of cases.***
- ***All hair or nearly all hair on the entire body is lost.***

Ophiasis

- ***Pattern of alopecia areata affecting occipital and lateral scalp.***
- ***Bald area can encircle scalp***

Diffuse alopecia areata


https://donovanmedical.com/hair-blog/aa-ophiasis-vs-ffa

- ***Sometimes called alopecia areata incognita***
- ***Presents with sudden diffuse thinning of scalp hair***
- ***Persisting hair tends to grey, thus descriptions of 'turning white overnight'***
- ***Positive hair pull test***
- ***May be confused with telogen effluvium or hair loss due to medications***

Alopecia areata of the nails

- ***Nail disease affects 10-50% of those with alopecia areata***
- ***Regular pitting and ridging are the most common findings***
- ***May also cause koilonychia, trachyonychia, Beau lines, onychorrhexis, onycho- madesis, onycholysis and red spots on the lunula***

Alopecia areata nails

Complications

Alopecia areata patients are at risk for psychosocial consequences of their disease, such as depression and anxiety.
They should be assessed for atopy, vitiligo, thyroid disease, and other autoimmune conditions.



https://education.lillymedical.com/en-us/disease-education-resources/dermatology/alopecia-areata/education-resources/al
https://link.springer.com/chapter/10.1007/978-3-319-89581-9_22

Diagnosis

Alopecia areata is diagnosed clinically. Although usually straightforward, additional tests are sometimes needed to confirm the diagnosis.
Trichoscopy (use of a dermatoscope to examine hair and scalp)

- ***Skin biopsy (histopathology)***

Treatment

- ***There is not yet any reliable cure for alopecia areata and other forms of autoimmune hair loss.***
- ***Because spontaneous regrowth is common in alopecia areata, and research has often been of poor quality, the effectiveness of reported treatments is mostly unknown.***

Topical

- ***Several topical treatments used for alopecia areata are reported to result in temporary improvement in some people.***
- ***Their role and efficacy are unknown.***
- ***The hair may fall out when they are stopped. These include:***
- ***Potent or ultrapotent topical steroids***
- ***Minoxidil solution or foam***
- ***Dithranol (anthralin) ointment***

Intralesional corticosteroid injections

- ***Injections of triamcinolone acetonide 2.5-10 mg/ml into patchy scalp, beard or eyebrow alopecia areata may speed up regrowth of hair.***
- ***Its effect is temporary. If bald patches reappear, they can be reinjected.***

Systemic corticosteroids

- ***Oral and pulse intravenous steroids in high dose can lead to temporary regrowth of hair.***
- ***Most physicians agree that long-term systemic steroid treatment is not justified because of potential and actual adverse effects.***

Immunotherapy

- ***The sensitizing agents diphenylcyclopropenone (diphencyprone) and dinitrochlorobenzene provoke contact allergic dermatitis in treated areas.***
- ***These sensitizers can be reapplied once weekly to bald areas on the scalp.***
- ***The resultant dermatitis is irritating and may be unsightly.***
- ***It is often accompanied by a swollen lymph gland.***

Other treatments

- ***A combination of the lipid lowering agents simvastatin and ezetimibe (which have immunomodulating effects) has been reported to be effective.***
- ***JAK inhibitors***
- ***Counselling and camouflaging hair loss***

Alopecia areata Scalp

A hairpiece is often the best solution to disguise the presence of hair loss.
These cover the whole scalp or only a portion of the scalp, using human or synthetic fibres tied or woven to a fabric base.
A full wig is a cap that fits over the whole head.
A partial wig must be clipped or glued to existing hair.
A hair integration system is a custom-made hair net that provides artificial hair where required, normal hair being pulled through the net.
Hair additions are fibres glued to existing hair and removed after 8 weeks
Styling products include gels, mousses and sprays to keep hair in place and add volume. They are reapplied after washing or styling the hair.

Alopecia areata Eyelashes

Artificial eyelashes come as singlets, demilashes and complete sets.
They can be trimmed If necessary. The lashes can irritate the eye and eyelids.
They are stuck on with methacrylate glue, which can also irritate and sometimes causes contact allergic dermatitis.
Eyeliner tattooing is permanent and should be undertaken by a professional cosmetic tattooist. The colour eventually fades and may move slightly from the original site.
It is extremely difficult to remove the pigment, should the result tum out to be unsatisfactory.

Alopecia areata Eyebrows

Artificial eyebrows are manufactured from synthetic or natural human hair on a net that is glued in place.
Tattooing can also be undertaken to disguise the loss of eyebrows, but tends to look rather unnatural because of the shine of hairless skin.

Outcome

In 80% of patients with a single bald patch, spontaneous regrowth occurs within a year.
Even in the most severe cases of alopecia totalis and alopecia universalis, recovery may occur at some

future date.

Poor prognostic factors include:

- ***Extensive disease***
- ***Bald patches persisting for more than 1 year***
- ***Ophiasis pattern of hair loss***
- ***Alopecia areata of the nails***
- ***Onset of alopecia areata before puberty***
- ***Family members with alopecia areata***
- ***Personal or family history of other autoimmune diseases***
- ***Down syndrome***

23. CUTANEOUS MANIFESTATION OF INTERNAL DISEASE

LEPROSY (HANSON'S DISEASE)

- Hansen's disease (also known as leprosy) is an infection caused by bacteria called *Mycobacterium leprae*.
- These bacteria grow very slowly and It may take up to 20 years to develop signs of the infection.
- The disease can affect the nerves, skin, eyes, and lining of the nose (nasal mucosa).
- The bacteria attack the nerves, which can become swollen under the skin. It can cause the affected areas to lose the ability to sense touch and pain, which can lead to injuries, like cuts and burns.
- The affected skin changes color and either becomes: lighter or darker, often dry or flaky, with loss of feeling, or reddish due to inflammation of the skin.
- If left untreated, the nerve damage can result in paralysis of hands and feet.
- In very advanced cases, the person may have multiple injuries due to lack of sensation, and eventually the body may reabsorb the affected digits over time, resulting in the apparent loss of toes and fingers.

Transmission

- **Prolonged, close contact with someone with untreated leprosy over many months is needed** to catch the disease.

Signs and Symptoms

- Symptoms mainly affect the skin, nerves, and mucous membranes (the soft, moist areas just inside the body's openings).
- The disease can cause skin symptoms such as: A large, discolored lesion on the chest of a person with Hansen's disease.
- Discolored patches of skin, usually flat, that may be numb and look faded (lighter than the skin around)
- Growths (nodules) on the skin
- Thick, stiff or dry skin
- Painless ulcers on the soles of feet
- Painless swelling or lumps on the face or earlobes
- Loss of eyebrows or eyelashes
- In over 90% of patients, the first symptom noticed is numbness.
- Temperature is the first sensation lost, followed by light touch, pain,
- and then deep pressure.
- It may precede the development of cutaneous lesions by years.
- The initial skin lesions are usually of the indeterminate type, presenting



https://www.cdc.gov/leprosy/images/health-care-workers/healthcare-1.jpg

- as a solitary or small number of hypopigmented patches before evolving into borderline tuberculoid or lepromatous types.

Symptoms caused by damage to the nerves are:

- Numbness of affected areas of the skin
- Muscle weakness or paralysis (especially in the hands and feet)
- Enlarged nerves (especially those around the elbow and knee and in the sides of the neck)
- Eye problems that may lead to blindness (when facial nerves are affected

Symptoms caused by the disease in the mucous membranes are:

- A stuffy nose
- Nosebleeds

If left untreated, the signs of advanced leprosy can include:

- Paralysis and crippling of hands and feet
- Shortening of toes and fingers due to reabsorption
- Chronic non-healing ulcers on the bottoms of the feet
- Blindness
- Loss of eyebrows
- Nose disfigurement

Other complications that may sometimes occur are:

- Painful or tender nerves
- Redness and pain around the affected area
- Burning sensation in the skin

Type of Leprosy

Tuberculoid leprosy

- Tuberculoid (TT) leprosy is the paucibacillary form defined clinically by:
- A few (1–2) sharply defined red patches with raised borders or
- a single larger hypopigmented patch less than 10 cm in diameter
- Loss of sweating with rough dry hairless skin in the patches
- Loss of sensation in lesions
- Affected nerves are thickened and tender on palpation.



https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2011/nejm_2011.364.issue-17/nejmicm1011992/production/images/img_large/nejmicm1011992_f1.jpeg

Borderline tuberculoid (BT)

- Borderline tuberculoid (BT) leprosy presents with:
- Similar lesions to TT but larger in size, more numerous (5-20), and can be less well-defined

- Asymmetrical distribution
- Satellite lesions
- Anaesthesia over the lesions is less pronounced compared to TT
- Peripheral nerves are affected in an asymmetrical pattern and can cause deformity and disability.



Ref: https://dermnetnz.org/topics/leprosy

Borderline borderline leprosy

- Borderline borderline (BB) leprosy is a rarely seen, transient, unstable form of
- leprosy defined by:
- Multiple lesions of varying size, shape, and distribution
- Skin-coloured or erythematous lesions
- Characteristic, but rare, inverted saucer-shaped lesions with sloping edges and
- punched out centre (Swiss cheese lesion).
- Red lesions of variable sizes,characterized swiss cheese appearance



https://dermnetnz.org/assets/collection/Leprosy/leprosy-borderline-borderline-00001__ProtectWyJQcm90ZWN0Il0_FocusFillWzI5NCwyMjIsInkiLDBd.jpg

Borderline lepromatous leprosy

- Borderline lepromatous (BL) leprosy is characterised by:
- Widespread bilaterally symmetrical lesions
- Macules, papules, and nodules of variable size and shape
- Sensation and hair growth remain normal within a lesion
- Characteristic glove and stocking numbness
- Widespread peripheral nerve involvement.

https://dermnetnz.org/assets/collection/Leprosy/leprosy-borderline-lepromatous-00001__ProtectWyJQcm90ZWN0Il0_FocusFillWzI5NCwyMjIsIngiLDFd.jpg

Lepromatous leprosy

- Lepromatous (LL) leprosy is the multibacillary form defined by:
- Early symptoms of nasal stuffiness, discharge, and bleeding
- Swelling and thickening of limbs, especially ankles and legs with subsequent ulceration

- Widespread poorly defined hypopigmented and erythematous macules with a shiny surface and normal sensation
- Progression to widespread infiltration of skin forming nodules and plaques
- Characteristic leonine facies with thickening of the forehead, loss of eyebrows and eyelashes (madarosis), distortion of the nose, and thickening of the earlobes
- Involvement of other systems:
- Eyes — corneal anaesthesia, keratitis, corneal ulceration, uveitis, glaucoma, irreversible blindness
- Testes — orchitis, testicular atrophy, sterility
- Liver — hepatitis, hepatic amyloidosis
- Kidneys — glomerulonephritis, renal amyloidosis
- Bones — osteoporosis, resorption of digits.

Lepromatous leprosy



Ref: https://dermnetnz.org/topics/leprosy

- A number of clinical variants of lepromatous leprosy are
- Histoid leprosy — multiple dome-shaped, skin-coloured to coppery-red papules and nodules (histoid lepromas) of variable size mainly on the limbs and trunk, or along peripheral nerves particularly in males. difficult.
- Lucio leprosy (diffuse lepromatous leprosy) — presents as a smooth infiltration of the skin, especially on the face and hands. It is particularly seen in Central and South America where It is called 'lepra bonita' (pretty leprosy).
- Verrucous lepromatous lesions — are filiform, horn-like, or fissured hyperkeratotic warty projections or plaques on the distal lower limb and feet. It is a rarely described presentation seen in advanced lepromatous leprosy.

Fig. Dome shaped papules and nodules in skin colour https://dermnetnz.org/topics/leprosy

Pure neural leprosy



https://d3i71xaburhd42.cloudfront.net/ecaa65d9f82578a0b4fe71bcbf69e1cb071107bc/3-Figure5-1.png

- Pure neural leprosy (PNL) is common in India and Nepal.
- It presents with only peripheral nerve tenderness and thickening without skin lesions.
- However, the nerve damage can result in loss of sensation and hence trophic ulcers.
- Diagnosis is difficult and requires nerve biopsy.

Complications of leprosy

- Lepra reactions occur in 30–50% of patients with leprosy. They may occur before, or more often, after the start of treatment.
- These are sudden responses resulting from the release of immunologically active bacilli or its products leading to localised or systemic symptoms and signs. Such reactions are responsible for most of the nerve damage, deformity, and disability.

Diagnosis

- Leprosy has very characteristic clinical features, and dermoscopy is being used more often to aid clinical diagnosis.
- Skin SlIt Smear — a small slIt is made using a sharp blade over the skin of the earlobe, forehead, or lesional skin, then a smear is made by scraping the exposed dermis onto a glass slide and examining for acid fast bacilli under microscopy; useful for multibacillary leprosy only.
- Lepromin test — is an intradermal test for delayed type hypersensitivity to *M. leprae* antigens; although not specific, It is helpful for classifying the type of leprosy.
- Skin biopsy — may show typical features, depending on the type of leprosy (see Leprosy pathology); special stains may be required to demonstrate the bacilli.
- *M. leprae* DNA PCR is very specific for detecting leprosy organisms.

Treatment

- ***The treatment of leprosy aims to stop active infection and minimise complications and deformity.***
- ***Residual disabilities may require corrective reconstructive surgery to allow day-to-day activity.***

- ***Most endemic countries follow the WHO recommended multi-drug therapy (MDT) of antibiotics; the combination of drugs selected and duration of treatment depends on the type of leprosy.***
- ***First-line antibiotics used in the treatment of leprosy are dapsone, rifampicin and clofazimine.***
- ***Other drug options include ofloxacin, moxifloxacin, minocycline, clarithromycin, rifapentine, and diarylquinolone. Vaccines and other forms of immunotherapy are being trialed.***

WHO recommended multi-drug therapy (MDT)

Table 3. Recommended treatment regimens

Age group	Drug	Dosage and frequency	Duration	
			MB	PB
Adult	Rifampicin	600 mg once a month	12 months	6 months
	Clofazimine	300 mg once a month and 50 mg daily		
	Dapsone	100 mg daily		
Children (10–14 years)	Rifampicin	450 mg once a month	12 months	6 months
	Clofazimine	150 mg once a month, 50 mg on alternate days		
	Dapsone	50 mg daily		
Children <10 years old or <40 kg	Rifampicin	10 mg/kg once month	12 months	6 months
	Clofazimine	100 mg once a month, 50 mg twice weekly		
	Dapsone	2 mg/kg daily		

Note: The treatment for children with body weight below 40 kg requires single formulation medications since no MDT combination blister packs are available. For children between 20 and 40 kg, it would be possible to follow the instructions of the Operational Manual, Global Leprosy Strategy 2016–2020 on how to partly use (MB-Child) blister packs for treatment (60).

CUTANEOUS TUBERCULOSIS

- Cutaneous tuberculosis (TB) results from skin infection with *Mycobacterium tuberculosis (M. tuberculosis)*, the same bacterium that causes tuberculosis of the lungs (pulmonary TB).
- Cutaneous tuberculosis is an uncommon form of extrapulmonary TB (TB infection of organs and tissues other than the lungs).
- TB is common, such as the Indian subcontinent, sub-Saharan Africa, and China, cutaneous tuberculosis is rare (<0.1%).

Risk factors for developing tuberculosis include:

- Close contact with a patient with active TB
- Living in or visiting a country or community where TB is common
- Living in a crowded community, including institutions such as aged care residences, long-stay hospitals, and prisons
- Working in hospitals and healthcare environments.

Cutaneous Tuberculosis classification

A. Exogenous cutaneous tuberculosis

   Tuberculous chancre and Tuberculosis verrucosa cutis

B. Endogenous cutaneous tuberculosis

a) By contiguity or autoinoculation (Scrofuloderma, orificial tuberculosis and some cases of lupus vulgaris)

b) By hematogenic dissemination (Lupus vulgaris, tuberculous gumma and acute miliary tuberculosis)

C. Tuberculids

- Papulonecrotic tuberculid
- Lichen scrofulosorum

D. Cutaneous tuberculosis secondary to BCG vaccination

Clinical features of cutaneous tuberculosis


https://onlinelibrary.wiley.com/doi/10.1111/j.1365-4632.2008. 03579.x

- Primary cutaneous tuberculosis
- Direct inoculation of the skin or mucous membranes with tubercle bacilli from an outside source results in a tuberculous chancre.
- Children are predominantly affected. Infection may follow piercings, tattooing, or other penetrating skin injury.
- The face, hands, and legs are the commonest sites involved.
- The tuberculous chancre appears 1-4 weeks after inoculation, presenting initially as a firm red papule which becomes a painless shallow ulcer with a granular base and undermined edge.
- Sporotrichoid lesions and enlarged regional lymph nodes can develop.

Tuberculosis verrucosa cutis (warty tuberculosis)

- It occurs after direct inoculation of tubercle bacilli into the skin of someone who has been previously infected and developed good immunity.
- It was called "prosector's wart" when It followed accidental injury in the autopsy room.
- Presents as a purplish or brownish-red warty growth
- Lesions most often occur on the knees, elbows, hands, feet and buttocks
- Lesions may persist for years but can clear up even without treatment

Tuberculosis verrucosa cutis and tuberculosis chancre



https://www.sciencedirect.com/science/article/abs/pii/S0733863507001386 and https://www.sciencedirect.com/science/article/abs/pii/S0190962200762189

Reinoculation /reinfection cutaneous tuberculosis

Lupus vulgaris

- It is the most common presentation of reinfection cutaneous tuberculosis.
- Any skin site can be involved, but the head and neck are the most commonly reported

affected sites.

- Persistent and progressive form of cutaneous TB
- Small sharply defined reddish-brown papules merge into plaques with a gelatinous consistency (called apple-jelly nodules)
- Lesions persist for years, leading to disfigurement and sometimes skin cancer



lupus vulgaris Ref: https://doctorhoogstra.com/en/wiki/tuberculosis-cutaneous/

Orificial tuberculosis (tuberculosis cutis orificialis)

- It follows autoinoculation from advanced internal disease depositing tubercle bacilli at mucocutaneous junctions such as around the nose and mouth.
- Skin lesions at mucocutaneous junctions e.g., perianal
- Associated with advanced internal disease
- Shallow ulcers

Tuberculosis cutis orificialis

Extension into the skin from an underlying infective focus

Scrofuloderma

- It follows the direct invasion of the skin from tuberculosis in an underlying lymph node or bone, often in association with pulmonary TB.
- The most common sites involved are around the neck and under the jawline.
- Firm, painless lesions that eventually ulcerate with a granular base
- May heal even without treatment but this takes years and leaves unsightly scars



Scrofuloderma

Ref: https://doctorhoogstra.com/en/wiki/tuberculosis-cutaneous/

Haematogenous spread to the skin

Miliary tuberculosis

- It follows generalised spread of tubercle bacilli via the bloodstream from an active internal focus of tuberculosis.
- It is seen mainly in children and immunocompromised patients.
- Skin involvement is called disseminated cutaneous tuberculosis or acute cutaneous miliary tuberculosis.
- Haematogenous spread of tuberculosis to skin
- Skin lesions are small (millet-sized) red spots that become necrotic, developing into ulcers and abscesses
- The patient is generally sick
- Prognosis is poor (many patients die even If diagnosed and treated)




Cutaneous miliary tuberculosis Tuberculous gumma

https://www.google.com/search?q=cutaneous+tuberculosis&tbm

Metastatic tuberculous abscess (tuberculous gumma)

- It is also due to haematogenous spread to the skin in children and immunocompromised adults, but presents as a subcutaneous nodule or cold abscess on an extremity.
- The overlying skin breaks down to form an ulcer with sinus tracts.
- Metastatic tuberculous abscess (tuberculous gumma) is also due to haematogenous spread to the skin in children and immunocompromised adults, but presents as a subcutaneous nodule or cold abscess on an extremity.
- The overlying skin breaks down to form an ulcer with sinus tracts and fistulae.

Tuberculid

- A tuberculid is a hypersensitivity reaction presenting as skin changes in association with tuberculosis elsewhere in the body.
- *Mycobacterium tuberculosis* organisms cannot be isolated from the tuberculid skin lesions.
- Four types of tuberculid are usually recognised: erythema induratum (Bazin disease), papulonecrotic tuberculid, lichen scrofulosorum, and nodular tuberculid, and more than one type of tuberculid may be present.



- *Ref: https://www.annsaudimed.net/doi/10.4103/0256-4947.77495*

Diagnosis of cutaneous tuberculosis

- The diagnosis of cutaneous tuberculosis is usually made or confirmed by characteristic histopathological features on skin biopsy.
- Typical tubercles are caseating epithelioid granulomas that contain acid-fast bacilli (AFB).
- However, in some forms of cutaneous tuberculosis these can be very difficult to locate due to very low numbers of bacilli in the skin.
- Tubercle bacilli can be detected in the skin by special tissue stains such as Ziehl-Neelsen, polymerase chain reaction (PCR), and culture in the laboratory.
- Other tests that may be necessary include:
- Tuberculin skin test (Mantoux or PPD test)
- Interferon-gamma release assay (IGRA) blood test such as QuantiFERON-TB gold
- Sputum culture (It may take a month or longer for results to be reported)
- Chest X-ray and other radiological tests for extrapulmonary infection.
- Severe Mantoux test reactions (active TB)



- *Ref: https://doctorhoogstra.com/en/wiki/tuberculosis-cutaneous/*

Treatment of cutaneous tuberculosis

- Patients with pulmonary or extrapulmonary TB need an adequate course of appropriate multi-drug anti-tuberculous treatment.

Treat with according to WHO TB guideline.

- This usually involves a combination of isoniazid, rifampicin, pyrazinamide, and ethambutol given over a period of six months for a standard course.
- Multi-drug resistant tuberculosis has become a significant problem worldwide.
- Patients with latent TB infection but no active disease may also be treated with anti-tuberculous

drugs to prevent development of active disease. Single-drug therapy is discouraged.

- Occasionally surgical excision of localised cutaneous TB such as lupus vulgaris or scrofuloderma is recommended.
- Plastic surgical reconstruction may be required by some patients disfigured by lupus vulgaris.

Outcome of cutaneous tuberculosis

- Spontaneous healing can occur for tuberculous chancre, scrofuloderma, and tuberculosis verrucosa cutis.
- Lupus vulgaris is usually progressive If untreated, as are most cases of tuberculosis verrucosa cutis, and scrofuloderma.
- Some presentations of cutaneous tuberculosis, such as miliary tuberculosis, indicate significant systemic disease which may be fatal.
- Treatment is usually successful with an adequate course of appropriate multi-drug therapy, although some skin lesions are slow to heal.

24. CUTANEOUS MANIFESTATION OF DIABETES MELLITUS

Strongly associated with Diabetes Mellitus

Acanthosis Nigricans

- is a classic dermatologic manifestation of diabetes mellitus that affects men and women of all ages.
- AN presents chronically as multiple poorly demarcated plaques with grey to dark-brown hyperpigmentation and a thickened velvety to verrucous texture.
- Classically, AN has a symmetrical distribution and is located in intertriginous or flexural surfaces such as the back of the neck, axilla, elbows, palmer hands (also known as “tripe palms”), inframammary creases, umbilicus, or groin.
- Affected areas are asymptomatic; however, extensive involvement may cause discomfort or fetor.
- The pathogenesis of AN is not completely understood.



Ref:https://dermnetnz.org/topics/skin-problems-associated-with-diabetes-mellitus

Treatment

- AN is best managed with lifestyle changes such as
  - dietary modifications,
  - increased physical activity, and
  - weight reduction.
- In patients with diabetes, pharmacologic adjuvants, such as metformin, that improve glycemic control and reduce insulin resistance are also beneficial
- thickened or macerated areas of skin, oral retinoids or topical keratolytics such as ammonium lactate, retinoic acid, or salicylic acid can be used to alleviate symptoms

Diabetic Dermopathy

- Dermopathy (DD), also known as pigmented pretibial patches or diabetic shin spots.
- It is the most common dermatologic manifestations of diabetes, presenting in as many as

one-half of those with diabetes.



https://dermnetnz.org/topics/skin-problems-associated-with-diabetes-mellitus

- DD initially presents with rounded, dull, red papules that progressively evolve over one-to-two weeks into well-circumscribed, atrophic, brown macules with a fine scale (figure)
- Normally after about eighteen to twenty-four months, lesions dissipate and leave behind an area of concavity and hyperpigmentation.
- At any time, different lesions can present at different stages of evolution.
- The lesions are normally distributed bilaterally and localized over bony prominences.
- The pretibial area is most commonly involved, although other bony prominences such as the forearms,

Treatment

Treatment is typically avoided given the asymptomatic and self-resolving nature of DD as well as the ineffectiveness of available treatments.

Diabetic bullae

- Diabetic bullae, also known as bullosis diabeticorum, are blister-like lesions that occur spontaneously on the feet and hands of diabetic patients.
- Although rare, diabetic bullae are a distinct marker for diabetes.
- Diabetic bullae are more common in men than women
- They are prevalent between the ages of 17 and 84 years.
- They are also more common in patients who have long-standing diabetes or multiple diabetic complications, particularly neuropathy.
- The blisters are painless and can be from 0.5–17 centimetres in size. They often have an irregular shape.
- Two types of diabetic bullae have been defined.
- Intraepidermal bullae — these are blisters filled with clear, sterile viscous fluid and normally heal spontaneously within 2–5 weeks without scarring and atrophy.
- Subepidermal bullae — these are less common and may be filled with blood. Healed blisters may show scarring and atrophy.
- In most cases, diabetic bullae heal spontaneously without treatment. Patients should make sure the blister remains unbroken to avoid secondary infection.

Diabetic bullae



Ref: https://dermnetnz.org/topics/skin-problems-associated-with-diabetes-mellitus

Diabetic Foot Syndrome

- Diabetic Foot Syndrome (DFS) encompasses the neuropathic and vasculopathic complications that develop in the feet of patients with diabetes.
- DFS presents initially with callosities and dry skin related to diabetic neuropathy.
- In later stages, chronic ulcers and a variety of other malformations of the feet develop.
- Between 15% and 25% of patients with diabetes will develop ulcers (21). Ulcers may be neuropathic, ischemic, or mixed.
- The most common type of ulcers are neuropathic ulcers, a painless ulceration resulting from peripheral neuropathy. Ulcers associated with peripheral vascular ischemia are painful but less common
- Secondary infection of ulcers is a serious complication that can result in gangrenous necrosis, osteomyelitis, and may even require lower extremity amputation.

Diabetic neuro-osteoarthropathy (also known as Charcot foot)

- It is an irreversible debilitating and deforming condition involving progressive destruction of weight-bearing bones and joints.
- Diabetic neuro-osteoarthropathy occurs most frequently in the feet and can result in collapse of the midfoot, referred to as "rocker-bottom foot."



-
- ***Ref:*** ***https://www.nature.com/articles/nrendo.2009.174***

Treatment

- ***It should involve an interdisciplinary team-based approach with a focus on prevention and management of current ulcers.***
- ***Prevention entails daily surveillance, appropriate foot hygiene, and proper footwear, walkers, or other devices to minimize and distribute pressure.***
- ***An appropriate wound care program should be used to care for ongoing ulcers***

Diabetic stiff skin

- Many patients with longstanding type 1 diabetes develop diabetic cheiroarthropathy or diabetic stiff skin (digital sclerosis).
- This results in restricted mobility of the joints of their hands and stiff, waxy, thickened and yellowed skin. --This is thought to be due to the reaction of glucose with proteins in the skin and increased glycation end products.
- These patients may also suffer from Dupuytren contracture (tendon tightening, which bends the fingers).

Diabetic stiff skin



Ref: https://tcoyd.org/2021/03/stiff-hands-trigger-finger-and-carpal-tunnel/

Diabetic Thick Skin

- Skin thickening is frequently observed in patients with diabetes.
- Affected areas of skin can appear thickened, waxy, or edematous.
- These patients are often asymptomatic but can have a reduction in sensation and pain.
- Although different parts of the body can be involved, the hands and feet are most frequently involved.
- Diabetic thick skin may represent another manifestation of scleroderma-like skin changes or limited joint mobility

Scleroderma-Like Skin Changes

- Scleroderma-like skin changes are a distinct and easily overlooked group of findings that are commonly observed in patients with diabetes.
- Ten to fifty percent of patients with diabetes present with the associated skin findings
- Scleroderma-like skin changes develop slowly and present with painless, indurated, occasionally waxy appearing, thickened skin.
- These changes occur symmetrically and bilaterally in acral areas.
- In patients with scleroderma-like skin changes the acral areas are involved, specifically the dorsum of the fingers (sclerodactyly), proximal interphalangeal, and metacarpophalangeal joints.



Ref: https://www.northstardermatology.com/blog/scleroderma

Treatment

- ***Scleroderma-like skin changes is a chronic condition that is also associated with joint and microvascular complication. Therapeutic options are extremely limited.***

Limited Joint Mobility

- Limited Joint Mobility (LJM), also known as diabetic cheiroarthropathy, is a relatively common complication of long-standing diabetes mellitus.
- The majority of patients with LJM also present with scleroderma-like skin changes.



https://d148x66490prkv.cloudfront.net/c360/imported/inline-images/1907C360_LJMS_1.jpg?VersionId=I8Xbg1AmbHb2g_sgZpuruBS2r9NdpR0y

The prevalence of LJM is 4% to 26% in patients without diabetes and 8% to 58% in patients with **diabetes**

Infection

- It is estimated that 30% of patients with diabetes mellitus will experience a skin problem at some stage throughout the course of their disease.
- Patients with type 2 diabetes also have twice the risk of developing the common scaly disease, psoriasis, as non-diabetics.
- common infection such as:

- Bacterial skin infections — including stye, boil, impetigo, abscess, paronychia, cellulitis
- Fungal infections — particularly *Candida albicans* *70 % of DM patients*



Candida interigo



Psoariasis

https://dermnetnz.org/topics/skin-problems-associated-with-diabetes-mellitus

Other dermatological conditions associated with diabetes

- Other common conditions in diabetics are foot ulcers and necrobiosis lipoidica.
- Diabetics with renal failure are also prone to reactive perforating collagenosis and Kyrle disease.
- Disseminated granuloma annulare
- Eruptive xanthoma on the hands, arms, feet, legs, and buttocks associated with high levels of cholesterol and triglycerides



Generalized granuloma annulare



Eruptive xanthoma



Xanthelasm

https://dermnetnz.org/topics/skin-problems-associated-with-diabetes-mellitus

Necrobiosis lipoidica

- Necrobiosis lipoidica is a rare, chronic granulomatous disease of the skin.
- Skin involvement usually begins as red-brown or violaceous papules, plaques, or nodules and rapidly progresses to yellow-brown, atrophic, telangiectatic plaques.
- The lower legs, especially the shins, are by far the most common sites of involvement.
- Ulceration is a common complication, occurring in 10 to 20 percent of patients

- Necrobiosis lipoidica frequently occurs in association with diabetes mellitus, which accounts for the past use of the term "necrobiosis lipoidica diabeticorum" for this disease.
- The treatment of necrobiosis lipoidica can be challenging.
- Topical or intralesional administration of corticosteroids is often used as initial therapy.
- immunomodulators, biologics, platelet inhibitors, phototherapy, and surgery.



https://dermnetnz.org/topics/skin-problems-associated-with-diabetes-mellitus

****

REFERENCE

- ***Andrews' Diseases of the skin, Clinical Dermatology, 11th Edition***
- ***Fitzpatrick's Color Atlas and Synosis of Clinical Dermatology, Klaus Wolff, Richard Allen Johnson, 6th Edition***
- ***Oxford Handbook of Medical Dermatology, Susan Brge with Dinny Walis***
- ***Dermatology 2nd Edition, Habif, Campbell Jr, Chapman, Dinulos,Zug***
- ***Hunter,J,J, Clinical Dermatology, 3rd Edition***
- ***Field guide to clinical dermatology (field guide series) second edition, by david h. Frankel md***
- ***Dermatology: 2-Volume Set, 4th Edition, By Jean L. Bolognia, MD, Julie V. Schaffer, MD and Lorenzo Cerroni***
- ***http://www.bad.org.uk/healthcare-professionals/clinical-standards/clinical-guidelines***
- ***https://www.aad.org/media/news-releases /guidelines-to-treat-nonmelanoma-skin- cancer***
- ***https://www.aad.orglpracticecenter/qualitylclinical-guidelines***
- ***https://www.guidelinecentral.com /summaries/organizations/american-academy-of- dermatology/***
- ***https://www.dermnetnz.org/topics/dermatology-practice-guidelines /***
- ***https://www.dermnetnz.org/topics/guidelines-for-the-management-of-adult-eczema /***
- ***https://www.dermnetnz.org/topics/guidelines-for-the-diagnosis-and-assessment-of- eczema/***
- ***http://www.bad.org.uk/library-***
- ***https://quizlet.com/553146266/27-human-papillomavirus-hpv-flash-cards/***
- ***https://www.aafp.org/pubs/afp/issues/2014/0901/p312.html***
- ***https://www.healthline.com/health/skin/warts***
- ***http://medwarts.com/warts-on-face-all-possible-locations-their-causes-and-effective-treatment/***
- ***https://www.nhs.uk/conditions/rubella/***
- ***https://www.bansalglobalhospital.com/dengue-hemorrhagic-fever-sign-and-causes/***
- ***https://island.lk/us-cdc-suspects-monkeypox-virus-to-be-airborne-advises-public-to-wear-masks/***
- ***https://my.clevelandclinic.org/health/diseases/4567-scabies***

- *https://step2.medbullets.com/dermatology/120061/scabies*
- *https://www.cmaj.ca/content/181/5/289*
- *https://www.marksimonianmd.com/lice*
- *https://benthamopen.com/FULLTEXT/TODJ-14-1/FIGURE/F1/*
- *https://www.dermcoll.edu.au/atoz/cutaneous-larva-migrans/*
- *https://www.westernexterminator.com/blog/mythbusters-allergic-to-bee-stings-and-wasp-stings/*
- *https://pestseek.com/how-to-get-rid-of-flea-bites/*
- *https://mypetandi.elanco.com/en_gb/parasites/fleas/6-ways-avoid-scratching-fleabite*
- *https://www.pinterest.com.mx/pin/424956914831026465/*
- *https://plasticsurgerykey.com/bites-and-stings-4/*
- *https://medizzy.com/feed/95077*
- *https://www.nhs.uk/conditions/impetigo/*
- *https://dermnetnz.org/cme/bacterial-infections/impetigo*
- *http://www.antimicrobe.org/new/photolink/gangrenosum.asp*
- *https://podiatryhq.com.au/are-you-suffering-from-cellulitis/*
- *https://www.researchgate.net/figure/Acne-and-Postinflammatory-Hyperpigmentation-Courtesy-of-Valerie-Callender-MD-Callender_fig2_313792481*
- *https://www.everydayhealth.com/rosacea/is-it-something-else/*
- *https://www.nhs.uk/conditions/rosacea/*
- *https://perridermatology.com/fungus-tinea-faciei/*
- *https://plasticsurgerykey.com/diseases-resulting-from-fungi-and-yeasts/*
- *https://dermnetnz.org/cme/fungal-infections/tinea-unguium*
- *https://step1.medbullets.com/dermatology/112095/onychomycosis*
- *https://en.wikipedia.org/wiki/Erysipelas*
- *https://www.pcds.org.uk/clinical-guidance/erysipeloid*
- *https://www.bajajfinservmarkets.in/insurance/health-insurance/health-problems/folliculitis.html*
- *https://www.pinterest.com/pin/137289488747443750/*
- *https://www.vinmec.com/en/oncology-radiotherapy/health-news/boils-on-thighs-what-you-need-to-know/*
- *https://www.pcds.org.uk/clinical-guidance/staphylococcal-scalded-skin-syndrome*
- *https://emedicine.medscape.com/article/169177-clinical*
- *https://healthjade.net/erythrasma/*
- *https://www.medicalnewstoday.com/articles/326911*
- *https://healingartsvalpo.com/lyme-disease-and-tick-borne-illness/*
- *https://www.nejm.org/doi/full/10.1056/NEJMp1915891*
- *https://www.orthobullets.com/basic-science/9045/acute-rheumatic-feve*
- *https://www.aafp.org/pubs/afp/issues/2011/0501/p1078.html*
- *https://www.theharleystreetdermatologyclinic.co.uk/conditions/hives-urticaria/*
- *https://step2.medbullets.com/dermatology/120085/pityriasis-rosea*
- *https://patient.info/childrens-health/viral-skin-infections-leaflet/pityriasis-rosea*
- *https://www.penndermspecialists.com/pityriasis-rosea/*
- *https://statmed.org/knowledge/lichen_planus*
- *https://dermnetnz.org/topics/lichen-planus*
- *https://almostadoctor.co.uk/encyclopedia/lichen-planus*
- *https://dermnetnz.org/topics/erosive-lichen-planus*
- *https://www.aaom.com/oral-lichen-planus*
- *https://dermnetnz.org/topics/lichen-planopilaris*
- *https://www.drbatras.com/lichen-planus-and-hair-loss*
- *https://www.medicaljournals.se/acta/content/html/10.2340/00015555-1957*
- *https://dermnetnz.org/images/nail-lichen-planus-images*
- *https://emedicine.medscape.com/article/1108072-overview*

- *https://www.dermatologyadvisor.com/home/topics/psoriasis/long-term-plaque-pso-treatment-clinician-recommendations/*
- *https://www.aad.org/public/diseases/psoriasis/what/symptoms*
- *https://www.pcds.org.uk/clinical-guidance/guttate-psoriasis*
- *https://www.healthline.com/health/inverse-psoriasis#gallery-open*
- *https://www.papaa.org/learn-about-psoriasis-and-psoriatic-arthritis/further-resources/pustular-psoriasis/*
- *https://www.verywellhealth.com/what-are-the-different-types-of-pustular-psoriasis-3876679*
- *https://dermnetnz.org/images/generalised-pustular-psoriasis-images*
- *https://www.verywellhealth.com/what-are-the-different-types-of-pustular-psoriasis-3876679*
- *https://dermnetnz.org/images/generalised-pustular-psoriasis-images*
- *https://www.uptodate.com/contents/image/print?imageKey=DERM%2F111552~DERM%2F111553~DERM%2F111554*
- *https://www.researchgate.net/figure/Nail-pitting-and-transverse-ridging-in-a-patient-with-psoriasis_fig7_232923694*
- *https://www.everydayhealth.com/psoriasis/guide/scalp-psoriasis/*
- *https://www.orthobullets.com/basic-science/9050/psoriatic-arthritis*
- *https://www.healthline.com/health/psoriasis/psoriasis-on-the-tongue#pictures*
- *https://www.aafp.org/pubs/afp/issues/2000/0201/p725.html*
- *https://www.cdc.gov/typhus/scrub/index.html*
- *https://www.thenationalskincentre.com/keloid.html*
- *https://drclementlo.com/refer/index.php/dermatology-jean-l?view=article&id=192&catid=98*
- *https://www.healthline.com/health/nevus-sebaceous*
- *https://www.pcds.org.uk/clinical-guidance/chondermatitis-nodularis-helicis*
- *https://www.researchgate.net/figure/The-epidermoid-cysts-multiplex-of-the-scrotum_fig1_263863774*
- *https://www.pcds.org.uk/clinical-guidance/pilar-cyst-syn-trichilemmal-cyst*
- *https://medicoapps.org/m-hypertrophic-scar-and-keloid/*
- *https://skinsurgeryclinic.co.uk/treatments/seborrhoeic-keratosis-removal/*
- *https://www.iskin.com.hk/syringomas-sebaceous-hyperplasia-seborrhoeic-keratosis/*
- *https://www.l-formulaclinic.co.uk/sebaceous-hyperplasia*
- *https://www.firstderm.com/skin-tags/*
- *https://www.sciencephoto.com/media/1273804/view/keratoacanthoma*
- *https://www.msdmanuals.com/en-sg/home/quick-facts-skin-disorders/noncancerous-skin-growths/dermatofibromas*
- *https://stamfordskin.com/en/dermatology/cutaneous-horn/*
- *https://healthjade.com/bowens-disease/*
- *https://skintechmedical.com.au/actinic-keratosis-statistics-risks-and-treatments-available/*
- *https://www.contemporarypediatrics.com/view/ataxia-telangiectasia*
- *https://www.msdmanuals.com/professional/hematology-and-oncology/bleeding-due-to-abnormal-blood-vessels/hereditary-hemorrhagic-telangiectasia*
- *https://en.wikipedia.org/wiki/Kaposi%27s_sarcoma*
- *https://medicoapps.org/m-lymphangioma/*
- *https://healthjade.net/venous-lake/*
- *https://www.ebmedicine.net/content.php?action=showPage&pid=351*
- *https://healthjade.net/angiokeratoma/*
- *https://www.sciencephoto.com/media/642200/view/fabry-s-disease*
- *https://contourclinics.com.au/treatment/cherry-angioma-removal/*
- *https://hemedicalclinic.com/scrotal-angiokeratoma/*
- *https://www.researchgate.net/figure/Vascular-papules-of-angiokeratoma-of-Fordyce-on-the-scrotum-of-the-same-patient_fig1_7194136*
- *https://twitter.com/SmartEnglish3/status/830003380391129088*

- *https://step2.medbullets.com/dermatology/120083/port-wine-stain*
- *https://childrenswi.org/medical-care/birthmarks-and-vascular-anomalies-center/conditions*
- *https://www.nejm.org/doi/full/10.1056/NEJMicm1610755*
- *https://www.nhs.uk/conditions/pagets-disease-nipple/*
- *https://step1.medbullets.com/oncology/121592/squamous-cell-carcinoma-scc-of-the-skin*
- *https://www.clinicaladvisor.com/home/topics/dermatology-information-center/gorlin-basal-cell-nevus-syndrome-diagnosis-and-management/*
- *https://www.skindoctor.co.za/skin-cancer-awareness/basal-cell-carcinoma-bcc-page*
- *https://healthjade.net/beckers-nevus/*
- *https://sifsof.com/clinical-apps/nevus-of-ota-and-laser-treatment/*
- *https://link.springer.com/chapter/10.1007/978-1-4614-6654-3_6*
- *https://www.google.com/search?q=Spitz+Nevus&tbm*
- *https://www.chandigarhayurvedcentre.com/blog/halo-nevus/*
- *https://www.google.com/search?q=Compound+Nevi&tbm=isch&ved*
- *https://www.sciencephoto.com/media/945767/view/intradermal-nevus*
- *https://www.chegg.com/flashcards/intro-to-derm-66909090-2c61-4220-8f70-810846218e7c/deck*
- *https://en.wikipedia.org/wiki/Nevus_spilus*
- *http://medical-dictionary.thefreedictionary.com/_/viewer.aspx?path*
- *https://www.your-doctor.net/derma_atlas/index.php?id=16#images-2*
- *https://www.sciencephoto.com/media/943431/view/melanoma-in-situ*
- *media/documents/Dermatology%20Standards%20FINAL%20-%20July%20201 J .pdf*
- *https://www.dermnetnz.org/topics!fungal-skin-infections/*
- *https://www.semanticscholar.org/paper/Cutaneous-lupus-and-the-Cutaneous-Lupus-Disease-and-Klein-Morganroth/b6f5cd0fa8967c9fea0a4c1cd9ba33a1c401e5b9*
- *http://www.yogavanahill.com/diseases/porphyria-cutanea-tardacongenital-erythropoietic-porphyria*
- *https://dermnetnz.org/topics/solar-urticaria*
- *https://www.healthline.com/health/polymorphous-light-eruption*
- *https://slideplayer.com/slide/10392080/*
- *https://www.healthline.com/health/skin-disorders/phytophotodermatitis*
- *https://link.springer.com/referenceworkentry/10.1007/978-3-319-40221-5_15-2*
- *https://www.cprcertificationonlinehq.com/blog/summertime-sun-safety*
- *https://www.todaysrdh.com/scleroderma-how-dental-hygienists-can-approach-oral-symptoms/*
- *https://doctorhoogstra.com/en/wiki/lentigo-solar/*
- *https://www.nejm.org/doi/full/10.1056/nejmicm1104059*
- *https://en.wikipedia.org/wiki/Freckle*
- *https://healthjade.net/scleroderma/*
- *https://www.meningitisnow.org/meningitis-explained/signs-and-symptoms/glass-test/*
- *https://drclementlo.com/refer/index.php/dermatology-jean-l?view=article&id=102&catid=19*
- *https://gladskin.com/blogs/resources/types-of-eczema-contact-dermatitis*
- *https://healthjade.net/phytophotodermatitis/*
- *https://ykhoa.org/d/image.htm?imageKey=DERM%2F70264%7EPEDS%2F70989%7EALLRG%2F51951%7EDERM%2F81309%7EDERM%2F51220%7EDERM%2F51066%7EALLRG%2F72864%7EDERM%2F67215*
- *https://sso.uptodate.com/contents/image?imageKey=PI%2F62784*
- *https://www.allergyuk.org/types-of-allergies/urticaria-hives-other-skin-allergy/*
- *https://coreem.net/core/angioedema/*
- *https://alrustom-laser.com/allergic-contact-rashes/*
- *https://www.mdedge.com/familymedicine/article/140009/dermatology/itchy-rash-neck*
- *https://plasticsurgerykey.com/42-lichen-simplex-chronicus-and-prurigo/*
- *https://en.drmakise.com/prurigo-nodularis/*

- *https://www.dermacaredirect.co.uk/advice/skincare-sd/*
- *https://www.dermatologyinfo.net/english/chapters/DSC02390.JPG*
- *https://www.pcds.org.uk/clinical-guidance/atopic-eczema*
- *https://www.amboss.com/us/knowledge/Atopic_dermatitis*
- *https://www.healthline.com/health/morphea*
- *https://www.atlasdermatologico.com.br/disease.jsf;jsessionid=12B7270274A0A1B77AFCA039FC1197E3?diseaseId=256*
- *https://skinbase.co.uk/blog/what-is-melasma/*
- *https://dermnetnz.org/topics/poikiloderma-of-civatte*
- *https://www.nhs.uk/conditions/vitiligo/*
- *https://www.medicalnewstoday.com/articles/245081*
- *https://www.foothillderm.com/blog/vitiligo-1*
- *https://dermnetnz.org/topics/pemphigoid-gestationis*
- *https://www.google.com/search?q=Pemphigus+Foliaceus&source=lnms&tbm=isch&sa=X&ved=2ahUKEwjV7f33tZX-AhXL9jgGHb78ABUQ_AUoAXoECAEQAw&biw=1366&bih=643&dpr=1#imgrc=9QIeuPcTQfRcXM*
- *https://www.pcds.org.uk/clinical-guidance/bullous-pemphigoid1*
- *https://www.google.com/search?q=bullous+pemphigoid+images&tbm*
- *https://www.nhs.uk/conditions/pemphigus-vulgaris/*
- *https://www.pcds.org.uk/clinical-guidance/pemphigus-foliaceus*
- *https:/lbpac.org.nz/magazine/2009/February/docs lbpj19Jungalnail _pages_ l 8-23.pdf*
- *https://link.springer.com/chapter/10.1007/978-3-319-89581-9_22*
- *https://nn.neurology.org/content/5/3/e454*
- *https://cancerhomoeoclinic.co.in/alopecia-areata-homeopathy-treatment/*
- *https://www.birminghamdermatologyclinic.co.uk/blog/myths-about-alopecia-areata/*
- *https://www.selfmanagescleroderma.com/lessons/intro-to-raynauds-phenomenon.html*
- *https://clinicalgate.com/eczema-basic-principlescontact-dermatitis/*
- *https://www.singhealth.com.sg/patient-care/conditions-treatments/atopic-dermatitis*
- *https://www.researchgate.net/figure/Chronic-cutaneous-lupus-erythematosus-Discoid-lupus-erythematosus-demonstrating_fig1_26890374*
- *https://www.jaad.org/article/S0190-9622%2819%2930455-4/pdf*
- *https://dermnetnz.org/topics/discoid-lupus-erythematosus*
- *https://www.researchgate.net/figure/Chronic-cutaneous-lupus-erythematosus-Discoid-lupus-erythematosus-demonstrating_fig1_26890374*
- *https://www.jaad.org/article/S0190-9622%2819%2930455-4/pdf*
- *https://dermnetnz.org/topics/discoid-lupus-erythematosus*
- *https://dermnetnz.org/topics/cutaneous-lupus-erythematosus*
- *https://www.dermatologyadvisor.com/home/decision-support-in-medicine/dermatology/subacute-cutaneous-lupus-erythematosus-scle/*
- *https://www.sciencedirect.com/science/article/pii/S1578219011001053*
- *https://www.sciencephoto.com/media/1185105/view/discoid-lupus-erythematosus*
- *https://www.sciencedirect.com/science/article/pii/S2352647519300887*
- *https://www.sciencedirect.com/science/article/pii/S2352647517300400*
- *https://dermnetnz.org/topics/chilblain-lupus-erythematosus*
- *https://www.rxlist.com/collection-of-images/acute_systemic_lupus_picture/pictures.htm*
- *https://www.aad.org/public/diseases/a-z/lupus-symptoms*
- *https://www.google.com/search?q=Subacute+cutaneous+lupus+erythematosus&tbm=isch&ved=2ahUKEwjdlY2qx4r-AhW9JrcAHWmsBn0Q2-cCegQIABAA&oq=Subacute+cutaneous+lupus+erythematosus&gs_lcp=CgNpbWcQAzIHCAAQigUQQzIFCW1nwAEB&sclient=img&ei=_x4pZJ2aM73N3LUP6dia6Ac&bih=643&biw=1349&hl=en#imgrc=Mgkj4Sw1qL-UYM*

- *https://www.medicalnewstoday.com/articles/320504*
- *https://dermnetnz.org/cme/dermatitis/dermatitis-overview*
- *https://www.medicalnewstoday.com/articles/320504#causes*
- *https://donovanmedical.com/hair-blog/aa-ophiasis -vs-ffa*
- *https://www.thedermatologyclinic.london/skin-conditions/angiokeratoma-treatment-london/*
- *https://www.aad.org/public/diseases/a-z/scleroderma-symptoms*
- *https://www.birpublications.org/doi/10.1259/bjrcr.20150203*
- *https://dermnetnz.org/topics/leprosy*
- *https://www.nejm.org/doi/full/10.1056/nejmicm1011992*
- *https://education.lillymedical.com/en-us/disease-education-resources/dermatology/alopecia-areata/education-resources/al*
- *https://onlinelibrary.wiley.com/doi/10.1111/j.1365-4632.2008.03579.x*
- *https://www.semanticscholar.org/paper/A-Rare-Combination-of-Pure-Neuritic-Leprosy-with-to-Prakash-Anoosha/ecaa65d9f82578a0b4fe71bcbf69e1cb071107bc/figure/4*
- *https://www.sciencedirect.com/science/article/abs/pii/S0190962200762189*
- *https://www.annsaudimed.net/doi/10.4103/0256-4947.77495*
- *https://doctorhoogstra.com/en/wiki/tuberculosis-cutaneous/*
- *https://www.google.com/search?q=cutaneous+tuberculosis&tbm=isch&ved=2ahUKEwieuYDenYj-AhVZyHMBHbteD3QQ2-cCegQIABAA&oq=cutaneous+tuberculosis&gs_lcp=CgNpbWcQAzIFCAAQgAQyBQgAEIAEMgUIABCABDIFCAAQgAQyBQgAEIAEMgUIABCABDIFCAAQgAQyBQgAEIAEMgUIABCABDIFCAAQgAQ6B*
- *https://dermnetnz.org/topics/skin-problems-associated-with-diabetes-mellitus*
- *https://dermnetnz.org/topics/skin-problems-associated-with-diabetes-*
- *https://www.consultant360.com/article/consultant360/limited-joint-mobility-syndrome-common-musculoskeletal-condition-overlooked?page=1mellitus#:~:text=Diabetic%20dermopathy% 20is%20a% 20skin-often%20 appearing%20on%20the%20shins.*
- *https://www.nature.com/articles/nrendo.2009.174*

CHAPTER (14) INFECTIONS AND INFESTATION PROBLEMS

Guide to Antibiotic Prescribing

Human Immunodeficiency Viral Infection

Tuberculosis

Malaria

Sexually Transmitted Diseases

Hepatitis B Infection

Hepatitis C Infection

Covid 19

Helminthiasis

GUIDE TO ANTIBIOTIC PRESCRIBING

For prevention of antimicrobial resistant infection, we must follow the guideline of prescribing antimicrobial agents.

DO NOT PRESCRIBE ANTIBIOTICS IN THE ABSENCE OF CLINICAL EVIDENCE OF BACTERIAL INFECTION, OR FOR A SELF-LIMITING CONDITION

- whey and antibiotics is not the best option
- alternative options, e.g. symptomatic treatment, delayed prescribing
- the views and expectations of the patients
- safety-netting advice: what the patient should do if their condition deteriorates.

Empirical treatment

Before prescribing empirical antibiotics

- Clinician should first determine whether antimicrobial therapy is warranted for a given patient
- Is antimicrobial agents indicated on the basis of clinical finding?
- Is it prudent to wait until such clinical findings become apparent?
- Can some simple bedside tests done to confirm your suspicion? (Microscopy, Gram staining)
- What are the likely aetiologic agents for the patient's illness?
- Is there clinical evidence (from clinical trials) that antimicrobial therapy will confer clinical benefit for the patients? (Evidence-based Medicine)

Definitive treatment

- Can a narrower spectrum agent be substituted for initial empiric drug?

Prophylactic treatment

Take microbiological samples before prescribing

especially for:

- hospital in-patient: review your prescription as soon as MC&S result is available
- recurrent or persistent infection
- non-severe infection: consider if your prescription can wait for MC&S results

Follow local guidelines first

- Best practice is informed by local epidemiology and sensitivities.

Consider benefit and harm for each individual patient

- Allergies: clarify that patient's reaction – the true incidence of penicillin allergy in patients who report that they are allergic is <10%. In those with a confirmed penicillin allergy, corss-reactivity with 3rd generation cephalosporins and carbapenems is possible but rare (<1%)
- Dose adjust for renal function and weight: use ideal body weight in extremes of BMI (or ideal weight plus a % of excess weight – see local guidelines)
- Check for medication interactions
- In pregnancy and lactation

Prescribe the shortest effective course.

- Most antibiotics have good oral availability. Use IV antibiotics only if in line with local and national (sepsis) guidelines.

Route of administration

- The route of administration an antibacterial often depends on the severity of the infection.
- Life threatening infections require intravenous therapy.
- Antibacterials that are well absorbed, may be given by mouth even for some serious infections.
- Parenteral administration is also appropriate when the oral route cannot be used (e.g. because of vomiting) or if absorption is inadequate.

Duration of therapy

- Duration of therapy depends on the nature of the infection and the response to treatment (can be assessed by procalcitonin level).
- Courses should not be unduly prolonged because they encourage resistance, they may lead to side-effects and they are costly.
- However, in certain infections such as tuberculosis or osteomyelitis it may be necessary to treat for prolonged periods.
- Conversely a single dose of an antibacterial may cure uncomplicated urinary tract infections. The prescriptions for an antibacterial should specify the duration of treatment or the date when treatment is to be reviewed.
- Then focus: review the clinical diagnosis and continuing need for antibiotics at 48 hr for all in-patients and all patients prescribed IV antibiotics:
    - Stop antibiotics if there is no evidence of infection
    - Switch from IV to oral whenever possible
    - Change to a narrow spectrum antibiotic whenever possible
    - Continue regular clinical review whilst antibiotics are prescribed

Reference:

1. *Zaw Lynn Aung, Antimicrobial Resistant-Rational antibiotic therapy, 20-1-2018, MOHS*

HUMAN IMMUNODEFICIENCY VIRAL INFECTION
HUMAN IMMUNO-DEFICIENCY VIRUS

- HIV is a virus that causes Acquired Immune Deficiency Syndrome (AIDS). The first virus was called HIV1 and the second virus was called HIV2.
- HIV is a retro virus infecting T- helper cells bearing CD4 receptor, which contains RNA in his core; the virus itself is surrounded by a protein and lipid envelope. To replicate itself in the human cells, the virus first selects and attaches cell carrying a special receptor known as CD4 antigen.

How does HIV replicate?

- Once HIV enters the human body, it specifically seeks out a particular type of T –lymphocyte in the blood, called the CD4 T-lymphocyte. The various stages of HIV replication are explained below:
    - HIV enters a CD4 cell.
    - HIV is a retrovirus, meaning that its genetic information is stored on single-stranded RNA instead of the double-stranded DNA found in most organisms. To replicate, HIV uses an enzyme known as reverse transcriptase to convert its RNA into DNA.
    - HIV DNA enters the nucleus of the CD4 cell and inserts itself into the cell's DNA. HIV DNA then instructs the cell to make many copies of the original virus.
    - With the help of the protease enzyme, new virus particles are assembled. These newly formed virus leaves the cell, ready to infect other CD4 cells.

What is "Primary HIV Infection"?

- The term "Primary HIV Infection" (also called "acute HIV INFECTION") refers to the illness which occurs when HIV first infects an individual. This stage is characterized by non- specific flu-like symptoms such as fever, lethargy, sore throat, malaise, rash, lymphadenopathy, arthralgia, myalgias, headaches and rarely meningitis. These symptoms usually occur within 2-6 weeks after acquiring the virus. Most symptoms usually resolve within 2- 3 weeks.
- Within 2 to 4 weeks after the initial infection, high levels of virus are present in the blood.
- The immune system now begins to recognize the virus and produce antibodies.
- HIV antibodies can be detected in the blood usually within 1- 3 weeks after symptoms appear.
- The time period during which the individual is infected with HIV, but has no antibodies in his blood, is called the 'window period". During the window period, the HIV – infected person is capable of transmitting the virus to others, and is infectious. This phase of primary HIV infection is also called the "acute seroconversion syndrome". The term "seroconversion" refers to the appearance of HIV antibodies in the blood. During the window period, the ELISA test will give a negative result; the only test for detecting HIV infection at this stage is the PCR test.

What is the difference between HIV infection and AIDS?

- It is important to distinguish between being infected with HIV and having AIDS. People infected with HIV may take 10 years before they develop AIDS. Acute HIV syndrome, associated with seroconversion of HIV can occur as early as few weeks after a person is infected. The person may be asymptomatic or develop" flu like symptoms and signs' The period before the development of an antibody response- usually between 6-12 weeks-is often referred to as the window period when a person is infectious but not positive in HIV antibody test.
- HIV infection
    - After primary infection, there is a long asymptomatic phase, which may last for several years. Thus, the patient who is infected with HIV, but is asymptomatic or mildly symptomatic, is referred to as "HIV positive". During this phase, the virus is actively

multiplying and destroying the CD4 cells.

- AIDS
    - When the CD4 cells decrease to 200cells/µl, or the patient starts suffering from a characteristic range of severe opportunistic infections (AIDS-define illnesses), he is said to be suffering from AIDS. It may take 8-10 years to reach this stage, although this may vary between patients.
    - Thus, AIDS represents an advanced stage of HIV infection, when the patient suffers from a characteristic range of opportunistic infections.

What is the natural history of HIV infection?

- HIV attacks the CD4 T- lymphocytes
- HIV has a special affinity for the CD4 T-lymphocyte. It multiplies rapidly and continuously within these cells. Although the body does replace the lostCD4 cells, the rate of destruction of the CD4 cells far exceeds the body's ability to replace them. Thus, as HIV infection progresses, there is a progressive decline in the number of CD4 T-lymphocytes. The CD4 count may drop to as low as 50 cells/ul or even lower, from the normal level of about 1000 cells/µl.
- **HIV infection leads to immunodeficiency.**
    - HIV destroys the CD4 cells, which play a vital role in immune function. The loss of CD4 cells leads to immunodeficiency in HIV-infected patients. In other words, these patients become susceptible to a variety of "opportunistic infections". Opportunistic infections are commonly encountered when the CD4 count is less than 200 cells/µl. The lower the number of CD4 cells, the more advanced is the stage of disease. Thus, HIV causes a progressive and irreversible destruction of immune system. Opportunistic infections occur due to the immune destruction caused by the virus.
- **Immunodeficiency cause opportunistic infections**
    - As the immune function declines, the HIV- positive patient is plagued by variety of opportunistic infections. Virtually no system or organ is spared. Moreover, as immunodeficiency increases, these infections become more difficult to treat, and have a greater tendency to relapse.
- **Immunodeficiency leads to death,**
    - If an HIV-positive patient is left untreated, over the years, his CD4 cells will continue to decline progressively, immune function will deteriorate, and ultimately, he would die because of the opportunistic infections that ravage his body.
- **Common opportunistic infections**
    - Tuberculosis, both pulmonary as well as extrapulmonary.
    - Oral candidiasis
    - Oesophageal candidiasis
    - Herpes zoster
    - Diarrhea, which may be due to a variety of pathogen:
        - Protozoral- amoeba, Giardia,
        - Cryptosporidium,
        - Helminth- Strongyloides,
        - Viral- Cytomegalovirus
    - Bacterial pneumonia and Pneumocystis carinii pneumonia
    - Toxoplasma encephalitis
    - Cryptococcal meningitis
    - Cytomegalovirus retinitis (CMV)
    - Cancers such as Kaposi's sarcoma and non-Hodgkin's lymphoma

Modes of transmission

- HIV is transmitted through unprotected sexual intercourse (anal or vaginal), transfusion of contaminated blood, sharing of contaminated needles, and between a mother and her infant

during pregnancy, childbirth and breastfeeding.

- HIV does not survive long outside the human body and it cannot be transmitted by air or water, insects including mosquito bites, saliva, tears or sweat, causal contact like shaking hands, sharing toilets or household utensils.

So, HIV is transmitted by the following routes:

- Sexual transmission
- Transfusion of infected blood and blood products
- Maternal transmission
- HIV –contaminated instruments

Which tests are used to diagnose HIV infection?

- Test which are commonly used to diagnose HIV infection are:
- ELISA:
  - This is the initial, or screening, test for HIV infection. It tests for the present of antibodies against HIV in the blood. A positive result is usually obtained within 3 months of acquiring the infection.
- Western Blot:
  - This is a confirmatory test. It detects antibodies against antigens coded by 3 different viral antigens. There are various criteria for a positive Western Blot. As per the WHO criteria, a positive Western Blot is defined as the presence of any two of the p24gp41 and gp12/gp160 bands. The presence of all bands is considered a negative test.
- Polymerase chain reaction (PCR) assays:
  - The PCR technique is used to assay for both HIV RNA and HIV DNA. The only test to diagnose HIV infection in window period is the HIV DNA PCR. The HIV RNA PCR test can measure the amount of HIV RNA in the blood (also referred to as the "viral load". The viral load indicates the rate of disease progression, with higher viral loads predicted of faster disease progression. HIV RNA PCR is also used to assess the response to anti-HIV therapy.
- WHO recommends 3 positive rapid tests as a confirmation of HIV diagnosis. The most commonly used 3 rapid tests (in Myanmar) are:
  - **Determine** (test 1),
  - **Unigold** (test2) and
  - **Stat Pak** (test 3);
  - the first being 99. 9% sensitive and the last 2 being 100% specific.
- The interval between " confirmation" and "verification" can be as close as a few days, in a patient starting ART rapidly. The individuals who test HIV reactive should be referred immediately to the nearest site approved or confirmatory testing to confirm their HIV status. . Approved sites for testing to confirm HIV status can be a community site, or health facility. or certified laboratory, or a health facility which provides ART.

Recognition of Symptomatic HIV infection

- Suggestive clinical findings:
  - Fever of more than one month's duration
  - Weight loss of more than 10%
  - Diarrhea of more than one month's duration
  - Mucocutaneous manifestations
  - Generalised lymphadenopathy (extra-inguinal)
  - Infections, severe or recurrent
    - Past or present multidermatomal herpes zoster
    - Hairy leukoplakia
    - Warts

        - Molluscum contagiosum
        - Oral thrush
        - Papulonecrotic lesion
        - Folliculitis
        - Vulvovaginitis
    - Others
        - Severe recurrent seborrheic dermatitis
        - Chronic prurigo
        - Reiter's syndrome
        - Kaposi 's sarcoma
        - Unexplained neurological manifestations (seizures, motor or sensory deficits, dementia and progressive headache
        - Chronic cough more than one month's duration or unexplained respiratory distress
        - Cytomegalovirus retinitis
        - Extrapulmonary pulmonary or disseminated and extensive pulmonary tuberculosis
        - Recurrent pneumonia
        - Invasive cervical carcinoma

WHO clinical case definition for AIDS

- Clinical AIDS in an adult is defined as an individual who has been identified as meeting the two criteria A and B below:
    - **Positive test for HIV infection by two tests based on preferably two different antigens:**
    - **Any one of the following criteria:**
        - Weight loss of 10% body weight or cachexia, not known to be due to a condition unrelated to HIV infection
        - Chronic diarrhea of one month's duration, intermittent or constant
        - Disseminated, military or extrapulmonary tuberculosis
        - Candidiasis of the oesophagus; diagnosable as dysphagia, odynophagia and or candidiasis
        - Neurological impairment restricting daily activities, not known to be due to a condition unrelated to HIV (trauma)
        - Kaposi's sarcoma

Clinical staging

- Recently WHO classifies patients as those with advanced disease (WHO stage 3 or 4 disease and/or CD4 <200 cells/ml) and those who are clinically well; such individuals may be ART naive or have interrupted treatment.

WHO clinical staging of HIV disease in adults, adolescents and children

Adults and Adolescents	Children
Clinical stage 1	
• Asymptomatic • Persistent generalized lymphadenopathy	• Asymptomatic • Persistent generalized lymphadenopathy
Clinical stage 2	
• Moderate unexplained weight loss (<10% of presumed or measured body weight) • Recurrent respiratory tract infections (sinusitis, tonsillitis, otitis media, pharyngitis) • Herpes zoster	• Unexplained persistent hepatosplenomegaly • Recurrent or chronic upper respiratory tract infections (otitis media, otorrhoea, sinusitis, tonsillitis) • Herpes zoster

• Angular cheilitis • Recurrent oral ulceration • Papular pruritic eruptions • Seborrhoeic dermatitis • Fugal nail infections	• Lineal gingival erythema • Recurrent oral ulceration • Papular pruritic eruption • Fungal nail infection • Extensive wart virus infection • Extensive molluscum contagiosum • Unexplained persistent parotid enlargement
Clinical stage 3	
• Unexplained severe weight loss (>10% of presumed or measured body weight) • Unexplained chronic diarrhoea for >1 month • Unexplained persistent fever (intermittent or constant for >1 month) • Persistent oral candidiasis • Oral hairy leukoplakia • Pulmonary tuberculosis • Severe bacterial infections (such as pneumonia, empyema, pyomyositis, bone or joint infection, meningitis, bacteraemia) • Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis • Unexplained anaemia (<8 g/dl), neutropaenia (<0.5 x 10^9/l) and/ or chronic thrombocytopaenia (<50 x 10^9/l)	• Unexplained moderate malnutrition not adequately responding to standard therapy • Unexplained persistent diarrhoea (14 days or more) • Unexplained persistent fever (above 37.5°C, intermittent or constant, for >1 month) • Persistent oral candidiasis (after first 6 weeks of life) • Oral hairy leukoplakia • Lymph node TB • Pulmonary TB • Severe recurrent bacterial pneumonia • Acute necrotizing ulcerative gingivitis or periodontitis • Unexplained anaemia (<8.0 g/dl), neutropaenia (<0.5 10^9/l) or chronic thrombocytopaenia (<50 10^9/l) • Symptomatic lymphoid interstitial pneumonitis • Chronic HIV-associated lung disease, including bronchiectasis
Clinical stage 4	
• HIV wasting syndrome • *Pneumocystis jirovecii* pneumonia • Recurrent severe bacterial pneumonia • Chronic herpes simplex infection (orolabial, genital or anorectal of more than 1 month's duration or visceral at any site) • Oesophageal candidiasis (or candidiasis of trachea, bronchi or lungs) • Extrapulmonary TB • Kaposi sarcoma • Cytomegalovirus infection (retinitis or infection of other organs) • Central nervous system toxoplasmosis • HIV encephalopathy • Extrapulmonary cryptococcosis, including meningitis • Disseminated non-tuberculous mycobacterial infection • Progressive multifocal leukoencephalopathy • Chronic cryptosporidiosis • Chronic isosporiasis	• Unexplained severe wasting, stunting or severe malnutrition not responding to standard therapy • Pneumocystis jirovecii pneumonia • Recurrent severe bacterial infections (such as empyema, pyomyositis, bone or joint infection, meningitis, but excluding pneumonia) • Chronic herpes simplex infection (orolabial or cutaneous of more than 1 month's duration or visceral at any site) • Oesophageal candidiasis (or candidiasis of trachea, bronchi or lungs) • Extrapulmonary TB • Kaposi sarcoma • Cytomegalovirus infection; retinitis or infection of other organs with onset at age older than 1 month • Central nervous system toxoplasmosis (after the neonatal period) • HIV encephalopathy

• Penicilliosis • Disseminated mycosis (extrapulmonary histoplasmosis, coccidioidomycosis) • Lymphoma (cerebral or B-cell non- Hodgkin) • Symptomatic HIV-associated nephropathy or HIV-associated cardiomyopathy • Recurrent septicaemia (including nontyphoidal Salmonella) • Invasive cervical carcinoma • Atypical disseminated leishmaniasis	• Extrapulmonary cryptococcosis, including meningitis • Disseminated non-tuberculous mycobacterial • infection • Progressive multifocal leukoencephalopathy • Chronic cryptosporidiosis (with diarrhoea) • Chronic isosporiasis • Disseminated endemic mycosis (extrapulmonary histoplasmosis, coccidioidomycosis, penicilliosis) • Cerebral or B-cell non-Hodgkin lymphoma • HIV-associated cardiomyopathy or nephropathy

- For children younger than 5 years, moderate malnutrition is defined as weight-for-height ≤2 z-score or mid-upper arm circumference ≥115 mm to <125 mm.
- For children younger than 5 years of age, severe wasting is defined as weight-for-height ≤3 z-score; stunting is defined as length-for-age/height-for-age ≤2 z-score; and severe acute malnutrition is either weight for height ≤3 z-score or mid-upper arm circumference <115 mm or the presence of oedema.

Initial Clinical Management

- The HIV "test and treat" policy to all people diagnosed with HIV. The "test and treat" policy involves providing lifelong ART to people living with HIV irrespective of CD4 or WHO HIV clinical staging. ART should be initiated at the earliest opportunity in all people with confirmed HIV infection, regardless of clinical stage or CD4 cell count.

ANTIRETROVIRAL THERAPY FOR PEOPLE LIVING WITH HIV THE GOAL OF ART

- The aim of antiretroviral therapy is to suppress viral load levels amongst PLHIV to undetectable levels, reduce the risk of morbidity
- and mortality associated with HIV, and reduce transmission of HIV.
- ART should be initiated at the earliest opportunity in all people with confirmed HIV infection, regardless of clinical stage or CD4 cell count.
- The guidelines update recommends the use of Dolutegravir, a newer drug, in combination with Tenofovir and Lamivudine as preferred first-line drug for eligible people living with HIV.
- In practice, while the HIV diagnostic tests, baseline investigations and co-infection diagnosis and OI screening investigations are process, the patient is offered CPT (co-trimoxazole prophylaxis therapy) which is 2 tablets of single strength (480mg) or one tablet of double strength (960mg) Septrin daily.

Cotrimoxazole prophylaxis

- Cotrimoxazole prophylaxis is an important part of the management of people living with HIV. It is recommended for adult including pregnant women with severe or advanced HIV clinical disease (WHO stage 3 or 4) and/or with CD4 count of <350/mm³. One double-strength tablet daily of Cotrimoxazole daily is recommended (sulfamethoxazole 800 mg/ trimethoprim 160 mg = 960 mg).
- Skin reaction is the commonest side effect with Cotrimoxazole. Other side effects are bone marrow toxicity and hepatotoxicity. Side effects can be monitored clinically. However, these drug-related adverse effects are not common and typically occur within the first few weeks of starting prophylaxis. Clinical monitoring is usually sufficient. The safety of Cotrimoxazole in long-term use has been established.

- Dapsone 100 mg a day may be used if there is hypersensitivity to Cotrimoxazole, but Dapsone is less effective than Cotrimoxazole. If there is hypersensitivity to both Cotrimoxazole and Dapsone, it may be possible to carry out Cotrimoxazole desensitization under careful supervision. Both Cotrimoxazole and Dapsone can cause intravascular haemolysis in patients with G6PD deficiency and should not be prescribed if the patient is known to be enzyme deficient.

Baseline Investigations

- Investigations done before staring ART are: CD4, STS, HBsAg, HCV antibody, CBC, Serum creatinine and e GFR LFT, HB.

Counseling sessions

- comprise of pretest, post-test, follow-up adherence counseling and ART counseling which can be spread over two or three visits. In the 3rd visit, verification result is available. Follow-up adherence and ART adherence counseling are done and ART is initiated.

What is the treatment approach for an HIV-positive patient?

- Basically, the treatment of an HIV-infected patient involves:
    - Inhibiting the replication of the virus using antiretrovirals
    - Treatment and prophylaxis of opportunistic infections.
    - Psychosocial support

What does antiretroviral therapy do?

- Antiretroviral therapy helps in:
    - Preserving immune function
    - Preventing disease progression
    - Reducing the incidence of opportunistic infections
    - Prolonging survival
    - So antiretroviral therapy has been proven to be effective in:
    - Decreasing viral load, increasing CD4 counts, decreasing the incidence of opportunistic infections, preventing disease progression and improving quality of life.

Classification of antiretrovirals

Generic name	Dose
Nucleoside reverse-transcriptase inhibitors (NRTIs)	
Abacavir (ABC)	300 mg twice daily or 600 mg once daily
Emtricitabine (FTC)	200 mg once daily
Lamivudine (3TC)	150 mg twice daily or 300 mg once daily
Zidovudine (AZT)	250-300 mg twice daily
Nucleotide reverse-transcriptase inhibitors (NtRTIs)	
Tenofovir (TDF)	300 mg once daily
Non-nucleoside reverse-transcriptase inhibitors (NNRTIs)	
Efavirenz (EFV)	400-600 mg once daily
Etravirine (ETV)	200 mg twice daily
Nevirapine (NVP)	200 mg once daily for 14 days, followed by 200 mg twice daily

Proteases inhibitors (PIs)	
Atazanavir + ritonavir (ATV/r)	300 mg + 100 mg daily
Darunavir + ritonavir (DRV/r)	800 mg + 100 mg daily a or 600 mg + 100 mg twice daily
Lopinavir + ritonavir (LPV/r)	400 mg/100 mg twice daily
	Consideration for individuals receiving TB therapy In the presence of rifabutin, no dose adjustment required. In the presence of rifampicin, adjusted dose of LPV/r: (LPV 800 mg + RTV 200 mg twice daily or LPV 400 mg +RTV 400 mg twice daily)
Integrase strand transfer inhibitors (InSTIs)	
Dolutegravir (DTG)	50 mg once daily In the presence of rifampicin, adjust the dosage of DTG as 50 mg twice daily
Raltegravir (RAL)	400 mg twice daily

ART regimens for Adults

First line ART	Second line ART	Third line ART
Tenofovir + Lamivudine + Efavirenz	Zidovudine + Lamivudine + Dolutegravir	Boosted Darunavir + INSTI+NRTI
Tenofovir + Lamivudine + Dolutegravir	Zidovudine + Lamivudine + Efavirenz	Boosted Darunavir + INSTI+NRTI

- HBP coinfected patients should always receive TDF regimen.
- Patients with significant anaemia should avoid Zidovudine.

RECOMMENDED FIRST-LINE REGIMEN FOR INITIATING ART IN ADULTS AND ADOLESCENTS

- AGED ≥10 AND ≥35kg
- All eligible HIV-infected adults and adolescents ≥10 years and weighing ≥ 35kg should be initiated on tenofovir, lamivudine and
- Dolutegravir (TDF+3TC+DTG) as a once-daily fixed dose combination with the exception of: Women and adolescent girls of child bearing potential that are pregnant, intend to become pregnant or are not on effective contraception

RATIONALE FOR USING DOLUTEGRAVIR (DTG)

a. **High Circulating levels of resistance to NNRTI-containing First-line Therapy**
NNRTI-containing combinations have been used as first-line regimens for adults

b. ***Superior Efficacy over Current Standard of Care Regimens***
DTG is superior to alternative ARV options and patients can experience rapid viral suppression, thereby reducing risk of transmitting HIV while prolonging time on first-line treatment. It has been shown that patients who receive DTG achieve viral suppression faster as compared to those who receive EFV.

c. ***Better Tolerability***
DTG shows improved tolerability versus current preferred regimens with substantial reductions in treatment-limiting adverse drug reactions. Specifically, patients can avoid some of the psychiatric adverse events of EFV (ie depression and suicidal tendencies). Overall, general

patient feedback supports DTG as a highly tolerated medicine that is less likely to result in treatment discontinuation.

d. Higher genetic barrier to resistance

The higher genetic barrier of DTG means patients are less likely to develop resistance and therefore prolonging the need for second line treatment

WHEN TO USE ALTERNATIVE FIRST LINE REGIMENS

- When to use TDF+3TC+EFV
- Adults and adolescents aged 10 years and above should only be initiated on TDF+3TC+EFV if they are ineligible for DTG i. e.
  a. Women and adolescent girls of child bearing potential that intend to become pregnant or are not on effective contraception
  b. Pregnant women
  c. If weight does not allow for use of the currently available DTG formulations (containing 50mg)
  d. Diabetic patients on metformin if close laboratory monitoring is limited

When to use ABC+3TC+DTG

- Adults and adolescents eligible for DTG and aged 10 years and aboveshould only be initiated on ABC+3TC+DTG if TDF is contraindicated, including the following conditions:
- Kidney disease and estimated glomerular filtration rate (GFR) below 60 ml/min
- Adolescents below 35kg of weight.

RECOMMENDED FIRST-LINE REGIMEN FOR INITIATING ART IN PREGNANT OR BREASTFEEDING WOMEN

- PREFERRED FIRST-LINE REGIMEN: TDF+3TC+EFV
- All HIV-infected pregnant, and breastfeeding women should be initiated on tenofovir, lamivudine, and efavirenz (TDF+3TC+EFV)

When to use TDF+3TC+ATV/r

- Pregnant or breastfeeding women should only be initiated on TDF+3TC+ATV/r if EFV is contraindicated, including patients with history of psychosis.

Recommended first-line ARV regimen in adults, Adolescents, pregnant or breastfeeding women and children

PATIENT CATEGORY	PREFERRED REGIMEN	ALTERNATIVE REGIMEN
1. Adults and adolescents aged ≥10 years and ≥35kg		
1. 1. Adult men and adolescent boys 1. 2. Adult women and adolescent girls on effective contraception 1. 3. Adult women and adolescent girls not of child bearing potential	TDF+3TC+DTG	If DTG is contraindicated 1: TDF+3TC+EFV If TDF is contraindicated2: ABC+3TC+DTG
1. 4. Adult women and adolescent girls of child bearing potential who are pregnant, intend to get pregnant or not on effective contraception3, 4	TDF+3TC+EFV	If EFV is contraindicated: TDF+3TC+ATVr If TDF is contraindicated2: ABC+3TC+EFV
2. Children aged 0-<10 years and <35kg		
2. 1. Children <3 months	ABC+3TC+LPV/r (syrup)	ABC+3TC+RAL
2. 2. Children ≥3 months to <3 years of	ABC+3TC+LPV/r	ABC+3TC+RAL

age	(pellets)	
2. 3. Children ≥3 years to <10 years old	ABC+3TC+LPV/r (tablets)	ABC+3TC+DTG or ABC+3TC+RAL
1. Contraindications for DTG • Patients taking anticonvulsants; Carbamazepine, Phenytoin, Phenobarbital. Both DTG and EFV are contraindicated in patients taking anticonvulsants, these patients should be given a Protease Inhibitor based regimen • Use DTG with caution if a patient is diabetic and taking Metformin		
Contraindications for TDF • Renal disease and/or GFR <60ml/min • Weight<35kg 3. Women of childbearing potential not on contraceptives should be given information and counseled about the potential benefits and risks of DTG, including the risk of potential birth defects to allow for an informed decision on their ART regimen and contraceptive choices. If they choose DTG, their choice should be clearly documented and endorsed by the patient, parent or legal guardian in writing. 4. Effective contraception implies consistent use of duo-contraception with hormonal contraceptives + Condoms, tubo-ligation, vasectomy, implants and IUDs. 5. Substitute children on ABC+3TC+LPVr (syrup) to ABC/3TC/LPVr (pellets) at 3 months of age and to tablets at 3 years of age.		

First line ART

- Tenofovir + Lamivudine + Efavirenz one tablet a day (HS)

New drug INSTI (Integrase strand trans inhibitors)

- Dolutegravir + Lamivudine + Tenofovir once a day
- Undetectable viral load within 3 months
- Need dose adjustment if used together with Rifampicin
- Not to be taken with Calcium or Iron supplements or antacid
- Avoid in first 8-12 weeks of pregnancy
- If CD4 less than 200 cells/mm^3 need cotrimoxazole prophylaxis.
- If less than 100 be aware of cryptococcal meningitis
- Very low level of CD4 is associated with CMV.
- Herpes zoster can happen at any CD4 level but if lowCD4 can have repeated episodes and more extensive, if eye involved, blindness is a possible complication.
    - Treatment: Acyclovir 800mg 5 times/day 1 week – 10 days
- Usually, an ART regimen is to be chosen from first line ART regimens. TDF(Tenofovir) and 3 TC (Lamivudine) should be included, especially in the case of HBP coinfection.
- If there is a contraindication to TDF ie-GFR <50 ml/min, AZT (Zidovudine)+ 3 TC should be considered AZT should not be used if Hb is < 8 G/dl. For patients with advanced infection, who cannot be prescribed either TDF, because of increased creatinine and AZT, due to anaemia, ABC(Abacavir) + 3TC is an alternative.
- These 2 NRT must be combined with either EFV(NNRTI) or DTG (Dolutegravir, an integrase inhibitor).
- In clinically well males, postmenopausal females with little risk of TB IRIS, TDG is the drug of choice. Women of childbearing age should be a consistent contraception to be able to take DTG, as safety in the first trimester is still unknown. After 8 weeks of pregnancy and especially in pregnant women who present in the third trimester, DTG is the drug of choice because it rapidly suppresses viral load compared to other regimens.
- If TB IRIS (Immune Reconstitution Inflammatory Syndrome), develops while taking DTG, the regimen should not be changed to FEV. Instead, the dose is increased from 50 mg once to twice

daily, and reduced backed to once daily after completion of anti-TB. For those already on anti-TB drugs, FEV containing is the preferred one.

- The usual dose of FEV is 600mg once daily. The dose of daily FEV 600mg is associated with higher drug level in Asians- so EFV 400mg daily has been recently introduce, in Myanmar National Guidelines. But 400mg daily dose is not recommended to be used together rifampicin and during pregnancy- in which case the usual 600 mg dose should be used.
- The possible side effects of FEV include CNS side effects like dizziness, insomnia (which are seen in first weeks), depression and frank psychosis with self-harm (which are very rare), severe hepatitis (also very rare) and maculopapular rash (which is seldom severe).
- When switching ART regimens was limited in the past, patients were encouraged to continue the regimen by adding sedatives, antipsychotics and antihistamines, but in case of severe symptoms, the drug is stopped and changed to a PI/r (ritonavir boosted Protease Inhibitor) regimen. Now since DTG is available, it is suitable substitute to change if patients experience EFV side effects.
- EFV 400 mg is hoped to reduce these symptoms but FEV 400mg is for new initiation but rather, it is intended to replace FEV 600 mg being taken by many patients.
- DTG plasma level is reduced when taken together with polyvalent Cat ions(Mg, AL, Ca, Zn, Fe)So DTG should be taken 2 hours before or 6 hours after vitamins with minerals and cation containing antacids, laxatives and buffered medications.
- The general recommendation is to first treat the opportunistic infection(s) e.g., TB, PCP, cerebral toxoplasmosis or penicilliosis and start ART 2 weeks later. There are two other specific recommendations regarding the timing of ART initiation: the first is in patients with CD4 < 50 cells/mm3 and active TB. ART Should be started within 2 weeks of TB treatment initiation. Another is in patients with Cryptococcal meningitis, it is better to start ART 4- 6 weeks after the initiation of amphotericin infusion.
- The first few weeks and months after ART initiation usually requires more frequent follow-up visits. Drug hypersensitivity reactions (usually associated with FEV, Cotrim, Anti TB, if present are more commonly seen in the first few weeks) and unmasking or paradoxical IRIS (seen in in the first three months) are complications-if immediate attention is given, more serious consequences can be prevented.

Monitoring

- The expected CD4 improvement is approximately- a rise of 100-150 cells/mm3/year. If a person is started on ART with a very low CD4 count, ie. 100 cells/mm3 or less-immune reconstitution, in terms of rise in CD4 will take longer. In those whose baseline CD4 is higher, the response is more robust.
- Time to achieve an undetectable HIV viral load can take up to 24 weeks after starting ART. Regular viral load monitoring is more preferable than CD4 for assessing ART treatment response.
- The best monitoring tool for treatment success is viral load which is done at 6 – 12 months after ART and then annually.
- CD4 is monitored every 6 months, but in those with suppressed viral load(<1000 copies/ul) for one year it might not be necessary.
- Side effect monitoring is regimen-based: in a person taking TDF regular monitoring of serum creatinine, plasma potassium and urine RE is necessary
- For a person receiving Zidovudine containing ART, CBC needs to be checked regularly.

Success vs Failure of Treatment

- The goal of ART is to achieve and maintain an undetectable HIV viral load. On the other hand, if the viral load is more than 1000 copies/ul in a person who has been on ART for more than 6 months and this result is confirmed on a repeat test 2-3 months later, and non-adherence of ART can be ruled out, first line ART treatment failure can be defined. Switching of ART to second

line needs to be considered.

- The long –term success of treatment depends much on treatment adherence and regular follow-up. As there is still no cure yet for HIV lifelong ART is the only option.
- People on ART might have pill fatigue, emotional exhaustion in the need to visit regularly their health care provider and social economic factors that might have a negative effect on their treatment adherence. Health care workers need to be aware of the challenges they face- and be prepared to address them accordingly.
- In Myanmar there are more than 100 ART treatment centers in the public sector providing comprehensive care. HIV counselling, expert medical consultation, necessary diagnostic investigations and treatment support including ART can be assessed who are in need.
- Proper timely referral of those already diagnosed and those who need HIV testing is a duty of all health care providers.

MANAGING COMMON INFECTIONS AND COMORBIDITIES

- Most people with HIV die of opportunistic infections. Major opportunistic infection is need to be diagnosed and
- treatment started before starting ART. Giving ART without diagnosing and treating major
- Opportunistic infections in late disease will lead to disaster. However, in advanced states of immunosuppression typical signs and symptoms of infections will be absent or masked.
- It is important to be vigilant in treating late HIV. Unusual infections that do not occur in immunocompetent persons will also occur.

Prevention, screening and management of common co-infections

- The following are the major opportunistic infections seen in Myanmar:
  1. Mycobacterium tuberculosis
  2. *Pneumocystis jirovecii pneumonia*
  3. Toxoplasmosis
  4. Cryptococcosis
  5. Penicilliosis
  6. Histoplasmosis

IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (IRIS)

Definition

Autoimmune diseases sometimes appear after starting ART and this is known as autoimmune

- IRIS (thyrotoxicosis, SLE, sarcoidosis and other autoimmune disorders have been described
- after starting ART).
- IRIS usually starts within 2 to 3 months of starting ART but it may also be delayed for many
- months.
- IRIS is a spectrum of clinical signs and symptoms thought to be associated with immune recovery brought about by a response to ART.
- It is a widely recognized phenomenon that occurs among 10–30% of the people initiating ART, usually within the first 4–8 weeks after initiating therapy. IRIS should be considered only when the presentation cannot be explained by a new infection, the expected course of a known infection, or drug toxicity. The most serious and life-threatening forms of IRIS occur in patients co-infected with TB, Cryptococcus, Kaposi's sarcoma and herpes zoster

Risk factors for IRIS include:

- Very low CD4 count at start of ART
- Very high Viral Load and very rapid fall in Viral load after ART
- Short interval between OI treatment and ART
- Immediate ART initiation is not recommended in HIV infected patients with cryptococcal

meningitis due to the high risk of IRIS that may be life threatening IRIS. ART should not be started within first 1-2 weeks of Amphotericin initiation. It can be **started** within 2-5 weeks of induction and consolidation treatment with amphotericin B-containing regimens ***until there is evidence of a sustained clinical response to antifungal therapy.***

- When the underlying condition has no specific treatment however ART can be started immediately. Cryptosporidiosis, HIV associated dementia and progressive multifocal leukoencephalopathy are examples where ART is indicated immediately.

Differential diagnosis of IRIS includes

- Treatment failure of the OI (e.g. MDR TB)
- Adverse drug reaction
- A new OI (which is unmasking IRIS)

Treatment

The excessive inflammatory response ***is controlled*** with NSAIDs or steroids if necessary, which are gradually tapered according to symptoms. It may be necessary to stop ART only very rarely in life-threatening IRIS.

Managing IRIS

- IRIS is generally self-limiting, and interruption of ART is rarely indicated. Treat any co-infections to reduce morbidity and symptoms.
- If the sympwtoms are protracted, reassure the patient to prevent discontinuation of, or poor adherence to ART.

Post- exposure prophylaxis for healthcare workers

- Healthcare workers whose activities involve contact with HIV –infected patients, or who may come in contact with blood or body fluid from HIV-positive patients in a health care or laboratory setting are at risk for occupational exposure to HIV.
- The risk of infection via percutaneous exposure is approximately 0. 3%.
- The risk of infection after mucous membrane exposure is about 0. 09%. Needlestick injuries are the most common type of occupational exposure.
- If PEP is indicated, it should be started within 1-2 hours of exposure.

Details of recommended regimens are:

Category	Drug regimen
Basic	Zidovudine 300mgbid+Lamivudine150mg bid for 28 days
Expanded	Basic regimen+Indinavir 800mg tid or Nelfinavir 750mg tid for 28 days

Post-exposure prophylaxis (PEP)

- Post-exposure Prophylaxis (PEP) is a short-term antiretroviral treatment to reduce the likelihood of HIV infection after all potential exposures. PEP should be provided for both occupational (e.g. within health sector) and non-occupational (e.g. condom break with high risk sexual partner) exposures.

Preferred recommendations for adults, adolescents and children are:

- Alignment with recommendations on ART regimens for different age groups
- Emphasis on simplification to support completion rates

- Full course prescription (28 days)
- Adherence support

When considering the eligibility for PEP, the best practice guidance is as follows;

- PEP should be offered, and initiated as early as possible, to all persons with a HIV exposure, and preferably within 72 hours.
- Assessing the eligibility for PEP should be based on the HIV status of the source whenever possible and may include consideration of background prevalence and local epidemiological patterns.

Exposures that may warrant PEP include:

- exposure to bodily fluids (e.g. blood, semen, cervico-vaginal secretions, breast milk, amniotic fluids, cerebrospinal fluids, etc.)
- through mucous membranes such as sexual exposure and splashes to eyes, nose or oral cavity through parenteral/percutaneous exposures

Exclusions for PEP would include:

- when the exposed individual is already HIV positive when the source is HIV negative exposure to the bodily fluids that do not pose significant risk, i.e. tears, non-bloodstained saliva, urine and sweat

PEP provision and monitoring

- A regimen for PEP for HIV with two ARV drugs is effective, but three drugs are preferred.
- PEP regimens for adults and adolescents:
    - TDF + 3TC (or FTC) is the preferred backbone.
    - LPV/r or ATV/r is the preferred third drug.
    - EFV is the alternative third drug.
- PEP regimens for children <10 years:
    - AZT+3TC is the preferred backbone.
    - ABC+3TC or TDF+3TC can be considered as alternatives.
    - LPV/r is the preferred third drugs.
- An age-appropriate alternative third drug can be identified among ATV/r, RAL, DRV, EFV and NVP.
- ***A 28 days prescription of antiretroviral drugs should be provided for PEP following initial risk assessment.***
- Timing of HIV testing in PEP: Baseline testing at day 0 (at the day of exposure) and follow-up testing is to be done at 3 and 6 month if day 0 is negative. If the exposed person is infected with Hepatitis C, window period may be prolonged. So follow up period may be prolonged up to one year.
- Enhanced adherence counselling is recommended for individuals initiating HIV PEP.

Prophylaxis for Maternal Transmission of HIV

- The risk of vertical transnmission of HIV from mother to baby ranges from 7% to 40% Maternal HIV transmission is the primary means by which infants become infected. Hence prevention of maternal HIV transmission is of paramnount importance. Maternal HIV transmission can occur in utreo, during labour and delivery, or after birth(via breast-feeding). About 50-70% of maternalHIV transmission occurs in late pregnancy or during labour and delivery.
- Prophylactic therapy with antiretrovirals for mother and baby is recommended to prevent maternal transmission of HIV. Use OF FORmular feeding for the infants reduces the risk of transmission via breast-feeding.

- Both Zidovudine and Nevirapine(administered as monotherapy for varying periods of time) have effective in reducing risk of maternal transmission.
- Nevirapine 200mg orally at onset of labour and 2mg/kg to babies within 72 hours of birth. This simple single- dose- to- mothe and single- dose-to-baby regimenof Nevirapine reduced maternal transmission.





Herpes Zooster infection in Immunocompromised patients





Pruritus Papular Nodules in immunocomprosied





Crusted scabies or Norwegian scabies in immunocomprosied patients



X-ray showed diffuse pulmonary infiltrates fanning out from the hilar region and sparing the apices and lower regions (Pneumocystis Pneumonia)



CT brain showing cerebral toxoplasmosis with multiple abscesses

CT brain showing cerebral toxoplasmosis with massive cerebral edema







Penicilliosis on face(Umbilicated popular eruption and Fungal bodies are seen inside macrophages with a characteristic central septation with Leshman's or Giemsa stain



CMV Retinitis showing haemorrhagic necrosis of the retina with exudates



Lipoatrophy in HIV patient with long term treated with Stavudine



HIV associated Lymphoma



Yeast cells of Cryptococcus neoformans in India ink preparation (Sketch)



Lipo-hypertrophy in dorso-cervical region or buffalo hump appearance due to stavudine therapy



Stevens-Johnson syndrome due to nevirapine involving the whole body as well as mucus membrane (Right)and Toxic epiderma necrolysis (Left)



Immune Reconstitution Inflammatory Syndrome or IRIS



CXR showing hilar lymphadenopathy in HIV/AIDS patient





Oral Thrush in immunocompromised patients

Oesophageal thrush with mucosal ulceration in Barium swallow







Intra-abdominal Lymphadenopathy in immunocompromised patients



Lymphadenopathy in HIV/TB patient



Mediastinal Lymphadenopathy and hilar lymphadenopathy in HIV/AIDS patient

TUBERCULOSIS

- Tuberculosis (TB) is a communicable disease that is a major cause of ill health and one of the leading causes of death worldwide. Until the coronavirus (COVID-19) pandemic, TB was the leading cause of death from a single infectious agent, ranking above HIV/AIDS.
- **Pulmonary TB** is the most common form of the disease. Pulmonary TB is the form of TB which can be infectious and is responsible for transmission of infection in the community.
- **Extra pulmonary TB** affects organs other the lungs, most commonly pleura, lymphnodes, spine, joints, genitourinary tract, the nervous system and abdomen. TB may affect any part of the body.

TRANSMISSION OF TB

- A patient with pulmonary TB expels droplets of sputum containing tubercle bacilli into the air when coughing, laughing, or sneezing. These droplets remain suspended in the air for several hours and if a person inhales these particles, he may contract TB bacilli resulting in tuberculosis infection.

IDENTIFICATION OF PRESUMPTIVE TB

- A presumptive TB is any person who presents with symptoms and signs suggestive of TB, in particular with **cough for more than 2 weeks.** Cough is the most common symptom of pulmonary TB and present in 95% of all sputum smear positive TB cases.
- Other TB symptoms include:
    - Sputum expectoration
    - Haemoptysis
    - Chest pain
    - Fever
    - Breathlessness
    - Weight loss, loss of appetite
    - Night sweating
    - Lethargy

TB CASE Can be classified as the following.

- Bacteriological Result
- Drug resistance pattern
- Anatomical site of the disease
- History of previous treatment
- HIV status of patient

Bacteriological Result

- **A** bacteriologically confirmed TB case:
    - A biological specimen is positive by smear microscopy, culture or Gene X'pert.
    - Bacteriologically sensitive/susceptible TB
    - Bacteriologically resistant TB

A clinically diagnosed TB case:

- Bacteriologically not confirmed but diagnosed as TB by Radiology, Histology, Clinical and decided to treat by the experience Medical officer.

Drug Resistance Pattern

- Drug Susceptible TB (DSTB) - TB bacteria is susceptible to first line anti TB drugs

- Drug Resistant TB (DR TB)
    - MDR TB – resistant to Rifampicin and INH
    - Mono Resistant TB – resistant to one of antiTB drug
    - Poly resistant TB – res; to more than one antiTB drugs
    - Extensive Drug resistance TB (XDR TB) - MDR + additional resistant to Quinolone and Group A drugs
    - Totally Drug Resistance TB (TDR- TB)- Resistance to all anti TB drugs

Site of the Disease

- Pulmonary TB (PTB): bacteriologically confirmed or clinically diagnosed TB involved in the lung parenchyma or tracheobronchial tree.
- Extra-pulmonary TB (EPTB): bacteriologically confirmed or clinically diagnosed TB involved any organs other than the Lungs.

History of Previous Treatment

- New patient: No or <1 month Rx.
- Previously treated patient: >1 month Rx.
    - Relapse
    - Treatment after failure
    - Treatment after loss to follow up
    - Other previously treated patient
    - Patient with unknown Rx history

HIV Status of Patient

- HIV positive TB patient: HIV test + at the time of diagnosis or previous documented evidence.
- HIV negative TB patient: Negative result of HIV test at the time of TB diagnosis.
- HIV status unknown TB patient: No result of HIV test and no documented evidence for HIV.

DIAGNOSIS OF PULMONARY TUBERCULOSIS

- Sputum examination

Direct Sputum microscopy

- It is an appropriate technology and simple, specific, cheap, reliable and with rapid result.
- Two sputum samples are required as one early morning (Home collection) and one spot collection.

Sputum culture and DST -MDRTB

- Culture is the gold standard for TB diagnosis and also for MDR TB diagnosis. Other test is LPA (Line Probe Assay)
- Sputum for Gene X'pert (GXP)-MDRTB
    - GXP is a newer PCR based molecular technology to detect Rifampicin resistance (RR) (MDR TB diagnosis).
- Although it can detect *M. tuberculosis*, it is not routinely used for TB diagnosis in our context.

Chest X-ray (Conventional CXR & Digital CXR)

- **HIV Counselling &Testing -(HCT)** should be done for all registered TB cases to check HIV serological status of all TB patients and also need to refer the TB patients to NAP or NGO/INGO center properly for further management (TB/HIV collaborative activities) if

HIV positive.

- **Diabetes Mellitus (DM)** should be screened for TB patients to check gylcemic status of TB patients especially age over 40 years as TB/DM is becoming a common co morbidity.

RECOMMENDED TREATMENT REGIMENS FOR DIFFERENT TYPES OF TB PATIENTS

Treatment Category	Types of TB patient	Treatment course	
		Initial Intensive Phase	Continuation Phase
Initial treatment Regimen (IR)	**New,** **>15 yrs,** **bacteriologically confirmed or clinically diagnosed,** **HIV seropositive or not** Pulmonary Extra pulmonary	**2HRZE**	**4HR**
Retreatment Regimen (RR)	**Previously treated,** **bacteriologically confirmed or clinically diagnosed,** **HIV sero-positive or not:** Relapse Treatment after loss to follow-up Treatment after failure Other previously treated Unknown previous history	**3HRZE** **5HRE** **(OR)** **6HRZE***	

MONITORING TB PATIENTS

- Monitoring TB patients is to ensure that TB patient is responding to the treatment, and to decide the treatment outcome.
    - Sputum Follow up Examination
    - Body Weight
    - CXR

Treatment Category	Timing for Sputum Specimen
New Sputum Smear (+)ve PTB cases	2,5,6
Previously Treated PTB cases	3,5,8
New Sputum Smear Negative PTB/ EPTB Case	2,6

- In case of GXP referral, if RR is seen, GPs need to refer respective NTP centers for further confirmation and MDR TB management.

CRITERIA FOR GENE X'PERT TESTING

- All Pulmonary TB Cases (New/ Retreatment)
- Sputum Smear Positive at the end of the intensive Phase (Non- Converter)
- TB Patients with Diabetes Mellitus (TB/DM)
- Presumptive TB Cases (PLHIV/ Contacts with MDR-TB Patients)
- Other Cases to be considered individually by MDR-TB committee
- Any CXR abnormalities suggestive of TB (2022)

- In Yangon Region:
  - All Registered TB Cases are eligible for GXP testing.
  - There are GXP machines in all of State/Regions and District TB centers and some townships in Myanmar. ***If GXP is not available in the respective townships, GPs can refer the patients to nearest NTP centres where GXP is available.***
  - Types of specimen for GXP
    - Sputum
    - CSF
    - Gastric aspirate
    - Lymph node aspirate
  - Quality of Sputum for GXP testing
    - 2 early morning sputum samples
    - Mucopurulent sputum, not saliva
    - at least 2 ml
    - Not containing blood and particles
  - Don't leave the sample at 35°C for more than 3 days (Stable 4-10 days at 4°C)
  - Specimens should be held at 2-8°C during transportation

MDR TB TREATMENT

Standardized MDR-TB regimens used in Myanmar (Duration: 20 months)
6 (Amk Z Lfx Eto Cs) / 14 (Lfx Eto Cs Z) *(Amk = Amikacin, Z = Pyrazinamide, Lfx = Levofloxacin, Eto = Ethionamide, Cs = Cycloserine)*
PAS / Clofazimine will be added to the Standard MDR-TB Regimen in followings:
• Failures of retreatment regimen • Resistant to ofloxacin • The presence of the inhA gene on LPA (because ethionamide may not be effective) • The patient has a history of second-line drug use • The patient is a contact of a patient who died on second line drug regimen or a contact of a patient with a known history of resistance to second-line drugs

Update on DR TB Treatment

- DR-TB treatment regimens as per the National DR-TB guidelines (updates) (2022)
- ***OSSTR (9-12 months):***
  - 4-6 Bdq (6), Eto, Lfx, Cfz, Z, Hh, E/5 Lfx, Cfz, Z, E (Oral Shorter Tx Regimen)
- ***OLTR (18 months):***
  - 6 Bdq-Lfx- Lzd-Cfz/ 12 Lfx-Lzd-Cfz (Oral Longer Tx Regimen)
- ***Oral Shorter Pre XDR/XDR TB Treatment (Bpal) 6-9 months*** (Under operational research)
- Bedaquiline, Linezolid, Pretomanid-Duration
  - BPaLM: 6-9 Months: Bdq,Pa, Lzd, Mfx, (Lzd 600 mg daily)
- The 9-month, all-oral, bedaquiline-containing regimens are preferred over the longer (>18 months) regimen in adults and children with MDR/RR-TB, without previous exposure to second-line treatment (including bedaquiline), without fluoroquinolone resistance and with no extensive pulmonary TB disease or severe extrapulmonary TB.
- In these regimens, 2 months of linezolid (600 mg) can be used as an alternative to 4 months of ethionamide. Access to rapid DST for ruling out fluoroquinolone resistance is required before starting a patient on one of these regimens.
- Patients with extensive forms of DR-TB (e.g. XDR-TB) or those who are not eligible for or have failed shorter treatment regimens will benefit from an individualized longer regimen designed using the priority grouping of medicines recommended in current WHO guidelines.
- The 6-month BPaLM regimen, comprising bedaquiline, pretomanid, linezolid (600 mg) and

moxifloxacin, may be used programmatically in place of 9-month or longer (>18 months) regimens, in patients (aged ≥15 years) with MDR/RR-TB who have not had previous exposure to bedaquiline, pretomanid and linezolid (defined as >1 month exposure).

- This regimen may be used without moxifloxacin (BPaL) in the case of documented resistance to fluoroquinolones (in patients with pre-XDR-TB). Drug susceptibility testing (DST) to fluoroquinolones is strongly encouraged, but DST should not delay treatment initiation.

CHILDHOOD TB

- Risk Factors for Developing Childhood Tuberculosis
  - Close contact (household, close relatives, caregiver, neighbour and teacher) with a newly diagnosed smear-positive case as well as smear-negative but culture-positive case
  - Age <5 years of age
  - HIV infection
  - Severe malnutrition, measles and immunosuppressive drugs or illnesses
  - Absence of BCG vaccination
  - Failure to thrive or weight loss (documented)

Criteria for suspecting TB in Children

- The child can be considered as presumptive TB Case if 2 out 3 following features are present.
  - Persistence symptoms: cough for more than 2 week or fever (38 C) for more than 2 week
  - Failure to gain weight or weight loss (consult weight chart)
  - History of contact with suspected or diagnosed TB patient
- Symptoms suggestive of childhood TB include:
  - Cough for more than 2 weeks which is not improving with full course of appropriate antibiotics and/or bronchodilators
  - Fever (38°C) for more than 2 weeks after exclusion of common causes of fever (e.g. malaria)
  - Failure to gain weight (Weight loss if known) See weight chart Unexplained loss of appetite or lethargy

Signs suggestive of childhood TB are:

Pulmonary TB

- signs of persistent pneumonia (cough or difficulty breathing with fast breathing or chest indrawing) after full course of appropriate antibiotics

Extrapulmonary TB:

- Highly suggestive
  - Pleural effusion
  - Acute vertebral gibbus
  - Non-painful glands with fistula formation and/or draining sinus
- Suggestive
  - Meningitis not responding to adequate antibiotics
  - Pericardial effusion
  - Swollen non-painful joints
  - Significant enlarged lymph glands more than 2 cm in diameter and more than 2 in number without fistula formation but with no known local cause and not responding to usual antibiotics
  - Distended abdomen with Ascites
  - Clinical features indicative of tuberculin hypersensitivity (Erythema Nodosum, Phlyctenular conjunctivitis)

General Approach to diagnosis of TB in children



Criteria for suspecting TB in Children

The child can be considered as a presumptive TB case if 2 out of 3 following features are present.

- persistent symptoms: cough for more than 2 weeks and/or fever (≥38°C) for more than 2 weeks (unexplained)
- failure to gain weight or weight loss (consult weight chart)
- history of contact with presumptive or diagnosed TB patient

CHILDHOOD TB TREATMENT

	Type of TB patients	TB cases	Regimen	
			Intensive phase	Continuation phase
Recommended treatment regimens for children in each TB diagnostic categories	New cases	Children <8 years of age (exception: see below)	2HRZ	4HR
		• Children ≥8 years of age • Children <8years of age with severe form of pulmonary/ extrapulmonary TB or who are HIV-infected	2HRZE	4HR
		• Meningitis/disseminated TB • Osteoarticular TB	2HRZE	10HR
	Previously	• Relapse	3HRZE	5HRE

	treated case	• Treatment after failure • Treatment after loss of follow-up		
	MDRTB		Specially designed standardized or individualized regimens (refer to Chapter 5 and Myanmar National guidelines on Management of MDR-TB	

INFECTIVE CONTROL MEASURES AT GP CLINICS

- As a health care provider, every GPs need to be aware of, and careful about TB infection control measures at their daily GP settings for themselves, clinic staff and other attendants at the GP clinics. Key points for TB infection control measures for health care providers are as follows;

Administrative control measures

- To reduce the chances of exposure to airborne droplet nuclei (It is also most important and least expensive mean to health care personals)
- Triage (Fast track service) - Promptly identify persons with symptoms suggestive of TB
- Separate or isolate potentially infectious patients
- Control the spread of pathogens (cough etiquette)
- Minimize time spent in healthcare facilities by persons with symptoms suggestive ofTB
- Provide a package of HIV and TB care and prevention, that may include TB screening for staff

Environmental control measures

- reduce the concentration of airborne droplet nuclei
- Natural ventilation: simplest and least expensive technique by maximizing natural ventilation through open windows and doors.
    - Natural ventilation relies on open doors and windows, and permanent openings to bring in air from the outside.
    - When fresh air enters a room it dilutes the concentration of air particles inside the room, such as droplet nuclei containing *M tuberculosis*.
    - Designing rooms with adequate windows to maximize natural ventilation, can help reduce the spread of TB.
    - A rule of thumb is openable window area of 20%, preferably at opposite walls.
- **Mechanical ventilation:** more complex and costly methods.
    - AIIR (Airborne Infection Isolation Room)
    - Mechanical ventilation measures include electrical and wind-driven fans which may assist to
        i. distribute the air (thus allowing better dilution of air)
        ii. evacuate the air (fans pulling air out of a
        iii. maintain negative pressure ventilation systems (to ensure that air is pulled from adjacent rooms into the negative pressure patient room).

Personal protective equipment

- **To** protects HCWs from inhaling infectious droplet nuclei
    - Surgical Masks
        - Reduce spread of Micro-organisms from wearer
        - Not provide protection to the wearer from inhaling small infectious aerosols.
        - Uses for **PATIENT** (not for staff)

- Respirators - N95/FFP2 for **Health Care Worker** (HCW) and non infected person

Health Education and Counselling

- Health Education and Counselling plays a crucial role for every TB patients, family and caregivers.
- GPs need to do HE& Counselling about TB mainly relating to the adherence to anti TB treatment, side effects of anti TB drugs, TB transmission and prevention, proper nutrition, follow up sputum examination, TB infection control etc...

TB PREVENTIVE THERAPY (TPT)

- The main health care intervention available to reduce the risk of TB infection progressing to active TB disease is TB preventive treatment. Other interventions are TB infection prevention and control, and vaccination of children with the bacille Calmette-Guérin (BCG) vaccine, which can confer protection, especially from severe forms of TB in children.
- WHO guidance recommends TB preventive treatment for people living with HIV, household contacts of bacteriologically confirmed pulmonary TB cases and clinical risk groups (e.g. those receiving dialysis)
- It is estimated that a quarter of the world population is infected with TB
- 5-10% of those will develop TB in their lifetime
- Most of those develop TB within 5 years since the infection
- With the current available LTBI treatment, the risk to progress from infection to active disease can be reduced 60-90%

LATENT TUBERCULOSIS INFECTION (LTBI):

- A state of persistent immune response to stimulation by Mycobacterium tuberculosis antigens with no evidence of clinically manifest active TB.

Diagnosis

- Two approved testing:
    i. Tuberculin skin test (TST)
    ii. Interferon γ release assay (IGRA), ex: TSPOT®TB Test, QuantiFERON®TB Gold in Tube Test)
- The tests measure the immune response against MTB, not the presence of MTB itself
- Neither TST nor IGRAs can distinguish LTBI from active TB and past TB
- Adjunct tests where diagnosis of TB is uncertain.

Algorithm for Initiation TPT in Myanmar



WHO recommended Treatment Options for LTBI

စဉ်	ကုထုံး	အတို ကောက်	အကြိမ်ရေ	ကိုယ်အလေးချိန်အရ သုံးရမည့် ဆေးပမာဏ	အများဆုံး သောက်ရမည့် ဆေးပမာဏ
၁။	INH ဖြေ	6H	နေ့စဉ် (၁) ကြိမ် (180 doses)	အသက်(၂)နှစ်အထိ - 10mg/kg/day (range, 7-15 mg/kg)	300 mg
၂။	Rifapentine နှင့် high dose Isoniazid ဥလ	3HP	အပတ်စဉ် (၁) ကြိမ် (12 doses)	အောက်ဖော်ပြပါဇယားအတိုင်း တွက်ချက်ပေးရမည်။	INH - 900mg Rifapentine - 900 mg

အသက် ၂ နှစ်မှ ၁၄နှစ် အထိ

Formulation	10-15 kg	16-23 kg	24-30 kg	31-34 kg	>34 kg
INH 100 mg	3	5	6	7	7
Rifapentine 150 mg	2	3	4	5	5
INH + rifapentine FDC (150 mg/ 150 mg)	2	3	4	5	5

အသက် ၁၄နှစ်အထက်

Formulation	30-35 kg	36-45 kg	46-55 kg	56-70 kg	>70kg
INH 300 mg	3	3	3	3	3
Rifapentine 150 mg	6	6	6	6	6
INH + rifapentine FDC (300 mg/ 300 mg)	3	3	3	3	3

REFERENCES

1. *Training manual on PPM TB for GPs (2020): NTPIWHOIMMA*
2. *Global TB Report, WHO (2021):*
3. *Guidelines for treatment of drug-susceptible TB in Myanmar (2020)*
4. *Update information from National TB Program/WHO (2021)*

MALARIA

DEFINITION:

- Malaria is a parasitic disease transmitted by bite of infected female Anopheles mosquitoes that bite at night.
- Human malaria parasites:
  - *Plasmodium falciparum* - most common (around 60%), and causes severe diseases.
  - *Plasmodium vivax*- around 40%, and rarely causes severe diseases.
  - Others are *Pl. ovale, Pl. malariae*

SUSPECTED MALARIA

- A person with fever within 7 days with or without other accompanying signs and symptoms, has either history of malaria or had stayed at night in areas where there is malaria transmission and has no obvious signs and symptoms of any other febrile disease.

PROBABLE MALARIA

- Test (either by microscopy and/or rapid diagnostic test) and is treated with full course of antimalaria drugs.

CONFIRMED MALARIA

- A case of febrile illness or asymptomic, infected with malaria parasites confirmed by either microscopy and /or rapid diagnostic test (RDT)

UNCOMPLICATED MALARIA

- Symptomatic malaria parasitaemia with no signs of severity and/ or evidence of vital organ dysfunction.

SEVERE FALCIPARUM MALARIA

- Acute falciparum malaria with signs of severity and/or evidence of vital organ dysfunction or malaria with pregnancy.

UNCOMPLICATED MALARIA

- A person living in malaria endemic area or history of travel to malaria area within past 6 weeks with onset of fever and one or more of the followings.
- Malaria attack (6-l0hr)

CLINICAL FEATURES
Symptoms

- Sensation of cold, shivering
- Intermittent fever
- headaches
- vomiting
- seizures in young children

- Sweats return to normal temperature
- Tiredness

Signs

- Temperature above 38° C
- Splenomegaly
- Pallor
- No other obvious signs of febrile diseases

DIAGNOSIS

- Microscopy with Giemsa stained thick and thin blood film (gold standard)
- RDT
- Immunochromatographic test for malaria antigen. Can detect malaria antigens in 15 minutes
- Positive as soon as the parasites present in the blood.
- RDTs to detect pLDH *(pan-Plasmodium* antigen lactate dehydrogenase) may remain positive up to *5-6 days after disappearance* of parasites, while those to detect HRP2 (Histidine rich protein 2) remain positive up *to 2-3 weeks after disappearance* of parasites. /-found in infected RBC or as free antigens in serum or plasma

Helpful in diagnosis of acute infection

- **Rapid Immunodiagnostic Strip Tests** Simple and rapid device tests Reliable; detects *Pf* alone or *P.f/P.v*
- RDT is interestingly used where microscopy is not feasible or quality of malaria microscopy result is not promising.

TREATMENT OF UNCOMPLICATED P. FALCIPARUM MALARIA

- ARTEMETHER-LUMEFANTRINE (20 mg/120 mg) (dosage 1.5/12mg/kg BD +
- primaquine 0.25mg/kg)
- DIHYDROARTEMISININ-PIPERAQUINE (40 mg/320 mg) (dosage 96.4 mg and
- 51.2mg/kg)
- ARTESUNATE -MEFLOQUINE

Treatment regime of P. falciparum malaria

Age group (Years)	Artemether-Lumefantrine + Primaquine						
	Day 0		Day1		Day2		
	AL 1st Dose	AL 2nd Dose	AL 1st Dose	AL 2nd Dose	AL 1st Dose	PQ (Stat)	AL 2nd Dose
<1	½	½	½	½	½	0	½
1 – 4	1	1	1	1	1	7.5mg	1
5 – 9	2	2	2	2	2	15mg	2
10 – 14	3	3	3	3	3	30mg	3
15+above	4	4	4	4	4	45 mg	4

Day0: Day of blood Test & Positive; Day1: one day after blood test (+);
Day2: 2days after blood test(+)
This regime has been updated in 2020. Primaquine is given for gametocytocidal purpose to prevent onward transmission.

TREATMENT OF P. VIVAX, P. MALARIAE, P. OVALE

- Chloroquine (dosage 25 mg base/kg for 3 days) is still the treatment of choice for malaria
- Radical cure is achieved by primaquine (dosage 0.25 mg/kg/day for 14 days) should be given for confirmed *P. vivax* and *ovale* infections with precautions.
- If the patient is expected to has G6PD deficiency then O.75 mg/kg is given once weekly for 8 weeks.

Age group (years)	Dose of chloroquine tablets (150 mg base)		
	Day 1	Day2	Day3
< 1	1/3	1/3	1/3
1- 4	l½	l½	l½
5-9	2	2	2
10 -14	3	3	3
>15	4	4	4

- Primaquine (for *P. vivax*, *P. ovale* Hyponozoites)
- Daily regime - good compliance, more side effects
- Weekly regime - compliance not good, but less side effects

IMPORTANT MESSAGE FOR PATIENTS

- Stop taking PQ if there is blue coloration of lips, nails or changing urine color (red/dark urine) and come immediately to the health center.

TREATMENT IF PLASMODIUM MALARIAE

- Chloroquine (25mg/kg) within 3 days is effective.

TREATMENT OF MIXED INFECTIONS (P.F+ OTHER)

- Any of the above three ACTs recommended for treatment of uncomplicated *P. falciparum* malaria in Myanmar should be given, plus a full course of Primaquine as appropriate for *P.vivax* and/or *P. ovale* infections.

TREATMENT OF MALARIA IN PREGNANCY

- *First trimester:*
  - Quinine plus Clindamycin is to be given for 7 days
  - AL for 3 days is indicated only if this is the only treatment immediately available, or if treatment with 7-day Quinine plus Clindamycin fails or if there is uncertainty of compliance with a 7-day treatment of Quinine or Clindamycin.
- *Second and Third trimester:*
  - AL to be given for 3 days (no primaquine)
- *Lactating Women:*
  - The amounts of anti-malarial that enter breast milk and are consumed by the breastfeeding infant are relatively small.
  - Tetracycline is contraindicated in breastfeeding mothers because of its potential effect on the infant's bone and teeth. Primaquine should not be used in nursing women up to 6 months of lactating period, unless the breastfed infant has been determined not to be G6PD-deficient.
  - AL to be given for 3 days
  - Primaquine should not be given to breast feeding mothers of infants <6 months of age

SEVERE MALARIA

Definitions

- **Severe P. falciparum malaria**
- For epidemiological purposes**, severe falciparum** malaria is defined as one or more of the following, occurring in the absence of an identified alternative cause and in the presence of *P. falciparum* asexual parasitaemia.

CLINICAL FEATURES

- Altered or decreased consciousness (e.g. confusion, delirium, coma)
- Convulsions more than two episodes in 24 hrs
- Persistent vomiting (this may also be a neurological manifestation)
- Prostration, i.e. generalized weakness so that the patient is unable to walk or sit up without assistance
- Hyperpyrexia (39° C & higher, with dry skin)
- Severe anaemia
- Failure to pass urine or passing a very small quantity of urine/ renal failure
- Pulmonary oedema (difficulty in lying flat due to breathing problems usually with cough, pink frothy sputum)
- Circulatory collapse (shock) - shown by a feeble, very rapid pulse and cold and clammy limbs
- Spontaneous bleeding
- Haemoglobinuria (black urine)
- Jaundice, yellow coloration of the eyes, failure to respond to treatment within 3 to 7 days
- (first four categories are included in Non per-os patients)
- Malaria *(Pf+)* in Pregnancy

LABORATORY FINDINGS:

- Hypoglycaemia (blood glucose< 2.2 mmol/1 or <40 mg/dl)
- Metabolic acidosis (plasma bicarbonate <15 mmol/1)
- Severe normocytic anaemia (Hb < 5 g/dl, packed cell volume <15%)
- Haemoglobinuria
- Hyperparasitaemia (>2%/100 000/micro 1 in low intensity transmission areas or >5% or 250000/ micro 1 in areas of high stable malaria transmission intensity)
- Hyperlactataemia (lactate - > 5mmol/l)
- Renal impairment (serum creatinine >265 µmol/1)

SEVERE *P. VIVAX* AND *P. KNOWLESI* MALARIA

- Severe *P. vivax* malaria is defined as for falciparum malaria but with no parasite density thresholds.
- Severe *P. knowlesi* malaria is defined as for falciparum malaria but with two differences:
- *P. knowlesi* hyperparasitaemia: parasite density>100 000/µL
- Jaundice and parasite density > 20 000/ µL.

TREATMENT OF SEVERE AND COMPLICATED MALARIA

- Treat adults and children with severe malaria (including infants, pregnant women in all trimesters and lactating women) with intravenous or intramuscular Artesunate for at least 24 hr and until they can tolerate oral medication
- Once a patient has received at least 24 h of parenteral therapy and can tolerate oral therapy,

complete treatment with 3 days of an ACT (Artimisinin based combination therapy) (A+L) plus primaquine if not contraindicated.

PRE-REFERRAL TREATMENT BEFORE REFERRAL

- Severe malaria is ***a medical emergency.*** After rapid clinical assessment, full doses of an effective parenteral antimalarial medicine that is immediately available should be given without delay, even when/where confirmatory diagnosis is not immediately possible.
- The drug of choice is Artesunate given by the intravenous (IV) or intramuscular (IM) route.
- Other options if intravenous or intramuscular Artesunate is not available - Artemether (IM) or Quinine dihydrochloride should be used immediately.
- ****50% Glucose injection for life saving if hypoglycemia is suspected**** especially in patients treated with Quinine (Quinine induced hypoglycaemia)*
- Artesunate
- Recommended Dose 2.4 mg/kg stat, 2.4 mg/kg after 12 and 24 hrs and daily until the patient can tolerate oral medication

CHEMOPROPHYLASIX

- Generally, chemoprophylaxis is not recommended because of drug side effects, false security and also poor effectiveness.

Stand-by Curative Treatment

- For travelers to endemic areas (>10 days) where early access to diagnosis and effective treatment is not possible, stand -by curative treatment is recommended using RDT and recommended ACTs.
- Other measures to prevent mosquito bites should be promoted such as use of repellents and LLINs or ITNs.
- There is no intervention that provides 100% effectiveness in preventing malaria.

Preventive measures

- Malaria prevention can be done through
- Insecticide Treated Nets (ITNs) and Long Lasing Insecticide Treated Nets (LLINs)
- Sleeping inside mosquito nets treated with insecticides at night is a cost-effective mean for malaria prevention for indoor biter vectors. Mosquito bite can be avoided by applying mosquito repellents over the exposed parts of the body.
- Control of Malaria Vectors
- Early Diagnosis and Effective Treatment with recommended drugs (EDET)

REFERANCES

1. *Therapeutic Manual Internal Medicine (1st Edition ,2016)*
2. *Malaria Manual for Clinicians and Private General Practitioners (3rd Edition,2017)*
3. *WHO Guideline for the Treatment of Malaria, Third Edition*

SEXUALLY TRANSMITTED DISEASES

- The term “sexually transmitted infection” (STI) refers to a pathogen that causes infection through sexual contact, whereas the term “sexually transmitted disease” (STD) refers to a recognizable disease state that has developed from an infection.
- Sexually transmitted diseases (STDs) — or sexually transmitted infections (STIs) — are generally acquired by sexual contact. The bacteria, viruses or parasites that cause sexually transmitted diseases may pass from person to person in blood, semen, or vaginal and other bodily fluids.
- Sometimes these infections can be transmitted nonsexually, such as from mothers to their infants during pregnancy or childbirth, or through blood transfusions or shared needles.

What are the top 10 sexually transmitted diseases

- Genital shingles (Herpes Simplex)
- Human papillomavirus (Genital warts)
- Hepatitis B
- Chlamydia
- Chancroid (Syphilis)
- Clap (Gonorrhea)
- Human immunodeficiency virus/Acquired immunodeficiency syndrome (HIV/AIDS)
- Trichomoniasis (Trich)
- Bacterial vaginosis

Syndrome	**Symptoms**	**Signs**	**Most common causes**
Vaginal discharge	*Unusual vaginal discharge* *Vaginal itching* *Dysuria (pain on urination)* *Dyspareunia (pain during sexual intercourse)*	*Abnormal vaginal discharge*	*VAGINITIS:* *– Trichomoniasis* *– Candidiasis* *CERVICITIS:* *– Gonorrhoea* *– Chlamydia*
Urethral discharge	*Urethral discharge* *Dysuria* *Frequent urination*	*Urethral discharge (if necessary, ask patient to milk urethra)*	*Gonorrhoea* *Chlamydia*
Genital ulcer	*Genital sore*	*Genital ulcer*	*Syphilis* *Chancroid* *Genital herpes*
Lower abdominal pain	*Lower abdominal pain* *Dyspareunia*	*Vaginal discharge* *Lower abdominal tenderness on palpation* *Temperature >38°*	*Gonorrhoea* *Chlamydia* *Mixed anaerobes*
Scrotal swelling	*Scrotal pain and swelling*	*Scrotal swelling*	*Gonorrhoea* *Chlamydia*
Inguinal bubo	*Painful enlarged inguinal lymph nodes*	*Enlarged inguinal lymph nodes* *Fluctuation* *Abscesses or fistulae*	*LGV* *Chancroid*
Neonatal conjunctivitis	*Swollen eyelids* *Discharge* *Baby cannot open eyes*	*Oedema of the eyelids* *Purulent discharge*	*Gonorrhoea* *Chlamydia*

- STDs or STIs can have a range of signs and symptoms, including no symptoms. That's why they

may go unnoticed until complications occur or a partner is diagnosed.

- Signs and symptoms that might indicate an STI include:
- Sores or bumps on the genitals or in the oral or rectal area
- Painful or burning urination
- Discharge from the penis
- Unusual or odorous vaginal discharge
- Unusual vaginal bleeding
- Pain during sex
- Sore, swollen lymph nodes, particularly in the groin but sometimes more widespread
- Lower abdominal pain
- Fever
- Rash over the trunk, hands or feet
- Signs and symptoms may appear a few days after exposure. However, it may take years before you have any noticeable problems, depending on the organism causing the STI.

When to see a doctor

- See a doctor immediately if:
- You are sexually active and may have been exposed to an STI
- You have signs and symptoms of an STI
- Make an appointment with a doctor:
- When you're considering becoming sexually active or when you're 21 — whichever comes first
- Before you start having sex with a new partner

Sexually transmitted disease (STD) symptoms

- If you have sex — oral, anal or vaginal intercourse and genital touching — you can get an STD, also called a sexually transmitted infection (STI). Regardless of your marital status or sexual orientation, you're vulnerable to STIs and STI symptoms. Thinking or hoping your partner doesn't have an STI is no protection — you need to know for sure.
- Condoms, when properly used, are highly effective for reducing transmission of some STDs. But no method is foolproof, and STI symptoms aren't always obvious. If you think you have STI symptoms or have been exposed to an STI, see a doctor. Also, inform your partner or partners so that they can be evaluated and treated.
- Some STIs are easy to treat and cure; others require more-complicated treatment to manage them.
- If untreated, STIs can increase your risk of acquiring another STI such as HIV. This happens because an STI can stimulate an immune response in the genital area or cause sores, either of which might raise the risk of HIV tntreated STIs can also lead to infertility, organ damage, certain types of cancer or death.

Asymptomatic STIs

Many STIs have no signs or symptoms (asymptomatic). Even with no symptoms, however, you can pass the infection to your sex partners. So it's important to use protection, such as a condom, during sex. And visit your doctor regularly for STI screening so you can identify and treat an infection before you can pass it on.

Chlamydia symptoms

- Chlamydia is a bacterial infection of your genital tract. Chlamydia may be difficult to detect because early-stage infections often cause few or no signs and symptoms. When they do occur, symptoms usually start one to three weeks after you've been exposed to chlamydia and may be mild and pass quickly.
- Signs and symptoms may include:
- Painful urination
- Lower abdominal pain
- Vaginal discharge in women
- Discharge from the penis in men
- Pain during sexual intercourse in women
- Bleeding between periods in women
- Testicular pain in men

Gonorrhea symptoms

- Gonorrhea is a bacterial infection of your genital tract. The bacteria can also grow in your mouth, throat, eyes and anus. The first gonorrhea symptoms generally appear within 10 days after exposure. However, some people may be infected for months before signs or symptoms occur.
- Signs and symptoms of gonorrhea may include:
- Thick, cloudy or bloody discharge from the penis or vagina
- Pain or burning sensation when urinating
- Heavy menstrual bleeding or bleeding between periods
- Painful, swollen testicles
- Painful bowel movements
- Anal itching

Trichomoniasis symptoms

- Trichomoniasis is a common STI caused by a microscopic, one-celled parasite called Trichomonas vaginalis. This organism spreads during sexual intercourse with someone who already has the infection.
- The organism usually infects the urinary tract in men, but often causes no symptoms. Trichomoniasis typically infects the vagina in women. When trichomoniasis causes symptoms, they may appear within five to 28 days of exposure and range from mild irritation to severe inflammation.
- Signs and symptoms may include:
- Clear, white, greenish or yellowish vaginal discharge
- Discharge from the penis
- Strong vaginal odor
- Vaginal itching or irritation
- Itching or irritation inside the penis
- Pain during sexual intercourse
- Painful urination

HIV symptoms

- HIV is an infection with the human immunodeficiency virus. HIV interferes with your body's ability to fight off viruses, bacteria and fungi that cause illness, and it can lead to AIDS, a chronic, life-threatening disease.
- When first infected with HIV, you may have no symptoms. Some people develop a flu-like illness, usually two to six weeks after being infected. Still, the only way you know if you have HIV is to be tested.

Early signs and symptoms

- Early HIV signs and symptoms usually disappear within a week to a month and are often mistaken for those of another viral infection. During this period, you're highly infectious. More-persistent or -severe symptoms of HIV infection may not appear for 10 years or more after the initial infection. Early-stage HIV symptoms may include:
    - Fever
    - Headache
    - Sore throat
    - Swollen lymph glands
    - Rash
    - Fatigue
- As the virus continues to multiply and destroy immune cells, you may develop mild infections or chronic signs and symptoms such as:
    - Swollen lymph nodes — often one of the first signs of HIV infection
    - Diarrhea
    - Weight loss
    - Fever
    - Cough and shortness of breath
    - Late-stage HIV infection
- Signs and symptoms of late-stage HIV infection include:
    - Persistent, unexplained fatigue
    - Soaking night sweats
    - Shaking chills or fever higher than 100.4 F (38 C) for several weeks
    - Swelling of lymph nodes for more than three months
    - Chronic diarrhea
    - Persistent headaches
    - Unusual, opportunistic infections

Genital herpes symptoms

- Genital herpes is a highly contagious STI caused by a type of the herpes simplex virus (HSV) that enters your body through small breaks in your skin or mucous membranes. Most people with HSV never know they have it, because they have no signs or symptoms or the signs and symptoms are so mild they go unnoticed.
- When signs and symptoms are noticeable, the first episode is generally the worst. Some people never have a second episode. Others, however, can have recurrent episodes for decades.
- When present, genital herpes signs and symptoms may include:
    - Small red bumps, blisters (vesicles) or open sores (ulcers) in the genital and anal areas and areas nearby
    - Pain or itching around the genital area, buttocks and inner thighs
    - Ulcers can make urination painful. You may also have pain and tenderness in your genital area until the infection clears. During an initial episode, you may have flu-like signs and symptoms, such as a headache, muscle aches and fever, as well as swollen lymph nodes in your groin.
    - In some cases, the infection can be active and contagious even when sores aren't present.

Human papillomavirus (HPV) infection and genital warts symptoms

- HPV infection is one of the most common types of STIs. Some forms of HPV put women at high risk of cervical cancer. Other forms cause genital warts. HPV usually has no signs or symptoms.
- The signs and symptoms of genital warts include:
    - Small, flesh-colored or gray swellings in your genital area
    - Several warts close together that take on a cauliflower shape

    - Itching or discomfort in your genital area
    - Bleeding with intercourse
- Often, however, genital warts cause no symptoms. Genital warts may be as small as 1 millimeter in diameter or may multiply into large clusters. Warts can also develop in the mouth or throat of a person who has had oral sex with an infected person.

Hepatitis symptoms

- Hepatitis A, hepatitis B and hepatitis C are all contagious viral infections that affect your liver. Hepatitis B and C are the most serious of the three, but each can cause your liver to become inflamed.
- Some people never develop signs or symptoms. But for those who do, signs and symptoms may occur several weeks after exposure and may include:
    - Fatigue
    - Nausea and vomiting
    - Abdominal pain or discomfort, especially in the area of your liver on your right side beneath your lower ribs
    - Loss of appetite
    - Fever
    - Dark urine
    - Muscle or joint pain
    - Itching
    - Yellowing of your skin and the whites of your eyes (jaundice)

Syphilis symptoms

- Syphilis is a bacterial infection. The disease affects your genitals, skin and mucous membranes, but it can also involve many other parts of your body, including your brain and your heart.
- The signs and symptoms of syphilis may occur in three stages — primary, secondary, and tertiary. Some people also experience latent syphilis, in which blood tests are positive for the bacteria but no symptoms are present.
- At first, only a small, painless sore (chancre) may be present at the site of infection, usually the genitals, rectum, tongue or lips. As the disease worsens, symptoms may include:
    - Rash marked by red or reddish-brown, penny-sized sores over any area of your body, including your palms and soles
    - Fever
    - Enlarged lymph nodes
    - Fatigue and a vague feeling of discomfort
    - Soreness and aching
- Without treatment, syphilis bacteria may spread, leading to serious internal organ damage and death years after the original infection.
- Some of the signs and symptoms of late-stage syphilis include:
    - Lack of coordination
    - Numbness
    - Paralysis
    - Blindness
    - Dementia

  There's also a condition known as congenital syphilis, which occurs when a pregnant woman with syphilis passes the disease to her unborn infant. Congenital syphilis can be disabling, even life-threatening, so it's important for pregnant women with syphilis to be treated.

Neurosyphilis

- At any stage, syphilis can affect the nervous system. Neurosyphilis may cause no signs or symptoms, or it can cause:
    - Headache
    - Behavior changes
    - Movement problems

Clinical Prevention Guidance

- Prevention and control of STIs are based on the following five major strategies (*3*):
    1. Accurate risk assessment and education and counseling of persons at risk regarding ways to avoid STIs through changes in sexual behaviors and use of recommended prevention services
    2. Pre-exposure vaccination for vaccine-preventable STIs
    3. Identification of persons with an asymptomatic infection and persons with symptoms associated with an STI
    4. Effective diagnosis, treatment, counseling, and follow-up of persons who are infected with an STI
    5. Evaluation, treatment, and counseling of sex partners of persons who are infected with an STI

STI and HIV Infection Risk Assessment

- Primary prevention of STIs includes assessment of behavioral risk (i.e., assessing the sexual behaviors that can place persons at risk for infection) and biologic risk (i.e., testing for risk markers for STI and HIV acquisition or transmission).
- Primary prevention of STIs includes assessment of behavioral risk (i.e., assessing the sexual behaviors that can place persons at risk for infection) and biologic risk (i.e., testing for risk markers for STI and HIV acquisition or transmission
- **The Five P's approach for health care providers obtaining sexual histories: partners, practices, protection from sexually transmitted infections, past history of sexually transmitted infections, and pregnancy intention**
- **1. Partners**
    - "Are you currently having sex of any kind?"
    - "What is the gender(s) of your partner(s)?"
- 2. Practices
    - "To understand any risks for sexually transmitted infections (STIs), I need to ask more specific questions about the kind of sex you have had recently."
    - "What kind of sexual contact do you have or have you had?" "Do you have vaginal sex, meaning 'penis in vagina' sex?"
    - "Do you have anal sex, meaning 'penis in rectum/anus' sex?"
    - "Do you have oral sex, meaning 'mouth on penis/vagina'?"
- 3. Protection from STIs
    - "Do you and your partner(s) discuss prevention of STIs and human immunodeficiency virus (HIV)?"
    - "Do you and your partner(s) discuss getting tested?"
    - For condoms: "What protection methods do you use? In what situations do you use condoms?"
- 4. Past history of STIs
    - "Have you ever been tested for STIs and HIV?"
    - "Have you ever been diagnosed with an STI in the past?"
    - "Have any of your partners had an STI?"
    - Additional questions for identifying HIV and viral hepatitis risk:
    - "Have you or any of your partner(s) ever injected drugs?"
    - "Is there anything about your sexual health that you have questions about?"
- 5. Pregnancy intention
    - "Do you think you would like to have (more) children in the future?"

- "How important is it to you to prevent pregnancy (until then)?"
- "Are you or your partner using contraception or practicing any form of birth control?"
- "Would you like to talk about ways to prevent pregnancy?"

STI and HIV Infection Prevention Counseling

Primary Prevention Methods

Pre-Exposure Vaccination

- Pre-exposure vaccination is one of the most effective methods for preventing transmission of HPV, HAV, and HBV, all of which can be sexually transmitted Hepatitis B vaccination is recommended for all unvaccinated, uninfected persons who are sexually active with more than one partner or are being evaluated or treated for an STI (*12*). In addition, hepatitis A and B vaccines are recommended for MSM, persons who inject drugs, persons with chronic liver disease, and persons with HIV or hepatitis C infections who have not had hepatitis A or hepatitis B (*12*). HAV vaccine is also recommended for persons who are homeless

Condoms

- External Condoms
- When used consistently and correctly, external latex condoms, also known as male condoms, are effective in preventing the sexual transmission of HIV infection
- Internal Condoms
- Condoms for internal vaginal use, also known as female condoms, Use of internal condoms can provide protection from acquisition and transmission of STIs,

Cervical Diaphragms

- In observational studies, diaphragm use has been demonstrated to protect against cervical gonorrhea, chlamydia, and trichomoniasis

Emergency Contraception

- Unprotected intercourse exposes women to risks for STIs and unplanned pregnancy. Providers should offer counseling about the option of emergency contraception if pregnancy is not desired.

These guidelines are primarily limited to the identification

Urethral discharge

- Male patients complaining of urethral discharge and/or dysuria (pain during urination) should be examined for evidence of discharge. The major STIs causing urethral discharge are gonorrhea and chlamydia. In the syndromic management, treatment of a patient with urethral discharge should adequately cover these two STIs. Where reliable laboratory facilities are available, a distinction can be made between the two organisms and specific treatment instituted. Persistent or recurrent symptoms of urethritis (inflammation of the urethra) may result from drug resistance, poor compliance with the treatment or reinfection. Where symptoms persist or recur after adequate treatment for gonorrhea and chlamydia in the patient and his/her partner(s), the patient should be treated for trichomoniasis if cases of this STI is found in the geographical location of the patient.

Vaginal discharge

- A spontaneous complaint of abnormal vaginal discharge (in terms of quantity, color or odor) is most commonly a result of a vaginal infection but can also be caused by an STI such as chlamydia and gonorrhea. Detecting these STIs are difficult because a large proportion of women with gonorrhea or chlamydia are asymptomatic. Among women presenting with discharge, one can attempt to identify those with an increased likelihood of being infected with gonorrhea and/or chlamydia. To identify women at greater risk of having a STI, an assessment of a woman's risk

status may be useful, especially when risk factors are adapted to the local situation. Knowledge of the local prevalence of gonorrhea and/or chlamydia in women presenting with vaginal discharge is important when making the decision to treat for STI. The higher the prevalence, the stronger the justification for treatment. Women with a positive risk assessment have a higher likelihood of cervical infection than those who are risk negative. Women with vaginal discharge and a positive risk assessment should, therefore, be offered treatment for gonorrhea and chlamydia.

- In some countries, syndromic management flowcharts have been used as a screening tool to detect STIs among women not presenting with a genital complaint (e.g. in family planning settings). While this may assist in detecting some women with STIs, it is likely that there will be substantial overdiagnosis.

Genital Ulcer Disease (GUD)

- The relative prevalence of infections causing genital ulcers varies considerably in different parts of the world and may change dramatically over time. Distinguishing between diseases with similar symptoms of genital ulcers is often inaccurate. Symptoms and patterns of genital ulcers may be further changed in the presence of HIV infection.
- After examination to confirm the presence of genital ulcers, treatment appropriate to local settings and antimicrobial sensitivity patterns should be given. In areas where both syphilis and chancroid are prevalent, for example, patients with genital ulcers should be treated for both conditions at the time of their initial presentation, to ensure adequate therapy in case of loss to follow-up.
- Prompt and appropriate treatment with the following regimens is critical to avoid severe health complications:
    - Chlamydia:
        - Doxycycline is now the first-line recommended treatment; 100 mg orally twice a day for 7 days.
    - Trichomoniasis:
        - Metronidazole is recommended for treating all women; 500 mg orally twice a day for 7 days.
    - PID:
        - The recommended outpatient regimen is ceftriaxone 500 mg intramuscularly in a single dose + doxycycline 100 mg orally twice a day for 14 days + metronidazole 500 mg orally twice a day for 14 days.
- Providers should treat uncomplicated gonorrhea among adolescents and adults with a single 500 mg injection of ceftriaxone and, if chlamydia has not been ruled out, treat with 100 mg doxycycline orally twice a day for 7 days. A test of cure is recommended in people with pharyngeal gonorrhea. Either a culture or a nucleic acid amplification test (NAAT) is recommended, 7-14 days after the initial treatment, regardless of the regimen. Providers should retest patients 3 months after treatment to detect possible reinfection.
- Prompt testing and treatment are key to managing nongonococcal urethritis (NGU)

Specific infections and their treatments

Diseases Characterized by Genital, Anal, or Perianal Ulcers

- The majority of young, sexually active patients who have genital, anal, or perianal ulcers have either genital herpes or syphilis.
- More than one etiologic agent (e.g., herpes and syphilis) can be present in any genital, anal, or perianal ulcer. Less common infectious causes of genital, anal, or perianal ulcers include chancroid, LGV, and granuloma inguinale (donovanosis). GUDs (e.g., syphilis, herpes, and LGV) might also present as oral ulcers. Genital herpes, syphilis, chlamydia, gonorrhea, and chancroid have been associated with an increased risk for HIV acquisition and transmission. Genital, anal, or perianal lesions can also be

Chancroid

- The combination of one or more deep and painful genital ulcers and tender suppurative inguinal adenopathy indicates the chancroid diagnosis; inguinal lymphadenitis typically occurs in <50% of cases

Treatment

- Successful antimicrobial treatment for chancroid cures the infection, resolves the clinical symptoms, and prevents transmission to others. In advanced cases, genital scarring and rectal or urogenital fistulas from suppurative buboes can result despite successful therapy.
- Recommended Regimens for Chancroid
    - Azithromycin 1 g orally in a single dose
        - or
    - Ceftriaxone 250 mg IM in a single dose
        - or
    - Ciprofloxacin 500 mg orally 2 times/day for 3 days
        - or
    - Erythromycin base 500 mg orally 3 times/day for 7 days

Genital Herpes

- Genital herpes is a chronic, lifelong viral infection. Two types of HSV can cause genital herpes: HSV-1 and HSV-2. Most cases of recurrent genital herpes are caused by HSV-2, and 11.9% of persons aged 14–49 years are estimated to be infected in the United States (*436*). However, an increasing proportion of anogenital herpetic infections have been attributed to HSV-1, which is especially prominent among young women and MSM (*186*,*437*,*438*).
- The majority of persons infected with HSV-2 have not had the condition diagnosed, many of whom have mild or unrecognized infections but shed virus intermittently in the anogenital area. Consequently, most genital herpes infections are transmitted by persons unaware that they have the infection or who are asymptomatic when transmission occurs. Management of genital HSV should address the chronic nature of the infection rather than focusing solely on treating acute episodes of genital lesions.
- Recommended Regimens for First Clinical Episode of Genital Herpes*
    - Acyclovir† 400 mg orally 3 times/day for 7–10 days
        - or
    - Famciclovir 250 mg orally 3 times/day for 7–10 days
        - or
    - Valacyclovir 1 g orally 2 times/day for 7–10 days
- * Treatment can be extended if healing is incomplete after 10 days of therapy.
- † Acyclovir 200 mg orally 5 times/day is also effective but is not recommended because of the frequency of dosing.

Recurrent HSV-2 Genital Herpes

- Almost all persons with symptomatic first-episode HSV-2 genital herpes subsequently experience recurrent episodes of genital lesions. Intermittent asymptomatic shedding occurs among persons with HSV-2 genital herpes infection, even those with longstanding clinically silent infection. Antiviral therapy for recurrent genital herpes can be administered either as suppressive therapy to reduce the frequency of recurrences or episodically to ameliorate or shorten the duration of lesions
- Recommended Regimens for **Suppression of Recurrent HSV-2 Genital Herpes**
    - Acyclovir 400 mg orally 2 times/day
        - or
    - Valacyclovir 500 mg orally once a day*
        - or
    - Valacyclovir 1 g orally once a day
        - or

    - Famciclovir 250 mg orally 2 times/day
- * Valacyclovir 500 mg once a day might be less effective than other valacyclovir or acyclovir dosing regimens for persons who have frequent recurrences (i.e., ≥10 episodes/year).
- Recommended Regimens for **Episodic Therapy for Recurrent HSV-2 Genital Herpes***
    - Acyclovir 800 mg orally 2 times/day for 5 days
        - or
    - Acyclovir 800 mg orally 3 times/day for 2 days
        - or
    - Famciclovir 1 g orally 2 times/day for 1 day
        - or
    - Famciclovir 500 mg orally once, followed by 250 mg 2 times/day for 2 days
        - or
    - Famciclovir 125 mg orally 2 times/day for 5 days
        - or
    - Valacyclovir 500 mg orally 2 times/day for 3 days
        - or
    - Valacyclovir 1 g orally once daily for 5 days
- Acyclovir 400 mg orally 3 times/day for 5 days is also effective but is not recommended because of frequency of dosing.
- Recommended Regimen for **Suppression of Recurrent Genital Herpes Among Pregnant Women***
    - Acyclovir 400 mg orally 3 times/day
        - or
    - Valacyclovir 500 mg orally 2 times/day
- * Treatment recommended starting at 36 weeks' gestation.

Granuloma Inguinale (Donovanosis)

- Granuloma inguinale (donovanosis) is a genital ulcerative disease caused by the intracellular gram-negative bacterium *Klebsiella granulomatis* (formerly known as *Calymmatobacterium granulomatis*Granuloma Inguinale (Donovanosis)
- Granuloma inguinale (donovanosis) is a genital ulcerative disease caused by the intracellular gram-negative bacterium *Klebsiella granulomatis* (formerly known as *Calymmatobacterium granulomatis*).
- Recommended Regimen for Granuloma Inguinale (Donovanosis)
    - Azithromycin 1 g orally once/week or 500 mg daily for >3 weeks and until all lesions have completely healed
- Alternative Regimens
    - Doxycycline 100 mg orally 2 times/day for at least 3 weeks and until all lesions have completely healed
        - or
    - Erythromycin base 500 mg orally 4 times/day for >3 weeks and until all lesions have completely healed
        - or
    - Trimethoprim-sulfamethoxazole one double-strength (160 mg/800 mg) tablet orally 2 time/day for >3 weeks and until all lesions have completely healed

Lymphogranuloma Venereum

- LGV is caused by *C. trachomatis* serovars L1, L2, or L3 (*539*,*540*). LGV can cause severe inflammation and invasive infection, in contrast with *C. trachomatis* serovars A–K that cause mild or asymptomatic infection. Clinical manifestations of LGV can include GUD, lymphadenopathy, or proctocolitis. Rectal exposure among MSM or women can result in proctocolitis, which is the most common presentation of LGV infection (*541*), and can mimic inflammatory bowel disease

with clinical findings of mucoid or hemorrhagic rectal discharge, anal pain, constipation, fever, or tenesmus

- Recommended Regimen for Lymphogranuloma Venereum
    - Doxycycline 100 mg orally 2 times/day for 21 days
- Alternative Regimens
    - Azithromycin 1 g orally once weekly for 3 weeks*
        - or
    - Erythromycin base 500 mg orally 4 times/day for 21 days
- Because this regimen has not been validated, a test of cure with *C. trachomatis* NAAT 4 weeks after completion of treatment can be considered

Syphilis

- Syphilis is a systemic disease caused by *T. pallidum*
- Primary syphilis classically presents as a single painless ulcer or chancre at the site of infection but can also present with multiple, atypical, or painful lesions (*564*). Secondary syphilis manifestations can include skin rash, mucocutaneous lesions, and lymphadenopathy. Tertiary syphilis can present with cardiac involvement, gummatous lesions, tabes dorsalis, and general paresis
- Latent infections (i.e., those lacking clinical manifestations) are detected by serologic testing. Latent syphilis acquired within the preceding year is referred to as early latent syphilis; all other cases of latent syphilis are classified as late latent syphilis or latent syphilis of unknown duration.
- *T. pallidum* can infect the CNS, which can occur at any stage of syphilis and result in neurosyphilis. Early neurologic clinical manifestations or syphilitic meningitis (e.g., cranial nerve dysfunction, meningitis, meningovascular syphilis, stroke, and acute altered mental status) are usually present within the first few months or years of infection. Late neurologic manifestations (e.g., tabes dorsalis and general paresis) occur 10 to >30 years after infection.
- Infection of the visual system (ocular syphilis) or auditory system (otosyphilis) can occur at any stage of syphilis but is commonly identified during the early stages and can present with or without additional CNS involvement. Ocular syphilis often presents as panuveitis but can involve structures in both the anterior and posterior segment of the eye, including conjunctivitis, anterior uveitis, posterior interstitial keratitis, optic neuropathy, and retinal vasculitis. Ocular syphilis can result in permanent vision loss. Otosyphilis typically presents with cochleo-vestibular symptoms, including tinnitus, vertigo, and sensorineural hearing loss. Hearing loss can be unilateral or bilateral, have a sudden onset, and progress rapidly. Otosyphilis can result in permanent hearing loss.
- Recommended Regimen for **Primary and Secondary Syphilis* Among Adults**
    - Benzathine penicillin G 2.4 million units IM in a single dose
- * Recommendations for treating syphilis among persons with HIV infection and pregnant women are discussed elsewhere in this report (see Syphilis Among Persons with HIV Infection; Syphilis During Pregnancy).
- Recommended Regimen for **Syphilis Among Infants and Children**
    - Benzathine penicillin G 50,000 units/kg body weight IM, up to the adult dose of 2.4 million units in a single dose
- Recommended Regimens for **Latent Syphilis* Among Adults**
- Early latent syphilis:
    - Benzathine penicillin G 2.4 million units IM in a single dose
- Late latent syphilis:
    - Benzathine penicillin G 7.2 million units total, administered as 3 doses of 2.4 million units IM each at 1-week intervals
- Recommendations for treating syphilis in persons with HIV and pregnant women are discussed elsewhere in this report (see Syphilis Among Persons with HIV Infection; Syphilis During Pregnancy
- Recommended Regimen for **Tertiary Syphilis Among Adults**

- Tertiary syphilis with *normal CSF examination*:
    - Benzathine penicillin G 7.2 million units total, administered as 3 doses of 2.4 million units IM each at 1-week intervals
- Recommended Regimen for **Neurosyphilis, Ocular Syphilis, or Otosyphilis Among Adults**
    - Aqueous crystalline penicillin G 18–24 million units per day, administered as 3–4 million units IV every 4 hours or continuous infusion for 10–14 days
- Alternative Regimen
    - Procaine penicillin G 2.4 million units IM once daily
    - plus
    - Probenecid 500 mg orally 4 times/day, both for 10–14 days
- Recommended Regimen for ***Syphilis During Pregnancy***
    - Pregnant women should be treated with the recommended penicillin regimen for their stage of infection
    - Recommended Regimens, Confirmed or Highly Probable Congenital Syphilis
    - Aqueous crystalline penicillin G 100,000–150,000 units/kg/body weight/day, administered as 50,000 units/kg body weight/dose IV every 12 hours during the first 7 days of life and every 8 hours thereafter for a total of 10 days
        - or
    - Procaine penicillin G 50,000 units/kg body weight/dose IM in a single daily dose for 10 days

Diseases Characterized by Urethritis and Cervicitis

Urethritis

- Urethritis, as characterized by urethral inflammation, can result from either infectious or noninfectious conditions. Symptoms, if present, include dysuria, urethral pruritis, and mucoid, mucopurulent, or purulent discharge. Signs of urethral discharge on examination can also be present among persons without symptoms. Although *N. gonorrhoeae* and *C. trachomatis* are well established as clinically important infectious causes of urethritis, *M. genitalium* has been strongly associated with urethritis and, less commonly, prostatitis
- Adenovirus can present with dysuria, meatal inflammation, and conjunctivitis. Other bacterial pathogens have been implicated as potential causes of clinical urethritis, either in clustered case series or as sporadic cases such as *Haemophilus influenzae* and *Haemophilus parainfluenzae*

Nongonococcal Urethritis

- NGU is a nonspecific diagnosis that can have various infectious etiologies
- C. trachomatis
- Recommended Regimen for Nongonococcal Urethritis
    - Doxycycline 100 mg orally 2 times/day for 7 days
- Alternative Regimens
    - Azithromycin 1 g orally in a single dose
        - or
    - Azithromycin 500 mg orally in a single dose; then 250 mg orally daily for 4 days

Cervicitis

- Two major diagnostic signs characterize cervicitis:
    - 1) a purulent or mucopurulent endocervical exudate visible in the endocervical canal or on an endocervical swab specimen (commonly referred to as mucopurulent cervicitis), and
    - 2) sustained endocervical bleeding easily induced by gentle passage of a cotton swab through the cervical os
- Recommended Regimen for Cervicitis*

    - Doxycycline 100 mg orally 2 times/day for 7 days
- Consider concurrent treatment for gonococcal infection if the patient is at risk for gonorrhea or lives in a community where the prevalence of gonorrhea is high (see Gonococcal Infections).
- Alternative Regimen
    - Azithromycin 1 g orally in a single dose

Chlamydial Infections

- Chlamydial Infection Among Adolescents and Adults
- Multiple sequelae can result from *C. trachomatis* infection among women, the most serious of which include PID, ectopic pregnancy, and infertility. Certain women who receive a diagnosis of uncomplicated
- Recommended Regimen for **Chlamydial Infection Among Adolescents and Adults**
    - Doxycycline 100 mg orally 2 times/day for 7 days
- Alternative Regimens
    - Azithromycin 1 g orally in a single dose
        - or
    - Levofloxacin 500 mg orally once daily for 7 days
- Recommended Regimen for **Chlamydial Infection During Pregnancy**
    - Azithromycin 1 g orally in a single dose
- Alternative Regimen
    - Amoxicillin 500 mg orally 3 times/day for 7 days
- Recommended Regimens for **Chlamydial Infection Among Infants and Children**
- For infants and children weighing <45 kg:
    - Erythromycin base or ethyl succinate 50 mg/kg body weight/day orally divided into 4 doses daily for 14 days
- Data are limited regarding the effectiveness and optimal dose of azithromycin for treating chlamydial infection among infants and children weighing <45 kg.
- For children weighing ≥45 kg but aged <8 years:
    - Azithromycin 1 g orally in a single dose
- For children aged ≥8 years:
    - Azithromycin 1 g orally in a single dose
        - or
    - Doxycycline 100 mg orally 2 times/day for 7 days

Gonococcal Infections

- Gonococcal Infection Among Adolescents and Adults
- Uncomplicated Gonococcal Infection of the Cervix, Urethra, or Rectum
- Recommended Regimen for Uncomplicated Gonococcal Infection of the Cervix, Urethra, or Rectum **Among Adults and Adolescents**
    - Ceftriaxone 500 mg* IM in a single dose for persons weighing <150 kg
- If chlamydial infection has not been excluded, treat for chlamydia with
    - doxycycline 100 mg orally 2 times/day for 7 days.
- For persons weighing ≥150 kg,
    - 1 g ceftriaxone should be administered.
- Recommended Regimen for Gonococcal Conjunctivitis Among Adolescents and Adults
    - Ceftriaxone 1 g IM in a single dose
- Providers should consider one-time lavage of the infected eye with saline solution

Treatment of Gonococcal Meningitis and Endocarditis

- Recommended Regimen for Gonococcal Meningitis and Endocarditis
    - Ceftriaxone 1–2 g IV every 24 hours

- If chlamydial infection has not been excluded, providers should treat for chlamydia with
    - doxycycline 100 mg orally 2 times/day for 7 days.
- Recommended Regimen to Prevent Ophthalmia Neonatorum Caused by *N. gonorrhoeae*
    - Erythromycin 0.5% ophthalmic ointment in each eye in a single application at birth

Mycoplasma genitalium

- *M. genitalium* causes symptomatic and asymptomatic urethritis among men
- Diseases Characterized by Vulvovaginal Itching, Burning, Irritation, Odor, or Discharge
- The majority of women will have a vaginal infection, characterized by discharge, itching, burning, or odor, during their lifetime

Bacterial Vaginosis

- BV is a vaginal dysbiosis resulting from replacement of normal hydrogen peroxide and lactic-acid–producing *Lactobacillus* species in the vagina with high concentrations of anaerobic bacteria, including *G. vaginalis*, *Prevotella* species, *Mobiluncus* species, *A. vaginae*, and other BV-associated bacteria
- Recommended Regimens for Bacterial Vaginosis
    - Metronidazole 500 mg orally 2 times/day for 7 days
        - or
    - Metronidazole gel 0.75% one full applicator (5 g) intravaginally, once daily for 5 days
        - or
    - Clindamycin cream 2% one full applicator (5 g) intravaginally at bedtime for 7 days
- Alternative Regimens
    - Clindamycin 300 mg orally 2 times/day for 7 days
        - or
    - Clindamycin ovules 100 mg intravaginally once at bedtime for 3 days*
        - or
    - Secnidazole 2 g oral granules in a single dose†
        - or
    - Tinidazole 2 g orally once daily for 2 days
        - or
    - Tinidazole 1 g orally once daily for 5 days
- * Clindamycin ovules use an oleaginous base

Vulvovaginal Candidiasis

- VVC usually is caused by *Candida albicans* but can occasionally be caused by other *Candida* species or yeasts. Typical symptoms of VVC include pruritus, vaginal soreness, dyspareunia, external dysuria, and abnormal vaginal discharge.
- Recommended Regimens for Vulvovaginal Candidiasis
    - Over-the-Counter Intravaginal Agents
        - Clotrimazole 1% cream 5 g intravaginally daily for 7–14 days
            - or
        - Clotrimazole 2% cream 5 g intravaginally daily for 3 days
            - or
        - Miconazole 2% cream 5 g intravaginally daily for 7 days
            - or
        - Miconazole 4% cream 5 g intravaginally daily for 3 days
            - or
        - Miconazole 100 mg vaginal suppository one suppository daily for 7 days
            - or
        - Miconazole 200 mg vaginal suppository one suppository for 3 days

        - or
      - Miconazole 1,200 mg vaginal suppository one suppository for 1 day
        - or
      - Tioconazole 6.5% ointment 5 g intravaginally in a single application
    - Prescription Intravaginal Agents
      - Butoconazole 2% cream (single-dose bioadhesive product) 5 g intravaginally in a single application
        - or
      - Terconazole 0.4% cream 5 g intravaginally daily for 7 days
        - or
      - Terconazole 0.8% cream 5 g intravaginally daily for 3 days
        - or
      - Terconazole 80 mg vaginal suppository one suppository daily for 3 days
    - Oral Agent
      - Fluconazole 150 mg orally in a single dose

Pelvic Inflammatory Disease

- Pelvic inflammatory disease (PID) is an infectious and inflammatory disorder of the upper female genital tract, including the uterus, fallopian tubes, and adjacent pelvic structures. Infection and inflammation may spread to the abdomen, including perihepatic structures (Fitz-Hugh−Curtis syndrome). The classic high-risk patient is a menstruating woman younger than 25 years who has multiple sex partners, does not use contraception, and lives in an area with a high prevalence of sexually transmitted disease (STD).
- Signs and symptoms of pelvic inflammatory disease
- The diagnosis of acute PID is primarily based on historical and clinical findings. Clinical manifestations of PID vary widely. Many patients exhibit few or no symptoms, whereas others have acute, serious illness. The most common presenting complaint is lower abdominal pain. Many women report an abnormal vaginal discharge.
- Diagnosis of pelvic inflammatory disease

Differential diagnosis

- includes appendicitis, cervicitis, urinary tract infection, endometriosis, ovarian torsion, and adnexal tumors. Ectopic pregnancy can be mistaken for PID; indeed, PID is the most common incorrect diagnosis in cases of ectopic pregnancy. Consequently, a pregnancy test is mandatory in the workup of women of childbearing age who have lower abdominal pain.
- PID may produce tubo-ovarian abscess (TOA) and may progress to peritonitis and Fitz-Hugh−Curtis syndrome (perihepatitis;). [1] Note that a rare but life-threatening complication of acute rupture of a TOA may result in diffuse peritonitis and necessitate urgent abdominal surgery.

Treatment

- PID treatment regimens should provide empiric, broad-spectrum coverage of likely pathogens. Multiple parenteral and oral antimicrobial regimens have been effective in achieving clinical and microbiologic cure in randomized clinical trials with short-term follow-up
- Recommended Parenteral Regimens for Pelvic Inflammatory Disease
  - Ceftriaxone 1 g by every 24 hours
  - plus
  - Doxycycline 100 mg orally or IV every 12 hours
  - plus
  - Metronidazole 500 mg orally or IV every 12 hours
    - or
  - Cefotetan 2 g IV every 12 hours
  - plus

    - Doxycycline 100 mg orally or IV every 12 hours
        - or
    - Cefoxitin 2 g IV every 6 hours
    - plus
    - Doxycycline 100 mg orally or IV every 12 hours
- Alternative Parenteral Regimens
    - Ampicillin-sulbactam 3 g IV every 6 hours
    - plus
    - Doxycycline 100 mg orally or IV every 12 hours
        - or
    - Clindamycin 900 mg IV every 8 hours
    - plus
    - Gentamicin loading dose IV or IM (2 mg/kg body weight), followed by a maintenance dose (1.5 mg/kg body weight) every 8 hours; single daily dosing (3–5 mg/kg body weight) can be substituted
- Recommended Intramuscular or Oral Regimens for Pelvic Inflammatory Disease
    - Ceftriaxone 500 mg* IM in a single dose
    - plus
    - Doxycycline 100 mg orally 2 times/day for 14 days with metronidazole 500 mg orally 2 times/day for 14 days
        - or
    - Cefoxitin 2 g IM in a single dose and probenecid 1 g orally administered concurrently in a single dose
    - plus
    - Doxycycline 100 mg orally 2 times/day for 14 days with metronidazole 500 mg orally 2 times/day for 14 days
        - or
    - Other parenteral third-generation cephalosporin (e.g., ceftizoxime or cefotaxime)
    - plus
    - Doxycycline 100 mg orally 2 times/day for 14 days with metronidazole 500 mg orally 2 times/day for 14 days
- * For persons weighing ≥150 kg, 1 g of ceftriaxone should be administered

Epididymitis

- Acute epididymitis is a clinical syndrome causing pain, swelling, and inflammation of the epididymis and lasting <6 weeks (*1191*). Sometimes a testicle is also involved, a condition referred to as epididymo-orchitis
- Acute epididymitis can be caused by STIs (e.g., *C. trachomatis, N. gonorrhoeae*, or *M. genitalium*) or enteric organisms (i.e., *Escherichia coli*) (*1192*). Acute epididymitis caused by an STI is usually accompanied by urethritis, which is frequently asymptomatic. Acute epididymitis caused by sexually transmitted enteric organisms might also occur among men who are the insertive partner during anal sex.
- Nonsexually transmitted acute epididymitis caused by genitourinary pathogens typically occurs with bacteriuria secondary to bladder outlet obstruction (e.g., benign prostatic hyperplasia
- Recommended Regimens for Epididymitis
- For acute epididymitis most likely caused by chlamydia or gonorrhea:
    - Ceftriaxone 500 mg* IM in a single dose
    - plus
    - Doxycycline 100 mg orally 2 times/day for 10 days
- For acute epididymitis **most likely caused by chlamydia, gonorrhea, or enteric organisms (men who practice insertive anal sex):**
    - Ceftriaxone 500 mg* IM in a single dose

    - plus
    - Levofloxacin 500 mg orally once daily for 10 days
- For acute epididymitis most likely caused by enteric organisms only:
    - Levofloxacin 500 mg orally once daily for 10 days
- * For persons weighing ≥150 kg,
    - 1 g of ceftriaxone should be
- Levofloxacin monotherapy should be considered if the infection is most likely caused by enteric organisms only, and gonorrhea has been ruled out by Gram, MB, or GV stain

Human Papillomavirus Infections

- Approximately 150 types of HPV have been identified, at least 40 of which infect the genital area (*1194*). The majority of HPV infections are self-limited and are asymptomatic or unrecognized. Sexually active persons are usually exposed to HPV during their lifetime

Treatment

- Treatment is directed to the macroscopic (e.g., genital warts) or pathologic precancerous lesions caused by HPV. Subclinical genital HPV infection typically clears spontaneously; therefore, specific antiviral therapy is not recommended to eradicate HPV infection.
- Precancerous lesions are detected through cervical cancer screening; HPV-related precancer should be managed on the basis of existing guidance (see Cervical Cancer).

Anogenital Warts

- Anogenital warts are a common disease, and 90% are caused by nononcogenic HPV types 6 or 11. These types can be commonly identified before or at the same time anogenital warts are detected

Treatment

- The aim of treatment is removal of the warts and amelioration of symptoms, if present
    - Surgical removal by tangential scissor excision, tangential shave excision, curettage, laser, or electrosurgery
        - or
    - Trichloroacetic acid (TCA) or bichloroacetic acid (BCA) 80%–90% solution
- Persons with external anal or perianal warts might also have intra-anal warts. Thus, persons with external anal warts might benefit from an inspection of the anal canal by digital examination, standard anoscopy, or high-resolution anoscopy.
- Might weaken condoms and vaginal diaphragms.
- Recommended Regimens for External Anogenital Warts (i.e., Penis, Groin, Scrotum, Vulva, Perineum, External Anus, or Perianus)*
- Patient-applied:
    - Imiquimod 3.75% or 5% cream†
        - or
    - Podofilox 0.5% solution or gel
        - or
    - Sinecatechins 15% ointment†
- Provider-administered:
    - Cryotherapy with liquid nitrogen or cryoprobe
- Recommended Regimens for Urethral Meatus Warts
    - Cryotherapy with liquid nitrogen
        - or
    - Surgical removal

Cancers and Precancers Associated with Human Papillomavirus

- Persistent infection with high-risk (oncogenic) types of HPV has a causal role in approximately all cervical cancers and in certain vulvar, vaginal, penile, anal, and oropharyngeal cancers (*1238*). However, cervical cancer is the only HPV-associated cancer for which routine screening is recommended

Prevention

- Three HPV vaccines can prevent diseases and cancers caused by HPV

Treatment

- Treatment is directed to the macroscopic (e.g., genital warts) or pathologic precancerous lesions caused by HPV. Subclinical genital HPV infection typically clears spontaneously; therefore, specific antiviral therapy is not recommended to eradicate HPV infection. Precancerous lesions are detected through cervical cancer screening; HPV-related precancer should be managed on the basis of existing guidance

Cervical Cancer

- Recommendations for cervical cancer screening. Clinics should weigh the benefits of each screening strategy as well as their resources, such as time and cost.
- The following additional management considerations are associated with performing Pap tests and HPV tests:
    - Cytology (Pap tests) and HPV tests should not be considered screening tests for STIs.
- All persons with a cervix should receive cervical cancer screening, regardless of sexual orientation or gender identity (i.e., those who identify as lesbian, bisexual, heterosexual, or transgender).
- A conventional cytology test (in which the sample is smeared onto a dry slide) should ideally be scheduled for 10–20 days after the first day of menses. Liquid-based cytology can be performed at any time during the menstrual cycle.
- If specific infections other than HPV (e.g., chlamydia or gonorrhea) are identified at the visit, a repeat cytology test after appropriate treatment for those infections might be indicated. However, in most instances (even in the presence of certain severe cervical infections), cytology tests will be reported as satisfactory for evaluation, and reliable final reports can be produced without the need to repeat the cytology test after treatment.

Proctitis, Proctocolitis, and Enteritis

- Sexually transmitted gastrointestinal syndromes include proctitis, proctocolitis, and enteritis. Evaluation for these syndromes should include recommended diagnostic procedures, including anoscopy or sigmoidoscopy, stool examination for WBCs, and microbiologic workup (e.g., gonorrhea, chlamydia [LGV PCR if available], herpes simplex NAAT, and syphilis serology). For those with enteritis, stool culture or LGV PCR also is recommended.
- Proctitis is inflammation of the rectum (i.e., the distal 10–12 cm) that can be associated with anorectal pain, tenesmus, or rectal discharge. Fecal leukocytes are common. Proctitis occurs predominantly among persons who have receptive anal exposures (oral-anal, digital-anal, or genital-anal). *N. gonorrhoeae, C. trachomatis* (including LGV serovars), HSV, and *T. pallidum* are the most common STI pathogens. Genital HSV and LGV proctitis are more prevalent among persons with HIV infection (*545,556,1382*). *M. genitalium* has been detected in certain cases of proctitis and might be

Diagnostic and Treatment Considerations for Acute Proctitis

- Persons with symptoms of acute proctitis should be examined by anoscopy. A Gram-stained smear of any anorectal exudate from anoscopic or anal examination should be examined for polymorphonuclear leukocytes

- Recommended Regimen for Acute Proctitis
    - Ceftriaxone 500 mg* IM in a single dose
    - plus
    - Doxycycline 100 mg orally 2 times/day for 7 days†
- * For persons weighing ≥150 kg,
    - 1 g of ceftriaxone should be administered.
    - † Doxycycline course should be extended to 100 mg orally 2 times/day for 21 days in the presence of bloody discharge, perianal or mucosal ulcers, or tenesmus and a positive rectal chlamydia test.

Diagnostic and Treatment Considerations for Proctocolitis or Enteritis

- Treatment for proctocolitis or enteritis should be directed to the specific enteric pathogen identified. Multiple stool examinations might be necessary for detecting *Giardia*, and special stool preparations are required for diagnosing cryptosporidiosis and microsporidiosis.

Ectoparasitic Infections

Pediculosis Pubis

- Persons who have pediculosis pubis (i.e., pubic lice) usually seek medical attention because of pruritus or because they notice lice or nits on their pubic hair. Pediculosis pubis is caused by the parasite *Phthirus pubis* and is usually transmitted by sexual contact (*1393*).

Diagnosis

- The clinical diagnosis is based on typical symptoms of itching in the pubic region. Lice and nits can be observed on pubic hair

Treatment

- Recommended Regimens for Pediculosis Pubis
    - Permethrin 1% cream rinse applied to affected areas and washed off after 10 minutes
        - or
    - Pyrethrin with piperonyl butoxide applied to the affected area and washed off after 10 minutes
- Alternative Regimens
    - Malathion 0.5% lotion applied to affected areas and washed off after 8–12 hours
        - or
    - Ivermectin 250 μg/kg body weight orally, repeated in 7–14 days

Scabies

- Scabies is a skin infestation caused by the mite *Sarcoptes scabiei*, which causes pruritus. Sensitization to *S. scabiei* occurs before pruritus begins. The first time a person is infested with *S. scabiei*, sensitization takes weeks to develop
- The first time a person is infested with *S. scabiei*, sensitization takes weeks to develop. However, pruritus might occur <24 hours after a subsequent reinfestation. Scabies amo
- Recommended Regimens for Scabies
    - Permethrin 5% cream applied to all areas of the body from the neck down and washed off after 8–14 hours
        - or
    - Ivermectin 200 ug/kg body weight orally, repeated in 14 days*
        - or
    - Ivermectin 1% lotion applied to all areas of the body from the neck down and washed off after 8–14 hours; repeat treatment in 1 week if symptoms persist
- * Oral ivermectin has limited ovicidal activity; a second dose is required for eradication.

Sexual Assault and Abuse and STIs

Adolescents and Adults

- These guidelines are primarily limited to the identification, prophylaxis, and treatment of STIs and conditions among adolescent and adult female sexual assault survivors Documentation of findings, collection of non microbiologic specimens for forensic purposes, and management of potential pregnancy or physical and psychological trauma are beyond the scope of these guidelines. Examinations of survivors of sexual assault should be conducted by an experienced clinician in a way that minimizes further trauma to the person. The decision to obtain genital or other specimens for STI diagnosis should be made on an individual basis.
- **Trichomoniasis, BV, gonorrhea, and chlamydia** are the most frequently diagnosed infections among women who have been sexually assaulted
- Recommended Regimen for Adolescent and Adult Female Sexual Assault Survivors
    - Ceftriaxone 500 mg* IM in a single dose
    - plus
    - Doxycycline 100 mg 2 times/day orally for 7 days
    - plus
    - Metronidazole 500 mg 2 times/day orally for 7 days
- For persons weighing ≥150 kg,
    - 1 g of ceftriaxone should be
- Recommended Regimen for Adolescent and Adult Male Sexual Assault Survivors
    - Ceftriaxone 500 mg* IM in a single dose
    - plus
    - Doxycycline 100 mg 2 times/day orally for 7 days
- For persons weighing ≥150 kg,
    - 1 g of ceftriaxone should be administered.

Reference:

1. STI Guideline 2021
2. WHO Guideline
3. https://encrypted-tbn0.gstatic.com/images?q=tbn:ANd9GcQpBJilC9Ep9rDnnQ08UuA_UA_chj8rEOe67g&usqp=CAU
4. https://data.unhcr.org/images/documents/big_3557cf4ee194e26dc3a500b6db4c154a4b32bb5e.jpg

Urethral Discharge

- Urethral Discharge (Pus or muco-purulent)
- Pain or burning while passing urine
- Increased frequency of urination
- Systemic symptoms like malaise, fever

Tab. Azithromycin 1 gm
OD Stat +
Tab. Cefixime 400 mg
OD Stat

KIT 1/Grey



Treat all recent partners

Cervical Discharge

- Nature and type of discharge (quantity, color and odor)
- Burning while passing urine, increased frequency
- Genital complaints by sexual partners
- Low backache
  (Take menstrual history to rule out pregnancy)

Tab. Azithromycin 1 gm
OD Stat +
Tab. Cefixime 400 mg
OD Stat

KIT 1/Grey



Treat partners when symptomatic

Painful Scrotal Swelling

- Swelling and pain in the scrotal region
- Pain or burning while passing urine
- Systemic symptoms like malaise, fever
- History of urethral discharge

Tab. Azithromycin 1 gm
OD Stat +
Tab. Cefixime 400 mg
OD Stat

KIT 1/Grey

Treat all recent partners

Vaginal Discharge

- Nature and type of discharge (quantity, color and odor)
- Burning while passing urine, increased frequency
- Genital complaints by sexual partners
- Low backache
  (Take menstrual history to rule out pregnancy)

Tab. Secnidazole 2 g
OD Stat +
Cap. Fluconazole 150 mg
OD Stat

KIT 2/Green

Treat partners when symptomatic

Genital Ulcer-Non Herpetic

- Genital ulcer, single or multiple, painful or painless
- Burning sensation in the genital area
- Enlarged lymph nodes

Inj. Benzathine penicillin
(2.4 MU) - 1 vial
Tab. Azithromycin (1 gm) -
Single dose

KIT 3/White

If allergic to Inj. Penicillin:
Doxycycline 100 MG
(Bid for 15 days)
Azithromycin 1GM (Single dose)

KIT 4/Blue



Treat all sexual partners for past 3 months

https://encrypted-tbn0.gstatic.com/images?q=tbn:ANd9GcQpBJilC9Ep9rDnnQ08UuA_UA_chj8rEOe67g&usqp=CAU



https://data.unhcr.org/images/documents/big_3557cf4ee194e26dc3a500b6db4c154a4b32bb5e.jpg






3. GENITAL ULCERS
Patient complains of a genital sore or ulcer
Take history and examine
Vesicles, Sore or Ulcer present?
No
Yes
1. Counsel on risk reduction
2. Promote and provide condoms
3. Offer HIV Counseling and Testing
1. Treat for syphilis
• Benzathine benzylpenicillin 2.4 million IU deep IM single dose
2. Treat for Chancroid
• Azithromycin 1 g orally, single dose
Keep ulcer dry and clean
1. Counsel on risk reduction
2. Promote and provide condoms
3. Offer HIV Counseling and Testing
4. Review in 7 days, if not healed or improved, refer if possible


4. INGUINAL BUBO
Patient complains of inguinal swelling
Take history and examine
Inguinal and femoral bubo(s) present?
No
Yes
Any other genital disease?
Ulcers present?
No
Yes
No
Yes
1. Counsel on risk reduction
2. Promote and provide condoms
3. Offer HIV Counseling and Testing
Use appropriate flow chart
1. Treat for Lymphogranuloma venerum (LGV)
• Doxycycline¹ 100mg x 2/day x 14 days
2. Treat for chancroid
• Azithromycin 1 g single oral dose
OR
• Ciprofloxacin¹ orallly 500mg x 2/ day for 3 days
OR
• Erythromycin¹ orally 500mg x 4/day for 7 days
3. If patient is pregnant, breastfeeding or under 16 years old:
• Erythromycin 500mg x 4/day x 14 days (for both LGV and chancroid)
4. DO NOT INCISE
5. Treatment of bubo requires aspiration
6 REFER, if necessary
7. Educate on treatment compliance
Use genital ulcer flow chart
1. Counsel on risk reduction
2. Promote and provide condoms
3. Offer HIV Counseling and Testing
4. Manage and treat partner
5 Review in 7 days and continue treatment if improving or refer if worse


5. SCROTAL SWELLING
Patient complaints of scrotal swelling/ pain
Take history and examine
Swelling/ pain confirmed?
No
Yes
Testis rotated, elevated or history of trauma?
No
Yes
1. Treat for gonococcal infection
• Cefixime 400mg single oral dose
2. Treat for chlamydia infection
• Azithromycin 1 g single oral dose
Refer urgently for surgical opinion
• Reassure patient and educate
• Provide analgesics, if necessary
• Promote and provide condoms
• Offer HIV Counseling and Testing.
1. Counsel on risk reduction
2. Promote and provide condoms
3. Offer HIV Counseling and Testing
4. Manage and treat Partner
5. Review in 7 days or earlier, if necessary, if worse refer


6. LOWER ABDOMINAL PAIN
Patient complains of lower abdominal pain
Take history and conduct abdominal and vaginal examination
Any of the following present?
• Missed/overdue periods
• Recent delivery, abortion or miscarriage
• Abdominal guarding and/or rebound tenderness
• Abnormal vaginal bleeding
• Abdominal mass
No
Yes
1. Set up an IV line and apply resuscitatory measures if necessary
2. Refer for surgical and gynaecological opinion and assessment
Lower abdominal tenderness?
No
Yes
Any vaginal discharge?
No
Yes
Follow vaginal discharge flow chart
Any other illnesses?
No
Yes
Manage appropri-ately
1. Counsel on risk reduction
2. Promote and provide condoms
3. Offer HIV Counseling and Testing
Refer to higher level care for Rx which includes:
1.Cefixime 400mg single dose
2. • Azithromycine 1 g single dose OR
• Doxycycline 100mg x 2/day x 14 days
3.Metronidazole 500mg x 2 /day for 14 days
4. Review in 3 days
1. Continue treatment until completed
2. Counsel on risk reduction
3. Promote and provide con-doms
4. Offer HIV Counseling and Testing
5. Ask patient to return if necessary
Has the patient improved?
• Absence of fever
• Reduction in abdominal tenderness
No
REFER
Yes


7. NEONATAL CONJUNCTIVITIS
(Ophthalmia neonatorum)
Neonate with eye discharge
Take history and examine
Bilateral or unilateral swollen eyelids and purulent discharge?
No
yes
• Reassure mother
• Advise return, if necessary
1. Treat for gonococcal infection
• Cefixime, oral suspension, 8mg/kg body wt., single dose
2. Treat for chlamydia infection
• Azithromycin,suspension, 200 mg/5ml, give 10mg/kg body wt. single dose
3. Treat mother and her sexual partner(s) for gonorrhoea and chlamydia (see flowchart for vaginal discharge)
1. Educate mother
2. Counsel mother
3. Advise to return on the 3rd day
Improved?
No
Yes
REFER
1. Reassure mother
2. Continue treatment for 14 days
3. Educate mother
4. Counsel mother

HEPATITIS B (ENVELOPED DNA VIRUS)

- Common, Endemic in much of Asia and the Far East
- *National -wide prevalence* 6.5% (5/2015, Dept of Medical Research and Dept. of Public Health)
- The virus has 3 major structural antigens: HBsAg, HBcAg, HBeAg. Spread is via infected blood, sexual intercourse, from mother to newborn baby, or via human bites.
- *Incubation period* is 6- 23 weeks (average l 7weeks)
- HBV infection can be either acute or chronic and the associated illness ranges in severity from asymptomic to symptomic, progressive disease (cirrhosis, HCC).
- Antiviral agents active against HBV are available, and have been shown to suppress HBV replication, prevent to progression cirrhosis and reduce the risk of HCC and liver related deaths.
- However, currently available treatments fail to eradicate the virus in most of those treated, necessitating potentially lifelong treatment.



Summary of recommendations for persons with chronic hepatitis B infection

Non-invasive assessment of liver disease stage at baseline and during follow up

	APRI (aspartate aminotransferase [AST] to-platelet ratio index) is recommended as the preferred non-invasive test (NIT) to assess for the presence of cirrhosis (APRI score >2 in adults) in resource-limited settings. Transient elastography (e.g. Fibro Scan) or Fibro Test may be the preferred NITs in settings where they are available and cost is not a major constraint. (Conditional recommendation, low quality of evidence)

Who to treat and who not to treat in persons with chronic hepatitis B

Who to treat	*As a priority, all adults, adolescents and children with CHB and clinical evidence of compensated or decompensated cirrhosis (or cirrhosis based on APRI score >2 in adults) should be treated, regardless of ALT levels, HBeAg status or HBV DNA levels. (strong recommendation, moderate quality of evidence)* *Treatment is recommended for adults with CHB who do not have clinical evidence of cirrhosis (or based on APRI score: SI in adults), but are aged more than 30 years (in particular), and have persistently abnormal ALT levels and evidence of high-level HBV replication (HBV DNA >20 000 IU/L), regardless of HBeAg status. (strong recommendation, moderate quality of evidence)* *Where HBV DNA testing is not available. Treatment may be considered based on persistently abnormal ALT levels alone, regardless of HBeAg status. (Conditional recommendation, low quality of evidence).*
Existing recommendation for HBV/HIV-coinfected persons	*In HBV/HIV-coinfected adults, adolescents and children aged 3 years or older, tenofovir, tenofovir + lamivudine (or emtricitabine) + efavirenz as a fixed-dose combination is recommended as the preferred option to initiate ART. (Strong recommendation, moderate quality of evidence)* *Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach.*

Second-line antiviral therapies for the management of treatment failure

	In persons with confirmed or suspected antiviral resistance (i.e. history of prior exposure or primary non-response) to lamivudine, entecavir, adefovir or telbivudine, a switch to tenofovir 300 mg od is recommended. (Strong recommendation, low quality of evidence)

When to stop treatment

Lifelong NA therapy	*All persons **with cirrhosis** based on clinical evidence (or APRI score >2 in adults) require lifelong treatment with nucleos(t)ide analoges (NAs), and should not discontinue antiviral therapy because of the risk of reactivation, which can cause severe acute-on-chronic liver injury. (Strong recommendation, low quality of evidence)*
Discontinuation	*All persons **with cirrhosis** based on clinical evidence (or APRI score >2 in adults) require lifelong treatment with nucleos(t)ide*

	analoges (NAs), and should not discontinue antiviral therapy because of the risk of reactivation, which can cause severe acute-on-chronic liver injury. (Strong recommendation, low quality of evidence)
Discontinuation	*Discontinuation of NA therapy may be considered exceptionally in:* *Persons without clinical evidence of cirrhosis (or based on APRI score ≤2 in adults);* ***And** who can be followed carefully long term for reactivation;* ***And** if there is evidence of HBeAg loss and seroconversion to anti-HBe (in persons initially HBeAg positive) and after completion of at least one additional year of treatment;* ***And** in association with persistently normal ALT levels **and** persistently undetectable HBV DNA levels (where HBV DNA testing is available).* *Where HBV DNA testing is not available: Discontinuation of NA therapy may be considered in persons who have evidence of persistent HBsAg loss and after completion of at least one additional year of treatment, regardless of prior HBeAg status. (Conditional recommendation, low quality of evidence)*
Retreatment	*Relapse may occur after stopping therapy with NAs. Retreatment is recommended if there are consistent signs of reactivation (HBsAg or HBeAg becomes positive, ALT levels increase, or HBV DNA becomes detectable again) (where HBV DNA testing is available). (Strong recommendation, low quality of evidence)*

Monitoring

Monitoring for disease progression and treatment response in persons with CHB prior to, during and post-treatment	
	It is recommended that the following be monitored at least annually: *ALT level (and AST for APRI), HBsAg, HBeAg, and HBV DNA levels (where HBV DNA testing is available)* *Non-invasive tests (APRI score or Fibro scan) to assess for the presence of cirrhosis, in those without cirrhosis at baseline;* *If on treatment, adherence should be monitored regularly and at each visit.* *(Strong recommendation, moderate quality of evidence)*
More frequent monitoring	*In persons who do not yet meet the criteria for antiviral therapy: more frequent monitoring for disease progression may be indicated in: persons who have intermittently abnormal ALT levels or HBV DBA levels that fluctuate between 2,000 - 20,000 IU/ml (where HBV DNA testing is available), and in HIV-*

	coinfected persons, (Conditional recommendation, low quality of evidence) *In persons on treatment or following treatment discontinuation: More frequent on-treatment monitoring (at least every 3 months for the first year) is indicated in: persons with more advanced disease (compensated or decompensated cirrhosis): during the first year of treatment to assess treatment response and adherence; where treatment adherence is a concern; in HIV-coinfected persons; and in persons after discontinuation of a treatment. (Conditional recommendation, very low quality of evidence)*

Monitoring for tenofovir and entecavir toxicity

	Measurement of baseline renal function and assessment of baseline risk for renal dysfunction should be considered in all persons prior to initation of antiviral therapy. *Renal function should be monitored annually in persons on long-term tenofovir or entecavir therapy, and growth monitored carefully in children. (Conditional recommendation, very low quality of evidence)*

Monitoring for hepatocellular carcinoma

	Routine surveillance for HCC with abdominal ultrasound and alpha-fetoprotein (AFP) testing every six months is recommended for: • *Persons with cirrhosis, regardless of age or other risk factors (strong recommendation, low quality of evidence)* • *Persons with a family history of HCC (Strong recommendation, low quality of evidence)* • *Persons aged over 40 years (lower age may apply according to regional incidence of HCC), without clinical evidence of cirrhosis (or based on APRI score ::::2),and with HBV DNA level >2000 IU/ml (where HBV DNA testing is available). (Conditional recommendation, low quality of evidence)*

Prevention

Infant and neonatal hepatitis B vaccination	
Existing recommendations in infants and neonates[1]	*All infants should receive their first dose of hepatitis B vaccine as soon as possible after birth, preferably within 24 hours, followed by two or three* *doses.*

	[1]WHO. Hep atitis B vaccines. Wkly Epid emiol Rec. 2009;84:405-20.

Prevention of mother-to-child HBV transmission using antiviral therapy

	In HBV-monoinfected pregnant women, the indications for treatment are the same as for other adults, and tenofovir is recommended. No recommendation was made on the routine use of antiviral therapy to prevent mother-to-child HBV transmission.
Existing recommendations in HIV-infected pregnant and breastfeeding women	*In HIV-infected pregnant and breastfeeding women (including pregnant women in the first trimester of pregnancy and women of childbearing age), a once-daily fixed-dose combination of tenofovir + lamivudine (or emtricitabine) + efavirenz is recommended as first-line ART. This recommendation applies both to lifelong treatment and to ART initiated for PMTCT and then stopped. (Strong recommendation, low to moderate quality of evidence)* [2]*Consolidated guidelines on the use of antiretroviral drugsfor treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization; 2013. These guidelines will be updated in 2015.*

Prevention

- WHO recommends implementation of blood safety strategies and safer sex practices, including minimizing the number of partners and using barrier protective measures (condoms), also protect against transmission.

Management of Persons Who Are HBsAg Positive

Recommendations for management of all persons with HBsAg include the following:

- To verify the presence of chronic HBV infection, persons with HBsAg should be retested.
- The absence of IgM anti-HBc or the persistence of HBsAg for ≥6 months indicates chronic HBV infection.
- Persons with chronic HBV infection should be referred for evaluation to a specialist experienced in managing chronic hepatitis B infection.
- Household, sexual, and needle-sharing contacts of persons with chronic infection should be evaluated. Unvaccinated sex partners and household and needle-sharing contacts should be tested for susceptibility to HBV infection and receive the first dose of hepatitis B vaccine immediately after collection of the blood sample for serologic testing (see Prevaccination Serologic Testing).
- Susceptible persons should complete the vaccine series by using an age-appropriate vaccine dose and schedule.
- Sex partners of persons with HBsAg should be counseled to use latex condoms to protect themselves from sexual exposure to infectious body fluids (e.g., semen and vaginal secretions), unless they have been demonstrated to be immune after vaccination (anti-HBs ≥10 mIU/mL) or previously infected (anti-HBc positive).

To prevent or reduce the risk for transmission to others in addition to vaccination,

- persons with HBsAg also should be advised to use methods (e.g., condoms) to protect nonimmune sex partners from acquiring HBV infection from sexual activity until the partner can be vaccinated and immunity documented;
- cover cuts and skin lesions to prevent spread by infectious secretions or blood;
- refrain from donating blood, plasma, body organs, other tissue, or semen;
- and refrain from sharing household articles (e.g., toothbrushes, razors, or personal injecting equipment) that could become contaminated with blood, and refrain from premastication of food.

To protect the liver from further harm, persons with HBsAg should be advised

- to avoid or limit alcohol consumption because of the effects of alcohol on the liver;
- refrain from starting any new medicines, including over-the-counter and herbal medicines, without checking with their health care provider; and obtain vaccination against hepatitis A.

When seeking medical or dental care, persons who are HBsAg positive should be advised

- to inform their health care providers of their HBsAg status so that they can be evaluated and managed.

The following are key counseling messages for persons with HBsAg:

- HBV is not usually spread by hugging, coughing, food or water, sharing eating utensils or drinking glasses, or casual contact.
- Persons should not be excluded from work, school, play, childcare, or other settings because they are infected with HBV.
- Involvement with a support group might help patients cope with chronic HBV infection.
- HBV infection is a chronic condition that can be treated, and patients should receive prevention counseling and be evaluated for antiviral treatment.

Special Considerations

Pregnancy

- Regardless of whether they have been previously tested or vaccinated, all pregnant women should be tested for HBsAg at the first prenatal visit and again at delivery if at high risk for HBV infection. Pregnant women at risk for HBV infection and without documentation of a complete hepatitis B vaccine series should receive hepatitis B vaccination.

HIV Infection

- HIV infection can impair the response to hepatitis B vaccination. Persons with HIV should be tested for anti-HBs 1–2 months after the third vaccine dose .Modified dosing regimens, including a doubling of the standard antigen dose and administration of additional doses, might increase the response rate and should be managed in consultation with an infectious disease specialist

ALGORITHM OF WHO RECOMMENDATIONS ON THE MANAGEMENT OF PERSONS WITH CHRONIC HEPATITIS B INFECTION[a]



Reference

5. *WHO Treatment Guideline of Hepatitis B*
6. *https://www.who.int/news-room/fact-sheets/detail/hepatitis-b*
7. *https://www.cdc.gov/std/treatment-guidelines/hbv.htm*

HEPATITIS C (RNA VIRUS)

- HCV is a major cause of acute and chronic hepatitis.
- National wide prevalence survey HCV -2.7% (Dept of Medical research and Dept of public health 5/2015)
- Should be tested anybody attending clinic for any illness or patient's desire.

Natural history of HCV



Left untreated, chronic HCV infection can cause liver cirrhosis, liver failure and HCC (Fig. 2.2). Of those with chronic HCV infection, the risk of cirrhosis of the liver is 15–30% within 20 years *(71–73)*. The risk of HCC in persons with cirrhosis is approximately 2–4% per year *(74)*.

- Left untreated, chronic HCV infection can cause liver cirrhosis, liver failure and HCC (Fig. 2.2). Of those with chronic HCV infection, the risk of cirrhosis of the liver is 15-30% within 20 years *(71-73)*. The risk of HCC in persons with cirrhosis is approximately 2-4% per year *(74)*.
- Anti HCV antibody testing can be done by ICT or ELISA. ICT testing needs confirmation by ELISA.
- HCV RNA assay via PCR-quantitative for HCV genome.
- HCV genotyping is necessary for treatment option.



Management

- To clear HCV (not anti-HCV Ab, will persist for life)

Prioritization of HCV patients

- Patients with compensated cirrhosis
- With co-infections (HIV, HBV)
- Fibrosis stage F3 and F4
- Pretreatment assessment
- Alcohol consumption
- Exclusion of HCC
- HIV status, current ART treatment
- Pregnancy status (contraception during /after 6 months)
- Baseline biochemical test
- U&E, creatinine
- FBC
- Fetoprotein
- Fibroscan
- Direct acting antivirals (DAAs)
- Protease inhibitors (PI), Nucleotide inhibitor (NI), Non nucleotide inhibitor (NNI), NS5B inhibitors

Recommended regimens

- Sofosbuvir + Rabavrin *24week (for all genotypes)
- If Daclatasvir is available, Sofosbuvir + Daclatasvir * 2 wk (for all genotypes)
- If ledipasvir is available Sofosbuvir+ Ledipasvir* 12wk (for genotype 1& 6)
- 24weeks (for cirrhotic patients and Genotype 2,3,4 & 6)

Dosage

- **Oral Rabavirin** 200mg capsule /tab.
    - Body Wt. <75kg-2(morning),3 (evening)
- **Sofosbuvir**
- **Dacastasvir/Sofosbuvir Ledipsvir/Sofosbuvir**
    - >75kg-3(morning),3(evening) 400mg once daily(morning)
    - (30 or 60mg/ 400mg) once daily- morning (90 mg/400mg) once daily-morning
- The dose of daclatavir should be reduced to 30mg with the antibiotics (clarithromycin, erythromycin, ketoconazole, itraconazole)

Treatment monitoring

On treatment monitoring, baseline biochemical test may be necessary.

Post treatment Biochemical tests

- LFT, renal function (ALT, AST, Alkaline phosphate, bilirubin, Urea and creatinine) <3monthly>
- Alpha fetoprotein and USG .....<6monthly>

Post treatment assessment is done at 12wks after the termination of the treatment by viral load testing (SVR 12)

Patients who achieved SVR still needs to be followed -up regularly for the assessment of cirrhosis status and for the surveillance of HCC.

Those patients who do not receive treatment or treated and do not achieve SVR should also be followed-up.

Monitoring of drug side effects

Sofosbuvir

- The side effects of Sofosbuvir are fatigue, nausea, rash, itching, irritability, decreased appetite and diarrhea.

Supportive treatments

- Renal function should be checked regularly

Ribavirin containing regimen

- Mild anemia
- Significant teratogenic and/or embryocidal effects.
- Women of childbearing potential and/or their male partners must use an effective form of contraception during treatment and for a period of six months after the treatment has concluded.

Ribavirin should not be co-administered with Didanosine and Zidovudine. (WHO guideline 2014)

Daclatasvir

- The most common adverse reactions related to this drug are fatigue, headache and nausea.

Sofosbuvir and Ledipasvir

- In clinical studies, fatigue and headache were more common in patients treated with Sofosbuvir and Ledipasvir compared to placebo.

Prevention

Measures to avoid transmission of HCV

- HCV infected persons should be counseled to avoid sharing tooth brushes and dental or shaving equipment, and be cautioned to cover any bleeding wound in order to prevent contact of their blood with others.
- Persons should be counseled to stop using illicit drugs. Those who continue to inject drugs should be counseled to avoid reusing or sharing syringes, needles, water. Cotton or other paraphernalia.
- Persons with HCV infection should be provided information about how to protect their liver from further harm (i.e., hepatotoxic agents); for instance, persons with HCV infection should be advised to avoid drinking alcohol and taking any new medicines, including over-the-counter or herbal medications, without checking with their clinician.
- In addition, a need for hepatitis A and B vaccination should be determined; persons who are not immune should be vaccinated.
- HCV infected persons should be advised not to donate blood, body organs, other tissue or semen.
- HCV infected person should be counseled that the risk of sexual transmission is low, and that the infection itself is not a reason to change sexual practices (i.e, those in long term relationships need not start using barrier precautions, and others should always practice "safer" sex).

Primary prevention interventions recommended by WHO include:

- safe and appropriate use of health care injections;
- safe handling and disposal of sharps and waste;
- provision of comprehensive harm-reduction services to people who inject drugs;
- testing of donated blood for HBV and HCV (as well as HIV and syphilis);
- training of health personnel; and
- prevention of exposure to blood during sex.

Special Considerations

Pregnancy

- All pregnant women should be screened with each pregnancy for HCV antibodies at the first prenatal visit in settings where the HCV prevalence is >0.1%. HCV has not been reported to be transmitted through breast milk, although mothers with HCV infection should consider abstaining from breastfeeding if their nipples are cracked or bleeding

HIV Infection

- All persons with HIV infection should undergo serologic screening for HCV at initial evaluation.
- Acute HCV infection acquisition among persons with HIV infection can occur, especially among MSM, and regular screening of those with HIV is cost-effective.
- Antibody to HCV remains positive after spontaneously resolved infection or successful treatment; therefore, subsequent testing for potential HCV reinfection among persons with ongoing risk should be limited to HCV RNA testing only.
- Because a minimal percentage of persons with HIV infection do not develop HCV antibodies, HCV RNA testing should be performed for persons with HIV infection and unexplained liver disease who are anti-HCV negative.
- The course of liver disease is more rapid among persons with HIV and HCV, and the risk for cirrhosis is higher than that for persons with HCV infection alone.

Reference

1. *Therapeutic Manual, Internal Medicine, MMA, 1st Edition*
2. https://www.who.int/news-room/fact-sheets/detail/hepatitis-c (24 June 2022-WHO)
3. https://www.cdc.gov/std/treatment-guidelines/hbv.htm

OVERVIEW OF COVID-19

- *The COVID-19 pandemic has exploded since cases were first reported in China in December 2019. As of January 10, 2023, more than 600 million cases of COVID-19—caused by SARS-CoV-2 infection—have been reported globally, including more than 6 million deaths. In Myanmar, the first COVID 19 case was detected on 23.3.2020.*
- *Individuals of all ages are at risk for SARS-CoV-2 infection and severe disease. However, the probability of serious COVID-19 disease is higher in people aged ≥60 years, those living in a nursing home or long-term care facility, and those with chronic medical conditions.*
- *In an analysis of more than 1.3 million laboratory-confirmed cases of COVID-19 that were reported in the United States between January and May 2020, 14% of patients required hospitalization, 2% were admitted to the intensive care unit, and 5% died.*
- *The percentage of patients who died was 12 times higher among those with reported medical conditions (19.5%) than among those without medical conditions (1.6%), and the percentage of patients who were hospitalized was 6 times higher among those with reported medical conditions (45.4%) than among those without medical conditions (7.6%).*
- *Mortality was highest in patients aged >70 years, regardless of the presence of chronic medical conditions. Data on co morbid health conditions among patients with COVID-19 indicate that 32% had cardiovascular disease, 30% had diabetes, and 18% had chronic lung disease.*
- *Other conditions that may lead to a high risk for severe COVID-19 include cancer, kidney disease, liver disease (especially in patients with cirrhosis), obesity, sickle cell disease, and other immunocompromising conditions. Transplant recipients and pregnant people are also at a higher risk of severe COVID-19.*

SARS-CoV-2 Variants

- *Like other RNA viruses, SARS-CoV-2 is constantly evolving through random mutations. New mutations can potentially increase or decrease infectiousness and virulence. In addition, mutations can increase the virus' ability to evade adaptive immune responses from past SARS-CoV-2 infection or vaccination.*
- *This viral evolution may increase the risk of reinfection or decrease the efficacy of vaccines. There is evidence that some SARS-CoV-2 variants have reduced susceptibility to plasma from people who were previously infected or immunized, as well as to certain monoclonal antibodies (mAbs) that are being considered for prevention and treatment.*

- *Since December 2020, the World Health Organization (WHO) has assigned Greek letter designations to several identified variants.*
- *The Omicron (B.1.1.529) variant was designated a VOC in November 2021 and rapidly became the dominant variant across the globe. More recently, the Omicron subvariants BA.1, BA.1.1, and BA.2 have emerged. The Omicron VOC is more transmissible than other variants and is not susceptible to some of the anti-SARS-CoV-2 mAbs that have been developed for treatment and prevention.*
- *The Omicron VOC has surpassed Delta (B.1.617.2) as the dominant variant in the United States; the Delta variant was first identified in India and was the dominant variant in July 2021. Up to date , the dominant variants are BQ.1.1 and XBB 1.5 which are sub variants of omicron.*

Clinical Presentation

- *The estimated incubation period for COVID-19 is up to 14 days from the time of exposure, with a median incubation period of 4 to 5 days.*
- *The spectrum of illness can range from asymptomatic infection to severe pneumonia with acute respiratory distress syndrome and death. Among 72,314 people with COVID-19 in China, 81% of cases were reported to be mild (defined in this study as no pneumonia or mild pneumonia), 14% were severe (defined as dyspnoea, respiratory frequency ≥30 breaths/min, oxygen saturation ≤93%, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen [PaO2/FiO2] <300 mm Hg, and/or lung infiltrates >50% within 24 to 48 hours), and 5% were critical (defined as respiratory failure, septic shock, and/or multiple organ dysfunction syndrome or failure).*
- *In a report on more than 370,000 confirmed COVID-19 cases with reported symptoms in the United States, 70% of patients experienced fever, cough, or shortness of breath; 36% had muscle aches; and 34% reported headaches.*
- *Other reported symptoms have included, but are not limited to, diarrhoea, dizziness, rhinorrhea, anosmia, dysgeusia, sore throat, abdominal pain, anorexia, and vomiting. The abnormalities seen in chest X-rays of patients with COVID-19 vary, but bilateral multifocal opacities are the most common.*
- *The abnormalities seen in computed tomography of the chest also vary, but the most common are bilateral peripheral ground-glass opacities, with areas of consolidation developing later in the clinical course of COVID-19.31 Imaging may be normal early in infection and can be abnormal in the absence of symptoms.*
- *Common laboratory findings in patients with COVID-19 include leukopenia and lymphopenia. Other laboratory abnormalities have included elevated levels of aminotransferase, C-reactive protein, D-dimer, ferritin, and*

lactate dehydrogenase.

- *Although COVID-19 is primarily a pulmonary disease, emerging data suggest that it also leads to cardiac, dermatologic,hematologic,hepatic, neurologic, renal, and other complications.*
- *Thromboembolic events also occur in patients with COVID-19, with the highest risk occurring in critically ill patients. The long-term sequelae of COVID-19 survivors are currently unknown.*
- *Persistent symptoms after recovery from acute COVID-19 have been described . Lastly, SARS-CoV-2 infection has been associated with a potentially severe inflammatory syndrome in children (multisystem inflammatory syndrome in children, or MIS-C).*

Clinical Spectrum of SARS-CoV-2 Infection

- *Patients with SARS-CoV-2 infection can experience a range of clinical manifestations, from no symptoms to critical illness. In general, adults with SARS-CoV-2 infection can be grouped into the following severity of illness categories; however, the criteria for each category may overlap or vary across clinical guidelines and clinical trials, and a patient's clinical status may change over time.*
- *Asymptomatic or presymptomatic infection: Individuals who test positive for SARS-CoV-2 using a virologic test (i.e., a nucleic acid amplification test [NAAT] or an antigen test) but who have no symptoms that are consistent with COVID-19.*
- *Mild illness: Individuals who have any of the various signs and symptoms of COVID-19 (e.g., fever, cough, sore throat, malaise, headache, muscle pain, nausea, vomiting, diarrhea, loss of taste and smell) but who do not have shortness of breath, dyspnea, or abnormal chest imaging. •*
- *Moderate illness: Individuals who show evidence of lower respiratory disease during clinical assessment or imaging and who have an oxygen saturation (SpO2) ≥94% on room air at sea level.*
- *Severe illness: Individuals who have SpO2 <94% on room air at sea level, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) <300 mm Hg, a respiratory rate >30 breaths/min, or lung infiltrates >50%.*
- *Critical illness: Individuals who have respiratory failure, septic shock, and/or multiple organ dysfunctions. Infectious complications in patients with COVID-19 can be categorized as follows:*
- *Coinfections at presentation: Although most individuals present with only SARS-CoV-2 infection, concomitant viral infections, including influenza and other respiratory viruses, have been reported. Community-acquired bacterial pneumonia has also been reported, but it is uncommon, with a prevalence that ranges from 0% to 6% of people with SARS-CoV-2 infection Antibacterial therapy is generally not recommended unless additional*

evidence for bacterial pneumonia is present (e.g., leukocytosis, the presence of a focal infiltrate on imaging).

- *Reactivation of latent infections: There are case reports of underlying chronic hepatitis B virus and latent tuberculosis infections reactivating in patients with COVID-19 who receive immunomodulators as treatment, although the data are currently limited.*
- *Reactivation of herpes simplex virus and varicella zoster virus infections have also been reported. Cases of severe and disseminated strongyloidiasis have been reported in patients with COVID-19 during treatment with tocilizumab and corticosteroids.*
- *Many clinicians would initiate empiric treatment (e.g., with the antiparasitic drug ivermectin), with or without serologic testing, in patients who are from areas where Strongyloides is endemic (i.e., tropical, subtropical, or warm temperate areas). •*
- *Nosocomial infections: Hospitalized patients with COVID-19 may acquire common nosocomial infections, such as hospital-acquired pneumonia (including ventilator-associated pneumonia), line-related bacteremia or fungemia, catheter-associated urinary tract infection, and Clostridioides difficile–associated diarrhea. Early diagnosis and treatment of these infections are important for improving outcomes in these patients. •*
- *Opportunistic fungal infections: Invasive fungal infections, including aspergillosis and mucormycosis, have been reported in hospitalized patients with COVID-19. Although these infections are relatively rare, they can be fatal, and they may be seen more commonly in patients who are immunocompromised or receiving mechanical ventilation. The majority of mucormycosis cases have been reported in India and are associated with diabetes mellitus or the use of corticosteroids.The approach for managing these fungal infections should be the same as the approach for managing invasive fungal infections in other settings.*

Persistent Symptoms and Other Conditions after Acute COVID-19 (Post Covid Syndrome)

- *Some patients may experience persistent symptoms or other conditions after acute COVID-19. Adult and pediatric data on the incidence, natural history, and etiology of these symptoms and organ dysfunction are emerging.*
- *However, reports on these data have several limitations, including differing case definitions. In addition, many reports only included patients who attended post-COVID-19 clinics, and the studies often lack comparator groups. No specific treatments for persistent effects of COVID-19 have been shown to be effective, although general management strategies have been proposed.*
- *The CDC has defined post-COVID-19 conditions as new, returning, or*

ongoing symptoms that people experience ≥4 weeks after being infected with SARS-CoV-2. In October 2021, the World Health Organization published a clinical case definition that described the post-COVID-19 clinical condition as usually occurring 3 months after the onset of COVID-19 with symptoms that last for ≥2 months and cannot be explained by an alternative diagnosis.

Clinical Management of Adults Summary

- *Two main processes are thought to drive the pathogenesis of COVID-19.*
- *Early in the clinical course, the disease is primarily driven by the replication of SARS-CoV-2.*
- *Later in the clinical course, the disease appears to be driven by a dysregulated immune/inflammatory response to SARS-CoV-2 that leads to tissue damage. Based on this understanding, therapies that directly target SARS-CoV-2 are anticipated to have the greatest effect early in the course of the disease, while immunosuppressive/anti-inflammatory therapies are likely to be more beneficial in the later stages of COVID-19.*

Table 2a. Therapeutic Management of Nonhospitalized Adults With COVID-19

Patient Disposition	Panel's Recommendations
Does Not Require Hospitalization or Supplemental Oxygen	**For All Patients:** • All patients should be offered symptomatic management **(AIII)**. • The Panel **recommends against** the use of **dexamethasone**[a] or **other systemic corticosteroids** in the absence of another indication **(AIIb)**. **For Patients Who Are at High Risk of Progressing to Severe COVID-19**[b] *Preferred Therapies. Listed in order of preference:* • **Ritonavir-boosted nirmatrelvir (Paxlovid)**[c,d] **(AIIa)** • **Remdesivir**[d,e] **(BIIa)** *Alternative Therapies. For use ONLY when neither of the preferred therapies are available, feasible to use, or clinically appropriate. Listed in alphabetical order* • **Bebtelovimab**[f] **(CIII)** • **Molnupiravir**[d,g] **(CIIa)**
Discharged from Hospital Inpatient Setting in Stable Condition and Does Not Require Supplemental Oxygen	The Panel **recommends against** continuing the use of **remdesivir (AIIa)**, **dexamethasone**[a] **(AIIa)**, or **baricitinib (AIIa)** after hospital discharge.
Discharged from Hospital Inpatient Setting and Requires Supplemental Oxygen *For those who are stable enough for discharge but still require oxygen*[h]	There is insufficient evidence to recommend either for or against the continued use of remdesivir or dexamethasone.
Discharged from ED Despite New or Increasing Need for Supplemental Oxygen *When hospital resources are limited, inpatient admission is not possible, and close follow-up is ensured*[i]	The Panel recommends using **dexamethasone** 6 mg PO once daily for the duration of supplemental oxygen (dexamethasone use **should not exceed** 10 days) with careful monitoring for AEs **(BIII)**. Because remdesivir is recommended for patients with similar oxygen needs who are hospitalized,[j] clinicians may consider using it in this setting. As remdesivir requires IV infusions for up to 5 consecutive days, there may be logistical constraints to administering remdesivir in the outpatient setting.
Rating of Recommendations: A = Strong; B = Moderate; C = Weak **Rating of Evidence:** I = One or more randomized trials without major limitations; IIa = Other randomized trials or subgroup analyses of randomized trials; IIb = Nonrandomized trials or observational cohort studies; III = Expert opinion	

[a] There is currently a lack of safety and efficacy data on the use of dexamethasone in outpatients with COVID-19. Using systemic glucocorticoids in this setting may cause harm.

[b] For a list of risk factors, see the CDC webpage Underlying Medical Conditions Associated With Higher Risk for Severe COVID-19.

[c] Ritonavir-boosted nirmatrelvir has significant drug-drug interactions. Clinicians should carefully review a patient's concomitant medications and evaluate potential drug-drug interactions. See Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications for more information.

[d] If a patient requires hospitalization after starting treatment, the full treatment course can be completed at the health care provider's discretion.

[e] Administration of remdesivir requires 3 consecutive days of IV infusion.

[f] Bebtelovimab is active in vitro against all circulating Omicron (B.1.1.529) subvariants, but there are no clinical efficacy data from placebo-controlled trials that evaluated the use of bebtelovimab in patients who are at high risk of progressing to severe COVID-19. Therefore, bebtelovimab should be used only when the preferred treatment options are not available, feasible to use, or clinically appropriate.

[g] Molnupiravir has lower efficacy than the preferred treatment options. Therefore, it should be used only when the

- *COVID-19 Treatment Guidelines* 47

preferred options are not available, feasible to use, or clinically appropriate.

[h] These individuals should receive oximetry monitoring and close follow-up through telehealth, visiting nurse services, or in-person visits.

[i] Provide an advanced level of home care, including supplemental oxygen (whether patients are receiving oxygen for the first time or are increasing their baseline oxygen requirements), pulse oximetry, laboratory monitoring, and close follow-up through telehealth, visiting nurse services, or in-person visits.

- # General Management of Nonhospitalized Patients With Acute COVID-19

Last Updated: December 16, 2021

Summary Recommendations
• Management of nonhospitalized patients with acute COVID-19 should include providing supportive care, considerir the use of COVID-19-specific therapy for patients who have a high risk for disease progression, taking steps to red the risk of SARS-CoV-2 transmission (including isolating the patient), and advising patients on when to contact a health care provider and seek an in-person evaluation **(AIII)**.
• When possible, patients with symptoms of COVID-19 should be triaged via telehealth visits to determine whether tl require COVID-19-specific therapy and in-person care **(AIII)**.
• Patients with dyspnea should be referred for an in-person evaluation by a health care provider and should be follow closely during the initial days after the onset of dyspnea to assess for worsening respiratory status **(AIII)**.
• Management plans should be based on a patient's vital signs, physical exam findings, risk factors for progression t severe illness, and the availability of health care resources **(AIII)**.
• See Therapeutic Management of Nonhospitalized Adults With COVID-19 for specific recommendations on using pharmacologic therapy in nonhospitalized patients.
Rating of Recommendations: A = Strong; B = Moderate; C = Weak
Rating of Evidence: I = One or more randomized trials without major limitations; IIa = Other randomized trials or subgroup analyses of randomized trials; IIb = Nonrandomized trials or observational cohort studies; III = Expert opini

-

Managing Patients with COVID-19 in an Ambulatory Care Setting

- *Approximately 80% of patients with COVID-19 have mild illness that does not warrant medical intervention or hospitalization. Most patients with mild COVID-19 (defined as the absence of viral pneumonia and hypoxemia) can be managed in an ambulatory care setting or at home.*
- *Patients with moderate COVID-19 (those with viral pneumonia but without hypoxemia) or severe COVID-19 (those with dyspnea, hypoxemia, or lung infiltrates >50%) need in-person evaluation and close monitoring, as pulmonary disease can progress rapidly and require hospitalization.*
- *Health care providers should identify patients who may be at high risk for*

progression to severe COVID-19; these patients may be candidates for anti-SARS-CoV-2 monoclonal antibody treatment.. When managing outpatients with COVID-19, clinicians should provide supportive care, take steps to reduce the risk of SARS-CoV-2 transmission (e.g., wear a mask, isolate the patient),4,5 evaluate the need for COVID-19- specific therapy, and advise patients on when to seek in-person evaluation.6 Supportive care includes managing symptoms (as described below), ensuring that patients are receiving the proper nutrition, and paying attention to the risks of social isolation, particularly in older adults.

- *Other unique aspects of care for geriatric patients with COVID-19 include considerations related to cognitive impairment, frailty, fall risk, and polypharmacy. Older patients and those with chronic medical conditions have a higher risk for hospitalization and death; however, SARS-CoV-2 infection may cause severe disease and death in patients of any age, even in the absence of any risk factors. The decision to monitor a patient in the outpatient setting should be made on a case-by-case basis.*
- *Assessing the Need for In-Person Evaluation When possible, patients with symptoms of COVID-19 should be triaged via telehealth visits to determine whether they require COVID-19-specific therapy and in-person care (AIII).*
- *Outpatient management may include the use of patient self-assessment tools. During initial triage, clinic staff should determine which patients are eligible to receive supportive care at home and which patients warrant an in-person evaluation.8 Local emergency medical services, if called by the patient, may also be of help in deciding whether an in-person evaluation is indicated. Patient management plans should be based on the patient's vital signs, physical exam findings, risk factors for progression to severe illness, and the availability of health care resources (AIII).*
- *All patients with dyspnea, oxygen saturation (SpO2) ≤94% on room air at sea level (if this information is available), or symptoms that suggest higher acuity (e.g., chest pain or tightness, dizziness, confusion or other mental status changes) should be referred for an in-person evaluation by a health care provider (AIII).*
- *The criteria used to determine the appropriate clinical setting for an in-person evaluation may vary by location and institution; it may also change over time as new data and treatment options emerge. There should be a low threshold for in-person evaluation of older persons and those with medical conditions that are associated with a risk of progression to severe COVID-19. The individual who performs the initial triage should use their clinical judgement to determine whether a patient requires ambulance transport.*
- *There are unique considerations for residents of nursing homes and other long-term care facilities who develop acute COVID-19. Decisions about transferring these patients for an in-person evaluation should be a*

collaborative effort between the resident (or their health care decision maker), a hospital-based specialist (e.g., an emergency physician or geriatrician), and the clinical manager of the facility.

- *In some settings where clinical evaluation is challenged by geography, health care provider home visits may be used to evaluate patients.10 Patients who are homeless should be provided with housing where they can adequately self-isolate. Providers should be aware of the potential adverse effects of prolonged social isolation, including depression and anxiety. All outpatients should receive instructions regarding self-care, isolation, and follow-up, and should be advised to contact a health care provider or a local ED for any worsening symptoms.*
- *Clinical Considerations When Managing Patients in an Ambulatory Care Setting Persons who have symptoms that are compatible with COVID-19 should undergo diagnostic SARS-CoV-2 testing (see Prevention of SARS-CoV-2 Infection). Patients with SARS-CoV-2 infection may be asymptomatic or experience symptoms that are indistinguishable from other acute viral or bacterial infections (e.g., fever, cough, sore throat, malaise, muscle pain, headache, gastrointestinal symptoms).*
- *It is important to consider other possible etiologies of symptoms, including other respiratory viral infections (e.g., influenza), community-acquired pneumonia, congestive heart failure, asthma or chronic obstructive pulmonary disease exacerbations, and streptococcal pharyngitis. In most adult patients, if dyspnea develops, it tends to occur between 4 and 8 days after symptom onset, although it can also occur after 10 days.13 While mild dyspnea is common, worsening dyspnea and severe chest pain/tightness suggest the development or progression of pulmonary involvement.*
- *In studies of patients who developed acute respiratory distress syndrome, progression occurred a median of 2.5 days after the onset of dyspnea.14-16 Adult outpatients with dyspnea should be followed closely with telehealth or in-person monitoring, particularly during the first few days following the onset of dyspnea, to monitor for worsening respiratory status (AIII). If an adult patient has access to a pulse oximeter at home, SpO2 measurements can be used to help assess overall clinical status.*
- *Patients should be advised to use pulse oximeters on warm fingers rather than cold fingers for better accuracy. Patients should inform their health care provider if the value is repeatedly below 95% on room air at sea level. Pulse oximetry may not accurately detect occult hypoxemia, especially in Black patients. Additionally, SpO2 readings obtained through a mobile phone application may not be accurate enough for clinical use. Importantly, oximetry should only be interpreted within the context of a patient's entire clinical presentation (i.e., results should be disregarded if a patient is complaining of increasing dyspnea).*

Counseling Regarding the Need for Follow-Up

- *Health care providers should identify patients who are at high risk for disease progression. These patients may be candidates for anti-SARS-CoV-2 monoclonal antibody treatments, and clinicians should ensure that these patients receive adequate medical follow-up. The frequency and duration of follow-up will depend on the risk for severe disease, the severity of symptoms, and the patient's ability to self-report worsening symptoms.*
- *Health care providers should determine whether a patient has access to a phone, computer, or tablet for telehealth; whether they have adequate transportation for clinic visits; and whether they have regular access to food. The clinician should also confirm that the patient has a caregiver who can assist with daily activities if needed. All patients and/or their family members or caregivers should be counseled about the warning symptoms that should prompt re-evaluation through a telehealth visit or an in-person evaluation in an ambulatory care setting or ED.*
- *These symptoms include new onset of dyspnea; worsening dyspnea (particularly if dyspnea occurs while resting or if it interferes with daily activities); dizziness; and mental status changes, such as confusion. Patients should be educated about the time course of these symptoms and the possible respiratory decline that may occur, on average, 1 week after the onset of illness.*

Managing Adults With COVID-19 Following Discharge from the Emergency Department

- *There are no fixed criteria for admitting patients with COVID-19 to the hospital; criteria may vary by region and hospital facilities. Patients with severe disease are typically admitted to the hospital, but some patients with severe disease may not be admitted due to a high prevalence of infection and limited hospital resources. In addition, patients who could receive appropriate care at home but are unable to be adequately managed in their usual residential setting are candidates for temporary shelter in supervised facilities, such as a COVID-19 alternative care facility.*
- *For example, patients who are living in multigenerational households or who are homeless may not be able to self-isolate and should be provided resources such as dedicated housing units or hotel rooms, when available. Unfortunately, dedicated residential care facilities for COVID-19 patients are not widely available, and community-based solutions for self-care and isolation should be explored.*
- *In the cases where institutional resources (e.g., inpatient beds, staff members) are scarce, it may be necessary to discharge an adult patient and provide an advanced level of home care, including supplemental oxygen (if indicated), pulse oximetry, and close follow-up. Although early discharge of those with severe disease is not generally recommended by*

the Panel, it is recognized that these management strategies are sometimes necessary. In these situations, some institutions are providing frequent telemedicine follow-up visits for these patients or providing a hotline that allows patients to speak with a clinician when necessary.

- *Home resources should be assessed before a patient is discharged from the ED; outpatients should have a caregiver and access to a device that is suitable for telehealth. Patients and/or their family members or caregivers should be counseled about the warning symptoms that should prompt re-evaluation by a health care provider. Special consideration may be given to using certain therapeutics (e.g., dexamethasone) in this setting.*

Managing Adults With COVID-19 Following Hospital Discharge

- *Most patients who are discharged from the hospital setting should have a follow-up visit with a health care provider soon after discharge. Whether an in-person or a telehealth visit is most appropriate depends on the clinical and social situation. In some cases, adult patients are deemed to be stable for discharge from the inpatient setting even though they still require supplemental oxygen. Special consideration may be given to using certain therapeutics (e.g., dexamethasone) in this setting. When possible, these individuals should receive oximetry monitoring and close follow-up through telehealth visits, visiting nurse services, or in-person clinic visits.*
- *Considerations in Pregnancy Managing pregnant outpatients with COVID-19 is similar to managing nonpregnant patients .*
- *In pregnant patients, SpO2 should be maintained at 95% or above on room air at sea level; therefore, the threshold for monitoring pregnant patients in an inpatient setting may be lower than in nonpregnant patients.*
- *In general, there are no changes to fetal monitoring recommendations in the outpatient setting, and fetal management should be similar to the fetal management used for other pregnant patients with medical illness. However, these monitoring strategies can be discussed on a case-by-case basis with an obstetrician. Pregnant and lactating patients should be given the opportunity to participate in clinical trials of outpatients with COVID-19 to help inform decision-making in this population.*

Considerations in Children

- *Children and adolescents with acute COVID-19 are less likely than adults to require medical intervention or hospitalization, and most can be managed in an ambulatory care setting or at home. In general, the need for ED evaluation or hospitalization should be based on the patient's vital signs, physical exam findings (e.g., dyspnea), and risk factors for progression to severe illness. Certain groups, including young infants, children with risk factors, and those with presentations that overlap with multisystem inflammatory syndrome in children (MIS-C), may require*

hospitalization for more intensive monitoring.

- *However, this should be determined on a case-by-case basis. Most children with mild or moderate COVID-19, even those with risk factors, will not progress to more severe illness and will recover without specific therapy. There is insufficient evidence for the Panel to recommend either for or against the use of anti-SARS-CoV-2 monoclonal antibody products in nonhospitalized children with COVID-19 who have risk factors for severe disease.*
- *The available efficacy data for adults suggests that anti-SARS-CoV-2 monoclonal antibody products may be considered for use in children who meet the Food and Drug Administration Emergency Use Authorization (EUA) criteria, especially those who have more than 1 risk factor. The decision to use these products in children should be made on a case-by-case basis in consultation with a paediatric infectious disease specialist.*
- *The risk factors that predict progression to severe disease in adults can be used to determine the risk of progression in children aged ≥16 years. In general, paediatric patients should not continue receiving remdesivir, dexamethasone, or other COVID-19-directed therapies following discharge from an ED or an inpatient setting.*

Therapeutic Management of Non-hospitalized Adults With COVID-19

- *Several therapeutic options are now available to treat non-hospitalized adults with mild to moderate COVID-19 who are at high risk of disease progression (Age is the most significant risk factor which starts from at the age of 50 and unvaccinated / not fully vaccinated persons are also at high risk). Several factors affect the selection of the best treatment option for a specific patient.*
- *These factors include the clinical efficacy and availability of the treatment option, the feasibility of administering parenteral medications (i.e., remdesivir), the potential for significant drug-drug interactions (e.g., those associated with the use of ritonavir-boosted nirmatrelvir [Paxlovid]), and the regional prevalence of variants of concern (e.g., the regional prevalence of the Omicron BA.2 subvariant may affect which anti-SARS-CoV-2 monoclonal antibodies [mAbs] can be used for treatment). Table 2a outlines the COVID-19 Treatment Guidelines Panel's (the Panel) recommendations for using these therapeutic interventions outside the hospital inpatient setting.*

Risk Stratification for Antiviral therapy

- *Although age is the strongest risk factor for severe COVID-19 outcomes, patients with certain underlying medical conditions are also at higher risk. The more underlying conditions a person has, the higher the risk for severe COVID-19 outcomes. Providers should consider the patient's age, vaccination status, and*

presence of other underlying medical conditions and risk factors in determining the risk of severe COVID-19-associated outcomes for any patient. Among the underlying medical conditions, the listed below are at higher risk based on meta-analysis or systematic review:

- *Asthma*
- *Cancer*
- *Cerebrovascular disease*
- *Chronic kidney disease*
- *Chronic lung disease(COPD, PE, interstitial lung disease, bronchiectasis)*
- *Chronic liver disease*
- *Diabetes Type 1&2*
- *HIV*
- *Heart conditions(heart failure,CAD,CMP)*
- *Mental health conditions(mood disorders, Schizophrenia)*
- *Neurological conditions(dementia)*
- *Obesity*
- *Physical inactivity*
- *Pregnancy and recent pregnancy*
- *Primary immunodeficiency*
- *Smoking(current and former)*
- *Organ/blood stem cell transplant*
- *Use of steroid and other immunosuppressives*
- *Down syndrome*
- *Cystic fibrosis*

Table 2a. Therapeutic Management of Nonhospitalized Adults With COVID-19

Patient Disposition	Panel's Recommendations
Does Not Require Hospitalization or Supplemental Oxygen	**For All Patients:** • All patients should be offered symptomatic management **(AIII)**. • The Panel **recommends against** the use of **dexamethasone**[a] or **other systemic corticosteroids** in the absence of another indication **(AIIb)**. **For Patients Who Are at High Risk of Progressing to Severe COVID-19**[b] *Preferred therapies. Listed in order of preference:* • **Ritonavir-boosted nirmatrelvir (Paxlovid)**[c,d] **(AIIa)** • **Remdesivir**[d,e] **(BIIa)** *Alternative therapies. For use ONLY when neither of the preferred therapies are available, feasible to use, or clinically appropriate. Listed in alphabetical order:* • **Bebtelovimab**[f] **(CIII)** • **Molnupiravir**[d,g] **(CIIa)**
Discharged From Hospital Inpatient Setting in Stable Condition and Does Not Require Supplemental Oxygen	The Panel **recommends against** continuing the use of **remdesivir (AIIa)**, **dexamethasone**[a] **(AIIa)**, or **baricitinib (AIIa)** after hospital discharge.
Discharged From Hospital Inpatient Setting and Requires Supplemental Oxygen *For those who are stable enough for discharge but still require oxygen*[h]	There is insufficient evidence to recommend either for or against the continued use of remdesivir or dexamethasone.
Discharged From ED Despite New or Increasing Need for Supplemental Oxygen *When hospital resources are limited, inpatient admission is not possible, and close follow-up is ensured*[i]	The Panel recommends using **dexamethasone** 6 mg PO once daily for the duration of supplemental oxygen (dexamethasone use **should not exceed** 10 days) with careful monitoring for AEs **(BIII)**. Because remdesivir is recommended for patients with similar oxygen needs who are hospitalized,[j] clinicians may consider using it in this setting. As remdesivir requires IV infusions for up to 5 consecutive days, there may be logistical constraints to administering remdesivir in the outpatient setting.
Rating of Recommendations: A = Strong; B = Moderate; C = Weak **Rating of Evidence:** I = One or more randomized trials without major limitations; IIa = Other randomized trials or subgroup analyses of randomized trials; IIb = Nonrandomized trials or observational cohort studies; III = Expert opinion	

Table 2b. Dosing Regimens for the Drugs Listed in Table 2a

Drug Name	Dosing Regimen	Time From Symptom Onset[a]
Ritonavir-Boosted Nirmatrelvir (Paxlovid)	**eGFR ≥60 mL/min:** • Nirmatrelvir 300 mg with RTV 100 mg PO twice daily for 5 days **eGFR ≥30 to <60 mL/min:** • Nirmatrelvir 150 mg with RTV 100 mg PO twice daily for 5 days **eGFR <30 mL/min:** • **Not recommended** **Severe Hepatic Impairment (Child-Pugh Class C):** • **Not recommended**	≤5 days
Remdesivir	RDV 200 mg IV on Day 1, followed by RDV 100 mg IV once daily on Days 2 and 3.[b,c] Each infusion should be administered over 30–120 minutes. Patients should be observed for ≥1 hour after infusion as clinically appropriate.	≤7 days

Table 2b. Dosing Regimens for the Drugs Listed in Table 2a, continued

Drug Name	Dosing Regimen	Time From Symptom Onset[a]
Bebtelovimab	BEB 175 mg as a single IV injection, administered over ≥30 seconds. Patients should be observed for ≥1 hour after injection.	≤7 days
Molnupiravir	Molnupiravir 800 mg PO twice daily for 5 days	≤5 days

[a] Per EUA criteria or clinical trial entry criteria.

[b] See the Remdesivir section for a discussion of RDV use in patients with renal impairment.

[c] If RDV is administered to patients who have a new or increasing need for supplemental oxygen but who are discharged from the ED because hospital resources are limited and inpatient admission is not possible, the total duration of therapy is ≤5 days.

Key: BEB = bebtelovimab; ED = emergency department; eGFR = estimated glomerular filtration rate; EUA = Emergency Use Authorization; IV = intravenous; PO = orally; RDV = remdesivir; RTV = ritonavir

Rationale for the Use of Specific Agents Listed in Table 2a

- *The Panel's recommendations for the therapeutics that are used to treat nonhospitalized patients with mild to moderate COVID-19 who are at risk of clinical progression are based on the results of clinical trials for the antiviral drugs (ritonavir-boosted nirmatrelvir, remdesivir, and molnupiravir) and on laboratory assessments of the activity of the anti-SARS-CoV-2 mAb bebtelovimab.*
- *Several factors affect the selection of the best treatment option for a specific patient. These factors include the clinical efficacy of the treatment option against circulating variants, the availability of the treatment option, the feasibility of administering parenteral medications (i.e., remdesivir, bebtelovimab), and the potential for significant drug-drug interactions (i.e., the interactions associated with using ritonavir-boosted nirmatrelvir).*
- *The Panel recommends ritonavir-boosted nirmatrelvir and remdesivir as preferred therapy options because Phase 3 randomized placebo-controlled trials have reported high clinical efficacies for these agents in patients with COVID-19.3,4 The Panel favors the use of ritonavir-boosted nirmatrelvir in most high-risk, nonhospitalized patients with mild to moderate COVID-19. If ritonavir-boosted nirmatrelvir is not available or cannot be used because of drug-drug interactions, the Panel recommends using remdesivir as the second option.*
- *The Panel recommends bebtelovimab and molnupiravir as alternative therapy options. These drugs should ONLY be used when neither of the preferred treatment options are available, feasible to use, or clinically appropriate. The Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for bebtelovimab based on in vitro data that showed that bebtelovimab has activity against all circulating Omicron subvariants and clinical efficacy data from a small, Phase 2 clinical trial in individuals with mild to moderate COVID-19 who were at low risk of disease progression.5 However, there are no Phase 3 clinical trial data for bebtelovimab.*

- *Molnupiravir had lower clinical efficacy in Phase 3 clinical trials than the preferred treatment options. The Panel previously recommended the anti-SARS-CoV-2 mAb sotrovimab as a treatment option for certain nonhospitalized patients with COVID-19.*
- *However, sotrovimab, which is active against the Omicron BA.1 and BA.1.1 subvariants, has substantially decreased in vitro activity against the Omicron BA.2 subvariant.6-8 The distribution of sotrovimab has been paused, and the Panel no longer recommends using sotrovimab to treat COVID-19. There are currently no clinical trial data that directly compare the clinical efficacies of the 4 recommended therapies, and there are no data on the use of combinations of antiviral agents and/ or anti-SARS-CoV-2 mAbs for the treatment of COVID-19. The rationale for each of the Panel's recommendations is discussed below.*

Ritonavir-Boosted Nirmatrelvir (Paxlovid)(Paclovid available in Myanmar)

- *Nirmatrelvir is an orally bioavailable protease inhibitor that is active against MPRO, a viral protease that plays an essential role in viral replication by cleaving the 2 viral polyproteins.9 It has demonstrated antiviral activity against all coronaviruses that are known to infect humans.10 Nirmatrelvir is packaged with ritonavir (as Paxlovid), a strong cytochrome P450 (CYP) 3A4 inhibitor and pharmacokinetic boosting agent. Ritonavir is required to increase nirmatrelvir concentrations to the target therapeutic range. Recommendations •*
- *The Panel recommends using nirmatrelvir 300 mg with ritonavir 100 mg (Paxlovid) orally (PO) twice daily for 5 days in those aged ≥12 years and weighing ≥40 kg; treatment should be initiated as soon as possible and within 5 days of symptom onset (AIIa). •*
- *Ritonavir-boosted nirmatrelvir has significant and complex drug-drug interactions, primarily due to the ritonavir component of the combination. • Before prescribing ritonavir-boosted nirmatrelvir, clinicians should carefully review the patient's concomitant medications, including over-the-counter medications and herbal supplements, to evaluate potential drug-drug interactions. • A quick reference guide is also provided in Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications.*
- *The FDA EUA fact sheet for ritonavir-boosted nirmatrelvir, the Liverpool COVID-19 Drug Interactions website, and guidance from the Ontario COVID-19 Science Advisory Table should also be utilized to identify and manage drug-drug interactions. In the EPIC-HR trial, ritonavir-boosted nirmatrelvir reduced the risk of hospitalization or death by 88% compared to placebo in nonhospitalized adults with laboratory-confirmed SARS-CoV-2 infection.3,11*
- *This efficacy is comparable to the efficacies reported in similar patient populations for remdesivir (87% relative reduction)4 and greater than the efficacy reported for molnupiravir in this setting (30% relative reduction).12*

Ritonavir-boosted nirmatrelvir is expected to be active against all Omicron subvariants, although clinical efficacy data are lacking.

- *Because ritonavir-boosted nirmatrelvir has the potential for significant drug-drug interactions with concomitant medications, this regimen may not be a safe choice for all patients (see Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir [Paxlovid] and Concomitant Medications). However, because ritonavir-boosted nirmatrelvir is the only highly effective oral antiviral available for the treatment of COVID-19, drug-drug interactions that can be safely managed should not preclude the use of this medication. Case reports and results from the EPIC-HR trial have described SARS-CoV-2 viral rebound and the recurrence of COVID-19 symptoms in some patients who have completed treatment with ritonavir-boosted nirmatrelvir.*
- *Viral and symptomatic rebound can also occur in the absence of treatment with ritonavir-boosted nirmatrelvir. The frequency, mechanism, and clinical implications of these events are unclear. To date, recurrence of symptoms following the use of ritonavir-boosted nirmatrelvir has not been associated with progression to severe COVID-19. Longer treatment courses of ritonavir-boosted nirmatrelvir are not authorized based on the current EUA, and there are insufficient data on the efficacy of administering a second course.*
- *The EPIC-HR trial excluded pregnant and lactating individuals. Ritonavir has been used extensively during pregnancy in people with HIV, which suggests that it has an acceptable safety profile during pregnancy. Based on the mechanisms of action for both nirmatrelvir and ritonavir and the available animal data, the Panel recommends ritonavir-boosted nirmatrelvir for pregnant patients because the potential benefits likely outweigh the risks.*

Box 1. Commonly Prescribed Outpatient Medications Not Expected to Have Clinically Relevant Interactions With Ritonavir-Boosted Nirmatrelvir (Paxlovid)

Medications Without Clinically Relevant Interactions		
These commonly prescribed medications may be coadministered without dose adjustment and without increased monitoring.[a] This list is not inclusive of all noninteracting medications within each drug category.		
Acid reducing agents	**Diabetes medications**	**Pain medications**
• Famotidine	• Empagliflozin	• Acetaminophen
• Omeprazole	• Insulin	• Aspirin
• Pantoprazole	• Metformin	• Codeine
Allergy medications	• Pioglitazone	• Ibuprofen
• Cetirizine	**Immunosuppressants**	• Naproxen
• Diphenhydramine	• Methotrexate	**Respiratory medications**
• Loratadine	• Mycophenolate	• Corticosteroids (inhaled)
Anti-infective agents	• Prednisone	• Formoterol
• Azithromycin	**Lipid-modifying agents**	• Montelukast
• Hydroxychloroquine	• Ezetimibe	**Miscellaneous**
Cardiovascular agents	• Pitavastatin	• Allopurinol
• Aspirin	• Pravastatin	• Contraceptives (oral)[b]
• Atenolol	**Neuropsychiatric agents**	• Donepezil
• Carvedilol	• Amitriptyline	• Enoxaparin
• Furosemide	• Bupropion	• Finasteride
• Hydrochlorothiazide	• Citalopram	• Levothyroxine
• Irbesartan	• Duloxetine	• Ondansetron
• Isosorbide Dinitrate	• Escitalopram	
• Lisinopril	• Fluoxetine	
• Losartan	• Gabapentin	
• Metoprolol	• Lorazepam	
• Prasugrel	• Nortriptyline	
	• Olanzapine	
	• Paroxetine	
	• Sertraline	
	• Venlafaxine	

Box 2. Outpatient Medications That Have Clinically Relevant Drug-Drug Interactions With Ritonavir-Boosted Nirmatrelvir (Paxlovid)

Not all medications that may interact with ritonavir-boosted nirmatrelvir are included in Box 2. Deviation from the recommended strategies may be appropriate in certain clinical scenarios.

Prescribe Alternative COVID-19 Therapy		
For these medications, management strategies are not possible or feasible, or the risks outweigh the potential benefits.		
Anticonvulsants	**Cardiovascular agents**	**Pain medications**
• Carbamazepine	• Amiodarone	• Meperidine (pethidine)
• Phenobarbital	• Clopidogrel[a,b]	**Pulmonary hypertension medications**
• Phenytoin	• Disopyramide	• Sildenafil
• Primidone	• Dofetilide	• Tadalafil
Anti-infective agents	• Dronedarone	• Vardenafil
• Glecaprevir/pibrentasvir	• Eplerenone	**Miscellaneous**
• Rifampin	• Flecainide	• Bosentan
• Rifapentine	• Ivabradine	• Certain chemotherapeutic agents[c]
Immunosuppressants	• Propafenone	• Ergot derivatives
• Voclosporin	• Quinidine	• Lumacaftor/ivacaftor
	Neuropsychiatric agents	• St. John's wort
	• Clozapine	• Tolvaptan
	• Lumateperone	
	• Lurasidone	
	• Midazolam (oral)	
	• Pimozide	

Temporarily Withhold Concomitant Medication, If Clinically Appropriate		
Withhold these medications during ritonavir-boosted nirmatrelvir treatment and for at least 2–3 days after treatment completion. They may need to be withheld for longer if the patient is elderly or the medication has a long half-life. If withholding is not clinically appropriate, use an alternative concomitant medication or COVID-19 therapy.		
Anticoagulants • Rivaroxaban[d] **Anti-infective agents** • Erythromycin **BPH medications** • Alfuzosin • Silodosin **Cardiovascular agents** • Aliskiren • Ranolazine • Ticagrelor[b] • Vorapaxar **Immunosuppressants[f]** • Everolimus • Sirolimus • Tacrolimus	**Lipid-modifying agents** • Atorvastatin[e] • Lomitapide • Lovastatin[e] • Rosuvastatin[e] • Simvastatin[e] **Migraine medications** • Eletriptan • Rimegepant • Ubrogepant **Neuropsychiatric agents** • Clonazepam[g] • Clorazepate[g] • Diazepam[g] • Estazolam[g] • Flurazepam[g] • Suvorexant • Triazolam[g]	**Erectile dysfunction medications** • Avanafil **Respiratory medications** • Salmeterol **Miscellaneous** • Certain chemotherapeutic agents[c] • Colchicine[h] • Finerenone • Flibanserin • Naloxegol

Adjust Concomitant Medication Dose and Monitor for Adverse Effects		
Consult the Liverpool COVID-19 Drug Interactions website or the Ontario COVID-19 Science Advisory Table for specific dosing recommendations.[i] If the dose of the concomitant medication cannot be adjusted, withhold the medication (if clinically appropriate) or use an alternative concomitant medication or COVID-19 therapy.		
Anticoagulants • Apixaban • Dabigatran • Edoxaban **Anti-infective agents** • Clarithromycin • Itraconazole • Ketoconazole • Maraviroc • Rifabutin **BPH medications** • Tamsulosin **Cardiovascular agents** • Cilostazol • Digoxin • Mexiletine **Diabetes medications** • Saxagliptin	**Erectile dysfunction medications** • Sildenafil • Tadalafil • Vardenafil **Immunosuppressants[f]** • Cyclosporine **Neuropsychiatric agents** • Alprazolam[g] • Aripiprazole • Brexpiprazole • Buspirone • Cariprazine • Chlordiazepoxide[g] • Clobazam[g] • Iloperidone • Pimavanserin • Quetiapine • Trazodone	**Pain medications** • Fentanyl • Hydrocodone • Oxycodone **Pulmonary hypertension medications** • Riociguat **Miscellaneous** • Certain chemotherapeutic agents[c] • Darifenacin • Elexacaftor/tezacaftor/ivacaftor • Eluxadoline • Ivacaftor • Tezacaftor/ivacaftor

Remdesivir

- *Remdesivir is currently approved by the FDA for use in hospitalized patients with COVID-19 and in nonhospitalized patients with mild to moderate COVID-19 who are at high risk of disease progression. Remdesivir has been studied in nonhospitalized patients with mild to moderate COVID-19 who were at high risk of progressing to severe disease.*
- *The PINETREE trial showed that 3 consecutive days of intravenous (IV) remdesivir resulted in an 87% relative reduction in the risk of*

hospitalization or death compared to placebo.4 Remdesivir is expected to be active against the Omicron variant, although in vitro and in vivo data are currently limited.15 See Remdesivir for more information.

- *Recommendations • The Panel recommends using remdesivir 200 mg IV on Day 1, followed by remdesivir 100 mg IV once daily on Days 2 and 3 in those aged ≥12 years and weighing ≥40 kg; treatment should be initiated as soon as possible and within 7 days of symptom onset (BIIa). •*
- *Remdesivir should be administered in a setting where severe hypersensitivity reactions, such as anaphylaxis, can be managed. Patients should be monitored during the infusion and observed for at least 1 hour after infusion as clinically appropriate. Because remdesivir requires IV infusions for 3 consecutive days, there may be logistical constraints to administering remdesivir in many settings. However, it is an option if ritonavir-boosted nirmatrelvir is not available.*
- *The Panel recommends using remdesivir, dexamethasone, or both drugs together in hospitalized patients who require supplemental oxygen (see Therapeutic Management of Hospitalized Adults With COVID-19). When remdesivir is used in this setting, it is administered as a once-daily IV infusion for 5 days. There are rare instances when hospital resources are limited and admission to an inpatient unit is not possible for patients who need to initiate supplemental oxygen in the emergency department (ED) or who have increasing supplemental oxygen requirements. In these cases, patients may be discharged from the ED with close monitoring and are often prescribed dexamethasone for up to 10 days.*
- *Since remdesivir is often recommended for hospitalized patients with COVID-19 who have similar oxygen needs, clinicians can consider using it in this setting. However, it should be noted that the data on using remdesivir in this situation are limited and administering IV infusions for up to 5 consecutive days can be difficult in the outpatient setting.*

Molnupiravir

- *Molnupiravir is the oral prodrug of beta-D-N4-hydroxycytidine (NHC), a ribonucleoside that has broad antiviral activity against RNA viruses. NHC uptake by viral RNA-dependent RNA-polymerases results in viral mutations and lethal mutagenesis.22,23 Molnupiravir has potent antiviral activity against SARS-CoV-2.23 As a mutagenic ribonucleoside antiviral agent, there is a theoretical risk that molnupiravir will be metabolized by the human host cell and incorporated into the host DNA, leading to mutations.*
- *Molnupiravir has been evaluated in 2 in vivo rodent mutagenicity assays. One study produced equivocal results; in the other study, there was no evidence for mutagenicity. The FDA concluded that, based on the available genotoxicity data and the 5-day duration of treatment, molnupiravir has*

a low risk for genotoxicity.24 In addition, there have been concerns about the potential effects of molnupiravir on SARS-CoV-2 mutation rates; the FDA is requiring the manufacturer to establish a process to monitor genomic databases for the emergence of SARS-CoV-2 variants. Molnupiravir is expected to be active against the Omicron variant, although in vitro and in vivo data are currently limited.

- *Recommendation • The Panel recommends using molnupiravir 800 mg PO twice daily for 5 days in those aged ≥18 years ONLY when ritonavir-boosted nirmatrelvir (Paxlovid) and remdesivir are not available, feasible to use, or clinically appropriate (CIIa). In the MOVe-OUT trial, molnupiravir reduced the rate of hospitalization or death by 30% compared to placebo in nonhospitalized patients with COVID-19.*
- *Even though the different treatment options have not been directly compared in clinical trials, the Panel recommends using molnupiravir only when ritonavir-boosted nirmatrelvir and remdesivir are not available or cannot be used, because molnupiravir has lower efficacy than the other options.*
- *The FDA EUA states that molnupiravir is not recommended for use in pregnant patients due to concerns about the instances of fetal toxicity observed during animal studies. However, when other therapies are not available, pregnant people with COVID-19 who are at high risk of progressing to severe disease may reasonably choose molnupiravir therapy after being fully informed of the risks, particularly if they are beyond the time of embryogenesis (i.e., >10 weeks' gestation).*
- *The prescribing clinician should document that a discussion of the risks and benefits occurred and that the patient chose this therapy. People who engage in sexual activity that may result in conception should use effective contraception during and following treatment with molnupiravir.*

Dexamethasone For Nonhospitalized Patients With Mild to Moderate COVID-19

- *The Panel recommends against the use of dexamethasone or other systemic glucocorticoids to treat outpatients with mild to moderate COVID-19 who do not require hospitalization or supplemental oxygen (AIIb). However, patients who are receiving dexamethasone or another corticosteroid for other indications should continue therapy for their underlying conditions as directed by their health care providers (AIII).*
- *Medicare and FDA data show a significant increase in the number of prescriptions for systemic corticosteroids among nonhospitalized patients with COVID-19 despite a lack of safety and efficacy data on the use of systemic corticosteroids in this setting. Systemic glucocorticoids may cause harm in nonhospitalized patients with COVID-19.*
- *Results from 1 randomized controlled trial and 1 observational cohort*

study did not demonstrate a clinical benefit of dexamethasone among hospitalized patients who did not require supplemental oxygen, and dexamethasone may potentially cause harm in these patients.

- *In the RECOVERY trial, the use of dexamethasone had no effect on mortality among hospitalized patients with COVID-19 who did not require supplemental oxygen (rate ratio 1.19; 95% CI, 0.91–1.55). A large observational study of patients at Veterans Affairs hospitals reported no survival benefit for dexamethasone among patients with COVID-19 who did not require supplemental oxygen. Instead, these patients had an increased risk of 90-day mortality (HR 1.76; 95% CI, 1.47–2.12).*
- *However, hospitalized patients with COVID-19 are likely to have an increased risk of mortality compared to nonhospitalized patients, which is a limitation of observational trial data. See Table 6a for more information on the clinical trials that evaluated the use of corticosteroids, including dexamethasone.*

For Patients Who Are Discharged From the Hospital and Do Not Require Supplemental Oxygen

- *During the RECOVERY trial, dexamethasone was stopped at the time of hospital discharge. For hospitalized patients with COVID-19 who do not require supplemental oxygen after discharge, the Panel recommends against the continuation of dexamethasone (AIIa).*

For Patients Who Are Discharged From the Hospital and Require Supplemental Oxygen

- *In some cases, adult patients are deemed to be stable enough to be discharged from the inpatient setting even though they still require supplemental oxygen. This practice was likely uncommon during the RECOVERY trial; therefore, there is insufficient evidence for the Panel to recommend either for or against the continued use of dexamethasone after hospital discharge in patients who require supplemental oxygen.*
- *The use of corticosteroids can lead to adverse events (e.g., hyperglycemia, neuropsychiatric symptoms, secondary infections), which may be difficult to detect and monitor in an outpatient setting. If a patient continues to receive corticosteroids after discharge, consider continuing corticosteroids for the duration of supplemental oxygen. However, the total duration of corticosteroid use should not exceed 10 days (including days during hospitalization). Only patients who showed good tolerance to this therapy prior to discharge should continue to receive corticosteroids after discharge.*

For Patients Who Require Hospitalization and Supplemental Oxygen but Were Discharged From the Emergency Department Due to Scarce Resources

- *In rare cases, patients with COVID-19 who require supplemental oxygen and hospital admission may need to be discharged from the ED due to scarce resources (e.g., in cases where hospital beds or staff are not available). For these patients, the Panel recommends using dexamethasone 6 mg PO once daily for the duration of supplemental oxygen (dexamethasone use should not exceed 10 days) with careful monitoring for adverse events (BIII). These patients should receive oximetry monitoring and close follow-up through telehealth, visiting nurse services, or in-person visits.*
- *Other Agents That Have Been Studied or Are Under Investigation •*
- *The Panel recommends against the use of chloroquine or hydroxychloroquine with or without azithromycin (AI), lopinavir/ritonavir, and other HIV protease inhibitors (AIII) for the outpatient treatment of COVID-19. •*
- *The Panel recommends against the use of antibacterial therapy (e.g., azithromycin, doxycycline) for the outpatient treatment of COVID-19 in the absence of another indication (AIII). • Other agents have undergone or are currently undergoing investigation in the outpatient setting. Antiviral agents, such as ivermectin • Convalescent plasma • Immunomodulators, such as colchicine, fluvoxamine, and inhaled corticosteroids • Supplements, such as vitamin C, vitamin D, and zinc •*
- *The Panel recommends against the use of anticoagulants and antiplatelet therapy for the prevention of venous thromboembolism or arterial thrombosis unless the patient has other indications for the therapy or is participating in a clinical trial (AIIa). Health care providers should provide information about ongoing clinical trials of investigational therapies to eligible outpatients with COVID-19 so they can make informed decisions about participation (AIII).*

Concomitant Medication Management

- *In general, a patient's usual medication and/or supplement regimen should be continued after the diagnosis of COVID-19 (see Considerations for Using Concomitant Medications in Patients With COVID-19). Angiotensin-converting enzyme inhibitors, statin therapy, nonsteroidal anti-inflammatory drugs, and oral, inhaled, and intranasal corticosteroids that are prescribed for comorbid conditions should be continued as directed (AIII).*
- *Patients should be advised to avoid the use of nebulized medications in the presence of others to avoid potential aerosolization of SARS-CoV-2.28 In patients with HIV, antiretroviral therapy should not be switched or*

adjusted for the purpose of preventing or treating SARS-CoV-2 infection (AIII). For more information, see Special Considerations in People With HIV.

- *When a patient is receiving an immunomodulating medication, the prescribing clinician should be consulted about the risks and benefits that are associated with a temporary dose reduction or discontinuation. These risks and benefits will depend on the medication's indication and the severity of the underlying condition.*

Symptom Management

- *Symptomatic treatment includes using over-the-counter antipyretics, analgesics, or antitussives for fever, headache, myalgias, and cough. Patients with dyspnea may benefit from resting in the prone position rather than the supine position.1*
- *Health care providers should consider educating patients about breathing exercises, as severe breathlessness may cause anxiety.2 Patients should be advised to drink fluids regularly to avoid dehydration.*
- *Rest is recommended as needed during the acute phase of COVID-19, and ambulation and other forms of activity should be increased according to the patient's tolerance. Patients should be educated about the variability in time to symptom resolution and complete recovery.*

Clinical Management of Children Summary

- *Data from the Centers for Disease Control and Prevention demonstrate a lower incidence of SARS-CoV-2 infection, severe disease, and death in children compared with adults.*1-4 *Although only a small percentage of children with COVID-19 will require medical attention, the percentage of intensive care unit admissions among hospitalized children is comparable to the percentage among hospitalized adults with COVID-19.*5-16
- *Risk factors for severe COVID-19 have been identified through observational studies and meta-analyses primarily conducted before the availability of COVID-19 vaccines. Risk factors include having ≥1 severe comorbid conditions, such as medical complexity with respiratory technology dependence, a neurologic condition resulting in impaired mucociliary clearance, obesity (particularly severe obesity), severe underlying cardiac or pulmonary disease, or severely immunocompromised status. However, pediatric data on risk factors for severe COVID-19 are generally more limited and provide lower certainty than data for adults.*
- *In general, COVID-19 has similar clinical manifestations and disease stages in children and adults, including an early phase driven by viral replication and a late phase that appears to be driven by a dysregulated immune/inflammatory response to SARS-CoV-2 that leads to tissue damage. Respiratory complications in young children that can occur during the early clinical phase include croup and*

bronchiolitis. In addition, a small number of children who have recovered from acute SARS-CoV-2 infection develop multisystem inflammatory syndrome in children (MIS-C) 2 to 6 weeks after infection. MIS-C is a postinfectious inflammatory condition that can lead to severe organ dysfunction, which is in contrast to COVID-19, the acute, primarily respiratory illness due to infection with SARS-CoV-2.

- *There are no results available from clinical trials that evaluated treatments for COVID-19 in children, and data from observational studies are limited. Applying adult data from COVID-19 trials to children is a unique challenge because most children experience a mild course of illness with COVID-19. Relative to adults, children with COVID-19 have substantially lower mortality and less need for hospitalization. Because of these differences in epidemiology and disease severity, the effect sizes for children are likely to be smaller than those observed in adults; therefore, to produce a beneficial outcome, the number needed to treat is higher. Collectively, these factors influence the risk versus benefit balance for pharmacologic therapies in children.*
- *In the absence of sufficient clinical trial data on the treatment of children with COVID-19, the COVID-19 Treatment Guidelines Panel's (the Panel) recommendations for the therapeutic management of children are based largely on adult safety and efficacy data from clinical trials, the child's risk of disease progression, and expert opinion. In general, the older the child and the more severe the disease, the more reasonable it is to follow treatment recommendations for adult patients with COVID 19.*

Table 3a. Therapeutic Management of Nonhospitalized Children With COVID-19

Risk of Severe COVID-19	Panel's Recommendations	
	Aged 12–17 years	Aged <12 years
Symptomatic, Regardless of Risk Factors	• Provide supportive care **(AIII)**.	• Provide supportive care **(AIII)**.

High Risk[a,b]	• Use 1 of the following options (listed in order of preference):[c]
	  • **Ritonavir-boosted nirmatrelvir (Paxlovid)** within 5 days of symptom onset **(BIII)**
	  • **Remdesivir** within 7 days of symptom onset **(CIII)**
	• There is insufficient evidence to recommend either for or against the use of bebtelovimab.[d]
		• Ritonavir-boosted nirmatrelvir is not authorized by the FDA for use in children aged <12 years.
		• There is insufficient evidence to recommend either for or against routine use of remdesivir. Consider treatment based on age and other risk factors.

Intermediate Risk[b,e]	• There is insufficient evidence to recommend either for or against the use of any antiviral therapy. Consider treatment based on age and other risk factors.	• There is insufficient evidence to recommend either for or against routine use of remdesivir.
Low Risk[b,f]	• Manage with supportive care alone **(BIII)**.	• Manage with supportive care alone **(BIII)**.

Rating of Recommendations: A = Strong; B = Moderate; C = Weak

Rating of Evidence: I = One or more randomized trials without major limitations; IIa = Other randomized trials or subgroup analyses of randomized trials; IIb = Nonrandomized trials or observational cohort studies; III = Expert opinion

-

[a] Molnupiravir is not authorized by the FDA for use in children aged <18 years and should not be used.

[b] See Table 3b for the Panel's framework for assessing the risk of progression to severe COVID-19 based on patient conditions and COVID-19 vaccination status.

[c] Initiate treatment as soon as possible after symptom onset.

[d] Bebtelovimab is the only anti-SARS-CoV-2 mAb active against the current dominant circulating Omicron subvariants. In nonhospitalized adults, bebtelovimab may be used as an alternative therapy when none of the preferred therapies (i.e., ritonavir-boosted nirmatrelvir, remdesivir) are available, feasible to use, or clinically appropriate.

[e] The relative risk of severe COVID-19 for intermediate-risk patients is lower than the risk for high-risk patients but higher than the risk for low-risk patients.

[f] Low-risk patients include those with comorbid conditions that have a weak or unknown association with severe COVID-19. Patients with no comorbidities are included in this group.

Key: FDA = Food and Drug Administration; mAb = monoclonal antibody; the Panel = the COVID-19 Treatment Guidelines Panel

Table 3b. The Panel's Framework for Assessing the Risk of Progression to Severe COVID-19 Based on Patient Conditions and COVID-19 Vaccination Status

Conditions	Risk Level by Vaccination Status[a]		
	Unvaccinated	Primary Series	Up to Date
Strong or Consistent Association With Progression to Severe COVID-19			
• Moderately or severely immunocompromised (see Special Considerations in People Who Are Immunocompromised)	High		
• Obesity (BMI ≥95th percentile for age), especially severe obesity (BMI ≥120% of 95th percentile for age)[b] • Medical complexity with dependence on respiratory technology[c] • Severe neurologic, genetic, metabolic, or other disability that results in impaired airway clearance or limitations in self care or activities of daily living • Severe asthma or other severe chronic lung disease requiring ≥2 inhaled or ≥1 systemic medications daily • Severe congenital or acquired cardiac disease • Multiple moderate to severe chronic diseases	High	Intermediate	
Moderate or Inconsistent Association With Progression to Severe COVID-19			
• Aged <1 year • Prematurity in children aged ≤2 years • Sickle cell disease • Diabetes mellitus (poorly controlled) • Nonsevere cardiac, neurologic, or metabolic disease[d]	Intermediate		
Weak or Unknown Association With Progression to Severe COVID-19			
• Mild asthma • Overweight • Diabetes mellitus (well controlled)	Low		

[a] **Unvaccinated** = individuals who are not eligible for COVID-19 vaccination or are <2 weeks from the final dose of the primary series. **Vaccinated with primary series** = individuals who completed the primary series of 2 or 3 doses (the current CDC term is "fully vaccinated") and are >2 weeks after the final dose of the primary series but have not received a booster, if they are eligible for a booster. Children aged <5 years are not currently eligible for booster doses. **Vaccinated and up to date** = individuals who received the recommended booster dose(s) if eligible or have completed the primary series but are not yet eligible for a booster. See the CDC for more information.

[b] The degree of risk conferred by obesity in younger children is less clear than it is in older adolescents.

[c] Includes tracheostomy or NIV.

[d] Data for this group are particularly limited.

Key: BMI = body mass index; CDC = Centers for Disease Control and Prevention; NIV = noninvasive ventilation; the Panel = the COVID-19 Treatment Guidelines Panel

Prevention of SARS-CoV-2 Infection

Summary Recommendations

• The COVID-19 Treatment Guidelines Panel (the Panel) recommends COVID-19 vaccination as soon as possible for everyone who is eligible according to the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices **(AI)**.
• The Panel recommends using **tixagevimab 300 mg plus cilgavimab 300 mg (Evusheld)** administered as 2 consecutive 3-mL intramuscular (IM) injections **(BIIb)** as SARS-CoV-2 pre-exposure prophylaxis (PrEP) for adults and adolescents (aged ≥12 years and weighing ≥40 kg) who do not have SARS-CoV-2 infection, who have not been recently exposed to an individual with SARS-CoV-2 infection, **AND** who:
  • Are moderately to severely immunocompromised and may have an inadequate immune response to COVID-19 vaccination; *or*
  • Are not able to be fully vaccinated with any available COVID-19 vaccines due to a history of severe adverse reactions to a COVID-19 vaccine or any of its components.
• The Panel recommends repeat dosing of **tixagevimab 300 mg plus cilgavimab 300 mg** administered as IM injections every 6 months **(BIIb)**.
• The Food and Drug Administration Emergency Use Authorization states that individuals who received tixagevimab 150 mg plus cilgavimab 150 mg should be given a second dose as soon as possible.
  • If the initial dose was administered ≤3 months prior, the second dose should be tixagevimab 150 mg plus cilgavimab 150 mg.
  • If the initial dose was administered >3 months prior, the second dose should be tixagevimab 300 mg plus cilgavimab 300 mg.
• **Tixagevimab plus cilgavimab is not a substitute for COVID-19 vaccination and should not be used in unvaccinated individuals for whom COVID-19 vaccination is recommended.**
• The Panel recommends against the use of **bamlanivimab plus etesevimab** and **casirivimab plus imdevimab** for post-exposure prophylaxis (PEP), as the Omicron variant and its subvariants, which are not susceptible to these agents, are currently the dominant SARS-CoV-2 variants circulating in the United States **(AIII)**.

Rating of Recommendations: A = Strong; B = Moderate; C = Weak **Rating of Evidence:** I = One or more randomized trials without major limitations; IIa = Other randomized trials or subgroup analyses of randomized trials; IIb = Nonrandomized trials or observational cohort studies; III = Expert opinion

General Prevention Measures

- *Transmission of SARS-CoV-2 is thought to occur primarily through exposure to respiratory droplets. Exposure can occur when someone inhales droplets or particles that contain the virus (with the greatest risk of transmission occurring within 6 feet of an infectious source) or touches their mucous membranes with hands that have been contaminated with the virus. Exhaled droplets or particles can also deposit the virus onto exposed mucous membranes.1*
- *Less commonly, airborne transmission of small droplets and particles of SARS-CoV-2 to people farther than 6 feet away can occur; in rare cases, people passing through a room that was previously occupied by an infectious person may become infected. SARS-CoV-2 infection via airborne transmission of small particles tends to occur after prolonged exposure (i.e., >15 minutes) to an infectious person who is in an enclosed space with poor ventilation.The risk of SARS-CoV-2 transmission can be reduced by covering coughs and sneezes and maintaining a distance of at least 6 feet from others.*
- *When consistent distancing is not possible, face coverings may reduce the spread of infectious droplets from individuals with SARS-CoV-2 infection to others. Frequent handwashing also effectively reduces the risk of infection.2 Health care providers should follow the Centers for Disease Control and Prevention (CDC)*

recommendations for infection control and the appropriate use of personal protective equipment.

Reference:

4. https://www.covid19treatmentguidelines.nih.gov

HELMINTHS PROBLEMS

- **Helminths** (the word is derived from the Greek meaning "worms") have plagued humans since before the era of our earliest recorded history.
- The eggs of intestinal helminths can be found in the mummified feces of humans dating back thousands of years, and we can recognize many of the characteristic clinical features of helminth infections from the ancient writings of Hippocrates, Egyptian medical papyri, and the Bible .
- There are two major phyla of helminths.

I. The nematodes (also known as roundworms) include:

- the major intestinal worms (also known as soil-transmitted helminths)
- the filarial worms that cause lymphatic filariasis (LF) and
- onchocerciasis.

II. the platyhelminths (also known as flatworms) include the flukes (also known as trematodes), such as

- the schistosomes, and
- the tapeworms (also known as the cestodes), such as the pork tapeworm that causes cysticercosis

The most common helminthiases are those caused by infection with

- intestinal helminths,
- ascariasis,
- trichuriasis, and
- hookworm, followed by
- schistosomiasis and
- lymphatic filariasis ,LF .

Table 1

The major human helminthiases and their global prevalence and distribution

Table 1

The major human helminthiases and their global prevalence and distribution

Disease	Major etiologic agent	Global prevalence	Regions of highest prevalence
Soil-transmitted nematodes			
Ascariasis	*Ascariasis lumbricoides* (roundworm)	807 million	Developing regions of Asia, Africa, and Latin America
Trichuriasis	*Trichuris trichiura* (whipworm)	604 million	Developing regions of Asia, Africa, and Latin America
Hookworm	*Necator americanus*; *Ancylostoma duodenale*	576 million	Developing regions of Asia, Africa, and Latin America (especially areas of rural poverty)
Strongyloidiasis	*Strongyloides stercoralis* (thread worm)	30–100 million	Developing regions of Asia, Africa, and Latin America (especially areas of rural poverty)
Filarial nematodes			
LF	*Wuchereria bancrofti*; *Brugia malayi*	120 million	Developing regions of India, Southeast Asia, and sub-Saharan Africa
Onchocerciasis (river blindness)	*Onchocerca volvulus*	37 million	Sub-Saharan Africa
Loiasis	*Loa loa*	13 million	Sub-Saharan Africa
Dracunculiasis (guinea worm)	*Dracunculus medinensis*	0.01 million	Sub-Saharan Africa
Platyhelminth flukes			
Schistosomiasis	*Schistosoma haematobium*; *Schistosoma mansoni*; *Schistosoma japonicum* (blood flukes)	207 million	Sub-Saharan Africa Sub-Saharan Africa and Eastern Brazil China and Southeast Asia
Food-borne trematodiases	*Clonorchis sinensis* (liver fluke); *Opisthorchis viverinni* (liver fluke); *Paragonimus spp.* (lung flukes); *Fasciolopsis buski* (intestinal fluke); *Fasciola hepatica* (intestinal fluke)	>40 million	Developing regions of East Asia
Platyhelminth tapeworms			
Cysticercosis	*Taenia solium* (pork tapeworm)	0.4 million (Latin America only)	Developing regions of Asia, Latin America, and sub-Saharan Africa

SOILTRANSMITTED HELMINTHS (STHS)

Mode of transmission

- Soil-transmitted helminths refer to the intestinal worms infecting humans that are transmitted through contaminated soil ("helminth" means parasitic worm):
- Ascaris lumbricoides (sometimes called just "Ascaris"), approximately 807-1,121 million with Ascaris
- whipworm (Trichuris trichiura), approximately 604-795 million with whipworm
- hookworm (Ancylostoma duodenale and Necator americanus) approximately 576-740 million with hookworm.
- A large part of the world's population is infected with one or more of these soil-transmitted helminths:
- Soil-transmitted helminth infection is found mainly in areas with warm and moist climates where sanitation and hygiene are poor, including in temperate zones during warmer months.
- These STHs are considered neglected tropical diseases (NTDs) because they inflict tremendous disability and suffering yet can be controlled or eliminated.
- Soil-transmitted helminths live in the intestine and their eggs are passed in the feces of infected persons.
- If an infected person defecates outside (near bushes, in a garden, or field) or if the feces of an infected person are used as fertilizer, eggs are deposited on soil.
- Ascaris and hookworm eggs become infective as they mature in soil.
- People are infected with Ascaris and whipworm when eggs are ingested.
- This can happen when hands or fingers that have contaminated dirt on them are put in the mouth or by consuming vegetables and fruits that have not been carefully cooked, washed or peeled.
- Hookworm eggs are not infective. They hatch in soil, releasing larvae (immature worms) that mature into a form that can penetrate the skin of humans.
- Hookworm infection is transmitted primarily by walking barefoot on contaminated soil. One kind of hookworm (Ancylostoma duodenale) can also be transmitted through the ingestion of larvae.
- People with light soil-transmitted helminth infections usually have no symptoms.
- Heavy infections can cause a range of health problems, including abdominal pain, diarrhea, blood and protein loss, rectal prolapse, and physical and cognitive growth retardation.
- Soil-transmitted helminth infections are treatable with medication prescribed by your health care provider.

ASCARIASIS

- An estimated 807 million–1.2 billion people in the world are infected with **Ascaris lumbricoides** (sometimes called just Ascaris or ascariasis).
- Ascaris, hookworm, and whipworm are parasitic worms known as soil-transmitted helminths (STH).
- Together, they account for a major burden of parasitic disease worldwide.
- Ascaris parasites live in the intestine. Ascaris eggs are passed in the feces (poop) of infected people.
- If an infected person defecates outside (for example, near bushes, in a garden, or in a field), or if the feces of an infected person is used as fertilizer, worm eggs are deposited on soil.
- The worm eggs can then grow into a form of the parasite that can infect others. Ascariasis is caused by ingesting those worm eggs.

- This can happen when hands or fingers that have contaminated dirt on them are put in the mouth, or by eating vegetables or fruits that have not been carefully peeled, washed, or cooked.

Epidemiology & Risk Factors

- Ascariasis caused by *Ascaris lumbricoides* is one of the most common intestinal worm infections.
- It is found where access to personal hygiene and proper sanitation practices are not available, and in places where human feces is used as fertilizer.
- Ascariasis caused by *Ascaris suum* is found where there are pigs.
- People who raise pigs or use raw pig manure as fertilizer may be at risk.
- Contact with pigs should be considered when someone is diagnosed with ascariasis.

Geographic Distribution

- *Ascaris lumbricoides* infections happen all over the world.
- The eggs from the parasite are passed in human feces and can contaminate the soil. The eggs survive best in warm, humid areas and must grow in the soil before they can infect others.
- Most cases occur in tropical and subtropical areas of Asia, sub-Saharan Africa, and the Americas
- *Ascaris suum* is found wherever pigs are found
- The standard method for diagnosing ascariasis is by identifying Ascaris eggs in a stool sample using a microscope. Because eggs may be difficult to find in light infections, a concentration procedure is recommended.

Figure: Left/Right: Fertilized eggs of A. lumbricoides in unstained wet mounts of stool.

Center: Adult female A. lumbricoides.

Symptoms

- People with ascariasis often show no symptoms.
- If symptoms occur, they can be light.
- Symptoms include abdominal discomfort or pain. Heavy infections can block the intestines and slow growth in children.
- Other symptoms such as cough are due to migration of the worms through the body. Ascariasis is treatable with medication prescribed by your healthcare provider.
- Humans can also be infected by pig roundworm (Ascaris suum). Ascaris lumbricoides (human roundworm) and Ascaris suum (pig roundworm) are hard to tell apart. It is unknown how many people worldwide are infected with Ascaris suum.

Treatment

- Anthelmintic medications (drugs that remove parasitic worms from the body), such as albendazole and mebendazole, are the drugs of choice for treatment of Ascaris infections, regardless of the species of worm.
- A single dose of albendazole (400 mg),
- Pyrantel pamoate (11 mg/kg; maximum 1 g),
- Ivermectin (150-200 µg/kg) or
- Levimisole 120-150 mg (single dose) or
- Mebendazole (100 mg twice daily for 3 days) is effective for intestinal ascariasis.
- Patients should be warned that they might expel numerous whole, large worms. Obstruction due to ascariasis should be treated with nasogastric suction, piperazine and intravenous fluids.
- Infections are generally treated for 1–3 days.
- The drugs are effective and appear to have few side effects.

Prevention & Control

- The best way to prevent people from getting ascariasis from humans or pigs is to always do the following:
- Avoid ingesting soil that may be contaminated with human or pig feces, including where human fecal matter ("night soil"), wastewater, or pig manure is used to fertilize crops.
- Wash your hands with soap and water before handling food.
- Wash your hands with soap and water after touching or handling pigs, cleaning pig pens, or handling pig manure.
- Teach children the importance of washing hands to prevent infection.
- Supervise children around pigs, ensuring that they do not put unwashed hands in their mouths.
- Wash, peel, or cook all raw vegetables and fruits before eating, particularly those that have been grown in soil that has been fertilized with manure.
- Transmission of Ascaris lumbricoides infection to others in a community setting can be prevented by: Not defecating outdoors and effective sewage disposal systems.
- More emphasis on: handwashing
- Ascaris suum eggs left in the soil from pigs can survive for up to 10 years. The eggs are very hardy and can survive extreme environmental conditions like freezing and extreme heat.
- It is virtually impossible to completely remove Ascaris suum eggs from the environment where an infected pig has been present.
- Consult a veterinarian for recommendations on preventing and controlling Ascaris suum in your pigs.

HOOKWORM

(Ancylostoma duodenale and Necator americanus)

- An estimated 576-740 million people in the world are infected with hookworm.
- Hookworm, Ascaris, and whipworm are known as soil-transmitted helminths (parasitic worms). Together, they account for a major burden of disease worldwide.
- Hookworms live in the small intestine. Hookworm eggs are passed in the feces of an infected person. If the infected person defecates outside (near bushes, in a garden, or field) or if the feces of an infected person are used as fertilizer, eggs are deposited on soil.
- They can then mature and hatch, releasing larvae (immature worms).
- The larvae mature into a form that can penetrate the skin of humans.
- Hookworm infection is mainly acquired by walking barefoot on contaminated soil.
- One kind of hookworm can also be transmitted through the ingestion of larvae.



- Figure : Left: Filariform (L3) hookworm larva in a wet mount. Right: Hookworm rhabditiform larva (wet preparation)

Symptoms

- Most people infected with hookworms have no symptoms.
- Some have gastrointestinal symptoms, especially persons who are infected for the first time.
- The most serious effects of hookworm infection are blood loss leading to anemia, in addition to protein loss.
- Hookworm infections are treatable with medication prescribed by your health care provider.

Disease

- Highly magnified histologic section showing hookworm (Ancylostoma sp) attached to the intestine.
- High-intensity hookworm infections occur among both school-age children and adults, unlike the soil-transmitted helminths Ascaris and whipworm. High-intensity infections with these worms are less common among adults.
- The most serious effects of hookworm infection are the development of anemia and protein deficiency caused by blood loss at the site of the intestinal attachment of the adult worms.
- When children are continuously infected by many worms, the loss of iron and protein can retard growth and mental development.

Investigation

- The standard method for diagnosing the presence of hookworm is by identifying hookworm eggs in a stool sample using a microscope.
- Because eggs may be difficult to find in light infections, a concentration procedure is recommended.

Treatment

- Anthelminthic medications (drugs that rid the body of parasitic worms),
- such as albendazole and mebendazole, are the drugs of choice for treatment of hookworm infections.
- A single dose of albendazole (400 mg) is the treatment of choice.
- Alternatively, mebendazole 100 mg twice daily for 3 days may be used.
- Infections are generally treated for 1-3 days.
- The recommended medications are effective and appear to have few side effects.
- Iron supplements may also be prescribed if the infected person has anemia.

Prevention & Control

- The best way to avoid hookworm infection is not to walk barefoot in areas where hookworm is common and where there may be human fecal contamination of the soil.
- Also, avoid other skin contact with such soil and avoid ingesting it.

- Infection can also be prevented by not defecating outdoors and by effective sewage disposal systems.

TRICHIURIASIS (ALSO KNOWN AS WHIPWORM INFECTION)

- An estimated 604-795 million people in the world are infected with whipworm.
- Whipworm, hookworm, and Ascaris are known as soil-transmitted helminths (parasitic worms).
- They account for a major burden of disease worldwide.
- Whipworms live in the large intestine and whipworm eggs are passed in the feces of infected persons.
- If the infected person defecates outside (near bushes, in a garden, or field) or if human feces as used as fertilizer, eggs are deposited on soil. They can then mature into a form that is infective. Whipworm infection is caused by ingesting eggs.
- This can happen when hands or fingers that have contaminated dirt on them are put in the mouth or by consuming vegetables or fruits that have not been carefully cooked, washed or peeled.
- People infected with whipworm can suffer light or heavy infections. People with light infections usually have no symptoms.
- People with heavy infections can experience frequent, painful bowel movements that contain a mixture of mucus, water, and blood.
- Rectal prolapse (when the rectum sags and comes out of the anus) can also occur. Children with heavy infections can become severely anemic and may grow more slowly. Whipworm infections are treatable with medication prescribed by a health care provider.



- Figure : Left: Egg of T. trichiura in an iodine-stained wet mount. Center: Micrograph of an adult female Trichuris human whipworm that is approximately 4cm long. Right: Egg of T. trichiura in an unstained wet mount.

Disease

- People infected with whipworm can suffer light or heavy infections. People with light infections usually have no symptoms.
- People with heavy symptoms can experience frequent, painful passage of stool that contains a mixture of mucus, water, and blood.
- Rectal prolapse can also occur.
- Heavy infection in children can lead to severe anemia, growth retardation, and impaired cognitive development. Whipworm infections are treatable with medication prescribed by your health care provider.
- The standard method for diagnosing the presence of whipworm is by microscopically identifying whipworm eggs in a stool sample. Because eggs may be difficult to find in light infections, a concentration procedure is recommended.

Treatment

- Anthelminthic medications (drugs that rid the body of parasitic worms), such as albendazole and mebendazole, are the drugs of choice for treatment.
- Infections are generally treated for 3 days. The recommended medications are effective. Health care providers may decide to repeat a stool exam after treatment.
- Iron supplements may also be prescribed if the infected person suffers from anemia.

Prevention & Control

- The best way to prevent whipworm infection is to always:
- Avoid ingesting soil that may be contaminated with human feces, including where human fecal matter ("night soil") or wastewater is used to fertilize crops.
- Wash your hands with soap and warm water before handling food.
- Teach children the importance of washing hands to prevent infection.
- Wash, peel, or cook all raw vegetables and fruits before eating, particularly those that have been grown in soil that has been fertilized with manure.
- More focus on: Handwashing
- Transmission of infection to others can be prevented by: Not defecating outdoors and effective sewage disposal systems.

STRONGYLOIDIASIS

- *Strongyloides stercoralis* is a very small nematode (2 mmx 0.4 mm) which parasitises the mucosa of the upper part of the small intestine, often in large numbers, causing persistent eosinophilia.
- The eggs hatch in the bowel but only larvae are passed in the faeces.
- In moist soil, they mould and become the infective filariform larvae.
- After penetrating human skin, they undergo a development cycle similar to that of hookworms, except that the female worms burrow into the intestinal mucosa and submucosa.
- Some larvae in the intestine may develop into filariform larvae, which may then penetrate the mucosa or the perianal skin and lead to autoinfection and persistent infection.
- Patients with Strongyloides infection persisting for more than 35 years have been described.
- Strongyloidiasis occurs in the tropics and subtropics.

Clinical features of strongyloidiasis

- Penetration of skin by infective larvae
    - Itchy rash
- Presence of worms in gut
    - Abdominal pain, diarrhoea, steatorrhoea, weight loss
- Allergic phenomena
    - Urticarial plaques and papules, wheezing, arthralgia
- Autoinfection
    - Transient itchy, linear, urticarial weals across abdomen and buttocks (larva currens)
- Systemic (super) infection
    - Diarrhoea, pneumonia, meningoencephalitis, death
- The classic triad of symptoms consists of abdominal pain, diarrhoea and urticaria.
- Cutaneous manifestations, either urticaria or larva currens (a highly characteristic pruritic, elevated, erythematous lesion advancing along the course of larval migration), are

characteristic and occur in 66% of patients.

- Systemic strongyloidiasis (the Strongyloides hyperinfection syndrome), with dissemination of larvae throughout the body, occurs in association with immune suppression (intercurrent disease, HIV and HTLV-1 infection, corticosteroid treatment).
- Patients present with severe, generalised abdominal pain, abdominal distension and shock. Massive larval invasion of the lungs causes cough, wheeze and dyspnoea; cerebral involvement has manifestations ranging from subtle neurological signs to coma.
- Gram-negative sepsis frequently complicates the picture.

Investigations

- There is eosinophilia. Serology (ELISA) is helpful but definitive diagnosis depends upon finding the larvae.
- The faeces should be examined microscopically for motile larvae; excretion is intermittent and so repeated examinations may be necessary.
- Larvae can also be found in jejunal aspirate or detected using the string test (p. 369). Larvae may also be cultured from faeces.

Management

- A course of two doses of ivermectin (200 µg/kg), administered on successive days, is effective.
- Alternatively, albendazole is given orally in a dose of 15 mg/kg body weight twice daily for 3 days. A second course may be required.
- For the Strongyloides hyperinfection syndrome, ivermectin is given 200 µg/kg for 5-7 days.

FILARIASIS OR LYMPHATIC FILARIASIS

- It is Filarial nematodes
- Lymphatic filariasis impairs the lymphatic system and can lead to the abnormal
- An essential, recommended package of care can alleviate suffering and prevent further disability among people living with disease caused by lymphatic filariasis.
- Lymphatic filariasis, commonly known as elephantiasis, is a neglected tropical disease. Infection occurs when filarial parasites are transmitted to humans through mosquitoes. Infection is usually acquired in childhood causing hidden damage to the lymphatic system.
- The painful and profoundly disfiguring visible manifestations of the disease, lymphoedema, elephantiasis and scrotal swelling occur later in life and can lead to permanent disability. These patients are not only physically disabled, but suffer mental, social and financial losses contributing to stigma and poverty.
- In 2020, 863 million people in 50 countries were living in areas that require preventive chemotherapy to stop the spread of infection.
- The global baseline estimate of people affected by lymphatic filariasis was 25 million men with hydrocele and over 15 million people with lymphoedema. At least 36 million people remain with these chronic disease manifestations. Eliminating lymphatic filariasis can prevent unnecessary suffering and contribute to the reduction of poverty.

Cause and transmission

- Lymphatic filariasis is caused by infection with parasites classified as nematodes (roundworms) of the family Filariodidea.
- There are 3 types of these thread-like filarial worms:
- *Wuchereria bancrofti*, which is responsible for 90% of the cases
- *Brugia malayi*, which causes most of the remainder of the cases

- *Brugia timori*, which also causes the disease.
- Adult worms nest in the lymphatic vessels and disrupt the normal function of the lymphatic system. The worms can live for approximately 6–8 years and, during their lifetime, produce millions of microfilariae (immature larvae) that circulate in the blood.
- Mosquitoes are infected with microfilariae by ingesting blood when biting an infected host. Microfilariae mature into infective larvae within the mosquito.
- When infected mosquitoes bite people, mature parasite larvae are deposited on the skin from where they can enter the body.
- The larvae then migrate to the lymphatic vessels where they develop into adult worms, thus continuing a cycle of transmission.
- Lymphatic filariasis is transmitted by different types of mosquitoes for example by the Culex mosquito, widespread across urban and semi-urban areas, Anopheles, mainly found in rural areas, and *Aedes*, mainly in endemic islands in the Pacific.

Symptoms

- Lymphatic filariasis infection involves asymptomatic, acute, and chronic conditions. The majority of infections are asymptomatic, showing no external signs of infection while contributing to transmission of the parasite.
- These asymptomatic infections still cause damage to the lymphatic system and the kidneys and alter the body's immune system.
- When lymphatic filariasis develops into chronic conditions it leads to lymphoedema (tissue swelling) or elephantiasis (skin/tissue thickening) of limbs and hydrocele (scrotal swelling).
- Involvement of breasts and genital organs is common. Such body deformities often lead to social stigma and sub-optimal mental health, loss of income-earning opportunities and increased medical expenses for patients and their caretakers.
- Acute episodes of local inflammation involving skin, lymph nodes and lymphatic vessels often accompany chronic lymphoedema or elephantiasis. Some of these episodes are caused by the body's immune response to the parasite.
- Most are the result of secondary bacterial skin infection where normal defenses have been partially lost due to underlying lymphatic damage.
- These acute attacks are debilitating, may last for weeks and are the primary cause of lost wages among people suffering with lymphatic filariasis.

Large-scale treatment (preventive chemotherapy)

- Elimination of lymphatic filariasis is possible by stopping the spread of the infection through preventive chemotherapy.
- The WHO recommended preventive chemotherapy strategy for lymphatic filariasis elimination is mass drug administration (MDA).
- MDA involves administering an annual dose of medicines to the entire at-risk population. The medicines used have a limited effect on adult parasites but effectively reduce the density of microfilariae in the bloodstream and prevent the spread of parasites to mosquitoes.
- The mass drug administration (MDA) regimen recommended depends on the co-endemicity of lymphatic filariasis with other filarial diseases.
- WHO recommends the following MDA regimens:
    - albendazole (400 mg) alone twice per year for areas co-endemic with loiasis
    - ivermectin (200 mcg/kg) with albendazole (400 mg) in countries with onchocerciasis
    - diethylcarbamazine citrate (DEC) (6 mg/kg) and albendazole (400 mg) in countries without onchocerciasis
- Recent evidence indicates that the combination of all three medicines can safely clear almost all microfilariae from the blood of infected people within a few weeks, as opposed to years using the routine two-medicine combination.

- WHO now recommends the following MDA regimen in countries without onchocerciasis:
    - ivermectin (200 mcg/kg) together with diethylcarbamazine citrate (DEC) (6 mg/kg) and albendazole (400 mg) in certain settings
- The impact of MDA depends on the efficacy of the regimen and the coverage (proportion of total population ingesting the medicines). MDA with the two-medicine regimens have interrupted the transmission cycle when conducted annually for at least 4–6 years with effective coverage of the total population at risk. Salt fortified with DEC has also been used in a few unique settings to interrupt the transmission cycle.
- Success in 2030 will be achieved if people affected by lymphatic filariasis have access to the following essential package of care:
    - treatment for episodes of adenolymphangitis (ADL);
    - guidance in applying simple measures to manage lymphoedema to prevent progression of disease and debilitating, inflammatory episodes of ADL;
    - surgery for hydrocele;
    - treatment for infection
    - **Vector control**
    - Mosquito control is a supplemental strategy supported by WHO. It is used to reduce transmission of lymphatic filariasis and other mosquito-borne infections.

ENTEROBIUS VERMICULARIS (THREADWORM)

Causal Agent

- The nematode (roundworm) *Enterobius vermicularis* is widely known as the human pinworm due to the female's long, pointed tail.
- In some areas the common names "seatworm" and "threadworm" are used (the latter of which is sometimes also used to refer to *Strongyloides stercoralis*).
- Another putative pinworm species, *Enterobius gregorii*, has been described and reported from humans in Europe, Africa, and Asia.
- However, further morphologic and molecular evidence suggests *E. gregorii* likely represents an immature form of *E. vermicularis.* The rat pinworm, *Syphacia obvelata*, has also very rarely been reported infecting humans.



Life cycle of enterobius vermicularis

Source: https://www.cdc.gov/dpdx/enterobiasis/modules/Enterobius_LifeCycl_lg.jpg

- Gravid adult female *Enterobius vermicularis* deposit eggs on perianal folds.
- Infection occurs via self-inoculation (transferring eggs to the mouth with hands that have scratched the perianal area) or through exposure to eggs in the environment (e.g. contaminated surfaces, clothes, bed linens, etc.).
- Following ingestion of infective eggs, the larvae hatch in the small intestine
- and the adults establish themselves in the colon, usually in the cecum.
- The time interval from ingestion of infective eggs to oviposition by the adult females is about one month. At full maturity adult females measure 8 to 13 mm, and adult males 2 to 5 mm; the adult life span is about two months. Gravid females migrate nocturnally outside the anus and oviposit while crawling on the skin of the perianal area.
- The larvae contained inside the eggs develop (the eggs become infective) in 4 to 6 hours under optimal conditions.
- Rarely, eggs may become airborne and be inhaled and swallowed. Retroinfection, or the migration of newly hatched larvae from the anal skin back into the rectum, may occur but the frequency with which this happens is unknown.

Hosts

- Oxyurid nematodes (pinworms) generally exhibit high host specificity. Humans are considered the only host for *E. vermicularis,* although occasional infections have been reported in captive chimpanzees.

Geographic Distribution

- *E. vermicularis* occurs worldwide, with infections occurring most frequently in school- or preschool-children and in crowded conditions.

Clinical Presentation

- Enterobiasis is frequently asymptomatic. The most typical symptom is perianal pruritus, especially at night, which may lead to excoriations and bacterial superinfection. Occasionally, invasion of the female genital tract with vulvovaginitis and pelvic or peritoneal granulomas can occur.
- Other symptoms include, teeth grinding, enuresia, insomnia, anorexia, irritability, and abdominal pain, which can mimic appendicitis.
- *E. vermicularis* larvae are often found within the appendix on appendectomy, but the role of this nematode in appendicitis remains controversial.
- Very rare instances of eosinophilic colitis associated with *E. vermicularis* larvae have been reported.

Treatment

- Mebendazole is the drugs of choice, taken by mouth. Dosage in children from 6 months to 17 years is 100 mg for one dose, if reinfection occur, second dose may be needed after two weeks. In adult, dosage is 100mg for one dose, if reinfection occur, second dose may be needed after two weeks.
- Albendazole (400 mg), pyrantel pamoate (11 mg/kg) or piperazine (4 g) is given and may be repeated after 2 weeks to control auto-reinfection.
- If infection recurs in a family, each member should be treated as above. During this all nightclothes and bed linen are laundered. Fingernails must be kept short and hands washed carefully before meals.
- A bath taken immediately after rising will remove ova laid during the night. Subsequent therapy is reserved for those family members who develop recurrent infection.

LOIASIS

- Loiasis is caused by infection with the filaria Loa loa. The adult worms, 3- 7 cm x 4 mm, chiefly parasitise the subcutaneous tissue of humans, releasing larval microfilariae into the peripheral blood in the daytime.
- The vector is Chrysops, a forest-dwelling, day-biting fly.
- The host response to Loa loa is usually absent or mild, so that the infection may be harmless.
- From time to time a short-lived, inflammatory, oedematous swelling (a Calabar swelling) is produced around an adult worm. Heavy infections, especially when treated, may cause encephalitis.

Clinical features

- The infection is often symptomless. The incubation period is commonly over a year but may be just 3 months. The first sign is usually a Calabar swelling, an irritating, tense, localised swelling that may be painful, especially if it is near a joint.
- The swelling is generally on a limb; it measures a few centimetres in diameter but sometimes is more diffuse and extensive. It usually disappears after a few days but may persist for 2 or 3 weeks.
- A succession of such swellings may appear at irregular intervals, often in adjacent sites. Sometimes, there is urticaria and pruritus elsewhere.
- Occasionally, a worm may be seen wriggling under the skin, especially that of an eyelid, and may cross the eye under the conjunctiva, taking many minutes to do so.

Investigations

- Diagnosis is by demonstrating microfilariae in blood taken during the day, but they may not always be found in patients with Calabar swellings.
- Antifilarial antibodies are positive in 95% of patients and there is massive eosinophilia. Occasionally, a calcified worm may be seen on X-ray.

Management

- Diethylcarbamazine (DEC) is curative, in a dose of 9-12 mg/kg daily, continued for 21 days.
- Treatment may precipitate a severe reaction in patients with a heavy microfilaraemia characterised by fever, joint and muscle pain, and encephalitis; microfilaraemic patients should be given corticosteroid cover.

Prevention

- Protection is afforded by building houses away from trees and by having dwellings wire screened. Protective clothing and insect repellents are also useful.
- Diethylcarbamazine (DEC) in a dose of 5 mg/kg daily for 3 days each month is partially protective.

CESTODES (TAPEWORMS)

- Cestodes are ribbon-shaped worms which inhabit the intestinal tract. They have no alimentary system and absorb nutrients through the tegumental surface. The anterior end, or scolex, has suckers for attaching to the host.
- From the scolex, a series of progressively developing segments arise, the proglottides, which may continue to show active movements when shed. Cross-fertilisation takes place between segments. Ova, present in large numbers in mature proglottides, remain viable for weeks, and during this period, they may be consumed by the intermediate host.
- Larvae liberated from the ingested ova pass into the tissues, forming larval cysticerci.

Tapeworms cause two distinct patterns of disease, either intestinal infection or systemic cysticercosis.

- Taenia saginata (beef tapeworm), Taenia asiatica and Diphyllobothrium latum (fish tapeworm) cause only intestinal infection, following human ingestion of intermediate hosts that contain cysticerci (the larval stage of the tapeworm). Taenia solium causes intestinal infection.
- If a cysticerci-containing intermediate host is ingested, and cysticercosis (systemic infection from larval migration) if ova are ingested. Echinococcus granulosus (dog tapeworm) does not cause human intestinal infection, but causes hydatid disease (which is analogous to cysticercosis) following ingestion of ova and subsequent larval migration.

INTESTINAL TAPEWORM

- Humans acquire tapeworm by eating undercooked beef infected with the larval stage of T. saginata, undercooked pork containing the larval stage of T. solium or T. asiatica, or undercooked freshwater fish containing larvae of D. latum.
- Usually, only one adult tapeworm is present in the gut but up to ten have been reported. The ova of all the three Taenia are indistinguishable microscopically.
- However, examination of scolex and proglottides candifferentiate: T. solium has a rostellum and two rows of hooklets on the scolex, and discharges multiple proglottides (3-5) attached together with lower degrees of uterine branching (approximately 10);
- T. saginata has only four suckers in its scolex, and discharges single proglottids with greater uterine branching (up to 30); T. asiatica has a rostellum without hooks on its scolex, and is difficult to differentiate from T. saginata, except that there are fewer uterine branches (16-21).

TAENIA SAGINATA

- Infection with *T. saginata* occurs in all parts of the world.
- The adult worm may be several metres long and produces little or no intestinal upset in human beings, but knowledge of its presence, by noting segments in the faeces or on underclothing, may distress the patient.
- Ova may be found in the stool.
- Praziquantel is the drug of choice; niclosamide or nitazoxanide is an alternative. Prevention depends on efficient meat inspection and the thorough cooking of beef.

TAENIA SOLIUM

- *T. solium,* the pork tapeworm, is common in central Europe, South Africa, South America and parts of Asia.
- It is not as large as *T. saginata.* The adult worm is found only in humans following the eating of undercooked pork containing cysticerci.
- Intestinal infection is treated with praziquantel (5- 10 mg/kg) or niclosamide (2 g), both as a single dose, or alternatively with nitazoxanide (500 mg twice daily for 3 days).
- These are followed by a mild laxative (after 1-2 hours) to prevent retrograde intestinal autoinfection.
- Cooking pork well prevents intestinal infection. Great care must be taken while attending a patient harbouring an adult worm to avoid ingestion of ova or segments.

TAENIA ASIATICA

- *T. asiatica* is a newly recognised species of *Taenia,* restricted to Asia. It is acquired by eating

uncooked meat or viscera of pigs.
- Clinical features and treatment are similar to those of *T. saginata.*

CYSTICERCOSIS

- Human cysticercosis is acquired by ingesting *T. solium* tapeworm ova, from either contaminated fingers or food.
- The larvae are liberated from eggs in the stomach, penetrate the intestinal mucosa and are carried to many parts of the body, where they develop and form cysticerci, 0.5-1 cm cysts that contain the head of a young worm.
- They do not grow further or migrate. Common locations are the subcutaneous tissue, skeletal muscles and brain.

Clinical features

- When superficially placed, cysts can be palpated under the skin or mucosa as pea-like ovoid bodies.
- Here they cause few or no symptoms, and will eventually die and become calcified. Heavy brain infections, especially in children, may cause features of encephalitis.
- More commonly, however, cerebral signs do not occur until the larvae die, 5-20 years later.
- Epilepsy, personality changes, staggering gait or signs of hydrocephalus are the most common features.

Investigations

- Calcified cysts in muscles can be recognised radiologically.
- In the brain, however, less calcification takes place and larvae are only occasionally visible by plain X-ray; usually CT or MRI will show them.
- Epileptic fits starting in adult life suggest the possibility of cysticercosis if the patient has lived in or travelled to an endemic area.
- The subcutaneous tissue should be palpated and any nodule excised for histology. Radiological examination of the skeletal muscles may be helpful. Antibody detection is available for serodiagnosis

Management and prevention

- Albendazole, 15 mg/kg daily for a minimum of 8 days, has now become the drug of choice for parenchymal neurocysticercosis.
- Praziquantel is another option, 50 mg/kg in three divided doses daily for 10 days.
- Prednisolone, 10 mg 3 times daily, is also given for 14 days, starting 1 day before the albendazole or praziquantel.
- In addition, anti-epileptic drugs should be given until the reaction in the brain has subsided. Operative intervention is indicated for hydrocephalus. Studies from India and Peru suggest that most small, solitary cerebral cysts will resolve without treatment.

ECHINOCOCCUS GRANULOSUS HYDATID DISEASE (TAENIA ECHINOCOCCUS)

- Dogs are the definitive hosts of the tiny tapeworm *E. granulosus.* The larval stage, a hydatid cyst, normally occurs in sheep, cattle, camels and other animals that are infected from contaminated pastures or water.
- By handling a dog or drinking contaminated water, humans may ingest eggs. The embryo is liberated from the ovum in the small intestine and gains access to the blood stream and

thus to the liver.

- The resultant cyst grows very slowly, sometimes intermittently. It is composed of an enveloping fibrous pericyst, laminated hyaline membrane (ectocyst) and inner germinal layers (endocyst) which gives rise to daughter cysts, or germinating cystic brood capsule in which larvae (protoscolices) develop.
- Over time, some cysts may calcify and become non-viable. The disease is common in the Middle East, North and East Africa, Australia and Argentina.
- *E. multilocularis*, which has a cycle between foxes and voles, causes a similar but more severe infection, 'alveolar hydatid disease', which invades the liver like cancer.

Clinical features

- A hydatid cyst is typically acquired in childhood and may, after growing for some years, cause pressure symptoms. These vary, depending on the organ or tissue involved. In nearly 75% of patients with hydatid disease, the right lobe of the liver is invaded and contains a single cyst. In others, a cyst may be found in lung, bone, brain or elsewhere.

Investigations

- The diagnosis depends on the clinical, radiological and ultrasound findings in a patient who has lived in close contact with dogs in an endemic area.
- Complement fixation and ELISA are positive in 70-90% of patients.

Management and prevention

- Hydatid cysts should be excised wherever possible. Great care is taken to avoid spillage and cavities are sterilised with 0.5% silver nitrate or 2.7% sodium chloride. Albendazole (400 mg twice daily for 3 months) should also be used.
- The drug is now often combined with PAIR (percutaneous puncture, aspiration, injection of scolicidal agent and re-aspiration) to good effect.
- Praziquantel (20 mg/kg twice daily for 14 days) also kills protoscolices perioperatively.

References:

1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2276811/
2. https://www.cdc.gov/parasites/sth/index.html
3. https://www.who.int/news-room/fact-sheets/detail/lymphatic-filariasis
4. https://www.cdc.gov/dpdx/enterobiasis/index.html

CHILD HEALTH

- Acute Diarrhoea
- Dysentery
- Vomiting
- Cough / Difficulty in Breathing
- Stridor
- Croup
- Bronchiolitis
- Cough and Cold
- Asthma
- Pneumonia
- Childhood TB
- Convulsions
- Differential Diagnosis of Rashes
- Chicken Pox
- Measles
- Rubella
- Meningococcaemia
- Dengue Haemorrhagic Fever
- Shock
- Anaphylaxis
- Oedematous Child
- Acute Malnutrition in Children
- Immunization for Children in Myanmar
- Burns and Scald

ACUTE DIARRHOEA

Definition

- Passage of unusually loose or watery stools, usually at least three times in a 24 hour period

History

A careful feeding history is essential in the management of a child with diarrhoea. Inquiries should also be made about:

- frequency of stools
- number of days of diarrhoea
- blood in stools
- report of a cholera outbreak in the area
- recent antibiotic or other drug treatment
- attacks of crying with pallor in an infant.

Examination

Look for:

- Signs of some dehydration or severe dehydration:
  - restlessness or irritability
  - lethargy or reduced level of consciousness
  - sunken eyes
  - skin pinch returns slowly or very slowly
  - thirsty or drinks eagerly, or drinking poorly or not able to drink
- blood in stools
- signs of severe malnutrition
- abdominal mass
- abdominal distension.
- There is no need for routine stool microscopy or culture m children with non-bloody diarrhoea.

Classification of the severity of dehydration in children with diarrhoea

Classification	Signs or Symptoms	Treatment
Severe dehydration	Two or more of the following signs: • lethargy or • unconsciousness • sunken eyes • unable to drink or • drinks poorly • skin pinch goes back • very slowly C: 2 s)	• Referral to Hospital • Give fluids for severe dehydration (treatment plan C)
Some dehydration	Two or more of the following signs: • restlessness, • irritability • sunken eyes • drinks eagerly, thirsty • skin pinch goes back slowly	• Give fluid and food for some dehydration (diarrhea treatment plan B) • After rehydration, advise mother on home treatment and when to return immediately • Follow up in 5 days if not improving.

No dehydration	• Not enough signs to classify as some or severe dehydration	• Give fluid and food to treat diarrhoea at home • (diarrhoea treatment plan A) • Advise mother on when to return immediately • Follow up in 5 days if not improving.

- Being lethargic and sleepy are not the same. A lethargic child is not simply asleep: the child's mental state is dull and the child cannot be fully awakened; the child may appear to be drifting into unconsciousness.
- In some infants and children, the eyes normally appear somewhat sunken. It is helpful to ask the mother if the child's eyes are normal or more sunken than usual.
- The skin pinch is less useful in infants or children with marasmus or kwashiorkor, or obese children. Other signs may be altered in children with severe malnutrition.

Severe dehydration

- Referral to Hospital

Fluids for severe dehydration (treatment plan C)

Age(months)	First, give 30ml/kg in:		Then, give 70ml/kg in:
<12	1 hour		5 hours
>12	30min		2 hours and 30 min

- Reassess the patient every 1-2 hours. If hydration is not improving, give the IV drip more rapidly.
- After six hours (infants) or three hours (older patients), evaluate the patient using the assessment chart. Then choose the appropriate treatment plan (A, B or C) to continue treatment.
- If Ringer's Lactate Solution is not available, normal saline may be used
- Repeat once if radial pulse is still very weak or not detectable
- **Suspect cholera** in children over 2 years old who have acute watery diarrhoea and signs of severe dehydration, if cholera is occurring in the local area
- Assess and treat dehydration as for other acute diarrhoea
- Give oral antibiotic:
- Give an oral antibiotic to which strains of *V choleraein* the area are known to be sensitive. Possible choices are: erythromycin, ciprofloxacin and cotrimoxazole
- Tetracycline 12.5mg/kg/does 6hourly for 3days for children over 8years (OR)
- Norfloxacin 6mg/kg/dose 12hourly for 3years
- Prescribe zinc supplementation as soon as vomiting stops

Monitoring

- Reassess the child every 15-30 minutes until a strong radial pulse is present
- If hydration is not improving, give the IV solution more rapidly
- If signs of severe dehydration are still present, repeat the I V fluid infusion as outlined earlier
- If the child is improving but still shows signs of some dehydration, discontinue IV treatment and give ORS solution for 4 hours
- If there are no signs of dehydration, follow the guidelines for no dehydration

Some dehydration (PLAN B)

- Children should be given ORS solution, for the first 4 hours at a clinic while the child is monitored.

Treatment

- In the first 4 hours, give the child the following approximate amounts of ORS solution, according to the child's weight (or age if the weight is not known)
- Determine amount of ORS to give during first 4 hours

Age*	Up to 4 months	4 months up to 12 months	12 months up to 2 years	2 years up to 5 years
Weight	<6kg	6-<l0kg	10-<12kg	12-<20kg
Among of fluid	200-400	400-700	700-900	900-1400

**Use the child's age only when you do not know the weight.*

The approximate amount of ORS required (in ml) can also be calculated by multiplying the child's weight (in kg) by 75. However, if the child wants more to drink, give more.

- Show the mother how to give the child ORS solution, a teaspoonful every 1-2 minutes if the child is under 2 years; frequents from a cup for an older child
- Advise breastfeeding mothers to continue to breastfeed whenever the child wants
- If the mother cannot stay for 4 hours, show her how to prepare ORS solution and give her enough ORS packets to complete the rehydration at home plus enough for 2 more days
- Reassess the child after 4 hours, checking for signs of dehydration listed earlier

If there is no dehydration, teach the mother the four rules of home treatment: (Swift to **Plan A)**

- Give extra fluid
- Give zinc supplements for 10-14 days
- Continue feeding
- Return if the child develops any of the following signs:
- Drinking poorly or unable to drink or break feed
- Becomes more sick
- Develops a fever
- Has blood in the stool
- If the child still has some dehydration, repeat treatment for another 4 hours with ORS solution, as above, and start to offer food, milk or juice and breastfeed frequently
- If signs of severe dehydration have developed, treatment for severe dehydration

No DEHYDRATION (PLAN A)

Treatment

- Treat the child as an outpatient.
- Counsel the mother on the 4 rules of home treatment:
- Give extra fluid, as follows;
    - If the child is being breastfed, advise the mother to breastfeed frequently and for longer at each feed. If the child is exclusively breastfed, give ORS solution or clean water in addition to breast milk. After the diarrhoea stops, exclusive breastfeeding should be resumed, if appropriate to the child's age
- In non-exclusively breastfed children, give one or more of the following:
    - ORS solution
    - Food- based fluids (such as soup, rice water and yoghurt drinks)
    - Clean water
- To prevent dehydration from developing, advise the mother to give extra fluids- as much as the child will take

    - For children <2 years, about 50-100 ml after each loose stool
    - For children 2 years or over, about 100-200 ml after each loose stool
    - Tell the mother to give small sips from a cup. lf the child vomits, wait l0minutes and then give more slowly. She should continue giving extra fluid the diarrhoea stops
- Give zinc supplements for 10-14 days
    - Up to 6 months 1/2 tablet (10mg) per day
    - 6months and more **1** tablet (20 mg) per day
    - Show the mother how to give the zinc supplements
    - Infants, dissolve the tablet in a small amount of clean water, expressed milk or ORS.
    - Older children, tablet can be chewed or dissolve

Suitable fluids

- Most fluids that a child normally takes can be used such as:
    - ORS solution (Low osmolarity)
    - salted drinks (e.g. rice water or a yoghurt drink)
    - vegetable or chicken soup with salt
    - plain water
    - water in which a cereal has been cooked (e.g. unsalted rice water)
    - yoghurt drinks
    - green coconut water
    - weak tea (unsweetened)
    - unsweetened fresh fruit juice.

Unsuitable fluids

- A few fluids are potentially dangerous and should be avoided during diarrhoea. Some examples are:
    - commercial carbonated beverages
    - commercial fruit juices
    - sweetened tea, Coffee

DYSENTERY

- Diarrhoea presenting with loose frequent stools containing blood
- Most episodes are due to *Shigella* and nearly all require antibiotic treatment

Diagnosis

- The diagnostic signs of dysentery are frequent loose stools with visible red blood
- Other findings
  - Abdominal pain
  - Fever
  - Convulsions
  - Lethargy
  - Dehydration
  - Rectal prolapse

Treatment

- **Following should be referred to hospital:**
  - Children with severe malnutrition
  - Young infants (<2 months old)
  - Children who are toxic and lethargic
  - Abdominal distension and tenderness
  - Convulsions
- Give an antibiotic
  - Give an oral antibiotic (for 5 days) to which most local strains of *Shigella* are sensitive.
  - Give ciprofloxacin at 15 mg/kg twice a day for 3 days if antibiotic sensitivity is unknown.
  - If local antimicrobial sensitivity is known, follow local guidelines.
  - Give ceftriaxone IV or IM at 50-80 mg/kg per day for 3 days to severely ill children or as second-line treatment.
  - Trimethoprim-sulphamethoxazole: dose TMP 4mg/kg/dose and SMX 20mg/kg/dose BD for 3 days (OR)
  - Norfloxacin-l0mg/kg/dose BD for 3days
- If not improved or presence of trophozoites form of *E. histolytica* in stool examination add Metronidazole (oral) -l0mg/kg/dose tds for 5days
- Zinc supplement

Follow-up

- Follow -up after two days
- Look for signs of improvement such as no fever, stools with less blood, improved appetite
- If there is no improvement after two days
  - Check for other conditions
  - Stop the first antibiotic
  - Give the child a second-line antibiotic which is known to be effective against *Shigella* in the area
  - If the two antibiotics, which are usually effective for *Shigella* in the area, have each been given for 2 days and produced no signs of clinical improvement.
  - Check for other conditions
  - Admit the child if there is another condition requiring hospital treatment
  - Otherwise treat as an outpatient for possible amoebiasis
- Give the child metronidazole
  - (l0mg/kg, 3 times a day) for 5 days

    - young infants (< 2 months)
- Examine the young infant for surgical causes of blood in the stools (for example, intussusception and refer to a surgeon, if appropriate
    - Give IM /IV ceftriaxone (l00mg/kg) once daily for 5 days

Supportive care

- Treatment of dehydration
- Assess the child for sings of dehydration and give fluids according to treatment Plan A, B or C as appropriate
- Nutritional management
- Ensuring a good diet is very important as dysentery has a marked adverse effect on nutritional status

Prevention of diarrhoea

1. Breast feeding - exclusive breast feeding for 6 months and continue at least 2 years
2. Use of safe water - by using cleanest available and protecting it from contamination water
3. Improves weaning practice - starts at 6 months old with good feeding practice (selecting nutritious foods and using hygienic practice)
4. Food safety - concerning the preparation & consuming of food
5. Hand washing
6. Use of latrines & safe disposal of stool of young children
7. Measles immunization

References:

1. *Pediatric Management Guidelines, Myanmar Pediatric Society-2nd Ed 2011*
2. *Guidelines for the management of common illnesses, WHO-2nd Ed-2013*

VOMITING

Definition

- **Vomiting** is a very common symptom in all paediatric age group. It may be associated with a variety of disturbances, both trivial and serious.
- **Regurgitation, possetting and vomiting:** The return of small amounts of food during or shortly after eating is called regurgitation.
- When this occurs in a baby at or after milk feeding is known as possetting. More complete emptying of the stomach is called vomiting.

Common causes of vomiting in different age group

- **Infancy**
  - Gastroenteritis
  - Gastro-oesophageal reflux
  - Overfeeding
  - Anatomic obstruction - pyloric stenosis, intussusception
  - Systemic infection particularly meningitis, pyelonephritis
- **Childhood**
  - Gastroenteritis
  - Systemic infection
  - Toxic ingestion or medication
  - Whooping cough
- **Adolescence**
  - Gastroenteritis
  - Systemic infection
  - Migraine
  - Pregnancy
  - Bulimia

Aetiology of vomiting

The causes of vomiting are numerous, but the following categories of disease should be considered:

1.	Infective	Gastroenteritis, Urinary tract infection, Meningitis, Tonsillitis, Otitis media or lower respiratory tract infection
2.	Intestinal obstruction	Intussusception, Pyloric stenosis, infection, Intestinal atresia, Acute appendicitis, Volvulus, strangulated hernia
3.	Gastro-oesophageal reflux	
4.	Intracranial pathology	Minor head injury, Raised intracranial pressure from subdural haematoma, Hydrocephalus, Intracranial tumour, Encephalitis, Meningitis
5.	Food allergy or intolerance	Cow's milk, egg, soy, rice intolerance
6.	Metabolic causes	Diabetic ketoacidosis, inborn errors of metabolism, Uraemia, Reye's syndrome, Hypercalcaemia
7.	Psychological cause	As a feature of cyclical vomiting or infrequently with excitement or anxiety
8.	Drugs and toxins	Cytotoxic agents, antibiotics, Theophylline, Opiates, Iron, Digoxin, Lead poisoning

Approach to the vomiting child

- In the infant the first step is to differentiate simple regurgitation from vomiting. If vomiting is truly the problem, the underlying diagnosis can usually be suspected by a thorough history and

physical examination.

History

General well- being

- The general health of the child, and particularly appetite, is a guide to the severity of the complaint.
- Significant vomiting is likely to be accompanied by poor weight gain, if not weight loss. Fever suggests an infective cause.

Characteristics of the vomiting

- The history should be able to differentiate posseting and regurgitation from true vomiting.
- Vomiting from infectious causes tends to be non-projectile, whereas the vomitus in pyloric stenosis can be dramatically projected over some distance.
- Paroxysm of coughing such as blood-stained vomiting indicates inflammation in the upper gastrointestinal tract.
- Bile-stained vomitus is serious sign, suggestive of intestinal obstruction and must be investigated urgently.

Associated symptoms

- Gasteroenteritis and other infections are usually accompanied by diarrhoea.
- Constipation suggests intestinal obstruction.
- Irritability or pain may accompany infection or reflux.
- Aspiration and apnoea are worrying signs of gastro-oesophageal reflux.

Adolescence

- In adolescents, question is somewhat different and needs to include symptoms of migraine, and consideration of gynaecological causes.
- Bulimia rarely presents as vomiting as the adolescent is careful to hide the symptom.
- If the nature or frequency of vomiting is difficult to establish from the history alone, a period of in-patient observation may be of value.

Physical examination

General examination

- A full examination is required to exclude infection in sites other than the gastrointestinal tract, particularly if there is fever.
- There may be signs of local or systemic infection.
- Height and weight should be plotted on the centile charts.
- Poor weight gain is indicative of dehydration in the short-term, and malnutrition in the longer term.
- Hypertension should be excluded.

Signs of dehydration

- Persistent vomiting leads to dehydration.

Abdomen

- Careful examination of the abdomen is essential and may reveal masses, tenderness or distension.
- The abdomen may be tender in gastroenteritis with increased bowel sounds.
- In the rate event of intestinal obstruction, the bowel sounds are tinkling or absent.
- In the vomiting infant, palpation of an olive is diagnostic of pyloric stenosis.

Worrying features in vomiting child for referral

- Bile-stained vomitus -this suggests intestinal obstruction and is always a serious sign which must be investigated urgently
- blood in the vomitus
- drowsiness

- refusal to feed
- malnutrition
- dehydration
- frequent severe abdominal pain
- bloody bowel movement
- fever higher than 102°F (39°C) once or 101°F (38.4°) for more than 3 d

Key points in evaluation of vomiting

- In the infant differentiate posseting from vomiting
- Look for evidence of infection whether gastroenteritis or extra-gastrointestinal
- Differentiate whether the child is dehydrated
- In the infant with projectile vomiting palpate the abdomen carefully for pyloric stenosis
- Suspect reflux in the infant or child with physical disability if there is failure to thrive, blood-stained vomitus, irritability, aspiration or apnoea
- Exclude hypertension as a cause

Management of vomiting

- Monitor for dehydration
- Dehydrated children require rehydration
- Can continue to eat a regular diet as tolerated
- Antiemetics might be recommended in certain situations (to reduce risk of dehydration in children who vomit repeatedly or to reduce motion sickness

REGURGIATION AND POSSETTING

- In the early weeks of life, many normal newborn babies regurgitate after feeds and provided thrive, reassurance only necessary.

GASTRO-OESOPHAGEAL REFLUX

- This is the commonest form of vomiting in infancy due to lax gastro-oesophageal sphincter. At times the vomiting commences soon after birth, but may be delayed a few weeks. After a feed a small amount is regurgitated and may continue until the next feed. At times, the vomiting is forceful. The vomitus may contain altered blood in infant with oesophagitis. Oesophagitis causes irritability and anorexia. Aspiration can manifest itself as episodes of choking and must be suspected in the baby with recurrent episodes of pneumonia.
- In mild cases a careful clinical assessment is sufficient, and confirmation of diagnosis is made by the response to treatment. In more severe or complex cases a barium swallow can be helpful. The severity and frequency of reflux can be documented by continuous pH monitoring (usually 24 hours) with a probe placed in the lower third of the oesophagus.
- In mild uncomplicated cases,
    - propping the child,
    - thickening the feeds and
    - attending to burping may resolve the problem.
- If oesophagitis is present H2 receptor antagonist as ranitidine or frequent use of antacids can be helpful.
- If symptoms do not respond to a good trial of medical agents, or recurrent aspiration apnoea are major problems, surgery is indicated, the commonest procedure being Nissen fundoplication.

PYLORIC STENOSIS

- Pyloric stenosis is caused by hypertrophy of and hyperplasia of pylorus muscle. It usually develops in the first 4-6 weeks of life, is commonest in first-born male children.
- Vomiting is characteristically projectile and generally occurs during or immediately after feeding. The infant is hungry and prepared to take another feed immediately.
- **Physical examination**
- reveals weight loss and varying degree of dehydration.
- Visible peristalsis from the left upper quadrant to the right is most prominent immediately after a feed or just prior to vomiting.
- Careful palpation should reveal a hard mobile tumour (the pylorus) just to the right of the epigastrium.
- Once tumour is felt, further investigation is unnecessary.
- If diagnosis is suspected the loss of acidity from the stomach results in hypochoraemic alkalosis and reduced sodium and potassium levels in the serum.
- **Treatment:** is surgical pyloromyotomy. If the infant is dehydrated, re-hydration must be take place prior to surgery.

INTUSSUSCEPTION

- Vomiting commences early in intussusception.
- A typical history is of dramatic onset of colicky abdominal pain, vomiting, pallor and lethargy.
- The passage of altered blood per rectum occurs in only about half the cases.
- A sausage shaped mass can be felt in the abdomen in 60% of the cases.

ACUTE APPENDICITIS AND PERITONITIS

- In appendicitis in childhood vomiting is the rule, but is preceded by pain.
- In the older child the physical signs are well known.
- However, in younger child (1-5) vomiting with or without diarrhoea may be the only symptom.
- **Physical examination** in this age group can be difficult and unreliable.
- It is only by **repeated examination** of abdomen and an ongoing high index of suspicion that the diagnosis will be made before widespread peritonitis has developed.

POISONING

- Accidental poisoning and attempted suicide need to be considered.
- Vomiting, respiratory and circulatory collapse in a previously well child should raise the possibility of poisoning.

Reference

1. *Module on Paediatrics, Family Medicine*

COUGH/DIFFICULTY IN BREATHING

History

- Pay particular attention to:
  - cough
  - duration in days
  - paroxysms with whoops or vomiting or central cyanosis
  - exposure to someone with TB (or chronic cough) in the family
- history of choking or sudden onset of symptoms
- known or possible HIV infection
- vaccination history: BCG; diphtheria, pertussis, tetanus (DPT); measles; *Haemophilus influenza* type b and pneumococcus
- personal or family history of asthma.

Examination

- The symptoms and signs listed below are a guide for the clinician to reach a diagnosis. Not all children will show every symptom or sign.

General

- central cyanosis
- apnoea, grunting, nasal flaring, audible wheeze, stridor
- head nodding (a movement of the head synchronous with inspiration indicating severe respiratory distress)
- tachycardia
- severe palmar pallor

Chest

- respiratory rate (count during 1 min when the child is calm)
- fast breathing:
  - < 2 months-60 breaths and above
  - 2-11 months-50 breaths and above
  - 5 years-40 breaths and above
- lower chest wall indrawing
- hyperinflated chest
- apex beat displaced or trachea shifted from midline
- raised jugular venous pressure
- **on auscultation**, coarse crackles, no air entry or bronchial breath sounds or wheeze
- abnormal heart rhythm on auscultation
- **percussion** signs of pleural effusion (stony dullness) or pneumothorax (hyper- resonance)
- ***Note:*** *Lower chest wall indrawing is when the lower chest wall goes in when the child breathes in; if only the soft tissue between the ribs or above the clavicle goes in when the child breathes, this is not lower chest wall indrawing.*

Abdomen

- abdominal masses (e.g. lymphadenopathy)
- enlarged liver and spleen

Investigations

- pulse oximetry to detect hypoxia and as a guide to when to start or stop oxygen therapy
- full blood count
- chest X-ray only for children with severe pneumonia or pneumonia that does not respond to treatment or complications or unclear diagnosis or associated with HIV

Differential diagnosis in a child presenting with cough or difficulty in breathing

Diagnosis	In Favour
Pneumonia	▪ Cough with fast breathing ▪ Lower chest wall indrawing ▪ Fever ▪ Coarse crackles or bronchial breath sounds ordullness to percussion ▪ Grunting
Bronchiolitis	▪ Cough ▪ Wheeze and crackles ▪ Age usually < 1 year
Asthma or wheeze	▪ Recurrent episodes of shortness of breath or wheeze ▪ Night cough or cough and wheeze with exercise ▪ Response to bronchodilators ▪ Known or family history of allergy or asthma
Tuberculosis	▪ Chronic cough(> 14 days) ▪ History of contact with TB patient ▪ Poor growth, wasting or weight loss ▪ Positive Mantoux test ▪ Diagnostic chest X-ray may show primary complex or miliary TB ▪ Sputum positive in older child
Pertussis	▪ Paroxysms of cough followed by whoop, vomiting, cyanosis or apnoea ▪ No symptoms between bouts of cough ▪ No fever ▪ No history of DPT vaccination
Croup	▪ Inspiratory stridor ▪ Current measles ▪ Barking character to cough ▪ Hoarse voice
Diphtheria	▪ No history of DPT vaccination ▪ Inspiratory stridor ▪ Grey pharyngeal membrane ▪ Cardiac arrhythmia
Foreign body	▪ History of sudden choking ▪ Sudden onset of stridor or respiratory distress ▪ Focal areas of wheeze or reduced breath sounds
Cardiac failure	▪ Raised jugular venous pressure in older children ▪ Apex beat displaced to the left ▪ Heart murmur (in some cases) ▪ Gallop rhythm ▪ Fine crackles in the bases of the lung fields ▪ Enlarged palpable liver

STRIDOR

Definition

- High pitched sound resulting from turbulent air flow due to obstruction in the upper airway
- Primarily inspiratory

Common causes

- should be considered according to onset
- **Acute stridor**
  - Infection: croup, epiglottis, diphtheria
  - Anaphylaxis
  - Inhaled foreign body
  - (Make certain that you have excluded other causes before treating as "croup" in case of acute onset)
- **Chronic stridor (weeks to months)**
  - Laryngomalacia

Initial assessment and management of stridor

- History taking and physical examination
- If patient is distressed, defer further examination until equipment and facilities are available for emergency airway management

Assess

- Chest recession
- Respiratory rate
- Grunting
- Accessory muscle use and flare of ala nasi
- Breath sounds and air entry
- Heart rate
- Skin color
- Mental status
- Monitor oxygen saturation with pulse oximeter if available and if the child accepts probe
- Give oxygen via face mask if it needs to maintain oxygen saturation >92%

If the child is ill, toxic looking and drooling

- Consider epiglottis or diphtheria
- REFER urgently.

CROUP

Key clinical features

- Acute onset of barking cough, inspiratory stridor and hoarseness
- Preceded by symptoms of a mild upper respiratory tract infection

Assessment of severity

Clinical assessment of croup (Wagener)

Severity

- **Mild** - Stridor with excitement or at rest, with no respiratory distress
- **Moderate** - Stridor at rest with intercostal, subcostal or sternal recession
- **Severe** - stridor at rest with marked recession, decreased air entry and altered level of consciousness
- Pulse oximetry is helpful but not essential.
- Arterial blood gas is not helpful because the blood parameters may remain normal to the late stage. The process of blood taking may distress the child.

Management

- **Mild Cases** - Outpatient
  - Dexamethasone-Oral or parenteral 0.15mg/kg single dose may repeat at 12, 24 hours
  - Prednisolone-1-2 mg/kg stat
  - if vomiting (+), Nebulised Budesonide -2mg single dose only.
- **Moderate and Severe cases –**
  - **REFER TO HOSPITAL.**

Reference

1. *Facility Based IMNCJ (F-IMNCJ) Participants Manual, WHO -2015*
2. *Pediatric Management Guidelines, Myanmar Pediatric Society-2nd Ed 2011*

BRONCHIOLITIS

- Bronchiolitis is a lower respiratory viral infection, which is typically most severe in young infants, occurs in annual epidemics and is characterized by airways obstruction and wheezing. It is most commonly caused by respiratory syncytial virus. Secondary bacterial infection may occur

Diagnosis

- Typical features of bronchiolitis, on examination, include:
  - wheezing that is not relieved by up to three doses of a rapid-acting bronchodilator
  - hyperinflation of the chest, with increased resonance to percussion
  - lower **chest wall indrawing**
  - **fine crackles** and **wheeze** on auscultation of the chest
  - **difficulty in feeding, breastfeeding** or drinking owing to respiratory distress
  - nasal discharge, which can cause severe nasal obstruction.

Treatment

- Most children can be treated at home, but those with the following signs of severe pneumonia should be treated in hospital:
  - oxygen saturation < 90% or central cyanosis.
  - apnoea or history of apnoea
  - inability to breastfeed or drink, or vomiting everything
  - convulsions, lethargy or unconsciousness
  - gasping and grunting (especially in young infants).

Follow-up

- Infants with bronchiolitis may have cough and wheeze for up to 3 weeks. As long as they are well with no respiratory distress, fever or apnoea and are feeding well they do not need antibiotics.
- High-risk infants include:
  - Premature babies
  - Babies <6 wk-old Children with underlying lung disease, congenital heart disease or immunosuppression.

COUGH AND COLD

- These are common, self-limited viral infections that require only supportive care.
- Antibiotics should not be given.
- Wheeze or stridor may occur in some children, especially infants.
- Most episodes end within 14 days

Diagnosis

- Common features:
  - cough
  - nasal discharge
  - mouth breathing
  - fever
- The following are **absent:**
  - general danger signs (e.g. cyanosis, convulsion, respiratory distress, drowsiness)
  - signs of severe pneumonia or pneumonia
  - stridor when the child is calm Wheezing may occur in young children

Treatment

- Treat the child as an outpatient.
- Soothe the throat and relieve the cough with a safe remedy, such as a warm, sweet drink.
- Relieve high fever (39 °C or 102.2 °F) with paracetamol if the fever is causing distress to the child.
- Clear secretions from the child's nose before feeds with a cloth soaked in water that has been twisted to form a pointed wick.
- Give normal fluid requirements plus extra breast milk or fluids if there is fever. Small frequent drinks are more likely to be taken and less likely to be vomited.
- Do **not** give any of the following:
  - an antibiotic (they are not effective and do not prevent pneumonia)
  - remedies containing atropine, codeine or codeine derivatives, or alcohol (these may be harmful) or mucolytics medicated nose drops.

Follow-up

- Advise the mother to:
  - feed the child
  - watch for fast or difficult breathing and return if either develops
  - return if the child becomes sicker or is unable to drink or breastfeed.
- *Reasons to prescribe antibiotics immediately*
  - Investigate further and/or give antibiotics (e.g. amoxicillin 500mg tds) if:
    - Systemically very unwell
    - Symptoms/signs of serious illness or complications, e.g. pneumonia
    - At high risk of serious complications because of pre-existing co-morbidity, e.g. significant heart, lung, renal, liver, or neuromuscular disease, immunosuppression, CF, or young children born prematurely

ASTHMA

Diagnosis

- Mainly based on clinical features
- Consider asthma if any of the following clinical features are present:
- **Persistent or frequent** episodes of **wheezing** in the absence of any other apparent cause
- **Activity-induced** cough or wheeze
- **Nocturnal** cough
- Symptoms **occur or worsen** in the presence of animals with fur, aerosol chemicals, changes in temperature, domestic dust mites, drugs, exercise, pollen, respiratory viral infections, smoke, strong emotional expression
- Recurrent URTIs or take **more than 10 days** to clear up
- Symptoms **improve to adequate** bronchodilator therapy
- **Family history** of asthma or atopy (eczema, rhinitis)

Assessment

History

- Present complaints
- Duration of illness
- Precipitants/Triggers
- Any disturbance of sleep or day time activity
- Any episodes of choking/vomiting/reflux
- Past History
- Age of onset
- Previous severe episodes -hospital admissions, emergency visits, PICU admissions, IV treatment
- Interim symptoms e.g. cough/ wheeze at night or with exercise
- Review the severity of symptoms e.g., exercise limitation, sleep disturbance, school absence
- Current medications
- Dose, method of delivery and emergency plan (action plan)
- Family History
- Atopy, pets and smoking

Physical examination

- Assess for
- Ability to speak
- Conscious level/ exhaustion
- Feeding and drinking
- Central cyanosis
- Accessory muscle use
- Sternal/Chest recession
- Respiratory rate
- Heart rate
- Wheeze on auscultation
- Pre and post nebulizer Sp02%

Management of Exacerbation of Asthma

(Refer to Algorithm for management of acute exacerbation of asthma in children)

Assessment of "Severity" during Acute Asthma exacerbations should be based on the following parameters.

	Mild	**Moderate**	**Severe**
	Admission unlikely	May need admission	Admission needed
Altered consciousness	No	No	Yes
Physical exhaustion	No	No	Yes
Talk in:	Sentences	Phrases	Words
Pulsus paradoxus	Not palpable	May be palpable	Palpable
Central cyanosis	Absent	Absent	Present
Rhonchi	Present	Present	Silent chest
Use of accessory muscle	Absent	Moderate	**Marked**
Sternal retraction	Absent	Moderate	**Marked**
Initial PEF	>60%	40-60%	<40%
Oxygen saturation	>93%	91-93%	<90%

N.B: *patients should be treated as in more severe category if features of more than one are present.*

- Chest X-ray is not helpful in management of acute asthma but should be done if the following is suspected:
  - Pneumothorax
  - Pneumonia
  - Collapse lung
- Blood gas assessment is necessary for severe exacerbations.

Long-term management of ASTHMA

- The goal of asthma care is to achieve and maintain control of the clinical manifestations of the disease for prolonged periods. When asthma is controlled, patients can prevent most attacks, avoid troublesome symptoms day and night, and keep physically active.
- To reach this goal, four interrelated components of therapy are required:
  - **Component 1.** Develop patient/family/doctor partnership
  - **Component 2.** Identify and reduce exposure to risk factors
  - **Component 3.** Assess, treat, and monitor asthma
  - **Component 4.** Manage asthma exacerbations
  - **Component 5.** Special Considerations
- Every component is equally important for successful achievement of good asthma control.

Component 1: Develop patient / family / doctor partnership

- Interactive education of patient and family using all available methods is an integral part of management.
- They should learn to
  - Avoid risk factors
  - Take medications correctly
  - Understand the difference between "controller" and "reliever" medications
  - Monitor asthma control status using symptoms and, if available, PEF in children older than 5 years of age
  - Recognize signs that asthma is worsening and take action
  - Seek medical help as appropriate

Component 2: Identify and reduce exposure to risk factors

- Risk factors should be identified and exposure to risk factor should be reduced or, if possible, avoided.
  - Multiple factors that are ubiquitous to environment - tobacco smoke, drugs, allergens and additives, house dust mites, animals with fur, cockroaches, outdoor pollens and mold, indoor mold
  - Should not avoid exercise (use preventive therapy - rapid acting Beta2 agonist inhalation or oral Leucotriene antagonist)
  - Influenza vaccination should be provided to patients with asthma when vaccination to the general population is advised. However, routine influenza vaccination of children and adults with asthma does not appear to protect them from asthma exacerbations or improve asthma control



Component 3: Assess, Treat, and Monitor Asthma

- Assessing Asthma control is reviewed by day and night time symptom, limitation of activities, need for reliever/rescue treatment, and exacerbations.
- If possible, monitor lung function (PEF or FEVl).

Classification of asthma by level of control

Table: Assessment of Asthma Control in Children 5 years and younger

A. Level of asthma control in **young children**				
In the past 4 weeks, has the child had		Well controlled	Partly controlled	Uncontrolled
Day time symptoms for more than a few minutes	Yes □No D	None of these	1-2 of these	3-4 of these
Any activity limitation due to asthma? (run/play less than other children, tires easily during walks/playing)	Yes □No D			
Reliever needed more than once a week?	Yes □No D			

Any night waking or night coughing due to asthma?	Yes □No D			
B. Risk factors for poor asthma outcomes in young children				
Risk factors for flare-up (exacerbations) in the next few months Uncontrolled asthma One or severe exacerbation in the previous year The start of the child's flare-up season (especially if autumn/fall) Exposures: tobacco smoke, indoor or outdoor air pollution, indoor allergens (e.g. house dust mite, cockroach, pets, mold) especially in combination with viral infection Major psychological or socio-economic problems for child or family Poor adherence with controller medication or incorrect inhaler technique ***Risk factors for fixed airflow limitation*** Severe asthma with several hospitalization History of bronchiolitis ***Risk factors for medication side-effects*** Systemic: frequent courses of OCS, high dose and/or ICS Local: moderate/high dose or potent ICS, incorrect inhaler technique, failure to protect skin or eyes when using ICS by nebulizer or spacer with face mask				

Day to day management of asthma will depend on how well the patient's symptoms are controlled.

Figure. Management Approach Based on Control

For Children older than 5 years and adolescents



	Asthma education Enviroment control			
As needed rapid-acting β_2 agonist	As needed rapid-acting β_2 agonist			
	Select one	Select one	Add one or more	Add one or more
Controller Options	Low-dose inhaled ICS*	Low-dose ICS plus long-acting β_2 agonist	Medium- or high-dose ICS plus long-acting β_2 agonist	Oral glucocortico-steroid (lowest dose)
	Leukotriene modifier**	Medium- or high-dose ICS	Leukotriene modifier	Anti-IgE treatment
		Low-dose ICS plus Leukotriene modifier	Sustained release theophylline	
		Low-dose ICS plus sustained release theophylline		

- Alternative reliever treatments include inhaled anticholinergic, short-acting oral $_2$ agonists, some long acting $_2$ agonist, and short-acting theophylline.
- Regular dosing with short and long-acting $_2$ agonist is not advised unless accompanied by regular use of an inhaled glucocorticosteroid.

Adjusting medication:

- If asthma is not controlled on the current treatment regimen, step up treatment. Generally, improvement should be seen within 1 month. But first review the patient's medication technique, compliance, and avoidance of risk factors
- If asthma is partly controlled, consider stepping up treatment, depending on whether more effective options are available, safety and cost of possible treatment options, and the patient's satisfaction with the level of control achieved
- If control is maintained for at least 3 months, step down with a gradual, stepwise reduction in treatment. The goal is to decrease treatment to the least medication necessary to maintain control.
- For the children younger than 5 years of age start low-dose inhaled corticosteroids for partly controlled cases. For children uncontrolled or partly controlled with low-dose inhaled steroids, either double the ICS dose or add Leukotriene antagonists.

Low daily dose of inhaled corticosteroids for children 5 year and younger

Drug	Low Daily Dose(µg)
Beclomethasone dipropionate	100
Budesonide	200
Fluticasone	100

Choice of Inhaler Device For Children

Age Group	Preferred Device	Alternative Device
Younger than 4 Yrs	Pressurized metered-dose Inhaler plus spacer with mask	Nebulizer with face mask
4-6 yrs	Pressurized metered-dose Inhaler plus spacer with mouthpiece	Nebulizer with face mask
Older than 6 Yrs	Dry powder inhaler, or Breath-actuated pressurized metered-dose inhaler, or Pressurized metered-dose inhaler with spacer	Nebulizer with mouthpiece

Component 4: Manage acute asthma exacerbations

- should be based on clinical severity Primary therapies for exacerbations include
- Repetitive administration of rapid-acting inhaled $_2$ - agonist
- Early introduction of systemic glucocorticosteroids
- Oxygen supplementation
- Closely monitor response to treatment with serial measures of lung function is necessary.

References

1. *British guideline on the management of asthma. A national clinical guideline. May 2008, Revised June 2016.*
2. *Pocket guide for asthma management and prevention (For adults and children older than 5 years).Global initiative for asthma. Updated 2017.*
3. *Pocket guide for asthma management and prevention in children 5 years or younger. Global Initiative for asthma. Updated 2017.*
4. *Global Initiative for asthma (GINA) Teaching slide set,January 2013*

PNEUMONIA

- Pneumonia is caused by viruses or bacteria. It is usually not possible to determine the specific cause of pneumonia by clinical features or chest X-ray appearance.
- Pneumonia is classified as severe or non-severe on the basis of clinical features, the management being based on the classification.
- Antibiotic therapy should be given in most cases of pneumonia and severe pneumonia.
- Severe pneumonia may require additional supportive care, such as oxygen, to be given in hospital.

Classification of the severity of pneumonia

Siens and Symptoms	Classification	Treatment
• Cough or difficulty in breathing with: • Oxygen saturation < 90% or central cyanosis • Severe respiratory distress (e.g. grunting, very severe chest indrawing) • Signs of pneumonia with a general danger sign (inability to breastfeed or drink, lethargy or reduced level of consciousness, convulsions)	**Severe pneumonia**	REFER to hospital. • Give oxygen if saturation< 90%. • Manage airway as appropriate. • Give recommended antibiotic. • Treat high fever if present.
• Fast breathing: • ≥50 breaths/min in a child aged 2-11 months • ≥40 breaths/min in a child aged 1- 5 years • Chest indrawing	**Pneumonia**	Home care • Give appropriate antibiotic. • Advise the mother when to return Immediately if symptoms of severe pneumonia. • Follow up after 3 days.
No signs of pneumonia or severe Pneumonia	**No pneumonia: cough or cold**	Home care • Soothe the throat and relieve cough with safe remedy. • Advise the mother when to return. • Follow up after 5 days if not improving • If coughing for more than 14 days, • Refer to chronic cough (Asthma, Pertussis, TB, Foreign body, HIV)

Diagnosis

- Cough or difficult breathing plus at least one of the following signs:
  - fast breathing: age 2-11 months, 50/min and above
  - age 1-5 years, 40/min and above
  - lower chest wall indrawing

Treatment

- Treat child as outpatient.
- Advise carers to give normal fluid requirements plus extra breast milk or fluids if there is a fever. Small frequent drinks are more likely to be taken and less likely to be vomited

Antibiotic therapy

- Give the first dose at the clinic and teach the mother how to give the other doses at home.
- Give oral amoxicillin:
  - In settings with high HIV infection rate, give oral amoxicillin at least 40 mg/kg per dose twice a day for 5 days.

    - In areas with low HIV prevalence, give amoxicillin at least 40 mg/kg per dose twice a day for 3 days
- Second choice: Co-amoxiclav (30 mg of Amoxycillin/kg/dose 8 hourly) OR Azithromycin Child over 6 months 10 mg/kg once daily (max. 500mg once daily) for 5 days
- Avoid unnecessary harmful medications such as remedies containing atropine, codeine derivatives or alcohol.

Follow-up

- Encourage the mother to feed the child. Advise her to bring the child back after 3 days, or earlier if the child becomes sicker or is unable to drink or breastfeed. When the child returns, check:
    - Whether the breathing has improved (slower), there is no chest indrawing, less fever, and the child is eating better; complete the antibiotic treatment.
    - If the breathing rate and/or chest indrawing or fever and/or eating have not improved, exclude a wheeze.
    - If no wheeze, admit to hospital for Investigations to exclude complications or alternative diagnosis.
    - If signs of severe pneumonia are present, admit the child to hospital and treat as above.
- Address risk factors such as malnutrition, indoor air pollution and parental smoking.

CHILDHOOD TB

Risk factors for Developing Childhood Tuberculosis

- Presence of one or more of the following risk factors
    - Close contact (household, close relatives, caregiver, neighbour and teacher) with a newly diagnosed smear positive case as well as smear negative-culture positive case
    - Age <5 years of age
    - HIV infection
    - Severe malnutrition, measles and immunosuppressive drugs or illnesses
    - Absence of BCG vaccination
    - Failure to thrive or weight loss (documented)

Criteria to Identify TB Suspect in Children

- The child can be considered as a TB-suspect if 2 out of 3 following features are present.
- Fever (38°C) for more than 2 weeks and/ or cough for more than 2 weeks
- Failure to gain weight (Weight loss if known/consult weight chart)
- History of contact with suspected or diagnosed TB patient

Symptom suggestive of childhood TB

- Cough for more than 2 weeks which is not improving with full course of antibiotic and/or bronchodilators
- Fever (>38°C) for >2 weeks after exclusion of common causes of fever (e.g. malaria)
- Failure to gain weight (Weight loss if known/see weight chart)
- Unexplained loss of appetite

MDR TB should be suspected in a child with TB-related symptoms who has:

- History of previous treatment for TB within the past 12 months
- Close contact with a person known to have MDR-TB
- Close contact with TB case that has died, failed TB treatment or is non-adherent to TB treatment
- Failure to improve clinically - persistence of symptoms, failure to gain weight after 2 to 3 months of first-line TB treatment, including persistence of positive smear or culture

Signs suggestive of childhood TB

Pulmonary tuberculosis:

- Signs of persistent pneumonia after full course of appropriate antibiotics (ATB)

Highly suggestive Extra-pulmonary tuberculosis (EPTB):

- Pleural effusion
- Acute vertebral gibbus
- Non-painful glands with draining sinus

Suggestive EPTB

- Meningitis not responding to antibiotics
- Pericardial effusion
- Swollen non-painful joints
- Significant enlarged lymph glands more than 2 cm in diameter and more than 2 in number with no known local cause and not responding to usual antibiotics
- Distended abdomen with ascites
- Clinical features indicative of Tuberculin hypersensitivity (e.g. erythema nodosum phlyctenular

conjunctivitis)

Diagnosis

- Diagnosis is very difficult in children due to non-specific features and the radiological features are not as easy to interpret as in the adult.
- However, in children with risk factors who have suspicious clinical criteria, more definitive diagnosis can be made if appropriate investigations are done

Diagnosis to be based on a combination of

- History of contact.
- Risk factors
- Clinical presentation
- Bacteriological confirmation (Sputum/CSF/Biopsy examination wherever possible)
- Imaging-Chest X-ray /CT
- Immunological evidence of TB infection Mantoux test (Positive if induration >10 mm after 48-72 hours) (not a strong factor to be considered for diagnosis of active TB disease)

Diagnostic Tests

Bacteriological confirmation

- A definitive diagnosis of TB can be achieved only by the demonstration of presence of mycobacterium bacillus in the lesion or its product.
- The main laboratory methods used to detect *Mycobacterium tuberculosis* in a sample from a child suspected of having TB are smear for acid-fast bacilli, Xpert MTB/RIF assay (using real-time PCR) or mycobacterial culture.
- Xpert MTB/RIF (and culture if available) is recommended in all children that are suspected of having MDR-TB.

Sputum examination

- Indicated in children older than 8 years or in any younger children who is able to provide a good quality sputum
- Sputum should be collected spot, early morning and spot strategy
- Gastric lavage (aspiration)-Indicated in children less than 8 years or in children who is unable to produce sputum (Should be carried out after 4 hours of not eating or drinking (starvation))

Chest X ray

- No specific radiological signs
- Features suggestive in the diagnosis of TB
- Unequivocal hilar lymph gland enlargement with or without parenchyma opacification
- Miliary mottling (especially in HIV non-infected host)
- Large pleural effusion (≥⅓ of pleural cavity) in children >5 years
- Apical opacification with cavitation (adult type disease; very rare in children, common in adolescents)

Tuberculin skin tests (TST)

- Tuberculin skin tests are useful in the diagnosis of TB infection in young children for contact tracing.
- It is also useful as an adjunct test where the diagnosis of TB is uncertain.
- TB should never be ruled out in children based on a negative TST result.
- Induration >10 mm is considered positive irrespective of whether BCG has been administered (not a strong factor to be considered for diagnosis of active TB disease)

- Induration >5 mm is considered positive in HIV positive children
- Negative TST never rule out TB in children

Interferon-gamma release assays (IGRAs)

- should not replace the tuberculin skin test (TST) in low- and middle-income countries for the diagnosis of latent TB infection in children or for the diagnostic work-up of children (irrespective of HIV status) suspected of TB disease in these settings.
- *Commercial sero-diagnostics should not be used in children suspected of active pulmonary or extra-pulmonary TB, irrespective of their HIV status.*

Diagnostic tests for other extra-pulmonary

Disease	Special investigation
Cervical / other lymph glands	Biopsy / Fine needle aspiration (FNA)
TB Meningitis	lumbar puncture (LP), Computerized Tomography (CT) of brain
TB Arthritis	Aspiration, biopsy
TB Abdomen/ascites	Ultrasound (US), Analysis of Aspiration
TB Vertebra	Vertebral X-ray; CT/MRI of vertebral column
TB pleural Effusion	Pleural tap for cytology

General Approach to diagnosis of TB in children



Treatment of TB in children

- Effective management of TB relies on
  - Rapid diagnosis of TB
  - Rapid detection of drug resistance
  - Rapid initiation of effective treatment regime
- The main objectives of anti-TB treatment are to:
  - Cure the patient with TB (by rapidly eliminating most of the bacilli);
  - Prevent death from active TB or its late effects;
  - Prevent relapse of TB (by eliminating the dormant bacilli);
  - Prevent the development of drug resistance (by using a combination of drugs);

- Decrease TB transmission to others (smear-positive cases)

Type of TB Patient	TB cases	Regimen	
		Intensive phase	Continuation phase
New case	-Children <8 years of age (exception: see below)	2HRZ	4HR
	• Children ≥8 years of age • Children <8 years of age with severe forms of pulmonary/extra pulmonary TB or who are HIV-infected	2HRZE	4HR
	• Meningitis/disseminated TB disease • Osteoarticular TB	2HRZE	10HR
Previously treated case	• Relapse • Treatment after failure • Treatment after loss to follow-up	3HRZE	5HRE
MDR-TB		**Specially designed standardized or individualized regimens (refer to Myanmar National guidelines on Management of MDR-TB)**	

Recommended treatment regimens for children in each TB diagnostic Category

Recommended doses of first line anti-TB drug

Drug	Recommended daily dosing	
	Dose and range (mg/kg)	Maximum (mg)
Isoniazid (H)	10 (7-15)	300
Rifampicin (R)	15 (10-20)	600
Pyrazinamide (Z)	35 (30-40)	
Ethambutol (E)	20 (15-25)	

Indications for Hospitalization

- TB meningitis
- Miliary TB
- Respiratory distress in any form of TB
- Spinal TB
- Severe adverse events (e.g. hepatoxicity)

Follow up

- Ideally, each child should be assessed at least at the following intervals: 2 weeks after treatment initiation, and at two, five and six-month.
- The assessment should include, as a minimum; symptom assessment, assessment of treatment adherence, enquiry about any adverse events and weight measurement.
- Medication dosages should be adjusted to account for any weight gain.
- Adherence should be assessed by reviewing the treatment card, and pill count or blister pack count.
- A follow - up sputum sample for smear microscopy at 2, 5 and 6 months after treatment initiation should be obtained for any child who was smear-positive at diagnosis.

- Follow up chest radiographs not routinely required in children
- Indications for follow up CXR
    - Extensive pulmonary involvement
    - Continued symptoms
    - Treatment failure regardless of smear positivity

Contact tracing and management

- Young children living in close contact with a source case of smear-positive pulmonary TB are at particular risk of TB infection and disease.
- The risk of infection is greatest if the contact is close and prolonged such as the contact an infant or toddler has with a mother or other caregivers in the household and especially so if the index case is not treated.

The main purposes of child contact screening are to:

- Identify symptomatic children (e.g. children of any age with undiagnosed TB disease);
- Provide preventive therapy for susceptible individuals (e.g. asymptomatic children of <5 years of age in close contact with a smear-positive pulmonary TB case)

Definitions

Source case - A case of pulmonary TB (usually sputum smear positive) which results in infection or disease among contacts

Contacts for screening- All close contacts of a source case of any age, including young children < 5 years, should be screened for symptoms suggestive of TB.

Close contact- Living in the same household as a source case or in frequent contact with a source case (e.g caregiver, grandparents, relatives)

Strategy for Contact Tracing-

Contact tracing should be reinforced in two ways:

- Through index adult case (Detection of TB in close contacts of usually adult source case particularly sputum smear positive cases) (downstream tracing)
- Through close contacts of childhood TB cases (Detection of source case for a paediatric TB patient, also known as reverse contact tracing) (upstream tracing)
- Parents and caregivers are to be strongly encouraged to bring children for contact screening to health centre (passive contact screening). Alternatively, if the child is found with TB disease, his/her family members and neighbours should also undergo TB screening.

Approach to Contact screening-

- Three main steps used for contact screening
    - clinical screening: symptoms assessment of all contacts of any age, including children
    - clinical evaluation for TB: any contact with symptoms suggestive of TB should be further evaluated for TB, e.g. sputum, Chest X-ray etc.
    - contacts who are younger than 5 years of age or HIV-infected of any age, and do not have active TB should be offered preventive therapy

Tuberculosis Preventive Treatment (TPT)

- Asymptomatic children under 5 years of age after exclusion of active TB, exposed to an adult with infectious (smear positive) TB from the same household, will be given 6 months of Isoniazid (10mg/kg daily) or daily Rifampicin (15mg/kg)/Isoniazid (10mg/kg) for 3 months.

Algorithm for screening HIV negative infants and children less than 5 years household contacts of people with TB



References

1. *Revised national guideline on management of tuberculosis in children, NTP/WHO(2016)*
2. *Guidelines for the Management of DR-TB in Myanmar (2017)*
3. *National Tuberculosis Management Guideline, Republic of South Africa, 2014*
4. *Management of Drug-Resistant TB in Children: A Field Guide. Boston, USA 2015, 2nd Edition*
5. *Guidance for national tuberculosis programme on the management of tuberculosis in children, 2nd Edition. WHO 2014*
6. *Latent tuberculosis infection, WHO 2018*
7. *Pediatric Management Guidelines, Myanmar Pediatric Society, 3rd Edition,2018*

CONVULSIONS

- A child with coma or convulsions is always an emergency. When a child comes with convulsion, it is need to differentiate convulsion with fever or convulsion without fever. Febrile convulsion is the commonest cause of convulsion in children but serious disease like meningitis and encephalitis should be considered in every child with convulsion.

Common causes of convulsions with fever

- Febrile convulsion
- Pyogenic meningitis
- Cerebral malaria
- Encephalitis
- TB meningitis
- Brain abscess

Common causes of convulsions without fever

- Epilepsy
- Hypertensive encephalopathy
- Lead encephalopathy
- Sub-duralhaematoma
- Brain tumour

FEBRILE CONVULSION

Definition

- Convulsions occurring in association with fever in children between 6 months and 6 years of age, in whom there is no evidence of intracranial pathology or metabolic derangement

	Simple febrile convulsion	**Complex febrile convulsion**
Duration	<15 minutes	>15 minutes
Type	Generalized	Focal
Recurrence	Not recur during one febrile episode	>one seizure during one febrile episode

Investigations

- Most febrile convulsion follows acute viral infection and investigations are usually not necessary.
- Appropriate investigations should be done only when underlying infection is suspected.

Management

First aid measures for seizure

- Semi prone position
- Check Airway, Breathing and Circulation.
- Adequate airway and suction, 02
- Clothing must be loosened. Excess clothing removed.
- Don't put anything into mouth
- To control fits if more than 4 minutes - PR Diazepam - 0.3 - 0.5 mg/kg

Control fever

- Take off clothing and give tepid sponging.

- Antipyretic e.g. oral or rectal Paracetamol 15 mg/kg 4-6 hourly.

Not all children need to be admitted. The main reasons for admission are: -

- To exclude intracranial pathology especially infection
- Fear of recurrent fits
- To investigate and treat the cause of fever
- To allay parental anxiety, especially if they are staying far from the hospital.

Reassess the child

Exclusion of other intracranial causes of fits

- Meningitis - signs of meningism, tense or bulging anterior fontanelle, prolonged or frequent fits (check Full blood count, Lumbar puncture)
- Encephalitis - change in sensorium, neurological signs may be present
- Cerebral malaria - came from or travelled to malaria endemic area, change m sensorium, (check Malaria parasites)
- Features of Complex febrile convulsion
- Persistent lethargy

Prevention of recurrence

- Generally, not recommended because
    - The risks and potential side effects of antiepileptic medications outweigh the benefits.
    - No medication has been shown to prevent the future onset of epilepsy.
- Long term prophylaxis with daily anticonvulsants is not routinely used even if episodes are frequent. However intermittent prophylaxis (like oral diazepam at the start of temperature and every 8 hours for 24 hours only) can be considered for such children with frequent episodes.

Risk factors for recurrent febrile convulsion

- Family history of febrile convulsion in **1st** degree relative
- Early onset (<lyear)
- Low grade fever during 1st febrile convulsion
- Brief duration (<1-2 hour) between onset of fever and seizure

Risk factors for epilepsy

- Family history of epilepsy in **1st**degree relative
- Underlying neurodevelopmental abnormality
- Complex febrile convulsion

DIFFERENTIAL DIAGNOSIS OF RASHES

RASHES

- Eruptions of skin and mucous membrane accompanied by inflammation.

Classification of rashes

- Maculopapular
- Nodular
- diffuse erythematous
- vesicobullous
- petechial

Differential diagnosis of maculopapular rashes

- Measles
- Rubella
- Roseolar infantum (6th disease)



https://vaccinelin ks Jiles.wordpress.com/2014/08/rubella-measles-roseola jpg?w=800&h =26 7

MEASLES

Causative agent	-	Measles virus
Age	-	All ages
Clinical syndrome	-	Fever, cough; coryza; conjunctivitis
Type of Rash	-	Koplik spots Maculopapular eruption of upper trunk, face; spreads to lower trunk, extremities; becomes confluent.
Distribution	-	Starts on face, move downward.
Similar Entitles	-	Enteroviral infection, Mycoplasma, Drug eruption.

ROSEOLA INFANTUM (EXANTHEM SUBITUM)

Causative agent	-	Herpes virus-6
Age	-	6 months-4 years
Clinical syndrome	-	Fever, irritability: rapid lysis of fever with appearance of rash
Type of Rash	-	Discrete macular or papular rash
Distribution	-	Trunk with extension to neck, extremities, face

Similar Entitles - Rubella

RUBELLA

Causative agent - Rubella virus
Age - All age
Clinical syndrome - In childhood: coryzal prodrome, the rash follows 1-5 days later.
Type of Rash - Maculopapular.
Distribution - It spreads from face to trunk within 24hr, and by the time limbs are involved. It is beginning to fade from the face. Occipital lymph-adenopathy is prominent. Encephalitis is rare. Arthralgia is commoner in adult women
Similar Entitles - Measles

Treatment

- To give appropriate treatment.

References

1. *Module on Paediatrics, Family Medicine*

CHICKEN POX

Causal Organism

- Varicella Zoster virus (VZV)
- Human herpes virus 3 (HHV3)
- DNA virus

Incubation Period

- 2 to 3 weeks
- Infectious period: 2 days before and up to 5 days after onset

Clinical Features



http://kidshealth.org/EN/images/illustrations/ChickenPoxPR-A-enlL.jpg

- Mild malaise, fever may or may not be present or absent
- ***Rash*** –
    - The rash as a crop of macules which within hour pass through a papular stage to become vesicular. The vesicular stage persists for 3 to 4 days becoming pustular and finally forming a crust.
    - The spots are superficial and vesicle may be irregular in shape and they are often surrounded by red areola.
- Lesions at different stages may be seen.
- The trunk is principally involved. Face, scalp and proximal part oflimbs By the time there is vesiculation - there is intense pruritus
- Enantham
- Vesiculation over palate, tongue and buccal membrane, conjunctiva and vagina

Differential Diagnoses

Differential diagnosis of vesicles and pustules

- Impetigo
- Scabies
- Dermatitis hepatiformis
- Eczema hepaticum or vaccinatum
- Erythema multiforme

Common Complications

- Secondary skin infection - cellulitis, erysipelas
- Pneumonitis
    - Usually in adult and immunocompromised children.

    - Present with acute respiratory distress syndrome or haemoptysis
    - **CXR** - Diffuse nodular infiltration, Miliary calcification
    - In a normal child - most likely to be bacterial due to *Streptococcal pneumoniae* and group A streptococcus or *Staphylococcus aureus*
- Neurological
    - Post infectious encephalitis
    - Cerebella ataxia - excellent prognosis
    - CSF - Mild lymphocytic pleocytosis , slight elevation of protein Reye syndrome (10%) secondary to chicken pox
    - Transverse myelitis
    - Acute infantile hemiplegia Guallian Barre syndrome
- Appendicitis
- Others
    - Myocarditis
    - Pericarditis
    - Endocarditis
    - Hepatitis
    - Glomerulonephritis

Treatment outline

Symptomatic therapy

- Non-aspirin antipyretics, cool baths and careful hygiene.
- Timely referral for severe cases

Indication for antiviral therapy and prevention

- Chicken pox in immunocompromised patients
- Healthy patients with unusually severe or complicated chicken pox.

For prevention

- A live attenuated vaccine is licensed in several countries. It appears safe for all individuals, including some immunocompromised children.
- Passive immunity can be induced by use of Varicella-Zoster immune globulin (VZIG). It is indicated within 96 hrs of exposure for susceptible individuals at risk for severe illness.

Candidates for VZIG

- Immunocompromised individuals
- Neonate of infected mothers who had onset of chicken pox within 5 days before delivery or within 48 hours after delivery
- Premature infants of less than 28 wks gestation or <l000gm regardless of maternal history
- Preterm infants (>28 wks of gestation) whose mother lacks prior history of chicken pox
- Possibly children older than 15 yrs or adults with a close exposure to Varicella.
- Pregnant women (Check antibody levels if immune status is unknown)

References

1. *Paediatric SID-2nd Ed:*
2. *Module on Paediatrics, Family Medicine*

MEASLES

Clinical features

- Age - common in preschool children
- **Prodromal phase**
    - Moderate elevation of temperature
    - Dry hacking cough
    - Running of nose
    - Sneezing
    - Redness of eye & excessive lacrimation
    - 2^{nd} or 3^{rd} day of illness,
        - Koplik spots appear on the inner side of cheek opposite the lower molar teeth. Single or multiple and appear as greyish or bluish white grains of sands surrounded by reddish areola. Koplik spots increase in number for 2-3 days and disappear by the end of second day if rash.



- **Exanthematous stage**
    - Maculopapular rash first appear behind the ear near the hairline on the forehead, face & neck spread to trunk, extremities, palms and soles within 3 days.
    - Rash starts disappearing after 4 to 5 days in the same order in which it appeared. It leaves behind a browny desquamation.
    - Anorexia and malaise are often present,
    - Moderate generalised lymphadenopathy may also seen,
- **Convalescent stage**
- **Modified measles -** in partially immune individuals
    - Symptoms are mild and duration of illness is shorter
- **Atypical measles** - in previously immunized person after exposure to natural infection.
- **Haemorrhagic measles** - high fever, convulsion, delirium, stupor and even coma.
    - Bleeding occur from the mouth, nose and bowel may result in death.

Differential diagnosis

1) Rubella

- Incubation period is 10-18 days
- Prodromal symptoms are minimal
- Rash is pink, maculopapular and discrete. Mid and last for 3-5 days. Lymph nodes enlarge characteristically even the occipital protuberance.

2) Exanthema subitum (Sixth Disease) caused by Human herpes virus - 6
    - High fever and irritability are present
    - Fever is gradually come down with the appearance of rash
    - Febrile convulsion are usual
3) Erythema infectiosum (Fifth Disease) caused by Parvovirus B19 Slapped cheek
    - Prodromal period is absent
    - No fever
4) Drug rash
    - History of drug ingestion is present
    - Itchiness is present
    - Features of hypersensitivity reaction are present
5) Infectious mononucleosis
    - Rash is associated with generalized lymphadenopathy and hepatosplenomegaly.
6) Meningococcaemic rash
    - Rash appears within 24 hours.
    - Fever, vomiting, malaise, irritability and stiff neck are present.
    - Petechiae and ecchymoses are seen.

Common complications

1. Respiratory complications
    - Otitis media, cervical lymphadenopathy, laryngitis, laryngotracheitis, interstitial pneumonia and bronchopneumonia
    - Flare up of the pulmonary tuberculosis
2. Non suppurative complications
    - GI tract - diarrhoea, cancrum oris, stomatitis, mesenteric lymphadenitis, malnutrition.
    - CNS - measles encephalitis, SSPE
3. Others.
    - Acute glomerulonephritis, Steven Johnson syndrome, DIC.

Supportive treatment

- Body and oral hygiene
- Adequate amount of fluid
- Good nourishing diet
- Fever is controlled by paracetamol and hydrotherapy
- Cough - clearing the mucus
- Vitamin A <1 yr 100,000 unit for 2 days.
  >1 yr 200,000 unit for 2 days.

Treatment of complications

- Antibiotics for pneumonia
- 02
- Diazepam and phenobarbitone for convulsion
- ORT for diarrhoea

Preventive measures

- Active immunization according to EPI
- Passive immunization - exposed infants and younger siblings, gamma globulin i.m.
- 0.25 ml/kg for <1 yr child and 0.5 ml/kg for>1 yr.
- Improve personal hygiene and environmental sanitation.

Referral

- Any general danger signs
- clouding of cornea,
- deep or extensive mouth ulcer

- Pus draining from the eye >2 days treatment with tetracycline eye ointment

References

1. *Paediatric SIG-2nd Edition*
2. *Module on Paediatrics, Family Medicine*

RUBELLA

Mode of transmission

- Droplet infection

Incubation period

- 18 to 21 days
- Infectious period: 5-7 days after rash develops

Clinical features

Prodromal stage

- Rare to have prodromal stage in children
- In female adult, there are malaise, headache, fever, and conjunctivitis and arthritis.

Appearance of rash

- Start over face (maculopapular rash)
- Soon spreads to cover the trunk and later the limbs
- Basic lesion appears as fine, pink macules which is originally discrete but can soon coalesce over the face and trunk

No desquamation of rashes

- Usually disappear 2 to 3 days

Lymph node enlargement

- Usually one week before the rash
- Cervical, post auricular and sub occipital glands are involved
- Tender and sometime unassociated with any rash



https://downhousesoftware.files.wordpress.com/2013/04/rube_lla.jpg

CONGENITAL RUBELLA SYNDROME

- Most serious complication of rubella
- May occur when a non-immune mother acquires rubella in early pregnancy.
- Result in uterofoetal infection
- Most dangerous during first 12 week of pregnancy

Clinical features of congenital rubella syndrome

- Abortion, IUGR, SGA
- Microcephaly, mental retardation
- Heart defect - PDA, VSD, PS, TOF
- Deafness
- Ocular defect - Cataract, glaucoma, micro-ophthalmia, retinopathy

Differential diagnoses of rubella

- **Measles**
  - Main different from measles rash
  - Subclinical or clinical infection

    - Rash with no conjunctivitis, no desquamation
    - No staining
    - Associated with polyarthritis or arthralgia
- **Enteroviral infection** e.g. Echo Coxsackie virus
- **Infectious mononucleosis**
- **Scarlet fever**
- **Erythema infectiosum**
- **Various drug eruption/ rash (drug allergic rash)**

Management

Conservative treatment

- No specific treatment in rubella infection.
- Conservative management or symptomatic management only

Preventive measure & importance of prevention

- To prevent Congenital Rubella Syndrome especially for the girls before child bearing age
- Active immunization with MMR (Measles vaccine conjunction with mumps and rubella) vaccine
- First dose at one year of age, second dose - preschool or 12 to 14 year old
- Contraindication - immune deficiency, symptomatic HIV Infection, anaphylactic egg allergy

References

1. *Paediatric 510*
2. *Module on Paediatrics, Family Medicine*

MENINGOCOCCAEMIA

Clinical feature

	Symptoms	Signs
Meningitis	• Fever, Headache, Nausea, Vomiting, Rash, • Drowsiness or irritability • Neck and back pain and stiffness Convulsion	• Fever, Non-blanching rash • Neck stiffness, • +ve Kerning's sign • Opisthotonous, • Decreased conscious level
Meningococcal	• Fever, petechial / purpuric rash • shivering/ rigor, malaise and lethargy/confusion, Headache, nausea, vomiting, limb and joint pain • Absence of neck stiffness • Collapse	• Fever, petechial / purpuric rash
Septicaemia		**Shock** • Tachycardia, low pulse volume, cool peripheries, capillary refill time > 2 seconds • Hypotension (late sign) • Urine Output reduced (< 1 ml/ kg / hr) • Tachypnoea, Hypoxaemia • Decreased conscious level **Cardiac Insufficiency** Pulmonary Oedema, Hepatomegaly
Mixed picture of Meningitis and Septicaemia	Life threatening feature of meningococcal disease • (SHOCK) • Raised intracranial pressure	

Treatment Outline

- Immediate measures in meningococcal disease: need for **immediate referral** after giving first dose Antibiotic
- ANTIBIOTICS
  - Inj Ceftriaxone I/V 100mg/kg/24hr in once day (OR)
  - Inj Cefotaxime I/V 100mg/kg/24hr in 4 divided does
- Treatment of shock : A,B,C
  - : fluid - Colloid/Inotropes:
- Notification to local public health authority

Prevention

- Antibiotic **prophylaxis**
  - Household or close contacts
    - Rifampicin : Oral : <1 month 5mg/kg x BD x 2 days
      1month - 1yr 5mg/kg x BD x 2 days
      1 yr -12yr 10mg/kg x BD x 2days
      >12 years 600mg x BD x 2 days
    - Ciprofloxacin: Oral 2-5yr – 125 mg stat
      5-12yr 250 mg stat

Adult- 500mg (single dose Adult only)

- Health-care workers
  - Chemoprophylaxis rarely indicated
  - Only recommended in situations where there has been mouth to mouth contact or direct exposure to infectious droplets

Vaccination

- Vaccination
- Meningococcal vaccine to household and day care nursery contacts.
- Booster after 3 month and 12-18 month.

Reference

1. *Pediatric Management Guidelines-Myanmar Pediatric Society-May 2011*
2. *Paediatrics SIO*
3. *Module on Paediatrics, Family Medicine*

DENGUE HAEMORRHAGIC FEVER (DHF)

- **Dengue virus Infections:** Dengue Fever, Dengue Haemorrhagic Fever, Dengue Shock Syndrome
- **Dengue Fever (DF):** a flu-like illness that mostly affects older children and adults and rarely causes death
- **Dengue Haemorrhagic Fever (DHF):** is a serious viral disease transmitted by the bite of a mosquito. DHF is a more severe form of acute febrile illness associated with haemorrhagic diathesis and a tendency to develop fatal shock, **Dengue Shock Syndrome (DSS).**
- DHF is more common in children less than 15 years of age.

WHO case definition of DHF

- Acute sudden onset of high fever for 2- 7 days
- Haemorrhagic manifestations with at least a positive tourniquet test
- Platelet count <l00x 10^9/1
- Haemoconcentration (rising packed cell volume >20%) or other evidence of plasma leakage-for example, ascites, pleural effusions, low level of serum protein/albumin

Severity grading (WHO classification)

The disease severity of DHF has been classified into four grades according to the clinical hallmarks of bleeding and plasma leakage.

- Grade I - Only positive tourniquet test
- Grade II - Positive tourniquet test with spontaneous superficial bleeding
- Grade III - Shock
- Grade IV - Profound shock with unrecordable blood pressure and/or pulse

Stepwise approach

Step I. Overall assessment

- History, including information on symptoms, past medical and family history
- Physical examination, including full physical and mental assessment
- Investigations, including routine laboratory and dengue-specific tests

Step II. Diagnosis, assessment of disease phase and severity

Step III. Management

- Management decisions
- Depending on the clinical manifestations and other circumstances, patients may:
- Be sent home (Group A)
- Require in-hospital management (Group B)
- Require emergency treatment (Group C)

Suggested dengue case classification and levels of severity



WHO New Grading of Dengue (2009)

CRITERIA FOR DENGUE± WARNING SIGNS		CRITERIA FOR SEVERE DENGUE
Probable dengue	**Warning signs***	
Live in/travel to dengue endemic area Fever and 2 of the following criteria • Nausea, vomiting • Rash • Aches and pains • Tourniquet test positive • Leucopenia • Any warning signs **Laboratory-confirmed dengue** *(Important when no sign of plasma leaka5<e)*	• Abdominal pain or tenderness • Persistent vomiting • Clinical fluid accumulation • Mucosal bleed • Lethargy, restlessness • Liver enlargement >2 cm • Laboratory: increase in haematocrit (HCT), concurrent with rapid decrease in platelet count. **(Requiring strict observation and medical intervention)*	1. **Severe plasma leakage leading to:** • Shock (DSS) • Fluid accumulation with respiratory distress 2. **Severe bleeding** as evaluated by clinician 3. **Severe organ involvement** • Liver: AST or ALT 2':1000 • CNS: Impaired conscious-ness • Heart and other organs

Overall assessment

History

- The history should include:
- Date of onset of fever / illness
- Quantity of oral intake
- Assessment for warning signs
- Diarrhoea
- Change in mental state / seizure / dizziness
- Urine output (frequency, volume and time of last voiding)
- Other important relevant histories, such as family or neighborhood dengue, travel to dengue endemic areas
- Travelling to malaria endemic area (consider malaria)

Physical examination

- The physical examination should include:
- Assessment of mental state
- Assessment of hydration status
- Assessment of hemodynamic status
- Checking for tachypnoea/acidotic breathing/pleural effusion
- Checking for abdominal tenderness/hepatomegaly/as cites
- Examination for rash and bleeding manifestations
- Tourniquet test (repeat if previously negative or if there is no bleeding manifestation)

Management decisions

Depending on the clinical manifestations and other circumstances, patients should be classified as:

- (*Group* A) - Patients who may be sent home
- (*Group* B) - Patients who require in-hospital management
- (*Group* C) - Patients who require emergency treatment
- Group A - Patients who may be sent home
- Are able to tolerate adequate volumes of oral fluids
- Pass urine at least once every six hours
- Do not have any of the warning signs

- Those with stable haematocrit (Hct) can be sent home after being advised to ***return to the hospital immediately if they develop any of the warning signs*** and to adhere to the following action plan
- **Fluids:** Encourage oral intake of oral rehydration solution (ORS), fruit juice and other fluids containing electrolytes and sugar to replace losses from fever and vomiting
- **Antipyretics:** paracetamol for high fever if the patient is uncomfortable. The interval of paracetamol dosing should not be less than six hours
- **Instruct** the care - givers that the patient should be brought to hospital immediately if any of the following occur:
- No clinical improvement
- Deterioration around the time of defervescense
- Severe abdominal pain
- Persistent vomiting
- Cold and clammy extremities
- Lethargy or irritability/ restlessness
- Bleeding (e.g. black stools or coffee - ground vomiting)
- Not passing urine for more than 4-6 hour

MANAGEMENT OF THE CHILD WITH SHOCK

Definition

- State of circulatory dysfunction leading to inadequate cellular perfusion and tissue hypoxia Inadequate perfusion of the body's vital organs resulting in anaerobic metabolism and tissue acidosis.
- Multiple end - organ failure and death if insufficient compensation to reverse these changes.

Compensated shock

- Prolong capillary refill and cold peripheries (reduce blood flow to non vital organs)
- Increase in heart rate (up to 200 beats per minute for a finite period of time)
- Increase in respiratory rate (to improve oxygen delivery)
- Reduce urine output (<0.5 ml/kg/hour)
- Agitation and confusion
- Blood pressure is maintained

Uncompensated shock

- Anuria
- (A further) reduction of conscious level: GCS <8, only response to pain (AVPU)
- Respiratory failure
- Hypotension (pre-terminal sign)
- In children, the two commonest forms of shock are;
- Hypovolaemic shock secondary to trauma or gastroenteritis
- Septic shock, i.e. distributive

Management chart for child with shock

Condition	Immediate Management
• drowsy restless cold extremities • reduced urine output • rapid thready pulse • low BP or narrow pulses pressure	• Clear airway • IV fluid (e.g. R/L or N/S or D/S 20ml/kg/hr)

In a child with shock, the following conditions should be considered

ASK	LOOK FOR	POSSIBLE DIAGNOSIS	INVESTI-GATION	MANAGEMNET
1. Diarrhoea, Vomiting	Two of the following signs: • Lethargic/ unconscious • Sunken eyes • Not able to drink or drinks poorly • Skin pinch goes back very slowly	Acute watery diarrhoea with severe dehydration	• Stool RE • Serum U, C&E if available	Treat as diarrhea (**See Plan C)**
Rapid Onset	• Rice water stool, • Fishy smell, • Washer woman's hands	SUSPECTED CHOLERA	• Rectal swab	>8yrs • Tetracycline 12.5mg/kg/dose 6H x 3 days • Norfloxacin6mg/kg/dose12H x 3 days

ASK	LOOK FOR	POSSIBLE DIAGNOSIS	INVESTI-GATION	MANAGEMNET
Ingestion of mushroom or Tapioca	Constricted pupil in mushroom poisoning	MUSHROOM OR TAPIOCA POISIONING		• Inj. atropine sulphate 0.02mg/kg IM or SC for mushroom poisoning • Refer to hospital
2. Fever with Diarrhoea	Febrile, Toxic Splenomegaly	Acute Watery diarrhoea with septicaemic shock		• Cefotaxime 50mg/kg I/V or I/M or • Ceftriazone 50mg/kg • Referred to hospital
Fever with septic foci	• Toxic • Febrile (or) hypothermia • Bounding pulse • Splenomegaly • Focus of infection ± • Pallor ±	Septicaemic shock		• Cefotaxime 50mg/kg I/V or I/M or • Ceftriazone 50mg/kg • Referred to hospital
High continuous fever < 7days with • vomiting • Bleeding manifestations (coffee ground vomiting /Melaena)	• Hypotension • Narrow pulse pressure 9<20 mmHg) • Hepatomegaly	Dengue Shock Syndrome (DSS)		• Treated as DSS
Acute onset Fever with skin rash	• Characteristic skin rash • Purpuric rash with central necrosis • Petechiae	Meningo-coccaemia		• IV N/S 20ml/kg bolus • if shock not revived give 2nd bolus of N/S
H/O travel to malaria endemic area within last 6 month	• Splenomegaly ± • Pallor ±	Algid malaria		• Inj: Artesunate I/V • N/S 20ml/kg bolus • Refer to Hospital
3. History of taking Drugs (eg. Penicillin/ **Streptomycin)**	• Dyspnoea • Wheezing ± • Vomiting, • Diarrhoea if due to streptomycin	Anaphylactic shock		• N/S 20ml/kg bolus • IM Adrenalin (1:1000 Solution) • >12 yrs→ 0.5 ml • 6- 12yrs→0.3ml • <6 yrs→0.15ml • Repeat after 5min if not better • Injection-Hydrocortisone • Injection-Chlorpheniramine
4. History suggestive of blood loss/any blunt injury	• Evidence of external injuries • Pallor ± • Abd: pain, rigidity	Shock due to blood loss		• N/S 20ml/kg • Refer to hospital

- If a child ***came in with shock***, the commonest causes of shock in children are considered in five groups
  - **Shock associated with diarrhea & vomiting**
  - **Shock associated with fever**
  - **Shock associated with some drugs**
  - **Shock after blood loss**
  - **Cardiogenic**

ANAPHYLAXIS

- Anaphylaxis is the most urgent of clinical immunologic events. It is defined as the clinical response to an immediate (type) immunologic reaction.
- Anaphylaxis is a severe allergic reaction, which may cause upper airway obstruction with stridor, lower airway obstruction with wheezing or shock or all three. Common causes include allergic reactions to antibiotics, to vaccines, to blood transfusion and to certain foods, especially nuts.
- Consider the diagnosis if any of the following symptoms is present and there is a history of previous severe reaction, rapid progression or a history of asthma, eczema or atopy.

Severity of anaphylaxis

Severity	Symptoms	Signs	Treatment
Mild	• Itching mouth • Nausea	• Urticaria • Oedema of the face • Conjunctivitis • Throat congestion	• Remove the allergen as appropriate • Give oral anti histamine
Moderate	• Cough or wheeze • Diarrhoea • Sweating	• Wheeze • Tachycardia • Pallor	• Give adrenaline 0.15ml ofl :1000 IM into the thigh; the dose may be repeated every 5-15 mints
Severe	• Difficulty in breathing • Collapse • Vomiting	• Severe wheeze with poor air entry • Oedema of the larynx • Shock • Respiratory arrest • Cardiac arrest	• If the child is not breathing, start basic life support • Give adrenaline 0.15 ml ofl:1000 IM and repeat every 5-15 min. • Give 100% oxygen. • Ensure stabilization of the airway, breathing, circulation and secure IV access • Administer 20 ml/kg normal saline 0.9% or Ringer's lactate solution IV as rapidly as possible. IfIV access is not possible, insert an intraosseous line

Reference

1) *Management of critically ill children, 2nd Edition 2005*
2) *Padiatric Management Guidelines, 2nd Edition 2011*
3) *Module on Paediatrics, Family Medicine*
4) *Pediatric Management Guidelines, Myanmar Pediatric Society-2nd Ed 2011*

OEDEMATOUS CHILD

- **Oedematous:** accumulation of the excess fluid in the interstitial space
- The cardinal sign of subcutaneous oedema is the pitting of the skin, made by applying firm pressure with the examiner's finger or thumb for a few seconds.
- The pitting may persist for several minutes. However, myxoedema due to infiltration of the tissues by a firm mucinous material does not pit on pressure, chronic lymphoedema may also fail to pit.

The contributing factors

- Increased hydrostatic pressure
  - e.g. portal hypertension, constructive pericarditis, Budd. Chiari syndrome
- Decreased oncotic pressure & decreased protein
  - e.g. inadequate intake, impaired production & loss of protein.
- Increased capillary permeability
  - e.g. allergic reaction & inflammatory reaction
- Low tissue tension
  - e.g. localization of slight edema in periorbital region, scrotum & vulva
- Sodium & water retention
  - e.g. Heart failure, AGN, Nephrotic Syndrome
- Impairment of lymphatic return
  - e.g. filariasis

Types and causes of oedema

1. Generalized oedema - due to transudation of salt & water
   - e.g. Hypoproteinaemia Congestive cardiac failure Acute glomerulonephritis
2. Localized edema due to increased permeability of small blood vessels.
   - e.g. Infection Trauma Bums, Malignant infiltration Lymphatic obstruction, Filariasis, Venous obstruction Thrombosis

Diagnosis of oedema

Most important: identify primary diseases of oedema Quickly evaluate the clinical features

A. GENERALIZED OEDEMA

Renal cause

e.g. Acute glomerulonephritis, Nephrotic syndrome

- starts from face
- H/O previous streptococcal infection may be resent in AGN.
- Hypertension may be present in AGN (Present or absent in Nephrotic syndrome)
- Hypoproteinaemia may be present in Nephrotic syndrome

Protein Energy Malnutrition

- Generalized oedema associated with muscle wasting
- Skin changes (flaky pavement dermatitis)
- Vitamin deficiencies (e.g. Vit A deficiency Bitot's spot)
- weight is <3rd centile
- <60% of expected weight

Heart failure

- Breathless & sleeps propped up.
- Swelling of the ankle is followed by generalized oedema
- History of migratory joint pain may be present in rheumatic valvular heart disease.
- cyanosis (+)
- Murmur (+) in PDA, VSD Fallot's tetralogy.
- Murmur (-) in paroxysmal tachycardia, coarctation of aorta, Fallot's tetralogy, in early infancy,

transposition of vessels, total anomalous pulmonary venous drainage, myocarditis, fibroelastosis or severe anaemia.

Hepatic cause

- Ascites is especially marked in cirrhosis of liver
- Portal hypertension with splenomegaly
- Hypoalbuminaemia (+)
- Enlarged liver in early stage with palmar erythema & spider nevi.
- Jaundice, collateral circulation in abdomen.

Angioneurotic oedema

- Sudden swelling of the eyelids with swelling of lip & tongue
- Rash may be(+)
- Previous similar attack with known allergic subject may be(+)
- eosinophilia (+)

Management of oedema

- Mild oedema without symptoms does not need special treatment. Oedema which gives the patient discomfort or the consequential complications should be ameliorated.

Supportive management

- **Bed rest:** shifts blood volume into central circulation from the peripheral venous pooling; leads to an increase in cardiac output, renal and hepatic perfusion.
- **Sodium restriction:** restricting salt intake to amount **1** to 1.5 mEq/kg/ day is generally sufficient. This degree of restriction may be achieved by avoiding salty foods.
- **Water restriction:** In severe oedematous state, adequate water restriction is effective in preventing further oedema formation.

Medical therapy of oedema

- Treatment of underlying cause.

Refer

- Depend on the underlying cause

References

1. *Module on Paediatrics, Family Medicine*

ACUTE MALNUTRITION IN CHILDREN

Definition of Acute Malnutrition

- **Severe Acute malnutrition** is defined as wasting (thinness) and/or presence of bilateral pitting edema.
- **Moderate acute malnutrition** (MAM), is defined by moderate wasting.

Types of Acute Malnutrition

There are two types of acute malnutrition

- Moderate Acute malnutrition (MAM) and
- Severe Acute malnutrition (SAM) which is divided again into
  - SAM without complications and
  - SAM with complication.

Indicators	Moderate Acute Malnutrition (MAM)	Severe Acute malnutrition (SAM)
Bilateral Pitting Oedema	Absent	Present
Mid Upper Arm Circumference (MUAC)	≥115mm and <125mm	<115mm
Weight For Height (WFH) Z-Score	≥-3 SD and <-2SD	<-3SD

Integrated Management of Acute Malnutrition

There are **four components**:

1. Community Mobilization with active case finding among community

- It is a process aims to raise awareness of community (on what malnutrition is, what underlying causes of malnutrition are and its consequences) followed by increased community demand for IMAM services starting from Active Case Finding to Treatment services until child with Acute Malnutrition is cured.

2. Supplementary Feeding Programme (SFP) for MAM

- The children with Moderate Acute Malnutrition are provided with
  - Ready to Use Supplementary Food (RUSF) or
  - Fortified Blended Food (FBF) until their Mid Upper Arm Circumference(MUAC) reach 125 mm or
  - Weight For Height (WFH) Z-Score reach – 2 SD and above respectively.
- This service will be provided in community, based on the immunization platform, by Basic Health Staff (BHS) as Fixed site or Outreach service delivery in villages with RHC/SRHC.

3. Out-patient Therapeutic Programme (OTP) for SAM without complication

- The children with Severe Acute Malnutrition are treated with Ready to Use Therapeutic Food (RUTF).
- This service will be delivered as Fixed-site service or Outreach service, based on immunization service delivery platform, as well as may be delivered in hospital as Recovery Phase of SAM at

Inpatient Treatment Programme.

4. Inpatient Therapeutic Program (ITP) for SAM with complication

- When the child with Severe Acute Malnutrition has complications or oedema of +++, they are treated in
- hospital (which may range from Station Hospital to Tertiary Hospital).
- These four components are linking with each other.

Clinical Features of Acute Malnutrition

The clinical features of Acute Malnutrition are mentioned in the table below.[1]

Site	**Sign**
Face	Puffy Face (Kwaishorkor = oedematous malnutrition)/ Oldman face (Marasmus = severe wasting)
Eye	Dry eyes, pale conjunctiva, Bitot spots (vitaminA), periorbital edema
Mouth	Angular stomatitis, cheilitis, glossitis, spongy bleeding gums (vitaminC)
Hair	Dull, sparse, brittle hair; hypopigmentation; flagsign (alternating bands of light and normal color); broomstick eyelashes; alopecia
Skin	Loose and wrinkled (marasmus); Shiny and edematous (kwashiorkor); dry,follicular hyperkeratosis; patchy hyper- and hypopigmentation ("crazy paving" or "flaky paint" dermatoses); erosions; poor wound healing
Nails	Koilonychia; thin and soft nail plates, fissures, or ridges
Skeleton	Sign of Vit D deficiency –Rickette Rosery, Knock Knee
Musculature	Musclewasting, particularly buttocks and thighs; (Baggy Pants)
Abdmen	Distended: hepatomegaly with fatty liver; ascites may be present
CVS	Bradycardia, hypotension, reduced cardiac output,
Neurology	Global developmental delay, loss of knee and ankle reflexes, impaired memory
Haematology	Pallor, Petechiae
Behavioural	Lethargic, apathetic, irritable on handling
Oedma	(+) = Mild: both feet /ankle (++) = Moderate: both feet plus lower legs, hands or lower arms (+++) = Severe: generalized oedema including feet, legs, hands, arms and face 

Management of children with Acute Malnutrition

- Management of Acute Malnutrition in SAM without complication is different from that in SAM with complications.

1. Treatment of Severe Acute Malnutrition SAM without complication at OTP (Age 6 to 59 months)

1. Treat as OPD patient at hospital/ RHC/SRHC in (OTP Outpatient Therapeutic Programme).
2. Ready to use Therapeutic Food (RUTF) (150 – 200 kcal/kg/day) 1 Sachets 92gm of RUTF provides 500 Kcal. RUTF is an energy-dense, mineral/vitamin-enriched food that is equivalent to F-100. It is a groundnut paste composed of vegetable fat, peanut butter, skimmed milk powder, lactoserum, maltodextrin, sugar and mineral and vitamin complex
3. RUTF is the only food to be taken in the OTP treatment except Breastmilk.
4. Antibiotic to all children with SAM - Amoxil or Cotrimoxazole can be given
5. Vitamin A
6. Continue Breast Feeding
7. IYCF counselling
8. Immunizations

Routine medicines given in OTP

Drug Supplement	When	Age/Weight	Prescription	Dose
Vitamin A	4th week [4th visit)	6 – 12 months	100,000 IU	1 Dose
		> 12 months	200,000 IU	
		Do not give in child with Oedema		
No vitamin A dose is provided if the child is on F-75, F 100 or RUTF that comply with WHO specifications. Not already been taken in the past 2 months.				
Amoxycillin	At Admission	All SAM Cases	<5 kg→ 62.5 mg 5-10 kg→ 125 mg 10-20 kg→ 250 mg 20 -35 kg→ 375 mg >35 kg→ 500 mg	3 times a day for 5 days
Cotrimoxazole	At Admission	All SAM cases	24mg/kg	2 times a day for 5 days
Albendazole	4th week [4th visit)	<12 months	DO NOT GIVE	NONE
		12 – 24 months	200 mg	Single Dose
		≥24 months	400 mg	
Measles Vaccination	4th week [4th visit)	≥9 months	Give a second dose if received the first vaccination when SAM in ITP	

References

1. *National Guideline Integrated Management of Acute Malnutrition 2017; National Nutrition Centre, Department of Public Health and MOH S Myanmar*
2. *Nutrition, Food Security and Health; Nelson Textbook of Paediatrics 21st Edition; chapter 57, page 331-342*
3. *Protocol Integrated Management of Acute Malnutrition; Micheal Golden & Yuonne G, 2012*
4. *Training Course on Inpatient Management of Severe Acute Malnutrition WHO 2013*
5. *Update on Management of Severe Acute Malnutrition in Infants and Children. WHO guideline 2013*

IMMUNIZATION FOR CHILDREN IN MYANMAR

Vaccination guideline used by EPI in Myanmar

(၂၀၂၀) ခုနှစ်တွင် စတင်မည့် ပုံမှန်ကာကွယ်ဆေး ထိုး/တိုက်အစီအစဉ်

* Preferably within 24 hrs and at lease within 7 days

** At birth or at 2 months

- Immunization doses should be at least 28 days apart
- Additional immunizations like mass immunization and booster immunization should not be counted as regular doss
- Other vaccines available in private sector

Rota virus	PO 1.5 ml at lease every 4 weeks for 2 doses within 6-24 weeks of age (preferably within 6-16 weeks)
Mumps, Measles and Rubella	IM or deep SC 0.5 ml, first dose: 12-13 months of age, second dose: 40-60 months of age
Hepatitis A	IM 0.5 ml, 2 doses with 6-18 months interval, within 1-17 years of age
Influenza	IM 0.5 ml, 2 doses with 4 weeks interval for children who have not receives previously and within 6 months to 9 years of age, and then annually. One dose for children 9-17 years of age
Typhoid	IM 0.5 ml 1 dose for 2-17 years of age at least 2 weeks before potential exposure
Meningococcus A, C, W125 and Y	IM 0.5 ml, 1 dose for 1-17 years of age, repeat after 1 year if still at risk
Pneumococcus 23	IM or SC 0.5 ml, 1 dose for 2-17 years of age
Rabies	IM 1 ml 5 dose days, 0,3,7,14,28-30 after exposure

Chicken pox	SC 0.5 ml, 2 doses with 4-6 weeks interval for 1-17 years
Hep B immunization children of HB +ve mothers	IM HBIG (Hepatitis B immunoglobulin) 200 unit within 12-48 hours after delivery (no later than 7 days) + IM Hepatitis B vaccine 10 µg at 0,1,2 and 12 months of age or 0,1 months of age and then follows EPI

Recommended immunization schedule for HIV-exposed or HIV infected children

Vaccine	Age					
	At birth	2 month	4 month	6 month	9 month	18 month
BCG	BCG					
Hepatitis B	HVB					
Pentavalent DPT-Hib-HepB		Penta 1	Penta 2	Penta 3		
PCV		PCV 1	PCV 2	PCV 3		
Polio		Polio 1	Polio 2	Polio 3		
Measles				M 1	M 2	M 3
JEV					JEV	

Note

- BCG is recommended at birth for all babies born to HIV infected mothers.
- BCG is contraindicated in children with proved HIV-infection status
- Either IPV or OPV can be used.
- All the optional vaccines are considered according to feasibility and affordability.
- HIV-exposed infants and children should receive all vaccines in Expanded Programme for Immunization according to the National Schedules.

Recommendation for other altered immunocompetence

Corticosteroids

- 2mg/kg/day or 20 mg/day of prednisolone or equivalent x 14 days - should not receive live vaccine until therapy has been discontinued for at least one month. (same dose <14 days - 2 weeks, lower dose - may be vaccinated while on therapy)

Malignancies, transplant, immunosuppressive or radiation therapy

- Live vaccines are withheld depending on their immune status
- After chemotherapy for leukemia children may need to be reimmunized with age appropriate single dose of previously administered vaccine.

Preterm

- Same chronological age as term except Hepatitis B vaccine for infants weighing <2 mg at birth (should be deferred until 30 days of age if mother's is hepatitis B antigen negative. If positive, same as term)

Recommended intervals between vaccines

- For killed vaccines - any interval
- For killed and alive - any interval
- For live vaccine - same day or at least one month apart

Recommendation for future immunization programme

- Booster dose for Penta at 18 months and Td (Tetanus and Diptheria) at school entry
- To switch from MR to MMR
- Rota vaccine
- Meningococcal conjugated vaccine
- Human Papilloma Virus (HPV) vaccine
- Influenza vaccine

References

1. *Paediatric Management Guidelines, 3rd Edition, 2018*

MANAGEMENT OF THE CHILD WITH BURNS AND SCALD

- Common cause of injury, disability and permanent disfigurement in children
- Majority of thermal injury in childhood result from an accident in their home
- Toddlers are naturally inquisitive and tend to be burned by hot liquids

Classification

- According to **aetiology** –
  - ***Scalds,***
  - ***flame burn,***
  - ***electrical or chemical burn***
- According to **depth of burn**

Superficial or 1'[1] degree burn	**Partial thickness or 2nd degree burn**		**Full Thickness or 3rd degree burn**
	Superficial Partial Thickness	**Deep Partial Thickness**	
• Erythema and discomfort only • Healing-complete no scarring • Painful.	• Blisters • Basal layers not destroyed. • Regeneration is quick • Usually heals in 2-3 weeks • Extremely painful	• More severe with more damage to skin. • Skin will only survive and heal under the most optimal conditions	• skin totally destroyed • Requires skin grafting for closure. • Painless.

Body Surface Area

- The surface areas of the head and limbs change with age. For example, the surface area of the head of an infant is 19%, which is quite large.
- For each year of age 1% is subtracted from 19 and added to the figure for the lower extremities. ie. up to 10 years.
- "Rule of Nines" cannot be applied in children because of their head-chest size discrepancies, and limb differentials compared with the adults.
- Severity of bum depends on
  1) Depth of bum
  2) Percentage of Total Body Surface Area involvement (TBSA)
  3) Age of the patient
  4) Site-face, hands, feet and perineum

% **Body surface area in relation to age and region (Land-Brauder chart)**

Region \ **Age**	0-1	1-2	2-3	3-4	4-5	5-6	6-7	7-8	8-9	9-10	>10
Head/Neck	19	18	17	16	15	14	13	12	11	10	9
UL-Rt	9	9	9	9	9	9	9	9	9	9	9
UL-Lt	9	9	9	9	9	9	9	9	9	9	9
Chest-Front	9	9	9	9	9	9	9	9	9	9	9
Chest-Back	9	9	9	9	9	9	9	9	9	9	9
Rt-LL-Front	6.5	6.75	7	7.25	7.5	7.75	8	8.25	8.5	8.75	9
Rt LL-Back	6.5	6.75	7	7.25	7.5	7.75	8	8.25	8.5	8.75	9
Lt LL-Front	6.5	6.75	7	7.25	7.5	7.75	8	8.25	8.5	8.75	9
Lt LL-Back	6.5	6.75	7	7.25	7.5	7.75	8	8.25	8.5	8.75	9
Abdo-Front	9	9	9	9	9	9	9	9	9	9	9

Abdo-Back	9	9	9	9	9	9	9	9	9	9	9
Perineum	1	1	1	1	1	1	1	1	1	1	1
Percenta2e of Burn	..... %										

ASK	LOOK FOR	POSSIBLE DIAGNOSIS	MANAGEMENT
• **Type of burn** • **Burning agent due to hot liquid**	• A total surface area of burn< 10% of the body surface area (or) • partial thickness (or) • does not involve special areas	Minor burn	• Inj: TT 0.5 ml • Local application with silver sulphadiazine cream • Relieve pain
	• 10-20 % of total body surface area (or) • < 10% but full thickness	Moderate burn	Refer to Hospital
	• > 20 % of body surface area of any thickness (or) • <2 years of age or involve special area such as face, hands, • feet and perineum	Severe burn	Refer to Hospital

Local wound care

- Exposure therapy –
- With the **exposure method** a dry eschar forms over the bum wound and acts as a physiological dressing to prevent numerical proliferation of bacteria. It is useful for patients with bums & scalds over the face, genitalia and anal areas.
- **Semi-open technique** with topical chemotherapy. The topical application of chemotherapeutic agents is the main stay of infection prophylaxis.
- The most frequently used **topical agent** is silver-sulphadiazine. The bum wound is reassessed after one week. If the injury is superficial and partial thickness in depth, healing will occur spontaneously by regeneration from epidermal elements in the dermis.
- The deep partial thickness and full thickness injuries require **skin grafting.**

Prevention

- The best effective treatment of Bums is Prevention.
  1) Fire - safe cigarettes
  2) Smoke detectors
  3) Anti-scalding devices
- Public health education and legislative efforts are active measures to prevent bum injury.

Referral to tertiary unit

- Partial thickness bums, >10%
- Full thickness bums, >2%
- Bums of special area, face, neck, perineum, hands & feet
- Any inhalation injury
- All electrical and chemical injuries
- All suspected case of child abuse

Reference

1) *Pediatric Management Guidelines, Myanmar Pediatric Society (2011)*
2) *Management of Critically Ill Children-2005*

OBSTETRICS AND GYNAECOLOGY

Antenatal Care
Prescribing Medications in Pregnancy
Minor Problems of Pregnancy and Management
Other common minor disorders
Hyperemesis Gravidarum
Abnormal Uterine Bleeding
Antepartum Haemorrhage
Bleeding in Early Pregnancy
Medical Diseases in Pregnancy
Abnormal Puerperium
Post-Natal Care
Contraception
Infertility
Premenstrual Syndrome
Menopause
Vaginal Discharge
Itchy Vulva (Pruritus Vulvae)
Cervical Cancer

ANTENATAL CARE

Introduction

There are three main purposes to antenatal care:

- health promotion,
- preparation for labour and parenthood and
- surveillance of risks.

Objective

- To conduct routine antenatal care in standard guidelines for every pregnant woman

Responsible care-giver

- All General Practitioners

First visit or booking visit:

Antenatal history on booking visit to detect risk factors that may indicate referral to specialist centre for joint care above that provided to low risk women. AN history summary (Annex 1)

History

- Complete history: to identify risk factors
- Menstrual History:
- LMP, EDD and Gestation.

Examination

General examination

- Measure body weight in kilogram and height in meter to calculate **BMI** (BMI=Kg/m^2) if woman is in first trimester (BMI=Kg/m^2)
- Perform a thorough physical examination to detect medical diseases including anemia.
- Measure **BP,** Look for pallor, **pedal oedema**

Obstetric examination

- To confirm pregnancy, its maturity
- Fundal height, Measure symphysial fundal height (SFH) in cm after 20 weeks
- Number of fetus, lie, presentation, and listen FHS by Pinard fetal stethoscope or Doppler

Pretest counseling

- PMCT- HIV in group and individual if the woman requests

Arrange for antenatal investigations

- Blood grouping and Rhesus typing, Rh negative women should counsel for testing Husband's Rh typing. Referral for counseling for Anti D vaccine at 28 weeks and post-delivery or if indicated.
- Blood for CP and Platelets.
- Urinalysis – RE, Urine protein

- To do 75 g **OGTT at *24-28* weeks** if woman is potential diabetic (if available)
- HBs antigen,
- HCV antibody,
- STSNDRL.
- HIV antibody test after VCCT under PMCT program and referral to the nearest PMCT centre.
- Routine dating Scan: At booking visit to determine gestational age
    - *Detail fetal anomaly scan around 18-20 weeks*

Health education

- Counseling and give information on diet and life style consideration
- Give information on danger signs (e.g. bleeding, abdominal pain, dribbling)

Intervention

- Folic acid supplementation (400µg *I* day ideally 6 weeks pre-pregnant and up to 12 weeks of gestation)
- Injection tetanus toxoid (TT) for 2 doses with at least one month apart
- Prescribe iron when morning sickness is relieved
- Arrange **next visit** at 1 - 4 weeks depending upon gestational age
- **Refer** to Specialist Assistants/ specialist centre if the pregnancy is at high risk

Second Visit

- Review, discuss and record results of all investigations
- Post-test counseling
- Measure BP and urine protein
- Obstetric examination
- Finalize EDD by history and clinical examination, USS
- Identify abnormal findings and treat accordingly,
- If Hb <11 gm/dl, treat according to anaemia in pregnancy guideline
- UTI to be treated with Amoxil500tds for 5days/ cephalosporin 500mg tds for 5 days if no contraindication. Re-check 1week after antibiotics or change antibiotics if not responding well. Urine for C&S if facility is available before starting antibiotics
- PMCT post-test counseling, reassuring if test result is negative
- If test positive, treat according to guideline on PMCT

Subsequent Visits

- Provide routine antenatal care during follow up visits monthly till 28 weeks, every 2 weeks till 36 weeks and weekly there after
- At 28 week - offer anti D if Rh negative in non-sensitized women
- At 34 week - recheck placental localization if low-lying in previous scan
- At 36 week - check presentation and inform senior if any abnormal presentation.
- breast feeding counseling, birth plan and neonatal care
- At 40 week - To be seen by OG for counseling about complications regarding post-date. Note foetal kick count (count to 10); ask to come back if fetal movements reduce. Plan to transfer where induction procedure is feasible

Woman with risk factors who may need refer to specialist centre

Risk factors

- Present pregnancy
    - Associated medical diseases (joint care) including who need PMCT (when there is

positive HIV screening)
    - Extreme of age under 18/over 40 years; BMI >35 or <18.
    - Discrepancy between maturity by USG report, uterine size and by LMP
- Antenatal complications –
    - Gestational hypertension,
    - PE,
    - abnormal lie/presentation, twins, APH placenta previa
- Previous History of
    - Maternal complication such as Previous PE or eclampsia.
    - Previous caesarean section or any uterine scar (myomectomy, etc.)
    - Two or more miscarriages
    - Previous psychiatric illness or puerperal psychosis
- Neonatal complication such as:
    - Previous preterm birth or mid-trimester loss.
    - Previous neonatal death or stillbirth, congenital anomalies
    - Previous small or large for gestational age
- Family history of genetic disorder

PRESCRIBING MEDICATIONS IN PREGNANCY

- Drugs can have harmful effects on embryo or fetus at any time during pregnancy.
- During the first trimester drugs can produce congenital anomalies or (teratogenesis) to the fetus especially between **third to the eleventh weeks of pregnancy.**
- During the second and third trimester drugs can affect the **growth or functional development** of the fetus and sometimes toxic effects on the skin.
- Penicillin, Ampicillin, Amoxicillin and cephalosporin are safe during pregnancy until stated otherwise.
- Quinolones should be avoided during pregnancy as they have shown to cause arthropathy in animal studies.
- Triazole antifungals should be avoided during pregnancy. Multiple congenital anomalies have been reported.

THE MINOR PROBLEMS OF PREGNANCY AND MANAGEMENT

Nausea and Vomiting in Early Pregnancy (Morning Sickness)

- Usually occurs between 6 & 14 weeks of pregnancy
- More of nausea and retching than vomiting
- Exact aetiology is not known. It may be psychological or may be due to increased HCG and estrogen levels

Treatment

- reassurance, advice frequent small meals and fluid
- avoid greasy and spicy food
- sometimes may need antiemetics (Nosic = doxylamine + B6), cyclizine 50 mg tds.
- If severe, it may lead to hyperemesis gravidarum and need referral as it may sometime need intensive care

Constipation

- Frequent complaint
- Due to the effect of progesterone in slowing gut motility, weight of gravid uterus on the rectum & concomitant use of iron preparation

Advice

- to take high fibre diet & milk, fluids, fruits and vegetable; non-stimulant laxatives such as lactulose or cream of magnesia, bulk forming laxative (ispaghula husk)

Heart Burn

- Burning in the chest or discomfort often on lying down
- Common in the third trimester but can occur earlier
- Caused by irritation of the lower end of oesophagus by gastric contents
- Due to relaxation of oesophageal sphincter

Advice

- Low-fat, bland food, small and frequent meals,
- Avoidance of lying supine or bending, eating late, caffeine.
- Liquid antacid preparations,
- Stop smoking & reduce alcohol intake,
- Severe refractory dyspeptic symptoms may warrant GI referral.

Oedema

- Oedema of some degree 1s common during pregnancy due to increased capillary permeability

Advice

- frequent periods of rest with elevation of legs over a pillow, occasionally may need support stocking, Removal of rings if fingers are excessively swollen
- If it is marked, need to check BP & urine for protein to exclude preeclamsia, and also need to exclude

underlying cardiac impairment, nephrotic syndrome or severe by hypoproteinaemia

Varicose Veins & Piles

- They become worse in later part of the pregnancy
- Due to the relaxant action of progesterone on the vascular smooth muscle
- Varicose vein of legs
    - Dependent venous stasis due to weight of the uterus on Inferior vena cava.
    - Avoid prolong standing
    - Symptomatically improved by support stocking
- Piles
    - Advice to take high fibre diet & avoid constipation
    - Local anaesthetic or ice packs can be given
- Varicose vein of vulva and vagina
    - Uncommon but sometimes troublesome bleeding may occur if superficial veins are traumatised at the time of delivery (episiotomy, tears)

Pruritus Vulvae & Vaginal Discharge

- **Vaginal candidiasis** - curdled milk like discharge per vagina with pruritus
    - ***Treatment:*** oral antifungal are not advisable during pregnancy, clotrimazole cream or vaginal tablets
- **Trichomoniasis** - yellowish or greenish frothy discharge with pruritus
    - ***Treatment:*** metronidazole ***after first trimester***

Acroparethesia

- **Tingling** & numbness of the fingers due to compression of the median nerve by soft tissue swelling in the Carpal tunnel
    - ***Treatment:*** splinting of the affected hand, cure after delivery, steroid injection

Backache & Sacroiliac Pain

- Due to slackening of ligaments & lumber lordosis of pregnancy

Treatment

- rest, maintenance of correct posture, avoid high heels
- avoid lifting heavy objects
- regular physiotherapy
- simple analgesia

OTHER COMMON MINOR DISORDERS

- headache,
- fainting,
- breast soreness,
- tiredness,
- nose-bleed, leg cramps,
- insomnia
- striae gravidarum,
- chloasma & itchiness.
-

HYPEREMESIS GRAVIDARUM

- Excessive vomiting during pregnancy
- May occur in molar pregnancy & multiple pregnancy
- In very severe cases
    - starvation, dehydration, ketosis, hypotension, oliguria vitamin B deficiency & neurological disorders
- Mallory - Weiss syndrome - tearing of the mucosa of lower end of oesophagus with bleeding from the small vessels leading to haematemesis
- It is important to exclude other causes of vomiting like pyelonephritis, hydatidiform mole, intestinal obstruction & hepatitis

Management

- **Admission to hospital** is mandatory
- Antiemetics like metoclopramide or prochlorperazine as regular basis
- Intravenous hydration support with vitamin B6 and B complex including Thiamine
- Monitor intake & output
- Oral feeding as soon as possible, then semisolid and later full diet

Reference

1. *Obstetrics and Gynaecology Mangement Guidelines, F' Edition (2015), O&G Society, MMA*
2. *Oxford handbook of General Practice, 4''' Edition*

ABNORMAL UTERINE BLEEDING

MENORRHOGIA

Menorrhagia (heavy menstrual bleeding) is defined as *excessive cyclical menstrual blood loss* which interferes with the woman's physical, emotional, social and material quality of life over several consecutive cycles in an otherwise normal menstrual cycle.

INTERMENSTRUAL BLEEDING

- It is defined as bleeding from the vagina *at any* **time** in the menstrual cycle other than normal menstruation.

POST-MENOPAUSAL BLEEDING (PMB)

- Bleeding from the vagina *12 months* after the **last period.**
- Any PMB should be assumed to be to endometrial carcinoma until proved otherwise and **refer to OG for further assessment.**

DYSFUNCTIONAL UTERINE HAEMORRHAGE (DUH)

- It is defined as the occurrence of **irregular** or *excessive uterine bleeding in the absence* of pregnancy, infection, trauma, new growth or hormone treatment.
    - **Oligomenorrhea:** menstruation occurring with intervals of *more than 35 days*
    - **Polymenorrhea:** menstruation occurring regularly with intervals of *less than 21 days*
    - **Metrorrhagia:** menstrual bleeding occurring *at irregular* intervals or bleeding between menstrual cycles
    - **Menorrhagia:** regular menstrual cycles with excessive flow (technically more than 80mL of volume) or menstruation lasting more than 7 days
    - **Menometrorrhagia:** menstrual bleeding occurring *at irregular* intervals with excessive flow or duration
    - **Abnormal Menstrual cycles:** that are longer than 35 days or shorter than 21 days

Causes of abnormal uterine bleeding

Menorrhagia	Intermenstrual bleeding	PMB	Post coital bleeding
• Pelvic endometriosis • Fibroid* • PID* • Endometrial hyperplasia* • Hyperthyroid • Clotting Disorder • Iatrogenic -IUCD • Poor control anticoagulant	Anovulatory bleeding Cervix ectropian Low grade infection Ca cervix Polyp IUCD **COC** Depo injection	Exogenous estrogen Atrophic endometritis Ca endometrium Hyperplasia Ca cervix Polyp Ovarian oestrogen secreting tumour	Ca cervix Cervical polyp

History

- **Age**
    - teenage, perimenopause, post menopause, old age

- **Type of bleeding**
  - (Menorrhagia, Metrorrhagia, Metromenorrhagia, Oligomenorrhoea)
  - severity, associated pelvic pain or dysmenorrhoea
  - previous similar episode, vaginal discharge
  - recent unexplained weight loss, loss of appetite
  - signs and symptoms suggestive of anaemia as well as thyroid dysfunction
- **Family history-**
  - family history of uterine fibroid, Ca, endometriosis, bleeding disorders
- **O&G history-**
  - multiparous, nulliparous, h/o abortion, D & C, surgery, pap smear, PID,
- **Menstrual history**
  - irregularity, spotting or breakthrough bleeding
- **Drugs history**
  - OC pills, IUCD, Hormone Replacement Therapy (HRT), antiepileptic, anticoagulant, tamoxifen
  - h/o others comorbid disease - DM, Hypertension

Examination

- Look for signs of anaemia
- Abdominal examination: any palpable mass, tenderness, guarding (in post abortion)
- VE: Assessment of uterine size and consistency (only if it is necessary), bimanual examination,
- Speculum examination (except in virgin): to visualize the cervix, to detect any abnormality (e.g. Ca Cx, polyp, ectopy)
- Pap smear: (if there is facilities, provided no active bleeding PV) or refer for pap smear

Investigation

- test for HCG to exclude pregnancy (complications) even in single after counselling
- Complete Blood Count to assess Anaemia in case of Heavy menstrual bleeding (HMB), Intermenstrual bleeding (IMB)
- Thyroid function test (TFT) only if symptom & sign suggestive of hyper or hypothyroid
- Pelvic USG or Transvaginal USG if structural abnormality is suspected
- Bleeding time, clotting time if bleeding disorders suspected

Treatment

- HMB (menorrhagia) without structural abnormality DUB treatment

DUH treatment

Fig 1. Medical management of menorrhagia in primary care



ENDOMETRIOSIS

Symptoms:

- Pelvic pain: cyclical + - non-cyclical, dyspareunia, dysmenorrhoea (spasmodic dysmenorrhoea is highly predictive of endometriosis), dyschezia (pain defecation)
- Menorrhagia
- Infertility

Sign on VE:

- tender uterosacral ligaments or enlarged ovaries or normal finding
- palpable deeply infiltrated nodules on the US ligaments or POD or
- visible lesions on vagina or cervix especially during menstruation (VE during menstruation favours detection)
- for definite diagnosis ***Refer to OG***

Treatment:

- Empirical treatment without definite diagnosis
- Counselling,
- adequate analgesic
- progesterone or COC pills (Medroxyprogesterone 10 tds/day for 9 days) or Depo inj: *(to remember that NSAIDs have side effect including anti-ovulatory effect when taken at mid-cycle and suppression of ovarian function for 6 months with hormonal drugs reduce endometriosis associated pain)*

ADENOMYOSIS

- usually multiparous, premenopausal, woman age >35 years
- may be asymptomatic, Dysmenorrhoea (pain peak towards the end of menstruation, dyspareunia, menorrhagia,
- Pelvic examination 7 Uterus may be enlarged symmetrically
- **Refer to OG** for further investigation and management

INTERMENSTRUAL BLEEDING CERVICAL ECTOPY

- spontaneous bleeding or post coital bleeding, vaginal discharge, teenage, during pregnancy or women with OC pills
- VE- red ring around the os
- ***Refer to OG***

CA CERVIX OR POLYPS

- post coital bleeding, discharge, dyspareunia, intermenstrual bleeding
- ***Refer to OG***

IUCD

- may act as irritant
- Refer for removal or further option of treatment

DUB

- especially just after menarche and perimenopausal women
- may be Anovulatory Uterine bleeding
- see treatment guideline

BREAK THROUGH BLEEDING

- with low dose OCP or and contraceptive pills
- Treatment
    - take 2 pills on the day when the breakthrough bleeding is occurring or
    - change to stronger pill preparation
    - Obesity, cigarette smoking
    - counselling, reassurance
    - NSAID or
    - COCPs or Norethisterone 15 mg daily from days 5 to 26 of the mens cycle or
    - injected long-acting progesterone

PMB

- Risk of endometrial Ca if history of taking Tamoxifen, Unopposed oestrogen T, Polycystic ovarian syndrome and obesity
- Investigation: USG - if endometrial thickness less than 5 mm (?Atrophic vaginitis)
- observe or give conservative treatment
- Pap smear (if available)- (except in virgin) or refer for pap smear

USG finding

- If endometrium thickness on USG in Postmenopausal woman >5 mm → refer to OG
- Endometrial polyp, fibroid more than 5 cm → refer to OG
- Endometrial thickness in reproductive woman varies with cycle and the maximum thickness is 14 mm.
- If endometrial thickness >14 mm → refer to OG (likely to be after post abortion without taking proper treatment like E&C) post-abortal problem, PID

Criteria for referral to secondary care are:

- very heavy bleeding with shock, or
- anaemia secondary to heavy bleeding, or
- failure of medical treatment in women under 40 years old, or
- irregular or heavy period in a woman of any age with a structurally abnormal uterus, or
- if a woman is over 40 years old with menorrhagia of recent onset or persistent intermenstrual bleeding.
- A patient over 40 years old may require referral for irregular periods because it may be difficult to distinguish between intermenstrual and menstrual loss.
- If there is suspicion from the history of increased risk of pathology, such as carcinoma (e.g. family history or endometrial or colonic cancer, nulliparity, obesity, tamoxifen or unopposed oestrogen therapy, abnormal smear, PCOS)
- In women over 45 years with heavy menstrual bleeding.
- If there is persistent intermenstrual bleeding

Reference

1. *Obstetrics and Gynaecology Management Guidelines, 1st Edition (2015), O&G Society, MMA*
2. *Oxford handbook of General Practice, 4th Edition*

ANTEPARTUM HAEMORRHAGE

Definition

- Bleeding from the genital tract during pregnancy after 24 weeks of pregnancy before the onset of labour.

Causes

- Placental causes
  - Placenta previa
  - Abruptio placentae
  - Vasa previa
- Local Causes (Incidental causes)
  - Cervicitis, cervical erosion, cervical trauma Vaginal trauma, vaginal infection
  - Genital tract tumours - cervical carcinoma Varicosities
- Undermined causes

Fig: Normal Placenta, Abruptio Placentae and Placenta Previa



Normal Placenta Placenta Abruption Placenta Previa

PLACENTA PRAEVIA

Definition

- Defined as a placenta partially or wholly situated in the lower uterine segment. It is graded in two ways, as either 1-4 or minor/major.
- Grade 1:
  - the placental edge is in the lower segment but does not reach the internal OS
- Grade 2:
  - the placental edge reaches but does not cover the internal OS
- Grade 3:
  - the placenta covers the internal OS and is asymmetrically situated
- Grade 4:
  - the placenta covers the internal OS and is centrally situated
- G 1, 2 = minor degree,
- G 3, 4, G (2) posterior = major degree

Incidence

- 0.4 - 0.8% of pregnancies

Fig: Placenta Previa Gradings



https://medicaljunkies.com/wp-content/uploads/2022/04/Placenta-previa.jpg

Aetiology

- Previous uterine surgery - Previous LSCS, curettage, myomectomy
- Maternal age - Increases with advancing maternal age
- Smoking
- Multiple gestation

Associations

- Fetal abnormality
- IUGR -because of multiple bleeds
- Co-existent abruption

Clinical features

- Painless, causeless, recurrent vaginal bleeding
- Uterus is soft
- High presenting part
- Fetal parts easily palpable
- Abnormal lie or abnormal presentation
- Satisfactory fetal condition until severe maternal condition Diagnosis confirmed by ultrasound

Management

- Immediate treatment outside the hospital
- Warning –
    - do not perform a vaginal examination
    - Restore blood volume (N/S or R/L with blood set)
- Transfer to hospital immediately

Difference between the Abruptio Placentae and Placenta Previa

Clinical Features	Placenta praevia	Abruptio placenta
Nature of bleeding	• Painless, causeless, and recurrent • Bleeding is always revealed	• Painful, often attributed to toxaemia or trauma and continuous • Revealed, concealed or usually mixed

Character of blood	• Bright red	• Dark coloured
General condition	• Proportionate to visible blood loss	• Out of proportion to the visible blood loss and anaemia in concealed type
Features of pre-eclampsia	• Not relevant	• Present in most of cases

Abdominal examination

Height of uterus	• Proportionate to gestation • Soft and relaxed	• May be disproportionately enlarged in concealed type • May be tense, tender and rigid
Malpresentation	• Malpresentation is common • The head is high floating	• Unrelated • The head may be engaged
FHS	• Usually present	• Usually absent especially in concealed type
Vaginal Examination	• Placenta is felt on the lower segment	• Placenta is not felt on lower segment. Blood clots should not be confused with placenta
Speculum Examination	• To exclude extra-placenta causes	• Speculum examination was done 3 days after bleeding is stopped
USG	• Placenta in lower segment	• Placenta is upper segment

PLACENTAL ABRUPTION (ACCIDENTAL HAEMORRHAGE)

Definition

- APH following premature separation of normally sited placenta
- The bleeding is maternal and/or fetal and abruption is acutely dangerous for both mother and fetus.

Types

- Revealed type (2/3 of cases) - 80% of cases, placenta separates at the edges. Bleeding is apparent.
- Concealed type (1/3 of cases) - 20% of cases, placenta separates at the center. Bleeding is concealed between placenta and uterine wall.
- Mixed type

Incidence

- 5% of pregnancies. Perinatal mortality rate is 4 per 1000.Recurrence is 4 - 12.5%

Fig: Different Types of Placental Abruption



Mild Concealed Severe Concealed Revealed Mixed

Aetiology and Associations

- The aetiology is unclear, but there are a number of recognized associations.
- High parity
- Rapid uterine decompression (rupture of membrane with poly hydramnios) Previous abruption
- Fetal abnormality
- Trauma (e.g., Assault, ECV) Smoking
- Pre-eclampsia
- Chronic chorioamnionitis
- Abnormal placentation (circumvallate placenta etc.) Underlying thrombophilia

Clinical features

Symptoms

- Asymptomatic in mild concealed type or Symptomatic
- Revealed Type
- Slight to heavy bleeding Per Vagina Abdominal discomfort
- Tenderness (anterior placentation)
- Uterus felt normal, fetal heart present, fetal parts are easily felt
- Differential diagnosis - placenta previa
- ***No VE until placenta previa is excluded by placenta localization.***
- **Concealed and Mixed type**
- Symptoms
- Acute constant severe abdominal pain which may be localized or diffused.
- Dark vaginal bleeding results from escape of blood from the retroplacental haematoma.
- Cessation of fetal movement is common.
- Past history of PE, Hypertension may be present.

Signs

- General Examination
- **Shock** is usually present and may be marked and not proportionate to the amount of visible bleeding due to Concealed and/or revealed haemorrhage
- Over distension of the uterus and damage of the myometrium causing neurogenic shock.

- Blood Pressure may be subnormal due to haemorrhage Normal due to falling from previous hypertension High due to slight bleeding in hypertensive patient
- Tachycardia
- Pallor is severe and out of proportion to the visible bleeding
- Urine output is usually diminished
- Abdominal Examination
    - Uterus is large for date and increasing gradually in size due to retained blood.
- Uterus is tense, very tender and hard (board-like).
- Fetal parts are difficult to be felt.
- FHS may be absent due to fetal death in severe cases or distressed in mild cases.

Differential diagnosis

- Other causes of antepartum haemorrhage and acute abdomen

Investigations

- Ultrasound: detects normally sited placenta with retroplacental haematoma that may dissect the placental margin. Should be used to
- confirm fetal viability
- assess fetal growth
- measure liquor volume
- confirm fetal normality
- exclude placenta praevia
- perform umbilical artery Doppler velocities
- Blood Hb is markedly lower
- Tests for DIC [BT, CT, platelet, fibrinogen, PTT (partial thromboplastin time)]
- Urine for albumin - usually present

Management

- Immediate Treatment
    - IV line with fluid (with wide bore needle)
    - Admission to hospital

Complications

- Maternal & Fetal
- Maternal mortality - 10% due to haemorrhage, DIC, renal failure Maternal morbidity is related to C.S, haemorrhage, coagulopathy
- Fetal mortality - 20-40% depend on the extent of abruption
- Fetal morbidity - is caused by the insult of abruption itself and related to prematurity
- Placental abruption effect on the mother
    - Hypovolemic shock DIC
    - Acute renal failure
    - PPH and Couvelaire uterus *(a blood infiltration of the uterine myometrium due to the formation of a massive retroplacental hematoma)*
    - Sheehan's syndrome due to ischaemia of anterior pituitary Maternal mortality
- Placental abruption effect on the fetus
    - Prematurity Perinatal mortality IUGR, IUFD

UTERINE RUPTURE

Incidence

- 0.05% for all pregnancies
- 0.8% after a previous low transverse c/s 75% in prior classical c/s
- 25% in prior uterine myomectomy

Risk factors

- Surgical procedures of uterus
- C/S, myomectomy, perforation, cornual resection, hysteroscopic or laparoscopic injuries, penetrating abdominal wounds
- Grand multiparity Obstetric trauma Fetal macrosomia Malpresentation Breech extraction
- Instrumental vaginal deliveries

Diagnosis

- **Before delivery**
  - History
    - History of prolonged or obstructed labour
    - History of previous caesarean section or myomectomy scar Bleeding per vagina
    - Severe abdominal pain which may decrease after rupture Sign and symptoms of shock - palpitation, fainting attack Ripping lower abdominal Pain
    - Referred Shoulder Pain On examination
    - Pallor, rapid pulse, BP less than 90/60 mmHg Abdominal distension and tenderness Abnormal uterine contour
    - Easily palpable fetal parts Loss of fetal presentation part
    - Absent fetal movement and Fetal Bradycardia or absent FHS
    - ruptured of lower uterine segment into broad ligament will not release blood into abdominal cavity, uterus deviate to one side by broad ligament haematoma High presenting part on vaginal examination
- **After delivery**
  - History
    - PPH - bright red blood
    - History of difficult instrumental delivery, previous uterine scar Abdominal pain
    - Symptom of shock
  - On examination
    - Pallor, sing of shock
    - Tender abdomen, uterus is irregular in shape, deviate to one side if there is broad ligament haematoma

Management

- Rapid evaluation of general condition and vital signs
- IV line and give crystalloid (normal saline or Ringer lactate) Refer to Hospital immediately
- She may need urgent laparotomy and hysterectomy or repair of tear (Repair → recurrent rupture: 19%)

Reference

(1) *Obstetrics and Gynaecology Management Guidelines, 1st Edition (2015), O&G Society, MMA*
(2) *Oxford handbook of General Practice, 4th Edition*

BLEEDING IN EARLY PREGNANCY

Definition

- Bleeding up to 14 weeks into pregnancy
- Bleeding in early pregnancy occurs in 1 in 4 pregnancies

Causes

- Bleeding in normal pregnancy - largest group
- Miscarriage
- Ectopic pregnancy
- Trophoblastic disease
- Non - obstetric conditions e.g., friable cervix, polyp, cervical neoplasia

Assessment

History

- Pain and bleeding: pain preceding bleeding (ectopic), any product of conception
- LMP and pregnancy test
- Pulse (>100 = shock), BP and temperature (toxic?)
- Abdomen: guarding, peritonism, and /or unilateral tenderness

Initial management

- If severe bleeding and/or pain, shocked or toxic →admit as emergency.
- If shocked → try to gain IV access and refer.

Complication of bleeding

- Significant sub-chorionic haematoma is associated with increased risk of premature rupture of membrane, Intrauterine growth retardation (UGR) → Refer to O&G
- Rhesus-negative women:
    - If there is clinical doubt, give anti-D
- *Bleeding <12wk gestation:*
    - Anti-D is not required for:
        - Threatened miscarriage unless heavy or repeated bleeding and/or abdominal pain, or
        - Complete miscarriage where no medical or surgical uterine evacuation
- *Bleeding >12wk gestation, ectopic pregnancy, and/or medical/surgical evacuation of the uterus at any gestation*
    - Give anti-D immunoglobulin (250iu IM if gestation <20wk) within 72 hours of bleeding-*whether or not* the pregnancy is lost
- *Bleeding in early normal pregnancy:* Often termed threatened miscarriage. If fetal heart is seen on USG (6-7 week) then -97% chance of the pregnancy continuing to progress. There is no evidence that rest or abstinence from sex improve outcome.

MISCARRIAGE

- Also termed spontaneous abortion, occurs m 1 in 5 pregnancies - 80% at 12 week gestation.

Risk Factors

- Maternal age >35 year or paternal age >40 years
- Smoking
- BMI >29 kg/m^2 - 32 kg/$m^{2,}$ risk is increased by 30%
- Excess alcohol

Causes

- Fetal abnormalities (50%)
- Multiple pregnancy
- Uterine abnormality: fibroid, polyps, congenital abnormality, cervical incompetence (late second trimester miscarriage)
- Systemic disease: renal, autoimmune or connective tissue disease - SLE, Poly cystic ovarian syndrome (PCOS), DM, systemic infection
- Drugs: cytotoxics, diethylstilbestrol
- Placental vascular abnormalities

Classification

- Complete miscarriage
  - Bleeding (+), No products of conception in the uterus.
  - Provide psychological support
- Incomplete miscarriage
  - Bleeding (+), product of conception in the uterus (+) No fetal heart sound
  - Usually refer or watch and wait (At 3 days, 86% will be complete)
- Missed or delayed miscarriage
  - No bleeding, No heart beat (USG scan)
  - Refer (evacuation of retained products of conception), or watch and wait (4 week only 66% complete and associated with longer bleeding.

Medical management

- With prostaglandin analogue (PGE1 misoprostol 200 µg bd orally) ± antiprogesterone (mifepristone) priming
- Fertility may increase immediately after miscarriage.

Complications

- Early: perforation of uterus, retained products of conception, infection
  - Treat with antibiotics if infection is suspected (doxycycline 100 mg od)
  - Readmit /refer if shock, pain, heavy bleeding, or bleeding is not settled
- Later: uterine synechiae (Asherman's syndrome, cervical incompetence, psychological sequelae

RECURRENT MISCARRIAGE

- 3 or more consecutive spontaneous miscarriages
- Age: increased with age (both man and woman)
- History
  - How many Miscarriages?

    - Confirmed pregnancy?
    - With same partner?
    - What gestation?
- The more miscarriage the lower the chance of successful pregnancy
- Fertility treatment 25-30% of women who miscarry
- **Past history:** gynaecological problems (cervical instrumentation, PCOS), systemic disease
- **Family History:** recurrent miscarriage, thrombosis/thrombophilia

Management

Refer:

- ***In treatable*** *causes*
    - Antiphospholipid antibodies (15%)
    - Low dose asprin+lower molecular weight heparin (LMWH) 6-34 weeks improves outcome.
- **Inherited thrombophilia (Factor V Leiden, prothrombin gene mutation or protein** S ***(vitamin K-dependent plasma glycoprotein synthesized in the liver)*** **deficiency)**
    - If **recurrent miscarriage:** 10 weeks, treatment with LMWH increased live birth rate
- **Cervical incompetence**
    - History of 2: late second trimester or early third trimester miscarriage (usually painless leaking of liquor or gradual painless dilation of cervix)
    - **Refer**
- **Chromosomal abnormality in one parent** (3-5%)
    - **Refer**

ECTOPIC PREGNANCY

- Egg implants outside the uterine cavity - 95% in a fallopian tube Incidence - 1 in 1000 pregnancies.

Risk factors:

- Pelvic inflammatory disease (single episode increase risk 7 times)
- Previous ectopic (11%)
- IUD (14%)
- Infertility (15%)
- Tubal surgery
- Age >35 years
- Smoking
- Multiple partners

History

- **Abdominal pain** (97%).
- Unilateral or bilateral, may start before bleeding; radiates to shoulder tip; increase on passing urine/opening bowels
- **Amen6ti7orrhoea** (75%).
- Peak incidence after 7wk amenorrhoea
- Irregular vaginal bleeding (79%).
- Described as "prune juice" but may be fresh blood; usually not heavy. May pass decidual cast

Examination

- Anaemia (marked pallor)
- Shock in 15-20%;

- Abdominal tenderness ± rebound or guarding (71%);
- Pelvis - enlarged uterus, adnexal mass, and/or cervical excitation.

Management

- Admit immediately for further investigation.
- **Resuscitate** before admission as needed.
- Hospital management may be expectant (watch and pregnancy resolves spontaneously), medical (methotrexate), or surgical (laparotomy or laparoscopic surgery).
- Offer early USS in future pregnancies to confirm pregnancy is intrauterine.

Complications

- Death if undetected, infertility (pregnancy rate post-ectopic pregnancy is 66% with 10% having a further ectopic pregnancy).

TROPHOBLASTIC DISEASES

HYDATIDIFORM MOLE

- Trophoblastic tumour containing 46 chromosomes (usually of paternal origin) and no fetal material
- 8-2-% become invasive and penetrated the uterus and/or metastasize to the lungs
- Presents with:
    - Bleeding in early pregnancy ± **exaggerated symptoms** of pregnancy
    - Uterus is usually **large for dates,** and **no fetal heart** can be heard.
- Ultrasound has a typical appearance
- Blood: increased serum HCG
- Rarely symptoms of metastatic spread: haemoptysis, pleurisy
- Refer urgently to gynaecology.
- If mole is confirmed, women are followed up by specialist centres.
- Invasive disease requires chemotherapy.
- Combined hormonal contraception is contraindicated until normal HCG values are obtained.
- Pregnancy is not advised until completion of the surveillance period.
- Investigate with early Ultrasound and -HCG as incidence of further molar pregnancy is **1** in 80.

PARTIAL MOLE

- Tumour of trophoblast containing 69 chromosomes, **1** maternal and 2 paternal set, with **some fetal tissue**
- A **fetal heart** may be seen on **early ultrasound** but is **absent by 8-9 wk.**
- Treat as for mole.
- Rarely becomes malignant (0.5%).

CHORIOCARCINOMA

- Malignant trophoblastic tumour following molar (rarely normal) pregnancy
- Presents with vaginal bleeding and/or metastases (shadows on CXR, dyspnoea, hemoptysis)
- Excellent prognosis after treatment with chemotherapy
- No contraceptive restrictions after completion of therapy; pregnancy is possible >**1** year after treatment.

PLACENTAL SITE TROPHOBLASTIC TUMOUR (PSTT)

- Rare
- Follows 3-4 years after normal pregnancy

- Prognosis is good

PSYCHOLOGICAL EFFECTS OF EARLY LOSS OF PREGNANCY

- Broach the subject with all women who have suffered early loss of pregnancy, include the woman's partner if possible.
- Legitimize grief and acknowledge it - not all women grieve - adjust your approach accordingly; discuss worries/concerns
- Provide information about the condition which caused the loss; risk to future pregnancies (if <3 miscarriages, risk of further miscarriage is not significantly increase risk of further ectopic pregnancy is - 2 in 10); and self-help/support organizations, e.g. Miscarriage Association

Reference

(1) *Obstetrics and Gynaecology Management Guidelines, 1st Edition (2015), O&G Society, MMA*

(2) *Oxford handbook of General Practice, 4th Edition*

MEDICAL DISEASE IN PREGNANCY

HYPERTENSIVE DISORDERS IN PREGNANCY

Definitions

CHRONIC HYPERTENSION:

- Hypertension presents at booking visit or before 20 weeks or that is being treated at the time of referral to maternity services. It can be primary or secondary in aetiology.

ECLAMPISA:

- *Convulsive condition* associated with pre-eclampsia.

GESTATIONAL HYPERTENSION:

- New hypertension presenting *after 20 weeks* without significant proteinuria.

PRE-ECLAMPSIA:

- New hypertension presenting after 20 weeks with *significant proteinuria.*

SEVERE PRE-ECLAMPSIA:

- Pre-eclampsia with severe hypertension and/or with **symptoms,** and/or **biochemical** and/or **haematological impairment.**
- Pregnancy related blood pressure problems (such as pregnancy-induced hypertension or pre-eclampsia) do not occur before 20 weeks. The raised ambulatory blood pressure readings exclude a diagnosis of white-coat hypertension.
- Note the use of the term pre-existing hypertension rather than essential hypertension. Raised blood pressure in a 36-year-old female is not that common and raises the possibility of secondary hypertension.
- Women who are at high risk of developing pre-eclampsia should take aspirin 75mg OD from 12 weeks until the birth of the baby.

High risk groups

- Hypertensive disease during previous pregnancies
- Chronic kidney disease
- Autoimmune disorders such as SLE or antiphospholipid syndrome
- Type 1 or 2 Diabetes Mellitus

In normal pregnancy:

- Blood pressure usually falls in the first trimester (particularly the diastolic), and continues to fall until 20-24 weeks.
- After this time the blood pressure usually increases to pre-pregnancy levels by term.

Hypertension is defined as

- Systolic >140 mmHg or diastolic >90 mmHg
- Or an increase above booking readings of >30 mmHg systolic or >15 mmHg diastolic After establishing that the patient is hypertensive, they should be categorized into one of the following

groups.

Pre-existing hypertension

- A history of hypertension before pregnancy or an elevated blood pressure >140/90 mmHg before 20 weeks gestation
- No proteinuria, no oedema
- Occurs in 3-5% of pregnancies and is more common in older women

- **Pregnancy-induced hypertension** (PIH, also known as gestational hypertension)
  - Hypertension (as defined above) occurring in the second half of pregnancy (i.e. after *20 weeks)*
  - No proteinuria, no oedema
  - Occurs in around 5-7% of pregnancies
  - Resolves following birth (typically after one month). Women with PIH are at increased risk of future pre-eclampsia or hypertension later in life.
- **Pre-eclampsia**
  - Pregnancy-induced hypertension in association with *proteinuria* (>0.3 g/24 hour)
  - *Oedema* may occur but is now less commonly used as a criteria
  - Occurs in around 5%of pregnancies.
- **Severe pre-eclampsia** is associated with *hyper-reflexia* and *clonus.*
  - A low platelet count may indicate the patient is developing HELLP syndrome (life-threatening liver disorder characterized by haemolysis, elevated liver enzymes, and low platelet count)
  - Pre-eclampsia is important as it predisposes to the following problems
  - Foetal: prematurity, intrauterine growth retardation
- **Eclampsia**
- **Haemorrhage:** placental abruption, intra-abdominal, intra- cerebral
- **Cardiac failure**
- **Multi-organ failure**

Risk factors

- >40 years old
- Nulliparity (or new partner)
- Multiple pregnancy
- Body mass index >30 kg/m^2
- Diabetes mellitus
- Pregnancy interval of more than 10 years
- Family history of pre-eclampsia
- Previous history of pre-eclampsia
- Pre-existing vascular disease such as hypertension or renal disease

Features of Severe Pre-eclampsia

- Hypertension: typically >170/ 110 mmHg and proteinuria as above
- Proteinuria: dipstick ++/+++
- Headache
- Visual disturbance
- Papilloedema
- Right upper quadrant (RUQ)/epigastric pain
- Hyperreflexia
- Platelet count <100 x 10^6 /1, abnormal liver enzymes or HELLP syndrome

Management

- Consensus guidelines recommend treating blood pressure >160/ 110 mmHg although many

clinicians have a lower threshold.

- Oral labetalol 100 mg bd is now first-line following 2010 NICE guidelines. Nifedipine and hydralazine may also be used.
- Delivery of the baby is the most important and definitive management step. The timing depends on the individual clinical scenario.

Management of Severe Pre-eclampsia with Pregnancy

Degree of Hypertension	Mild hypertension (140/90 to 149/99mmHg)	Moderate Hypertension (150/100 to 159/109mmHg)	Severe Hypertension (160/110 mmHg onwards)
Admit to Hospital	Yes	Yes	Yes
Treat?	No	With oral labetalol as first-line treatment	With oral labetalol as first-line treatment
Measure BP	At least four times a day	At least four times a day	More than four times a day

PREGNANCY: DIABETES MELLITUS

- The oral glucose tolerance test remains the investigation of choice for gestational diabetes.
- Women who are at risk of gestational diabetes should have an oral glucose tolerance test as soon as possible after booking, rather than waiting to 16-18 weeks as was previously advocated.
- *Insulin* should be started straight away given the blood glucose levels and evidence of macrosomia.
- *Aspirin* should also be considered as she is at increased risk of pre-eclampsia.
- Diabetes mellitus may be a pre-existing problem or develop during pregnancy, gestational diabetes. It complicates around 1 in 40 pregnancies NICE updated the guidance in 2015

Risk factors for gestational diabetes

- BMI of >30 kg/m^2
- Previous macrosomic baby weighing 4.5 kg or above
- Previous gestational diabetes
- First-degree relative with diabetes
- Family origin with a high prevalence of diabetes (South Asian, black Caribbean and Middle Eastern)

Screening for gestational diabetes

- Women who've previously had gestational diabetes: oral glucose tolerance test (OGTT) should be performed as soon as possible after booking and at 24-28 weeks if the first test is normal. NICE also recommend that *early self-monitoring of blood glucose* is an alternative to the OGTTs
- Women with any of *the other risk factors should be offered an OGTT at 24-28 weeks*

Diagnostic thresholds for gestational diabetes

- These have recently been updated by NICE, gestational diabetes 1s diagnosed if either:
- Fasting glucose is >5.6 mmol /1 (100 mg%)
- 2-hour glucose is >7.8 mmol /1 (140 mg%)

Management of gestational diabetes

- Newly diagnosed women should be seen in a joint diabetes and antenatal clinic within a week.
- Women should be taught about self-monitoring of blood glucose (SMBG)

- Advice *about diet* (including eating foods with a low glycaemic index) *and exercise* should be given.
- If the fasting plasma glucose level is <7 mmol / 1, a trial of diet and exercise should be offered.
- If glucose targets are not met within 1-2 weeks of altering diet/ exercise *metformin* should be started.
- If glucose targets are still not met *insulin* should be added to diet/exercise/metformin.
- If at the time of diagnosis, the fasting glucose level *is* >7 *mmol / l* insulin should be started.
- If the plasma glucose level is *between 6 - 6.9 mmol / l, and there is evidence of complications such as macrosomia or hydramnios, insulin should be offered.*
- Glibenclamide ***should only*** be offered for women who cannot tolerate metformin or those who fail to meet the glucose targets with metformin but decline insulin treatment.
- NICE have recently changed their gestational diabetes guidelines. Insulin should be started in the fasting glucose is >7 mmol /l.
- Aspirin should also be considered given the increased risk of pre-eclampsia.

Management of pre-existing diabetes

- *Weight loss for* women with BMI of >27 kg/m^2
- Stop oral hypoglycaemic agents, apart from *metformin, and* commence insulin.
- *Folic acid 5mg/day* from pre-conception to 12 weeks gestation
- *Detailed anomaly scan at 20 weeks* including four-chamber view of the heart and outflow tracts
- Tight glycaemic control reduces complication rates.
- *Treat retinopathy* as can worsen during pregnancy and refer. Diabetes in pregnancy: *detailed heart scan at 18-20 weeks*
- Targets for self-monitoring of pregnant women (pre-existing and gestational diabetes)

Time	***Target***
Fasting	5.3 mmol/1 (95 mg%)
1 hour after meals	7.8 mmol/1 (140 mg%)
2 hours after meals	6.4 mmol/1 (115 mg%)

- Patients with diabetes (type 1 and 2) should take aspirin 75 mg daily from 12 weeks gestation to reduce the risk of *pre-eclampsia.* They are also at higher risk of *neural tube defects,* therefore should take the *higher dose of Jolie acid, 5mg daily,* whilst trying to conceive until 12 weeks gestation. Pregnant women who have risk factors such as this should be referred at booking.
- All pregnant and breastfeeding women are advised to take *vitamin D 10 µg (400 JU) daily.*
- A *vitamin B12 supplement* may be advised for pregnant women who eat a vegan diet

Pregnancy: diabetes + complications

Maternal complications

- Polyhydramnios - 25%, possibly due to fetal polyuria
- Preterm labour- 15%, associated with polyhydramnios Neonatal complications
- Macrosomia (although diabetes may also cause small for gestational age babies)
- Hypoglycaemia (secondary to beta cell hyperplasia)
- Respiratory distress syndrome: surfactant production is delayed
- Polycythaemia: therefore, more neonatal jaundice.
- Malformation rates increase 3-4 folds, e.g., sacral agenesis, CNS and CVS malformations (hypertrophic cardiomyopathy)
- Stillbirth
- Hypomagnesaemia
- Hypocalcaemia
- Shoulder dystocia (may cause Erb's palsy)

PREGNANCY: ANAEMIA

- Pregnant women are screened for anaemia at:
    - The booking visit (often done at 8-10 weeks), and at 28 weeks
- NICE use the following cut-offs to determine whether a woman should receive oral iron therapy:

Gestation	Cut-off
Booking visit	<11 g/dl
28 weeks	<10.5 g/dl

Rhesus negative pregnancy

- Anti-D is still required following delivery even if the mother received routine antenatal anti-D prophylaxis.
- Subsequent pregnancies are most at risk following the sensitizing event of the first childbirth. A basic understanding of the pathophysiology is essential to understand the management of Rhesus negative pregnancies.
- Along with the ABO system the *Rhesus system* is the most important antigen found on red blood cells. *The D antigen* is the most important antigen of the rhesus system
- Around 15% of mothers are rhesus negative Rh(-ve)
- If a Rh(-ve) mother delivers a Rh(+ve) child a leak of fetal red blood cells may occur.
- This causes anti-D IgG antibodies to form in mother.
- In later pregnancies these can cross placenta and cause haemolysis in fetus.
- This can also occur in the first pregnancy due to leaks.

Prevention

- Test for D antibodies in all Rh(-ve) mothers at booking.
- NICE (2008) advise giving anti-D to non- sensitized Rh(-ve) mothers at 28 and 34 weeks or 'depending on local guideline'.
- Anti-D is prophylaxis - once sensitization has occurred it is irreversible.
- If event is 2nd - 3rd trimester, give large dose of anti-D and perform Kleihauer-Betke test - determines proportion of fetal RBCs present.
- **Anti-D immunoglobulin** should be given as soon as possible (but *always within 72 hours)* in the following situations:
- Delivery of a Rh(+ve) infant, whether live or stillborn
- Any termination of pregnancy
- Miscarriage if gestation is >12 weeks
- Ectopic pregnancy
- External cephalic version
- Antepartum haemorrhage
- Amniocentesis, chronic villus sampling, fetal blood sampling

Tests

- All babies born to Rh (-ve) mother should have *cord blood taken at delivery* for FBC, blood group & direct Coombs test.
- Coombs test: direct antiglobulin, will demonstrate antibodies on RBCs of baby.
- Kleihauer-Betke test: add acid to maternal blood, fetal cells are resistant.

AFFECTED FETUS

- Oedematous (hydrops fetalis, as liver devoted to RBC production albumin falls)
- Jaundice, anaemia, hepatosplenomegaly
- Heart failure
- Kernicterus

Treatment:

- transfusions, UV phototherapy

PREGNANCY: THYROID PROBLEMS HYPERTHYROIDISM

- Propylthiouracil is traditionally taught as the antithyroid drug of choice in pregnancy. This approach was supported by the 2007 Endocrine Society consensus guidelines. It also has the advantage of being excreted to a lesser extent than carbimazole in breast milk.
- Despite this some endocrinologists use carbimazole and the BNF states both drugs may be used in pregnancy. Carbimazole has rarely been associated *with aplasia cutis of the neonate* In pregnancy there is an increase in the levels of thyroxine-binding globulin (TBG). This causes an increase in the levels of total thyroxine but does not affect the free thyroxine level.

Thyrotoxicosis

- Untreated thyrotoxicosis increases the risk of fetal loss, maternal heart failure and pre mature labour.
- Graves' disease is the most common cause of the thyrotoxicosis in pregnancy. It is also recognized that *activation of the TSH receptor* by HCG levels will fall in second and third trimester.

Management

- Propylthiouracil has traditionally been the antithyroid drug of choice.
- Maternal free thyroxine levels should be kept in the *upper third of the normal reference range to avoid fetal hypothyroidism*
- **Thyrotrophin receptor stimulating antibodies** should be checked at *30-36 weeks gestation*, helps to determine risk of neonatal thyroid problems. Block-and-replace regimes should *not be* used in pregnancy.
- **Radioiodine therapy is contraindicated**

Hypothyroidism

- Thyroxine is safe during pregnancy
- Serum thyroid stimulating hormone measured in *each trimester* and 6-8 weeks post- partum.
- Some women require an increased dose of thyroxine during pregnancy
- Breast feeding is safe whilst on thyroxine.

EPILEPSY: PREGNANCY AND BREAST FEEDING

- Epilepsy + pregnancy = 5mg folic acid
- The risks of uncontrolled epilepsy during pregnancy generally out-weight the risks of medication to the fetus. All women thinking about becoming pregnant should be advised to take folic acid 5mg per day well before pregnancy to minimize the risk of neural tube defects. Around 1-2% of newborn born to non-epileptic mothers have congenital defects. This rises to 3-4% if the mother takes antiepileptic medication.

Other points

- *Aim for monotherapy*
- There is no indication to monitor antiepileptic drug levels.
- ***Sodium valproate:*** associated with *neural tube defects*

- ***Carbamazepine:*** often considered the least teratogenic of the older antiepileptics.
- ***Phenytoin:*** associated with *cleft palate*
- ***Lamotrigine:*** studies to date suggest the rate of congenital malformations may be low. The dose of lamotrigine may need to be increased in pregnancy.

Breast feeding

- is generally considered safe for mothers taking antiepileptics with the possible *exception of the barbiturates.*
- It is advised that pregnant woman taking phenytoin are given. **Vitamin** *K in the last month of pregnancy* to prevent clotting disorders in the newborn

Sodium valproate:

- The November 2013 issue of the Drug Safety Update also carried a warning about new evidence showing a significant risk of neurodevelopmental delay in children following maternal use of sodium valproate.
- The update concludes that *sodium valproate should not be used* during pregnancy and in
- woman of childbearing age unless clearly necessary. **Women of childbearing age should not start treatment without specialist neurological or psychiatric advice.**

PREGNANCY: JAUNDICE

Intrahepatic cholestasis of pregnancy

- Pruritus
- Bilirubin <100
- Occurs in 2nd and 3rd trimester

Management

- Risk of preterm labour, fetal distress, stillbirth
- Give Vitamin K to both the mother and the baby
- Ursodeoxycholic acid to reduce pruritus

Acute fatty liver of pregnancy

- Acute fatty liver of pregnancy is rare complication which may occur on the third trimester or the period immediately following delivery.

Features

- Abdominal pain
- Nausea & vomiting
- Headache
- Jaundice
- Hypoglycaemia
- Severe disease may result in pre-eclampsia

Investigations

- ALT is typically elevated e.g., 500u/l

Management

- Support care
- Once stabilized delivery is the definitive management
- Gilbert's, Dubin-Johnson syndrome, may be exacerbated during pregnancy HELLP (Haemolysis, Elevated Liver enzymes, Low Platelets)

HEPATITIS B in PREGNANCY

- Without intervention the vertical transmission rate is around 20%, which increases to 90% if the woman is positive for HBeAg.
- HBeAg is a marker of infectivity. The Green Book guidelines advise giving both the vaccine and immunoglobulin in this situation. If the patient had antibodies against HBe (anti-HBe), rather than the HBeAg, then only the vaccine would need to be given.

Basics

- All pregnant women are offered screening for hepatitis B
- Babies born to mothers who are chronically infected with hepatitis B or to mothers who've had acute hepatitis B during pregnancy should receive a complete course of vaccination + hepatitis B immunoglobulin
- Studies are currently evaluating the role of oral antiviral treatment (e.g. Lamivudine) in the latter part of pregnancy
- There is little evidence to suggest caesarean section reduces vertical transmission rates.
- Hepatitis B cannot be transmitted via breastfeeding (in contrast to HIV).

MIGRAINE: PREGNANCY

- Contraception and other hormonal factors
- SIGN produced guidelines in 2008 on the management of migraine, the following is selected highlights:

Migraine during pregnancy

- Paracetamol one gram is first-line
- Aspirin 300mg or ibuprofen 400 mg can be used second-line in the first and second trimester

Migraine and the combined oral contraceptive (COC) pill

- If patients have **migraine with aura,** then the COC is absolutely contraindicated due to an risk of stroke (relative risk 8.72)

Migraine and menstruation.

- Many women find that the frequency and severity of migraines increase around the time of menstruation.
- SIGN recommends that women are treated with mefenamic acid or a combination of aspirin, paracetamol and caffeine. Triptans are also recommended in the acute situation

Migraine and hormone replacement therapy (hrt)

- Safe top prescribes HRT for patients with a history of migraine but it may make migraines worse.

RHEUMATOID ARTHRITIS: PREGNANCY

- Rheumatoid arthritis (RA) typically develops in women of a reproduction age.
- Patients with early or poorly controlled RA should be advised to defer conception until their disease is more stable.
- RA symptoms tend to improve in pregnancy but only resolve in a small minority. Patients tend to have a flare following delivery
- Methotrexate is not safe in pregnancy and needs to be stopped at least 3 months before conception
- Leflunomide is not safe in pregnancy
- *Sulfasalazine and hydroxychloroquine* are considered safe in pregnancy
- Interesting studies looking at pregnancy outcomes in patients treated
- With TNF-a blockers do not show any significant increase in adverse outcomes. It should be noted however that many of the patients included in the study stopped taking TNF-a blockers when they found out they were pregnant.
- Low-dose corticosteroids may be used in pregnancy to control symptoms.
- NSAIDs may be used until 32 weeks but after this time should be withdraw due to the risk of early close of the *ductus arteriosus*
- Patients should be referred to an obstetric anaesthetist due to the risk of atlanto-axial subluxation.

HIV AND PREGNANCY

- The aim of treating HIV positive women during pregnancy is to minimize harm to both the mother and fetus, and to reduce the chance of vertical transmission.
- Factors which reduce vertical transmission (from 25-30% to 2%)
- Maternal antiretroviral therapy
- Mode of delivery (caesarean section)
- Neonatal antiretroviral therapy
- Infant feeding (bottle feeding)

Screening

- NICE guidelines recommend offering HIV screening to all pregnant women

Anti-Retroviral Therapy

- All pregnant women diagnosed HIV infected should receive antiretroviral therapy regardless of whether they were taking it previously.
- Prevention of mother to child transmission (PMCT) can be started whatever the gestational age.
- Treatment is recommended life-long but, if possible, should at least be given until one week after cessation of breastfeeding.

Mode of Delivery

- Vaginal delivery is recommended if viral load is *less than 50 copies/ml at 36 weeks*, otherwise caesarian section is recommended.
- A zidovudine infusion should be started four hours before beginning the caesarean section

Neonatal Anti-Retroviral Therapy

- Zidovudine is usually administered orally to the neonate if maternal viral load is <50 copies/ml. otherwise *triple ART* should be used. Therapy should be continued for 4-6 weeks.

Infant Feeding

- Infant feeding options include either exclusive breastfeeding or formula feeding alone.
- Mixed feeding is not encouraged.

BACTERIAL VAGINOSIS

- This history and presence of clue cells suggests a diagnosis of bacterial vaginosis. The BNF suggests topical clindamycin as an alternative treatment for patients who are allergic to metronidazole.
- Bacterial vaginosis increases the risk of miscarriage and premature birth. There is increasing evidence that metronidazole is safe in pregnancy. Of note there is no evidence of teratogenicity with its use in the first trimester of pregnancy. The guidelines recommend the treatment of symptomatic patients at all stages of pregnancy. Metronidazole and oral clindamycin enter breast milk. Clindamycin intravaginal gel is recommended for breast feeding women.

CHICKENPOX EXPOSURE IN PREGNANCY

- Chicken pox is caused by primary infection with varicella zoster virus. Shingles is reactivation of dormant virus in dorsal root ganglion. In pregnancy there is a risk to both the mother and also the fetus, a syndrome now termed fetal varicella syndrome.

Risk to the mother

- 5 times greater risk of pneumonitis

Fetal varicella syndrome (FVS)

- Risk of FVS following maternal varicella exposure is around 1% if occurs before 20 weeks gestation.
- Studies have shown a very small number of cases occurring between 20-28 weeks gestation and none following 28 weeks
- Features of FVS include skin scarring, eye defects (microphthalmia), limb hypoplasia, microcephaly and learning disabilities

Other risks to the fetus

- Shingles in infancy: 1-2% risk if maternal exposure in the second or third trimester
- Severe neonatal varicella: if mother develops rash between 5 days before and 2 days after birth there is a risk of neonatal varicella, which may be fatal to the newborn child in around 20% of cases

Managements of Chickenpox Exposure

- If there is any doubt about the mother previously having chickenpox maternal blood should be urgently checked for varicella antibodies\
- If the pregnant woman is not immune to varicella, she should be given varicella zoster immunoglobulin (VZIG) as soon as possible. RCOG and Greenbook guidelines suggest VZIG is effective up to 10 days post exposure
- Consensus guidelines suggest oral acyclovir should be given if pregnant women with chickenpox present within 24 hours of onset of the rash
- A second dose of VZIG may be required if a further exposure is reported and 3 weeks have elapsed since the last dose.

- Chickenpox exposure in pregnancy - first step is to check antibodies
- The negative IgG indicates no previous exposure to chickenpox
- Chickenpox exposure in pregnancy - if not immune give VZIG
- If there is any doubt about the mother previously having chickenpox maternal blood should be checked for varicella antibodies

URINARY TRACT INFECTION IN ADULTS: MANAGEMENT

- A test of cure MSU should be sent in pregnant women treated for a UTI
- Pregnant women should be prescribed a 7 days course of antibiotics. Nitrofurantoin should only be avoided in the third trimester
- Amoxicillin is also recommended in this situation (38 weeks preg). Nitrofurantoin should be avoided near term as it may cause neonatal haemolysis but it may be used earlier in the pregnancy.

ASYMPTOMATIC BACTERIURIA IN PREGNANT WOMEN

- Repeat MSU
- If confirmed treat with amoxicillin or a cephalosporin
- SIGN advised that pregnant women with asymptomatic bacteriuria should have a second urine culture to confirm the result.

Lower urinary tract infections in non-pregnant women

- Trimethoprim or cephalexin for 3 days
- Pregnant women with symptomatic bacteriuria should be treated with an antibiotic for 7 days. A urine culture should be sent.

For asymptomatic pregnant women:

- A urine culture should be performed routinely at the first antenatal visit
- If positive, a second urine culture should be sent to confirm the presence of bacteriuria
- SIGN recommend to treat asymptomatic bacteriuria detected during pregnancy with an antibiotic
- A 7 days course of antibiotics should be given
- A further urine culture should be sent following completion of treatment as a test of cure.
- For patients with sign of acute pyelonephritis, hospital admission should be considered
- Local antibiotic guidelines should be followed if available.
- The BNF currently recommends a broad-spectrum cephalosporin or a quinolone for 10-14days.

HERPES SIMPLEX VIRUS

- This patient has genital herpes simplex virus (HSV). The guidelines recommend treatment with oral (or intravenous) *acyclovir at any stage in pregnancy*. Acyclovir is not licensed in pregnancy but is considered safe and not associated with birth defects. It is well tolerated in pregnancy. Paracetamol and topical lidocaine 2% gel can be used for symptomatic relief
- The primary purpose of treatment is to reduce the risk of transmission to the neonate at birth. The risk is much more considerable with primary genital herpes simplex within the final six weeks of pregnancy. *Caesarian section* should be the recommended mode of delivery for all women developing the first episode of genital HSV in the third trimester.
- There are two strains of the herpes simplex virus (HSV) in humans: HSV **-1** and HSV-2. Whilst it was previously thought HSV-1 accounted for oral lesions (cold sores) and HSV-2 for genital herpes it is now known there is considerable overlap.

Features

- Primary infection: may present with a severe gingivostomatitis
- Cold sores
- Painful genital ulceration

Management

- Gingivostomatitis: oral acyclovir, chlorhexidine mouthwash
- Cold sores: topical acyclovir although the evidence base for this is modest
- Genital herpes: oral acyclovir. Some patients with frequent exacerbations may benefit from longer term acyclovir.

HYPEREMESIS GRAVIDARUM

- Smoking is associated with a decreased incidence of hyperemesis gravidarum.
- Hyperemesis is gravidarum describes excessive vomiting during pregnancy. It occurs in around 1% of pregnancies and is thought to be related to raised beta hCG levels.
- Hyperemesis gravidarum is most common between 8 and 12 weeks but may persist up to 20 weeks.
- Multiple pregnancies
- Trophoblastic disease
- Hyperthyroidism
- Nulliparity
- Obesity
- Smoking is associated with a decreased incidence of hyperemesis

Management

- Antihistamines should be used first-line (BNF suggests promethazine as first-line)
- Admission may be needed for IV hydration

Complications

- Wernicke's encephalopathy
- Mallory-Weiss tear
- Central pontine myelinolysis
- Acute tubular necrosis
- Fetal: small for gestational age, pre-term birth and in very rare cases beyond 20 weeks.

PRESCRIBING IN PREGNANT PATIENTS

- Orlistat is not a known teratogenic it should be used with 'caution' in pregnancy according to the BNF and the benefits are very likely outweighed by risks.
- Very few drugs are known to be completely safe in pregnancy.

The list below largely comprises of those known to be harmful.

Antibiotics

- Tetracyclines
- Aminoglycosides

- Sulphonamides and trimethoprim
- Quinolones: e.g., ciprofloxacin the BNF advises to avoid due to arthropathy in some animal studies

Other drugs

- ACE inhibitors, angiotensin II receptor antagonists
- Statins
- Warfarin
- Sulfonylureas
- Retinoids (including topical)
- Cytotoxic agents
- The majority of anti-epileptics including valproate, carbamazepine and phenytoin are known to be potentially harmful. The decision to stop such treatments however is difficult as uncontrolled epilepsy is also a risk
- Warfarin is contraindicated in pregnancy. Most women are switched to low-molecular weight heparin for the duration of the pregnancy.
- The BNF advises avoiding quinolones in pregnancy due to arthropathy in animal studies.
- There have been some reports of an increased risk of necrotizing entercolitis following the use of co-amoxiclav in pregnancy. The evidence is however inconclusive and the BNF states that co-amoxiclav is 'not known to be harmful'. A link is provided both to the BNF and the UK teratology information service.

SUPPLEMENTS IN PREGNANCY

Folic acid

- Folic acid is converted to tetrahydrofolate (THF). Green, leafy vegetables are a good source of folic acid.

Functions

- THF plays a key role in the transfer of I-carbon units (e.g., methyl, methylene, and formyl groups) to the essential substrates involved in the synthesis of DNA & RNA

Causes of Folic Acid Deficiency

- Phenytoin
- Methotrexate
- Pregnancy
- Alcohol excess

Consequences of folic acid deficiency:

- Macrocytic, megaloblastic anaemia
- Neural tube defects
- Women are advised to take folic acid 400 mcg when trying to conceive through to 12 weeks gestation to reduce the incidence of neural tube defects.
- A higher dose of 5mg is indicated if there are additional risk factors e.g. diabetes or personal or family history of neural tube defects.
- A daily supplement of vitamin D 1Omcg is also advised throughout pregnancy for bone health, and should be continued for the duration of breastfeeding.
- If a woman chooses to take a multivitamin in pregnancy, she should be advised to ensure it does

not contain vitamin A (retinol) as it is teratogenic in high doses.

Vitamin b12 (cobalamin)

- A B12 supplement may be indicated for breastfeeding women who eat a vegan diet. This is because vitamin B12 is mainly found in meat and dairy products. Dietary sources of vitamin B12 suitable for vegans may include fortified breakfast cereals, and yeast extracts (e.g., Marmite).
- The NHS also advises that all breastfeeding women - whatever their diet - should take a daily supplement of vitamin D **10** mcg for the bone health of themselves and their baby. Some women may be eligible for free supplements, if they qualify for Healthy Start vouchers; the Health Visitor can advise.
- Vitamin B12 is a water-soluble vitamin of the B complex group.
- Typically, humans have enough reserves of vitamin B12 to last 5 years.
- Vitamin B12 is unusual in only being found in animal products.

Functions

- Cofactor for the conversion of homocysteine into methionine via the enzyme homocysteine methyltransferase
- Cofactor for the isomerization of the methylmalonyl CoA to Succinyl CoA via the enzyme methylmalonyl mutase
- Used to regenerate folic acid in the body

Causes of vitamin B12 deficiency:

- Pernicious anemia
- Diphyllobothrium latum infection
- Crohn's disease

Consequences of vitamin B12 deficiency:

- Macrocytic, megaloblastic anaemia
- Peripheral neuropathy

Vitamin d supplementation

- Vitamin D 10 µg is now recommended throughout pregnancy for all women.
- Low dose folic acid 400 µg is recommended for all women for the first 12 weeks of pregnancy. Women with pregnancies at risk of neural tube defects should take 5 mg folic acid for the first 12 weeks of pregnancy.
- A B12 supplement may be indicated for breastfeeding women who eat a vegan diet.
- Pregnant women should be advised that if they wish to take a multivitamin tablet to ensure it does not contain vitamin A, as this can be teratogenic in high doses.
- Pregnancies at high risk of neural tube defects are those in which either partner has a neural tube defect (or either partner has a family history of neural tube defects), if they have had a previous pregnancy affected by a neural tube defect, or if the woman has coeliac disease (or other condition causing malabsorption), diabetes mellitus, sickle-cell anaemia, or is taking antiepileptic medicines, Soft-cheese should be avoided during pregnancy due to the risk of Listeria.

The following groups should be advised to take vitamin D supplementation:

- All pregnant and breastfeeding women should take a daily supplement containing 10 µg of Vitamin D
- All children aged 6 months - 5 years. Babies fed with formula milk do not need to take a supplement if they are taking more than 500 ml of milk a day, as formula milk is fortified with

vitamin D
- Adults >65 years
- "People who are not exposed to much sun should also take a daily supplement"

Testing for Vitamin D Deficiency

- The key message is that not many people warrant a vitamin D test. The National Osteoporosis Society (NOS) guidelines specify that testing may be appropriate in the following situations:
- Patients with bone diseases that may be improved with Vitamin D treatment e.g. known osteomalacia or Paget's disease
- Patient with bone diseases, prior to specific treatment where correcting vitamin deficiency is appropriate e.g., prior to intravenous zoledronate or denosumab
- Patients with musculoskeletal symptoms that could be attributed to vitamin D deficiency e.g. bone pain? Osteomalacia
- Patients with osteoporosis should always be given calcium with vitamin D supplements to testing is not considered necessary. People who are at higher risk of Vitamin D deficiency (see above) should be treated anyway so again testing is not necessary.

Vitamin A (retinol)

- Vitamin A is a fat-soluble vitamin

Functions

- Converted into retinal, an important visual pigment
- Important in epithelial cell differentiation
- antioxidant

Consequences of Vitamin A Deficiency

- Night blindness
- Vitamin A is *teratogenic in high doses*, and *pregnant women should not exceed a daily intake of >10,000 JU* Women are therefore advised to avoid any supplements containing vitamin A, such as normal multivitamin tablets, in pregnancy (NHS Choices). However, as supplements in the UK are now limited to a maximum Vitamin A content of 6,000 IU, if they have been taking one it should not be cause for concern. Pregnant women are also advised to avoid eating liver, as it has high levels of Vitamin A.

ABNORMAL PUERPERIUM

Puerperal pyrexia including:

- Puerperal sepsis
- Breast problem
- Bowel problem
- UTI and others
- Thrombophlebitis
- Wound infection
- Psychological upset

PUERPERAL PYREXIA

- 100.4 °F within 14 days after confinement or miscarriage and termination of pregnancy

Causes OF puerperal pyrexia

- **Genital causes**
  - genital tract infection
- **Extra-genital causes**
  - urinary tract infection
  - breast engorgement/infection
  - wound infection
  - respiratory tract infection
  - intercurrent febrile illness
  - thrombophlebitis

Puerperal sepsis (genital tract infection)

- Infection of the genital tract after confinement or miscarriage and termination of pregnancy

Aetiology

- Sites of infection
  - **Placenta site:** raw area -uterine wall
  - **Wounds:** cervix, perineum Bacteriology
  - **Endogenous:** Coliforms, Enterococci (*Strep faecalis*) Chlamydia, GC, *Clostridium perfringens*, Anaerobic streptococci, Bacteroides
  - **Exogenous:** *Haemolytic streptococci* (Group A), *Staphylococcus aureus*

Pathology (classification)

- Mild infection
  - infection localized (birth canal, placental site)
- Moderate infection
  - salpingitis
  - pelvic cellulitis -pelvic peritonitis - pelvic abscess
- Severe infection
  - general peritonitis
  - septicemia

Severity of disease

- depend on virulence of organisms, resistance of patient, amount of trauma, resultant dead tissues, appropriate antibiotic treatment, effective blood supply of infected area.

Clinical features

- Fever - may appear within 24 hours - abrupt, step-like, rigor
- Pulse - increase
- Headache, backache
- Lower abdominal pain - Signs of inflammation of pelvic peritoneum
- Tender uterus and adnexa- Signs of inflammation of pelvic peritoneum
- Distension
- Vomiting } in general peritonitis
- Diarrhoea

Diagnosis

- Fever - 24hr after delivery or miscarriage and termination of pregnancy
- Delayed involution of uterus
- Infected wound - laceration, episiotomy
- Lochia - offensive
- Induration of parametrium

Investigation

- Midstream Urine for C & S
- High vaginal swab for C & S
- Full blood count
- Blood culture if septicemia suspect: rigor / high temperature
- USG for retained products of conception (RPOC), fluid collection in pelvic cavity.

Prevention

- VE - sterile gloves (during labour)
- Adequate aseptic precautions
- Reduce trauma at delivery
- Personal hygiene
- Prophylactic antibiotics - Caesarean section (CS), Premature rupture of membrane (PROM)

Treatment

- **REFER** for Admission
- Good nursing care
- Adequate fluid intake
- Analgesics for pain
- Sedation for rest
- Correct anaemia - (Hb%-? Blood transfusion)
- Antibiotics - according to C&S
- STO - if infected perineal wound

Surgical treatment

- Exploration of uterine cavity if there are retained pieces of placenta
- Incision & drainage (POD), Posterior colpotomy if there is pelvic abscess
- Laparotomy and Drainage of pus
- Total or subtotal Hysterectomy

BREAST PROBLEMS

- Multi-factorial
- Present with feeding problems (common)

Feeding problems

- D/t combination of physical & psychosocial factors
- Cause tremendous stress and anxiety to mother & her family

Management

- counseling (sensitive issue)
- careful h/o to establish source of problem
- close attention to feeding technique & support

Sore nipples

- No evidence to support limiting suckling time.
- ***Optimal attachment & positioning is effective.***
- Removing baby from breast & nipple shield have negative effect on lactation.

Milk engorgement

- Pain and tender breast,
    - usually occur on day 3-5 of puerperium.
    - Rarely occurs with good feeding technique
- *Milk expression* can relieve the condition.

Advice

- to use warm compress and warm shower before feeding
- to support with binder or brassiere after feeding
- to use cold compress to reduce swelling and pain
- Encourage her to feed frequently.
- Give analgesia (paracetamol) if necessary.

Mastitis

- Cause - milk stasis from engorgement
- Typically localized to one breast, confined to one lobe (often upper-outer quadrant)
- Symptoms- extreme malaise, flu-like symptoms, muscular aching
- Treatment (Local);
    - Hot & cold compress, gentle hand expression
    - Analgesics, Antipyretics
    - Advise to rest but not to restrict feeding, support breasts.
    - Antibiotic therapy is rarely necessary (most cases are non-infective, benign and self-limiting)

Infective mastitis

- should be diagnosed by microbiological techniques

- Antibiotics -Fluclox 500 mg qid (according to C& S) and Ibuprofen 400 mg tds and pm
- Prolonged treatment (10 - 14 days) to prevent recurrence.

Breast abscess

- Incision and drainage
- Antibiotics

Insufficient milk supply

- Most cases are perceived insufficiencies
- Teach proper attachment
- Good information and psychological support

URINARY TRACT INFECTION

- Commonest cause of puerperal pyrexia



Clinical Features

- Symptoms - Dysuria, frequency, urgency
- Signs - Fever with chills & rigors

Diagnosis

- Urine RE - Pus cells+++
- MSU for C & S - Colony count >100,000/ml

Treatment

- If history of UTI (+), give prophylactic antibiotics
- Fluid intake - not <3L/24 hour
- Give appropriate antibiotics according to C&S results

URINARY RETENTION

- Risk factors are prolonged labour, caesarean section (epidural analgesia), etc.
- Over-distension of bladder can lead to detrusor instability.
- Should encourage micturition.
- No women should be allowed more than 6 hours without voiding.
- Document urine void within 6 hours.

STRESS INCONTINENCE

- Post common urinary incontinence
- Can persist for months or even years
- Can affect physical, psychological and social well-being
- *Pelvic floor exercises* appear to be effective
- Referral to physiotherapist is recommended

DETRUSOR INSTABILITY

- 2nd most common urinary incontinence
- Avoid caffeine
- Physiotherapy
- Medical & surgical treatment

VESICOVAGINAL FISTULA

- Continuous leakage of urine
- Risk factors are prolonged and difficult labour
- Refer

BOWEL PROBLEMS

CONSTIPATION

- Common in immediate post-partum days
- d/t reduced dietary intake, perineal trauma and inactivity

Treatment

- encourage high-fiber diet and adequate fluid intake and laxatives

Complication

- can cause acute anal fissure

HAEMORRHOIDS

- dietary advice, fecal softener and topical application of cream (proctosedyl), ice packs can relieve

ANAL INCONTINENCE

- appropriate management of 3rd & 4th degree perineal tears

PERINEAL PAIN AND DYSPAREUNIA

- Associate with mode of birth, trauma and method of wound closure
- If signs of infection and inadequate wound repair or breakdown---- need to investigate
- Pain killers, local anesthetic gel or ice packs, cooling gel pads ----- effective
- Information and advice to couples how to reduce soreness on penetration e.g. use of lubricating gel

THROMBOPHLEBITIS

- 4^{th} – 10^{th} day
- Can be superficial (tender varicose vein) or associated with deep vein thrombosis (calf vein)
- Can lead to embolization to lungs and other sites

Treatment

- Exclude DVT and refer
- Encourage - bed-rest, elevation of foot-end, icepack,
- Recovery usually occurs within a few days
- Give pain relief, Antibiotics, local Anticoagulant (heparin gel)
- Ambulation

WOUND INFECTION

- CS wound – l in 12 infected
- Prophylactic antibiotics can prevent wound infection

Signs of infection

- redness, tenderness, serosenguinous discharge & purulent discharge
- Can lead to wound dehiscence & burst abdomen

DEPRESSION AND PSYCHOLOGICAL PROBLEMS

POSTNATAL OR BABY BLUES

- 80% of women may experience the post- natal in **first** two week.
- symptoms are fatigue, short temperedness, difficulties in sleeping, depress mood and tearfulness

Treatment

- usually mild and resolve spontaneously in the majorities of the cases
- If 'baby blue' persists- treatment for PND is indicated

POSTNATAL DEPRESSION (PND)

- is a form of non-psychotic postnatal depressive illness, peak -12wk after delivery
- mild to moderate severity

Risks

- Depression during pregnancy A bad birth experience
- Social problems (e.g. poor social support, financial problems)
- Past medical or family history of depression or postnatal depression Alcohol or drug abuse

Treatment

- keep women with early onset PND in close review, check thyroid function test (TFT) (presenting with tiredness)
- avoid overlooking as severe psychiatric illness
- give emotional support

- treat with antidepressants SSRI sertraline 50 mg od
- **REFER** if suicidal or harm to the baby

PUERPERIAL PSYCHOSIS

- Risks factors are previous history puerperal psychosis, severe non-postpartum depressive illness and family h/o of bipolar disorder/affective psychosis.
- Characteristics symptoms are restless agitation, insomnia, perplexity, confusion, delusions, hallucination, failure to eat and drink, thoughts of self-harm, depressive symptoms (guilt, self-worthlessness, hopeless), loss of insight

Treatment

- include acute treatment with neuroleptics (risperidone, haloperidol)
- REFER to hospital

OTHER PROBLEMS

- Fatigue
- Headache
- Anaemia
- Musculoskeletal problems (backache, etc.)

CIRCULATORY PROBLEMS

- Varicose veins

Reference

1. *Obstetrics and Gynaecology Management Guidelines, 1st Edition (2015),* O&G *Society, MMA*
2. *Oxford handbook of General Practice, 4[1] Edition*

POSTNATAL CARE

Definition

- Postnatal period begins immediately after the birth of baby and extends up to six weeks after birth during which the maternal systems especially the pelvic organs more or less return to pre-pregnant state.

PHYSIOLOGICAL CHANGES

TEMPERATURE (Elevated temperature)

- may be normal finding for first 24 hours.
- may be sign of dehydration, infection.

PULSE

- rises for few hours after normal delivery.
- should return to normal by 2nd or 3rd day.

Tachycardia

- infection, haemorrhage, pain, anxiety.

Bradycardia

- may be normal finding

BLOOD PRESSURE

- ***Elevated Blood Pressure*** due to pregnancy induced hypertension
- ***Lowered Blood pressure*** due to orthostatic hypotension or shock

POSTPARTUM CHANGES IN GENITAL TRACT

UTERUS

- Contraction and retraction continue to occur after birth.
- Discomfort is greater in multipara. Contraction is necessary for controlling bleeding and involution. Placenta site begins healing immediately by vasoconstriction and thromboses. It takes about 6 weeks to completely regenerate.

Involution of uterus

- Involution: returns to non-pregnant state by contraction and retraction of uterine muscle
- Uterine muscle → autolysis → peptone (in urine)
- Level of uterus: Immediately after delivery at umbilicus
- Postpartum 10th day at symphysis pubis (pelvic organ)

Height of the fundus of the uterus

- immediately after delivery - umbilical level
- postpartum 10th day - unable to palpate abdominally as becomes the pelvic organ
- 6th week postpartum - returns to normal size

Delayed involution of uterus (causes)

- Infection
- Retained pieces of placenta

- Fibroid
- Multiple pregnancy

LOCHIA

- is a postpartum uterine discharge
- lasts for 3-4 weeks of puerperium
- is alkaline, have a peculiar odour
- **Contents** –
    - decidual debris, vaginal epithelium, peptones, bacteria, cervical discharge
- **Types of lochia** (3-7days for each type)
    - Lochia rubra - red colour, blood, blood clot
    - Lochia serosa -pink colour, blood, WBC
    - Lochia alba - white colour, WBC, fibrin, mucous
- **Persistent red lochia** suggests delayed involution.
- Offensive lochia + pyrexia + tender uterus suggest infection.

CERVIX

- By 18 hours after birth, it has shortened and regained pre-pregnancy shape.
- Lower segment remains thin & fragile for several days.
- Os remains open for about 2 weeks.
- Center of opening is no longer round but a horizontal slit.

VAGINA & PERINEUM

- Vaginal rugae are flattened by delivery but reappearing by week 4.
- Introitus with good hygiene healed by week 2.
- Episiotomy is the same as any wound and healed by week 2.
- Haemorrhoids decrease in size during the week of postpartum.

HORMONAL CHANGES

- Most hormones return to pre-pregnant level by week 2 unless lactating.

CARDIOVASCULAR SYSTEM CHANGES

- Blood pressure decreases until 3-4 wks.
- Cardiac output takes about 60 minutes to return to normal.

GASTRO-INTESTINAL SYSTEM

Constipation

- Common due to - interrupted food intake, dehydration during labour, lax abdominal muscle, perineal laceration, and episiotomy.
- Prevented by high fiber diet or bulk forming drugs (methylcellulose).
- If not act, then gives laxatives, suppositories, or enema.

URINARY SYSTEM

- Diuresis by 2nd or 3rd day
- Lactouria –Peptones in urine, by 2nd or 4th day
- Cystitis - *E. coli* is common organism; catheterization can predispose to infection; Retention of urine can be due to difficult labour & prolonged labour; pain resulting from bruising and laceration of vulva.

Incontinence of urine

- true incontinence/fistula stress incontinence
- Dilatation of ureters decreases by 2-8weeks post-partum

ONSET OF LACTATION

- colostrum can be expressed from 16 weeks of pregnancy till 2nd post-partum after which replaced by milk.
- milk production is initiated by prolactin from anterior pituitary but action 1s suppressed by estrogen before delivery.
- milk ejection or let-down reflex is stimulated by oxytocin from posterior pituitary.



HAEMATOLOGICAL SYSTEM

- Haemoglobin level is stable by 5th day.
- WBC reduced to 10,000/cumm.
- Platelet is increased by 4th to 10th day.

History taking and physical examination

- Personal identification, h/o present pregnancy, h/o present delivery
- Place of delivery
- Accoucheur
- Date and time of delivery
- Mode of delivery
- Duration of first stage: (from onset of labour pain to onset of urge to push)
- Duration of 2nd stage: (from pushing to delivery of baby)

- Duration of 3rd stage: (from delivery of baby to delivery of placenta and membrane)
- Any complication and any intervention during 1st stage, 2nd stage and 3rd stage of labour process
- Baby's condition
- H/o puerperium & h/o present illness
- assess discomfort, assess whether she can sleep well, assess appetite, assess the bowel, bladder function, assess breastfeeding.
- Menstrual h/o Marital h/o
- **Past Obstetric h/o**
- **Past Medical & Surgical h/o Gynaecological h/o**
- **Family h/o, Personal h/o, Social h/o, Drug h/o**
- **Physical Examination**
    - Assess general condition
    - Temperature, Pallor (anaemia), oedema, dyspnoea, CVS, Respiration
    - Breast
        - Can be soft, firm, lumpy Secretion of colostrum
        - Engorgement? Signs of inflammation?
        - Assessment of nipples for retraction, crack and fissures
    - Abdominal examination
        - Uterus - Fundal height: inches below umbilicus, symphysio-fundal height in cm, tenderness (+/-)
    - Perineal Examination
        - Lochia- amount, color, smell Episiotomy wound and perineal tear, assessment for haematoma,
        - signs of inflammation/ infection, suture line
    - Roman's sign - assessment for thrombophlebitis (swelling, redness, warmth, pain) Unilateral finding is more suspicious
    - C/S cases are at higher risk.

For patient who had epidural

- Assessment of lower extremities for sensation movement
- Remains on bed rest

For patient who had undergone caesarean section

- Additional assessment: incision, fluid intake, bladder & bowel, ambulation/orthostatic hypotension, thrombophlebitis

Documentation of finding is important.

Management

AIMS OF MANAGEMENT

- To monitor and promote the health of mother
- To facilitate the mother and other family members to care baby safely and confidently
- To establish proper breast feeding
- To enable the mother and her partner to develop their parenting skills
- To prevent the complications

Give information on:

- daily lifestyle (nutrition, ambulation, exercise, rest & sleep, bathing)
- ambulation as soon as possible
- breast feeding within half an hour

- application of self-care techniques such as taking gentle exercise, taking time to rest, having help to care for baby, personal hygiene.

Give advice on:

- Diet: Full balanced diet (fruits & vegetables, more proteins)
- Adequate intake of fluid (not excessive)
- Sleep: night (8 hours), afternoon (2 hours)
- Care of Perineal stitches
- Carry out assessment of perineum.
- Assessment of lower extremities for sensation movement Remains on bed rest

For patient who had undergone Caesarean section

- **Additional assessment:** incision, fluid intake, bladder & bowel, ambulation/orthostatic hypotension, thrombophlebitis
- **Documentation of finding** is important.
- If perineal pain is present, evaluate signs and symptoms of infection, inadequate repair or wound breakdown.
- Wash with soap and water dried apply dry sterile vulval pad (change frequently)
- STO on 5th day if non absorbable suture was used.
- **Bowel (for LSCS):**
    - Assessment for signs and symptoms of peritonitis esp. in prolonged labour
- **Bladder**
    - Assessment for bladder distension
    - May need catheterization if not able to void urine after 6 hours.
    - Measure Urine Output.
- **Breast feeding**
    - Assess effectiveness of breastfeeding and care of breast.
    - Offer information about how to hand-express their breast milk.
- **Mental Health & Emotional status**
- Many new adjustments have to be made.
- Mothers are frequently tired and can have labile emotion.
- Lack of support can exacerbate tiredness, feeling of sadness.
- **Emotion** can be affected by
    - unanswered questions about the labour.
    - attention shifting from mother to baby.
    - anxiety about parenting competence.
    - baby crying more than expected.
- Assess the patient whether there is any abnormality or complication Treat accordingly if present.
- **Give iron tablets for 3 months if anaemia is present.**
- **Before discharge, give information on**
    - Promoting health of both mother and baby.
    - The physiological process of recovery after birth.
    - Normal pattern of emotional changes (within 3 days of delivery).
    - Recognition of **common health problems** such as baby blues, perineal pam, discomfort, offensive odour or dyspareunia, headache, persistent fatigue, backache, constipation, haemorrhoids, faecal and urinary incontinence, urinary retention.
    - Recognition of signs and symptoms of **life-threatening conditions** such as sudden and profuse blood loss, change in consciousness, fever, chill and rigor, abdominal pain, severe persistent headache, raised blood pressure, breathlessness or chest pain, unilateral calf pain, redness and swelling.
    - To contact breast feeding support groups if there is any breastfeeding problems.
    - Information on perineal hygiene, methods and timing of resumption of contraception

- Postnatal exercise- breathing, abdominal and pelvic muscles, and legs.
- Advice for postnatal checkup at 6 weeks after delivery.

FAMILY PLANNING (BIRTH SPACING)

Contraceptive advice:

- Inform and counsel about various methods of contraception, its efficacy, and side effect, its effect on breast feeding, impact on future fertility.

Various methods:

- Natural method including Lactational Amenorrhoea Method (LAM).
- Barrier method e.g., condom
- Hormonal method
- Injection Depo-provera (Methoxy progesterone acetate)
- Progestogen only pill (POP)
- Combined oestogen, progestogen containing pill (COC)
- Intrauterine contraceptive device (IUCD)
- Progestogen containing implant
- Sterilization
- *LAM is only effective **if** exclusive breast feeding is applied and patient has amenorrhoea.*
- *Progestogen containing contraception is suitable in breastfeeding mother.*
- *COC should be avoided in first 6 month.*

CONTRACEPTION

CONTRACEPTION

Intentional prevention of conception or impregnation through the use of various devices, agents, drugs, sexual practices or surgical procedures.

FAMILY PLANNING

A program to regulate the number and spacing of children in a family through the practice of contraception or other methods of birth control.

BIRTH SPACING METHODS

Permanent Methods	**Temporary Method**
Male (Vasectomy) & Female (Tubal Ligation) sterilization	Natural Methods - Lactational Amenorrhoea - Calendar Method, etc. Hormonal Methods - COC, POP, Injectables, ECP, Norplant, IUS Non-hormonal Methods - IUD, Male and Female condoms, Spermicides

Contraception

- A woman's choice of contraceptives methods should be informed one, and should be based on knowledge of the various options available to her.
- A combination of good counseling and adequate skill on the part of the provider is required.
- The provider must be able to explain the characteristics of the contraceptives.
- Six steps in counseling the clients
    - G = greet client
    - A = Ask client about themselves
    - T = Tell clients about choices
    - H = Help clients make informed choice
    - E = Explain how to use chosen method
- R = Return visits should be welcome Not Abortifacient!! ***No abortifacient!***

COC	**POP**
Composition	
• Contain estrogen & progestin • Standard =.05mg ethinyl estradiol and progestin(C5) • Low dose =ethinyl estradiol 0.03 mg and levonorgestrel (*2nd generation*) 0.15 mg in each tablet- 21+ placebo 7 tablets (microgynon) • Ethinyl estradiol 0.03mg and desogestrel (*3rd generation*) 0.15 mg in each tablet+ placebo 7 tablets (marvelon) 99% effective	• Contain very small amount of Progestin only Lynestrenol 0.5mg -28 active hormone pills (Exluton) • 97% effective if taken according to instructions

How they work?	
• Inhibit ovulation (effect of estrogen and progesterone centrally) • Prevent Implantation (local effect of progesterone) • Thickening of the cervical mucus (local effect of progesterone) • * Not disrupt an existing pregnancy	
Advantages	

• Highly effective
• Safe, reversible
• Fertility returns soon after discontinuing (approximately 3 months)
• Non contraceptive benefit:
  • Improve premenstrual syndrome, acne
  • Reduce risk of ca ovary and ca endometrium, Ovarian and Breast cysts, Fibroids & Iron Deficiency anaemia pelvic inflammatory disease
• Regulates monthly periods
• Less risk of ectopic pregnancy
	• Breast feeding women can use
	• No estrogen side effect so can use in old age, DM, CVD risk
	• Relieve dysmenorrhoea
	• Highly effective during Breast feeding
	• Prevent benign breast dis, endometrial & Ovarian Ca, PID

Disadvantages	
• Client dependent • Regular, daily use • To take at about the same time every day • No protection against STI & HIV	
• Not appropriate choice for lactating Mothers • Minor side effect usually common in 1st 3 months of use and irregular use include spotting, nausea, • amenorrhoea, breast tenderness, headache or weight gain	• Few hour late - increase the chance of Pregnancy • Missing 2 pills - greatly increase the chance of Pregnancy • Changes in menstrual bleeding among non-Breastfed women • More expensive
Timing	
• Take the first pill on the first day of period. • Continue taking one pill every day, in the order shown as arrow on the packet • Take with food. • Start the next packet straight away when finished the first packet	• Take the first pill on 1st day of menstrual period • At the same time • (e.g.,: Between 6 to 8 pm evening mealtime) • Start the next packet when finished the first packet • Do not miss a day

Hormonal method (oral)

What to suggest if client missed pill (COC)

- If she misses 1or 2 pills,
  - the client should take it as soon as she remembers.
  - Take the next one at the regular time.
- **IF SHE FORGETS TO TAKE TWO OR THREE PILLS, SHE SHOULD DO THE FOLLOWING (COC)**
- If she misses the two or three pills in **1st week**,

- take one missed pill as soon as she remembers and then continues to take regular pills regular time.
- Need EMERGENCY pill if unprotected sex, and
- Use back up method (condom) for 7 days at the same time.

- If 3 or more pills are missed in **2nd week**,
  - needs to use condoms for 7days
- **IF SHE MISSES 3 OR MORE PILLS OF 3rd row (7 PILLS) (COC)**
  - Take one missed pill as soon as remember
  - Take the remaining pills of the third row at regular time
  - After completion of third row, not to take the remaining pills of the fourth rows and start a new packet
  - At the same time, use back up method (condom) for 7 days
- **IF SHE MISSES THE PILLS OF THE LAST LINE (4th row) (COC)**
  - Throw away the missed pills.
  - Continue to take the remaining pills as in order

Absolute contraindications to COC

- Breast feeding <6wks postpartum
- Smoking >15 cigarettes/day or more cigarettes and age over **35**
- Multiple risk factors for CVD
- Hypertension >160/ 100 mmHg or more
- Hypertension with vascular disease
- Current or history DVT/pulmonary embolism
- Major surgery with prolong immobilization
- Known thrombogenic mutation
- Current or history of IHD, stroke
- Complicated valvular heart disease
- Migraine with aura
- Migraine without aura and over 35
- Current breast cancer
- DM (>20yr) with severe vascular disease or with nephropathy, retinopathy, neuropathy
- Active viral hepatitis
- Severe cirrhosis
- Benign or malignant liver tumours

COC/POP with special situation

- IF POP commenced after day 5, it takes 2 days to get protection.
- IF switching from COC, give immediate protection if take day 21 of COC
- Concurrent antibiotic use - precautions should still be taken with enzyme inducing antibiotics (e.g., rifampicin)
- For women taking phenytoin, carbamazepine, barbiturates, primidone, topiramate, oxcarbazepine
- If missed pill <3 hours, continue as normal
- If >3 hours, take missed pill as soon as possible, continue the rest of pack, use condoms for 2 days (diarrhoea and vomiting assume missed pill)

Hormonal method (injectable)

3 **month injection (DMP**A)	**1 month injection** (CIC)
- Depo- medroxyprogesterone acetate	- Combined injectable contraceptive - 2 main types * (approved by WHO) - Natural Estrogen Estradiol (NEE) Cypionate 5 mg & DPMA 25 mg - NEE Valerate 5 mg & progestin norethisterone enanthate 50 mg (OK 1)
Composition	
- 150 mg of synthetic progestin	- Progestin & Natural estrogen
How they work	
- Inhibit ovulation - *(at least 12 weeks)* with DMPA - Inhibit implantation - Thickening of the cervical mucus	-
Advantages - Highly effective - Safe, private, confidential & easy to use - Completely reversible	
- Weight gain - Who stop DMPA - 4 months longer than usual to become pregnant.	-
Instruction	
- 1st to 5th days of Period - Any other time – use back up method for 7 days - Do not message/ rub injection site - Can give if she is not pregnant	
Next injection	
- 12 weeks - -Up to 4 weeks early - -Up to 2 weeks late	- 30day +/- 3days
Side effects	
- Weight gain 8lbs in first year - Unexpected bleeding/spotting Breast tenderness - Delay in return of fertility - Headaches - amenorrhoea - increased risk of osteoporosis - Depression / dizziness Nausea	-
When to return	
- If she has questions/problems - Heavy vaginal bleeding - Excessive weight gain - Headaches - Severe abdominal pain - danger of ectopic pregnancy - Chest pain / Shortness of breath - Severe headaches (with blurred vision) - Swelling / Severe pain in one leg	-
If irregular bleeding: • *Give one of the following -* • COC • NSAID - Ponsten 500 mg tds • Antifibrinolytic - Azeptil 500mg tds • Capillary stabilizer - K stat 500 mg tds	-

SUMMARY

- Estrogen & progestin - COC, CIC
- (Main difference is presence of a natural estrogen in CIC versus a synthetic estrogen in COC)
- Progestin only - POP, DMPA
- Time until effective (if not first day period)
- -instant: IUD 2 days: POP
- 7 days: COC, injection, implant, IUS

INTRA-UTERINE CONTRACEPTIVE DEVICE (IUCD)

Types:

Cu T380, Multiload 375, Mirena

- Copper bearing devices
- Hormone releasing IUD
- Prevent fertilization and implantation, inhibit sperm transport
- Extremely effective - 99%

Long term use- Cu T380

- 10 years, gold standard of Cu

IUDs Multiload 375

- 5 years
- Insert during menstrual cycle, post-abortion, 4-6 weeks post-partum
- Reversible

Composition

- Polyethylene body
- A copper wire wound around the stem A monofilament nylon thread Polypropylene inserter tube
- Sliding polyethylene measuring ring Multiload Cu 375 SL- 29*21mm For 5 to8mm uterine length Recommended in-situ time -5 years Low expulsion rate
- Low rate of removal for bleeding and pain

How they work

- inhibit sperm transport
- Inhibit fertilization than implantation
- Sterile inflammatory foreign body reaction in endometrium Sperms frequently absent in upper female genital tract
- Low rate of recovery of ova from fallopian tube

Contraindication

- Current acute or chronic genital tract infection Known or suspected pregnancy
- Abnormal uterine bleeding of unknown origin Confirmed or suspected malignancy of genital tract Certain uterine abnormalities
- Assess with special consideration in nulliparity for future fertility

Timing for insertion

- Anytime during menstrual cycle

- Better within 2 weeks after the start of last period Immediately after birth
- 6 weeks after delivery
- Up to 5 days after unprotected coitus

Complication

- Pelvic discomfort Low back pain Uterine cramp
- Fainting with insertion Uterine perforation
- Increased risk of PID within first 20 days Expulsion
- Unexpected pregnancy following poor insertion

Follow-up

- Advise to check the thread in vagina once a month
- In early months, attention should be paid for expulsion and displacement Any delay in period or abnormal discharge should be check
- Any problems at any time

Removal

- Any time during menstrual cycle Severe pain
- Excessive bleeding Wish to have pregnancy
- Remove by gentle traction on the thread with forceps

HORMONAL IMPLANTS (NORPLANT, IMPLANON, JADELLE)

- Implants are placed in the body which release hormone that prevents pregnancy Inserted in simple 15 minutes outpatient procedure
- Elastic capsules, the size of paper match sticks, inserted under the skin in the arm 99.95% effectiveness rate

Norplant	Implanon	Jadelle
Side effect-same as Depo-Provera	Single rod implant 4 cm in length, 2mm diameter Control release of etonogestrel Insert subdermally in the medial aspect of upper arm	2 thin flexible capsules filled with levonogestrel
6 capsules- 5 years 2 capsules- 3 years	Remove after 3years	Up to 5 years
How they work - Suppress ovulation - Decrease tubal mortality - Change endometrium - Thicken cervical mucous		- Suppress ovulation - Decrease tubal mortality - Change endometrium - Thicken cervical mucous - Do not effect breast feeding - Rapidly effective <24hrs - Immediate return fertility on removal
Contraindication - Liver Infection, liver tumor - Current Venous thromboembolism (VTE) - Un explained vaginal bleeding - Current on past h/o Ca breast - Medication for seizure/TB		**Contraindication** - Liver Infection, liver tumor - Current VTE - Un explained vaginal bleeding - Current on past h/o Ca breast - Medication for seizure/TB
Side effects		Changes in bleeding pattern

BARRIER METHODS

- Male condoms, Female condoms

	Male condom	Female condom
Composition	A rubber sheath (latex, polyurethane)	A loose plastic sheath (polyurethane)
	Cheap Barrier that prevents sperm and infections form entering vagina	More expensive Barrier that prevents sperm and infections form entering vagina re expensive
How to use	-Open package carefully -Place condom on tip of penis with rolled rim facing away from body -Unroll condom all the way to base of penis -After ejaculation, hold rim of condom so it will not slip off and withdraw penis from vagina while still erect -Throw away used condom properly	-Open package carefully -Make sure the condom is lubricated -Choose a comfortable position -squat, raise one leg, sit or lie down Squeeze the inner ring at the closed end -gently insert inner ring into vagina -place the index finger inside condom, push the inner ring up as far as it will go -make sure outer ring is outside the vagina, condom is not twisted -to remove, twist the outer ring and gently pull -throw away condom properly
When to use	-Every time you have sex -If condom break, EC as soon as possible -Store away from direct sunlight -Check expiry date -single use only	Use a new condom for -each intercourse -insert before penis touches vagina -insert up to 8 hrs. ahead of time -sometimes need extra lubricant -after sex, take care about spillage of semen on to vagina

SPERMICIDE

- Most common is nonoxynol -9
- Available in creams, films, foams, gels, suppositories, sponges and tablets Best use with barrier methods
- Failure rate 6%
- Do not protect against STI and HIV

EMERGENCY CONTRACEPTION

Definition

- EC is any contraception, which is used after the potential time of implantation. It refers methods that can be used by women following unprotected intercourse to pregnancy.
- EC is a back-up method for occasional use, and should not be used as a regular method of birth control.

Method

- Emergency contraceptive pills
- Emergency IUD insertion

EMERGENCY CONTRACEPTIVE PILLS

	POP	COC
Composition	Levonogestrel 0.75mg (postinor, Ecee 2, pill72)	Levonogestrel 0.5mg+ethinyl estradiol 100mg
How they work	-By affecting movement of sperm through Cervical mucous -by affecting transport of sperm, ovum or embryo -by interfering with Ciliary function -by preventing fertilization -by inhibiting implantation	-By affecting movement of sperm through Cervical mucous -by affecting transport of sperm, ovum or embryo -by interfering with ciliary function -by preventing fertilization -by inhibiting implantation
How to use	One pill taken as soon as possible after unprotected sex, within 72 hour 2nd dose taken 12 hour after 1st dose	One pill taken as soon as possible after unprotected sex, within 72 hour 2nd dose taken 12 hour after 1st dose
Side effects	-Abdominal pain, vomiting,headache, dizziness, cramping, breast tenderness -Next period may be 1 week or late, if more than 1wk may be pregnant, do pregnancy test	-Abdominal pain, vomiting,headache, dizziness, cramping, breast tenderness -Next period may be 1 week or late, if more than 1 week may be pregnant, do pregnancy test
Contraindication	Known pregnancy No medical contraindication by WHO	Known pregnancy No medical contraindication by WHO
Effectiveness	95%- within 24 hours 85%- within 48 hours 58%- within 72 hours	74%-within 24 hours 36%- within 48 hours 31%- within 72 hours
When to start regular contraception after ECP use	-The day after she takes ECP -No need to wait for next monthly bleeding -New user, begin new pill pack -Continuing user, use as before -need to use back up method for first 7 days	

EMERGENCY CONTRACEPTIVE IUD INSERTION

Composition:

- IUD with banded copper on the arms, containing at least 380 mm2 of copper (The lowest failure rate and the first line choice)

When to use:

- Within 5 days of unprotected sex after exclusion of infection and pregnancy

How they work:

- The direct toxicity of copper ions on sperms inhibiting fertilization, because the copper in the endometrium inhibit implantation.

Complication:

- pelvic pain Abnormal bleeding Infection
- Expulsion and perforation
- Follow up for ECP users:
- Women should be advised to have pregnancy test if: her period is more than 7 days
- menstrual bleeding is lighter than usual
- she wants to use regular family planning method she needs some clarification about ECP use.

INFERTILITY

Definition

- Inability to conceive after 1-2 years of regular, unprotected sexual intercourse (not less than twice weekly)
- Primary infertility applies to a couple without a prior pregnancy.
- Secondary infertility is used when the couple has previously succeeded in achieving at least one pregnancy, including abortion and ectopic pregnancy.

Causes

- Male factor 30%
- Unexplained 20%
- Ovulation failure 20%
- Tubal damage l5%
- Other 15%

History

- History concerning about causes of male subfertility,
    - e.g. smoking, alcohol, undescended testes, varicose vein in the scrotum, or damage of genital tract from previous infection or operation to know factors that affect the production or transportation of sperm
    - h/o childhood mumps, erectile or ejaculatory problem.
    - Hereditary factor (no sperm or very low sperm count in some patients)
- History concerning about causes of female subfertility
    - e.g. irregular menstrual history (to know ovulatory disorders due to hormonal disturbances)
    - Symptoms suggestive of endometriosis or pelvic infection like dysmenorrhea, pelvic pam
    - history of operation, structural abnormalities of the uterus (for pelvic adhesion or blockage of fallopian tubes)
- female age (for aging)
- History of any coital difficulty- if present, to access if there is psychological or physiological

Investigation

For male:

- **Semen analysis:** abnormal result may be due to 'inaccurate collection of the specimen, or history of recent illness. To make a male factor subfertility - it is at least two abnormal samples collected on separate occasions at least 3 months apart are necessary.

For female:

- ask them to keep **menstrual calendar** for 2- 3 months to assess the possible time of the ovulation
- to **provide LH kit** and teach them how to use (to check with LH kits at the time of ovulation, usually between 10-14 days of menstrual cycle)
- ask them to observe the passage of **stretchable mucous** at the possible time of ovulation (10-14 days of cycle)
- check **USG** to detect the abnormalities of uterus or ovaries(the genital tract problem)

Treatment

If all the above tests are normal

- Let the couple try for 3 months General measures before undergoing treatment Advise them to
- Avoid smoking in both couples
- Keep body weight normal (BMI 20-25) as significant overweight or underweight will cause difficulty to get pregnant.
- Have proper diet and exercise for optimal reproductive function.
- Prescribe folic acid
- Counseling:
- explain the couple about the chance of conception: that is 80% of couples in the general population will conceive within **1** year if: the woman is aged under 40 years and they do not use contraception and have regular sexual intercourse
- **explain about the frequency and timing of sexual intercourse:** vaginal sexual intercourse every 2 to 3 days optimizes the chance of pregnancy (to tell them - too frequent sexual intercourse, say once every night, may result in decrease in number of sperm in semen. On the contrary, too infrequent sexual intercourse, say less than once per week, may lower the motility of sperm. Both conditions may adversely reduce the chance of pregnancy)
- **advise** to maintain regular normal intercourse, say two to three times a week, with a slight increase in frequency (such as once every 2 days) around the time of ovulation.

Refer to OG

- *If above measures fail.*
- Normal semen results:
    - Volume >1.5 ml, pH >7.2
    - Sperm concentration >20 million/ml
    - Morphology >30% normal forms
    - Motility >25% progressive motility
    - Vitality >75% live spermatozoa

PREMENSTRUAL SYNDROME

- PMS- Symptoms present 1-14 days before menstruation (Luteal phase) and disappear at the onset or on the day of the heaviest flow. More than 150 symptoms are reported to be associated with premenstrual syndrome (PMS)
- History- patient may present with one or more of the following symptoms

Psychological and behavioural symptoms

Mood swings and depression	Tearfulness or feeling 'low'
Tiredness, fatigue or lethargy	Tension or unease
Irritability	Clumsiness/poor coordination
Difficulty in concentrating	Altered interest in sex
Sleep disorders	Food cravings
Aggression	Loss of self-control

Physical symptoms

Breast tenderness	Swollen/bloated feelings
Puffiness of face, abdomen or fingers	General aches and pains, especially backache
Headaches	Weight gain
Appetite changes	Acne or other skin rashes
Constipation or diarrhoea	Muscle or joint stiffness
Exacerbation of epilepsy, migraine, asthma, rhinitis or urticaria	Abdominal pain/cramps

Diagnosis

- No lab test necessary
- Ask patient to keep the *menstrual chart at least for two cycles* to know- precise dates of menstruation and symptoms- the presence of symptoms before and their absence after menstruation gives a clue to diagnose

Treatment

- Symptomatic treatment only
- Wear loose clothes if bloated
- Adequate sleep and regular exercise
- Eat regularly
- Reduce fluid intake
- COC, SSRI, spironolactone, NSAIDS
- For all treatments try a 3-6 months trial.
- Ask women to keep a symptom diary.
- Be sure to FOLLOW UP- as the first treatment may not work.
- If symptoms are severe or primary management is ineffective → REFER.


Mild to moderate PMS
Encouragement of healthier lifestyle, improved nutrition and regular exercise
- Less fat, sugar, salt, caffeine and alcohol
- Frequent starchy meals, preferably high in fibre
- More fibre, fruits, vegetables
Stress management
- relaxation
- yoga
- meditation
- breathing techniques
Counselling/ Support
- Family
- Friends
Vitamins and Minerals
- vitamin B6 maximum 50mg /day (with GP supervision)
- magnesium 250mg/day, use in premenstrual phase
- Frovatriptan 2.5mg bd or Zolmitriptan 2.5mg bd
EPO for breast tenderness, can cause fits in epilepsy pts
Moderate to severe PMS
Refer to OG

MENOPAUSE

Definition

- Menopause is the permanent cessation of menstruation that results from loss of ovarian follicular activity, after one year of amenorrhoea.
- The climacteric is the period prior to the menopause where women may experience symptoms, as ovarian function starts to fail.
- Women >50 years of age - FSH level >30 IU/dl
- Women <50 years of age – 2 FSH levels of >30 IU/dl, taken a few weeks apart. Premature menopause - menopause before 40 years of age

History

- Age of menopause (to know early menopause or normal or late)
- If present with hot flush (i.e. vasomotor symptoms)
- ask severity, if troublesome at night or interfering with sleep, night sweat
- If symptoms suggestive of psychological effects - irritability, confusion, lethargy, memory loss, loss of libido, depression, insomnia
- Ask for onset, similar experience before to differentiate from other psychological causes
- If present with palpitation (CVS symptoms) o ask for duration, frequency
- Ask for any breast lump or previous history of breast disease, family h/o breast disease
- Ask for urogenital symptoms like urgency, stress incontinence, dysuria, frequency dyspareunia, vaginal dryness, itchiness, h/o PMB, vaginal discharge
- History of taking pap smear
- Any symptoms suggestive of arthritis, osteoporosis
- History of other co-morbid diseases like DM, hypertension

Examination

- General examination like Body weight, BP, CVS
- Breast examination- any palpable mass
- Abdominal examination- any mass
- VE- any discharge, dryness

Investigation

- Investigate as necessary only if there are co-morbid diseases like DM, Hypertension, IHD

Management

Alternative therapies to hormone replacement therapy (HRT)

Life style measures- advise them to

- take regular sustained aerobic exercise - walking, swimming, jogging (infrequent high impact exercise should be avoided as it can worsen the symptoms)
- avoid smoking, avoidance or limit caffeine intake to reduce the vasomotor symptoms
- reduce body weight in case of obesity
- Lighter clothing, less stress and avoiding triggers eg. spicy food
- beta-blocker if there is palpitation or tachycardia (contraindication in Asthma)

- diet and supplements- calcium, calcitonin, Vit D supplements, Soy beans, Ginger, tofu, dark green vegetables to prevent osteoporosis,

Complementary therapies-

- Evening Primrose Oil (EPO) for mood swings and breast tenderness (may potentiate seizures)
- psychological support and prescribe a 2 weeks trial of fluoxetine (20mg daily), citalopram (20 mg daily) or venalafaxine (37.5 mg twice a day) as necessary in insomnia
- vaginal dryness- advise to use moisturizer

For HRT

- Should not prescribe in primary care level and always refer to OG if HRT is considered in case of
    - Early menopause (to prevent osteoporosis)
    - If symptoms are distressing

Note

- It is recommended to use effective contraception until the diagnosis has been confirmed using:
- 12 months after the last period in women >50 years 24 months after the last period in women <50 years
- HRT adding a progestogen increases risk of breast cancer Unopposed oestrogen increase risk of endometrial cancer

VAGINAL DISCHARGE

- Vaginal discharge is a common presenting symptom and is not always pathological.

Common causes

- **Physiological:**
  - e.g. COC, pregnancy, ovulation
- **Infective:**
  - Candida
  - Bacterial vaginosis
  - STI
  - Trichomonas vaginalis (Moniliasis)
  - Gonorrhoea
  - Chlamydia
- **Non-infective**
  - Ectropion
  - Foreign body
  - Cervical cancer

CANDIDIASIS (FUNGAL INFECTION)

- Fungal infection
- 20% of patients are asymptomic.



Predisposing factor

- Diabetes Mellitus
- Steroid treatment
- Immunosuppression
- Pregnancy
- Long term Antibiotics
- Cushing's or Addison's disease
- Chemotherapy or Radiotherapy
- Vaginal trauma
- Tight-fitting synthetic underwear

Presentation

- Pruritus vulva, superficial dyspareunia, dysuria,
- Vulva erythema, fissuring, satellite lesion
- Thick creamy non-offensive discharge

Examination

- cottage cheese discharge
- Sore vulva, crack or fissure

Investigation

- a swab from anterior fornix for C&S

Treatment

- The standard treatment is Clotrimazole vaginal tablet or pessary 500 mg x one night
- Econazole nitrate vaginal pessary 150 mg, 1 to 3 nights (can also be used)
- Oral treatment for vaginal candidiasis is rarely used because of side-effects .

RECURRENT VAGINAL CANDIDIASIS

Compliance

- Exclude differential diagnosis e.g. lichen sclerosis
- Exclude predisposing factors
- Induction- maintenance regime, with daily treatment of Fluconazole 150 mg every 3 days for 3 doses followed by 150 mg weekly for 6 months as maintenance treatment.
- *A single individual may have more than one STI simultaneously*

BACTERIA VAGINOSIS

- Vagina flora are changed from lactobacillus to anaerobes: *Gardnerella vagina/is*

Presentation

- *offensive, fishy grey/white, thin vaginal discharge*
- Vulva soreness (-)
- Cervix looks normal

Amsel's criteria (3 of following 4 points)

- Thin white homogenous discharge
- Clue cells on microscopy -stippled vaginal epithelial cells
- **Vaginal pH >4.5**
- Positive whiff test (addition of potassium hydroxide results in fishy odour)

Investigation

- high vaginal swab for C&S

Treatment

- Tablet Metronidazole 400 mg BD for 7 days (or)
- Tablet Metronidazole 2 gm single dose (or)
- Tablet Tinidazole 2 G single dose if patient is tolerable 70- 80% initial cure rate
- Relapse rate >50% within 3 months
- metronidazole 0.75% gel 2 times / wk x 4-6 months
- Clindamycin 2% cream PV daily x **1** week

Bacterial Vaginosis in Pregnancy:

- Increased risk of preterm labour, low birth weight and chorioamnionitis, late miscarriage

CHLAMYDIA

- Major cause of pelvic pain and infertility in women
- Incubation period 7-21 days

Screening

- Chlamydia is a preventable cause of infertility, ectopic pregnancy and pelvic inflammatory disease.

Presentation in Men

- Asymptomatic, urethritis

Presentation in Women

- Asymptomatic (70%), vaginal discharge (30%)
- Post coital or intermenstrual bleeding
- PID (10-30%)
- Dysuria

Examination

- Mucopurulent cervicitis, hyperaemia and oedema of cervix +/- contact bleeding
- Tender adnexa, cervical excitation

Investigation

- Nuclear acid application tests (NAAT) to confirm diagnosis.
- Chlamydia notification
- Symptomatic men: all partners from the 4 weeks prior to onset of symptoms.
- Women + asymptomic men: all partners from the last 6 months or the most recent partner

Management

- Tablet Azithromycin l G single oral dose (or)
- Tablet Doxycycline 100 mg twice daily for 7 days (or)
- Tablet Erythromycin 500mg 4 times a day for 7 days (or)
- Tablet Tetracycline 500mg 4 times a day for 7 days
- Tablet Ofloxacin 200 mg bd (or) 400 mg od for 7 days
- ***If pregnancy/breastfeeding (+):*** erythromycin 500mg qid for 2 weeks
- partner notification and treat both partner
- abstain from sex until 7 days after both partners were fully treated
- full sexual health screen is ideal.

GONORRHOEA

Symptoms and signs

- 50% asymptomatic
- Mucopurulent vaginal discharge (50%)
- Lower abdominal pain (25%)
- Dysuria (12%) but not frequency
- Intermenstrual bleeding +/- postcoital bleeding
- Pelvic or lower abdominal tenderness (<5%)
- No abnormal findings on examination

Management

- Partner notification (covering previous 3 months)
- Avoid sex until clear and partner has been treated.

- Injection ceftriazone 250mg IM (or) cefixime 400mg PO +Azithromycin 1G PO (for associated Chlamydia in 40% of women)

TRICHOMONIASIS

Symptoms and signs

- Asymptomatic (10-50%)
- Vaginal discharge (70%) -frothy yellowish discharge (10-30%)
- Vaginal itching
- Dysuria and lower abdominal pain
- Offensive odour
- Vulvitis and vaginitis
- Strawberry cervix (2%)
- No examination abnormalities

Investigation

- Direct observation under microscope of wet smear slide from posterior fomix

Management

- Avoid sex until both partners treated.
- Full sexual health screen (HBsAg, HCV, HIV, syphilis)
- Tablet Metro 400-500 mg bd for 7days (or) 2 gm single dose (or) Tinidazole 2 gm
- single dose
- Refer if resistant
- Trichomoniasis in pregnancy: preterm delivery, low birth weight

ITCHY VULVA (PRURITUS VULVAE)

- 'Pruritus vulvae' simply means itching of the vulva.
- The vulva is the area of skin just outside the vagina. Most women experience a slight vulval itch now and again. However, pruritus vulvae mean the itch is persistent and causes distress. The itch may be particularly bad at night and may disturb your sleep. About 1 woman in 10 sees a doctor about a persistent itchy vulva at some stage in her life. Vulval itching can affect any woman, at any age. It can lead to scratching and rubbing which can break the skin and can lead to soreness, bleeding and skin infections.
- An itchy vulva (pruritus vulvae) is a symptom, not a condition in itself It can be caused by many different conditions. Therefore, if you have a persistent itchy vulva, you should see your doctor to find out the cause.

Causes

- Causes of an itchy vulva tend to differ slightly between adults and children. However, they can include the following:

1. Infections
    - Thrush.
    - Threadworms.
    - Scabies.
    - Some sexually transmitted infections, such as trichomoniasis and genital warts.
2. Sensitisation of the vulval skin
    - Creams, including treatments for, for example, thrush.
    - Soaps.
    - Perfumes.
    - Deodorants.
    - Excessive sweat.
    - Condoms.
    - Wet wipes.
    - Textile dyes
    - Detergents.
    - Fabric conditioners
    - Panty liners.
    - Sanitary pads and tampons.
3. Skin conditions that may affect vulval skin
    - Atopic eczema.
    - Psoriasis.
    - Lichen simplex
    - Lichen planus
    - Lichen sclerosus
4. Urinary or faecal incontinence
5. Menopause
6. Pregnancy (due to swelling of the veins in the vulva (vulval engorgement) and an increased risk of vaginal discharge and thrush
7. Breast-feeding due to low oestrogen levels.
8. Generalised body itch
    - side-effect of some medicines or
    - due to some blood disorders,
    - thyroid problems or
    - kidney or liver disease.
9. Diabetes

10. Cancer of the vulval skin
11. Stress
12. Unknown causes

Diagnosis

- Find out from History and Examination

Investigations

- Look for diabetes, or thyroid, kidney or liver problems Skin patch testing in specialist centre

Treatment

By treating the cause if possible.
Treatments for itchy vulva (pruritus vulvae) vary, depending on the cause. For example:

- Identifying and stopping the use of anything that may be sensitising the vulval skin.
- Using antifungal cream for thrush.
- Using antibiotic medicines for certain infections,
- Using steroid cream for various skin conditions.
- Using hormone cream or hormone replacement therapy (HRT) if the itch is related to the menopause.

In young girls, learning to wipe gently from front to back, and to wash and rinse well and dry even when showering (when the vulva can be missed or left soapy).

Moisturisers

- Bland moisturisers (emollients) such as emulsifying ointment can help to ease the itch. Some of the creamier emollients can be stored in the refrigerator to keep them cool.
- Vaginal moisturisers and lubricants can also be very helpful, especially if the itch is on the inside as well as the outside.

Try to avoid the itch-scratch cycle

- The itch-scratch cycle occurs when scratching causes more itching - which causes more scratching - which causes more itching - etc. It may make the itch worse. Excessive scratching can also cause thickening of the skin - which then becomes even itchier. Therefore, apart from any other treatment, try not to scratch if at all possible.
- Keep nails cut short and don't wear nail varnish. Scratching may also damage the vulval skin and increase the risk of the skin becoming infected with germs (bacteria).

General vulval skin care and other advice

- Clothes
- Wear loose, 100% cotton underwear
- Change your underwear daily.
- Avoid tight-fitting clothes
- Consider wearing no underwear - for example, when you are at home, and at night.

Washing

- Wash vulva gently, once a day. Do not scrub or wash vigorously and avoid using a sponge or flannel to wash with.
- Taking a shower than having a bath,

- Dry the skin gently

Other general advice

- Don't use any of sensitive soap, cream, cloth
- Avoid antiseptics or special vaginal washes.
- Avoid condoms that are lubricated with spermicide, avoid perfumed lubricants.
- Do not shave pubic hair.
- An antihistamine medicine at bedtime may help if sleep is affected.
- In most cases, a cause can be found for an itchy vulva (pruritus vulvae). Treatment is then aimed at the underlying cause. However, in some cases no cause can be found. The general advice on clothes, washing, etc., will usually help.
- **Note:** steroid ointments can make some conditions of the vulva worse.

Reference

- *https://patient.info/health/vulval-problems-leajlet/itchy-vulva-pruritus-vulvae*

CERVICAL CANCER

Prevention and control: a comprehensive approach

- It is caused by the sexually transmitted HPV, which is the most common viral infection of the reproductive tract. Almost all sexually active individuals will be infected with HPV at some point in their lives and some may be repeatedly infected. The peak time for infection is shortly after becoming sexually active.
- The majority of HPV infections resolves spontaneously and do not cause symptoms or disease. *However, persistent infection with specific types of HPV (most frequently, types 16 and 18) may lead to precancerous lesions. If untreated, these lesions may progress to cervical cancer.*
- The core principle of a comprehensive approach to cervical cancer prevention and control is to act across the life course using the natural history of the disease to identify opportunities in relevant age groups to deliver effective interventions.

Primary prevention

Girls 9-13 years (role of general practitioners)

- HPV vaccination (Girls and boys, as appropriate)
- Health information and warnings about tobacco use*
- Sexuality education tailored to age & culture
- Condom promotion/provision for those engaged in sexual activity
- Male circumcision

Secondary prevention

Women >30 years of age (if facilities available)

- "Screen and treat" with low-cost technology VIA followed by cryotherapy
- HPV testing for high-risk HPV types (e.g. types 16, 18 and others)

Tertiary prevention

All women as needed (treatment of invasive cancer at any age)

- (Refer to specialist centre)
- Ablative surgery
- Radiotherapy
- Chemotherapy

Key facts about HPV vaccines

- Seventy-percent (70%) of cervical cancers worldwide are caused by only two HPV types (16 and 18).
- Two vaccines against HPV are licensed in most countries.
- Both vaccines prevent over 95% of HPV infections caused by HPV types 16 and 18, and may have some cross-protection against other less common HPV types which cause cervical cancer. One of the vaccines also protects against HPV types 6 and 11 which cause anogenital warts.

- Both vaccines work best if administered prior to exposure to HPV.
- The vaccines cannot treat HPV infection or HPV-associated disease.
- The WHO recommended target group for vaccination is 9-13 year-old girls who have not yet become sexually active.
- Both vaccines require 3-doses administered over a period of 6 months.
- Safety of these vaccines is being closely monitored, and thus far, is very reassuring.
- HIV-infected individuals can be vaccinated.

Screening and treatment of precancerous lesions

- Cervical cancer screening is the systematic application of a test to identify cervical abnormalities in an asymptomatic population. Women targeted for screening may actually feel perfectly healthy and see no reason to visit health facilities.
- Screening services may be provided either as organized or opportunistic (i.e. taking advantage of a woman's visit to the health facility for another purpose) services or a combination of both.
- For treatment of precancerous lesions, the technology of choice is *loop electrosurgical excision procedure (LEEP). In low resource settings*, recent WHO guidelines recommend *cryotherapy* as a good alternative treatment for eligible VIA positive lesions. In high- resource settings, other techniques such as cold knife conisation can be used.

Criteria for age and frequency of cervical cancer screening

- Women younger than 30 years of age should not undergo screening except for women known to be HIV-infected or living in a high HIV prevalence area.
- At a minimum, a national programme should prioritize women who are *between 30*-49 year-old for screening.
- The screening *interval* (frequency) *should not be less than* 5*years* (and not less than 10 years, if using an HPV test).
- Priority should be given to maximizing coverage within the at-risk target age group and assuring complete follow-up of those women with abnormal screening test results rather than maximizing the number of tests performed in a woman's lifetime.
- In high HIV prevalence countries, women who screen positive for cervical cancer should be offered HIV testing and counselling.

Key facts about cervical cancer screening and treatment

- Cervical cancer screening is the testing for precancer and cancer of women at risk, most of whom will be without symptoms.
- At a minimum, screening is recommended for every woman 30-49 years of age at least once in a life time.
- Globally, in 2012, there were nearly a billion women between 30 and 49 years old, most of whom have never been screened even once in their life.
- Early detection and treatment of precancerous lesions can prevent the majority of cervical cancers.
- Three different types of tests are currently available:
- Conventional (Pap) and liquid based cytology (LBC)
- Visual inspection with Acetic Acid (VIA)
- HPV testing for high-risk HPV types (e.g. types 16 and 18).
- HPV vaccination does not replace cervical cancer screening. In countries where HPV vaccine is introduced, screening programme may need to be developed or strengthened.

Treatment of cervical cancer

- The most common treatment for cervical cancer is surgery and / or combination of chemotherapy and radiotherapy.
- Treatment varies with the stages of the disease. For early invasive cancer, surgery is the treatment of choice.

Reference

1. *Comprehensive cervical cancer prevention and control: a healthier future for girls and women, WHO publication, 2013*

CHAPTER (17)

SEXUAL HEALTH PROBLEMS

- Introduction and Relevance to General Practice
- Objectives of General Assessment
- Creating a Safe Space for the Patients
- Taking Sexual History from Every Patient
- History Taking from the Patients with Sexual Health Problems
- Physical Examination
- Sexual Dysfunction (Sexual Health Concerns)
- Hypoactive Sexual Desire Disorder
- Female Sexual Arousal Disorder
- Dyspareunia
- Female Orgasmic Disorder
- Erectile Dysfunction
- Andropause/Male Menopause
- Premature Ejaculation
- Health Care for Transgender and Gender-diverse Persons
- The Small Penis Syndrome
- Sexuality in the Elderly
- Intimate Partner Violence and Sexual Violence

INTRODUCTION AND RELEVANCE TO GENERAL PRACTICE

- Family doctors are often asked to provide advice and help for sexual concerns and are continually challenged to detect such problems presenting in some other guise. Most of the cases are usually encountered as" hidden agenda".
- Although some patients may present directly with a complaint of sexual dysfunction, many will be less direct and use some other pretext or complaint as a 'ticket of entry' for their sexual concerns.
- Family physicians should use a proactive, integrated, patient-centered approach to sexual health that includes, not only disease identification and treatment, but also providing a safe environment in which patients can consensually discuss issues related to sex and sexuality across their life span.

SEXUAL HEALTH (current working definition)

- "…a state of physical, emotional, mental and social well-being in relation to sexuality; it is not merely the absence of disease, dysfunction or infirmity. Sexual health requires a positive and respectful approach to sexuality and sexual relationships, as well as the possibility of having pleasurable and safe sexual experiences, free of coercion, discrimination and violence. For sexual health to be attained and maintained, the sexual rights of all persons must be respected, protected and fulfilled." *(WHO, 2006a)*

SEXUALITY

- Sexuality is experienced and expressed in thoughts, fantasies, desires, beliefs, attitudes, values, behaviours, practices, roles and relationships. While sexuality can include all these dimensions, not all of them are always experienced or expressed. *(WHO, 2006a)*

OBJECTIVES OF GENERAL ASSESSMENT ARE TO:

- Create a safe space for the patients.
- Establish a constructive relationship with the patient to enable patient and doctor to communicate effectively and serve as the basis for any subsequent therapeutic relationship.
- Determine whether the patient has a sexual health problem and, if so, what that is.
- Find out (where possible) what caused that problem.
- Assess the patient's emotions and attitudes towards the problem.
- Be aware of signs of anxiety/distress. Recognize non-verbal cues.
- Establish how it might be treated.
- Confidentiality issues should be emphasized.

CREATING A SAFE SPACE FOR THE PATIENTS

- An initial self-assessment of physician's own comfort by discussing sex with various patient groups and identifying any unrecognized or implicit biases that they might have.
- Physicians should focus on creating a welcoming environment by training staff and clinicians in culturally sensitive terminology, using gender-inclusive language on forms and displaying diverse images in marketing and waiting areas.

- using the two-step method (asking two questions regarding both gender identity and sex assigned at birth) or using self-identified pronouns.

HISTORY TAKING FROM THE PATIENTS WITH SEXUAL HEALTH PROBLEMS

- Use open questions at the start becoming directive when necessary.
- clarify, reflect, facilitate, listen.
- ***Ask about:*** *Presenting complaint in* chronological account and concerns.
- If appropriate, ask about:
    - Vaginal or urethral discharge
    - Dysuria/other urinary symptoms
    - Dyspareunia -pain on intercourse
    - Erectile dysfunction
    - Genital skin problems - soreness, itching, ulceration, warts
    - Perianal/anal symptoms
- Other symptoms, e.g. pelvic/abdominal/groin pain, deformity of the penis, haematospermia, retrograde ejaculation
- Past medical history
    - Similar symptoms - for suspected sexually transmitted infections (STIs), ask about previous STI, date of diagnosis, and treatment.
    - Obstetric history for women
    - Urological problems and treatments or pelvic surgery
    - Chronic medical problems – endocrine, cardiovascular.
    - HIV testing
- Vaccination history: Hepatitis B, Human papilloma virus
- Drugs
    - Prescription drugs, e.g. drugs associated with erectile dysfunction
    - Illicit drugs - may be associated with erectile dysfunction, and history of injecting drug misuse is associated with increased hepatitis/HIV risk.
- Allergies
- Social history
- Smoker?
- Alcohol consumption
- Travel abroad - if suspected STI, ask whether the patient had sexual intercourse abroad other than with their travelling partner, and with whom.
- Attitudes and beliefs
    - How does the patient see the problem?
    - What does he/she think is wrong?
    - How does he/she think his/her partner views the situation?
    - What does the patient want you to do about it?

TAKING SEXUAL HISTORY FROM EVERY PATIENT

- Obtaining an accurate and detailed sexual history is essential for proper screening for sexually transmitted infections (STIs).
- While this conversation may be uncomfortable for both physician and patient, a comprehensive sexual history should be part of routine, preventive health care.
- The sample script below can help physicians with a standardized approach to obtaining a sexual history.
- **Step 1: Set the Stage:**

- Introduce the topic and explain confidentiality.
- It is a good idea to set the stage for the conversation before jumping into questions about a patient's sexual health. You can help put a patient at ease by assuring them that obtaining a sexual health history is a routine part of a physical exam/medical visit and that everything shared will remain confidential.
- Here is a sample opener or a conversation starter for a conversation on sexual health:
- *"I am going to ask you a few questions about your sexual history. I ask everyone these questions, as they are important to understand your health. Everything you tell me is confidential."*

- **Step 2: The Questions to Ask Patients (as appropriate)**
  - Have you ever been sexually active?
  - What is/are the sex and gender of your partner(s)?
  - How many partners have you had in the last 12 months?
  - What types of sexual activity do you have (oral/anal/vaginal/use of sex toys/other)?
  - When was the last time you got tested for STIs?
- **Step 3: Respond to the History**
  - Based upon the patient's answers, determine if a more detailed risk assessment is needed. Use the **5 P's approach:**
    - **P**artners: What are the genders of your partners? How many partners in the past 6 months? Your lifetime? long-term or casual partner.
    - **P**ractices: What type of sexual activities do you participate in? Do you participate in vaginal sex? Oral sex? Anal sex?
    - **P**ast history/**P**rotection from STIs: Have you ever had any sex-related diseases? Do you have, or have you ever had, any risk factors for HIV? Have you ever been tested for HIV? Would you like to be? What do you do to protect yourself from contracting HIV?
    - **P**regnancy plans: Are you trying to become a parent? Would you like to get pregnant (or father a child)? What method do you use for contraception?
    - **P**leasure: Do you ever have pain with intercourse? Do you have any difficulty with lubrication? Do you have any difficulty achieving orgasm? Do you have any difficulty obtaining and maintaining an erection? Do you have difficulty with ejaculation? Do you have any questions or concerns about your sexual functioning? Is there anything about your (or your partner's) sexual activity (as individuals or as a couple) that you would like to change?

Table 1. BEST PRACTICE TIP: Language is important

AVOID	INSTEAD USE
Are you married?	What is your current relationship status?
You're married so you don't need STI testing, right?	Have you had any new sexual partners in the last year?
Do you think your partner is cheating on you?	Does your partner have other partners?
Do you sleep with a lot of people?	How many sexual partners have you had?
Are you an IV drug user?	Have you ever injected drugs?

Ref: Taking an Accurate Sexual History Sample Script: www.aafp.org/sti

PHYSICAL EXAMINATION

- Physical examination is mandatory.
- Examine the external genitalia and perianal area.
- Check groins for lymphadenopathy if STI is suspected.
- For women, perform pelvic and vaginal speculum examination.
- Consider digital rectal examination if indicated.

- *Explain the need for and offer a suitable medically qualified chaperone for the examination of all patients.*
- *Record if a chaperone is declined.*

ACTION

1. Summarize the history back to the patient and give an opportunity for the patient to fill in any gaps.
2. Check that the patient has no other concerns.
3. Develop a problem list and outline a management plan.
4. Further investigations and interventions are guided by the findings on history and examination - so a good history and examination is essential.
5. Set a review date.

SEXUAL DYSFUNCTION (SEXUAL HEALTH CONCERNS)

- Between 50% and 98% of women report at least one sexual health concern, including interest in sex, difficulty with orgasm, inadequate lubrication, dyspareunia, body image concerns, unmet sexual needs, the need for information about sexual issues, physical and sexual abuse, and sexual coercion.
- Around 40% of men report at least one sexual health concern, most commonly erectile dysfunction, or premature ejaculation.[5]
- Not all sexual health concerns are related to genital issues. Chronic conditions, including pulmonary disease, cardiac disease, osteoarthritis, and mental health issues, and diabetes mellitus (27-55%) can affect sexual activity and satisfaction.
- It is most appropriate to enquire about these issues in the post-myocardial infarction, the post-prostatectomy, the patient taking antihypertensives or other drugs, and the post-mastectomy or post-hysterectomy patient.
- Sexual problems may have a physical or psychological basis, but *all* develop a psychological aspect in time.
- Both partners have a problem in 30% cases.

Assessment

- A caring and compassionate physician who is comfortable discussing sex, who knows the patient and has seen her before, and who seems concerned about her sexual health is one with whom patients will feel most comfortable discussing sex.
- A brief set of questions or a screening questionnaire (Table 2) should be used for an initial approach to the patient.

Table 2. Brief sexual symptom checklist for women

Sexual Symptom Checklist for Women	
Please answer the following questions about your overall sexual function:	
1.	Are you satisfied with your sexual function: □ Yes □ No
If no, please continue.	
2.	How long have you been dissatisfied with your sexual function?_____.
3.	Mark which of the following problems you are having, and circle the one that is most bothersome:
	□ Little or no interest in sex
	□ Decreased genital sensation (Feeling)
	□ Decreased vaginal lubrication (Dryness)
	□ Problem reaching orgasm
	□ Pain during sex
	□ Other: _____
4.	Would you like to talk about it with your doctor? □ Yes □ No

History of the problem

What is the problem? If new, when did it start? Why consult now? What outcome does the patient want? Is the patient complaining or is his/her partner?

Sexual history

Details of sex knowledge; attitude towards sex; past history of sexual problems (or lack of problems)
It is important to be alert for psychiatric disorders and situational factors and not to predict a person's sexual disposition.
Avoid being too formal or too familiar.
Ideally, it is best to see a couple together if the problem is occurring within a steady relationship.
Doctors may recognize such an association and initiate a tactful psychosocial history that includes questions about sexuality.

Medical history

Chronic diseases, chronic back pain, pelvic pain, vaginal discharge; tiredness, insomnia, tension headache, psychiatric problems; current medication.

Social history and recent life events

Always consider psychological aspects
Poor self-image; anger or resentment relationship/financial difficulties, children, parents, work stress; ignorance or misunderstanding; shame, embarrassment, or guilt - view that sexuality is 'bad', sexual abuse; anxiety/fear about sex- fear of closeness, vulnerability, letting go, loss and failure.

Examination

BP measurement, genital examination and neurological examination where indicated.
A careful vaginal and pelvic examination should be an opportune educational experience for the patient and an exercise in preventive medicine.

Investigations

No particular routine tests are recommended. Tests for male erectile dysfunction(impotence) may help exclude significant causes of low libido are those for diabetes, liver dysfunction, thyroid dysfunction and endocrine dysfunction (prolactin, free testosterone, FSH, LH and oestradiol estimations.)
Other investigations may include pelvic ultrasonography, colposcopy, or laparoscopy.

Basic sexual counselling

The family doctor can learn to be an effective sex counsellor. Sex counselling can be emotionally demanding and, while good interviewing skills, interest, support, and basic advice are important.
The Ex-PLISSIT counselling model can be used.

Ex-P: Extended Permission giving
LI: Limited Information
SS: Specific Suggestions
IT: Intensive Therapy

Throughout the conversation, the family physician is encouraged to give the patient permission to be curious and to ask open-ended questions such as, “Many people are concerned about how this condition might affect their sex life. What is your experience?”

The patient's response determines what information the physician offers about the diagnosis and sexual function connection. Physicians should confirm patient understanding before using shared decision-making to brainstorm ideas to address any specific concerns.



Fig. 1. The Ex-PLISSIT (extended permission giving, limited information, specific suggestions, and intensive therapy) model.

HYPOACTIVE SEXUAL DESIRE DISORDER

Hypoactive sexual desire disorder (i.e., persistent or recurrent deficiency or absence of sexual desire or receptivity to sexual activity) is the most common sexual dysfunction in women, with an estimated prevalence between 5.4 and 13.6 percent. The disorder peaks in women 40 to 60 years of age and in those who have undergone surgical menopause.

In younger women, this disorder is often associated with situational circumstances, such as dysfunctional relationships, frustrating partner's performance (e.g. ED), chronic disease, depression, gynecologic disorders, posttraumatic events, and use of certain medications (e.g., selective serotonin reuptake inhibitors [SSRIs], oral contraceptives, corticosteroids).

In older women it may be situational, such as in depression or chronic disease (e.g., endocrine disorders with adrenal insufficiency), or it may be associated with medication use.

Treatment

Psychotherapy and antidepressants for patients who have associated anxiety. Transdermal testosterone is also effective for short-term therapy; however, there is little evidence to support long-term use (longer than six months).

FEMALE SEXUAL AROUSAL DISORDER

- It is an inability to complete sexual activity with adequate lubrication occurs in approximately 5 percent of U.S. women. It often affects women with gynecologic or chronic medical conditions and those who are taking certain medications (especially SSRIs).

Treatment

Treatment of the underlying condition or adjustment of the medication.

DYSPAREUNIA

Recurrent or persistent painful sexual intercourse, which is a source of considerable distress both physically and psychologically for the patient, and also for her partner. It may be one of the 'hidden agenda' presentations with a vague complaint.
Dyspareunia is a complex disorder often involving both psychosocial and physical conditions, requiring a detailed genitourinary examination and clinician knowledge of risk factors and the multifactorial nature of the disorder.

Risk factors

- **Demographic risk factors:** younger age, lower socioeconomic status, and being in the postpartum, perimenopausal, or postmenopausal period.
- **Psychosocial risk factors:** depression, anxiety, low sexual satisfaction, and a history of sexual abuse or intimate partner violence.
- **Obstetric and Gynecological Risk Factors:** a vacuum-assisted or forceps vaginal delivery, breastfeeding, or pelvic floor surgery
- **Others:** irritable bowel syndrome, musculoskeletal disorders, and fibromyalgia.

History Taking

In a safe and welcoming environment where patients feel comfortable discussing their sexuality.
A detailed history includes asking patients to describe:

- the characteristics of the pain (e.g., location, intensity, duration)
- symptoms involving other organs, such as the bladder, bowel, or musculoskeletal system.
- sexual behaviors that cause pain
- psychological history and symptoms
- current medical conditions.

Management

Table 3. Causes of Dyspareunia & Management

Ref; Dyspareunia in Women: American Family Physician: Volume 103, Number 10 ◆ May 15, 2021

Diagnosis	Entry or Deep	Historical clues	Treatment options
Vulva and Vagina			
Dermatologic diseases (e.g., lichen sclerosus, lichen planus, contact dermatitis)	Entry	Burning, dryness, pruritus	Usually topical steroids; depends on diagnosis

Inadequate lubrication	Both	Dryness; history of diabetes mellitus; history of chemotherapy or use of progestogens, aromatase inhibitors, tamoxifen, or gonadotropin-releasing hormone agonists	Discontinuation of causative medication if possible; use of vaginal moisturizers or lubricants
Pelvic floor dysfunction	Both	Difficulty evacuating stool or emptying bladder; aching after intercourse; pain in lower back, thighs, or groin	Pelvic floor physical therapy, gabapentin, trigger point injections with local anesthetics or onabotulinum toxin A (Botox), neuromodulation
Vaginal atrophy	Both	Burning, dryness	Vaginal moisturizers or lubricants, topical estrogen, ospemifene (Osphena), prasterone (Intrarosa)
Vaginismus	Entry	Difficulty achieving penetration; possible history of anxiety, sexual abuse or trauma, or other causes of painful penetration; sometimes no prior risk factors are present	Multidisciplinary approach includes cognitive behavior therapy, psychotherapy, relationship and sexual counseling, lubricants, sequential vaginal dilators, a sensate focus program, and onabotulinumtoxinA injection
Vaginitis	Both	Discharge, burning, or odor	Antibiotic or antifungal therapy according to diagnosis
Vulvodynia	Entry	Chronic burning, tearing, aching, or stabbing vulvar pain of at least three months' duration	Patient education about vulvar hygiene and using cotton underwear and pads, 2% lidocaine jelly or ointment applied by cotton ball placed on vulva at bedtime, amitriptyline, oral or compounded vaginal gabapentin, compounded vaginal muscle relaxants, estrogen, selective serotonin or norepinephrine reuptake inhibitors, pelvic floor physical therapy,cognitive behavior therapy, amitriptyline, surgical excision
Bladder			

Interstitial cystitis	Deep	Urinary urgency, frequency, and nocturia	Dietary modification; antispasmodics; cimetidine; amitriptyline
Uterus and adnexa			
Ovarian masses	Deep	Lateralized pain with intercourse	Observation or laparoscopy as indicated
Uterine retroversion	Deep	Pain may be related to sexual position; may be associated with endometriosis	Modify sexual positions; vaginal pessary; hysterectomy
Pelvis			
Adhesions or chronic pelvic inflammatory disease	Deep	May have lateralized, sharp pain; history of pelvic inflammatory disease or pelvic surgery	Nonopioid analgesics; laparoscopic adhesiolysis
Endometriosis	Deep	Family history; dysmenorrhea common	Nonopioid analgesics, combined oral contraceptives, progestogens, levonorgestrel-releasing intrauterine system elagolix, laparoscopic excision

FEMALE ORGASMIC DISORDER

- Female orgasmic disorder (i.e., persistent or recurrent delay in or absence of orgasm after a normal excitement phase) occurs in 3.4 to 5.8 percent of U.S. women. It can be either primary (i.e., patient has never achieved orgasm) or secondary (i.e., resulting from another sexual dysfunction, typically hypoactive sexual desire disorder).

Table 4. Female Orgasmic Disorders

Type of Orgasmic Disorder	Possible causes	Treatment
Primary	May be genetic Often associated with a history of trauma or abuse.	Psychotherapy and couples counseling No effective therapy for unexplained primary orgasmic disorder
Secondary	Hypoactive sexual desire disorder or other sexual dysfunctions	typically resolves with treatment of the primary dysfunction. Adjunctive education on masturbation techniques may be helpful.

ERECTILE DYSFUNCTION

- Erectile dysfunction (impotence) is the inability to achieve or maintain an erection sufficient for satisfactory sexual intercourse.
- Erectile dysfunction is a common problem. US data shows the prevalence to be 39% of males at 40 years and 67% of males aged 70.
- 50% men aged 40-70yr experience inability to obtain/maintain sufficient rigidity of the penis to allow satisfactory sexual performance.
- In the past, ED was commonly believed to be caused by psychological problems. It is now known that ED is caused by physical problems for most men, usually related to the blood supply of the penis.

Causes

Organic causes (>80%)

- Cardiovascular: CHD- multi-vessel than single-vessel coronary artery disease; peripheral vascular disease, Hypertension
- Diabetes Mellitus: 35 - 50% of diabetic men have erectile dysfunction.
- Endocrine disorders (e.g., hypogonadism, testosterone deficiency, hyperprolactinemia, thyroid disorders)
- Genital pain
- Hyperlipidemia
- Metabolic syndrome
- Obesity
- Neurological, e.g. pelvic surgery, spinal injury, stroke, multiple sclerosis, Parkinson disease.
- Prostate cancer treatment (e.g., surgery, radiation, hormone therapy)
- Side effects of prescription drugs: Consider changing medication if onset of erectile dysfunction is within 2-4wk of initiation of drug therapy e.g. thiazides
- Smoking, alcohol, or drug abuse (e.g. amphetamines, barbiturates, cocaine, marijuana, opiates)
- Peyronie' s disease

- Trauma
- Venous leakage (caused by any conditions that changes the architecture of the penile erectile tissue which fails to compress the small veins)

Psychogenic causes

- Performance anxiety
- Depression or stress
- Marital or Relationship failure
- Fear of intimacy
- Guilt
- History of sexual Abuse

Drugs causing erectile dysfunction

- Antihypertensives (e.g. alpha blockers, beta blockers, calcium channel blockers, clonidine, methyldopa)
- Antidepressants (e.g., lithium, monoamine oxidase inhibitors, Selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants)
- Anticonvulsants (e.g., phenobarbital, phenytoin [Dilantin])
- Antihistamines (e.g., dimenhydrinate, diphenhydramine, promethazine)
- Antipsychotics (e.g., chlorpromazine, haloperidol, pimozide, thioridazine, thiothixene)
- Cardiovascular agents (e.g., digoxin, disopyramide, gemfibrozil [Lopid])
- Cytotoxic agents (e.g., methotrexate)
- Diuretics (e.g., spironolactone, thiazides)
- Major tranquillizers (e.g. benzodiazepines)
- Hormones and hormone-active agents (e.g., 5-alpha-reductase inhibitors, androgen receptor blockers, androgen synthesis inhibitors, corticosteroids, estrogens, gonadotropin-releasing hormone analogs, progesterones)
- Immunomodulators (e.g., interferon alfa)
- Cimetidine (Hyperestrogenic side effect due to inhibition of estradiol 2-hydroxylation)

Diagnosis

One of diagnostic options for erectile dysfunction include a single-question self-assessment (Table 5).

Table 5. Single-Question Assessment of Erectile Dysfunction

Impotence means not being able to get and keep an erection that is rigid enough for satisfactory sexual activity. How would you describe yourself?		
A	Not impotent	Always able to get and keep an erection good enough for sexual intercourse.
B	Minimally impotent	Usually able to get and keep an erection good enough for sexual intercourse.
C	Moderately impotent	Sometimes able to get and keep an erection good enough for sexual intercourse.
D	Completely impotent	Never able to get and keep an erection good enough for sexual intercourse.

The five-question International Index of Erectile Function (IIEF-5) allows rapid clinical assessment of ED and can measure the effectiveness of ED treatments.

Table 6. International Index of Erectile Function-5 (IIEF-5)

Over the Past 6 months:					
1. How do you rate your confidence that you could get and keep an erection?	Very low 1	Low 2	Moderate 3	High 4	Very high 5
2. When you had erection with sexual stimulation, how often were your erections hard enough for	Almost never/never 1	A few times (much less than half the	Sometimes (about half the time) 3	Most times (much more than half the	Almost always/always 5

penetration?		time) 2		time) 4	
3. During sexual intercourse, how often were you able to maintain your erection after you had penetrated (entered) your partner?	Almost never/never 1	A few times (much less than half the time) 2	Sometimes (about half the time) 3	Most times (much more than half the time) 4	Almost always/always 5
4. During sexual intercourse, how difficult was it to maintain your erection to completion of intercourse?	Extremely difficult 1	Very difficult 2	Difficult 3	Slightly difficult 4	Not difficult 5
5. When you attempted sexual intercourse, how often was it satisfactory for you?	Almost never/never 1	A few times (much less than half the time) 2	Sometimes (about half the time) 3	Most times (much more than half the time) 4	Almost always/always 5

IIEF-5 Scoring

The IIEF-5 score is the sum of the ordinal responses to the 5 times.

22-25: No erectile dysfunction
17-21: Mild erectile dysfunction
12-16: Mild to moderate erectile dysfunction
8-11: Moderate erectile dysfunction
5-7: Severe erectile dysfunction

Evaluation

History

Medical and surgical history, sexual history, use of medications and other substances, and an assessment of psychological and relationship health are key components of the patient history.

Ensure the presenting problem is erectile dysfunction and not other sexual difficulties; identify risk factors and distinguish psychogenic from organic causes.
Ask about nocturnal and early morning erections. ED of mixed organic and psychogenic origin is common. Psychogenic causes are more likely when the patient has normal erections with masturbation or when nocturnal penile tumescence is normal.
Many patients with organic erectile dysfunction develop a psychogenic component which perpetuates symptoms.

Physical examination

Essential parts of the physical examination include measurement of blood pressure, body mass index, and waist circumference to assess abdominal obesity; peripheral pulses; a genital examination; and an assessment of male secondary sex characteristics.
Also Check the cremasteric and bulbocavemosus reflexes.

Psychological assessment

Consider depression or anxiety screening.

Investigations

- The A1C or fasting glucose level
- A lipid panel
- A thyroid-stimulating hormone level
- Routine measurement of testosterone levels is controversial. (Morning total testosterone measurement may be considered for men with small testes, lack of male secondary sex characteristics, significantly low libido, or a history of inadequate response to phosphodiesterase-5 (PDE-5) inhibitors)

Treatment options for erectile dysfunction

Lifestyle modifications

- Regular exercise, weight loss in obese or overweight men, and improved control of diabetes, hypertension, and hyperlipidemia can improve International Index of Erectile Function-5 (IIEF-5) scores in men with ED. Statin use seems to improve ED, as measured by IIEF-5 scores.
- Tobacco cessation is highly recommended. The risk of ED is increased by 51% in current smokers and 20% for ex-smokers) Current smoking is significantly associated with ED, and smoking cessation has a beneficial effect on the restoration of erectile function (Recommendation A)
- Men with metabolic syndrome should be counseled to make lifestyle modifications to reduce the risk of cardiovascular events and ED. (Recommendation B)

Medications

- Phosphodiesterase-5 inhibitors are the first-line treatment for ED. (Recommendation A).
- The PDE-5 inhibitor helps to maintain the erection by enhancing the vasodilatory effects of endogenous nitric oxide.
- All are effective within about one hour of dosing and are typically used on an as-needed basis. The effects may be delayed or decreased if the patient has recently eaten a fatty meal, particularly for sildenafil and vardenafil.
- The patients should be taught how to titrate dose to effect (most people with DM need the maximum dose); warn the patient he may need up to 8 attempts before a satisfactory erection occurs; side effects include headache, flushing, and acid reflux. PDE-5 inhibitors are contraindicated in men using nitroglycerin or other nitrates because of the risk of catastrophic low blood pressure.

Table 7. PDE-5 Inhibitors for Treatment of Erectile Dysfunction

Medications	Dosage	Minimum time from dosing to sexual activity	Elimination half-time	Availability
Avanafil	50, 100, or 200 mg once daily as needed	15 minutes	Five to 10 hours	NA
Sildenafil	20, 25, 50, or 100 mg once daily as needed	30 minutes	Three to five hours	Available
Tadalafil	10 or 20 mg once daily as needed. 2.5 or 5 mg once daily	30 minutes	17.5 hours	Available
Vardenafil	10 or 20 mg once daily as needed	60 minutes	Four to five hours	NA

Do not prescribe testosterone to men with erectile dysfunction who have normal testosterone levels. (American Urological Association)

Procedural therapy

- Second-line treatments for ED include alprostadil (Caverject) and vacuum devices.
- These treatments can be used to establish an erection before sexual stimulation. They should be avoided in men who are receiving anticoagulants or who have sickle cell disease or other bleeding or clotting disorders.
- Alprostadil is available in injectable and intraurethral forms and can be used in combination with PDE-5 inhibitors.
- Patients should be warned to seek emergency urologic treatment if an erection **lasts four hours or longer.** Penile fibrosis is another possible adverse effect; in one study, persistent fibrotic changes occurred in 4.9% of patients using intracavernosal alprostadil for four years.

- Vacuum devices consist of a tube that is placed over the penis and sealed at the base with lubricant. Vacuum devices can be cumbersome, require several minutes to produce an erection, may lead to bending at the base of the penis. However, success and satisfaction rates are fairly high. Vacuum devices can be used in combination with an oral PDE-5 inhibitor or with alprostadil.

Prostheses

- Surgically implanted penile prostheses are a third-line treatment option for ED when other treatments have been ineffective. Semirigid malleable prostheses are the simplest and easiest to implant but they can be difficult to conceal because the penis is always erect.
- Inflatable prostheses typically consist of two tubes that replace the corpora cavernosa, plus a pump in the scrotum and an intra-abdominal reservoir. Mechanical failure or infection may require removal of the prosthesis.

Managing psychogenic ED

- Psychogenic ED occurs at all ages but is most common in men younger than 40 years. Although men and their partners may resist a psychological explanation for ED, counseling can be effective.
- When ED coexists with depression or anxiety, treatment of the mood disorder may be the most appropriate first step. If antidepressants are used, the specific agent should be one that is less likely to worsen ED (e.g., bupropion, mirtazapine, fluvoxamine).
- PDE-5 inhibitors are effective in men with depression and can be used in combination with treatments for mood disorders.

ANDROPAUSE/MALE MENOPAUSE

- The term "male menopause" has been used to describe decreasing testosterone levels related to aging. But aging-related hormone changes in women and men are different. In men, production of testosterone and other hormones declines over a period of many years and the consequences aren't necessarily clear. This gradual decline of testosterone levels is called **late-onset hypogonadism** or age-related low testosterone.
- For men older than 35 years, testosterone declines at an average rate of 1.6% per year. There is no cutoff for low testosterone, although a level of 300 ng per dL (10.41 nmol per L) is used in most trials.
- But most older men still have testosterone levels within the normal range and only an estimated 10% to 25% having levels considered to be low.
- Testosterone levels can be checked by a blood test, but tests aren't routinely done. And many men who have low testosterone levels experience no symptoms. In addition, the signs and symptoms associated with low testosterone aren't specific to low testosterone.
- They can also be caused by a person's age, medication use or other conditions, such as having a body mass index of 30 or higher.

PRESENTATION

Signs and symptoms suggestive of low testosterone include:

- Reduced sexual desire and activity
- Decreased spontaneous erections or erectile dysfunction
- Breast discomfort or swelling
- Infertility
- Height loss, low trauma fracture or low bone mineral density
- Hot flushes or sweats
- Other possible symptoms include decreased energy, motivation and confidence, depressed mood, and poor concentration. It's also possible to experience increased sleepiness, sleep disturbances, mild unexplained anemia, reduced muscle bulk and strength, and increased body fat.

Management

- In 2020, the American College of Physicians (ACP) recommended following guidelines for testosterone treatment in adult men with age-related low testosterone.
- 1a) Doctors consider starting testosterone treatment in men with sexual dysfunction **who want to improve their sexual function**, after explaining the risks and benefits.
- 1b) Clinicians should discontinue testosterone treatment in men with age-related low testosterone with sexual dysfunction in whom there is no improvement in sexual function is seen.
- 1c) ACP suggests that clinicians consider intramuscular rather than transdermal formulations when initiating testosterone treatment.
- 2) ACP suggests that clinicians **not initiate** testosterone treatment in men with age-related low testosterone to improve energy, vitality, physical function, or cognition.
- Testosterone therapy might stimulate growth of metastatic prostate and breast cancer. Testosterone therapy may also increase the risk of heart attack and stroke and contribute to the formation of deep vein thrombosis.

PREMATURE EJACULATION

- Premature ejaculation is defined as 'ejaculation that occurs sooner than a man or his partner would like during sex'.
- In the U.S., about 1 in 3 men between 18 to 59 years old have problems with PE. The problem is often thought to be psychological, but biology may also play a role. It may not be clearly described by the patient so a careful history is necessary to define the problem.
- Sometimes PE is a problem for men who have erectile dysfunction. Since an erection goes away after ejaculation, it can be tough to know if the problem is PE or ED. ED should be treated first. Premature ejaculation may not be a problem once the ED is treated.

Cause

- Though the exact cause of PE is not known, serotonin may play a role. High amounts of serotonin in the brain increase the time to ejaculation. Low amounts can shorten the time to ejaculation, and lead to PE.

Treatment

- There are many approaches to treatment but they are aimed either at prolonged ejaculatory control or at satisfactory sexual activity without preoccupation with ejaculation and anticipation of better control with time and experience.
- Psychological therapy, behavioral therapy and drugs are the main treatments for PE.

Psychological therapy

- Psychological therapy is a way to work through the feelings and emotions that may lead to problems with sexual relationships. The goal of this type of therapy is to learn the source of problems and find solutions that may help PE by lowering performance anxiety, building sexual confidence and understanding to help the partner's satisfaction.

Behavioral therapy

Behavioral therapy uses exercises to help build tolerance to delay ejaculation. The goal is to help the patient train his body away from PE.

- The Squeeze Method

The patient or the partner stimulates his penis and firmly squeeze it when close to ejaculation, so the erection partly goes away. The goal is to become aware of the sensations leading to climax and delay climax on his own.

- The Stop-Start Method

The patient or the partner stimulates the penis and stop until the urge to climax lets up. And start stimulating penis again as the patient regains control, This process is repeated 3 times and let ejaculate on the fourth time. Repeat this method 3 times a week until the patient has gained more control.

The medications and others

- The SSRIs have also been reported as effective - using fluoxetine 20 mg or sertraline 50 mg or paroxetine 20 mg, all once daily - but are "off-label" use and still being evaluated. Pre-intercourse dosing regimen is generally not effective. Trial the agents for 3-6 months and then slowly titrate down to cessation.
- Dapoxetine 30 mg, not more than 60 mg OD (taken 2-3 hours before intercourse) is also being evaluated for approval.
- Numbing creams or sprays: lignocaine 2.5 %, prilocaine 2.5%, and sprays may be put on glans penis about 20 to 30 minutes before sex. Wash the cream off the penis 5 to 10 minutes before sex.
- Wearing a condom can also help dull sensation.

HEALTH CARE FOR TRANSGENDER AND GENDER-DIVERSE PERSONS

- In Myanmar, sexuality and gender identity remain taboo topics, and those that identify as LGBTQI can face discrimination in many aspects of their lives. A 2020 study revealed that 1-in-3 people of a national sample did not accept or support LGBTQI people.[13]
- The data from a large observational study suggests that 24% of transgender persons report unequal treatment in health care environments, 19% report refusal of care altogether, and 33% do not seek preventive services.

Gender-related terminology

- **Affirmed gender** - When one's gender identity is validated by others as authentic
- **Agender** - Person who identifies as genderless or outside the gender continuum
- **Gender expression** - External display of gender identity through appearance (e.g., clothing, hairstyle), behavior, voice, or interests
- **Gender identity** - Internalized sense of self as being male, female, or elsewhere along or outside the gender continuum; some persons have complex identities and may identify as agender, gender nonbinary, genderqueer, or gender fluid
- **Cisgender** - Not transgender; a person whose gender identity and/or expression aligns with their sex assigned at birth
- **Transgender** - General term used to describe persons whose gender identity or expression differs from their sex assigned at birth
  - Transgender female - a transgender person designated as male at birth
  - Transgender male - a transgender person designated as female at birth
- **Genderqueer** - Umbrella term for a broad range of identities along or outside the gender continuum; also called gender nonbinary
- **Gender diverse** - General term describing gender behaviors, expressions, or identities that are not congruent with those culturally assigned at birth;
  May include transgender, nonbinary, genderqueer, gender fluid, or non-cisgender identities.
  May be more dynamic and less stigmatizing than prior terminology (e.g., gender nonconforming); this term is not used as a clinical diagnosis.
- **Gender dysphoria** - Distress or impairment resulting from incongruence between one's experienced or expressed gender and sex assigned at birth; DSM-5 criteria for adults include at least six months of distress or problems functioning due to at least two of the following:
  - Marked incongruence between one's experienced or expressed gender and primary and/or secondary sex characteristics
  - Strong desire to be rid of one's primary and/or secondary sex characteristics
  - Strong desire for the primary and/or secondary sex characteristics of the other gender
  - Strong desire to be of the other gender
  - Strong desire to be treated as the other gender
  - Strong conviction that one has the typical feelings and reactions of the other gender
- **Gender incongruence** - The discrepancy between a person's experienced gender and assigned sex but does not imply dysphoria or a preference for treatment.[The International Classification of Diseases, 11th revision (ICD-11)]
- **Sexual orientation** - An enduring physical and emotional attraction to another group; sexual orientation is distinct from gender identity and is defined by the individual.

Creating optimal clinical environment

It is important for clinicians to establish a safe and welcoming environment for transgender patients, with an emphasis on establishing and maintaining rapport. The following are transgender friendly actions for clinicians.

- ***Advocate for the patient in the community*** - Foster sources of social support, provide information on community resources and appropriate referrals.
- ***Approach the patient with sensitivity and awareness*** - Build rapport and trust by providing nonjudgmental care. Examine how aspects of one's identity (e.g., gender, sexual orientation, race, ethnicity, disability) intersect in creating one's experience. Treat all patients with empathy, respect, and dignity.
- ***Create a transgender-friendly clinical environment*** - Ask staff to perform a personal assessment of internal biases. Consider including the two-step method (two questions to identify chosen gender identity and sex assigned at birth) to collect gender identity data. Ensure that intake forms and records use gender-neutral or inclusive language (e.g., partnered instead of married). Designating at least one gender-neutral restroom, displaying LGBT-friendly flags and posters.
- ***Maintain open communication with the promise of confidentiality*** - Establish openness to discuss sexual and reproductive health concerns, inquire about unfamiliar terminology to prevent miscommunication, minimize threats to confidentiality.
- ***Provide culturally sensitive adolescent care*** - Ensure timely referral for puberty suppression if feasible and mental health services, obtain an age-appropriate and confidential psychosocial histor.

Evaluation

- When assessing transgender patients for gender-affirming care, the clinician should evaluate the magnitude, duration, and stability of any gender dysphoria or incongruence. This is ideally accomplished with multidisciplinary care and may require several visits to fully evaluate.
- Efforts to convert a person's gender identity to align with their sex assigned at birth (so-called gender conversion therapy) are **unethical and incompatible** with current guidelines and evidence. (Recommendation C)
- Ex-PLISSIT model of counseling (see above) can be used also for transgender health in primary care.

Physical examination

- Examinations should be based on the patient's current anatomy and specific needs for the visit, and should be explained, chaperoned, and stopped as indicated by the patient's comfort level.
- In the absence of gender-affirming hormone therapy, an initial examination may be warranted to assess for sex characteristics that are incongruent with sex assigned at birth. Such findings may warrant referral to an endocrinologist or other subspecialist.

Mental health

- Clinicians should consider routine screening for depression, anxiety, posttraumatic stress disorder, eating disorders, substance use, intimate partner violence, self-injury, bullying, truancy, homelessness, high-risk sexual behaviors, and suicidality. However, it is important to avoid assumptions that any concerns are secondary to being transgender. (Recommendation C)
- The clinicians should provide first-line treatments for depression or anxiety and refer patients to subspecialists when warranted.

Preventive care

- Preventive services are similar for transgender and cisgender (not transgender) persons. Detailed recommendations are based on the patient's current anatomy, medication use, and behaviors.
- Screening recommendations for hyperlipidemia, diabetes mellitus, tobacco use, hypertension, and

obesity are according to the respective guidelines in this book. Clinicians should be vigilant for signs and symptoms of venous thromboembolism (VTE) and metabolic disease in the patients receiving hormone therapy. Screening for osteoporosis is also based on hormone use.

- Cancer screening recommendations are determined by the patient's current anatomy. Transgender females with breast tissue and transgender males who have not undergone complete mastectomy should receive screening mammography based on guidelines for cisgender persons.
- Screening for cervical and prostate cancers should be based on current guidelines and the presence of relevant anatomy.
- Recommendations for immunizations (e.g., human papillomavirus) and, screening and treatment for sexually transmitted infections (including human immunodeficiency virus) are based on sexual practices. Pre- and postexposure prophylaxis for human immunodeficiency virus infection should be considered for patients who meet treatment criteria including men who have sex with men.

Gender-affirming hormone therapy

- Feminizing and masculinizing hormone therapies are partially irreversible treatments to facilitate development of secondary sex characteristics of the experienced gender. Not all gender-diverse persons require or seek hormone treatment; however, those who receive treatment generally report improved quality of life, self-esteem, and anxiety.
- Patients must give consent to therapy after being informed of the potentially irreversible changes in physical appearance, fertility potential, and social circumstances, as well as other potential benefits and risks.
- Feminizing hormone therapy includes estrogen and antiandrogens to decrease the serum testosterone level below 50 ng per dL (1.7 nmol per L). Masculinizing hormone therapy includes testosterone to increase serum levels to 320 to 1,000 ng per dL (11.1 to 34.7 nmol per L).

Gender-affirming surgical treatments

- Gender-affirming surgical treatments may not be required to minimize gender dysphoria, and care should be individualized. Mastectomy or breast augmentation, facial and laryngeal surgery, voice therapy, or hair removal are the surgical treatment options.

Transgender youth

- Some gender-diverse prepubertal children subsequently identify as gay, lesbian, or bisexual adolescents, or other identities instead of transgender, as opposed to those in early adolescence, when gender identity may become clearer. Clinicians may preferentially focus on assisting the child and family members in an affirmative care strategy that individualizes healthy exploration of gender identity.
- The clinician should advocate for supportive family and social environments. Unsupportive environments in which patients are bullied or victimized can have adverse effects on psychosocial functioning and well-being.
- Transgender adolescents may experience distress at the onset of secondary sex characteristics. Clinicians should consider initiation of or timely referral for a gonadotropin-releasing hormone agonist (GnRHa) therapy to suppress puberty when the patient has reached stage 2 or 3 of sexual maturity. No hormonal intervention is warranted before the onset of puberty.
- Some persons prefer to align their appearance (e.g., clothing, hairstyle) or behaviors with their gender identity. The risks and benefits of social affirmation should be weighed. Transmasculine postmenarcheal youth may undergo menstrual suppression, which typically provides an additional contraceptive benefit (testosterone alone is insufficient). Breast binding may be used to conceal breast tissue but may cause pain, skin irritation, or skin infections.
- Multiple studies report improved psychosocial outcomes after puberty suppression and subsequent

gender-affirming hormone therapy. A study shows that (98%) people who had started gender-affirming medical treatment in adolescence continued to use gender-affirming hormones at follow-up.[15]

THE SMALL PENIS SYNDROME

- In general practice it is not uncommon to counsel men and adolescent males for anxiety, sometimes pathological, about the relatively small size of their penis and its possible impact on sexual adequacy.
- This attitude is related to the myth that a man's sexual performance depends on the size of his penis. The patient may present with minor (often trivial) non-sexual complaints as a 'ticket of entry' into the consulting room or perhaps as a manifestation of anxiety or depression related to preoccupation with penile size.

MEASUREMENT

- Irrespective of physique or facial configuration most men are concerned about penile size. However, as for all parts of the body, there is considerable variation in size and shape of the penis.
- The average adult penis, when measured from the symphysis pubis to the meatus, is 7.5-10.5 cm (3-4 inches) long when flaccid.
- The erect penis has an average length of 15 cm (6 inches) with a range of slightly more than 2.5cm (1 inch).

Psychological factors

- Virility and performance are not related to the size of the penis. Orgasm in the female does not depend on deep vaginal penetration. Penile size was found to have little relationship to a partner's satisfaction from sexual intercourse. The vagina, which is 10 cm (4 inches) long in the unstretched state, tended to accommodate itself to the size of the penis.

Counselling

- Counselling the male with fears about sexual inadequacy related to penis size is based on providing reassuring information about the preceding anatomical and physiological facts. The reasons for the patient's concerns should be explored. It should be pointed out that the feeling of inadequacy often follows comparisons with unreal images of macho men portrayed in the media.
- It is important to emphasize that there is no way of physically enlarging a penis and this includes regular masturbation and coitus.
- Furthermore, it should be explained that size generally has no relationship with physical serviceability or with the capacity to satisfy a partner.

SEXUALITY IN THE ELDERLY

- The sexual needs of the elderly in our society tend to be ignored or misunderstood.
- They have the same needs as younger people namely, the need for closeness, intimacy and body contact. The same studies have shown that significant numbers of elderly people continue to enjoy both sexual interest and activity throughout their lives.
- Their activity is determined by factors such as marital status, knowledge about sexuality, prior patterns of sexual expression, privacy and physical health. Intercourse in the elderly may be difficult or not possible so it is appropriate to advise 'outercourse' which is an extension of foreplay, and which provides loving body contact and reassuring intimacy.
- Many women require additional lubrication and need advice about the use of oestrogen cream or lubricating jelly. Testosterone cream has been reported to be beneficial for elderly women with vulvar dryness and fissuring.
- The application of the Ex-PLISSIT model applies to the elderly with an emphasis initially on extensive permission.

INTIMATE PARTNER VIOLENCE AND SEXUAL VIOLENCE

- **Intimate Partner Violence** is a pattern of coercive and abusive behaviors used by one partner to maintain power and control over another partner in an intimate relationship.
  This includes people with any current or former romantic involvement, for example dating, previously dating, on again/off again, married, divorced, living together or apart.
  Intimate partner violence can occur between people of any gender identity or sexual orientation, and can include manipulation, threats, or the actual use of physical, sexual, emotional, verbal, psychological, or financial abuse**.**
- **Family Violence** is any abusive behavior that occurs between members of a family or household who are not involved in a romantic relationship. This includes chosen family as well as people related by blood, marriage, foster care, adoption or any other familial relationships. Family violence can include threats or the actual use of physical, sexual, emotional, verbal, psychological, or financial abuse.
- **Domestic Violence** is an umbrella term that encompasses both Intimate Partner Violence and Family Violence.
- **Sexual violence** is a broad term that encompasses all sexual acts, committed or attempted, without consent or that occur when the person is unable to consent, which includes rape or attempted rape, unwanted touching, and sexual coercion.

INTIMATE PARTNER VIOLENCE

- Intimate partner violence (IPV) is a prevalent worldwide health problem, affecting women more commonly than men. It can include physical, emotional, sexual, and financial abuse, as well as control over contraception or pregnancy and medical care. IPV occurs in heterosexual as well as same-sex relationships.
- Patients who are being abused exhibit chronic physical and emotional symptoms in addition to injuries sustained as a result of physical and sexual violence. They are also at risk of death from homicide. IPV is largely underrecognized and underaddressed as a health issue.
- IPV affects pregnancy outcomes and reproductive health, leading to higher rates of miscarriage, preterm labor, and low-birth-weight infants. Children living in homes where they witness IPV have the same risk of significant long-term physical and mental health problems as children who have been abused themselves.

Table 8. Key Recommendation for Practice

Clinical recommendation	Evidence rating
All women of childbearing age should be screened for IPV. There is a low risk of negative effects from screening.	**A**
Women who screen positive for IPV should receive intervention services.	**C**
There are multiple screening tools effective for IPV. (Table 9,10, 11)	**C**

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case serie

- Factors that increase the risk of IPV include alcohol consumption, psychiatric illness, a history of violent relationships in childhood, and academic and financial underachievement.
- The coronavirus disease 2019 (COVID-19) pandemic is exacerbating domestic violence. Family

physicians can mitigate this urgent issue during telemedicine visits by screening every patient for IPV using tools which require only yes or no questions like The STAT model (Slapped, Threatened, and Throw).

Screening tools for IPV

Screening tools are limited by the patient's readiness to disclose the abuse. Some patients may not feel ready to admit that they are in an abusive situation. However, this should not deter physicians from screening patients with one of the multiple screening tools.

Table 9, 10, 11. Some Screening Tools for IPV

STAT (Slapped, Threatened, and Throw) – physician administered
Have you ever been in a relationship where your partner has pushed or slapped you?
Have you ever been in a relationship where your partner threatened you with violence?
Have you ever been in a relationship where your partner has thrown, broken, or punched things?
A positive answer to any of these questions is a positive screen.

HITS (Hurt, Insult, Threaten, Scream) – self report or physician administered
How often does your partner physically hurt you?
How often does your partner insult or talk down to you?
How often does your partner threaten you with physical harm?
How often does your partner scream at you?
Scoring: never = 1 point, rarely = 2 points, sometimes = 3 points, fairly often = 4 points, frequently = 5 points. A score of greater than 10 points is a positive screen.

WAST (Woman Abuse Screening Tool) – self report
In general, how would you describe your relationship? No tension, some tension, a lot of tension?
Do you and your partner work out arguments with no difficulty, some difficulty, or great difficulty?
Do arguments ever result in you feeling down or bad about yourself?
Do arguments ever result in hitting, kicking, or pushing?
Do you ever feel frightened about what your partner says or does?
Does your partner ever abuse you physically?
Does your partner ever abuse you emotionally?
Does your partner ever abuse you sexually?
The physician performs scoring subjectively, using clinical judgment.

Discussing IPV with female patients

- Research shows that patients, with and without a history of IPV, favor physicians inquiring about IPV at wellness visits. The patient should always be clothed when discussing IPV. The patient's partner or children older than three years should not be present.

Approach to patients in an abusive relationship

- Patients who screen positive for IPV may respond in unexpected ways. Many will not be ready to leave the relationship, whether it be for emotional or more practical reasons, such as financial or safety concerns.
- Concern for children and the hope that a partner will change are also common reasons for staying in an abusive relationship.
- Regardless, it is important for physicians to be supportive and provide or refer for intervention services. The risk of immediate harm should be assessed at the time of IPV identification and at all subsequent visits.
- An ongoing relationship with the same physician improves patient openness to discussing IPV

The assessment of the risk of immediate harm

- If patients answer **"yes" to at least three** of these questions, they are at high risk of harm or injury, with a sensitivity of 83% and a specificity of 56%.
  - Has physical violence increased over the past six months?

- Has your partner used a weapon or threatened you with a weapon?
- Do you believe your partner is capable of killing you?
- Have you been beaten while pregnant?
- Is your partner violently and constantly jealous of you?

Physical examination

- The physician should show extra sensitivity with physical examinations (explaining each next step in the examination and getting the patient's approval to move forward is a way of giving the patient back a sense of control over her body).
- It is critical for the physician to document any injuries thoroughly and provide a detailed record of what happened, including direct quotes from the patient when appropriate. This can aid the patient if charges are pressed.

Safety planning

- A safety plan helps prepare the patient to leave if the situation acutely worsens, and they are at immediate risk. It may include:
  - making copies of personal documents
  - making copies of keys
  - securing money, and packing a bag with essential items
  - identifying a safe place to go (e.g., a relative's house, local domestic violence shelter)
  - establishing Code words with trusted friends or family so that the patient can call and alert them to imminent danger in the presence of the abuser.

Prevention

- The World Health Organization recommends legislative reform and media campaigns to increase IPV awareness. School-based education programs dealing with dating violence have been shown to reduce unwanted sexual advances.
- Early intervention services in at-risk families have been shown to reduce mistreatment of children and may reduce violent behaviors later in life.
- Comprehensive services from the health, legal, and law enforcement sectors should be made available to survivors.

SEXUAL VIOLENCE (SV)

- The National Intimate Partner and Sexual Violence Survey (CDC) reported that 43.6% of women experienced sexual violence in their lifetimes, with one in five women experiencing rape or attempted rape.
- Populations at increased risk include people who are physically or mentally disabled, adolescents, college students, homeless people, survivors of child maltreatment, people living in poverty, users of drugs or alcohol, people who engage in sex work, and people living in prisons, institutions, or areas of military conflict.
- Approximately one-half of transgender people and bisexual women experience sexual violence in their lifetimes.
- Among survivors of rape, only 16% to 38% report the crime to law enforcement, with similar percentages presenting for medical evaluation. Approximately two-thirds of survivors will disclose the assault to their primary care physician.

Consequences of sexual assault

- Sexual assault has short- and long-term consequences on women's physical, mental, sexual, and reproductive health.

Short-term health implications:

- *Acute physical injuries* - range in severity from abrasions and bruises to concussions, fractures, and bullet wounds.
- Sexually transmitted infections (STIs) - Chlamydia trachomatis, gonorrhea, trichomoniasis, and HIV
- *Pregnancy* (5%) - more likely to choose to terminate the pregnancy

Long-term health implications:

- Chronic pelvic pain, other chronic pain syndromes, sexual dysfunction, dysmenorrhea, menorrhagia, headaches, irritable bowel syndrome, and fibromyalgia.
- **Psychological implications:** Posttraumatic stress disorder (PTSD), depression, anxiety, substance use disorders, eating disorders, sleep disorders, contemplation of suicide, and attempted suicide.

Screening SV

- The World Health Organization, American Medical Association, and American College of Obstetricians and Gynecologists recommend screening all women for a history of sexual violence.
- **Two-Question Screening Tool** is a validated tool that can be implemented in primary care. It includes one screening question each for intimate partner violence and sexual violence.

Box 1. Two-Question Screening Tool for IPV and SV

- ***Have you ever been hit, slapped, kicked, or otherwise physically hurt by your partner?***
- ***Have you ever been forced to have sexual activities?***

- Another validated tool to screen and evaluate the SV victims is **the SAVE model** (screen, ask, validate, evaluate).

Box 2. The SAVE Model

The SAVE Model

SCREEN all patients for sexual assault- Assure confidentiality.

ASK direct questions in a nonjudgmental way - Make eye contact. Do not minimize the experience. Never blame a patient.

VALIDATE the patient -Use language that validates, supports and empowers such as:

- *Thank you for telling me.*
- *It took a lot of courage to share this with me.*
- *I am really sorry that happened to you.*
- *It is not your fault. You did not do anything to deserve this.*

EVALUATE, educate, and refer - Evaluate for present danger from the assailant. Evaluate the physical and psychological impact. Evaluate for suicidal ideations. Refer the patient to survivor advocacy and crisis support agencies.

Evaluation of acute presentation

- Most sexual assault survivors who present acutely will go to an urgent care center or emergency department. If patients contact their physician before visiting their office, the patients' concerns must be noted, and their autonomy supported. Patients should receive information on where to report for care and be advised that bathing, changing clothes, urinating, defecating, douching, and delays in seeking care could alter evidence collection.
- Clinicians who evaluate survivors acutely must adhere to medical and legal requirements, and those with limited or no experience should request assistance from trained personnel.
- **Initial assessment** includes evaluation for life-threatening conditions, serious injuries, or psychiatric emergencies. Patients may require urgent stabilization and hospitalization or surgery.
- When assessing and treating injuries, precautions should be taken to prevent destruction or contamination of evidence (e.g., wear nonpowdered gloves, avoid obtaining urine specimens, avoid giving oral or rectal medications unless needed for stabilization).
- **History:** a complete history is crucial. The clinician should use a supportive and nonjudgmental approach, and documentation should include the patient's own words. Details of the assault, including about sexual contact and exposure to bodily fluids, should be documented.
- **Physical examination:** it begins with an assessment of injuries. Physical injuries are noted in approximately one-half of all reported sexual assaults, with non-genital injuries more common than genital ones. The clinician should perform a detailed examination of the entire body and photograph or draw injuries. In the absence of major trauma, evidence collection is done concurrently with the physical examination.

Testing after sexual assault

Table 12. Suggested Tests and Timing

Test	Timing
Urine pregnancy	On presentation, repeat if missed menses
Serum HIV	On presentation, consider repeat at six weeks
Serum hepatitis B antigen	On presentation, Repeat at six months
Serum rapid plasma reagin for syphilis	On presentation. Consider repeat at four to six weeks and three months
Serum hepatitis C	On presentation. Consider repeat at three and six months.
Urine drug screen	When concern for drug-facilitated sexual assault.

Treatment after sexual assault

- All sexual assault survivors should receive timely treatment for pregnancy and disease prevention,

as indicated in table 13.

Table 13. Treatment Regimen

Treatment	When to consider	Regimen
Pregnancy prevention/emergency contraception	All survivors with a negative pregnancy test result	Levonorgestrel 1.5 mg up to 72 hours after assault Or Copper intrauterine device inserted within five days of assault.
Empiric sexually transmitted infection treatment for chlamydia, gonorrhea, and trichomoniasis	All survivors	Ceftriaxone 250 mg intramuscularly in a single dose plus Azithromycin 1 g as a single dose plus Metronidazole 2 g as a single dose or Tinidazole 2 g as a single dose
Hepatitis B postexposure prophylaxis	All survivors who have been previously vaccinated and Have known hepatitis B antigen negative status and Assailants with known hepatitis B antigen negative status	Not recommended
	All survivors who have been previously vaccinated and Have unknown hepatitis B antigen status or Assailants with unknown hepatitis B antigen status	Hepatitis B vaccination as a single booster only
	All survivors with unknown vaccination status or unknown immunity and Have assailants with unknown hepatitis B antigen status	Hepatitis B vaccination series only
	All survivors known to be hepatitis B antigen positive or Have assailants known to be hepatitis B antigen positive	Hepatitis B vaccination series plus Hepatitis B immunoglobulin
HIV postexposure prophylaxis	Survivors with significant exposure: Direct contact of the vagina, penis, anus, or mouth with the semen or blood of assailant with or without physical injury or tissue damage, Broken skin or mucous membranes of the survivor have been in contact with blood or semen of	Preferred three-drug regimen*: Tenofovir, 300 mg per day and Emtricitabine 200 mg per day and Raltegravir 400 mg twice per day or Dolutegravir 50 mg per day

	the alleged assailant, Bites that result in visible blood	
Tetanus vaccination	If skin abrasions present and immunization status is unknown or greater than 10 years If high-risk wound and immunization status unknown or greater than 5 years	Tetanus booster
Human papilloma-virus vaccination	All survivors nine to 26 years of age who have not previously completed vaccine series Shared clinical decision-making for patients 26 to 45 years of age.	Age-appropriate vaccine series

Delayed presentation

- Delayed presentation is common, particularly when the initial disclosure is in the primary care setting.
- Helpful responses include validating the disclosure, providing emotional support, and providing tangible aid and informational support, and avoiding blaming the survivor and treating the survivor differently after disclosure.

Prevention

- Primary prevention of sexual violence requires a comprehensive approach with interventions to address individual, relational, community, and societal factors. The Centers for Disease Control and Prevention has developed STOP SV, a technical package highlighting effective strategies for prevention (Table 14).
- Programs mobilizing boys and men as allies and focusing on **bystander approaches** can prevent sexual violence.
- Empowerment-based training for college-aged women has been shown to decrease the risk of victimization. Transportation policies, campus safety programs, and crime prevention programs have been shown to decrease the sexual assault.

Table 14. STOP SV Model

Sexual Assault Prevention Strategies: STOP SV Mnemonic		
S	Promote social norms that protect against violence	Bystander approaches can empower young people to intervene in peer groups Mobilizing boys and men as allies
T	Teach skills to prevent sexual violence	Implementing social-emotional learning to change the way children and adolescents think and feel about violence Promoting healthy sexuality through comprehensive sex education that includes consent and respect Teaching healthy safe dating and relationship skills to adolescents through effective programs like Safe Dates Empowerment-based training to increase participants' ability to identify and reduce exposure to risky situations.
O	Provide opportunities to empower girls and women	Strengthening economic supports for women and families Strengthening opportunities for leadership and empowerment for girls
P	Create protective	Improving safe physical spaces and increasing staff monitoring in

	environments	schools Establishing safe workplace policies and taking proactive measures to reduce harassment and violence in the workplace
SV	Support victims to lessen harms	Survivor-centered services like rape crisis centers Comprehensive treatment for sexual violence survivors, including mental health services Treatment for children who were exposed to violence in their homes and communities and are at risk of violence perpetration.

REFERENCE

1. *American Academy of Family Physicians. Taking an Accurate Sexual History Sample Script. https://www.aafp.org/dam/AAFP/documents/patient_care/sti/hops19-sti-script.pd*
2. *A Guide to Taking a Sexual History: Centers for Disease Control and Prevention, Division of STD Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, last reviewed: January 14, 2022*
3. *Sexual Health History: Techniques and Tips; epub February 1, 2020 American Family Physician*
4. *John Murtagh 's Handbook of General Practice, Edition,*
5. *Oxford Handbook of General Practice, Edition, p733*
6. *Seehusen DA, Baird DC, Bode DV. Dyspareunia in women. Am Fam Physician. 2014;90(7):465-470. Accessed September 6, 2019. https://www.aafp.org/afp/2014/1001/p465.html*
7. *Rew KT, Heidelbaugh JJ. Erectile dysfunction. Am Fam Physician. 2016;94(10):820-827. Accessed October 12, 2019. https://www.aafp.org/afp/2016/1115/p820.html*
8. *Dyspareunia in Women: American Family Physician: Volume 103, Number 10 May 15,*
9. *American College of Obstetricians and Gynecologists (ACOG) Guideline on Sexual Dysfunction in Women: Obstetrics & Gynecology, April 2011: http://journals.lww.com/greenjournal/Citation/2011/04000/Practice_Bulletin_No_119_Female_Sexual.38.aspx http://journals.lww.com/greenjournal/Citation/2011/*
10. *Testosterone Therapy for Age-Related Low Testosterone: Guidelines from the ACP: American Family Physician: Volume 103, Number 1 Jan 1, 2021*
11. *Testosterone Treatment in Adult Men With Age-Related Low Testosterone: A Clinical Guideline From the American College of Physicians https://www.acpjournals.org/doi/10.7326/M19-0882*
12. *Premature Ejaculation: American Urological Association: https://www.urologyhealth.org/urology-a-z/p/premature-ejaculation*
13. *LGBTQI+ inclusion initiatives piloted under a new project by UNOPS in Myanmar give hope for delivering accessible and sensitive healthcare across the country; United Nations Myanmar:17 December 2021*
14. *Caring for Transgender and Gender-Diverse Persons: What Clinicians Should Know; December 1,2018 Volume 98, Number 11: American Family Physician*
15. *Continuation of gender-affirming hormones in transgender people starting puberty suppression in adolescence: a cohort study in the Netherlands: The Lancet: October 20, 2022DOI:https://doi.org/10.1016/S2352-4642(22)00254-1*
16. *Sexual Assault of Women; February 1,2021 Volume 103, Number 3;American Family Physician*
17. *Intimate Partner Violence: October 15, 2016 Volume 94, Number 8; American Family Physician*
18. *Basile KC, DeGue S, Jones K, et al. STOP SV: a technical package to prevent sexual violence. Atlanta: National Center for Injury Prevention and Control; Centers for Disease Control and Prevention; 2016:11.Accessed August 26, 2020.*

CHAPTER (18) SURGICAL PROBLEMS

- Acute Abdomen
- Upper GI Bleeding
- Lower GI Bleeding
- Dyspepsia
- Dysphagia
- Abdominal Wall Hernia
- Breast Problems
- Perianal Problems
- Haemorrhoids (Piles)
- Rectal Prolapse
- Perianal Haematoma
- Anal Fissure
- Perianal Abscess
- Fistula – In –Ano
- Pilonidal Sinus
- Peripheral Vascular Diseases
- Wound Infection and Wound Care
- Acute Retention of Urine
- Principle and procedures of minor surgery in general practice

•

ACUTE ABDOMEN

- Patients presenting with undiagnosed acute (severe) abdominal pain of less than one week (usually less than 48 hours) duration – may or may not be required surgical treatment
- Might be trivial to life threatening
- Therefore, to get diagnosis is crucial and sometimes to get diagnosis is tricky. So wide range of causes are worked out by basic clinical acumen such as history taking proper abdominal examination and some blood tests and imaging. Closed monitoring and observation by reassessment is also vital because sign and symptoms are changing with time and management is depending on causes.

Causes according to site (Quadrant of abdomen)



https://d17h1fcixtjvd3.cloudfront.net/uploads/production/aa82646faa4aa02efdd64a33b1c345608dc896aa9524296003865614.jpg

To get diagnosis

- Thorough history taking about pain → site, onset, character, radiation, timing, aggravating and relieving factors, severity and associated factors, menstrual history in women with reproductive age
- Symptoms of other medical diseases (e.g., DM, chronic renal failure, history of herpes infection recently)
- History of trauma/injury recently
- Examination – general features of shock, fever, anaemia and jaundice are hints for diagnostic clues

Abdominal Examination

- Inspection, Palpation, Percussion and Auscultation
- Per Rectum and Vaginal examination (if necessary)
- Signs of peritonism and intestinal obstruction – must be looked for
- Don't miss to see inguinal regions for hernia

Investigations

Laboratory tests

- Full Blood Count, Urinalysis, UCG as baseline
- Specific lab tests if any suspicious pathology, e.g., serum amylase in case of suspicious for acute pancreatitis.

Imaging

- Plain X ray abdomen/chest (erect and supine - to detect gut perforation, intestinal obstruction, pneumonia or obliteration of pleurophrenic angle)
- USG (abdomen and pelvis) – any fluid collection, organ enlargement and other genitourinary and gynaecological pathology
- CT scan – e.g., acute pancreatitis, abdominal aorta aneurysm rupture

Management

- **Treat the cause.**
- **If unsure, admit as a surgical emergency to hospital.**
- **If possible, give analgesia prior to transfer to hospital.**
- **It is safe to start with liquid diet, and then semisolid to solid if improved**
- IV access, fluid replacement if necessary
- Conservative management/- watchful waiting if patient is stable without signs of peritonism or shock
- Laparoscopy or laparotomy if diagnosis remains unclear and not responding to conservative treatment

Timing for referral

- If the patient with shock or features of peritonism → prompt referral with IV access and resuscitation
- If the diagnosis is doubtful and not response to conventional treatment → refer to hospital to work up and observation under closed assessment

UPPER GI BLEEDING

Definition

- *Haematemesis* and *Melaena* due to blood loss from the upper GI tract, usually from proximal to the duodeno-jejunal junction

Haematemesis

- **Vomiting of coffee ground colour altered blood**, (need to differentiate from haemoptysis – containing froth, fresh blood and no nausea, occurred with coughing)

Melaena

- Passing of black tarry stool per rectum (need to differentiate from haematochesia – passing of fresh blood per rectum)

Causes



- In young adults, PUD, congenital lesions and varices are common causes.
- In the elderly, tumors, PUD and angiodysplasia are common causes.
- Most tumors more commonly cause anaemia than frank haematemesis.

to get diagnosis
History taking

- **History** of regurgitation, dysphagia, alcoholic/non-alcoholic liver diseases & features of liver insufficiency and history of forceful vomiting (Mallory- Weiss syndrome); History of PUD (peptic ulcer disease), dyspeptic symptoms, anaemic symptom, history of Duodenal Ulcer
- History of taking anticoagulant and antiplatelets and analgesics

Physical Examination

- **General – assess vital signs (Blood Pressure, Pulse Rate, Respiratory Rate, Temperature), Conscious level, pallor, Jaundice,**
- **Features of chronic liver insufficiency**
- **Abdominal exam – features of portal hypertension, any mass**

Investigations

- Laboratory: FBC, LFT (suspicious of varices), coagulation profiles
- Ultrasound: can diagnose liver cirrhosis, ascites, mass or tumour
- Endoscopy: **Investigation of choice** for diagnosis (site of lesion, severity accurately, biopsy), Test for *H. pylori* infection and therapeutics (varices – injection, banding; ulcer – injection/cautery)
- Angiography or CT angiography
- Barium meal and follow through: only for diagnosis, not therapeutic use

Management

- Refer for surgery (urgent endoscopy) if suspected.
- Rapid access of intravenous fluid and Proton-pump inhibitor (PPI) is the first priority.

Essential management of upper GI bleeding



Prevention

- H pylori eradication,
- Portal pressure reduction –banding through OGDS and Beta blocker
- Abstinence of alcohol drinking

LOWER GI BLEEDING

Definition

- Bleeding per rectum
- ***Anorectal bleeding*** *is characteristically bright red, associated with defecation.*
- ***Left sided/sigmoid bleeding*** *is characteristically dark red, with clots, may be mixed with stool.*
- ***Proximal colonic/ileal bleeding*** *is usually dark red, fully mixed with the stool or occult.*

Causes



Diagnosis

Depends on age

- **in children:** usually with anal fissure, Meckel's diverticulum and intussusception
- **in young adults:** anal causes (haemorrhoids, fissure, proctitis), colitis polyps are common causes
- **in the elderly:** colorectal tumors, diverticular disease, angiodysplasia and colonic ischaemia should be considered.

PER RECTAL EXAMINATION AND PROCTOSCOPY ± FLEXIBLE SIGMOIDOSCOPY

Investigations

- FBC, coagulation profile, FOB testing
- Abdominal X ray and ultrasound – intussusception

- Flexible sigmoidoscopy: suspicious colitis, sigmoid tumor or diverticular disease
- Colonoscopy: diverticular disease, colonic tumors and angiodysplasia.
- Angiography: angiodysplasia, small bowel causes (especially Meckel's diverticulum- needs active bleeding 0.5ml/min, highly accurate when positive, invasive, allows embolization therapy)
- Technetium-99m-pertechnate labeled RBC scan: angiodysplasia, small bowel causes including Meckel's diverticulum, obscure colonic causes (needs active bleeding 1ml/min, less accurate placement of source, non- invasive, non-therapeutic.)
- Small bowel enema: small bowel tumor

Management

- Refer urgently to surgery if suspicious lower gastrointestinal tract symptoms and signs are present.
- Any age with:
- Right lower abdominal mass consistent with involvement of large bowel
- A palpable rectal mass (intraluminal, not pelvic; a pelvic mass outside the bowel would warrant an urgent referral to a urologist)
- Unexplained iron deficiency anaemia (Hb ≤11g/dL for male; ≤10g/dL for a non-menstruating female)
- Aged ≥40 yr
- Reporting rectal bleeding with a change of bowel habit towards looser stools and/or increased stool frequency persisting ≥6wk.
- Aged ≥60 yr with:
- Rectal bleeding persisting for ≥6wk without a change in bowel habit and without anal symptoms
- Change in bowel habit to looser stools and/or more frequent stools persisting for ≥6wk without rectal bleeding
- ! In a patient with equivocal symptoms who is not unduly anxious, it is reasonable to 'treat, watch, and wait'.

FLOW CHART



https://i0.wp.com/basicmedicalkey.com/wp-content/uploads/2017/04/c07uf005.jpg?fit=812%2C418&ssl=1&w=640

- **If bleeding piles detected – treat haemorrhoids (first medical treatment, refer surgeon later if needed)**
- **If tumours detected or suspected – surgical referral**

DYSPEPSIA

Definition:

- The feeling of discomfort or pain in the upper abdomen or lower chest. Indigestion may be used by the patient to mean dyspepsia, regurgitation symptoms or flatulence.

New dyspepsia is <u>the only presenting symptom of upper GI malignancy</u>.

All older patients with **alarm symptoms** (dysphagia, vomiting, anorexia and weight loss, GI bleeding) should have endoscopy.

- In young adults, gastro-oesophageal reflux and *Helicobacter pylori*- positive gastritis are common causes.
- Dyspepsia in young people without alarm symptoms are very unlikely to be due to malignancy.
- Dyspepsia is rarely the only symptom of gallstones- they are often incidental findings

Causes of dyspepsia



Differential Diagnosis

- Reflux oesophagitis
- Oesophageal carcinoma
- Gastritis
- Gastric ulcer
- Carcinoma of the stomach
- Hiatus hernia
- Duodenal Ulcer (*H. pylori* infection)
- Duodenitis (associated with alcohol and smoking)
- Gallstones – rare symptom

Investigations

- **FBC-** anaemia suggests malignancy
- Test for *H. pylori* – Urease breath test and endoscopic biopsy test
- OGDS –can detect tumors, PUD, oesophagitis etc.
- 24 hours pH monitoring- GORD
- Oesophagealmanometry – for dysmobility
- Ultrasound – to detect gallstones

Management

Treat the causes and when to refer are vital in dyspeptic patients



DYSPHAGIA

Definition

- Difficulty with swallowing, which may be associated with ingestion of solid or liquid or both

- Most causes of dysphagia are oesophageal in origin.
- **In children**, foreign bodies and corrosive liquid are common causes.
- **In young adults**, reflux stricture and achalasia are common.
- **In middle aged and elderly**, carcinoma and reflux are common.

- Because the segmental nerve supply of the oesophagus corresponds to the intercostal dermatomes, a patient with dysphagia can accurately pinpoint the level of obstruction.
- Any new symptoms of progressive dysphagia should be assumed to be malignant until proven otherwise. All need endoscopic ± radiological investigation. Tumor and achalasia may mimic each other. Endoscopy and biopsy are advisable unless the diagnosis is clear.

Causes



Investigations

All

FBC: Anaemia (tumours much more commonly cause this than reflux)

LFTs: (hepatic disease)

↓

OGD

(moderate risk, specialist, good for differentiating tumour vs. achalasia vs. reflux stricture, allows biopsy for tissue diagnosis, allows possible treatment)

Video contrast swallow

(low risk, easy, good for possible fistula, high tumour, diverticulum, reflux)

If ?dysmotility
achalasia
neurogenic causes

↓

Video contrast swallow
Oesophageal manometry

If ?extrinsic compression

↓

CXR (AP and lateral)
CT scan: low risk, good for extrinsic compression, allows tumour staging

Management

- If there is any cause of dysphagia, referral to specialist thoracic surgeon to proceed confirmation of diagnosis and treatment.

ABDOMINAL WALL HERNIA

Definition

The protrusion of a viscus or part of viscus through an abnormal congenital or acquired opening in its covering



Complications of hernias

- **Irreducible hernia**: contents cannot be returned into the abdomen, thus risk of strangulation at any time
- **Obstructed hernia**: Irreducible hernia containing intestine which is obstructed from without or within but no interference to the blood supply to the bowel, usually go on to strangulation.

- **Strangulation hernia** (including Richter's hernia): blood supply of its content is seriously impaired, rendering the contents ischaemic and also has intestinal obstruction, gangrene can occur within 6 hrs.
- **Inflamed hernia**: Contents of sac have become inflamed (inflamed appendix, salpingitis)
- **Sliding hernia**: The sac contains loops of bowel and some bowel contents forming the wall of the sac
- **Incarceration**: the contents are fixed in the sac because of their size and adhesions
- **Maydl's hernia**: Hernia in W, when 2 adjacent loops of bowel are in the sac

Diagnosis of hernia

- Presence of swelling
- Cough impulse
- Reducibility

Diagnosis of complicated hernia

- Pain at swelling or abdomen, nausea, vomiting, ± the features of intestinal obstruction
- Increased size, tense, irreducible, loss of cough impulse, peritonitis and septicaemia

Management

- Assessment of the hernia for severity of symptoms, risk of complications (type and size of neck: e.g., femoral hernia)
- Assessment of the patient for fitness for surgery, impact of hernia on lifestyles (job, hobbies)
- Refer for Surgical assessment and surgical repair
    - Hernias in risk of complications
    - Hernias with previous symptoms
    - Hernias at low risk of complications but symptoms interfering with lifestyle

BREAST PROBLEMS

Introduction

- A woman presenting with breast problems is a common occurrence in general practice. Breast problems are ranging from mild pain to frank malignancy.

COMMON BREAST PROBLEMS

The most common breast symptoms presented to the GP are

(1) Breast lump with or without pain
(2) Breast pain alone
(3) Nipple discharge
(4) Swollen tender breast
(5) Change in the skin of the breast/nipple change
(6) Abnormal screening mammogram

How to get diagnosis

In a patient who presents with a breast lump or other symptoms suspicious of carcinoma, the diagnosis should be made by a combination of 'Triple Assessment'

(1) Clinical assessment
(2) Radiological assessment
(3) Cytological or histological assessment



Clinical assessment

History:

- appropriate history focused on the complaint; important point is duration of the compliant
- Evaluation of risk factors such as age, family history, menstrual history, child bearing history, personal history of breast cancer, personal history of ductal hyperplasia

Physical Examination:

- breast, axillary and supraclavicular areas is mandatory
- General examination of the patient focused on the lungs, chest wall and abdomen also must be performed



Incidence of breast cancer and benign conditions against age

Radiological assessment

- Breast imaging is the starting point for assessment of breast problems
- Mammogram and ultrasound form the basis of most imaging
- MRI is used infrequently for diagnostic assessment of common clinical problems
- Generally, mammogram is not indicated for women age <30 because of low sensitivity and specificity

BIRADS (Breast Imaging and Reporting Data System)

- BIRADS 1: Normal — Annual follow-up
- BIRADS 2: Benign — Annual follow-up
- BRAIDS 3: Probably benign — Short interval (6 months) follow-up
- BRAIDS 4: Suspicious finding — Biopsy recommended
- BRAIDS 5: Highly suggestive of malignancy — Biopsy mandatory

Cytological or histological assessment

Techniques:

- Fine needle aspiration
- Core needle biopsy
- Image guided core biopsy
- Wire localized excisional biopsy
- Excisional biopsy
- Incisional biopsy (rarely used)

DIAGNOSTIC WORK UP FOR BREAST PROBLEMS

Evaluation of breast lump



Evaluation of breast pain



Evaluation of nipple discharge



Management

Treatment of benign breast disease

- Fibrocystic changes – Reassurance
- Fibroadenoma – Refer for excision or observation (depending on age, size and patient's wish)
- Duct papilloma – Refer for duct excision
- Breast cyst – Aspiration & cytology if fluid is blood-stained
- Breast abscess – Antibiotic, percutaneous drainage or open drainage

Treatment of breast pain

- Non-pharmacologic therapies
  - Mechanical support: wearing a well-supporting bra
  - Life style change: smoking cessation, stress reduction
  - Complementary & alternative medicine: Evening primrose oil
- Pharmacologic intervention
  - Analgesic
  - Danazol
  - Bromocriptine
  - Tamoxifen

Treatment of Ca. breast

Refer to hospital for a multidisciplinary treatment planning approach.

Treatment of early breast cancer

- **Locoregional treatment**

Surgery

- Breast-conserving therapy (Lumpectomy, breast radiation & surgical staging of the axilla)

- Modified radical mastectomy (Total mastectomy + axillary clearance)
- Total mastectomy + Sentinel lymph node biopsy

Adjuvant radiation therapy

- Postmastectomy in axillary node-positive tumor
- After breast-conserving surgery

Adjuvant systemic therapy

- Despite optimal local treatment, virtually all patients with invasive breast cancer have some risk of systemic relapse. Therefore, all women with invasive breast cancer stand to benefit from systemic treatment to try and reduce this risk.
-

Chemotherapy

Hormonal therapy

Treatment of advanced breast cancer

- Treatment for systemic disease is palliative in intent
- Goals of treatment include improving quality of life and prolongation of life
- Surgery may be indicated for selected patients (e.g., Mastectomy for fungating tumor)
- Radiation therapy is major role in palliation of localized symptomatic metastasis
- Systemic therapy

Referral criteria

URGENT REFERRAL

Those patients whose symptoms are highly suggestive of breast cancer

(i) Presence of a discrete lump in the appropriate age group
(ii) There are definite signs of cancer such as ulceration, skin nodules or skin distortion

CONDITIONS THAT REQUIRE REFERRAL TO A SURGEON WITH A SPECIAL INTEREST IN BREAST DISEASES

(i) Lump
- Any new discrete lump
- New lump in pre-existing nodularity
- Asymmetrical nodularity that persists at review after menstruation
- Abscess
- Cyst persistently refilling or recurrent cyst

(ii) Pain
- If associated with lump
- Intractable pain not responding to treatment
- Unilateral persistent pain in post-menopausal women

(iii) Nipple discharge
- All women aged 50 and over
- Women under 50 with bilateral discharge sufficient to stain clothes, blood-stained discharge, persistent single duct discharge

(iv) Nipple retraction or distortion, nipple eczema
(v) Change in skin contour

(vi) Family history
- Women with strong family history of breast cancer

Women who can be managed, at least initially, by their GP

(i) Young women with tender lumpy breasts and older women with symmetrical nodularity without localized abnormality
(ii) Women with minor and moderate degree of breast pain who do not have a discrete palpable lesion
(iii) Women aged under 50 who have nipple discharge which is intermittent, from more than one duct and is neither blood-stained nor troublesome
(iv) Asymptomatic women with minor family histories at low risk of developing breast cancer

Health promotion and disease prevention

Reducing /changing the risk factors

- Get regular, intentional physical activity
- Weight reduction
- Dietary advice

Early detection

- Health education
  - Breast self-examination
- Screening mammogram
  - Screening mammogram must be recommended every one to two years for women ages 50-75 years
  - Screening mammogram could be recommended to women ages 40-49 and over the age of 75

Genetic testing if having increased risk

- High risk
  - 2 first-degree relatives (mother, sisters, daughters) with breast cancer, one diagnosed when <50 years of age
  - 3 or more first or second-degree relatives (including grandmothers, aunts) with breast cancer
  - Both breast and ovarian cancer among 1st and 2nd degree relatives
  - A 1st degree relative diagnosed with cancer in both breasts
  - 2 or more 1st or 2nd degree relatives diagnosed with ovarian cancer
  - A male relative with breast cancer

Breast cancer chemoprevention

- Chemoprevention is the use of drugs to reduce the risk of cancer
  - Tamoxifen
  - Raloxifene
  - Aromatase inhibitors (Anastrozole, Letrozole)

Preventive surgery

- Prophylactic mastectomy
- Prophylactic oophorectomy

PERIANAL PROBLEMS

Differential Diagnoses



HAEMORRHOIDS (PILES)

A submucosal swelling in the anal canal consisting of a dilated venous plexus, a small artery and areolar tissue

- internal: only involves tissue of upper anal canal above dentate line
- external: involves tissue of lower anal canal below dentate line

Causes

- increased venous pressure from straining (low- fibre diet) or altered haemodynamics (e.g., during pregnancy) causes chronic dilation of submucous venous plexus.
- Found at 3' 7' 11' o'clock of anal canal

Classification

- First degree – bulge into lumen but do not prolapse
- Second degree – prolapse during defaecation with spontaneous reduction
- Third degree – prolapsed during defaecation and require manual reduction
- Fourth degree – irreducible and may strangulate

Clinical presentations

- Bright red bleeding per anus, pruritus, pain, prolapse and thrombosis

Treatment

- First degree – bulk laxative, high fluid and fibre diet
- Second degree (rubber band (Barron's) ligation, injection, sclerotherapy, cryotherapy

Refer to hospital

- Third degree –haemorrhoidectomy (closed/open/stapled)
- Fourth degree (i.e., inflamed prolapsed piles) – need hospital admission and prompt antibiotics to avoid septicaemia followed by surgery 48- 72 hours later
- Complications of treatment- bleeding, anal stenosis, pain

RECTAL PROLAPSE

Definition

The protrusion from the anus to a variable degree of rectal mucosa (partial) or rectal wall (full thickness)

Clinical presentations

- Faecal incontinence, constipation, mucous discharge, bleeding, tenesmus, obvious prolapse
- 10% of children with prolapse have cystic fibrosis

Treatment

- Manual reduction in young children
- Refer to Surgery – Delorme's perianal mucosal resection
    - Laparoscopic or open surgical rectopexy ± sigmoid resection

PERIANAL HAEMATOMA

Painful anal condition due to rupture of small blood vessel in the perianal area

Diagnosis – highly suspicion and evacuation of clot is necessary treatment

ANAL FISSURE

Longitudinal tear in the mucosa of anal canal, in the midline posterior (90%) or anterior (10%) due to passage of hard stool and potentiated by spasm of exposed internal anal sphincter

Other causes: pregnancy, delivery, Crohn's disease, sexually transmitted infections (lateral position), carcinoma of anus

Clinical features

Pain during defaecation with small amount of bright red blood on toilet paper, sphincter spasm, skin tag at distal end of tear (sentinel pile)

Treatment

- Stool softeners/bulking agent, local anaesthetic gel, 0.2/0.4 % nitroglycerine ointment
- Topical calcium channel blocker
- **Refer to hospital** for lateral internal sphincterectomy (95% cure, but risk of minor incontinence in 10 %)
- EUA and biopsy for atypical /suspicious abnormal fissure (e.g., Crohn's disease)

PERIANAL ABSCESS

Focus of infection starts in anal glands (cryptoglandular sepsis) and spreads into perianal tissues to cause

- perianal abscess
- ischioanal abscess
- para- rectal abscess

Early diagnosis of painful swollen mass with signs of sepsis and prompt incision and drainage of abscess with antibiotics

FISTULA – IN –ANO

- Abnormal communication between the perianal skin and anal canal
- Commonest cause is a consequence of inadequate drainage of perianal abscess,
- Association with Crohn's and TB

Types –

- Low: below 50% of external anal sphincter
- High: crossing 50%or more of the external anal sphincter

Clinical diagnosis –

chronic perianal discharge with granulation tissue perianally

Treatment

depending on the types (**referral to surgeon is mandatory**)

PILONIDAL SINUS

A blind-ending track containing hair in the skin of the natal cleft, may be due to trauma or congenital presenting as natal cleft abscess

Treatment:

Good personal hygiene and removal of hair, **refer to hospital** for incision and drainage of abscess, excision of sinus network with primary or delayed closure or tissue flap

PERIPHERAL VASCULAR DISEASES

Peripheral vascular diseases consist of arterial and venous disorders (acute and chronic).

PERIPHERAL ARTERIAL DISEASE (PAD)

- (Peripheral arterial occlusive disease, peripheral occlusive vascular disease) is a common disorder caused by acute or chronic interruption of blood supply to the limbs, usually due to atherosclerosis.
- All patients with PAD require screening for associated coronary or carotid disease.
- Most patients with PAD respond to conservative management.
- Surgery or interventional radiology is indicated for limb threatening (critical) ischaemia or disabling claudication.
- The presence of PAD is one of the best predictors of future death, stroke or MI.
- Male > female before 65 years.
- Increased risk with increased age.
- Affects 10 % of population >65 years in Western world.

Aetiology

- atherosclerosis and thrombosis
- embolism (80% cardiac in origin, microthrombi cause 'blue toe syndrome')
- vascular trauma
- vasculitis (e.g., Burger's disease)

Risk Factors

- Cigarette smoking, hypertension, hyperlipidaemia, diabetes mellitus, elevated homocysteine, family history

Pathology

- Reduction in blood flow to peripheral tissue results in ischaemia which may be acute or chronic. Critical ischaemia is present when tissue viability cannot be sustained (i.e., tissue loss, rest pain for two weeks, ankle pressure ≤50 mmHg).

Clinical features

Fontaine classification

- Stage I. Asymptomatic.
- Stage II. Intermittent claudication
- Stage III. Rest pain /night pain
- Stage IV. Necrosis/gangrene

Chronic ischaemia

- Intermittent claudication in calf (femoral disease), thigh (iliac disease) or buttock (aorto-iliac disease)
- Cold peripheries and prolonged capillary refill time.
- Rest pain, especially at night
- Venous guttering
- Absent pulses
- Arterial ulcers, especially over pressure points (heels, toes)
- Knee contractures
- Leriche's syndrome (intermittent claudication, impotence, absent femoral pulses) indicates aortic occlusion.

Acute ischaemia

- Pain

- Pallor
- Pulseless
- Paraesthesia and paralysis – indicate life threatening ischaemia that requires immediate treatment.
- Perishing cold
- Pistol shot onset
- Mottling Muscle rigidity

Investigations

Chronic ischaemia

- ABPI (normal >0.9) at rest and post-exercise on treadmill
- Digital pressure (normal toe pressure >50 mmHg)
- FBC (to exclude polycythaemia)
- Doppler waveform analysis
- Digital plethysmography (in diabetes)
- Duplex Ultrasound e.g., assessing a stenosis in the femoral artery.
- Angiography (MRA, CTA or catheter angiography)

Acute ischaemia

- ECG, cardiac enzymes
- Angiography, may be performed preoperatively.
- Ultrasound aorta for AAA

Management

Non- disabling claudication

- Stop smoking
- Exercise programme (exercise until claudication occurs, rest until pain subsides, repeat cycles for 45 – 60 minutes)
- Antiplatelet agents: aspirin or clopidogrel
- Statin: regardless of baseline cholesterol levels
- Cilostazol (pletal) 100 mg bd- improves claudication distance (contraindicated in patient with CCF)
- Pentoxyfylline (trental) improves blood flow by increasing RBC deformability and blood viscosity

Disabling claudication/critical ischaemia

- Immediate refer to vascular surgeon
- (Balloon angioplasty ± intravascular stent Bypass surgery or Amputation)

Acute ischaemia

- Need immediate referral to vascular surgeon
- Heparin anticoagulation
- Surgical or radiological (aspiration) embolectomy
- Thrombolytic therapy

*** in acute iscahemia case – revascularization (pharmacological or surgical means) must be within golden hour (6 hours)

In critical ischaemia → whether limb saving surgery or life-saving amputation depending on viability of limbs

VENOUS DISORDER

Deep vein thrombosis and pulmonary embolism is important disorder especially in surgical patients.

DVT

Wells' clinical prediction score for DVT (quantifies probability of DVT)

Active cancer	+1
Post bed rest for >3 days or major surgery	+1
Entire leg swelling	+1
Pitting oedema	+1
Collateral superficial veins (non-varicose)	+1
Paralysis or recent POP lower limb	+1
Tender over deep venous system	+1
Calf swelling >3 cm over other leg	+1
Previous documented DVT	+1
Alternative diagnosis more likely	-2

Probability of DVT: high ≥3, medium 1 or 2, low 0.

PATHOPHYSIOLOGY, SIGNS, TREATMENT AND OUTCOME OF DVT



WOUND INFECTION AND WOUND CARE

Wound: disruption of normal skin structure and function due to internal or external injury. Chronic wounds are those unresponsive to initial therapy or persistent in spite of appropriate care.

Healing process – very complex orchestral cascade of biomedical and cellular process triggered by tissue injury.

Healing phases – vascular response, inflammatory response, proliferation and maturation

Factors affecting wound healing – advanced age, smoking, underlying disorders (diabetes, cancer, malnutrition, dehydration), other treatment modalities (chemotherapy and radiotherapy), and poor wound care and surgical technique.

WOUND CARE

- For the wound care proper wound assessment is essential.
- Information – patient and family member on the extent of the problem (odour of the wound, amount and types of exudates, and type of wound), nursing and medical notes, direct observation, and history and physical examination of other organ systems.
- Clinical history and physical examination should include a certain minimum set of information.

WOUND MANAGEMENT

Four main principles: effective debridement, infection control, optimal dressing and promotion of healing

TIME: Tissue Management, Infection and Inflammation control, Moisture balance and Epithelial advancement

Wound cleansing and pressure relief

- Universal precautions should be followed at all times.
- Wound with no debris does not require cleansing.
- Irrigate wound with physiological solution (0.9% normal saline)
- Take swabs if necessary – take separate swabs for apparently separate areas
- Pressure relief – by repositioning time schedule and using pressure reducing devices (mattress, cushions, gutter, splint, etc. in limb oedema)

Tissue management

Debride all necrotic, poorly vascularized and infected tissues. Irrigate with saline. Antiseptic solutions are not recommended as they are toxic to human tissues and may delay healing. Dry hard eschar with normal looking surrounding skin may be left alone.

Infection control

Contamination – wound acquiring the pathogen transiently with no invasion or multiplication

Colonization – the microbial pathogen grows and multiplies but does not invade the host or interferes with wound healing

Wound infection – the infecting organisms interferes with the normal functioning of the host, utilizes the host's resources and interrupts the normal healing process.

Diagnosis – swabs for C &S must be obtained from relevant infected sites (separately) using aseptic technique

Plain X ray, Bone scan, and/or MRI scan in suspected osteomyelitis in exposed bone, open fracture, underlying internal fixation, gangrenous wound, persistent sinus tract, and non- healing wound are considered to confirm and assess the extent of infection.

Bone culture and biopsy should be obtained.

Treatment

- Supportive –reassurance to patient, pain relief
- Surgical drainage and debridement
- Systemic antibiotics in all established wound infections empirically and must change the antibiotic according to C&S results.
- Topical antibiotics are only use with precaution in wounds with poor blood supply, wound with frequent contamination, unsuccessful long term systemic antibiotics with bacterial resistant, antibiotic allergy and planned delayed primary closure.

WOUND DRESSING

Ideal dressing should protect, cleanse, optimize and promote the healing process.

Selection of dressing depends on:

- accurate assessment of wound e.g., heavy or slight exudative, odorous, sloughy and/or infected
- dressing types – alginate, hydrogel, hydrocolloids, surgical absorbent, low adherent, non-adherent foam, odour absorbing etc.,

Stage if healing process e.g., wounds required assisted debridement of sloughs, high absorbing intact dressing for infected exudates, moist environment for granulation tissue or promotion of the final healing and epithelialization stage

**During wounds assessment, if there is complicated wound, referral to specialist is advisable to improve patient's life and scar.

ACUTE RETENTION OF URINE

Definition

Sudden inability to pass urine associated with painful bladder distension

Causes

Local cause

- Prostatic enlargement (BPH or Ca prostate)
- Post- urological surgery. e.g., post TURP, clot retention
- Bladder or urethral stone impaction
- Pressure on bladder e.g., Late pregnancy, faecal impaction
- Pelvic organ prolapse in female, e.g. cystoclele, rectocele, uterine prolapse
- Urinary tract infection

General cause

- Pharmacological – e.g.- anticholinergic side effect of many drugs, anaesthetic drugs, alcohol intoxication, alpha sympathomimetic drugs
- Post – non urological surgery – abdominal surgery with lower abdominal pain
- And epidural or spinal anaesthesia
- Loss of normal neurological control – spinal injury, CVA, autonomic or peripheral lesion (e.g. –autonomic neuropathy, DM, Guillain-Barre syndrome)

Management

Confirm the diagnosis of Acute retention of urine

Symptoms

- SPA pain
- Inability to pass urine despite desire
- May dribble urine especially if there is underlying chronic retention

Signs

- Tenderness and mass in SPA
- Dullness at SPA on percussion

Emergency management

- give analgesia. It will help relaxation and may aid spontaneous micturition.
- warm bath or ice pack on SPA
- catheterize if retention persist, under aseptic condition
- Suprapubic catheterization if urethral catheterization failed of if there is known or suspected urethral disease
- Document initial volume passed after catheterization. Large volume suggest underlying chronic retention.

Find out the underlying cause
history

- Previous history of LUTS, urological surgery or injury
- Spinal injury

- Medications

Clinical examination

- Full clinical examination including neurological finding, rectal examination and vaginal examination (in female patients)

Investigations

- Urine RE, C & S
- Blood for FBC, U &E, Creatinine
- USG (abdomen)
- KUB X ray or X ray Bladder area if suspicious of stone

Early treatment

- Monitor renal function especially if there is underlying chronic retention. Renal function may deteriorate even often relief of the obstruction
- Monitor fluid balance in the first 48 hr if there is associated chronic retention. A secondary diuresis may occur.
- Start antibiotics according to local protocols if there is evidence of UTI

Definitive management

- Refer to urologist for definitive management.

PRINCIPLE AND STEPS OF PROCEDURES

- Abscess Incision and Drainage (I & D)
- Excision of cyst
- Nail avulsion

ABSCESS: INCISION AND DRAINAGE

- Abscess is commonly encountered among patients presenting for treatment in primary care offices and emergency departments.
- Cutaneous abscesses can occur in any area of the body but are commonly found in the
- axillae,
- buttocks, and
- extremities.
- Incision and drainage - the primary therapy for the management of cutaneous abscess;
- Abscess incision and drainage are most often outpatient procedures, most localized skin abscesses without associated cellulitis can be managed without antibiotics.
- Antibiotic treatment alone is inadequate for treating many loculated collections of infectious material.

Diagnosis of a skin abscess

- The majority of skin abscesses - tender and fluctuant or erythematous with induration.
- diagnosis of an underlying abscess
- on the basis of swelling,
- pain,
- redness, and
- fluctuance
- Spontaneously draining skin abscesses
- Needle aspiration of a suspected skin abscess can facilitate the diagnosis of a localized abscess (in equivocal case)
- Use of ultrasonography is increasing and can be helpful for diagnosis.
- Once the diagnosis of an abscess is made, the next step is to determine whether incision and drainage are necessary.
- Most cutaneous abscesses are appropriate for incision and drainage when they are larger than 5 mm in diameter and are in an accessible location.

Contraindications

- Extremely large abscesses or deep abscesses in areas that are difficult to anesthetize
- may be treated more appropriately in a formal operating room.
- not indicated for cutaneous cellulitis without an underlying abscess.

Special considerations

- The transient bacteremia associated with incision and drainage may require preoperative treatment with antibiotics
- reconsideration of the timing of the procedure for patients at increased risk for endocarditis, such as those with abnormal or artificial heart valves.
- Consultation with an appropriate surgical specialist -Abscesses of the palms, soles, or nasolabial folds
- Advice from an appropriate specialist -specific cosmetic concerns, such as the face or breast.



Natural crease lines on the face.



Acceptable incisions on the palmar aspect of the hand.





Equipment

- Universal precautions for potential exposure to bodily fluids
- a gown, gloves, and a face mask with shield.
- Under aseptic and sterile procedures for abscess drainage whenever possible.
- Materials needed for the incision and drainage of an abscess
- For preparation and anesthesia, obtain a skin-cleansing agent, sterile gauze, local anesthetic, a 5-to-10-ml syringe, and a 25-gauge or 30-gauge needle.
- One percent lidocaine is an appropriate anesthetic for this procedure.
- Lidocaine with epinephrine offers advantages such as reduced bleeding and extended duration of action.
- Anesthetics with epinephrine are contraindicated in areas with a single blood supply, and their use in these areas is typically avoided.
- Bupivacaine is another option that offers an increased duration of action.
- a scalpel blade (number 11 or 15) with handle
- a small curved hemostat

- normal saline with a sterile bowl,
- a large syringe with a splash guard or a needleless 18-gauge angiocatheter for irrigation of the wound.
- Swabs for bacterial culture,
- wound-packing material, scissors, gauze, and tape should be available to complete the procedure and dress the wound.

Obtain informed consent after discussing the procedure and its risks and benefits to discuss the possibilities of pain, bleeding, and scar formation with patients before obtaining consent.

Time out-

- the correct patient,
- to identify the correct surgical site,
- to obtain agreement on the procedure to be performed, and
- to ensure availability of all necessary equipment.
- Wash your hands with antibacterial soap and water before beginning the procedure.
- Place all equipment within reach, on a bedside table.
- Position the patient so that the area for drainage is fully exposed and easily accessible, while ensuring the patient's comfort.
- Adjust the lighting to allow easy visualization of the abscess.
- Apply a skin cleanser, such as chlorhexidine or povidone iodine, in a circular motion, starting at the peak of the abscess.
- Cover a wide area outside the wound to prevent contamination of equipment.
- Anesthetize the top of the wound by inserting a 25-gauge or 30-gauge needle just under and parallel to the surface of the skin.
- Inject anesthetic into the intradermal tissues.



- Once the entire open bore of the needle is under the skin, use gentle pressure to infiltrate the skin with the anesthetic agent.
- will note blanching of the tissue as the anesthetic spreads out.
- Continue with infiltration until covered an area over the top of the abscess large enough to anesthetize the area of incision.

For some abscesses, additional injections of anesthetic in a local field block pattern, parenteral analgesic agents, or procedural sedation may be required for the patient's comfort.

ABSCESS INCISION AND DRAINAGE PROCEDURE

- Hold the scalpel between the thumb and forefinger to make initial entry directly into the abscess.
- Make an incision directly over the center of the cutaneous abscess;
-





- the incision should be oriented along the long axis of the fluid collection.
- Subsequent treatment with antibiotics is not required after most successful incision and drainage procedures performed in healthy patients.
- Patients with extensive cellulitis beyond the abscess area or with significant comorbidities may require supplemental treatment with antibiotics.







- Providers are encouraged to use local bacterial-culture susceptibility data to guide any such empiric therapy (if available for C&S)
- Knowing and following your regional management guidelines is imperative.
- Some communities have reported up to a 74% incidence of this pathogen in cutaneous abscesses, although there is no evidence to suggest that abscesses caused by community-acquired MRSA are more likely to require empiric antibiotic therapy.
- Cover the abscess wound with a sterile, nonadherent dressing.
- Check that the patient's tetanus immunizations are up-to-date.
- Remove packing material from all abscesses within a few days; schedule a follow-up appointment for 2 or 3 days after the procedure, to remove packing material from the wound.
- Instruct the patient to return before the scheduled appointment if there are any signs of worsening, including
- redness,
- swelling, or
- development of systemic symptoms such as fever.
- The acidic environment of infected tissue can lead to difficulties with providing sufficient anesthesia with local agents.
- Using appropriate amounts of anesthetic, allowing sufficient time after injection, or supplementing with oral or parenteral agents can increase the patient's comfort.
- Progression to surrounding cellulitis or lymphangitis, development of fever, or other signs of clinical worsening may mean that repeat incision and drainage or antibiotic treatment should be considered.
- If an abscess recurs despite adequate drainage, further investigation may be warranted to rule out underlying risk factors or abnormalities such as staphylococcal colonization or anatomic, immunologic, or infectious disorders.

- Most abscesses respond well to simple incision and drainage and do not require treatment beyond the changing of packing material and the application of local wound care.

EXCISION OF CYST

- Excision of sebaceous cysts is recommended as they enlarge, often become infected, and seldom regress spontaneously.
- It is important to excise them completely in order to prevent recurrence.
- They arise from the deep layers of the skin and are most satisfactorily excised in a similar manner to that used for other skin lesions, through an elliptical incision.



- The punctum, where the overlying skin is tethered to the cyst, should be in the centre of an ellipse.
- The length of the ellipse approximates the diameter of the cyst.
- The width of the ellipse is determined by planning the skin closure, and will vary with the degree of skin stretching that has occurred.
- First the skin ellipse is incised, and care must be taken not to enter the cyst with this initial incision.
- The plane is then developed immediately outside the cyst wall. This plane can be difficult to enter, especially where stretched skin is closely applied to the cyst wall.
- It is often easier to dissect initially at the two ends of the ellipse ensuring that the skin incision is full thickness into subcutaneous fat.
- Artery forceps, applied to the freed ends of the ellipse, and a skin hook placed under the lateral skin edge, can be used to retract and counterretract to identify the plane



Figure 1.17 *Excision of a sebaceous cyst. The artery forceps on the freed corner is useful for retraction as the lateral skin edge is lifted initially with a skin hook.*

- In all dissections natural planes between structures can be found and developed by a blunt or a sharp method of dissection.
- In *blunt dissection*, reliance is placed on the assumption that natural cleavage occurs between structures.
- If however there is inflammatory scarring, the line of least resistance to separation may be through the cyst wall or out into the fat, and there is tearing of tissue.
- In all areas of surgery *sharp dissection* allows far more accurate dissection, and has the potential for more complete removal of pathology with preservation of delicate adjacent structures.
- Forceps or scissors can be used to develop a plane by blunt dissection.
- For sharp dissection the areolar tissue of the plane must be held on stretch and divided under direct vision with scissors, scalpel or diathermy.
- If any inflammation is present, removal of the cyst should be deferred until this has subsided.
- A frankly infected sebaceous cyst should be simply incised and the contents drained.
- No attempt should be made to excise it as wound complications and disappointing scars are often the result.
- In addition, the infection frequently destroys the lining of the cyst and no further treatment may be necessary. If the cyst does recur, excision can be planned at a later date.

NAIL AVULSION

- If a finger or toenail is avulsed the nail regrows from the nail bed.
- Avulsion can therefore only be a good surgical option for a self-limiting condition.
- For example, trauma to a digit – with the associated soft tissue swelling – can result in a previously trouble-free nail growing into the oedematous tissue of the nail fold and causing further damage and infection.
- The curved nails which cause ‘in-growing toenails’ are really only a chronic variant of this as the condition is almost unknown in bare-foot people.
- An avulsion to allow the infection to settle may be successful if the patient is prepared to adapt their nail cutting and footcare when the new nail regrows.
- A nail may also be avulsed to examine – and even biopsy – a dark stain under a nail when there is doubt as to whether this is a haematoma or a malignant melanoma. If, however, there have been recurrent problems with an ingrowing nail, or a nail is thickened with onychogryphosis, the nail bed must be removed, or destroyed, otherwise the problem will simply recur as the nail regrows.
- The nail bed may be excised using a Zadek’s operation (Fig. 1.18), or it can be destroyed with phenol.

- Either a general anaesthetic or a digital block is suitable for toenail surgery, and a toe tourniquet will give a bloodless field.



- The nail is first avulsed.
- One blade of a heavy artery forceps is introduced under the nail, either in the medial or the lateral third.
- Rotation of the closed forceps lifts the medial or lateral nail edge out of the basal corner and the nail fold
- The manoeuvre is repeated on the other side and the whole nail avulsed.
- The tissue overgrowth and proud granulations are curetted or excised from the nail folds.
- The raw nail bed is dressed with tulle gras, absorbent dressings and a crepe bandage. The distal

pulp skin should be visible beyond the dressing so that adequate perfusion can be confirmed.

- The nail bed is then dressed in the standard fashion.
- Recurrent nail growth may be a problem with either method but can be largely avoided by meticulous technique.
- Some patients with in-growing toenails are anxious to retain a toenail.
- It is possible to avulse only a lateral or a medial third of the nail, and then to excise or destroy only that area of germinal matrix.
  Unfortunately, the original problem may recur at the new edge of the nail, and many of these patients will finallyf need a full nail bed ablation.

EYE PROBLEMS

Content

OCULAR TRAUMA

- Depending on the structures involved - Eyelid trauma, Orbital trauma, Eyeball (globe) rupture/ perforation
- Nature of injury - blunt trauma, penetrating injuries and chemical injuries

EYELID INJURY

- Lid laceration occurs in the context of both blunt and sharp injuries

Management

- Repair of eyelid laceration needs the expertise and proper suture material and suturing technique.
- It is best to repair in the hand of an ophthalmologist. (REFER)
- Never cut and throw any periocular tissue.
- As blood supply is abundant in facial area, even a necrotic looking tissue can survive later.
- Check the immune status for tetanus and systemic antibiotics is recommended.

ORBITAL INJURIES

- Resulting in soft tissue oedema and haemorrhage within the non-expansile bony orbit. It is usually associated with facial or head injuries.
- Therefore, it is important to assess any associated life threatening injury (airway, chest or neuro) associated before referring eye centre.

Management

- Prioritize where to REFER the patient.

EYEBALL INJURIES (GLOBE) RUPTURE/PERFORATION

- Injury with blunt objects can result the globe rupture and optic nerve trauma.

PENETRATING INJURY

- Following injury from sharp objects and projectiles with high mass and/or velocity.
- Penetrating injuries are three times more common in males than females, and typically occur in a younger age group (50% aged 15-34).
- The most frequent causes are assault, domestic and occupational accidents, and sport.

Management

- Patch the eye with a clean pad in eyeball injury.
- No eye drops or ointment into the eye is advisable. Then refer the patient to the eye center.
- Health education on use of protective eyewear
- Serious eye trauma from penetrating injuries could be prevented by the appropriate use of protective eyewear at work or during sports activity.

CHEMICAL INJURIES

- May occur in domestic, industrial and military settings, any corrosive agents
- common alkali, oven cleaning fluid, caustic soda and plaster
- Common acids - battery fluid, lavatory cleaning fluid, bleach and pool cleaning fluid

Management

- Can lead to blindness if timely referral and treatment is not possible.
- However, immediate irrigation with any available clean water for at least 30 min at the scene of injury is the most important determinant of outcome.
- Therefore, irrigate copiously in case of chemical injury at least an hour before referring eye center.

RED EYES

CONJUNCTIVITIS

- Bacterial
- Simple bacterial conjunctivitis
- Gonococcal keratoconjunctivitis
- Viral
- Adenoviral keratoconjunctivitis
- Herpes simplex conjunctivitis
- Chlamydial
- Trachoma
- Adult chlamydial keratoconjunctivitis
- Neonatal chlamydial conjunctivitis - Acute, profuse, purulent discharge, hyperaemia and chemosis, Corneal ulceration, perforation and endophthalmitis if severe

Presentations

- Crusted eyelids and conjunctival injection, mucopurulent discharge in Bacterial conjunctivitis
- Vision - unaffected, clear cornea and quiet anterior chamber

Treatment

- broad-spectrum topical antibiotics

Management of viral conjunctivitis

- Most of the conjunctivitis is viral in origin and takes time to resolve totally (two weeks).
- Symptomatic relief is mainly indicated - ample lubricant use and ice compression.
- Simple antibiotic eye-drop can be given to prevent secondary bacterial infection in severe cases, but not always necessary.
- Steroid eye drops should be avoided before proper ophthalmic assessment.
- Simple conjunctivitis never affects the eye sight (except transient blurring from mucous discharge)
- If the course of illness is more than few days or vision is deteriorating or affected from the beginning, please refer the patient to eye centre.

CORNEAL ULCERS

- It is a serious condition and requires ophthalmic REFERRAL
- The injudicious use of topical steroid in corneal infection predisposes to develop corneal ulcers.

CORNEAL INFECTION - KERATITIS

- Bacterial keratitis
- Fungal keratitis

- Acanthamoeba keratitis
- Herpes simplex keratitis
- Herpes zoster keratitis

Presentation

painful red eye with reduced vision in affected eye

BACTERIAL KERATITIS

- Predisposing factors - contact lens wear, defective ocular surface - trauma, post herpetic, exposure, administration of topical corticosteroids
- Staph aureus, Strep pneumoniae: oval, yellow - white, densely opaque stromal suppuration surrounding relatively clear cornea
- Pseudomonus: thick mucopurulent exudates, diffuse liquifactive necrosis and semi- opaque ground glass appearance of adjacent stroma - rapid progression
- Corneal perforation common within 48 hours

Management

- URGENT REFERRAL to ophthalmic centre since hospital admission is advisable in severe cases

ANGLE CLOSURE GLAUCOMA

(see common eye diseases)

EYELID INFECTION & INFLAMMATION

STYLE

- Acute small staphylococcal abscess of a lash follicle and its associated glands.
- Tender inflamed swelling pointing anteriorly through the skin

Treatment

- no treatment is necessary as spontaneous resolution in most cases
- Hot compression, Epilation (removal of lip hair by roots) is helpful.
- Systemic antibiotics are recommended.

CHALAZION

- Chronic lipogranulomatous inflammatory lesion caused by blockage of gland orifices and stagnation of sebaceous secretions
- Presents with painless, roundish, firm nodule

Treatment

- Surgery (incision & curettage)
- Steroid injection
- Systemic antibiotics

EYELID TUMORS

- Numerous benign and malignant cutaneous neoplasms can develop in the periocular skin.
- The malignant lesions that most frequently affect the eyelids are basal cell carcmoma, squamous cell carcinoma, sebaceous cell carcinoma, and melanoma.

Presentations

- slow, painless growth of a lesion
- ulceration, drainage, bleeding, and crusting
- pigmentary changes
- destruction of normal eyelid margin architecture.

Management

- Any benign looking tumors should be monitored with photographic document and regular follow-up.
- Any suspected cutaneous malignancies should be REFERED to the eye center for a biopsy for histologic examination.

LEUKOCORIA (WHITE PUPIL)

What is leukocoria?

Leukocoria literally means "white pupil."
It occurs when the pupil is white rather than the usual black.

How is leukocoria detected?

In obvious cases the pupil may appear white on casual observation.
Sometimes leukocoria is detected from photographs when one pupil has an abnormal or "white reflex" compared to the other eye having a normal "red reflex."

What conditions cause leukocoria?

Leukocoria can be caused by congenital or acquired eye diseases.
This is an ophthalmologic emergency particularly because of the need to promptly diagnose and treat conditions such as retinoblastoma, glaucoma, retinal detachment and infections.

The differential diagnosis

Includes many diseases. Important causes -

- Cataract
- Corneal opacity
- Glaucoma
- Persistent hyperplastic primary vitreous
- Retinal detachment
- Toxocara infection
- Endophthalmitis

RETINOBLASTOMA

Are any of these conditions serious?

All diseases which cause leukocoria represent a serious threat to vision and some pose a threat to life.
Prompt evaluation of leukocoria by an ophthalmologist is always appropriate.

STRABISMUS (SQUINTING EYES)

- What is strabismus and how common is it?
- Strabismus is any misalignment of the eyes. It is estimated that 4% of the population has strabismus.

Types

- Based on direction of the eye misalignment
- Common types of strabismus are

esotropia,

exotropia,

hypertropia,

hypotropia.



Picture credit: www.hollywoodvision.com

Based on its cause

- The 3 cranial nerves (III, IV, VI) responsible for eye movement can be weak or palsied and cause strabismus.
- Some examples of paralytic strabismus include:
- third nerve palsy
- superior oblique palsy.

Special patterns of strabismus:

- Brown syndrome,
- Duane syndrome.

HORIZONTAL STRABISMUS ESOTROPIA

- Inward turning of the eyes
- Infantile esotropia,
- Accommodative esotropia,
- Sixth nerve palsy.

EXOTROPIA

- Outward turning of the eyes

VERTICAL STRABISMUS

- Hypertropia
- Hypotropia

Hypertropia

- is an abnormal eye higher than the normal eye. Hypotropia is when the abnormal eye is lower than the normal eye.

Causes

- Most strabismus is the result of an abnormality of the poorly understood neuromuscular (including brain) control of eye movement. Less commonly, a problem with the actual eye muscle causes strabismus.

Strabismus related to poor vision

- Eye misalignment can cause amblyopia (lazy eye) in children. When the eyes are oriented in different directions, the brain receives 2 different visual images. The brain may ignore the image from the misaligned eye to avoid double vision, resulting in poor vision development of that eye. Also, an eye that sees poorly tends to be misaligned.
- The visual loss from amblyopia cannot be corrected by wearing glasses. However, it is usually treatable.
- If amblyopia is not treated before the age of about 7-8 years, the visual impairment usually remains permanent.

Who develops strabismus as a child?

- Strabismus often occurs in children who are otherwise completely normal.
- However, disorders that affect the brain such as cerebral palsy, Down syndrome, hydrocephalus and brain tumor are more likely to develop strabismus.

Trauma causing strabismus

- Trauma can cause strabismus by
- brain damage that impairs control of eye movement,
- damage of the nerves that control eye movement and/or
- damage of the eye muscles either directly or secondarily from trauma to the eye socket.

Treatment

- The goal of strabismus treatment is to improve eye alignment which allows for the eyes to better work together (binocular vision).
- Treatment may involve eye glasses, eye exercises, prism, and/ or eye muscle surgery. Problems associated with strabismus (including amblyopia, ptosis, and cataract) are usually treated prior to eye muscle surgery.

Is strabismus serious?

- All children with squinting eyes may have threat to vision and prompt evaluation by an ophthalmologist is always appropriate.

Reference

1. Provided by Eye Society, Department of Ophthalmology, Yangon., University of Medicine(]), Yangon Eye Hospital, and Yangon Eye Hospital

COMMON EYE PROBLEMS

REFRACTIVE ERRORS

- Refractive errors are a type of vision problem that makes it hard to see clearly.
- They happen when the shape of eye keeps light from focusing correctly on the retina (a light-sensitive layer of tissue in the back of the eye).
- Refractive errors are the most common type of vision problem.

Types

There are 4 common types of refractive errors:

- Nearsightedness (myopia)
- Farsightedness (hyperopia)
- Astigmatism
- Presbyopia

Symptoms

The most common symptom is blurry vision. Other symptoms include:

- Double vision
- Hazy vision
- Seeing a glare or halo around bright lights
- Squinting
- Headaches
- Eye strain (when eyes feel tired or sore)
- Trouble focusing when reading or looking at a computer
- Some people may not notice the symptoms of refractive errors.

Causes

- Refractive errors can be caused by:
- Eyeball length (when the eyeball grows too long or too short)
- Problems with the shape of the cornea (the clear outer layer of the eye)
- Aging of the lens (an inner part of the eye that is normally clear and helps the eye focus)

Treatment

- Refer to Eye Specialist.
- Eye doctors can correct refractive errors with glasses or contact lenses, or fix the refractive error with surgery.
- Glasses. Eyeglasses are the simplest and safest way to correct refractive errors.
- Eye doctor will prescribe the right eyeglass lenses to give the clearest possible vision.
- Contacts. Contact lenses sit on the surface of the eyes and correct refractive errors.
- Eye doctor will fit for the right lenses and show how to clean and wear them safely.
- Surgery. Some types of surgery, like laser eye surgery, can change the shape of cornea to fix refractive errors.

CATARACTS

- A cataract is a cloudy area in the lens of the eye.
- **Cataracts are very common when get older.**

- At first, the person may not notice that he has a cataract. But over time, cataracts can make the vision blurry, hazy, or less colorful.
- Trouble in reading or doing other everyday activities.
- Surgery can get rid of cataracts. Cataract surgery is safe and corrects vision problems caused by cataracts.

Types

- Most cataracts are **age-related**
- After an eye injury or after surgery for another eye problem (like glaucoma).
- No matter what type of cataract, the treatment is always surgery.
- By age 80, most people either have cataracts or have had cataract surgery

Symptoms

- No symptoms when cataracts are mild.
- When cataracts grow, changes in vision.
- Vision is cloudy or blurry
- Colors look faded
- Can't see well at night
- Lamps, sunlight, or headlights seem too bright
- See a halo around lights
- Double (this sometimes goes away as the cataract gets bigger)
- Change the prescription for glasses often
- Over time, cataracts can lead to vision loss.

Risk for cataracts

- Diabetes mellitus
- Smoke
- Drink too much alcohol
- family history of cataracts
- an eye injury, eye surgery, or radiation treatment on upper body
- spent a lot of time in the sun
- Take steroids (medicines used to treat a variety of health problems, like arthritis and rashes)

Causes of cataracts

- Most cataracts are caused by normal changes in your eyes as you get older.
- Around age 40, the proteins in the lens of the eye start to break down and clump together.
- This clump makes a cloudy area on lens — or a cataract. Over time, the cataract gets more severe and clouds more of the lens.

Prevention

- Protect the eyes and delay cataracts.
- Wear sunglasses and a hat with a brim to block the sun.
- Quit smoking.
- Eat healthy. Eat plenty of fruits and vegetables — especially dark, leafy greens like spinach, kale, and collard greens.
- Get a dilated eye exam. If age 60 or older, get a dilated eye exam at least once every 2 years.

Treatment

- Refer to eye specialist.
- check for cataracts as part of a dilated eye exam
- Surgery is the only way to get rid of a cataract.
- Use brighter lights at home or work
- Wear anti-glare sunglasses
- Use magnifying lenses for reading and other activities
- **New glasses or contacts.** A new prescription for eyeglasses or contact lenses can help to see better with cataracts early on.
- **Surgery.** During cataract surgery, the doctor removes the clouded lens and replaces it with a new, artificial lens (also called an intraocular lens, or IOL). This surgery is very safe, and 9 out of 10 people who get it can see better afterwards.

GLAUCOMA

- Glaucoma is a group of eye diseases that can cause vision loss and blindness by damaging a nerve in the back of the eye called the optic nerve.
- The symptoms can start so slowly that may not notice them.
- There's no cure for glaucoma, but early treatment can often stop the damage and protect the vision.

Types of glaucoma

- There are many different types of glaucoma, but the most common type is called **open-angle glaucoma** .
- Acute angle closure glaucoma
- Less common type, like angle-closure glaucoma and congenital glaucoma.

Symptoms of glaucoma

- At first, glaucoma doesn't usually have any symptoms. That's why half of people with glaucoma don't even know they have it.
- Over time, it may slowly lose vision, usually starting with the side (peripheral) vision — especially the part of vision that's closest to the nose.
- Because it happens so slowly, many people can't tell that their vision is changing at first.
- But as the disease gets worse, it may start to notice that it can't see things off to the side anymore.
- Without treatment, glaucoma can eventually cause blindness.

ACUTE ANGLE CLOSURE GLAUCOMA

- It is the glaucoma from blockage of the angle, from closure of the angle.
- It is characterized by intense pain, in the globe of the eye, in neighboring regions, the forehead, and above the affected eye.
- Sometimes it is located in the tooth area or upper jaw. Other times the picture is accompanied by general with abdominal symptoms. The presence of vomiting is very frequent.

Symptoms

- >40 years, typically elderly, long-sighted worsen with early cataract.

- The patient complains of clouded vision, colored halos around lights, considerable reduction, or loss of sight.

Signs

- Examination will reveal
- Increased intraocular pressure, between 60 and 100 mmHg
- When acute glaucoma continues without treatment with very high pressures for more than 6 h, the optic nerve is definitively damaged and atrophies or becomes complicated with a retinal vascular occlusion.
- Corneal edema, generally subepithelial, which leads to iridescence, clouded vision, or loss of vision.
- Dilated pupil, reduced, and sometimes missing, reaction to light.
- Very flat chamber.

Management

- It is an ocular emergency and needs to REFER URGENTLY. Timely referral and treatment can save the vision.
- Symptomatic treatment for severe vomiting and pain is helpful.

Referral for red eye

- Reduce visual acuity
- Pain deep in the eye not surface irritation as with conjunctivitis
- Absent or sluggish pupil response
- Corneal damage on fluorescein staining
- History of trauma
- Refer the patient to be seen by a specialist the same

Risk factor

- Anyone can get glaucoma, but some people are at higher risk. .Higher risk if
- Are over age 60
- Are African American and over age 40
- Have a family history of glaucoma

Red Flag sign

- Angle-closure glaucoma can cause these sudden symptoms:
- Intense eye pain
- Upset stomach (nausea)
- Red eye
- Blurry vision

Causes of glaucoma

- many people with glaucoma have high eye pressure.

Examination for glaucoma

- Eye specialist can check for glaucoma as part of a comprehensive dilated eye exam.
- The exam includes a visual field test to check your side vision.

Treatment for glaucoma

- **Medicines.** Eye drops are the most common treatment. They lower the pressure in the eye and prevent damage to optic nerve.
- Prostaglandins, like Xalatan (latanoprost), Travatan Z (travoprost), Zioptan (tafluprost), and Lumigan (bimatoprost)
- Rho kinase inhibitor, like Rhopressa (netarsudil)
- Nitric oxides, like Vyzulta (latanoprostene bunod)
- Miotic or cholinergic agents, like Isopto Carpine (pilocarpine)

side effects

- Stinging, itching, burning, and redness in your eye
- Blurry vision
- Changes in your eye color or the skin around your eye
- Headaches
- Dry mouth
- Changes in your energy level, heartbeat, or breathing
- **Laser treatment.** To lower the eye pressure, doctors can use lasers to help the fluid drain out of the eye. It's a simple procedure that the doctor can do in the office.
- **Surgery.** If medicines and laser treatment don't work, your doctor might suggest surgery.

MACULAR DEGENERATION

- Macular degeneration (also called age-related macular degeneration or AMD) is an eye disease that affects the central vision.
- It damages the macula, which is the center area of retina that allows to see fine details. It's the leading cause of vision loss in people over the age of 60.
- Macular degeneration can either be wet or dry.
- Wet AMD happens when abnormal blood vessels grow under the macula and leak blood and fluid. This damages the macula and leads to loss of central vision.
- Dry AMD results in the thinning of the macula, which blurs your central vision over time. Dry AMD is more common than the wet form, accounting for 70% to 90% of cases.
- Symptoms of AMD, which usually aren't noticed until the disease has progressed, include:
- Blurred central vision.
- Black or dark spots in the center part of field of vision.
- Wavy or curved appearance to straight lines.
- Although there is no cure, treatment can slow the progress of disease or prevent severe vision loss.
- Recent advances have been made in the treatment of wet AMD using intraocular injections of anti-VEGF medications.

FLOATERS

- These are tiny spots or specks that float across your field of vision. Most people notice them in well-lit rooms or outdoors on a bright day.
- Floaters are usually normal, but they sometimes can be a sign of a more serious eye problem, like retinal detachment. That's when the retina at the back of the eye separates from the layer

underneath. When this happens, it might also see light flashes along with the floaters or a dark shadow come across the edge of the sight.

- If you notice a sudden change in the type or number of spots or flashes, see or a new dark “curtain" in peripheral vision, go to eye doctor as soon as possible.

DRY EYES

- This happens when eyes can't make enough good-quality tears. It might feel like something is in the eye or like it’s burning. Rarely, in severe cases, extreme dryness can lead to some loss of vision.
- Some treatments include:
    - Using a humidifier in home
    - Special eye drops that work like real tears
    - Plugs in tear ducts to lessen drainage
- Lipiflow, a procedure that uses heat and pressure to treat dry eyes
- Testosterone eyelid cream
- Nutritional supplements with fish oil and omega-3
- If your dry eye problem is chronic, it may have dry eye disease. Eye specialist could prescribe medicated drops like cyclosporine (Cequa, Restasis) or lifitegrast (Xiidra) to stimulate tear production.

DIABETES AND THE EYE

Magnitude of the problem

- Ten percent or more Diabetic patient - visual impairment within 15 years of diagnosis
- Prevalence of Diabetic Retinopathy increases with duration of diabetes and patient age
- Major cause of visual loss in adults (20-64 years - 8% of legally blind) in most of the world is due to Diabetic Retinopathy (DR)

Effects of diabetes mellitus on the eye

- Prolong hyperglycemia can affect the eye
- Anterior segment - cornea epithelial erosion/ impaired healing (diabetic neuropathy), chronic open-angle glaucoma, neovascular glaucoma,transient variations in refractive error - changing glasses too often
- Increased incidence in development of senile cataract
- Posterior segment - Diabetic Retinopathy*
- Orbital / intraocular infection
- Neuro-ophthalmic presentations - ischaemic optic neuropathy, 3rd (pupil sparing), 4th,6th cranial nerves palsies.

DIABETIC RETINOPATHY (DR)

- It is an eye condition that can cause vision loss and blindness in people who have diabetes. It affects blood vessels in the retina (the light-sensitive layer of tissue in the back of your eye).

Symptoms of diabetic retinopathy

- The early stages of diabetic retinopathy usually don't have any symptoms.
- Some people notice changes in their vision, like trouble reading or seeing faraway objects.
- These changes may come and go.
- In later stages of the disease, blood vessels in the retina start to bleed into the vitreous.
- If this happens, it may see dark, floating spots or streaks that look like cobwebs. Sometimes, the spots clear up on their own — but it's important to get treatment right away.
- Without treatment, scars can form in the back of the eye. Blood vessels may also start to bleed again, or the bleeding may get worse.

Other problems associate diabetic retinopathy

- **Diabetic macular edema (DME).** Over time, about 1 in 15 people with diabetes will develop DME. DME happens when blood vessels in the retina leak fluid into the macula . This causes blurry vision.
- **Neovascular glaucoma.** Diabetic retinopathy can cause abnormal blood vessels to grow out of the retina and block fluid from draining out of the eye. This causes a type of glaucoma.
- **Retinal detachment.** Diabetic retinopathy can cause scars to form in the back of the eye. When the scars pull your retina away from the back of the eye, it's called tractional retinal detachment.

Risk for diabetic retinopathy

- Anyone with any kind of diabetes can get diabetic retinopathy — including people with type 1,

type 2, and gestational diabetes, - commoner in type 1 (40%) than in type 2 (20%)

- Duration of diabetes - most important risk factor - incidence of DR after 10 years is 50% and after 30 years 90% in type 1 DM, 5% in type 2 DM at presentation
- Risk increases the longer it has diabetes. Over time, more than half of people with diabetes will develop diabetic retinopathy.
- Women with diabetes who become pregnant — or women who develop gestational diabetes — are at high risk for getting diabetic retinopathy.
- Poor metabolic control and other risk factors - obesity, hyperlipidaemia and anaemia, Pregnancy, Hypertension, Nephropathy
- No prophylactic treatment apart from good metabolic control

Causes diabetic retinopathy

- It is caused by high blood sugar due to diabetes. Over time, having too much sugar in the blood can damage retina
- The damage to the eyes starts when sugar blocks the tiny blood vessels that go to the retina, causing them to leak fluid or bleed.
- To make up for these blocked blood vessels, the eyes then grow new blood vessels that don't work well. These new blood vessels can leak or bleed easily.

Check for diabetic retinopathy

- Eye doctors can check for diabetic retinopathy as part of a dilated eye exam.
- Regular eye exams of diabetes patient is important.
- If develop diabetic retinopathy, early treatment can stop the damage and prevent blindness.
- A fluorescein angiogram test is also important.

Clinical staging

- Non proliferative, proliferative and advanced DR.
- The progression and changes occur in a predictable stepwise fashion.

Clinical importance

- To maintain the good glycemic control
- To identify the stage of diabetic retinopathy when the active intervention is required to prevent further visual loss

DR SCREENING PROGRAM

- Awareness of importance of Screening and regular follow-up
- TIMELY REFERRAL is utmost important since DR is the preventable blindness if treated early
- For treating ophthalmologists, periodic assessment and identification of people at risk and giving in-time treatment
- Beginning 5 years after the onset of diabetes - type I diabetes mellitus
- Patients with type II diabetes mellitus - shortly after the diagnosis of diabetes
- Initial detailed retinal examinations - good peripheral retinal view
- Follow-up visits based on the clinical staging of DR

Management

- Always refer EVERY diabetic patient to eye center and
- check the patient if he or she attends without fail.
- Encourage the patient to attend the eye clinic on next follow-up appointment.

- Keep the blood glucose level as in normal range as possible.

Prevention

- Managing good control of blood sugar levels in a normal range. (A1C goal must be normal)
- Having high blood pressure or high cholesterol along with diabetes increases your risk for diabetic retinopathy.
- So controlling your blood pressure and cholesterol can also help lower your risk for vision loss.

Treatment for diabetic retinopathy and DME

- Good control your diabetes, blood pressure, and cholesterol.
- **Injections.** Medicines of anti-VEGF drugs can slow down or reverse diabetic retinopathy. Other medicines, called corticosteroids, can also help.
- **Laser treatment.** To reduce swelling in retina, lasers can be used to make the blood vessels shrink and stop leaking.
- **Eye surgery.** If retina is bleeding a lot or have a lot of scars in eye ,a vitrectomy surgery may needed.

Reference

1. *Provided by Eye Society, Department of Ophthalmology, Yangon., University of Medicine (1), Yangon Eye Hospital, and Yangon Eye Hospital*
2. *https://www.cdc.gov/visionhealth/basics/ced/index.html*
3. *https://my.clevelandclinic.org/health/diseases/17130-eye-diseases*
4. *https://www.bluecrossmn.com/wellbeing/preventive-care/5-most-common-eye-problems*
5. *https://www.nhs.uk/conditions/glaucoma/*
6. *https://www.mayoclinic.org/diseases-conditions/diabetic-retinopathy/symptoms-causes/syc-20371611*

CHAPTER (20)

EAR, NOSE, THROAT, HEAD & NECK PROBLEMS

Content

Ear Problems

1. Otitis Externa (OE)
2. Otitis Media
    a. Acute Suppurative Otitis Media
    b. Chronic Suppurative Otitis Media
    c. Otitis Media with Effusion
3. Wax
4. Foreign bodies Ear
5. Trauma
6. Hearing Loss
7. Vertigo

Nose Problems

1. Allergic Rhinitis
2. Rhinosinusitis
3. Epistaxis
4. Foreign Bodies Nose
5. Nasal Polyp

Throat Problems

1. Tonsillitis, Tonsillectomy, peritonsillar Abscess
2. Pharyngitis
3. Foreign Bodies Throat
4. Stridor
5. Tracheostomy

Head and Neck Problems

1. Disorders of thyroid gland
2. Cervical Lymphadenopathy

EAR PROBLEMS

OTITIS EXTERNA (OE)

- Inflammation of external ear.

Types:

A. Infective group
   1. Bacterial: Generalized/ localized (Furuncle- Otomycosis)/Malignant
   2. Fungal: Aspergillus Niger, Monilial and other fungi
   3. Viral: Herpes zoster oticus

B. Reactive group
   1. Eczematous OE
   2. Seborrhoeic OE
   3. Neurodeermatitis

Risk Factors:

- Trauma, immunosuppression, DM, eczema, water entering into ear

Symptoms

- Pain: may be severe as skin is adherent to underlying cartilage.
- Discharge
- Deafness- due to collection of discharge. EAC swelling
- Tinnitus
- Itching- often present (may be the cause of OE)

Signs:

- Swelling- generalized/ Localized
- EAC- congested, edematous
- Otomycosis
  - Cotton-like growth- in EAC (Black specks in Aspergillus Niger)
  - Wet newspaper-like mass- multi-colored appearance
- Discharge- present in EAC
- Tenderness- movement of pinna are extremely tender

Treatment:

- Aural toilet- secretions and debris in EAC are removed
- Ear drops- Antibiotic + steroid ear drop - to reduce edema
- Antibiotics- to control infection
- Analgesics- strong analgesics may be needed for severe pain
- Diabetes- if present, should be treated.

OTITIS MEDIA- INFECTION OF MIDDLE EAR

ACUTE SUPPURATIVE OTITIS MEDIA (ASOM)

- common in children, due to their short, wide eustachian tube and presence of adenoids

Stages	C/F	Tympanic Membrane
1. Catarrhal stage	Fullness, severe pain, deafness tinnitus, autophony Constitutional symptoms	Retraction Congestion Loss of light reflex
2.Exudation	All symptoms more severe	Bulging
3.Suppuration	Pain and constitutional symptoms lessen Discharge begins	Perforation Pulsating discharge
4.Healing	Healing may begin from any stage	
5.Complication	Mastoiditis	

Treatment:

- Penicillin therapy, analgesic, antipyretic

CHRONIC SUPPURATIVE OTITIS MEDIA (CSOM)

Aetiology

- Age: all ages
- Sex: Both the sexes are equally affected.

Predisposing Factors:

- Unresolved Acute Otitis Media
- Large traumatic perforation
- Retraction due to Eustachian tube obstruction

Causal Organisms:

- Streptococcal, Staphylococcal, pneumococcal,
- General: Unhygienic conditions, disease of nose, poverty and undernourishment

Types:

Sage (tubo-tympanic)	Unsafe (attico-antral)
Limited to middle ear and Eustachian tube	Destructive chlesteatoma (+) in attic and antrum
Central Perforation	Marginal perforation
Complications very rare	Life-threatening complications
Polyp: occasional	Polyp: common

Clinical Features:

- Discharge, deafness

Diagnosis:

- Otoscopic examination- perforation, discharge Hearing test- Conductive Deafness

Treatment:

- Regular examination under microscope (EUM) and suction clearance Ear drops, antibiotics and analgesics
- Prevent infection from outside- Eustachian tube, mastoid Surgery: Aural polypectomy for drainage, biopsy
- Myringoplasty for persistent perforation and deafness Mastoidectomy for clearance of disease in middle ear cleft (Modified Radical Mastoidectomy)
- Medical treatment should be continued with surgery

Complications:

Intracranial	Extracranial
Meningitis Encephalitis Subdural abscess Extradural abscess Brain abscess Otitis Hydrocephalus	Mastoid abscess and neck abscesses Facial nerve palsy Labyrinthitis Lateral sinus thrombophlebitis

OTITIS MEDIA WITH EFFUSION (OME)

- Common cause of conductive hearing loss

Aetiology:

Eustachian tube dysfunction	**Increased secretory activity of middle ear mucosa**
Adenoid hyperplasia PNS tumor Chronic rhinitis and sinusitis Chronic tonsillitis Palatal defect: cleft palate	Allergy: inhalants/ food

- Glue ear- common 3 to 6 years
- Unlike thin, straw-colored exudate of adult, middle ear fluid in children tends to be tenacious (Glue ear).
- NOT to be ignored because marked and persistent hearing loss may interfere with schooling

Treatment:

Medical	Surgical

• Decongestant
  ○ Nasal drop/spray/systemic
• Antihistamines, steroids
• Antibiotics
	• Myringotomy and aspiration of fluid
	• Grommet insertion
	• Tympanotomy /cortical mastoidectomy
	  ○ removal of loculated thick fluid
	• Surgical treatment of causative factors
	  ○ Adenoidectomy
	  ○ Tonsillectomy

Sequelae:

- Atrophic tympanic membrane and atelectasis of middle ear
- Ossicular necrosis Tympanosclerosis
- Retraction pockets and cholesteatoma

WAX

- Wax is produced in the outer half of the ear canal and migrates outwards along with the canal skin
- Inappropriate instrumentation can cause impaction
- Sudden expansion after getting water in can cause sudden deafness or pain Management: Sodium bicarbonate drops (SBG)

REFER:

- **tympanic membrane perforation or** previous ear surgery (need micro suction)
- only hearing ear
- pain or vertigo,
- Hearing loss persists after wax removal

FOREIGN BODIES EAR

Types:

- Animate
- Inanimate
    - Vegetable
    - Non-vegetable –
        - Compressible
        - Non-compressible –
            - Hard, smooth
            - Sharp, pointed

Clinical Features

- pain, block, deafness.
- F/B (+) in otoscopy

Treatment

- Kill living insect first by fluid & remove
- Requirements –
    - Proper light, instrument, method,
    - Patient's co-operation, skills and experience
    -

REFER

- Impacted, Infected, Bleeding, Perforated ear

TRAUMA

AURICLE

- Blunt: hematoma, perichondritis, cauliflower ear
- Sharp: Lacerated wound, dah cut wound, human bite

Treatment-

- Requires minimal debridement and suturing of perichondrium and skin in alignment.
- Primary closure is successful due to excellent blood supply in this area.
- Plastic repair may be required

Referral:

- When duration is more than six hours.
- Total separation or nearly total separation of auricle in first six hours.
- Need for plastic repair

EXTERNAL AUDITORY CANAL (EAC)

Causes:

- Loss of cotton tipped swab or sharp object to remove wax
- Foreign body in EAC e.g., insect
- Blunt trauma to ear (car accident)
- Sports injury
- Recent head injury
- Recent flying or diving causing barotrauma.

Examination:

- bleeding in ear, Tympanic membrane perforation.

Treatment:

- Sofra-tulle dressing, Ear drops, Hearing assessment later, Health education

TYMPANIC MEMBRANE

- Solid
  - Accidental perforation during ear pricking.
  - Unskilled removal of FB ear.
- Liquid
  - During syringing and Thingyan water festival.
- Air
  - Hand slapping & blunt injury

Management

- Keep ear dry by avoiding instillation of ear drops & water

- Avoid forceful nose blowing
- Systemic antibiotic and analgesic only

Referral

- Patient complained of earache, otorrhea, blood discharge, hearing loss and tinnitus
- Unhealed perforation that needs for myringoplasty

INNER EAR

Causes:

- Head injury especially temporal bone fracture (transverse #).
- Exposure to high decibel noise

High risk for acoustic trauma:

- Work at a job where equipment operates noisily
- Live or work near factory
- Frequently attend music concerts with high decibel noise.

Symptoms:

- Noise-induced Hearing Loss
- Tinnitus

Treatment:

- Can be treated but cannot be cured
- Oral steroids,
- Hearing aids,
- Cochlear implant.

Ear Protection:

- Recommend using hearing protective devices such as ear plug, ear muff
- Regular hearing assessments
- Health education to workers and owner.

HEARING LOSS

Types:

- Conductive Deafness (CD): due to outer ear and middle ear pathologies
- Sensorineural Hearing Loss (SNHL): due to cochlear and retro-cochlear pathologies
- Mixed Deafness (MD): combined CD and SNHL
- Consequences of unaddressed hearing loss:
- social withdrawal and isolation,
- early retirement (Huddle et al, 2017)
- emotional dysfunction,
- depression (Lawrence et al. 2020), and
- mental and physical decline including poor balance and falls.

Highlights

Newborn/ children	children learn to speak by imitating the voices of others such as parents, and those with hearing loss may suffer from delayed speech * If they could have hearing assessments and appropriate interventions such as hearing aids/ cochlear implants in the golden period during which speech and language develops, they can lead the life as their peers with normal hearing. Therefore, every newborn babies should be screened for hearing
School going children	Children and young adult with hearing loss have barriers to communication and learning process. If they can be helped to regain their hearing, better academic results can be achieved. Therefore, every child of school going age should be screened for hearing, better incorporated in school health program.
Adult	loss of productivity and wages,
Older people	increased risk of cognitive decline and dementia and intervention of hearing loss reduces risk of dementia by 8% at population level (Livingston et al, 2020) * should be screened for hearing and interventions provided.

Causes:

Conductive Deafness	Sensorineural Hearing Loss
1.Congenital • atresia of EAC • Ossicular deformity	1.Congenital: • malformation, maternal rubella, Rh incompatibility, birth trauma
2.Infection: • OE, OM, E/T obstruction	2.Infection + metabolic: • Diabetes Herpes zoster, Labyrinthitis
3.Trauma: • TM perforation, foreign body, EAC, ossicular destruction, Severe head injury	3.Trauma: • Noise-induced hearing Loss • Head injury, • Blast injury

Neoplastic: • carcinoma ear, tumor postnasal space, papilloma EAC	Neoplastic: • acoustic neuroma
Miscellaneous: • Wax, Otosclerosis	5. Miscellaneous: • Presbyacusis • Meniere's disease

WHO Classification: Pure Tone Audiogram showing

Up to 25 dB	No Hearing impairment
26 to 40 dB	Mild hearing loss
41 to 60 dB	Moderate hearing loss
61 to 80 dB	Severe hearing loss
>80 dB	Profound hearing loss



https://goo.gl/images/NLqLKK

Definite diagnosis of hearing loss can be made only when the person comes to the diagnostic center for hearing tests. However, we can presume that the person may be hearing impaired by the following conditions. Awareness is a crucial factor. General practitioners with awareness can refer to the diagnostic centers to confirm hearing loss. Another method to identify hearing loss is screening the newborn, school children and adults.

RED FLAGS OF HEARING LOSS

Newborn to 3	No sounds (cooing)/quiet baby; does not react to you
4 to 6 months	No sounds/ quiet baby; no eye contact with you; no attention to voice or music
7 to 12 months	No sound play or bubbling; few vocalization; does not respond to voice or sound
12 to 15 months	No communicative gestures such as pointing or pulling, No response to parent's vocalization; no response to name; no imitative skills, Vocalization with only vowels
15 to 18 months	**No single words** by 16 months no response to directions with cues, No **imitative skills** Limited consonants in speech
18 to 21 months	Few words; **vowel distortions;** limited imitative skills, Limited variety of consonants

21 to 24 months	**Limited spoken vocabulary;** distortions of vowels or sound, Limited variety of consonants, Little response to name, directions, questions
24 to 36 months	**No language** explosion by 30 months; unintelligible speech small vocabulary, No simple 2-word combinations by 27 months Little response to questions or directions by 36 months
48 months	Unable to follow directions involving 3 or more steps no imagination play, no story telling no generation of simple rhymes "cat-bat"
60 months	cannot follow group directions "all the boys get a toy" Does not understand "if-then" ..."If you are wearing runners then line up for gym", Cannot speak to please his/her friends
Adults	Finger rub, Free field test can be considered hearing impaired if there is no response

INVESTIGATIONS

History:

Children
Maternal infection, AN care regular or not, detailed history of delivery, neonatal period, exchange blood transfusion, kernicterus, severe illness, ototoxic drug therapy, delayed milestone and speech and language development, family history of hearing loss, ear trauma, ear infection (CSOM, Otitis Media with Effusion, etc), difficulty in school (Syndromic hearing loss: renal/ cardiac signs and symptoms maybe present)
Adult- Family history of hearing loss, ear infection, ear trauma, severe illness, ototoxic drug therapy, TB, Malaria, exposure to noise (occupational/ recreational)

Examination:

Children: Craniofacial abnormalities, ear abnormalities, ear discharge, wax, foreign bodies, inflammation, tympanic membrane perforation, bulging or retracted TM, fluid or air bubbles
Adult: Ear discharge, wax, inflammation, TM perforation Tuning Fork Tests

	Rinne's test	Webers' test
Conductive deafness	negative	lateralize to bad ear
Sensorineural hearing loss	Positive	lateralize to better ear
Normal	Positive	no lateralized

Treatment

- Treat the cause, such as CSOM, wax, removal of foreign bodies ear
- Hearing aids: according to the audiogram, better fitted by audiologist/ENT specialist
- Implants: cochlear/Middle ear
- Speech therapy

Hearing aids

- Electroacoustic device designed to amplify and modulate sound

Cochlear Implant



Indication for immediate referral

- Babies should be referred as soon as possible to be confirmed of hearing loss so that early intervention could be given.
- Adults with suspected hearing loss should also be referred for further confirmation and treatment.

Health education

- Public should be informed about the impact, possible causes, how to prevent the preventable causes, and to seek proper treatment and rehabilitation

VERTIGO

- Disturbance of sense of equilibrium and movements, where the person feels that either his surroundings are going round him, or he himself is rotating.

Highlights

- Independent of lesion site the underlying pathophysiology is that of asymmetrical neural activity
    - asymmetrical neural activity could occur anywhere from the labyrinth through lesions in the pons and even posterior cerebellum
    - Highly unlikely to get true vertigo from lesion above the level of the pons --- more likely to get imbalance, lightheadedness
    - Highly unlikely to get true vertigo from lesion in area of anterior circulation – carotid arteries

Causes:

Peripheral	Central
• Benign paroxysmal positional vertigo • Labyrinthitis • Meniere's disease • Vestibular neuronitis • Others: Head injury, Drugs	• Migraine • Multiple sclerosis Brain tumor stroke

BENIGN PAROXYSMAL POSITIONAL VERTIGO (BPPV)

One of the most common causes of vertigo, BPPV triggers short-lived but intense vertigo attacks -triggered by

- head's positions (or)
- when you stand up,
- bend over or turn over in bed.

Caused by-

- build-up of fragments (or crystals) within the posterior semicircular canal

Most cases- over 50 years of age

LABYRINTHITIS

- An infection of the inner ear (or labyrinth) most often caused by a viral infection such as a cold or flu
- cause sudden dizziness with a spinning sensation, nausea and unsteadiness.
- also cause hearing loss, tinnitus, ear pain and a raised temperature.
- a few days to a few weeks,
- recurrent symptoms, either spontaneously or when they have another cold or bout of flu.

MÉNIÈRE'S DISEASE

- Rare condition that affects the inner ear that can cause vertigo, tinnitus, ear pressure and hearing loss.
- It can cause sudden and repeated attacks of vertigo, accompanied by nausea and vomiting, that can last from two to 24 hours.

VESTIBULAR NEURONITIS

- is usually caused by a viral infection.

Symptoms:

- vertigo, unsteadiness, nausea and vomiting for a few hours or days

CENTRAL VERTIGO

- Caused by some types of neurological disorders, less common than peripheral vertigo.

MIGRAINE

- Throbbing headache, nausea, vomiting, visual disturbances and sensitivity to light and vertigo.

MULTIPLE SCLEROSIS

- A condition that affects the brain and spinal cord (central nervous system), multiple sclerosis can cause vertigo too in some people.

BRAIN TUMOUR

- Cerebellar tumor, Acoustic neuroma cause vertigo

STROKE

- In transient ischemic attack (TIA or mini stroke), the blood supply to part of your brain has been disrupted temporarily. This can cause dizziness and problems with balance and co-ordination.

Duration of vertigo

Seconds	psychogenic
<one minute	BPPV (Benign Paroxysmal Positional Vertigo)
Minutes	Vascular/ischemic
Hours	Meniere's disease or vestibular migraine
Hours to days	Vestibular neuronitis, central causes possible e.g., stroke, vestibular migraine, multiple sclerosis
Recurrent with headache, photophobia, phonophobia	Vestibular migraine

Examination:

CVS	BP: Standing and supine- 3 minutes for each position *Significant drop in BP 2:20 mmHg (when moving from supine to standing)- presyncope ECG: Heart rate, rhythm Auscultation of the neck: Carotid bruit -to exclude TIA or stroke
Eye	Nystagmus, papilledema

Ear	Inflammation, infection, secretion, malodour, signs of cholesteotoma Herpes zoster vesicles Hearing tests: Pure Tone Audiometry Balance tests: Caloric, Videonystagmography, Head Impulse test* Dix-Hallpike test for benign paroxysmal positional vertigo
Neurological	Motor /sensory changes in face, upper limbs. Cerebellar functions *If present= Central cause

Test for presence or absence of vestibulo-ocular reflex (VOR), a sign of unilateral vestibular dysfunction
Nystagmus- involuntary, rapid and repeated movement of the eye

Peripheral- horizontal Central- Vertical

Investigations:

- Laboratory: Hemogram, glucose tolerance test, VDRL, Thyroid function tests Imaging: Mastoid X' ray, Cervical spine and skull, CT/ MRI head

Treatments for vertigo:

1. Specific: If there is a cause, it should be treated
   - Acute vestibular neuritis- corticosteroids, antihistamines, vestibular rehabilitation where brain is 'retrained' to adapt and rely on the signals from other parts of the body than the inner ear.
   - BPPV- Epley manoeuvre (a series of 4 head movements holding for at least 30 seconds), If ineffective, Brandt-Daroff exercises which can be done at home. Vertigo persists for months, or years may need surgery.
   - Labyrinthitis- wait to clear up viral infection and vestibular rehabilitation
2. General treatment:
   - Avoid stressful situations
   - Give up smoking- Nicotine in tobacco smoke causes vasoconstriction reducing blood supply to inner ear.
   - Drink less alcohol-

Ménière's disease





Red flags in vertigo diagnosis

Indicating possible serious underlying cause

1. Vertigo that continues for several signs
2. Nystagmus that is down-beating and continuing unremitting headache and nausea
3. Ataxia, cerebellar signs
4. Progressive hearing loss
5. Signs of suppurative labyrinthitis: bulging, erythematous tympanic membrane, fever, balance disturbance

NOSE PROBLEMS

ALLERGIC RHINITIS

- Ig E mediated type I hypersensitivity disease of mucous membrane of nasal airways characterized by
    - Sneezing
    - Itching
    - Watery nasal discharge and nasal congestion
- Associated with conjunctivitis and asthma
- Occurs in atopic individuals who are exposed to common aeroallergens

Classification:

1. Based on triggering allergens-
    a. seasonal (Hay fever due to pollen, grass)
    b. Perennial due to hypersensitivity-
    c. House dust mite, domestic pets, cockroach
2. Based on duration of clinical symptoms –
    a. periodic/ chronic
3. Based on intensity of symptoms-
    a. Mild, Moderate to severe

Clinical Features:

- Eye:
    - long, silky eyelashes
    - Dennie's Lines- horizontal lines in lower eyelids (allergic shiners) Conjunctivitis' burning & itching
    - Lymphoid aggregates on palpebral conjuntivitis
- Nose:
    - itching
    - Allergic salute and supratip crease associated with itching and rubbing: the hand lifts the nasal tip to respond to itching while temporarily opening the nasal airway.
    - Repeating this maneuver causes transverse nasal crease. Facial grimacing due to itching
    - Nasal obstruction due to enlarged inferior turbinate, sneezing,
- Mouth:
    - mouth breathing, palatal itching, nocturnal tooth grinding
- Pharynx:
    - Irritated sore throat, repeated throat clearing,
- Larynx and lungs:
    - Hoarseness, Asthma, wet cough esp. mold allergy Diagnosis:
- History:
    - inquire about - diet, pets, fumes, dust, cosmetic, soap, powder,
    - family history of AR

Clinical classification-

Intermittent	Persistent
Symptoms <4 days a week along the year Or Symptoms daily but for <4 weeks a year (<4 days a week, <4 weeks a year)	Symptoms occur daily for over 4 days a week Or >4 days a week or >4 weeks a year (>4 days a week, >4 weeks a year)

- Examination: Characteristic appearance of nasal mucosa and note presence/ absence of ethmoid polyp, hypertrophic turbinate, discharge
- Skin tests by intradermal injections
- Radio allegro sorbent test (RAST)- sensitive invitro test for assay of specific antibodies

Treatment:

- Avoiding the allergens or desensitization against allergen- ideal treatment.
- Symptomatic: Next-generation ARIA-GRADE guidelines
    - Pharmacotherapy for AR patients is considered to control the disease. It depends on patient empowerment and preferences, prominent symptoms, symptoms severity and multi-morbidity, efficacy and safety of the treatment, speed of onset of action of treatment, current treatment, historic response to treatment, impact on sleep and work productivity, self-management strategies and resource used.
- Antihistamines:
    - control the wet symptoms - rhinorrhea, sneezing, itching mucus membrane
    - 1st generation:
        - chlorpheniramine, brompheniramine, triprolidine
        - Compete with histamine for receptor site on target organ
        - SE: sedation due to BBB crossing, anticholinergic effects such as bladder neck obstruction, prostatism, excessive dryness, prolonged use- tachycardia.
    - 2nd generation:
        - Terfenadine, Astemizole, Loratadine, Cetrizine, Acrivastine
        - Non-sedative due to not crossing BBB, direct effect on allergic mediator
        - less pronounced anticholinergic effect, lack of tachyphylaxis
        - Terfenadine, Astemizole- increased risk of cardiac arrhythmias esp. when administered with macrolide antibiotic and antifungal.
    - 3rd generation:
        - Livostine, Azelastine: topically
- Designer antihistamine: Telfast
    - Fexofenadine- better safety profile, no anticholinergic activity with rapid onset of action
- Decongestant-
    - systemic:
        - Pseudoephedrine, Phenyl Ephrine alfa-adrenergic agonist-
        - oral route
        - S/E: increase BP, insomnia
    - Topical: Oxymetazoline, phenylephrine, Xylometazoline
        - Potentially addicting
        - (Should not use >5 to 7 days and not >3 times/day)
- Mast cell stabilizer:
    - Cromolyn sodium (4% spray)- prophylactically 3-4 times/day
- Corticosteroid:
    - Topical for acute phase and systemic for late phase Short acting: cortisone, hydrocortisone
- Intermediate acting:
    - prednisolone, methylprednisolone, triamcinolone Long acting: dexamethasone,

betamethasone

- Topical steroid-
  - minimize SE and systemic toxicity e.g., Fluticasone, budesonide, triamcinolone acetate
- Anticholinergic:
  - Systemic - profound over drying effect, provoke nasal crusting, thick nasal and sinus secretion
  - Topical - ipratropium bromide- decrease rhinorrhea, but not relieve congestion, sneezing, itching
- Immunotherapy:
  - when patients fail to respond to conventional therapy, specific allergen is administered with incremental dose resulting in decreased clinical symptoms.

RHINOSINUSITIS

- Rhinosinusitis can be defined as the inflammation of the lining of the nose and paranasal sinuses characterized by one or more of the following symptoms.

MAJOR SYMPTOMS	MINOR SYMPTOMS
• Facial pain/pressure • Facial congestion/fullness • Nasal obstruction/blockage • Nasal discharge/purulence/discolored posterior drainage • Hyposmia/anosmia • Purulence on nasal examination • Fever (acute RS only)	• Headache • Fever (nonacute) • Halitosis • Fatigue • Dental pain • Cough • Earpain/pressure/fullness

*Requires two major factors, **or** one major and two minor symptoms for diagnosis.*

Causes	Predisposing Factors
1. Acute rhinitis 2. Dental infection 3. Pharyngeal infection 4. Trauma 5. Swimming and diving 6. FB nose	Poor general environment (poor housing) Prolonged exposure to large number of people, cold, Obstruction due to nasal polyp, tumor, deviated nasal septum, enlarged middle turbinate Impaired clearance due to -ciliary dyskinesia (immotile cilia syndrome & Kartergener's syndrome) - impaired immune status

Clinical Features:

General symptoms	Local symptoms
-Malaise - Fever -Headache - General toxemia	-Nasal discharge, postnasal drip -loss of smell, cacosmia -epistaxis -Pain

Investigations:

- Nasal Endoscopy: plays a key role on identifying anatomical structural variations and mucosal

changes of middle meatus and osteomeatal complex causing drainage block leading to chronic Rhinosinusitis (CRS)

- Radiology: Sinus X-ray, CT nose and paranasal sinuses

Treatment

Medical:

- Analgesic,
- Antibiotic: Minimum 2 weeks or more
  - Oral Amoxicillin/clavulanate drug of choice
  - Dental origin – caused by anaerobic organism & mixed flora
  - give – Amoxicillin & metronidazole, coamoxiclav, clindamycin
- Decongestants: oxymetazoline and xylometazoline hydrochloride * Not > few weeks
- Mucolytic: Guaiphenecsin, Acetyl cysteine & carbocysteine
- Nasal toilet: saline spay or irrigation clear thick nasal and sinus secretion
- Corticosteroid: reduces mucosal swelling

Surgical treatment:

- when medical treatment fails
- correction of predisposing factor
- removal of primary inflammatory focus
  - *Functional Endoscopic Sinus Surgery*
  - Preserve normal structures
  - Reduce bacterial or fungal load
  - Allow post-op medical and surgical management
  - Restore physiological mucous clearance



EPISTAXIS: BLEEDING FROM THE NOSE

- 90% of cases occurs in Kiesselbach's plexus, localized at the anterior portion of the septum (Little's area).

Causes:

Local	Systemic
1. Congenital: Osler's d/s 2. Traumatic: injury to nose, head, post-op, nose picking 3. Inflammatory: Acute: nasal diptheria, acute vestibulitis, acute rhinitis & sinusitis, adenoids Chronic: Chronic rhinitis & sinusitis, atrophic rhinitis, TB, syphilis, leprosy 4. Tumors: Nasopharyngeal angiofibroma, angioma 5. Miscellaneous: Foreign bodies, Rhinolith, Vicarious menstruation	1. Hypertension 2. Bleeding disorders 3. Increased pressure in superior Vena Cava (mitral stenosis, Superior mediastinal tumor, Whooping cough, pneumonia) 4. Environmental: high altitude 5. Infections: Influenza, measle, enteric fever, rheumatic fever 6. Drugs: salicylate, anticoagulant, quinine 7. chronic kidney disease:

Management

(1) Immediate management

- Pinch nose with thumb and index finger for about 5 minutes
- Trotter's Method: Patient is made to sit leaning a little forward over a basin to spit any blood and breathe quietly from the mouth
- Cold compress: to cause vasoconstriction

- If not controlled- nasal packing
  - Anterior: Merocel
- If persists-
  - posterior packing: Foley catheter, double balloon device



Epistaxis balloon. Smaller (10 ml) posterior balloon and bigger (30 ml) anterior balloon are inflated. Channel of catheter provides airway for nasal breathing

(2) General management:

- Antihypertensive, haemostatic drug, sedation, replacement of loss Transfusion of blood or blood substitute if necessary
- Administration of hemostatic agents if there is deficiency. Sedatives. Systemic antibiotics

(3) Definitive management:

- Cauterization of bleeding point
- Investigation and treatment of underlying causes

Refer when:

- Bleeding cannot be controlled by any means
- Repeated attack of bleeding which need to find out the cause

For proper investigation and management

- History: Blood loss – onset, amount, site, general condition, past medical and surgical history
- Examination: Airway patency
- Anterior rhinoscopy: Bleeding, discharge

FOREIGN BODIES NOSE:

- Usually seen in children
- Common types are paper, seeds, buttons, pebbles, eraser, etc.

Suspect if presents with

- Foul smelling of one side of the nose
- Blockage of one side of the nose
- Blood- stained nasal discharge

On examination:

- Foreign body is seen in the nasal cavity which may be covered by discharge Excoriation of the nasal vestibular skin and upper lip may be present

Treatment:

- Good light and proper restraining of the child are essential
- In cooperative child, removal can be done in out-patient setting But uncooperative child may need GA
- During removal under GA, there is a risk of foreign body inhalation The other nostril must be examined to exclude a second foreign body
- Foreign body (battery) should be removed urgently

Refer when:

- FB impacted on swelling blocked for introduction of instrument Posteriorly placed FB
- Battery and buttons in nasal cavity

NASAL POLYPS

- non-neoplastic masses of edematous nasal or sinus mucosa

Aetiology

- Inflammatory condition of nasal mucosa: Rhinosinusitis
- Disorders of ciliary motility: Kartagener's syndrome
- Abnormal composition of nasal mucus: Cystic fibrosis
- Associated with - asthma, aspirin tolerance, chronic rhinosinusitis, Young syndrome, cystic fibrosis, Kartagener's syndrome

Pathogenesis:

- Nasal mucosa becomes edematous due to collection of ECF leading to polypoidal change, may become pedunculated due to gravity and excessive sneezing
- Early stage: surface of nasal polyp is covered by ciliated columnar epithelium. In response to atmospheric irritation, metaplastic changes to transitional and squamous epithelium
- Submucosa: Large ICS filled with serous fluid and infiltration with eosinophils and round cells

Site of origin:

- Lateral wall of nose, usually from middle meatus

Symptoms:

- Mostly seen in adult
- Nasal stuffiness leading to nasal obstruction
- Partial/total loss of smell
- Headache (associated with sinusitis)
- Sneezing and watery nasal discharge (associated with allergy)
- Protruding mass

Signs:

- Polyp appears as –
    - smooth, glistering Grape-like masses, pale in color
    - May be sessile or pedunculated
    - Insensitive to probing
- Do not bleed on touch
- Often multiple and bilateral
- May protrude from nostril and appear pink and vascular, simulating neoplasm
- Purulent discharge (associated sinusitis)
- Broadening of nose in long standing case

Diagnosis:

- Clinical examination, CT paranasal sinus, Histology

Treatment:

- Conservative:
    - Antihistamine to control allergy
    - Short course of steroid (associated with asthma)
- Surgery:

- Polypectomy, Endoscopic Sinus Surgery

Antro-choanal polyp:

- arise from mucosa of maxillary antrum and grows in the choana and nasal cavity, usually single, unilateral
- Parts-
  - Antral (thin stalk), choanal (round and globular), nasal
- Symptoms:
  - unilateral or bilateral nasal obstruction, nasal discharge
- Signs:
  - posterior rhinoscopy- globular mass filling choana
  - A large polyp may hang down behind soft palate and present in oropharynx
- Treatment:
  - Endoscopic Sinus Surgery

	Ethmoid polyp	AC polyp
Age	Common in adults	Common in children
Etiology	Allergy/ multifocal	Infection
Number	Multiple	Solitary
Laterality	Bilateral	unilateral
Origin	Ethmoidal sinus	Maxillary sinus
Growth	Mostly anteriorly, may present at nares	Backwards to choana, hang down behind soft palate
Size and shape	Usually small ± grape-like masses	Trilobed
Recurrence	Common	Uncommon if removed completely
Treatment	Polypectomy, endoscopic surgery	Polypectomy, endoscopic surgery

THROAT PROBLEMS

TONSILLITIS

- Tonsils - large lymphoid tissue situated in the lateral wall of oropharynx form lateral part of Waldeyer's ring occupy the tonsillar fossa between diverging palate-pharyngeal and palatoglossal folds

ACUTE TONSILLITIS

- Mainly a disease of childhood but is also seen in adults. May occur primarily as infection of the tonsils themselves or may occur as a result of URTI following viral infection.
- Organisms: Beta-hemolytic streptococcus, Staphylococcus, Hemophilus influenzae Pneumococcus

Symptoms:	Signs
Discomfort in throat Difficulty in swallowing Generalized body ache Fever Earache and Thick speech	Swollen congested tonsils with exudates Enlarged tender Jugulo-digastric lymph nodes

Complications:

1. Local: spread of infection and inflammation to the hypopharynx and larynx
   may occasionally produce increasing respiratory obstruction
2. Peritonsillar abscess means that infection has spread outside tonsillar capsule.
   Spread of infection from tonsil or more usually from a peritonsillar abscess through the superior constrictor muscle of the pharynx first results in cellulitis of the neck and later in parapharyngeal space abscess
3. Systemic or general complications- rare
   Septicemia: untreated acute tonsillitis can result in septicemia with septic abscess, septic arthritis and meningitis.
4. Acute rheumatic fever and glomerulonephritis
   - follow infection with Beta-hemolytic streptococcus.
   Antibodies produced against the streptococcus may in some instances cross react with patient's own tissue.

Treatment:

- Bed rest, plenty of fluids
- Analgesic: paracetamol
- Antibiotics: Penicillin- drug of choice x 7-10 days.

Complications:

- Chronic tonsillitis, Peritonsillar abscess, Parapharyngeal abscess, cervical abscess
- Acute Otitis Media, Rheumatic fever, acute glomerulonephritis, subacute bacterial endocarditis

TONSILLECTOMY

Indications

- Local:
- Obstructive Sleep Apnea
- Repeated attack of acute tonsillitis
- Chronic tonsillitis.
- Peritonsillar abscess.
- Enlarged tonsil causing snoring, speech problem, suspicious of malignancy.
- Focal: Septic focus for Rheumatic fever or Nephritis Contraindications: Acute stage of tonsillitis, Blood dyscrasia, Polio endemic.

Complications:

- Bleeding, Pain, Infection, Trauma

PERITONSILLAR ABSCESS (QUINSY)

- collection of pus between fibrous capsule of the tonsil usually at its upper pole and the superior constrictor muscle of pharynx.

Clinical features

- repeated attacks of acute tonsillitis.
- Preceded by a sore throat for 2-3 days
- ill with fever, often a headache and severe throat, referred otalgia
- pain and swelling in the neck due to infective lymphadenopathy

Signs-

- Ill looking patient, Pyrexia, severe trismus. oedema and hyperemia of the soft palate Enlarged hyperemic and displaced tonsil,
- Usually enlarged lymph nodes in JD region

Treatment:

- Admitted to hospital
- analgesics and antibiotics
- early peritonsillar abscess (peritonsillar cellulitis)- incision and drainage are not recommended
- I/D - undertaken at the point of maximum bulge.
- Interval tonsillectomy after 6 weeks

Complications:

- potentially lethal condition
- Pharyngeal & Laryngeal oedema, Parapharyngeal space abscess
- Pharyngitis-inflammation of pharynx

ACUTE PHARYNGITIS

- a sudden painful inflammation of pharynx,

Causes:

- Viral: adenovirus, influenza virus, Epstein-Barr virus, herpes simplex virus.
- Bacteria: Group A streptococcus (GAS), Mycoplasma pneumoniae, Neisseria gonorrhoeae, influenzae type B

Clinical features:

- Pain (body, swallowing), dry cough, fever, edema, Redness and swelling in tonsillar pillars, uvula, soft palate Lymph node enlargement

Diagnosis:

- History, physical examination, culture and sensitivity test, blood tests, Rapid streptococcal antigen test

Treatment:

- Antibiotics-
    - Doxycycline 100 mg twice daily for 5-7 days Azithromycin once daily for 3 days Cefuroxime for 5-10 days
- Anti-inflammatory: ibuprofen
- Potassium permanganate gargle
- Soft, bland. Warm diet

CHRONIC PHARYNGITIS

- Persistent inflammation of pharynx, characterized by multiple, white elongated keratinized epithelial outgrowths project from the surface of tonsil, base of tongue or posterior pharyngeal wall.
- common in adults who work in dusty surroundings, use their voice to excess, suffer from chronic cough
- Habitually use alcohol and tobacco.

Types:

- **Hypertrophic:** General thickening and congestion of pharyngeal mucus membrane
- **Atrophic:** Mucus membrane – thin wrinkled
- **Chronic granular (Clergyman's sore throat):** Numerous swollen lymph follicles on pharyngeal wall

Clinical features:

- Foreign body sensation
- Constant sense of irritation/ fullness in the throat

Treatment

- Avoidance of exposure to irritants, correct URTI
- Nasal decongestants
- Antihistamine, pseudoephedrine

- Aspirin/ acetaminophen
- Tonsillectomy

FOREIGN BODIES THROAT

- FB in oropharynx: Sharp - fish bone, pins, wires
- Blunt - coins, chicken bone, duck bones, Meat bolus Site of impaction: Tonsils, posterior 1/3 of tongue, post-cricoid, pyriform Management:

Confirmed by:

- History, oral examination, palpation
- Advice to stop further swallowing of banana and rice ball
- Radiological confirmation
- Removal with forceps

Refer:

- When F/B is in posterior 1/3 of tongue or post- cricoid.
- Present of F/B on lateral neck X ray film.
- Tenderness on palpation of neck.

Complications:

- Retro-pharyngeal abscess
- Para-pharyngeal abscess

FB IN TRACHEA-BRONCHIAL TREE:

- Vegetable- ground nut, Auza seeds
- Non-vegetable- plastic ball, candy

Management:

- As an emergency, hanging of patient upside down & slapping of the back in small children.
- Heimlich manouvre in older children & adults

Inhaled foreign body



Management of a foreign body.

Abdominal thrusts using the Heimlich manoeuvre in older children to expel an inhaled foreign body. One hand is formed into a fist and placed against the child's abdomen above the umbilicus and below the xiphisternum. The other hand is placed over the fist. Both hands are thrust into the abdomen. This is repeated several times. The child can be standing, kneeling, sitting or supine.



In infants, back blows and chest thrusts are recommended to expel an inhaled foreign body. Abdominal thrusts are best avoided in infants as they may cause intra-abdominal injury.

Refer

- Presence of noisy breathing.
- Sign of respiratory distress
- Reduced movement of right side of the chest (or) reduced air-entry to right side of the chest

STRIDOR

Noisy breathing due to partial upper airway obstruction.

Causes:

- Congenital: Laryngomalacia (soft larynx), Laryngeal stenosis.
- Trauma: Ext –blow, Int-F/bs.
- Infections:
    - Acute Epiglotitis, Diphtheria, Acute laryngo-tracheobrochitis, Ludwig's angina-
- Neoplasia: papilloma, carcinoma. Neuro…bilateral vocal cord palsy, bulbar palsy,
- Miscellaneous: Angioneurotic edema.

Management:

Emergency management-

- Relief of stridor is more important than diag.
- Oxygen inhalation.
- Tracheostomy –Don't wait for obvious cyanosis which may be very late.

Definitive treatment.

- Confirm the cause of stridor-
    - history (onset, duration, associated symptoms)
    - Examination: general condition, severity, cyanosis
    - ENT- IDL, MPL, neck exam
    - Radiological- Neck, chest, CT, MRI
- Remove the causes.
- Regular follow up.

HEAD AND NECK PROBLEM

DISORDERS OF THYROID

- Benign disorder
  - Hypothyroidism
  - Hyperthyroidism
- Malignant disorder (Thyroid cancers)
  - Well differentiated
  - Papillary
  - Follicular
  - Hurtle cell Carcinoma
- Undifferentiated
  - Anaplastic
- Medullary
- Lymphoma
- Metastatic to thyroid

HYPOTHYROIDISM

- due to low levels of thyroid hormones

Causes:

- Iodine deficiency (most common),
- Hashimoto thyroiditis,
- subtotal/Total thyroidectomy,
- radiation to neck as for lymphoma or head and neck cancers
- radioactive iodine for Graves' disease
- drugs inducing hypothyroidism (amiodarone, lithium) and antithyroid drugs
- Goitrogenic substances in diet

Signs and Symptoms:

Symptoms	Signs
- fatigue and weakness - intolerance to cold - dry skin - coarse and sparse hair - hoarseness - poor memory and lack of concentration - weight gain - excessive menstrual bleeding followed by oligomenorrhoea/ amenorrhea - constipation - Hearing loss	- dry and coarse skin - puffy face - puffiness of hands and feet - bradycardia

Treatment:

- Exogenous thyroid hormone

SIGNIFICANCE: NEONATAL HYPOTHYROIDISM

- It can occur in neonates (1:5000) and thus there is need to test them after birth. Cretinism causes lethargy, stunted growth, mental retardation, and hearing loss.

Causes:

- Inadequate iodine in mother's diet
- Administration of anti-thyroid drugs or radioactive iodine to mother to treat her thyrotoxicosis
- Agenesis of thyroid in the infant
- It is therefore essential for all pregnant mothers to maintain euthyroid state.

HYPERTHYROIDISM

- due to high levels of thyroid hormones.

Causes:

- Graves' disease- autoimmune disorder
- Toxic multinodular goiter
- Autonomous nodule
- TSH-secretory pituitary tumor
- Functioning thyroid cancer/ metastases
- Exogenous intake of thyroid hormone

THYROIDITIS

GRAVES' DISEASE

- features of hyperthyroidism, goiter, opthalmopathy, uncommon dermopathy
- women: men= 5;1 to 10:1
- caused by antibodies against TSH receptors. When antibodies react with receptors, thyroid cells are stimulated to form excess thyroid hormones.

Symptoms	Signs
Nervousness, irritability, hyperactivity, heat intolerance and sweating, weight loss despite increased appetite, diarrhea, palpitation, fatigue/weakness, oligomenorrhea	Tremors, warm moist skin, tachycardia, atrial fibrillation, diffuse/nodular goiter, diffuse alopecia, high pulse pressure, Graves' disease only: Lid retraction, exophthalmos, periorbital edema, thyroid dermopathy (myxedema)

Diagnosis-

- C/F of hyperthyroidism
- Lab tests: TSH is suppressed. T4 (free and bound) is raised.

MALIGNANT DISORDERS

Sex -	Female: Male = 2 to 4: 1 Genetic factor-plays a part
Type:	Papillary Carcinoma (65-70%), Follicular (10-15%), Anaplastic (<5%), Medullary (5%), Lymphoma
Age:	PCT-3rd to 4th decade, Follicular-at age 50, Anaplastic- 60-80 years, MCT-50 to 60 years, Lymphoma- 60-80 years
Sex (Female:Male):	PCT-2 to 3:1, Follicular-3:1, Anaplastic-3:2, Medullary- 1:1 Lymphoma-3:1
Risk factors:	Ionizing radiation and familial (5-10% - family history of thyroid CA) Arise from: Follicular cell-PCT, follicular carcinoma Parafollicular C cell- Medullary B cell-Non-Hodgkin Lymphoma (pre-existing Hashimoto thyroiditis)

Clinical feature

PCT:	Asymptomatic mass in thyroid, Metastatic nodes in the neck, Symptoms of local invasion, Pulmonary/bone metastasis
Follicular:	Solitary thyroid nodules, Distant metastasis due to blood spread 10-15%
Anaplastic:	Aggressive- stridor, dyspnea, dysphagia, LN involvement 80%, Distant metastasis-brain, bone
Medullary:	Aggressive- Neck mass with cervical nodes Types: sporadic 80% and unifocal 20% Included in MEN IIa and MEN IIb
Lymphoma:	Rapidly growing painless thyroid mass…. invades surrounding structures causing stridor, hoarseness, dypsnea, dysphagia

Treatment:

- Surgery- Lobectomy/Near Total Thyroidectomy/Total Thyroidectomy
- Neck Dissection if cervical LNs are palpable

Prognosis:

- PCT- favorable, Follicular, Anaplastic, Medullary- poor

LYMPHADENOPATHY

- The majority of neck nodes in children are benign; the majorities in adults are malignant.

INFECTIVE LYMPHADENOPATHY:

- Non-specific: Jugulo-digastric node enlargement during tonsilitis
- Specific: TB, HIV, Toxoplasmosis, Brucellosis, glandular fever

Diagnosis

- blood test and CXR, FNAC and even excision biopsy may be needed to exclude malignancy.

NEOPLASTIC LYMPHADENOPATHY:

- Lymphoma- primary malignant tumour of the lymphatic tissue.

Clinical features:

- Multiple nodes of a rubbery consistency.
- night sweats ± weight loss, axillary or groin nodes, and lethargy.

Investigation:

- FNAC may be suspicious of malignancy, but an excision biopsy is often required to confirm the diagnosis and allow for sub typing.
- Blood tests- FBC, ESR/CRP, Paul- Bunnell/monospot/IM screen, Toxoplasma, HIV test.
- A CXR and/or a Chest CT scan may be done, or, for staging, a CT scan of the abdomen or pelvis.
- Bone marrow may be needed for staging.

Treatment

- REFER to Hematology & Oncology
- May involve chemotherapy and/or radiotherapy. The patient may need a lymphoma Multi-Disciplinary Team review.

SQUAMOUS CELL CARCINOMA:

- primary muco-cutaneous malignancy which commonly spreads to local lymph nodes.
- Single or multiple nodes.

Clinical features:

- ENT - related symptoms such as a sore throat, a hoarse voice.
- The nodes may have a firm or hard consistency. The patient may have a history of smoking.

Investigations:

- FNAC,
- ENT examination looking for ENT primary carcinoma
- CT or MRI scan of the neck, a CT scan of the chest and/or CXR (metastases), a pan- endoscopy and excisional biopsy.
- Where no ENT primary is seen on examination, a rigorous search should be done for a silent tumor. This will usually involve imaging as above with ipsilateral tonsillectomy, biopsy of the tongue base, post-nasal space and piriform fossa as a mm1mum.

Referral

- Any inflammatory mass persistent beyond 3 weeks with antibiotic treatment
- Lump associated with hoarseness and persisting for >3 weeks; with or without CXR being suggestive of upper aerodigestive tract malignancy
- Suspected infectious mononucleosis or Tuberculosis

CONGENITAL

- Persistent neck mass (non-inflammatory) beyond 4-6 weeks
- Mass is rapidly enlarging with or without inflammatory and/or fixe
- Mass is in the thyroid gland
- Mass is in the parotid gland
- Lump associated with features of malignancy
    - oral mucosa ulcer >3 weeks,
    - oral swelling >3 weeks,
    - red or red & white patches of oral mucosa,
    - dysphagia >3 weeks,
    - unilateral nasal obstruction with purulent discharge,

- cranial neuropathies,
- orbital mass,
- lymphadenopathy (> **1 cm**) persisting more than 6 weeks,
- hepatosplenomegaly,
- features of thyroid malignancy
- Lump presenting with stridor

EMERGENCY MEDICINE

- Shock
- Anaphylaxis
- Adult Basic Life Support
- Acute Chest Pain
- Pulmonary Embolism
- Pneumothorax
- Status Asthmaticus in Adult
- Thyroid Crisis
- Snake Bite
- Insect Bite and Sting
- Acute Poisoning and Overdose
- Surgical Emergencies – Refer to Surgical Section Chapter
- Obstetrics Emergencies
- Acute Asthma in Children
- Convulsion / Febrile convulsion
- Management of Child with Shock
- Fractures
- Essential Trauma Care
- Head Injury
- Chest Trauma
- Abdominal and pelvic Trauma
- Limb Trauma
- Drowning
- Electrical Injuries
- Chocking

SHOCK

Definition

- Shock is a state of inadequate perfusion to vital organs, resulting in hypotension (systolic BP <80-90 mmHg) and reduced urine output.

Causes

- Anaphylactic shock
- Hypovolaemic (bleeding, fluid loss, heat exhaustion)
- Cardiogenic shock (pump failure, dysarrhythmia, AMI)
- Septic shock
- Obstructive cause (cardiac tamponade, pulmonary embolism)
- Adrenal failure

How to get diagnosis

- While conducting history taking and examination (rapid assessment), initial resuscitation should be done at the same time.
- Putting large bore cannula/cannulae & set up IV line (Normal Saline or Colloid). Give 100% 0_2 If available.

ANAPHYLACTIC SHOCK

- Rapid onset of shock with preceding history of i.v/oral drugs (or) food and food additives (or) insect bites (IM Diclofenac injection often causes hypotension in febrile patients)
- Difficult breathing, wheeze, feeling that throat is closing, tachypnoea, cyanosis (late)
- Pallor, clammy, tachycardia, agitation, confusion, urticaria, flushing, angioedema
- Abdominal pain, vomiting or incontinence

CARDIOGENIC SHOCK

- History of chest pain, dyspnoea, palpitation, past history of IHD, valvular heart, cardiovascular risk factors, alcohol history
- Dyspnoea ± Cyanosis, cold &clammy extremities, tachycardia (or) bradycardia (or) irregular heartbeats, displaced apex beat (If structural heart disease) present
- Raised JVP and basal crepitation may or may not be present.

SEPTIC SHOCK

- Ill toxic, T >38 °C or <36 °C
- Widened pulse pressure, tachypnoea, mental obtundation or agitation
- ± Acidotic breathing
- [Source of sepsis: obvious infection source like may cellulitis gangrene or hidden infection, biliary sepsis, pyelonephritis and in the patients of reproductive age - don't forget septic abortion]
- The old (or) immunocompromised patient may not have fever.

HYPOVOLAEMIC SHOCK

- History of diarrhea, vomiting, dehydrated skin turgor, (or) obvious bleeding like GI bleeding

(or) menorrhagia

- Hidden bleeding like leaking abdominal aortic aneurysm, splenic rupture, haemorrhage from HCC, 3rd space loss (acute pancreatitis). Undue pallor and tachycardia lead to diagnosis of blood loss.

HYPOADRENALISM

- Lethargy, weight loss, skin crease/scar pigmentation, hypotension, hypoglycemia,
- Tuberculous adrenalitis is not uncommon.

DIAGNOSTIC WORK UP

- **Hypotension with**
- **Tachypnoea:**
  - cardiac failure, pneumothorax, pulmonary embolism, acidosis
- **Tachycardia:**
  - seen in most of the cause except heart block, overdose β-blockers
  - check If abnormal rhythm (Atrial fibrillation, flutter, multiple VPCs).
- **Unequal pulse:**
  - check BP on both arms (thoracic aortic dissection)
- **Cardiac murmur:**
  - →underlying valvular heart (or) acute valvular lesion.
- **Crepitation:**
  - localised +Bronchial breath sound →Pneumonia
- **Wide spread crepts**
  - +gallop rhythm, orthopnoea → failure
  - +proceeding fever (or) underlying COPD → severe pneumonia
- Pallor + cold extremities + cyanosis → Cardiogenic Shock
- + Warm and vasodilated (bounding pulse), toxic looking → Septic Shock
- Undue pallor + tachycardia + no orthopnoea + no basal crepts → Haemorrhagic Shock (do per-rectal examination to detect concealed loss)
- Urticaria + wheezing + soft tissue swelling eyelid/lip → Anaphylaxis

Management

General

- Rapid assessment of vital sign, airway, BP, PR/HR, 0_2 saturation (If pulse oximeter is in hand).
- IV Access.
- Fluid challenge 200ml N/S over 5-10 mins.
- High flow 0_2 (If available)
- If pulmonary oedema present, inotrope support is indicated as fluid replacement can precipitate pulmonary oedema. (Dobutamine 5-20 µg/kg/min If cardiogenic shock, dopamine 2.5-20 µg/kg/min If septicemia but be aware uncontrolled rate on the way to hospital which may precipitate arrhythmia)
- Hypovolaemic shock: appropriate fluid replacement (rapid and adequate replacement is important)

Specific

- Septic - Intravenous 3rd generation cephalosporin (ceftriaxone, cefotaxime) after test dose can be given. (Blood culture should be taken prior to antibiotic If feasible.) Hypoadrenalism - IV hydrocortisone 100 mg stat.
- SVT (narrow complex tachycardia) - carotid sinus massage can be tried (gentle
- massage on carotid artery at level of thyroid cartilage on either side for 8 secs, be careful in elderly, risk of embolisation).

Anaphylaxis

- Lie flat, secure the airway, give0 2
- Give IM adrenaline 0.5mg - 1 mg (0.5ml - 1 ml of 1:1000) repeat every 10 minutes according to BP and pulse and respiration even before searching for IV access. Secure IV access
- IV Chlorpheniramine 10 mg and IV hydrocortisone 4 mg 6 hrly for at least 24 - 48 hrs. Add IV ranitidine 50 mg tds.
- If bronchospasm does not subside, nebulized salbutamol (or) aminophylline infusion can be given.

Transfer and referral

- After initial resuscitation, transfer the patients to nearest hospital. If patient has AMI, transfer to the hospital with facility to thrombolysis.
- Referral letter should include vital sign records and initial treatment that is helpful to the doctors from hospital.

ANAPHYLAXIS

Definition

- Severe systemic allergic reaction that is life-threatening.

Common causes

- Foods: Nuts, milk, fruit, fish and shellfish, eggs, pulses (beans, peas)
- Drugs: Antibiotics, aspirin and other NSAIDs, opioids
- Insect stings Wasp or bee
- Latex
- Idiopathic

Clinical features

- Often history of anaphylaxis/severe allergic reaction. Anaphylaxis is likely when *all* of the following are met:
    - Sudden onset/rapid progression of symptoms over minutes
    - Life-threatening:
- Airwayproblems: difficulty breathing/swallowing; feeling that throat is closing; hoarseness; stridor, *and/or*
- Breathing problems: increased respiratory rate; wheeze; shortness of breath; oxygen saturation <92%; cyanosis (late sign); confusion due to anoxia; respiratory arrest, *and/or* Circulation problems: shock (pallor, clammy, tachycardia; bradycardia is a late feature); decreased BP; faintness/dizziness; collapse; agitation/confusion; loss of consciousness.
- May cause myocardial ischaemia and ECG changes even If normal coronary arteries
- Skin and/or mucosal changes -Flushing, erythema, urticaria, and/ or angioedema, rhinitis and/or conjunctivitis. Skin or mucosal changes alone are *not* a sign of an anaphylactic reaction, although they may develop into one.

Other symptoms

- Abdominal symptoms, e.g., abdominal pam, vomiting or incontinence; anxiety with/without sense of impending doom.

Differential diagnosis

- Life-threatening- Severe asthma; septic shock
- Non-life-threatening- Simple faint; hyperventilation/panic attack; breath-holding attacks in small children; lone urticaria /angio-oedema

Management urgent action

- If suspected when the initial call comes in, request an emergency ambulance immediately.
- Ask If the patient has had a similar event before.
- If so, does he/she have an adrenaline auto-injector device? If yes, advise immediate use.
- Then visit-on attendance, follow the algorithm in Figure 1.
- Patients with airway/breathing problems may prefer to sit up; If low blood pressure, lie flat (on left side If pregnant) with legs elevated; If unconscious and breathing, place in the recovery position.

First-line treatment (adults)

- Oxygen 8 L/min (by face mask)

- Adrenaline 0.3-0.5 mg (1:1000) IM best given in mid antero-lateral thigh (mg= mL of 1:1000 adrenaline)
- Remove cause (e.g., bee sting) If possible.
- Set up IV access.
- If no rapid improvement:
    - repeat IM adrenaline every 3-5 minutes
    - set up adrenaline infusion: 1 mg adrenaline to 1000 mL N saline (i.e. 1 mL = 1 µg adrenaline) bolus of 50 µg (= 50 mL) can be given as required (best with ECG monitor)
    - Set up additional IV line (preferably two 'wide bore' lines) and infuse crystalloid solution (e.g., Normal saline 1-2 L) with bolus (20 mL/kg) over 1-2 min
    - Salbutamol aerosol inhalation (or nebulisation If severe), especially If wheeze/stridor
- Patients who have refractory or very severe anaphylaxis should be referredto hospital.
- If very severe add glucagon 1 mg IM or IV (If available)

Note

- Proper documentation is obligatory.
- Record resuscitations and medications (Name, dose and given time)
- Proper explanations and counsellings
- Show of care and concern
- Admission of the patient accompanied with family doctor/general practitioner 1s advised.

Anaphylactic reaction

↓

Check (A, B, C, D, E)

A=**A**irway, **B**=**B**reathing, **C**=**C**irculation, **D**=**D**isability (e.g., confusion, coma),
E=**E**xposure (e.g., Skin changes, facial or lip swelling, wheezing/stridor)

↓

Diagnosis: Look for

- Acute onset of illness, and
- Life threatening airway changes: swelling, hoarseness, stridor and/or
- Life threatening breathing changes: rapid breathing, wheeze, fatigue, cyanosis, oxygen saturation <92%, confusion, and/or
- Life threatening circulation problems: pale, clammy, low BP, drowsy/coma and usually
- Skin changes

↓

Call for help / Lie the patient flat / Raise the patient's legs

↓

Give adrenaline (epinephrine) 1:1000 solution

- >12 years → 0.5 ml (500 µg) i.m
- 6-12 years → 0.3 ml (300 µg) i.m
- <6 years → 0.15 ml (150 µg) i.m

If skills and equipment are available

Establish an airway

Monitor

- Pulse Oximetry
- ECG
- BP

Give after initial resuscitation
Antihistamine (Chlorphenamine)
i.m or slow iv
>12 years →10 mg;
6-12 years → 5 mg;
6 month-6 years → 2.5 µg/kg;
<6 month → 250 µg
Hydrocortisone
Im or slow iv
>12 years → 200 mg
6-12 yrears → 100 mg
6 months – 6 years → 50 mg
<6 months → 25 mg

Give as soon as possible:
High flow oxygen (>10 L/min)
IV fluid challenges:
Adult → 500 ml – 1 L
Child → crystalloid 20 ml/kg
Repeated as needed
Stop i.v colloid if this might be the cause of

Follow-up

- Warn patients or parents of the possibility of recurrence.
- Advise sufferers to wear a device (e.g., Medic-Alert bracelet) that will inform bystanders or medical staff should a future attack occur.
- *Consider supplying sufferers (or parents) with an adrenaline auto-injector device (e.g., EpiPen®) which can be used to administer IM adrenaline (epinephrine) immediately should symptoms recur. *If you supply an auto-injector device, teach anyone likely to need to use it how to operate the device. IM adrenaline is very safe.
  *(*Currently in Myanmar it is not available to use Medic Alert bracelet and EpiPen)*

- In case of anaphylactic shock, General Practitioners should note the following medications as the ABCD mnemonics.
  A. Adrenaline (IM)
  B. Burmeton (Chlorpheniramine)
  C. Corticosteroid (Hydrocortisone/ Solumedrol)
  D. Drip(N/S)

Reference:

1. *Oxford handbook of General Practice 4th Edition*
2. *John Murtagh General Practice 6th Edition*

ADULT BASIC LIFE SUPPORT

- Basic life support (BLS) is the backbone of effective resuscitation following a cardiorespiratory arrest. The aim is to maintain adequate ventilation and circulation until the underlying cause for the arrest can be reversed. A period of 3-4 minutes without adequate perfusion (less If the patient is hypoxic) will lead to irreversible cerebral damage.
- Occasionally you will be the first to discover the unresponsive patient, and it is important to rapidly assess the patient and begin cardiopulmonary resuscitation (CPR). The various stages in BLS are described here and summarized in Figure 1.1.

Figure 1.1 Stages in basic life support



Assessment of the patient

Ensure safety of rescuer and victim.

- Check whether the patient is responsive. Gently shake the victim and ask loudly, "Are you all right?"
  - If the victim responds, place them in recovery position and get help.
  - If the victim is unresponsive, shout for help and move on to assess airway (see below).

Airway assessment

- Open the airway. With two fingertips under the point of the chin, tilt the head up. If this fails, place your fingers behind the angles of the lower jaw and apply steady pressure upward and forward. Remove ill-fitting dentures and any obvious obstruction. If the patient starts breathing, roll patient over into the recovery position and try to keep the airway open until an orophyrangeal airway can be inserted. Use jaw thrust without head extension, If trauma is suspected (see Fig. 1.2).



https://s3.us-east-2.amazonaws.com/medictests/app/public/ckeditor_assets/pictures/522/content_headtilt_chinlift.jpg

- Keep the airway open; look, listen, and feel for breathing. Look for chest movements, listen at the victim 's mouth for breathing sounds, and feel for air on your cheek (for no more than 10 seconds).
- If the patient is breathing, tum patient into the recovery position, check for continued breathing, and get help.
- If the patient is not breathing or is making occasional gasps or weak attempts at breathing, send someone (or go for help If alone). (On return) Start rescue breaths by giving two slow effective breaths, each resulting in a visible rise and fall in the chest wall; a mouth-to- barrier device may be used.

Assessment of circulation

- Assess signs of circulation by feeling the carotid pulse for no more than 10 seconds.
- If there are signs of circulation but no breathing, continue rescue breaths and check for signs of breathing every 10 breaths.
- If there are no signs of circulation, start chest compression. Combine rescue breaths and compression at the rate of 30 compressions to two effective breaths, repeating this cycle 5 times in approximately 2 minutes.
- The ratio of compressions to lung inflation remains the same for resuscitation with two persons.
- Kneel by the side of the victim and place the heel of one hand in the centre of the victim's chest. Place the heel of your other hand on top of the first hand. Interlock the fingers of your hands and ensure that pressure is not applied the victim's ribs. Don't apply any pressure over the upper abdomen or the bottom end of the bony sternum.
- Position yourself vertically above the victim's chest and with arms straight.
- Press down on the sternum 5-6 cm.
- After each compression, release all the pressure on the chest without losing contact between your hands and the sternum. Compression and release should take an equal amount of time.
- Repeat at the rate of 100-120 times/minute.

ACUTE CHEST PAIN

Definition

- Pain over precordium developed within minutes to hours.

Life threatening causes

- Acute Myocardial Infarct
- Massive Pulmonary Embolism
- Acute Aortic dissection
- Tension Pneumothorax
- Oesophageal rupture

Other causes

- Acute Pericarditis
- Pleurisy
- Musculoskeletal pain

Immediate questions

- location of Chest pain
- Radiation
- Character
- Precipitating Factors
  - associated symptoms (palpitation, sweating, syncope, haemoptysis, shortness of breath, vomiting)
  - Previous history of Cardiovascular risk factors
  - Prolong immobilization, recent major surgery

Rapid assessment

- fever
- pallor/cyanosis
- sweating
- anxious/restlessness
- unequal pulse
- raised JVP
- Tracheal shift, equality of breath sound
- Blood pressure & heart rate
- Respiratory Rate
- DVT
- Tenderness on Chest wall

Check

- pulse oximetry
- RBS with glucometer
- ECG -7 arrhythmia, ST elevation (always compare with previous ECG If available)
- Urgent portable Chest X-





ray → Tension Pneumothorax

Pointers for AMI

- Prolong cardiac pain >30 mins
- Central compressing pain
- Radiation to neck, jaw, arm, epigastrium or back
- Anxiety and fear of impending death
- Marked nausea, vomiting & sweating
- Shortness of breath, syncope,
- Precipitated by cold wind, stress

Pointers of pulmonary embolism

- Cyanosis
- Tachycardia
- Raised JVP
- Hypotension
- Predisposing factors such as DVT

Pointers of acute aortic dissection

- sudden tearing chest pain radiate to back
- sweating, pallor
- unequal radial pulse & BP

Pointers of tension pneumothorax

- Very Sudden onset
- Unilateral sharp chest pain
- Tracheal shift
- Hypotension
- unilateral reduced breath sound

Pointers for oesophageal rupture

- burning central chest pain
- sweating
- preceded by excessive vomiting

Pointers for pericarditis

- Central
- worsen on inspiration or lying flat
- relieved by sitting forward

Emergency management

A. Symptomatic management
    a. Oxygen inhalation (4L to 6L)
    b. Sublingual GTN
    c. IV antiemetic
    d. NSAID for musculoskeletal pain
B. Disease management
    a. P.O Aspirin 300mg and P.O Clopidogrel 300 mg (unless contraindicated) for AMI
C. Immediate Referral Criteria *(referral detail with given Tx and vital signs)*
    a. Ongoing Chest Pain

b. Pallor / Cyanosis / Sweating
c. Restless
d. Hypotension
e. Arrhythmia
f. ↓Sp02
g. Unequal radial pulse
h. Unequal breath sound

Further Reading

1. *Davidson's Principle and Practice of Medicine, 21' [1] Edition, 20I 0*
2. *Oxford Handbook of General Practice, 3rd Edition, 2010*
3. *Current Medical Diagnosis & Treatment, 48[1] Edition, 2009*

PULMONARY EMBOLISM

Definition

- Venous thrombi, usually from a deep vein thrombosis in the leg pass into the pulmonary circulation and block blood flow to the lungs. Without treatment, 20% with proximal deep vein thrombosis develop pulmonary embolus (PE).

Symptoms

- Acute dyspnoea,
- Pleuritic chest pain
- Haemoptysis
- Syncope
- Large clots can be rapidly fatal

Signs

- Hypotension
- Tachycardia
- Cyanosis
- Increased JVP
- Tachypnoea
- Pleural rub

Differential diagnosis

- Pneumonia and pleurisy
- Acute coronary syndrome
- Other causes of acute breathlessness: acute LVF, asthma, exacerbation of COPD, pneumothorax, shock (e.g., due to anaphylaxis), arrhythmia, hyperventilation
- Other causes of acute chest pain: aortic dissection, rib fracture, musculoskeletal chest pain, pericarditis, oesophageal spasm, shingles

Investigation

- Chest X-ray and ECG
- Wells score for DVT

Cancer	+l
Paralysis or recent plaster cast	+l
Bed rest >3 days or surgery <4 wks	+l
Pain on palpation of deep veins	+l
Swelling of entire leg	+l
Diameter difference on affected calf >3cm	+l
Pitting oedema (affected side only)	+l
Dilated superficial vein (affected side)	+l
Alternative diagnosis at least as probable as DVT	-2

(0) Low risk, (1-2) Intermediate risk, (3) High risk

Diagnostic algorithm for clinically suspected DVT/PE



CUS = compression ultrasonography

Management

Immediate action

- Most of the pulmonary embolism deaths occur within 1 hour.
- It is an acute medical emergency.
- Give i.v access for haemodynamic instability patient before refer to hospital.
- If suspected, give oxygen as soon as possible (aim to keep Sp02 at 94-98%).
- Needs supportive medical care and anti-coagulation
- Initial anticoagulation with LMWH and warfarin, then followed by oral anticoagulant
- LMWH should be continued for at least 4 day and anti INR is in therapeutic range for
- 2:2 day. Target INR 2.5 (Range 2-3)
- Oral anticoagulants reduce risk of further thromboembolism and should be continued for 3-6 months after a single DVT
- If a patient has a DVT and there is no obvious cause
- If <45 yr, consider thrombophilia
- If>45 yr, consider undiagnosed cancer

Further management

- In all cases of proven PE, anticoagulation is started in hospital before discharge to general practice.
- Warfarin should be continued for 2:3 months. Aim to keep the INR 2.5 (range 2-3)
- Malignancy: continue treatment with LMWH for 6 months or until cure of cancer
- Pregnancy: LMWH is continued until delivery or end of pregnancy

Refer

- All suspected DVT/PE cases must be referred to hospital (urgently).

Reference:

1. *Oxford Handbook of General Practice, 4th Edition*
2. *John MURTAGH's Handbook of General Practice, 5th Edition*

PNEUMOTHORAX

Definition

- Pneumothorax is the present of air in the pleural space which can occur spontaneously or result from iatrogenic injury or trauma to the lung or chest wall.
- Primary spontaneous pneumothorax occurs in patients with no history of lung disease in whom smoking, tall stature and the present of apical subpleural blebs are additional risk factors.

Classification of pneumothorax

- Spontaneous
    - Primary
        - No evidence of overt lung disease. Air escape from the lung into the pleural space through rupture of a small subpleural emphysematous bullae or pleural bleb, or the pulmonary end of a pleural adhesion.
    - Secondary
        - Underlying lung disease, most commonly COPD and TB; also seen in asthma, lung abscess, pulmonary infarcts, bronchogenic carcinoma, all forms of fibrotic and cystic lung disease.
- Traumatic
    - Iatrogenic (e.g., following thoracic surgery or biopsy) or chest wall injury.

Types of spontaneous pneumothorax

- Closed type
- Open type
- Tension (valvular) type

Clinical feature

- sudden onset unilateral pleuritic chest pain
- breathlessness
- pallor ± or tachycardia

Physical examination

- normal in small pneumothorax,
- tracheal shift to opposite side
- hyper-resonance on percussion and obliteration of cardiac dullness
- decreased or absent breath sound in large pneumothorax

Investigation

- Chest X-ray

Management

- Primary pneumothorax in which lung edge is less than 2 cm from the chest wall and the patient is not breathless normally resolves without intervention. 50% collapse takes 40 days to be resolved.
- In young patients presenting with a moderate or large spontaneous pneumothorax, acute respiratory distress, chest pain, percutaneous (16-l 8G cannula through the 2nd intercostal space just above the 3rd rib at mid clavicular line) aspiration of air is a simple and well-tolerated alternative to intercostal tube drainage, with a 60-80% chance of avoiding the needle for a chest

drain.

- When needed, intercostal drains are inserted in the 4th, 5th or 6th intercostal space in the *mid-axillary line connected to an underwater seal or one-way Heimlich valve and secured firmly to the chest wall or refer depending upon clinical judgement.*
- Smoking cessation reduces risk of recurrence.

Refer

- Tension pneumothorax is the medical emergency. It was indicated/categoraized as urgent referral.

Reference

1. *Davison's Principles and Practice of Medicine, 22nd Edition*

STATUS ASTHMATICUS IN ADULTS

Symptoms/signs of a severe asthma attack

- PEFR 30-50% predicted or best
- 0_2 saturation 2:92%
- unable to talk in sentences
- intercostal recession
- tachypnoea, respiratory rate 2:25 breaths/min
- tachycardia, heart rate 2:110 bpm

Life-threatening signs

- PEFR <33% predicted or best
- 0_2 saturation <92%
- Arrhythmia
- Hypotension
- Cyanosis
- Exhaustion
- Poor respiratory effort
- Silent chest (inaudible wheeze)
- Altered consciousness

Differential diagnosis

Airflow obstruction= FEV1/FVC <0.7

- AIRFLOW OBSTRUCTION
  - COPD
  - Bronchiectasis
  - Inhaled foreign body
  - Obliterative bronchiolitis
  - Large airway stenosis
  - Lung cancer
  - Sarcoidosis
- NO AIRFLOW OBSTRUCTION
  - Chronic cough syndrome
  - Hyperventilation syndrome
  - Vocal cord dysfunction
  - Rhinitis
  - Gastro-oesophageal reflux
  - Heart failure
  - Pulmonary fibrosis

Management of acute asthma

Drug treatment of asthma

- Use a stepwise approach
  - Start at the step most appropriate to the initial severity of symptoms. The aim is to achieve early control of the condition and then to decrease treatment by stepping down.



**All doses given refer to hydrofluoroalkane - beclometasone dipropionate (BDP-HFA) equivalent inhalers. For other drugs/ formulations adjust dose accordingly*

Fig 1: Summary of Stepwise management of asthma in adult

- Exacerbations
    - Treat early. In adult patients on 200 µg doses of inhaled steroids, a 5 times increase in dose reduces severity of exacerbations.
    - Alternatively, and in all other cases, use prednisolone 30-40 mg od for 1-2wk.
- *Selection of inhaler device*
    - If possible, use an MDI. Inadequate technique may result in drug failure. Patients must inhale slowly and hold their breath for 10s after inhalation.
    - Demonstrate inhaler technique before prescribing and check at follow-ups.
    - Spacers/breath-activated devices are useful If patients find activation difficult. Dry powder inhalers are an alternative.
- *Short-acting β2-agonists (e.g., salbutamol)*
    - Work more quickly and with fewer side effects than alternatives. Use pm unless shown

to benefit from regular dosing. Using 2:2 canisters/month or >10-12 puffs/d is a marker of poorly controlled asthma.
    - A budesonide /formoterol combination inhaler is an alternative rescue medication.
- *Inhaled corticosteroids*
    - Effective preventer. May be beneficial even for patients with mild asthma.
    - Consider if:
        - exacerbation of asthma in the last 2 year requiring steroids;
        - using inhaled 2 agonists 2:3 times/wk;
        - symptomatic 2:3 times/wk or
        - symptomatic 2:1 night/wk.
- *Oral steroids*
    - Prescribe as a single dose in the morning. Often started at high dose (e.g., 40-50mg od) to suppress disease process and then stopped after improvement.
    - If used as maintenance therapy, use the minimum dose that controls disease. Supply with a 'steroid card'
- *Add-on therapy*
    - Aims to improve lung function/symptoms. Before initiating a new drug, check compliance, inhaler technique, and eliminate trigger factors. Only continue If of demonstrable benefit.
        - Inhaled long-acting β2 agonists (LABA) (e.g., salmeterol)
        - Do not use without inhaled steroids. Combination inhalers (steroid + LABA) improve compliance
        - Leukotriene receptor agonists (e.g., montelukast) decrease exacerbations
        - Theophylline Side effects are common
- *Omalizumab*
    - Monoclonal antibody that binds to circulating IgE. Useful for adults and children >6 yr If allergy is a factor in asthma, on high-dose inhaled steroid + LABA, and frequent exacerbations. Given subcutaneously every 2-4wk. Always specialist-initiated.

DIFFICULT ASTHMA

- Persistent symptoms and/or frequent exacerbations despite treatment at step 4/5.
- Check diagnosis and exacerbating factors.
- Assess adherence to medication. Find out about family, psychological, or social problems that may be interfering with effective management.

THYROID CRISIS (THYROID STORM)

- Clinical features are marked anxiety, weight loss, weakness, proximal muscle weakness, hyperpyrexia, tachycardia (>150/ minute), heart failure and arrhythmias.
- It is usually precipitated by surgery or an infection in an undiagnosed patient.
- Referral is required for urgent intensive hospital management with antithyroid drugs; IV saline infusion, IV corticosteroids, anti-heart failure and antiarrhythmia therapy.

ADDISONIAN CRISIS

- An addisonian crisis develops because of an inability to increase cortisol in response to stress, which may include intercurrent infection, surgery or trauma.

Clinical features

- Nausea and vomiting
- Acute abdominal pain
- Severe hypotension progressing to shock
- Weakness, drowsiness progressing to coma

Urgent management

- Establish IV line with IV fluids
- Hydrocortisone sodium succinate 200 mg IV and 100-200 mg 4-6 hourly
- Arrange urgent hospital admission

EMERGENCY PSYCHIATRIC MANAGEMENT

SUICIDE ATTEMPTS AND SUICIDAL THOUGHTS

- suicidal attempt is considered to be one of the commonest psychiatric emergencies.
- Suicide is a type of deliberate self-harm and is defined as an intentional human act of killing oneself.

Aetiology

- Psychiatric Disorders:
  - Major depression
  - Schizophrenia
  - Drug or alcohol abuse
  - Dementia
  - Delirium
- Personality disorder Physical Disorders:
  - Patients with incurable or painful physical disorders like, cancer and AIDS.
- Psychosocial Factors:
  - Failure in examination
  - Dowry harassment
  - Marital problems
  - Loss of loved object
  - Isolation and alienation from social groups
  - Financial and occupational difficulties

Risk factors for suicide

- Age:
  - Males above 40 years of age
  - Females above 55 years of age
- Sex:
  - Men have greater risk of completed suicide
  - Suicide is three times more common in men than in women.
  - Women have higher rate of attempted suicide.
- Being unmarried, divorced widowed, or separated
- Having a definite suicidal plan
- History of previous suicidal attempts
- Recent losses

Suicidal tendency in psychiatric disorder management

- Be aware of certain signs which may indicate that the individual may commit suicide;
  - Suicidal threat
  - Writing farewell letters
  - Giving away treasured articles
  - Making a will
  - Closing bank accounts
  - Appearing peaceful and happy after a period of depression
  - Refusing to eat or drink, maintain personal hygiene.
- Monitoring the patient's safety needs:

- Take all suicidal threats or attempts seriously and notify psychiatrist.
- Search for toxic agents such as drugs/alcohol.
- Do not leave the drug tray within reach of the patient, make sure that the daily medication is swallowed.
- Remove sharp instruments such as razor, blades, knives, glass bottles from his environment.
- Remove straps and clothing such as belts, neckties.
- Do not allow the patient to bolt his door on the inside, make sure that somebody accompanies him to the bathroom.
- Patient should be kept in constant observation and should never be left alone.
- Have good vigilance especially during morning hours.
- Spend time with him, talk to him, and allow him to ventilate his feelings.
- Encourage him to talk about his suicidal Plans/ methods.
- If suicidal tendencies are very severe, sedation should be given as prescribed.
- Encourage verbal communication of suicidal ideas as well as his/ her fear and depressive thoughts.
- Enhance self-esteem of the patient by focusing on his strengths rather than weaknesses. His positive qualities should be emphasized with realistic praise and appreciation. This fosters a sense of self-worth and enables him to take control of his life situation.

Management of attempted suicide

- Assess for vital signs, check airway, If necessary clear airway.
- If pulse is weak, start IV fluids.
- Tum patient's head and neck to one side to prevent regurgitation and swallowing of vomitus.
- Emergency measures to be instituted in case of self-inflicted injuries.

Management of shock

- Transfer the patient to medical centre immediately.
- If there is no evidence of life, leave the body in the same position/room in which it was found (move the patient in case suicide from a common living area for example, dining room or TV room)
- Inform authorities, record the incident accurately
- Once the patient is transferred to mortuary or police custody clean the place with disinfectant solution

SNAKE BITES

- Major poisonous snakes in Myanmar
    - Russel's viper (more than 90%), Cobra, Krait, Sea snake, Green snake, Green pit viper

Signs of local envenomation

- local pain and inflammation, local bleeding, bruising, lymphangitis and lymph node enlargement, blistering, skin necrosis.

Early clues of severe envenoming

- snake identified as a dangerous species, rapid extension of local swelling, early tender enlarged regional lymph nodes, early systemic features (nausea, vomiting, collapse, headache, heaviness of eyelids, ptosis, inappropriate drowsiness, spontaneous systemic bleeding).

Clinical syndromes of envenomation (As a clue for species diagnosis)

- Syndrome 1: Local envenomation with bleeding/ clotting disturbance (Viperidae,
- green snake)
- Syndrome 2: Local envenomation with bleeding/clotting disturbance, shock, acute kidney injury, proteinuria, conjunctival edema (Russell's viper)
- Syndrome 3: Local envenomation with paralysis (Cobra)
- Syndrome 4: Paralysis with minimal local envenomation sign (bitten on land while sleeping on ground- Krait) (bitten in the sea- sea snake)
- Syndrome 5: Paralysis with dark brown urine and acute kidney injury (sea snake)
- Note: There may be considerable overlap of clinical features caused by venom of different species.

Management

- First Aid
- Reassurance, immobilize whole body by laying in a comfortable and safe position, immobilize the bitten limb by splinting, pressure-immobilization or application of pressure pad, avoidance of incision, vigorous cleaning, massage and application of chemicals.

Rapid assessment and resuscitation

- Airway, Breathing, Circulation, Disability of nervous system (paralysis and impaired consciousness). Give intravenous fluid to combat the shock. Give oral analgesic (Paracetamol) for pain relief but NSAIDs should be avoided.

Transport to hospital

- quickly, safely and comfortably (in recovery position, if possible, with immobilization of bitten limb)

Anti-venom treatment

- Antivenom may be given before transfer to hospital If it is available and there is definite indication.

Indications

- If and when a patient with proven or suspected snake bite develops one or more of the features of local and/or systemic envenomation (See above). Should only be given when benefits are

considered likely to exceed the risks of anti-venom treatment.

Dose and route

- 40-80 ml of monovalent or 80-160 ml of polyvalent anti-venom by slow intravenous injection (not more than 2 ml/min) or intravenous infusion after dilution with 250- 500 ml isotonic saline (over one hour).
- Note: skin sensitivity test is not recommended.

Caution:

- Epinephrine should be drawn up in readiness in case of anaphylaxis.
- Never inject/infiltrate anti-venom locally
- Intramuscular route should not be used unless intravenous injection is not possible.
- Closely observe for at least one hour for possible reaction.
- In cobra envenomation, anti-venom treatment alone may not be solely reliable.
- Timely detection of respiratory muscle paralysis and artificial breathing/ventilation is important and life-saving.



Fig: Pressure immobilization method

INSECT BITES AND STINGS

Mild reaction-

- itching or stinging sensation and mild swelling that disappear within a day or so. A delayed reaction may cause fever, urticaria, joint pain and lymph node enlargement.

Management of mild reaction

- **Move to a safe area** to avoid more stings.
- **Remove the stinger**, especially If it is stuck in the skin to prevent the release of more venom. Wash the area with soap and water.
- **Apply a cold** pack or cloth filled with ice to reduce pain and swelling.
- **Analgesics** such as ibuprofen or paracetamol, to ease pain from bites or stings.
- Apply a **topical cream** to ease pain and provide itch relief Creams containing ingredients such as hydrocortisone, lidocaine or may help control pain. Other creams, such as calamine lotion or lotion containing baking soda, can help soothe itchy skin.
- **Antihistamine** containing diphenhydramine or chlorpheniramine maleate orally.
- Severe reactions affect more than just the site of the insect bite and may progress rapidly.

Signs and symptoms are:

- Difficulty breathing, swelling of the lips or throat, lightheadedness and syncope, dizziness, confusion, tachycardia, urticaria, nausea, cramps and vomiting, hypotension and shock.

Management of severe reaction

- Epinephrine - 0.5 -1 mg intramuscularly to the lateral thigh.
- Antihistamine - Intravenous chlorpheniramine maleate.
- Corticosteroid- Intravenous hydrocortisone 100-200 mg.
- Loosen tight clothing and cover the person with a blanket. Don't give anything to drink.
- Turn the person on his or her side to prevent choking If there's vomiting or bleeding from the mouth.
- Start CPR If there are no signs of circulation or breathing.

ACUTE POISONING AND OVERDOSE

Diagnosis of acute poisoning

- Mainly from history given by the patient or witness or by circumstantial evidences such as empty bottle or package of drug, suicide note, trace of the poison on the mouth or body and peculiar smell.

NOTE:

- Acute poisoning should be considered as a differential diagnosis in a patient with unexplained coma.
- Presence of lateralizing signs (i.e. asymmetry of pupils, posture, movement, plantar response) virtually excludes the diagnosis of poisoning.
- There should be high index of suspicion of head injury.

TOXIDROMES

- A clinical syndrome caused by dangerous level of poison in the body. It may indicate a medical emergency requiring treatment at poison center. They are often variable and often obscured by co-ingestion of multiple agents.

SYMPTOMS	BP	HR	RR	Temp	Pupils	Bowel sound	Diaphoresis
Anticholenergic		Up		Up	Up	Down	Down
Cholenergic					Down	Up	Up
Hallocinogic	Up	Up	Up		Up		Up
Sympathomimetic	Up	Up	Up	Up	Up		Up
Sedative/ hypnotic	Down	Down	Down	Down		Down	Down
Opiate	Down	Down	Down	Down	Down	Down	

Toxidromes and possible causative agents

Anticholenergic: Atropine, benztropine, antihistamine, antispasmodics, anti-parkinsonism, antipsychotics.
Cholenergic: Organophosphates, carbamates, nerve gas, mushroom,
Hallucinogic: Amphetamine, cocaine, LSD
Sympathomimetics: Methamphetamine, phenylpropanolamine, ephendrine, pseudoephendrine, cocaine, salbutamol
Sedative/hypnotic: Benzodiazepines, anticonvulsants, barbiturates, methaqualone, ethanol
Opiates- Opioids

Indications for hospital referral

- All patients who show features of poisoning
- Patients who have taken poisons with delayed action (aspirin, iron, paracetamol, tricyclic antidepressants, modified-released preparations)

Prehospital management

- Remove from toxic atmosphere (inhalational poison) without rescuer themselves being put at risk.

- Maintain ABC (Airway, breathing and circulation)
- Remove contaminated clothing and wash the skin.
- Correct hypoglycemia If suspected or detected by finger prick test.
- Give thiamine in possible alcohol abuse.
- Treat the shock.
- Treat prolonged and recurrent major fit by rectal or IV diazepam.
- Keep in semi-prone position.
- May try gastric suction or induced vomiting IF:
- Patient has possibly taken dangerous amount of poison
- Patient is conscious and there is no or low risk of chocking/aspiration.
- There is possible delay in transfer to hospital.
- Patient has not taken - corrosives, hydrocarbons, paraquet (weed killer)
- Initiation of antidotes may be considered If poison can be identified and specific antidote is available.

Common poisoning: diagnostic features and readily available antidotes

Methanol/ethylene glycol

- Diagnosis: History, multiple victims from the same source (in methanol poisoning),
- acidosis, blurring of vision (methanol)
- Antidote- ethyl alcohol, IV $NAHC0_3$ for acidosis

Mushroom

- Diagnosis: History and features of cholinergic toxidrome.
- Antidote: IV Atropine

Opiates

- Diagnosis: circumstantial diagnosis, opiate toxidrome
- Antidote: Naloxone

Organophosphate/ carbamate insecticide

- Diagnosis: peculiar smell, features of cholinergic toxidrome.
- Antidote: IV Atropine 0.6- 1.2 mg (may repeat every 15-30 minutes If cholinergic features persist)

Paracetamol

- Diagnosis: History and circumstantial evidence only as there is no specific clinical feature in early phase.
- Antidote: N-acetyl-cystiene (a mucolytic agent Musol/Actein) 140mg/kg stat followed by 70mg/kg every 4 hours.

Stimulants (amphetamine, ephedrine)

- Diagnosis: sympathomimetic toxidrome, hyperthermia.
- Antidote: β-blockers, Diazepam

Tricyclic antidepressants

- Diagnosis: History, circumstantial evidence and features of anticholenergic toxidrome.
- Antidote: No specific antidote, correct acidosis by IV $NaHC0_3$ and monitor arrhythmias
- If in doubt: about the diagnosis and how to act-

- ***Contact Poison Treatment Centre, New Yangon General Hospital or National Poison Control Centre, DMR (Lower Myanmar)***
- ***NPCC (DMR) - 01379480, 01 379481***
- ***PTC (NYGH) - 01 384493***

Prevention

- Small amount only of drug should be bought
- Keep drugs in safe place
- Keep drugs and liquids in their original containers
- Child resistant drug containers should be used
- Prescription for any susceptible patient must be monitored carefully
- Household products should be labeled and kept safely, away from children.

SURGICAL EMERGENCIES

Refer Chapter 17 page
GI Bleeding
Acute Abdomen
Burns and Scold

OBSTETRIC EMERGENCIES

ECLAMPSIA

- Occurs when a pregnant woman has fit as a result of preclampsia. Usually, blood pressure is very high and if the baby is not yet born, it becomes distressed. There is a serious risk of stroke in the mother.
- Women with preeclampsia has a chance of eclamptic seizure. 44% occur after the baby is born usually less than 24hours after delivery.
- Give PR diazepam 10-20mg or intravenous If available. Urgent referral is required.

HELLP SYNDROME

- Occurs in pregnancy or 48 hours after delivery.
- Associated with severe eclampsia.
- Haemolysis
- Elevated liver enzymes
- Low platelets

Signs

- Hypertension (80%)
- Right upper quadrant pain (90%)
- Nausea
- Vomiting (50%)
- Oedema

Management

- Refer for obstetric assessment.

OBSTETRIC SHOCK

Causes

- Haemorrhage: APH (page - 885), placenta abruption (page - 887), PPH
- Ruptured uterus
- Inverted uterus
- Pulmonary embolus
- Anaphylaxis (usually drug)
- Amniotic fluid embolism
- Broad ligament haematoma
- Septicaemia

Management

- Give intravenous access and start intravenous fluids, give oxygen
- Treat the cause If apparent.
- Immediate refer to hospital.

FETAL DISTRESS

Signifies hypoxia Signs:

- Passage of meconium during labour
- Fetal tachycardia (>160 bpm at term)
- Fetal bradycardia

Management

- Give mother oxygen via a face mask and tum her onto her side.
- Refer to hospital for assessment+/- delivery.

ACUTE ABDOMINAL PAIN IN PREGNANCY

- Non- obstetric causes of abdominal pain may be forgotten or signs may be less well localized than in the non-pregnant patient (acute abdominal pain in surgery)

APPENDICITIS

- Mortality is higher in pregnancy and perforation more common (15-20%).
- Fetal mortality is 5-10% for simple appendicitis but rise to 30% when there is perforation.
- Due to the pregnancy, the appendix is displaced and pain is often felt in the paraumblical region or subcostally.
- Refer immediately If suspected.

CHOLECYSITITIS

- Pregnancy encourages gallstone formation. Symptoms include right upper quadrant pain, nausea and vomiting. Diagnosis can be confirmed on ultrasound.
- Treatment is the same as outside pregnancy aiming for interval cholecystectomy after birth.

TORSION OR RED DEGENERATION OF FIBROIDS

- Fibroid s increase in size in pregnancy. They may twist if pedunculated.
- Red degeneration occurs usually after 20 week and may occur until the puerperium.
- It presents as abdominal pain+/- localized tenderness+ /- vomiting and low-grade fever. Confirm diagnosis with USS. Treatment is with rest and analgesia. Pain resolves within one week.
- If not relieved, refer.

TORSION OR RUPTURE OF *OVARIAN CYSTS*

- Torsion or rupture of a cyst may both cause abdominal pain as may bleeding into a cyst. USS can confirm the presence of a cyst.

Management

- Depends on the nature of cyst and the severity of the pain.
- Refer for assessment and treatment.
- *If less than 20 weeks gestation,* also consider

ECTOPIC PREGNANCY

- *If more than 20 weeks gestation*, also consider

HAEMATOMA OF THE RECTUS ABDOMINIS

- Rarely bleeding into the rectus sheath and haematoma formation occurs spontaneously or after coughing in late pregnancy. May cause swelling and abdominal tenderness. USG can be helpful. If unsure of diagnosis, refer to hospital.

UTERINE RUPTURE

- Associated with maternal mortality of 5% and fetal mortality of 30%.70% are due to dehiscence of Caesarean section scars. Rupture occurs most commonly during labour but occasionally in the third trimester or after an otherwise normal delivery.

Presentation

- Pain is variable but usually severe, bursting, constant lower abdominal pain+/- heavy vaginal bleeding.
- Generally associated with profound shock in the mother and fetal distress. If in labour, the presenting part may disappear from the pelvis+/- contraction stop.

Management

- Refer as an emergency.

PLACENTAL ABRUPTION (ABRUPTION PLACENTA)

- Part of the placenta becomes detached from the uterus. Consequences depend on degree of separation and the amount of blood loss.

Presentation

- Typically, constant pain -may be felt in the back If posterior placenta
- Woody hard, tender uterus
- Shock+/-PV bleeding
- Fetal heart absent or signs of fetal distress (fetal tachycardia or bradycardia)

Management

- If suspected, refer as an acute emergency.

SHOULDER DYSTOCIA

- After less than 1% deliveries but is life-threatening emergency. Occurs when the anterior shoulder impacts upon the symphysis pubis after the head has delivered and prevents the rest of the body following. Most cases of shoulder dystocia are unanticipated.

Clues

- Prolonged first or second stage of labour
- Head bobbing: the head consistently descends then returns to its original position during a contraction or pushing in second stage

Management

- If no time to refer
    - Do episiotomy. Then try any of these procedure (no particular order)
    - Roll the mother onto hands and knees and try delivering POSTERIOR SHOULDER FIRST
    - FLEX AND ABDUCT THE MOTHER'S LEG UP TO HER ABDOMEN
    - (UPSIDE DOWN SQUATTING POSITION) → try deliver again
    - Deliver the POSERIOR ARM → put a hand in the vagina in front of the baby → ensure the posterior elbow is flexed in front of the body and pull to deliver the forearm. The anterior shoulder usually follows
    - EXTERNAL PRESSURE - ask an assistant to apply suprapubic pressure with the heel of hand
    - (A Rocking movement can help)
    - Adduction of the most accessible (preferably anterior) shoulder.
    - Simultaneously put pressure on the posterior clavicle to turn the baby
    - If unsuccessful continue rotation through 180 degrees and try again

CORD PROLAPSE

- The cord passes through the os in front of the presenting part of the baby. If the presenting part squashes the cord, umbilical blood flow is restricted causing fetal hypoxia and distress (fetal mortality 10%- 17%)

Risk factors

- Malpresentation --- breech / transverse /oblique
- Cephalo-pelvic disproportion
- Multiple pregnancy
- Preterm rupture of membranes
- Polyhydramnios
- Pelvic tumours

Management

- Minimize handling of the cord to prevent spasm.
- Try to keep the cord within VAGINA.
- Aim to prevent presenting part from occluding the cord. Try
    - Displacing to prevent presenting part upwards with the examining hand
    - Get patient into knee/elbow position-----head down
    - If possible, drop the head end of the bed
    - Fill the bladder with 500-750ml normal saline via a catheter and clamp the catheter
- REFER as an emergency for emergency Caesarean section (usually)

RETAINED PLACENTA

- The third stage of labour is complete in less than 97% of labours. If the placenta has not been delivered in 30 min (to allow for cervical spasm) it will probably not delivered spontaneously.

Management

- Avoid excessive cord traction.
- Check the placenta is not in the vagina- remove If it is
- Check the uterus

- If the uterus is well contracted
- Cervical spasm is probably trapping an otherwise separated placenta- wait for cervix to enable removal of the placenta.
- If the uterus is bulky,
- The placenta may have failed to separate. Try Rubbing up a contraction.
- Putting the baby to the breast (stimulated uterus contraction)
- Give a further dose of syntometrine
- If the placenta will still not deliver, refer as emergency for manual removal.

UTERINE INVERSION

Management

- Do not remove the placenta If attached until the uterus is replaced. If not early, try to replace the uterus. Otherwise refer as an emergency. The mother may become profoundly shocked so set up an intravenous infusion before transfer If possible, and give oxygen via face mask.

BROAD LIGAMENT HAEMATOMA

- Presents in a recently delivered women as obstetric shock without excessive bleeding per vagina Pain, tenderness on the affected side. The uterus is deviated from that side.

Management

- Refer as acute emergency to the nearest hospital.

AMNIOTIC FLUID EMBOLISM

- Presents with shock, cyanosis and dyspnea. May occur at the height of contraction
- If suspected
- Resuscitate -Airway, breathing, circulation and refer as an emergency to hospital.

ACUTE ASTHMA IN CHILDREN



CONVULSION

Common causes of convulsions with fever

- Febrile convulsion
- Pyogenic meningitis
- Cerebral malaria
- Encephalitis
- TB meningitis
- Brain abscess

Common causes of convulsions without fever

- Epilepsy
- Hypertensive encephalopathy
- Lead encephalopathy
- Sub-dural haematoma
- Brain tumour

FEBRILE CONVULSION

Definition

- Convulsions occurring in association with fever in children between 6 months and 6 years of age, in whom there is no evidence of intracranial pathology or metabolic derangement.

	Simple febrile convulsion	**Complex febrile convulsion**
Duration	<15 minutes	>15 minutes
Type	Generalized	Focal
Recurrence	Not recur during one febrile episode	>one seizure during one febrile episode

Investigations

- Most febrile convulsion follows acute viral infection and investigations are usually not necessary.
- Appropriate investigations should be done only when underlying infection is suspected.

Management

First aid measures for seizure

- Semi-prone position
- Check Airway, Breathing and Circulation.
- Adequate airway and suction, 02
- Clothing must be loosened. Excess clothing removed.
- Don't put anything into mouth
- To control fits If more than 4 minutes - PR Diazepam - 0.3 - 0.5 mg/kg

Control fever

- Take off clothing and give tepid sponging.

- Antipyretic e.g., oral or rectal Paracetamol 15 mg/kg 4-6 hourly.
- NOT ALL CHILDREN NEED TO BE ADMITTED.

The main reasons for admission are: -

- To exclude intracranial pathology especially infection
- Fear of recurrent fits
- To investigate and treat the cause of fever
- To allay parental anxiety, especially If they are staying far from the hospital.

Reassess the child

- Exclusion of other intracranial causes of fits
- Meningitis - signs of meningism, tense or bulging anterior fontanelle, prolonged or frequent fits (check Full blood count, Lumbar puncture)
- Encephalitis - change in sensorium, neurological signs may be present
- Cerebral malaria - came from or travelled to malaria endemic area, change m sensorium, (check Malaria parasites)
- Features of Complex febrile convulsion
- Persistent lethargy

Prevention of recurrence

- Generally, not recommended because
- The risks and potential side effects of antiepileptic medications outweigh the benefits.
- No medication has been shown to prevent the future onset of epilepsy.
- Long term prophylaxis with daily anticonvulsants is not routinely used even If episodes are frequent. However intermittent prophylaxis (like oral diazepam at the start of temperature and every 8 hours for 24 hours only) can be considered for such children with frequent episodes.

Risk factors for recurrent febrile convulsion

- Family history of febrile convulsion in 1st degree relative
- Early onset (<l year)
- Low grade fever during 1st febrile convulsion
- Brief duration (<1-2 hour) between onset of fever and seizure

Risk factors for epilepsy

- Family history of epilepsy in 1^{51}degree relative
- Underlying neurodevelopmental abnormality
- Complex febrile convulsion

MANAGEMENT OF THE CHILD WITH SHOCK

Definition

- State of circulatory dysfunction leading to inadequate cellular perfusion and tissue hypoxia
- Inadequate perfusion of the body's vital organs resulting in anaerobic metabolism and tissue acidosis.
- Multiple end- organ failure and death If insufficient compensation to reverse these changes

Compensated shock

- Prolong capillary refill and cold peripheries (reduce blood flow to non vital organs)
- Increase in heart rate (up to 200 beats per minute for a finite period of time)
- Increase in respiratory rate (to improve oxygen delivery)
- Reduce urine output (<0.5 ml/kg/hour)
- Agitation and confusion
- Blood pressure is maintained

Uncompensated shock

- Anuria
- (A further) reduction of conscious level: GCS <8, only response to pain (AVPU)
- Respiratory failure
- Hypotension (pre-terminal sign)
- In children, the two commonest forms of shock are;
- Hypovolaemic shock secondary to trauma or gastroenteritis
- Septic shock, i.e. distributive

Management chart for child with shock

Condition	**Immediate Management**
drowsy restless cold extremities reduced urine output rapid thready pulse low BP or narrow pulses pressure	Clear airway IV fluid (e.g., R/L or N/S or D/S 20ml/kg/hr)

In a child with shock, the following conditions should be considered

ASK	LOOK FOR	POSSIBLE DIAGNOSIS	INVESTI-GATION	MANAGEMNET
1. Diarrhoea, Vomiting	Two of the following signs: Lethargic/ unconscious Sunken eyes Not able to drink or drinks poorly Skin pinch goes back very slowly	Acute watery diarrhoea with severe dehydration	•Stool RE Serum U, C&E If available	Treat as diarrhea (See Plan C)

ASK	LOOK FOR	POSSIBLE DIAGNOSIS	INVESTI-GATION	MANAGEMNET
•Rapid Onset	Rice water stool, Fishy smell, •Washer woman's hands	•SUSPECTED CHOLERA	• Rectal swab	>8yrs Tetracycline 12.5mg/kg/dose 6H x 3 days Norfloxacin6mg/kg /dosel2H x 3 days
•Ingestion of mushroom or Tapioca	Constricted pupil in mushroom poisoning	•MUSHROOM OR TAPIOCA POISIONING		Inj. atropine sulphate 0.02mg/kg IM or SC for mushroom poisoning Refer to hospital
2. Fever with Diarrhoea	Febrile, Toxic Splenomegaly	•Acute Watery diarrhoea with septicaemic shock		Cefotaxime 50mg/kg IN or I/Mor Ceftriazone 50mg/kg Referred to hospital
Fever with septic foci	•Toxic •Febrile (or) hypothermia Bounding pulse Splenomegaly •Focus of infection± •Pallor±	Septicaemic shock		Cefotaxime 50mg/kg IN or I/Mor Ceftriazone 50mg/kg Referred to hospital
High continuous fever <7days with •vomiting •Bleeding manifesta- tions (coffee ground vomiting /Melaena)	Hypotension •Narrow pulse pressure 9<20 mmHg) Hepatomegaly	Dengue Shock Syndrome (DSS)		•Treated as DSS
Acute onset Fever with skin rash	Characteristic skin rash Purpuric rash with central necrosis Petechiae	Meningo-coccaemia		IV N/S 20ml/kg bolus If shock not revived give 2nd bolus ofN/S
H/O travel to malaria endemic area within last 6 month	Splenomegaly ± •Pallor±	• Algid malaria		Inj: Artesunate IN • N/S 20ml/kg bolus Refer to Hospital
3. History of taking Drugs (e.g., Penicillin/ Streptomycin)	Dyspnoea •Wheezing± •Vomiting, Diarrhoea If due to streptomycin	Anaphylactic shock		• N/S 20ml/kg bolus IM Adrenalin (1:1000 Solution) • >12 yrs7 0.5 ml • 6- 12yrs70.3ml • <6 yrs70.15ml Repeat after 5min if not better Injection-Hydrocortisone Injection-Chlorpheniramine
4. History suggestive of blood loss/any blunt injury	Evidence of external injuries •Pallor± • Abd: pain, rigidity	Shock due to blood loss		• N/S 20ml/kg Refer to hospital

ANAPHYLAXIS

- Anaphylaxis is the most urgent of clinical immunologic events. It is defined as the clinical response to an immediate (type) immunologic reaction.
- Anaphylaxis is a severe allergic reaction, which may cause upper airway obstruction with stridor, lower airway obstruction with wheezing or shock or all three. Common causes include allergic reactions to antibiotics, to vaccines, to blood transfusion and to certain foods, especially nuts.
- Consider the diagnosis If any of the following symptoms is present and there is a history of previous severe reaction, rapid progression or a history of asthma, eczema or atopy.
- Severity of anaphylaxis

Severity	Symptoms	Signs	Treatment
Mild	Itching mouth •Nausea	•Urticaria Oedema of the face Conjunctivitis Throat congestion	Remove the allergen as appropriate Give oral anti histamine
Moderate	Cough or wheeze •Diarrhoea •Sweating	•Wheeze Tachycardia •Pallor	•Give adrenaline 0.15ml ofl:1000 IM into the thigh; the dose may be repeated every 5-15 mints
Severe	Difficulty in breathing •Collapse •Vomiting	Severe wheeze with poor air entry Oedema of the larynx •Shock Respiratory arrest Cardiac arrest	If the child is not breathing, start basic life support •Give adrenaline 0.15 ml ofl:1000 IM and repeat every 5-15 min. Give 100% oxygen. •Ensure stabilization of the airway, breathing, circulation and secure IV access Administer 20 ml/kg normal saline 0.9% or Ringer 's lactate solution IV as rapidly as possible. If IV access is not possible, insert an intraosseous line

FRACTURE





Sling

Sling with swathe



If you have enough facilities, you can do splintage.

GAMEKEEPER'S THUMB



- Forced thumb abduction causes rupture of the ulnar collateral ligament.
- Can occur on wringing a pheasant's neck-hence the name, or, more commonly, by catching the thumb in the matting on a dry ski slope.
- The thumb is very painful and pincer grip weak.
- Refer-open surgical repair is the most effective treatment.

PULLED ELBOW

- Common in children <5 years.
- Traction injury to elbow causes subluxation of radial head. Often occurs when the child is pulled up suddenly by the hand. Child will not use the arm. No clinical signs.
- M >F, Left arm >Right arm, X-rays are unhelpful.

Management

- Apply anterior pressure with the thumb on the radial head whilst supinating and extending the forearm. Immediate recovery is seen after reduction.



Subluxation and dislocation
Anterior view

GUIDELINES FOR ESSENTIAL TRAUMA CARE

- Nobody is immune to trauma.
- Trauma may be life threatening or limb threatening.
- A basic general principle of management is the same in all kind of trauma cases such as primary survey assessment, secondary survey assessment, etc.

Primary survey

- **Airway management**
  - Its primary objective is to diagnose an obstructed or potentially obstructed airway, to clear the obstruction and keep the airway patent.
  - If any abnormalities are detected, measures to intervene are instituted immediately.
  - The skills to assess a patient for obstruction of the airway, to establish and maintain a patent airway, and to ensure adequate ventilation and oxygenation of the patient, are essential.
  - It is essential that healthcare personnel know the signs of airway obstruction and are skilled in manual maneuvers to keep an airway patent while maintaining cervical spine protection [Chin lift, Jaw thrust, recovery position]
  - Suction is very important step.
  - Correct Methods of insertion of oropharyngeal airway in children and adults.
  - Skill in using Bag-Mask-Valve is important.
  - Cricothyroidotomy is generally considered to be the surgical airway of choice in emergency situations and can be performed in several seconds.
- **Breathing: Management of respiratory distress**
  - The ability to assess a patient for respiratory distress and adequacy of ventilation is essential
  - To understand important of adequate oxygenation to all trauma patient.
  - The recognition of tension pneumothorax, its primary treatment by needle thoracostomy and definitive treatment by tube thoracostomy are essential.
  - Recognition of the presence of a sucking chest wound and the ability to apply a three-way dressing for immediate treatment is essential.
- **Circulation-Management of Shock**
  - The ability to assess a patient for the presence of shock is essential.
  - The ability to recognize signs and symptoms of shock depending on amount of blood loss.
  - Control of external haemorrhage through manual pressure and through the application of a pressure dressing is essential.
  - Ability to know indication and complication of arterial tourniquet.
  - splinting of fractured extremities and pelvic binding are effective way of controlling internal bleeding and to relieve pain.
  - Fluid replacement with crystalloid is essential in hypovolemic shock. Two Large bore needle intravenous line is recommended.
  - Intraosseous route is very effective and safe in children especially under five years.
- **Disability**
  - Assess the patient for neurological disability from brain or spine injury.
  - Examine the pupil size and reaction to light on both sides.
  - Is the patient **A**wake? Opening eyes to **V**oice? Opening eyes to **p**ain? **U**nresponsive? **U**
- **Exposure**
  - Undress the patient and look for hidden injury.
  - Cover the patient as soon as possible to keep the temperature stable.

HEAD INJURIES

Introduction and relevant to GP

- Head trauma is a major cause of death and disability in children and adults. Rapid and effective assessment and management save lives and reduces disability. Hypoxia and hypotension double the mortality of head-injured patients.

How to diagnose

- The assessment of neurological status including determination of level of consciousness usingthe Glasgow coma scale
- Recognition of lateralizing signs
- Determination of pupillary size and reflexes
- Skull X ray and CT scan

Points to diagnose

- *Extradural haematoma—*
    - commonly results after an impact to the head.
    - Features of acute extradural haematoma include:
        - An initial loss of consciousness after the impact
        - The patient may wake up (lucid interval)
        - Then rapid deterioration and unconsciousness
    - Arterial bleeding with rapid increase in intracranial pressure
    - Boggy scalp swelling over the site of the fracture
    - The development of paralysis on the opposite side with a fixed pupil on the same side as the impact to the head.
- *Acute subdural haematoma---*
    - commonly occurs in association with severe head injury. It results from bleeding from blood vessels around the brain and may be associated with significant primary brain injury.
    - Features of Acute subdural haematoma include:
        - Venous bleeding and clotted blood in the subdural space
        - Frequently severe bruising or damage to the underlying brain.
- *Base-of-skull fractures* -
    - bruising of the eyelids (Racoon eyes) or over the mastoid process (Battle's sign),
    - cerebrospinal fluid (CSF) leak from ears and/or nose

Management

- General principles of management
- The priority of management is stabilisation of the airway, breathing and circulation, with immobilisation of the cervical spine.
- Keeping the oxygen level as high as possible and the systolic blood pressure above 90mmHg is the most important aim in emergency treatment for patients with head injury.
- Monitoring of vital signs, pupils and regular neurological observations.
- Elevate the head of the bed, if possible, without bending the neck.
- Keep the temperature stable.
- Mannitol 20% infusion may reduce intracranial pressure.

Referral criteria

- Patients who need endotrachaeal intubation.

- Patients who need CT scan.
- Patients who need surgical interventions.
- Patients who need conservative treatment.

CHEST TRAUMA

Introduction and relevant to GP

- Approximately a quarter of the deaths due to trauma are attributed to chest injury.
- Immediate deaths can result from disruption to the airway, injury to the great vessels or from injury to the heart.

How to diagnose

- Clinical evaluation starts with obtaining a good history regarding the mechanism of injury followed by clinical examination and most often a radiological evaluation.

Point to diagnose and management

- Rib Fractures
- History of trauma, tenderness, crepitus and painful, particularly with movement, deep breaths or coughing on affected area.
- Signs and symptoms of lung, liver, and spleen injury may be present.
- CXR (PA and lateral) is useful (sensitivity is 50%). Sometime CT scan may need.
- Ribs fractures are managed analgesia alone as they tend to heal without complication.

PNEUMOTHORAX
TENSION PNEUMOTHORAX –

- It is a clinical diagnosis, not on X-ray.
- Signs and symptoms include:
    - Restless and short of breath.
    - Absent breath sounds.
    - Resonance to hyper resonance to percussion on the affected side with tracheal shift to the opposite side.

Immediate management

- It consists of insertion of large bore needle in second intercostal space in mid- clavicular line on affected site follow by proper intercostals drainage.

SIMPLE PNEUMOTHORAX

- does not have an increase in intrathoracic pressure on the affected side. Chest X-ray to confirm the diagnosis and size of the pneumothorax. Treatment is insertion of proper chest drain.

FLAIL CHEST

- Flail chest is a clinical anatomic diagnosis noted in blunt trauma patients with paradoxical or reverse motion of a chest wall segment while spontaneously breathing, two or more fractures per rib in at least two ribs.
- The flail segment moves independently of the rest of the thoracic cage. The degree of respiratory insufficiency is typically related to the underlying lung injury.
- Management includes good analgesia with ventilatory support.

HAEMOTHORAX

- Reduced chest wall movement, reduced air entry, dullness on percussion on affected side. Insertion of a chest tube to drain blood and re-expansion of lung is enough in most of the cases.
- The conditions need for refer are initial drainage more than 1.5 litres of blood, ongoing blood loss more than 250 ml per hour and failure of lung re-expansion after chest tube insertion.

PULMONARY CONTUSION

- A high degree of suspicion based on the mechanism of injury is necessary.
- Patient may be asymptomatic to severely distress.
- Signs and symptoms include chest pain, shortness of breath, reduced oxygen saturation. Ventilatory support may need in severe cases.

OPEN (SUCKING) CHEST WOUND

- Air is sucked into the chest cavity, and severe cases mediastinum may shift to opposite site.
- As a temporary measure a dressing may be applied on top of wound with three sides sealed to act as a 'valve' follow by proper intercostal drain.

MYOCARDIAL CONTUSION

- This can follow blunt trauma to sternum. An abnormal ECG, signs of heart failure, and low blood pressure indicate underlying cardiac contusion. Need to refer for higher level care.

PERICARDIAL TAMPONADE

- Usually, history of penetrating injury to heart and patient present with cardiogenic shock.
- Urgent refer is require.

RUPTURE OF THE AORTA

- Very high on-site mortality rate.

RUPTURE OF TRACHEA OR MAJOR BRONCHI

- Up to 50% mortality rate. Clinical signs include shortness of breath, haemoptysis, and collapsed lung on the affected side on X-ray.

INJURY TO THE OESOPHAGUS AND INJURY TO THE DIAPHRAGM

- Early surgeon involvement cans safe life.

ABDOMINAL AND PELVIC TRAUMA

Introduction and relevance to GP

- Patients involved in major trauma should be considered to have an abdominal injury until otherwise excluded. Blunt and penetrating trauma can present with significant abdominal injury.

Classification of the mechanism of injury:

- Penetrating trauma e.g., gunshot, knife wounds
- Blunt trauma e.g., compression, crush and deceleration injuries
- Explosions can cause both blunt and penetrating trauma as well as blast pressure injuries to the lungs and hollow viscera.
- Life threatening haemorrhage is a frequent complication of major pelvic fractures and causes 30% of polytrauma deaths.

Diagnosis and management

- The initial assessment of the abdominal and pelvic trauma patient is the Primary Survey: ABCDE.
- The assessment of the "Circulation" during the Primary Survey involves careful evaluation of the abdomen and pelvis for possible hidden haemorrhage, especially in hypotensive patients.
- Repeating the primary survey and serial physical examinations of the abdomen will identify clinical deterioration and assist in making the diagnosis.
- Physical examination includes inspection, palpation, percussion and auscultation of the abdomen as well as examination of:
    - Urethra, perineum, and gluteal region
    - Rectum (tone, blood, prostate position),
    - Vagina
    - Pelvis (fractures and stability)

Useful investigations (optional)

- Diagnostic peritoneal lavage (DPL)
- ultrasound (Focused Assessment Sonography in Trauma or FAST)
- abdominal computed tomography (CT)

The management of abdominal injury

- may include early surgical intervention and stabilization.

The management of pelvic fractures

- includes early identification and immobilisation to stop bleeding, using either simple stabilization with a sheet pulled tight and tied round the hips (femoral greater trochanters) or commercially available pelvic slings.

LIMB TRAUMA

Introduction and relevance to GP

- Injuries to the extremities are the primary cause of injury-related disability.
- These disabilities can be greatly reduced If promptly recognized and corrected.
- The diagnosis of major limb injuries and recognition of associated neurovascular compromise (including compartment syndrome) are essential at all health care levels. Peripheral haemorrhage is a preventable cause of early death with limb trauma.

Diagnosis and management

- Begins with Primary Survey ABCDE.
- *Examination* must include inspection and palpation:
- Skin colour and temperature
- Grazes and bleeding sites
- Limb alignment and deformities
- Active and passive movements
- Pulse assessment comparing proximal to distal to a fracture and with the other side
- Unusual movements and crepitation
- Level of pain.

General principles of management of limb injuries:

- Keep blood flowing to peripheral tissues
- Prevent skin necrosis and infection
- Prevent damage to peripheral nerves
- Provide pain relief

Special issues relating to limb trauma

- *Active bleeding:*
  - Stop the bleeding and replace the blood loss.
- *Open fractures and joint injuries:*
  - Any fracture or joint injury situated near a wound must be considered as "open".

Principles of the treatment of open fracture include:

- Stop external bleeding
- Immobilise
- Relieve pain
- Early surgical consultation.

Amputated parts of extremities

- Cover the wound with sterile gauze. Wrap the amputated part with moistened saline gauze and place into a sterile plastic bag.

COMPARTMENT SYNDROME

- Compromise perfusion to tissues within an anatomical compartment due to increased pressure within that compartment. Suspect it in patients that have pain out of proportion to the injury.
- The earliest and most important sign is increasing pain especially on passive stretching of the muscles. Loss of pulse or sensation are very late signs.

Management

- It is by early detection and referral to hospital.
- Consider fasciotomy If the condition is urgent and the doctor is competent.

CRUSH INJURY

- localised tissue injury that occurs when a compressive force is applied.

Crush syndrome

- Is a systemic condition that results from injuries sustained by compressive forces sufficient in duration and pressure to cause widespread ischaemia and necrosis of soft tissues.
- The limb may become tense, swollen and pulseless.
- Myoglobinuria and/or haemoglobinuria due to skeletal muscle destruction make the urine tea-coloured quite early on.
- Hypovolaemic shock and acidosis are present.

Management

- The main goal of treatment is to prevent crush injury syndrome developing.
- Start IV fluids (ideally before the limb is freed and decompressed) and insert a urinary catheter.
- Refer to appropriate center.

DROWNING

Definition

- Drowning is defined as death due to asphyxiation following immersion in a fluid, whilst near-drowning is defined as survival for longer than 24 hours after suffocation by immersion.
- Drowning remains a common cause of accidental death. In about 10% of cases no water enters the lungs and death following intense laryngospasm (dry drowning).
- Prolonged immersion in cold water, with or without water inhalation results in a rapid fall in core body temperature and hypothermia
- Following inhalation of water, there is a rapid onset of ventilation-perfusion imbalance with hypoxemia and development of diffuse pulmonary oedema.
- Fresh water is hypotonic and, although rapidly absorbed across alveolar membranes, impairs surfactant function which leads to alveolar collapse and right-to -left shunting of unoxygenated blood.
- Absorption of large amounts of hypotonic fluid can result in haemolysis. Salt water is hypertonic and inhalation provokes alveolar oedema, but the overall clinical effect is similar that of fresh water drowning.

Clinical features

- Those rescued alive (near-drowning) are often unconscious and not breathing. Hypoxaemia and metabolic acidosis are inevitable features. Acute lung injury usually resolves rapidly over 48-72 hours, unless infection occurs.

Complications

- include dehydration, hypotension, haemoptypsis, rhabdomyolysis, renal failure and cardiac dysarrhythmias. A small number of patients, mainly the more severely ill, progress to develop the acute respiratory distress syndrome.
- Survival is possible after immersion for periods of up to 30 minutes in very cold water. Long term outcome depends on the severity of the cerebral hypoxic injury and is predicted by the duration of immersion, delay in resuscitation, intensity of acidosis and the present of cardiac arrest.

Management

- Initial management requires cardiopulmonary resuscitation with administration of oxygen, and maintenance of the circulation. The victims can respond to resuscitation after considerable immersion time (up to 30 minutes) and that mouth-to-mouth resuscitation should always be attempted even If pulseless or with fixed dilated pupils.
- It is important to clear the air-way of foreign bodies and protect the cervical spine.
- Continuous positive airways pressure should be considered. Hypothermia should be attended to with warming, such as a hot-air blanket If available and warm fluid.
- Observation is required for a minimum of 24 hours. Prophylactic antibiotics are only required If exposure was to obviously contaminated water

Reference:

1. *Davidson's Principle and Practice of Medicine, 21st Edition*
2. *John Murtagh* 's *Handbook of General Practice, 6th Edition*

ELECTRICAL INJURIES

- Electrical injuries have 3 clinical presentations
    - Direct trauma from electrical current causing through the body
    - Trauma from conversion of electrical energy to thermal energy
    - Mechanical effects of electrical current including violent muscle contraction and falls.
- Emergent evaluation of electrical injuries should follow the traditional pathway of primary and secondary surveys, followed by a detailed and specific history and physical examination describing specific injuries by system.

Cutaneous injuries

- Bums are the most common injury associated with electrical accidents. Low -voltage injuries tend to create small, well-demarcated contact bums at the site of skin entry and exit. In high-voltage injuries, the bums are serious and appear as painless, depressed, yellow-gray, charred creaters with central necrosis.
- High-voltage injuries may largely spare the skin surface but cause massive damage to underlying soft tissue and bone, necessitating escharotomies, fasciotomies, or amputations.
- The 'kissing' bum is sometimes associated with electrical injury. This bum occurs at flexor creases such as antecubital fossa when a current arcs across both flexor surfaces. It is important to recognize this type of injury because it is often associated with extensive underlying tissue damage.

Cardiac

- The most serious presentation of electrical injury is cardiac arrest. Ventricular fibrillation is more common with low-voltage AC injuries, whereas asystole is seen more often with DC high-voltage injuries.
- Autonomic dysfunction following electrical injuries can cause serious cardiovascular complications related to the release of catecholamines.
- This may lead to cardiac arrest, transient hypertension, tachycardia, vasovagal syncope, thermo-dysregulation, and vasoconstriction.
- Electrical exposure may cause direct myocardial tissue damage ie caused by electric current flowing horizontally (head to foot).

Respiratory

- Respiratory arrest as a result of tetanic contraction of the thoracic musculature, injury to the respiratory control center of the central nervous system or
- Combined cardiopulmonary arrest secondary to asystole or ventricular fibrillation.
- Blunt chest trauma due to falls or being thrown from a high-voltage source may cause pulmonary contusion.

Vascular

- Greatest damage to the media layer of blood vessels and can lead to delayed aneurysm formation or rupture.
- Most severe in the small muscle branches lead to tissue necrosis.
- Any vascular injury can also lead to edema and compartment syndrome.

Neurologic

- CNS lesions are more common with lighting injury, while PNS lesions are seen more often with electrical injuries.
- Spinal cord damage is the most common delayed consequence of electrical injury.

- The high-voltage entry sites in the head and neck, an exit site in the lower extremities led to paraplegia, where as an exit site in the upper extremities led to quadriplegia

Musculoskeletal

- Direct electrothermal energy leading to coagulation necrosis, become edematous and necrotic, resulting in rhabdomyolysis or compartment syndrome.
- A bone has the highest degree of resistance, severe electrothermal bone damage such as periosteal bums and osteonecrosis is seen.
- Falls secondary to electrical injury and forceful tetanic muscle contractions create fractures and joint dislocations.

Renal

- Myoglobin release from muscle damage also cause renal tubular damage and subsequent renal failure.

Other

- Cataracts may occur immediately but more often develop months after the injury. Hearing loss is well-known sequela of lightning injury and may also occur after electrical injury.
- Injury to eighth cranial nerve may also suffer from chronic tinnitus and imbalance problems.

Summary of multi-system presentations of electrical injuries

System	Presentation
Skin	Cutaneous bum
Cardiac	Arrhythmias, cardiac arrest
Respiratory	Respiratory arrest due to muscle tetany or central nervous system causes
Vascular	Aneurysm formation, tissue ischaemia
Neurologic	Loss of consciousness,transient paralysis or parathesia, peripheral neuropathy, spinal cord injury
Musculoskeletal	Fractures or dislocations secondary to muscle spasm or falls, muscle necrosis, compartment syndrome
Renal	Myoglobinuria leading to renal failure.
Others	Cataracts, neuropsychological effects

Management

- History
- Physical examination
- Diagnostic studies
- Electrocardiogram
- laboratory tests
- Radiology
- Laboratory test recommended for patients with Electrical injuries
- CBC
- Electrolytes
- BUN and creatinine
- Urinalysis
- Serum myoglobin
- Liver function tests/amylase/lipase
- Coagulation profile
- Blood type and screen/cross match


Check ABC's Perform history and physical exam
Obtain ECG, O_2, LABS (including CK, UA) IV fluids
Low voltage injuries
High voltage injuries
ECG normal and no history of loss of consciousness, arrhythmia or other injury requiring admission
ECG with evidence of ischemia or history of loss of consciousness, arrhythmia or other injury requiring admission
Already at burn center?
Discharge home
Admit
yes
no
Involve appropriate consultants (surgery, orthopaedics), perform serial neurovascular exams of extremities and admit to hospital
Transfer to regional burn center for admission

CHOKING

- It is a blockage of the upper airway by food or other objects, which prevents a person from breathing effectively. Choking can cause a simple coughing fit, but complete blockage of the airway may lead to death.
- Choking is a true medical emergency that requires fast, appropriate action by anyone available. Emergency medical teams may not arrive in time to save a choking person's life.
- The brain is extremely sensitive to this lack of oxygen and begins to die within four to six minutes. It is during this time that first aid must take place. Irreversible brain death occurs in as little as 10 minutes.

Causes

- Choking is caused when a piece of food or other objects gets stuck in the upper airway.
- Any object that ends up in the airway will become stuck as the airway narrows.
- Normal swallowing mechanisms may be slowed If a person has been drinking alcohol or taking drugs, and if the person has certain illnesses such as Parkinson's disease.
- In older adults, risk factors for choking include advancing age, poor fitting dental work, and alcohol consumption.
- In children, choking is often caused by chewing food incompletely, attempting to eat large pieces of food or too much food at one time, or eating hard candy.
- Children also put small objects in their mouths, which may become lodged in their throat. Nuts, pins, marbles, or coins, for example, create a choking hazard.

Choking symptoms

- If an adult is choking, you may observe the following behaviors:
- Coughing or gagging
- Hand signals and panic (sometimes pointing to the throat)
- Sudden inability to talk
- Clutching the throat: The natural response to choking is to grab the throat with one or both hands. This is the universal choking sign and a way of telling people around you that you are choking.
- Wheezing
- Passing out
- Turning blue: Cyanosis, a blue coloring to the skin, can be seen earliest around the face, lips, and fingernail beds. You may see this, but other critical choking signs would appear first.
- If an infant is choking, more attention must be paid to an infant's behavior. They cannot be taught the universal choking sign.
- Difficulty breathing
- Weak cry, weak cough, or both

Management

Fig 1: Pictures of Abdominal Thrusts (Heimlich Maneuver)

- In adults and children older than one year of age, abdominal thrusts (formerly referred to as the "**Heimlich Maneuver**") should be attempted. This is a thrust that creates an artificial cough. It may be forceful enough to clear the airway.
- *The quick, upward abdominal thrusts force the diaphragm upward very suddenly, making the chest cavity smaller. This has the effect of rapidly compressing the lungs and forcing air out. The rush of air out will force out whatever is causing the person to choke. (see Fig 1)*
- This maneuver should be repeated until the person is able to breathe or loses consciousness.
- If the person loses consciousness gently lay him or her flat on their back on the floor. To clear the airway, kneel next to the person and put the heel of your hand against the middle of the abdomen, just below the ribs. Place your other hand on top and press inward and upward five times with both hands. If the airway clears and the person is still unresponsive, begin CPR.
- For babies (younger than one year of age), the child will be too small for abdominal thrusts to be successful. Instead, the infant should be picked up and five back blows should be

administered, followed by five chest thrusts. Be careful to hold the infant with the head angled down to let gravity assist with clearing the airway. Also be careful to support the infant's head. *If the infant turns blue or becomes unresponsive, CPR should be administered.*

Variations of abdominal thrusts for special circumstances:

- **The victim is seated**:
    - The maneuver may be performed with the victim seated. In this instance, the back of the chair acts as a support for the victim. The rescuer still wraps his or her arms around the victim and proceeds as described above. The rescuer will often have to kneel down. In the event that the back of the chair the victim is sitting in is too high, either stand the victim up or rotate the victim 90 degrees, so that the back of the chair is now to one side of the victim.
- **For small rescuers and large victims,** particularly children rescuing an adult:
    - Instead of standing behind the victim, have the victim lie down on his or her back. Straddle the victim's waist. Place one hand on the belly, halfway between the belly button and the edge of the breastbone. Thrust inward and upward. This is the same technique used in unconscious people.
- **Pregnant/obese people**:
    - Abdominal thrusts may not be effective in people who are in the later stages of pregnancy or who are obese. In these instances, chest thrusts can be administered.
- For the **conscious person sitting or standing**, take the following steps:
    - Place your hands under the victim's armpits.
    - Wrap your arms around the victim's chest.
    - Place the thumb side of your fist on the middle of the breastbone.
    - Grab your fist with your other hand and thrust backward. Continue this until the object is expelled or until the person becomes unconscious.
- For the **unconscious pregnant or obese person**:
    - The sequence of events is the same as those for an unconscious adult. Chest thrusts, rather than abdominal thrusts, are delivered.
- To position yourself for chest thrusts, take the following steps:
    - Kneel on one side of the victim.
    - Slide two fingers up the bottom edge of the rib cage until you reach the bottom edge of the breastbone called the xiphoid process.
    - With your two fingers on the xiphoid, place your other hand on the breastbone, just above your fingers. The thrusts should be quick and forceful to remove the object.
    - Care should be taken because complications such as rib fractures and heart muscle damage have been known to occur with chest thrusts.
- If at all possible, **subdiaphragmatic (below the ribcage) abdominal thrusts** should be used in the pregnant woman, especially If there is still room between the enlarging uterus and baby, and the rib cage to perform the maneuver.
- If facilities available:
    - Intubation:
        - a breathing tube is passed into a person's windpipe (trachea). This may push the object that is obstructing the airway out of the way enough to provide air to the lungs.
        - To perform intubation, a metal scope is inserted into the back of the throat to aid in seeing the vocal cords, which mark the opening of the trachea.
        - If, while using this scope, the object causing the obstruction can be seen, it may then be removed with a long instrument called a Magill forceps.
- If unsuccessful, perform a surgical procedure called a cricothyrotomy.

Prevention tips for children

- Don't give young children hard foods or small objects that are likely to become lodged in their airways.
- Cut foods such as hot dogs, sausages, and grapes into small pieces before serving them to young children.
- Look over toys to find small pieces
- Choking on a rubber balloon including dangerous objects.
- Store small objects, such as buttons and batteries, out of a child's reach.
- Do not allow children to play sports with food or gum in their mouths.
- Tell babysitters and older brothers and sisters, what foods and objects should not be given to young children.
- Instruct children to chew their food thoroughly before swallowing.

Prevention tips for adults

- Avoid placing objects such as nails or pins in your mouth for quick access.
- Take small bites and chew food thoroughly.
- Be aware that alcohol may impair your ability to chew and swallow, and increase your risk of choking.

Choking Prognosis

- The lack of oxygen caused by choking can result in brain damage or death in four to six minutes. Unless immediate action is taken to open a completely obstructed airway, the chances for survival and complete recovery decrease rapidly. If the object can be removed quickly and breathing returns to normal, recovery should be complete.

Reference

1. *https://www.emedicinehealth.com/choking/ topic-guide.htm*